<SEC-DOCUMENT>0000944809-22-000026.txt : 20220509
<SEC-HEADER>0000944809-22-000026.hdr.sgml : 20220509
<ACCEPTANCE-DATETIME>20220509170928
ACCESSION NUMBER:		0000944809-22-000026
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220509
DATE AS OF CHANGE:		20220509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OPKO HEALTH, INC.
		CENTRAL INDEX KEY:			0000944809
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752402409
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33528
		FILM NUMBER:		22906090

	BUSINESS ADDRESS:	
		STREET 1:		4400 BISCAYNE BLVD.
		CITY:			MIAMI
		STATE:			FL
		ZIP:			33137
		BUSINESS PHONE:		305-575-4181

	MAIL ADDRESS:	
		STREET 1:		4400 BISCAYNE BLVD.
		CITY:			MIAMI
		STATE:			FL
		ZIP:			33137

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Opko Health, Inc.
		DATE OF NAME CHANGE:	20070621

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	eXegenics Inc
		DATE OF NAME CHANGE:	20040505

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXEGENICS INC
		DATE OF NAME CHANGE:	20011114
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>opk-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:b1bc5044-98fa-41ae-b2d0-b9b87eb185ce,g:64b4497f-89ba-4c5f-8ed3-b19012dfc871,d:1cac816ff800494ea2979c434f00b37c--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:opk="http://www.opko.com/20220331" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>opk-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180L2ZyYWc6NDUzYWFlY2ZkMDY4NGM5NWI3MWM3YjY5YzU0MzAzMDUvdGFibGU6MjJlMWIwYTZmYjJjNDdlYjg1ZGZjYzZiYWUxYzc1YjAvdGFibGVyYW5nZToyMmUxYjBhNmZiMmM0N2ViODVkZmNjNmJhZTFjNzViMF8yLTEtMS0xLTM1MzMw_ce42b0b4-3748-4fba-a623-29a68069cdbe">0000944809</ix:nonNumeric><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180L2ZyYWc6NDUzYWFlY2ZkMDY4NGM5NWI3MWM3YjY5YzU0MzAzMDUvdGFibGU6MjJlMWIwYTZmYjJjNDdlYjg1ZGZjYzZiYWUxYzc1YjAvdGFibGVyYW5nZToyMmUxYjBhNmZiMmM0N2ViODVkZmNjNmJhZTFjNzViMF8zLTEtMS0xLTM1MzMw_1695b842-d4b0-4abc-b58b-f2e281030a26">false</ix:nonNumeric><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180L2ZyYWc6NDUzYWFlY2ZkMDY4NGM5NWI3MWM3YjY5YzU0MzAzMDUvdGFibGU6MjJlMWIwYTZmYjJjNDdlYjg1ZGZjYzZiYWUxYzc1YjAvdGFibGVyYW5nZToyMmUxYjBhNmZiMmM0N2ViODVkZmNjNmJhZTFjNzViMF80LTEtMS0xLTM1MzMw_a682b275-5d60-4318-a5b2-f54d8bf6063b">2022</ix:nonNumeric><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180L2ZyYWc6NDUzYWFlY2ZkMDY4NGM5NWI3MWM3YjY5YzU0MzAzMDUvdGFibGU6MjJlMWIwYTZmYjJjNDdlYjg1ZGZjYzZiYWUxYzc1YjAvdGFibGVyYW5nZToyMmUxYjBhNmZiMmM0N2ViODVkZmNjNmJhZTFjNzViMF81LTEtMS0xLTM1MzMw_19769624-1d96-4f1c-ab8f-58f7be816be4">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180L2ZyYWc6NDUzYWFlY2ZkMDY4NGM5NWI3MWM3YjY5YzU0MzAzMDUvdGFibGU6MjJlMWIwYTZmYjJjNDdlYjg1ZGZjYzZiYWUxYzc1YjAvdGFibGVyYW5nZToyMmUxYjBhNmZiMmM0N2ViODVkZmNjNmJhZTFjNzViMF82LTEtMS0xLTM1MzMw_1f0012ed-2f27-4478-bf45-1f6736a002dd">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ic4da1298681e4425aee6f3a5032a8365_D20210101-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNS0wLTEtMS0zNTMzMA_919511f1-ba2b-471c-9afb-64ee3d8de324">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i3a645b4fb40d4c90b63cf8887a6813ce_D20190201-20190228" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182MS9mcmFnOmViY2RhNWI5ODE2MjQ5NDdiNjRhNWZhM2RhODZlNDI5L3RhYmxlOjA4Y2FhZjc4ZGQ2MTRmZmVhZjQ1ZGY1ZmNhNjczZGVlL3RhYmxlcmFuZ2U6MDhjYWFmNzhkZDYxNGZmZWFmNDVkZjVmY2E2NzNkZWVfMy0xLTEtMS0zNTMzMA_ed17d1c2-b8f4-4acb-bafd-853d7d79db80">0.2367424</ix:nonFraction><ix:nonNumeric contextRef="i137b80025d3d4485b08482ba89272156_I20220331" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMy0wLTEtMS0zNTMzMA_c6bd7dfc-1515-470c-8640-321ba294369d">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="opk-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d11b917135448a38fea47851772958f_I20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i137b80025d3d4485b08482ba89272156_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i0e59dec8141549aa8b911e469e798a72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2f9c95a502354f4c9bd791e55a1b1acc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fd3f89e217e4e329bca14b9905edffa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85501a743668421b8f9b4903a091161f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a1bb9d88fbc42c0b66fe51d04025dd1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e961cfc73ca4fc995f9df88000a19c4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66109927d116428aafb21943a884db23_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3804ba279de40cdb6e0567ff03eedfd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied0a49adeefd4e1fac80ec50e4698621_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbf602f14f46471d9d178ec252d385a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6d0ba7a733345be9b1fdc07bf34b423_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22bb54bd14a34a3ab35f37edf368d2bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i646a74fab4f84bf98ac3afc12ad3422e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ec1789e0468407da526985ac43b1656_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4da1298681e4425aee6f3a5032a8365_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6af8b25ddc04918b13d874863276327_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb2b0dab2c974aca988d625e077fe49b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfe95975785f4da2a0792b40c68274b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2b1a62808234ad7b78fb28d31a7ee36_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08134a4538f24e06bd29a6faf920f1bf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idad4ab8f901e456a921f38433308a875_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63a9708ca6b241cbbf8a971c348c1b9c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95f76eb90058493b8b9714b06a32ca6a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86a2019e2f9a4c668d4bcb4561aaf856_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5ac38aea5024455837e4b0a72c6cc5c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e33b9f98a1b4d2196ed092e6e422c9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf50959849a64f92b031a93fb028f210_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i776417f572dd43b785ccc5de1a3fdd29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3c39548fd884077aba54bc5130c8aa6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dd9c60c32484868940a0edb35f5b606_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08082c8210bd41e08e8e6102a684ff8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1a9671afbc747319965e4950c1d5673_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c2c25cd759044e8a8b1ac83a456a490_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia73d31bf5c2240cdb0ccd63c8a4348c1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69f0a1d1a7fd49089a06dcef395b5c5b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc66eff602d7434281e15843b60d6d9a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91568ba4c6ad4c9bbb8a6d13b2cca42c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d685f0119934d39a093d66dd07cd19f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8f0316ac515435b82f539c2ec2dd817_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i632c4e422f024ca6bb911a55e1259fcb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i402dd9684c2f477db500daa02097978b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>opk:employee</xbrli:measure></xbrli:unit><xbrli:context id="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:DetectGenomixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:Sema4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-29</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i906abe6eed0f4cd69f9561fd532d9d48_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">opk:WaterfordIrelandFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="facility"><xbrli:measure>opk:facility</xbrli:measure></xbrli:unit><xbrli:context id="ia99d14c06e6e4e28ad5a8c3f4c6cc028_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">opk:WaterfordIrelandFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59cf764445af4de7b91ff994ed949ca9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i086b3193d0a84e44b65e89593c24a20b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="opk:TestingTypeAxis">opk:GenomicTestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="idce190630bea4cf9936f6557989275fb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="opk:TestingTypeAxis">opk:RoutineClinicalTestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id75b8d1d54904cb9bed9cb560d7ee790_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:COVID19TestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">opk:COVID19TestingRevenueConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i888fe358d78645888869e9e2f5f6b316_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:COVID19TestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">opk:COVID19TestingRevenueConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77c9c6ea887e4115b1c0992f4beef719_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">opk:DetectGenomixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30dd8bae361a48dc85516ce870eae7cb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">opk:DetectGenomixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cf8b83bf2c647cc819974ea2adb86c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80eb499192104b008d7af0e0148d19c8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9f8b48ec3cc43d09aa306ad85bdfbd6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec064528f8b46c799fcf289c9791518_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37bc1ddf248145949cf20c844e5cd267_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52d41c803f754caab224bc8b150c6c59_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieada14ab28484d7f825d8053db57205d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2a83411c64144f1b9355c9cfd56237d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63f3da17eaeb419fa6e03d78593bf2bd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide29c575be14417383ac7d390f9234c4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2ff2edaeb5d4865a0321ebe71317039_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d47b2edbf174a649ea86051fd83bd31_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i318d31f5642447988322e0b46296a5e2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idab50d068e1f4bfc9aa0aa0073ec3fdd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">opk:AutomobilesandAircraftMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie29d2a5269334fb397d32c99e041731a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">opk:AutomobilesandAircraftMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i530fe1c9f119438894b0dd5623106eed_D20220331-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">opk:FederalAndStateGovernmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-31</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50900f2255f341c596bd800b3f7c7a4d_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">opk:FederalAndStateGovernmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c46f5c9a39a4c32b5cd190bec420d89_D20220331-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">opk:StatesCitiesAndOtherMunicipalitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-31</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a7d513d6e904c0884c28baf601bb35d_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">opk:StatesCitiesAndOtherMunicipalitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1dca7ce0a2b48abb1378746d081a87a_D20220331-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">opk:IndividualPatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-31</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b22ccaca70a4b119871d37e30563967_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">opk:IndividualPatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>opk:segment</xbrli:measure></xbrli:unit><xbrli:context id="ib396f0384c4549d6ad4a1d99b89fcf7f_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceb6a701923f4d27a6905238cab5243d_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04b7a30acb9a4f81a6cd5179f6dc9cd0_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67b75a0644d1431cb32ac4d221554a5d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e0d3411daf7457fa18aa8ab1b20c33e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56733675f4354dacaf825a860ec99f82_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e18e3e9d8bb41f0b30d8b956511195e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b12b303a8a149ee9de06097429266da_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bc8466e91704c55a14be646d891acd3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i651cb43b8a074339b0ee2e20b061a461_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09284eae734a4ba29ea813474543bb46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied8dda5c25884eaf9d82544f0dd21140_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3692b70dac746208ee532bd6a7af7c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfa555861b884871b2953ab02fd8033e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie04e073effab4668baaebc0c91e50e9e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c1e9306ccee49fab2b6d9c8a64eaa45_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">opk:ProductRegistrationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56e6470febfe488b82cf6de3a567026d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">opk:ProductRegistrationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i614f229d8ed7468cb77cc7cbb19df994_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e7d2ec22c3f471facc97d6879e5b1be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cd76bb4cb054c24a6c2232c8ce7f462_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67eb7ca1a153436b9c63f40b1643cbb5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4f4333f6b854395908e42b29b11c12c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0e396b6f94a488d87020d832f3a71dd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie350ba9cd5734e9ca2f654f54c4f32e6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie02675a24f9347258a91c2e8689dac1f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c94852de80d4e20b88966f2a5803300_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">opk:CovenantsNotToCompeteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51146bd0393e4abea9ad351cc048bb8b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f99fa3607f14b209d98541827fcf560_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fcfed0a51964bf2bb060f3eac1da896_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22564da49818430d93721eda04c22d10_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eec319fe4fc4382817c6990539e0de1_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:CURNAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4fc148ac1604fe99eb055c71362744f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:CURNAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199321e556e1463989019c01f39f4666_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:CURNAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a7de7c9d3994710a52433ef3622e975_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:CURNAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dc68b2fcd3343aca45a1f78bea968ab_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29b82614912a4396b69e605161eac8c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa9e641d3a3f43bba301ff2922df3bc7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d8091552aab4b19b8c4d08ef13537d5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd18b46a79c64b6d83b27c4f2d210742_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:FineTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf902a5a04b14f7babb55f3b843e3a80_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:FineTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i114289ac9f494783bd9d11890dec12dc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:FineTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff62ea5a28684fc8a6b1dc70be867c32_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:FineTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i061dafbf8ba241378db298ff55bea551_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30ac8d0d0c694b82a5397dcb0df95a8e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8b2c36299ad4032aad14bf2b2486edf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd5e493ead0e4e5e9162c5c722db4e35_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5febec8e3a34d12aeeeb1e3f39919ca_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoChileMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9587f6a4f274caaba6009524613917d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoChileMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id78bb5a3b0424167a9c9b348ea5cf5cc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoChileMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i926fe15bf7e14648af39eaf884ccac95_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoChileMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eaedf3c190742929a4c020e7afc76b8_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9565f1ff76984a2d87c2caae18caa32a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied7c009dbf6647c2a36b57156c5ce4de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22ef152d20d46f5b505759af9ebb7f8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if107abf0de7a41faa040731b1223de77_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOMexicoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec024cce2a2496984ae03706c8870ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOMexicoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefd76cc953044df3aa7d05cbb5e5cf00_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOMexicoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i076891eda5724f9e8facc0d32cf101a3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOMexicoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf39b19d11f0451580b5298ca4e70ed2_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:TransitionTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a89597a3caa42bab28aa9233a6692fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:TransitionTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1a2689178204969b6be3b7c80a94903_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:TransitionTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id469bfa162ed497c8fd73817abe740dc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:TransitionTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87bdb1d33c654930a1c1073348ae533c_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaf793477c8f470eaeaeaee2fe7d1534_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9c0e49d0f844798a8cde4028560528e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0be93569346549e6b40179e6f26f198c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f702a5c58d541e398fbf371ddd14f4d_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoDiagnosticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55f7b3a49175491f81bd49d3873d7ef6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoDiagnosticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56ce2a0713064856b4736ba58073e798_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoDiagnosticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e77dbdc6364495093a3daccd4d4c89e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoDiagnosticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e74f63daa08493f8fddebb9af0d512f_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2da87d4b1cea40abb7f65c8419989f04_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:PharmsynthezMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief9f3d5f2c21400fbcb87f69615b8cf1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:CocrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a5eea0a1fa844b19b8baa7361a45542_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NonInvasiveMonitoringSystemsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e737b98458d4a859ab982878352b552_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c6fa53ff434aeea2559a0e6fca1f8f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:InCellDxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefc49f12f9a24f6a8438f9164321e4b9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:BioCardiaInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide7dce2757b14a7e80beaf9e7f36bc70_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:XeneticBiosciencesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e85d9626c1c441cb3ee913546454e58_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:LeaderMedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i345405f3f02b45a1bf5c9b950dde0383_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8ff88bb39754838bea82d4aa6fe8b0d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3269e9e5de645f7ab9c3fa24f73c940_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c994275c6324f47a249b3109e183353_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i735a6dd4044144048e04b19307ebbe2d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:PhioPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93c10577f5fe4cf5aa85dbf6a728072b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:VBIVaccinesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb8abbb296ab4fd6bec8792f90ed897c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ChromaDexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i745a5d9c8eda4157b142bcd4ae5184df_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:EloxxPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9dabca72cbc43ae823846a3ceb570c6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:CAMP4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74ad64c47d06402791389d97af41b417_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:HealthSnapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i045c2a8d58864ccc84d9e26f6de225bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:BioCardiaInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1b622c3fa27402b9211c7b4ccf25f7f_D20210914-20210914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:LeaderMedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">opk:LeaderMedJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-14</xbrli:startDate><xbrli:endDate>2021-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36d25b2cfa03459783a6e94281295ca5_I20210914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:LeaderMedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">opk:LeaderMedJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8156096c5d249378540b9fe04c480dc_D20210914-20210914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:LeaderMedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">opk:LeaderMedJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-14</xbrli:startDate><xbrli:endDate>2021-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibadd78e70def4793bd8033df5fdbe911_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:DetectGenomixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a78517025804d929c0e5e426c1b9a4b_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:DetectGenomixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i025ab7646b8144b688675d0f4247839f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bba573814e746888e84c5b2aa904dc8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iced2ab36569e4ad68d856b5c48df2e03_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e46f99237c8496ca82c13bda9e7f294_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc38b647115245d9a1d1122f23f15088_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46d6876e7be847069467c27ec77a4a44_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:A5ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i487322626c254451bb84eeb5072abbac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:A5ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fba9c7092e04a5ba143a73b73dada89_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4a642fa3cc44c77b27622488a3dcf17_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a2bb52ee16c4f3cbd50cd8ebe53b377_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia66232faa6934fc58bd350c3c5087464_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea90eb5c3a649d1a00ba71dfd8d4665_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14a4df5ee1294c10a8f972615bb565fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1511200111f48499ddfcbcdc01ff960_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:ConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70922a4b40e947b7a60140a1158f9de6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:ConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0fe0dcaa05548b79dc808f805d895bf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:LineOfCreditAndNotesAndLoansPayableCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i314f83bf93da4b8a953b12a86b015762_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:LineOfCreditAndNotesAndLoansPayableCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c5f0e2847a64769ab9be88846f125c4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae497a6420cd4f4faf38ce9662826b4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77752216e0a74e5e94c99ae54b2ab33f_I20200225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ba35bd01ebf48fc928c6575df35dcf4_D20200225-20200225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-25</xbrli:startDate><xbrli:endDate>2020-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1b9e43d842649f78bdeeb877a771557_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2696a40617340cf8c06f43678aedbcc_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d3e367b0c444609b24109041edeb01b_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40061516e65d48a1b5e3f3064a40b794_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>opk:day</xbrli:measure></xbrli:unit><xbrli:context id="i9df45c289aa6458e8a7b184c9d9eb1f5_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f67d9074c764297ade8fcccc8dc5b7a_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93cfe6ee9aef4ae3bb7d5b05ab545903_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f1f20509fa846cf8da8cbaef989bbe8_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0582da3183f40ca88c4cb1db58d7e0c_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4609448adb58436ab818127efb5758c2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c2ad3f0dc804c1d9adea93dace26206_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia70bad4845e84935a8ef37f70822b5d7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i227355c0a3f841b09e53338c115c186d_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id91a4eb6cea742e4b1b93c700e56993f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e68b8b37fc848168cc743f1b5049318_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b205efadb964c1cb4dff4ca72b078bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacfe2e319d1e4f1cad4106efad251be5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i994823b7aa8d4a3aab131ffa60b3a73f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4045f45f8fc4c08bec50e050b1907c7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a7f42702b824de08c6bd810d766790d_I20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:A5ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ff2cf21d2ee42b7ba76f7ede2a71895_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:A5ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f373341aeaa45d6ab5311cefa00161e_I20130130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36deaadef6af48b695564914f629b5db_D20130130-20130130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-30</xbrli:startDate><xbrli:endDate>2013-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3247cd104cc0482786e56f99c0599cc1_D20130101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaf8381567b542449202a80cc3f77a99_D20130101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c98930de814fef80fda4f22e14c6c6_I20190201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1da72e5734474e44a7f6fca5196486fb_D20130101-20130131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b4eb504ab9242d79f116b3ef21235d5_I20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60f953c97dd24968839eeaafb2ffad17_I20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fdc1aa37b674237997e3b022f56dbf1_I20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce132bbea2745af8c284fc6419ab2af_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c287aafd1a44262b8db089d441d0bb1_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbeb409c21e94c8a9efee99f6cb87652_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">opk:LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16716fcbd59e454387ebc09f7b61c881_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">opk:LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63c4e5c98e7243cfaba30273d9ca0a87_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="opk:LineOfCreditFacilityRevolvingCommitmentAxis">opk:LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i525c6ba5bfb44a68bf4601181c4282fa_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="opk:LineOfCreditFacilityRevolvingCommitmentAxis">opk:LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9be636d2eb7646a68e48135793798985_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="institution"><xbrli:measure>opk:institution</xbrli:measure></xbrli:unit><xbrli:context id="ib898228cd3484e429a53c453f0951cbe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:JPMorganChaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie92eade637fa4c5b9fdf19e5892fcb78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:JPMorganChaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6da40689dc7f4a57940604c58ea95ca9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ItauBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b77ee2f3fcc47b49cb358c6cb4a05b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ItauBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc72bc81c8cf4007b02a8ed9c7371fab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BankOfChileMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42c606619dd84425ac6654cc299669d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BankOfChileMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff25469e62df48448ca837a11e16442a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BiceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic54dc237b91f42858c86967daeeda551_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BiceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db2a74d8f95441691817b18709c0fcb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ScotiabankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaabb83a0b7e84cc69c57763fdb275a6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ScotiabankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2be89554ae224d2faa3b30914675e795_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4836259242c4bb19d20c064b534eab1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e0c19da9e644a0394218df762658838_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9cd8644076f4859be4a248297d5c636_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib013afdad6c7474cb6b2dcd9f1b5930b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:EstadoBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0e78a0e78664a1dab1c8a3083fe0278_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:EstadoBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0241e35fea8242e191eb554ad8160555_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BCIBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb458c405a9e4aa4840e82ae7757acf6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BCIBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd2141f359c14b2c98459ad1cfb7f950_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:Corpbanca1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f90114729e40eb8be4a760cfaff843_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:Corpbanca1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6754e9ff1da42ec9e1a4cc77eec4acd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:InternationalBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9c38a5f8c564a40be8991b68c4b3ffc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:InternationalBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcca8a13d6eb4da998ed98c0c425049d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ConsoorcioBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec848e00bda4f5681fac4c00ce92faa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ConsoorcioBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d54584ff4454273875eb07cb16d7afd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BancoDeSabadellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f26530ceb664987a7569db40b3af4e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BancoDeSabadellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f72279f02e748babf4db23480b635fb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBank2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5d45b4e640d41ceb4caa171b741efa1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBank2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if35733f1b3cb4b5e8d6885a8d8e2c00b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">opk:NotesPayableAndOtherLongTermLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb18ba3550a7419cac96f92422977cff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">opk:NotesPayableAndOtherLongTermLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1aa77c7b6eb749fe884b2a879d8b362c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i073357239cf9481992cd2d0593039c41_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idace7175aff140538ca299c503a1f3fe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i590b5239584e49aabed9114cc2b084f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a645b4fb40d4c90b63cf8887a6813ce_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4a22c80a9934fab9c03ed0fda0558a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f44824dbb444200a5bdcdb490ef2b6c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id414151061b84ff297849734c822f37f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i422ca1837f244677badf0cc87f681909_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e71299ca85d400ca49f6ca9cedc36ee_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1f2bf6624724fa3aecc40088836c8be_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idff81e7e63834f27b0191f9f89a1a47c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf4f3576ecda4c91b9dd4d47459c40de_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91f678126fc847348f1523f27f8297d9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bec48bd714c48508a9e6c19e44bf474_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i672ca210ee9a4a0bba0dfc16dae64dcd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcb3f1c307104b52a50b42c818e7727d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33c3fc92127145a39d48943be5758504_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f7f39684e77498888d13da9df62d5b9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b6b0142454d4f3c928a9719fc52a6aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ece04f6d15a44e8b8535afca85eea3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6167a5561ea048c0992072722768dc50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id20bcd0b3e1c441a9da0bd8ff7b7c148_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id821c49b028b4f61851f46ac73519641_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50def469aee442b7a18f3ee936adf68d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0175b050f64543bdbaed71566aab0b0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66b1ce0a8e104dd48bd6e56c4cca780b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f5b8f39523b4a5683ccaea181d847f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85019ba01b1f439c855e8144c410bd64_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedb36d1e48e34543b075c30a1123563a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6f84a8a9e11457c9fe326e89f4deef6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i940d0629800f44c09521f8583790b804_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if17f3344f32f4bd18794617bc4d70c76_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eeb8b6fb39840dc8dd12bd08e9bde47_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i170972a9d6e34cec89fae7f37a41e059_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a68d34ffea6486da4d468c553cccb2f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">opk:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie89c145a5bdf45b8b2c4856b5dd6d167_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">opk:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19db139199c944d1a3ba5a1234a8c6cb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">opk:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic33ae5da06dc4f819b6dcd183aecaebe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dd929a7397e49f0ab13af7ad0be9d63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b034a9ad25047b59a622208212d95e1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i339ef703a5544c01b8dbb210e3619b01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c9e493caa0e47609d6a6dc891471ba6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie52baf79fca2489f9435b6f9e9014cda_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied8a1708f69d41239c1f9de8d8facd76_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e8e55382c6349dba42db7b0d47c339c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i320a0c5cf0c54c369df4652d6c4aaee3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf311fd02fe0429098a14a89aaff1a31_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9043229605240dc9166035e1b850972_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5916426f99024163a0c1c7044beb1897_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50674a6b6023457196ed8f17e7e4cf51_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:DetectGenomixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:MednaxServicesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ecfd405f7e848e8a4e0bde064b5beaf_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:DetectGenomixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:MednaxServicesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee2076cde68b4576afe09b95b5942af6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">opk:SharesReceivedUponClosingofXeneticTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ae393d9880f48be85feb8757df68b73_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief99b9b8fe8e4816986a723ffacc2c18_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ChromadexCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba2fbb366c7942ee8c1f1d0688aeacd7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NIMSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica59f07c68a7496dadf29dc004ea21da_I20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:DrFrostandMrPfennigerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:MuseumofScienceIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib24c230ab8774444a8491338133155c0_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:DrFrostandMrPfennigerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:MuseumofScienceIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86ce37219a974882a0746dff7fc5dd55_I20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:FrostRealEstateHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i02020232c72342119d53b27eaa44b338_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:CivilInvestigativeDemandsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i522709e2d34e47b9b839338702492788_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:CivilInvestigativeDemandsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc90d86f2b4c4d5a8429f7ad7154f525_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:CivilInvestigativeDemandsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70de44f4e3b347cfb81ce995f5cf73fe_I20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:ChanceryCourtOfDelawareVsCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i676c769373684cfba8382f5367b6370f_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:ChanceryCourtOfDelawareVsCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ef8f6dc8b5e486b8e9f8f96b1343e13_D20200922-20200922"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:SouthernDistrictOfNewYorkVsBioReferenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-22</xbrli:startDate><xbrli:endDate>2020-09-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b576227129140fcb81ae5986936e0a5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:HealthInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c5cff8bc69f43c19ce205c66e3547e9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:HealthInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i874e9141286747c28f30293d988fb218_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:GovernmentPayersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e8101af777f47df9da8ece465836a9c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:GovernmentPayersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d41bb470d9447f9a98b8d23e1a42b68_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:ClientPayersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7186cb07c47349b0b7397d1c5851b571_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:ClientPayersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c5acb3b505f4483bf34a77f2c5e788e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99d9faa02d9d40f389d88742df8865d3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e7950d75f0444d93f095f4040135b3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief2e45330b2c4c668f762e3119a6fbae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea7a07d482240c5a1a9daa77497e119_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7745e7dd9842490f8a4d3aa14b8bb285_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic32fd42c04ee410bade14b9fa49da67d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49b8dfcf4b0a47ceb082dba3ba22e4e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a4781da5440461fa4b0023e40c75529_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e9ad9bd7fa74daeae00d3f5d5742096_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2dedc717e1341d5886ca72f83560353_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4abfbe41a46e407a91e30f4caa372833_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15c57ea2417945928b8420c5f3724908_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia48d7bc49b584c93b505e1441ca49b05_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5e653d3db9e490db849e824a8a8a9a5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeecfb112c664416a33c945ad8da2700_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56348d7a5e4f475181fad615300d4502_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2139d12433584f65aa24b38284d118c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie128a7c076a046209f0782cf5784b0a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d0eefa269f14f9f977234ed680b56f9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id28b381bb36e4f06a4682b864bdd7356_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c111d78df63437e89c6efa75cc8851b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i111f3c1bfdd14e20811f5bc40a649d17_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b398c50b3cd40b5b0170eef129c73b1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86896d2c37ea4f34aec16a43eaaedc8a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i966cf82bdb2540cbba62a1e436cfbd92_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba783e62870149cda0cee98d8bc74cf5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6880e4f214144d89a4f0b87a7b1c3f55_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd88e0b9dc2432ca9c87a42295d0f14_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:ViforFreseniusMedicalCarePharmaLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31eed14eff354f918546bd944177b06f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:LeaderMedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">opk:LeaderMedJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6c87132b4964cd485ec8ec605a41b8b_D20210706-20210706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:CAMP4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-06</xbrli:startDate><xbrli:endDate>2021-07-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5d22ca705ba48a9b83984b98bb175db_D20210706-20210706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:CAMP4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-06</xbrli:startDate><xbrli:endDate>2021-07-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0c873c67ff541cd805db5011768482b_D20210706-20210706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:CAMP4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:DravetSyndromeProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-06</xbrli:startDate><xbrli:endDate>2021-07-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2421576a6eb245f5963c8fd546b2202d_D20210706-20210706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:CAMP4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:NonDravetSyndromeProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-06</xbrli:startDate><xbrli:endDate>2021-07-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10db571f9a22486186e3b342bd39d781_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:NicoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic69f79db9b644be990ff9dd9110a1bc1_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="opk:MilestoneAxis">opk:PhaseThreeInitiationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:NicoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c7fb2b0fdc148b3a2a1cbb14048e04b_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:NicoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="opk:MilestoneAxis">opk:RegulatoryAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9744194c20ba46758d55f0a601deef68_D20200505-20200505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-05</xbrli:startDate><xbrli:endDate>2020-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cd5fcc524ba4f4da070564f37ec0b94_D20200505-20200505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-05</xbrli:startDate><xbrli:endDate>2020-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b365c1cad364899b9b410fc05c6ee03_D20200505-20200505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:SalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-05</xbrli:startDate><xbrli:endDate>2020-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i004085a346bb457f8e5d14f98a53a911_D20160501-20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:ExclusiveOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:ViforFreseniusMedicalCarePharmaLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-01</xbrli:startDate><xbrli:endDate>2016-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i439818f5135849e981ffb5c0b3e4a5fa_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1ab3dcfa70a42a4af7efe061a160e4c_D20191021-20191021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-21</xbrli:startDate><xbrli:endDate>2019-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdde5003bfd44ea6b9fbccdf4b85628d_D20150101-20150131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4213e7e67f624f758de6da611795d601_D20150101-20150131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b406679fa14d95928f83c7db184e47_D20150101-20150131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec21a25c43404529ae8e1b869bd25df4_D20150101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248c2f7f347a4e28bf2c05816ec8ead1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e591c4c9d6a40d7ba41cbe1d1512d6b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdbda16c863b431ba3f7cf99e015a97d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib33dc7d9f44c424a9584b48898909842_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3c4e79123684c96996efacf35e4cf15_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ec2e176eb00448f977e91fc55c4ac65_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44f799de78174d999399f2edd81a8ded_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12f23d1e4f7149df81a204a4274bb85f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39c1bc4e90f445ff86ac8569a2ddbc9d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i209dc12bb8ce4a749fed4f87ebc36e68_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a55931e091d4a3c887296abefde8504_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i082e04104d194b92a685d699a64a0014_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idffcd8ebe9be487185a9b4b68675f7fe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id657dc78714d4c38b4795e9de8978786_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8558bb5f637404994c8de52c35676cd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i393ae4fb48ac46c791cf4386477ae160_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7b01ac51664446b81224ec66b765954_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70da593d5a914041bc7e0c120158a9af_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5fcb23d84e40e0bd666630c86cc3ae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53640b46e2fd4c808aaed4db666adb92_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e92aea3d2094ffebb2b18c6d66c89c7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i003285ed88bd4bfea42439162c0e7038_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifda4aeb385b4420c98ee831dcb7e2e3e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfbd64ac384549c288a217c1e278ff5a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb337610dc2a44669c089130ab28f864_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd847808c4214f4fa04fde3ad6d1af41_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i343e534f8fb94404bbef65e665f2bd82_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia423aa5eee2b482c9db466bda75c3161_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51de4ac755574afeb66162a7f5862660_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d7aa53c3c054c22ac7e21fed6039914_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2814670edf7c4a62a9c261600d7c6daa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia46e96d43b2549a8a62460a4e0218f58_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieac6faccf2c2445a906e11ebfd78a899_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644924ad6fec4277940108274a5fb5cf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaae85104e75449f082ec0bb4c1170ebc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id089ec5023d147288f24951b1c9d421c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379322a119a345fc8841df842ee7ad3e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie15b0e5103c443a0a508317a579c958d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">opk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3beab81522d0420c95c34143d9e9a514_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">opk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib27f714c1aa84e6a935be26300cfaa00_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8886b20cd82e4c7e8073ac81cd611ee9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i437311d9507444baa08d2ca5476a8beb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87097699235d4d2fb348f69eb54508e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05c6a762af174fe8b29069a742a32bb3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib66ac7571d2d48f48825d3fd8073639a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f3663059edd4d60a02442357262179d_D20220509-20220509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000944809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:AgreementAndPlanOfMergerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-09</xbrli:startDate><xbrli:endDate>2022-05-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1cac816ff800494ea2979c434f00b37c_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:150.00pt"><tr><td style="width:1.0pt"></td><td style="width:148.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xODY2_75146f51-e45e-4d6c-982b-58c1bee82d61">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:150.00pt"><tr><td style="width:1.0pt"></td><td style="width:148.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6MzIzYmVhM2QyOWVkNDQ1NThlYWU3MDc4NmY1ZTZkNGYvdGFibGVyYW5nZTozMjNiZWEzZDI5ZWQ0NDU1OGVhZTcwNzg2ZjVlNmQ0Zl8wLTAtMS0xLTM1MzMw_fcbc73c8-795b-466c-be27-42b486983a16">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xMzQ_34fc0e1e-908d-4876-ba04-5c913b111f09">March 31, 2022</ix:nonNumeric>.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6MDQ4YWNlYzEyYWU2NGQzNmFlOTIwNzRmYzExYWYzMDMvdGFibGVyYW5nZTowNDhhY2VjMTJhZTY0ZDM2YWU5MjA3NGZjMTFhZjMwM18wLTAtMS0xLTM1MzMw_5cccf5fb-c6ac-47b0-a99f-a5f0ab7df0a9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xODY3_e210bf1f-f84d-44d8-bc68-ab2fd26ab353">001-33528</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:150.00pt"><tr><td style="width:1.0pt"></td><td style="width:148.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xODY4_3ffe151d-6676-4ddb-a448-d633b183c6e4">OPKO Health, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:150.00pt"><tr><td style="width:1.0pt"></td><td style="width:148.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:238.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:28.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:238.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6NThiYzVjZjhjMjJmNDczYWI5YzlkNWVjZThlMGNjZDkvdGFibGVyYW5nZTo1OGJjNWNmOGMyMmY0NzNhYjljOWQ1ZWNlOGUwY2NkOV8wLTAtMS0xLTM1MzMw_230f1534-b2fb-47ee-bbdb-42d981f9b5d9">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6NThiYzVjZjhjMjJmNDczYWI5YzlkNWVjZThlMGNjZDkvdGFibGVyYW5nZTo1OGJjNWNmOGMyMmY0NzNhYjljOWQ1ZWNlOGUwY2NkOV8wLTItMS0xLTM1MzMw_86ed2836-1ee1-4b34-ac4a-1032c0c13cce">75-2402409</ix:nonNumeric></span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:228.75pt"><tr><td style="width:1.0pt"></td><td style="width:100.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:100.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YzQ2NGE3MzIwMWNlNDA2NGExYmFlZTM3YTM0YzhkNjYvdGFibGVyYW5nZTpjNDY0YTczMjAxY2U0MDY0YTFiYWVlMzdhMzRjOGQ2Nl8wLTAtMS0xLTM1MzMw_3da85fd4-1a83-4bae-9b7d-1c3641c74bb6">4400 Biscayne Blvd.</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YzQ2NGE3MzIwMWNlNDA2NGExYmFlZTM3YTM0YzhkNjYvdGFibGVyYW5nZTpjNDY0YTczMjAxY2U0MDY0YTFiYWVlMzdhMzRjOGQ2Nl8xLTAtMS0xLTM1MzMw_5b4514e9-ec4a-49d4-8a0a-13f7fccf7ab3">Miami</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YzQ2NGE3MzIwMWNlNDA2NGExYmFlZTM3YTM0YzhkNjYvdGFibGVyYW5nZTpjNDY0YTczMjAxY2U0MDY0YTFiYWVlMzdhMzRjOGQ2Nl8xLTEtMS0xLTM1MzMw_2a56636c-0036-465b-8514-09850aa7445c">FL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YzQ2NGE3MzIwMWNlNDA2NGExYmFlZTM3YTM0YzhkNjYvdGFibGVyYW5nZTpjNDY0YTczMjAxY2U0MDY0YTFiYWVlMzdhMzRjOGQ2Nl8xLTItMS0xLTM1MzMw_b5190482-a8db-434a-bf5e-f9d3db19ea10">33137</ix:nonNumeric></span></td></tr><tr style="height:23pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices) (Zip Code)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YzQ2NGE3MzIwMWNlNDA2NGExYmFlZTM3YTM0YzhkNjYvdGFibGVyYW5nZTpjNDY0YTczMjAxY2U0MDY0YTFiYWVlMzdhMzRjOGQ2Nl80LTAtMS0xLTM1MzMw_8f58d8fc-04be-47aa-a308-243deb3c46c0">(305)</ix:nonNumeric>&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YzQ2NGE3MzIwMWNlNDA2NGExYmFlZTM3YTM0YzhkNjYvdGFibGVyYW5nZTpjNDY0YTczMjAxY2U0MDY0YTFiYWVlMzdhMzRjOGQ2Nl80LTEtMS0xLTM1MzMw_961bc631-1fad-4f68-ac3f-9371f38287e6">575-4100</ix:nonNumeric></span></td></tr><tr style="height:23pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YWQ2OWMzNDYyNTg0NDM3Yzk5MTlhNDEyNDIzZWNjN2UvdGFibGVyYW5nZTphZDY5YzM0NjI1ODQ0MzdjOTkxOWE0MTI0MjNlY2M3ZV8xLTAtMS0xLTM1MzMw_f4032598-7033-4d6c-b793-e39ef1ed3d4c">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YWQ2OWMzNDYyNTg0NDM3Yzk5MTlhNDEyNDIzZWNjN2UvdGFibGVyYW5nZTphZDY5YzM0NjI1ODQ0MzdjOTkxOWE0MTI0MjNlY2M3ZV8xLTEtMS0xLTM1MzMw_77e87e69-602f-4d2f-9010-dd0117e4c6c9">OPK</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YWQ2OWMzNDYyNTg0NDM3Yzk5MTlhNDEyNDIzZWNjN2UvdGFibGVyYW5nZTphZDY5YzM0NjI1ODQ0MzdjOTkxOWE0MTI0MjNlY2M3ZV8xLTItMS0xLTM1MzMw_ef223c6d-4ccf-40aa-8a9d-1e24aea1591d">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt;text-align:justify"><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xODY5_02fec727-55c2-4bbe-8d37-4db66497cc8d">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;NO</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xODcw_fd0eea8f-85ca-4b11-a49c-829303c45ba0">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;NO</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Rule&#160;12b-2 of the Exchange Act:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6ODhjMGJhYmZhZWYwNDIxYjgwMzRiN2Y0YTJhZTEzZjgvdGFibGVyYW5nZTo4OGMwYmFiZmFlZjA0MjFiODAzNGI3ZjRhMmFlMTNmOF8wLTAtMS0xLTM1MzMw_f01ec141-2870-4c4d-85a3-b62fa9b846a2">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168; </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6ODhjMGJhYmZhZWYwNDIxYjgwMzRiN2Y0YTJhZTEzZjgvdGFibGVyYW5nZTo4OGMwYmFiZmFlZjA0MjFiODAzNGI3ZjRhMmFlMTNmOF8xLTMtMS0xLTM1MzMw_cc5336ea-7541-43be-ab20-dc3de8b75c02">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6ODhjMGJhYmZhZWYwNDIxYjgwMzRiN2Y0YTJhZTEzZjgvdGFibGVyYW5nZTo4OGMwYmFiZmFlZjA0MjFiODAzNGI3ZjRhMmFlMTNmOF8yLTMtMS0xLTM1MzMw_16337620-87c9-4174-9244-cee4940b66df">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act):&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xODcx_a58f9f4d-8bd2-4ec5-93fe-3b56e733f058">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;YES&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;NO</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;25, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i2d11b917135448a38fea47851772958f_I20220425" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xODI5_1a9203e1-ab26-4d32-a242-0a2e80915c1f">681,525,181</ix:nonFraction> shares of Common Stock outstanding.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_13">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:63pt;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_16">Item&#160;1.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_16">Financial Statements</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_19">Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_19">7</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:47.25pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_25">Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_25">8</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:47.25pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_28">Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_28">9</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:47.25pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_31">Condensed Consolidated Statements of Equity for the three months ended March 31, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_31">10</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:47.25pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_34">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_34">11</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:47.25pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_37">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_37">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:63pt;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_97">Item&#160;2.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_97">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_97">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:63pt;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_115">Item&#160;3.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_115">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_115">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:63pt;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_118">Item&#160;4.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_118">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_118">56</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_121">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:63pt;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_124">Item&#160;1.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_124">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_124">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:63pt;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_127">Item&#160;1A.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_127">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_127">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:63pt;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_130">Item&#160;2.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_130">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_130">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:63pt;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_133">Item&#160;3.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_133">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_133">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:63pt;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_136">Item&#160;4.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_136">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_136">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_139">Item&#160;5.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_139">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_142">Item&#160;6.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_142">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_142">59</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_145">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_145">60</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements,&#8221; as that term is defined under the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;), Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).  Forward-looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or prospects, including the potential impact of the COVID-19 pandemic on our businesses, operating results, cash flows and/or financial condition.  You can identify forward-looking statements by the fact that these statements do not relate strictly to historical or current matters.  Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.  Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements.  Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements.  These factors include those described below and in &#8220;Item 1A-Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2021, and described from time to time in our other filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;).  We do not undertake any obligation to update forward-looking statements, except to the extent required by applicable law.  We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.  These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks and uncertainties, the occurrence of which could adversely affect our business, include the following:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our business may be materially adversely affected by the coronavirus (COVID-19) pandemic, including the impact from potential declines in testing needs as infection rates decline;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have had a history of losses and may not generate sustained positive cash flow sufficient to fund our operations and research and development programs; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need for, and ability to obtain, additional financing when needed on favorable terms, or at all;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse results in material litigation matters or governmental inquiries;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks inherent in developing, obtaining regulatory approvals for and commercializing new, commercially viable and competitive products and treatments; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research and development activities may not result in commercially viable products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">that we may fail to obtain regulatory approval for  Somatrogon (hGH-CTP) in the United States (&#8220;U.S.&#8221;) and other territories in which we have applied, or successfully commercialize hGH-CTP Somatrogon (hGH-CTP);</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">that we may not generate or sustain profits or cash flow from our laboratory operations or substantial revenue from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our other pharmaceutical and diagnostic products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and our distribution and marketing partners&#8217; ability to comply with regulatory requirements regarding the sales, marketing and manufacturing of our products and product candidates and the operation of our laboratories; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the performance of our third-party distribution partners, licensees and manufacturers over which we have limited control;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulation and policies in the U.S. and other countries, including increasing downward pressure on healthcare reimbursement;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage our growth and our expanded operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased competition, including price competition;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changing relationships with payors, including the various state and multi-state programs, suppliers and strategic partners; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efforts by third-party payors to reduce utilization and reimbursement for clinical testing services;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain reimbursement coverage for our products and services, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4Kscore</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> test; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to timely or accurately bill and collect for our services;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the information technology systems that we rely on may be subject to unauthorized tampering, cyberattack or other data security or privacy incidents that could impact our billing processes or disrupt our operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to obtain and retain new clients and business partners, or a reduction in tests ordered or specimens submitted by existing clients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to establish, and perform to, appropriate quality standards to assure that the highest level of quality is observed in the performance of our testing services;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain the security of patient-related information;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain intellectual property protection for our products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to defend our intellectual property rights with respect to our products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to operate our business without infringing the intellectual property rights of others; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key scientific and management personnel; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that the carrying value of certain assets may exceed the fair value of the assets causing us to impair goodwill or other intangible assets;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to obtain and maintain regulatory approval outside the U.S.; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legal, economic, political, regulatory, currency exchange, and other risks associated with international operations. </span></div><div style="margin-top:6pt;padding-left:54pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this Quarterly Report on Form 10-Q to the &#8220;Company&#8221;, &#8220;OPKO&#8221;, &#8220;we&#8221;, &#8220;our&#8221;, &#8220;ours&#8221;, and &#8220;us&#8221; refer to OPKO Health, Inc., a Delaware corporation, including our consolidated subsidiaries.</span></div><div id="i1cac816ff800494ea2979c434f00b37c_16"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 1. Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPKO Health, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMy0xLTEtMS0zNTMzMA_f21be620-593a-467c-b3f0-2cf3aa7b9de8">102,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMy0zLTEtMS0zNTMzMA_f2359377-174d-4fdb-9b76-9f187ffbc8b3">134,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNS0xLTEtMS0zNTMzMA_8be66249-eed3-4de5-94d5-98145ec3f937">212,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNS0zLTEtMS0zNTMzMA_54d56fde-eb1d-4261-9656-531493460ef7">259,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNi0xLTEtMS0zNTMzMA_0a718205-148b-417e-b352-8c9fae0fa9a6">99,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNi0zLTEtMS0zNTMzMA_b3bd4ad8-03d8-40b5-8712-ffe590fe3987">86,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNy0xLTEtMS0zNTMzMA_8bc30df9-4afa-4520-8a14-ae587a479293">23,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNy0zLTEtMS0zNTMzMA_29dfcede-0a9b-4eb8-881a-4f01c805f016">27,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfOC0xLTEtMS0zNTMzMA_9aeb5dab-ca32-410f-bedb-7f3f580125ff">316,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfOC0zLTEtMS0zNTMzMA_ba0c9d18-ccaf-4896-945c-525905363fe5">314,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfOS0xLTEtMS0zNTMzMA_9687977b-0f2c-4d81-b8b3-2d79c65950fc">754,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfOS0zLTEtMS0zNTMzMA_9747d123-b27d-4905-aae1-9ebbbbb901c7">823,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTAtMS0xLTEtMzUzMzA_ab2e6e0f-15d7-4e45-9a84-ce559f510e8d">81,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTAtMy0xLTEtMzUzMzA_7e5d20cb-6454-412d-b311-f1f2d3be2d76">79,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTEtMS0xLTEtMzUzMzA_2423f5bc-db3b-4b22-845f-8f82f5e6cb24">890,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTEtMy0xLTEtMzUzMzA_52f6f430-6192-47b2-b8b4-99f1550657a2">321,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="opk:InProcessResearchandDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTItMS0xLTEtMzUzMzA_12f8e391-25c7-4b3b-9420-b14522dff48e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="opk:InProcessResearchandDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTItMy0xLTEtMzUzMzA_38ee1064-1c99-43d9-824b-1dce29ebd685">590,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTMtMS0xLTEtMzUzMzA_3c00cd13-239d-4c77-9af9-01acfe527a7f">519,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTMtMy0xLTEtMzUzMzA_37eb9d92-ec99-47be-804b-4503e24b69ac">520,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTQtMS0xLTEtMzUzMzA_153bf782-c84a-4d4a-8ac0-53fe1dc7ceae">9,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTQtMy0xLTEtMzUzMzA_0b5e89f6-3da8-43cf-98df-8421bddcbe70">10,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTUtMS0xLTEtMzUzMzA_81659776-9a19-40c4-9ccb-91ccbfc9a927">42,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTUtMy0xLTEtMzUzMzA_d5713c88-02bb-498a-bbf8-d27fae2d9211">44,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTYtMS0xLTEtMzUzMzA_7bff3223-450c-45ad-83f9-d341d843d707">9,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTYtMy0xLTEtMzUzMzA_e3cd9b45-81d2-4c6a-99ed-55994b64ed87">9,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTctMS0xLTEtMzUzMzA_6aea720f-37c3-4f6f-94ed-0c7e7d92f72a">2,306,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTctMy0xLTEtMzUzMzA_e20f1e80-f79d-43d2-903c-49600e56a13d">2,399,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjAtMS0xLTEtMzUzMzA_ca537725-7c99-4d8f-ba08-adf36e00469d">94,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjAtMy0xLTEtMzUzMzA_f4308b23-deda-4d7a-877c-3fac6288df65">82,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjEtMS0xLTEtMzUzMzA_31521a56-9ac9-4625-bc30-b164d2987f21">157,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjEtMy0xLTEtMzUzMzA_58422f3c-9dfe-4051-a7ae-0e74c4e94f27">193,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjItMS0xLTEtMzUzMzA_50c04f68-4c60-4c37-ab31-fa1a51a13661">11,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjItMy0xLTEtMzUzMzA_fb9d5126-4d8e-4fd6-b50b-d36a8cac96b0">11,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities associated with assets held-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjMtMS0xLTEtMzUzMzA_bd85dd97-b232-4233-91f3-411dc6952413">28,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjMtMy0xLTEtMzUzMzA_83e5d292-ef5d-411f-b26f-90d00c4d1aff">28,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lines of credit and notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LinesOfCreditCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjQtMS0xLTEtMzUzMzA_f162f9c9-bbc5-476d-9f0d-59cb6be7ad4b">17,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:LinesOfCreditCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjQtMy0xLTEtMzUzMzA_d8cb0ad9-a39b-485f-95c3-4986a8ebc7c3">14,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjUtMS0xLTEtMzUzMzA_c1b1ebb7-8f55-4a2e-b1f4-6faae1ca104c">309,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjUtMy0xLTEtMzUzMzA_25683b40-e79d-4623-bd27-ed098c9e53a9">330,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjYtMS0xLTEtMzUzMzA_43954c33-2f8c-4808-a0bc-f63ed3c5fe65">31,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjYtMy0xLTEtMzUzMzA_de0e7ce1-0ce9-4acc-a760-e1f1a264f6e2">33,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjctMS0xLTEtMzUzMzA_c71ea73b-a1d3-4499-9228-6e6d6074916d">210,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjctMy0xLTEtMzUzMzA_e7b329fa-a81a-407d-82c3-d00c461d822e">187,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjgtMS0xLTEtMzUzMzA_081b196b-1dc5-4e97-bdd7-34ed4bcb6762">125,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjgtMy0xLTEtMzUzMzA_e92b2f9a-3ff5-4fdb-8284-562c632be7fb">148,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities, principally contract liabilities, contingent consideration and lines of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjktMS0xLTEtMzUzMzA_c60f58bd-47c4-4e19-86da-636dfe798fdd">15,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjktMy0xLTEtMzUzMzA_c5b79645-8211-4c2d-b366-20ac29cf1351">15,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzAtMS0xLTEtMzUzMzA_6ab1bde8-c6c1-4cfc-84ad-6233665e0a78">382,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzAtMy0xLTEtMzUzMzA_8be78217-a35a-4cde-8920-166707bd8e3d">384,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzEtMS0xLTEtMzUzMzA_50348783-fca9-41ce-8e97-3f94784f8f56">691,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzEtMy0xLTEtMzUzMzA_88d630b4-1b11-4e62-b4ba-b1969a1b579c">714,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjoyMzk0Mzk5ZDJlZWU0OGNkOTBmYzRiYjU1ZTk5MDQ1Ml8xOQ_3bcd4241-7eb4-4028-beb8-640eb0c9e747"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjoyMzk0Mzk5ZDJlZWU0OGNkOTBmYzRiYjU1ZTk5MDQ1Ml8xOQ_3e31a9c7-2cd7-4f9c-a78f-0a64e8661112">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjoyMzk0Mzk5ZDJlZWU0OGNkOTBmYzRiYjU1ZTk5MDQ1Ml8zMw_4d9a7693-00a5-4f4e-880e-4460f8640cbc"><ix:nonFraction unitRef="shares" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjoyMzk0Mzk5ZDJlZWU0OGNkOTBmYzRiYjU1ZTk5MDQ1Ml8zMw_84b904c9-8b09-4354-b7b8-cfadb7b53282">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjoyMzk0Mzk5ZDJlZWU0OGNkOTBmYzRiYjU1ZTk5MDQ1Ml81NQ_07e82c81-a720-4efc-9b61-54fc8bc844bc">690,138,033</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjoyMzk0Mzk5ZDJlZWU0OGNkOTBmYzRiYjU1ZTk5MDQ1Ml82Mg_2aaa09e1-ebed-43b4-a9c5-fe799bc6eadf">690,082,283</ix:nonFraction> shares issued at March 31, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMS0xLTEtMzUzMzA_58aa7e42-1468-4085-9ab5-1280d694af39">6,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMy0xLTEtMzUzMzA_e488a678-b745-4d4e-b613-08b7ab498eae">6,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury Stock - <ix:nonFraction unitRef="shares" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzgtMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjo4N2FiZDU2ZGY3MjA0ZmQ3OTM0OTkyZTMxOGVmOGZiNF8yMQ_93dcc49f-d83f-45a9-a45b-e8221c0b8771">8,655,082</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzgtMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjo4N2FiZDU2ZGY3MjA0ZmQ3OTM0OTkyZTMxOGVmOGZiNF8yOA_f6b4849d-6c74-4ca4-a382-ea8bb8e12741">8,655,082</ix:nonFraction> shares at March 31, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzgtMS0xLTEtMzUzMzA_dd95fe53-b24b-4c56-9bbc-8d95c3c82172">1,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzgtMy0xLTEtMzUzMzA_ade995da-cb24-4b1e-87fa-c7d82a62df3e">1,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzktMS0xLTEtMzUzMzA_3c579e14-f504-44d4-894e-d5d8532427ec">3,191,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzktMy0xLTEtMzUzMzA_2dfcc91c-08cd-43a5-90a7-7b60555b55f5">3,222,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDAtMS0xLTEtMzUzMzA_529c6e72-308a-45fc-a956-f6d2a4ef447c">31,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDAtMy0xLTEtMzUzMzA_83bef1f6-f9b9-49a9-8fdf-227f05fedf89">30,495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDEtMS0xLTEtMzUzMzA_de2f0d27-3cd8-4cb9-8cf1-27cb72e218a1">1,549,951</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDEtMy0xLTEtMzUzMzA_15d18622-ee98-4857-8292-c64a150d3974">1,511,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDQtMS0xLTEtMzUzMzA_fb22003e-6f8a-4d98-8d0f-90a387e530db">1,614,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDQtMy0xLTEtMzUzMzA_2a8ae8ad-6503-4036-b2fd-2cd4c824d1b4">1,685,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDUtMS0xLTEtMzUzMzA_28c99eb9-ca10-4871-9cd5-815636747a5d">2,306,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDUtMy0xLTEtMzUzMzA_89563672-ffda-46a4-b97f-338cb14dc380">2,399,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPKO Health, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March&#160;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f9c95a502354f4c9bd791e55a1b1acc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMy0xLTEtMS0zNTMzMA_f8a04afe-b689-4dbf-b3c2-43fcb8f39a66">286,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fd3f89e217e4e329bca14b9905edffa_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMy0zLTEtMS0zNTMzMA_372225d9-55ea-4ffa-aa1f-71937d6a7ea7">506,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85501a743668421b8f9b4903a091161f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNC0xLTEtMS0zNTMzMA_a470b2df-cba8-4c73-ad9c-7a7ee3f7d3a7">36,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a1bb9d88fbc42c0b66fe51d04025dd1_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNC0zLTEtMS0zNTMzMA_ffad1752-cbfe-4031-8e00-0258af6c40e4">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from transfer of intellectual property and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e961cfc73ca4fc995f9df88000a19c4_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNS0xLTEtMS0zNTMzMA_00249b19-ca00-43d3-a43d-0946fa7bfda2">5,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66109927d116428aafb21943a884db23_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNS0zLTEtMS0zNTMzMA_b26a5b3d-0430-47ea-aa2b-45b271c101a2">4,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNi0xLTEtMS0zNTMzMA_b3661dca-a357-44ac-9ec0-193f705ee850">329,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNi0zLTEtMS0zNTMzMA_debb286a-d31d-491a-b328-af687976acd6">545,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of service revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f9c95a502354f4c9bd791e55a1b1acc_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfOC0xLTEtMS0zNTMzMA_e57b8ea8-a6dd-4bbb-886e-a03aab66b05b">221,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fd3f89e217e4e329bca14b9905edffa_D20210101-20210331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfOC0zLTEtMS0zNTMzMA_7a1d9636-10c4-4ea2-89c8-85a9ff2641c4">339,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85501a743668421b8f9b4903a091161f_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfOS0xLTEtMS0zNTMzMA_511ba50c-b857-4a59-872c-c22b5c684b3a">22,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a1bb9d88fbc42c0b66fe51d04025dd1_D20210101-20210331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfOS0zLTEtMS0zNTMzMA_f7e18221-8d71-44de-b888-44617672a042">24,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTEtMS0xLTEtMzUzMzA_29de4488-ccfd-4121-bcc4-3cac71898855">117,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTEtMy0xLTEtMzUzMzA_881614df-4012-4a25-a0a6-0decee5c0be3">112,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTItMS0xLTEtMzUzMzA_9d1c1c82-fcf6-4123-a836-2846ad46abba">18,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTItMy0xLTEtMzUzMzA_c868840d-190c-4103-a009-b1689ea6cca9">19,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTQtMS0xLTEtMzUzMzA_fcddb405-e92e-4a00-aeaa-8758937f8083">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTQtMy0xLTEtMzUzMzA_ff5b29f0-9c7b-4461-b45c-abb710fc662a">957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTUtMS0xLTEtMzUzMzA_a601e3e5-59b6-4eda-9471-c72b611e502a">22,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTUtMy0xLTEtMzUzMzA_3909eddb-e8e6-411d-9b33-60cc2c9871ca">12,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTctMS0xLTEtMzUzMzA_72c42a07-fa3f-4982-ad4a-b8aa98e00e4d">401,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTctMy0xLTEtMzUzMzA_b95cf624-919c-4cd6-94e5-b09ea4b23283">506,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTgtMS0xLTEtMzUzMzA_47a89dfd-789c-4d1c-a103-cf7bbbb58785">72,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTgtMy0xLTEtMzUzMzA_3552a372-4aed-4934-acb4-033f61d23ca8">38,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income and (expense), net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="opk:InterestIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjAtMS0xLTEtMzUzMzA_f4758e2b-910d-4f05-96c5-d45fddc6bbfa">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="opk:InterestIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjAtMy0xLTEtMzUzMzA_d409292a-e232-44c6-be32-219122c47a57">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="opk:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjEtMS0xLTEtMzUzMzA_7f06f4e4-c1a5-48ca-81d7-0f3e1a3b5d66">2,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="opk:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjEtMy0xLTEtMzUzMzA_0be3eeaa-373e-4b32-a88e-e976ea7aa2e8">5,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value changes of derivative instruments, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjItMS0xLTEtMzUzMzA_096dbfa8-567e-4567-8e3e-cb2908d6188e">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjItMy0xLTEtMzUzMzA_d7fe104c-2128-474e-b666-91a384ae5c1c">439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjMtMS0xLTEtMzUzMzA_5af47c2c-da8e-4f72-a561-f8ee2280eb79">1,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjMtMy0xLTEtMzUzMzA_14c73d4b-3a26-46f3-97e2-6f9e7390081d">927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income and (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjQtMS0xLTEtMzUzMzA_1c18dc26-95da-4f28-89b6-ffe3fb46af96">4,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjQtMy0xLTEtMzUzMzA_2554828d-ff55-42cc-98c9-ee6e232c4b6b">6,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) before income taxes and investment losses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjUtMS0xLTEtMzUzMzA_24508596-bf1c-4e0d-89c5-6ffbe742a067">76,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjUtMy0xLTEtMzUzMzA_c43c4322-7bf7-4e07-90c6-2d097dde95b8">31,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit (provision)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjYtMS0xLTEtMzUzMzA_d2a14a09-fbd3-4223-a941-6738bccea430">21,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjYtMy0xLTEtMzUzMzA_cf735dc8-b8a5-427c-87fc-fc7306a907ce">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) before investment losses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="opk:IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjctMS0xLTEtMzUzMzA_abac7f00-cb27-4171-a8d0-63f8cc9d89be">55,384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="opk:IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjctMy0xLTEtMzUzMzA_2c685f56-3766-4d6a-928f-dfe4fd758b69">31,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from investments in investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjgtMS0xLTEtMzUzMzA_04b90bcb-b8b0-4500-aef5-1d0b895b3249">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjgtMy0xLTEtMzUzMzA_e118202f-5ea9-472b-bd04-4516ecf31d63">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjktMS0xLTEtMzUzMzA_07a060cb-e529-457f-9f3f-197c34701a9e">55,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjktMy0xLTEtMzUzMzA_5cf353fa-8fc5-412d-863b-25286cb646aa">31,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) per share, basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMzktMS0xLTEtMzUzMzA_3de76f2e-15cd-4625-be79-a540c9b328a3"><ix:nonFraction unitRef="usdPerShare" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMzktMS0xLTEtMzUzMzA_b8eaac05-9a5f-4f64-9175-4c976f8b4d7f">0.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMzktMy0xLTEtMzUzMzA_690a8eb1-9f14-4db1-87d0-b8b1bfde33fe"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMzktMy0xLTEtMzUzMzA_9749e45c-be52-4819-b307-cfbb8ed5459e">0.05</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNDEtMS0xLTEtMzUzMzA_5600001b-486f-40ba-94c1-1e7d72fb71b4"><ix:nonFraction unitRef="shares" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNDEtMS0xLTEtMzUzMzA_b824e8d8-29df-4783-83e3-fe9c697f92bf">660,302,426</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNDEtMy0xLTEtMzUzMzA_1e0e06c7-f731-40d4-8d84-aae1abb6614a"><ix:nonFraction unitRef="shares" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNDEtMy0xLTEtMzUzMzA_b1ba8089-c2cf-4f7e-a1d3-45ef73fd5a1b">640,853,200</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPKO Health, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March&#160;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yOC9mcmFnOjQxZmRjMGM3NjRhOTQyNDVhMDYzY2NhMjQ0MGU5Yzg4L3RhYmxlOjlmMGEwNTZlZGI2NTQ5ZGY4ZWZmYjk1ZTE5MTg4ZjMyL3RhYmxlcmFuZ2U6OWYwYTA1NmVkYjY1NDlkZjhlZmZiOTVlMTkxODhmMzJfMi0xLTEtMS0zNTMzMA_569d9a4d-a6f0-414e-b2f4-072d28a25b9e">55,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yOC9mcmFnOjQxZmRjMGM3NjRhOTQyNDVhMDYzY2NhMjQ0MGU5Yzg4L3RhYmxlOjlmMGEwNTZlZGI2NTQ5ZGY4ZWZmYjk1ZTE5MTg4ZjMyL3RhYmxlcmFuZ2U6OWYwYTA1NmVkYjY1NDlkZjhlZmZiOTVlMTkxODhmMzJfMi0zLTEtMS0zNTMzMA_7228f3a5-dd05-4a64-bf85-46b159ec61cb">31,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in foreign currency translation and other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yOC9mcmFnOjQxZmRjMGM3NjRhOTQyNDVhMDYzY2NhMjQ0MGU5Yzg4L3RhYmxlOjlmMGEwNTZlZGI2NTQ5ZGY4ZWZmYjk1ZTE5MTg4ZjMyL3RhYmxlcmFuZ2U6OWYwYTA1NmVkYjY1NDlkZjhlZmZiOTVlMTkxODhmMzJfNC0xLTEtMS0zNTMzMA_4dd504c9-7ecb-4137-94f4-5a11056d23a2">920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yOC9mcmFnOjQxZmRjMGM3NjRhOTQyNDVhMDYzY2NhMjQ0MGU5Yzg4L3RhYmxlOjlmMGEwNTZlZGI2NTQ5ZGY4ZWZmYjk1ZTE5MTg4ZjMyL3RhYmxlcmFuZ2U6OWYwYTA1NmVkYjY1NDlkZjhlZmZiOTVlMTkxODhmMzJfNC0zLTEtMS0zNTMzMA_01123ca9-8b4d-4761-9b6f-409d6864944c">9,070</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yOC9mcmFnOjQxZmRjMGM3NjRhOTQyNDVhMDYzY2NhMjQ0MGU5Yzg4L3RhYmxlOjlmMGEwNTZlZGI2NTQ5ZGY4ZWZmYjk1ZTE5MTg4ZjMyL3RhYmxlcmFuZ2U6OWYwYTA1NmVkYjY1NDlkZjhlZmZiOTVlMTkxODhmMzJfOS0xLTEtMS0zNTMzMA_a22fe0b4-65b4-4a29-bfe5-088137a9b2eb">56,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yOC9mcmFnOjQxZmRjMGM3NjRhOTQyNDVhMDYzY2NhMjQ0MGU5Yzg4L3RhYmxlOjlmMGEwNTZlZGI2NTQ5ZGY4ZWZmYjk1ZTE5MTg4ZjMyL3RhYmxlcmFuZ2U6OWYwYTA1NmVkYjY1NDlkZjhlZmZiOTVlMTkxODhmMzJfOS0zLTEtMS0zNTMzMA_5940d681-7257-43d9-b2b7-530f2c226366">22,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022 and 2021</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.567%"><tr><td style="width:1.0%"></td><td style="width:30.095%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.473%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3804ba279de40cdb6e0567ff03eedfd_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi01LTEtMS0zNTMzMA_53f03fb8-d0d5-45d0-b421-c752ff8556a9">690,082,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3804ba279de40cdb6e0567ff03eedfd_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi03LTEtMS0zNTMzMA_fb3283a4-e21a-40ae-842e-c9d9038bd8f9">6,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ied0a49adeefd4e1fac80ec50e4698621_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi05LTEtMS0zNTMzMA_f63aea21-d550-47b1-8ede-b8178b4ebfc3">8,655,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied0a49adeefd4e1fac80ec50e4698621_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi0xMS0xLTEtMzUzMzA_cb46a799-f828-4134-ad9c-6be459f7c50f">1,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf602f14f46471d9d178ec252d385a7_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi0xMy0xLTEtMzUzMzA_3a40d007-234d-4394-8251-81b7c5c11bca">3,222,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6d0ba7a733345be9b1fdc07bf34b423_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi0xNS0xLTEtMzUzMzA_97275988-08dd-4ab4-88f2-dac95dae6bca">30,495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22bb54bd14a34a3ab35f37edf368d2bc_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi0xNy0xLTEtMzUzMzA_7017e338-56e3-4f6d-b22f-2ce142f035a1">1,511,976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi0yMS0xLTEtMzUzMzA_88cf3be2-6161-4c91-923a-91a292e90d44">1,685,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a74fab4f84bf98ac3afc12ad3422e_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMy0xMy0xLTEtMzUzMzA_4af8e062-0859-4023-923d-387e7aaacef3">7,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMy0yMS0xLTEtMzUzMzA_27e17007-6d7e-4a53-bd5a-65a6d816b703">7,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of common stock options and warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ec1789e0468407da526985ac43b1656_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNC01LTEtMS0zNTMzMA_f3359923-fba4-4a1b-b432-09e6c00de6a9">55,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec1789e0468407da526985ac43b1656_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNC03LTEtMS0zNTMzMA_46257127-1165-45bb-ba9f-25c30566a9d8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a74fab4f84bf98ac3afc12ad3422e_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNC0xMy0xLTEtMzUzMzA_aba39d35-517b-4aa4-8f8c-7158d77a2db5">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNC0yMS0xLTEtMzUzMzA_d16de3a1-89fb-4687-9c92-7c7ba412f157">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNS0wLTEtMS0zNTMzMA_919511f1-ba2b-471c-9afb-64ee3d8de324">Adoption of ASU 2020-06</span></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6af8b25ddc04918b13d874863276327_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNS0xMy0xLTEtMzUzMzA_fe353639-7a24-4669-8f82-e2e47717b18d">39,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb2b0dab2c974aca988d625e077fe49b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNS0xNy0xLTEtMzUzMzA_ede1afa8-8cfe-403b-8d18-09eccd7d02db">17,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfe95975785f4da2a0792b40c68274b7_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNS0yMS0xLTEtMzUzMzA_0135d185-a5d5-4c46-97e5-e7406be19306">21,642</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2b1a62808234ad7b78fb28d31a7ee36_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNy0xNy0xLTEtMzUzMzA_0aeda4ca-8823-46ad-928e-d3f7ec810183">55,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNy0yMS0xLTEtMzUzMzA_a2f8c011-1aa0-4316-a2fc-27a95e05a3e2">55,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08134a4538f24e06bd29a6faf920f1bf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOC0xNS0xLTEtMzUzMzA_11e13fe6-09d3-4775-96dc-b63d207264d9">920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOC0yMS0xLTEtMzUzMzA_e5457284-5174-4a58-9c07-b1d9506674c4">920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idad4ab8f901e456a921f38433308a875_I20220331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS01LTEtMS0zNTMzMA_0bf79391-890b-43e1-9484-8d01309a48f2">690,138,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad4ab8f901e456a921f38433308a875_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS03LTEtMS0zNTMzMA_18117c13-3154-4280-bc33-28df6106da43">6,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i63a9708ca6b241cbbf8a971c348c1b9c_I20220331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS05LTEtMS0zNTMzMA_b786c731-8680-41d9-bbb3-7549afccc794">8,655,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63a9708ca6b241cbbf8a971c348c1b9c_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS0xMS0xLTEtMzUzMzA_f4e42ee7-42c7-46ca-a391-64acf353ca1f">1,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f76eb90058493b8b9714b06a32ca6a_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS0xMy0xLTEtMzUzMzA_c3d54c9a-8c68-430c-89af-b3c4f46cdc73">3,191,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86a2019e2f9a4c668d4bcb4561aaf856_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS0xNS0xLTEtMzUzMzA_7f4aeb33-39e9-4fd1-a43f-dd98d286938e">31,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5ac38aea5024455837e4b0a72c6cc5c_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS0xNy0xLTEtMzUzMzA_1f45ecce-95f5-4c7f-ac8c-c4efeb4d8f13">1,549,951</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS0yMS0xLTEtMzUzMzA_c88e4d4f-c9a3-45d4-b3d4-5fcda99e25df">1,614,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.567%"><tr><td style="width:1.0%"></td><td style="width:30.095%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.473%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive Income<br/>(loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e33b9f98a1b4d2196ed092e6e422c9c_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi01LTEtMS0zNTMzMA_e0dd765a-ea3d-48db-9199-ac08adaac069">670,585,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33b9f98a1b4d2196ed092e6e422c9c_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi03LTEtMS0zNTMzMA_3b952556-63cb-4c16-9734-1af22aaa6c93">6,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idf50959849a64f92b031a93fb028f210_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi05LTEtMS0zNTMzMA_5371623b-6a0b-4965-8701-84fe192e8232">549,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf50959849a64f92b031a93fb028f210_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi0xMS0xLTEtMzUzMzA_077a987c-7879-44a7-b68a-e4dbd9a4a014">1,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776417f572dd43b785ccc5de1a3fdd29_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi0xMy0xLTEtMzUzMzA_0550021f-29a3-4e6d-a0a2-68bd03bcb2ac">3,152,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c39548fd884077aba54bc5130c8aa6_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi0xNS0xLTEtMzUzMzA_24646164-a592-4888-8470-91d8ae8bc854">4,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dd9c60c32484868940a0edb35f5b606_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi0xNy0xLTEtMzUzMzA_5be237b3-c563-46fe-9407-818bc5ee7316">1,481,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08082c8210bd41e08e8e6102a684ff8b_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi0yMS0xLTEtMzUzMzA_4b6537a6-5783-49f7-b601-7597424fb735">1,671,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1a9671afbc747319965e4950c1d5673_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMy0xMy0xLTEtMzUzMzA_bc173071-598f-498f-991a-787260541585">2,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMy0yMS0xLTEtMzUzMzA_d3bdb71c-82f3-4a47-b56d-5417eaabeeaf">2,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of common stock options and warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c2c25cd759044e8a8b1ac83a456a490_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfNC01LTEtMS0zNTMzMA_1b17e296-40c3-45a3-bc64-d92d07b5b518">117,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c2c25cd759044e8a8b1ac83a456a490_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfNC03LTEtMS0zNTMzMA_2172d4e8-9a70-494d-a616-7f3a3b73a379">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1a9671afbc747319965e4950c1d5673_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfNC0xMy0xLTEtMzUzMzA_6c359d29-cc42-4bad-8288-9a3311d09b30">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfNC0yMS0xLTEtMzUzMzA_0038e5d0-ac11-47d5-8702-b2fd48fa4a18">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73d31bf5c2240cdb0ccd63c8a4348c1_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfNy0xNy0xLTEtMzUzMzA_846104ca-41a2-4525-a2b9-05d4d67541da">31,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfNy0yMS0xLTEtMzUzMzA_55c7b830-620c-49fb-b095-cafe5e227d46">31,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69f0a1d1a7fd49089a06dcef395b5c5b_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOC0xNS0xLTEtMzUzMzA_47e8f5df-0e58-46ff-a29f-57d493a460af">9,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOC0yMS0xLTEtMzUzMzA_bdceb34c-4240-4723-919b-893c761c2f9e">9,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc66eff602d7434281e15843b60d6d9a_I20210331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS01LTEtMS0zNTMzMA_e8686a37-00f8-4307-9ad7-b3c9f9d43773">670,703,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc66eff602d7434281e15843b60d6d9a_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS03LTEtMS0zNTMzMA_113e81e7-d384-4b03-9af9-b49511ebf4d4">6,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i91568ba4c6ad4c9bbb8a6d13b2cca42c_I20210331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS05LTEtMS0zNTMzMA_bdd7e993-eb63-482c-85f6-00280f704672">549,907</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91568ba4c6ad4c9bbb8a6d13b2cca42c_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS0xMS0xLTEtMzUzMzA_b9e5ed18-85ac-4656-b409-e4ab2b6ffadc">1,791</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d685f0119934d39a093d66dd07cd19f_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS0xMy0xLTEtMzUzMzA_9201a2e1-e6cf-4dfd-8e6a-6297a6598e68">3,155,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8f0316ac515435b82f539c2ec2dd817_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS0xNS0xLTEtMzUzMzA_b80761ad-94de-4c4d-bd93-d4dced17bf73">13,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e422f024ca6bb911a55e1259fcb_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS0xNy0xLTEtMzUzMzA_a6b3ca4f-940a-4f86-8f9d-f8904a98a476">1,450,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402dd9684c2f477db500daa02097978b_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS0yMS0xLTEtMzUzMzA_4fc0450c-6546-40e7-a1cb-ac603a85256a">1,696,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_34"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPKO Health, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMy0xLTEtMS0zNTMzMA_8badcd60-9a1d-4bf9-a93c-689f11fe25d5">55,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMy0zLTEtMS0zNTMzMA_b993d9e5-04f7-40dd-adb6-6de8acd3d664">31,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNi0xLTEtMS0zNTMzMA_bd5d0e63-ff74-40f3-b571-8b8c4e6345a8">27,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNi0zLTEtMS0zNTMzMA_872b9ad8-9820-43a3-84b9-137570863ba1">19,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNy0xLTEtMS0zNTMzMA_a9e4eca8-ffac-41b7-a4a4-13e02923ef77">678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNy0zLTEtMS0zNTMzMA_abd47f67-67cb-44d1-9a0d-3894392e4268">2,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfOC0xLTEtMS0zNTMzMA_80a1aac8-586e-4ebe-bc3f-8c29d15e800e">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfOC0zLTEtMS0zNTMzMA_3f7b0823-2676-40e0-bdac-99c2798042f8">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses from investments in investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTAtMS0xLTEtMzUzMzA_50fdb5e4-fcdb-42e7-af15-1409412fb8a3">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTAtMy0xLTEtMzUzMzA_50e0c144-924b-49e7-9e20-b4d2dfc12b3d">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation &#8211; employees and non-employees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTEtMS0xLTEtMzUzMzA_e8094011-9318-49a6-be68-ebb9980e2283">7,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTEtMy0xLTEtMzUzMzA_fbe74af1-853f-45dd-880c-22bdd93aeb77">2,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realized loss (gain) on disposal of fixed assets and sales of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTUtMS0xLTEtMzUzMzA_b0808da1-5bef-4f81-b273-eb35b7b42494">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTUtMy0xLTEtMzUzMzA_c06a2c1c-15b7-4c66-8ccb-0e488402158b">3,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity securities and derivative instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="opk:IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTgtMS0xLTEtMzUzMzA_10a28473-42e3-4680-b401-950210c02834">1,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="opk:IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTgtMy0xLTEtMzUzMzA_a20f319d-7595-4dd2-9a1e-f37b97d08118">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjAtMS0xLTEtMzUzMzA_7b40202c-4583-4a70-a683-c8afb2bc58d9">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjAtMy0xLTEtMzUzMzA_59782d3b-31d0-48f5-a39f-011712706212">957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjQtMS0xLTEtMzUzMzA_450a3386-736f-44a1-a3c1-9e17d9963ce1">22,356</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjQtMy0xLTEtMzUzMzA_0767bee0-30d8-4b27-bb50-eacc6e25e9cf">1,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjYtMS0xLTEtMzUzMzA_0b9f9491-f6ef-4dde-9afe-36e0e1760f96">44,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjYtMy0xLTEtMzUzMzA_45008fa7-90a1-4a11-ab1d-d807ad6a0e45">35,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjctMS0xLTEtMzUzMzA_19e6e616-e6b8-4806-894e-b8512acde105">9,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjctMy0xLTEtMzUzMzA_f71850c6-a43b-451e-a829-a95051b6888d">27,912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjgtMS0xLTEtMzUzMzA_92ef2329-4b9e-4d3a-bc4d-abcfb92f5f55">2,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjgtMy0xLTEtMzUzMzA_57fd001a-95bd-416b-9f72-bc91148b0b8f">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjktMS0xLTEtMzUzMzA_0859c111-c778-4bc4-875a-108f7608d7af">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjktMy0xLTEtMzUzMzA_688411d1-8312-48ce-b9ec-4dfbe0609a42">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzAtMS0xLTEtMzUzMzA_25a32327-af4b-4f82-b388-64c5e9f6a137">16,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzAtMy0xLTEtMzUzMzA_ca249f99-c141-446e-884c-c0ff260a1aeb">62,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency measurement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="opk:IncreaseDecreaseinForeignCurrencyMeasurement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzEtMS0xLTEtMzUzMzA_59361262-8b19-4d97-ab00-c55234e2e277">2,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="opk:IncreaseDecreaseinForeignCurrencyMeasurement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzEtMy0xLTEtMzUzMzA_05089e88-035f-4882-926d-b8a128a51108">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzItMS0xLTEtMzUzMzA_c69e5015-e7a9-448e-b9f1-9f6b115b70b2">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzItMy0xLTEtMzUzMzA_ffba4af4-8a6d-446a-b558-5a6d428ab773">790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzMtMS0xLTEtMzUzMzA_c437574b-2c63-4a17-9b64-07a087785130">36,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzMtMy0xLTEtMzUzMzA_ac5b4c07-b37d-4eb7-bd15-c4d4fa3241fa">27,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzYtMS0xLTEtMzUzMzA_090afc85-b373-4115-a709-c2192e0b9811">19,856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzYtMy0xLTEtMzUzMzA_52e56f11-519a-48be-956f-68306de637d0">26,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzktMS0xLTEtMzUzMzA_73f70656-3e98-497c-beb1-76d991590b3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzktMy0xLTEtMzUzMzA_5a5f1294-517b-4b39-94af-676f7e30bd79">8,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the sale of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNDMtMS0xLTEtMzUzMzA_5bcc9d15-b20b-44b9-9ab9-1819052ef1c4">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNDMtMy0xLTEtMzUzMzA_442cc5e7-589d-49f0-bdf0-f787773d88c0">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNDUtMS0xLTEtMzUzMzA_93549031-03b5-4664-b13f-12480a296b7f">5,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNDUtMy0xLTEtMzUzMzA_456f078f-c518-4631-9a07-3278fccf09e1">9,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNDYtMS0xLTEtMzUzMzA_dc99d5f1-ab5c-448c-92ef-bcd898befdcd">4,903</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNDYtMy0xLTEtMzUzMzA_b1d160c1-37e3-46dd-8699-dc1aad88ecf2">1,106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the exercise of common stock options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTEtMS0xLTEtMzUzMzA_8110f3d8-9f17-4384-bffb-1b7b3557bed3">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTEtMy0xLTEtMzUzMzA_0102bd28-26c0-47b1-a23b-03ca78760cda">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Borrowings on lines of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTQtMS0xLTEtMzUzMzA_6c8ee646-1a1d-4ee8-a575-4d4ee95a9f36">1,649,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTQtMy0xLTEtMzUzMzA_004e1952-5f19-401b-828a-47edfc79079a">472,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of lines of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTUtMS0xLTEtMzUzMzA_ec5c79f3-1651-45a8-967f-e7743c256f62">1,657,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTUtMy0xLTEtMzUzMzA_1c19ae39-2060-4ffa-ad43-d469c22dd59d">479,713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTktMS0xLTEtMzUzMzA_a3df4a92-0725-4aa3-9e11-da14096e181c">7,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTktMy0xLTEtMzUzMzA_629622e0-bfa3-4639-8208-ef20e7cf91cf">7,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjAtMS0xLTEtMzUzMzA_6760dfc3-b2d5-4b8e-a208-1847231d1371">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjAtMy0xLTEtMzUzMzA_5cf90384-702e-4d54-a30c-c1373beac330">447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjEtMS0xLTEtMzUzMzA_e7a8255b-fb0b-428e-91cf-50c86e0ba44b">32,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjEtMy0xLTEtMzUzMzA_ca06e956-f9f9-4174-ad85-07498ddd2938">17,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjItMS0xLTEtMzUzMzA_8f8a1817-a187-4c56-9270-8f80da4875a2">134,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08082c8210bd41e08e8e6102a684ff8b_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjItMy0xLTEtMzUzMzA_1e92d0cb-50e4-48fa-a653-066006a8c31f">72,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjMtMS0xLTEtMzUzMzA_8d107a28-215e-4046-b6db-1f5551dea90d">102,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402dd9684c2f477db500daa02097978b_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjMtMy0xLTEtMzUzMzA_8a3ff4ce-666c-42ae-9607-18a0e85a48a4">89,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SUPPLEMENTAL INFORMATION:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjUtMS0xLTEtMzUzMzA_debb568c-5c94-407d-8f30-de737a454092">3,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjUtMy0xLTEtMzUzMzA_af3acd9d-0454-4d1d-a79b-b4b003a3ce28">4,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes paid, net of refunds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjYtMS0xLTEtMzUzMzA_d6441740-c553-46ab-84b2-ce0646670ee7">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjYtMy0xLTEtMzUzMzA_46848741-5798-4107-adf9-aa3a8fc9f079">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPKO Health, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div id="i1cac816ff800494ea2979c434f00b37c_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzU3Nw_6fdd886f-d075-4608-a707-548badf9a653" continuedAt="i7bdcfaad983846758c8ef73b14edb2dd" escape="true">BUSINESS AND ORGANIZATION</ix:nonNumeric></span></div><ix:continuation id="i7bdcfaad983846758c8ef73b14edb2dd" continuedAt="i158b10b7e2044b72b6e88f4d7fbdac7e"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">medical markets. Our diagnostics business includes BioReference Health, LLC, formerly known as BioReference Laboratories, Inc. (&#8220;BioReference&#8221;), one of the nation&#8217;s largest full service laboratories with an almost <ix:nonFraction unitRef="employee" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-1" name="opk:NumberofSalesEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzY1_8a175340-0700-4fe2-b945-90b5225b3ef8">250</ix:nonFraction>-person sales and marketing team to drive growth and leverage new products. Our pharmaceutical business features </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved treatment for secondary hyperparathyroidism (&#8220;SHPT&#8221;) in adults with stage 3 or 4 chronic kidney disease (&#8220;CKD&#8221;) and vitamin D insufficiency and a pipeline of products in various stages of development. Our leading product in development is Somatrogon (hGH-CTP), a once-weekly human growth hormone for which we have partnered with Pfizer, Inc. (&#8220;Pfizer&#8221;) and successfully completed a phase 3 study in August 2019. Regulatory applications for Somatrogon (hGH-CTP) have been submitted to the applicable regulatory bodies for review in several countries around the world.  In February 2022, the European Commission granted marketing authorization in the European Union for Somatrogon (hGH-CTP) under the brand name NGENLA&#174; to treat children and adolescents from as young as three years of age with growth disturbance due to insufficient secretion of growth hormone, and we recently received pricing approval in Germany. In January 2022, the Ministry of Health, Labour and Welfare in Japan approved NGENLA&#174; (Somatrogon) for the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone and we recently received pricing approval. In October 2021, Health Canada approved NGENLA&#174; for the long-term treatment of pediatric patients who have growth hormone deficiency, and Australia&#8217;s Therapeutic Goods Administration approved NGENLA&#174; for the long-term treatment of pediatric patients with growth disturbance due to insufficient secretion of growth hormone.  We also submitted the initial Biologics License Application (&#8220;BLA&#8221;) with the FDA for approval of Somatrogon (hGH-CTP) in the United States and Pfizer received a Complete Response Letter in January 2022.  Pfizer and OPKO are evaluating the FDA&#8217;s comments and will work with the agency to determine the best path forward for Somatrogon (hGH-CTP) in the United States.  We are incorporated in Delaware, and our principal executive offices are located in leased offices in Miami, Florida.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through BioReference, we provide laboratory testing services, primarily to customers in the larger metropolitan areas in New York, New Jersey, Florida, Texas, Maryland, California, Pennsylvania, Delaware, Washington, DC, Illinois and Massachusetts, as well as to customers in a number of other states.  We offer a comprehensive test menu of clinical diagnostics for blood, urine and tissue analysis.  This includes hematology, clinical chemistry, immunoassay, infectious&#160;diseases, serology, hormones, and toxicology assays, as well as Pap smear, anatomic pathology (biopsies) and other types of tissue analysis.  We market our laboratory testing services directly to physicians, geneticists, hospitals, clinics, correctional and other health facilities.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate established pharmaceutical platforms in Ireland, Chile, Spain, and Mexico, which are generating revenue and from which we expect to generate positive cash flow and facilitate future market entry for our products currently in development.  In addition, we have a development and commercial supply pharmaceutical company and a global supply chain operation and holding company in Ireland.  We own a specialty active pharmaceutical ingredients (&#8220;APIs&#8221;) manufacturer in Israel, which we expect will facilitate the development of our pipeline of molecules and compounds for our proprietary molecular diagnostic and therapeutic products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities are primarily performed at facilities in Woburn, MA, Waterford, Ireland, Kiryat Gat, Israel, and Barcelona, Spain.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, Sema4 Holdings Corp. (&#8220;Sema4&#8221;) and OPKO entered into an Agreement and Plan of Merger and Reorganization (the &#8220;GeneDx Merger Agreement&#8221;), pursuant to which Sema4 agreed to acquire OPKO&#8217;s wholly owned subsidiary, GeneDx LLC, formerly GeneDx, Inc. (&#8220;GeneDx&#8221;), subject to satisfaction of customary closing conditions (the &#8220;GeneDx Transaction&#8221;). The GeneDx Transaction closed on April 29, 2022. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the GeneDx Merger Agreement, Sema4 acquired GeneDx for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzg0ODI5MDcwODk3OA_54e3eba9-4777-4160-b66e-33be7385a9e7">150</ix:nonFraction>&#160;million in cash, subject to adjustments, plus <ix:nonFraction unitRef="shares" contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzg0ODI5MDcwODk5Mg_aa84fab9-4d52-49a1-b555-20778560379d">80.0</ix:nonFraction>&#160;million shares of Sema4&#8217;s Class A common stock, and Sema4 has agreed to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429" decimals="-6" name="opk:BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzg0ODI5MDcwODk2NA_a45535cc-438e-4f68-9855-0e4138633e9a">150</ix:nonFraction>&#160;million in consideration subject to the satisfaction of certain revenue-based milestones over the next <ix:nonNumeric contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429" name="opk:BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzg0ODI5MDcwOTAzMw_f70b862f-a649-4d7e-8dab-2555bcc23882">two years</ix:nonNumeric> (which will be payable in cash or shares of Sema4&#8217;s Class A common stock at Sema4&#8217;s discretion). Based on the closing stock price of Sema4 as of April 29, 2022, the total upfront consideration represents approximately $<ix:nonFraction unitRef="usd" contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429" decimals="-6" name="opk:BusinessCombinationUpfrontConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzg0ODI5MDcwOTAwNg_ce6e4ff5-74df-45a8-b95e-79039bfe660a">322</ix:nonFraction>&#160;million, and the total aggregate consideration including potential milestones is approximately $<ix:nonFraction unitRef="usd" contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzg0ODI5MDcwOTAyMA_2e2033f9-36c4-4d02-beac-9b955eeb2dd0">472</ix:nonFraction>&#160;million.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December 31, 2021, GeneDx met the held-for-sale accounting criteria and, its related assets and liabilities are classified as held for sale in the consolidated balance sheet. GeneDx was included in our diagnostics segment as of March&#160;31, 2022 and December 31, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i158b10b7e2044b72b6e88f4d7fbdac7e">In June 2021, EirGen Pharma Limited (&#8220;EirGen&#8221;), our wholly owned subsidiary, entered into a definitive agreement to sell <ix:nonFraction unitRef="facility" contextRef="i906abe6eed0f4cd69f9561fd532d9d48_D20210601-20210630" decimals="INF" name="opk:DisposalGroupNumberOfFacilitiesSold" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzA2Ng_d409bbfc-0f94-43c7-8366-e0e21750e369">one</ix:nonFraction> of its facilities in Waterford, Ireland to Horizon Therapeutics plc for $<ix:nonFraction unitRef="usd" contextRef="ia99d14c06e6e4e28ad5a8c3f4c6cc028_I20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzE0MQ_c099f855-9a47-4c02-8868-6aa6296aff3f">65</ix:nonFraction>&#160;million in cash less certain assumed and accrued liabilities relating to transferred employees. The facility, which was formerly included in our pharmaceutical segment, housed EirGen&#8217;s sterile-fill-finish business and was no longer a core component of our ongoing operations and business strategy. The transaction closed in the third quarter of 2021. We recognized a gain on the sale of the facility in the third quarter of 2021 of $<ix:nonFraction unitRef="usd" contextRef="i59cf764445af4de7b91ff994ed949ca9_D20210701-20210930" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMjc0ODc3OTA4MTI5MA_0280c7ad-da38-4c45-965f-8e9fedf346e4">31.5</ix:nonFraction>&#160;million.</ix:continuation></span></div><div style="margin-top:9pt;text-indent:24.75pt"><span><br/></span></div><div id="i1cac816ff800494ea2979c434f00b37c_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180My9mcmFnOmI3N2E2YWRlY2U3NTRjMTViMGUzNGQwMTdmYTIyZjYxL3RleHRyZWdpb246Yjc3YTZhZGVjZTc1NGMxNWIwZTM0ZDAxN2ZhMjJmNjFfNjQ3Mw_d90c2036-ce3f-4c31-a6c5-c75fcd1109b8" continuedAt="i93f8f0c876734de795837f07d1de4e66" escape="true">IMPACT OF COVID-19</ix:nonNumeric></span></div><ix:continuation id="i93f8f0c876734de795837f07d1de4e66"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to be a part of the coordinated public and private sector response to SARS-CoV-2, a novel strain of coronavirus, referred to as COVID-19.  There continues to be a high level of uncertainty relating to how the pandemic will evolve, how governments and consumers will react, progress on the distribution of vaccines and whether the pandemic will have a longer-term effect on the healthcare industry and patient habits. BioReference is providing COVID-19 solutions, including diagnostic molecular testing and serology antibody testing, to meet the testing needs of its customers, including physicians, health systems, long-term care facilities, governments, schools, employers, professional sports teams and entertainment venues, as well as the general public through relationships with retail pharmacy chains.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since the pandemic began in the U.S., we have invested in testing capabilities and infrastructure to meet demand for our molecular and antibody testing for COVID-19.  Throughout the last two years, we have managed our company-wide lab operations specimen acquisition, logistics, procurement, customer service, and initiatives to manage our cost structure to match the ever changing COVID-19 testing volumes and to manage efficiency gains in our core clinical lines of business.  We anticipate that COVID-19 will continue to impact our business in 2022 and demand for COVID-19 testing will fluctuate with the potential for increases and decreases in demand at different times and across different geographies; however, overall, we expect COVID-19 test demand to trend down in 2022 as compared to 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenue from services for the three months ended March 31, 2022 decreased by $<ix:nonFraction unitRef="usd" contextRef="i2f9c95a502354f4c9bd791e55a1b1acc_D20220101-20220331" decimals="-5" sign="-" name="opk:IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180My9mcmFnOmI3N2E2YWRlY2U3NTRjMTViMGUzNGQwMTdmYTIyZjYxL3RleHRyZWdpb246Yjc3YTZhZGVjZTc1NGMxNWIwZTM0ZDAxN2ZhMjJmNjFfMTA5OTUxMTY2MDg0NA_225a4d5f-3337-4b33-8058-7777e7e8d947">220.4</ix:nonFraction> million as compared to the three months ended March 31, 2021 due to lower COVID-19 testing volumes. We maintain our ability to quickly scale-up COVID-19 PCR testing capacity, even during periods of reduced demand.  In doing so, we are able to immediately and effectively respond to surges in positive cases and testing needs. We are unable to predict how long the demand will continue for our COVID-19 related testing, or whether pricing and reimbursement policies for testing will be sustained.  Excluding COVID-19 test volumes, for the three months ended March 31, 2022, genomic and routine clinical test volume increased <ix:nonFraction unitRef="number" contextRef="i086b3193d0a84e44b65e89593c24a20b_D20220101-20220331" decimals="3" name="opk:ChangeInTestingVolumePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180My9mcmFnOmI3N2E2YWRlY2U3NTRjMTViMGUzNGQwMTdmYTIyZjYxL3RleHRyZWdpb246Yjc3YTZhZGVjZTc1NGMxNWIwZTM0ZDAxN2ZhMjJmNjFfNjU5NzA2OTgwMjE4OQ_96863489-5a8e-4b64-b8e6-1e206b2b4ede">14.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="idce190630bea4cf9936f6557989275fb_D20220101-20220331" decimals="3" name="opk:ChangeInTestingVolumePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180My9mcmFnOmI3N2E2YWRlY2U3NTRjMTViMGUzNGQwMTdmYTIyZjYxL3RleHRyZWdpb246Yjc3YTZhZGVjZTc1NGMxNWIwZTM0ZDAxN2ZhMjJmNjFfNjU5NzA2OTgwMjE5Mw_a60f2a25-c59d-455d-943b-97f99cbfe36c">0.4</ix:nonFraction>% respectively, as compared to such volumes for the three months ended March 31, 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2022, the U.S. Health Resources and Services Administration ("HRSA") informed providers that, after March 22, 2022, it would stop accepting claims for testing and treatment for uninsured individuals under the HRSA COVID-19 Uninsured Program and that claims submitted prior to that date would be subject to eligibility and availability of funds. For the three months ended March 31, 2022, revenue for testing of uninsured individuals under the HRSA COVID-19 Uninsured Program represented approximately <ix:nonFraction unitRef="number" contextRef="id75b8d1d54904cb9bed9cb560d7ee790_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180My9mcmFnOmI3N2E2YWRlY2U3NTRjMTViMGUzNGQwMTdmYTIyZjYxL3RleHRyZWdpb246Yjc3YTZhZGVjZTc1NGMxNWIwZTM0ZDAxN2ZhMjJmNjFfMjc0ODc3OTEyNTQ3Ng_950806e0-cf51-4648-91b8-8d4df3fe207f">7.9</ix:nonFraction>% of our COVID-19 testing revenue. As of March 31, 2022, less than <ix:nonFraction unitRef="number" contextRef="i888fe358d78645888869e9e2f5f6b316_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180My9mcmFnOmI3N2E2YWRlY2U3NTRjMTViMGUzNGQwMTdmYTIyZjYxL3RleHRyZWdpb246Yjc3YTZhZGVjZTc1NGMxNWIwZTM0ZDAxN2ZhMjJmNjFfMjc0ODc3OTEyNTQ4Mg_c2b30ca5-2ca3-4a69-a77c-e472c8a402cc">6</ix:nonFraction>% of our net accounts receivable was associated with claims for reimbursement for COVID-19 testing of uninsured individuals. Although we believe that our estimates for contractual allowances and patient price concessions are appropriate, actual results could differ from those estimates.</span></div></ix:continuation><div id="i1cac816ff800494ea2979c434f00b37c_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQxMDQ_b6344f30-3554-411a-a7a0-6516de668d16" continuedAt="id0248f854767443493d78d59daf375d9" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="id0248f854767443493d78d59daf375d9" continuedAt="i630394b66f8442c6a3851b1aa754f90f"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQxMjU_08eedb84-890a-4f35-93e9-a8f5e82ce4ac" continuedAt="i30daea90455945c4818b58dba6689ef9" escape="true">Basis of presentation</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i30daea90455945c4818b58dba6689ef9">.  The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all information and notes required by GAAP for complete financial statements.  In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Company&#8217;s results of operations, financial position and cash flows have been made.  The results of operations and cash flows for the three months ended March 31, 2022 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2022 or any other future periods.  The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</ix:continuation>  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwMzM_ccc9b294-236d-43ec-b15e-e98a2e4a2a11" continuedAt="i2545fd88b2fc40a6ba7727b5a2d16fe9" escape="true">Principles of consolidation</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2545fd88b2fc40a6ba7727b5a2d16fe9">.  The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and our wholly-owned subsidiaries.  All intercompany accounts and transactions are eliminated in consolidation.</ix:continuation>   </span></div><div style="margin-top:9pt;text-indent:24.75pt"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwMjg_a9354c6f-2e0a-4b9a-a051-b23d6bbac951" continuedAt="ide663d01b13c4977b5a9dab481f20578" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and </span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i630394b66f8442c6a3851b1aa754f90f" continuedAt="i6174c25b67d0453dac7a7e288ad79df1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ide663d01b13c4977b5a9dab481f20578">liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from these estimates.</ix:continuation></span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQxNDA_f76d314a-d5a1-44a7-aae9-d1077aae6cee" continuedAt="ic0113c4a54c8404195cbc55a068132a4" escape="true">Cash and cash equivalents</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic0113c4a54c8404195cbc55a068132a4">.  Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase.  We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents.  These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQxMjc_c2980754-c11e-4f89-9e8d-8153f4735c90" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Inventories are valued at the lower of cost and net realizable value.  Cost is determined by the first-in, first-out method.  We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value.  Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which are used in our testing laboratories.  Inventory obsolescence expense for the three months ended March 31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjk5Ng_091bbd13-bd05-48a6-9f60-c1c9a002efed">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMzAwMw_ab0fb4cf-16b6-42c4-b0ab-bf23629ffd89">3.1</ix:nonFraction> million, respectively.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwODU_e013fbfc-9cef-4427-aee9-01a057205205" continuedAt="i509fa511e62a47b7b3349abb60df0dc9" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting.  Refer to Note 5.  Goodwill, in-process research and development (&#8220;IPR&amp;D&#8221;) and other intangible assets acquired in business combinations, licensing and other transactions was $<ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-8" name="opk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMzk0Nw_0b31cbbb-8ffc-49f5-ab2c-6f541d2f0389"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-8" name="opk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMzk0Nw_c9a49375-2757-473c-a05f-96c18ec0613a">1.4</ix:nonFraction></ix:nonFraction> billion at both March&#160;31, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values.  Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill.  At acquisition, we generally determine the fair value of intangible assets, including IPR&amp;D, using the &#8220;income method.&#8221;</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was $<ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMzg0ODI5MDczODM5MA_8c7974fd-fe9f-4a13-9b34-b61909939b28">519.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMzg0ODI5MDczODQyMQ_9209a2e3-8b36-48ff-9f2a-ac00eca514b0">520.6</ix:nonFraction>&#160;million, respectively, at March&#160;31, 2022 and December&#160;31, 2021, Assets held for sale includes $<ix:nonFraction unitRef="usd" contextRef="i77c9c6ea887e4115b1c0992f4beef719_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTA5NDE3OA_77515025-1bb8-41da-874a-deb1e23015b4"><ix:nonFraction unitRef="usd" contextRef="i30dd8bae361a48dc85516ce870eae7cb_I20220331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTA5NDE3OA_e60ee941-0f3e-458f-aef0-a08abac0a2e2">151.8</ix:nonFraction></ix:nonFraction>&#160;million of goodwill related to GeneDx. Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.  We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing.  Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net intangible assets other than goodwill was $<ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfNTMyOA_2e2f3a0e-1b63-4066-a15b-daf100f94093">890.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfNTMzNQ_36521611-e2c5-4599-a1d8-96ea43231eb8">911.9</ix:nonFraction> million, including IPR&amp;D of $<ix:nonFraction unitRef="usd" contextRef="i3cf8b83bf2c647cc819974ea2adb86c0_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDQxOQ_e6beb21d-f4c7-4550-ac3f-990f7e29e7a2">590.2</ix:nonFraction>&#160;million at December&#160;31, 2021, respectively.  Intangible assets are highly vulnerable to impairment charges, particularly newly acquired assets for recently launched products and IPR&amp;D.  Considering the high risk nature of research and development and the industry&#8217;s success rate of bringing developmental compounds to market, IPR&amp;D impairment charges may occur in future periods.  Estimating the fair value of IPR&amp;D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon obtaining regulatory approval, IPR&amp;D assets are then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life.  If the project is abandoned, the IPR&amp;D asset is charged to expense.  Finite lived intangible assets are tested for impairment when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.  The testing includes a comparison of the carrying amount of the asset to its estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our estimates and assumptions in testing goodwill and other intangible assets, including IPR&amp;D, for</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impairment are reasonable and otherwise consistent with assumptions that marketplace participants would use in their estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of fair value. However, if future results are not consistent with our estimates and assumptions, including as a result of the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 global pandemic, then we may be exposed to additional impairment charges, which could be material.  We submitted the initial BLA with the FDA for approval of Somatrogon (hGH-CTP) in the United States and Pfizer received a Complete Response Letter in January 2022. Pfizer and OPKO are evaluating the FDA&#8217;s comments and will work with the agency to determine the best path forward for Somatrogon (hGH-CTP) in the United States.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i6174c25b67d0453dac7a7e288ad79df1" continuedAt="i18c98cb12ac7472f8bf70cc134282e93"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i509fa511e62a47b7b3349abb60df0dc9" continuedAt="i85f7ee6de5c14759bd01d6ab62c85406">In the first quarter of 2022, we reclassified $<ix:nonFraction unitRef="usd" contextRef="i80eb499192104b008d7af0e0148d19c8_I20220331" decimals="-5" sign="-" name="opk:InProcessResearchandDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDUzMg_6c576472-d3ea-4da8-9670-fb74a77b0fb8"><ix:nonFraction unitRef="usd" contextRef="ie9f8b48ec3cc43d09aa306ad85bdfbd6_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDUzMg_ed31b481-2f4f-458e-83fd-7958dbd3241b">590.0</ix:nonFraction></ix:nonFraction>&#160;million of IPR&amp;D related to Somatrogon (hGH-CTP) from IPR&amp;D in our Condensed Consolidated Balance Sheet upon the approval of NGENLA (Somatrogon) in Europe and Japan. The assets will be amortized on a straight-line basis over their estimated useful life of approximately <ix:nonNumeric contextRef="i1ec064528f8b46c799fcf289c9791518_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDU1Mw_c4eb890c-1f3b-463b-ab4c-e1b9669f8cd9">12</ix:nonNumeric> years.</ix:continuation></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i85f7ee6de5c14759bd01d6ab62c85406">We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from <ix:nonNumeric contextRef="i37bc1ddf248145949cf20c844e5cd267_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfNzI1NA_ff871ea6-2345-4a36-9eee-fb5bdb785631">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i52d41c803f754caab224bc8b150c6c59_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfNzI2MA_6c205bc2-6413-4f9e-b3a3-4c7c53651237">20</ix:nonNumeric> years.  We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up.</ix:continuation>  Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfNzQ4MQ_34700a43-14f3-4fb2-aaa5-ce0896ebcd6a">22.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfNzQ4OA_333fc9be-43b9-43b8-b7e9-533cd7a6b5a4">12.6</ix:nonFraction> million for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwNTI_d9df3d4c-bc8b-4f46-ae00-80857d2dc416" continuedAt="i250a2f0713684cae9ac3f2d6f196752b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments.  Investments that are considered equity securities as of March&#160;31, 2022 and December&#160;31, 2021 are predominately carried at fair value.  Our debt under the credit agreement with JPMorgan Chase Bank, N.A. approximates fair value due to the variable rate of interest applicable to such debt.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i250a2f0713684cae9ac3f2d6f196752b">In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates.  The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts.  Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange.</ix:continuation>  Refer to Note 9.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwMzY_d23a6df9-fd2b-4f73-a66f-b3c85197ee63" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense.  Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability.  Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions.  The assumptions used in estimating fair value require significant judgment.  The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwOTk_e269f579-46fa-40a7-a51c-417e1be34edc" continuedAt="i75820520c9e449ee8b632385d6d18083" escape="true">Derivative financial instruments</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i75820520c9e449ee8b632385d6d18083">.  We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges.  For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At March&#160;31, 2022 and December&#160;31, 2021, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognized all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations.</ix:continuation>  Refer to Note 10.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwODc_fbaf2628-0c6d-4e5c-9cdc-ba0c1cc7a8db" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Property, plant and equipment are recorded at cost or fair value if acquired in a business combination.  Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases.  The estimated useful lives by asset class are as follows: software - <ix:nonNumeric contextRef="ieada14ab28484d7f825d8053db57205d_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTA4MTE_d6fe24b8-dcc4-4bec-b18c-d6541d0e80a8">3</ix:nonNumeric> years, machinery, medical and other equipment - <ix:nonNumeric contextRef="ie2a83411c64144f1b9355c9cfd56237d_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTA4NjI_b37371d6-9a1a-456b-b626-abf1e8c489fb">5</ix:nonNumeric>-<ix:nonNumeric contextRef="i63f3da17eaeb419fa6e03d78593bf2bd_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTA4NjU_d96dd03b-96b2-4815-ac0d-cc146431ddb0">8</ix:nonNumeric> years, furniture and fixtures - <ix:nonNumeric contextRef="ide29c575be14417383ac7d390f9234c4_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTA5MDA_5333c467-d03a-4598-83e0-f868ccf9b939">5</ix:nonNumeric>-<ix:nonNumeric contextRef="if2ff2edaeb5d4865a0321ebe71317039_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTA5MDM_1613fe07-d45d-43b8-aa14-b800f32de1dd">12</ix:nonNumeric> years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - <ix:nonNumeric contextRef="i3d47b2edbf174a649ea86051fd83bd31_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTEwMTg_7091eea1-a818-446c-823f-2f9436ab96b2">10</ix:nonNumeric>-<ix:nonNumeric contextRef="i318d31f5642447988322e0b46296a5e2_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTEwMjE_29fa2aa4-060d-4111-9069-e8b294ee6d89">40</ix:nonNumeric> years, and automobiles - <ix:nonNumeric contextRef="idab50d068e1f4bfc9aa0aa0073ec3fdd_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTEwNDk_d0e6b039-6764-409f-b5b8-68c1ca71d64a">3</ix:nonNumeric>-<ix:nonNumeric contextRef="ie29d2a5269334fb397d32c99e041731a_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTEwNTI_53191fcf-7920-4b1a-916d-c5efd2878d3c">5</ix:nonNumeric> years.  Expenditures for repairs and maintenance are charged to expense as incurred.  Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTExNjY_198a4c0d-1f3e-44c5-927a-bccb7397cd92">5.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTExNzM_2ec049ba-2d7c-42f9-842e-34cf4b596314">7.4</ix:nonFraction> million for three months ended March 31, 2022 and 2021, respectively. Assets held under finance leases are included within Property, plant and equipment, net in our Consolidated Balance Sheets and are amortized over the shorter of their useful lives or the expected term of their related leases.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwMjE_56a35a68-915f-4aa3-a2e4-d8480004944b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of long-lived assets.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment and assets held for sale, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwMTc_68593fd9-d146-487e-a605-0f1dd4dc163a" continuedAt="if44549df72fd49a0926c6821a1615bdd" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax </span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i18c98cb12ac7472f8bf70cc134282e93" continuedAt="i44271d75971f4731b0ca5c6ce982c8f7"><ix:continuation id="if44549df72fd49a0926c6821a1615bdd"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment. Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in various countries and tax jurisdictions globally.&#160; For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results.&#160; For the three months ended March 31, 2022, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwNTM_eb282167-4d63-4384-bd0d-f3877b19dcec" continuedAt="i1d2a8071de8747dfb238e940bf6ea66f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 606&#8221;).  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.  </span></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1d2a8071de8747dfb238e940bf6ea66f" continuedAt="i30f618499f844279af87c095787519ac">We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.  At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct.  We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied.</ix:continuation>  For a complete discussion of accounting for Revenues from services, Revenues from products and Revenue from transfer of intellectual property and other, refer to Note 13.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQxMDE_93cf5e5f-635d-4b13-a58e-47fe99f69bb4" continuedAt="i42309850662e412fbd128384e8f938b6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of credit risk and allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable.  Substantially all of our accounts receivable are with either companies in the healthcare industry or patients.  However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i42309850662e412fbd128384e8f938b6">While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.</ix:continuation>   On March&#160;31, 2022 and December&#160;31, 2021, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were <ix:nonFraction unitRef="number" contextRef="i530fe1c9f119438894b0dd5623106eed_D20220331-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTY0ODM_ee2e64bd-0f11-44f7-af9d-f2ea245e1a49">10</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i50900f2255f341c596bd800b3f7c7a4d_D20211231-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTY0OTA_554fcf9f-6cd7-431c-ae35-fafbe9a8abd9">6</ix:nonFraction>%, respectively, of our consolidated Accounts receivable, net. On March&#160;31, 2022 and December&#160;31, 2021, receivable balances (net of explicit and implicit price concessions) due directly from states, cities and other municipalities, specifically related to our real-time reverse-transcription polymerase chain reaction (real-time RT-PCR) assay to detect COVID-19, were <ix:nonFraction unitRef="number" contextRef="i8c46f5c9a39a4c32b5cd190bec420d89_D20220331-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTY4NDg_ce520d1e-8b3c-43b7-a147-2c91146c22b1">4.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6a7d513d6e904c0884c28baf601bb35d_D20211231-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTY4NTU_86085823-e451-4c22-909a-4f04988a0ce8">4.1</ix:nonFraction>% of our consolidated accounts receivable, net, respectively. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk.  At March&#160;31, 2022 and December&#160;31, 2021, receivables due from patients represented approximately <ix:nonFraction unitRef="number" contextRef="ie1dca7ce0a2b48abb1378746d081a87a_D20220331-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTcxMDQ_96ab3be3-d56b-40bd-b404-d231954bcea9">2.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2b22ccaca70a4b119871d37e30563967_D20211231-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTcxMTE_978d7da2-c383-4c85-8fe2-2b27dc0ffea8">0.7</ix:nonFraction>%, respectively, of our consolidated Accounts receivable, net.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwNTU_fe8f6653-9d75-4aa6-9361-4bb5969a904c" escape="true">We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer&#8217;s ability to pay.  Actual results could differ from those estimates.</ix:nonNumeric>  The allowance for credit losses was $<ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTc1Njc_206ab166-1d54-4381-bf1c-afef63dd4b6b">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTc1NzQ_62bbf2e1-34a7-4e9d-b6f0-0d903e74b877">1.8</ix:nonFraction> million at March&#160;31, 2022 and December&#160;31, 2021, respectively.  The credit loss expense for the three months ended March 31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-5" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTc2NTU_e1f4d966-edd1-4ce6-a522-97a444c0cda7">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-5" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTc2NjI_cb0c1666-289c-4020-a74f-f5f7ba25b725">0.3</ix:nonFraction> million, respectively.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwMDQ_da7ee4be-007a-46d9-a295-ecaabeadf645" continuedAt="i578b3c3b82bf456b8c7cb2f6077a82c0" escape="true">Equity-based compensation</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i578b3c3b82bf456b8c7cb2f6077a82c0">.  We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award.  That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award.  We record excess tax benefits realized from the exercise of stock options as cash flows from operations.</ix:continuation>  For the three months ended March 31, 2022 and 2021 we recorded $<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTA5OTA0OQ_00d405b6-3675-4866-ba91-37c5762d1c21">7.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTA5OTA0Mw_567e5860-efec-4968-ac47-05870cf71428">2.6</ix:nonFraction> million, respectively, of equity-based compensation expense.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQxMzg_bd49acee-fa69-46f5-a8cb-0b9afe7b966d" continuedAt="i59d3bad9463d40cdbc58c7b67a032464" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include external and internal expenses.  External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs.  Research and development employee-related expenses include salaries, benefits and equity-based compensation expense.  Other internal research and </span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i44271d75971f4731b0ca5c6ce982c8f7" continuedAt="if2c88501253c4beea2a2b9a5f6fd160a"><ix:continuation id="i59d3bad9463d40cdbc58c7b67a032464"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.  We expense these costs in the period in which they are incurred.  We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received.  As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility, and which have no alternative future use.  For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed.  Once the development process has been completed the asset will be amortized over its remaining estimated useful life.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwNDE_54747c39-34cf-43a6-88f5-fd5f96382a39" continuedAt="ic0f7a68fab4744489415044e4f9c57ba" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Our chief operating decision-maker (&#8220;CODM&#8221;) is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis.  We manage our operations in <ix:nonFraction unitRef="segment" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjA0Mjk_59b8144d-92d7-4ae8-bb8b-96be14d622c1">two</ix:nonFraction> reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic0f7a68fab4744489415044e4f9c57ba"> product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of clinical and genomics laboratory operations through BioReference and point-of-care operations.  There are no significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is no inter-segment allocation of interest expense or income taxes.</ix:continuation>  Refer to Note 15.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><ix:continuation id="i30f618499f844279af87c095787519ac"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shipping and handling costs.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not charge customers for shipping and handling costs.  Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.</span></ix:continuation></div><div style="margin-top:9pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjM5ODk_077784f1-0eb7-4cdf-9112-72b95eb391aa" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The financial statements of certain of our foreign operations are measured using the local currency as the functional currency.  The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date and the local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods.  Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss). During the three months ended March 31, 2022 and 2021, we recorded $<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDQ0MA_a9a43f4d-afb9-4d48-85c0-178fad7af2db">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDQ2NQ_efee849b-e3fd-42c0-b66e-f5bbc1a59293">4.8</ix:nonFraction>&#160;million, respectively of transaction losses.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwNjk_bee5e7cd-0926-4d7c-b600-349121e747e4" continuedAt="ic7784b5bb6f54185a23c38bc0f3c22ff" escape="true">Variable interest entities</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic7784b5bb6f54185a23c38bc0f3c22ff">.  The consolidation of a variable interest entity (&#8220;VIE&#8221;) is required when an enterprise has a controlling financial interest.  A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE.</ix:continuation>  Refer to Note 6.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwNTg_798b4693-ebd5-4981-85bd-40773e3d5555" continuedAt="i6ede51b4f99c49dfa3b3d3a419a22d20" escape="true">Investments</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6ede51b4f99c49dfa3b3d3a419a22d20">.  We have made strategic investments in development stage and emerging companies.  We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees.  For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations.  Refer to Note 6.  For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value.</ix:continuation>  Refer to Note 6.</span></div><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwMjc_ed9cdf72-a134-416c-8df5-c25a0c438319" continuedAt="iea33db9f2916455eb58fdac2ebfb729e" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently adopted accounting pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40).&#8221; ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2021, with early adoption permitted.   As required, we adopted ASU 2020-06 on January 1, 2022 and used the modified retrospective approach for all convertible debt instruments at the beginning of the period of adoptions.  Results for reporting periods beginning January 1, 2022 are presented under ASU 2020-06, while prior period amounts were not adjusted and continue to be reported in accordance with historic with accounting guidance. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the modified approach, entities will apply the guidance to all financial instruments that are outstanding as of the beginning of the year of adoption with the cumulative effect recognized as an adjustment to the opening balance of retained earnings. ASU 2020-06 eliminates the cash conversion and beneficial conversion feature models in ASC 470-20 that require an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if2c88501253c4beea2a2b9a5f6fd160a"><ix:continuation id="iea33db9f2916455eb58fdac2ebfb729e">equity. The adoption of ASU 2020-06 at January 1, 2022 resulted in an increase of the Convertible notes of $<ix:nonFraction unitRef="usd" contextRef="ib396f0384c4549d6ad4a1d99b89fcf7f_I20220101" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDUwMA_856536e2-bd38-435b-9408-e2525230ced2">21.6</ix:nonFraction>&#160;million, a reduction of the Accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="iceb6a701923f4d27a6905238cab5243d_I20220101" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDQ4NQ_2d5d7d61-860e-486f-8a4b-a31a072914e8">17.5</ix:nonFraction>&#160;million and a reduction of Additional paid-in capital of $<ix:nonFraction unitRef="usd" contextRef="i04b7a30acb9a4f81a6cd5179f6dc9cd0_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDUxNw_57d8ee44-f438-4151-9a2f-8f1f679207e5">39.1</ix:nonFraction>&#160;million.</ix:continuation></ix:continuation></span></div><div id="i1cac816ff800494ea2979c434f00b37c_49"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjk5NA_368a1b79-e6b0-4f0e-a466-ce9ef907fb6d" continuedAt="iad54b95d6a914bd4bce42257b02fbe19" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="iad54b95d6a914bd4bce42257b02fbe19"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is computed by dividing our net income (loss) by the weighted average number of shares of our common stock par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMTg2_7ec61557-caba-4176-9b5c-ab19352bb5ba">0.01</ix:nonFraction> per share (&#8220;Common Stock&#8221;) outstanding during the period.  Shares of Common Stock outstanding under the&#160;share lending&#160;arrangement entered into in conjunction with the 2025 Notes (as defined in Note 7) are excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.  Refer to Note 7.  For diluted earnings per share, the dilutive impact of stock options and warrants is determined by applying the &#8220;treasury stock&#8221; method.  The dilutive impact of the 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes (each, as defined and discussed in Note 7) has been considered using the &#8220;if converted&#8221; method. For periods in which their effect would be antidilutive, no effect is given to Common Stock issuable under outstanding options or warrants or the potentially dilutive shares issuable pursuant to the 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes in the dilutive computation.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A total of <ix:nonFraction unitRef="shares" contextRef="i67b75a0644d1431cb32ac4d221554a5d_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMTQ0Nw_2759604f-c62c-4d88-8caf-2830cdfe58a0">57,985,925</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7e0d3411daf7457fa18aa8ab1b20c33e_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMTQ1NA_ce7cb999-1e0c-4755-8c34-a083a5d423ce">74,623,270</ix:nonFraction> potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the three months ended March 31, 2022, and 2021, respectively, because their inclusion would be antidilutive. A full presentation of diluted earnings per share has not been provided because the required adjustments to the numerator and denominator resulted in diluted earnings per share equivalent to basic earnings per share.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, <ix:nonFraction unitRef="shares" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="INF" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjIzMA_9ab2e352-8dfc-4258-8b91-ee86ac36e126">55,750</ix:nonFraction> Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="INF" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjM2NA_3116b208-723b-4833-9bf3-a706cf0316cd">55,750</ix:nonFraction> shares of Common Stock.  Of the <ix:nonFraction unitRef="shares" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="INF" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjM5OQ_9ab2e352-8dfc-4258-8b91-ee86ac36e126">55,750</ix:nonFraction> Common Stock options and Common Stock warrants exercised, <ix:nonFraction unitRef="shares" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="INF" name="opk:SharesSurrenderedInLieuOfCashPayment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjQ2MA_a83df8c8-d2c3-4df0-b6b2-32a457b7612f">no</ix:nonFraction> shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;March 31, 2021, <ix:nonFraction unitRef="shares" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="INF" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjYzNg_9e41f12f-7c28-414c-abe7-9f712a781410">117,500</ix:nonFraction> Common Stock options or Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="INF" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjc2OQ_394ba2cd-b11f-491e-a2aa-9e9ed96c6a88">117,500</ix:nonFraction> shares of Common Stock.  Of the <ix:nonFraction unitRef="shares" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="INF" name="opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjgwNA_9e41f12f-7c28-414c-abe7-9f712a781410">117,500</ix:nonFraction> Common Stock options and Common Stock warrants exercised, <ix:nonFraction unitRef="shares" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="INF" name="opk:SharesSurrenderedInLieuOfCashPayment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjg2NQ_708c03e1-cc3e-4375-b9d5-9fc871db2cc7"><ix:nonFraction unitRef="shares" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="INF" name="opk:SharesSurrenderedInLieuOfCashPayment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjg2NQ_d067f0ca-23bb-4e4b-a3b2-0b84d3587144">no</ix:nonFraction></ix:nonFraction> shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMTA5Ng_423fe275-63cb-433f-837b-fd3621cbb251" continuedAt="i34a4f519f9f9449185570c15d48d5787" escape="true">COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i34a4f519f9f9449185570c15d48d5787" continuedAt="if9e359c2b3ea42afb9239267de4770bb"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="opk:CompositionOfCertainFinancialStatementCaptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMTA5Nw_b6fa7b24-7dd9-4121-bd39-9ff76f4245d7" continuedAt="ia5b3b4c7f8bc41a29fdeb9e94dcb2561" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMi0xLTEtMS0zNTMzMA_ea8c8557-78f8-4e05-986d-b4fefbd519c5">214,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMi0zLTEtMS0zNTMzMA_eea29e60-1368-4640-8c87-356d2b0f63a3">261,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMy0xLTEtMS0zNTMzMA_77bf0062-4036-4010-a312-8424385df6c2">1,979</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMy0zLTEtMS0zNTMzMA_27d6addb-ebd9-4115-8702-e0c26a1e92ee">1,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNC0xLTEtMS0zNTMzMA_aefcf394-74cf-4316-8fc0-32bf1dff8a51">212,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNC0zLTEtMS0zNTMzMA_ccc2dbb2-0458-484d-8579-ee29c4533ec4">259,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumable supplies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OtherInventorySupplies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNi0xLTEtMS0zNTMzMA_10952f10-e1d1-4403-ac0a-f1c07b06ea74">48,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:OtherInventorySupplies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNi0zLTEtMS0zNTMzMA_c17a2630-0f09-424d-8e66-8549e34af8f2">39,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNy0xLTEtMS0zNTMzMA_eab188df-2d6e-48c7-a187-3d7835fbdc25">46,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNy0zLTEtMS0zNTMzMA_6b5ff161-1ed9-44a2-b4ec-0cf46f5bd863">44,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfOC0xLTEtMS0zNTMzMA_1cec6b50-89ff-44f5-8497-65b11b75f1f5">2,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfOC0zLTEtMS0zNTMzMA_a132ff68-b3ef-4d92-8933-6857824970ad">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfOS0xLTEtMS0zNTMzMA_d3648183-c736-41a2-ac62-e10b67f0ba1b">6,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfOS0zLTEtMS0zNTMzMA_bd949156-5069-4ae1-ae5a-1539ef3adaed">6,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: inventory reserve</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTAtMS0xLTEtMzUzMzA_1f491cda-f184-49fa-8687-a58ae3f4b033">5,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTAtMy0xLTEtMzUzMzA_058523d5-b344-461a-a9c8-f78003c7a4bd">4,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTEtMS0xLTEtMzUzMzA_3609c972-d3ba-448a-9f2a-28f26765f61c">99,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTEtMy0xLTEtMzUzMzA_2f16beef-0052-4935-b664-1a201919fe9b">86,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes recoverable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="opk:TaxesRecoverableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTMtMS0xLTEtMzUzMzA_fbc44725-279a-4409-b44e-3b8ad008bbc5">6,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="opk:TaxesRecoverableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTMtMy0xLTEtMzUzMzA_4332ca1c-8fb2-4b2a-a890-ab51633590f3">5,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:Supplies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTQtMS0xLTEtMzUzMzA_c570a16b-042d-4a95-ae86-68edb0d1c010">8,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:Supplies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTQtMy0xLTEtMzUzMzA_62a99355-5702-46e3-9d7e-baa3e7824497">10,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTgtMS0xLTEtMzUzMzA_c7ffd334-442f-48ab-9416-7c3851f1e143">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTgtMy0xLTEtMzUzMzA_521ffe01-49d2-4aae-829a-6c773cda0fa4">4,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTktMS0xLTEtMzUzMzA_b4916923-4a4c-4099-ae83-73a720aa9b92">2,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTktMy0xLTEtMzUzMzA_97a3b7b8-46e2-43f3-b9e9-72dddfce1a78">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjAtMS0xLTEtMzUzMzA_8cdf629d-8bea-4b55-9a7a-f04072d16e05">4,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjAtMy0xLTEtMzUzMzA_8938936c-aa9e-4fa1-bbde-0c6ea12d4f6f">6,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjEtMS0xLTEtMzUzMzA_7fdfaf1d-ff35-4386-9260-2df99c96eb71">23,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjEtMy0xLTEtMzUzMzA_18cc3be0-4be2-49fe-a54e-24a1640825c2">27,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56733675f4354dacaf825a860ec99f82_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjMtMS0xLTEtMzUzMzA_b0d907f2-aeb4-46c5-9129-898e2851da40">314,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e18e3e9d8bb41f0b30d8b956511195e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjMtMy0xLTEtMzUzMzA_936bdf51-7cb5-45b3-9755-76b752d22a95">314,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technologies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b12b303a8a149ee9de06097429266da_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjQtMS0xLTEtMzUzMzA_7e9be27e-207a-4309-bdeb-835e5016b830">832,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc8466e91704c55a14be646d891acd3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjQtMy0xLTEtMzUzMzA_6cb11745-4768-4e32-a58d-9be4f520acc7">246,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i651cb43b8a074339b0ee2e20b061a461_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjUtMS0xLTEtMzUzMzA_07d9e33c-b52b-443a-9ded-b850cd48d40c">49,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09284eae734a4ba29ea813474543bb46_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjUtMy0xLTEtMzUzMzA_83c09e91-15fe-424e-91ac-b517a5ad33fe">49,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8dda5c25884eaf9d82544f0dd21140_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjctMS0xLTEtMzUzMzA_fb021fd3-336f-4549-83be-b40a39227a6a">12,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3692b70dac746208ee532bd6a7af7c5_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjctMy0xLTEtMzUzMzA_1ab25362-f9a9-4163-beb1-09d3f689a466">12,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa555861b884871b2953ab02fd8033e_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjgtMS0xLTEtMzUzMzA_f8d480f1-d2a1-4ada-bfa7-434c18834087">5,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie04e073effab4668baaebc0c91e50e9e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjgtMy0xLTEtMzUzMzA_16ec490b-d49b-4761-8eda-4f140edf1775">5,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product registrations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e9306ccee49fab2b6d9c8a64eaa45_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjktMS0xLTEtMzUzMzA_ceed0514-8951-410a-8d4f-3a097d35b8bb">7,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56e6470febfe488b82cf6de3a567026d_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjktMy0xLTEtMzUzMzA_69989b18-74e3-4eb1-b54d-0acd1b11b239">6,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i614f229d8ed7468cb77cc7cbb19df994_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzAtMS0xLTEtMzUzMzA_54877ce0-2d7f-49a4-8728-df9a96bc64ad">6,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7d2ec22c3f471facc97d6879e5b1be_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzAtMy0xLTEtMzUzMzA_7a6486c6-7422-4dc6-ae64-fec86fb62eb7">6,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzEtMS0xLTEtMzUzMzA_1d59b5ee-beee-426b-9c6e-1e9bb7a574a6">338,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzEtMy0xLTEtMzUzMzA_9c3d7577-a5f8-4bd0-b0d4-fd3c24ecaf2e">320,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzItMS0xLTEtMzUzMzA_a5527123-1c95-4c0e-965a-118dfedbd8f8">890,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzItMy0xLTEtMzUzMzA_1811ec88-99de-48f8-ac03-3667d7609633">321,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory received but not invoiced</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="opk:InventoryReceivedNotInvoicedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzQtMS0xLTEtMzUzMzA_940aa3d3-2b19-4d1c-8d2b-9dcd8d054ae3">22,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="opk:InventoryReceivedNotInvoicedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzQtMy0xLTEtMzUzMzA_cbee96c8-db96-4980-a502-5a6c302349b2">40,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="opk:AccruedCommitmentsandContingenciesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzUtMS0xLTEtMzUzMzA_2d7f8412-7022-4647-a7a4-149029f3468e">26,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="opk:AccruedCommitmentsandContingenciesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzUtMy0xLTEtMzUzMzA_c8111959-b5b5-4c06-8712-20e78e5c22de">27,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzYtMS0xLTEtMzUzMzA_1558e717-83c8-45fb-93ee-639743d660cc">50,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzYtMy0xLTEtMzUzMzA_fb79ef7b-a162-4742-9c87-26cf2d1c4dae">45,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzctMS0xLTEtMzUzMzA_06d8b18a-24b0-40c8-b910-be70f7430611">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzctMy0xLTEtMzUzMzA_47102ca6-ff09-45ca-ab74-9fa08dd0771e">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="opk:AccruedClinicalTrialsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzgtMS0xLTEtMzUzMzA_736e94bc-771b-4d25-912d-fe334be6b639">4,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="opk:AccruedClinicalTrialsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzgtMy0xLTEtMzUzMzA_5865ca80-3e2a-49ca-8cd6-774cb9ffe6e1">4,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDAtMS0xLTEtMzUzMzA_83e79fff-a322-4d84-ab40-1228b0a6cad9">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDAtMy0xLTEtMzUzMzA_7003aa85-9333-418f-9566-3cf3c8b83ed5">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases short-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDEtMS0xLTEtMzUzMzA_bbcc95fb-1df9-47f9-ada6-c3304a6c03b9">2,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDEtMy0xLTEtMzUzMzA_1cfcaad5-2a9b-4021-9337-6be3ebb7d5ae">2,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDMtMS0xLTEtMzUzMzA_dba1758f-ca15-4767-a5ee-42cf5d3104db">2,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDMtMy0xLTEtMzUzMzA_796e4edc-31be-4d95-bbe8-5ce050129fbb">2,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDYtMS0xLTEtMzUzMzA_4d7ec5a9-2378-4834-ab8c-a89c1bd405de">47,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDYtMy0xLTEtMzUzMzA_802ae0c4-0c04-4889-a14d-b1c9dddaddac">69,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDctMS0xLTEtMzUzMzA_ec5cd979-fa21-4f12-a651-789357b4befd">157,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDctMy0xLTEtMzUzMzA_6e81cef4-cebc-407b-946a-89bde57e6893">193,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="if9e359c2b3ea42afb9239267de4770bb"><div style="margin-top:5pt"><ix:continuation id="ia5b3b4c7f8bc41a29fdeb9e94dcb2561"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTEtMS0xLTEtMzUzMzA_5ceeb7dc-194e-43fe-8e2b-58e5f6a4a787">2,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTEtMy0xLTEtMzUzMzA_1b674dc8-2d67-4b9c-93f2-0b896aa9d6b0">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgages and other debts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OtherLongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTMtMS0xLTEtMzUzMzA_e26109da-d919-40ab-9a30-471e87455bb2">1,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:OtherLongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTMtMy0xLTEtMzUzMzA_7dd09951-b52b-43f4-8b2b-e2941f951f4c">2,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTQtMS0xLTEtMzUzMzA_59ea4cc9-005e-416e-b556-9d99c7b1d6b4">3,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTQtMy0xLTEtMzUzMzA_4a5a25f1-e775-42a4-98cd-14f94efa90de">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTUtMS0xLTEtMzUzMzA_02b7ef5f-6a57-4ea9-8e20-354e87ca5ff0">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTUtMy0xLTEtMzUzMzA_4c6d8856-320c-4da7-ad88-3768825a80f1">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesAndDeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTYtMS0xLTEtMzUzMzA_0c608880-01fa-41e7-bed5-264c7fd1b070">7,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesAndDeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTYtMy0xLTEtMzUzMzA_eedeb179-e1b7-48e8-8c52-d5c0175b4dba">7,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTctMS0xLTEtMzUzMzA_7360588c-39c7-4c4a-b501-55371bdde9da">15,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTctMy0xLTEtMzUzMzA_f9351742-a8b0-42f4-86e2-d48b5dcdcd9b">15,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:4pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets and goodwill relate principally to our completed acquisitions of OPKO Renal, OPKO Biologics, EirGen and BioReference.  We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives.  The estimated useful lives by asset class are as follows:  technologies - <ix:nonNumeric contextRef="i7cd76bb4cb054c24a6c2232c8ce7f462_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMzkz_37bc8bba-91df-4a49-bac5-288524a8008c">7</ix:nonNumeric>-<ix:nonNumeric contextRef="i67eb7ca1a153436b9c63f40b1643cbb5_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMzk2_58abc8e3-3a58-40c7-8670-2affd6666292">17</ix:nonNumeric> years, customer relationships - <ix:nonNumeric contextRef="ib4f4333f6b854395908e42b29b11c12c_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNDMx_304cdc47-54da-451e-833c-45d2e653202d">7</ix:nonNumeric>-<ix:nonNumeric contextRef="if0e396b6f94a488d87020d832f3a71dd_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNDM0_8b9acaa1-a4be-4fcf-bc92-9ecba8e47115">20</ix:nonNumeric> years, product registrations - <ix:nonNumeric contextRef="ie350ba9cd5734e9ca2f654f54c4f32e6_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNDY4_d9f2f798-ae18-4487-99e4-4b685866902e">7</ix:nonNumeric>-<ix:nonNumeric contextRef="ie02675a24f9347258a91c2e8689dac1f_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNDcx_c48517df-f089-4133-a3d5-5ee161bee06c">10</ix:nonNumeric> years, covenants not to compete - <ix:nonNumeric contextRef="i0c94852de80d4e20b88966f2a5803300_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNTA4_9a74c3e6-b408-4a5a-8d48-e0521828fd88">5</ix:nonNumeric> years, trade names - <ix:nonNumeric contextRef="i51146bd0393e4abea9ad351cc048bb8b_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNTMy_9ec2c753-3255-41e8-8946-a29eba2899ad">5</ix:nonNumeric>-<ix:nonNumeric contextRef="i1f99fa3607f14b209d98541827fcf560_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNTM1_a5f776d0-237f-49d1-b530-fee6af15e370">10</ix:nonNumeric> years, other <ix:nonNumeric contextRef="i1fcfed0a51964bf2bb060f3eac1da896_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNTUx_43dffc20-b53c-458b-982f-6ad6547eccde">9</ix:nonNumeric>-<ix:nonNumeric contextRef="i22564da49818430d93721eda04c22d10_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNTU0_64a77a43-c4cc-47a9-8cc6-f7b48b89a6c1">13</ix:nonNumeric> years.  We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred.  Our goodwill is not tax deductible for income tax purposes in any jurisdiction in which we operate.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, GeneDx met the held-for-sale accounting criteria and its related assets and liabilities are recognized at the lower of carrying value or fair value less costs to sell in the consolidated balance sheet. In addition, at March 31, 2022 and December 31, 2021, Assets held for sale included $<ix:nonFraction unitRef="usd" contextRef="i77c9c6ea887e4115b1c0992f4beef719_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMjc0ODc3OTA3MDkzMQ_77515025-1bb8-41da-874a-deb1e23015b4"><ix:nonFraction unitRef="usd" contextRef="i30dd8bae361a48dc85516ce870eae7cb_I20220331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMjc0ODc3OTA3MDkzMQ_e60ee941-0f3e-458f-aef0-a08abac0a2e2">151.8</ix:nonFraction></ix:nonFraction>&#160;million of goodwill related to GeneDx. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we reclassified $<ix:nonFraction unitRef="usd" contextRef="i80eb499192104b008d7af0e0148d19c8_I20220331" decimals="-5" sign="-" name="opk:InProcessResearchandDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMjc0ODc3OTA3MjA2MQ_6c576472-d3ea-4da8-9670-fb74a77b0fb8"><ix:nonFraction unitRef="usd" contextRef="ie9f8b48ec3cc43d09aa306ad85bdfbd6_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMjc0ODc3OTA3MjA2MQ_ed31b481-2f4f-458e-83fd-7958dbd3241b">590.0</ix:nonFraction></ix:nonFraction>&#160;million of IPR&amp;D related to Somatrogon from IPR&amp;D in our Condensed Consolidated Balance Sheet upon the approval of NGENLA (Somatrogon) in Europe and Japan. The assets will be amortized on a straight-line basis over their estimated useful life of approximately <ix:nonNumeric contextRef="i1ec064528f8b46c799fcf289c9791518_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMjc0ODc3OTA3MjAxMg_c4eb890c-1f3b-463b-ab4c-e1b9669f8cd9">12</ix:nonNumeric> years. Other changes in value of the intangible assets and goodwill during the three months ended March 31, 2022 and 2021 were primarily due to foreign currency fluctuations between the Chilean Peso, and the Euro against the U.S. dollar.  </span></div><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMTA4OA_e143c443-3699-46f2-98d5-bd1f78919259" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in Goodwill by reporting unit during the three months ended March 31, 2022.</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.615%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross goodwill  at January 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative impairment at January 1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CURNA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eec319fe4fc4382817c6990539e0de1_I20220101" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMy0xLTEtMS0zNTMzMA_ffb78dfa-74f7-4309-a43e-287e11f457c7">4,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4fc148ac1604fe99eb055c71362744f_I20211231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMy0yLTEtMS0zNTMzMA_5ce1c8df-6c6a-4d99-aa4c-295b7a3f27eb">4,827</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i199321e556e1463989019c01f39f4666_D20220101-20220331" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMy00LTEtMS0zNTMzMA_1976217b-ee81-4627-82b7-11e1d198678c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a7de7c9d3994710a52433ef3622e975_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMy01LTEtMS0zNTMzMA_f0e619c2-a02b-46b1-9163-f34f3f6bd80f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dc68b2fcd3343aca45a1f78bea968ab_I20220101" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNC0xLTEtMS0zNTMzMA_cc692269-03e5-4022-a805-9f168512372d">86,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b82614912a4396b69e605161eac8c8_I20211231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNC0yLTEtMS0zNTMzMA_e584c55c-3310-432c-9304-2b7ef10eef4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e641d3a3f43bba301ff2922df3bc7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNC00LTEtMS0zNTMzMA_68a50649-4b19-4b30-9f5c-a7f962c66966">1,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d8091552aab4b19b8c4d08ef13537d5_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNC01LTEtMS0zNTMzMA_2ffd8c9d-af66-4098-b03c-f269463f115a">84,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FineTech</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd18b46a79c64b6d83b27c4f2d210742_I20220101" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNS0xLTEtMS0zNTMzMA_2b26470d-0727-449c-a8ac-0db11e521dcf">11,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf902a5a04b14f7babb55f3b843e3a80_I20211231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNS0yLTEtMS0zNTMzMA_c7764c2c-0366-47c7-b191-e3fc6895fe7f">11,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i114289ac9f494783bd9d11890dec12dc_D20220101-20220331" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNS00LTEtMS0zNTMzMA_d843dd2e-1797-4ba8-9dd2-903831181211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff62ea5a28684fc8a6b1dc70be867c32_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNS01LTEtMS0zNTMzMA_6296043e-8c06-45c2-94a9-b3e2b1b6b108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Biologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i061dafbf8ba241378db298ff55bea551_I20220101" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNi0xLTEtMS0zNTMzMA_58b1841f-47ff-4b27-bed1-b05cc815c153">139,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30ac8d0d0c694b82a5397dcb0df95a8e_I20211231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNi0yLTEtMS0zNTMzMA_89d3a9c9-286e-45df-af8e-ba2357dbaa46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b2c36299ad4032aad14bf2b2486edf_D20220101-20220331" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNi00LTEtMS0zNTMzMA_fabacf02-4006-4b42-9c4a-eb4f743a9ff8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd5e493ead0e4e5e9162c5c722db4e35_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNi01LTEtMS0zNTMzMA_c21837fe-0cdf-43bd-bbe9-97c570a1a7cc">139,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Chile</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5febec8e3a34d12aeeeb1e3f39919ca_I20220101" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNy0xLTEtMS0zNTMzMA_d4c4af48-dac1-4894-97bf-7033de8859e8">3,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9587f6a4f274caaba6009524613917d_I20211231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNy0yLTEtMS0zNTMzMA_087e1c9e-172d-47dd-aea9-80fd5020d24d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78bb5a3b0424167a9c9b348ea5cf5cc_D20220101-20220331" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNy00LTEtMS0zNTMzMA_4384a7d3-4adb-4ea1-9ae4-7e4beaa0eb0e">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926fe15bf7e14648af39eaf884ccac95_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNy01LTEtMS0zNTMzMA_73b290cd-c579-41b7-a5da-176a14766425">4,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Health Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eaedf3c190742929a4c020e7afc76b8_I20220101" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOC0xLTEtMS0zNTMzMA_6b2c238a-f98b-4db1-ba2d-4a317005e32d">7,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9565f1ff76984a2d87c2caae18caa32a_I20211231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOC0yLTEtMS0zNTMzMA_679d3b58-6444-4530-9873-c251bf8bf310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied7c009dbf6647c2a36b57156c5ce4de_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOC00LTEtMS0zNTMzMA_7f762a22-d6d1-4dc7-89b5-079207d88316">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22ef152d20d46f5b505759af9ebb7f8_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOC01LTEtMS0zNTMzMA_8350d5c9-aa60-40f4-a468-0e9e4623599d">7,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if107abf0de7a41faa040731b1223de77_I20220101" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOS0xLTEtMS0zNTMzMA_54a6212d-ba92-4113-aecd-cd7e0d21f698">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ec024cce2a2496984ae03706c8870ce_I20211231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOS0yLTEtMS0zNTMzMA_a6922b13-05ee-4494-96b5-fbfd4fdad874">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd76cc953044df3aa7d05cbb5e5cf00_D20220101-20220331" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOS00LTEtMS0zNTMzMA_ec4330df-cc60-45f4-9a78-3a3e9fbbbf6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076891eda5724f9e8facc0d32cf101a3_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOS01LTEtMS0zNTMzMA_8996b834-4ff7-42ba-9478-ee733425ba3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transition Therapeutics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf39b19d11f0451580b5298ca4e70ed2_I20220101" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTAtMS0xLTEtMzUzMzA_0232f136-722e-484a-b843-348dc6226ff1">3,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a89597a3caa42bab28aa9233a6692fd_I20211231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTAtMi0xLTEtMzUzMzA_77100aab-0e81-42a9-9c6a-b8b3fe1d8f84">3,421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a2689178204969b6be3b7c80a94903_D20220101-20220331" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTAtNC0xLTEtMzUzMzA_ec0b8d17-61a8-4802-88a9-865ebade44b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id469bfa162ed497c8fd73817abe740dc_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTAtNS0xLTEtMzUzMzA_e1f5044f-031a-40c0-b5a2-165aed4d3417">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BioReference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87bdb1d33c654930a1c1073348ae533c_I20220101" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTMtMS0xLTEtMzUzMzA_b1571b38-985d-44b4-80e3-f106e80e920f">434,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf793477c8f470eaeaeaee2fe7d1534_I20211231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTMtMi0xLTEtMzUzMzA_4552475d-3c18-43f7-b6cb-24ffdd4bc736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9c0e49d0f844798a8cde4028560528e_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTMtNC0xLTEtMzUzMzA_efb5eae6-6bfb-40c1-8a28-5a282782620f">151,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0be93569346549e6b40179e6f26f198c_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTMtNS0xLTEtMzUzMzA_f210b8b3-9992-48ce-8410-517d80076a11">283,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Diagnostics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f702a5c58d541e398fbf371ddd14f4d_I20220101" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTQtMS0xLTEtMzUzMzA_4072dfd4-1047-46ba-a671-f1ec173c8f00">17,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55f7b3a49175491f81bd49d3873d7ef6_I20211231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTQtMi0xLTEtMzUzMzA_b15e238b-e8ae-43a7-93ac-c6f4bea762d1">17,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ce2a0713064856b4736ba58073e798_D20220101-20220331" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTQtNC0xLTEtMzUzMzA_4e9904d2-2452-4b0b-b38c-3b8a647050a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e77dbdc6364495093a3daccd4d4c89e_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTQtNS0xLTEtMzUzMzA_18017c9e-a60e-4e13-88ad-e25d0edb77e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e74f63daa08493f8fddebb9af0d512f_I20220101" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTUtMS0xLTEtMzUzMzA_734ac1b9-afda-4005-a531-4362d0d57d21">710,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTUtMi0xLTEtMzUzMzA_0625ed0e-c475-4b76-87fc-5bcb89522ca2">38,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTUtNC0xLTEtMzUzMzA_d8ad223b-47e1-41e0-b454-7b91e8cf3a43">153,333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTUtNS0xLTEtMzUzMzA_6cf14393-d033-4110-a9f4-bfea5c07c04b">519,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other amounts for three months ended March 31, 2022 includes amounts related to GeneDx which is included as Assets held for sale at March 31, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:InvestmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNjg4NA_7b3a882b-52fe-4b4b-bd7d-adb724f7b29b" continuedAt="i5e62a3af5dd84b158797f6f7e717927d" escape="true">INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i5e62a3af5dd84b158797f6f7e717927d" continuedAt="ia38ac91e482540478d093bd44ce6ab9d"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span></div><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:InvestmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNjg5NA_0ae9003a-da9d-4abb-baff-cc1d6f681bfa" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of March&#160;31, 2022 and December 31, 2021:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:46.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment type</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment Carrying Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Underlying Equity in Net Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment Carrying Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Underlying Equity in Net Assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="opk:EquityMethodInvestmentExcludingVariableInterestEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMi0yLTEtMS0zNTMzMA_b39d7fa6-14c7-4aaf-9243-7cf7405243ef">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMi00LTEtMS0zNTMzMA_ce337c95-895b-4d93-99ee-a83fa407621b">4,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="opk:EquityMethodInvestmentExcludingVariableInterestEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMi02LTEtMS0zNTMzMA_49d7ac36-ae83-4443-9e07-779dbee744f8">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMi04LTEtMS0zNTMzMA_bc1153ab-bf7a-4f70-80f0-082b4686abe6">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable interest entity, equity method</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="opk:EquityMethodInvestmentVariableInterestEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMy0yLTEtMS0zNTMzMA_da197235-8de9-464b-94e8-735c77749b4a">773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="opk:EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMy00LTEtMS0zNTMzMA_2060c3e0-24a3-4123-9a94-0e23f9e45efb">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="opk:EquityMethodInvestmentVariableInterestEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMy02LTEtMS0zNTMzMA_d2cb6359-b5a9-4db0-aee0-95a031b9bfbb">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="opk:EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMy04LTEtMS0zNTMzMA_dbd63afa-97b9-4e3a-ab53-8d6ea9ec8ea5">3,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNC0yLTEtMS0zNTMzMA_3fd368e5-1167-4802-b904-47eb7832cb04">3,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNC02LTEtMS0zNTMzMA_6cef44b3-ea3a-45ab-9646-67e7b7ecc735">4,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with no readily determinable fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNS0yLTEtMS0zNTMzMA_b32dd7a3-7231-43d7-9b44-b6d812c51152">5,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNS02LTEtMS0zNTMzMA_702ab09a-f1fd-441f-98d2-72855e916db8">5,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants and options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="opk:StockOptionandWarrantInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNi0yLTEtMS0zNTMzMA_b1cca7b1-9998-4ae8-87b0-5bd8be4b27e5">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="opk:StockOptionandWarrantInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNi02LTEtMS0zNTMzMA_af8ea7f1-e28b-4d21-ba49-a14c30e13665">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNy0yLTEtMS0zNTMzMA_d2f7c1ad-c8e0-4904-828b-5d57b4419cf2">9,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNy02LTEtMS0zNTMzMA_df2728e9-1339-4ae6-9b8a-642a3df52950">10,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Equity method investments</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity method investments consist of investments in Pharmsynthez (ownership <ix:nonFraction unitRef="number" contextRef="i2da87d4b1cea40abb7f65c8419989f04_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMzEz_c987587f-d3ef-4b8c-ad28-8d55402bee88">9</ix:nonFraction>%), Cocrystal Pharma, Inc. (&#8220;COCP&#8221;) (<ix:nonFraction unitRef="number" contextRef="ief9f3d5f2c21400fbcb87f69615b8cf1_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMzUx_ff4c87ff-a99a-4456-91bb-d0b852bc86b1">3</ix:nonFraction>%), Non-Invasive Monitoring Systems, Inc. (&#8220;NIMS&#8221;) (<ix:nonFraction unitRef="number" contextRef="i2a5eea0a1fa844b19b8baa7361a45542_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNDA0_0a9844f5-8dfe-49c7-b5df-9f345a6e9a5d">1</ix:nonFraction>%), Neovasc, Inc. (&#8220;Neovasc&#8221;) (<ix:nonFraction unitRef="number" contextRef="i4e737b98458d4a859ab982878352b552_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNDM2_f938b0c8-1b39-41a4-bd13-468aa30cdc7b">1</ix:nonFraction>%), InCellDx, Inc. (&#8220;InCellDx&#8221;) (<ix:nonFraction unitRef="number" contextRef="i61c6fa53ff434aeea2559a0e6fca1f8f_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNDcw_8550f2f9-b086-4bb7-9b7f-f776ea7b1ebd">29</ix:nonFraction>%), BioCardia, Inc. (&#8220;BioCardia&#8221;) (<ix:nonFraction unitRef="number" contextRef="iefc49f12f9a24f6a8438f9164321e4b9_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNTA2_4b8d7905-59d4-4115-8999-9023f57eaa52">1</ix:nonFraction>%), Xenetic Biosciences, Inc. (&#8220;Xenetic&#8221;) (<ix:nonFraction unitRef="number" contextRef="ide7dce2757b14a7e80beaf9e7f36bc70_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNTUw_3ebfd2c2-09e2-4813-8137-392e2e0a3a13">1</ix:nonFraction>%), and LeaderMed Health Group Limited (&#8220;LeaderMed&#8221;) (<ix:nonFraction unitRef="number" contextRef="i3e85d9626c1c441cb3ee913546454e58_D20220101-20220331" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMTA5OTUxMTY0MzgzMA_6b74935e-6ac9-4594-a789-719ac72d6fef">47</ix:nonFraction>%).  The aggregate amount of assets, liabilities, and net losses of our equity method investees as of and for the three months ended March 31, 2022 were $<ix:nonFraction unitRef="usd" contextRef="i345405f3f02b45a1bf5c9b950dde0383_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNzI4_2b35e11e-08b1-4d9e-aa6b-783f2564ec08">222.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i345405f3f02b45a1bf5c9b950dde0383_I20220331" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNzMy_a71cfe62-42b3-4e24-b2ea-3f2ac545fe97">37.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ic8ff88bb39754838bea82d4aa6fe8b0d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNzQw_3d9a6a1c-f9ba-4740-a4de-e253122af1e2">19.0</ix:nonFraction> million, respectively.  The aggregate amount of assets, liabilities, and net losses of our equity method investees as of and for the year ended December 31, 2021 were $<ix:nonFraction unitRef="usd" contextRef="ib3269e9e5de645f7ab9c3fa24f73c940_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfOTAy_c82173c4-d8a6-4401-b0a5-f90c7a9baef6">223.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ib3269e9e5de645f7ab9c3fa24f73c940_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfOTA2_3294dc7a-16a3-42f0-b621-ea89659f8b6e">37.9</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i0c994275c6324f47a249b3109e183353_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfOTE0_d0f9e205-6b8b-4234-bd04-5dd0136c7b7c">69.4</ix:nonFraction>&#160;million, respectively. We have determined that we and/or our related parties can significantly influence control of our equity method investments through our board representation and/or voting power.  Accordingly, we account for our investment in these entities under the equity method and record our proportionate share of their losses in Loss from investments in investees in our Condensed Consolidated Statement of Operations.  The aggregate value of our equity method investments based on the quoted market prices of their respective shares of common stock and the number of shares held by us as of March&#160;31, 2022 and December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-5" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMTUxOQ_b03889f8-637f-42a9-a703-7db7dc89fa8f">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjc0ODc3OTA3NjQxNg_0b58d32a-b51a-440d-aa4b-3e9919a058b2">4.5</ix:nonFraction>&#160;million, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity securities consist of investments in Phio Pharmaceuticals (&#8220;Phio&#8221;) (ownership <ix:nonFraction unitRef="number" contextRef="i735a6dd4044144048e04b19307ebbe2d_I20220331" decimals="4" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMTY0Nw_6d07e43c-eefd-4c21-b59c-f9af8862da4c">0.01</ix:nonFraction>%), VBI Vaccines Inc. (&#8220;VBI&#8221;) (<ix:nonFraction unitRef="number" contextRef="i93c10577f5fe4cf5aa85dbf6a728072b_I20220331" decimals="2" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMTY3OQ_ebca1b48-b37e-449a-a6c0-fc2ec5e6daa3">1</ix:nonFraction>%), ChromaDex Corporation (&#8220;ChromaDex&#8221;) (<ix:nonFraction unitRef="number" contextRef="idb8abbb296ab4fd6bec8792f90ed897c_I20220331" decimals="3" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMTcyMQ_55b70578-4f4a-4d01-8679-e0feec244537">0.1</ix:nonFraction>%), Eloxx Pharmaceuticals, Inc. (&#8220;Eloxx&#8221;) (<ix:nonFraction unitRef="number" contextRef="i745a5d9c8eda4157b142bcd4ae5184df_I20220331" decimals="2" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMTc2NQ_bf8a4df2-26a6-4516-a7af-2e2f4e273526">1</ix:nonFraction>%), and CAMP4 Therapeutics Corporation (&#8220;CAMP4&#8221;) (<ix:nonFraction unitRef="number" contextRef="ic9dabca72cbc43ae823846a3ceb570c6_I20220331" decimals="2" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMTgxNg_6616cbdc-27f4-4c9a-836f-7d66fe6c465c">5</ix:nonFraction>%) and HealthSnap, Inc. (<ix:nonFraction unitRef="number" contextRef="i74ad64c47d06402791389d97af41b417_I20220331" decimals="2" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMzg0ODI5MDcxMjc1Nw_3082c6fc-c956-43b4-8df9-fc98d1ac2ff8">7</ix:nonFraction>%).  We have determined that our ownership, along with that of our related parties, does not provide us with significant influence over the operations of these investments.  Accordingly, we account for our investment in these entities as equity securities, and we record changes in the fair value of these investments in Other income (expense) each reporting period when they have readily determinable fair value. Equity securities without a readily determinable fair value are adjusted to fair value when there is an observable price change. <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNjg4OA_9152b516-679f-4b74-a1c3-e5b6d108b69b" continuedAt="iee80bd0d45834261a9e9aec04e235180" escape="true">Net gains and losses on our equity securities for the three months ended March 31, 2022, and 2021 were as follows:</ix:nonNumeric></span></div><div style="margin-top:14pt"><ix:continuation id="iee80bd0d45834261a9e9aec04e235180"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March&#160;31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity Securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gains and losses recognized during the period on equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOjExOTkxNmQ0NjhiNzRhMGY5NTdmZGMyYjkyMWJiYjNiL3RhYmxlcmFuZ2U6MTE5OTE2ZDQ2OGI3NGEwZjk1N2ZkYzJiOTIxYmJiM2JfMy0xLTEtMS0zNTMzMA_8fbbb26f-9edc-4df9-a3c7-6976e7575a35">1,162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOjExOTkxNmQ0NjhiNzRhMGY5NTdmZGMyYjkyMWJiYjNiL3RhYmxlcmFuZ2U6MTE5OTE2ZDQ2OGI3NGEwZjk1N2ZkYzJiOTIxYmJiM2JfMy0zLTEtMS0zNTMzMA_9e80955d-f23c-478c-9358-3ebd50e27f54">2,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net gains realized during the period on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOjExOTkxNmQ0NjhiNzRhMGY5NTdmZGMyYjkyMWJiYjNiL3RhYmxlcmFuZ2U6MTE5OTE2ZDQ2OGI3NGEwZjk1N2ZkYzJiOTIxYmJiM2JfNC0xLTEtMS0zNTMzMA_1aad6664-9901-4523-a2b5-3776fc3a9b42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOjExOTkxNmQ0NjhiNzRhMGY5NTdmZGMyYjkyMWJiYjNiL3RhYmxlcmFuZ2U6MTE5OTE2ZDQ2OGI3NGEwZjk1N2ZkYzJiOTIxYmJiM2JfNC0zLTEtMS0zNTMzMA_47a1857c-ca66-4336-843e-87733f7eee9f">2,981</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized net gains and losses recognized during the period on equity securities still held at the reporting date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOjExOTkxNmQ0NjhiNzRhMGY5NTdmZGMyYjkyMWJiYjNiL3RhYmxlcmFuZ2U6MTE5OTE2ZDQ2OGI3NGEwZjk1N2ZkYzJiOTIxYmJiM2JfNS0xLTEtMS0zNTMzMA_ff0db4d2-27a8-4db2-a6eb-b37120d031dc">1,162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOjExOTkxNmQ0NjhiNzRhMGY5NTdmZGMyYjkyMWJiYjNiL3RhYmxlcmFuZ2U6MTE5OTE2ZDQ2OGI3NGEwZjk1N2ZkYzJiOTIxYmJiM2JfNS0zLTEtMS0zNTMzMA_97a7cbb3-71ee-4b29-b397-565387dc402b">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales of investments</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="ia38ac91e482540478d093bd44ce6ab9d" continuedAt="i18e126f5e0b24a7dbc4983bd38254af5"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains (losses) included in earnings from sales of our investments are recorded in Other income (expense), net in our Condensed Consolidated Statement of Operations.  The cost of securities sold is based on the specific identification method.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants and options</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our equity method investments and equity securities, we hold options to purchase <ix:nonFraction unitRef="shares" contextRef="i045c2a8d58864ccc84d9e26f6de225bf_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjgyOA_e4467966-b652-4375-ab5d-8ce167efda02"><ix:nonFraction unitRef="shares" contextRef="iefc49f12f9a24f6a8438f9164321e4b9_I20220331" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjgyOA_fc84d79c-64db-40b9-ba38-a995824da217">47</ix:nonFraction></ix:nonFraction> thousand additional shares of BioCardia, all of which were vested as of March&#160;31, 2022 and December 31, 2021, and <ix:nonFraction unitRef="shares" contextRef="ief9f3d5f2c21400fbcb87f69615b8cf1_I20220331" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjkyNA_ab791920-d7e7-4bf9-8198-381c210ddb0c">33</ix:nonFraction> thousand and <ix:nonFraction unitRef="shares" contextRef="i61c6fa53ff434aeea2559a0e6fca1f8f_I20220331" decimals="-5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjkyOA_965d2d2f-25e6-490d-980e-68dd03e38526">0.7</ix:nonFraction> million to purchase additional shares of COCP and InCellDx, respectively.  We recorded the changes in the fair value of the options and warrants in Fair value changes of derivative instruments, net in our Condensed Consolidated Statement of Operations.  We also recorded the fair value of the options and warrants in Investments, net in our Condensed Consolidated Balance Sheet.  See further discussion of the Company&#8217;s options and warrants in Note 9 and Note 10.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in variable interest entities</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that we hold variable interests in LeaderMed, Detect Genomix, LLC (&#8220;Detect Genomix&#8221;) and Zebra Biologics, Inc. (&#8220;Zebra&#8221;). We made this determination as a result of our assessment that they do not have sufficient resources to carry out their principal activities without additional financial support.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2021, we and LeaderMed, a pharmaceutical development company with operations based in Asia, announced the formation of a joint venture to develop, manufacture and commercialize two of OPKO&#8217;s clinical stage, long-acting drug products in Greater China and eight other Asian territories. Under the terms of the agreements, we have granted the joint venture exclusive rights to develop, manufacture and commercialize (a) OPK88003, an oxyntomodulin analog being developed for the treatment of obesity and diabetes, and (b) Factor VIIa-CTP, a novel long acting coagulation factor being developed to treat hemophilia, in exchange for <ix:nonFraction unitRef="shares" contextRef="id1b622c3fa27402b9211c7b4ccf25f7f_D20210914-20210914" decimals="INF" name="opk:NoncontrollingInterestSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjc0ODc3OTA3ODM4OA_c3efc113-a120-4427-8903-73504e16450a">4,703</ix:nonFraction> shares <ix:nonFraction unitRef="number" contextRef="i36d25b2cfa03459783a6e94281295ca5_I20210914" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjc0ODc3OTA3ODM5NQ_36eae7dd-3c9b-42bc-9cbc-129ced9ecb7a">47</ix:nonFraction>% ownership interest in the joint venture. In addition, we received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ie8156096c5d249378540b9fe04c480dc_D20210914-20210914" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjc0ODc3OTA3ODM3NA_6a39db1e-d108-4fb1-8540-07c207feaaee">1.0</ix:nonFraction>&#160;million and will be reimbursed for clinical trial material and technical support we provide the joint venture.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the primary beneficiary of the joint venture, we evaluated our investment and our related parties&#8217; investment, as well as our investment combined with the related parties&#8217; investment to identify if we had the power to direct the activities that most significantly impact the economic performance of the joint venture. Based on the capital structure, governing documents and overall business operations of the joint venture, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact the joint venture&#8217;s economic performance and do not have an obligation to fund expected losses. We did determine that we can significantly influence control of the joint venture through our board representation and voting power. Therefore, we have the ability to exercise significant influence over the joint venture&#8217;s operations and account for our investment in the joint venture under the equity method.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, GeneDx LLC, a subsidiary of the Company, announced that it had entered into an agreement with Pediatrix Medical Group (&#8220;Pediatrix&#8221;), a provider of maternal-fetal, and pediatric medical and surgical subspecialty physician services, to offer genomic sequencing to support clinical diagnosis in neonatal intensive care units staffed by Pediatrix&#8217;s affiliated neonatologists. The offering is planned to include whole exome and whole genome sequencing and genomic support services under the brand Detect Genomix. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial capital investment in Detect Genomix was $<ix:nonFraction unitRef="usd" contextRef="ibadd78e70def4793bd8033df5fdbe911_D20200801-20200831" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNDM1Mw_77bebb7f-a795-40ef-bbe3-00b2a847d966">245,000</ix:nonFraction> for which we received a <ix:nonFraction unitRef="number" contextRef="i4a78517025804d929c0e5e426c1b9a4b_I20200831" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNDM4MA_b063342a-e16c-4a8f-ac39-6699f3e966df">49</ix:nonFraction>% ownership interest in Detect Genomix. We had been required to make additional capital contributions to Detect Genomix in accordance with our percentage interests if Detect Genomix were unable to generate positive cash flow from operations or is unable to obtain alternative financing.  We have not made any other investments in or loans to Detect Genomix through March 31, 2021. In January 2022, the Detect Genomix agreement was terminated.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the primary beneficiary of Detect Genomix, we evaluated our investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Detect Genomix.  Based on the capital structure, governing documents and overall business operations of Detect Genomix, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Detect Genomix&#8217;s economic performance.  We determined, however, that we can significantly influence control of Detect Genomix through our board representation and voting power.  Therefore, we have the ability to exercise significant influence over Detect Genomix&#8217;s operations and account for our investment in Detect Genomix under the equity method.  The joint venture was dissolved in January 2022.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own <ix:nonFraction unitRef="shares" contextRef="i025ab7646b8144b688675d0f4247839f_I20220331" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNTU1OA_192b4ee2-b94d-47e5-866c-d631771902f1">1,260,000</ix:nonFraction> shares of Zebra Series A-2 Preferred Stock and <ix:nonFraction unitRef="shares" contextRef="i0bba573814e746888e84c5b2aa904dc8_D20220101-20220331" decimals="INF" name="opk:SharesReceivedAsGift" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNTYwOA_1db58503-29da-4af0-b29d-3ae6648beadc">900,000</ix:nonFraction> shares of Zebra restricted common stock (ownership <ix:nonFraction unitRef="number" contextRef="iced2ab36569e4ad68d856b5c48df2e03_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNTY2Mg_23057728-8e3d-405a-8413-28883cf49479">29</ix:nonFraction>% at March&#160;31, 2022).  Zebra is a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drugs.  Dr. Richard Lerner, M.D., a former member of our Board of Directors, is a founder of Zebra and, along with Dr. Frost, serves as a member of Zebra&#8217;s Board of Directors.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i18e126f5e0b24a7dbc4983bd38254af5">In order to determine the primary beneficiary of Zebra, we evaluated our investment and our related parties&#8217; investment, as well as our investment combined with the related parties&#8217; investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Zebra.  Based on the capital structure, governing documents and overall business operations of Zebra, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Zebra&#8217;s economic performance and have no obligation to fund expected losses.  We determined, however, that we can significantly influence control of Zebra through our board representation and voting power.  Therefore, we have the ability to exercise significant influence over Zebra&#8217;s operations and account for our investment in Zebra under the equity method.</ix:continuation></span></div><div id="i1cac816ff800494ea2979c434f00b37c_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTU3Mzg_a39f9a91-45a7-4740-a584-df305fd8d95f" continuedAt="ib04eb1b43719489cadadc7b456e95247" escape="true">DEBT</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib04eb1b43719489cadadc7b456e95247" continuedAt="i2f761df4292f4d67867e8ccf591450f0">&#160;&#160;&#160;&#160;</ix:continuation></span></div><ix:continuation id="i2f761df4292f4d67867e8ccf591450f0" continuedAt="i02c0497868fe47d2a81010bdf58176b7"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTU3NDE_557dc244-5c74-4f36-bed5-749cef33ea11" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, our debt consisted of the following:</span></div><div style="margin-top:9pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e46f99237c8496ca82c13bda9e7f294_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMS0xLTEtMS0zNTMzMA_c124cf43-a5cd-4f78-9274-d3fc87a4c4bf">141,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc38b647115245d9a1d1122f23f15088_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMS0zLTEtMS0zNTMzMA_d3451135-89f0-44d7-97bb-067b1a7051e8">119,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Convertible Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46d6876e7be847069467c27ec77a4a44_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMi0xLTEtMS0zNTMzMA_970fe1c3-6c37-41f2-90c5-b6c084226273">66,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i487322626c254451bb84eeb5072abbac_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMi0zLTEtMS0zNTMzMA_17e50eb6-7f40-4d1d-94b0-780d9fa5945e">65,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2033 Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fba9c7092e04a5ba143a73b73dada89_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMy0xLTEtMS0zNTMzMA_f902c829-e20f-4260-9ec1-ac0e8e8261f8">3,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a642fa3cc44c77b27622488a3dcf17_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMy0zLTEtMS0zNTMzMA_48e5b8a2-64ab-43ef-bbb4-9251beb8585a">3,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chilean and Spanish lines of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a2bb52ee16c4f3cbd50cd8ebe53b377_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfNS0xLTEtMS0zNTMzMA_afe88224-0f53-4ef1-bbca-da98c87a4d50">16,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66232faa6934fc58bd350c3c5087464_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfNS0zLTEtMS0zNTMzMA_39b250f1-23c0-4bfa-8041-0e8e7622b68b">13,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea90eb5c3a649d1a00ba71dfd8d4665_I20220331" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfNi0xLTEtMS0zNTMzMA_226b7cf9-883d-40c4-9b05-f6deaa2b0907">882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14a4df5ee1294c10a8f972615bb565fa_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfNi0zLTEtMS0zNTMzMA_5b50337c-0d5e-4fc3-bfee-4344ae9782f6">1,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long term portion of notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea90eb5c3a649d1a00ba71dfd8d4665_I20220331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfNy0xLTEtMS0zNTMzMA_9f54f58e-47fd-4968-813a-8b0ee235207d">2,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14a4df5ee1294c10a8f972615bb565fa_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfNy0zLTEtMS0zNTMzMA_2d280fd6-7396-492e-9375-f30cdedbc628">2,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfOC0xLTEtMS0zNTMzMA_692c7a60-3555-4005-b839-ffed229d0b03">230,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfOC0zLTEtMS0zNTMzMA_eb5292cf-d1f7-4a85-b2fe-0e4499c79195">205,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance sheet captions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1511200111f48499ddfcbcdc01ff960_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTEtMS0xLTEtMzUzMzA_fd1364ff-3ee5-403c-a106-28bc60fb867e">210,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70922a4b40e947b7a60140a1158f9de6_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTEtMy0xLTEtMzUzMzA_ada9d6b4-35cd-4768-88aa-83fdc5baacb6">187,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lines of credit and notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0fe0dcaa05548b79dc808f805d895bf_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTItMS0xLTEtMzUzMzA_8ee7bae7-75ab-43ec-9abb-20ee17979990">17,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314f83bf93da4b8a953b12a86b015762_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTItMy0xLTEtMzUzMzA_13283ce3-d853-4c1e-ad79-cbc398af4abc">14,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LT notes payable included in long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5f0e2847a64769ab9be88846f125c4_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTMtMS0xLTEtMzUzMzA_39ab4a4d-4fc9-4e82-86d9-1ba73dac9fce">2,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae497a6420cd4f4faf38ce9662826b4e_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTMtMy0xLTEtMzUzMzA_14161ee6-f27f-4bbc-b1f0-440f34188e2f">2,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTQtMS0xLTEtMzUzMzA_a3331659-5b36-4f37-aba5-b0d1ef3051e5">230,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTQtMy0xLTEtMzUzMzA_1400be7e-21ce-49bd-b7eb-a7a5ba3a3c80">205,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2020, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="i77752216e0a74e5e94c99ae54b2ab33f_I20200225" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjY3_496ef3a8-888d-4934-96bf-1d776b1176c7">100</ix:nonFraction> million.  The line of credit called for a commitment fee equal to <ix:nonFraction unitRef="number" contextRef="i9ba35bd01ebf48fc928c6575df35dcf4_D20200225-20200225" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMzI4_f7b9a0d3-3313-4b1b-b8ad-b589908a9ebc">0.25</ix:nonFraction>% per annum of the unused portion of the line. <ix:nonFraction unitRef="usd" contextRef="ia1b9e43d842649f78bdeeb877a771557_I20220331" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNDUz_637f99d5-c303-4b95-9add-74e05b4b9e9f">No</ix:nonFraction> funds were borrowed under this line of credit and we terminated this line of credit in June 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we issued $<ix:nonFraction unitRef="usd" contextRef="ie2696a40617340cf8c06f43678aedbcc_I20190228" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTE5_0ada0b1a-2302-4542-b83b-42fee1b2d32b">200.0</ix:nonFraction> million aggregate principal amount of Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in an underwritten public offering.  The 2025 Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="i3d3e367b0c444609b24109041edeb01b_I20190228" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNjg0_c0a934b1-d341-4347-8523-0bfaf87d27cf">4.50</ix:nonFraction>% per year, payable semiannually in arrears on February&#160;15 and August&#160;15 of each year.  The notes mature on February&#160;15, 2025, unless earlier repurchased, redeemed or converted.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2025 Notes into shares of Common Stock at their option at any time prior to the close of business on the business day immediately preceding November&#160;15, 2024 only under the following circumstances:  (1)&#160;during any calendar quarter commencing after the calendar quarter ended March&#160;31, 2019 (and only during such calendar quarter), if the last reported sale price of our Common Stock for at least <ix:nonFraction unitRef="day" contextRef="i40061516e65d48a1b5e3f3064a40b794_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTI4Nw_7251fabc-c971-487e-8265-e3e968a2a07d">20</ix:nonFraction> trading days (whether or not consecutive) during a period of <ix:nonFraction unitRef="day" contextRef="i9df45c289aa6458e8a7b184c9d9eb1f5_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTM1MQ_60883b02-bc64-4ed8-9de8-098859a9af5f">30</ix:nonFraction> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="i5f67d9074c764297ade8fcccc8dc5b7a_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTQ4NA_ffaf311f-eea7-4ef4-89ab-1734b21d968b">130</ix:nonFraction>% of the conversion price on each applicable trading day; (2)&#160;during the <ix:nonFraction unitRef="day" contextRef="i93cfe6ee9aef4ae3bb7d5b05ab545903_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTU1OA_520d04e2-724f-4415-a9fe-ac4b309e5696">five</ix:nonFraction> business day period after any <ix:nonFraction unitRef="day" contextRef="i8f1f20509fa846cf8da8cbaef989bbe8_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTU5MQ_6ad84543-d837-42f7-a5d0-fa9aa551b71a">five</ix:nonFraction> consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of 2025 Notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="id0582da3183f40ca88c4cb1db58d7e0c_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTc4Mg_94b1662a-423a-44f6-9156-a8d6a2b9700c">98</ix:nonFraction>% of the product of the last reported sale price of our Common Stock and the conversion rate on each such trading day; (3)&#160;if we call any or all of the 2025 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4)&#160;upon the occurrence of specified corporate events set forth in the indenture governing the 2025 Notes.  On or after November&#160;15, 2024, until the close of business on the business day immediately preceding the maturity date, holders of the 2025 Notes may convert their notes at any time, regardless of the foregoing conditions.  Upon conversion, we will pay or deliver, as the case may be, cash, shares of our Common Stock, or a combination of cash and shares of our Common Stock, at our election.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial and current conversion rate for the 2025 Notes is 236.7424 shares of Common Stock per $1,000 principal amount of 2025 Notes (equivalent to a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ie2696a40617340cf8c06f43678aedbcc_I20190228" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc1OA_7c174e29-f190-465d-bfcd-c0dd5801ff30">4.22</ix:nonFraction> per share of Common Stock).  The conversion </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i02c0497868fe47d2a81010bdf58176b7" continuedAt="i4c9057ad95d944bea1b61a1bd1c3dfe3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rate for the 2025 Notes is subject to adjustment in certain events but will not be adjusted for any accrued and unpaid interest.  In addition, following certain corporate events that occur prior to the maturity date of the 2025 Notes or if we deliver a notice of redemption, in certain circumstances the indenture governing the 2025 Notes requires an increase in the conversion rate of the 2025 Notes for a holder who elects to convert its notes in connection with such a corporate event or notice of redemption, as the case may be.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not redeem the 2025 Notes prior to February&#160;15, 2022.  We may redeem for cash any or all of the 2025 Notes, at our option, on or after February&#160;15, 2022, if the last reported sale price of our Common Stock has been at least <ix:nonFraction unitRef="number" contextRef="i4609448adb58436ab818127efb5758c2_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMzg0ODI5MDcxNTIwMQ_6cc1bae3-6a4f-4ede-a1c3-b23feaf37c8a">130</ix:nonFraction>% of the then current conversion price for the notes for at least <ix:nonFraction unitRef="day" contextRef="i7c2ad3f0dc804c1d9adea93dace26206_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMzg0ODI5MDcxNTIxNw_071d0f6e-3967-47a5-b007-615ba5789ff9">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="day" contextRef="ia70bad4845e84935a8ef37f70822b5d7_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMzg0ODI5MDcxNTIwOQ_90aefee8-65ff-4039-bfa8-f7fcfd22fa42">30</ix:nonFraction> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i4609448adb58436ab818127efb5758c2_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMzg0ODI5MDcxNTIyMw_26601551-b55a-427e-97aa-a42a707f88e5">100</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.  No sinking fund is provided for the 2025 Notes.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change, as defined in the indenture governing the 2025 Notes, prior to the maturity date of the 2025 Notes, holders may require us to repurchase for cash all or any portion of their notes at a repurchase price equal to <ix:nonFraction unitRef="number" contextRef="i5f67d9074c764297ade8fcccc8dc5b7a_D20190201-20190228" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNDM0Nw_495f989d-d4b5-4341-9008-6ce921b2e559">100</ix:nonFraction>% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.  The 2025 Notes are our senior unsecured obligations and rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2025 Notes; equal in right of payment to any of our existing and future liabilities that are not so subordinated; effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into exchange agreements with certain holders of the 2025 Notes, pursuant to which the holders exchanged $<ix:nonFraction unitRef="usd" contextRef="i227355c0a3f841b09e53338c115c186d_D20210501-20210531" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTE4OQ_69273baa-fc42-4b0c-bb4a-2797f48eae3e">55.4</ix:nonFraction>&#160;million in aggregate principal amount of the outstanding 2025 Notes for <ix:nonFraction unitRef="shares" contextRef="i227355c0a3f841b09e53338c115c186d_D20210501-20210531" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTI1Ng_37dd201c-f941-42ea-9b8a-eb3362dd2d65">19,051,270</ix:nonFraction> shares of our Common Stock (the &#8220;Exchange&#8221;). We recorded an $<ix:nonFraction unitRef="usd" contextRef="i227355c0a3f841b09e53338c115c186d_D20210501-20210531" decimals="-5" sign="-" name="opk:GainLossOnConversionOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTMxOQ_e905507b-53f8-42fe-944a-3bbd3d950225">11.1</ix:nonFraction>&#160;million non-cash loss related to the Exchange during the second quarter of 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the issuance of the 2025 Notes, we agreed to loan up to <ix:nonFraction unitRef="shares" contextRef="ie2696a40617340cf8c06f43678aedbcc_I20190228" decimals="INF" name="opk:DebtInstrumentConvertibleDebtMaximumSharesIssuable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTQzNw_19d62cd4-415f-47ec-bc5e-9e3e04b4b625">30,000,000</ix:nonFraction> shares of our Common Stock to affiliates of the underwriter in order to assist investors in the 2025 Notes to hedge their position. Following consummation of the Exchange, the number of outstanding borrowed shares of Common Stock was reduced by approximately <ix:nonFraction unitRef="shares" contextRef="i227355c0a3f841b09e53338c115c186d_D20210501-20210531" decimals="INF" sign="-" name="opk:DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTY5OQ_5b447b2c-4dde-4e05-9437-0c80229e064e">8,105,175</ix:nonFraction> shares. As of&#160;March&#160;31, 2022 and December 31, 2021, a total of&#160;<ix:nonFraction unitRef="shares" contextRef="id91a4eb6cea742e4b1b93c700e56993f_D20220101-20220331" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTc1Mw_87f300c6-bddc-430e-a3a1-a787abb8f83f">21,144,825</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5e68b8b37fc848168cc743f1b5049318_D20210101-20211231" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTc2MQ_1b7da18b-6654-43ce-90bd-359ab4a7f014">21,144,825</ix:nonFraction> shares remained outstanding under the&#160;share lending&#160;arrangement, respectively. We will not receive any of the proceeds from the sale of the borrowed shares, but we received a one-time nominal fee of $<ix:nonFraction unitRef="usd" contextRef="id91a4eb6cea742e4b1b93c700e56993f_D20220101-20220331" decimals="-5" name="opk:ProceedsFromConvertibleDebtConversionFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTk2Mw_086cdda4-4b09-450b-9e3a-66a43309b15e">0.3</ix:nonFraction> million for the newly issued shares. Shares of our Common Stock outstanding under the&#160;share lending&#160;arrangement are excluded from the calculation of basic and diluted earnings per share. See Note 4.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by ASC 470-20, &#8220;Debt with Conversion and Other Options,&#8221; we calculated the equity component of the 2025 Notes, taking into account both the fair value of the conversion option and the fair value of the&#160;share lending arrangement. The equity component was valued at&#160;$<ix:nonFraction unitRef="usd" contextRef="ie2696a40617340cf8c06f43678aedbcc_I20190228" decimals="-5" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNjQzMw_0b7a0555-1ac2-41a2-bd36-94e842aea33f">52.6</ix:nonFraction> million&#160;at issue date and this amount was recorded as Additional paid-in capital, which resulted in a discount on the 2025 Notes. The discount is being amortized to Interest expense over the term of the 2025 Notes, which results in an effective interest rate on the 2025 Notes of <ix:nonFraction unitRef="number" contextRef="i7e46f99237c8496ca82c13bda9e7f294_I20220331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNjcwOA_82ac124a-13f4-4770-af15-350bba48588e">11.2</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTU3NjA_f8d9a94c-e1c9-4eea-a4f9-137c245c51c7" continuedAt="i50022cfcdafa4983866227fc6715822e" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information related to the 2025 Notes which is included in our Condensed Consolidated Balance Sheet as of March&#160;31, 2022:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 Senior Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt Issuance Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b205efadb964c1cb4dff4ca72b078bb_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfMS0xLTEtMS0zNTMzMA_134c397a-b799-4b43-883e-72b7318a6083">144,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b205efadb964c1cb4dff4ca72b078bb_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfMS0zLTEtMS0zNTMzMA_96d5b554-ba7b-4f11-bce8-1ca679570a12">22,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b205efadb964c1cb4dff4ca72b078bb_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfMS01LTEtMS0zNTMzMA_af8d7d0e-3512-41bf-bb9f-8c0e39c1e828">2,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b205efadb964c1cb4dff4ca72b078bb_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfMS03LTEtMS0zNTMzMA_9ec88805-e894-4268-993d-99da3d9f4235">119,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacfe2e319d1e4f1cad4106efad251be5_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfMy0zLTEtMS0zNTMzMA_f026ea0b-1476-4c89-8757-8bd7de23a1ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacfe2e319d1e4f1cad4106efad251be5_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfMy01LTEtMS0zNTMzMA_3c438d58-39a7-49d5-9d1c-e7c7f439ef26">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacfe2e319d1e4f1cad4106efad251be5_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfMy03LTEtMS0zNTMzMA_42e586f9-a61b-4479-a74a-706057d7ac2e">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adoption of ASU 2020-06</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i994823b7aa8d4a3aab131ffa60b3a73f_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS0xLTEtMS0zOTUzMA_1c38fe42-4f4b-46bf-a5a0-e0d529e13eb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i994823b7aa8d4a3aab131ffa60b3a73f_I20211231" decimals="-3" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS0zLTEtMS0zOTUzMA_3c84d621-ff42-447d-bd47-d99d5b6078cd">22,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i994823b7aa8d4a3aab131ffa60b3a73f_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS01LTEtMS0zOTUzMA_2059ea8b-aea2-4747-840a-c72cd57d5e3b">1,104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i994823b7aa8d4a3aab131ffa60b3a73f_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS03LTEtMS0zOTUzMA_2e799a0d-dfe4-4314-a44f-a39ca814f04a">21,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4045f45f8fc4c08bec50e050b1907c7_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS0xLTEtMS0zNTMzMA_d17a1cb3-68c4-4618-95ea-b5bfc826069b">144,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4045f45f8fc4c08bec50e050b1907c7_I20220331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS0zLTEtMS0zNTMzMA_f172df26-46d8-4f13-9fa6-41dbeeae427d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4045f45f8fc4c08bec50e050b1907c7_I20220331" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS01LTEtMS0zNTMzMA_9f6d7e1e-d190-45ca-a4af-b7d8be711db5">3,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4045f45f8fc4c08bec50e050b1907c7_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS03LTEtMS0zNTMzMA_41c5f797-386e-4bc4-aeb8-7e9fc9d509e7">141,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40).&#8221; ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2021, with early adoption permitted.   As required, we adopted ASU 2020-06 on January 1, 2022 and used the modified retrospective approach for all convertible debt instruments at the beginning of the period of adoptions.  Results for reporting periods beginning January 1, 2022 are presented under ASU 2020-06, while prior period amounts were not adjusted and continue to be reported in accordance with historic accounting guidance. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i4c9057ad95d944bea1b61a1bd1c3dfe3" continuedAt="i15f893260bfe42f7b6577e438b830e93"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the modified approach, entities will apply the guidance to all financial instruments that are outstanding as of the beginning of the year of adoption with the cumulative effect recognized as an adjustment to the opening balance of retained earnings. ASU 2020-06 eliminates the cash conversion and beneficial conversion feature models in ASC 470-20 that require an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity. The adoption of ASU 2020-06 at January 1, 2022 resulted in an increase of the Convertible notes of $<ix:nonFraction unitRef="usd" contextRef="ib396f0384c4549d6ad4a1d99b89fcf7f_I20220101" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA5MTMyMQ_856536e2-bd38-435b-9408-e2525230ced2">21.6</ix:nonFraction>&#160;million, a reduction of the Accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="iceb6a701923f4d27a6905238cab5243d_I20220101" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA5MTM2OA_2d5d7d61-860e-486f-8a4b-a31a072914e8">17.5</ix:nonFraction>&#160;million and a reduction of Additional paid-in capital of $<ix:nonFraction unitRef="usd" contextRef="i04b7a30acb9a4f81a6cd5179f6dc9cd0_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA5MTQyMQ_57d8ee44-f438-4151-9a2f-8f1f679207e5">39.1</ix:nonFraction>&#160;million.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, we issued a series of <ix:nonFraction unitRef="number" contextRef="i1a7f42702b824de08c6bd810d766790d_I20180228" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNjg5Ng_acde52b7-0d35-4574-9526-b1fdc97f2449">5</ix:nonFraction>% Convertible Promissory Notes (the &#8220;2023 Convertible Notes&#8221;) in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i1a7f42702b824de08c6bd810d766790d_I20180228" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNjk5Ng_6d6ba3f2-5d71-4660-9e73-5202b51790f9">55.0</ix:nonFraction> million.  The 2023 Convertible Notes mature <ix:nonNumeric contextRef="i7ff2cf21d2ee42b7ba76f7ede2a71895_D20180201-20180228" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNzAzNQ_787fcb03-e216-476b-b0d0-d6092a7b4b18">five years</ix:nonNumeric> following the date of issuance.  Each holder of a 2023 Convertible Note has the option, from time to time, to convert all or any portion of the outstanding principal balance of such 2023 Convertible Note, together with accrued and unpaid interest thereon, into shares of our Common Stock at a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1a7f42702b824de08c6bd810d766790d_I20180228" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNzM1MQ_0ee1433b-bed1-47cc-ba81-bd327baa184a">5.00</ix:nonFraction> per share.  We may redeem all or any part of the then issued and outstanding 2023 Convertible Notes, together with accrued and unpaid interest thereon, pro rata among the holders, upon no fewer than <ix:nonNumeric contextRef="i7ff2cf21d2ee42b7ba76f7ede2a71895_D20180201-20180228" name="opk:DebtInstrumentConvertibleConversionNoticeThresholdMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNzU1Mw_37cb84e9-859e-4776-9ef4-707126638aea">30</ix:nonNumeric> days, and no more than <ix:nonNumeric contextRef="i7ff2cf21d2ee42b7ba76f7ede2a71895_D20180201-20180228" name="opk:DebtInstrumentConvertibleConversionNoticeThresholdMaximum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNzU3OQ_8e78282e-22dc-4863-b920-0dd4167062c0">60</ix:nonNumeric> days, notice to the holders.  The 2023 Convertible Notes contain customary events of default and representations and warranties of OPKO.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchasers of the 2023 Convertible Notes included an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2013, we entered into note purchase agreements with respect to the issuance and sale of our <ix:nonFraction unitRef="number" contextRef="i3f373341aeaa45d6ab5311cefa00161e_I20130130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfODA0MQ_ec2b2b05-4ddc-4055-bad3-106a13d2e29b">3.0</ix:nonFraction>% Senior Notes due 2033 (the &#8220;2033 Senior Notes&#8221;) in a private placement exempt from registration under the Securities Act.  We issued the 2033 Senior Notes on January&#160;30, 2013.  The 2033 Senior Notes, which totaled $<ix:nonFraction unitRef="usd" contextRef="i3f373341aeaa45d6ab5311cefa00161e_I20130130" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfODI1OA_d5bbf2c6-73e0-49f8-aceb-a02e32733b71">175.0</ix:nonFraction> million in original principal amount, bear interest at the rate of <ix:nonFraction unitRef="number" contextRef="i3f373341aeaa45d6ab5311cefa00161e_I20130130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfODMyMA_bb641089-7eaf-4b5d-bd17-19d637461ec7">3.0</ix:nonFraction>%&#160;per year, payable semiannually on February&#160;1 and August&#160;1 of each year.  The 2033 Senior Notes mature on February&#160;1, 2033, unless earlier repurchased, redeemed or converted.  Upon a fundamental change, as defined in the indenture governing the 2033 Senior Notes, subject to certain exceptions, the holders may require us to repurchase all or any portion of their 2033 Senior Notes for cash at a repurchase price equal to <ix:nonFraction unitRef="number" contextRef="i36deaadef6af48b695564914f629b5db_D20130130-20130130" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfODc0NA_23339384-1941-45c6-91d5-e8991392ef05">100</ix:nonFraction>% of the principal amount of the 2033 Senior Notes being repurchased, plus any accrued and unpaid interest to, but not including, the related fundamental change repurchase date.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2013 to 2016, holders of the 2033 Senior Notes converted $<ix:nonFraction unitRef="usd" contextRef="i3247cd104cc0482786e56f99c0599cc1_D20130101-20161231" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfODk4NQ_0a5f0284-7a67-4113-b94c-542d1b182c00">143.2</ix:nonFraction> million in aggregate principal amount into an aggregate of <ix:nonFraction unitRef="shares" contextRef="icaf8381567b542449202a80cc3f77a99_D20130101-20161231" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfOTAzOQ_e02fb7c1-5658-4003-93a5-67b7f03d18ab">21,539,873</ix:nonFraction> shares of Common Stock. On February 1, 2019, approximately $<ix:nonFraction unitRef="usd" contextRef="if8c98930de814fef80fda4f22e14c6c6_I20190201" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfOTEwMQ_fd782dac-a1da-49a8-9d55-51895e2efa3f">28.8</ix:nonFraction> million aggregate principal amount of 2033 Senior Notes were tendered by holders pursuant to such holders&#8217; option to require us to repurchase the 2033 Senior Notes as set forth in the indenture, governing the 2033 Senior Notes, following which repurchase only $<ix:nonFraction unitRef="usd" contextRef="if8c98930de814fef80fda4f22e14c6c6_I20190201" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfOTM1Ng_6954c2af-acf1-4bb4-a0b0-cd3ef4fb96f3">3.0</ix:nonFraction> million aggregate principal amount of the 2033 Senior Notes remained outstanding.  Holders of the remaining $<ix:nonFraction unitRef="usd" contextRef="if8c98930de814fef80fda4f22e14c6c6_I20190201" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfOTQ1OQ_8da0e983-8cf3-4b43-86b4-79e328208a62">3.0</ix:nonFraction> million principal amount of the 2033 Senior Notes may require us to repurchase such notes for <ix:nonFraction unitRef="number" contextRef="i1da72e5734474e44a7f6fca5196486fb_D20130101-20130131" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfOTU0OA_0be9b38f-ce10-4c21-9447-e66368a1fe57">100</ix:nonFraction>% of their principal amount, plus accrued and unpaid interest, on February 1, 2023, on February 1, 2028, or following the occurrence of a fundamental change as described above.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the 2033 Senior Notes, include, among others: (i) rights to convert the notes into shares of our Common Stock, including upon a fundamental change; and (ii) a coupon make-whole payment in the event of a conversion by the holders of the 2033 Senior Notes on or after February 1, 2017 but prior to February 1, 2019.  We determined that these specific terms were embedded derivatives.  Embedded derivatives are required to be separated from the host contract, the 2033 Senior Notes, and carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument.  We concluded that the embedded derivatives within the 2033 Senior Notes met these criteria and, as such, were valued separate and apart from the 2033 Senior Notes and recorded at fair value each reporting period.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting and financial reporting purposes, we combined these embedded derivatives and valued them together as one unit of accounting. In 2017, certain terms of the embedded derivatives expired pursuant to the original agreement and the embedded derivatives no longer met the criteria to be separated from the host contract and, as a result, the embedded derivatives were no longer required to be valued separate and apart from the 2033 Senior Notes and were reclassified to additional paid in capital. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, BioReference and certain of its subsidiaries entered into a credit agreement with JPMorgan Chase Bank, N.A. (&#8220;CB&#8221;), as lender and administrative agent, as amended (the &#8220;Credit Agreement&#8221;).  The Credit Agreement provides for a $<ix:nonFraction unitRef="usd" contextRef="i7b4eb504ab9242d79f116b3ef21235d5_I20151130" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTE0ODQ_17ae8856-88ba-4d23-891d-72a7cd8760dd">75.0</ix:nonFraction> million secured revolving credit facility and includes a $<ix:nonFraction unitRef="usd" contextRef="i60f953c97dd24968839eeaafb2ffad17_I20151130" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTE1MzY_4f9a5dfd-32c7-4052-a250-d8793faeaa32">20.0</ix:nonFraction> million sub-facility for swingline loans and a $<ix:nonFraction unitRef="usd" contextRef="i0fdc1aa37b674237997e3b022f56dbf1_I20151130" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTE1Nzg_77fc7888-9cfc-4595-90e7-7d0971ff8547">20.0</ix:nonFraction> million sub-facility for the issuance of letters of credit. </span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i15f893260bfe42f7b6577e438b830e93" continuedAt="i729ef03348b04c719f36638ba1349fec"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, the Credit Agreement was amended and restated (the &#8220;A&amp;R Credit Agreement&#8221;). The A&amp;R Credit Agreement is guaranteed by all of BioReference&#8217;s domestic subsidiaries.  The A&amp;R Credit Agreement is also secured by substantially all assets of BioReference and its domestic subsidiaries, as well as a non-recourse pledge by us of our equity interest in BioReference.  Availability under the A&amp;R Credit Agreement is based on a borrowing base composed of eligible accounts receivables of BioReference and certain of its subsidiaries, as specified therein.  As of March&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i5ce132bbea2745af8c284fc6419ab2af_I20220331" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTIyMTI_4fed9a6e-f4fc-4b86-ae5e-37f3240ddd84">64.8</ix:nonFraction> million remained available for borrowing under the Credit Agreement. Principal under the Credit Agreement is due upon maturity on August 30, 2024. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At BioReference&#8217;s option, borrowings under the A&amp;R Credit Agreement (other than swingline loans) will bear interest at (i) the CB floating rate (defined as the higher of (a) the prime rate and (b) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) for an interest period of one month plus <ix:nonFraction unitRef="number" contextRef="i4c287aafd1a44262b8db089d441d0bb1_D20151101-20151130" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTI2ODQ_5b041950-afbd-41f3-9138-035cfe403282">2.50</ix:nonFraction>%) plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="ibbeb409c21e94c8a9efee99f6cb87652_D20151101-20151130" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTI3MTc_4699d50a-9460-4365-876c-d97ab0d0f425">0.75</ix:nonFraction>% or (ii) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="i16716fcbd59e454387ebc09f7b61c881_D20151101-20151130" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTI4NDc_24626fdf-6382-4a35-b448-60b8ef3ad3c7">1.75</ix:nonFraction>%.  Swingline loans will bear interest at the CB floating rate plus the applicable margin.  The A&amp;R Credit Agreement also calls for other customary fees and charges, including an unused commitment fee of <ix:nonFraction unitRef="number" contextRef="i63c4e5c98e7243cfaba30273d9ca0a87_D20151101-20151130" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTMwNTI_9f4f0a53-8ec4-4cbb-a7a8-f9f93f9122c2">0.375</ix:nonFraction>% if the average quarterly availability is 50% or more of the revolving commitment, or <ix:nonFraction unitRef="number" contextRef="i525c6ba5bfb44a68bf4601181c4282fa_D20151101-20151130" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTMxMzk_17c9d877-0450-4f6f-b6db-cde017a27938">0.25</ix:nonFraction>% if the average quarterly availability is less than or equal to 50% of the revolving commitments.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2022 and December 31, 2021, <ix:nonFraction unitRef="usd" contextRef="i5ce132bbea2745af8c284fc6419ab2af_I20220331" decimals="INF" name="us-gaap:LongTermLineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTMyODk_f058d18c-fe04-460c-b7c4-f44f136ad234">no</ix:nonFraction> amount was outstanding under the A&amp;R Credit Agreement.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R Credit Agreement contains customary covenants and restrictions, including, without limitation, covenants that require BioReference and its subsidiaries to maintain a minimum fixed charge coverage ratio if availability under the new credit facility falls below a specified amount and to comply with laws and restrictions on the ability of BioReference and its subsidiaries to incur additional indebtedness or to pay dividends and make certain other distributions to the Company, subject to certain exceptions as specified therein.  Failure to comply with these covenants would constitute an event of default under the A&amp;R Credit Agreement, notwithstanding the ability of BioReference to meet its debt service obligations.  The A&amp;R Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the A&amp;R Credit Agreement and execution upon the collateral securing obligations under the A&amp;R Credit Agreement.  Substantially all the assets of BioReference and its subsidiaries are restricted from sale, transfer, lease, disposal or distributions to the Company, subject to certain exceptions. As of March&#160;31, 2022, BioReference and its subsidiaries had net assets of approximately $<ix:nonFraction unitRef="usd" contextRef="i9be636d2eb7646a68e48135793798985_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTQ2NTM_49c76381-d173-4cec-b45f-8a231b983fe5">1,037.1</ix:nonFraction> million, which included goodwill of $<ix:nonFraction unitRef="usd" contextRef="i9be636d2eb7646a68e48135793798985_I20220331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTQ2ODQ_6f52ca9c-611b-470b-9c32-ad6d9f5a1b64">283.0</ix:nonFraction> million and intangible assets of $<ix:nonFraction unitRef="usd" contextRef="i9be636d2eb7646a68e48135793798985_I20220331" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTQ3MTI_ad76546b-002a-4b1f-ac2d-73bc853bfa7f">199.5</ix:nonFraction> million.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 29, 2022, the A&amp;R Credit Agreement was amended to, among other things, (i) waive specified defaults under the A&amp;R Credit Agreement resulting from certain internal reorganization transactions that resulted in both BioReference and GeneDx changing their respective forms of organization from New Jersey corporations to Delaware limited liability companies, (ii) provide for the disposition of GeneDx pursuant to the transactions contemplated by the merger agreement with Sema4, (iii) amend certain reporting requirements under the A&amp;R Credit Agreement and (iv) provide that the borrowers under the A&amp;R Credit Agreement may effect certain restricted payments to the extent necessary for their parent entities to pay income tax in respect of income earned by the borrowers. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i729ef03348b04c719f36638ba1349fec" continuedAt="i12032e9ba3b7463bbd7ae5b389568690"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the A&amp;R Credit Agreement with CB, we had line of credit agreements with <ix:nonFraction unitRef="institution" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="INF" name="opk:DebtInstrumentsNumberofFinancialInstitutions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTQ4MDM_85184fa9-a2fa-4f83-8f81-343683ec1104"><ix:nonFraction unitRef="institution" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="INF" name="opk:DebtInstrumentsNumberofFinancialInstitutions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTQ4MDM_85996cd7-ce46-42b3-968d-2f5b1aa677a5">thirteen</ix:nonFraction></ix:nonFraction> other financial institutions as of March&#160;31, 2022 and eleven other financial institutions as of December&#160;31, 2021 in the U.S., Chile and Spain.  These lines of credit are used primarily as  sources of working capital for inventory purchases.</span></div><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTU3NDQ_c9bcb09d-3f0d-4159-a579-32f13500bcb7" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:39.575%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.001%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(Dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Balance Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lender</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest&#160;rate&#160;on<br/>borrowings at <br/>March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit&#160;line<br/>capacity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JPMorgan Chase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib898228cd3484e429a53c453f0951cbe_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMi0yLTEtMS0zNTMzMA_aa74de24-a6cf-4b1c-a1db-cd04ad57838d">3.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib898228cd3484e429a53c453f0951cbe_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMi00LTEtMS0zNTMzMA_fe9ac166-9261-4774-b1b7-60649086a2e3">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib898228cd3484e429a53c453f0951cbe_I20220331" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMi02LTEtMS0zNTMzMA_035ba9f0-32c8-4138-8326-7abe57b68a32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92eade637fa4c5b9fdf19e5892fcb78_I20211231" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMi04LTEtMS0zNTMzMA_b3249219-a0f8-413d-a611-819ce5410f5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Itau Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6da40689dc7f4a57940604c58ea95ca9_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMy0yLTEtMS0zNTMzMA_a1bf172e-6007-42af-81fa-48b72e3f2316">5.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da40689dc7f4a57940604c58ea95ca9_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMy00LTEtMS0zNTMzMA_d7049de3-f1ef-47f4-b51e-bb4897bcf6fc">1,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da40689dc7f4a57940604c58ea95ca9_I20220331" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMy02LTEtMS0zNTMzMA_ba7ab46c-f70c-4bdd-9761-3fd7feefad7b">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b77ee2f3fcc47b49cb358c6cb4a05b0_I20211231" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMy04LTEtMS0zNTMzMA_3a7206c8-c539-47c1-808f-a57ba44f1210">1,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bank of Chile</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc72bc81c8cf4007b02a8ed9c7371fab_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNC0yLTEtMS0zNTMzMA_4ee09470-4c9c-4f29-9c71-68484edbfc61">6.60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc72bc81c8cf4007b02a8ed9c7371fab_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNC00LTEtMS0zNTMzMA_eee0b58a-69d5-4e97-a61e-0b80c25af854">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc72bc81c8cf4007b02a8ed9c7371fab_I20220331" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNC02LTEtMS0zNTMzMA_da748c7b-5393-4d63-9f01-7a16f01fd48b">1,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c606619dd84425ac6654cc299669d1_I20211231" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNC04LTEtMS0zNTMzMA_630fbf9b-d49f-442c-aa16-b3e9379946ec">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BICE Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff25469e62df48448ca837a11e16442a_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNS0yLTEtMS0zNTMzMA_0d5b5c17-526a-41b9-ac8e-dc8224fb980d">5.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff25469e62df48448ca837a11e16442a_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNS00LTEtMS0zNTMzMA_d99f2502-d6ef-4236-b4a6-1dd7d2e5cc81">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff25469e62df48448ca837a11e16442a_I20220331" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNS02LTEtMS0zNTMzMA_bb61f0c5-5d2d-4535-bab8-2ea344d68a28">1,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54dc237b91f42858c86967daeeda551_I20211231" decimals="-3" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNS04LTEtMS0zNTMzMA_1f09f47a-c234-4441-9e52-518092f730e2">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scotiabank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5db2a74d8f95441691817b18709c0fcb_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNi0yLTEtMS0zNTMzMA_3a1fb7a3-0e90-4032-92de-a63524a3c3ea">5.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db2a74d8f95441691817b18709c0fcb_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNi00LTEtMS0zNTMzMA_4ebf4059-18a8-4793-a95e-88d4e59b1c29">5,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db2a74d8f95441691817b18709c0fcb_I20220331" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNi02LTEtMS0zNTMzMA_53175547-bd12-437d-a1ba-6b2496008e2c">2,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabb83a0b7e84cc69c57763fdb275a6c_I20211231" decimals="-3" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNi04LTEtMS0zNTMzMA_15a7a3d5-0f89-44c6-a40f-fc4603975768">567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Santander Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2be89554ae224d2faa3b30914675e795_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNy0yLTEtMS0zNTMzMA_620a87a8-736a-4790-a04e-cfdcad1966fd">5.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be89554ae224d2faa3b30914675e795_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNy00LTEtMS0zNTMzMA_0c2bb816-88e1-490b-844d-4e69a7efa7f8">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be89554ae224d2faa3b30914675e795_I20220331" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNy02LTEtMS0zNTMzMA_68824033-a506-4744-b08e-d4e1b9c52561">3,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4836259242c4bb19d20c064b534eab1_I20211231" decimals="-3" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNy04LTEtMS0zNTMzMA_47b48e91-2823-4d25-ab52-26f6eac3d71c">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Security Bank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e0c19da9e644a0394218df762658838_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOC0yLTEtMS0zNTMzMA_9e1a6ca3-9544-4a2a-97ca-d3437ee7de72">5.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0c19da9e644a0394218df762658838_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOC00LTEtMS0zNTMzMA_273fdc2e-86a7-4ce6-8cfd-de8abf8f2e70">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0c19da9e644a0394218df762658838_I20220331" decimals="-3" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOC02LTEtMS0zNTMzMA_167a33af-0609-4279-bf37-07f171aad0c5">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9cd8644076f4859be4a248297d5c636_I20211231" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOC04LTEtMS0zNTMzMA_7ac6e774-81b9-4540-b2d2-8a5f932ef3cd">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estado Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib013afdad6c7474cb6b2dcd9f1b5930b_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOS0yLTEtMS0zNTMzMA_5fd042ca-40a8-41ce-a2bf-81242203bc4b">5.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib013afdad6c7474cb6b2dcd9f1b5930b_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOS00LTEtMS0zNTMzMA_eadcfbd7-9872-4e13-a5df-b3e1956910fd">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib013afdad6c7474cb6b2dcd9f1b5930b_I20220331" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOS02LTEtMS0zNTMzMA_b4546788-a54f-4aea-8bdb-5808cc64d2d3">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0e78a0e78664a1dab1c8a3083fe0278_I20211231" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOS04LTEtMS0zNTMzMA_008d48ac-4356-4caf-848d-06380b266b81">2,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BCI Bank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0241e35fea8242e191eb554ad8160555_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTAtMi0xLTEtMzUzMzA_10bf9e7f-042c-4950-9011-16cf3bfbb7ff">5.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0241e35fea8242e191eb554ad8160555_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTAtNC0xLTEtMzUzMzA_e27ae081-2fdb-4c93-a830-163575cd1633">2,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0241e35fea8242e191eb554ad8160555_I20220331" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTAtNi0xLTEtMzUzMzA_14f39ec2-5c1a-40d5-a874-63786740f484">2,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb458c405a9e4aa4840e82ae7757acf6_I20211231" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTAtOC0xLTEtMzUzMzA_b1ac6134-6d89-4f91-931c-ba923eb5bc00">2,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corpbanca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd2141f359c14b2c98459ad1cfb7f950_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTEtMi0xLTEtMzUzMzA_404af20a-2073-4524-8d0e-6535350051a6">5.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2141f359c14b2c98459ad1cfb7f950_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTEtNC0xLTEtMzUzMzA_1411a32c-d3ab-42f1-a013-4cc2d4b134e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2141f359c14b2c98459ad1cfb7f950_I20220331" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTEtNi0xLTEtMzUzMzA_2906bd3a-b8d3-4f5f-9d1d-88d5cf9efbf8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f90114729e40eb8be4a760cfaff843_I20211231" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTEtOC0xLTEtMzUzMzA_ac9a095f-bcfa-4593-91ac-6aab278d3420">2,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Bank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6754e9ff1da42ec9e1a4cc77eec4acd_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItMi0xLTEtNDA0MTU_c41f0e8f-9183-4596-8b46-29f76d4ba1b1">5.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6754e9ff1da42ec9e1a4cc77eec4acd_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItNC0xLTEtNDA0MTU_1d57d663-ac55-4bc8-a3c2-4df16358eea6">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6754e9ff1da42ec9e1a4cc77eec4acd_I20220331" decimals="-3" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItNi0xLTEtNDA0MTU_44eee8a8-ca6e-4538-b558-4d4c28f380a1">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c38a5f8c564a40be8991b68c4b3ffc_I20211231" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItOC0xLTEtNDA0MTU_42b626e3-78f6-4937-bdbe-11356dab7e16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consoorcio Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcca8a13d6eb4da998ed98c0c425049d_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtMi0xLTEtNDA0MTU_9b29c08e-4b5a-4a19-841c-4692ca965bd3">5.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcca8a13d6eb4da998ed98c0c425049d_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtNC0xLTEtNDA0MTU_343a3df0-9072-425a-8820-e6eb120eb51f">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcca8a13d6eb4da998ed98c0c425049d_I20220331" decimals="-3" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtNi0xLTEtNDA0MTU_991db1ce-cde4-4f6d-8cb0-e3dbd6c07e07">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec848e00bda4f5681fac4c00ce92faa_I20211231" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtOC0xLTEtNDA0MTU_917ba11a-8dd5-4b6e-bcf8-2fa5e2da0669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Banco De Sabadell</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d54584ff4454273875eb07cb16d7afd_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItMi0xLTEtMzUzMzA_404f71cb-d1d7-42fe-a3c4-8b7d3178de3c">1.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d54584ff4454273875eb07cb16d7afd_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItNC0xLTEtMzUzMzA_399976d7-85f5-467d-aafc-a379d7e4eebd">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d54584ff4454273875eb07cb16d7afd_I20220331" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItNi0xLTEtMzUzMzA_e8870e2c-aca3-436a-9b12-4b430034f01b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26530ceb664987a7569db40b3af4e4_I20211231" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItOC0xLTEtMzUzMzA_b83b3b96-d0e8-4be1-bac1-5cda307e6aeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Santander Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f72279f02e748babf4db23480b635fb_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtMi0xLTEtMzUzMzA_d611db66-2068-4934-b8db-a809f9f84cee">1.82</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f72279f02e748babf4db23480b635fb_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtNC0xLTEtMzUzMzA_e3e11149-fc64-4395-a4bd-8b8b74a52002">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f72279f02e748babf4db23480b635fb_I20220331" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtNi0xLTEtMzUzMzA_e3be904f-3e91-4eb3-aa46-bb4cda5e9c09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d45b4e640d41ceb4caa171b741efa1_I20211231" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtOC0xLTEtMzUzMzA_1dac47fc-bb60-42b3-a511-c19d8c60ca26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTUtNC0xLTEtMzUzMzA_022d1146-8864-42fc-bdcb-ce245933d4ec">103,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTUtNi0xLTEtMzUzMzA_1188507d-875d-4cff-815b-0788a476a3b4">16,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTUtOC0xLTEtMzUzMzA_eeb0a5f8-2cb8-46ee-b25f-90b29ba20f99">13,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022 and December&#160;31, 2021, the weighted average interest rate on our lines of credit was approximately <ix:nonFraction unitRef="number" contextRef="i2a2bb52ee16c4f3cbd50cd8ebe53b377_I20220331" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA4NTU3NQ_c5faec36-fc3a-4aa2-8ee0-560d07b2e900">5.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia66232faa6934fc58bd350c3c5087464_I20211231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA4NTU3OQ_20546bee-828d-4279-a07e-05281f16a239">5.4</ix:nonFraction>%, respectively.</span></div><ix:continuation id="i50022cfcdafa4983866227fc6715822e"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022 and December&#160;31, 2021, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the 2025 Notes, the A&amp;R Credit Agreement and amounts outstanding under lines of credit described above) as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:59.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35733f1b3cb4b5e8d6885a8d8e2c00b_I20220331" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjRiNDJiYmYxMzU1ZDQ3MTFhYjA5N2M1NmMwNTUyNzgyL3RhYmxlcmFuZ2U6NGI0MmJiZjEzNTVkNDcxMWFiMDk3YzU2YzA1NTI3ODJfMS0xLTEtMS0zNTMzMA_617c4a7e-4d98-4660-acca-32ae34d20c90">882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb18ba3550a7419cac96f92422977cff_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjRiNDJiYmYxMzU1ZDQ3MTFhYjA5N2M1NmMwNTUyNzgyL3RhYmxlcmFuZ2U6NGI0MmJiZjEzNTVkNDcxMWFiMDk3YzU2YzA1NTI3ODJfMS0zLTEtMS0zNTMzMA_d226ca28-6b6d-497c-b124-a54fecec1bf8">1,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35733f1b3cb4b5e8d6885a8d8e2c00b_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjRiNDJiYmYxMzU1ZDQ3MTFhYjA5N2M1NmMwNTUyNzgyL3RhYmxlcmFuZ2U6NGI0MmJiZjEzNTVkNDcxMWFiMDk3YzU2YzA1NTI3ODJfMi0xLTEtMS0zNTMzMA_396b3d62-b1f5-47a1-b6f9-528b93708417">2,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb18ba3550a7419cac96f92422977cff_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjRiNDJiYmYxMzU1ZDQ3MTFhYjA5N2M1NmMwNTUyNzgyL3RhYmxlcmFuZ2U6NGI0MmJiZjEzNTVkNDcxMWFiMDk3YzU2YzA1NTI3ODJfMi0zLTEtMS0zNTMzMA_483d34c3-0ee0-4249-b025-78ae3dc3e7b5">2,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35733f1b3cb4b5e8d6885a8d8e2c00b_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjRiNDJiYmYxMzU1ZDQ3MTFhYjA5N2M1NmMwNTUyNzgyL3RhYmxlcmFuZ2U6NGI0MmJiZjEzNTVkNDcxMWFiMDk3YzU2YzA1NTI3ODJfMy0xLTEtMS0zNTMzMA_e382de36-921d-44fd-bd14-c530dcefebcf">3,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb18ba3550a7419cac96f92422977cff_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjRiNDJiYmYxMzU1ZDQ3MTFhYjA5N2M1NmMwNTUyNzgyL3RhYmxlcmFuZ2U6NGI0MmJiZjEzNTVkNDcxMWFiMDk3YzU2YzA1NTI3ODJfMy0zLTEtMS0zNTMzMA_13451677-afaa-4501-9806-f0a8eb7bc402">3,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i12032e9ba3b7463bbd7ae5b389568690">The notes and other debt mature at various dates ranging from 2022 through 2026, bearing variable interest rates from <ix:nonFraction unitRef="number" contextRef="i1aa77c7b6eb749fe884b2a879d8b362c_I20220331" decimals="3" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA4NTU5NQ_11b93f28-ec8f-4e0e-ad56-c2a34c8242aa">0.7</ix:nonFraction>% up to <ix:nonFraction unitRef="number" contextRef="i073357239cf9481992cd2d0593039c41_I20220331" decimals="3" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA4NTU5OQ_18ae31ba-c257-489e-affc-75898216a899">3.8</ix:nonFraction>%.  The weighted average interest rate on the notes and other debt was <ix:nonFraction unitRef="number" contextRef="idace7175aff140538ca299c503a1f3fe_I20220331" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA4NTU4Mw_c41625d1-ac82-4345-a22b-5c6695b02bc6">1.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i590b5239584e49aabed9114cc2b084f2_I20211231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTU2NDk_c7693b43-beba-4b69-a88b-c8957773e93c">1.5</ix:nonFraction>% on March&#160;31, 2022 and December&#160;31, 2021. The notes are partially secured by our office space in Barcelona.</ix:continuation>  </span></div><div id="i1cac816ff800494ea2979c434f00b37c_64"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182NC9mcmFnOjdkMDE5N2IyZjA4MjRiNzdiODc1OTU0NTc2Y2JkYzA2L3RleHRyZWdpb246N2QwMTk3YjJmMDgyNGI3N2I4NzU5NTQ1NzZjYmRjMDZfMTU1_006fb6cf-e6ab-4931-8b30-c087f9c12be4" continuedAt="id494fe2b607a483499d101726c039d7b" escape="true">ACCUMULATED OTHER COMPREHENSIVE LOSS</ix:nonNumeric></span></div><ix:continuation id="id494fe2b607a483499d101726c039d7b"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182NC9mcmFnOjdkMDE5N2IyZjA4MjRiNzdiODc1OTU0NTc2Y2JkYzA2L3RleHRyZWdpb246N2QwMTk3YjJmMDgyNGI3N2I4NzU5NTQ1NzZjYmRjMDZfMTQ2_8ff7105a-690e-47d0-ad4f-bfa6a53e9bb1" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, changes in Accumulated other comprehensive loss, net of tax, were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.370%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4a22c80a9934fab9c03ed0fda0558a8_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182NC9mcmFnOjdkMDE5N2IyZjA4MjRiNzdiODc1OTU0NTc2Y2JkYzA2L3RhYmxlOjFlMjdhNThlMTYxNzQ0M2Y5MWY5YTc3MmNkNWMxODMwL3RhYmxlcmFuZ2U6MWUyN2E1OGUxNjE3NDQzZjkxZjlhNzcyY2Q1YzE4MzBfMS0xLTEtMS0zNTMzMA_30c0c5d1-7046-424c-944f-9d60ad32b45d">30,495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:20.25pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f44824dbb444200a5bdcdb490ef2b6c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182NC9mcmFnOjdkMDE5N2IyZjA4MjRiNzdiODc1OTU0NTc2Y2JkYzA2L3RhYmxlOjFlMjdhNThlMTYxNzQ0M2Y5MWY5YTc3MmNkNWMxODMwL3RhYmxlcmFuZ2U6MWUyN2E1OGUxNjE3NDQzZjkxZjlhNzcyY2Q1YzE4MzBfMi0xLTEtMS0zNTMzMA_1a0c62d4-aad9-4e12-840a-a761b64a31de">920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id414151061b84ff297849734c822f37f_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182NC9mcmFnOjdkMDE5N2IyZjA4MjRiNzdiODc1OTU0NTc2Y2JkYzA2L3RhYmxlOjFlMjdhNThlMTYxNzQ0M2Y5MWY5YTc3MmNkNWMxODMwL3RhYmxlcmFuZ2U6MWUyN2E1OGUxNjE3NDQzZjkxZjlhNzcyY2Q1YzE4MzBfNS0xLTEtMS0zNTMzMA_ba832a99-9e3d-4bc0-9f16-b7c12f53b2db">31,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i1cac816ff800494ea2979c434f00b37c_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMzI0OA_3c1a0f25-d51c-4f2a-907c-30c7ee86092b" continuedAt="i7f2e121d147b46549c4e7820098dde5e" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i7f2e121d147b46549c4e7820098dde5e" continuedAt="i7b3088e4943b4a729f97014f364da55e"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record fair values at an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.  We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.  These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had equity securities (refer to Note 6), forward foreign currency exchange contracts for inventory purchases (refer to Note 10) and contingent consideration related to the acquisitions of CURNA, OPKO Diagnostics and OPKO Renal that are required to be measured at fair value on a recurring basis.  In addition, in connection with our investment and our consulting agreement with BioCardia, we record the related BioCardia options at fair value as well as the warrants from COCP and InCellDx.</span></div><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMzIzMQ_db8b3901-b29f-4b4c-8ce6-447c328632be" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities measured at fair value on a recurring basis are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value measurements as of March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets for<br/>identical<br/>assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i422ca1837f244677badf0cc87f681909_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNS0xLTEtMS0zNTMzMA_19b846db-afb2-4508-8b8d-f48aa7e6b6ed">3,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e71299ca85d400ca49f6ca9cedc36ee_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNS0zLTEtMS0zNTMzMA_666d8cb2-8070-486a-8395-53f853634af3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f2bf6624724fa3aecc40088836c8be_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNS01LTEtMS0zNTMzMA_8644ca3b-d619-4b8a-aef7-6ea52b6ab4a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNS03LTEtMS0zNTMzMA_42f9e64a-8ee1-4a17-816f-ba91679fb4e1">3,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options/warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idff81e7e63834f27b0191f9f89a1a47c_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNi0xLTEtMS0zNTMzMA_621f632d-0cde-4543-93d6-63e965fdd251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf4f3576ecda4c91b9dd4d47459c40de_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNi0zLTEtMS0zNTMzMA_e80c3c8e-af0f-48c7-8195-cdcd216412d1">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91f678126fc847348f1523f27f8297d9_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNi01LTEtMS0zNTMzMA_f98988ea-cd5b-452d-bafc-af38d4f96760">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bec48bd714c48508a9e6c19e44bf474_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNi03LTEtMS0zNTMzMA_9e5b0cf3-7d24-43ca-a690-f0374b23bc45">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i422ca1837f244677badf0cc87f681909_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfOC0xLTEtMS0zNTMzMA_c81e5b0f-243b-4722-9eb2-8bf2a6fb1d4e">3,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e71299ca85d400ca49f6ca9cedc36ee_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfOC0zLTEtMS0zNTMzMA_8e980d39-a58d-4e55-ae97-d43e712c1439">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f2bf6624724fa3aecc40088836c8be_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfOC01LTEtMS0zNTMzMA_cf9c39c5-5309-4f13-b78d-68f5ab65de32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfOC03LTEtMS0zNTMzMA_1e07b206-f4a1-47a6-ac29-041065987e8f">3,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i672ca210ee9a4a0bba0dfc16dae64dcd_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTEtMS0xLTEtMzUzMzA_caddbbf1-df99-4e08-8b6a-9568dec3c06d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb3f1c307104b52a50b42c818e7727d_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTEtMy0xLTEtMzUzMzA_adb2f6b3-a468-4a34-837c-b04e1143cae9">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c3fc92127145a39d48943be5758504_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTEtNS0xLTEtMzUzMzA_fc1a65b8-a4b3-4158-975b-b80db5d9aace">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7f39684e77498888d13da9df62d5b9_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTEtNy0xLTEtMzUzMzA_2a764ec3-6570-4993-958b-674930867f4b">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i422ca1837f244677badf0cc87f681909_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTMtMS0xLTEtMzUzMzA_fd1d7211-c0b4-4006-aae3-e29dd5adc946">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e71299ca85d400ca49f6ca9cedc36ee_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTMtMy0xLTEtMzUzMzA_eefdd3cb-e3f6-4876-9db8-17b34b06b11e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f2bf6624724fa3aecc40088836c8be_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTMtNS0xLTEtMzUzMzA_4f7d09be-43c4-4c39-b3af-8a720ab473db">2,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTMtNy0xLTEtMzUzMzA_9f6a619a-dc5f-48b2-bcd4-e3238ce15833">2,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i422ca1837f244677badf0cc87f681909_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTQtMS0xLTEtMzUzMzA_93cd13e8-6d51-4150-b02f-72c37cbacb10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e71299ca85d400ca49f6ca9cedc36ee_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTQtMy0xLTEtMzUzMzA_a2a6119f-d603-4238-9dbd-175eebb58e43">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f2bf6624724fa3aecc40088836c8be_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTQtNS0xLTEtMzUzMzA_ac1d6f39-858e-4479-841c-d8684d863ed6">2,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTQtNy0xLTEtMzUzMzA_23c1ad69-1586-418f-b5b0-26654fda4c35">3,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value measurements as of December&#160;31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets for<br/>identical<br/>assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b6b0142454d4f3c928a9719fc52a6aa_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNi0xLTEtMS0zNTMzMA_a7cfb6fc-f4a7-44c7-8c08-f930cff75d6e">4,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ece04f6d15a44e8b8535afca85eea3b_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNi0zLTEtMS0zNTMzMA_516008ce-1445-4a88-b93a-6a44d00dc4ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6167a5561ea048c0992072722768dc50_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNi01LTEtMS0zNTMzMA_b44a26d9-6e2e-4d94-ae4b-0a328da1dc4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNi03LTEtMS0zNTMzMA_38c84ec9-7783-4f4d-8c26-3713caf299c9">4,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options/warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id20bcd0b3e1c441a9da0bd8ff7b7c148_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNy0xLTEtMS0zNTMzMA_6e102044-01fc-488e-ace2-777b7a70834c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id821c49b028b4f61851f46ac73519641_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNy0zLTEtMS0zNTMzMA_9094b5fc-f8d5-4007-a0c2-e8c8a8563f83">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50def469aee442b7a18f3ee936adf68d_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNy01LTEtMS0zNTMzMA_27d592e7-40c8-495b-a856-e9d819776c21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0175b050f64543bdbaed71566aab0b0a_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNy03LTEtMS0zNTMzMA_7e87a74f-be51-48cd-aafc-d0187eaa3e37">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b1ce0a8e104dd48bd6e56c4cca780b_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOC0xLTEtMS0zNTMzMA_46d1569f-843c-453f-b682-8d371288e5b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5b8f39523b4a5683ccaea181d847f9_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOC0zLTEtMS0zNTMzMA_f29768eb-3246-498f-a344-e8a992525130">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85019ba01b1f439c855e8144c410bd64_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOC01LTEtMS0zNTMzMA_b11c1c5f-8a34-4ebd-b172-6be72870f745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb36d1e48e34543b075c30a1123563a_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOC03LTEtMS0zNTMzMA_01d46c2e-bebc-447e-852a-ead1cc9bff72">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b6b0142454d4f3c928a9719fc52a6aa_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOS0xLTEtMS0zNTMzMA_f9f30453-4c6b-4956-9810-357b6b913ef0">4,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ece04f6d15a44e8b8535afca85eea3b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOS0zLTEtMS0zNTMzMA_b049daeb-2d48-4cd4-805e-cda5f9aeb929">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6167a5561ea048c0992072722768dc50_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOS01LTEtMS0zNTMzMA_9ee39407-86be-4d6e-8072-76bd3a4c019e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOS03LTEtMS0zNTMzMA_0b0a1dc7-f6cd-4971-8385-102b1aa68cc9">4,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b6b0142454d4f3c928a9719fc52a6aa_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTQtMS0xLTEtMzUzMzA_01cdf46b-07b2-4634-8c20-306ad7990cfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ece04f6d15a44e8b8535afca85eea3b_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTQtMy0xLTEtMzUzMzA_a0e9d9fe-bbd1-415d-8b46-faa8dc6ca0f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6167a5561ea048c0992072722768dc50_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTQtNS0xLTEtMzUzMzA_7332cc8f-c5c6-4e9a-8392-2f664d621c1d">2,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTQtNy0xLTEtMzUzMzA_206fd361-196e-4ccd-ad3b-57c499914a04">2,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b6b0142454d4f3c928a9719fc52a6aa_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTUtMS0xLTEtMzUzMzA_275766e6-e970-4cf6-8c2c-bfee46a3f082">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ece04f6d15a44e8b8535afca85eea3b_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTUtMy0xLTEtMzUzMzA_347f1eac-2b15-4ac1-8ef1-44406fd16571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6167a5561ea048c0992072722768dc50_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTUtNS0xLTEtMzUzMzA_7ee51255-d002-4238-94c1-8cc944f2c0b0">2,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTUtNy0xLTEtMzUzMzA_c7c49c6b-03b2-44fd-b514-b95285734784">2,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMzI1MQ_5e8a9adb-034f-43ed-86de-483abf50ab34" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and estimated fair value of our 2025 Notes, as well as the applicable fair value hierarchy tiers, are contained in the table below.  The fair value of the 2025 Notes is determined using inputs other than quoted prices in active markets that are directly observable.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="27" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6f84a8a9e11457c9fe326e89f4deef6_I20220331" decimals="-3" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjIwZTBmMTU2YjA4YTQ1NzA4ZTIxOTFmY2FlOWZmMWI0L3RhYmxlcmFuZ2U6MjBlMGYxNTZiMDhhNDU3MDhlMjE5MWZjYWU5ZmYxYjRfMi0xLTEtMS0zNTMzMA_62ecbe8e-92d6-4dd1-9054-cf848aaa881c">141,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940d0629800f44c09521f8583790b804_I20220331" decimals="-3" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjIwZTBmMTU2YjA4YTQ1NzA4ZTIxOTFmY2FlOWZmMWI0L3RhYmxlcmFuZ2U6MjBlMGYxNTZiMDhhNDU3MDhlMjE5MWZjYWU5ZmYxYjRfMi0zLTEtMS0zNTMzMA_b92b6753-73ca-43d7-bbb1-1a5371b5b22d">164,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17f3344f32f4bd18794617bc4d70c76_I20220331" decimals="-3" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjIwZTBmMTU2YjA4YTQ1NzA4ZTIxOTFmY2FlOWZmMWI0L3RhYmxlcmFuZ2U6MjBlMGYxNTZiMDhhNDU3MDhlMjE5MWZjYWU5ZmYxYjRfMi01LTEtMS0zNTMzMA_852fac91-fa67-4450-a15d-50f869136925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eeb8b6fb39840dc8dd12bd08e9bde47_I20220331" decimals="-3" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjIwZTBmMTU2YjA4YTQ1NzA4ZTIxOTFmY2FlOWZmMWI0L3RhYmxlcmFuZ2U6MjBlMGYxNTZiMDhhNDU3MDhlMjE5MWZjYWU5ZmYxYjRfMi03LTEtMS0zNTMzMA_2ce05192-da96-42c0-aef9-16bb5947d1ec">164,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i170972a9d6e34cec89fae7f37a41e059_I20220331" decimals="-3" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjIwZTBmMTU2YjA4YTQ1NzA4ZTIxOTFmY2FlOWZmMWI0L3RhYmxlcmFuZ2U6MjBlMGYxNTZiMDhhNDU3MDhlMjE5MWZjYWU5ZmYxYjRfMi05LTEtMS0zNTMzMA_04abf8c8-c652-4f5b-8142-7fa101acfa5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i7b3088e4943b4a729f97014f364da55e" continuedAt="i98fc9f2b5e8d412a8e81bdc71fda3cfa"><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no transfers between Level 1 and Level 2 and no transfers to or from Level 3 of the fair value hierarchy.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, the carrying value of our other financial instrument assets approximates their fair value due to their short-term nature or variable rate of interest.</span></div><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMzIzMg_44605afe-328b-4e5c-b272-a037be299e47" escape="true"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMzI2MA_0d3faf27-7913-42d3-bca2-c2f8b5b90204" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of March&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent<br/>consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a68d34ffea6486da4d468c553cccb2f_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjQzOTQ3YWRiNzJiNzRhZWZiMmJjZTQ3NjE4YmRhNzY1L3RhYmxlcmFuZ2U6NDM5NDdhZGI3MmI3NGFlZmIyYmNlNDc2MThiZGE3NjVfMi0xLTEtMS0zNTMzMA_ae542c00-87b7-44e4-84a1-19c334f1e7df">2,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in results of operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89c145a5bdf45b8b2c4856b5dd6d167_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjQzOTQ3YWRiNzJiNzRhZWZiMmJjZTQ3NjE4YmRhNzY1L3RhYmxlcmFuZ2U6NDM5NDdhZGI3MmI3NGFlZmIyYmNlNDc2MThiZGE3NjVfNS0xLTEtMS0zNTMzMA_36b8cf5a-9e66-4029-bb82-2f013d889977">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89c145a5bdf45b8b2c4856b5dd6d167_D20220101-20220331" decimals="-3" sign="-" name="opk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjQzOTQ3YWRiNzJiNzRhZWZiMmJjZTQ3NjE4YmRhNzY1L3RhYmxlcmFuZ2U6NDM5NDdhZGI3MmI3NGFlZmIyYmNlNDc2MThiZGE3NjVfNi0xLTEtMS0zNTMzMA_9659d6f5-794a-446f-90f6-0be58d332dff">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19db139199c944d1a3ba5a1234a8c6cb_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjQzOTQ3YWRiNzJiNzRhZWZiMmJjZTQ3NjE4YmRhNzY1L3RhYmxlcmFuZ2U6NDM5NDdhZGI3MmI3NGFlZmIyYmNlNDc2MThiZGE3NjVfOS0xLTEtMS0zNTMzMA_fc959ad6-e7ef-4246-9382-212b73b36fa0">2,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of our financial instruments have been determined by using available market information and what we believe to be appropriate valuation methodologies.  We use the following methods and assumptions in estimating fair value:</span></div></ix:continuation><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i98fc9f2b5e8d412a8e81bdc71fda3cfa" continuedAt="i6d81377256474a4da0bbef6ca69cd69a">Contingent consideration</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6d81377256474a4da0bbef6ca69cd69a"> &#8211; We estimate the fair value of the contingent consideration utilizing a discounted cash flow model for the expected payments based on estimated timing and expected revenues.  We use several discount rates depending on each type of contingent consideration related to OPKO Diagnostics, CURNA and OPKO Renal transactions. As of March&#160;31, 2022, of the $<ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMjc3OA_fbd37c62-8868-4087-9999-fda6b461ae79">2.7</ix:nonFraction> million of contingent consideration, $<ix:nonFraction unitRef="usd" contextRef="ic33ae5da06dc4f819b6dcd183aecaebe_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMjgxMA_91155703-900f-41c5-9bb4-e918e6cf6df5">0.5</ix:nonFraction> million was recorded in Accrued expenses and $<ix:nonFraction unitRef="usd" contextRef="i4c5f0e2847a64769ab9be88846f125c4_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMjg1MA_9f7605fa-1486-4c02-bcfd-ba6e99d6d54d">2.2</ix:nonFraction> million was recorded in Other long-term liabilities.  As of December&#160;31, 2021, of the $<ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMjkxNg_b94c6bd4-d326-4f2d-803a-479c2ef372f5">2.8</ix:nonFraction> million of contingent consideration, $<ix:nonFraction unitRef="usd" contextRef="i0dd929a7397e49f0ab13af7ad0be9d63_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMjk0OA_7cd6ba65-8920-4897-a6a6-afac9ade56d9">0.5</ix:nonFraction> million was recorded in Accrued expenses and $<ix:nonFraction unitRef="usd" contextRef="iae497a6420cd4f4faf38ce9662826b4e_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMjk4OA_fe543472-4e7a-42bb-a12f-0225bd30f0f9">2.3</ix:nonFraction> million was recorded in Other long-term liabilities. As a result of our execution of the CAMP4 Agreement (as defined in Note 14), we will have to pay a percentage of any payments received under the CAMP4 Agreement to the former CURNA stockholders.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RleHRyZWdpb246ZWMzZjE3NTEwODNjNGRjOGEzNmY4ODAyNzE0MTc5ZWNfMTIxMA_f568b21a-d5b9-47d3-b8a7-a16a3d8dcc25" continuedAt="ife34c632db18418a87b934f0dd474122" escape="true">DERIVATIVE CONTRACTS</ix:nonNumeric></span></div><ix:continuation id="ife34c632db18418a87b934f0dd474122"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RleHRyZWdpb246ZWMzZjE3NTEwODNjNGRjOGEzNmY4ODAyNzE0MTc5ZWNfMTE4Nw_cef1441f-1dcb-46ce-aa6d-d12f77dea401" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair values and the presentation of our derivative financial instruments in the Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:36.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Component</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock options/warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b034a9ad25047b59a622208212d95e1_I20220331" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOjgwZTYwYjY1NzQ4YjQ3MGZiYjM2NjcyNGU0YmIwYWE0L3RhYmxlcmFuZ2U6ODBlNjBiNjU3NDhiNDcwZmJiMzY2NzI0ZTRiYjBhYTRfMy0zLTEtMS0zNTMzMA_191669e0-f0e7-47d7-98da-c932a60907d4">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i339ef703a5544c01b8dbb210e3619b01_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOjgwZTYwYjY1NzQ4YjQ3MGZiYjM2NjcyNGU0YmIwYWE0L3RhYmxlcmFuZ2U6ODBlNjBiNjU3NDhiNDcwZmJiMzY2NzI0ZTRiYjBhYTRfMy01LTEtMS0zNTMzMA_49e373fb-2071-404d-94fa-851aee1a051a">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses.  Unrealized (losses) on forward contracts are recorded in Accrued expenses.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c9e493caa0e47609d6a6dc891471ba6_I20220331" decimals="-3" sign="-" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOjgwZTYwYjY1NzQ4YjQ3MGZiYjM2NjcyNGU0YmIwYWE0L3RhYmxlcmFuZ2U6ODBlNjBiNjU3NDhiNDcwZmJiMzY2NzI0ZTRiYjBhYTRfNS0zLTEtMS0zNTMzMA_d276590d-638f-4bef-9c24-5f8c3a5f553b">462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie52baf79fca2489f9435b6f9e9014cda_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOjgwZTYwYjY1NzQ4YjQ3MGZiYjM2NjcyNGU0YmIwYWE0L3RhYmxlcmFuZ2U6ODBlNjBiNjU3NDhiNDcwZmJiMzY2NzI0ZTRiYjBhYTRfNS01LTEtMS0zNTMzMA_c979c3f2-956e-41cb-ad34-bf2d4b7f2bf6">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency forward exchange contracts with respect to the risk of exposure to exchange rate differences arising from inventory purchases on letters of credit.  Under these forward contracts, for any rate above or below the fixed rate, we receive or pay the difference between the spot rate and the fixed rate for the given amount at the settlement date.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To qualify the derivative instrument as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At March&#160;31, 2022 and December&#160;31, 2021, our derivative financial instruments did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognize the changes in Fair value of derivative instruments, net in our Condensed Consolidated Statement of Operations.  <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RleHRyZWdpb246ZWMzZjE3NTEwODNjNGRjOGEzNmY4ODAyNzE0MTc5ZWNfMTIwNw_c33037bb-d8e4-40e6-b75c-eec859f534b6" continuedAt="i3031d927f95c424fa98f8c597305ec4e" escape="true">The following table summarizes the losses and gains recorded for the three and three months ended March 31, 2022 and 2021:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i3031d927f95c424fa98f8c597305ec4e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.560%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative gain (loss):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock options/warrants </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied8a1708f69d41239c1f9de8d8facd76_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOmY2Zjg1MTRkOTRmMDQzOGVhMDZiMjE0NjhkOWM5NmI3L3RhYmxlcmFuZ2U6ZjZmODUxNGQ5NGYwNDM4ZWEwNmIyMTQ2OGQ5Yzk2YjdfNC02LTEtMS0zNTMzMA_17eabba7-9bc4-4258-9bde-d68f34e36acd">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e8e55382c6349dba42db7b0d47c339c_D20210101-20210331" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOmY2Zjg1MTRkOTRmMDQzOGVhMDZiMjE0NjhkOWM5NmI3L3RhYmxlcmFuZ2U6ZjZmODUxNGQ5NGYwNDM4ZWEwNmIyMTQ2OGQ5Yzk2YjdfNC04LTEtMS0zNTMzMA_81ef41be-d6de-4f7a-91a6-edb4c2805a18">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i320a0c5cf0c54c369df4652d6c4aaee3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOmY2Zjg1MTRkOTRmMDQzOGVhMDZiMjE0NjhkOWM5NmI3L3RhYmxlcmFuZ2U6ZjZmODUxNGQ5NGYwNDM4ZWEwNmIyMTQ2OGQ5Yzk2YjdfNi02LTEtMS0zNTMzMA_d16242c4-f8cd-4a3a-8442-7994f30c486d">131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf311fd02fe0429098a14a89aaff1a31_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOmY2Zjg1MTRkOTRmMDQzOGVhMDZiMjE0NjhkOWM5NmI3L3RhYmxlcmFuZ2U6ZjZmODUxNGQ5NGYwNDM4ZWEwNmIyMTQ2OGQ5Yzk2YjdfNi04LTEtMS0zNTMzMA_3974f9af-4a3c-4547-8705-50934a2d3a65">460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9043229605240dc9166035e1b850972_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOmY2Zjg1MTRkOTRmMDQzOGVhMDZiMjE0NjhkOWM5NmI3L3RhYmxlcmFuZ2U6ZjZmODUxNGQ5NGYwNDM4ZWEwNmIyMTQ2OGQ5Yzk2YjdfNy02LTEtMS0zNTMzMA_1276d196-3f03-4972-9ee3-35efaa9103b5">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5916426f99024163a0c1c7044beb1897_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOmY2Zjg1MTRkOTRmMDQzOGVhMDZiMjE0NjhkOWM5NmI3L3RhYmxlcmFuZ2U6ZjZmODUxNGQ5NGYwNDM4ZWEwNmIyMTQ2OGQ5Yzk2YjdfNy04LTEtMS0zNTMzMA_773d645c-ccd8-4726-96cd-c6132ec6920d">439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="i1cac816ff800494ea2979c434f00b37c_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfNDc3NQ_12dc6462-bedf-40c1-9361-d3356bc201bb" continuedAt="i3d522520296e44eb833436c00d18a49d" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="text-indent:24.75pt"><span><br/></span></div><ix:continuation id="i3d522520296e44eb833436c00d18a49d" continuedAt="id637d308105a4086958b29da56228c05"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, GeneDx entered into an agreement with Mednax Services, Inc. (&#8220;Mednax Services&#8221;), a subsidiary of MEDNAX, Inc., (&#8220;MEDNAX&#8221;) pursuant to which the parties formed a joint venture under the brand Detect Genomix.  GeneDx&#8217;s initial capital investment in Detect Genomix was $<ix:nonFraction unitRef="usd" contextRef="ibadd78e70def4793bd8033df5fdbe911_D20200801-20200831" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMTA4NA_77bebb7f-a795-40ef-bbe3-00b2a847d966">245,000</ix:nonFraction> for which GeneDx received a <ix:nonFraction unitRef="number" contextRef="i4a78517025804d929c0e5e426c1b9a4b_I20200831" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMTExNQ_b063342a-e16c-4a8f-ac39-6699f3e966df">49</ix:nonFraction>% ownership interest in Detect Genomix, and Mednax Services contributed $<ix:nonFraction unitRef="usd" contextRef="i50674a6b6023457196ed8f17e7e4cf51_D20200801-20200831" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMTE4OA_d30f4a3c-22ac-4790-b68b-e672feaccb90">255,000</ix:nonFraction> in exchange for a <ix:nonFraction unitRef="number" contextRef="i4ecfd405f7e848e8a4e0bde064b5beaf_I20200831" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMTIwOQ_d9b74682-c77b-4954-851a-1db4e938743f">51</ix:nonFraction>% ownership interest in Detect Genomix.  Adam Logal, the Company&#8217;s CFO, was the chair and sat on the Board of Managers of the joint venture.  Mednax Services provided administrative services to the joint venture pursuant to an administrative services agreement.  GeneDx provided laboratory services to the joint venture.  Dr. Roger Medel, a director of the Company, is the former Chief Executive Officer of MEDNAX and Mednax Services.  Dr. Medel continues to serve on the board of MEDNAX.  The joint venture was dissolved in January 2022.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 25, 2020, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="i77752216e0a74e5e94c99ae54b2ab33f_I20200225" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMTg3OQ_496ef3a8-888d-4934-96bf-1d776b1176c7">100</ix:nonFraction> million.  The line of credit called for a commitment fee equal to <ix:nonFraction unitRef="number" contextRef="i9ba35bd01ebf48fc928c6575df35dcf4_D20200225-20200225" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMTk0MA_f7b9a0d3-3313-4b1b-b8ad-b589908a9ebc">0.25</ix:nonFraction>% per annum of the unused portion of the line. We terminated this line of credit in June 2021 and as of March 31, 2022 and December 31, 2021, <ix:nonFraction unitRef="usd" contextRef="ia1b9e43d842649f78bdeeb877a771557_I20220331" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMzg0ODI5MDcxNjIzNQ_724ec36b-8bda-44c2-86a7-41568ce59e30">no</ix:nonFraction> amount was outstanding thereunder.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns approximately <ix:nonFraction unitRef="number" contextRef="i2da87d4b1cea40abb7f65c8419989f04_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjEzNQ_c2fbfc79-f7a2-475a-9265-d1ea479ce7bb">9</ix:nonFraction>% of Pharmsynthez and Pharmsynthez is Xenetic&#8217;s largest and controlling stockholder. Dr. Richard Lerner, a director of the Company until his death on December 2, 2021, was a co-inventor of Xenetic&#8217;s technology and received <ix:nonFraction unitRef="shares" contextRef="iee2076cde68b4576afe09b95b5942af6_I20220331" decimals="INF" name="opk:RelatedPartyTransactionShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjMyMg_b42e0ced-ede0-4d07-955a-a53243c7da2e">31,240</ix:nonFraction> shares of Xenetic upon the closing of the Xenetic transactions described above.  Adam Logal, our Senior Vice President and Chief Financial Officer, is a director of Xenetic.   </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold investments in Zebra (ownership <ix:nonFraction unitRef="number" contextRef="i4ae393d9880f48be85feb8757df68b73_D20220101-20220331" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjU3MA_27d7064d-2de9-4521-910b-f5f02869ab15">29</ix:nonFraction>%), Neovasc (<ix:nonFraction unitRef="number" contextRef="i4e737b98458d4a859ab982878352b552_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjU4NA_a3003a6b-ffd5-4b7d-8f81-b2bd4dc64e8c">1</ix:nonFraction>%), ChromaDex Corporation (<ix:nonFraction unitRef="number" contextRef="ief99b9b8fe8e4816986a723ffacc2c18_I20220331" decimals="3" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjYxMg_9d5584c1-4202-43c2-8ded-140a87378772">0.1</ix:nonFraction>%), COCP (<ix:nonFraction unitRef="number" contextRef="ief9f3d5f2c21400fbcb87f69615b8cf1_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjYyMw_ff4c87ff-a99a-4456-91bb-d0b852bc86b1">3</ix:nonFraction>%), NIMS (<ix:nonFraction unitRef="number" contextRef="iba2fbb366c7942ee8c1f1d0688aeacd7_I20220331" decimals="2" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjYzNA_08afefb2-dde9-4d35-9598-ee6d52685ffd">1</ix:nonFraction>%), Eloxx (<ix:nonFraction unitRef="number" contextRef="i745a5d9c8eda4157b142bcd4ae5184df_I20220331" decimals="2" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjY0Ng_bf39d421-2e9e-4854-8469-0da48ce8ee8f">1</ix:nonFraction>%), BioCardia (<ix:nonFraction unitRef="number" contextRef="iefc49f12f9a24f6a8438f9164321e4b9_I20220331" decimals="2" name="opk:EquitySecurityFVNIOwnershipPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjY2Ng_416127fb-d292-4a4e-ad39-d4b22b66c6c0">1</ix:nonFraction>%) and LeaderMed Health Group Limited (<ix:nonFraction unitRef="number" contextRef="i3e85d9626c1c441cb3ee913546454e58_D20220101-20220331" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMzg0ODI5MDcxNjI0NA_6b74935e-6ac9-4594-a789-719ac72d6fef">47</ix:nonFraction>%).  These investments were considered related party transactions as a result of our executive management&#8217;s ownership interests and/or board representation in these entities.  See further discussion of our investments in Note 6.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="id637d308105a4086958b29da56228c05"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, we entered into a Pledge Agreement with the Museum of Science, Inc. and the Museum of Science Endowment Fund, Inc. pursuant to which we agreed to contribute an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ica59f07c68a7496dadf29dc004ea21da_I20161130" decimals="-5" name="opk:RelatedPartyTransactionFutureContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMzA4OQ_33168278-7edf-4b81-968b-02c5a8c46457">1.0</ix:nonFraction> million over a <ix:nonNumeric contextRef="ib24c230ab8774444a8491338133155c0_D20161101-20161130" name="opk:RelatedPartyTransactionFutureContributionTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfNDc3Mw_6d1388d5-466e-4117-adee-1d11b1141fb7">four-year</ix:nonNumeric> period for constructing, equipping and the general operation of the Frost Science Museum.  Dr. Frost and Mr. Richard Pfenniger serve on the Board of Trustees of the Frost Science Museum and Mr. Pfenniger is the Vice Chairman of the Board of Trustees.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space from Frost Real Estate Holdings, LLC (&#8220;Frost Holdings&#8221;) in Miami, Florida, where our principal executive offices are located.  Effective August 1, 2019, we entered into an amendment to our lease agreement with Frost Holdings.  The lease, as amended, is for approximately <ix:nonFraction unitRef="sqft" contextRef="i86ce37219a974882a0746dff7fc5dd55_I20190801" decimals="-2" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMzY1MQ_2a5b1f55-3fc7-44a1-9e84-5d8ee49cf7c3">29,500</ix:nonFraction> square feet of space.  The lease provides for payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i86ce37219a974882a0746dff7fc5dd55_I20190801" decimals="-3" name="opk:OperatingLeasesMonthlyPaymentsYearOne" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMzcyNg_9e16e6ec-323c-4dee-a009-8f3ffaa03861">89</ix:nonFraction> thousand per month in the first year increasing annually to $<ix:nonFraction unitRef="usd" contextRef="i86ce37219a974882a0746dff7fc5dd55_I20190801" decimals="-3" name="opk:OperatingLeasesMonthlyPaymentsYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMzc4MA_e2c795e5-2df2-4e18-b834-cefef4c1e4bf">101</ix:nonFraction> thousand per month in the fifth year, plus applicable sales tax.  The rent is inclusive of operating expenses, property taxes and parking.   </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioReference purchases and uses certain products acquired from InCellDx, a company in which we hold a <ix:nonFraction unitRef="number" contextRef="i61c6fa53ff434aeea2559a0e6fca1f8f_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfNDAxOA_8550f2f9-b086-4bb7-9b7f-f776ea7b1ebd">29</ix:nonFraction>% minority interest.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reimburse Dr.&#160;Frost for Company-related use by Dr.&#160;Frost and our other executives of an airplane owned by a company that is beneficially owned by Dr.&#160;Frost.  We reimburse Dr. Frost for out-of-pocket operating costs for the use of the airplane by Dr. Frost or Company executives for Company-related business.  We do not reimburse Dr.&#160;Frost for personal use of the airplane by Dr.&#160;Frost or any other executive.  For the three months ended March 31, 2022 and 2021, we reimbursed approximately $<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfNDUwNQ_5076745b-7760-4a02-b3af-3524f0a88972">31</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfNDY4OA_dc3ae997-1e60-4d75-84ab-299ab5336fe4">0&#160;thousand</ix:nonFraction>, respectively, for Company-related travel by Dr. Frost and other OPKO executives.</span></div></ix:continuation><div id="i1cac816ff800494ea2979c434f00b37c_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfNjM0Mw_85187583-4f2b-4fc9-ba66-3955a339966a" continuedAt="i381c1d2bca6440e5b9ff952140e1c6bc" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i381c1d2bca6440e5b9ff952140e1c6bc" continuedAt="ia1cbb0b031b64041a692e7dcec640c9f"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of CURNA, OPKO Diagnostics and OPKO Renal, we agreed to pay future consideration to the sellers upon the achievement of certain events.  As a result, as of March 31, 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMjQ1_5beb9cd6-768b-4021-bd69-b69158306cf5">2.7</ix:nonFraction> million as contingent consideration, with $<ix:nonFraction unitRef="usd" contextRef="ic33ae5da06dc4f819b6dcd183aecaebe_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMjgy_ed3ddd0b-aceb-49fc-8189-ef0f13971d50">0.5</ix:nonFraction> million recorded within Accrued expenses and $<ix:nonFraction unitRef="usd" contextRef="i4c5f0e2847a64769ab9be88846f125c4_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMzIy_5f6ac5a9-0746-43cd-83f9-c7b070035ae5">2.2</ix:nonFraction> million recorded within Other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets.  Refer to Note 5 and Note 17.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2019, the Company received a Civil Investigative Demand (&#8220;CID&#8221;) from the U.S. Department of Justice (&#8220;DOJ&#8221;), Washington, DC. The CID sets forth document requests and interrogatories in connection with allegations that the Company and certain of its affiliates violated the False Claims Act and/or the Anti-Kickback Statute. On January 13, 2022, the Federal Government notified the U.S.D.C., Middle District Florida, Jacksonville Division, that it is declining to intervene in the matter but retains the right, via the Attorney General, to consent to any proposed dismissal of the action by the Court. On February 9, 2022, the States of Florida, Georgia, and Commonwealth of Massachusetts notified the U.S.D.C., Middle District Florida, Jacksonville Division, that they are declining to intervene in the matter. Notwithstanding the above declinations, on February 17, 2022, the Company was served with the Relator&#8217;s Summons and Complaint (&#8220;Complaint&#8221;), which had been previously sealed. The complaint alleges violations of the False Claims Act, the California Fraud Preventions Act, the Florida False Claims Act, the Massachusetts False Claims Act, the Georgia False Medicaid Claims Act, and illegal kickbacks. The Company is reviewing and assessing the allegations made in the Complaint and, at this point, has not determined whether there is any merit to these claims nor can it determine the extent of any potential liability. While management cannot predict the outcome of these matters at this time, the ultimate outcome could be material to our business, financial condition, results of operations, and cash flows.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">         As previously reported, BioReference receives and is routinely required to respond to Civil Investigative Demands (&#8220;CID&#8221;) in the ordinary course of business. On November 26, 2019, BioReference received a CID from the DOJ. The CID states that DOJ is investigating whether BioReference paid unlawful remuneration to health care practitioners in violation of the Anti-Kickback Statute or Stark law and thus submitted or caused to be submitted false claims to government health care programs in violation of the False Claims Act. The time period covered by DOJ&#8217;s requests is January 1, 2011 through November 26, 2019. BioReference has fully cooperated with the DOJ by submitting the requested information and making current employees available for interviews, and the DOJ made a presentation to BioReference regarding its position. The parties have reached verbal agreement on the settlement amount, which is anticipated to be approximately $<ix:nonFraction unitRef="usd" contextRef="i02020232c72342119d53b27eaa44b338_D20220101-20220331" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMTQ0MA_a6ede8ae-c53b-49d0-a64f-8dd09e48ad3b">10</ix:nonFraction>&#160;million, excluding attorney fees. As of March&#160;31, 2022 and December 31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i522709e2d34e47b9b839338702492788_I20220331" decimals="-5" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMjc0ODc3OTA4NzgzOA_9bea715d-43df-4ab9-be20-fd46e2641533">10.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idc90d86f2b4c4d5a8429f7ad7154f525_I20211231" decimals="-5" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMjc0ODc3OTA4Nzg3MQ_dac662ec-63ef-42ea-b5f9-9932cc8ca5af">10.0</ix:nonFraction>&#160;million was recorded in Accrued expenses, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="ia1cbb0b031b64041a692e7dcec640c9f"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2019, MabVax Therapeutics Holdings, Inc. filed a lawsuit in the Superior Court of California, County of San Diego against a number of individuals and entities, including the Company, Dr. Frost, Steven Rubin, the Company&#8217;s Executive Vice President-Administration, and an entity affiliated with Dr. Frost, based on the allegations raised in the SEC Complaint. The lawsuit seeks an award for actual and punitive damages, pre- and post-judgment interest; that the defendants be required to make full disclosure and accounting of their interests and transactions in plaintiff&#8217;s securities; costs of the suit, and reasonable attorney&#8217;s fees; and such other legal and equitable relief as the Court may deem proper under the circumstances. On January 31, 2022, plaintiffs entered into a confidential mutual release and settlement agreement with the Company, Dr. Frost, Frost Gamma Investment Trust, and Steve Rubin (the &#8220;Settlement Agreement&#8221;). The Settlement Agreement  has been approved by the United States Bankruptcy Court for the District of Delaware.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2019, former shareholders of Claros Diagnostics, Inc. filed a complaint in the Chancery Court of Delaware against the Company, alleging among other things, that the Company breached the Agreement and Plan of Merger dated October 13, 2011 by and among the Company, Claros Merger Subsidiary, LLC and Claros Diagnostics, Inc. (the &#8220;Claros Merger Agreement&#8221;): (i) by failing to make a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i70de44f4e3b347cfb81ce995f5cf73fe_I20190405" decimals="-3" name="opk:LossContingencyMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMTg3Nw_75ea946e-c70f-493d-a8ae-32d252138a8d">2.375</ix:nonFraction>&#160;million (payable in OPKO Common Stock) upon obtaining FDA approval of the Claros PSA test; and (ii) by repudiating its obligations to make additional future milestone payments as required under the Claros Merger Agreement. In January 2021, the Company and the shareholder representative entered into a settlement agreement providing, among other things, that the Company pay the shareholders $<ix:nonFraction unitRef="usd" contextRef="i676c769373684cfba8382f5367b6370f_D20210101-20210131" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMjI1Nw_456c2648-3c11-4d4f-8de8-4bc9b238002b">1.2</ix:nonFraction>&#160;million, which the Company has paid in full.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2017, the Civil Division of the United States Attorney&#8217;s Office for the Southern District of New York (the &#8220;SDNY&#8221;) informed BioReference that it believed that, from 2008 to 2012, BioReference had, in violation of the False Claims Act, improperly billed Medicare and TRICARE (both are federal government healthcare programs) for clinical laboratory services provided to hospital inpatient beneficiaries at certain hospitals.  In April 2019, the SDNY also informed BioReference that it believed that BioReference provided physicians subsidies for electronic health record systems prior to 2012 that violated regulations adopted by HHS in 2006 which allowed laboratories to provide these donations under certain conditions.  BioReference and the SDNY reached a settlement with respect to these matters and a final settlement and release, including BioReference&#8217;s payment of an approximately $<ix:nonFraction unitRef="usd" contextRef="i3ef8f6dc8b5e486b8e9f8f96b1343e13_D20200922-20200922" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMjc0ODc3OTA5MjIwNQ_481a53d5-7e5a-4b8c-9918-8307c91b3945">11.5</ix:nonFraction>&#160;million settlement amount, was approved on September 22, 2020. The settlement amount has been paid. The amount of relator attorneys&#8217; fees is currently being negotiated.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may receive inquiries, document requests, CIDs or subpoenas from the Department of Justice, OCR, CMS, various payors and fiscal intermediaries, and other state and federal regulators regarding investigations, audits and reviews.  In addition to the matters discussed in this note, we are currently responding to CIDs, subpoenas, payor audits, and document requests for various matters relating to our laboratory operations.  Some pending or threatened proceedings against us may involve potentially substantial amounts as well as the possibility of civil, criminal, or administrative fines, penalties, or other sanctions, which could be material.  Settlements of suits involving the types of issues that we routinely confront may require monetary payments as well as corporate integrity agreements.  Additionally, qui tam or &#8220;whistleblower&#8221; actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act&#8217;s requirements for filing such suits.  Also, from time to time, we may detect issues of non-compliance with federal healthcare laws pertaining to claims submission and reimbursement practices and/or financial relationships with physicians, among other things.  We may avail ourselves of various mechanisms to address these issues, including participation in voluntary disclosure protocols.  Participating in voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action.  The Company generally has cooperated, and intends to continue to cooperate, with appropriate regulatory authorities as and when investigations, audits and inquiries arise.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to other litigation in the ordinary course of business.  While we cannot predict the ultimate outcome of legal matters, we accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss.  It&#8217;s reasonably possible the ultimate liability could exceed amounts currently estimated and we review established accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information.  To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.  Because of the high degree of judgment involved in establishing loss estimates, the ultimate outcome of such matters will differ from our estimates and such differences may be material to our business, financial condition, results of operations, and cash flows.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, we were committed to make future purchases for inventory and other items in 2022 that occur in the ordinary course of business under various purchase arrangements with fixed purchase provisions aggregating approximately $<ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfNjMzOA_0cbba1f7-08c0-47d8-9100-9827c934f5ed">252.4</ix:nonFraction> million.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMTY5NTU_d82ee311-9d06-4061-879c-425d395947a6" continuedAt="i3d1c6369ec44440aa004fa60a391817e" escape="true">REVENUE RECOGNITION</ix:nonNumeric></span></div><ix:continuation id="i3d1c6369ec44440aa004fa60a391817e" continuedAt="idd7153015af440748f4aaf9413c303e4"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from services, products and intellectual property as follows:</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from services</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for laboratory services is recognized at the time test results are reported, which approximates when services are provided and the performance obligations are satisfied.  Services are provided to patients covered by various third-party payor programs including various managed care organizations, as well as the Medicare and Medicaid programs.  Billings for services are included in revenue net of allowances for contractual discounts, allowances for differences between the amounts billed and estimated program payment amounts, and implicit price concessions provided to uninsured patients which are all elements of variable consideration.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are descriptions of our payors for laboratory services:</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Insurers.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules.  Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements.  Adjustments to the allowances, based on actual receipts from the third-party payors, are recorded upon settlement.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Payors.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursements from government payors are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid.  Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements.  Adjustments to the allowances, based on actual receipts from the government payors, are recorded upon settlement.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Client Payors.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Client payors include physicians, hospitals, employers, and other institutions for which services are performed on a wholesale basis, and are billed and recognized as revenue based on negotiated fee schedules.  Client payors also include cities, states and companies for which BioReference provides COVID-19 testing services.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patients.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients.  Insured patients (including amounts for coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers.  Collection of billings from patients is subject to credit risk and ability of the patients to pay.  Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with our policies and implicit price concessions.  Implicit price concessions represent differences between amounts billed and the estimated consideration that we expect to receive from patients, which considers historical collection experience and other factors including current market conditions.  Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement.  </span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, require us to estimate the potential for retroactive adjustments as an element of variable consideration in the recognition of revenue in the period the related services are rendered.  Actual amounts are adjusted in the period those adjustments become known. For the three months ended March 31, 2022 and 2021, positive revenue adjustments due to changes in estimates of implicit price concessions for performance obligations satisfied in prior periods of $<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMzc4Mg_0d9c5466-20e9-4448-833c-64d8056b39fd">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMzk1MA_f8e4256e-7af2-4655-8221-0f3b7cbcaa50">28.0</ix:nonFraction> million, respectively, were recognized.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors, including government programs, may decide to deny payment or recoup payments for testing they contend were improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received.  Our revenues may be subject to retroactive adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payors in interpretations, requirements, and &#8220;conditions of participation&#8221; in various programs.  We have processed requests for recoupment from third-party payors in the ordinary course of our business, and it is likely that we will continue to do so in the future.  If a third-party payor denies payment for testing or recoups money from us in a later period, reimbursement for our testing could decline.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an integral part of our billing compliance program, we periodically assess our billing and coding practices, respond to payor audits on a routine basis, and investigate reported failures or suspected failures to comply with federal and state healthcare reimbursement requirements, as well as overpayment claims which may arise from time to time without fault on the part of the Company.  We may have an obligation to reimburse Medicare, Medicaid,&#160;and third-party payors for </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="idd7153015af440748f4aaf9413c303e4" continuedAt="i67eede20a95e40c6ab544d70cfd8c3e4"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overpayments&#160;regardless of fault.  We have periodically identified and reported&#160;overpayments, reimbursed payors for&#160;overpayments&#160;and taken appropriate corrective action.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are also considered variable consideration and are included in the determination of the estimated transaction price for providing services.  These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and our historical settlement activity, including an assessment of the probability a significant reversal of cumulative revenue recognized will occur when the uncertainty is subsequently resolved.  Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. As of March&#160;31, 2022 and December&#160;31, 2021, we had liabilities of approximately $<ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-5" name="opk:AccruedExpensePayorOverpaymentReimbursementLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfNjYwNw_4ca03b58-beec-43f5-a90c-5e5bc0debb26">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-5" name="opk:AccruedExpensePayorOverpaymentReimbursementLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfNjYxNA_abb20e23-3d0f-4dc1-811c-1da6c9da44b3">5.0</ix:nonFraction> million, respectively, within Accrued expenses and Other long-term liabilities related to reimbursements for payor overpayments.</span></div><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMTY5NjA_197c1023-b65d-47e3-94b1-62064aa6e260" escape="true"><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of Revenue from services by payor for the three months ended March 31, 2022 and 2021 was as follows:</span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three months ended March&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b576227129140fcb81ae5986936e0a5_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfMi01LTEtMS0zNTMzMA_e498d3a2-c5bc-4cd4-ac40-e3f7a51a97d6">95,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c5cff8bc69f43c19ce205c66e3547e9_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfMi03LTEtMS0zNTMzMA_b7933619-e853-41e5-9040-1bc90f62b643">164,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874e9141286747c28f30293d988fb218_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfMy01LTEtMS0zNTMzMA_a396f2ac-524b-4815-92d1-84d0436e5500">27,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8101af777f47df9da8ece465836a9c_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfMy03LTEtMS0zNTMzMA_a0e7aaca-d45a-43a3-9756-f9edb7e7398d">73,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d41bb470d9447f9a98b8d23e1a42b68_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfNC01LTEtMS0zNTMzMA_7141beb7-1530-48a7-a072-1dbc921b1f11">159,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7186cb07c47349b0b7397d1c5851b571_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfNC03LTEtMS0zNTMzMA_c783f49f-655e-4f3b-8fa4-a8188d97dc82">262,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5acb3b505f4483bf34a77f2c5e788e_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfNS01LTEtMS0zNTMzMA_f1a8d340-8d4f-42ec-b9c5-fa2b8e9c2f10">4,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d9faa02d9d40f389d88742df8865d3_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfNS03LTEtMS0zNTMzMA_5cb15d79-2e23-40ec-8030-b633457a7e4e">5,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f9c95a502354f4c9bd791e55a1b1acc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfNi01LTEtMS0zNTMzMA_73ae7418-c68c-4940-8b8c-51db4a3146a4">286,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fd3f89e217e4e329bca14b9905edffa_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfNi03LTEtMS0zNTMzMA_e4a3be07-ae01-4426-a29c-a8b8876e61f5">506,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from products</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from product sales when a customer obtains control of promised goods or services.  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and our evaluation of specific factors that may increase or decrease the risk of product returns.  Product revenues are recorded net of estimated rebates, chargebacks, discounts, co-pay assistance and other deductions (collectively, &#8220;Sales Deductions&#8221;) as well as estimated product returns which are all elements of variable consideration.  Allowances are recorded as a reduction of revenue at the time product revenues are recognized.  The actual amounts of consideration ultimately received may differ from our estimates.  If actual results in the future vary from our estimates, we will adjust these estimates, which would affect Revenue from products in the period such variances become known.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is distributed in the U.S. principally through the retail pharmacy channel, which initiates with the largest wholesalers in the U.S. (collectively, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Customers&#8221;).  In addition to distribution agreements with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers, we have entered into arrangements with many healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue for shipments of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time of delivery to customers after estimating Sales Deductions and product returns as elements of variable consideration utilizing historical information and market research projections. For the three months ended March 31, 2022 and 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="id0e7950d75f0444d93f095f4040135b3_D20220101-20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfODcxNw_1e665636-9f2e-44cb-bada-9d5d3a169b70">5.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ief2e45330b2c4c668f762e3119a6fbae_D20210101-20210331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfODg2Ng_c57b3e20-4696-4358-bd5f-6d74705d0feb">5.8</ix:nonFraction>&#160;million, respectively, in net product revenue from sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="opk:ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMTY5NTc_cdbd2ce3-6cfb-4d30-984e-ba9c91041a5c" continuedAt="i354f8e89329746eaa99a86e32cd9e49c" escape="true">The following table presents an analysis of product sales allowances and accruals for the three months ended March 31, 2022 and 2021:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i67eede20a95e40c6ab544d70cfd8c3e4" continuedAt="i58de47c66cdc41108aa8f2c2ed86ded7"><ix:continuation id="i354f8e89329746eaa99a86e32cd9e49c"><div style="margin-bottom:5pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chargebacks, discounts, rebates and fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Governmental </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea7a07d482240c5a1a9daa77497e119_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMS0yLTEtMS0zNTMzMA_95c8f467-84f5-4686-a1dc-b26ecd79e9d5">2,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7745e7dd9842490f8a4d3aa14b8bb285_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMS00LTEtMS0zNTMzMA_160bef3c-f8b7-42e5-bb01-bedc2f1be267">5,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic32fd42c04ee410bade14b9fa49da67d_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMS02LTEtMS0zNTMzMA_e4207f39-6a10-44a9-b60c-740e71599a6f">2,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b8dfcf4b0a47ceb082dba3ba22e4e2_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMS04LTEtMS0zNTMzMA_78880c5e-f240-448b-9f01-22b7cfc8005e">10,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Provision related to current period sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a4781da5440461fa4b0023e40c75529_D20220101-20220331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMi0yLTEtMS0zNTMzMA_69f753ac-4e6c-4ed8-b072-4d40aad2f793">3,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e9ad9bd7fa74daeae00d3f5d5742096_D20220101-20220331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMi00LTEtMS0zNTMzMA_fb96cb2d-668b-4535-bbfc-380b4dd192ad">4,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2dedc717e1341d5886ca72f83560353_D20220101-20220331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMi02LTEtMS0zNTMzMA_0a043b8d-e6ea-4b3b-927f-4c1bf775f4e1">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e7950d75f0444d93f095f4040135b3_D20220101-20220331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMi04LTEtMS0zNTMzMA_a57b10b8-6400-45fe-9515-364ce19ae0cb">8,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Credits or payments made</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a4781da5440461fa4b0023e40c75529_D20220101-20220331" decimals="-3" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNC0yLTEtMS0zNTMzMA_f67f6214-798b-4650-80b8-51f3d80cd826">3,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e9ad9bd7fa74daeae00d3f5d5742096_D20220101-20220331" decimals="-3" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNC00LTEtMS0zNTMzMA_74381b71-c8af-41ca-b125-2e6490696567">5,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2dedc717e1341d5886ca72f83560353_D20220101-20220331" decimals="-3" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNC02LTEtMS0zNTMzMA_1401386d-0c21-46f0-bf26-aa0ee55fc082">575</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e7950d75f0444d93f095f4040135b3_D20220101-20220331" decimals="-3" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNC04LTEtMS0zNTMzMA_f9393b3a-e2b1-4963-a03f-c13bb248f3ec">9,302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abfbe41a46e407a91e30f4caa372833_I20220331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNS0yLTEtMS0zNTMzMA_cea3fc1a-ef33-4934-8d19-e2528d581a8a">1,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c57ea2417945928b8420c5f3724908_I20220331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNS00LTEtMS0zNTMzMA_5d8b5e86-79f1-4874-9464-56bd956161d7">5,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48d7bc49b584c93b505e1441ca49b05_I20220331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNS02LTEtMS0zNTMzMA_99d09146-75dc-406b-91a4-1169781734c8">2,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e653d3db9e490db849e824a8a8a9a5_I20220331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNS04LTEtMS0zNTMzMA_73cd6cff-3b1d-44f4-a4db-b29da351e789">9,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e7950d75f0444d93f095f4040135b3_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNy04LTEtMS0zNTMzMA_4032b70c-a70a-4e5e-b02f-2d480b3ccd8d">13,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales allowances and accruals as a percentage of gross </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0e7950d75f0444d93f095f4040135b3_D20220101-20220331" decimals="2" name="opk:AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfOC04LTEtMS0zNTMzMA_d09e747c-77c7-47e1-9ccb-835c28e16360">62</ix:nonFraction>%</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chargebacks, discounts, rebates and fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Governmental </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeecfb112c664416a33c945ad8da2700_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMS0yLTEtMS00MDgyOQ_ce2fc1e4-38dd-4ac6-82fd-ab588c5f448a">2,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56348d7a5e4f475181fad615300d4502_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMS00LTEtMS00MDgyOQ_0d9bddd5-8202-43af-8840-5cd3998aecbc">5,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2139d12433584f65aa24b38284d118c9_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMS02LTEtMS00MDgyOQ_c21056a5-06fd-4264-b094-d79d18e60317">3,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie128a7c076a046209f0782cf5784b0a3_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMS04LTEtMS00MDgyOQ_ec78926a-5823-4264-b872-8fdb3fd7fcfe">11,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Provision related to current period sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d0eefa269f14f9f977234ed680b56f9_D20210101-20210331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMi0yLTEtMS00MDgyOQ_5691a5a5-1c4f-414a-aa2e-a496dcead81a">3,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id28b381bb36e4f06a4682b864bdd7356_D20210101-20210331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMi00LTEtMS00MDgyOQ_0bcd0457-b64f-4739-aaf5-1cc054239276">5,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c111d78df63437e89c6efa75cc8851b_D20210101-20210331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMi02LTEtMS00MDgyOQ_e3e8338b-2ddf-4076-ad21-49dbf072f757">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e45330b2c4c668f762e3119a6fbae_D20210101-20210331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMi04LTEtMS00MDgyOQ_ad3511c5-a46c-4719-8ae4-73704b9d003a">9,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Credits or payments made</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d0eefa269f14f9f977234ed680b56f9_D20210101-20210331" decimals="-3" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNC0yLTEtMS00MDgyOQ_dae14588-c4d3-44bc-ad4d-a93d1386edf4">4,454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id28b381bb36e4f06a4682b864bdd7356_D20210101-20210331" decimals="-3" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNC00LTEtMS00MDgyOQ_bf0e88a6-37c7-4455-8c36-a7fa1b0526bc">5,297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c111d78df63437e89c6efa75cc8851b_D20210101-20210331" decimals="-3" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNC02LTEtMS00MDgyOQ_adf9b731-0a05-4150-9cc3-2473637dccc6">419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2e45330b2c4c668f762e3119a6fbae_D20210101-20210331" decimals="-3" name="opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNC04LTEtMS00MDgyOQ_e3853cbd-f9c6-4b48-b0da-9ebd3630f57e">10,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111f3c1bfdd14e20811f5bc40a649d17_I20210331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNS0yLTEtMS00MDgyOQ_da933fa5-f45d-43c1-8f73-e46bc017e089">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b398c50b3cd40b5b0170eef129c73b1_I20210331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNS00LTEtMS00MDgyOQ_3fa7d634-5a75-433a-bafe-a8b9bbd0144d">6,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86896d2c37ea4f34aec16a43eaaedc8a_I20210331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNS02LTEtMS00MDgyOQ_7bb47607-dade-4420-ad35-473cee138344">3,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966cf82bdb2540cbba62a1e436cfbd92_I20210331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNS04LTEtMS00MDgyOQ_f4745e1f-a0df-4a8f-9fd7-399f996914d3">11,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e45330b2c4c668f762e3119a6fbae_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNy04LTEtMS00MDgyOQ_00816af9-790e-4e0d-a627-b4e4ced75d0d">15,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales allowances and accruals as a percentage of gross </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief2e45330b2c4c668f762e3119a6fbae_D20210101-20210331" decimals="2" name="opk:AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfOC04LTEtMS00MDgyOQ_a1c35501-b781-42e1-ad0f-2ef65880faf8">63</ix:nonFraction>%</span></td></tr></table></div></ix:continuation><div style="margin-bottom:5pt;margin-top:9pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes collected from customers related to revenues from services and revenues from products are excluded from revenues.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from intellectual property and other</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenues from the transfer of intellectual property generated through license, development, collaboration and/or commercialization agreements.  The terms of these agreements typically include payment to us for one or more of the following:  non-refundable, up-front license fees; development and commercialization milestone payments; funding of research and/or development activities; and royalties on sales of licensed products.  Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For research, development and/or commercialization agreements that result in revenues, we identify all material performance obligations, which may include a license to intellectual property and know-how, and research and development activities.  In order to determine the transaction price, in addition to any upfront payment, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract.  We constrain (reduce) our estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract.  When determining if variable consideration should be constrained, we consider whether there are factors outside of our control that could result in a significant reversal of revenue.  In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue.  These estimates are re-assessed each reporting period as required.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront License Fees:  If a license to our intellectual property is determined to be functional intellectual property distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement.  The revenue is recognized when the license is transferred to the customer and the customer is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.  If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i58de47c66cdc41108aa8f2c2ed86ded7"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development and Regulatory Milestone Payments:  Depending on facts and circumstances, we may conclude that it is appropriate to include the milestone in the estimated transaction price or that it is appropriate to fully constrain the milestone.  A milestone payment is included in the transaction price in the reporting period that we conclude that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods.  We may record revenues from certain milestones in a reporting period before the milestone is achieved if we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods.  We record a corresponding contract asset when this conclusion is reached.  Milestone payments that have been fully constrained are not included in the transaction price to date.  These milestones remain fully constrained until we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods.  We re-evaluate the probability of achievement of such development milestones and any related constraint each reporting period.  We adjust our estimate of the overall transaction price, including the amount of revenue recorded, if necessary.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Activities:  If we are entitled to reimbursement from our customers for specified research and development expenses, we account for them as separate performance obligations if distinct.  We also determine whether the research and development funding would result in revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation.  The corresponding revenues or offset to research and development expenses are recognized as the related performance obligations are satisfied.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales-based Milestone and Royalty Payments:  Our customers may be required to pay us sales-based milestone payments or royalties on future sales of commercial products.  We recognize revenues related to sales-based milestone and royalty payments upon the later to occur of (i) achievement of the customer&#8217;s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to our intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Potential Products and Services:  Arrangements may include an option for license rights, future supply of drug substance or drug product for either clinical development or commercial supply at the licensee&#8217;s election.  We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the inception of the contract and revenue is recognized only if the option is exercised and products or services are subsequently delivered or when the rights expire.  If the promise is based on market terms and not considered a material right, the option is accounted for if and when exercised.  If we are entitled to additional payments when the licensee exercises these options, any additional payments are generally recorded in license or other revenues when the licensee obtains control of the goods, which is upon delivery.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Three months ended March&#160;31, 2022 and 2021, revenue from transfer of intellectual property and other reflects $<ix:nonFraction unitRef="usd" contextRef="iba783e62870149cda0cee98d8bc74cf5_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMjc0ODc3OTA4NzI0MQ_ecf3cd7e-0de1-42f1-a341-6e338b18b424">2.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6880e4f214144d89a4f0b87a7b1c3f55_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMjc0ODc3OTA4ODA3NQ_baae4487-c92b-4787-8c26-317fbd997d03">2.8</ix:nonFraction>&#160;million of revenue related to the Pfizer Transaction (as defined below).  For the three months ended March&#160;31, 2022 revenue from transfer of intellectual property and other includes $<ix:nonFraction unitRef="usd" contextRef="i5fd88e0b9dc2432ca9c87a42295d0f14_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMjc0ODc3OTA5MDk4OQ_413e644f-d764-4ecd-8d29-f3229caa5e1a">3.0</ix:nonFraction>&#160;million related to a sales milestone from VFMCRP (as defined below).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities relate to cash consideration that OPKO receives in advance of satisfying the related performance obligations. <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMTY5NjU_4f55e4df-479f-4593-b2e2-cbc0f3fd5792" continuedAt="ie67d613a032c4d458e2fb7050bdb5e4d" escape="true">Changes in the contractual liabilities balance during the three months ended March 31, 2022 are as follows:</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:22.5pt"><ix:continuation id="ie67d613a032c4d458e2fb7050bdb5e4d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjcyNTIwZjIyNGI3MjRiNmE5NjUzMGQxYWNmM2E0MTlkL3RhYmxlcmFuZ2U6NzI1MjBmMjI0YjcyNGI2YTk2NTMwZDFhY2YzYTQxOWRfMS0xLTEtMS0zNTMzMA_b9bc07aa-677d-46b6-bb0c-c87fa08850fa">466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjcyNTIwZjIyNGI3MjRiNmE5NjUzMGQxYWNmM2E0MTlkL3RhYmxlcmFuZ2U6NzI1MjBmMjI0YjcyNGI2YTk2NTMwZDFhY2YzYTQxOWRfMi0xLTEtMS0zNTMzMA_cbd7997c-1518-42bb-9095-12dcbab06dce">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized in the period from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in contracts liability at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjcyNTIwZjIyNGI3MjRiNmE5NjUzMGQxYWNmM2E0MTlkL3RhYmxlcmFuZ2U6NzI1MjBmMjI0YjcyNGI2YTk2NTMwZDFhY2YzYTQxOWRfNC0xLTEtMS0zNTMzMA_b305add5-ec05-4c27-b8af-db3d92cdd07a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div id="i1cac816ff800494ea2979c434f00b37c_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="opk:StrategicAlliancesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTYyNzU_269877b0-bcec-45c0-a313-c4751aec7596" continuedAt="iee707b4abe664dcdbb2371f328cfb7f5" escape="true">STRATEGIC ALLIANCES</ix:nonNumeric></span></div><ix:continuation id="iee707b4abe664dcdbb2371f328cfb7f5" continuedAt="i228c0213afff4420befdf86474ca3555"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LeaderMed</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2021, we and LeaderMed Health Group Limited (&#8220;LeaderMed&#8221;), a pharmaceutical development company with operations based in Asia, announced the formation of a joint venture to develop, manufacture and commercialize two of OPKO&#8217;s clinical stage, long-acting drug products in Greater China and eight other Asian territories. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreements, we have granted the joint venture exclusive rights to develop, manufacture and commercialize (a) OPK88003, an oxyntomodulin analog being developed for the treatment of obesity and diabetes, and (b) Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia, in exchange for a <ix:nonFraction unitRef="number" contextRef="i36d25b2cfa03459783a6e94281295ca5_I20210914" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfNzI1_44df1b75-d4fd-4b81-8b4d-233278e09693">47</ix:nonFraction>% ownership </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i228c0213afff4420befdf86474ca3555" continuedAt="i4c54ea7ee2174967a3bb027886d4d937"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest in the joint venture. In addition, we received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ie8156096c5d249378540b9fe04c480dc_D20210914-20210914" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfODE2_f457bdb7-2acd-4445-be26-9c9ef9a4c8ce">1</ix:nonFraction>&#160;million and will be reimbursed for clinical trial material and technical support we provide the joint venture. We recognized the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i31eed14eff354f918546bd944177b06f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMzg0ODI5MDcxOTUxMA_5afd41e0-50f7-4298-8d88-af47982123ce">1</ix:nonFraction>&#160;million as revenue from transfer of intellectual property and other during the year ended December 31, 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LeaderMed has agreed to be responsible for funding the joint venture&#8217;s operations, development and commercialization efforts and, together with its syndicate partners, initially invested $<ix:nonFraction unitRef="usd" contextRef="id1b622c3fa27402b9211c7b4ccf25f7f_D20210914-20210914" decimals="-6" name="us-gaap:PaymentsToAcquireInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTI1OQ_c7454668-fdcd-46b6-855f-e811b216c84d">11</ix:nonFraction>&#160;million in exchange for a <ix:nonFraction unitRef="number" contextRef="i36d25b2cfa03459783a6e94281295ca5_I20210914" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTI4MA_e172eb63-46d7-4f56-ac33-ceb1dab69a42">53</ix:nonFraction>% ownership interest. We retain full rights to oxyntomodulin and Factor VIIa-CTP in all other geographies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CAMP4 Therapeutics</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2021, we entered into an exclusive license agreement (the &#8220;CAMP4 Agreement&#8221;) with CAMP4, pursuant to which we granted to CAMP4 an exclusive license to develop, manufacture, commercialize or improve therapeutics utilizing the AntagoNAT technology, an oligonucleotide platform developed under OPKO CURNA, which includes the molecule for the treatment of Dravet syndrome, together with any derivative or modification thereof (the &#8220;Licensed Compound&#8221;) and any pharmaceutical product that comprises or contains the Licensed Compound, alone or in combination with one or more other active ingredients (&#8220;Licensed Product&#8221;), worldwide. The CAMP4 Agreement grant covers human pharmaceutical, prophylactic, and therapeutic and certain diagnostic uses.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received an initial upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ib6c87132b4964cd485ec8ec605a41b8b_D20210706-20210706" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjIwMg_3184a4fa-b59a-482d-9a5b-293b149ec414">1.5</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="ib5d22ca705ba48a9b83984b98bb175db_D20210706-20210706" decimals="INF" name="opk:CollaborativeArrangementUpfrontPaymentShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjIwOQ_ba7ee28a-1e32-4941-b793-de1ba01b4db3">3,373,008</ix:nonFraction> shares of CAMP4&#8217;s Series A Prime Preferred Stock (&#8220;Preferred Stock&#8221;), which equates to approximately <ix:nonFraction unitRef="number" contextRef="ib5d22ca705ba48a9b83984b98bb175db_D20210706-20210706" decimals="2" name="opk:CollaborativeArrangementPercentOfOutstandingShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjMxMw_35530510-ebe7-4201-9ac9-e8a572db3d59">9</ix:nonFraction>% of the outstanding shares of CAMP4, and we are eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="if0c873c67ff541cd805db5011768482b_D20210706-20210706" decimals="-5" name="opk:CollaborativeArrangementDevelopmentMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjM4OQ_8932a9d9-469f-4051-ac8b-eb92030da73a">3.5</ix:nonFraction>&#160;million in development milestone payments for Dravet syndrome products, and $<ix:nonFraction unitRef="usd" contextRef="i2421576a6eb245f5963c8fd546b2202d_D20210706-20210706" decimals="-6" name="opk:CollaborativeArrangementDevelopmentMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjQ2MA_f13f2126-54b0-4508-81fa-81db36ae45be">4</ix:nonFraction>&#160;million for non-Dravet syndrome products, as well as sales milestones of up to $<ix:nonFraction unitRef="usd" contextRef="if0c873c67ff541cd805db5011768482b_D20210706-20210706" decimals="-6" name="opk:CollaborativeArrangementSalesMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjUzNA_2f4e5039-51d5-4951-8415-64620e25e270">90</ix:nonFraction>&#160;million for Dravet syndrome products and up to $<ix:nonFraction unitRef="usd" contextRef="i2421576a6eb245f5963c8fd546b2202d_D20210706-20210706" decimals="-6" name="opk:CollaborativeArrangementSalesMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjU3Ng_6ac62d69-6cd9-4878-8636-f67ea74c162d">90</ix:nonFraction>&#160;million for non-Dravet syndrome products. We may also receive double digit royalty payments on the net sales of royalty bearing products, subject to adjustment. In addition, upon achievement of certain development milestones, we will be eligible to receive equity consideration of up to <ix:nonFraction unitRef="shares" contextRef="if0c873c67ff541cd805db5011768482b_D20210706-20210706" decimals="INF" name="opk:CollaborativeArrangementDevelopmentMilestonePaymentShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjg1OA_784b374e-2608-4097-ba18-f85aa052f1ab">5,782,299</ix:nonFraction> shares of Preferred Stock in connection with Dravet syndrome products and up to <ix:nonFraction unitRef="shares" contextRef="i2421576a6eb245f5963c8fd546b2202d_D20210706-20210706" decimals="INF" name="opk:CollaborativeArrangementDevelopmentMilestonePaymentShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjk0MQ_2ed94d01-a37b-4e7b-a524-8b0c62007cd7">1,082,248</ix:nonFraction> shares of Preferred Stock in connection with non-Dravet syndrome products. In connection with our acquisition of CURNA, we agreed to pay future consideration to the sellers upon the achievement of certain events. As a result of our execution of the CAMP4 Agreement, we will have to pay a percentage of any payments received under the CAMP4 Agreement to the former CURNA stockholders. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the CAMP4 Agreement will remain in effect on a Licensed Product-by-Licensed Product and country by-country basis until such time as the royalty term expires for a Licensed Product in a country, and expires in its entirety upon the expiration of the royalty term for the last Licensed Product in the last country. CAMP4&#8217;s royalty obligations expire on the later of (i) the expiration, invalidation or abandonment date of the last patent right in connection with the royalty bearing product, or (ii) ten (<ix:nonNumeric contextRef="ib5d22ca705ba48a9b83984b98bb175db_D20210706-20210706" name="opk:CollaborativeArrangementPeriodFollowingFirstCommercialSale" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfNDA2OQ_a7b94a01-ec23-4c6d-88a1-7196b67c0095">10</ix:nonNumeric>) years after a royalty bearing product&#8217;s first commercial sale in a country. In addition to termination rights for material breach and bankruptcy, CAMP4 is permitted to terminate the Agreement after a specified notice period.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NICOYA Macau Limited</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, EirGen, our wholly owned subsidiary, and NICOYA Macau Limited (&#8220;Nicoya&#8221;), a Macau corporation and an affiliate of NICOYA Therapeutics, entered into a Development and License Agreement (the &#8220;Nicoya Agreement&#8221;) granting Nicoya the exclusive rights for the development and commercialization of extended release calcifediol (the &#8220;Nicoya Product&#8221;) in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan (collectively, the &#8220;Nicoya Territory&#8221;). Extended release calcifediol is marketed in the U.S. by OPKO under the tradename </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The license grant to Nicoya covers the therapeutic and preventative use of the Nicoya Product for SHPT in non-dialysis and hemodialysis chronic kidney disease patients (the &#8220;Nicoya Field&#8221;).</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EirGen has received an initial upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i10db571f9a22486186e3b342bd39d781_D20210618-20210618" decimals="-6" name="opk:ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfNTEyOQ_6ce9118f-0093-49bb-8f7c-4030ca0b9623">5</ix:nonFraction>&#160;million and is eligible to receive an additional $<ix:nonFraction unitRef="usd" contextRef="ic69f79db9b644be990ff9dd9110a1bc1_D20210618-20210618" decimals="-6" name="opk:ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfNTE3Mw_05f9cbde-8e17-4274-b265-01c2ee50e425">5</ix:nonFraction>&#160;million upon the first to occur of (A) a predetermined milestone and (B) the first anniversary of the effective date. EirGen is also eligible to receive up to an additional aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i5c7fb2b0fdc148b3a2a1cbb14048e04b_D20210618-20210618" decimals="-6" name="opk:ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfNTM2MQ_9f1978d1-54d1-457f-82c4-d204d77d6232">115</ix:nonFraction>&#160;million upon the achievement of certain development, regulatory and sales-based milestones by Nicoya for the Nicoya Product in the Nicoya Territory. EirGen will also receive tiered, double digit royalty payments at rates in the low double digits on net product sales within the Nicoya Territory and in the Nicoya Field.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nicoya will, at its sole cost and expense, be responsible for performing all development activities necessary to obtain all regulatory approvals for the Nicoya Product in the Nicoya Territory and for all commercial activities pertaining to the Nicoya Product in the Nicoya Territory.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Nicoya Agreement will remain in effect until such time as all royalty payment terms and extended payment terms have expired, and Nicoya shall have no further payment obligations to EirGen under the terms of the Nicoya Agreement. Nicoya&#8217;s royalty obligations expire on the later of (i) expiration of the last to expire valid patent claim </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i4c54ea7ee2174967a3bb027886d4d937" continuedAt="i707202dc90ee44dd8ade90b8fb308eaa"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">covering the Nicoya Product sold in the Nicoya Territory, (ii) expiration of all regulatory and data exclusivity applicable to the Nicoya Product in the Nicoya Territory, and (iii) on a product-by-product basis, ten (<ix:nonNumeric contextRef="i10db571f9a22486186e3b342bd39d781_D20210618-20210618" name="opk:CollaborativeArrangementPeriodAfterFirstCommercialSale" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfNjU0NQ_5396c9cd-73a3-446a-a930-c7b290c2e373">10</ix:nonNumeric>) years after such Nicoya Product&#8217;s first commercial sale in the Nicoya Territory. In addition to termination rights for material breach and bankruptcy, Nicoya is permitted to terminate the Nicoya Agreement after a specified notice period.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vifor Fresenius Medical Care Renal Pharma Ltd</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, EirGen and Vifor Fresenius Medical Care Renal Pharma Ltd. (&#8220;VFMCRP&#8221;) entered into a Development and License Agreement (the &#8220;VFMCRP Agreement&#8221;) for the development and commercialization of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Product&#8221;) worldwide, except for (i) the U.S., (ii) any country in Central America or South America (including Mexico), (iii) Russia, (iv) China, (v) South Korea, (vi) Ukraine, (vii) Belorussia, (viii) Azerbaijan, (ix) Kazakhstan, (x) Taiwan (xi) the Middle East, and (xii) all countries of Africa (the &#8220;VFMCRP Territory&#8221;), as amended.  The license to VFMCRP potentially covers all therapeutic and prophylactic uses of the Product in human patients (the &#8220;VFMCRP Field&#8221;), provided that initially the license is for the use of the Product for the treatment or prevention of SHPT related to patients with CKD and vitamin D insufficiency/deficiency (the &#8220;VFMCRP Initial Indication&#8221;).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022 we recognized a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i5fd88e0b9dc2432ca9c87a42295d0f14_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjc0ODc3OTA5MTc1OQ_413e644f-d764-4ecd-8d29-f3229caa5e1a">3.0</ix:nonFraction>&#160;million in revenue from transfer of intellectual property and other for the first sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May 23, 2021, we entered into an amendment to the VFMCRP Agreement pursuant to which the parties thereto agreed to include Japan as part of the VFMCRP Territory.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May 5, 2020, we entered into an amendment to the VFMCRP Agreement pursuant to which the parties agreed to exclude Mexico, South Korea, the Middle East and all of the countries of Africa from the VFMCRP Territory.  In addition, the parties agreed to certain amendments to the milestone structure and to reduce minimum royalties payable.  As revised, the Company has received a $<ix:nonFraction unitRef="usd" contextRef="i9744194c20ba46758d55f0a601deef68_D20200505-20200505" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfODIzNg_2d38acdb-b81c-4700-b6b5-c03b28d4e308">3</ix:nonFraction>&#160;million payment triggered by the first marketing approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe and is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i9cd5fcc524ba4f4da070564f37ec0b94_D20200505-20200505" decimals="-6" name="opk:CollaborativeArrangementMaximumMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfODM1OA_ec90d9e3-f66d-41b4-8f7d-847722ae41c4">17</ix:nonFraction>&#160;million in regulatory milestones and $<ix:nonFraction unitRef="usd" contextRef="i9b365c1cad364899b9b410fc05c6ee03_D20200505-20200505" decimals="-6" name="opk:CollaborativeArrangementMaximumMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfODM5MA_4f6668c3-306a-4a81-a2e1-53ef358b3652">207</ix:nonFraction>&#160;million in milestone payments tied to launch, pricing and sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and tiered, double-digit royalties.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to share responsibility with VFMCRP for the conduct of trials specified within an agreed-upon development plan, with each company leading certain activities within the plan.  EirGen will lead the manufacturing activities within and outside the VFMCRP Territory and the commercialization activities outside the VFMCRP Territory and outside the VFMCRP Field in the VFMCRP Territory and VFMCRP will lead the commercialization activities in the VFMCRP Territory and the VFMCRP Field.  For the initial development plan, the companies have agreed to certain cost sharing arrangements.  VFMCRP will be responsible for all other development costs that VFMCRP considers necessary to develop the Product for the use of the Product for the VFMCRP Initial Indication in the VFMCRP Territory in the VFMCRP Field except as otherwise provided in the VFMCRP Agreement.  The first of the clinical studies provided for in the development activities commenced in September 2018.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the VFMCRP Agreement, the parties entered into a letter agreement pursuant to which EirGen granted to VFMCRP an exclusive option (the &#8220;Option&#8221;) to acquire an exclusive license under certain EirGen patents and technology to use, import, offer for sale, sell, distribute and commercialize the Product in the U.S. solely for the treatment of SHPT in dialysis patients with CKD and vitamin D insufficiency (the &#8220;Dialysis Indication&#8221;).  Upon exercise of the Option, VFMCRP will reimburse EirGen for all of the development costs incurred by EirGen with respect to the Product for the Dialysis Indication in the U.S.  VFMCRP would also pay EirGen up to an additional aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i004085a346bb457f8e5d14f98a53a911_D20160501-20160531" decimals="-6" name="opk:CollaborativeArrangementMaximumMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTAxNjk_6b68d41c-3b17-49f8-b3a7-b1fb9cc79725">555</ix:nonFraction>&#160;million of sales-based milestones upon the achievement of certain milestones and would be obligated to pay royalties at percentage rates that range from the mid-teens to the mid-twenties on sales of the Product in the U.S. for the Dialysis Indication.  To date, VFMCRP has not exercised its option.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received for regulatory milestones and sales milestones are non-refundable.  The regulatory milestones are payable if and when VFMCRP obtains approval from certain regulatory authorities and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met.  We account for the sales milestones as royalties and sales milestones payments will be recognized as revenue in the period in which the associated milestone is achieved or sales occur, assuming all other revenue recognition criteria are met.    </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2014, we entered into an exclusive worldwide agreement (the &#8220;Pfizer Agreement&#8221;) with Pfizer for the development and commercialization of our long-acting Somatrogon (hGH-CTP) for the treatment of growth hormone </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="i707202dc90ee44dd8ade90b8fb308eaa"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deficiency (&#8220;GHD&#8221;) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (the &#8220;Pfizer Transaction&#8221;).  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2022, the European Commission and Ministry of Health, Labour and Welfare in Japan approved the next-generation long-acting recombinant human growth hormone NGENLA (Somatrogon), a once-weekly injection to treat pediatric growth hormone deficiency, and we received pricing approvals in Germany and Japan. With the achievement of these milestones, we are entitled to receive an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i439818f5135849e981ffb5c0b3e4a5fa_D20220401-20220430" decimals="-5" name="opk:CollaborativeArrangementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMzg0ODI5MDcxOTk1OQ_fbdc6934-c8d8-41e8-a3cd-c31bfbf692b7">85.0</ix:nonFraction>&#160;million in milestone payments. Further, Canada and Australia approved NGENLA in October and November of 2021, respectively.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the FDA issued a Complete Response Letter for the BLA for Somatrogon (hGH-CTP). Pfizer and OPKO are evaluating the FDA&#8217;s comments and will work with the agency to determine the best path forward for Somatrogon (hGH-CTP) in the United States.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we entered into an Amended and Restated Development and Commercialization License Agreement (the &#8220;Restated Pfizer Agreement&#8221;) with Pfizer, effective January 1, 2020, pursuant to which the parties agreed, among other things, to share all costs for Manufacturing Activities, as defined in the Restated Pfizer Agreement, for developing a licensed product for the three indications included in the Restated Agreement.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2019, we and Pfizer announced that the global phase 3 trial evaluating Somatrogon dosed once-weekly in prepubertal children with GHD met its primary endpoint of non-inferiority to daily Genotropin&#174; (somatropin) for injection, as measured by annual height velocity at <ix:nonNumeric contextRef="if1ab3dcfa70a42a4af7efe061a160e4c_D20191021-20191021" name="opk:CollaborativeArrangementAnnualHeightVelocityatPointinTime" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTI4Mzk_9ea04781-b646-42c6-adfe-0c9ee43fedf7">12</ix:nonNumeric> months.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Pfizer Transaction, as restated, we received non-refundable and non-creditable upfront payments of $<ix:nonFraction unitRef="usd" contextRef="ifdde5003bfd44ea6b9fbccdf4b85628d_D20150101-20150131" decimals="-5" name="opk:CollaborativeArrangementUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTI5NjU_74d554a2-008f-4a1a-9178-c13a33fdb597">295.0</ix:nonFraction> million and are eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="ifdde5003bfd44ea6b9fbccdf4b85628d_D20150101-20150131" decimals="-5" name="opk:CollaborativeAgreementAdditionalMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTMwMTY_1a0fd251-79e8-431b-a9c0-7db99e69b2e1">275.0</ix:nonFraction> million upon the achievement of certain regulatory milestones.  Pfizer received the exclusive license to commercialize Somatrogon worldwide.  In addition, we are eligible to receive initial tiered royalty payments associated with the commercialization of Somatrogon for adult GHD with percentage rates ranging from the high teens to mid-twenties.  Upon the launch of Somatrogon for pediatric GHD in certain major markets, the royalties will transition to regional, tiered gross profit sharing for both Somatrogon and Pfizer&#8217;s Genotropin&#174;.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement with Pfizer will remain in effect until the last sale of the licensed product, unless earlier terminated as permitted under the Pfizer Agreement.  In addition to termination rights for material breach and bankruptcy, Pfizer is permitted to terminate the Pfizer Agreement in its entirety, or with respect to one or more world regions, without cause after a specified notice period.  If the Pfizer Agreement is terminated by us for Pfizer&#8217;s uncured material breach, or by Pfizer without cause, provision has been made for transition of product and product responsibilities to us for the terminated regions, as well as continued supply of product by Pfizer or transfer of supply to us in order to support the terminated regions.       </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the non-refundable $<ix:nonFraction unitRef="usd" contextRef="ifdde5003bfd44ea6b9fbccdf4b85628d_D20150101-20150131" decimals="-5" name="opk:CollaborativeArrangementUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTQzMzA_fbae3ed5-5130-4bc8-9c7d-fada7af11fba">295.0</ix:nonFraction> million upfront payments as revenue as the research and development services were completed and as of both March 31, 2022 and December 31, 2021, we had no contract liabilities related to the Pfizer Transaction.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pfizer Transaction includes milestone payments of $<ix:nonFraction unitRef="usd" contextRef="ifdde5003bfd44ea6b9fbccdf4b85628d_D20150101-20150131" decimals="-5" name="opk:CollaborativeArrangementMaximumMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTQ1OTQ_33bf2b15-991b-47ef-8e1e-814492d27de3">275.0</ix:nonFraction> million upon the achievement of certain milestones.  The milestones range from $<ix:nonFraction unitRef="usd" contextRef="i4213e7e67f624f758de6da611795d601_D20150101-20150131" decimals="-5" name="opk:CollaborativeArrangementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTQ2Njg_ac2c4ecd-5e36-4452-a7a7-f8b178fb9a15">20.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i89b406679fa14d95928f83c7db184e47_D20150101-20150131" decimals="-5" name="opk:CollaborativeArrangementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTQ2NzQ_2fef1d5f-8758-47e7-975d-a676b3960217">90.0</ix:nonFraction> million each and are based on achievement of regulatory approval in the U.S. and regulatory approval and price approval in other major markets.  The milestone payments will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met.  To date, <ix:nonFraction unitRef="usd" contextRef="iec21a25c43404529ae8e1b869bd25df4_D20150101-20220331" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTQ5OTU_0bcef0b4-d99e-4762-a961-8f2275843243">no</ix:nonFraction> revenue has been recognized related to the achievement of the milestones. See Note 17, Subsequent Events.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed strategic deals with numerous institutions and commercial partners.  In connection with these agreements, upon the achievement of certain milestones we are obligated to make certain payments and have royalty obligations upon sales of products developed under the license agreements.  At this time, we are unable to estimate the timing and amounts of payments as the obligations are based on future development of the licensed products.</span></div></ix:continuation><div id="i1cac816ff800494ea2979c434f00b37c_85"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RleHRyZWdpb246MjIxMmMxNDE1NWIxNDVmODg2N2IyYTIyZTFlMmJmOTVfMTAwNw_d14e300b-3692-4ccc-b431-bb7242de8945" continuedAt="i1ed690f8c02c4b8d86b2935606a08b15" escape="true">SEGMENTS</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:24.75pt"><ix:continuation id="i1ed690f8c02c4b8d86b2935606a08b15" continuedAt="ie5eb6c1ae26043e084e7f40a73f3a409"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our operations in <ix:nonFraction unitRef="segment" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RleHRyZWdpb246MjIxMmMxNDE1NWIxNDVmODg2N2IyYTIyZTFlMmJmOTVfNTA_b8c0ec37-a056-46ad-a7df-0d9179b206f1">two</ix:nonFraction> reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of our clinical and genomics laboratory operations through BioReference and our point-of-care operations.  There are <ix:nonFraction unitRef="usd" contextRef="i248c2f7f347a4e28bf2c05816ec8ead1_D20220101-20220331" decimals="INF" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RleHRyZWdpb246MjIxMmMxNDE1NWIxNDVmODg2N2IyYTIyZTFlMmJmOTVfNDU0_1cffbf11-952d-42df-90d8-6d7fcb680f5b">no</ix:nonFraction> significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is <ix:nonFraction unitRef="usd" contextRef="i248c2f7f347a4e28bf2c05816ec8ead1_D20220101-20220331" decimals="INF" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RleHRyZWdpb246MjIxMmMxNDE1NWIxNDVmODg2N2IyYTIyZTFlMmJmOTVfNTgw_b0c7bbf7-6487-41f7-b550-49d19d64165a">no</ix:nonFraction> inter-segment allocation of interest expense and income taxes.</span></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="ie5eb6c1ae26043e084e7f40a73f3a409" continuedAt="i32c28ad6b77247859bd413bdab578a2e"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RleHRyZWdpb246MjIxMmMxNDE1NWIxNDVmODg2N2IyYTIyZTFlMmJmOTVfMTAwMw_09fc6f1b-f572-4132-93a4-dacabe04da96" continuedAt="i1c894e995e264f389b5829f7b88b0dbf" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e591c4c9d6a40d7ba41cbe1d1512d6b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMy01LTEtMS0zNTMzMA_ed692c6a-8a1a-45e9-9368-8341b234c744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbda16c863b431ba3f7cf99e015a97d_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMy03LTEtMS0zNTMzMA_60b8a07b-20d5-4461-a124-d9e5edfee015">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib33dc7d9f44c424a9584b48898909842_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNC01LTEtMS0zNTMzMA_3475d882-e0f9-4d9d-96f1-b8a106042a73">286,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c4e79123684c96996efacf35e4cf15_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNC03LTEtMS0zNTMzMA_fe6f1fc0-a2bb-4b72-adb3-8eb969e961a7">506,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec2e176eb00448f977e91fc55c4ac65_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNS01LTEtMS0zNTMzMA_ed866a9e-4600-4c24-af3f-ae8cfd0606a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f799de78174d999399f2edd81a8ded_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNS03LTEtMS0zNTMzMA_f3f8a40b-c825-44c3-8a57-5b3fc7316ac9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f9c95a502354f4c9bd791e55a1b1acc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNi01LTEtMS0zNTMzMA_520a2f3c-07da-495d-8763-e5e191fb1cb4">286,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fd3f89e217e4e329bca14b9905edffa_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNi03LTEtMS0zNTMzMA_684d4548-3c6a-46b9-8b5f-45c190da4cde">506,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from products:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f23d1e4f7149df81a204a4274bb85f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfOC01LTEtMS0zNTMzMA_32af78a6-8250-4700-82d0-3fb4d547502d">36,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39c1bc4e90f445ff86ac8569a2ddbc9d_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfOC03LTEtMS0zNTMzMA_c0c63d6e-e3a9-49e2-bac9-38e622e8f6ec">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209dc12bb8ce4a749fed4f87ebc36e68_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfOS01LTEtMS0zNTMzMA_b8f84a84-ea78-490f-9276-4a54f0c5d87b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a55931e091d4a3c887296abefde8504_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfOS03LTEtMS0zNTMzMA_4389d89e-ae9c-40ac-9c28-655b74656569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i082e04104d194b92a685d699a64a0014_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTAtNS0xLTEtMzUzMzA_cb74201e-81e4-4c8d-ae53-5943b7276d8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idffcd8ebe9be487185a9b4b68675f7fe_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTAtNy0xLTEtMzUzMzA_2a617666-6898-4954-b70d-efa33e86b233">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85501a743668421b8f9b4903a091161f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTEtNS0xLTEtMzUzMzA_14d0fb3d-cc1c-48d4-a31c-16ebcc43814e">36,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a1bb9d88fbc42c0b66fe51d04025dd1_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTEtNy0xLTEtMzUzMzA_2a65e467-8303-464c-b5e3-a3ac6b707e93">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from transfer of intellectual property and other: </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id657dc78714d4c38b4795e9de8978786_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTMtNS0xLTEtMzUzMzA_f0f509ba-f944-4fe3-a89b-846300785f78">5,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8558bb5f637404994c8de52c35676cd_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTMtNy0xLTEtMzUzMzA_bee4abd4-e3f0-40a1-9602-d4069b7a8567">4,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i393ae4fb48ac46c791cf4386477ae160_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTQtNS0xLTEtMzUzMzA_7d8426a2-b304-4070-9381-7a4a987a18fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7b01ac51664446b81224ec66b765954_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTQtNy0xLTEtMzUzMzA_515fdf74-f062-47fe-ba42-7761cd7fa003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70da593d5a914041bc7e0c120158a9af_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTUtNS0xLTEtMzUzMzA_da75a62d-a233-45d7-b90c-0a451fd8a9c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5fcb23d84e40e0bd666630c86cc3ae_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTUtNy0xLTEtMzUzMzA_ec5a13b6-0a38-46ba-88a5-9e0efb88aabf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e961cfc73ca4fc995f9df88000a19c4_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTYtNS0xLTEtMzUzMzA_c8b680d9-057e-406a-a813-9e283e77180e">5,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66109927d116428aafb21943a884db23_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTYtNy0xLTEtMzUzMzA_87bb4f58-bb86-4d3a-94fa-6369b2e09b39">4,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53640b46e2fd4c808aaed4db666adb92_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTgtNS0xLTEtMzUzMzA_b66a521c-01f2-4764-96e7-3ecb826aa637">18,108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e92aea3d2094ffebb2b18c6d66c89c7_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTgtNy0xLTEtMzUzMzA_b42ae554-ecd8-4029-8e83-5cee8a0c7b00">19,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i003285ed88bd4bfea42439162c0e7038_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTktNS0xLTEtMzUzMzA_cf6d4aca-9379-4cf7-b4d5-49fc4850ba02">43,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda4aeb385b4420c98ee831dcb7e2e3e_D20210101-20210331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTktNy0xLTEtMzUzMzA_34c0927f-71f8-4694-9659-80e7783cbb98">67,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfbd64ac384549c288a217c1e278ff5a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjAtNS0xLTEtMzUzMzA_d0a7b2a4-a670-4b5a-8495-6870bf008ca0">10,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb337610dc2a44669c089130ab28f864_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjAtNy0xLTEtMzUzMzA_d56d7f74-ec05-4638-a056-2c37d0debff9">9,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjItNS0xLTEtMzUzMzA_f341982b-cd5c-4a24-957b-a005930301ac">72,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjItNy0xLTEtMzUzMzA_256dacc6-b205-4443-a7d9-b6fefb62f0e1">38,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53640b46e2fd4c808aaed4db666adb92_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjQtNS0xLTEtMzUzMzA_18c7cd3e-54c4-4a82-87ae-f118d912a438">15,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e92aea3d2094ffebb2b18c6d66c89c7_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjQtNy0xLTEtMzUzMzA_f1daca15-7151-4b12-882e-19e8cb2d8527">7,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003285ed88bd4bfea42439162c0e7038_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjUtNS0xLTEtMzUzMzA_5f2191e3-71ea-4b00-9f73-2b0a1eb628dc">12,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda4aeb385b4420c98ee831dcb7e2e3e_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjUtNy0xLTEtMzUzMzA_df9dac17-b8f8-40e2-ac88-d78cf626043d">12,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbd64ac384549c288a217c1e278ff5a_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjYtNS0xLTEtMzUzMzA_7bc43917-db32-419b-acfc-201e6e8eab76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb337610dc2a44669c089130ab28f864_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjYtNy0xLTEtMzUzMzA_74c96fd4-3d49-4ed3-833a-3f5ae1e3ae70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjctNS0xLTEtMzUzMzA_69182511-f856-4298-8364-0c2167f94af6">27,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjctNy0xLTEtMzUzMzA_bf71f211-f888-43db-9554-e1d821dca823">19,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from investment in investees:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53640b46e2fd4c808aaed4db666adb92_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjktNS0xLTEtMzUzMzA_365dfe16-b631-4ab3-a7b9-b6661ff6a29b">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e92aea3d2094ffebb2b18c6d66c89c7_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjktNy0xLTEtMzUzMzA_0475e2c2-4181-43e7-b31d-25e3eef010a0">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003285ed88bd4bfea42439162c0e7038_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzAtNS0xLTEtMzUzMzA_77b467ac-8bd0-49f0-9470-5bf4b1acf90b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda4aeb385b4420c98ee831dcb7e2e3e_D20210101-20210331" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzAtNy0xLTEtMzUzMzA_ae1964dd-5ce6-408a-b1cf-6a01599cfd5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbd64ac384549c288a217c1e278ff5a_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzEtNS0xLTEtMzUzMzA_b6e028db-8fc6-4cc3-b791-36f695ccf99f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb337610dc2a44669c089130ab28f864_D20210101-20210331" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzEtNy0xLTEtMzUzMzA_6e62b960-346b-4cfd-a430-bd0d70e6e7ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzItNS0xLTEtMzUzMzA_5370e331-4b01-495f-9748-fd26b0afaf19">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzItNy0xLTEtMzUzMzA_a91c9152-db55-46b5-b7d1-da45e416d3c9">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd847808c4214f4fa04fde3ad6d1af41_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzQtNS0xLTEtMzUzMzA_82605179-06c7-4d2a-b1c6-e6c85888cf36">291,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343e534f8fb94404bbef65e665f2bd82_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzQtNy0xLTEtMzUzMzA_0bb08d54-6f85-4056-993b-7faf0c7fb388">512,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia423aa5eee2b482c9db466bda75c3161_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzUtNS0xLTEtMzUzMzA_1641f832-318d-43b7-89d8-6f35a8e495d1">8,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51de4ac755574afeb66162a7f5862660_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzUtNy0xLTEtMzUzMzA_2a797d38-dd07-4a29-8997-a48b0b15a85b">7,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7aa53c3c054c22ac7e21fed6039914_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzYtNS0xLTEtMzUzMzA_ebb46416-2fa8-490d-8af7-891086fd77c4">16,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2814670edf7c4a62a9c261600d7c6daa_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzYtNy0xLTEtMzUzMzA_c870efbe-1bf6-4427-9f33-259585550a4d">14,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia46e96d43b2549a8a62460a4e0218f58_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzctNS0xLTEtMzUzMzA_3927685d-7ea2-4608-9acb-942be7649b5e">7,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac6faccf2c2445a906e11ebfd78a899_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzctNy0xLTEtMzUzMzA_3faeb0e2-d7f1-49cb-a66c-70feafb01a48">5,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644924ad6fec4277940108274a5fb5cf_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzgtNS0xLTEtMzUzMzA_c58982ca-11a3-4171-8eec-792d8487fe7f">1,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaae85104e75449f082ec0bb4c1170ebc_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzgtNy0xLTEtMzUzMzA_3938df38-8462-4490-98d9-447a34962c58">2,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id089ec5023d147288f24951b1c9d421c_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzktNS0xLTEtMzUzMzA_66b4a184-17fa-4d90-b1d8-449a9b097565">3,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379322a119a345fc8841df842ee7ad3e_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzktNy0xLTEtMzUzMzA_61be33d3-5836-49b6-ae14-715603dd6e0b">2,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15b0e5103c443a0a508317a579c958d_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNDAtNS0xLTEtMzUzMzA_420816c0-460b-4ee3-a1e9-94a00d4c6dd7">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3beab81522d0420c95c34143d9e9a514_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNDAtNy0xLTEtMzUzMzA_72c0d91e-f9e2-41db-b57e-74cc16d2307f">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNDEtNS0xLTEtMzUzMzA_641e8307-3f95-48b4-88fe-7594d1f4191e">329,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNDEtNy0xLTEtMzUzMzA_d53cb4c5-038d-470b-b381-2193bf302f0f">545,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="text-align:center"><ix:continuation id="i32c28ad6b77247859bd413bdab578a2e" continuedAt="i7f2a695d47994917bb91650166dd8b98"><ix:continuation id="i1c894e995e264f389b5829f7b88b0dbf"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib27f714c1aa84e6a935be26300cfaa00_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfMi0xLTEtMS0zNTMzMA_5f4ebc48-d85c-4913-a827-f900384ddf4a">1,099,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8886b20cd82e4c7e8073ac81cd611ee9_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfMi0zLTEtMS0zNTMzMA_649e4d6c-5ce8-4ea4-98a1-b30e9ff50fbe">1,114,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437311d9507444baa08d2ca5476a8beb_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfMy0xLTEtMS0zNTMzMA_44ffcbb5-7000-4bb4-834d-95a350fde4a6">1,152,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87097699235d4d2fb348f69eb54508e6_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfMy0zLTEtMS0zNTMzMA_7a6ad3c8-5a66-4e7b-962b-862e44624ece">1,238,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c6a762af174fe8b29069a742a32bb3_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfNC0xLTEtMS0zNTMzMA_b7b238d1-673c-423e-8b0a-6d4b342072b4">55,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib66ac7571d2d48f48825d3fd8073639a_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfNC0zLTEtMS0zNTMzMA_12e19004-2301-425e-abba-c906b1d25b85">46,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfNS0xLTEtMS0zNTMzMA_36a76ba6-737a-44d7-a1d1-5c51a5c39e4c">2,306,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfNS0zLTEtMS0zNTMzMA_8e16f202-0624-4398-946c-e061a9c8d002">2,399,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib27f714c1aa84e6a935be26300cfaa00_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfNy0xLTEtMS0zNTMzMA_955dcd08-11ea-4abf-ae25-4274cd94a085">236,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8886b20cd82e4c7e8073ac81cd611ee9_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfNy0zLTEtMS0zNTMzMA_1712e324-2dd6-462c-b984-ba895802a6b8">237,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437311d9507444baa08d2ca5476a8beb_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfOC0xLTEtMS0zNTMzMA_65878d9d-a0c6-478b-9edc-3ded7547928a">283,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87097699235d4d2fb348f69eb54508e6_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfOC0zLTEtMS0zNTMzMA_86a2d57f-fb00-4d92-8c0a-ac566b5bfb87">283,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfMTAtMS0xLTEtMzUzMzA_e01762de-2398-4f2b-8091-c53d1be2dc55">519,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfMTAtMy0xLTEtMzUzMzA_ea5d0c35-f03a-446a-8436-8a2b20ffea99">520,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="padding-left:72pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7f2a695d47994917bb91650166dd8b98">No customer represented more than 10% of our total consolidated revenue during the three months ended March 31, 2022 and 2021. As of March&#160;31, 2022 and December&#160;31, 2021, no customer represented more than 10% of our accounts receivable balance.</ix:continuation> </span></div><div id="i1cac816ff800494ea2979c434f00b37c_88"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 16 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjUxMQ_fa5099e7-f49a-41f1-8945-ee31054051c6" continuedAt="iac389ee30fd7451e9bb7877b71a51adb" escape="true"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjUwNA_07bc7366-7ff9-4006-9286-601f4c6e1b18" continuedAt="i36e81ed4b9cc45e5b1a085e1d9b1c463" escape="true">LEASES</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="iac389ee30fd7451e9bb7877b71a51adb" continuedAt="id6b9b7df2333449b970f06c0bb76f8c2"><ix:continuation id="i36e81ed4b9cc45e5b1a085e1d9b1c463" continuedAt="ib0b72f40888f4c259615c8d83514ef59"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating leases for office space, laboratory operations, research and development facilities, manufacturing locations, warehouses and certain equipment.  We determine if a contract contains a lease at inception or modification of a contract.  Our leases generally do not provide an implicit interest rate, and we therefore use our incremental borrowing rate as the discount rate when measuring operating lease liabilities.  The incremental borrowing rate represents an estimate of the interest rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment.  We used the incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date.  Many of our leases contain rental escalation, renewal options and/or termination options that are factored into our determination of lease payments as appropriate.  Variable lease payment amounts that cannot be determined at the commencement of the lease are not included in the right-to-use assets or liabilities.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the use of permitted practical expedients of not recording leases on our Consolidated Balance Sheet when the leases have terms of 12 months or less, and we elected not to separate nonlease components from lease components and instead account for each separate lease component and the nonlease components associated with that lease component as a single lease component.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="opk:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjUyMA_e1c7c6bc-4a6e-40e0-bdd8-166eb702305d" continuedAt="i108a7059f8dd4157b4abceea0b969e8c" escape="true">The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of March 31, 2022 and December 31, 2021:</ix:nonNumeric></span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><ix:continuation id="id6b9b7df2333449b970f06c0bb76f8c2" continuedAt="iac8445fd3710453a81c2240ff1a309e0"><ix:continuation id="ib0b72f40888f4c259615c8d83514ef59" continuedAt="ia58cde8903544a2d982d06241a4c059a"><div style="margin-top:14pt;text-align:center"><ix:continuation id="i108a7059f8dd4157b4abceea0b969e8c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMi00LTEtMS0zNTMzMA_4d1eab8b-14e0-4a19-882e-fecd055fc60f">42,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMi02LTEtMS0zNTMzMA_1a4a7eda-b48f-4a8a-84ed-17489a8b9b27">44,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMy0wLTEtMS0zNTMzMA_c6bd7dfc-1515-470c-8640-321ba294369d">Finance lease assets</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMy00LTEtMS0zNTMzMA_de441688-0b1b-4db2-9d86-ff106db9a5f7">6,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMy02LTEtMS0zNTMzMA_f530ceed-f097-42a2-a7d5-e3bc6e74fcdc">5,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfNy00LTEtMS0zNTMzMA_62b55b82-b113-42a0-a9e0-c10beeb73136">11,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfNy02LTEtMS0zNTMzMA_663522c2-98a4-4e30-95c2-553f15ad6964">11,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfOC00LTEtMS0zNTMzMA_6bcae11c-c1df-4c3a-b0a0-1bef8aa8e872">2,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfOC02LTEtMS0zNTMzMA_95a01b8c-0cd7-4b60-bc13-0eec9d77fcef">2,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTAtNC0xLTEtMzUzMzA_e8071d1c-bf4c-413b-ab7c-1b918359cb5b">31,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTAtNi0xLTEtMzUzMzA_65bcacfb-512a-413a-bddd-b738fbbeaccd">33,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTEtNC0xLTEtMzUzMzA_0d569f0a-58dd-44b6-aaca-de3e7bc2ecd6">3,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTEtNi0xLTEtMzUzMzA_9183e604-5eaa-4d83-8159-d389bb6f87da">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i137b80025d3d4485b08482ba89272156_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTQtNC0xLTEtMzUzMzA_78c133e1-38dc-4a83-b0ce-192598a536c4">7.1</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTQtNi0xLTEtMzUzMzA_c5e3e230-c7c7-4400-99e1-6e498795988e">7.2</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i137b80025d3d4485b08482ba89272156_I20220331" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTUtNC0xLTEtMzUzMzA_09a615b2-925a-43a9-aeda-24f66856ef6e">2.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTUtNi0xLTEtMzUzMzA_02dd5feb-dd6c-4680-8a0d-e7dec3c41350">2.4</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTctNC0xLTEtMzUzMzA_be5d8d41-462b-4721-8e0e-e29d86c35317">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTctNi0xLTEtMzUzMzA_e8347d28-3915-4e1f-8b77-f362bd6b217f">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTgtNC0xLTEtMzUzMzA_9528c38a-b3e8-4801-8610-e2f7710f621e">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTgtNi0xLTEtMzUzMzA_cb2c5120-3a32-45c5-9833-1cd633b56d7c">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjUwOQ_9e7ccce5-da5c-447b-81ad-fc90a2e49f50" escape="true"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjUxNA_7574dabe-5949-433e-a1e0-95e28a23b342" escape="true"><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of March 31, 2022:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 1, 2022 through December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfMS0xLTEtMS0zNTMzMA_8d079914-104e-4fd5-842f-236c33a6aba2">10,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfMS0zLTEtMS0zNTMzMA_b8a5a57a-47fb-4f25-b577-a51d9fb51189">1,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfMi0xLTEtMS0zNTMzMA_68c2e126-e93d-41ac-be42-5d81c11e0eb8">10,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfMi0zLTEtMS0zNTMzMA_c5601c84-2c90-4409-9ba1-878f3585935c">2,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfMy0xLTEtMS0zNTMzMA_2345b3b5-d58b-4d15-b485-ef306a2e2390">8,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfMy0zLTEtMS0zNTMzMA_4ee96ab4-d3ef-4104-90cd-fc0761c42a87">1,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNC0xLTEtMS0zNTMzMA_cb5e65e3-32d1-4561-b477-7e0cfd553176">5,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNC0zLTEtMS0zNTMzMA_aead1ef5-78ee-42af-99c0-1caed39865da">919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNS0xLTEtMS0zNTMzMA_ddb689d9-7db0-4936-aae6-87d6a497a869">5,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNS0zLTEtMS0zNTMzMA_8dd95279-5716-44fc-8259-c0b03f2b23bb">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="opk:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNi0xLTEtMS0zNTMzMA_9ca1274c-3f86-4c4e-8be9-1cf2a1166580">24,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="opk:FinanceLeaseLiabilityPaymentsDueAfterYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNi0zLTEtMS0zNTMzMA_b305813e-dcd1-44c2-84f1-f7ddc4e98b75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total undiscounted future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNy0xLTEtMS0zNTMzMA_26a3ddb1-455c-4d4b-8b6c-f1ba9d1dbbe7">64,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNy0zLTEtMS0zNTMzMA_31c0c367-6732-435d-9871-bf6807d1a019">6,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Difference between lease payments and discounted lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfOC0xLTEtMS0zNTMzMA_bc062ee1-6404-47ee-a923-0c8e6ffbe037">10,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfOC0zLTEtMS0zNTMzMA_e69ae199-6b79-4ba9-92e3-e059edbe1543">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfOS0xLTEtMS0zNTMzMA_de71b7b5-c7f8-47a7-be63-679c67d8c867">54,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b80025d3d4485b08482ba89272156_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfOS0zLTEtMS0zNTMzMA_160d68aa-a531-4659-8dc2-ee6338904f34">6,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense under operating leases and finance leases was $<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjAzOQ_4b29291d-e22a-46fa-b21b-e8c323cb365d">4.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfNjA0NzMxMzk1NTQwOA_88ebc037-2062-4cde-9045-4b6803f2b492">0.7</ix:nonFraction>&#160;million, respectively, for the three months ended March 31, 2022, which includes $<ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjEwMQ_a7a7564b-359e-47bc-9735-6fa7ce0c94fd">0.4</ix:nonFraction> million of variable lease costs. Expense under operating leases and finance leases was $<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjE4Mw_95758ae2-8c94-4f6f-b52b-dfa7ed6d02c1">4.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjE5MA_71c8526d-364b-46fb-b3f9-9382c89d0100">0.6</ix:nonFraction> million, respectively, for the three months ended March 31, 2021, which includes $<ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjI0NQ_52fdb3b4-a92b-4dc3-814e-a62f9c95b10b">0.7</ix:nonFraction> million of variable lease costs. Operating lease costs and finance lease costs are included within Operating loss in the Condensed Consolidated Statement of Operations. Short-term lease costs were not material.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjUwNQ_bc485e38-eca7-4fde-8906-147ce7923def" continuedAt="i7dadc38ab46548c5a78153a10e78057d" escape="true">Supplemental cash flow information is as follows:</ix:nonNumeric></span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><ix:continuation id="iac8445fd3710453a81c2240ff1a309e0"><ix:continuation id="ia58cde8903544a2d982d06241a4c059a"><ix:continuation id="i7dadc38ab46548c5a78153a10e78057d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfMi0xLTEtMS0zNTMzMA_ac8b6e8c-8429-49fa-a0d6-40cbe90a0012">4,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfMi0zLTEtMS0zNTMzMA_517bd5ca-a562-4db7-b8dc-a55fef458779">4,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash out flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfMy0xLTEtMS0zNTMzMA_efaf101a-fcb4-43ee-9123-6112d9ef2ae8">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfMy0zLTEtMS0zNTMzMA_2ffb05c6-2626-42ea-a6ae-480b5b2ca27b">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfNC0xLTEtMS0zNTMzMA_cb287b9f-d652-4a0a-9991-97e0b3ab45fc">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfNC0zLTEtMS0zNTMzMA_7ec5ccef-a799-4063-8a0a-9e684fbb30dc">525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" decimals="-3" name="opk:PaymentsForLeases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfNS0xLTEtMS0zNTMzMA_19395ff1-22f2-40eb-83cc-9d775c6c39e2">4,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331" decimals="-3" name="opk:PaymentsForLeases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfNS0zLTEtMS0zNTMzMA_dffc7385-4351-42e6-bd33-1ee340a701d2">4,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></ix:continuation></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="i1cac816ff800494ea2979c434f00b37c_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 17 <ix:nonNumeric contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMzI0_5c6ae607-dc1c-4ec8-84f1-3a3f5ee3c31c" continuedAt="ib75872984cf64ee0b21a5a3d4e9dc73a" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="ib75872984cf64ee0b21a5a3d4e9dc73a"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 18, 2022, Sema4 and OPKO announced they had entered into a definitive agreement pursuant to which Sema4 has agreed to acquire OPKO&#8217;s wholly owned subsidiary, GeneDx, a leader in genomic testing and analysis. The GeneDx Transaction closed on April 29, 2022.  Under the terms of the GeneDx Merger Agreement, Sema4 acquired GeneDx for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMjc0ODc3OTA3Mzc4NQ_54e3eba9-4777-4160-b66e-33be7385a9e7">150</ix:nonFraction>&#160;million in cash, subject to adjustments, plus <ix:nonFraction unitRef="shares" contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMjc0ODc3OTA3MzgwMg_aa84fab9-4d52-49a1-b555-20778560379d">80.0</ix:nonFraction>&#160;million shares in Sema4, with up to an additional $<ix:nonFraction unitRef="usd" contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429" decimals="-6" name="opk:BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMjc0ODc3OTA3Mzg0OA_a45535cc-438e-4f68-9855-0e4138633e9a">150</ix:nonFraction>&#160;million revenue-based milestones over the next <ix:nonNumeric contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429" name="opk:BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMjc0ODc3OTA3Mzg5MQ_f70b862f-a649-4d7e-8dab-2555bcc23882">two years</ix:nonNumeric> (which will be payable in cash or Sema4 shares at Sema4&#8217;s discretion). Based on the closing stock price of Sema4 as of April 29, 2022, the total upfront consideration represents approximately $<ix:nonFraction unitRef="usd" contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429" decimals="-6" name="opk:BusinessCombinationUpfrontConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMjc0ODc3OTA3NDA4NA_ce6e4ff5-74df-45a8-b95e-79039bfe660a">322</ix:nonFraction>&#160;million, and the total aggregate consideration including potential milestones is approximately $<ix:nonFraction unitRef="usd" contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMjc0ODc3OTA3NDE3NQ_2e2033f9-36c4-4d02-beac-9b955eeb2dd0">472</ix:nonFraction>&#160;million.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2022, Pfizer notified OPKO that NGENLA (Somatrogon), a once-weekly injection to treat pediatric growth hormone deficiency, has received pricing approval in Germany and Japan. NGENLA was granted marketing authorization by the Ministry of Health, Labour and Welfare in Japan and by the European Commission in January and February of this year, respectively. With the achievement of these milestones, we are entitled to receive an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i439818f5135849e981ffb5c0b3e4a5fa_D20220401-20220430" decimals="-5" name="opk:CollaborativeArrangementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMzg0ODI5MDcwMDM2OQ_a8e96ea1-0e87-407a-88f3-6f8308f226c5">85.0</ix:nonFraction>&#160;million in milestone payments.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 9, 2022, the Company entered into an Agreement and Plan of Merger with Orca Acquisition Sub, Inc. (&#8220;Merger Sub &#8220;, a subsidiary of the Company formed for the purposes of this transaction), ModeX Therapeutics, Inc., (&#8220;ModeX&#8221; or &#8220;Seller&#8221;) and Sellers&#8217; representative (the &#8220;Merger Agreement&#8221;), pursuant to which Merger Sub was merged with and into ModeX, with ModeX becoming a wholly owned subsidiary of the Company (the &#8220;Merger&#8221;). The Company paid an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i5f3663059edd4d60a02442357262179d_D20220509-20220509" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMzg0ODI5MDcwNzQxMA_66f6bfbd-b597-42cd-9715-b317beb973bf">300</ix:nonFraction>&#160;million for all of the outstanding equity of ModeX, as adjusted  by customary adjustments. The consideration paid at closing consisted of shares of our common stock, which was valued based on the average of the daily volume-weighted average price over the thirty (<ix:nonNumeric contextRef="i5f3663059edd4d60a02442357262179d_D20220509-20220509" name="opk:BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMzg0ODI5MDcwNzQyNA_c39d0483-7be4-4578-bc30-97b719a54a8c">30</ix:nonNumeric>) trading days prior to the date that is two (<ix:nonNumeric contextRef="i5f3663059edd4d60a02442357262179d_D20220509-20220509" name="opk:BusinessCombinationPeriodPriorToSigningOfAgreement" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMzg0ODI5MDcyMjkyMQ_ed9bb748-887b-43d1-8e7b-4ec703398e10">2</ix:nonNumeric>) trading days prior to the signing of the Merger Agreement . In addition, the Company has made a number of management changes in connection with the Merger. Elias Zerhouni, M.D., Gary Nabel, M.D., PhD.,  and Alexis Borisy were appointed to the Board of the Company, with Dr. Zerhouni appointed as the Vice Chair. Elizabeth Nabel, one of the founders of ModeX, is the new Chief Medical Officer of the Company.  Dr. Gary Nabel has been named the CEO of ModeX and Chief Innovation Officer of the Company and Dr. Zerhouni has been named the President of the Company.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed all events and transactions that occurred after the March&#160;31, 2022 Condensed Consolidated Balance Sheet date, through the time of filing this Quarterly Report on Form 10-Q.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</span></div><div id="i1cac816ff800494ea2979c434f00b37c_100"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read this discussion together with the unaudited Condensed Consolidated Financial Statements, related notes, and other financial information included elsewhere in this Quarterly Report on Form 10-Q together with our audited consolidated financial statements, related notes, and other information contained in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;Form 10-K&#8221;).  The following discussion contains assumptions, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under &#8220;Risk Factors,&#8221; in Part I, Item&#160;1A of the Form 10-K and as described from time to time in our other filings with the Securities and Exchange Commission.  These risks could cause our actual results to differ materially from those anticipated in these forward-looking statements.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Our diagnostics business includes BioReference Health LLC, formerly BioReference Laboratories, Inc. (&#8220;BioReference&#8221;), one of the nation&#8217;s largest full service laboratories with an almost 250-person sales and marketing team to drive growth and leverage new products. Our pharmaceutical business features </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, a U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved treatment for secondary hyperparathyroidism (&#8220;SHPT&#8221;) in adults with stage 3 or 4 chronic kidney disease (&#8220;CKD&#8221;) and vitamin D insufficiency and a pipeline of products in various stages of development. Our leading product in development is Somatrogon (hGH-CTP), a once-weekly human growth hormone for which we have partnered with Pfizer, Inc. (&#8220;Pfizer&#8221;) and successfully completed a phase 3 study in August 2019. Regulatory applications for Somatrogon (hGH-CTP) have been submitted to several countries around the world for review.  In February 2022, the European Commission granted marketing authorization in the European Union for Somatrogon (hGH-CTP) under the brand name NGENLA&#174; to treat children and adolescents from as young as three years of age with growth disturbance due to insufficient secretion of growth hormone and we received pricing approval in Germany in April 2022. In January 2022, the Ministry of Health, Labour and Welfare in Japan approved NGENLA&#174; (Somatrogon) for the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone and we received pricing approval in April 2022. In October 2021, Health Canada approved NGENLA&#174; for the long-term treatment of pediatric patients who have growth hormone deficiency, and Australia&#8217;s Therapeutic Goods Administration approved NGENLA&#174; for the long-term treatment of pediatric patients with growth disturbance due to insufficient secretion of growth hormone.  We also submitted the initial Biologics License Application (&#8220;BLA&#8221;) with the FDA for approval of Somatrogon (hGH-CTP) in the United States, and Pfizer received a Complete Response Letter in January 2022.  Pfizer and OPKO are evaluating the FDA&#8217;s comments and will work with the agency to determine the best path forward for Somatrogon (hGH-CTP) in the United States.  We are incorporated in Delaware, and our principal executive offices are located in leased offices in Miami, Florida.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through BioReference, we provide laboratory testing services, primarily to customers in the larger metropolitan areas in New York, New Jersey, Florida, Texas, Maryland, California, Pennsylvania, Delaware, Washington, DC, Illinois and Massachusetts, as well as to customers in a number of other states.  We offer a comprehensive test menu of clinical diagnostics for blood, urine and tissue analysis.  This includes hematology, clinical chemistry, immunoassay, infectious&#160;diseases, serology, hormones, and toxicology assays, as well as Pap smear, anatomic pathology (biopsies) and other types of tissue analysis.  We market our laboratory testing services directly to physicians, geneticists, hospitals, clinics, correctional and other health facilities.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate established pharmaceutical platforms in Ireland, Chile, Spain, and Mexico, which are generating revenue and from which we expect to generate positive cash flow and facilitate future market entry for our products currently in development.  In addition, we have a development and commercial supply pharmaceutical company and a global supply chain operation and holding company in Ireland.  We own a specialty active pharmaceutical ingredients manufacturer in Israel, which we expect will facilitate the development of our pipeline of molecules and compounds for our proprietary molecular diagnostic and therapeutic products.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; </span></div><div id="i1cac816ff800494ea2979c434f00b37c_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT DEVELOPMENTS</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2022, each of the European Commission and the Ministry of Health, Labour and Welfare in Japan approved the next-generation long-acting recombinant human growth hormone NGENLA (Somatrogon), a once-weekly injection to treat pediatric growth hormone deficiency in Europe and Japan, respectively. Further, Canada and Australia approved NGENLA in October and November of 2021, respectively.  In April 2022, Pfizer notified OPKO that NGENLA has received pricing approval in Germany and Japan. With the achievement of these milestones, we are entitled to receive an aggregate of $85.0 million in milestone payments.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2022, VFMCRP initiated the commercial launch of Rayaldee in Germany, the first launch of Rayaldee outside the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. VFMCRP is OPKO&#8217;s commercial partner for Rayaldee in Europe and selected markets outside the U.S.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the FDA issued a Complete Response Letter for the BLA for Somatrogon. Pfizer and OPKO are evaluating the FDA&#8217;s comments and will work with the agency to determine the best path forward for Somatrogon (hGH-CTP) in the United States.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, Sema4 Holdings Corp. (&#8220;Sema4&#8221;) and OPKO entered into a definitive agreement (the &#8220;GeneDx Merger Agreement&#8221;), pursuant to which Sema4 agreed to acquire OPKO&#8217;s wholly owned subsidiary, GeneDx  LLC, formerly GeneDx, Inc. (&#8220;GeneDx&#8221;), a leader in genomic testing and analysis, subject to the satisfaction of customary closing conditions (the &#8220;GeneDx Transaction&#8221;).  The GeneDx Transaction closed on April 29, 2022.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 9, 2022, the Company entered into an Agreement and Plan of Merger with Orca Acquisition Sub, Inc. (&#8220;Merger Sub &#8220;, a subsidiary of the Company formed for the purposes of this transaction), ModeX Therapeutics, Inc., (&#8220;ModeX&#8221; or &#8220;Seller&#8221;) and Sellers&#8217; representative (the &#8220;Merger Agreement&#8221;), pursuant to which Merger Sub was merged with and into ModeX, with ModeX becoming a wholly owned subsidiary of the Company (the &#8220;Merger&#8221;). The Company paid an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$300&#160;million </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for all of the outstanding equity of ModeX, as adjusted  by customary adjustments. The consideration paid at closing consisted of shares of our common stock, which was valued based on the average of the daily volume-weighted average price over the thirty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (30) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">trading days prior to the date that is two (2) days prior to the signing of the Merger Agreement . In addition, the Company has made a number of management changes in connection with the Merger. Elias Zerhouni, M.D., Gary Nabel, M.D., PhD.,  and Alexis Borisy were appointed to the Board of the Company, with Dr. Zerhouni appointed as the Vice Chair. Elizabeth Nabel, one of the founders of ModeX, is the new Chief Medical Officer of the Company.  Dr. Gary Nabel has been named the CEO of ModeX and Chief Innovation Officer of the Company and Dr. Zerhouni has been named the President of the Company.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to be a part of the coordinated public and private sector response to SARS-CoV-2, a novel strain of coronavirus, referred to as COVID-19.  There continues to be a high level of uncertainty relating to how the pandemic will evolve, how governments and consumers will react, progress on the distribution of vaccines and whether the pandemic will have a longer-term effect on the healthcare industry and patient habits. BioReference is providing COVID-19 solutions, including  diagnostic molecular testing and serology antibody testing, to meet the testing needs of its customers, including physicians, health systems, long-term care facilities, governments, schools, employers, professional sports teams and entertainment venues, as well as the general public through relationships with retail pharmacy chains.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since the pandemic began in the U.S., we have invested in testing capabilities and infrastructure to meet demand for our molecular and antibody testing for COVID-19.  Throughout the last two years, we have managed our company-wide lab operations specimen acquisition, logistics, procurement, customer service, and initiatives to manage our cost structure to match the ever changing COVID-19 testing volumes and to manage efficiency gains in our core clinical lines of business.  We anticipate that COVID-19 will continue to impact our business in 2022 and demand for COVID-19 testing will fluctuate with the potential for increases and decreases in demand at different times and across different geographies; however, overall, we expect COVID-19 test demand to trend down in 2022 as compared to 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenue from services for the three months ended March 31, 2022 decreased by $220.4 million as compared to 2021 due to lower COVID-19 testing volumes. We maintain our ability to quickly scale-up COVID-19 PCR testing capacity, even during periods of reduced demand.  In doing so, we are able to immediately and effectively respond to surges in positive cases and testing needs. We are unable to predict how long the demand will continue for our COVID-19 related testing, or whether pricing and reimbursement policies for testing will be sustained. Excluding COVID-19 test volumes, for the three months ended March 31, 2022, genomic and routine clinical test volume increased 14.0% and 0.4% respectively, as compared to volumes for the three months ended March 31, 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2022, the U.S. Health Resources and Services Administration ("HRSA") informed providers that, after March 22, 2022, it would stop accepting claims for testing and treatment for uninsured individuals under the HRSA COVID-19 Uninsured Program and that claims submitted prior to that date would be subject to eligibility and availability of funds. For the three months ended March 31, 2022, revenue for testing of uninsured individuals under the HRSA COVID-19 Uninsured Program represented approximately 7.9% of our COVID-19 testing revenue. As of March 31, 2022, less than 6% of our net accounts receivable was associated with claims for reimbursement for COVID-19 testing of uninsured individuals. Although we believe that our estimates for contractual allowances and patient price concessions are appropriate, actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated income (loss) from operations for the three months ended March&#160;31, 2022 and 2021 is as follows:  </span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220,352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from transfer of intellectual property and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,219&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,946)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,085)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,424)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,861)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Diagnostics </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220,352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,599&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,951&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220,352)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,937&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,790)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,548)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,562)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Revenue from services for the three months ended March&#160;31, 2022 decreased by approximately $220.4 million compared to the three months ended March 31, 2021. The decrease in revenue for the three months ended March&#160;31, 2022 reflects lower demand for COVID-19 testing and lower COVID-19 reimbursement of $164.0 million and $26.6 million, respectively.  BioReference performed 2.0 million molecular tests for COVID-19 and 0.1 million serology antibody tests during the three months ended March&#160;31, 2022, which represented 46.9% of total volume for that period. In comparison, the three months ended March 31, 2021 included 4.1 million molecular tests for COVID-19 and 0.2 million serology antibody tests. The reduction in reimbursement reflects an increase in utilization of antigen point of care diagnostic tests as well as a change in the mix of customers which have varying contract prices depending on the level of services we provide.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, clinical test reimbursement decreased $44.9 million as a result of the mix of testing ordered.  Partially offsetting the decrease in COVID-19 test volumes and clinical test reimbursement, were an improvement in genomic test reimbursement of $9.7 million, an increase in clinical test volume of $1.9 million, and genomic test volume of $3.2 million, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated collection amounts are subject to the complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, and require us to consider the potential for retroactive adjustments when estimating variable consideration in the recognition of revenue in the period the related services are rendered.  For the three months ended March&#160;31, 2022 and 2021, positive revenue adjustments due to changes in estimates of implicit price concessions for performance obligations satisfied in prior periods of $2.0 million and $28.0 million were recognized, respectively.  Revenue adjustments for the three months ended March&#160;31, 2022 and 2021 were primarily due to an improvement in COVID-19 test reimbursement estimates.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of Revenue from services by payor for the three months ended March&#160;31, 2022 and 2021 was as follows:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three months ended March&#160;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,829&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,951&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Client payors include cities, states and companies for which BioReference provides COVID-19 testing services.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Cost of revenue for the three months ended March&#160;31, 2022 decreased $118.2 million compared to the three months ended March 31, 2021.  Cost of revenue decreased primarily due to a decline in the volume of COVID-19 tests performed during the three months ended March&#160;31, 2022 compared to 2021. Cost of revenue for the three months ended March&#160;31, 2022 also decreased due to changes in the test mix during the period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Selling, general and administrative expenses for the three months ended March&#160;31, 2022 and 2021 were $95.0 million and $89.3 million, respectively.  Selling, general and administrative expenses in our diagnostics segment increased primarily due to increased investment in our commercial digital organization resulting in higher professional fees, personnel expenses and equity-based compensation due to the acceleration of certain option awards. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The following table summarizes the components of our research and development expenses: </span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and Development Expenses</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three months ended March&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PMA studies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development employee-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other internal research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,631&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in research and development expenses for the three months ended March&#160;31, 2022 resulted primarily related to the development of clinical and genomics testing services at BioReference.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Amortization of intangible assets was $7.8 million and $7.6 million, respectively, for the three months ended March&#160;31, 2022 and 2021.  Amortization expense reflects the amortization of acquired intangible assets with defined useful lives. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Pharmaceuticals</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from products</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from transfer of intellectual property and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,795)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(957)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,728&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,357&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,108)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,157)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The increase in revenue from products for the three months ended March&#160;31, 2022 compared to the three months ended March 31, 2021 was primarily attributable to an increase in sales at most of our international operating companies.  Revenue from sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for the three months ended March&#160;31, 2022 and 2021 was $5.1 million and $5.8&#160;million, respectively. Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in 2022 and 2021 have been negatively impacted as a result of challenges in onboarding new patients due to the COVID-19 pandemic. Revenue from transfer of intellectual property and other for the three months ended March&#160;31, 2022 and 2021 reflect $2.2 million and $2.8 million, respectively, of revenue related to the Pfizer Transaction.  In addition, OPKO recognized a $3.0 million milestone payment from VFMCRP in transfer of intellectual property and other during the three months ended March 31, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Cost of revenue for the three months ended March&#160;31, 2022 decreased $1.4 million compared to the three months ended March 31, 2021 primarily due to a $2.7 million inventory reserve recognized for Rayaldee inventory for the three months ended March 31, 2021. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Selling, general and administrative expenses for the three months ended March&#160;31, 2022 and 2021 were $11.6 million and $13.4 million, respectively.  The decrease in selling, general and administrative expenses was primarily due to a decrease in legal expenses and selling expenses related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling, general and administrative expenses for the pharmaceutical segment for the three months ended March&#160;31, 2022 and 2021 included equity-based compensation expense of $0.3&#160;million and $0.3 million, respectively.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Research and development expenses for the three months ended March&#160;31, 2022 and 2021 were $12.3 million and $15.8 million, respectively.  Research and development expenses include external and internal expenses, partially offset by third-party grants and funding arising from collaboration agreements.  External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs.  We track external research and development expenses by individual program for phase 3 clinical trials for drug approval and premarket approval for diagnostics tests, if any.  Internal expenses include employee-related expenses such as salaries, benefits and equity-based compensation expense.  Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our research and development expenses: </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:63.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and Development Expenses</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three months ended March&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing expense for biological products</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Post-marketing studies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earlier-stage programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development employee-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other internal research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party grants and funding from collaboration agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,291&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in research and development expenses for the three months ended March&#160;31, 2022 was primarily due to a decrease in research and development expenses for Somatrogon (hGH-CTP), a once-weekly human growth hormone injection for which we have partnered with Pfizer and successfully completed a phase 3 study in August 2019. Ongoing expenses on the Somatrogon program support open label extension studies that will continue until market launch of Somatrogon in certain countries, as well as the preparation of applications for marketing approvals.  Research and development expenses for the pharmaceutical segment for the three months ended March&#160;31, 2022 and 2021 included equity-based compensation expense of $0.3 million and $0.4 million, respectively. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Contingent consideration for the three months ended March&#160;31, 2022 and 2021 was $0.1 million and $1.0 million reversal of expense, respectively.  Contingent consideration for the three months ended March&#160;31, 2022 and 2021 was primarily attributable to changes in assumptions regarding the timing of achievement of future milestones for OPKO Renal, and potential amounts payable to former stockholders of OPKO Renal in connection therewith, pursuant to our acquisition agreement in March 2013.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Amortization of intangible assets was $14.3 million and $5.0 million, respectively, for the three months ended March&#160;31, 2022 and 2021.  Amortization expense reflects the amortization of acquired intangible assets with defined useful lives.  In the first quarter of 2022, we reclassified $590.2 million of IPR&amp;D related to Somatrogon (hGH-CTP) from IPR&amp;D in our Condensed Consolidated Balance Sheet upon the approval of NGENLA (Somatrogon) in Europe and Japan. The assets will be amortized on a straight-line basis over their estimated useful life of approximately 12 years.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Corporate</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,768&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,420)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,348)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss for our unallocated corporate operations for the three months ended March&#160;31, 2022 and 2021 was $10.8 million and $9.4 million, respectively, and principally reflect general and administrative expenses incurred in connection with our corporate operations. Operating loss for our unallocated corporate operations for the three months ended March&#160;31, 2022 was driven by an increase in legal fees.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Other</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Interest income for the three months ended March&#160;31, 2022 and 2021 was not significant as our cash investment strategy emphasizes the security of the principal invested and fulfillment of liquidity needs.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Interest expense for the three months ended March&#160;31, 2022 and 2021 was $2.7 million and $5.4 million, respectively.  Interest expense was principally related to interest incurred on the 2025 Notes, the 2023 Convertible Notes, the 2033 Senior Notes, and BioReference&#8217;s outstanding debt under the A&amp;R Credit Agreement. The decrease in interest expense was primarily due to the impact of the adoption of ASU 2020-06 on the 2025 Notes.  Due to the adoption of ASU 2020-06, interest expense decreased due to the elimination of the discount created by recognizing a component of convertible debt in equity.  Refer to Note 7.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value changes of derivative instruments, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Fair value changes of derivative instruments, net for the three months ended March&#160;31, 2022 and 2021, was $0.1 million and $0.4 million of expense, respectively.  Derivative expense for the three months ended March&#160;31, 2022 and 2021, was principally related to the change in fair value on foreign currency forward exchange contracts at OPKO Chile.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Other income (expense), net for the three months ended March&#160;31, 2022 and 2021, was $1.4 million of income and $0.9 million of expense, respectively.  Other income (expense) for the three months ended March&#160;31, 2022 and 2021 primarily consisted of foreign currency transaction gains (losses) recognized during the period.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income tax benefit (provision)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Our income tax benefit (provision) for the three months ended March&#160;31, 2022 and 2021 was $21.3 million and $(0.6) million, respectively, and reflects quarterly results using our expected effective tax rate.&#160; For the three months ended March&#160;31, 2022, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to a $22.0 million discrete benefit resulting from reduced tax rates that will be applicable to existing foreign deferred tax liabilities, as well as the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and operating results in tax jurisdictions which do not result in a tax benefit.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss from investments in investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We have made investments in certain early stage companies that we perceive to have valuable proprietary technology and significant potential to create value for us as a shareholder or member.  We account for these investments under the equity method of accounting, resulting in the recording of our proportionate share of their losses until our share of their loss exceeds our investment.  Until the investees&#8217; technologies are commercialized, if ever, we anticipate they will report net losses.  Loss from investments in investees was $49 thousand and $43 thousand for the three months ended March&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At March&#160;31, 2022, we had cash and cash equivalents of approximately $102.3 million.  Cash used in operations of $19.9 million for the three months ended March 31, 2022 principally reflects general and administrative expenses related to our corporate operations and research and development activities.  Cash used in investing activities for the three months ended March 31, 2022 primarily reflects capital expenditures of $5.3 million.  Cash used in financing activities of $7.9 million primarily reflects net repayments on our lines of credit.  We have historically not generated sustained positive cash flow sufficient to offset our operating and other expenses, and our primary sources of cash have been from the public and private placement of equity, the issuance of the 2033 Senior Notes, 2023 Convertible Notes and 2025 Notes and credit facilities available to us.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2022, Pfizer notified OPKO that NGENLA (Somatrogon), a once-weekly injection to treat pediatric growth hormone deficiency, has received pricing approval in Germany and Japan. NGENLA was granted marketing authorization by the Ministry of Health, Labour and Welfare in Japan and by the European Commission in January and February of this year, respectively. With the achievement of these milestones, we are entitled to receive an aggregate of $85.0 million in milestone payments.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2022, we and Sema4 announced the execution of the GeneDx Merger Agreement, pursuant to which Sema4 has agreed to acquire our wholly owned subsidiary, GeneDx.  The GeneDx Transaction closed on April 29, 2022.  As of March&#160;31, 2022 and December 31, 2021, GeneDx met the held-for-sale accounting criteria and the related assets and liabilities are classified as held for sale in the consolidated balance sheet.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the GeneDx Merger Agreement, Sema4 has agreed to acquire GeneDx for an upfront payment of $150&#160;million in cash, subject to adjustments, plus 80.0&#160;million shares in Sema4, with up to an additional $150&#160;million revenue-based milestones over the next two years (which will be payable in cash or Sema4 shares at Sema4&#8217;s discretion). Based on the closing stock price of Sema4 as of April 29, 2022, the total upfront consideration represents approximately $322&#160;million, and the total aggregate consideration including potential milestones is approximately $472&#160;million.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we issued $200.0 million aggregate principal amount of the 2025 Notes in an underwritten public offering.  The 2025 Notes bear interest at a rate of 4.50% per year, payable semiannually in arrears on February&#160;15 and August&#160;15 of each year.  The notes mature on February&#160;15, 2025, unless earlier repurchased, redeemed or converted.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2025 Notes into shares of Common Stock at their option at any time prior to the close of business on the business day immediately preceding November&#160;15, 2024, subject to the satisfaction of certain conditions.  Upon conversion, we will pay or deliver, as the case may be, cash, shares of our Common Stock, or a combination of cash and shares of our Common Stock, at our election.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current conversion rate for the 2025 Notes is 236.7424 shares of Common Stock per $1,000 principal amount of 2025 Notes (equivalent to a conversion price of approximately $4.22 per share of Common Stock).  The conversion rate for the 2025 Notes is subject to adjustment in certain events but will not be adjusted for any accrued and unpaid interest.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into exchange agreements with certain holders of the 2025 Notes pursuant to which the holders exchanged $55.4&#160;million in aggregate principal amount of the outstanding 2025 Notes for 19,051,270 shares of our Common Stock (the &#8220;Exchange&#8221;). </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the total commitments under our A&amp;R Credit Agreement with CB and our lines of credit with financial institutions in Chile and Spain were $89.5 million, of which $16.5 million was drawn as of March&#160;31, 2022.  At March&#160;31, 2022, the weighted average interest rate on these lines of credit was approximately 5.5%.  These lines of credit are short-term and are used primarily as a source of working capital.  The highest aggregate principal balance at any time outstanding during the three months ended March 31, 2022 was $16.6 million.  We intend to continue to draw under these lines of credit as needed.  There is no assurance that these lines of credit or other funding sources will be available to us on acceptable terms, or at all, in the future.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R Credit Agreement provides for a $75.0 million secured revolving credit facility and includes a $20.0 million sub-facility for swingline loans and a $20.0 million sub-facility for the issuance of letters of credit.  The A&amp;R Credit Agreement matures on August 30, 2024 and is guaranteed by all of BioReference&#8217;s domestic subsidiaries, subject to certain exceptions.  The A&amp;R Credit Agreement is also secured by substantially all assets of BioReference and its domestic subsidiaries, subject to certain exceptions, as well as a non-recourse pledge by us of our equity interest in BioReference.  Availability under the A&amp;R Credit Agreement is based on a borrowing base composed of eligible accounts receivables of BioReference and certain of its subsidiaries, as specified therein.  As of March&#160;31,&#160;2022, $64.8 million remained available for borrowing under the A&amp;R Credit Agreement. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with our agreements with Pfizer, VFMCRP, Nicoya and CAMP4, we are eligible to receive various milestone payments and royalty considerations.  Under the terms of the Pfizer Agreement, we are eligible to receive up to an additional $275.0 million upon the achievement of certain regulatory milestones, including $85 million of milestone payments we expect to receive during the second quarter of 2022. In addition, we are eligible to receive initial tiered royalty payments associated with the commercialization of Somatrogon for adult GHD with percentage rates ranging from the high teens to mid-twenties. Upon the launch of Somatrogon for pediatric GHD in certain major markets, the royalties will transition to regional, tiered gross profit sharing for both Somatrogon and Pfizer&#8217;s Genotropin&#174;.  Under the terms of the VFMCRP Agreement, we are entitled to receive up to an additional $17 million in regulatory milestones and $207 million in milestone payments tied to launch, pricing and sales of Rayaldee, including a $3.0 million milestone payment we recognized during the three months ended March 31, 2022 upon the first sale of Rayaldee in Europe. In addition, we are eligible to receive tiered, double-digit royalty payments.  Under the terms of the Nicoya Agreement, we received an initial upfront payment of $5 million and are eligible to receive an additional $5 million upon the first to occur of (A) a predetermined milestone and (B) the first anniversary of the effective date. We are also eligible to receive up to an additional aggregate amount of $115 million upon the achievement of certain development, regulatory and sales-based milestones by Nicoya for the Nicoya Product in the Nicoya Territory. We will also receive tiered, double digit royalty payments at rates in the low double digits on net product sales within the Nicoya Territory and in the Nicoya Field.  Under the terms of the CAMP4 Agreement, we received an initial upfront payment of $1.5 million and we are eligible to receive up to $3.5 million in development milestone payments for Dravet syndrome products, and $4 million for non-Dravet syndrome products, as well as sales milestones of up to $90 million for Dravet syndrome products and up to $90 million for non-Dravet syndrome products.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of CURNA, OPKO Diagnostics and OPKO Renal, we agreed to pay future consideration to the sellers upon the achievement of certain events, including up to an additional $19.1 million in shares of our Common Stock to the former stockholders of OPKO Diagnostics upon and subject to the achievement of certain milestones; and up to an additional $125.0 million in either shares of our Common Stock or cash, at our option subject to the achievement of certain milestones, to the former shareholders of OPKO Renal.  As a result of our execution of the CAMP4 Agreement, we will have to pay a percentage of any payments received under the CAMP4 Agreement to the former CURNA stockholders.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the cash and cash equivalents on hand at March&#160;31, 2022, cash from the Pfizer milestone payments of $85 million, the $150&#160;million of cash paid at the closing of the Sema4 transaction and the amounts available to be borrowed under our lines of credit are sufficient to meet our anticipated cash requirements for operations and debt service beyond the next 12 months.  We based this estimate on assumptions that may prove to be wrong or are subject to change, and we may be required to use our available cash resources sooner than we currently expect.  If we acquire additional assets or companies, accelerate our product development programs or initiate additional clinical trials, we will need additional funds.  Our future cash requirements, and the timing of those requirements, will depend on a number of factors, including the evolving impact of the COVID-19 pandemic on our business, the approval and success of our products in development, particularly our long acting Somatrogon for which we have received approval in Europe, Japan, Australia and Canada, submitted for approval in the U.S. and received a Complete Response Letter in January 2022, the approval and success of Somatrogon outside the United States, including in Europe, Japan, Australia and Canada, the commercial success of Rayaldee, including from the recent launch of Rayaldee by Vifor and in other territories expected in 2022, BioReference&#8217;s financial performance, possible acquisitions and dispositions, the continued progress of research and development of our product candidates, the timing and outcome of clinical trials and regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims and other intellectual property rights, the status of competitive products, the availability of financing, our success in developing markets for our product candidates and results of government investigations, payor claims, and legal proceedings that may arise, including, without limitation class action and derivative litigation to which we are subject, and our ability to obtain insurance coverage for such claims.  We have historically not generated sustained positive cash flow and if we are not able to secure additional funding when needed, we may have to delay, reduce the scope of, or eliminate one or more of our clinical trials or research and development programs or possible acquisitions or reduce our marketing or sales efforts or cease operations.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the rapid development and fluidity of the&#160;COVID-19 pandemic and new variants of the virus makes it very difficult to predict its ultimate impact on our business, results of operations and liquidity.  The pandemic presents a significant uncertainty that could materially and adversely affect our results of operations, financial condition and cash flows, including a negative impact on non-COVID-related diagnostics testing services provided by BioReference in our diagnostics segment, notwithstanding that our results of operations have been positively impacted by our provision of COVID-19 testing services.  Further, deteriorating economic conditions globally as a result of the COVID-19 pandemic have in the past resulted, and may in the future result in a challenging capital raising environment, which could materially limit our access to capital, whether through the issuance and sale of our Common Stock, debt securities or otherwise, as well as through bank facilities and lines of credit.  Events resulting from the effects of COVID-19 or new variants of the virus could negatively impact our ability to comply with certain covenants&#160;in the A&amp;R Credit Agreement or require that we pursue alternative financing.  We can provide no assurance that any such alternative financing, if required, could be obtained on acceptable terms or at all.  The combination of potential disruptions to our business resulting from&#160;COVID-19 together with and volatile credit and capital markets could </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adversely impact our future liquidity, which could have an adverse effect on our business and results of operations.  We will continue to monitor and assess the impact&#160;COVID-19 and new variants of the virus may have on our business and financial results.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information as of March&#160;31, 2022, with respect to the amounts and timing of our known contractual obligation payments due by period.  </span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual obligations<br/>(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining nine&#160;months ending December&#160;31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Open purchase orders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252,411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2033 Senior Notes, 2025 and 2023 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgages and other debts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lines of credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest commitments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286,119&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,429&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,396&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556,119&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preceding table does not include information where the amounts of the obligations are not currently determinable, including the following: </span></div><div style="margin-top:9pt;padding-left:67.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Contractual obligations in connection with clinical trials, which span over two years, and that depend on patient enrollment.  The total amount of expenditures is dependent on the actual number of patients enrolled and as such, the contracts do not specify the maximum amount we may owe. </span></div><div style="margin-top:9pt;padding-left:67.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Product license agreements effective during the lesser of 15 years or patent expiration whereby payments and amounts are determined by applying a royalty rate on uncapped future sales.</span></div><div style="margin-top:9pt;padding-left:67.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Contingent consideration that includes payments upon achievement of certain milestones including meeting development milestones such as the completion of successful clinical trials, NDA approvals by the FDA and revenue milestones upon the achievement of certain revenue targets all of which are anticipated to be paid within the next seven years and are payable in either shares of our Common Stock or cash, at our option, and that may aggregate up to $144.1 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes to our critical accounting policies and estimates described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, that have a material impact on our Condensed Consolidated Financial Statements and related notes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently adopted accounting pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40).&#8221; ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2021, with early adoption permitted.   As required, we adopted ASU 2020-06 on January 1, 2022 and used the modified retrospective approach for all convertible debt instruments at the beginning of the period of adoptions.  Results for reporting periods beginning January 1, 2022 are presented under ASU 2020-06, while prior period amounts were not adjusted and continue to be reported in accordance historic accounting guidance. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the modified approach, entities will apply the guidance to all financial instruments that are outstanding as of the beginning of the year of adoption with the cumulative effect recognized as an adjustment to the opening balance of retained earnings. ASU 2020-06 eliminates the cash conversion and beneficial conversion feature models in ASC 470-20 that require an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity. The adoption of ASU 2020-06 at January 1, 2022 resulted in an increase of the Convertible notes of $25.6 million, a reduction of the Accumulated deficit of $17.5 million and a reduction of Additional paid-in capital of $39.1 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of doing business, we are exposed to the risks associated with foreign currency exchange rates and changes in interest rates.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign Currency Exchange Rate Risk &#8211; We operate globally and, as such, we are subject to foreign exchange risk in our commercial operations as portions of our revenues are exposed to changes in foreign currency exchange rates, primarily the Chilean Peso, the Mexican Peso, and the Euro.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not speculate in the foreign exchange market, we may from time to time manage exposures that arise in the normal course of business related to fluctuations in foreign currency exchange rates by entering into offsetting positions through the use of foreign exchange forward contracts.  Certain firmly committed transactions may be hedged with foreign exchange forward contracts.  As exchange rates change, gains and losses on the exposed transactions are partially offset by gains and losses related to the hedging contracts.  Both the exposed transactions and the hedging contracts are translated and fair valued, respectively, at current spot rates, with gains and losses included in earnings.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities, which consist of foreign exchange forward contracts, are initiated to economically hedge forecasted cash flows that are exposed to foreign currency risk.  The foreign exchange forward contracts generally require us to exchange local currencies for foreign currencies based on pre-established exchange rates at the contracts&#8217; maturity dates.  As exchange rates change, gains and losses on these contracts are generated based on the change in the exchange rates that are recognized in the Condensed Consolidated Statements of Operations and offset the impact of the change in exchange rates on the foreign currency cash flows that are hedged.  If the counterparties to the exchange contracts do not fulfill their obligations to deliver the contracted currencies, we could be at risk for currency related fluctuations.  Our foreign exchange forward contracts primarily hedge exchange rates on the Chilean Peso to the U.S. dollar.  If Chilean Pesos were to strengthen or weaken in relation to the U.S. dollar, our loss or gain on hedged foreign currency cash-flows would be offset by the derivative contracts, with a net effect of zero.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not engage in trading market risk sensitive instruments or purchasing hedging instruments or &#8220;other than trading&#8221; instruments that are likely to expose us to significant market risk, whether interest rate, foreign currency exchange, commodity price, or equity price risk.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest Rate Risk &#8211; Our exposure to interest rate risk relates to our cash and investments and to our borrowings.  We generally maintain an investment portfolio of money market funds and marketable securities.  The securities in our investment portfolio are not leveraged, and are, due to their very short-term nature, subject to minimal interest rate risk.  We currently do not hedge interest rate exposure.  Because of the short-term maturities of our investments, we do not believe that a change in market interest rates would have a significant negative impact on the value of our investment portfolio except for reduced income in a low interest rate environment.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, we had cash and cash equivalents of $102.3 million.  The weighted average interest rate related to our cash and cash equivalents for the three months ended March 31, 2022 was less than 1%.  As of March&#160;31, 2022, the principal outstanding balances under BioReference&#8217;s A&amp;R Credit Agreement with CB and our Chilean and Spanish lines of credit was $16.5 million in the aggregate at a weighted average interest rate of approximately 5.5%.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our $3.0 million aggregate principal amount of our 2033 Senior Notes has a fixed interest rate of 3%, our $55.0 million aggregate principal amount of our 2023 Convertible Notes has a fixed interest rate of 5%, and our $200.0 million aggregate principal amount of the 2025 Notes has a fixed interest rate of 4.50%, and therefore are not subject to fluctuations in market interest rates.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk.  To achieve this objective, we may invest our excess cash in debt instruments of the U.S. Government and its agencies, bank obligations, repurchase agreements and high-quality corporate issuers, and money market funds that invest in such debt instruments, and, by policy, restrict our exposure to any single corporate issuer by imposing concentration limits.  To minimize the exposure due to adverse shifts in interest rates, we maintain investments at an average maturity of generally less than three months.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Controls and Procedures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, have evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the  Exchange Act  as of the end of the period covered by this Quarterly Report on Form 10-Q.  Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the Securities and Exchange Commission.  Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.  Based on this evaluation, management concluded that our disclosure controls and procedures were effective as of March&#160;31, 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to the Company&#8217;s Internal Control Over Financial Reporting </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the Company&#8217;s internal control over financial reporting that occurred during the quarter ended March&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i1cac816ff800494ea2979c434f00b37c_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Legal Proceedings</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, from time to time, party to various legal proceedings arising out of our business. During the reporting period, covered by this Quarterly Report on Form 10-Q, except as set forth below, there have been no material changes to the description of legal proceedings set forth in our Annual Report on Form 10-K for the year ended December 31, 2021. The following should be read in conjunction with the information provided in Part I, Item 3 of such Annual Report.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2019, MabVax Therapeutics Holdings, Inc. filed a lawsuit in the Superior Court of California, County of San Diego against a number of individuals and entities, including the Company, Dr. Frost, Steven Rubin, the Company&#8217;s Executive Vice President-Administration, and an entity affiliated with Dr. Frost, based on the allegations raised in the SEC Complaint. The lawsuit seeks an award for actual and punitive damages, pre- and post-judgment interest; that the defendants be required to make full disclosure and accounting of their interests and transactions in plaintiff&#8217;s securities; costs of the suit, and reasonable attorney&#8217;s fees; and such other legal and equitable relief as the Court may deem proper under the circumstances. On January 31, 2022, plaintiffs entered into a confidential mutual release and settlement agreement with the Company, Dr. Frost, Frost Gamma Investment Trust, and Steve Rubin (the &#8220;Settlement Agreement&#8221;). The Settlement Agreement  has been approved by the United States Bankruptcy Court for the District of Delaware.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See Note 12 to the interim unaudited condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q for information regarding the status of other legal proceedings involving the Company, which information is incorporated by reference herein.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Factors </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our risk factors as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div><span><br/></span></div><div id="i1cac816ff800494ea2979c434f00b37c_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i1cac816ff800494ea2979c434f00b37c_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Defaults Upon Senior Securities</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i1cac816ff800494ea2979c434f00b37c_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div id="i1cac816ff800494ea2979c434f00b37c_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Information</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000944809/000094480922000002/ex2-1mergeragmt.htm">Exhibit&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000944809/000094480922000002/ex2-1mergeragmt.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000944809/000094480922000002/ex2-1mergeragmt.htm">.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000944809/000094480922000002/ex2-1mergeragmt.htm">Agreement and Plan of Merger and Reorganization, dated as of January 14, 2022, by and</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000944809/000094480922000002/ex2-1mergeragmt.htm">  </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000944809/000094480922000002/ex2-1mergeragmt.htm">among the Company, Sema4 Holdings Corp., Orion Merger Sub I, Inc., Orion Merger Sub II,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000944809/000094480922000002/ex2-1mergeragmt.htm">  </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000944809/000094480922000002/ex2-1mergeragmt.htm">LLC, GeneDx Inc. and GeneDx Holding 2, Inc. (filed as Exhibit 2.1 to the Company&#8217;s Current</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000944809/000094480922000002/ex2-1mergeragmt.htm">  </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000944809/000094480922000002/ex2-1mergeragmt.htm">Report on Form 8-K filed with the SEC on January 18, 2022 and incorporated by reference </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000944809/000094480922000002/ex2-1mergeragmt.htm">herein)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/944809/000094480922000002/ex10-1shagmt.htm">Exhibit 10.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/944809/000094480922000002/ex10-1shagmt.htm">Shareholder Agreement, dated as of January 14, 2022, by and among the Company and Sema4 Holdings Corp.  (filed as Exhibit 10.1 to the Company&#8217;s Current  Report on Form 8-K filed with the SEC on January 18, 2022 and incorporated by reference herein).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/944809/000094480922000020/jpmcfexhibit4-29x22.htm">Exhibit 10-2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/944809/000094480922000020/jpmcfexhibit4-29x22.htm">Waiver Under and Amendment No. 1 to Amended and Restated Credit Agreement, dated as of April</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/944809/000094480922000020/jpmcfexhibit4-29x22.htm">29, 2022, by and among BioReference Health LLC, GeneDx, LLC, the other subsidiary borrowers and loan parties thereto, the Lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/944809/000094480922000020/jpmcfexhibit4-29x22.htm"> (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/944809/000094480922000020/jpmcfexhibit4-29x22.htm">filed as Exhibit 10.1 to the Company&#8217;s Current</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/944809/000094480922000020/jpmcfexhibit4-29x22.htm">  </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/944809/000094480922000020/jpmcfexhibit4-29x22.htm">Report on Form 8-K filed with the SEC on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/944809/000094480922000020/jpmcfexhibit4-29x22.htm">May</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/944809/000094480922000020/jpmcfexhibit4-29x22.htm"> 4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/944809/000094480922000020/jpmcfexhibit4-29x22.htm">, 2022 and incorporated by reference herein)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/944809/000094480922000020/jpmcfexhibit4-29x22.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex311.htm">Exhibit&#160;31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex311.htm">Certification by Phillip Frost, Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex311.htm">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex311.htm"> 3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex311.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex311.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex311.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex311.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex312.htm">Exhibit&#160;31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex312.htm">Certification by Adam Logal, Chief Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex312.htm">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex312.htm"> 3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex312.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex312.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex312.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex312.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex321.htm">Exhibit&#160;32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex321.htm">Certification by Phillip Frost, Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex321.htm">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex321.htm"> 3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex321.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex321.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex321.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex321.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex322.htm">Exhibit&#160;32.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex322.htm">Certification by Adam Logal, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex322.htm">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex322.htm"> 3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex322.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex322.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex322.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="opk-3312022xex322.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Pursuant to Item 601(b)(10)(iv) of Regulation S-K, portions of this exhibit have been omitted because the Company </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customarily and actually treats the omitted portions as private or confidential, and such portions are not material and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would likely cause competitive harm to the Company if publicly disclosed. The Company will supplementally provide </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a copy of an unredacted copy of this exhibit to the U.S. Securities and Exchange Commission or its staff upon request.</span></div><div style="margin-top:3pt;padding-left:22.5pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:22.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-27pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-27pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-27pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:22.5pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i1cac816ff800494ea2979c434f00b37c_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1cac816ff800494ea2979c434f00b37c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:21.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 9, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OPKO Health, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Adam Logal</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam Logal</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>opk-3312022xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i67d985f2d0ec4f71a74ecfa3b5538ae5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Exhibit 31.1</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CERTIFICATIONS</font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">I, Phillip Frost, certify that&#58;</font></div><div style="padding-left:36pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt">I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.&#59;</font></div><div style="padding-left:36pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Phillip Frost, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phillip Frost, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>opk-3312022xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibc74b76f72234ed991636e9aa1fa7bc5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Exhibit 31.2</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CERTIFICATIONS</font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">I, Adam Logal, certify that&#58;</font></div><div style="padding-left:36pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt">I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.&#59;</font></div><div style="padding-left:36pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:15.34pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:60.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Adam Logal</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam Logal</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>opk-3312022xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i341a9701a3884d2c9612e315582ecdc7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant Section 906 of the Sarbanes-Oxley Act of 2002, I, Phillip Frost, Chief Executive Officer of OPKO Health, Inc. (the &#8220;Company&#8221;), hereby certify that&#58;</font></div><div style="margin-bottom:9pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Phillip Frost, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phillip Frost, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>opk-3312022xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6618a20aae04473d80fd692c831b4445_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant Section 906 of the Sarbanes-Oxley Act of 2002, I, Adam Logal, Chief Financial Officer of OPKO Health, Inc. (the &#8220;Company&#8221;), hereby certify that&#58;</font></div><div style="margin-bottom:9pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Adam Logal</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam Logal</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>opk-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b1bc5044-98fa-41ae-b2d0-b9b87eb185ce,g:64b4497f-89ba-4c5f-8ed3-b19012dfc871-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:opk="http://www.opko.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.opko.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="opk-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="opk-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="opk-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="opk-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVERPAGE" roleURI="http://www.opko.com/role/COVERPAGE">
        <link:definition>0001001 - Document - COVER PAGE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFEQUITY" roleURI="http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessandOrganization" roleURI="http://www.opko.com/role/BusinessandOrganization">
        <link:definition>2101101 - Disclosure - Business and Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessandOrganizationDetails" roleURI="http://www.opko.com/role/BusinessandOrganizationDetails">
        <link:definition>2402401 - Disclosure - Business and Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpactofCOVID19" roleURI="http://www.opko.com/role/ImpactofCOVID19">
        <link:definition>2103102 - Disclosure - Impact of COVID-19</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpactofCOVID19Details" roleURI="http://www.opko.com/role/ImpactofCOVID19Details">
        <link:definition>2404402 - Disclosure - Impact of COVID-19 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2105103 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2206201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.opko.com/role/EarningsLossPerShare">
        <link:definition>2108104 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetails" roleURI="http://www.opko.com/role/EarningsLossPerShareDetails">
        <link:definition>2409404 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainFinancialStatementCaptions" roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions">
        <link:definition>2110105 - Disclosure - Composition of Certain Financial Statement Captions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainFinancialStatementCaptionsTables" roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables">
        <link:definition>2311301 - Disclosure - Composition of Certain Financial Statement Captions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainFinancialStatementCaptionsDetails" roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails">
        <link:definition>2412405 - Disclosure - Composition of Certain Financial Statement Captions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainFinancialStatementCaptionsNarrativeDetails" roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails">
        <link:definition>2413406 - Disclosure - Composition of Certain Financial Statement Captions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails" roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails">
        <link:definition>2414407 - Disclosure - Composition of Certain Financial Statement Captions - Changes in Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.opko.com/role/Investments">
        <link:definition>2115106 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.opko.com/role/InvestmentsTables">
        <link:definition>2316302 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofInvestmentsDetails" roleURI="http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails">
        <link:definition>2417408 - Disclosure - Investments - Summary of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.opko.com/role/InvestmentsNarrativeDetails">
        <link:definition>2418409 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails" roleURI="http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails">
        <link:definition>2419410 - Disclosure - Investments - Schedule of Net Gains and Losses on Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.opko.com/role/Debt">
        <link:definition>2120107 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.opko.com/role/DebtTables">
        <link:definition>2321303 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofDebtDetails" roleURI="http://www.opko.com/role/DebtScheduleofDebtDetails">
        <link:definition>2422411 - Disclosure - Debt - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.opko.com/role/DebtNarrativeDetails">
        <link:definition>2423412 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofNotesDetails" roleURI="http://www.opko.com/role/DebtScheduleofNotesDetails">
        <link:definition>2424413 - Disclosure - Debt - Schedule of Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtLinesofCreditDetails" roleURI="http://www.opko.com/role/DebtLinesofCreditDetails">
        <link:definition>2425414 - Disclosure - Debt - Lines of Credit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNotesPayableandOtherDebtDetails" roleURI="http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails">
        <link:definition>2426415 - Disclosure - Debt - Notes Payable and Other Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLoss" roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLoss">
        <link:definition>2127108 - Disclosure - Accumulated Other Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossTables" roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables">
        <link:definition>2328304 - Disclosure - Accumulated Other Comprehensive Loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossDetails" roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails">
        <link:definition>2429416 - Disclosure - Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.opko.com/role/FairValueMeasurements">
        <link:definition>2130109 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.opko.com/role/FairValueMeasurementsTables">
        <link:definition>2331305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" roleURI="http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails">
        <link:definition>2432417 - Disclosure - Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails" roleURI="http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails">
        <link:definition>2433418 - Disclosure - Fair Value Measurements - Carrying Amount and Estimated Fair Value of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsLevel3ReconciliationDetails" roleURI="http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails">
        <link:definition>2434419 - Disclosure - Fair Value Measurements - Level 3 Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.opko.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2435420 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeContracts" roleURI="http://www.opko.com/role/DerivativeContracts">
        <link:definition>2136110 - Disclosure - Derivative Contracts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeContractsTables" roleURI="http://www.opko.com/role/DerivativeContractsTables">
        <link:definition>2337306 - Disclosure - Derivative Contracts (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeContractsBalanceSheetComponentDetails" roleURI="http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails">
        <link:definition>2438421 - Disclosure - Derivative Contracts - Balance Sheet Component (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeContractsDerivativeGainsLossesDetails" roleURI="http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails">
        <link:definition>2439422 - Disclosure - Derivative Contracts - Derivative Gains (Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.opko.com/role/RelatedPartyTransactions">
        <link:definition>2140111 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.opko.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2441423 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.opko.com/role/CommitmentsandContingencies">
        <link:definition>2142112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.opko.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2443424 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.opko.com/role/RevenueRecognition">
        <link:definition>2144113 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.opko.com/role/RevenueRecognitionTables">
        <link:definition>2345307 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://www.opko.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>2446425 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionScheduleofDisaggregationofRevenueDetails" roleURI="http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails">
        <link:definition>2447426 - Disclosure - Revenue Recognition - Schedule of Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails" roleURI="http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails">
        <link:definition>2448427 - Disclosure - Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionChangesinContractualLiabilitiesBalanceDetails" roleURI="http://www.opko.com/role/RevenueRecognitionChangesinContractualLiabilitiesBalanceDetails">
        <link:definition>2449428 - Disclosure - Revenue Recognition - Changes in Contractual Liabilities Balance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StrategicAlliances" roleURI="http://www.opko.com/role/StrategicAlliances">
        <link:definition>2150114 - Disclosure - Strategic Alliances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StrategicAlliancesDetails" roleURI="http://www.opko.com/role/StrategicAlliancesDetails">
        <link:definition>2451429 - Disclosure - Strategic Alliances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segments" roleURI="http://www.opko.com/role/Segments">
        <link:definition>2152115 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsTables" roleURI="http://www.opko.com/role/SegmentsTables">
        <link:definition>2353308 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsNarrativeDetails" roleURI="http://www.opko.com/role/SegmentsNarrativeDetails">
        <link:definition>2454430 - Disclosure - Segments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsOperationsandAssetsInformationDetails" roleURI="http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails">
        <link:definition>2455431 - Disclosure - Segments - Operations and Assets Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.opko.com/role/Leases">
        <link:definition>2156116 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.opko.com/role/LeasesTables">
        <link:definition>2357309 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseAssetsandLiabilitiesDetails" roleURI="http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails">
        <link:definition>2458432 - Disclosure - Leases - Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseLiabilityMaturityDetails" roleURI="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails">
        <link:definition>2459433 - Disclosure - Leases - Lease Liability Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseLiabilityMaturityDetails_1" roleURI="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1">
        <link:definition>2459433 - Disclosure - Leases - Lease Liability Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.opko.com/role/LeasesNarrativeDetails">
        <link:definition>2460434 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCashFlowInformationDetails" roleURI="http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails">
        <link:definition>2461435 - Disclosure - Leases - Lease Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.opko.com/role/SubsequentEvents">
        <link:definition>2162117 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.opko.com/role/SubsequentEventsDetails">
        <link:definition>2463436 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="opk_MuseumofScienceIncMember" abstract="true" name="MuseumofScienceIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_NumberofSalesEmployees" abstract="false" name="NumberofSalesEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="opk_NewCreditAgreementMember" abstract="true" name="NewCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" abstract="true" name="PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" abstract="true" name="EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_TestingTypeAxis" abstract="true" name="TestingTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" abstract="false" name="AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="opk_AccruedExpensePayorOverpaymentReimbursementLiability" abstract="false" name="AccruedExpensePayorOverpaymentReimbursementLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_CollaborativeArrangementDevelopmentMilestonePayment" abstract="false" name="CollaborativeArrangementDevelopmentMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_OperatingLeasesMonthlyPaymentsYearFive" abstract="false" name="OperatingLeasesMonthlyPaymentsYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_RelatedPartyTransactionFutureContributionTerm" abstract="false" name="RelatedPartyTransactionFutureContributionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_ChargebacksDiscountsRebatesAndFeesMember" abstract="true" name="ChargebacksDiscountsRebatesAndFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments" abstract="false" name="BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_NotesDueFebruary12033Member" abstract="true" name="NotesDueFebruary12033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_OpkoDiagnosticsMember" abstract="true" name="OpkoDiagnosticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable" abstract="false" name="DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_ProceedsFromConvertibleDebtConversionFee" abstract="false" name="ProceedsFromConvertibleDebtConversionFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_BusinessCombinationPeriodPriorToSigningOfAgreement" abstract="false" name="BusinessCombinationPeriodPriorToSigningOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" abstract="false" name="ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_LineOfCreditAndNotesAndLoansPayableCurrentMember" abstract="true" name="LineOfCreditAndNotesAndLoansPayableCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_EstadoBankMember" abstract="true" name="EstadoBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_EloxxPharmaceuticalsMember" abstract="true" name="EloxxPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_SharesReceivedAsGift" abstract="false" name="SharesReceivedAsGift" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_CURNAMember" abstract="true" name="CURNAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_DiagnosticsMember" abstract="true" name="DiagnosticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_DisposalGroupNumberOfFacilitiesSold" abstract="false" name="DisposalGroupNumberOfFacilitiesSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="opk_IndividualPatientsMember" abstract="true" name="IndividualPatientsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_Corpbanca1Member" abstract="true" name="Corpbanca1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_OperatingLeasesMonthlyPaymentsYearOne" abstract="false" name="OperatingLeasesMonthlyPaymentsYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_StockOptionandWarrantInvestments" abstract="false" name="StockOptionandWarrantInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_PhioPharmaceuticalsMember" abstract="true" name="PhioPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="FinanceLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_HealthInsurersMember" abstract="true" name="HealthInsurersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_MednaxServicesIncMember" abstract="true" name="MednaxServicesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_ItauBankMember" abstract="true" name="ItauBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime" abstract="false" name="CollaborativeArrangementAnnualHeightVelocityatPointinTime" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="opk_ExclusiveOptionMember" abstract="true" name="ExclusiveOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_XeneticBiosciencesInc.Member" abstract="true" name="XeneticBiosciencesInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_NonDravetSyndromeProductsMember" abstract="true" name="NonDravetSyndromeProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_BCIBankMember" abstract="true" name="BCIBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_DravetSyndromeProductsMember" abstract="true" name="DravetSyndromeProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_EquityMethodInvestmentVariableInterestEntity" abstract="false" name="EquityMethodInvestmentVariableInterestEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_NicoyaMember" abstract="true" name="NicoyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_InProcessResearchandDevelopment" abstract="false" name="InProcessResearchandDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_GovernmentPayersMember" abstract="true" name="GovernmentPayersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_DetectGenomixMember" abstract="true" name="DetectGenomixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_CollaborativeArrangementSalesMilestonePayment" abstract="false" name="CollaborativeArrangementSalesMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_TransferOfIntellectualPropertyAndOtherMember" abstract="true" name="TransferOfIntellectualPropertyAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum" abstract="false" name="DebtInstrumentConvertibleConversionNoticeThresholdMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_InternationalBankMember" abstract="true" name="InternationalBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="opk_VBIVaccinesIncMember" abstract="true" name="VBIVaccinesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" abstract="false" name="IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_GovernmentalMember" abstract="true" name="GovernmentalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" abstract="false" name="AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_RelatedPartyTransactionFutureContributions" abstract="false" name="RelatedPartyTransactionFutureContributions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_BancoDeSabadellMember" abstract="true" name="BancoDeSabadellMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_COVID19TestingMember" abstract="true" name="COVID19TestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_BioCardiaInc.Member" abstract="true" name="BioCardiaInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum" abstract="false" name="DebtInstrumentConvertibleConversionNoticeThresholdMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_SouthernDistrictOfNewYorkVsBioReferenceMember" abstract="true" name="SouthernDistrictOfNewYorkVsBioReferenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_LeaderMedMember" abstract="true" name="LeaderMedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_CollaborativeArrangementUpfrontPayment" abstract="false" name="CollaborativeArrangementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_BankOfChileMember" abstract="true" name="BankOfChileMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax" abstract="false" name="IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_WeightedAverageDiscountRateAbstract" abstract="true" name="WeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" abstract="false" name="IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_CovenantsNotToCompeteMember" abstract="true" name="CovenantsNotToCompeteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_SalesReturnsMember" abstract="true" name="SalesReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_InventoryReceivedNotInvoicedCurrent" abstract="false" name="InventoryReceivedNotInvoicedCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_StrategicAlliancesTextBlock" abstract="false" name="StrategicAlliancesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="opk_InCellDxIncMember" abstract="true" name="InCellDxIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_CollaborativeArrangementMaximumMilestonePayments" abstract="false" name="CollaborativeArrangementMaximumMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_LeaderMedJointVentureMember" abstract="true" name="LeaderMedJointVentureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod" abstract="false" name="BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_OPKOBiologicsMember" abstract="true" name="OPKOBiologicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_ChangeInTestingVolumePercent" abstract="false" name="ChangeInTestingVolumePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="opk_NonInvasiveMonitoringSystemsInc.Member" abstract="true" name="NonInvasiveMonitoringSystemsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement" abstract="false" name="BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_CollaborativeAgreementAdditionalMilestonePayment" abstract="false" name="CollaborativeAgreementAdditionalMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_CollaborativeArrangementPeriodAfterFirstCommercialSale" abstract="false" name="CollaborativeArrangementPeriodAfterFirstCommercialSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember" abstract="true" name="LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_OPKOHealthEuropeMember" abstract="true" name="OPKOHealthEuropeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_ZebraMember" abstract="true" name="ZebraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_FineTechMember" abstract="true" name="FineTechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_AutomobilesandAircraftMember" abstract="true" name="AutomobilesandAircraftMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_COVID19TestingRevenueConcentrationRiskMember" abstract="true" name="COVID19TestingRevenueConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_BiceBankMember" abstract="true" name="BiceBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_PatientsMember" abstract="true" name="PatientsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_TestingTypeDomain" abstract="true" name="TestingTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_CollaborativeArrangementPercentOfOutstandingShares" abstract="false" name="CollaborativeArrangementPercentOfOutstandingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="opk_JPMorganChaseMember" abstract="true" name="JPMorganChaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_ViforFreseniusMedicalCarePharmaLtdMember" abstract="true" name="ViforFreseniusMedicalCarePharmaLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_CollaborativeArrangementUpfrontPaymentShares" abstract="false" name="CollaborativeArrangementUpfrontPaymentShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" abstract="true" name="EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_DrFrostandMrPfennigerMember" abstract="true" name="DrFrostandMrPfennigerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_AgreementAndPlanOfMergerMember" abstract="true" name="AgreementAndPlanOfMergerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_SharesReceivedUponClosingofXeneticTransactionMember" abstract="true" name="SharesReceivedUponClosingofXeneticTransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_LineOfCreditFacilityRevolvingCommitmentDomain" abstract="true" name="LineOfCreditFacilityRevolvingCommitmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" abstract="true" name="LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_NeovascMember" abstract="true" name="NeovascMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_ConvertibleNotesMember" abstract="true" name="ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember" abstract="true" name="LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_LossContingencyMilestonePayment" abstract="false" name="LossContingencyMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_SecurityMember" abstract="true" name="SecurityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_EirGenPharmaLimitedMember" abstract="true" name="EirGenPharmaLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_ScotiabankMember" abstract="true" name="ScotiabankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_RelatedPartyTransactionShares" abstract="false" name="RelatedPartyTransactionShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_LineOfCreditFacilityRevolvingCommitmentAxis" abstract="true" name="LineOfCreditFacilityRevolvingCommitmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="opk_PharmsynthezMember" abstract="true" name="PharmsynthezMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_NIMSMember" abstract="true" name="NIMSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_ConsoorcioBankMember" abstract="true" name="ConsoorcioBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_RegulatoryAndDevelopmentMember" abstract="true" name="RegulatoryAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_SantanderBank2Member" abstract="true" name="SantanderBank2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_SharesSurrenderedInLieuOfCashPayment" abstract="false" name="SharesSurrenderedInLieuOfCashPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" abstract="false" name="StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets" abstract="false" name="EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" abstract="false" name="ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable" abstract="false" name="DebtInstrumentConvertibleDebtMaximumSharesIssuable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_FrostRealEstateHoldingsLLCMember" abstract="true" name="FrostRealEstateHoldingsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_CivilInvestigativeDemandsMember" abstract="true" name="CivilInvestigativeDemandsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_ClientPayersMember" abstract="true" name="ClientPayersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_WeightedAverageRemainingLeaseTermAbstract" abstract="true" name="WeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_InterestExpenseNonoperating" abstract="false" name="InterestExpenseNonoperating" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" abstract="true" name="LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale" abstract="false" name="CollaborativeArrangementPeriodFollowingFirstCommercialSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="opk_GainLossOnConversionOfDebt" abstract="false" name="GainLossOnConversionOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_HealthSnapMember" abstract="true" name="HealthSnapMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_StatesCitiesAndOtherMunicipalitiesMember" abstract="true" name="StatesCitiesAndOtherMunicipalitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" abstract="true" name="FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="opk_InterestIncomeNonoperating" abstract="false" name="InterestIncomeNonoperating" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="opk_CAMP4Member" abstract="true" name="CAMP4Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_CollaborativeArrangementMilestonePayment" abstract="false" name="CollaborativeArrangementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_ChanceryCourtOfDelawareVsCompanyMember" abstract="true" name="ChanceryCourtOfDelawareVsCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_BioReferenceMember" abstract="true" name="BioReferenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" abstract="false" name="ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_GenomicTestMember" abstract="true" name="GenomicTestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_EquityMethodInvestmentExcludingVariableInterestEntity" abstract="false" name="EquityMethodInvestmentExcludingVariableInterestEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_FederalAndStateGovernmentsMember" abstract="true" name="FederalAndStateGovernmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_SantanderBankMember" abstract="true" name="SantanderBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract" abstract="true" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_TaxesRecoverableCurrent" abstract="false" name="TaxesRecoverableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_Sema4Member" abstract="true" name="Sema4Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" abstract="true" name="FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_AccruedClinicalTrialsCurrent" abstract="false" name="AccruedClinicalTrialsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_TransitionTherapeuticsInc.Member" abstract="true" name="TransitionTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_RayaldeeMember" abstract="true" name="RayaldeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_OPKOMexicoMember" abstract="true" name="OPKOMexicoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_ChromaDexMember" abstract="true" name="ChromaDexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_DebtInstrumentsNumberofFinancialInstitutions" abstract="false" name="DebtInstrumentsNumberofFinancialInstitutions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="opk_CollaborativeArrangementDevelopmentMilestonePaymentShares" abstract="false" name="CollaborativeArrangementDevelopmentMilestonePaymentShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_ProductRegistrationsMember" abstract="true" name="ProductRegistrationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_IncreaseDecreaseinForeignCurrencyMeasurement" abstract="false" name="IncreaseDecreaseinForeignCurrencyMeasurement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_ChromadexCorporationMember" abstract="true" name="ChromadexCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock" abstract="false" name="CompositionOfCertainFinancialStatementCaptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_SalesMilestonesMember" abstract="true" name="SalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_DebtInstrumentRollForward" abstract="true" name="DebtInstrumentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_NotesPayableAndOtherLongTermLiabilitiesMember" abstract="true" name="NotesPayableAndOtherLongTermLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_EquitySecurityFVNIOwnershipPercent" abstract="false" name="EquitySecurityFVNIOwnershipPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="opk_ConvertibleSeniorNotesDue2025Member" abstract="true" name="ConvertibleSeniorNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_CocrystalMember" abstract="true" name="CocrystalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_WaterfordIrelandFacilityMember" abstract="true" name="WaterfordIrelandFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_NoncontrollingInterestSharesIssued" abstract="false" name="NoncontrollingInterestSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="opk_BusinessCombinationUpfrontConsiderationTransferred" abstract="false" name="BusinessCombinationUpfrontConsiderationTransferred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_OpkoChileMember" abstract="true" name="OpkoChileMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_PhaseThreeInitiationMember" abstract="true" name="PhaseThreeInitiationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_AccruedCommitmentsandContingenciesCurrent" abstract="false" name="AccruedCommitmentsandContingenciesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="opk_RoutineClinicalTestMember" abstract="true" name="RoutineClinicalTestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="opk_A5ConvertibleNotesMember" abstract="true" name="A5ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="opk_PaymentsForLeases" abstract="false" name="PaymentsForLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>opk-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b1bc5044-98fa-41ae-b2d0-b9b87eb185ce,g:64b4497f-89ba-4c5f-8ed3-b19012dfc871-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="opk-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e01bb69e-4544-4fb2-a0f9-c28f71fd0b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_dd2c93e7-bc94-492c-9a72-31b5417a035e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e01bb69e-4544-4fb2-a0f9-c28f71fd0b9d" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_dd2c93e7-bc94-492c-9a72-31b5417a035e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ffca82ba-c55a-4125-b83d-bcffbba3ced3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e01bb69e-4544-4fb2-a0f9-c28f71fd0b9d" xlink:to="loc_us-gaap_LiabilitiesCurrent_ffca82ba-c55a-4125-b83d-bcffbba3ced3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_b7a56d1c-fb08-4b0d-a9a2-f4e87415e7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3777af63-552d-4989-ad10-933c1b78d5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_b7a56d1c-fb08-4b0d-a9a2-f4e87415e7cd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3777af63-552d-4989-ad10-933c1b78d5fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_65378f9f-6b4a-4f32-adda-09188e8c057c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_b7a56d1c-fb08-4b0d-a9a2-f4e87415e7cd" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_65378f9f-6b4a-4f32-adda-09188e8c057c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_67bdcf4e-6d7e-4414-a2f7-e564bfe680c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_b7a56d1c-fb08-4b0d-a9a2-f4e87415e7cd" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_67bdcf4e-6d7e-4414-a2f7-e564bfe680c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_514a06b5-bcd1-4b12-b5c7-5dd80cd7e3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_b7a56d1c-fb08-4b0d-a9a2-f4e87415e7cd" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_514a06b5-bcd1-4b12-b5c7-5dd80cd7e3bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6561216a-237b-4c4a-a886-973bbbb1f99d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1fd6ef93-eefd-467e-a289-4de36a5944dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6561216a-237b-4c4a-a886-973bbbb1f99d" xlink:to="loc_us-gaap_CommonStockValue_1fd6ef93-eefd-467e-a289-4de36a5944dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_1c5cc0e5-ca3b-4f6a-9f28-52686a786d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6561216a-237b-4c4a-a886-973bbbb1f99d" xlink:to="loc_us-gaap_TreasuryStockValue_1c5cc0e5-ca3b-4f6a-9f28-52686a786d58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fe603010-dc62-4de6-9083-23c36d065da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6561216a-237b-4c4a-a886-973bbbb1f99d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fe603010-dc62-4de6-9083-23c36d065da5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2efdcf94-210f-4f54-b456-7138d9a87e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6561216a-237b-4c4a-a886-973bbbb1f99d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2efdcf94-210f-4f54-b456-7138d9a87e28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0cc9a74-b88b-4328-a57b-daff46b31dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6561216a-237b-4c4a-a886-973bbbb1f99d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0cc9a74-b88b-4328-a57b-daff46b31dc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e3f1b326-8226-4c57-9d64-bddacc2e7d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10e6ea98-6abd-49e8-9018-0702c4ba32a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e3f1b326-8226-4c57-9d64-bddacc2e7d08" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10e6ea98-6abd-49e8-9018-0702c4ba32a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_18fe294f-61dd-4729-8516-74214c0cbfec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e3f1b326-8226-4c57-9d64-bddacc2e7d08" xlink:to="loc_us-gaap_Liabilities_18fe294f-61dd-4729-8516-74214c0cbfec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b14fc539-d2ae-40d1-a2f4-380e4dae5676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_66bfa221-9d66-4ddb-afdd-4654cf81eb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b14fc539-d2ae-40d1-a2f4-380e4dae5676" xlink:to="loc_us-gaap_InventoryNet_66bfa221-9d66-4ddb-afdd-4654cf81eb1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_23ed500e-2ab0-48cb-bdd3-aa0191185609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b14fc539-d2ae-40d1-a2f4-380e4dae5676" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_23ed500e-2ab0-48cb-bdd3-aa0191185609" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_710a5fd8-de95-4b9a-946f-8a132bf47c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b14fc539-d2ae-40d1-a2f4-380e4dae5676" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_710a5fd8-de95-4b9a-946f-8a132bf47c83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a38ec0b6-08e8-4aa5-aa92-845b823dcc17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b14fc539-d2ae-40d1-a2f4-380e4dae5676" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a38ec0b6-08e8-4aa5-aa92-845b823dcc17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_67b6cbe8-54cf-4a52-a509-b213c1520cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b14fc539-d2ae-40d1-a2f4-380e4dae5676" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_67b6cbe8-54cf-4a52-a509-b213c1520cbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f691a1fb-62b4-4b2a-896b-8b78558ef156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8b8787dc-3245-4f67-b791-e9b30c1443fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f691a1fb-62b4-4b2a-896b-8b78558ef156" xlink:to="loc_us-gaap_AccountsPayableCurrent_8b8787dc-3245-4f67-b791-e9b30c1443fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_e1f41c84-48f7-48de-a8f2-338c858d0e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f691a1fb-62b4-4b2a-896b-8b78558ef156" xlink:to="loc_us-gaap_LinesOfCreditCurrent_e1f41c84-48f7-48de-a8f2-338c858d0e79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8d1e6177-3df1-4687-861e-20b500046465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f691a1fb-62b4-4b2a-896b-8b78558ef156" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8d1e6177-3df1-4687-861e-20b500046465" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c28a0673-7094-4777-af75-7f344999d738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f691a1fb-62b4-4b2a-896b-8b78558ef156" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c28a0673-7094-4777-af75-7f344999d738" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3b77aeee-c188-4bba-b2d5-d18b5becd86a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f691a1fb-62b4-4b2a-896b-8b78558ef156" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3b77aeee-c188-4bba-b2d5-d18b5becd86a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c9414e50-3b2b-466a-8fa5-2cb0151dd4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InProcessResearchandDevelopment_526b6e80-fd6c-4b16-9531-f1ecc870d825" xlink:href="opk-20220331.xsd#opk_InProcessResearchandDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c9414e50-3b2b-466a-8fa5-2cb0151dd4d3" xlink:to="loc_opk_InProcessResearchandDevelopment_526b6e80-fd6c-4b16-9531-f1ecc870d825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_46b40022-5607-4c21-82c5-e17e83de3ada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c9414e50-3b2b-466a-8fa5-2cb0151dd4d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_46b40022-5607-4c21-82c5-e17e83de3ada" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_c4ecc486-f26b-4c92-b920-19f512844fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c9414e50-3b2b-466a-8fa5-2cb0151dd4d3" xlink:to="loc_us-gaap_LongTermInvestments_c4ecc486-f26b-4c92-b920-19f512844fe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_785e2b28-0ca7-4b6e-a31f-3cb19f406b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c9414e50-3b2b-466a-8fa5-2cb0151dd4d3" xlink:to="loc_us-gaap_Goodwill_785e2b28-0ca7-4b6e-a31f-3cb19f406b43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_39d5116a-9271-4d43-88d3-4026ac026f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c9414e50-3b2b-466a-8fa5-2cb0151dd4d3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_39d5116a-9271-4d43-88d3-4026ac026f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_471d2b37-ad51-44ac-b233-e0c74dc8de73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c9414e50-3b2b-466a-8fa5-2cb0151dd4d3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_471d2b37-ad51-44ac-b233-e0c74dc8de73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_80e8f46d-2fe8-45c2-a237-4438bf6158ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c9414e50-3b2b-466a-8fa5-2cb0151dd4d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_80e8f46d-2fe8-45c2-a237-4438bf6158ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2ca53c67-89f3-44ec-aedc-dfb3bf21c10f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c9414e50-3b2b-466a-8fa5-2cb0151dd4d3" xlink:to="loc_us-gaap_AssetsCurrent_2ca53c67-89f3-44ec-aedc-dfb3bf21c10f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="opk-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c12ab31a-2461-486a-a040-fbd44aacac97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cb264692-f5fd-4afa-b6c9-c602e856227c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c12ab31a-2461-486a-a040-fbd44aacac97" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cb264692-f5fd-4afa-b6c9-c602e856227c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax_64bce9f1-5d22-478e-9e21-8614c069d789" xlink:href="opk-20220331.xsd#opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c12ab31a-2461-486a-a040-fbd44aacac97" xlink:to="loc_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax_64bce9f1-5d22-478e-9e21-8614c069d789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax_c5bd36e6-89a0-4c88-910c-8f0a8d4d782c" xlink:href="opk-20220331.xsd#opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1d85b158-cb30-4784-a53a-1d8855ce42dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax_c5bd36e6-89a0-4c88-910c-8f0a8d4d782c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1d85b158-cb30-4784-a53a-1d8855ce42dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f29e057f-2a66-40e1-9aa5-9e2238aa4a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax_c5bd36e6-89a0-4c88-910c-8f0a8d4d782c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f29e057f-2a66-40e1-9aa5-9e2238aa4a7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8c2db588-8f26-4586-946f-16bca540f223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1dd0e4d4-c9a8-4fcb-b2de-960a630d7996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8c2db588-8f26-4586-946f-16bca540f223" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1dd0e4d4-c9a8-4fcb-b2de-960a630d7996" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8c5dfc79-0cae-4b0c-bc44-b497605661fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8c2db588-8f26-4586-946f-16bca540f223" xlink:to="loc_us-gaap_OperatingExpenses_8c5dfc79-0cae-4b0c-bc44-b497605661fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32f3cbc1-91e9-4a0b-a598-9fbe5902f1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d16dfe93-3991-46d3-971d-9b6f8cb4550e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32f3cbc1-91e9-4a0b-a598-9fbe5902f1a1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d16dfe93-3991-46d3-971d-9b6f8cb4550e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5288bc62-419d-4ca8-8855-4ad97624a1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32f3cbc1-91e9-4a0b-a598-9fbe5902f1a1" xlink:to="loc_us-gaap_OperatingIncomeLoss_5288bc62-419d-4ca8-8855-4ad97624a1c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6b7c8a0e-1edc-4b68-aa81-c755b26da2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestIncomeNonoperating_6401c49e-1b09-4756-a1ff-9a934cf62230" xlink:href="opk-20220331.xsd#opk_InterestIncomeNonoperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6b7c8a0e-1edc-4b68-aa81-c755b26da2e2" xlink:to="loc_opk_InterestIncomeNonoperating_6401c49e-1b09-4756-a1ff-9a934cf62230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestExpenseNonoperating_1157899b-eba5-45e0-b935-19304e24599a" xlink:href="opk-20220331.xsd#opk_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6b7c8a0e-1edc-4b68-aa81-c755b26da2e2" xlink:to="loc_opk_InterestExpenseNonoperating_1157899b-eba5-45e0-b935-19304e24599a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_e354097e-8acb-46b0-8e20-18d7a04403e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6b7c8a0e-1edc-4b68-aa81-c755b26da2e2" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_e354097e-8acb-46b0-8e20-18d7a04403e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a80573df-0d3d-4e7b-9360-6b20c7851e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6b7c8a0e-1edc-4b68-aa81-c755b26da2e2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a80573df-0d3d-4e7b-9360-6b20c7851e11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_691bbe1b-b566-4e43-8672-a9ffbcab2298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3fc65824-916c-48e7-a256-ab9ca0676438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_691bbe1b-b566-4e43-8672-a9ffbcab2298" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3fc65824-916c-48e7-a256-ab9ca0676438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_46e529f3-f0df-4174-965b-617f72059a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_691bbe1b-b566-4e43-8672-a9ffbcab2298" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_46e529f3-f0df-4174-965b-617f72059a39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a1f59500-89e9-40ca-b4fa-db4376cad79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_691bbe1b-b566-4e43-8672-a9ffbcab2298" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a1f59500-89e9-40ca-b4fa-db4376cad79f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2f99518f-cb2e-47b1-979c-f659d7353a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_691bbe1b-b566-4e43-8672-a9ffbcab2298" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2f99518f-cb2e-47b1-979c-f659d7353a94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e82c2faf-368a-494c-a041-d9a1018010b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_691bbe1b-b566-4e43-8672-a9ffbcab2298" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e82c2faf-368a-494c-a041-d9a1018010b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="opk-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4c161f66-ec9d-4847-b32a-f7904a9c4ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0056f6fb-8309-4f95-b342-5fbb019fc101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4c161f66-ec9d-4847-b32a-f7904a9c4ce1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0056f6fb-8309-4f95-b342-5fbb019fc101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f5cbcc25-62e6-48ab-af64-049ebc741fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4c161f66-ec9d-4847-b32a-f7904a9c4ce1" xlink:to="loc_us-gaap_NetIncomeLoss_f5cbcc25-62e6-48ab-af64-049ebc741fc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="opk-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6eff9144-d0c7-405f-97e6-4cb1728e5ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6eff9144-d0c7-405f-97e6-4cb1728e5ab1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_236f3a10-18de-4276-9b6e-8d67b507e2be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_236f3a10-18de-4276-9b6e-8d67b507e2be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a5b4fa23-ac8c-4cca-8978-815389566ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a5b4fa23-ac8c-4cca-8978-815389566ef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7092c8f4-3f13-45e3-bb3a-8e55484dbc39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7092c8f4-3f13-45e3-bb3a-8e55484dbc39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8614b822-27ec-4fc1-96b8-3be34b3ac86a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_ShareBasedCompensation_8614b822-27ec-4fc1-96b8-3be34b3ac86a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_5f91a841-741d-43f6-9ce0-e310d86d8788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_5f91a841-741d-43f6-9ce0-e310d86d8788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_471736f8-acc7-4f9c-93ae-b3d6f183cb06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_471736f8-acc7-4f9c-93ae-b3d6f183cb06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_e1b711b4-488d-42e5-9ca0-4296520f9373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_PaidInKindInterest_e1b711b4-488d-42e5-9ca0-4296520f9373" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseinForeignCurrencyMeasurement_1eec93fa-c046-45f4-937c-b9e5bb71c495" xlink:href="opk-20220331.xsd#opk_IncreaseDecreaseinForeignCurrencyMeasurement"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_opk_IncreaseDecreaseinForeignCurrencyMeasurement_1eec93fa-c046-45f4-937c-b9e5bb71c495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cdc4692d-22e0-4eb5-a19c-fe0a83ac0c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cdc4692d-22e0-4eb5-a19c-fe0a83ac0c31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7cb77399-98be-4935-b288-1855a52ac515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_NetIncomeLoss_7cb77399-98be-4935-b288-1855a52ac515" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1e10b2d3-e3c7-4bea-bde6-ddfba1e37f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1e10b2d3-e3c7-4bea-bde6-ddfba1e37f91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_91e58267-41d9-4c25-93a3-44b51ec4b53f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_91e58267-41d9-4c25-93a3-44b51ec4b53f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1e20b402-6d1a-48e8-9dbd-c551d2bd23f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1e20b402-6d1a-48e8-9dbd-c551d2bd23f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a5a6d0fa-5998-44f9-8245-40c4c4f80411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a5a6d0fa-5998-44f9-8245-40c4c4f80411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1c66ee20-2316-41ac-a055-b8abe128fef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1c66ee20-2316-41ac-a055-b8abe128fef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments_116beb84-10fd-435c-a34e-008f0cc5d93f" xlink:href="opk-20220331.xsd#opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments_116beb84-10fd-435c-a34e-008f0cc5d93f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_43de3807-a80d-458e-b4d5-98d1ecdc2981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00d60824-4d61-45bc-a232-ebdedf13d510" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_43de3807-a80d-458e-b4d5-98d1ecdc2981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c53f0e89-a999-47db-9818-bba9b69a8154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_abc1a849-d55f-47e4-b4ce-7700a9c86c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c53f0e89-a999-47db-9818-bba9b69a8154" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_abc1a849-d55f-47e4-b4ce-7700a9c86c1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_9c118902-bcd8-4e7c-ada4-e9923517f50a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c53f0e89-a999-47db-9818-bba9b69a8154" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_9c118902-bcd8-4e7c-ada4-e9923517f50a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_a8a74fdf-2bbb-42cc-a5d0-7776324940c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c53f0e89-a999-47db-9818-bba9b69a8154" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_a8a74fdf-2bbb-42cc-a5d0-7776324940c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f99855a4-b7a7-4353-949e-dee85ab5ee41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_7ca0b0e7-844c-4ff7-955c-75dc629d1b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f99855a4-b7a7-4353-949e-dee85ab5ee41" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_7ca0b0e7-844c-4ff7-955c-75dc629d1b5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_9223b637-6ded-4744-af1a-9b08abd415d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f99855a4-b7a7-4353-949e-dee85ab5ee41" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_9223b637-6ded-4744-af1a-9b08abd415d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_15f686c3-ccba-4a5c-9993-d4cbe2f471c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f99855a4-b7a7-4353-949e-dee85ab5ee41" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_15f686c3-ccba-4a5c-9993-d4cbe2f471c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7fd2f585-a391-4961-adb3-69b27e3086e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9cb4ed7f-1675-4572-8869-430783adb613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7fd2f585-a391-4961-adb3-69b27e3086e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9cb4ed7f-1675-4572-8869-430783adb613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7cb03a30-250f-46e6-9541-fd3346199057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7fd2f585-a391-4961-adb3-69b27e3086e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7cb03a30-250f-46e6-9541-fd3346199057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_10e32155-c1a9-4325-bf64-91a21c1f8e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7fd2f585-a391-4961-adb3-69b27e3086e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_10e32155-c1a9-4325-bf64-91a21c1f8e56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_585c7ca4-5747-4c52-9791-8aa059b5f5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7fd2f585-a391-4961-adb3-69b27e3086e9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_585c7ca4-5747-4c52-9791-8aa059b5f5ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#CompositionofCertainFinancialStatementCaptionsDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6daefece-745e-4f5a-acd9-846b4919e85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_4fbee281-4e84-4e3c-9df6-85e874ce5704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6daefece-745e-4f5a-acd9-846b4919e85b" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_4fbee281-4e84-4e3c-9df6-85e874ce5704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2231875b-c14d-4a43-98a5-4daaed1a2cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6daefece-745e-4f5a-acd9-846b4919e85b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2231875b-c14d-4a43-98a5-4daaed1a2cbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedCommitmentsandContingenciesCurrent_614231df-211e-49b8-82e1-da5f3568682c" xlink:href="opk-20220331.xsd#opk_AccruedCommitmentsandContingenciesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6daefece-745e-4f5a-acd9-846b4919e85b" xlink:to="loc_opk_AccruedCommitmentsandContingenciesCurrent_614231df-211e-49b8-82e1-da5f3568682c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_74cf7160-e5e5-48b7-a425-9e1afe70eeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6daefece-745e-4f5a-acd9-846b4919e85b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_74cf7160-e5e5-48b7-a425-9e1afe70eeb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f83530ad-4bcf-4392-a473-f242a069a4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6daefece-745e-4f5a-acd9-846b4919e85b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f83530ad-4bcf-4392-a473-f242a069a4ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InventoryReceivedNotInvoicedCurrent_e4de7e0f-88bf-4a91-ba89-65ce86a290c5" xlink:href="opk-20220331.xsd#opk_InventoryReceivedNotInvoicedCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6daefece-745e-4f5a-acd9-846b4919e85b" xlink:to="loc_opk_InventoryReceivedNotInvoicedCurrent_e4de7e0f-88bf-4a91-ba89-65ce86a290c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_4f5b91b5-6cec-447a-8290-7468ed49376d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6daefece-745e-4f5a-acd9-846b4919e85b" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_4f5b91b5-6cec-447a-8290-7468ed49376d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_e2a865cb-ca6b-443d-b52c-7e9954017a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6daefece-745e-4f5a-acd9-846b4919e85b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_e2a865cb-ca6b-443d-b52c-7e9954017a88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedClinicalTrialsCurrent_ea027dd7-1de4-4e2a-9ba4-5073169566b5" xlink:href="opk-20220331.xsd#opk_AccruedClinicalTrialsCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6daefece-745e-4f5a-acd9-846b4919e85b" xlink:to="loc_opk_AccruedClinicalTrialsCurrent_ea027dd7-1de4-4e2a-9ba4-5073169566b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7581e44e-d511-4a9d-856b-2bd5bffc3c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_20ad3186-daa4-4a3c-8305-5b5c4a88fb43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_7581e44e-d511-4a9d-856b-2bd5bffc3c75" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_20ad3186-daa4-4a3c-8305-5b5c4a88fb43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_efba54c7-d532-4d73-8804-0928e752b8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_7581e44e-d511-4a9d-856b-2bd5bffc3c75" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_efba54c7-d532-4d73-8804-0928e752b8f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fc5217ad-7c0a-4178-a62a-e716143ab26a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_f6a61671-4f0a-48f9-91c4-30403d002e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_fc5217ad-7c0a-4178-a62a-e716143ab26a" xlink:to="loc_us-gaap_OtherInventorySupplies_f6a61671-4f0a-48f9-91c4-30403d002e87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_34f1aa67-d28f-449d-8259-691adbff4155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_fc5217ad-7c0a-4178-a62a-e716143ab26a" xlink:to="loc_us-gaap_InventoryFinishedGoods_34f1aa67-d28f-449d-8259-691adbff4155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_a83cdb2c-55d0-4de3-a656-85fda97ca582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_fc5217ad-7c0a-4178-a62a-e716143ab26a" xlink:to="loc_us-gaap_InventoryWorkInProcess_a83cdb2c-55d0-4de3-a656-85fda97ca582" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_3b64a2ab-2b56-4db6-a77c-0c5d1b9e3ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_fc5217ad-7c0a-4178-a62a-e716143ab26a" xlink:to="loc_us-gaap_InventoryRawMaterials_3b64a2ab-2b56-4db6-a77c-0c5d1b9e3ded" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_519ae551-c1c5-400a-8664-53ff3924bd90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_fc5217ad-7c0a-4178-a62a-e716143ab26a" xlink:to="loc_us-gaap_InventoryValuationReserves_519ae551-c1c5-400a-8664-53ff3924bd90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_547b07bf-9e42-4df8-9ac8-8f0cc3ca498e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fbc2171a-b874-474a-936b-1b35ae2b1c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_547b07bf-9e42-4df8-9ac8-8f0cc3ca498e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fbc2171a-b874-474a-936b-1b35ae2b1c68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_c7c42ba7-a967-4526-a837-99203a826e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_547b07bf-9e42-4df8-9ac8-8f0cc3ca498e" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent_c7c42ba7-a967-4526-a837-99203a826e50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b67b7eb8-8271-4143-8398-c06a148032ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_547b07bf-9e42-4df8-9ac8-8f0cc3ca498e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b67b7eb8-8271-4143-8398-c06a148032ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_17637da1-a1e9-48bc-911e-413bdca3e6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_547b07bf-9e42-4df8-9ac8-8f0cc3ca498e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_17637da1-a1e9-48bc-911e-413bdca3e6f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_572922b5-e515-4ab7-9bae-4f5e35b68fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_547b07bf-9e42-4df8-9ac8-8f0cc3ca498e" xlink:to="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_572922b5-e515-4ab7-9bae-4f5e35b68fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_18cc8a6b-4c97-479b-bcfd-527ca56b66a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TaxesRecoverableCurrent_8e5616d5-421f-484b-a686-311f5b09cd13" xlink:href="opk-20220331.xsd#opk_TaxesRecoverableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_18cc8a6b-4c97-479b-bcfd-527ca56b66a7" xlink:to="loc_opk_TaxesRecoverableCurrent_8e5616d5-421f-484b-a686-311f5b09cd13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_e1f66a79-6ab4-411d-aa3b-887ae4da4a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_18cc8a6b-4c97-479b-bcfd-527ca56b66a7" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_e1f66a79-6ab4-411d-aa3b-887ae4da4a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_13b58fab-b74a-4a30-9f10-44435a8d3a10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Supplies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_18cc8a6b-4c97-479b-bcfd-527ca56b66a7" xlink:to="loc_us-gaap_Supplies_13b58fab-b74a-4a30-9f10-44435a8d3a10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_255f584b-3c28-4fc1-83ba-934ef0e1cf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_18cc8a6b-4c97-479b-bcfd-527ca56b66a7" xlink:to="loc_us-gaap_PrepaidInsurance_255f584b-3c28-4fc1-83ba-934ef0e1cf8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2c575cf0-2e8c-4a63-8275-5178546dda6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_18cc8a6b-4c97-479b-bcfd-527ca56b66a7" xlink:to="loc_us-gaap_OtherAssetsCurrent_2c575cf0-2e8c-4a63-8275-5178546dda6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c0647282-f17a-4e26-951d-330588ae198a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_774d1613-7e6e-433f-a5c5-7be00d4f6abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c0647282-f17a-4e26-951d-330588ae198a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_774d1613-7e6e-433f-a5c5-7be00d4f6abe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8528a949-51c5-4d25-ae8c-9e18335e4d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c0647282-f17a-4e26-951d-330588ae198a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8528a949-51c5-4d25-ae8c-9e18335e4d4c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_3ab5af84-99eb-43b1-ba6b-846170b33f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentExcludingVariableInterestEntity_89cc2f7e-0af1-4fa2-98f5-245c814e86ad" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentExcludingVariableInterestEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_3ab5af84-99eb-43b1-ba6b-846170b33f6b" xlink:to="loc_opk_EquityMethodInvestmentExcludingVariableInterestEntity_89cc2f7e-0af1-4fa2-98f5-245c814e86ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentVariableInterestEntity_abdb7c35-1728-48b4-8dcf-4abc9a1060e6" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentVariableInterestEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_3ab5af84-99eb-43b1-ba6b-846170b33f6b" xlink:to="loc_opk_EquityMethodInvestmentVariableInterestEntity_abdb7c35-1728-48b4-8dcf-4abc9a1060e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_703ba241-5a4c-453c-9763-9bf04f99950d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_3ab5af84-99eb-43b1-ba6b-846170b33f6b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_703ba241-5a4c-453c-9763-9bf04f99950d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_24c05ccd-fbda-40e6-8b1f-27319c524298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_3ab5af84-99eb-43b1-ba6b-846170b33f6b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_24c05ccd-fbda-40e6-8b1f-27319c524298" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockOptionandWarrantInvestments_3b00ca0d-a035-4ddc-990c-81daae00e255" xlink:href="opk-20220331.xsd#opk_StockOptionandWarrantInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_3ab5af84-99eb-43b1-ba6b-846170b33f6b" xlink:to="loc_opk_StockOptionandWarrantInvestments_3b00ca0d-a035-4ddc-990c-81daae00e255" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d33ed306-74f2-4274-8f3e-04039aaa3be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_48d8a019-2a1c-4069-ac69-faaa517cdbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d33ed306-74f2-4274-8f3e-04039aaa3be0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_48d8a019-2a1c-4069-ac69-faaa517cdbbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f1918afa-a1e1-4522-8658-76738bf65da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d33ed306-74f2-4274-8f3e-04039aaa3be0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f1918afa-a1e1-4522-8658-76738bf65da5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtScheduleofNotesDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DebtScheduleofNotesDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/DebtScheduleofNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_6b07f21d-8971-43fa-9bc0-2070f7bf6f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_783e9ba9-cf3d-40a1-bdb6-64f4f1a825ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_6b07f21d-8971-43fa-9bc0-2070f7bf6f50" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_783e9ba9-cf3d-40a1-bdb6-64f4f1a825ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_4b559df7-53b8-425e-869e-2656f34def0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_6b07f21d-8971-43fa-9bc0-2070f7bf6f50" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_4b559df7-53b8-425e-869e-2656f34def0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5ddc467a-2430-495e-a146-04002e1cced0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_416885a0-b0ab-474a-8be6-f709647eb4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5ddc467a-2430-495e-a146-04002e1cced0" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_416885a0-b0ab-474a-8be6-f709647eb4b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_88da2331-91d4-4ff6-849b-e696335773bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5ddc467a-2430-495e-a146-04002e1cced0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_88da2331-91d4-4ff6-849b-e696335773bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_bc934908-9140-459d-b1ec-043cbf84e2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5ddc467a-2430-495e-a146-04002e1cced0" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_bc934908-9140-459d-b1ec-043cbf84e2dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DebtNotesPayableandOtherDebtDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c665b6e2-e7cd-4332-9960-8bc786c08a02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_69ba3543-ae74-4a61-8abc-7a4dbf724960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c665b6e2-e7cd-4332-9960-8bc786c08a02" xlink:to="loc_us-gaap_LongTermDebtCurrent_69ba3543-ae74-4a61-8abc-7a4dbf724960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d2048946-9999-4062-9345-766ba0339979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c665b6e2-e7cd-4332-9960-8bc786c08a02" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d2048946-9999-4062-9345-766ba0339979" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_56b43b8d-26e7-4e0d-812d-7ef8fa504f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_eb9b024d-4aa0-47ab-ba4c-af543ba0dae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_56b43b8d-26e7-4e0d-812d-7ef8fa504f23" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_eb9b024d-4aa0-47ab-ba4c-af543ba0dae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_08cc1120-0db5-48b6-8296-24fc086500ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_56b43b8d-26e7-4e0d-812d-7ef8fa504f23" xlink:to="loc_us-gaap_DerivativeAssets_08cc1120-0db5-48b6-8296-24fc086500ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6a6d953d-9e8d-4263-80c6-181df5a5042f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fe2378b8-2363-4b4c-a771-35b994624cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6a6d953d-9e8d-4263-80c6-181df5a5042f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fe2378b8-2363-4b4c-a771-35b994624cea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_a5ff2b5e-4520-450d-9815-b10be20b599d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6a6d953d-9e8d-4263-80c6-181df5a5042f" xlink:to="loc_us-gaap_DerivativeLiabilities_a5ff2b5e-4520-450d-9815-b10be20b599d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#LeasesLeaseLiabilityMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8b803292-2942-497f-b605-9bd0b43307c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_83717a3c-07b2-4331-9a59-0cae6d7f3d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8b803292-2942-497f-b605-9bd0b43307c3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_83717a3c-07b2-4331-9a59-0cae6d7f3d85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_3d873f04-bed6-4e99-979f-b6758adf86bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8b803292-2942-497f-b605-9bd0b43307c3" xlink:to="loc_us-gaap_FinanceLeaseLiability_3d873f04-bed6-4e99-979f-b6758adf86bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a042f8e1-8faa-429e-9d48-fafb5c6ea2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_759da937-7d1e-4230-a372-ceae0bd01cd9" xlink:href="opk-20220331.xsd#opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a042f8e1-8faa-429e-9d48-fafb5c6ea2cb" xlink:to="loc_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_759da937-7d1e-4230-a372-ceae0bd01cd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e4255551-e050-4178-a13d-fdaf945ab87d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a042f8e1-8faa-429e-9d48-fafb5c6ea2cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e4255551-e050-4178-a13d-fdaf945ab87d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c8680c9-bb8f-42c8-b4ff-1ee5a691f0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a042f8e1-8faa-429e-9d48-fafb5c6ea2cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c8680c9-bb8f-42c8-b4ff-1ee5a691f0c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bb5894b7-af91-4707-9ce6-859ff9f33417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a042f8e1-8faa-429e-9d48-fafb5c6ea2cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bb5894b7-af91-4707-9ce6-859ff9f33417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_03106594-a64d-432f-a64b-482b1112e500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a042f8e1-8faa-429e-9d48-fafb5c6ea2cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_03106594-a64d-432f-a64b-482b1112e500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b94c59c0-294e-4ffd-a915-4e5e54a02423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a042f8e1-8faa-429e-9d48-fafb5c6ea2cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b94c59c0-294e-4ffd-a915-4e5e54a02423" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1" xlink:type="simple" xlink:href="opk-20220331.xsd#LeasesLeaseLiabilityMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a0b76729-62f0-4335-a13e-2af5577a0838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_40e0aebd-2a6f-4799-a07b-5fcf62e6d796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a0b76729-62f0-4335-a13e-2af5577a0838" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_40e0aebd-2a6f-4799-a07b-5fcf62e6d796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_22ab0e02-2d02-4404-93b1-84e27a491ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a0b76729-62f0-4335-a13e-2af5577a0838" xlink:to="loc_us-gaap_OperatingLeaseLiability_22ab0e02-2d02-4404-93b1-84e27a491ad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b22fd7e6-666c-42aa-95e3-37828119a73d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_beef1103-374d-4283-beac-68fc6dd61f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b22fd7e6-666c-42aa-95e3-37828119a73d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_beef1103-374d-4283-beac-68fc6dd61f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour_949347a4-ea70-4a9a-8117-c15f53b60746" xlink:href="opk-20220331.xsd#opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b22fd7e6-666c-42aa-95e3-37828119a73d" xlink:to="loc_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour_949347a4-ea70-4a9a-8117-c15f53b60746" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a0077240-7c57-4e8a-8c1b-35820c27c3df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b22fd7e6-666c-42aa-95e3-37828119a73d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a0077240-7c57-4e8a-8c1b-35820c27c3df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0cc3be9c-77cb-443c-9b2c-c7af5a8153e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b22fd7e6-666c-42aa-95e3-37828119a73d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0cc3be9c-77cb-443c-9b2c-c7af5a8153e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_5dc11b3f-cb59-455c-9cb0-c597c4bc1085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b22fd7e6-666c-42aa-95e3-37828119a73d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_5dc11b3f-cb59-455c-9cb0-c597c4bc1085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_28e310de-3c98-4094-9476-92ccb2d5d8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b22fd7e6-666c-42aa-95e3-37828119a73d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_28e310de-3c98-4094-9476-92ccb2d5d8bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#LeasesLeaseCashFlowInformationDetails"/>
  <link:calculationLink xlink:role="http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_opk_PaymentsForLeases_8bed92c9-bbe8-4b62-8fef-3e0a03fc922e" xlink:href="opk-20220331.xsd#opk_PaymentsForLeases"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5c25b847-6dc2-4c70-9453-9e451f60529d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_opk_PaymentsForLeases_8bed92c9-bbe8-4b62-8fef-3e0a03fc922e" xlink:to="loc_us-gaap_OperatingLeasePayments_5c25b847-6dc2-4c70-9453-9e451f60529d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_348078bc-3a4f-4dc2-8ad4-151376752c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_opk_PaymentsForLeases_8bed92c9-bbe8-4b62-8fef-3e0a03fc922e" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_348078bc-3a4f-4dc2-8ad4-151376752c42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_4b411ba4-443b-4b39-b4bf-d66826240c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_opk_PaymentsForLeases_8bed92c9-bbe8-4b62-8fef-3e0a03fc922e" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_4b411ba4-443b-4b39-b4bf-d66826240c58" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>opk-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b1bc5044-98fa-41ae-b2d0-b9b87eb185ce,g:64b4497f-89ba-4c5f-8ed3-b19012dfc871-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="opk-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i4b2bc1aa283c4c86a10d94af03cffd89_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_57e6530b-2533-47e5-9f1c-97f5a36d9177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_RevenuesAbstract_57e6530b-2533-47e5-9f1c-97f5a36d9177" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a87aa26-0549-48e0-83a9-84b5cabefd67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_57e6530b-2533-47e5-9f1c-97f5a36d9177" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a87aa26-0549-48e0-83a9-84b5cabefd67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1cd2cd8c-cece-4b8d-8711-d6ebf5a3d538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1cd2cd8c-cece-4b8d-8711-d6ebf5a3d538" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c52ca1d7-dedf-4c3c-9ee4-bea6f6d1c8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c52ca1d7-dedf-4c3c-9ee4-bea6f6d1c8c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61a2cdd0-c776-42cc-a533-241854adab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61a2cdd0-c776-42cc-a533-241854adab1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e47e49fa-d707-4f9b-bfd5-9d3ef7d58a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e47e49fa-d707-4f9b-bfd5-9d3ef7d58a7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1591caa3-dea9-4469-a8ee-1564bb807c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1591caa3-dea9-4469-a8ee-1564bb807c23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3d4c04b9-ded1-49c2-8e72-f6b87dfc2b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:to="loc_us-gaap_OperatingExpenses_3d4c04b9-ded1-49c2-8e72-f6b87dfc2b7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f5ab2b80-700c-48a8-9f2a-4a5129719e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_OperatingIncomeLoss_f5ab2b80-700c-48a8-9f2a-4a5129719e56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e73cb9b2-dfd4-4b10-9cba-f284927c2fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e73cb9b2-dfd4-4b10-9cba-f284927c2fc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestIncomeNonoperating_78b91f75-57d7-4241-baed-0543e7d68ac5" xlink:href="opk-20220331.xsd#opk_InterestIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e73cb9b2-dfd4-4b10-9cba-f284927c2fc7" xlink:to="loc_opk_InterestIncomeNonoperating_78b91f75-57d7-4241-baed-0543e7d68ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestExpenseNonoperating_c5d74e3b-a4e1-4433-8172-b93614bac25f" xlink:href="opk-20220331.xsd#opk_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e73cb9b2-dfd4-4b10-9cba-f284927c2fc7" xlink:to="loc_opk_InterestExpenseNonoperating_c5d74e3b-a4e1-4433-8172-b93614bac25f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_5ee5ef8a-05e4-400d-924c-9d3826eebaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e73cb9b2-dfd4-4b10-9cba-f284927c2fc7" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_5ee5ef8a-05e4-400d-924c-9d3826eebaf4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_37571fff-b817-42ec-8442-b259c98ede72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e73cb9b2-dfd4-4b10-9cba-f284927c2fc7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_37571fff-b817-42ec-8442-b259c98ede72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6309772f-9abe-427c-89a2-2d2a8e6fef99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e73cb9b2-dfd4-4b10-9cba-f284927c2fc7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6309772f-9abe-427c-89a2-2d2a8e6fef99" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dab5d3e3-ff8b-4e5e-a785-a21eced34aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dab5d3e3-ff8b-4e5e-a785-a21eced34aee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e74d6400-04fa-404d-97ad-2e93874c4ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e74d6400-04fa-404d-97ad-2e93874c4ed3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax_0cce8459-14c8-4770-b7e2-4d70ee758b07" xlink:href="opk-20220331.xsd#opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax_0cce8459-14c8-4770-b7e2-4d70ee758b07" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0dddf4f5-ec41-4084-b6cd-eaafad6bcc79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0dddf4f5-ec41-4084-b6cd-eaafad6bcc79" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ab9f4db2-b34d-4131-a672-3087d80ced64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_NetIncomeLoss_ab9f4db2-b34d-4131-a672-3087d80ced64" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_37a0910a-dad2-4871-8b9c-c741a736f2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_EarningsPerShareAbstract_37a0910a-dad2-4871-8b9c-c741a736f2f9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b14d868f-ae42-4998-9bf9-25cbbff32e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37a0910a-dad2-4871-8b9c-c741a736f2f9" xlink:to="loc_us-gaap_EarningsPerShareBasic_b14d868f-ae42-4998-9bf9-25cbbff32e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_054fb6a5-1a90-4914-be5b-2b829b45d3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37a0910a-dad2-4871-8b9c-c741a736f2f9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_054fb6a5-1a90-4914-be5b-2b829b45d3ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dd05403f-d0eb-47a8-9a15-ab494fc5e779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dd05403f-d0eb-47a8-9a15-ab494fc5e779" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb448668-5046-40af-83c6-2e25d0c487f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb448668-5046-40af-83c6-2e25d0c487f6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ae257dfc-3539-480a-8176-19e454434db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_StatementTable_ae257dfc-3539-480a-8176-19e454434db3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ab306190-b450-4150-9934-cadd7a929e1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ae257dfc-3539-480a-8176-19e454434db3" xlink:to="loc_srt_ProductOrServiceAxis_ab306190-b450-4150-9934-cadd7a929e1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab306190-b450-4150-9934-cadd7a929e1f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ab306190-b450-4150-9934-cadd7a929e1f" xlink:to="loc_srt_ProductsAndServicesDomain_ab306190-b450-4150-9934-cadd7a929e1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b81d842-82bf-43c7-9d00-840770a9189b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ab306190-b450-4150-9934-cadd7a929e1f" xlink:to="loc_srt_ProductsAndServicesDomain_8b81d842-82bf-43c7-9d00-840770a9189b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_99f804fb-0930-4305-a049-2cbe10b5c18c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8b81d842-82bf-43c7-9d00-840770a9189b" xlink:to="loc_us-gaap_ServiceMember_99f804fb-0930-4305-a049-2cbe10b5c18c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4bb9c55f-ced6-4269-84b4-5eba299b00a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8b81d842-82bf-43c7-9d00-840770a9189b" xlink:to="loc_us-gaap_ProductMember_4bb9c55f-ced6-4269-84b4-5eba299b00a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_65beabff-7799-421d-b6ed-1cd65b268752" xlink:href="opk-20220331.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8b81d842-82bf-43c7-9d00-840770a9189b" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_65beabff-7799-421d-b6ed-1cd65b268752" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="opk-20220331.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended" id="i00585325f8564d56a076de73bfa3ae24_CONSOLIDATEDSTATEMENTSOFEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ef13f2b9-3e06-4f53-800c-8dd19e470bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ef13f2b9-3e06-4f53-800c-8dd19e470bc4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_04c6700f-8eef-4c56-ab23-1954b7768194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_SharesIssued_04c6700f-8eef-4c56-ab23-1954b7768194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_86a6f4ef-7d78-4c2d-ad53-b208f6abd1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_86a6f4ef-7d78-4c2d-ad53-b208f6abd1b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_aee84bde-eb49-40f0-af17-4130d7eab0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_aee84bde-eb49-40f0-af17-4130d7eab0b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d26d47c1-6463-4160-8029-fd1996f96477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d26d47c1-6463-4160-8029-fd1996f96477" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_15a1d07b-75b8-4370-a9ce-fc57f7adad5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_15a1d07b-75b8-4370-a9ce-fc57f7adad5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_79c6c5c4-1d38-4a5e-8140-b42ed2a81559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_NetIncomeLoss_79c6c5c4-1d38-4a5e-8140-b42ed2a81559" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e5e6fba9-e627-4849-9ab1-aeacd1e6cb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e5e6fba9-e627-4849-9ab1-aeacd1e6cb1a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_528e350c-583a-43e6-b833-65d9f877de4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59548c0e-40fa-4449-9125-aeed82fed3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_520a1a06-b9c4-404d-888f-91727296bde3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ef13f2b9-3e06-4f53-800c-8dd19e470bc4" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_520a1a06-b9c4-404d-888f-91727296bde3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_645fa22c-371a-474e-b929-4d469812b415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ef13f2b9-3e06-4f53-800c-8dd19e470bc4" xlink:to="loc_us-gaap_StatementTable_645fa22c-371a-474e-b929-4d469812b415" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_45ea1c58-8d5d-4c12-8add-0d460a3b4a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_645fa22c-371a-474e-b929-4d469812b415" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_45ea1c58-8d5d-4c12-8add-0d460a3b4a9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_45ea1c58-8d5d-4c12-8add-0d460a3b4a9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_45ea1c58-8d5d-4c12-8add-0d460a3b4a9a" xlink:to="loc_us-gaap_EquityComponentDomain_45ea1c58-8d5d-4c12-8add-0d460a3b4a9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_befd2af6-2874-420c-a70c-b04dd21169c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_45ea1c58-8d5d-4c12-8add-0d460a3b4a9a" xlink:to="loc_us-gaap_EquityComponentDomain_befd2af6-2874-420c-a70c-b04dd21169c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_069ab135-f46f-4463-b4b5-290cf349b857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_befd2af6-2874-420c-a70c-b04dd21169c4" xlink:to="loc_us-gaap_CommonStockMember_069ab135-f46f-4463-b4b5-290cf349b857" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_4ccadd0c-d130-4dad-bb27-981af6e68838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_befd2af6-2874-420c-a70c-b04dd21169c4" xlink:to="loc_us-gaap_TreasuryStockMember_4ccadd0c-d130-4dad-bb27-981af6e68838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_399f80ec-aa03-4a93-9350-ce324a25bc64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_befd2af6-2874-420c-a70c-b04dd21169c4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_399f80ec-aa03-4a93-9350-ce324a25bc64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_24dca3bb-5e9f-4961-ab49-51499c59a814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_befd2af6-2874-420c-a70c-b04dd21169c4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_24dca3bb-5e9f-4961-ab49-51499c59a814" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f52f6d35-6b31-4cb8-ae7a-0ea21be53688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_befd2af6-2874-420c-a70c-b04dd21169c4" xlink:to="loc_us-gaap_RetainedEarningsMember_f52f6d35-6b31-4cb8-ae7a-0ea21be53688" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_916ebb34-7bf8-4aee-b8b8-64a22c74b945" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_645fa22c-371a-474e-b929-4d469812b415" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_916ebb34-7bf8-4aee-b8b8-64a22c74b945" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_916ebb34-7bf8-4aee-b8b8-64a22c74b945_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_916ebb34-7bf8-4aee-b8b8-64a22c74b945" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_916ebb34-7bf8-4aee-b8b8-64a22c74b945_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ed1deea9-6ef3-4fb3-828b-c187b604c71a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_916ebb34-7bf8-4aee-b8b8-64a22c74b945" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ed1deea9-6ef3-4fb3-828b-c187b604c71a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fac982ab-5861-44df-8ba2-888d4cec017d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ed1deea9-6ef3-4fb3-828b-c187b604c71a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fac982ab-5861-44df-8ba2-888d4cec017d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/BusinessandOrganizationDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#BusinessandOrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/BusinessandOrganizationDetails" xlink:type="extended" id="i6844702cc1284103b2fc3a270b32e235_BusinessandOrganizationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NumberofSalesEmployees_79c5f234-0b72-4063-b59f-28e09549ca75" xlink:href="opk-20220331.xsd#opk_NumberofSalesEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_opk_NumberofSalesEmployees_79c5f234-0b72-4063-b59f-28e09549ca75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8fc10641-60df-42b6-8e3a-f3ad26b83ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8fc10641-60df-42b6-8e3a-f3ad26b83ffd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_783e80c9-3cdb-4aa2-b911-aeb9cf6e80f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_783e80c9-3cdb-4aa2-b911-aeb9cf6e80f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments_1835f00c-6469-4a02-ab92-9d7d940a9ef9" xlink:href="opk-20220331.xsd#opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments_1835f00c-6469-4a02-ab92-9d7d940a9ef9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod_55719ee1-b3c5-472f-a215-5b2f4b591117" xlink:href="opk-20220331.xsd#opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod_55719ee1-b3c5-472f-a215-5b2f4b591117" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationUpfrontConsiderationTransferred_02cb486b-6a89-4c5a-85fe-e472aa843f2d" xlink:href="opk-20220331.xsd#opk_BusinessCombinationUpfrontConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_opk_BusinessCombinationUpfrontConsiderationTransferred_02cb486b-6a89-4c5a-85fe-e472aa843f2d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a30d02ff-a34a-4f75-bbef-6b7f5b2c1de1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a30d02ff-a34a-4f75-bbef-6b7f5b2c1de1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DisposalGroupNumberOfFacilitiesSold_bfe4fd9c-7586-466d-ad4b-616ec2332135" xlink:href="opk-20220331.xsd#opk_DisposalGroupNumberOfFacilitiesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_opk_DisposalGroupNumberOfFacilitiesSold_bfe4fd9c-7586-466d-ad4b-616ec2332135" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_405eb7cf-37d9-40d1-abf0-8e073131ead7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_405eb7cf-37d9-40d1-abf0-8e073131ead7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_619a1c13-2cb2-4b53-a623-ea8a4b55a718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_619a1c13-2cb2-4b53-a623-ea8a4b55a718" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_15dfe042-6582-497d-9793-6824c66e2563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_15dfe042-6582-497d-9793-6824c66e2563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_15dfe042-6582-497d-9793-6824c66e2563_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_15dfe042-6582-497d-9793-6824c66e2563" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_15dfe042-6582-497d-9793-6824c66e2563_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ecfc9888-cd94-4870-b6cc-f34e3950f997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_15dfe042-6582-497d-9793-6824c66e2563" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ecfc9888-cd94-4870-b6cc-f34e3950f997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8b47a530-0080-4160-ba56-6ced9c7e1cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ecfc9888-cd94-4870-b6cc-f34e3950f997" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8b47a530-0080-4160-ba56-6ced9c7e1cd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7fa034f7-279f-4bbc-8b9d-ebc91f596267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7fa034f7-279f-4bbc-8b9d-ebc91f596267" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7fa034f7-279f-4bbc-8b9d-ebc91f596267_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7fa034f7-279f-4bbc-8b9d-ebc91f596267" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7fa034f7-279f-4bbc-8b9d-ebc91f596267_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_69988bc7-6716-4c38-a22b-82bcef0eb8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7fa034f7-279f-4bbc-8b9d-ebc91f596267" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_69988bc7-6716-4c38-a22b-82bcef0eb8d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_WaterfordIrelandFacilityMember_bc68f846-6ebc-4962-adde-4193493e1c14" xlink:href="opk-20220331.xsd#opk_WaterfordIrelandFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_69988bc7-6716-4c38-a22b-82bcef0eb8d7" xlink:to="loc_opk_WaterfordIrelandFacilityMember_bc68f846-6ebc-4962-adde-4193493e1c14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_af4b305d-d68b-47cf-a58d-834748aa42f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_af4b305d-d68b-47cf-a58d-834748aa42f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af4b305d-d68b-47cf-a58d-834748aa42f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_af4b305d-d68b-47cf-a58d-834748aa42f7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af4b305d-d68b-47cf-a58d-834748aa42f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_823c4d2a-bada-4dd5-946d-9d1f7728ca6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_af4b305d-d68b-47cf-a58d-834748aa42f7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_823c4d2a-bada-4dd5-946d-9d1f7728ca6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DetectGenomixMember_77e5fd73-2839-4da0-949f-5ed0e8cced00" xlink:href="opk-20220331.xsd#opk_DetectGenomixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_823c4d2a-bada-4dd5-946d-9d1f7728ca6f" xlink:to="loc_opk_DetectGenomixMember_77e5fd73-2839-4da0-949f-5ed0e8cced00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_03ef1b33-40d1-4b34-a871-3d423217237b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:to="loc_dei_LegalEntityAxis_03ef1b33-40d1-4b34-a871-3d423217237b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_03ef1b33-40d1-4b34-a871-3d423217237b_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_03ef1b33-40d1-4b34-a871-3d423217237b" xlink:to="loc_dei_EntityDomain_03ef1b33-40d1-4b34-a871-3d423217237b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2836ca25-a968-4c60-be77-35e895c525df" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_03ef1b33-40d1-4b34-a871-3d423217237b" xlink:to="loc_dei_EntityDomain_2836ca25-a968-4c60-be77-35e895c525df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_Sema4Member_224c32da-c74b-41dc-8d24-66815360fcde" xlink:href="opk-20220331.xsd#opk_Sema4Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2836ca25-a968-4c60-be77-35e895c525df" xlink:to="loc_opk_Sema4Member_224c32da-c74b-41dc-8d24-66815360fcde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_559cdd3f-76fa-4d34-86fe-2b7826113aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_559cdd3f-76fa-4d34-86fe-2b7826113aaa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_559cdd3f-76fa-4d34-86fe-2b7826113aaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_559cdd3f-76fa-4d34-86fe-2b7826113aaa" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_559cdd3f-76fa-4d34-86fe-2b7826113aaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a52af880-0743-49fa-bb14-02d2ef098b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_559cdd3f-76fa-4d34-86fe-2b7826113aaa" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a52af880-0743-49fa-bb14-02d2ef098b4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_29c61cab-1c10-4193-8078-c5d9468b7ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a52af880-0743-49fa-bb14-02d2ef098b4c" xlink:to="loc_us-gaap_SubsequentEventMember_29c61cab-1c10-4193-8078-c5d9468b7ee0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/ImpactofCOVID19Details" xlink:type="simple" xlink:href="opk-20220331.xsd#ImpactofCOVID19Details"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/ImpactofCOVID19Details" xlink:type="extended" id="ib64bae31e1274b1583c2bfaeb88f0ad4_ImpactofCOVID19Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_8a16dfd3-2107-4981-aada-c7ad42f4ca9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_a4a1763c-47b1-434d-9e0f-7c68967c48c7" xlink:href="opk-20220331.xsd#opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_8a16dfd3-2107-4981-aada-c7ad42f4ca9a" xlink:to="loc_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_a4a1763c-47b1-434d-9e0f-7c68967c48c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChangeInTestingVolumePercent_cf3686c4-ba3f-4726-8f27-059a08120cc5" xlink:href="opk-20220331.xsd#opk_ChangeInTestingVolumePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_8a16dfd3-2107-4981-aada-c7ad42f4ca9a" xlink:to="loc_opk_ChangeInTestingVolumePercent_cf3686c4-ba3f-4726-8f27-059a08120cc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b7a2fca8-9bcf-48ab-927b-c6efa944e503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_8a16dfd3-2107-4981-aada-c7ad42f4ca9a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b7a2fca8-9bcf-48ab-927b-c6efa944e503" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_40537ef4-997c-4777-9b59-6441d8da2306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_8a16dfd3-2107-4981-aada-c7ad42f4ca9a" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_40537ef4-997c-4777-9b59-6441d8da2306" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_018cc4ca-10df-4f19-8e11-48c1f1fa5608" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_40537ef4-997c-4777-9b59-6441d8da2306" xlink:to="loc_srt_ProductOrServiceAxis_018cc4ca-10df-4f19-8e11-48c1f1fa5608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_018cc4ca-10df-4f19-8e11-48c1f1fa5608_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_018cc4ca-10df-4f19-8e11-48c1f1fa5608" xlink:to="loc_srt_ProductsAndServicesDomain_018cc4ca-10df-4f19-8e11-48c1f1fa5608_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8a37fee7-0bc8-4347-9d39-41ecad66f30f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_018cc4ca-10df-4f19-8e11-48c1f1fa5608" xlink:to="loc_srt_ProductsAndServicesDomain_8a37fee7-0bc8-4347-9d39-41ecad66f30f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_95ca98a5-0887-4d5c-877b-397522601b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a37fee7-0bc8-4347-9d39-41ecad66f30f" xlink:to="loc_us-gaap_ServiceMember_95ca98a5-0887-4d5c-877b-397522601b4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestingMember_86eeaa49-8b2f-4da9-9f14-981cb3a39dca" xlink:href="opk-20220331.xsd#opk_COVID19TestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a37fee7-0bc8-4347-9d39-41ecad66f30f" xlink:to="loc_opk_COVID19TestingMember_86eeaa49-8b2f-4da9-9f14-981cb3a39dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TestingTypeAxis_a26871f1-fcaa-4724-beae-0ba474c9d597" xlink:href="opk-20220331.xsd#opk_TestingTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_40537ef4-997c-4777-9b59-6441d8da2306" xlink:to="loc_opk_TestingTypeAxis_a26871f1-fcaa-4724-beae-0ba474c9d597" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TestingTypeDomain_a26871f1-fcaa-4724-beae-0ba474c9d597_default" xlink:href="opk-20220331.xsd#opk_TestingTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_opk_TestingTypeAxis_a26871f1-fcaa-4724-beae-0ba474c9d597" xlink:to="loc_opk_TestingTypeDomain_a26871f1-fcaa-4724-beae-0ba474c9d597_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TestingTypeDomain_49251aa5-f115-4256-af77-01557fbca870" xlink:href="opk-20220331.xsd#opk_TestingTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_opk_TestingTypeAxis_a26871f1-fcaa-4724-beae-0ba474c9d597" xlink:to="loc_opk_TestingTypeDomain_49251aa5-f115-4256-af77-01557fbca870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GenomicTestMember_3c8684dd-307a-4bbf-b7e1-ead6b0390482" xlink:href="opk-20220331.xsd#opk_GenomicTestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_TestingTypeDomain_49251aa5-f115-4256-af77-01557fbca870" xlink:to="loc_opk_GenomicTestMember_3c8684dd-307a-4bbf-b7e1-ead6b0390482" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RoutineClinicalTestMember_fa36f1e9-b71c-4779-83b1-2b6bf6b06b4a" xlink:href="opk-20220331.xsd#opk_RoutineClinicalTestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_TestingTypeDomain_49251aa5-f115-4256-af77-01557fbca870" xlink:to="loc_opk_RoutineClinicalTestMember_fa36f1e9-b71c-4779-83b1-2b6bf6b06b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0a3cd95f-f45e-468f-91a7-b011cb25b79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_40537ef4-997c-4777-9b59-6441d8da2306" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0a3cd95f-f45e-468f-91a7-b011cb25b79f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0a3cd95f-f45e-468f-91a7-b011cb25b79f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0a3cd95f-f45e-468f-91a7-b011cb25b79f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0a3cd95f-f45e-468f-91a7-b011cb25b79f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a0bfe1b4-adbd-4149-aad4-3af77827ea5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0a3cd95f-f45e-468f-91a7-b011cb25b79f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a0bfe1b4-adbd-4149-aad4-3af77827ea5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestingRevenueConcentrationRiskMember_5a01639a-95bd-420a-be98-4c06a948cc78" xlink:href="opk-20220331.xsd#opk_COVID19TestingRevenueConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a0bfe1b4-adbd-4149-aad4-3af77827ea5f" xlink:to="loc_opk_COVID19TestingRevenueConcentrationRiskMember_5a01639a-95bd-420a-be98-4c06a948cc78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1e84f18f-b1c8-43f3-9cc0-20a3b0d084bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_40537ef4-997c-4777-9b59-6441d8da2306" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1e84f18f-b1c8-43f3-9cc0-20a3b0d084bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1e84f18f-b1c8-43f3-9cc0-20a3b0d084bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1e84f18f-b1c8-43f3-9cc0-20a3b0d084bd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1e84f18f-b1c8-43f3-9cc0-20a3b0d084bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1648b049-d31c-449f-bd86-0ef7a112f192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1e84f18f-b1c8-43f3-9cc0-20a3b0d084bd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1648b049-d31c-449f-bd86-0ef7a112f192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4d4af620-470e-48c2-b2ef-358e544bb097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1648b049-d31c-449f-bd86-0ef7a112f192" xlink:to="loc_us-gaap_SalesRevenueNetMember_4d4af620-470e-48c2-b2ef-358e544bb097" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_4ab55609-4f82-450a-8ace-f0328c868d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1648b049-d31c-449f-bd86-0ef7a112f192" xlink:to="loc_us-gaap_AccountsReceivableMember_4ab55609-4f82-450a-8ace-f0328c868d50" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i7335c79122aa46b5a47c99ce5976baad_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:href="opk-20220331.xsd#opk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_b0f91eae-e22e-42c2-b4c9-81d83ea9e952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_InventoryWriteDown_b0f91eae-e22e-42c2-b4c9-81d83ea9e952" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets_ecee965b-c72c-4565-9991-aeebb43def07" xlink:href="opk-20220331.xsd#opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets_ecee965b-c72c-4565-9991-aeebb43def07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_318d6f31-1a9d-4268-917c-62629c842643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_Goodwill_318d6f31-1a9d-4268-917c-62629c842643" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4a47b498-30a3-4086-9dba-b8283a124712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4a47b498-30a3-4086-9dba-b8283a124712" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_07158741-36d7-4815-b935-43acbec09340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_07158741-36d7-4815-b935-43acbec09340" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InProcessResearchandDevelopment_fdb799ac-d416-479e-ba61-496f6991466d" xlink:href="opk-20220331.xsd#opk_InProcessResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_opk_InProcessResearchandDevelopment_fdb799ac-d416-479e-ba61-496f6991466d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0d05a4a8-b827-4997-9ba6-5f889e2eb46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0d05a4a8-b827-4997-9ba6-5f889e2eb46f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_eb3cd6cd-f54a-46e7-b4ef-e71023db2788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_eb3cd6cd-f54a-46e7-b4ef-e71023db2788" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2e4b2b81-bbdc-41b9-9122-cf08481f73d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2e4b2b81-bbdc-41b9-9122-cf08481f73d5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e700aaa0-7303-4387-9113-c11d8aeef9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_Depreciation_e700aaa0-7303-4387-9113-c11d8aeef9b6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1b468c8a-a96b-4378-b32e-179b40a0cc18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1b468c8a-a96b-4378-b32e-179b40a0cc18" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_84cffbaa-0dd2-4cf5-9599-02760a3fdb62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_84cffbaa-0dd2-4cf5-9599-02760a3fdb62" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_e7d4a4ed-431d-41d2-a97e-fcb5176fdc25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_e7d4a4ed-431d-41d2-a97e-fcb5176fdc25" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a0abc587-6aa3-414c-924c-379834126be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a0abc587-6aa3-414c-924c-379834126be7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_c57aef52-0534-4654-a93f-bb0e61250290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_NumberOfReportableSegments_c57aef52-0534-4654-a93f-bb0e61250290" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c3da9a52-afd2-4b98-a484-e26633a65c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c3da9a52-afd2-4b98-a484-e26633a65c00" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7da1eda-5fac-46c7-8172-bac4705a1b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7da1eda-5fac-46c7-8172-bac4705a1b08" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:href="opk-20220331.xsd#opk_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_08eb03f4-4913-4874-8a02-b5838348ffb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_08eb03f4-4913-4874-8a02-b5838348ffb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_08eb03f4-4913-4874-8a02-b5838348ffb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_08eb03f4-4913-4874-8a02-b5838348ffb6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_08eb03f4-4913-4874-8a02-b5838348ffb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bb310fbc-2e8b-4765-917e-2bafbb4d46fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_08eb03f4-4913-4874-8a02-b5838348ffb6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bb310fbc-2e8b-4765-917e-2bafbb4d46fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2673d1bb-0292-4a39-b101-31c898e68a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bb310fbc-2e8b-4765-917e-2bafbb4d46fe" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2673d1bb-0292-4a39-b101-31c898e68a71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b164faa8-f7c6-464d-9796-e4d35c57a5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b164faa8-f7c6-464d-9796-e4d35c57a5fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b164faa8-f7c6-464d-9796-e4d35c57a5fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b164faa8-f7c6-464d-9796-e4d35c57a5fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b164faa8-f7c6-464d-9796-e4d35c57a5fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbf7448f-6e2e-4824-86af-4fe4929b97ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b164faa8-f7c6-464d-9796-e4d35c57a5fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbf7448f-6e2e-4824-86af-4fe4929b97ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b8e3e547-c365-4b26-8ac0-951b5579aec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbf7448f-6e2e-4824-86af-4fe4929b97ef" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b8e3e547-c365-4b26-8ac0-951b5579aec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_1f863197-ed2b-455d-b7d4-d874a85474fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbf7448f-6e2e-4824-86af-4fe4929b97ef" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_1f863197-ed2b-455d-b7d4-d874a85474fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_46d0f384-4cc9-49e4-8580-a6a3dba35c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbf7448f-6e2e-4824-86af-4fe4929b97ef" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_46d0f384-4cc9-49e4-8580-a6a3dba35c37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_6d33c471-c773-4424-8631-dd89edbf3677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbf7448f-6e2e-4824-86af-4fe4929b97ef" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_6d33c471-c773-4424-8631-dd89edbf3677" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AutomobilesandAircraftMember_02f21613-7db1-48a1-8ee4-0d1cbdf5242f" xlink:href="opk-20220331.xsd#opk_AutomobilesandAircraftMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbf7448f-6e2e-4824-86af-4fe4929b97ef" xlink:to="loc_opk_AutomobilesandAircraftMember_02f21613-7db1-48a1-8ee4-0d1cbdf5242f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1b3124d0-dba7-4790-9012-ed7f015ed603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1b3124d0-dba7-4790-9012-ed7f015ed603" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1b3124d0-dba7-4790-9012-ed7f015ed603_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1b3124d0-dba7-4790-9012-ed7f015ed603" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1b3124d0-dba7-4790-9012-ed7f015ed603_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8adb21a0-9486-406a-9b4f-40f3cf01cdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1b3124d0-dba7-4790-9012-ed7f015ed603" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8adb21a0-9486-406a-9b4f-40f3cf01cdd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_d702d376-67ff-470b-8bea-f22599a4aca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8adb21a0-9486-406a-9b4f-40f3cf01cdd7" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_d702d376-67ff-470b-8bea-f22599a4aca2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_d2cc6a0e-0184-4a81-9747-0783615d6f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8adb21a0-9486-406a-9b4f-40f3cf01cdd7" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_d2cc6a0e-0184-4a81-9747-0783615d6f89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_7ec9199d-79c5-4d16-bf97-fc8a1be8f08c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8adb21a0-9486-406a-9b4f-40f3cf01cdd7" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_7ec9199d-79c5-4d16-bf97-fc8a1be8f08c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f9da68bf-f190-4fd4-9cbb-4701dd6958d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f9da68bf-f190-4fd4-9cbb-4701dd6958d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f9da68bf-f190-4fd4-9cbb-4701dd6958d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f9da68bf-f190-4fd4-9cbb-4701dd6958d0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f9da68bf-f190-4fd4-9cbb-4701dd6958d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_727d3cbd-3548-4d48-8bd7-f46a9a18d117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f9da68bf-f190-4fd4-9cbb-4701dd6958d0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_727d3cbd-3548-4d48-8bd7-f46a9a18d117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_1fbcd399-da8b-4c80-9a47-743789f581b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_727d3cbd-3548-4d48-8bd7-f46a9a18d117" xlink:to="loc_us-gaap_AccountsReceivableMember_1fbcd399-da8b-4c80-9a47-743789f581b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_44bc05c7-3d75-479c-829c-12702afd5377" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_srt_RangeAxis_44bc05c7-3d75-479c-829c-12702afd5377" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_44bc05c7-3d75-479c-829c-12702afd5377_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_44bc05c7-3d75-479c-829c-12702afd5377" xlink:to="loc_srt_RangeMember_44bc05c7-3d75-479c-829c-12702afd5377_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e9b78af3-474b-44f9-b73e-dce0a0065ec2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_44bc05c7-3d75-479c-829c-12702afd5377" xlink:to="loc_srt_RangeMember_e9b78af3-474b-44f9-b73e-dce0a0065ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_315a8118-24cf-4e52-b41a-8d791e9e14b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e9b78af3-474b-44f9-b73e-dce0a0065ec2" xlink:to="loc_srt_MinimumMember_315a8118-24cf-4e52-b41a-8d791e9e14b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5471be72-0111-40c2-84e3-da03241b0955" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e9b78af3-474b-44f9-b73e-dce0a0065ec2" xlink:to="loc_srt_MaximumMember_5471be72-0111-40c2-84e3-da03241b0955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b3504832-87f8-4c04-9353-83489ef87961" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_srt_MajorCustomersAxis_b3504832-87f8-4c04-9353-83489ef87961" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b3504832-87f8-4c04-9353-83489ef87961_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_b3504832-87f8-4c04-9353-83489ef87961" xlink:to="loc_srt_NameOfMajorCustomerDomain_b3504832-87f8-4c04-9353-83489ef87961_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7f2484a1-ec28-4008-8a04-1abf35f3a2da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_b3504832-87f8-4c04-9353-83489ef87961" xlink:to="loc_srt_NameOfMajorCustomerDomain_7f2484a1-ec28-4008-8a04-1abf35f3a2da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FederalAndStateGovernmentsMember_a04d9228-6011-45f6-9d1b-93fdfeb56755" xlink:href="opk-20220331.xsd#opk_FederalAndStateGovernmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f2484a1-ec28-4008-8a04-1abf35f3a2da" xlink:to="loc_opk_FederalAndStateGovernmentsMember_a04d9228-6011-45f6-9d1b-93fdfeb56755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StatesCitiesAndOtherMunicipalitiesMember_cfa11752-18c6-49ff-bf80-19bf8a317227" xlink:href="opk-20220331.xsd#opk_StatesCitiesAndOtherMunicipalitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f2484a1-ec28-4008-8a04-1abf35f3a2da" xlink:to="loc_opk_StatesCitiesAndOtherMunicipalitiesMember_cfa11752-18c6-49ff-bf80-19bf8a317227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IndividualPatientsMember_32c532d0-edc6-4047-a7d6-c0f0c8bece5a" xlink:href="opk-20220331.xsd#opk_IndividualPatientsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f2484a1-ec28-4008-8a04-1abf35f3a2da" xlink:to="loc_opk_IndividualPatientsMember_32c532d0-edc6-4047-a7d6-c0f0c8bece5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_089b9406-e2ea-4b71-9982-fa19639d2b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_us-gaap_ReportingUnitAxis_089b9406-e2ea-4b71-9982-fa19639d2b0d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_089b9406-e2ea-4b71-9982-fa19639d2b0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_089b9406-e2ea-4b71-9982-fa19639d2b0d" xlink:to="loc_us-gaap_ReportingUnitDomain_089b9406-e2ea-4b71-9982-fa19639d2b0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_fccadbe7-4c72-434a-9d5c-7efcfd386064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_089b9406-e2ea-4b71-9982-fa19639d2b0d" xlink:to="loc_us-gaap_ReportingUnitDomain_fccadbe7-4c72-434a-9d5c-7efcfd386064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DetectGenomixMember_83dc9305-4291-4275-9a87-a78b077bf4a4" xlink:href="opk-20220331.xsd#opk_DetectGenomixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_fccadbe7-4c72-434a-9d5c-7efcfd386064" xlink:to="loc_opk_DetectGenomixMember_83dc9305-4291-4275-9a87-a78b077bf4a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOBiologicsMember_1254d9e8-c1c3-43b6-a0d4-eb8d7c70a5ae" xlink:href="opk-20220331.xsd#opk_OPKOBiologicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_fccadbe7-4c72-434a-9d5c-7efcfd386064" xlink:to="loc_opk_OPKOBiologicsMember_1254d9e8-c1c3-43b6-a0d4-eb8d7c70a5ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cbefbfae-78a1-445f-9e6b-2020b9b8ed61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cbefbfae-78a1-445f-9e6b-2020b9b8ed61" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbefbfae-78a1-445f-9e6b-2020b9b8ed61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cbefbfae-78a1-445f-9e6b-2020b9b8ed61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbefbfae-78a1-445f-9e6b-2020b9b8ed61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_82625515-1a25-4b1e-b727-58372c4efbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cbefbfae-78a1-445f-9e6b-2020b9b8ed61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_82625515-1a25-4b1e-b727-58372c4efbdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_453a1244-d326-4986-b547-b689f8b884f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_82625515-1a25-4b1e-b727-58372c4efbdf" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_453a1244-d326-4986-b547-b689f8b884f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cbd9507b-b40e-4a72-bcab-5d40b444bcbd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cbd9507b-b40e-4a72-bcab-5d40b444bcbd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_cbd9507b-b40e-4a72-bcab-5d40b444bcbd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cbd9507b-b40e-4a72-bcab-5d40b444bcbd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_cbd9507b-b40e-4a72-bcab-5d40b444bcbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_df713f79-d19a-446f-ab6b-1388653335bd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cbd9507b-b40e-4a72-bcab-5d40b444bcbd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_df713f79-d19a-446f-ab6b-1388653335bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_27e23e62-f1ed-418b-b8ce-c3d125216bbf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_df713f79-d19a-446f-ab6b-1388653335bd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_27e23e62-f1ed-418b-b8ce-c3d125216bbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e2ec97cc-be0b-4b05-ab61-0b16330d508b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e2ec97cc-be0b-4b05-ab61-0b16330d508b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e2ec97cc-be0b-4b05-ab61-0b16330d508b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e2ec97cc-be0b-4b05-ab61-0b16330d508b" xlink:to="loc_us-gaap_EquityComponentDomain_e2ec97cc-be0b-4b05-ab61-0b16330d508b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d3b03ec-25e9-41c0-93b1-3d3891c776fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e2ec97cc-be0b-4b05-ab61-0b16330d508b" xlink:to="loc_us-gaap_EquityComponentDomain_3d3b03ec-25e9-41c0-93b1-3d3891c776fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7fdc3270-a4cf-4658-aaa6-889dde4e0f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3d3b03ec-25e9-41c0-93b1-3d3891c776fd" xlink:to="loc_us-gaap_RetainedEarningsMember_7fdc3270-a4cf-4658-aaa6-889dde4e0f12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_645247b8-8d9a-46d0-ab4b-287cc007833a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3d3b03ec-25e9-41c0-93b1-3d3891c776fd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_645247b8-8d9a-46d0-ab4b-287cc007833a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#EarningsLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/EarningsLossPerShareDetails" xlink:type="extended" id="i8e42fae2a30d4ccdb35ec0cb7bf3a67d_EarningsLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd2ac46f-0b8a-4f50-9e92-f0b0c8ed528d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_aa3aab50-fdea-4e92-a4e7-afd9b402b013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd2ac46f-0b8a-4f50-9e92-f0b0c8ed528d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_aa3aab50-fdea-4e92-a4e7-afd9b402b013" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_db508a9a-5440-4ce1-b96f-f371edc2b42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd2ac46f-0b8a-4f50-9e92-f0b0c8ed528d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_db508a9a-5440-4ce1-b96f-f371edc2b42e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised_810a3f89-2ebd-4fd7-94cb-2c7187e2ccbe" xlink:href="opk-20220331.xsd#opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd2ac46f-0b8a-4f50-9e92-f0b0c8ed528d" xlink:to="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised_810a3f89-2ebd-4fd7-94cb-2c7187e2ccbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment_bc3cee17-01d2-4704-bd2d-13a0bf44c6ff" xlink:href="opk-20220331.xsd#opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd2ac46f-0b8a-4f50-9e92-f0b0c8ed528d" xlink:to="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment_bc3cee17-01d2-4704-bd2d-13a0bf44c6ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesSurrenderedInLieuOfCashPayment_62d47bb4-10a7-4c7c-b7fd-56718f699e6e" xlink:href="opk-20220331.xsd#opk_SharesSurrenderedInLieuOfCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd2ac46f-0b8a-4f50-9e92-f0b0c8ed528d" xlink:to="loc_opk_SharesSurrenderedInLieuOfCashPayment_62d47bb4-10a7-4c7c-b7fd-56718f699e6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb24f2b9-dca5-49bf-a903-ec65a4a4a534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd2ac46f-0b8a-4f50-9e92-f0b0c8ed528d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb24f2b9-dca5-49bf-a903-ec65a4a4a534" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fcc0355a-61de-4f38-863c-13f87c812b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb24f2b9-dca5-49bf-a903-ec65a4a4a534" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fcc0355a-61de-4f38-863c-13f87c812b4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fcc0355a-61de-4f38-863c-13f87c812b4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fcc0355a-61de-4f38-863c-13f87c812b4c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fcc0355a-61de-4f38-863c-13f87c812b4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a10f11b-378d-45e2-9b30-bbae021e9cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fcc0355a-61de-4f38-863c-13f87c812b4c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a10f11b-378d-45e2-9b30-bbae021e9cda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_83181f14-92bc-4812-806f-ab3908e61dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a10f11b-378d-45e2-9b30-bbae021e9cda" xlink:to="loc_us-gaap_CommonStockMember_83181f14-92bc-4812-806f-ab3908e61dbc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#CompositionofCertainFinancialStatementCaptionsDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails" xlink:type="extended" id="i865956ee9df54f0cbbc03157b08a0515_CompositionofCertainFinancialStatementCaptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetAbstract_67243664-5d74-4182-85a4-050ba65572c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:to="loc_us-gaap_AccountsReceivableNetAbstract_67243664-5d74-4182-85a4-050ba65572c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_0a8d1fa2-1958-44c8-bd87-9efd645cd00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_67243664-5d74-4182-85a4-050ba65572c2" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_0a8d1fa2-1958-44c8-bd87-9efd645cd00f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_66b634a9-5a2d-4bc0-92bf-3957a59623af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_67243664-5d74-4182-85a4-050ba65572c2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_66b634a9-5a2d-4bc0-92bf-3957a59623af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3ec86677-de29-4cb0-a015-41182f4bc19c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_67243664-5d74-4182-85a4-050ba65572c2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3ec86677-de29-4cb0-a015-41182f4bc19c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:to="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_95f49777-ebfb-4544-96ac-568ba749a16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:to="loc_us-gaap_OtherInventorySupplies_95f49777-ebfb-4544-96ac-568ba749a16d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_eb2625f3-ca4b-44c5-9ca6-ae7d654c4934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:to="loc_us-gaap_InventoryFinishedGoods_eb2625f3-ca4b-44c5-9ca6-ae7d654c4934" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_80d7e9ba-a068-42de-a172-c93f9b0d546b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:to="loc_us-gaap_InventoryWorkInProcess_80d7e9ba-a068-42de-a172-c93f9b0d546b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_8801ddca-2d02-417f-89ed-5c91f82adefd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:to="loc_us-gaap_InventoryRawMaterials_8801ddca-2d02-417f-89ed-5c91f82adefd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_ac5fb174-1b55-444c-908b-fbb6023efc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:to="loc_us-gaap_InventoryValuationReserves_ac5fb174-1b55-444c-908b-fbb6023efc6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2099637d-d5a9-409d-a9b2-379070cf8c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:to="loc_us-gaap_InventoryNet_2099637d-d5a9-409d-a9b2-379070cf8c35" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TaxesRecoverableCurrent_3dfc75a5-3179-4461-bf77-16f7af29636a" xlink:href="opk-20220331.xsd#opk_TaxesRecoverableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:to="loc_opk_TaxesRecoverableCurrent_3dfc75a5-3179-4461-bf77-16f7af29636a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_a71985df-bca3-4684-a1e6-28695734ae34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Supplies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:to="loc_us-gaap_Supplies_a71985df-bca3-4684-a1e6-28695734ae34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_2018849b-b3f3-4cb3-82f7-5dc73ef6ad1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:to="loc_us-gaap_PrepaidInsurance_2018849b-b3f3-4cb3-82f7-5dc73ef6ad1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_602db0b1-6821-42d0-b909-9026c16f9e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_602db0b1-6821-42d0-b909-9026c16f9e93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5666dea6-4665-4c76-aad9-997dd365fdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:to="loc_us-gaap_OtherAssetsCurrent_5666dea6-4665-4c76-aad9-997dd365fdf9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4885afce-0847-4f76-ba13-656b138b7f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4885afce-0847-4f76-ba13-656b138b7f27" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8a405dca-3b87-4ddb-b3da-5d31a922a1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8a405dca-3b87-4ddb-b3da-5d31a922a1c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3df31aa2-6a85-4d08-b0c8-26ec5c4b039d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8a405dca-3b87-4ddb-b3da-5d31a922a1c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3df31aa2-6a85-4d08-b0c8-26ec5c4b039d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e8ba5382-af8f-4b55-9ba3-41b71dcdce8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8a405dca-3b87-4ddb-b3da-5d31a922a1c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e8ba5382-af8f-4b55-9ba3-41b71dcdce8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_28604bb2-3b34-4b35-b2f5-f5550178af93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8a405dca-3b87-4ddb-b3da-5d31a922a1c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_28604bb2-3b34-4b35-b2f5-f5550178af93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InventoryReceivedNotInvoicedCurrent_fc3f9fba-889e-4107-9a79-409e065d3607" xlink:href="opk-20220331.xsd#opk_InventoryReceivedNotInvoicedCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_opk_InventoryReceivedNotInvoicedCurrent_fc3f9fba-889e-4107-9a79-409e065d3607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedCommitmentsandContingenciesCurrent_72265df6-5a7b-4560-a7c3-241f25641931" xlink:href="opk-20220331.xsd#opk_AccruedCommitmentsandContingenciesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_opk_AccruedCommitmentsandContingenciesCurrent_72265df6-5a7b-4560-a7c3-241f25641931" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_0c416bab-f15c-400a-8a2a-6abccbd2044b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_0c416bab-f15c-400a-8a2a-6abccbd2044b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f2d7f410-98e7-4502-9425-850b7111c175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f2d7f410-98e7-4502-9425-850b7111c175" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedClinicalTrialsCurrent_e20a59e3-32c2-4829-b8e3-a240782aa6a4" xlink:href="opk-20220331.xsd#opk_AccruedClinicalTrialsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_opk_AccruedClinicalTrialsCurrent_e20a59e3-32c2-4829-b8e3-a240782aa6a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5f6598fe-830b-4537-b0f0-a1dec4df25b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5f6598fe-830b-4537-b0f0-a1dec4df25b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_44752699-dbea-44c3-9f98-4aeccb7fb932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_44752699-dbea-44c3-9f98-4aeccb7fb932" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_b7d4b03c-35c1-485d-9e33-d477ec327e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_b7d4b03c-35c1-485d-9e33-d477ec327e54" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b77f3b2a-cf3c-4aa1-9828-6edd0232a533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b77f3b2a-cf3c-4aa1-9828-6edd0232a533" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0b7e5729-191a-4b54-b06b-5775104f3083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0b7e5729-191a-4b54-b06b-5775104f3083" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_63c09f1c-020a-4b01-9ee8-50aee0b3c836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_63c09f1c-020a-4b01-9ee8-50aee0b3c836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_c61b3f5c-58ab-4d11-b318-3bd1fffb8958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent_c61b3f5c-58ab-4d11-b318-3bd1fffb8958" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_148c3dee-e078-41bd-bfa2-db002447282f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_148c3dee-e078-41bd-bfa2-db002447282f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ec8960af-b1d3-4c03-bb95-f3575c28f224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ec8960af-b1d3-4c03-bb95-f3575c28f224" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_3cbe05b2-22d2-4dc8-a837-d8242c2ababa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:to="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_3cbe05b2-22d2-4dc8-a837-d8242c2ababa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_74a11bd0-96ba-4573-bd9c-1c92163fcb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_74a11bd0-96ba-4573-bd9c-1c92163fcb6c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_1bc8d246-2baa-4e65-b626-29c98756543a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_1bc8d246-2baa-4e65-b626-29c98756543a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fd6abcc8-b36d-4497-bde3-59293fbdd7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_1bc8d246-2baa-4e65-b626-29c98756543a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fd6abcc8-b36d-4497-bde3-59293fbdd7e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fd6abcc8-b36d-4497-bde3-59293fbdd7e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fd6abcc8-b36d-4497-bde3-59293fbdd7e9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fd6abcc8-b36d-4497-bde3-59293fbdd7e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fd6abcc8-b36d-4497-bde3-59293fbdd7e9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_eebf7956-c61a-4c29-a523-7ca72b6136b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:to="loc_us-gaap_CustomerRelationshipsMember_eebf7956-c61a-4c29-a523-7ca72b6136b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_97fa7622-c234-4dbc-94ff-91f987cf6408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_97fa7622-c234-4dbc-94ff-91f987cf6408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_e3698099-f82b-43f0-a1e9-7a7233d589c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:to="loc_us-gaap_TradeNamesMember_e3698099-f82b-43f0-a1e9-7a7233d589c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_cd217a04-9bd6-4eb0-9309-a598f590070f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_cd217a04-9bd6-4eb0-9309-a598f590070f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_6fd283ca-e789-4160-af6f-31d8ba5f3ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:to="loc_us-gaap_LicensingAgreementsMember_6fd283ca-e789-4160-af6f-31d8ba5f3ed1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProductRegistrationsMember_730d5ac2-1045-4de9-b5c5-c2534d718398" xlink:href="opk-20220331.xsd#opk_ProductRegistrationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:to="loc_opk_ProductRegistrationsMember_730d5ac2-1045-4de9-b5c5-c2534d718398" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_ab56c1f8-9598-45f4-a6ba-a221941ebc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_ab56c1f8-9598-45f4-a6ba-a221941ebc8a" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#CompositionofCertainFinancialStatementCaptionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails" xlink:type="extended" id="icfa80e4ecd864166b18e8571b8507a4c_CompositionofCertainFinancialStatementCaptionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_59baedc3-be1d-4423-94cb-75275e0d40cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4839c2c0-fe6d-4ec1-82b1-2c0c4afb415b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_59baedc3-be1d-4423-94cb-75275e0d40cc" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4839c2c0-fe6d-4ec1-82b1-2c0c4afb415b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c0e4892f-b192-4807-9af0-77b477875f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_59baedc3-be1d-4423-94cb-75275e0d40cc" xlink:to="loc_us-gaap_Goodwill_c0e4892f-b192-4807-9af0-77b477875f9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e8bb2b5f-a116-4736-96cd-915264e5482e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_59baedc3-be1d-4423-94cb-75275e0d40cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e8bb2b5f-a116-4736-96cd-915264e5482e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0eac4d99-0a2e-497c-8dff-98507f31c176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_59baedc3-be1d-4423-94cb-75275e0d40cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0eac4d99-0a2e-497c-8dff-98507f31c176" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InProcessResearchandDevelopment_23155d91-5f76-4b4e-a30d-6329f8d3d3e8" xlink:href="opk-20220331.xsd#opk_InProcessResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_59baedc3-be1d-4423-94cb-75275e0d40cc" xlink:to="loc_opk_InProcessResearchandDevelopment_23155d91-5f76-4b4e-a30d-6329f8d3d3e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ca26d086-cff9-4f5b-ba46-70040cdfd6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_59baedc3-be1d-4423-94cb-75275e0d40cc" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ca26d086-cff9-4f5b-ba46-70040cdfd6af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d89aa4f4-3446-4300-8a76-d0034e47e402" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ca26d086-cff9-4f5b-ba46-70040cdfd6af" xlink:to="loc_srt_RangeAxis_d89aa4f4-3446-4300-8a76-d0034e47e402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d89aa4f4-3446-4300-8a76-d0034e47e402_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d89aa4f4-3446-4300-8a76-d0034e47e402" xlink:to="loc_srt_RangeMember_d89aa4f4-3446-4300-8a76-d0034e47e402_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37829658-f74c-4e50-9754-133f02ca4854" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d89aa4f4-3446-4300-8a76-d0034e47e402" xlink:to="loc_srt_RangeMember_37829658-f74c-4e50-9754-133f02ca4854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1ab486e8-33bc-4fe2-9637-9060dcfe4a10" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_37829658-f74c-4e50-9754-133f02ca4854" xlink:to="loc_srt_MinimumMember_1ab486e8-33bc-4fe2-9637-9060dcfe4a10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_06c6e4b0-b371-4084-9e71-b7babb98e4ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_37829658-f74c-4e50-9754-133f02ca4854" xlink:to="loc_srt_MaximumMember_06c6e4b0-b371-4084-9e71-b7babb98e4ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f5676af-a742-4ea2-953a-d558f9882ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ca26d086-cff9-4f5b-ba46-70040cdfd6af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f5676af-a742-4ea2-953a-d558f9882ea0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6f5676af-a742-4ea2-953a-d558f9882ea0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f5676af-a742-4ea2-953a-d558f9882ea0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6f5676af-a742-4ea2-953a-d558f9882ea0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f5676af-a742-4ea2-953a-d558f9882ea0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_c4c633b9-627e-42f8-aae0-0e4662a0d741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_c4c633b9-627e-42f8-aae0-0e4662a0d741" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6b01f0d2-f188-4815-835d-3a4256cd3300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6b01f0d2-f188-4815-835d-3a4256cd3300" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5ba2ad26-d08f-4bc8-819c-bcbb8229ac26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:to="loc_us-gaap_ProductMember_5ba2ad26-d08f-4bc8-819c-bcbb8229ac26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CovenantsNotToCompeteMember_2c1d905e-8654-467f-b1ee-305f5a1598b6" xlink:href="opk-20220331.xsd#opk_CovenantsNotToCompeteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:to="loc_opk_CovenantsNotToCompeteMember_2c1d905e-8654-467f-b1ee-305f5a1598b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_38150ff9-10f2-4767-ba93-98cff0cd9030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:to="loc_us-gaap_TradeNamesMember_38150ff9-10f2-4767-ba93-98cff0cd9030" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_7306a1df-29bf-443e-95bc-8d31f230bf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_7306a1df-29bf-443e-95bc-8d31f230bf2a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_46a15d63-eabe-4b6a-89b6-a6b8bd09cabe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_46a15d63-eabe-4b6a-89b6-a6b8bd09cabe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_fcd3a635-4372-4a7a-82f2-1a0e35f8f41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ca26d086-cff9-4f5b-ba46-70040cdfd6af" xlink:to="loc_us-gaap_ReportingUnitAxis_fcd3a635-4372-4a7a-82f2-1a0e35f8f41e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_fcd3a635-4372-4a7a-82f2-1a0e35f8f41e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_fcd3a635-4372-4a7a-82f2-1a0e35f8f41e" xlink:to="loc_us-gaap_ReportingUnitDomain_fcd3a635-4372-4a7a-82f2-1a0e35f8f41e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_a105d41f-712e-4a27-8ace-5acd090a18b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_fcd3a635-4372-4a7a-82f2-1a0e35f8f41e" xlink:to="loc_us-gaap_ReportingUnitDomain_a105d41f-712e-4a27-8ace-5acd090a18b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DetectGenomixMember_55c7ebe3-8440-43c2-bb23-6c4623f3295b" xlink:href="opk-20220331.xsd#opk_DetectGenomixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_a105d41f-712e-4a27-8ace-5acd090a18b0" xlink:to="loc_opk_DetectGenomixMember_55c7ebe3-8440-43c2-bb23-6c4623f3295b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOBiologicsMember_4786984a-8104-4f70-875c-1a9091efb41a" xlink:href="opk-20220331.xsd#opk_OPKOBiologicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_a105d41f-712e-4a27-8ace-5acd090a18b0" xlink:to="loc_opk_OPKOBiologicsMember_4786984a-8104-4f70-875c-1a9091efb41a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails" xlink:type="extended" id="i0d747eab80384b7a9a7927ebd83cc996_CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_59523d1d-de19-4fe2-ab02-01536d998b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_af194e44-6656-4e52-9393-21bdc3f53519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_59523d1d-de19-4fe2-ab02-01536d998b47" xlink:to="loc_us-gaap_GoodwillRollForward_af194e44-6656-4e52-9393-21bdc3f53519" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9b8e4201-4d46-44cb-bfc9-9cd31686164b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_af194e44-6656-4e52-9393-21bdc3f53519" xlink:to="loc_us-gaap_Goodwill_9b8e4201-4d46-44cb-bfc9-9cd31686164b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f7725ff7-2bf6-42b9-9277-b8b202ec64af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_af194e44-6656-4e52-9393-21bdc3f53519" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f7725ff7-2bf6-42b9-9277-b8b202ec64af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_07c6d4a5-0608-4a2b-9594-bfa53ca774ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_af194e44-6656-4e52-9393-21bdc3f53519" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_07c6d4a5-0608-4a2b-9594-bfa53ca774ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dff44edd-6535-4351-aa2a-3c2851058485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_f56d9465-93fc-4584-833b-840ea595d0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_59523d1d-de19-4fe2-ab02-01536d998b47" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_f56d9465-93fc-4584-833b-840ea595d0b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0cf3026a-f822-4d53-89f5-1c8a394f8a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_f56d9465-93fc-4584-833b-840ea595d0b6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0cf3026a-f822-4d53-89f5-1c8a394f8a1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0cf3026a-f822-4d53-89f5-1c8a394f8a1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0cf3026a-f822-4d53-89f5-1c8a394f8a1e" xlink:to="loc_us-gaap_SegmentDomain_0cf3026a-f822-4d53-89f5-1c8a394f8a1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a3fc09c0-bd48-43b2-90a3-545876153841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0cf3026a-f822-4d53-89f5-1c8a394f8a1e" xlink:to="loc_us-gaap_SegmentDomain_a3fc09c0-bd48-43b2-90a3-545876153841" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmaceuticalMember_a75357c6-88cc-4b4d-a097-36ade7fd6d80" xlink:href="opk-20220331.xsd#opk_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a3fc09c0-bd48-43b2-90a3-545876153841" xlink:to="loc_opk_PharmaceuticalMember_a75357c6-88cc-4b4d-a097-36ade7fd6d80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticsMember_7a00e22f-3424-4c35-ac7f-de7d1b7af526" xlink:href="opk-20220331.xsd#opk_DiagnosticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a3fc09c0-bd48-43b2-90a3-545876153841" xlink:to="loc_opk_DiagnosticsMember_7a00e22f-3424-4c35-ac7f-de7d1b7af526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_26f94f49-710e-4089-9964-ea7ba654c347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_f56d9465-93fc-4584-833b-840ea595d0b6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_26f94f49-710e-4089-9964-ea7ba654c347" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_26f94f49-710e-4089-9964-ea7ba654c347_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26f94f49-710e-4089-9964-ea7ba654c347" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_26f94f49-710e-4089-9964-ea7ba654c347_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26f94f49-710e-4089-9964-ea7ba654c347" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CURNAMember_5efbd718-b43f-4d26-ae96-b71047e4a926" xlink:href="opk-20220331.xsd#opk_CURNAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_CURNAMember_5efbd718-b43f-4d26-ae96-b71047e4a926" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EirGenPharmaLimitedMember_fe454cef-16e9-4c0c-98fb-ef26465219b3" xlink:href="opk-20220331.xsd#opk_EirGenPharmaLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_EirGenPharmaLimitedMember_fe454cef-16e9-4c0c-98fb-ef26465219b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FineTechMember_7109644b-acb5-4e6d-9bd6-12f83ace0dbe" xlink:href="opk-20220331.xsd#opk_FineTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_FineTechMember_7109644b-acb5-4e6d-9bd6-12f83ace0dbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOBiologicsMember_4d387f89-eb24-4890-a244-08eeea4243bf" xlink:href="opk-20220331.xsd#opk_OPKOBiologicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_OPKOBiologicsMember_4d387f89-eb24-4890-a244-08eeea4243bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OpkoChileMember_1f137e02-4372-41d7-acd2-1362e6966f8b" xlink:href="opk-20220331.xsd#opk_OpkoChileMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_OpkoChileMember_1f137e02-4372-41d7-acd2-1362e6966f8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOHealthEuropeMember_63b11a06-e505-40da-92cb-f6aba142bd31" xlink:href="opk-20220331.xsd#opk_OPKOHealthEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_OPKOHealthEuropeMember_63b11a06-e505-40da-92cb-f6aba142bd31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOMexicoMember_b9961c59-6c96-496d-b49d-cb5817ce5b00" xlink:href="opk-20220331.xsd#opk_OPKOMexicoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_OPKOMexicoMember_b9961c59-6c96-496d-b49d-cb5817ce5b00" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransitionTherapeuticsInc.Member_7816e312-72fd-446f-9fdf-52a83f53f6b6" xlink:href="opk-20220331.xsd#opk_TransitionTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_TransitionTherapeuticsInc.Member_7816e312-72fd-446f-9fdf-52a83f53f6b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioReferenceMember_fd4923bd-351d-407f-a445-97dc3c269e49" xlink:href="opk-20220331.xsd#opk_BioReferenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_BioReferenceMember_fd4923bd-351d-407f-a445-97dc3c269e49" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OpkoDiagnosticsMember_fab65fcc-faec-4828-bfca-302af60008c5" xlink:href="opk-20220331.xsd#opk_OpkoDiagnosticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_OpkoDiagnosticsMember_fab65fcc-faec-4828-bfca-302af60008c5" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#InvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/InvestmentsNarrativeDetails" xlink:type="extended" id="iffc1b0d476a7480993eb88a5598977b9_InvestmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a957a184-1d3e-4a9c-9aa3-d10d7730930b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a957a184-1d3e-4a9c-9aa3-d10d7730930b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b550b7b0-7954-4a37-9c95-3dd5f18995cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_Assets_b550b7b0-7954-4a37-9c95-3dd5f18995cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fcc1260b-d02c-40ac-9ebf-d50bcf009f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_Liabilities_fcc1260b-d02c-40ac-9ebf-d50bcf009f96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_af029403-587b-4349-a2f3-11946b722164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_ProfitLoss_af029403-587b-4349-a2f3-11946b722164" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_461aeb3f-89fb-44e1-9ab2-9db54be6ddd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_461aeb3f-89fb-44e1-9ab2-9db54be6ddd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquitySecurityFVNIOwnershipPercent_4e6edbc8-4f33-4692-890c-014f4f3c87dc" xlink:href="opk-20220331.xsd#opk_EquitySecurityFVNIOwnershipPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_opk_EquitySecurityFVNIOwnershipPercent_4e6edbc8-4f33-4692-890c-014f4f3c87dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_cb9ca8fe-38fc-4790-9b16-feab2d5085a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_cb9ca8fe-38fc-4790-9b16-feab2d5085a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NoncontrollingInterestSharesIssued_2bd44fdb-7428-4038-95b6-0bebf5b5b40e" xlink:href="opk-20220331.xsd#opk_NoncontrollingInterestSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_opk_NoncontrollingInterestSharesIssued_2bd44fdb-7428-4038-95b6-0bebf5b5b40e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_e98233ef-2368-4a7b-b06b-a32c3e48cc03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_e98233ef-2368-4a7b-b06b-a32c3e48cc03" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85912a07-346c-4080-ab2e-488bba724c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85912a07-346c-4080-ab2e-488bba724c18" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_c309bc90-636b-4f88-8a43-362b6c136529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_c309bc90-636b-4f88-8a43-362b6c136529" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_9e3a8920-ee5c-43ec-ae5f-05e020a0bda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_9e3a8920-ee5c-43ec-ae5f-05e020a0bda3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedAsGift_31bcf960-fe74-41fb-815e-cec2433b346c" xlink:href="opk-20220331.xsd#opk_SharesReceivedAsGift"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_opk_SharesReceivedAsGift_31bcf960-fe74-41fb-815e-cec2433b346c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_facf824a-e2a0-46f1-a257-6b2b26c10cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_facf824a-e2a0-46f1-a257-6b2b26c10cdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_facf824a-e2a0-46f1-a257-6b2b26c10cdf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_facf824a-e2a0-46f1-a257-6b2b26c10cdf" xlink:to="loc_us-gaap_ClassOfStockDomain_facf824a-e2a0-46f1-a257-6b2b26c10cdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fcef0fb9-932b-476b-9286-47f7803034fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_facf824a-e2a0-46f1-a257-6b2b26c10cdf" xlink:to="loc_us-gaap_ClassOfStockDomain_fcef0fb9-932b-476b-9286-47f7803034fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5156fd75-d1b1-4316-bc77-bc6f2b869322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fcef0fb9-932b-476b-9286-47f7803034fb" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5156fd75-d1b1-4316-bc77-bc6f2b869322" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0272e416-95bd-4686-b63b-efcf92aaf7db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fcef0fb9-932b-476b-9286-47f7803034fb" xlink:to="loc_us-gaap_RestrictedStockMember_0272e416-95bd-4686-b63b-efcf92aaf7db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_720c2381-5877-4af2-85a0-01abf32decdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_720c2381-5877-4af2-85a0-01abf32decdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_720c2381-5877-4af2-85a0-01abf32decdf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_720c2381-5877-4af2-85a0-01abf32decdf" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_720c2381-5877-4af2-85a0-01abf32decdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_720c2381-5877-4af2-85a0-01abf32decdf" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmsynthezMember_d3e758a9-9622-4e88-a935-5d4c294c890a" xlink:href="opk-20220331.xsd#opk_PharmsynthezMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_PharmsynthezMember_d3e758a9-9622-4e88-a935-5d4c294c890a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CocrystalMember_b74b985d-f62d-416f-b3dc-51af7354f1e2" xlink:href="opk-20220331.xsd#opk_CocrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_CocrystalMember_b74b985d-f62d-416f-b3dc-51af7354f1e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NonInvasiveMonitoringSystemsInc.Member_1842faae-1c8b-4f6e-9d55-855a1b646dcb" xlink:href="opk-20220331.xsd#opk_NonInvasiveMonitoringSystemsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_NonInvasiveMonitoringSystemsInc.Member_1842faae-1c8b-4f6e-9d55-855a1b646dcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NeovascMember_3b4532e1-8db4-4b6d-9d1c-3d9f3aeb04f0" xlink:href="opk-20220331.xsd#opk_NeovascMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_NeovascMember_3b4532e1-8db4-4b6d-9d1c-3d9f3aeb04f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InCellDxIncMember_218e1eb4-008c-4709-ac3b-772e5007f7d1" xlink:href="opk-20220331.xsd#opk_InCellDxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_InCellDxIncMember_218e1eb4-008c-4709-ac3b-772e5007f7d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioCardiaInc.Member_84cd7949-36c1-4b6e-b2dc-d1537130f373" xlink:href="opk-20220331.xsd#opk_BioCardiaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_BioCardiaInc.Member_84cd7949-36c1-4b6e-b2dc-d1537130f373" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_XeneticBiosciencesInc.Member_7b146966-9236-46c2-857a-33f438ef6120" xlink:href="opk-20220331.xsd#opk_XeneticBiosciencesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_XeneticBiosciencesInc.Member_7b146966-9236-46c2-857a-33f438ef6120" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PhioPharmaceuticalsMember_de4ab131-99bc-4c7c-a68c-8b674aeb8452" xlink:href="opk-20220331.xsd#opk_PhioPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_PhioPharmaceuticalsMember_de4ab131-99bc-4c7c-a68c-8b674aeb8452" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_VBIVaccinesIncMember_e447dc85-c526-4c1a-b9b6-28688302d019" xlink:href="opk-20220331.xsd#opk_VBIVaccinesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_VBIVaccinesIncMember_e447dc85-c526-4c1a-b9b6-28688302d019" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChromaDexMember_f26688bd-1d44-4cf4-9fd7-593cff32d81b" xlink:href="opk-20220331.xsd#opk_ChromaDexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_ChromaDexMember_f26688bd-1d44-4cf4-9fd7-593cff32d81b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EloxxPharmaceuticalsMember_6f0e07f3-820d-4dc4-b4b4-3af745ecb667" xlink:href="opk-20220331.xsd#opk_EloxxPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_EloxxPharmaceuticalsMember_6f0e07f3-820d-4dc4-b4b4-3af745ecb667" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CAMP4Member_5f6d3bc1-f861-40b2-8bdf-bba45156c12c" xlink:href="opk-20220331.xsd#opk_CAMP4Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_CAMP4Member_5f6d3bc1-f861-40b2-8bdf-bba45156c12c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_HealthSnapMember_a2e47cec-a2ef-4ced-a065-bf3f07e45787" xlink:href="opk-20220331.xsd#opk_HealthSnapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_HealthSnapMember_a2e47cec-a2ef-4ced-a065-bf3f07e45787" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LeaderMedMember_78b43e84-381c-4c8d-ba0a-b623e7250bc8" xlink:href="opk-20220331.xsd#opk_LeaderMedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_LeaderMedMember_78b43e84-381c-4c8d-ba0a-b623e7250bc8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DetectGenomixMember_f4ef1f8e-6852-414e-8b50-3b8cfc6f7aa4" xlink:href="opk-20220331.xsd#opk_DetectGenomixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_DetectGenomixMember_f4ef1f8e-6852-414e-8b50-3b8cfc6f7aa4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ZebraMember_d5fdad77-3caf-4b10-b8df-1d9af7c7a9a1" xlink:href="opk-20220331.xsd#opk_ZebraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_ZebraMember_d5fdad77-3caf-4b10-b8df-1d9af7c7a9a1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_ab3a15a8-0f72-42e5-82db-552b65929cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_ab3a15a8-0f72-42e5-82db-552b65929cbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_ab3a15a8-0f72-42e5-82db-552b65929cbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_ab3a15a8-0f72-42e5-82db-552b65929cbe" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_ab3a15a8-0f72-42e5-82db-552b65929cbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4debf188-8b21-4b27-9d2a-a6ae6116fbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_ab3a15a8-0f72-42e5-82db-552b65929cbe" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4debf188-8b21-4b27-9d2a-a6ae6116fbe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_a3106de7-6f5b-4709-9b03-0d066475d91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4debf188-8b21-4b27-9d2a-a6ae6116fbe0" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_a3106de7-6f5b-4709-9b03-0d066475d91e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_266f7c42-242c-4958-858d-a1aabd16aacf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_srt_ConsolidatedEntitiesAxis_266f7c42-242c-4958-858d-a1aabd16aacf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_266f7c42-242c-4958-858d-a1aabd16aacf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_266f7c42-242c-4958-858d-a1aabd16aacf" xlink:to="loc_srt_ConsolidatedEntitiesDomain_266f7c42-242c-4958-858d-a1aabd16aacf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_94e0eb50-ff24-44d0-9a90-d1c205d2afd6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_266f7c42-242c-4958-858d-a1aabd16aacf" xlink:to="loc_srt_ConsolidatedEntitiesDomain_94e0eb50-ff24-44d0-9a90-d1c205d2afd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_c5e9660b-07f6-48e2-8f10-4d907543a559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_94e0eb50-ff24-44d0-9a90-d1c205d2afd6" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_c5e9660b-07f6-48e2-8f10-4d907543a559" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_675b30cf-7f09-4d6c-ad4e-a4227d023237" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_srt_CounterpartyNameAxis_675b30cf-7f09-4d6c-ad4e-a4227d023237" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_675b30cf-7f09-4d6c-ad4e-a4227d023237_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_675b30cf-7f09-4d6c-ad4e-a4227d023237" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_675b30cf-7f09-4d6c-ad4e-a4227d023237_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6164ca94-929b-4d19-bf3c-fe859836fed9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_675b30cf-7f09-4d6c-ad4e-a4227d023237" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6164ca94-929b-4d19-bf3c-fe859836fed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LeaderMedMember_df9b0900-a4ba-434b-971d-34963ca1a3bf" xlink:href="opk-20220331.xsd#opk_LeaderMedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6164ca94-929b-4d19-bf3c-fe859836fed9" xlink:to="loc_opk_LeaderMedMember_df9b0900-a4ba-434b-971d-34963ca1a3bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5d68512d-406e-410c-a19d-2e4a79cedfe2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_srt_OwnershipAxis_5d68512d-406e-410c-a19d-2e4a79cedfe2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5d68512d-406e-410c-a19d-2e4a79cedfe2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_5d68512d-406e-410c-a19d-2e4a79cedfe2" xlink:to="loc_srt_OwnershipDomain_5d68512d-406e-410c-a19d-2e4a79cedfe2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_007084f8-5630-48af-8301-0f9e63a6b525" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_5d68512d-406e-410c-a19d-2e4a79cedfe2" xlink:to="loc_srt_OwnershipDomain_007084f8-5630-48af-8301-0f9e63a6b525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LeaderMedJointVentureMember_20df0c93-fd32-4b99-a61c-b4cd1195362b" xlink:href="opk-20220331.xsd#opk_LeaderMedJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_007084f8-5630-48af-8301-0f9e63a6b525" xlink:to="loc_opk_LeaderMedJointVentureMember_20df0c93-fd32-4b99-a61c-b4cd1195362b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_441da562-a141-4411-8365-f6ae18c5798e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_441da562-a141-4411-8365-f6ae18c5798e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_441da562-a141-4411-8365-f6ae18c5798e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_441da562-a141-4411-8365-f6ae18c5798e" xlink:to="loc_us-gaap_RelatedPartyDomain_441da562-a141-4411-8365-f6ae18c5798e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_643bda56-7edf-4d81-9929-f3192e6858f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_441da562-a141-4411-8365-f6ae18c5798e" xlink:to="loc_us-gaap_RelatedPartyDomain_643bda56-7edf-4d81-9929-f3192e6858f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_701bc2ea-ca0a-46f1-82af-03d6ae0f1384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_643bda56-7edf-4d81-9929-f3192e6858f8" xlink:to="loc_us-gaap_CorporateJointVentureMember_701bc2ea-ca0a-46f1-82af-03d6ae0f1384" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_943bb446-5928-4b8b-a186-43e516de35e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_srt_ProductOrServiceAxis_943bb446-5928-4b8b-a186-43e516de35e3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_943bb446-5928-4b8b-a186-43e516de35e3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_943bb446-5928-4b8b-a186-43e516de35e3" xlink:to="loc_srt_ProductsAndServicesDomain_943bb446-5928-4b8b-a186-43e516de35e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2a46b7b6-1c1a-4759-9f80-a55feb7b31e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_943bb446-5928-4b8b-a186-43e516de35e3" xlink:to="loc_srt_ProductsAndServicesDomain_2a46b7b6-1c1a-4759-9f80-a55feb7b31e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_b8142100-171f-4cb6-8078-c7d01db9fcc0" xlink:href="opk-20220331.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a46b7b6-1c1a-4759-9f80-a55feb7b31e8" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_b8142100-171f-4cb6-8078-c7d01db9fcc0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtScheduleofDebtDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DebtScheduleofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DebtScheduleofDebtDetails" xlink:type="extended" id="ib13fff21e533488782bbaed83d2a627f_DebtScheduleofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a9da8d56-4d6f-43b8-a175-c3d5c2062623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_601677b5-3b1e-42b6-bfae-90625b0469c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9da8d56-4d6f-43b8-a175-c3d5c2062623" xlink:to="loc_us-gaap_LongTermDebt_601677b5-3b1e-42b6-bfae-90625b0469c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b286aa66-5b4b-406b-907a-50821f730a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9da8d56-4d6f-43b8-a175-c3d5c2062623" xlink:to="loc_us-gaap_LongTermDebtCurrent_b286aa66-5b4b-406b-907a-50821f730a40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_44bfd9f8-54d0-412b-b8db-0dec2201d3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9da8d56-4d6f-43b8-a175-c3d5c2062623" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_44bfd9f8-54d0-412b-b8db-0dec2201d3ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e30a42d4-efb6-462f-ba2e-116e910c98f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9da8d56-4d6f-43b8-a175-c3d5c2062623" xlink:to="loc_us-gaap_DebtInstrumentTable_e30a42d4-efb6-462f-ba2e-116e910c98f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9d4e734d-193e-41e7-9633-d5971891b98e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e30a42d4-efb6-462f-ba2e-116e910c98f0" xlink:to="loc_us-gaap_DebtInstrumentAxis_9d4e734d-193e-41e7-9633-d5971891b98e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9d4e734d-193e-41e7-9633-d5971891b98e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d4e734d-193e-41e7-9633-d5971891b98e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9d4e734d-193e-41e7-9633-d5971891b98e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_157d7b56-b7bf-4e6e-b974-a36b23bb71cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d4e734d-193e-41e7-9633-d5971891b98e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_157d7b56-b7bf-4e6e-b974-a36b23bb71cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ConvertibleSeniorNotesDue2025Member_c55a896b-7ee1-45a0-98ec-eeee4bda873a" xlink:href="opk-20220331.xsd#opk_ConvertibleSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_157d7b56-b7bf-4e6e-b974-a36b23bb71cc" xlink:to="loc_opk_ConvertibleSeniorNotesDue2025Member_c55a896b-7ee1-45a0-98ec-eeee4bda873a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_A5ConvertibleNotesMember_60a04b73-6dd8-4a2c-b6d0-05a4e829dd6d" xlink:href="opk-20220331.xsd#opk_A5ConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_157d7b56-b7bf-4e6e-b974-a36b23bb71cc" xlink:to="loc_opk_A5ConvertibleNotesMember_60a04b73-6dd8-4a2c-b6d0-05a4e829dd6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NotesDueFebruary12033Member_4897104a-44e5-4daf-bb8e-b882ea3ada09" xlink:href="opk-20220331.xsd#opk_NotesDueFebruary12033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_157d7b56-b7bf-4e6e-b974-a36b23bb71cc" xlink:to="loc_opk_NotesDueFebruary12033Member_4897104a-44e5-4daf-bb8e-b882ea3ada09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_86b4ab33-8962-4850-96b2-cf9749a0b30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e30a42d4-efb6-462f-ba2e-116e910c98f0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_86b4ab33-8962-4850-96b2-cf9749a0b30c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_86b4ab33-8962-4850-96b2-cf9749a0b30c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_86b4ab33-8962-4850-96b2-cf9749a0b30c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_86b4ab33-8962-4850-96b2-cf9749a0b30c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3890c795-d210-473f-877c-f431b85879f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_86b4ab33-8962-4850-96b2-cf9749a0b30c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3890c795-d210-473f-877c-f431b85879f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_fb62dd66-84e8-4c6d-8279-5e9bf43077fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3890c795-d210-473f-877c-f431b85879f0" xlink:to="loc_us-gaap_ConvertibleDebtMember_fb62dd66-84e8-4c6d-8279-5e9bf43077fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_c9aae9b0-b7a8-49ea-9caf-1eb43c74aad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3890c795-d210-473f-877c-f431b85879f0" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_c9aae9b0-b7a8-49ea-9caf-1eb43c74aad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_0e56c7ea-1e4b-426a-8f70-533082f9d836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3890c795-d210-473f-877c-f431b85879f0" xlink:to="loc_us-gaap_LineOfCreditMember_0e56c7ea-1e4b-426a-8f70-533082f9d836" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_34fe8a95-56ae-4114-9ab0-d6c5c66e1f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3890c795-d210-473f-877c-f431b85879f0" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_34fe8a95-56ae-4114-9ab0-d6c5c66e1f6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1c28e818-4e98-40d2-bd5e-35233b68c546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e30a42d4-efb6-462f-ba2e-116e910c98f0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1c28e818-4e98-40d2-bd5e-35233b68c546" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1c28e818-4e98-40d2-bd5e-35233b68c546_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1c28e818-4e98-40d2-bd5e-35233b68c546" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1c28e818-4e98-40d2-bd5e-35233b68c546_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_861db5cb-2898-4ed3-b3c4-a4a70bf2d85c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1c28e818-4e98-40d2-bd5e-35233b68c546" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_861db5cb-2898-4ed3-b3c4-a4a70bf2d85c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ConvertibleNotesMember_9676aef8-a618-4f52-8a31-9554f0425bc0" xlink:href="opk-20220331.xsd#opk_ConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_861db5cb-2898-4ed3-b3c4-a4a70bf2d85c" xlink:to="loc_opk_ConvertibleNotesMember_9676aef8-a618-4f52-8a31-9554f0425bc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditAndNotesAndLoansPayableCurrentMember_73cf7881-8a88-4454-ba88-566494eacb90" xlink:href="opk-20220331.xsd#opk_LineOfCreditAndNotesAndLoansPayableCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_861db5cb-2898-4ed3-b3c4-a4a70bf2d85c" xlink:to="loc_opk_LineOfCreditAndNotesAndLoansPayableCurrentMember_73cf7881-8a88-4454-ba88-566494eacb90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e26a7616-9fe2-42cf-9d53-5ec4d17ce6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_861db5cb-2898-4ed3-b3c4-a4a70bf2d85c" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e26a7616-9fe2-42cf-9d53-5ec4d17ce6ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7070f6c8-f240-4437-9286-361b6a4add84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e30a42d4-efb6-462f-ba2e-116e910c98f0" xlink:to="loc_us-gaap_CreditFacilityAxis_7070f6c8-f240-4437-9286-361b6a4add84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7070f6c8-f240-4437-9286-361b6a4add84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_7070f6c8-f240-4437-9286-361b6a4add84" xlink:to="loc_us-gaap_CreditFacilityDomain_7070f6c8-f240-4437-9286-361b6a4add84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3245c87a-5b98-488d-a28a-866597814532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_7070f6c8-f240-4437-9286-361b6a4add84" xlink:to="loc_us-gaap_CreditFacilityDomain_3245c87a-5b98-488d-a28a-866597814532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f2ca5e67-4824-4db4-9fad-fed454541119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_3245c87a-5b98-488d-a28a-866597814532" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f2ca5e67-4824-4db4-9fad-fed454541119" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DebtNarrativeDetails" xlink:type="extended" id="i119138d33b4c46a19afb1939c7006513_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7c2b1caa-1930-43d9-8a81-2b7cafe1a8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7c2b1caa-1930-43d9-8a81-2b7cafe1a8b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_fbb7306f-d896-44a5-a87e-c26161b636db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_fbb7306f-d896-44a5-a87e-c26161b636db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_2d7dc40d-5c36-4603-977b-e61c09b7b6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LineOfCredit_2d7dc40d-5c36-4603-977b-e61c09b7b6c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_dc0de6d1-9904-44f9-861d-956fbc0c7dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_dc0de6d1-9904-44f9-861d-956fbc0c7dfe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c6ea105-1bb3-4b21-ba9d-41785693511a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c6ea105-1bb3-4b21-ba9d-41785693511a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_7c762d0d-37ec-41a6-94d7-72513f419d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_7c762d0d-37ec-41a6-94d7-72513f419d14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0a7d5fef-c19c-4959-9fca-3fd1d7ae4f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0a7d5fef-c19c-4959-9fca-3fd1d7ae4f23" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_db971637-d22b-4ab7-ae3c-d44d2c4c4769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_db971637-d22b-4ab7-ae3c-d44d2c4c4769" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_11dd4ed8-22f5-4079-b074-a9e9a98b6d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_11dd4ed8-22f5-4079-b074-a9e9a98b6d5d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d5c223fe-1fe3-4ae0-9210-8baa74307fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d5c223fe-1fe3-4ae0-9210-8baa74307fcc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3a28dea8-eb77-4d55-88db-65b04ba5ea1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3a28dea8-eb77-4d55-88db-65b04ba5ea1d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_7eedda53-f293-4aae-ba93-eea38788e47e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_7eedda53-f293-4aae-ba93-eea38788e47e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_22932238-a35c-4c14-81e8-73de036ee075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_22932238-a35c-4c14-81e8-73de036ee075" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GainLossOnConversionOfDebt_b466caa0-0047-43cf-b721-536100217d84" xlink:href="opk-20220331.xsd#opk_GainLossOnConversionOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_opk_GainLossOnConversionOfDebt_b466caa0-0047-43cf-b721-536100217d84" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable_9ec4fc2e-6b87-47fe-a2f6-9433c06d7c4b" xlink:href="opk-20220331.xsd#opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable_9ec4fc2e-6b87-47fe-a2f6-9433c06d7c4b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable_1e290230-3476-4d63-b157-7ee529c86f8b" xlink:href="opk-20220331.xsd#opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable_1e290230-3476-4d63-b157-7ee529c86f8b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromConvertibleDebtConversionFee_c02de2ba-b459-4bfd-b8d4-e03f46290165" xlink:href="opk-20220331.xsd#opk_ProceedsFromConvertibleDebtConversionFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_opk_ProceedsFromConvertibleDebtConversionFee_c02de2ba-b459-4bfd-b8d4-e03f46290165" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_c7fbdb23-3a1a-47c7-9150-4950adfad1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_c7fbdb23-3a1a-47c7-9150-4950adfad1d4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_af4553d9-d37d-42b2-a6b7-a1bc7c45c909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_af4553d9-d37d-42b2-a6b7-a1bc7c45c909" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2a9fde0-74ff-4bb8-8c3d-adf7b450b922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2a9fde0-74ff-4bb8-8c3d-adf7b450b922" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_1877a839-c6c2-4292-acce-b228787b693c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentTerm_1877a839-c6c2-4292-acce-b228787b693c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum_639c8f9b-41f7-4c1a-af58-b019071b6207" xlink:href="opk-20220331.xsd#opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum_639c8f9b-41f7-4c1a-af58-b019071b6207" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum_4ac03ef4-cac9-411c-822e-4d3fc96487ce" xlink:href="opk-20220331.xsd#opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum_4ac03ef4-cac9-411c-822e-4d3fc96487ce" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_93408de1-1169-404e-8454-f02b282510e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_93408de1-1169-404e-8454-f02b282510e7" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_60d720cb-aee2-4007-8ad4-1eb6ec1c3a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LongTermDebt_60d720cb-aee2-4007-8ad4-1eb6ec1c3a3c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_2d6d8a30-023b-4c10-bfe8-98da9bbb7071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_2d6d8a30-023b-4c10-bfe8-98da9bbb7071" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9d693411-80ca-4452-beda-b4be56fd9d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9d693411-80ca-4452-beda-b4be56fd9d3b" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_64481e5b-ef06-436e-810b-503363484962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_64481e5b-ef06-436e-810b-503363484962" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_d56b2887-599d-4819-858d-cb2b92b398bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LongTermLineOfCredit_d56b2887-599d-4819-858d-cb2b92b398bc" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6000a5a7-8c80-4d26-a6d9-4eeff5f23ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_StockholdersEquity_6000a5a7-8c80-4d26-a6d9-4eeff5f23ab1" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_901c88bc-4f53-4f89-979b-74aa313c91ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_Goodwill_901c88bc-4f53-4f89-979b-74aa313c91ba" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0a53f3a4-f47e-4acd-a6df-3786286cc256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0a53f3a4-f47e-4acd-a6df-3786286cc256" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentsNumberofFinancialInstitutions_885b4e7f-4739-49ae-93b1-c2d4718b21f7" xlink:href="opk-20220331.xsd#opk_DebtInstrumentsNumberofFinancialInstitutions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_opk_DebtInstrumentsNumberofFinancialInstitutions_885b4e7f-4739-49ae-93b1-c2d4718b21f7" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_b1260d65-70b5-40f9-948a-8ccd587fa6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_b1260d65-70b5-40f9-948a-8ccd587fa6ed" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_40962dfb-366f-4f38-b606-e360a0f74d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_40962dfb-366f-4f38-b606-e360a0f74d80" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ca46bc02-aa4d-4d6b-bc33-e27d80adbf21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ca46bc02-aa4d-4d6b-bc33-e27d80adbf21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ca46bc02-aa4d-4d6b-bc33-e27d80adbf21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ca46bc02-aa4d-4d6b-bc33-e27d80adbf21" xlink:to="loc_us-gaap_ClassOfStockDomain_ca46bc02-aa4d-4d6b-bc33-e27d80adbf21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_34b6f171-e060-4ff6-9728-747a680d877e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ca46bc02-aa4d-4d6b-bc33-e27d80adbf21" xlink:to="loc_us-gaap_ClassOfStockDomain_34b6f171-e060-4ff6-9728-747a680d877e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_95e7b631-179a-4995-9540-02d3de87c103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_34b6f171-e060-4ff6-9728-747a680d877e" xlink:to="loc_us-gaap_CommonStockMember_95e7b631-179a-4995-9540-02d3de87c103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_bccd96c8-3832-4bb9-b399-4865350cece4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_VariableRateAxis_bccd96c8-3832-4bb9-b399-4865350cece4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_bccd96c8-3832-4bb9-b399-4865350cece4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_bccd96c8-3832-4bb9-b399-4865350cece4" xlink:to="loc_us-gaap_VariableRateDomain_bccd96c8-3832-4bb9-b399-4865350cece4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4569615d-05a8-4efc-9212-69c61ada4157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_bccd96c8-3832-4bb9-b399-4865350cece4" xlink:to="loc_us-gaap_VariableRateDomain_4569615d-05a8-4efc-9212-69c61ada4157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e13952dd-bb73-42ee-b01a-993afe620093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4569615d-05a8-4efc-9212-69c61ada4157" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e13952dd-bb73-42ee-b01a-993afe620093" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember_6773cfab-5fe5-4cc4-b472-53a059d0d5e6" xlink:href="opk-20220331.xsd#opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4569615d-05a8-4efc-9212-69c61ada4157" xlink:to="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember_6773cfab-5fe5-4cc4-b472-53a059d0d5e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember_8e3b492a-a206-4a2c-9ed8-dfba8c82d43a" xlink:href="opk-20220331.xsd#opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4569615d-05a8-4efc-9212-69c61ada4157" xlink:to="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember_8e3b492a-a206-4a2c-9ed8-dfba8c82d43a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_081f3f12-0903-4813-96c4-54a6f423bfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_CreditFacilityAxis_081f3f12-0903-4813-96c4-54a6f423bfc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_081f3f12-0903-4813-96c4-54a6f423bfc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_081f3f12-0903-4813-96c4-54a6f423bfc5" xlink:to="loc_us-gaap_CreditFacilityDomain_081f3f12-0903-4813-96c4-54a6f423bfc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_55287289-6b77-4e77-b29b-e54f22528c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_081f3f12-0903-4813-96c4-54a6f423bfc5" xlink:to="loc_us-gaap_CreditFacilityDomain_55287289-6b77-4e77-b29b-e54f22528c6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2de05934-b88e-450f-962d-a148c53d62ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_55287289-6b77-4e77-b29b-e54f22528c6b" xlink:to="loc_us-gaap_LineOfCreditMember_2de05934-b88e-450f-962d-a148c53d62ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a8f6fd15-777e-4f5f-9a4f-571e8bdcd158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_55287289-6b77-4e77-b29b-e54f22528c6b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a8f6fd15-777e-4f5f-9a4f-571e8bdcd158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_a5ddde11-37d3-412f-92ac-36dd2514e76d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_55287289-6b77-4e77-b29b-e54f22528c6b" xlink:to="loc_us-gaap_BridgeLoanMember_a5ddde11-37d3-412f-92ac-36dd2514e76d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_d63c8246-4847-40fe-b01a-a4467ca6f49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_55287289-6b77-4e77-b29b-e54f22528c6b" xlink:to="loc_us-gaap_LetterOfCreditMember_d63c8246-4847-40fe-b01a-a4467ca6f49f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3c396b6f-256a-41a9-9aa9-5a1a455fd51a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3c396b6f-256a-41a9-9aa9-5a1a455fd51a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3c396b6f-256a-41a9-9aa9-5a1a455fd51a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3c396b6f-256a-41a9-9aa9-5a1a455fd51a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3c396b6f-256a-41a9-9aa9-5a1a455fd51a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cd4bfc8f-626c-416e-bf9f-4e512b27a0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3c396b6f-256a-41a9-9aa9-5a1a455fd51a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cd4bfc8f-626c-416e-bf9f-4e512b27a0b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_9ead634e-3c0f-4d26-bb93-6729562f16e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cd4bfc8f-626c-416e-bf9f-4e512b27a0b6" xlink:to="loc_us-gaap_UnsecuredDebtMember_9ead634e-3c0f-4d26-bb93-6729562f16e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_b5f80023-47bd-41a6-ae94-fdef7805903d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cd4bfc8f-626c-416e-bf9f-4e512b27a0b6" xlink:to="loc_us-gaap_LineOfCreditMember_b5f80023-47bd-41a6-ae94-fdef7805903d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_e019cbe2-aca5-4475-8a32-9fbf81ec9376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cd4bfc8f-626c-416e-bf9f-4e512b27a0b6" xlink:to="loc_us-gaap_ConvertibleDebtMember_e019cbe2-aca5-4475-8a32-9fbf81ec9376" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_aaf5a073-ffd9-451c-bb4d-d30c45b807a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cd4bfc8f-626c-416e-bf9f-4e512b27a0b6" xlink:to="loc_us-gaap_SeniorNotesMember_aaf5a073-ffd9-451c-bb4d-d30c45b807a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_309b7dbb-362c-4a27-98ad-25e3edf0c2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cd4bfc8f-626c-416e-bf9f-4e512b27a0b6" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_309b7dbb-362c-4a27-98ad-25e3edf0c2c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_99e5e34e-c120-4903-9c5d-0001db7cc535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_DebtInstrumentAxis_99e5e34e-c120-4903-9c5d-0001db7cc535" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_99e5e34e-c120-4903-9c5d-0001db7cc535_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_99e5e34e-c120-4903-9c5d-0001db7cc535" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_99e5e34e-c120-4903-9c5d-0001db7cc535_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6e0cac74-6047-4a50-bebf-bff71d0aac1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_99e5e34e-c120-4903-9c5d-0001db7cc535" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6e0cac74-6047-4a50-bebf-bff71d0aac1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NewCreditAgreementMember_12647a50-03af-4541-b4b0-a936e6972e73" xlink:href="opk-20220331.xsd#opk_NewCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6e0cac74-6047-4a50-bebf-bff71d0aac1c" xlink:to="loc_opk_NewCreditAgreementMember_12647a50-03af-4541-b4b0-a936e6972e73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ConvertibleSeniorNotesDue2025Member_88ae14b2-eb47-4ab4-a3b5-3d442b1f97d6" xlink:href="opk-20220331.xsd#opk_ConvertibleSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6e0cac74-6047-4a50-bebf-bff71d0aac1c" xlink:to="loc_opk_ConvertibleSeniorNotesDue2025Member_88ae14b2-eb47-4ab4-a3b5-3d442b1f97d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_A5ConvertibleNotesMember_de5ba9bc-22a4-4c84-a2e3-88cb185c85d7" xlink:href="opk-20220331.xsd#opk_A5ConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6e0cac74-6047-4a50-bebf-bff71d0aac1c" xlink:to="loc_opk_A5ConvertibleNotesMember_de5ba9bc-22a4-4c84-a2e3-88cb185c85d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NotesDueFebruary12033Member_da6ba75e-54d0-4dac-8b22-7595efe07c36" xlink:href="opk-20220331.xsd#opk_NotesDueFebruary12033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6e0cac74-6047-4a50-bebf-bff71d0aac1c" xlink:to="loc_opk_NotesDueFebruary12033Member_da6ba75e-54d0-4dac-8b22-7595efe07c36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e1bcd881-57e6-4381-b74b-ed2b521bd61d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e1bcd881-57e6-4381-b74b-ed2b521bd61d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e1bcd881-57e6-4381-b74b-ed2b521bd61d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e1bcd881-57e6-4381-b74b-ed2b521bd61d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e1bcd881-57e6-4381-b74b-ed2b521bd61d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f225c56-795a-4a7b-a11a-4e3f754174bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e1bcd881-57e6-4381-b74b-ed2b521bd61d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f225c56-795a-4a7b-a11a-4e3f754174bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_24f1bef3-96f7-406a-bfb0-de86709d939f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f225c56-795a-4a7b-a11a-4e3f754174bd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_24f1bef3-96f7-406a-bfb0-de86709d939f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5dc3e09a-feaf-42e6-bc8f-2d798b22ba3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f225c56-795a-4a7b-a11a-4e3f754174bd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5dc3e09a-feaf-42e6-bc8f-2d798b22ba3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_1ec3d728-5825-42c6-8209-a7e2df7bef74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f225c56-795a-4a7b-a11a-4e3f754174bd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_1ec3d728-5825-42c6-8209-a7e2df7bef74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8abe1d03-c4e9-486b-96a8-17ba233acf7c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_srt_RangeAxis_8abe1d03-c4e9-486b-96a8-17ba233acf7c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8abe1d03-c4e9-486b-96a8-17ba233acf7c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8abe1d03-c4e9-486b-96a8-17ba233acf7c" xlink:to="loc_srt_RangeMember_8abe1d03-c4e9-486b-96a8-17ba233acf7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_30630e5b-e88e-4015-91bd-80b2455c6276" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8abe1d03-c4e9-486b-96a8-17ba233acf7c" xlink:to="loc_srt_RangeMember_30630e5b-e88e-4015-91bd-80b2455c6276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c4d677d4-48b9-4be1-ba8b-8d4ab895ed8a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_30630e5b-e88e-4015-91bd-80b2455c6276" xlink:to="loc_srt_MinimumMember_c4d677d4-48b9-4be1-ba8b-8d4ab895ed8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2792804c-673d-409c-a1d8-237529dc2725" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_30630e5b-e88e-4015-91bd-80b2455c6276" xlink:to="loc_srt_MaximumMember_2792804c-673d-409c-a1d8-237529dc2725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ddd97c20-1a48-4e9e-a476-04344a5ee06f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ddd97c20-1a48-4e9e-a476-04344a5ee06f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ddd97c20-1a48-4e9e-a476-04344a5ee06f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ddd97c20-1a48-4e9e-a476-04344a5ee06f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ddd97c20-1a48-4e9e-a476-04344a5ee06f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_967a90f7-3899-4fc5-b69b-a2e1bd05d1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ddd97c20-1a48-4e9e-a476-04344a5ee06f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_967a90f7-3899-4fc5-b69b-a2e1bd05d1e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioReferenceMember_efaf238e-1314-40ae-a537-53ea7dff13f7" xlink:href="opk-20220331.xsd#opk_BioReferenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_967a90f7-3899-4fc5-b69b-a2e1bd05d1e9" xlink:to="loc_opk_BioReferenceMember_efaf238e-1314-40ae-a537-53ea7dff13f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOHealthEuropeMember_dfafa645-74ea-4efb-aaba-d541c9e31384" xlink:href="opk-20220331.xsd#opk_OPKOHealthEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_967a90f7-3899-4fc5-b69b-a2e1bd05d1e9" xlink:to="loc_opk_OPKOHealthEuropeMember_dfafa645-74ea-4efb-aaba-d541c9e31384" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditFacilityRevolvingCommitmentAxis_3ce24e9f-291c-4000-a9c1-0c4d49b54e43" xlink:href="opk-20220331.xsd#opk_LineOfCreditFacilityRevolvingCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_opk_LineOfCreditFacilityRevolvingCommitmentAxis_3ce24e9f-291c-4000-a9c1-0c4d49b54e43" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditFacilityRevolvingCommitmentDomain_3ce24e9f-291c-4000-a9c1-0c4d49b54e43_default" xlink:href="opk-20220331.xsd#opk_LineOfCreditFacilityRevolvingCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_opk_LineOfCreditFacilityRevolvingCommitmentAxis_3ce24e9f-291c-4000-a9c1-0c4d49b54e43" xlink:to="loc_opk_LineOfCreditFacilityRevolvingCommitmentDomain_3ce24e9f-291c-4000-a9c1-0c4d49b54e43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditFacilityRevolvingCommitmentDomain_b1cc96c8-790d-4ae9-ba56-25aae9355464" xlink:href="opk-20220331.xsd#opk_LineOfCreditFacilityRevolvingCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_opk_LineOfCreditFacilityRevolvingCommitmentAxis_3ce24e9f-291c-4000-a9c1-0c4d49b54e43" xlink:to="loc_opk_LineOfCreditFacilityRevolvingCommitmentDomain_b1cc96c8-790d-4ae9-ba56-25aae9355464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember_51d23cc6-93fa-4059-a2b4-eccb54994ad3" xlink:href="opk-20220331.xsd#opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_LineOfCreditFacilityRevolvingCommitmentDomain_b1cc96c8-790d-4ae9-ba56-25aae9355464" xlink:to="loc_opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember_51d23cc6-93fa-4059-a2b4-eccb54994ad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember_5e7d5a99-5e48-4aae-b133-8361827dac21" xlink:href="opk-20220331.xsd#opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_LineOfCreditFacilityRevolvingCommitmentDomain_b1cc96c8-790d-4ae9-ba56-25aae9355464" xlink:to="loc_opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember_5e7d5a99-5e48-4aae-b133-8361827dac21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1cb8f3df-ba77-4959-bb72-28a38b90ce30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1cb8f3df-ba77-4959-bb72-28a38b90ce30" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1cb8f3df-ba77-4959-bb72-28a38b90ce30_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1cb8f3df-ba77-4959-bb72-28a38b90ce30" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1cb8f3df-ba77-4959-bb72-28a38b90ce30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_27ef0d40-22fe-4e21-ac88-6edefad3ef66" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1cb8f3df-ba77-4959-bb72-28a38b90ce30" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_27ef0d40-22fe-4e21-ac88-6edefad3ef66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fa348095-c1be-45fd-8933-3e5330606132" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_27ef0d40-22fe-4e21-ac88-6edefad3ef66" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fa348095-c1be-45fd-8933-3e5330606132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cf7a4304-e950-4ec4-bef4-ad3881f0e23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cf7a4304-e950-4ec4-bef4-ad3881f0e23a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_cf7a4304-e950-4ec4-bef4-ad3881f0e23a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cf7a4304-e950-4ec4-bef4-ad3881f0e23a" xlink:to="loc_us-gaap_TypeOfAdoptionMember_cf7a4304-e950-4ec4-bef4-ad3881f0e23a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_206f4e82-51f1-4867-bb9a-073600adb413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cf7a4304-e950-4ec4-bef4-ad3881f0e23a" xlink:to="loc_us-gaap_TypeOfAdoptionMember_206f4e82-51f1-4867-bb9a-073600adb413" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_0413886d-eb1a-453b-aac0-83289e9a4d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_206f4e82-51f1-4867-bb9a-073600adb413" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_0413886d-eb1a-453b-aac0-83289e9a4d74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_38d0a7ce-52d7-496c-9c30-27abcdb1ac72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_38d0a7ce-52d7-496c-9c30-27abcdb1ac72" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_38d0a7ce-52d7-496c-9c30-27abcdb1ac72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38d0a7ce-52d7-496c-9c30-27abcdb1ac72" xlink:to="loc_us-gaap_EquityComponentDomain_38d0a7ce-52d7-496c-9c30-27abcdb1ac72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_21aa5d87-4029-4295-b380-fb05029340bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38d0a7ce-52d7-496c-9c30-27abcdb1ac72" xlink:to="loc_us-gaap_EquityComponentDomain_21aa5d87-4029-4295-b380-fb05029340bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_397f615a-adab-4e2a-9123-4b640a1fde57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21aa5d87-4029-4295-b380-fb05029340bc" xlink:to="loc_us-gaap_RetainedEarningsMember_397f615a-adab-4e2a-9123-4b640a1fde57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f67b09fc-9cea-4c76-8b61-74d182dd06db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21aa5d87-4029-4295-b380-fb05029340bc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f67b09fc-9cea-4c76-8b61-74d182dd06db" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtScheduleofNotesDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DebtScheduleofNotesDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DebtScheduleofNotesDetails" xlink:type="extended" id="i29b71035f3d14ea4ba68f7850ed220bf_DebtScheduleofNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f5e608eb-4679-46e1-9240-adf8fd1851da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentRollForward_7bb7e602-8b1b-4902-adbb-b6d04a63bc3a" xlink:href="opk-20220331.xsd#opk_DebtInstrumentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f5e608eb-4679-46e1-9240-adf8fd1851da" xlink:to="loc_opk_DebtInstrumentRollForward_7bb7e602-8b1b-4902-adbb-b6d04a63bc3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_c34f9779-20eb-4ed4-8fe2-3e8ea162d852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_DebtInstrumentRollForward_7bb7e602-8b1b-4902-adbb-b6d04a63bc3a" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_c34f9779-20eb-4ed4-8fe2-3e8ea162d852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9c246c99-16fc-4aa2-8768-b8fe2e8520d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_c34f9779-20eb-4ed4-8fe2-3e8ea162d852" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9c246c99-16fc-4aa2-8768-b8fe2e8520d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ff9cfd12-f798-43c8-bdd4-96ef40cd153d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_afa8bf33-f609-46d9-bc6d-7b723c5c4eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_DebtInstrumentRollForward_7bb7e602-8b1b-4902-adbb-b6d04a63bc3a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_afa8bf33-f609-46d9-bc6d-7b723c5c4eb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4612580e-7fea-4b7e-94a2-423baccdc899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_afa8bf33-f609-46d9-bc6d-7b723c5c4eb9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4612580e-7fea-4b7e-94a2-423baccdc899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_e6362037-04c0-470c-8f8e-1c9c9dc954c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_afa8bf33-f609-46d9-bc6d-7b723c5c4eb9" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_e6362037-04c0-470c-8f8e-1c9c9dc954c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_023d9fe5-de43-4a5d-9e93-bee313512fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNetAbstract_4c3c0cd3-1cf6-494d-a979-5721339f3b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_DebtInstrumentRollForward_7bb7e602-8b1b-4902-adbb-b6d04a63bc3a" xlink:to="loc_us-gaap_DeferredFinanceCostsNetAbstract_4c3c0cd3-1cf6-494d-a979-5721339f3b80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_d850f94a-7fc0-4a5d-a57f-db730e5518ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_4c3c0cd3-1cf6-494d-a979-5721339f3b80" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_d850f94a-7fc0-4a5d-a57f-db730e5518ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_73c24fa7-ee92-4b25-ba11-8c826ea556e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_4c3c0cd3-1cf6-494d-a979-5721339f3b80" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_73c24fa7-ee92-4b25-ba11-8c826ea556e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_65bb1cf8-8cff-420f-9592-8c2d3d237df4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAbstract_e3538309-4151-4f2b-bde8-31b4d9b4b4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_DebtInstrumentRollForward_7bb7e602-8b1b-4902-adbb-b6d04a63bc3a" xlink:to="loc_us-gaap_LongTermDebtAbstract_e3538309-4151-4f2b-bde8-31b4d9b4b4b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_47325d0e-f45c-4605-ae27-cfc3358e2b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAbstract_e3538309-4151-4f2b-bde8-31b4d9b4b4b7" xlink:to="loc_us-gaap_LongTermDebt_47325d0e-f45c-4605-ae27-cfc3358e2b8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9f33d748-3636-4ee4-ad4f-4f1c35cc6310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAbstract_e3538309-4151-4f2b-bde8-31b4d9b4b4b7" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9f33d748-3636-4ee4-ad4f-4f1c35cc6310" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3702bbdd-7382-4215-89d8-4f0f42a80e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a7be0d02-972b-40bd-884f-e7e89fa98981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f5e608eb-4679-46e1-9240-adf8fd1851da" xlink:to="loc_us-gaap_DebtInstrumentTable_a7be0d02-972b-40bd-884f-e7e89fa98981" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6c2e52b3-97f6-42a9-82fc-0f0b47f3b7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a7be0d02-972b-40bd-884f-e7e89fa98981" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6c2e52b3-97f6-42a9-82fc-0f0b47f3b7c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6c2e52b3-97f6-42a9-82fc-0f0b47f3b7c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6c2e52b3-97f6-42a9-82fc-0f0b47f3b7c1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6c2e52b3-97f6-42a9-82fc-0f0b47f3b7c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_729e91e0-6d32-4fcd-bcf1-560621c7b989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6c2e52b3-97f6-42a9-82fc-0f0b47f3b7c1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_729e91e0-6d32-4fcd-bcf1-560621c7b989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f5dc8cb4-29f5-426f-b419-304f7e2ec068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_729e91e0-6d32-4fcd-bcf1-560621c7b989" xlink:to="loc_us-gaap_SeniorNotesMember_f5dc8cb4-29f5-426f-b419-304f7e2ec068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_32e02558-c77a-4049-9118-cc8f7fa243e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a7be0d02-972b-40bd-884f-e7e89fa98981" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_32e02558-c77a-4049-9118-cc8f7fa243e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_32e02558-c77a-4049-9118-cc8f7fa243e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_32e02558-c77a-4049-9118-cc8f7fa243e2" xlink:to="loc_us-gaap_TypeOfAdoptionMember_32e02558-c77a-4049-9118-cc8f7fa243e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_781e079e-cac1-4f3a-8ab9-1c6881b69671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_32e02558-c77a-4049-9118-cc8f7fa243e2" xlink:to="loc_us-gaap_TypeOfAdoptionMember_781e079e-cac1-4f3a-8ab9-1c6881b69671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_d65516bc-763f-4a79-9f7d-20f03075eb41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_781e079e-cac1-4f3a-8ab9-1c6881b69671" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_d65516bc-763f-4a79-9f7d-20f03075eb41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_588de987-7895-4b38-ae19-9a21a553e361" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a7be0d02-972b-40bd-884f-e7e89fa98981" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_588de987-7895-4b38-ae19-9a21a553e361" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_588de987-7895-4b38-ae19-9a21a553e361_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_588de987-7895-4b38-ae19-9a21a553e361" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_588de987-7895-4b38-ae19-9a21a553e361_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_94a31f81-bfca-40dd-9d38-7cd2f1386136" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_588de987-7895-4b38-ae19-9a21a553e361" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_94a31f81-bfca-40dd-9d38-7cd2f1386136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ff02544e-0511-4391-aaa6-6425c1741ec2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_94a31f81-bfca-40dd-9d38-7cd2f1386136" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ff02544e-0511-4391-aaa6-6425c1741ec2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtLinesofCreditDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DebtLinesofCreditDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DebtLinesofCreditDetails" xlink:type="extended" id="i451654ddccbf4d18b105db02a4630a98_DebtLinesofCreditDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_f53b29a8-4c03-465b-9937-85d6243f0972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_aae6cf07-1446-4e85-9782-67464a73085d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f53b29a8-4c03-465b-9937-85d6243f0972" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_aae6cf07-1446-4e85-9782-67464a73085d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_068ae5b2-d9a4-4942-8153-8303d2bb9434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f53b29a8-4c03-465b-9937-85d6243f0972" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_068ae5b2-d9a4-4942-8153-8303d2bb9434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_29779d4b-81ff-4a02-afa6-f3d3e7e62c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f53b29a8-4c03-465b-9937-85d6243f0972" xlink:to="loc_us-gaap_LineOfCredit_29779d4b-81ff-4a02-afa6-f3d3e7e62c2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_ebace9eb-83e9-417b-ae7d-91731565f617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f53b29a8-4c03-465b-9937-85d6243f0972" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_ebace9eb-83e9-417b-ae7d-91731565f617" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_55ea8839-ea15-40f3-b674-74721bb60518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_ebace9eb-83e9-417b-ae7d-91731565f617" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_55ea8839-ea15-40f3-b674-74721bb60518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_55ea8839-ea15-40f3-b674-74721bb60518_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_55ea8839-ea15-40f3-b674-74721bb60518" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_55ea8839-ea15-40f3-b674-74721bb60518_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_55ea8839-ea15-40f3-b674-74721bb60518" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_JPMorganChaseMember_4cf46c85-5567-4844-8419-7a58ff2d5bd0" xlink:href="opk-20220331.xsd#opk_JPMorganChaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_JPMorganChaseMember_4cf46c85-5567-4844-8419-7a58ff2d5bd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ItauBankMember_db13a4f7-a4a9-4fac-b8a3-6fa2b36e0995" xlink:href="opk-20220331.xsd#opk_ItauBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_ItauBankMember_db13a4f7-a4a9-4fac-b8a3-6fa2b36e0995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BankOfChileMember_78a670ef-9dee-4325-bd89-2ccf953770d6" xlink:href="opk-20220331.xsd#opk_BankOfChileMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_BankOfChileMember_78a670ef-9dee-4325-bd89-2ccf953770d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BiceBankMember_64dd2f52-996d-41a7-a2ce-5083cc4f5d30" xlink:href="opk-20220331.xsd#opk_BiceBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_BiceBankMember_64dd2f52-996d-41a7-a2ce-5083cc4f5d30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ScotiabankMember_4ce6bd56-bcc1-4bff-8743-67974243c7da" xlink:href="opk-20220331.xsd#opk_ScotiabankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_ScotiabankMember_4ce6bd56-bcc1-4bff-8743-67974243c7da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SantanderBankMember_d17a1322-0347-437b-a1c1-a0072f209773" xlink:href="opk-20220331.xsd#opk_SantanderBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_SantanderBankMember_d17a1322-0347-437b-a1c1-a0072f209773" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SecurityMember_ae420ab7-9f04-48c8-add8-da0a97f87ab0" xlink:href="opk-20220331.xsd#opk_SecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_SecurityMember_ae420ab7-9f04-48c8-add8-da0a97f87ab0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EstadoBankMember_830ea88d-cf85-4b21-bf91-c3802e7b849f" xlink:href="opk-20220331.xsd#opk_EstadoBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_EstadoBankMember_830ea88d-cf85-4b21-bf91-c3802e7b849f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BCIBankMember_983f5bf4-847c-4a40-b03a-8170375a4196" xlink:href="opk-20220331.xsd#opk_BCIBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_BCIBankMember_983f5bf4-847c-4a40-b03a-8170375a4196" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_Corpbanca1Member_9dd46260-7b46-4e3b-94c8-a0ae2e1a7223" xlink:href="opk-20220331.xsd#opk_Corpbanca1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_Corpbanca1Member_9dd46260-7b46-4e3b-94c8-a0ae2e1a7223" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InternationalBankMember_2c602943-7b39-499f-93d6-9bd90da2e258" xlink:href="opk-20220331.xsd#opk_InternationalBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_InternationalBankMember_2c602943-7b39-499f-93d6-9bd90da2e258" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ConsoorcioBankMember_350816ad-aa13-4924-b83d-24bcf4ccb2dc" xlink:href="opk-20220331.xsd#opk_ConsoorcioBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_ConsoorcioBankMember_350816ad-aa13-4924-b83d-24bcf4ccb2dc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BancoDeSabadellMember_ee859cd8-0ec9-4b49-85db-61db808f6495" xlink:href="opk-20220331.xsd#opk_BancoDeSabadellMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_BancoDeSabadellMember_ee859cd8-0ec9-4b49-85db-61db808f6495" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SantanderBank2Member_2b798b21-d3b0-487a-8cc9-0cb0e2680833" xlink:href="opk-20220331.xsd#opk_SantanderBank2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_SantanderBank2Member_2b798b21-d3b0-487a-8cc9-0cb0e2680833" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DebtNotesPayableandOtherDebtDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails" xlink:type="extended" id="i77657b144d0d4348b30c068eed79e3fe_DebtNotesPayableandOtherDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_27faff9f-f5ae-45d9-95cf-b5e9f5be8716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_cbd6dc08-1a33-4892-97f7-a47567880313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27faff9f-f5ae-45d9-95cf-b5e9f5be8716" xlink:to="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_cbd6dc08-1a33-4892-97f7-a47567880313" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ba4331e1-56af-4d43-980b-85b8b0f5be36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_cbd6dc08-1a33-4892-97f7-a47567880313" xlink:to="loc_us-gaap_LongTermDebtCurrent_ba4331e1-56af-4d43-980b-85b8b0f5be36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_243180ee-b02f-478c-b9e9-f73871e6d4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_cbd6dc08-1a33-4892-97f7-a47567880313" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_243180ee-b02f-478c-b9e9-f73871e6d4a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_49b1deb1-42d0-4368-b7ee-35ecd930163b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_cbd6dc08-1a33-4892-97f7-a47567880313" xlink:to="loc_us-gaap_LongTermDebt_49b1deb1-42d0-4368-b7ee-35ecd930163b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0f5bcaed-9770-4582-af98-bcdb8eeede86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27faff9f-f5ae-45d9-95cf-b5e9f5be8716" xlink:to="loc_us-gaap_DebtInstrumentTable_0f5bcaed-9770-4582-af98-bcdb8eeede86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e4deba5e-163b-4b34-b2a9-b7e3e81b8ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0f5bcaed-9770-4582-af98-bcdb8eeede86" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e4deba5e-163b-4b34-b2a9-b7e3e81b8ab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e4deba5e-163b-4b34-b2a9-b7e3e81b8ab9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e4deba5e-163b-4b34-b2a9-b7e3e81b8ab9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e4deba5e-163b-4b34-b2a9-b7e3e81b8ab9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0f12156f-c2b0-4ae3-919c-4a99bb73439a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e4deba5e-163b-4b34-b2a9-b7e3e81b8ab9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0f12156f-c2b0-4ae3-919c-4a99bb73439a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NotesPayableAndOtherLongTermLiabilitiesMember_2626e178-ea98-4a5d-b2cb-784190a0122d" xlink:href="opk-20220331.xsd#opk_NotesPayableAndOtherLongTermLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0f12156f-c2b0-4ae3-919c-4a99bb73439a" xlink:to="loc_opk_NotesPayableAndOtherLongTermLiabilitiesMember_2626e178-ea98-4a5d-b2cb-784190a0122d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#AccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i64cd65f0ed86404192120344b31f31a5_AccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8354df11-8428-486e-b16a-1c789e16f236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_cca531b1-72fe-4ec3-a0b3-7ed753abefcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8354df11-8428-486e-b16a-1c789e16f236" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_cca531b1-72fe-4ec3-a0b3-7ed753abefcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_76d4effb-ad96-4d22-a241-0106709b38e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_cca531b1-72fe-4ec3-a0b3-7ed753abefcf" xlink:to="loc_us-gaap_StockholdersEquity_76d4effb-ad96-4d22-a241-0106709b38e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9fd5532b-2c2c-46d2-bb3f-28ff6016a8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_cca531b1-72fe-4ec3-a0b3-7ed753abefcf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9fd5532b-2c2c-46d2-bb3f-28ff6016a8b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4aaf46b4-aa49-469b-b814-23043f0c03bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_100ce697-adbe-4c0a-b52c-6b197e9a9760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8354df11-8428-486e-b16a-1c789e16f236" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_100ce697-adbe-4c0a-b52c-6b197e9a9760" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8fc8746d-cd8d-4755-b7d2-c81e71c0429c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_100ce697-adbe-4c0a-b52c-6b197e9a9760" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8fc8746d-cd8d-4755-b7d2-c81e71c0429c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8fc8746d-cd8d-4755-b7d2-c81e71c0429c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8fc8746d-cd8d-4755-b7d2-c81e71c0429c" xlink:to="loc_us-gaap_EquityComponentDomain_8fc8746d-cd8d-4755-b7d2-c81e71c0429c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8154eaed-5e87-4eb2-b759-a27961ed0def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8fc8746d-cd8d-4755-b7d2-c81e71c0429c" xlink:to="loc_us-gaap_EquityComponentDomain_8154eaed-5e87-4eb2-b759-a27961ed0def" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e2f6de39-5424-4d67-8b96-2781b644ed14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8154eaed-5e87-4eb2-b759-a27961ed0def" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e2f6de39-5424-4d67-8b96-2781b644ed14" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended" id="i99d6a87e41b445898d87eb0729cdc4f5_FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bd8dd27a-db95-4b91-bb37-416e4ef961ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_55e93c98-889f-4b2d-833d-ef919b68d2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bd8dd27a-db95-4b91-bb37-416e4ef961ad" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_55e93c98-889f-4b2d-833d-ef919b68d2dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_2f0f136b-062d-4f77-8168-a06367f09251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_55e93c98-889f-4b2d-833d-ef919b68d2dc" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_2f0f136b-062d-4f77-8168-a06367f09251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_3931e19b-6323-4454-9e05-9ce8c3e51d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_55e93c98-889f-4b2d-833d-ef919b68d2dc" xlink:to="loc_us-gaap_DerivativeAssets_3931e19b-6323-4454-9e05-9ce8c3e51d2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9bf480f4-1359-462a-9b78-13704d21db51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_55e93c98-889f-4b2d-833d-ef919b68d2dc" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9bf480f4-1359-462a-9b78-13704d21db51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_478049c7-2741-44f0-90ea-8243fbe0bcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bd8dd27a-db95-4b91-bb37-416e4ef961ad" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_478049c7-2741-44f0-90ea-8243fbe0bcf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6ade72a8-8567-43e8-8b29-886f45369b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_478049c7-2741-44f0-90ea-8243fbe0bcf4" xlink:to="loc_us-gaap_DerivativeLiabilities_6ade72a8-8567-43e8-8b29-886f45369b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1037dbe0-be85-49f1-8e34-8bf6ae42fd53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_478049c7-2741-44f0-90ea-8243fbe0bcf4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1037dbe0-be85-49f1-8e34-8bf6ae42fd53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_e4549f51-d99c-4e06-8990-2c63ab3b54bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_478049c7-2741-44f0-90ea-8243fbe0bcf4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_e4549f51-d99c-4e06-8990-2c63ab3b54bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d824dbf8-515e-4c3d-8dfc-e4a5f2c2bf09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bd8dd27a-db95-4b91-bb37-416e4ef961ad" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d824dbf8-515e-4c3d-8dfc-e4a5f2c2bf09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b3aaba23-3578-4b02-86d3-eb0ff4b3da48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d824dbf8-515e-4c3d-8dfc-e4a5f2c2bf09" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b3aaba23-3578-4b02-86d3-eb0ff4b3da48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b3aaba23-3578-4b02-86d3-eb0ff4b3da48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b3aaba23-3578-4b02-86d3-eb0ff4b3da48" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b3aaba23-3578-4b02-86d3-eb0ff4b3da48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31d2513e-65e9-424d-bd61-3d14012278a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b3aaba23-3578-4b02-86d3-eb0ff4b3da48" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31d2513e-65e9-424d-bd61-3d14012278a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_6059e4fc-7d4d-4a7b-b4eb-6e8344cbe52b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31d2513e-65e9-424d-bd61-3d14012278a1" xlink:to="loc_us-gaap_EquitySecuritiesMember_6059e4fc-7d4d-4a7b-b4eb-6e8344cbe52b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_de48edf6-6766-4774-94e2-6993cba8273a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31d2513e-65e9-424d-bd61-3d14012278a1" xlink:to="loc_us-gaap_ForwardContractsMember_de48edf6-6766-4774-94e2-6993cba8273a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f99e0fd3-dad9-4091-9841-1f379cfbec15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d824dbf8-515e-4c3d-8dfc-e4a5f2c2bf09" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f99e0fd3-dad9-4091-9841-1f379cfbec15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f99e0fd3-dad9-4091-9841-1f379cfbec15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f99e0fd3-dad9-4091-9841-1f379cfbec15" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f99e0fd3-dad9-4091-9841-1f379cfbec15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61baa7cb-20d2-4b0c-b4b9-855b0f6a08f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f99e0fd3-dad9-4091-9841-1f379cfbec15" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61baa7cb-20d2-4b0c-b4b9-855b0f6a08f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9aee1ad0-46e8-494c-857e-c003192be9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61baa7cb-20d2-4b0c-b4b9-855b0f6a08f5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9aee1ad0-46e8-494c-857e-c003192be9f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8c7afa72-6ebd-4e24-b3d5-93e3288d4b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61baa7cb-20d2-4b0c-b4b9-855b0f6a08f5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8c7afa72-6ebd-4e24-b3d5-93e3288d4b93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3d3115b3-7f15-4327-9279-e16386d06eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61baa7cb-20d2-4b0c-b4b9-855b0f6a08f5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3d3115b3-7f15-4327-9279-e16386d06eb2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails" xlink:type="extended" id="i323fc50048434ff184a25bfb93f62dbc_FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fcbb7465-449d-4488-aa03-e011c84fd26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_3a93c388-d323-4e2b-b135-66c146e38ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fcbb7465-449d-4488-aa03-e011c84fd26b" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_3a93c388-d323-4e2b-b135-66c146e38ab8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bbcd1081-8f02-458b-9642-76cd5349051b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fcbb7465-449d-4488-aa03-e011c84fd26b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bbcd1081-8f02-458b-9642-76cd5349051b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_2f47aade-8283-4ee9-8dcb-38eafa784ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bbcd1081-8f02-458b-9642-76cd5349051b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_2f47aade-8283-4ee9-8dcb-38eafa784ccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2f47aade-8283-4ee9-8dcb-38eafa784ccc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2f47aade-8283-4ee9-8dcb-38eafa784ccc" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2f47aade-8283-4ee9-8dcb-38eafa784ccc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b04557bb-47a0-4be9-b775-b35068b79648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2f47aade-8283-4ee9-8dcb-38eafa784ccc" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b04557bb-47a0-4be9-b775-b35068b79648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a1f9899b-696d-44cd-8c7c-78aff30f1d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b04557bb-47a0-4be9-b775-b35068b79648" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a1f9899b-696d-44cd-8c7c-78aff30f1d93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6b80b527-11d9-43c0-878d-be29f2784f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b04557bb-47a0-4be9-b775-b35068b79648" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6b80b527-11d9-43c0-878d-be29f2784f4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_76ca0841-2a48-4f0d-898d-b91f218e9e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bbcd1081-8f02-458b-9642-76cd5349051b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_76ca0841-2a48-4f0d-898d-b91f218e9e9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_76ca0841-2a48-4f0d-898d-b91f218e9e9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_76ca0841-2a48-4f0d-898d-b91f218e9e9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_76ca0841-2a48-4f0d-898d-b91f218e9e9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_12a9f643-087f-40cb-be2e-4ae4e5b186cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_76ca0841-2a48-4f0d-898d-b91f218e9e9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_12a9f643-087f-40cb-be2e-4ae4e5b186cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_c478908c-f246-4540-8b7f-01ba775ba9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_12a9f643-087f-40cb-be2e-4ae4e5b186cd" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_c478908c-f246-4540-8b7f-01ba775ba9d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_77d681b6-4d82-472b-96e7-77f66753b697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bbcd1081-8f02-458b-9642-76cd5349051b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_77d681b6-4d82-472b-96e7-77f66753b697" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_77d681b6-4d82-472b-96e7-77f66753b697_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_77d681b6-4d82-472b-96e7-77f66753b697" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_77d681b6-4d82-472b-96e7-77f66753b697_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f38e1703-b6f2-404b-aa6f-9ffee3fffb54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_77d681b6-4d82-472b-96e7-77f66753b697" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f38e1703-b6f2-404b-aa6f-9ffee3fffb54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3ad409ef-0474-4a4f-9f95-0e342d8b0945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f38e1703-b6f2-404b-aa6f-9ffee3fffb54" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3ad409ef-0474-4a4f-9f95-0e342d8b0945" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d410c977-bdbe-4d25-98c3-b2488b708581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f38e1703-b6f2-404b-aa6f-9ffee3fffb54" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d410c977-bdbe-4d25-98c3-b2488b708581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_14be3295-6901-45e4-b1b1-a08b5b916701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f38e1703-b6f2-404b-aa6f-9ffee3fffb54" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_14be3295-6901-45e4-b1b1-a08b5b916701" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#FairValueMeasurementsLevel3ReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails" xlink:type="extended" id="i4828e945539b4105bdd09059662be01d_FairValueMeasurementsLevel3ReconciliationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_ee77cd16-4557-42cb-bacc-88f7a45cc97f" xlink:href="opk-20220331.xsd#opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bfbfa471-d941-43c2-a36c-91afafc2d17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_ee77cd16-4557-42cb-bacc-88f7a45cc97f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bfbfa471-d941-43c2-a36c-91afafc2d17e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_892aa168-1b75-4b50-aef9-b73465bf33f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bfbfa471-d941-43c2-a36c-91afafc2d17e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_892aa168-1b75-4b50-aef9-b73465bf33f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract_890d06e7-376d-4cff-9623-e09e02412fff" xlink:href="opk-20220331.xsd#opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bfbfa471-d941-43c2-a36c-91afafc2d17e" xlink:to="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract_890d06e7-376d-4cff-9623-e09e02412fff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_24c1a503-89a1-41e7-9ffd-dcf4baaa0892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract_890d06e7-376d-4cff-9623-e09e02412fff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_24c1a503-89a1-41e7-9ffd-dcf4baaa0892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact_cd9cde07-b89a-490a-9cd3-cfb79c53b688" xlink:href="opk-20220331.xsd#opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract_890d06e7-376d-4cff-9623-e09e02412fff" xlink:to="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact_cd9cde07-b89a-490a-9cd3-cfb79c53b688" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fc770312-aeb5-46fa-87af-db8d2c65bf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_ea00ac4d-81b7-45ec-b3cf-f178d6596b0c" xlink:href="opk-20220331.xsd#opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_ee77cd16-4557-42cb-bacc-88f7a45cc97f" xlink:to="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_ea00ac4d-81b7-45ec-b3cf-f178d6596b0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_05b49dfe-115d-4bd6-9c3a-ed866400615f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_ea00ac4d-81b7-45ec-b3cf-f178d6596b0c" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_05b49dfe-115d-4bd6-9c3a-ed866400615f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_05b49dfe-115d-4bd6-9c3a-ed866400615f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_05b49dfe-115d-4bd6-9c3a-ed866400615f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_05b49dfe-115d-4bd6-9c3a-ed866400615f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eaa581a1-bcfb-4f59-87e3-a8e0b3cde043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_05b49dfe-115d-4bd6-9c3a-ed866400615f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eaa581a1-bcfb-4f59-87e3-a8e0b3cde043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ContingentConsiderationMember_d26121d6-7aa1-4433-8c4d-79ceced3bfe3" xlink:href="opk-20220331.xsd#opk_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eaa581a1-bcfb-4f59-87e3-a8e0b3cde043" xlink:to="loc_opk_ContingentConsiderationMember_d26121d6-7aa1-4433-8c4d-79ceced3bfe3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="if437d2a348404d508e2b95c7674d1e78_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78babcd0-99b7-47c7-9052-e38b73e28271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ac76c7e2-d102-4701-9c49-ce661f9de051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78babcd0-99b7-47c7-9052-e38b73e28271" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ac76c7e2-d102-4701-9c49-ce661f9de051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e5924a0c-f765-475f-b4b5-33e8c24bd524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78babcd0-99b7-47c7-9052-e38b73e28271" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e5924a0c-f765-475f-b4b5-33e8c24bd524" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5f50e9a1-4f6e-4c31-8150-b6767038c96a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e5924a0c-f765-475f-b4b5-33e8c24bd524" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5f50e9a1-4f6e-4c31-8150-b6767038c96a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5f50e9a1-4f6e-4c31-8150-b6767038c96a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5f50e9a1-4f6e-4c31-8150-b6767038c96a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5f50e9a1-4f6e-4c31-8150-b6767038c96a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e50bf377-9e0b-4865-87ae-f00d273edb66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5f50e9a1-4f6e-4c31-8150-b6767038c96a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e50bf377-9e0b-4865-87ae-f00d273edb66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_1eca32b1-c91d-4b59-929b-acbfc04c02d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e50bf377-9e0b-4865-87ae-f00d273edb66" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_1eca32b1-c91d-4b59-929b-acbfc04c02d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1600f11c-8995-4a31-a9e4-ad0576f44070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e50bf377-9e0b-4865-87ae-f00d273edb66" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1600f11c-8995-4a31-a9e4-ad0576f44070" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DerivativeContractsBalanceSheetComponentDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails" xlink:type="extended" id="i6fec1c3dee2343f99605b9538866e66e_DerivativeContractsBalanceSheetComponentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_44a2ca9e-fc8d-40ed-b21e-c84c9c1289ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_73d3b92a-93f0-4118-9945-dcaef9faa8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_44a2ca9e-fc8d-40ed-b21e-c84c9c1289ed" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_73d3b92a-93f0-4118-9945-dcaef9faa8c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ded99093-48d2-4326-a307-94391bb6fb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_44a2ca9e-fc8d-40ed-b21e-c84c9c1289ed" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ded99093-48d2-4326-a307-94391bb6fb4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2b806178-0d62-407f-be0d-67431ec0210c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ded99093-48d2-4326-a307-94391bb6fb4b" xlink:to="loc_us-gaap_HedgingDesignationAxis_2b806178-0d62-407f-be0d-67431ec0210c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2b806178-0d62-407f-be0d-67431ec0210c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_2b806178-0d62-407f-be0d-67431ec0210c" xlink:to="loc_us-gaap_HedgingDesignationDomain_2b806178-0d62-407f-be0d-67431ec0210c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_36f0be2f-b639-493b-90e9-dde96bfac518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_2b806178-0d62-407f-be0d-67431ec0210c" xlink:to="loc_us-gaap_HedgingDesignationDomain_36f0be2f-b639-493b-90e9-dde96bfac518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a4e194ea-08f1-464b-85f7-79426ed92753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_36f0be2f-b639-493b-90e9-dde96bfac518" xlink:to="loc_us-gaap_NondesignatedMember_a4e194ea-08f1-464b-85f7-79426ed92753" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bca0a4b6-5ba9-49f5-ac3b-423a7118aa11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ded99093-48d2-4326-a307-94391bb6fb4b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bca0a4b6-5ba9-49f5-ac3b-423a7118aa11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bca0a4b6-5ba9-49f5-ac3b-423a7118aa11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bca0a4b6-5ba9-49f5-ac3b-423a7118aa11" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bca0a4b6-5ba9-49f5-ac3b-423a7118aa11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2fce3e08-574e-4536-a5df-8ba3af38b9db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bca0a4b6-5ba9-49f5-ac3b-423a7118aa11" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2fce3e08-574e-4536-a5df-8ba3af38b9db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_1c8cb6b4-3d6e-4add-a66c-93d8b34ab610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2fce3e08-574e-4536-a5df-8ba3af38b9db" xlink:to="loc_us-gaap_StockOptionMember_1c8cb6b4-3d6e-4add-a66c-93d8b34ab610" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_c25af0d6-8cd0-4e8c-85db-5742e5012182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2fce3e08-574e-4536-a5df-8ba3af38b9db" xlink:to="loc_us-gaap_ForwardContractsMember_c25af0d6-8cd0-4e8c-85db-5742e5012182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_56f08a1f-164c-4bde-9ae7-cec9c0c1cc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ded99093-48d2-4326-a307-94391bb6fb4b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_56f08a1f-164c-4bde-9ae7-cec9c0c1cc4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_56f08a1f-164c-4bde-9ae7-cec9c0c1cc4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_56f08a1f-164c-4bde-9ae7-cec9c0c1cc4d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_56f08a1f-164c-4bde-9ae7-cec9c0c1cc4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_94a169e6-fb7d-4d29-bd42-21a2b7ceb1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_56f08a1f-164c-4bde-9ae7-cec9c0c1cc4d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_94a169e6-fb7d-4d29-bd42-21a2b7ceb1d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_c821616e-18be-4d11-9a09-0931aae77e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_94a169e6-fb7d-4d29-bd42-21a2b7ceb1d9" xlink:to="loc_us-gaap_InvestmentsMember_c821616e-18be-4d11-9a09-0931aae77e26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember_a1e5f3ee-4c3c-4a54-a8bc-af29f7b007d0" xlink:href="opk-20220331.xsd#opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_94a169e6-fb7d-4d29-bd42-21a2b7ceb1d9" xlink:to="loc_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember_a1e5f3ee-4c3c-4a54-a8bc-af29f7b007d0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DerivativeContractsDerivativeGainsLossesDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails" xlink:type="extended" id="i641a5e17e92a46e6b88a4c92ebf03ae5_DerivativeContractsDerivativeGainsLossesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f5c53cd9-225a-4106-8a00-32e6ae763d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_dc4db281-47bb-4187-9326-575440f9942c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f5c53cd9-225a-4106-8a00-32e6ae763d81" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_dc4db281-47bb-4187-9326-575440f9942c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4468a255-df2a-4616-b7ca-d85a0e4240d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f5c53cd9-225a-4106-8a00-32e6ae763d81" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4468a255-df2a-4616-b7ca-d85a0e4240d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_787369b6-304e-4c21-8874-ae93c2ff4bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4468a255-df2a-4616-b7ca-d85a0e4240d7" xlink:to="loc_us-gaap_HedgingDesignationAxis_787369b6-304e-4c21-8874-ae93c2ff4bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_787369b6-304e-4c21-8874-ae93c2ff4bac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_787369b6-304e-4c21-8874-ae93c2ff4bac" xlink:to="loc_us-gaap_HedgingDesignationDomain_787369b6-304e-4c21-8874-ae93c2ff4bac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_253e956d-d948-4198-963b-e9f17f054560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_787369b6-304e-4c21-8874-ae93c2ff4bac" xlink:to="loc_us-gaap_HedgingDesignationDomain_253e956d-d948-4198-963b-e9f17f054560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_481dff84-d210-41ce-a1e1-d3888e01e835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_253e956d-d948-4198-963b-e9f17f054560" xlink:to="loc_us-gaap_NondesignatedMember_481dff84-d210-41ce-a1e1-d3888e01e835" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_19786fb3-10ff-4bbc-bea6-474f7e33e5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4468a255-df2a-4616-b7ca-d85a0e4240d7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_19786fb3-10ff-4bbc-bea6-474f7e33e5dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_19786fb3-10ff-4bbc-bea6-474f7e33e5dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_19786fb3-10ff-4bbc-bea6-474f7e33e5dd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_19786fb3-10ff-4bbc-bea6-474f7e33e5dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_61dbb868-67dc-49e3-a6c5-2a8839ea2ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_19786fb3-10ff-4bbc-bea6-474f7e33e5dd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_61dbb868-67dc-49e3-a6c5-2a8839ea2ecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_5cf25092-26d5-442a-8863-733bb8269b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_61dbb868-67dc-49e3-a6c5-2a8839ea2ecf" xlink:to="loc_us-gaap_StockOptionMember_5cf25092-26d5-442a-8863-733bb8269b05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_e46cf045-2896-4601-a425-ac7ec8bcfe6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_61dbb868-67dc-49e3-a6c5-2a8839ea2ecf" xlink:to="loc_us-gaap_ForwardContractsMember_e46cf045-2896-4601-a425-ac7ec8bcfe6d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i4a9d830fc1d340f1a7e91001791f76e2_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7596c173-40eb-4fa4-bf11-c2ced66b9433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7596c173-40eb-4fa4-bf11-c2ced66b9433" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_df43e569-b390-4240-ba15-6d294e38a984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_df43e569-b390-4240-ba15-6d294e38a984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3647726c-0d49-46a0-9e91-b1e4566fd4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3647726c-0d49-46a0-9e91-b1e4566fd4d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_055da180-1321-4ed6-a18f-e3812290e7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_055da180-1321-4ed6-a18f-e3812290e7c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_4a275f75-f92b-45ed-bdb8-5b0a224866b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_LineOfCredit_4a275f75-f92b-45ed-bdb8-5b0a224866b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionShares_faf9758e-bd03-4f51-b0f2-445e5bbac517" xlink:href="opk-20220331.xsd#opk_RelatedPartyTransactionShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_opk_RelatedPartyTransactionShares_faf9758e-bd03-4f51-b0f2-445e5bbac517" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_291a4a2a-3c86-4d96-87c8-c1cad13669c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_291a4a2a-3c86-4d96-87c8-c1cad13669c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquitySecurityFVNIOwnershipPercent_bcfec71b-2973-42ac-aed2-65ffa07626a3" xlink:href="opk-20220331.xsd#opk_EquitySecurityFVNIOwnershipPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_opk_EquitySecurityFVNIOwnershipPercent_bcfec71b-2973-42ac-aed2-65ffa07626a3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionFutureContributions_3916448e-1317-4f3e-8a15-b88b5671aee5" xlink:href="opk-20220331.xsd#opk_RelatedPartyTransactionFutureContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_opk_RelatedPartyTransactionFutureContributions_3916448e-1317-4f3e-8a15-b88b5671aee5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionFutureContributionTerm_fb8b7ac5-a5a3-4856-bfa7-5f3655260417" xlink:href="opk-20220331.xsd#opk_RelatedPartyTransactionFutureContributionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_opk_RelatedPartyTransactionFutureContributionTerm_fb8b7ac5-a5a3-4856-bfa7-5f3655260417" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_c732a21d-1171-4938-acc7-c7c38a0788d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_c732a21d-1171-4938-acc7-c7c38a0788d4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OperatingLeasesMonthlyPaymentsYearOne_b0486396-db7f-4962-86d3-1460737fd958" xlink:href="opk-20220331.xsd#opk_OperatingLeasesMonthlyPaymentsYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_opk_OperatingLeasesMonthlyPaymentsYearOne_b0486396-db7f-4962-86d3-1460737fd958" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OperatingLeasesMonthlyPaymentsYearFive_a51f0b8f-0fcf-4f73-b15b-56ac8d03bef7" xlink:href="opk-20220331.xsd#opk_OperatingLeasesMonthlyPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_opk_OperatingLeasesMonthlyPaymentsYearFive_a51f0b8f-0fcf-4f73-b15b-56ac8d03bef7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_12e56724-5baa-4934-979f-50e3d2202b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_12e56724-5baa-4934-979f-50e3d2202b01" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_baf9c67e-ccc7-425b-a3b8-08bb39e515f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_us-gaap_CreditFacilityAxis_baf9c67e-ccc7-425b-a3b8-08bb39e515f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_baf9c67e-ccc7-425b-a3b8-08bb39e515f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_baf9c67e-ccc7-425b-a3b8-08bb39e515f7" xlink:to="loc_us-gaap_CreditFacilityDomain_baf9c67e-ccc7-425b-a3b8-08bb39e515f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_59f23ba4-7caf-45f0-8bd6-ebb66ecb2817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_baf9c67e-ccc7-425b-a3b8-08bb39e515f7" xlink:to="loc_us-gaap_CreditFacilityDomain_59f23ba4-7caf-45f0-8bd6-ebb66ecb2817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2f4f03c3-9e30-48f5-b003-c06052a40425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_59f23ba4-7caf-45f0-8bd6-ebb66ecb2817" xlink:to="loc_us-gaap_LineOfCreditMember_2f4f03c3-9e30-48f5-b003-c06052a40425" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_df9bdee0-39a1-42e9-af3f-819d4b292873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_59f23ba4-7caf-45f0-8bd6-ebb66ecb2817" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_df9bdee0-39a1-42e9-af3f-819d4b292873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f445462c-6d8a-4013-a58a-ae81c6e988f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_us-gaap_DebtInstrumentAxis_f445462c-6d8a-4013-a58a-ae81c6e988f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f445462c-6d8a-4013-a58a-ae81c6e988f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f445462c-6d8a-4013-a58a-ae81c6e988f3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f445462c-6d8a-4013-a58a-ae81c6e988f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3ac2a32f-6542-4430-8096-9a68846dc694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f445462c-6d8a-4013-a58a-ae81c6e988f3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3ac2a32f-6542-4430-8096-9a68846dc694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NewCreditAgreementMember_a7b91100-7494-4469-ab5c-50061d9b7d86" xlink:href="opk-20220331.xsd#opk_NewCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3ac2a32f-6542-4430-8096-9a68846dc694" xlink:to="loc_opk_NewCreditAgreementMember_a7b91100-7494-4469-ab5c-50061d9b7d86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7579c0d4-77bc-4c2e-a5db-dee5b1f7cbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7579c0d4-77bc-4c2e-a5db-dee5b1f7cbf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7579c0d4-77bc-4c2e-a5db-dee5b1f7cbf3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7579c0d4-77bc-4c2e-a5db-dee5b1f7cbf3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7579c0d4-77bc-4c2e-a5db-dee5b1f7cbf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ba2c72cf-3c0b-4455-b02b-c6a46a2d93ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7579c0d4-77bc-4c2e-a5db-dee5b1f7cbf3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ba2c72cf-3c0b-4455-b02b-c6a46a2d93ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_7fa4f16f-716c-4926-b5ea-f822a3cf6280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba2c72cf-3c0b-4455-b02b-c6a46a2d93ee" xlink:to="loc_us-gaap_UnsecuredDebtMember_7fa4f16f-716c-4926-b5ea-f822a3cf6280" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1d844ce8-dc85-4c0b-98ab-f630829af1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba2c72cf-3c0b-4455-b02b-c6a46a2d93ee" xlink:to="loc_us-gaap_LineOfCreditMember_1d844ce8-dc85-4c0b-98ab-f630829af1a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2d4e30d0-36cd-460d-90a0-bfac82e2c518" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_dei_LegalEntityAxis_2d4e30d0-36cd-460d-90a0-bfac82e2c518" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2d4e30d0-36cd-460d-90a0-bfac82e2c518_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2d4e30d0-36cd-460d-90a0-bfac82e2c518" xlink:to="loc_dei_EntityDomain_2d4e30d0-36cd-460d-90a0-bfac82e2c518_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2a2bb798-24f1-4247-81e6-812376d4821e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2d4e30d0-36cd-460d-90a0-bfac82e2c518" xlink:to="loc_dei_EntityDomain_2a2bb798-24f1-4247-81e6-812376d4821e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MednaxServicesIncMember_cf777941-ac62-4037-b83a-c2acb81df4da" xlink:href="opk-20220331.xsd#opk_MednaxServicesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2a2bb798-24f1-4247-81e6-812376d4821e" xlink:to="loc_opk_MednaxServicesIncMember_cf777941-ac62-4037-b83a-c2acb81df4da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MuseumofScienceIncMember_659edd7e-ea92-4332-89dc-914ef1fb015a" xlink:href="opk-20220331.xsd#opk_MuseumofScienceIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2a2bb798-24f1-4247-81e6-812376d4821e" xlink:to="loc_opk_MuseumofScienceIncMember_659edd7e-ea92-4332-89dc-914ef1fb015a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3321320e-bb14-4841-aa98-9abeb1fcaaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3321320e-bb14-4841-aa98-9abeb1fcaaf2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3321320e-bb14-4841-aa98-9abeb1fcaaf2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3321320e-bb14-4841-aa98-9abeb1fcaaf2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3321320e-bb14-4841-aa98-9abeb1fcaaf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_04e2e005-eb34-444d-ba8d-83c9e35bdd09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3321320e-bb14-4841-aa98-9abeb1fcaaf2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_04e2e005-eb34-444d-ba8d-83c9e35bdd09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_a82abe20-fecd-406f-9292-b6ecbc0119b8" xlink:href="opk-20220331.xsd#opk_SharesReceivedUponClosingofXeneticTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_04e2e005-eb34-444d-ba8d-83c9e35bdd09" xlink:to="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_a82abe20-fecd-406f-9292-b6ecbc0119b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6beddbd4-487a-42ca-97a7-927412b1cd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6beddbd4-487a-42ca-97a7-927412b1cd2e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6beddbd4-487a-42ca-97a7-927412b1cd2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6beddbd4-487a-42ca-97a7-927412b1cd2e" xlink:to="loc_us-gaap_RelatedPartyDomain_6beddbd4-487a-42ca-97a7-927412b1cd2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cae75dbc-f8fe-4b95-a1a4-ef74c634e863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6beddbd4-487a-42ca-97a7-927412b1cd2e" xlink:to="loc_us-gaap_RelatedPartyDomain_cae75dbc-f8fe-4b95-a1a4-ef74c634e863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_8787ee2e-c1dc-4bfc-b3b2-55689d40d2c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cae75dbc-f8fe-4b95-a1a4-ef74c634e863" xlink:to="loc_srt_DirectorMember_8787ee2e-c1dc-4bfc-b3b2-55689d40d2c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_64ca942f-9af8-407e-a4fe-ae7456b73bc8" xlink:href="opk-20220331.xsd#opk_SharesReceivedUponClosingofXeneticTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cae75dbc-f8fe-4b95-a1a4-ef74c634e863" xlink:to="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_64ca942f-9af8-407e-a4fe-ae7456b73bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioCardiaInc.Member_f85fbf79-4a1d-4e3a-8835-655b10bc2089" xlink:href="opk-20220331.xsd#opk_BioCardiaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cae75dbc-f8fe-4b95-a1a4-ef74c634e863" xlink:to="loc_opk_BioCardiaInc.Member_f85fbf79-4a1d-4e3a-8835-655b10bc2089" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DrFrostandMrPfennigerMember_3e31d35c-22a0-470d-aa8c-a0d195a5ecdb" xlink:href="opk-20220331.xsd#opk_DrFrostandMrPfennigerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cae75dbc-f8fe-4b95-a1a4-ef74c634e863" xlink:to="loc_opk_DrFrostandMrPfennigerMember_3e31d35c-22a0-470d-aa8c-a0d195a5ecdb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FrostRealEstateHoldingsLLCMember_b2a334af-9798-4c2c-9531-937b1063ff4a" xlink:href="opk-20220331.xsd#opk_FrostRealEstateHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cae75dbc-f8fe-4b95-a1a4-ef74c634e863" xlink:to="loc_opk_FrostRealEstateHoldingsLLCMember_b2a334af-9798-4c2c-9531-937b1063ff4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_37bd18d1-e971-436b-aa84-e08958cfe9fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_37bd18d1-e971-436b-aa84-e08958cfe9fd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_37bd18d1-e971-436b-aa84-e08958cfe9fd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_37bd18d1-e971-436b-aa84-e08958cfe9fd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_37bd18d1-e971-436b-aa84-e08958cfe9fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_37bd18d1-e971-436b-aa84-e08958cfe9fd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DetectGenomixMember_3c67eba6-9de9-475b-bd4e-ce27bda71188" xlink:href="opk-20220331.xsd#opk_DetectGenomixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_DetectGenomixMember_3c67eba6-9de9-475b-bd4e-ce27bda71188" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmsynthezMember_c7d9694d-b5ca-4d07-a527-816533f26c47" xlink:href="opk-20220331.xsd#opk_PharmsynthezMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_PharmsynthezMember_c7d9694d-b5ca-4d07-a527-816533f26c47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ZebraMember_0a36849c-f8ba-4ca3-bfbb-8763cd46d361" xlink:href="opk-20220331.xsd#opk_ZebraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_ZebraMember_0a36849c-f8ba-4ca3-bfbb-8763cd46d361" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NeovascMember_71c253ec-ee0d-4603-a4ed-e9e598d97ae3" xlink:href="opk-20220331.xsd#opk_NeovascMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_NeovascMember_71c253ec-ee0d-4603-a4ed-e9e598d97ae3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChromadexCorporationMember_b90617de-418f-481a-aff0-a7484a014a5d" xlink:href="opk-20220331.xsd#opk_ChromadexCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_ChromadexCorporationMember_b90617de-418f-481a-aff0-a7484a014a5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CocrystalMember_46d99aab-7638-4495-b7cd-057ea8b30344" xlink:href="opk-20220331.xsd#opk_CocrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_CocrystalMember_46d99aab-7638-4495-b7cd-057ea8b30344" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NIMSMember_7e19a393-a94c-4bf6-b2f9-ebc7645ade9e" xlink:href="opk-20220331.xsd#opk_NIMSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_NIMSMember_7e19a393-a94c-4bf6-b2f9-ebc7645ade9e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EloxxPharmaceuticalsMember_e86397e8-6b43-4330-955a-a51d7bb500be" xlink:href="opk-20220331.xsd#opk_EloxxPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_EloxxPharmaceuticalsMember_e86397e8-6b43-4330-955a-a51d7bb500be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioCardiaInc.Member_94cba11c-5c16-496a-a85e-e2a5a7925519" xlink:href="opk-20220331.xsd#opk_BioCardiaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_BioCardiaInc.Member_94cba11c-5c16-496a-a85e-e2a5a7925519" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LeaderMedMember_91758f16-0162-43ad-a18c-b3ccc35e21db" xlink:href="opk-20220331.xsd#opk_LeaderMedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_LeaderMedMember_91758f16-0162-43ad-a18c-b3ccc35e21db" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InCellDxIncMember_354f63cd-56e0-4242-8a66-33733016bfa7" xlink:href="opk-20220331.xsd#opk_InCellDxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_InCellDxIncMember_354f63cd-56e0-4242-8a66-33733016bfa7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_424cae7a-6a02-4bfa-9f1a-59a44b890ead" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_srt_ConsolidatedEntitiesAxis_424cae7a-6a02-4bfa-9f1a-59a44b890ead" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_424cae7a-6a02-4bfa-9f1a-59a44b890ead_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_424cae7a-6a02-4bfa-9f1a-59a44b890ead" xlink:to="loc_srt_ConsolidatedEntitiesDomain_424cae7a-6a02-4bfa-9f1a-59a44b890ead_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_42ae2cbc-c1af-4d02-96c7-1f9707127207" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_424cae7a-6a02-4bfa-9f1a-59a44b890ead" xlink:to="loc_srt_ConsolidatedEntitiesDomain_42ae2cbc-c1af-4d02-96c7-1f9707127207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_6d11ecda-f474-4539-8871-eb3babf51f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_42ae2cbc-c1af-4d02-96c7-1f9707127207" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_6d11ecda-f474-4539-8871-eb3babf51f0d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i30e101b00ead4314ac67bc733ef38dbc_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_157cd345-873c-434d-98b9-c82d54cf6692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1790ca6b-0bd2-42f8-b2ed-c9c89bb75ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_157cd345-873c-434d-98b9-c82d54cf6692" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1790ca6b-0bd2-42f8-b2ed-c9c89bb75ad0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_117cdbb1-0df3-4dbf-8d61-60f241479c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_157cd345-873c-434d-98b9-c82d54cf6692" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_117cdbb1-0df3-4dbf-8d61-60f241479c52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_c1467bfb-59c6-40fb-9dd2-61556df654f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_157cd345-873c-434d-98b9-c82d54cf6692" xlink:to="loc_us-gaap_LitigationReserveCurrent_c1467bfb-59c6-40fb-9dd2-61556df654f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LossContingencyMilestonePayment_4e082f11-0e25-4366-b753-2bdc0c25a58e" xlink:href="opk-20220331.xsd#opk_LossContingencyMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_157cd345-873c-434d-98b9-c82d54cf6692" xlink:to="loc_opk_LossContingencyMilestonePayment_4e082f11-0e25-4366-b753-2bdc0c25a58e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_0f7ac722-de74-458f-ab71-33d49b5fd0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_157cd345-873c-434d-98b9-c82d54cf6692" xlink:to="loc_us-gaap_PurchaseObligation_0f7ac722-de74-458f-ab71-33d49b5fd0b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_31140deb-80f6-4ce2-82c5-354db8680e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_157cd345-873c-434d-98b9-c82d54cf6692" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_31140deb-80f6-4ce2-82c5-354db8680e2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_73b49fa4-b22b-4e37-ad99-d4b255970dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_31140deb-80f6-4ce2-82c5-354db8680e2c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_73b49fa4-b22b-4e37-ad99-d4b255970dd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_73b49fa4-b22b-4e37-ad99-d4b255970dd0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_73b49fa4-b22b-4e37-ad99-d4b255970dd0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_73b49fa4-b22b-4e37-ad99-d4b255970dd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3f69044d-8cee-4852-8f49-10008ef84571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_73b49fa4-b22b-4e37-ad99-d4b255970dd0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3f69044d-8cee-4852-8f49-10008ef84571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_e134862a-9825-4428-b39d-9750f6bc5d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3f69044d-8cee-4852-8f49-10008ef84571" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_e134862a-9825-4428-b39d-9750f6bc5d61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_ccd7b3fd-c6d2-421c-9f31-612add546baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3f69044d-8cee-4852-8f49-10008ef84571" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_ccd7b3fd-c6d2-421c-9f31-612add546baa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_513c1d43-6b96-4f46-b6be-19a06c48b318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_31140deb-80f6-4ce2-82c5-354db8680e2c" xlink:to="loc_us-gaap_LitigationStatusAxis_513c1d43-6b96-4f46-b6be-19a06c48b318" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_513c1d43-6b96-4f46-b6be-19a06c48b318_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_513c1d43-6b96-4f46-b6be-19a06c48b318" xlink:to="loc_us-gaap_LitigationStatusDomain_513c1d43-6b96-4f46-b6be-19a06c48b318_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_6ee51104-6d04-4a3a-89d4-f24ceff1b995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_513c1d43-6b96-4f46-b6be-19a06c48b318" xlink:to="loc_us-gaap_LitigationStatusDomain_6ee51104-6d04-4a3a-89d4-f24ceff1b995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_ec5394b5-8646-4762-b375-5536be63fb64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_6ee51104-6d04-4a3a-89d4-f24ceff1b995" xlink:to="loc_us-gaap_SettledLitigationMember_ec5394b5-8646-4762-b375-5536be63fb64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_cfd7e448-18f2-4fa4-ba96-d375a0b9d4e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_31140deb-80f6-4ce2-82c5-354db8680e2c" xlink:to="loc_srt_LitigationCaseAxis_cfd7e448-18f2-4fa4-ba96-d375a0b9d4e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_cfd7e448-18f2-4fa4-ba96-d375a0b9d4e3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_cfd7e448-18f2-4fa4-ba96-d375a0b9d4e3" xlink:to="loc_srt_LitigationCaseTypeDomain_cfd7e448-18f2-4fa4-ba96-d375a0b9d4e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f45f3f72-d7b7-41a7-aa0c-5dff34b6f77a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_cfd7e448-18f2-4fa4-ba96-d375a0b9d4e3" xlink:to="loc_srt_LitigationCaseTypeDomain_f45f3f72-d7b7-41a7-aa0c-5dff34b6f77a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CivilInvestigativeDemandsMember_23d421a7-a8a4-4b7a-8d86-92a35bc60212" xlink:href="opk-20220331.xsd#opk_CivilInvestigativeDemandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f45f3f72-d7b7-41a7-aa0c-5dff34b6f77a" xlink:to="loc_opk_CivilInvestigativeDemandsMember_23d421a7-a8a4-4b7a-8d86-92a35bc60212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChanceryCourtOfDelawareVsCompanyMember_05cc7b7e-476a-4e1b-8f5b-d52daafe63c7" xlink:href="opk-20220331.xsd#opk_ChanceryCourtOfDelawareVsCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f45f3f72-d7b7-41a7-aa0c-5dff34b6f77a" xlink:to="loc_opk_ChanceryCourtOfDelawareVsCompanyMember_05cc7b7e-476a-4e1b-8f5b-d52daafe63c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SouthernDistrictOfNewYorkVsBioReferenceMember_56bcbfb5-6fd2-42a0-844f-4fa7dcd4e52a" xlink:href="opk-20220331.xsd#opk_SouthernDistrictOfNewYorkVsBioReferenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f45f3f72-d7b7-41a7-aa0c-5dff34b6f77a" xlink:to="loc_opk_SouthernDistrictOfNewYorkVsBioReferenceMember_56bcbfb5-6fd2-42a0-844f-4fa7dcd4e52a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" id="ia5e627e5b8e7488b913b0b023c8ceea5_RevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7ca1bc1b-6d1c-4480-bbcd-1769ba35ac65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_427f1813-fb3a-4909-a30a-e243dd496f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7ca1bc1b-6d1c-4480-bbcd-1769ba35ac65" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_427f1813-fb3a-4909-a30a-e243dd496f87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedExpensePayorOverpaymentReimbursementLiability_61982cc2-e457-461a-8b6a-03e9d0f31bf1" xlink:href="opk-20220331.xsd#opk_AccruedExpensePayorOverpaymentReimbursementLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7ca1bc1b-6d1c-4480-bbcd-1769ba35ac65" xlink:to="loc_opk_AccruedExpensePayorOverpaymentReimbursementLiability_61982cc2-e457-461a-8b6a-03e9d0f31bf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9f9db6ee-01e5-4de8-a3c7-d23a1bc06abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7ca1bc1b-6d1c-4480-bbcd-1769ba35ac65" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9f9db6ee-01e5-4de8-a3c7-d23a1bc06abb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_194d21ee-3096-4f3c-913b-69224152590d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7ca1bc1b-6d1c-4480-bbcd-1769ba35ac65" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_194d21ee-3096-4f3c-913b-69224152590d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_44ef4ec6-cd65-49c6-86ca-9f0b8b512a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7ca1bc1b-6d1c-4480-bbcd-1769ba35ac65" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_44ef4ec6-cd65-49c6-86ca-9f0b8b512a90" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7c5af198-e88b-46eb-9868-46bf15fb333c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_44ef4ec6-cd65-49c6-86ca-9f0b8b512a90" xlink:to="loc_srt_CounterpartyNameAxis_7c5af198-e88b-46eb-9868-46bf15fb333c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c5af198-e88b-46eb-9868-46bf15fb333c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7c5af198-e88b-46eb-9868-46bf15fb333c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c5af198-e88b-46eb-9868-46bf15fb333c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3166df68-4feb-439a-b659-849fe1249f8c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7c5af198-e88b-46eb-9868-46bf15fb333c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3166df68-4feb-439a-b659-849fe1249f8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PfizerMember_65f559ed-5742-4856-bd2b-ef566be838bc" xlink:href="opk-20220331.xsd#opk_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3166df68-4feb-439a-b659-849fe1249f8c" xlink:to="loc_opk_PfizerMember_65f559ed-5742-4856-bd2b-ef566be838bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember_07f431bf-71da-4f16-8f70-af05b88a13f6" xlink:href="opk-20220331.xsd#opk_ViforFreseniusMedicalCarePharmaLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3166df68-4feb-439a-b659-849fe1249f8c" xlink:to="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember_07f431bf-71da-4f16-8f70-af05b88a13f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e2763036-106b-49a1-8d22-7ee8a78b1127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_44ef4ec6-cd65-49c6-86ca-9f0b8b512a90" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e2763036-106b-49a1-8d22-7ee8a78b1127" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2763036-106b-49a1-8d22-7ee8a78b1127_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e2763036-106b-49a1-8d22-7ee8a78b1127" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2763036-106b-49a1-8d22-7ee8a78b1127_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b05a96ef-9bfb-4b36-9860-46a758814305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e2763036-106b-49a1-8d22-7ee8a78b1127" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b05a96ef-9bfb-4b36-9860-46a758814305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f43ec1db-1a24-4aa1-9e26-5c9800acf2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b05a96ef-9bfb-4b36-9860-46a758814305" xlink:to="loc_us-gaap_ProductMember_f43ec1db-1a24-4aa1-9e26-5c9800acf2f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6f2a01e2-1d85-415b-a075-bfa803a752c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_44ef4ec6-cd65-49c6-86ca-9f0b8b512a90" xlink:to="loc_srt_ProductOrServiceAxis_6f2a01e2-1d85-415b-a075-bfa803a752c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f2a01e2-1d85-415b-a075-bfa803a752c6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6f2a01e2-1d85-415b-a075-bfa803a752c6" xlink:to="loc_srt_ProductsAndServicesDomain_6f2a01e2-1d85-415b-a075-bfa803a752c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_435784cc-c18d-4cc0-9695-c7d580d1d930" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6f2a01e2-1d85-415b-a075-bfa803a752c6" xlink:to="loc_srt_ProductsAndServicesDomain_435784cc-c18d-4cc0-9695-c7d580d1d930" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RayaldeeMember_f7f1d405-3d7c-4ce5-8dab-2fab0fa71bb3" xlink:href="opk-20220331.xsd#opk_RayaldeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_435784cc-c18d-4cc0-9695-c7d580d1d930" xlink:to="loc_opk_RayaldeeMember_f7f1d405-3d7c-4ce5-8dab-2fab0fa71bb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_7f125cc9-9c94-45cd-8311-4ecab3b7e8c4" xlink:href="opk-20220331.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_435784cc-c18d-4cc0-9695-c7d580d1d930" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_7f125cc9-9c94-45cd-8311-4ecab3b7e8c4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#RevenueRecognitionScheduleofDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="extended" id="i3b382faaae4140aa910713c4f151b3b9_RevenueRecognitionScheduleofDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_758ff1c1-deb2-41a9-9e54-c2b3017baefa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4e36956a-430c-48f7-85a4-f5a586746c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_758ff1c1-deb2-41a9-9e54-c2b3017baefa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4e36956a-430c-48f7-85a4-f5a586746c18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a2abba6c-ced9-44e4-b0db-169b661f6520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_758ff1c1-deb2-41a9-9e54-c2b3017baefa" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a2abba6c-ced9-44e4-b0db-169b661f6520" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_46858f58-772c-4c0b-8893-a4ec68c7fff0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2abba6c-ced9-44e4-b0db-169b661f6520" xlink:to="loc_srt_ProductOrServiceAxis_46858f58-772c-4c0b-8893-a4ec68c7fff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_46858f58-772c-4c0b-8893-a4ec68c7fff0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_46858f58-772c-4c0b-8893-a4ec68c7fff0" xlink:to="loc_srt_ProductsAndServicesDomain_46858f58-772c-4c0b-8893-a4ec68c7fff0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a561e10c-fe56-4f0f-93b9-c095938642f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_46858f58-772c-4c0b-8893-a4ec68c7fff0" xlink:to="loc_srt_ProductsAndServicesDomain_a561e10c-fe56-4f0f-93b9-c095938642f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_101ada4d-be2d-4957-8d7f-610572fa5165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a561e10c-fe56-4f0f-93b9-c095938642f8" xlink:to="loc_us-gaap_ServiceMember_101ada4d-be2d-4957-8d7f-610572fa5165" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_HealthInsurersMember_cc499b6f-e638-47d4-8555-458454a9b54f" xlink:href="opk-20220331.xsd#opk_HealthInsurersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServiceMember_101ada4d-be2d-4957-8d7f-610572fa5165" xlink:to="loc_opk_HealthInsurersMember_cc499b6f-e638-47d4-8555-458454a9b54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GovernmentPayersMember_6f4abd0c-e4bd-497e-a21c-e6aa31301d91" xlink:href="opk-20220331.xsd#opk_GovernmentPayersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServiceMember_101ada4d-be2d-4957-8d7f-610572fa5165" xlink:to="loc_opk_GovernmentPayersMember_6f4abd0c-e4bd-497e-a21c-e6aa31301d91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ClientPayersMember_96bf7117-6f55-48a2-8d9f-d7ba0553b4f9" xlink:href="opk-20220331.xsd#opk_ClientPayersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServiceMember_101ada4d-be2d-4957-8d7f-610572fa5165" xlink:to="loc_opk_ClientPayersMember_96bf7117-6f55-48a2-8d9f-d7ba0553b4f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PatientsMember_43cffa10-8033-42cc-b7f8-1e6e9a4754eb" xlink:href="opk-20220331.xsd#opk_PatientsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServiceMember_101ada4d-be2d-4957-8d7f-610572fa5165" xlink:to="loc_opk_PatientsMember_43cffa10-8033-42cc-b7f8-1e6e9a4754eb" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails" xlink:type="extended" id="i51ba21e1cefd4f8d83687b8eae0cf769_RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b1f88bcb-3c0d-478c-a6bf-10ccff980f2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7eb0afd4-12d8-4f49-b3e5-b7456fdecb88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b1f88bcb-3c0d-478c-a6bf-10ccff980f2a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7eb0afd4-12d8-4f49-b3e5-b7456fdecb88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_327bcada-0997-4866-a5ba-d4d8429bad81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7eb0afd4-12d8-4f49-b3e5-b7456fdecb88" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_327bcada-0997-4866-a5ba-d4d8429bad81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_853bf6f0-7e41-48ec-b2a5-1313508671d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7eb0afd4-12d8-4f49-b3e5-b7456fdecb88" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_853bf6f0-7e41-48ec-b2a5-1313508671d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments_5ae2d075-03b2-48af-8c9a-9ad586d4eb6b" xlink:href="opk-20220331.xsd#opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7eb0afd4-12d8-4f49-b3e5-b7456fdecb88" xlink:to="loc_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments_5ae2d075-03b2-48af-8c9a-9ad586d4eb6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_7815e2d1-ff07-4b73-ba59-2dd895cfcd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a9c7a7eb-47c0-4b51-a753-a01f436b9cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b1f88bcb-3c0d-478c-a6bf-10ccff980f2a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a9c7a7eb-47c0-4b51-a753-a01f436b9cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales_4ddfd788-510c-43a2-8357-4204b2e8c632" xlink:href="opk-20220331.xsd#opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b1f88bcb-3c0d-478c-a6bf-10ccff980f2a" xlink:to="loc_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales_4ddfd788-510c-43a2-8357-4204b2e8c632" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1c04490e-0e93-4e85-9fdb-b92ab798f43b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b1f88bcb-3c0d-478c-a6bf-10ccff980f2a" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1c04490e-0e93-4e85-9fdb-b92ab798f43b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_157d3f1c-834d-42c5-a1af-e1f9cd819503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1c04490e-0e93-4e85-9fdb-b92ab798f43b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_157d3f1c-834d-42c5-a1af-e1f9cd819503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_157d3f1c-834d-42c5-a1af-e1f9cd819503_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_157d3f1c-834d-42c5-a1af-e1f9cd819503" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_157d3f1c-834d-42c5-a1af-e1f9cd819503_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_cae93cb6-8ae1-40e5-a74d-fc2e659ea44b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_157d3f1c-834d-42c5-a1af-e1f9cd819503" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_cae93cb6-8ae1-40e5-a74d-fc2e659ea44b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChargebacksDiscountsRebatesAndFeesMember_795cad16-0709-45d3-9b8e-e7c6685dd191" xlink:href="opk-20220331.xsd#opk_ChargebacksDiscountsRebatesAndFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_cae93cb6-8ae1-40e5-a74d-fc2e659ea44b" xlink:to="loc_opk_ChargebacksDiscountsRebatesAndFeesMember_795cad16-0709-45d3-9b8e-e7c6685dd191" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GovernmentalMember_54aa9c1a-8ce5-4924-b48d-5bd55a33238b" xlink:href="opk-20220331.xsd#opk_GovernmentalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_cae93cb6-8ae1-40e5-a74d-fc2e659ea44b" xlink:to="loc_opk_GovernmentalMember_54aa9c1a-8ce5-4924-b48d-5bd55a33238b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesReturnsMember_37b53799-64bc-4d2d-a1b8-22438ea45965" xlink:href="opk-20220331.xsd#opk_SalesReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_cae93cb6-8ae1-40e5-a74d-fc2e659ea44b" xlink:to="loc_opk_SalesReturnsMember_37b53799-64bc-4d2d-a1b8-22438ea45965" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_12557015-ecd8-4f4e-b56e-7889b5118edc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1c04490e-0e93-4e85-9fdb-b92ab798f43b" xlink:to="loc_srt_ProductOrServiceAxis_12557015-ecd8-4f4e-b56e-7889b5118edc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_12557015-ecd8-4f4e-b56e-7889b5118edc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_12557015-ecd8-4f4e-b56e-7889b5118edc" xlink:to="loc_srt_ProductsAndServicesDomain_12557015-ecd8-4f4e-b56e-7889b5118edc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a1508ee9-56f9-4e3a-a79d-c33a62911240" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_12557015-ecd8-4f4e-b56e-7889b5118edc" xlink:to="loc_srt_ProductsAndServicesDomain_a1508ee9-56f9-4e3a-a79d-c33a62911240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RayaldeeMember_86df5f5a-dca4-4fad-b87b-d2a6867b8b1e" xlink:href="opk-20220331.xsd#opk_RayaldeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a1508ee9-56f9-4e3a-a79d-c33a62911240" xlink:to="loc_opk_RayaldeeMember_86df5f5a-dca4-4fad-b87b-d2a6867b8b1e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/StrategicAlliancesDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#StrategicAlliancesDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/StrategicAlliancesDetails" xlink:type="extended" id="i65d19c6fb8cf49d3a46a7f29acc66cdb_StrategicAlliancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_e8ff129e-8cc6-431f-a512-832343b02112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_e8ff129e-8cc6-431f-a512-832343b02112" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a1157ab-887a-43cd-ad10-92a32a6694f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a1157ab-887a-43cd-ad10-92a32a6694f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_76aee806-530f-49b3-88d6-0be3a04b43ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_76aee806-530f-49b3-88d6-0be3a04b43ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_21996b50-80f0-4506-9063-3331ffd7014d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_21996b50-80f0-4506-9063-3331ffd7014d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementUpfrontPaymentShares_49caeff9-20da-422c-8b9a-f0ee8eabcc31" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementUpfrontPaymentShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementUpfrontPaymentShares_49caeff9-20da-422c-8b9a-f0ee8eabcc31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementPercentOfOutstandingShares_aff58428-aba6-46bd-adde-b2b5ff762d43" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementPercentOfOutstandingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementPercentOfOutstandingShares_aff58428-aba6-46bd-adde-b2b5ff762d43" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementDevelopmentMilestonePayment_506ebfd9-714e-4511-b87e-46e8278c45e2" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementDevelopmentMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementDevelopmentMilestonePayment_506ebfd9-714e-4511-b87e-46e8278c45e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementSalesMilestonePayment_95648feb-7737-45ea-aa96-a39146dd90b1" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementSalesMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementSalesMilestonePayment_95648feb-7737-45ea-aa96-a39146dd90b1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares_f3778200-bbe5-4b1f-89a4-90164ac131ce" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementDevelopmentMilestonePaymentShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares_f3778200-bbe5-4b1f-89a4-90164ac131ce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale_2cddc9ea-9d4d-4715-9aa2-571b6e375624" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale_2cddc9ea-9d4d-4715-9aa2-571b6e375624" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment_c897572e-599a-4919-a7a0-53becb8348ca" xlink:href="opk-20220331.xsd#opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment_c897572e-599a-4919-a7a0-53becb8348ca" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment_74be4cc1-b378-4f78-8f46-aea2656352e2" xlink:href="opk-20220331.xsd#opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment_74be4cc1-b378-4f78-8f46-aea2656352e2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale_67ac5d66-3b6d-4b11-8fd8-67f6e622e2aa" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementPeriodAfterFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale_67ac5d66-3b6d-4b11-8fd8-67f6e622e2aa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMaximumMilestonePayments_49a60054-69ea-4e67-924e-4254031fad55" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementMaximumMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementMaximumMilestonePayments_49a60054-69ea-4e67-924e-4254031fad55" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime_d65e4381-3fd0-4cd2-a946-36247cbb8598" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime_d65e4381-3fd0-4cd2-a946-36247cbb8598" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementUpfrontPayment_4dabcfee-4366-49cd-ae1c-0e276059fc30" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementUpfrontPayment_4dabcfee-4366-49cd-ae1c-0e276059fc30" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeAgreementAdditionalMilestonePayment_fe48d8b0-6b5b-4ca0-9f11-309461981111" xlink:href="opk-20220331.xsd#opk_CollaborativeAgreementAdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeAgreementAdditionalMilestonePayment_fe48d8b0-6b5b-4ca0-9f11-309461981111" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMilestonePayment_8fde9862-5d54-42b2-80cd-6ec672f5df3a" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementMilestonePayment_8fde9862-5d54-42b2-80cd-6ec672f5df3a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dfa9ba64-19c3-433d-b3af-d264d2363027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dfa9ba64-19c3-433d-b3af-d264d2363027" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9fc4b0ba-fd91-48e4-883a-6d70d1f83f53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_srt_ProductOrServiceAxis_9fc4b0ba-fd91-48e4-883a-6d70d1f83f53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9fc4b0ba-fd91-48e4-883a-6d70d1f83f53_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9fc4b0ba-fd91-48e4-883a-6d70d1f83f53" xlink:to="loc_srt_ProductsAndServicesDomain_9fc4b0ba-fd91-48e4-883a-6d70d1f83f53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9fc4b0ba-fd91-48e4-883a-6d70d1f83f53" xlink:to="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_7cd6c4d5-ab39-4e56-88c3-962d2be683d8" xlink:href="opk-20220331.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_7cd6c4d5-ab39-4e56-88c3-962d2be683d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DravetSyndromeProductsMember_92107835-17e0-4baa-848b-69ff8d25bb50" xlink:href="opk-20220331.xsd#opk_DravetSyndromeProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:to="loc_opk_DravetSyndromeProductsMember_92107835-17e0-4baa-848b-69ff8d25bb50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NonDravetSyndromeProductsMember_f0a7dc34-6238-49ef-9b9e-9122f2efa928" xlink:href="opk-20220331.xsd#opk_NonDravetSyndromeProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:to="loc_opk_NonDravetSyndromeProductsMember_f0a7dc34-6238-49ef-9b9e-9122f2efa928" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3cef9b93-5863-4694-8140-a6fb8f3f4894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:to="loc_us-gaap_ProductMember_3cef9b93-5863-4694-8140-a6fb8f3f4894" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryMilestonesMember_3ee779b9-6736-4929-9c37-f33db03f9f61" xlink:href="opk-20220331.xsd#opk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:to="loc_opk_RegulatoryMilestonesMember_3ee779b9-6736-4929-9c37-f33db03f9f61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesMilestonesMember_297b2290-d811-4b43-897c-b2a914fa5292" xlink:href="opk-20220331.xsd#opk_SalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:to="loc_opk_SalesMilestonesMember_297b2290-d811-4b43-897c-b2a914fa5292" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ExclusiveOptionMember_ea57604b-9890-4406-921f-698b54d1a1d4" xlink:href="opk-20220331.xsd#opk_ExclusiveOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:to="loc_opk_ExclusiveOptionMember_ea57604b-9890-4406-921f-698b54d1a1d4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MilestoneAxis_786da8db-7fa8-42a9-a121-4c9555ad242e" xlink:href="opk-20220331.xsd#opk_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_opk_MilestoneAxis_786da8db-7fa8-42a9-a121-4c9555ad242e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MilestoneDomain_786da8db-7fa8-42a9-a121-4c9555ad242e_default" xlink:href="opk-20220331.xsd#opk_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_opk_MilestoneAxis_786da8db-7fa8-42a9-a121-4c9555ad242e" xlink:to="loc_opk_MilestoneDomain_786da8db-7fa8-42a9-a121-4c9555ad242e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MilestoneDomain_b409eb9b-c51b-4514-bce4-9a6c5ad6e4aa" xlink:href="opk-20220331.xsd#opk_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_opk_MilestoneAxis_786da8db-7fa8-42a9-a121-4c9555ad242e" xlink:to="loc_opk_MilestoneDomain_b409eb9b-c51b-4514-bce4-9a6c5ad6e4aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PhaseThreeInitiationMember_fe3d7ef4-9e2b-4cd3-a9f1-10a61c87a2ef" xlink:href="opk-20220331.xsd#opk_PhaseThreeInitiationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_MilestoneDomain_b409eb9b-c51b-4514-bce4-9a6c5ad6e4aa" xlink:to="loc_opk_PhaseThreeInitiationMember_fe3d7ef4-9e2b-4cd3-a9f1-10a61c87a2ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryAndDevelopmentMember_f461931f-cf04-46c0-992b-c501c784803b" xlink:href="opk-20220331.xsd#opk_RegulatoryAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_opk_MilestoneDomain_b409eb9b-c51b-4514-bce4-9a6c5ad6e4aa" xlink:to="loc_opk_RegulatoryAndDevelopmentMember_f461931f-cf04-46c0-992b-c501c784803b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_749b61fd-c771-4067-83a2-8b22c0cf1349" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_srt_RangeAxis_749b61fd-c771-4067-83a2-8b22c0cf1349" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_749b61fd-c771-4067-83a2-8b22c0cf1349_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_749b61fd-c771-4067-83a2-8b22c0cf1349" xlink:to="loc_srt_RangeMember_749b61fd-c771-4067-83a2-8b22c0cf1349_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f26e8378-81a8-4594-aab7-f5d4dcdec63f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_749b61fd-c771-4067-83a2-8b22c0cf1349" xlink:to="loc_srt_RangeMember_f26e8378-81a8-4594-aab7-f5d4dcdec63f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b7490dd9-c3c8-4a5d-95f1-005db6cde34a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f26e8378-81a8-4594-aab7-f5d4dcdec63f" xlink:to="loc_srt_MinimumMember_b7490dd9-c3c8-4a5d-95f1-005db6cde34a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bd17459b-df6a-4919-958d-83469d311bac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f26e8378-81a8-4594-aab7-f5d4dcdec63f" xlink:to="loc_srt_MaximumMember_bd17459b-df6a-4919-958d-83469d311bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_dc29f4c2-63a8-46bc-aaff-22774243332d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_srt_CounterpartyNameAxis_dc29f4c2-63a8-46bc-aaff-22774243332d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc29f4c2-63a8-46bc-aaff-22774243332d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_dc29f4c2-63a8-46bc-aaff-22774243332d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc29f4c2-63a8-46bc-aaff-22774243332d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_dc29f4c2-63a8-46bc-aaff-22774243332d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LeaderMedMember_ece22dae-5ec1-4eda-b7d7-2a66edb2b20b" xlink:href="opk-20220331.xsd#opk_LeaderMedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:to="loc_opk_LeaderMedMember_ece22dae-5ec1-4eda-b7d7-2a66edb2b20b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CAMP4Member_e68668c4-7238-47d7-9122-266544452e03" xlink:href="opk-20220331.xsd#opk_CAMP4Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:to="loc_opk_CAMP4Member_e68668c4-7238-47d7-9122-266544452e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NicoyaMember_10290f6e-d791-4d27-9b41-fa88ac2f2fb3" xlink:href="opk-20220331.xsd#opk_NicoyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:to="loc_opk_NicoyaMember_10290f6e-d791-4d27-9b41-fa88ac2f2fb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EirGenPharmaLimitedMember_a021cfe1-439b-4f9f-b242-7764968f9c70" xlink:href="opk-20220331.xsd#opk_EirGenPharmaLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:to="loc_opk_EirGenPharmaLimitedMember_a021cfe1-439b-4f9f-b242-7764968f9c70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember_913b02db-f7e5-453f-84fc-0ea392cefdfd" xlink:href="opk-20220331.xsd#opk_ViforFreseniusMedicalCarePharmaLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:to="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember_913b02db-f7e5-453f-84fc-0ea392cefdfd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PfizerMember_1c7c8b82-7810-4e77-8a09-383726bcd0ce" xlink:href="opk-20220331.xsd#opk_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:to="loc_opk_PfizerMember_1c7c8b82-7810-4e77-8a09-383726bcd0ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_851b7d71-e042-424a-9597-af04216a2615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_851b7d71-e042-424a-9597-af04216a2615" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851b7d71-e042-424a-9597-af04216a2615_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_851b7d71-e042-424a-9597-af04216a2615" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851b7d71-e042-424a-9597-af04216a2615_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc37ef82-06be-4722-8f42-28e2026ba173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_851b7d71-e042-424a-9597-af04216a2615" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc37ef82-06be-4722-8f42-28e2026ba173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e79ef0a9-e949-4a84-8361-c1dcebe54c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc37ef82-06be-4722-8f42-28e2026ba173" xlink:to="loc_us-gaap_ProductMember_e79ef0a9-e949-4a84-8361-c1dcebe54c1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryMilestonesMember_f7bf05b9-c3ea-4929-8244-3b07856a8725" xlink:href="opk-20220331.xsd#opk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc37ef82-06be-4722-8f42-28e2026ba173" xlink:to="loc_opk_RegulatoryMilestonesMember_f7bf05b9-c3ea-4929-8244-3b07856a8725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ExclusiveOptionMember_69cc4066-6513-4e05-b3e2-5deb391c5b42" xlink:href="opk-20220331.xsd#opk_ExclusiveOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc37ef82-06be-4722-8f42-28e2026ba173" xlink:to="loc_opk_ExclusiveOptionMember_69cc4066-6513-4e05-b3e2-5deb391c5b42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_582626c3-c31c-45d2-be66-4e8c81035668" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_srt_OwnershipAxis_582626c3-c31c-45d2-be66-4e8c81035668" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_582626c3-c31c-45d2-be66-4e8c81035668_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_582626c3-c31c-45d2-be66-4e8c81035668" xlink:to="loc_srt_OwnershipDomain_582626c3-c31c-45d2-be66-4e8c81035668_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2712984a-8def-44c9-8c3b-68638dc63e2f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_582626c3-c31c-45d2-be66-4e8c81035668" xlink:to="loc_srt_OwnershipDomain_2712984a-8def-44c9-8c3b-68638dc63e2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LeaderMedJointVentureMember_9eed39a0-4347-411d-b53f-70410fc9f640" xlink:href="opk-20220331.xsd#opk_LeaderMedJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2712984a-8def-44c9-8c3b-68638dc63e2f" xlink:to="loc_opk_LeaderMedJointVentureMember_9eed39a0-4347-411d-b53f-70410fc9f640" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ba1ec0d9-67bc-4df9-8a4d-09d89484d23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ba1ec0d9-67bc-4df9-8a4d-09d89484d23d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ba1ec0d9-67bc-4df9-8a4d-09d89484d23d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ba1ec0d9-67bc-4df9-8a4d-09d89484d23d" xlink:to="loc_us-gaap_RelatedPartyDomain_ba1ec0d9-67bc-4df9-8a4d-09d89484d23d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b418223e-a629-4065-9004-dbb230623693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ba1ec0d9-67bc-4df9-8a4d-09d89484d23d" xlink:to="loc_us-gaap_RelatedPartyDomain_b418223e-a629-4065-9004-dbb230623693" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_810a47d6-4566-41ce-a64e-3ecb57a19bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b418223e-a629-4065-9004-dbb230623693" xlink:to="loc_us-gaap_CorporateJointVentureMember_810a47d6-4566-41ce-a64e-3ecb57a19bdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_657f728e-36cb-4231-87cb-0888b708e6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_657f728e-36cb-4231-87cb-0888b708e6ba" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_657f728e-36cb-4231-87cb-0888b708e6ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_657f728e-36cb-4231-87cb-0888b708e6ba" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_657f728e-36cb-4231-87cb-0888b708e6ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7712f905-60c5-4d4a-8806-e07b15b404ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_657f728e-36cb-4231-87cb-0888b708e6ba" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7712f905-60c5-4d4a-8806-e07b15b404ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4c1c4c0a-f35b-45d0-a8c5-204fd6f93a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7712f905-60c5-4d4a-8806-e07b15b404ab" xlink:to="loc_us-gaap_SubsequentEventMember_4c1c4c0a-f35b-45d0-a8c5-204fd6f93a37" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#SegmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/SegmentsNarrativeDetails" xlink:type="extended" id="ia8e9a7fa759c4cd4b82179de397d5477_SegmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ddf732b9-d8a5-4be1-a473-41c7b1845817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_952930dc-2508-481c-a350-75210bcd6d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ddf732b9-d8a5-4be1-a473-41c7b1845817" xlink:to="loc_us-gaap_NumberOfReportableSegments_952930dc-2508-481c-a350-75210bcd6d73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cf6ed452-ea80-4771-8548-739d5235632d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ddf732b9-d8a5-4be1-a473-41c7b1845817" xlink:to="loc_us-gaap_Revenues_cf6ed452-ea80-4771-8548-739d5235632d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c91beef9-58c4-4891-a827-27e04cc84c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ddf732b9-d8a5-4be1-a473-41c7b1845817" xlink:to="loc_us-gaap_InterestExpense_c91beef9-58c4-4891-a827-27e04cc84c9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b345bf7-1ed8-493d-8ef0-0fe92b66877a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ddf732b9-d8a5-4be1-a473-41c7b1845817" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b345bf7-1ed8-493d-8ef0-0fe92b66877a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_5401ffca-4c41-4a3e-9934-b40b0c43fce7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b345bf7-1ed8-493d-8ef0-0fe92b66877a" xlink:to="loc_srt_ConsolidationItemsAxis_5401ffca-4c41-4a3e-9934-b40b0c43fce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_5401ffca-4c41-4a3e-9934-b40b0c43fce7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_5401ffca-4c41-4a3e-9934-b40b0c43fce7" xlink:to="loc_srt_ConsolidationItemsDomain_5401ffca-4c41-4a3e-9934-b40b0c43fce7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_157770ee-3077-4b76-81f6-f1dc94a4b41e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_5401ffca-4c41-4a3e-9934-b40b0c43fce7" xlink:to="loc_srt_ConsolidationItemsDomain_157770ee-3077-4b76-81f6-f1dc94a4b41e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_24c33278-88a6-4c62-b8ee-e2f8ca2b995a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_157770ee-3077-4b76-81f6-f1dc94a4b41e" xlink:to="loc_us-gaap_IntersegmentEliminationMember_24c33278-88a6-4c62-b8ee-e2f8ca2b995a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#SegmentsOperationsandAssetsInformationDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails" xlink:type="extended" id="i3519521aa6d44e17b2508f9f3d6e323e_SegmentsOperationsandAssetsInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_921359d7-a316-4ca5-8652-4647b17f7783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_921359d7-a316-4ca5-8652-4647b17f7783" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_38663062-5016-4a06-8962-ae09ced532ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:to="loc_us-gaap_OperatingIncomeLoss_38663062-5016-4a06-8962-ae09ced532ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_975bb6d4-498a-40e3-a904-9f28a9c29d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_975bb6d4-498a-40e3-a904-9f28a9c29d72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_8a8bd5b1-32b8-4e4f-8e16-8df5e88eab43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:to="loc_us-gaap_GainLossOnInvestments_8a8bd5b1-32b8-4e4f-8e16-8df5e88eab43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_74ced428-47e2-4a17-8b4b-1af88df0a407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:to="loc_us-gaap_Assets_74ced428-47e2-4a17-8b4b-1af88df0a407" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_987973ca-d71f-4d7e-8b9f-f59fc55d2f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:to="loc_us-gaap_Goodwill_987973ca-d71f-4d7e-8b9f-f59fc55d2f7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fa89a2ee-c247-4e49-8a4d-d067db74f677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fa89a2ee-c247-4e49-8a4d-d067db74f677" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5c57bf9e-6d36-478d-bfe3-a0f7ee22a8c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fa89a2ee-c247-4e49-8a4d-d067db74f677" xlink:to="loc_srt_ProductOrServiceAxis_5c57bf9e-6d36-478d-bfe3-a0f7ee22a8c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c57bf9e-6d36-478d-bfe3-a0f7ee22a8c7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5c57bf9e-6d36-478d-bfe3-a0f7ee22a8c7" xlink:to="loc_srt_ProductsAndServicesDomain_5c57bf9e-6d36-478d-bfe3-a0f7ee22a8c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf1036de-1394-4627-b2ec-9165281d6797" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5c57bf9e-6d36-478d-bfe3-a0f7ee22a8c7" xlink:to="loc_srt_ProductsAndServicesDomain_cf1036de-1394-4627-b2ec-9165281d6797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_747f1478-e510-433b-9a74-ac44db8036c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf1036de-1394-4627-b2ec-9165281d6797" xlink:to="loc_us-gaap_ServiceMember_747f1478-e510-433b-9a74-ac44db8036c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_db88509d-bd37-4940-a2fe-92690cdb342c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf1036de-1394-4627-b2ec-9165281d6797" xlink:to="loc_us-gaap_ProductMember_db88509d-bd37-4940-a2fe-92690cdb342c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_1719db39-b319-4cca-b1b8-1daa4b107dd2" xlink:href="opk-20220331.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf1036de-1394-4627-b2ec-9165281d6797" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_1719db39-b319-4cca-b1b8-1daa4b107dd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b8f33fc5-3c7f-442b-8445-041d088d884a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fa89a2ee-c247-4e49-8a4d-d067db74f677" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b8f33fc5-3c7f-442b-8445-041d088d884a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b8f33fc5-3c7f-442b-8445-041d088d884a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b8f33fc5-3c7f-442b-8445-041d088d884a" xlink:to="loc_us-gaap_SegmentDomain_b8f33fc5-3c7f-442b-8445-041d088d884a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_452d70b7-6fce-4991-95de-293da314594e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b8f33fc5-3c7f-442b-8445-041d088d884a" xlink:to="loc_us-gaap_SegmentDomain_452d70b7-6fce-4991-95de-293da314594e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmaceuticalMember_8d17bffc-b0fe-4d9c-8630-3c674d94bc3e" xlink:href="opk-20220331.xsd#opk_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_452d70b7-6fce-4991-95de-293da314594e" xlink:to="loc_opk_PharmaceuticalMember_8d17bffc-b0fe-4d9c-8630-3c674d94bc3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticsMember_c6b8bebf-6bc8-46c3-9807-998e92549c37" xlink:href="opk-20220331.xsd#opk_DiagnosticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_452d70b7-6fce-4991-95de-293da314594e" xlink:to="loc_opk_DiagnosticsMember_c6b8bebf-6bc8-46c3-9807-998e92549c37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f2a067ac-134d-46cb-80af-7b947fef629d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fa89a2ee-c247-4e49-8a4d-d067db74f677" xlink:to="loc_srt_ConsolidationItemsAxis_f2a067ac-134d-46cb-80af-7b947fef629d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f2a067ac-134d-46cb-80af-7b947fef629d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_f2a067ac-134d-46cb-80af-7b947fef629d" xlink:to="loc_srt_ConsolidationItemsDomain_f2a067ac-134d-46cb-80af-7b947fef629d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_739bc9d3-b0ae-40d8-a027-7a7fe070d366" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_f2a067ac-134d-46cb-80af-7b947fef629d" xlink:to="loc_srt_ConsolidationItemsDomain_739bc9d3-b0ae-40d8-a027-7a7fe070d366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_20a64d25-b0c1-41b3-b19b-5ddb50bf41f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_739bc9d3-b0ae-40d8-a027-7a7fe070d366" xlink:to="loc_us-gaap_OperatingSegmentsMember_20a64d25-b0c1-41b3-b19b-5ddb50bf41f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_771e459d-dbf6-497a-8680-39f78887524e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_739bc9d3-b0ae-40d8-a027-7a7fe070d366" xlink:to="loc_us-gaap_CorporateNonSegmentMember_771e459d-dbf6-497a-8680-39f78887524e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f1a9b5c2-288c-40b5-b21f-1d579ff72ca7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fa89a2ee-c247-4e49-8a4d-d067db74f677" xlink:to="loc_srt_StatementGeographicalAxis_f1a9b5c2-288c-40b5-b21f-1d579ff72ca7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f1a9b5c2-288c-40b5-b21f-1d579ff72ca7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f1a9b5c2-288c-40b5-b21f-1d579ff72ca7" xlink:to="loc_srt_SegmentGeographicalDomain_f1a9b5c2-288c-40b5-b21f-1d579ff72ca7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f1a9b5c2-288c-40b5-b21f-1d579ff72ca7" xlink:to="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_32bdfbf5-8cd5-4d50-a8fa-ec2429d5b839" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:to="loc_country_US_32bdfbf5-8cd5-4d50-a8fa-ec2429d5b839" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_fd5849d5-08c6-47bb-baa4-3be99a418143" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:to="loc_country_IE_fd5849d5-08c6-47bb-baa4-3be99a418143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CL_a0f037f9-aa1d-4c2c-afe3-3258ce80429e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:to="loc_country_CL_a0f037f9-aa1d-4c2c-afe3-3258ce80429e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_eff8faef-0fd8-446e-85d9-900b48363bf4" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:to="loc_country_ES_eff8faef-0fd8-446e-85d9-900b48363bf4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IL_530438ae-fe42-4b3d-ac47-1904c6acb092" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:to="loc_country_IL_530438ae-fe42-4b3d-ac47-1904c6acb092" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_88b75ab4-0c84-4616-856f-b8e3f979bacb" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:to="loc_country_MX_88b75ab4-0c84-4616-856f-b8e3f979bacb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OtherCountriesMember_da5c7331-271b-4d2b-a99c-772e3f7f3c1b" xlink:href="opk-20220331.xsd#opk_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:to="loc_opk_OtherCountriesMember_da5c7331-271b-4d2b-a99c-772e3f7f3c1b" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.opko.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.opko.com/role/SubsequentEventsDetails" xlink:type="extended" id="i650c3e27a43542db886aa644f46b9ecb_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_30323488-0fd9-4788-a16c-ebcebf2fadf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_30323488-0fd9-4788-a16c-ebcebf2fadf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c1273484-c757-4c59-bd6f-16b9fbe4a0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c1273484-c757-4c59-bd6f-16b9fbe4a0a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments_92246405-f6b4-463f-93fd-c3e1a83db5e1" xlink:href="opk-20220331.xsd#opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments_92246405-f6b4-463f-93fd-c3e1a83db5e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod_ff384d3d-8b59-4d0b-9771-41be5ff158df" xlink:href="opk-20220331.xsd#opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod_ff384d3d-8b59-4d0b-9771-41be5ff158df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationUpfrontConsiderationTransferred_3c24af8f-f455-49aa-a517-dd71b54a983e" xlink:href="opk-20220331.xsd#opk_BusinessCombinationUpfrontConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_opk_BusinessCombinationUpfrontConsiderationTransferred_3c24af8f-f455-49aa-a517-dd71b54a983e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f045f050-56a9-49bb-815d-2b2cd94866b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f045f050-56a9-49bb-815d-2b2cd94866b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMilestonePayment_51cf2250-2c51-4747-a6c9-3c1b4010d0bd" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_opk_CollaborativeArrangementMilestonePayment_51cf2250-2c51-4747-a6c9-3c1b4010d0bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement_5ce1796e-1f92-4421-96f6-7af50b52588a" xlink:href="opk-20220331.xsd#opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement_5ce1796e-1f92-4421-96f6-7af50b52588a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationPeriodPriorToSigningOfAgreement_49e9339e-0b12-4e10-a8af-3804c4a606fc" xlink:href="opk-20220331.xsd#opk_BusinessCombinationPeriodPriorToSigningOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_opk_BusinessCombinationPeriodPriorToSigningOfAgreement_49e9339e-0b12-4e10-a8af-3804c4a606fc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7d802030-b538-46be-850e-6da4eb814a1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:to="loc_srt_CounterpartyNameAxis_7d802030-b538-46be-850e-6da4eb814a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d802030-b538-46be-850e-6da4eb814a1a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7d802030-b538-46be-850e-6da4eb814a1a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d802030-b538-46be-850e-6da4eb814a1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_843f0197-17b2-4e79-b068-ce9adfd4a8f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7d802030-b538-46be-850e-6da4eb814a1a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_843f0197-17b2-4e79-b068-ce9adfd4a8f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PfizerMember_56320925-2bd3-491d-857a-ca838a970363" xlink:href="opk-20220331.xsd#opk_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_843f0197-17b2-4e79-b068-ce9adfd4a8f6" xlink:to="loc_opk_PfizerMember_56320925-2bd3-491d-857a-ca838a970363" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_09a16824-04a8-4713-be15-99ea982ef933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:to="loc_us-gaap_TypeOfArrangementAxis_09a16824-04a8-4713-be15-99ea982ef933" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09a16824-04a8-4713-be15-99ea982ef933_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_09a16824-04a8-4713-be15-99ea982ef933" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09a16824-04a8-4713-be15-99ea982ef933_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_608cd7af-d19d-4344-804b-c1656d259185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_09a16824-04a8-4713-be15-99ea982ef933" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_608cd7af-d19d-4344-804b-c1656d259185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6f481ad7-6eb0-4014-9f4d-38832f2c9dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_608cd7af-d19d-4344-804b-c1656d259185" xlink:to="loc_us-gaap_ProductMember_6f481ad7-6eb0-4014-9f4d-38832f2c9dab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ba3a8912-7ac6-4218-9003-12e676ca8dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ba3a8912-7ac6-4218-9003-12e676ca8dc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ba3a8912-7ac6-4218-9003-12e676ca8dc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ba3a8912-7ac6-4218-9003-12e676ca8dc3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ba3a8912-7ac6-4218-9003-12e676ca8dc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a59bd878-3494-4bc1-9564-503e2b52ab6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ba3a8912-7ac6-4218-9003-12e676ca8dc3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a59bd878-3494-4bc1-9564-503e2b52ab6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_eb785a64-d953-401a-ba4b-b48b4202caef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a59bd878-3494-4bc1-9564-503e2b52ab6e" xlink:to="loc_us-gaap_SubsequentEventMember_eb785a64-d953-401a-ba4b-b48b4202caef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f9136c92-ee22-47ea-8ad2-a80c3e7d751b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f9136c92-ee22-47ea-8ad2-a80c3e7d751b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f9136c92-ee22-47ea-8ad2-a80c3e7d751b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f9136c92-ee22-47ea-8ad2-a80c3e7d751b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f9136c92-ee22-47ea-8ad2-a80c3e7d751b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ee44e6-ca5a-4e45-94cb-5ba10756c4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f9136c92-ee22-47ea-8ad2-a80c3e7d751b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ee44e6-ca5a-4e45-94cb-5ba10756c4b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DetectGenomixMember_69d73c8e-0174-46e8-8a9b-378b07c83c47" xlink:href="opk-20220331.xsd#opk_DetectGenomixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ee44e6-ca5a-4e45-94cb-5ba10756c4b5" xlink:to="loc_opk_DetectGenomixMember_69d73c8e-0174-46e8-8a9b-378b07c83c47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AgreementAndPlanOfMergerMember_41e80b27-de66-4602-acf8-d5413c059ef0" xlink:href="opk-20220331.xsd#opk_AgreementAndPlanOfMergerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ee44e6-ca5a-4e45-94cb-5ba10756c4b5" xlink:to="loc_opk_AgreementAndPlanOfMergerMember_41e80b27-de66-4602-acf8-d5413c059ef0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2d880930-d5bd-43c9-9e00-8e9a10cbb2ab" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:to="loc_dei_LegalEntityAxis_2d880930-d5bd-43c9-9e00-8e9a10cbb2ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2d880930-d5bd-43c9-9e00-8e9a10cbb2ab_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2d880930-d5bd-43c9-9e00-8e9a10cbb2ab" xlink:to="loc_dei_EntityDomain_2d880930-d5bd-43c9-9e00-8e9a10cbb2ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bb266d7f-df0d-429e-b8ca-b7f505c2ed46" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2d880930-d5bd-43c9-9e00-8e9a10cbb2ab" xlink:to="loc_dei_EntityDomain_bb266d7f-df0d-429e-b8ca-b7f505c2ed46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_Sema4Member_fd7534ee-e442-4d4f-8613-a590e006703b" xlink:href="opk-20220331.xsd#opk_Sema4Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bb266d7f-df0d-429e-b8ca-b7f505c2ed46" xlink:to="loc_opk_Sema4Member_fd7534ee-e442-4d4f-8613-a590e006703b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>opk-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b1bc5044-98fa-41ae-b2d0-b9b87eb185ce,g:64b4497f-89ba-4c5f-8ed3-b19012dfc871-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_77477505-7921-4101-b777-68ca57b932c4_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_48e36793-83e9-4d7d-8dff-00ad2cb7109e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Quoted Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_7bbe04f7-8013-4c5a-ae89-3a505250ac7c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EquitySecurityFVNIOwnershipPercent_f3a04b27-97d4-470e-a688-6bc13599748c_terseLabel_en-US" xlink:label="lab_opk_EquitySecurityFVNIOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity security investments (as a percent)</link:label>
    <link:label id="lab_opk_EquitySecurityFVNIOwnershipPercent_label_en-US" xlink:label="lab_opk_EquitySecurityFVNIOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Security, FV-NI, Ownership Percent</link:label>
    <link:label id="lab_opk_EquitySecurityFVNIOwnershipPercent_documentation_en-US" xlink:label="lab_opk_EquitySecurityFVNIOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Security, FV-NI, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquitySecurityFVNIOwnershipPercent" xlink:href="opk-20220331.xsd#opk_EquitySecurityFVNIOwnershipPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EquitySecurityFVNIOwnershipPercent" xlink:to="lab_opk_EquitySecurityFVNIOwnershipPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_5368e3da-b543-49e3-8fa2-abd8462f75fd_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL INFORMATION:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_b939d230-6481-4870-852b-0b6d14fdb553_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_16b02cff-1693-48f3-8aed-6225fd6af20a_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_9717e5c1-ca0c-4975-9cc5-6963dfa940b9_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_b438bafa-a928-428a-82b1-52384356419c_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_975704b1-418d-4700-b1d4-63a6230133a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_59ac828b-ee7e-48bc-9983-f537ebe5358f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_790ae0ac-a3f3-4e53-b0c6-83f2b1d02b57_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e165dfbc-afb3-4da7-9b2b-800492634eb8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_4d8c02d7-30d0-4388-b575-644d35cc143d_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_19b658dc-47e3-485a-ade8-f305ad4db4c6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0288850e-5dbe-49a1-a083-08a56e83a554_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PharmaceuticalMember_9af07f33-6a5e-4292-84ad-5f72118a497b_terseLabel_en-US" xlink:label="lab_opk_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_opk_PharmaceuticalMember_label_en-US" xlink:label="lab_opk_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:label id="lab_opk_PharmaceuticalMember_documentation_en-US" xlink:label="lab_opk_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmaceuticalMember" xlink:href="opk-20220331.xsd#opk_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PharmaceuticalMember" xlink:to="lab_opk_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_RegulatoryAndDevelopmentMember_e1403c2b-76fd-4ff3-b48c-b93576ad9bc1_terseLabel_en-US" xlink:label="lab_opk_RegulatoryAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and Development</link:label>
    <link:label id="lab_opk_RegulatoryAndDevelopmentMember_label_en-US" xlink:label="lab_opk_RegulatoryAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory And Development [Member]</link:label>
    <link:label id="lab_opk_RegulatoryAndDevelopmentMember_documentation_en-US" xlink:label="lab_opk_RegulatoryAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryAndDevelopmentMember" xlink:href="opk-20220331.xsd#opk_RegulatoryAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_RegulatoryAndDevelopmentMember" xlink:to="lab_opk_RegulatoryAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7dae0a03-a508-48cf-801b-261218ef055d_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6b5615c9-f8cb-4f0b-a868-3d1f9a5ee6f8_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_444cc67d-5726-4b3f-a439-6a9e2556d12e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_64bff0b2-1d8b-4672-b255-0d6fdcdbe119_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_3509be5d-d95f-4721-b832-bc4319c3d8ad_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f30e24e2-a9dd-424b-83dd-94610e91443e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_6b4138da-8bee-4f5b-9b2f-37495868654d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_d2ad920c-49a5-4a64-8a5b-59c75f7f057c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration from sale of facility</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5cac7b16-97de-4198-920b-6a2424db9c02_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_53aca42e-9bf5-4edc-a011-fdba57f66846_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_62429461-530b-4e60-b150-4531575442e7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_ea1e019b-9938-4f14-adf7-276530255e00_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_d40453e1-1386-40cf-a4f3-b771174690d8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Contractual Liabilities Balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ChromaDexMember_febd5550-d6e7-449f-be5d-2511470df996_terseLabel_en-US" xlink:label="lab_opk_ChromaDexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChromaDex</link:label>
    <link:label id="lab_opk_ChromaDexMember_label_en-US" xlink:label="lab_opk_ChromaDexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChromaDex [Member]</link:label>
    <link:label id="lab_opk_ChromaDexMember_documentation_en-US" xlink:label="lab_opk_ChromaDexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChromaDex.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChromaDexMember" xlink:href="opk-20220331.xsd#opk_ChromaDexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ChromaDexMember" xlink:to="lab_opk_ChromaDexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ViforFreseniusMedicalCarePharmaLtdMember_b53baa9f-fffc-493c-bf43-8990118b6fc8_terseLabel_en-US" xlink:label="lab_opk_ViforFreseniusMedicalCarePharmaLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VFMCRP</link:label>
    <link:label id="lab_opk_ViforFreseniusMedicalCarePharmaLtdMember_label_en-US" xlink:label="lab_opk_ViforFreseniusMedicalCarePharmaLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vifor Fresenius Medical Care Pharma Ltd [Member]</link:label>
    <link:label id="lab_opk_ViforFreseniusMedicalCarePharmaLtdMember_documentation_en-US" xlink:label="lab_opk_ViforFreseniusMedicalCarePharmaLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vifor Fresenius Medical Care Pharma Ltd [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember" xlink:href="opk-20220331.xsd#opk_ViforFreseniusMedicalCarePharmaLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember" xlink:to="lab_opk_ViforFreseniusMedicalCarePharmaLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_506109f2-64bc-44dc-9e75-409d36deab99_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment_aa791f6d-3dfd-4883-9257-15885c56d233_terseLabel_en-US" xlink:label="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment from development and license agreement</link:label>
    <link:label id="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment_label_en-US" xlink:label="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Development And License Agreement, Upfront Payment</link:label>
    <link:label id="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Development And License Agreement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" xlink:href="opk-20220331.xsd#opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" xlink:to="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_edcc4b70-e656-4324-a732-59d97452a01d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_InventoryReceivedNotInvoicedCurrent_e7b1d8ad-9d62-4e63-b793-691f5f5243fc_terseLabel_en-US" xlink:label="lab_opk_InventoryReceivedNotInvoicedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory received but not invoiced</link:label>
    <link:label id="lab_opk_InventoryReceivedNotInvoicedCurrent_label_en-US" xlink:label="lab_opk_InventoryReceivedNotInvoicedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Received, Not Invoiced, Current</link:label>
    <link:label id="lab_opk_InventoryReceivedNotInvoicedCurrent_documentation_en-US" xlink:label="lab_opk_InventoryReceivedNotInvoicedCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Received, Not Invoiced, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InventoryReceivedNotInvoicedCurrent" xlink:href="opk-20220331.xsd#opk_InventoryReceivedNotInvoicedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_InventoryReceivedNotInvoicedCurrent" xlink:to="lab_opk_InventoryReceivedNotInvoicedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f4daec7f-c52f-4820-8b09-ca893c92d94b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AccruedExpensePayorOverpaymentReimbursementLiability_930e3463-c42f-4b83-b6b1-e3e3e4667279_terseLabel_en-US" xlink:label="lab_opk_AccruedExpensePayorOverpaymentReimbursementLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overpayment reimbursement liability</link:label>
    <link:label id="lab_opk_AccruedExpensePayorOverpaymentReimbursementLiability_label_en-US" xlink:label="lab_opk_AccruedExpensePayorOverpaymentReimbursementLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expense, Payor Overpayment Reimbursement, Liability</link:label>
    <link:label id="lab_opk_AccruedExpensePayorOverpaymentReimbursementLiability_documentation_en-US" xlink:label="lab_opk_AccruedExpensePayorOverpaymentReimbursementLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expense, Payor Overpayment Reimbursement, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedExpensePayorOverpaymentReimbursementLiability" xlink:href="opk-20220331.xsd#opk_AccruedExpensePayorOverpaymentReimbursementLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AccruedExpensePayorOverpaymentReimbursementLiability" xlink:to="lab_opk_AccruedExpensePayorOverpaymentReimbursementLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e70f165-3ce2-4f20-92c9-5051044a2152_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_XeneticBiosciencesInc.Member_5a426764-46d4-4758-8ca7-706c6a983840_terseLabel_en-US" xlink:label="lab_opk_XeneticBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenetic Biosciences, Inc.</link:label>
    <link:label id="lab_opk_XeneticBiosciencesInc.Member_label_en-US" xlink:label="lab_opk_XeneticBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenetic Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_opk_XeneticBiosciencesInc.Member_documentation_en-US" xlink:label="lab_opk_XeneticBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenetic Biosciences, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_XeneticBiosciencesInc.Member" xlink:href="opk-20220331.xsd#opk_XeneticBiosciencesInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_XeneticBiosciencesInc.Member" xlink:to="lab_opk_XeneticBiosciencesInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_d4c20845-e269-43e3-bab2-30d41a6a3da3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_7a5147a4-c15c-41f1-882c-ca1c96325f8b_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_9f4af0ec-3576-47c7-b9c6-de0fa30a028b_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b94ef7ab-00ca-4cb0-8f25-ecd22d8f6faf_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_9e7825bd-8913-419f-bce3-72134a1181b5_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ExclusiveOptionMember_3020cce9-ada2-4036-883d-9b7efac8f397_terseLabel_en-US" xlink:label="lab_opk_ExclusiveOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive Option</link:label>
    <link:label id="lab_opk_ExclusiveOptionMember_label_en-US" xlink:label="lab_opk_ExclusiveOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive Option [Member]</link:label>
    <link:label id="lab_opk_ExclusiveOptionMember_documentation_en-US" xlink:label="lab_opk_ExclusiveOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ExclusiveOptionMember" xlink:href="opk-20220331.xsd#opk_ExclusiveOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ExclusiveOptionMember" xlink:to="lab_opk_ExclusiveOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_670adf58-3210-4d2e-bbd8-267ea47f2b08_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_365c2708-88c2-469a-920a-9c6a603aeef3_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equivalent redemption price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1e8eb28f-38bb-48b9-92a5-7b9e6ae2f38c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_48e4b11e-b595-4c76-83cc-4d4e9e903bef_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_6ed5bf21-ec09-4f93-8a0f-fea753ab4199_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement paid to related party for travel</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_14e4d6c0-61d7-46b4-bb85-81d4acaef76f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Included in results of operations</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_c44518d5-f1ce-46ae-a1ed-b65ceff8a1a6_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized loss (gain) on disposal of fixed assets and sales of equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale_4d315ccb-c1cc-4a88-9a6a-4770914b22f6_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period after first commercial sale</link:label>
    <link:label id="lab_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale_label_en-US" xlink:label="lab_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Period After First Commercial Sale</link:label>
    <link:label id="lab_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Period After First Commercial Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementPeriodAfterFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale" xlink:to="lab_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b9298ef3-4ea9-4248-8c20-f9c469f20262_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_1e977bb9-e694-4d40-a8d2-e484d91c8dbc_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember" xlink:to="lab_us-gaap_CreditConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_3c7f8422-d04c-439a-a5bb-abf0acf85054_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod_423700d7-143a-4bca-981e-d783a1716e54_terseLabel_en-US" xlink:label="lab_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-based milestone period</link:label>
    <link:label id="lab_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod_label_en-US" xlink:label="lab_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Revenue-Based Milestone Payments, Period</link:label>
    <link:label id="lab_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod_documentation_en-US" xlink:label="lab_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Revenue-Based Milestone Payments, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod" xlink:href="opk-20220331.xsd#opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod" xlink:to="lab_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_04e1a711-f039-48c0-a54a-445d7cae72a1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e6e1c7ec-f656-46df-96e1-c0a414d7db8c_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_df3ab51f-df25-4a7f-b3cf-d43077aae492_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ad749ac1-c8bb-46bb-9539-635d33976109_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_fbad6a44-46b7-45f7-b3db-8eaed01a92d0_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CocrystalMember_3c58da34-bbea-4cda-86fe-09db505a555f_terseLabel_en-US" xlink:label="lab_opk_CocrystalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cocrystal</link:label>
    <link:label id="lab_opk_CocrystalMember_64d48ec3-e575-4d6a-a928-bec76c55ce57_verboseLabel_en-US" xlink:label="lab_opk_CocrystalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COCP</link:label>
    <link:label id="lab_opk_CocrystalMember_label_en-US" xlink:label="lab_opk_CocrystalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cocrystal [Member]</link:label>
    <link:label id="lab_opk_CocrystalMember_documentation_en-US" xlink:label="lab_opk_CocrystalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cocrystal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CocrystalMember" xlink:href="opk-20220331.xsd#opk_CocrystalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CocrystalMember" xlink:to="lab_opk_CocrystalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_392f035f-b1f2-4555-b399-fc3f6f7a491a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_02b33750-a2a1-4929-aaa7-680d370bc31a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of common stock options and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e96c1bb7-cefd-417f-8cdc-33466260222a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_df46b4f9-b770-415b-b36e-1d86fbc815e7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b9acd9e8-a5fe-474b-b87c-bbf726ae3fbb_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a114e05f-78c2-4985-8fc6-2575f25f3c06_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_901ab590-9e52-45ab-829e-2662b083bb05_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_9b071a1e-f2a4-4aa6-84c2-2ccbb3577c96_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ChangeInTestingVolumePercent_1abd7b29-87a0-4f94-9d5f-26f0cd4d3623_terseLabel_en-US" xlink:label="lab_opk_ChangeInTestingVolumePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in testing volume (as a percent)</link:label>
    <link:label id="lab_opk_ChangeInTestingVolumePercent_label_en-US" xlink:label="lab_opk_ChangeInTestingVolumePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Testing Volume, Percent</link:label>
    <link:label id="lab_opk_ChangeInTestingVolumePercent_documentation_en-US" xlink:label="lab_opk_ChangeInTestingVolumePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Testing Volume, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChangeInTestingVolumePercent" xlink:href="opk-20220331.xsd#opk_ChangeInTestingVolumePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ChangeInTestingVolumePercent" xlink:to="lab_opk_ChangeInTestingVolumePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AccruedCommitmentsandContingenciesCurrent_b7ddcd88-0b17-41db-93d6-e57e9e0f9492_terseLabel_en-US" xlink:label="lab_opk_AccruedCommitmentsandContingenciesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_opk_AccruedCommitmentsandContingenciesCurrent_label_en-US" xlink:label="lab_opk_AccruedCommitmentsandContingenciesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Commitments and Contingencies, Current</link:label>
    <link:label id="lab_opk_AccruedCommitmentsandContingenciesCurrent_documentation_en-US" xlink:label="lab_opk_AccruedCommitmentsandContingenciesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Commitments and Contingencies, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedCommitmentsandContingenciesCurrent" xlink:href="opk-20220331.xsd#opk_AccruedCommitmentsandContingenciesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AccruedCommitmentsandContingenciesCurrent" xlink:to="lab_opk_AccruedCommitmentsandContingenciesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_eb9b5a60-622a-41c5-9418-032ec927db13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_065bb807-8971-4ed2-b0f2-d8ae1ef60a5c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_46b7e484-05de-4a10-b9fe-ab5e527fc49c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_db19b81f-3c6c-4cef-a777-1f07cca45932_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest rates</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_11526fc1-ad57-4214-944d-042274e37384_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentsAbstract" xlink:to="lab_us-gaap_DebtInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_HealthSnapMember_124b2a4f-022f-467f-8e1a-fa71c2ce3c2f_terseLabel_en-US" xlink:label="lab_opk_HealthSnapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HealthSnap</link:label>
    <link:label id="lab_opk_HealthSnapMember_label_en-US" xlink:label="lab_opk_HealthSnapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HealthSnap [Member]</link:label>
    <link:label id="lab_opk_HealthSnapMember_documentation_en-US" xlink:label="lab_opk_HealthSnapMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HealthSnap</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_HealthSnapMember" xlink:href="opk-20220331.xsd#opk_HealthSnapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_HealthSnapMember" xlink:to="lab_opk_HealthSnapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9a858cfa-449a-49b2-b2eb-6cd3302c83e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_RayaldeeMember_b70c27b8-5afb-4604-8972-c68eeef81a39_terseLabel_en-US" xlink:label="lab_opk_RayaldeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rayaldee</link:label>
    <link:label id="lab_opk_RayaldeeMember_label_en-US" xlink:label="lab_opk_RayaldeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rayaldee [Member]</link:label>
    <link:label id="lab_opk_RayaldeeMember_documentation_en-US" xlink:label="lab_opk_RayaldeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rayaldee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RayaldeeMember" xlink:href="opk-20220331.xsd#opk_RayaldeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_RayaldeeMember" xlink:to="lab_opk_RayaldeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_58de8019-355e-45eb-9a50-7e4f06f1e1a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on converted debt (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LineOfCreditAndNotesAndLoansPayableCurrentMember_cbe14110-7502-42e8-9cb1-332ee393896c_terseLabel_en-US" xlink:label="lab_opk_LineOfCreditAndNotesAndLoansPayableCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lines of credit and notes payable</link:label>
    <link:label id="lab_opk_LineOfCreditAndNotesAndLoansPayableCurrentMember_label_en-US" xlink:label="lab_opk_LineOfCreditAndNotesAndLoansPayableCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit and Notes and Loans Payable, Current [Member]</link:label>
    <link:label id="lab_opk_LineOfCreditAndNotesAndLoansPayableCurrentMember_documentation_en-US" xlink:label="lab_opk_LineOfCreditAndNotesAndLoansPayableCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit and Notes and Loans Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditAndNotesAndLoansPayableCurrentMember" xlink:href="opk-20220331.xsd#opk_LineOfCreditAndNotesAndLoansPayableCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LineOfCreditAndNotesAndLoansPayableCurrentMember" xlink:to="lab_opk_LineOfCreditAndNotesAndLoansPayableCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementMilestonePayment_ff6a62a6-e43b-44eb-9977-a3b957330529_verboseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_opk_CollaborativeArrangementMilestonePayment_label_en-US" xlink:label="lab_opk_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:label id="lab_opk_CollaborativeArrangementMilestonePayment_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMilestonePayment" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementMilestonePayment" xlink:to="lab_opk_CollaborativeArrangementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_GovernmentalMember_740e8b74-8842-4d99-aaf6-cee7ed53fa85_terseLabel_en-US" xlink:label="lab_opk_GovernmentalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Governmental</link:label>
    <link:label id="lab_opk_GovernmentalMember_label_en-US" xlink:label="lab_opk_GovernmentalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Governmental [Member]</link:label>
    <link:label id="lab_opk_GovernmentalMember_documentation_en-US" xlink:label="lab_opk_GovernmentalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Governmental [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GovernmentalMember" xlink:href="opk-20220331.xsd#opk_GovernmentalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_GovernmentalMember" xlink:to="lab_opk_GovernmentalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_ae08e313-c699-4466-bdac-836a7b5a7311_verboseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock options/warrants</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ea762501-a2ca-47d0-884a-189c6daf4cd0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_1e2e9806-b238-4376-b5e7-3adb463efe10_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e4f129ff-582c-479a-b77f-6a911c7dc8bd_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_6ec7ade7-08a1-43f8-83f7-65d2eced6b0a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_542cd362-b6e5-4ad6-bd74-46622de5c6bd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DiagnosticsMember_a798815f-d7c1-43e1-a6a9-fa07b57bc2b2_terseLabel_en-US" xlink:label="lab_opk_DiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostics</link:label>
    <link:label id="lab_opk_DiagnosticsMember_ec480d00-1e62-4e40-a5b9-abeb6d3b46b3_verboseLabel_en-US" xlink:label="lab_opk_DiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostics</link:label>
    <link:label id="lab_opk_DiagnosticsMember_label_en-US" xlink:label="lab_opk_DiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostics [Member]</link:label>
    <link:label id="lab_opk_DiagnosticsMember_documentation_en-US" xlink:label="lab_opk_DiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostics.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticsMember" xlink:href="opk-20220331.xsd#opk_DiagnosticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DiagnosticsMember" xlink:to="lab_opk_DiagnosticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_75694301-ad86-4a51-af74-3d4f7516cbe0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative impairment at January 1</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_e4940494-a68e-412a-9bbc-5d371e681180_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_17ff014c-51c5-4ad3-ad41-7243aab4cfaf_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DERIVATIVE CONTRACTS</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_c0caf4e9-16e0-46a2-b5e2-3992ef393d73_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_4c87a9e0-5151-46fb-827a-8e1dfee038fe_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6da66892-2602-43f1-b046-28dd6a0aca8e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementMaximumMilestonePayments_e0fd5731-c51b-44dd-9e68-47249906f537_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementMaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payments</link:label>
    <link:label id="lab_opk_CollaborativeArrangementMaximumMilestonePayments_label_en-US" xlink:label="lab_opk_CollaborativeArrangementMaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payments</link:label>
    <link:label id="lab_opk_CollaborativeArrangementMaximumMilestonePayments_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementMaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMaximumMilestonePayments" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementMaximumMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementMaximumMilestonePayments" xlink:to="lab_opk_CollaborativeArrangementMaximumMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_55e6b7d6-8565-49c6-8bd0-9306472d57d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive trading days applicable conversion price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_d5d9cee5-8bb9-4b19-92e3-1bce83278481_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_596df76b-7c80-45b6-8a91-4f4635bcfd03_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_0767342b-6474-47d6-9c33-042259c81aff_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_effcc91b-883a-469c-8f0e-222dbd8ed68d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d0447c51-b58d-446e-8669-51f898c7e67a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_42613c8a-94bb-4741-a9c4-c2848c4b1bb1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OperatingLeasesMonthlyPaymentsYearFive_110c1af9-dfdb-4058-8078-edaee913d81e_terseLabel_en-US" xlink:label="lab_opk_OperatingLeasesMonthlyPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease payments per month in fifth year</link:label>
    <link:label id="lab_opk_OperatingLeasesMonthlyPaymentsYearFive_label_en-US" xlink:label="lab_opk_OperatingLeasesMonthlyPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Monthly Payments, Year Five</link:label>
    <link:label id="lab_opk_OperatingLeasesMonthlyPaymentsYearFive_documentation_en-US" xlink:label="lab_opk_OperatingLeasesMonthlyPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Monthly Payments, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OperatingLeasesMonthlyPaymentsYearFive" xlink:href="opk-20220331.xsd#opk_OperatingLeasesMonthlyPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OperatingLeasesMonthlyPaymentsYearFive" xlink:to="lab_opk_OperatingLeasesMonthlyPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_8e39bc3e-85e5-449a-9123-7cde96273b89_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of real estate property (in square feet)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NonInvasiveMonitoringSystemsInc.Member_a0e6124b-e46e-4097-85d2-ae75ed878843_terseLabel_en-US" xlink:label="lab_opk_NonInvasiveMonitoringSystemsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Invasive Monitoring Systems, Inc.</link:label>
    <link:label id="lab_opk_NonInvasiveMonitoringSystemsInc.Member_label_en-US" xlink:label="lab_opk_NonInvasiveMonitoringSystemsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Invasive Monitoring Systems, Inc. [Member]</link:label>
    <link:label id="lab_opk_NonInvasiveMonitoringSystemsInc.Member_documentation_en-US" xlink:label="lab_opk_NonInvasiveMonitoringSystemsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Invasive Monitoring Systems, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NonInvasiveMonitoringSystemsInc.Member" xlink:href="opk-20220331.xsd#opk_NonInvasiveMonitoringSystemsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NonInvasiveMonitoringSystemsInc.Member" xlink:to="lab_opk_NonInvasiveMonitoringSystemsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_54a3a04d-0d91-4d48-b1f5-6f42b0613364_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of COVID-19</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:to="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_61540595-3ec5-4c7f-b663-4ec286d9eaa8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_f1919391-1f84-4669-99bd-020288fb07a3_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest in joint venture (as a percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_57ecb00f-a097-4088-8d7b-0dd332a785ac_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DetectGenomixMember_78811212-af7e-4238-9124-99b7cdf531f5_terseLabel_en-US" xlink:label="lab_opk_DetectGenomixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detect Genomix</link:label>
    <link:label id="lab_opk_DetectGenomixMember_label_en-US" xlink:label="lab_opk_DetectGenomixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detect Genomix [Member]</link:label>
    <link:label id="lab_opk_DetectGenomixMember_documentation_en-US" xlink:label="lab_opk_DetectGenomixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detect Genomix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DetectGenomixMember" xlink:href="opk-20220331.xsd#opk_DetectGenomixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DetectGenomixMember" xlink:to="lab_opk_DetectGenomixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_31d1260e-573e-45dc-9a9f-0ca2e1715e9a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock ownership (as a percent)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1d943c49-a419-43a0-90a6-3f597c5b5e49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_InternationalBankMember_a3cd0014-2b52-4669-b2fa-51d142e63cee_terseLabel_en-US" xlink:label="lab_opk_InternationalBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Bank</link:label>
    <link:label id="lab_opk_InternationalBankMember_label_en-US" xlink:label="lab_opk_InternationalBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Bank [Member]</link:label>
    <link:label id="lab_opk_InternationalBankMember_documentation_en-US" xlink:label="lab_opk_InternationalBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InternationalBankMember" xlink:href="opk-20220331.xsd#opk_InternationalBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_InternationalBankMember" xlink:to="lab_opk_InternationalBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_37f941d1-765d-4025-81e0-b329c0fb5b34_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9270b72d-a97b-4c6e-a2f3-21495de51ea9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ClientPayersMember_4de72921-34e2-4b00-977a-17227f52d859_terseLabel_en-US" xlink:label="lab_opk_ClientPayersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client payers</link:label>
    <link:label id="lab_opk_ClientPayersMember_label_en-US" xlink:label="lab_opk_ClientPayersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client Payers [Member]</link:label>
    <link:label id="lab_opk_ClientPayersMember_documentation_en-US" xlink:label="lab_opk_ClientPayersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client Payers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ClientPayersMember" xlink:href="opk-20220331.xsd#opk_ClientPayersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ClientPayersMember" xlink:to="lab_opk_ClientPayersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_WaterfordIrelandFacilityMember_2c9216df-5656-4386-99c2-65728837228c_terseLabel_en-US" xlink:label="lab_opk_WaterfordIrelandFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waterford, Ireland Facility</link:label>
    <link:label id="lab_opk_WaterfordIrelandFacilityMember_label_en-US" xlink:label="lab_opk_WaterfordIrelandFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waterford, Ireland Facility [Member]</link:label>
    <link:label id="lab_opk_WaterfordIrelandFacilityMember_documentation_en-US" xlink:label="lab_opk_WaterfordIrelandFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waterford, Ireland Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_WaterfordIrelandFacilityMember" xlink:href="opk-20220331.xsd#opk_WaterfordIrelandFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_WaterfordIrelandFacilityMember" xlink:to="lab_opk_WaterfordIrelandFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4d369ab9-09ac-482f-becf-f4975af51ac0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ca70dcec-9b40-475e-a4af-87aa69d4e539_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_c3bbb455-ff39-4ddc-a581-17ece12b1f1d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum_7492b5e8-7480-4b5e-9e93-389398621250_terseLabel_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum conversion notice</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum_label_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Notice Threshold, Minimum</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum_documentation_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Notice Threshold, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum" xlink:href="opk-20220331.xsd#opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum" xlink:to="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9a81b44a-2654-4258-bf9b-49682dba6ec6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_Sema4Member_3135bbd0-454f-4e0b-a633-458a24d8604c_terseLabel_en-US" xlink:label="lab_opk_Sema4Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sema4</link:label>
    <link:label id="lab_opk_Sema4Member_label_en-US" xlink:label="lab_opk_Sema4Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sema4 [Member]</link:label>
    <link:label id="lab_opk_Sema4Member_documentation_en-US" xlink:label="lab_opk_Sema4Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sema4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_Sema4Member" xlink:href="opk-20220331.xsd#opk_Sema4Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_Sema4Member" xlink:to="lab_opk_Sema4Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_bf23aff1-a975-4c4d-b7c0-334715c490eb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash out flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_aba13547-0a75-4610-a33f-5fe73ac27e51_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_TransitionTherapeuticsInc.Member_7b948725-43db-4900-927a-aafecc4be473_terseLabel_en-US" xlink:label="lab_opk_TransitionTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Therapeutics</link:label>
    <link:label id="lab_opk_TransitionTherapeuticsInc.Member_label_en-US" xlink:label="lab_opk_TransitionTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_opk_TransitionTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_opk_TransitionTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransitionTherapeuticsInc.Member" xlink:href="opk-20220331.xsd#opk_TransitionTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_TransitionTherapeuticsInc.Member" xlink:to="lab_opk_TransitionTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_d88517f9-9437-4969-bddc-d0d80858209c_verboseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7464ce97-1d81-4de2-8224-8aa968185884_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_23c9c63c-bed8-47a2-a9f5-365814a00ee0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_3a7ba130-17c3-4c17-9037-9a1db1637ca1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net gains realized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_03334726-c7d2-4e0e-adea-1368da7c3ae9_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e234941f-d49b-4660-b40c-b3108c7bfb17_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5ad8a254-c90c-455e-ab3f-d6bfc4f1c453_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE RECOGNITION</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PfizerMember_0498c434-1e70-4568-b1d9-95c828be51de_terseLabel_en-US" xlink:label="lab_opk_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_opk_PfizerMember_label_en-US" xlink:label="lab_opk_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_opk_PfizerMember_documentation_en-US" xlink:label="lab_opk_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PfizerMember" xlink:href="opk-20220331.xsd#opk_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PfizerMember" xlink:to="lab_opk_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_77a8ab34-7808-459f-b6ab-8409bd6ae2c4_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3d7d959e-8fd3-4403-9790-02ca1c3d298c_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DebtInstrumentsNumberofFinancialInstitutions_46f47a5c-010f-4e0d-a3bc-b855f81049a9_verboseLabel_en-US" xlink:label="lab_opk_DebtInstrumentsNumberofFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of financial institutions</link:label>
    <link:label id="lab_opk_DebtInstrumentsNumberofFinancialInstitutions_label_en-US" xlink:label="lab_opk_DebtInstrumentsNumberofFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments, Number of Financial Institutions</link:label>
    <link:label id="lab_opk_DebtInstrumentsNumberofFinancialInstitutions_documentation_en-US" xlink:label="lab_opk_DebtInstrumentsNumberofFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of financial institutions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentsNumberofFinancialInstitutions" xlink:href="opk-20220331.xsd#opk_DebtInstrumentsNumberofFinancialInstitutions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DebtInstrumentsNumberofFinancialInstitutions" xlink:to="lab_opk_DebtInstrumentsNumberofFinancialInstitutions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_27775d4c-1619-40d9-9575-547b64d237b7_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_dc138712-012f-4e60-881e-5e3f2bc8117f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_df3466a5-fb3c-468e-bbb8-8ec6057f2242_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_23809e94-3385-4cef-b089-3681b6d5520a_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_a0105f3f-1bd7-4510-9bd3-db974fc3d009_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_cbf9b6ba-ce47-4713-b724-969a29d2672c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ProceedsFromConvertibleDebtConversionFee_6190a384-1dbe-41a8-9490-c37ac5c9240d_terseLabel_en-US" xlink:label="lab_opk_ProceedsFromConvertibleDebtConversionFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds one-time nominal fee</link:label>
    <link:label id="lab_opk_ProceedsFromConvertibleDebtConversionFee_label_en-US" xlink:label="lab_opk_ProceedsFromConvertibleDebtConversionFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Convertible Debt, Conversion Fee</link:label>
    <link:label id="lab_opk_ProceedsFromConvertibleDebtConversionFee_documentation_en-US" xlink:label="lab_opk_ProceedsFromConvertibleDebtConversionFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Convertible Debt, Conversion Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromConvertibleDebtConversionFee" xlink:href="opk-20220331.xsd#opk_ProceedsFromConvertibleDebtConversionFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ProceedsFromConvertibleDebtConversionFee" xlink:to="lab_opk_ProceedsFromConvertibleDebtConversionFee" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OpkoDiagnosticsMember_98dae80f-cb8a-4786-ab39-d9ca6ea0540e_terseLabel_en-US" xlink:label="lab_opk_OpkoDiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Diagnostics</link:label>
    <link:label id="lab_opk_OpkoDiagnosticsMember_label_en-US" xlink:label="lab_opk_OpkoDiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opko Diagnostics [Member]</link:label>
    <link:label id="lab_opk_OpkoDiagnosticsMember_documentation_en-US" xlink:label="lab_opk_OpkoDiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Diagnostics.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OpkoDiagnosticsMember" xlink:href="opk-20220331.xsd#opk_OpkoDiagnosticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OpkoDiagnosticsMember" xlink:to="lab_opk_OpkoDiagnosticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_MednaxServicesIncMember_e0e25213-8a5b-452a-b088-357719543795_terseLabel_en-US" xlink:label="lab_opk_MednaxServicesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mednax Services, Inc.</link:label>
    <link:label id="lab_opk_MednaxServicesIncMember_label_en-US" xlink:label="lab_opk_MednaxServicesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mednax Services, Inc. [Member]</link:label>
    <link:label id="lab_opk_MednaxServicesIncMember_documentation_en-US" xlink:label="lab_opk_MednaxServicesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mednax Services, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MednaxServicesIncMember" xlink:href="opk-20220331.xsd#opk_MednaxServicesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_MednaxServicesIncMember" xlink:to="lab_opk_MednaxServicesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CL_0bfe9790-604f-4b05-afa7-39275e43ef8b_verboseLabel_en-US" xlink:label="lab_country_CL" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chile</link:label>
    <link:label id="lab_country_CL_label_en-US" xlink:label="lab_country_CL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHILE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CL" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CL" xlink:to="lab_country_CL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_73273fe1-278a-48eb-9053-e4e5e2d57c7f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour_4a519300-2a36-42da-802d-758b40f5bd6e_terseLabel_en-US" xlink:label="lab_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due after Year Four</link:label>
    <link:label id="lab_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="opk-20220331.xsd#opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_46b27d3c-867d-494a-a4d3-daa5e5cba927_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_d98f3a36-d68c-4254-bc57-e8028ab1d7a2_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery, Medical and Other Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_e94edd96-d785-44fb-bdbe-64636fb16c87_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash out flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_a3b6ae2c-4e87-432c-ab9b-e171c806ef6e_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_JPMorganChaseMember_aa8fbb96-d584-40b4-9a15-3e37149b1623_terseLabel_en-US" xlink:label="lab_opk_JPMorganChaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JPMorgan Chase</link:label>
    <link:label id="lab_opk_JPMorganChaseMember_label_en-US" xlink:label="lab_opk_JPMorganChaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JP Morgan Chase [Member]</link:label>
    <link:label id="lab_opk_JPMorganChaseMember_documentation_en-US" xlink:label="lab_opk_JPMorganChaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JP Morgan Chase [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_JPMorganChaseMember" xlink:href="opk-20220331.xsd#opk_JPMorganChaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_JPMorganChaseMember" xlink:to="lab_opk_JPMorganChaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_b21790ac-d663-4bbe-9978-93ca4ee07f1c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract_8f26cf35-31f1-4079-858b-6f4bd2bab5d7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Equity in Net Assets</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_205c11e3-ae63-4b2a-873c-d6fe64301c2d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total aggregate consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_00655ea3-9853-4f8c-9b32-34c8223ce555_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to current period sales</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0c8dcbda-e58f-4bb3-bdf3-b2fb2b34ad57_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_853b14c4-5bd6-49b4-a04e-434744452185_periodStartLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_04b023dc-1672-44d5-9ad6-6baf6acaecfb_periodEndLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_bcfbed96-e2f2-4f42-a356-6b06911fa73e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_d04c84bf-1476-4b1a-b587-813f2de7e683_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption period two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_8592c682-ea6d-4f4f-8844-795b7c2a0543_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_d747f023-d273-4a3f-88df-9ded7c677622_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_227bbe8a-31b6-43ae-a33a-9920c1f22b9c_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_3da27f3c-638d-4ed4-9ecc-b1a721f3b06f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining principal</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_0fc15464-da00-4baa-b59f-3fa87cfae078_periodStartLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_69622ac9-47ff-43c8-ac51-1a7436715944_periodEndLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_9d91f2b1-5686-4e4c-b487-4c2bf69a485c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4fec6253-446c-4595-baac-af5ad6f4ed99_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted prices in active markets for identical assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d4fcc68c-9588-4238-9ae6-78f0c8246e0b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_146eafc7-9294-4e52-ad0d-3181e82c8aa5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cbfff3f0-f84a-452b-9214-74c140d45aea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets_63816ced-007b-4220-9c20-0a6ee0b7980d_terseLabel_en-US" xlink:label="lab_opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest entity, equity method, underlying equity in net assets</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets_label_en-US" xlink:label="lab_opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Variable Interest Entity, Underlying Equity in Net Assets</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets_documentation_en-US" xlink:label="lab_opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Variable Interest Entity, Underlying Equity in Net Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets" xlink:to="lab_opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CovenantsNotToCompeteMember_46985e00-240e-473e-b988-84727316b319_terseLabel_en-US" xlink:label="lab_opk_CovenantsNotToCompeteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenants not to compete</link:label>
    <link:label id="lab_opk_CovenantsNotToCompeteMember_label_en-US" xlink:label="lab_opk_CovenantsNotToCompeteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenants Not to Compete [Member]</link:label>
    <link:label id="lab_opk_CovenantsNotToCompeteMember_documentation_en-US" xlink:label="lab_opk_CovenantsNotToCompeteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenants not to compete.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CovenantsNotToCompeteMember" xlink:href="opk-20220331.xsd#opk_CovenantsNotToCompeteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CovenantsNotToCompeteMember" xlink:to="lab_opk_CovenantsNotToCompeteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_07da6f85-30fc-460f-a0d1-4be13a1080d1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_534ddb8a-6ebd-4775-9a8e-d56493b57b35_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_37ea9ebd-aa86-452b-b8cf-a48e350afc57_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_70b279b7-52b7-4012-ac7e-6ed78eed0dec_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_f0155f8a-7656-4d66-a968-77a9d2a8c660_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_4bce81b2-22fe-4a99-b230-1caee2b4ce96_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenants not to compete</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_463fa27a-66ef-49af-a3fd-d2d2030b7466_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_76d29437-5940-4dcd-88e3-d367e76ced9a_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_df2484b5-6894-4d96-9085-76ec8b7a00b9_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_ec70a005-8461-4e9b-9707-c20325d7c4b7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments_a50b7b23-b6bb-4c31-9cb4-131cc1768204_negatedTerseLabel_en-US" xlink:label="lab_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits or payments made</link:label>
    <link:label id="lab_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments_label_en-US" xlink:label="lab_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Doubtful Accounts Receivable, Decrease, Credits Or Payments</link:label>
    <link:label id="lab_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments_documentation_en-US" xlink:label="lab_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Doubtful Accounts Receivable, Decrease, Credits Or Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" xlink:href="opk-20220331.xsd#opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" xlink:to="lab_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_04d6e44f-39b8-4e20-be3f-f1239ce52875_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NumberofSalesEmployees_28506647-a264-4dba-8446-19146742321d_terseLabel_en-US" xlink:label="lab_opk_NumberofSalesEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of sales employees</link:label>
    <link:label id="lab_opk_NumberofSalesEmployees_label_en-US" xlink:label="lab_opk_NumberofSalesEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Sales Employees</link:label>
    <link:label id="lab_opk_NumberofSalesEmployees_documentation_en-US" xlink:label="lab_opk_NumberofSalesEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Sales Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NumberofSalesEmployees" xlink:href="opk-20220331.xsd#opk_NumberofSalesEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NumberofSalesEmployees" xlink:to="lab_opk_NumberofSalesEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_19d48595-6f07-489c-be24-61a931b683d8_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_50b933b7-51d6-4ca1-823f-6ecd02fce464_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_0d697770-5d1d-4cf0-9a61-0ecc5aa5ab2d_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains and losses recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_0d108a47-2cae-4bad-80e9-7e4503e7f466_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments (as a percent)</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4d9d9330-dd47-4207-8e10-c88d73ef3978_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_57aa3593-bc12-44de-81a4-cd44becfc816_verboseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NotesDueFebruary12033Member_fea0b1b3-20b9-44c6-9016-ace1ede0a89f_terseLabel_en-US" xlink:label="lab_opk_NotesDueFebruary12033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due February 1, 2033</link:label>
    <link:label id="lab_opk_NotesDueFebruary12033Member_label_en-US" xlink:label="lab_opk_NotesDueFebruary12033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due February 1, 2033 [Member]</link:label>
    <link:label id="lab_opk_NotesDueFebruary12033Member_documentation_en-US" xlink:label="lab_opk_NotesDueFebruary12033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due February 1, 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NotesDueFebruary12033Member" xlink:href="opk-20220331.xsd#opk_NotesDueFebruary12033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NotesDueFebruary12033Member" xlink:to="lab_opk_NotesDueFebruary12033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_c7fa7c4e-30e9-47f1-aa1b-cec77e5bee9b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses:</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermDebtNoncurrent_b9b456e3-24ac-4ef5-a061-ccb75c4e7db4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgages and other debts payable</link:label>
    <link:label id="lab_us-gaap_OtherLongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebtNoncurrent" xlink:to="lab_us-gaap_OtherLongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_24bc9fd4-fddf-4283-b8b3-b1e6e6072b11_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options and warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_2a7fabe6-ac01-4e60-ae88-f56ec069fdb5_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_253a68a9-a91d-4827-9835-ddc795913780_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of convertible debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5609f263-18e8-4ab0-af8b-0069870fc9a0_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BUSINESS AND ORGANIZATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_832013ea-a0f3-4936-bc0e-6ae20ee56c7f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3c18acf1-1700-49cb-93a6-33a10b252556_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BusinessCombinationUpfrontConsiderationTransferred_51e4b663-a70c-49a2-8cc5-e8b12e031011_terseLabel_en-US" xlink:label="lab_opk_BusinessCombinationUpfrontConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total upfront consideration transferred</link:label>
    <link:label id="lab_opk_BusinessCombinationUpfrontConsiderationTransferred_label_en-US" xlink:label="lab_opk_BusinessCombinationUpfrontConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Upfront Consideration Transferred</link:label>
    <link:label id="lab_opk_BusinessCombinationUpfrontConsiderationTransferred_documentation_en-US" xlink:label="lab_opk_BusinessCombinationUpfrontConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Upfront Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationUpfrontConsiderationTransferred" xlink:href="opk-20220331.xsd#opk_BusinessCombinationUpfrontConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BusinessCombinationUpfrontConsiderationTransferred" xlink:to="lab_opk_BusinessCombinationUpfrontConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_709905c3-1271-4a5e-801d-f25ac5317985_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SharesReceivedUponClosingofXeneticTransactionMember_c5c169b8-86eb-4992-8842-976a93b23f47_terseLabel_en-US" xlink:label="lab_opk_SharesReceivedUponClosingofXeneticTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received Upon Closing of Xenetic Transaction</link:label>
    <link:label id="lab_opk_SharesReceivedUponClosingofXeneticTransactionMember_label_en-US" xlink:label="lab_opk_SharesReceivedUponClosingofXeneticTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received Upon Closing of Xenetic Transaction [Member]</link:label>
    <link:label id="lab_opk_SharesReceivedUponClosingofXeneticTransactionMember_documentation_en-US" xlink:label="lab_opk_SharesReceivedUponClosingofXeneticTransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received Upon Closing of Xenetic Transaction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember" xlink:href="opk-20220331.xsd#opk_SharesReceivedUponClosingofXeneticTransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember" xlink:to="lab_opk_SharesReceivedUponClosingofXeneticTransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SantanderBankMember_8bd7fdfc-f349-4af7-853d-c1a24790205b_terseLabel_en-US" xlink:label="lab_opk_SantanderBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Santander Bank</link:label>
    <link:label id="lab_opk_SantanderBankMember_label_en-US" xlink:label="lab_opk_SantanderBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Santander Bank [Member]</link:label>
    <link:label id="lab_opk_SantanderBankMember_documentation_en-US" xlink:label="lab_opk_SantanderBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">santander Bank.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SantanderBankMember" xlink:href="opk-20220331.xsd#opk_SantanderBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SantanderBankMember" xlink:to="lab_opk_SantanderBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_7c8ca914-f510-4492-8fbb-7da23d560954_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts outstanding under line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_8211c2c4-fb49-4870-b2d4-0f769ea5cb39_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#160;Balance Outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75144c85-b90b-4c02-84b2-08cc8b7b0ace_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_373b1e75-b13d-40b4-b970-f90aa9e2519e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_c2f653f5-024c-4c1f-8e6c-e7b36923664b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_7871d7e7-6434-44e9-bc3f-7a2999004d12_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b8e24950-3fa4-4b41-bdc5-caaedc8e9c7a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes and investment losses</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_f6018521-351b-42a1-8643-12d1a77ecbdb_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_a6c357f1-7406-4899-b72b-73295c7bf284_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_f1339006-3f93-44e6-8578-9517328caacf_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_90b7a0f0-a3e3-4470-8c68-c1bb714fe547_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a091c2fb-223c-4864-8822-e802f43033d3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment_60edfb76-1bfb-4ef3-b8e9-2b5ccb8401dd_terseLabel_en-US" xlink:label="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment from development and license agreement</link:label>
    <link:label id="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment_label_en-US" xlink:label="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Development And License Agreement, Milestone Payment</link:label>
    <link:label id="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment_documentation_en-US" xlink:label="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Development And License Agreement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" xlink:href="opk-20220331.xsd#opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" xlink:to="lab_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAbstract_80a8212c-4b8d-47a1-9151-f21c0fc21583_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities:</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAbstract_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAbstract" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_TransferOfIntellectualPropertyAndOtherMember_55a4ecc2-4fa1-46e7-9457-d2ebf25bb007_verboseLabel_en-US" xlink:label="lab_opk_TransferOfIntellectualPropertyAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from transfer of intellectual property and other</link:label>
    <link:label id="lab_opk_TransferOfIntellectualPropertyAndOtherMember_3507e43d-4fa4-4bdb-ba25-786cf9e15cd8_terseLabel_en-US" xlink:label="lab_opk_TransferOfIntellectualPropertyAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of intellectual property and other</link:label>
    <link:label id="lab_opk_TransferOfIntellectualPropertyAndOtherMember_label_en-US" xlink:label="lab_opk_TransferOfIntellectualPropertyAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Intellectual Property And Other [Member]</link:label>
    <link:label id="lab_opk_TransferOfIntellectualPropertyAndOtherMember_documentation_en-US" xlink:label="lab_opk_TransferOfIntellectualPropertyAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Intellectual Property And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember" xlink:href="opk-20220331.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_TransferOfIntellectualPropertyAndOtherMember" xlink:to="lab_opk_TransferOfIntellectualPropertyAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_63100534-56e8-42cc-8628-d6386a48bd1d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NoncontrollingInterestSharesIssued_8861a8c3-1752-4cd1-933e-95e948a51db7_terseLabel_en-US" xlink:label="lab_opk_NoncontrollingInterestSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture (in shares)</link:label>
    <link:label id="lab_opk_NoncontrollingInterestSharesIssued_label_en-US" xlink:label="lab_opk_NoncontrollingInterestSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Shares Issued</link:label>
    <link:label id="lab_opk_NoncontrollingInterestSharesIssued_documentation_en-US" xlink:label="lab_opk_NoncontrollingInterestSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NoncontrollingInterestSharesIssued" xlink:href="opk-20220331.xsd#opk_NoncontrollingInterestSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NoncontrollingInterestSharesIssued" xlink:to="lab_opk_NoncontrollingInterestSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_0288ae75-672c-4ec1-96bc-03d9723ba747_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_e2fadbd0-486e-4629-af1f-1d8abbfa0603_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_113fc282-9526-4aca-b40f-1f5f49ed8a6a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_Corpbanca1Member_666c70d5-459d-40a8-9093-7a1fe2f49a5c_terseLabel_en-US" xlink:label="lab_opk_Corpbanca1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corpbanca</link:label>
    <link:label id="lab_opk_Corpbanca1Member_label_en-US" xlink:label="lab_opk_Corpbanca1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corpbanca1 [Member]</link:label>
    <link:label id="lab_opk_Corpbanca1Member_documentation_en-US" xlink:label="lab_opk_Corpbanca1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corpbanca1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_Corpbanca1Member" xlink:href="opk-20220331.xsd#opk_Corpbanca1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_Corpbanca1Member" xlink:to="lab_opk_Corpbanca1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_3c2b2945-7ee6-4cab-bef2-cdda97347e12_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_878ca753-8535-4f8f-8fdb-ec9c5d9fef2c_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6c131b24-636f-4b89-b2da-f5f9e4023d89_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember_44607e19-5ddb-4f4a-8437-8a17b206fabf_terseLabel_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR, First 12 Months</link:label>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember_label_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR), First Twelve Months [Member]</link:label>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember_documentation_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR), First Twelve Months [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" xlink:href="opk-20220331.xsd#opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" xlink:to="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_f3b7e756-22e0-426f-ba47-75a8e85b4d37_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_039ab5b3-8866-4aef-87cf-3a8e4ba5f8f0_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OtherCountriesMember_018f5b08-73d9-4eb9-9563-b86cbcf383cc_terseLabel_en-US" xlink:label="lab_opk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_opk_OtherCountriesMember_label_en-US" xlink:label="lab_opk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_opk_OtherCountriesMember_documentation_en-US" xlink:label="lab_opk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OtherCountriesMember" xlink:href="opk-20220331.xsd#opk_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OtherCountriesMember" xlink:to="lab_opk_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember_9c3ab93a-c19f-4125-be8c-0871ed6fc06a_terseLabel_en-US" xlink:label="lab_opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">50% or more of revolving commitment</link:label>
    <link:label id="lab_opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember_label_en-US" xlink:label="lab_opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, 50% Or More Of Revolving Commitment [Member]</link:label>
    <link:label id="lab_opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember_documentation_en-US" xlink:label="lab_opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, 50% Or More Of Revolving Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember" xlink:href="opk-20220331.xsd#opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember" xlink:to="lab_opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_8ce21c38-f437-43a8-9d05-871a2c376288_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_MilestoneAxis_82b05826-1f41-4825-99fd-ba543b7a1ebc_terseLabel_en-US" xlink:label="lab_opk_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_opk_MilestoneAxis_label_en-US" xlink:label="lab_opk_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_opk_MilestoneAxis_documentation_en-US" xlink:label="lab_opk_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MilestoneAxis" xlink:href="opk-20220331.xsd#opk_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_MilestoneAxis" xlink:to="lab_opk_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_0c6ac739-d9af-4d8c-8718-bfac807158e1_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_e8610996-e007-4c9a-9422-c1c24a05a434_terseLabel_en-US" xlink:label="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_documentation_en-US" xlink:label="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="opk-20220331.xsd#opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4bff7165-4654-4222-86a4-7fbb73f97e6d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_35155743-56fa-4975-b762-82f7c526df0e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_86a98d76-371c-442a-b25e-2131e22b8a6e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options/warrants</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_5209ea71-dc95-4cce-a515-65e858ce73bd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ZebraMember_be2cce33-59ca-4416-857f-20f112f7949d_terseLabel_en-US" xlink:label="lab_opk_ZebraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zebra</link:label>
    <link:label id="lab_opk_ZebraMember_label_en-US" xlink:label="lab_opk_ZebraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zebra [Member]</link:label>
    <link:label id="lab_opk_ZebraMember_documentation_en-US" xlink:label="lab_opk_ZebraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zebra [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ZebraMember" xlink:href="opk-20220331.xsd#opk_ZebraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ZebraMember" xlink:to="lab_opk_ZebraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_ES_623dff51-ba91-4f73-918b-b7d144e7149b_verboseLabel_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spain</link:label>
    <link:label id="lab_country_ES_label_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPAIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_ES" xlink:to="lab_country_ES" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_c6752148-ad3c-4954-b836-8da7c6e10cff_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument Risk [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_8b5cd3d6-7403-45c8-b564-3af0826fb6c3_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_bd3420e2-b6f1-4e8a-8590-dd2789568f5b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_ff777c66-06a5-48ac-a30f-ef3c471850a8_terseLabel_en-US" xlink:label="lab_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in revenue</link:label>
    <link:label id="lab_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label id="lab_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_documentation_en-US" xlink:label="lab_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="opk-20220331.xsd#opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_bb97d9f7-d7ea-423f-bdcd-05d492779d49_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f754904f-73ad-4814-8390-6ff30456eb5c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7bd22965-d29d-45d1-94fd-08a10ad49707_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency transaction gains (losses)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5ebb28d0-9484-4d01-8a95-c1a7ca353ef6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock - $0.01 par value, 1,000,000,000 shares authorized; 690,138,033 and 690,082,283 shares issued at March 31, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_758e6d2e-05d8-421b-bede-e0d682784cd4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_57acf789-195b-411f-b148-18c4b542e200_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_IndividualPatientsMember_a8dc843e-2277-4392-916c-48dad06cc33a_terseLabel_en-US" xlink:label="lab_opk_IndividualPatientsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Patients</link:label>
    <link:label id="lab_opk_IndividualPatientsMember_label_en-US" xlink:label="lab_opk_IndividualPatientsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Patients [Member]</link:label>
    <link:label id="lab_opk_IndividualPatientsMember_documentation_en-US" xlink:label="lab_opk_IndividualPatientsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IndividualPatientsMember" xlink:href="opk-20220331.xsd#opk_IndividualPatientsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_IndividualPatientsMember" xlink:to="lab_opk_IndividualPatientsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_285daad1-36ef-48f8-a318-410e06cf91f5_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income and (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_28baf43d-8866-4de7-ba7b-f5062a6ce2d9_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net:</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LeaderMedMember_72eeba85-9292-4072-adf1-6cd2c2414dd7_terseLabel_en-US" xlink:label="lab_opk_LeaderMedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LeaderMed</link:label>
    <link:label id="lab_opk_LeaderMedMember_label_en-US" xlink:label="lab_opk_LeaderMedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LeaderMed [Member]</link:label>
    <link:label id="lab_opk_LeaderMedMember_documentation_en-US" xlink:label="lab_opk_LeaderMedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LeaderMed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LeaderMedMember" xlink:href="opk-20220331.xsd#opk_LeaderMedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LeaderMedMember" xlink:to="lab_opk_LeaderMedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_a5d82968-2813-4fe7-ab3d-d422fe315733_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ItauBankMember_d2465055-f49e-461a-942a-0f0720be6631_verboseLabel_en-US" xlink:label="lab_opk_ItauBankMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Itau Bank</link:label>
    <link:label id="lab_opk_ItauBankMember_label_en-US" xlink:label="lab_opk_ItauBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Itau Bank [Member]</link:label>
    <link:label id="lab_opk_ItauBankMember_documentation_en-US" xlink:label="lab_opk_ItauBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Itau.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ItauBankMember" xlink:href="opk-20220331.xsd#opk_ItauBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ItauBankMember" xlink:to="lab_opk_ItauBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a7604f91-afbc-4bcb-930d-3c95644ccc34_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LossContingencyMilestonePayment_79e08c70-2151-459f-997c-a362ed4f64b1_terseLabel_en-US" xlink:label="lab_opk_LossContingencyMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_opk_LossContingencyMilestonePayment_label_en-US" xlink:label="lab_opk_LossContingencyMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Milestone Payment</link:label>
    <link:label id="lab_opk_LossContingencyMilestonePayment_documentation_en-US" xlink:label="lab_opk_LossContingencyMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LossContingencyMilestonePayment" xlink:href="opk-20220331.xsd#opk_LossContingencyMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LossContingencyMilestonePayment" xlink:to="lab_opk_LossContingencyMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_d3cd6bfe-8de9-4704-b491-5bb6c7a56522_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_830fbd12-38df-42ce-9c73-44b5b956a6a9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNetAbstract_207f74c1-ece4-4b38-9f6b-e71c707ea5eb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract" xlink:to="lab_us-gaap_DeferredFinanceCostsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CAMP4Member_584c368f-fe98-4719-bfcc-db48333f8997_terseLabel_en-US" xlink:label="lab_opk_CAMP4Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAMP4</link:label>
    <link:label id="lab_opk_CAMP4Member_label_en-US" xlink:label="lab_opk_CAMP4Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAMP4 [Member]</link:label>
    <link:label id="lab_opk_CAMP4Member_documentation_en-US" xlink:label="lab_opk_CAMP4Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAMP4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CAMP4Member" xlink:href="opk-20220331.xsd#opk_CAMP4Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CAMP4Member" xlink:to="lab_opk_CAMP4Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cf7eb729-592b-49c3-a7e8-78582ec2d297_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PhaseThreeInitiationMember_92d8e1be-fba7-4cdf-86ec-8b1fa53c73b2_terseLabel_en-US" xlink:label="lab_opk_PhaseThreeInitiationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase Three Initiation</link:label>
    <link:label id="lab_opk_PhaseThreeInitiationMember_label_en-US" xlink:label="lab_opk_PhaseThreeInitiationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase Three Initiation [Member]</link:label>
    <link:label id="lab_opk_PhaseThreeInitiationMember_documentation_en-US" xlink:label="lab_opk_PhaseThreeInitiationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase Three Initiation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PhaseThreeInitiationMember" xlink:href="opk-20220331.xsd#opk_PhaseThreeInitiationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PhaseThreeInitiationMember" xlink:to="lab_opk_PhaseThreeInitiationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_fe409aeb-bf23-4cf5-a24f-0f3176f54962_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount and Estimated Fair Value of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9001336c-771a-4a6e-91ed-1c375f709fa1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4217f762-ecae-4608-a1b3-53aaad6708ee_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_34c534c2-0407-4e93-8c81-be7b99a2a792_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementUpfrontPaymentShares_62142e52-2264-46a4-8071-d7a16ffa3297_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementUpfrontPaymentShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment (in shares)</link:label>
    <link:label id="lab_opk_CollaborativeArrangementUpfrontPaymentShares_label_en-US" xlink:label="lab_opk_CollaborativeArrangementUpfrontPaymentShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment, Shares</link:label>
    <link:label id="lab_opk_CollaborativeArrangementUpfrontPaymentShares_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementUpfrontPaymentShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementUpfrontPaymentShares" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementUpfrontPaymentShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementUpfrontPaymentShares" xlink:to="lab_opk_CollaborativeArrangementUpfrontPaymentShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_5bd24354-0f5e-4bce-962d-f4e12bca9a2c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for inventory obsolescence</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0d30526c-bbc2-4a95-9180-2ad03b64b83a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 1, 2022 through December 31, 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales_1354105e-6d8e-420a-b839-7912311c4573_terseLabel_en-US" xlink:label="lab_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales</link:label>
    <link:label id="lab_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales_label_en-US" xlink:label="lab_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Doubtful Accounts, Provision For Allowance As Percent Of Gross Sales</link:label>
    <link:label id="lab_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales_documentation_en-US" xlink:label="lab_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Doubtful Accounts, Provision For Allowance As Percent Of Gross Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" xlink:href="opk-20220331.xsd#opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" xlink:to="lab_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SouthernDistrictOfNewYorkVsBioReferenceMember_64270558-bc80-40a6-ad0e-3648c1dccc47_terseLabel_en-US" xlink:label="lab_opk_SouthernDistrictOfNewYorkVsBioReferenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District of New York vs BioReference</link:label>
    <link:label id="lab_opk_SouthernDistrictOfNewYorkVsBioReferenceMember_label_en-US" xlink:label="lab_opk_SouthernDistrictOfNewYorkVsBioReferenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District of New York vs BioReference [Member]</link:label>
    <link:label id="lab_opk_SouthernDistrictOfNewYorkVsBioReferenceMember_documentation_en-US" xlink:label="lab_opk_SouthernDistrictOfNewYorkVsBioReferenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District of New York vs BioReference</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SouthernDistrictOfNewYorkVsBioReferenceMember" xlink:href="opk-20220331.xsd#opk_SouthernDistrictOfNewYorkVsBioReferenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SouthernDistrictOfNewYorkVsBioReferenceMember" xlink:to="lab_opk_SouthernDistrictOfNewYorkVsBioReferenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_FederalAndStateGovernmentsMember_32223130-3fa9-4bc4-8ffa-e831f63d6b26_terseLabel_en-US" xlink:label="lab_opk_FederalAndStateGovernmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and State Governments</link:label>
    <link:label id="lab_opk_FederalAndStateGovernmentsMember_label_en-US" xlink:label="lab_opk_FederalAndStateGovernmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and State Governments [Member]</link:label>
    <link:label id="lab_opk_FederalAndStateGovernmentsMember_documentation_en-US" xlink:label="lab_opk_FederalAndStateGovernmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and State Governments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FederalAndStateGovernmentsMember" xlink:href="opk-20220331.xsd#opk_FederalAndStateGovernmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_FederalAndStateGovernmentsMember" xlink:to="lab_opk_FederalAndStateGovernmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_87f8dc43-5748-4923-a2e7-eafe6b439341_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_6f18f9a2-a699-46b5-ba92-b2c516292952_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_aa90f6a9-ff2e-4538-a072-41aba146e142_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_dc6e138e-b093-4ecb-b60e-536c514ca535_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_15ae7556-bb1d-4066-9ab9-0c688200a9c9_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b28e8c87-1471-4ed0-ac4f-c4782c6e0773_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_d9df3a89-8349-4d49-9f14-67e116c27c0f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_7ed7fc93-85c7-46ef-af95-5c4cdcd8abae_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e6c5b96b-663c-438a-9d65-8f1ac29acba2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_4c0f0fa8-6adf-452e-ab7b-5f13b46f81fa_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_COVID19TestingMember_e505b56b-4d26-410a-8ee3-69353b6d3fd0_terseLabel_en-US" xlink:label="lab_opk_COVID19TestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Testing</link:label>
    <link:label id="lab_opk_COVID19TestingMember_label_en-US" xlink:label="lab_opk_COVID19TestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Testing [Member]</link:label>
    <link:label id="lab_opk_COVID19TestingMember_documentation_en-US" xlink:label="lab_opk_COVID19TestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Testing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestingMember" xlink:href="opk-20220331.xsd#opk_COVID19TestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_COVID19TestingMember" xlink:to="lab_opk_COVID19TestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c4c6a64d-1130-42eb-a0f3-a26671d45c70_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_RelatedPartyTransactionFutureContributions_155903e2-3a90-48be-bf64-ed6b127cf4f6_terseLabel_en-US" xlink:label="lab_opk_RelatedPartyTransactionFutureContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party future contribution</link:label>
    <link:label id="lab_opk_RelatedPartyTransactionFutureContributions_label_en-US" xlink:label="lab_opk_RelatedPartyTransactionFutureContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Future Contributions</link:label>
    <link:label id="lab_opk_RelatedPartyTransactionFutureContributions_documentation_en-US" xlink:label="lab_opk_RelatedPartyTransactionFutureContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Future Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionFutureContributions" xlink:href="opk-20220331.xsd#opk_RelatedPartyTransactionFutureContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_RelatedPartyTransactionFutureContributions" xlink:to="lab_opk_RelatedPartyTransactionFutureContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dc1c33d7-ee0a-46be-a741-8a283f0fc9c3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Difference between lease payments and discounted lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PatientsMember_d550b782-c5cf-4fa9-bcb0-8d3cf24ca115_terseLabel_en-US" xlink:label="lab_opk_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients</link:label>
    <link:label id="lab_opk_PatientsMember_label_en-US" xlink:label="lab_opk_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients [Member]</link:label>
    <link:label id="lab_opk_PatientsMember_documentation_en-US" xlink:label="lab_opk_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PatientsMember" xlink:href="opk-20220331.xsd#opk_PatientsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PatientsMember" xlink:to="lab_opk_PatientsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_643af547-d8e7-4986-8abd-b48cd3eae613_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale_89e1f6bc-d8f8-407e-97f2-597a0d291e69_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period following first commercial sale in a country</link:label>
    <link:label id="lab_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale_label_en-US" xlink:label="lab_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Period Following First Commercial Sale</link:label>
    <link:label id="lab_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Period Following First Commercial Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale" xlink:to="lab_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8af4d6ae-f2ab-4aa0-8596-e8fbf13c51aa_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6476a566-1f0e-4bf6-97b5-bef88a06bc13_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EloxxPharmaceuticalsMember_34c25c94-91d6-4b8f-a4a6-f4c2bcfe5b1f_terseLabel_en-US" xlink:label="lab_opk_EloxxPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eloxx Pharmaceuticals</link:label>
    <link:label id="lab_opk_EloxxPharmaceuticalsMember_label_en-US" xlink:label="lab_opk_EloxxPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eloxx Pharmaceuticals [Member]</link:label>
    <link:label id="lab_opk_EloxxPharmaceuticalsMember_documentation_en-US" xlink:label="lab_opk_EloxxPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eloxx Pharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EloxxPharmaceuticalsMember" xlink:href="opk-20220331.xsd#opk_EloxxPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EloxxPharmaceuticalsMember" xlink:to="lab_opk_EloxxPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4af81ea9-bb1f-4e9d-bbf4-eb426551f2a2_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Beginning and Ending Balances of Level 3 Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_bf9dc8d6-0011-454d-9f22-712f9c5ea29d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_cdebfaa3-ad63-48df-9099-35dd8245201e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in business combination (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_69aef796-13bc-4706-a4bd-a24848621f11_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f5cba1c8-947e-4e91-a8b7-e3cea35374e4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_121a6cd2-0f54-48c0-8080-3eb0a57cc47c_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PhioPharmaceuticalsMember_dc2beb12-c255-4cd1-aa81-d14ba97d7362_terseLabel_en-US" xlink:label="lab_opk_PhioPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phio Pharmaceuticals</link:label>
    <link:label id="lab_opk_PhioPharmaceuticalsMember_label_en-US" xlink:label="lab_opk_PhioPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phio Pharmaceuticals [Member]</link:label>
    <link:label id="lab_opk_PhioPharmaceuticalsMember_documentation_en-US" xlink:label="lab_opk_PhioPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phio Pharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PhioPharmaceuticalsMember" xlink:href="opk-20220331.xsd#opk_PhioPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PhioPharmaceuticalsMember" xlink:to="lab_opk_PhioPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_15e00bfc-8990-4837-a1ae-406431d5b414_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_GovernmentPayersMember_d5796d97-dac4-4eae-a1a5-663b35c03d5f_terseLabel_en-US" xlink:label="lab_opk_GovernmentPayersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government payers</link:label>
    <link:label id="lab_opk_GovernmentPayersMember_label_en-US" xlink:label="lab_opk_GovernmentPayersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Payers [Member]</link:label>
    <link:label id="lab_opk_GovernmentPayersMember_documentation_en-US" xlink:label="lab_opk_GovernmentPayersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Payers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GovernmentPayersMember" xlink:href="opk-20220331.xsd#opk_GovernmentPayersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_GovernmentPayersMember" xlink:to="lab_opk_GovernmentPayersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CivilInvestigativeDemandsMember_b56cbc78-b191-4525-bd1d-89cc21616e4e_terseLabel_en-US" xlink:label="lab_opk_CivilInvestigativeDemandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Civil Investigative Demands</link:label>
    <link:label id="lab_opk_CivilInvestigativeDemandsMember_label_en-US" xlink:label="lab_opk_CivilInvestigativeDemandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Civil Investigative Demands [Member]</link:label>
    <link:label id="lab_opk_CivilInvestigativeDemandsMember_documentation_en-US" xlink:label="lab_opk_CivilInvestigativeDemandsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Civil Investigative Demands</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CivilInvestigativeDemandsMember" xlink:href="opk-20220331.xsd#opk_CivilInvestigativeDemandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CivilInvestigativeDemandsMember" xlink:to="lab_opk_CivilInvestigativeDemandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_8ef02f4b-1daa-4526-839a-738db449730c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Difference between lease payments and discounted lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BioCardiaInc.Member_c1df9a75-3c79-42d5-87ee-51efbe9466d8_terseLabel_en-US" xlink:label="lab_opk_BioCardiaInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCardia, Inc.</link:label>
    <link:label id="lab_opk_BioCardiaInc.Member_label_en-US" xlink:label="lab_opk_BioCardiaInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCardia, Inc. [Member]</link:label>
    <link:label id="lab_opk_BioCardiaInc.Member_documentation_en-US" xlink:label="lab_opk_BioCardiaInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCardia, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioCardiaInc.Member" xlink:href="opk-20220331.xsd#opk_BioCardiaInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BioCardiaInc.Member" xlink:to="lab_opk_BioCardiaInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_147e65b8-5e58-4831-98d0-d6361d062942_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial investment in joint venture</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DisposalGroupNumberOfFacilitiesSold_9d588e10-088f-4a85-b660-4dab6af54a61_terseLabel_en-US" xlink:label="lab_opk_DisposalGroupNumberOfFacilitiesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of facilities sold</link:label>
    <link:label id="lab_opk_DisposalGroupNumberOfFacilitiesSold_label_en-US" xlink:label="lab_opk_DisposalGroupNumberOfFacilitiesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Number of Facilities Sold</link:label>
    <link:label id="lab_opk_DisposalGroupNumberOfFacilitiesSold_documentation_en-US" xlink:label="lab_opk_DisposalGroupNumberOfFacilitiesSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Number of Facilities Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DisposalGroupNumberOfFacilitiesSold" xlink:href="opk-20220331.xsd#opk_DisposalGroupNumberOfFacilitiesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DisposalGroupNumberOfFacilitiesSold" xlink:to="lab_opk_DisposalGroupNumberOfFacilitiesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_9f260d98-183f-46fb-8e00-bd18c1253530_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c84ee32b-31e4-4a06-8173-68da432960df_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_79f936f2-6ca4-44ec-9190-122e267e833f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_c5d60a03-c3bd-49cf-8a6c-4755c36f256c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_838214dd-eb3e-405f-b95c-738f8e96ecd9_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_24b212bd-195b-4779-a089-95290557921d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime_8c850805-4b40-4e5e-86a2-68f69c0cad17_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual height velocity at point in time</link:label>
    <link:label id="lab_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime_label_en-US" xlink:label="lab_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Annual Height Velocity at Point in Time</link:label>
    <link:label id="lab_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Annual Height Velocity at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime" xlink:to="lab_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_6a13d467-4b70-4319-881b-72620637de23_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_95051766-00d2-48d0-ba35-5c0341eaedef_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_be216554-8328-4196-88ed-2a9609c48673_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_589ccebd-fb0a-48cc-85d4-04b77b9b91fa_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income and (expense), net:</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract_3acc953f-9711-4e19-b738-6f22dbeca5cb_terseLabel_en-US" xlink:label="lab_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value:</link:label>
    <link:label id="lab_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract_label_en-US" xlink:label="lab_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings [Abstract]</link:label>
    <link:label id="lab_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract_documentation_en-US" xlink:label="lab_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract" xlink:href="opk-20220331.xsd#opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract" xlink:to="lab_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_f0900a49-3ecc-4f86-a83d-e8615eeaa9b1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_310efe87-311c-48b9-ab03-7cd0e06ce413_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENTS</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e8ef63d4-b80f-48e0-9b8d-ae5380d2eea5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c419b8ce-6bc1-49a5-873d-68658f4e4691_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock_878e73ab-ff4d-433b-a6be-fe760c14272a_terseLabel_en-US" xlink:label="lab_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Sales Allowances and Accruals</link:label>
    <link:label id="lab_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock_label_en-US" xlink:label="lab_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Product Sales Allowances And Accruals [Table Text Block]</link:label>
    <link:label id="lab_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock_documentation_en-US" xlink:label="lab_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Product Sales Allowances And Accruals [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" xlink:href="opk-20220331.xsd#opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" xlink:to="lab_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_761ea0d8-6d5a-468c-ab37-1ebcbb74e7b2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current maturities of operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ba3979cb-8c07-439a-8d03-4bc41701a2f3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BCIBankMember_914f258f-86e7-4706-94bb-6b53de9a9876_terseLabel_en-US" xlink:label="lab_opk_BCIBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BCI Bank</link:label>
    <link:label id="lab_opk_BCIBankMember_label_en-US" xlink:label="lab_opk_BCIBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BCI Bank [Member]</link:label>
    <link:label id="lab_opk_BCIBankMember_documentation_en-US" xlink:label="lab_opk_BCIBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BCI Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BCIBankMember" xlink:href="opk-20220331.xsd#opk_BCIBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BCIBankMember" xlink:to="lab_opk_BCIBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_GenomicTestMember_0dfeed5d-9248-4153-994a-3af6d6609eca_terseLabel_en-US" xlink:label="lab_opk_GenomicTestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genomic Test</link:label>
    <link:label id="lab_opk_GenomicTestMember_label_en-US" xlink:label="lab_opk_GenomicTestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genomic Test [Member]</link:label>
    <link:label id="lab_opk_GenomicTestMember_documentation_en-US" xlink:label="lab_opk_GenomicTestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genomic Test</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GenomicTestMember" xlink:href="opk-20220331.xsd#opk_GenomicTestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_GenomicTestMember" xlink:to="lab_opk_GenomicTestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_1d09df2d-e152-43f8-b32f-dbf3f26484da_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5f3e3376-e478-4252-ac1e-7e67e2aa41c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c9709ca3-d74c-471c-9ede-9edb63cc9277_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_a0b25e05-b7dd-4a4d-83a0-5af0ee42b5ba_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8e54e0aa-1092-4422-9a0e-21aa38dee921_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation &#8211; employees and non-employees</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_b85e4f42-42cd-435f-b001-b5776e32a354_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_StockOptionandWarrantInvestments_6b08f612-6a62-46dc-9a5f-f8ba69da9dc6_terseLabel_en-US" xlink:label="lab_opk_StockOptionandWarrantInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and options</link:label>
    <link:label id="lab_opk_StockOptionandWarrantInvestments_label_en-US" xlink:label="lab_opk_StockOptionandWarrantInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option and Warrant Investments</link:label>
    <link:label id="lab_opk_StockOptionandWarrantInvestments_documentation_en-US" xlink:label="lab_opk_StockOptionandWarrantInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option and Warrant Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockOptionandWarrantInvestments" xlink:href="opk-20220331.xsd#opk_StockOptionandWarrantInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_StockOptionandWarrantInvestments" xlink:to="lab_opk_StockOptionandWarrantInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_be8e5283-5fb1-424b-bca2-5e7faae01136_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2aaf4c0e-8c8c-4e7c-b8e6-c9115bf352d0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3563bbd8-eda2-43f4-b932-cd8a725b3d05_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_5fb48ed1-03c8-4128-8263-62c99e9980db_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DebtInstrumentRollForward_7f57d2d6-f102-4833-b59f-c0bd4bb48a37_terseLabel_en-US" xlink:label="lab_opk_DebtInstrumentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Roll Forward]</link:label>
    <link:label id="lab_opk_DebtInstrumentRollForward_label_en-US" xlink:label="lab_opk_DebtInstrumentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Roll Forward]</link:label>
    <link:label id="lab_opk_DebtInstrumentRollForward_documentation_en-US" xlink:label="lab_opk_DebtInstrumentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentRollForward" xlink:href="opk-20220331.xsd#opk_DebtInstrumentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DebtInstrumentRollForward" xlink:to="lab_opk_DebtInstrumentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_0ae9fb78-dc4f-47dd-9cd6-57db2f5fe106_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_f0e2b5ab-fc07-4a43-8671-36917aa2b14d_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technologies</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EirGenPharmaLimitedMember_d138dd6f-3193-4684-80ba-a9fb186788fa_verboseLabel_en-US" xlink:label="lab_opk_EirGenPharmaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rayaldee</link:label>
    <link:label id="lab_opk_EirGenPharmaLimitedMember_da52c149-d1f1-4d70-8170-240158ce4054_terseLabel_en-US" xlink:label="lab_opk_EirGenPharmaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EirGen Pharma Limited</link:label>
    <link:label id="lab_opk_EirGenPharmaLimitedMember_label_en-US" xlink:label="lab_opk_EirGenPharmaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EirGen Pharma Limited [Member]</link:label>
    <link:label id="lab_opk_EirGenPharmaLimitedMember_documentation_en-US" xlink:label="lab_opk_EirGenPharmaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EirGen Pharma Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EirGenPharmaLimitedMember" xlink:href="opk-20220331.xsd#opk_EirGenPharmaLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EirGenPharmaLimitedMember" xlink:to="lab_opk_EirGenPharmaLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_c95c5e55-ee74-4539-93a5-886980754a5e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_1524036d-9a31-4375-8ab3-617d9d9419d8_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_4482bd16-698b-4395-8b7e-aa37fa814389_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_6316b7d5-ca69-40b0-9b75-7d2b4cd9645d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_370d1cfe-fce3-4c58-9985-79e38847dc18_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value changes of derivative instruments, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_59cc4a69-1a1b-41a1-aa13-9ffbe04feb4c_terseLabel_en-US" xlink:label="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_documentation_en-US" xlink:label="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" xlink:to="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_91ec71cd-87a3-441f-be9c-f10033cfc9b1_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_786b7e65-526f-44f7-9d34-8cec8fe6d633_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares into which warrants may be converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_8a17e72c-befa-46de-985a-1d97397ed2ea_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on lines of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_105107b3-17c4-4161-90c8-7d814e52add3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PaymentsForLeases_bef1d935-ec15-4300-b334-265a6f651499_totalLabel_en-US" xlink:label="lab_opk_PaymentsForLeases" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_opk_PaymentsForLeases_label_en-US" xlink:label="lab_opk_PaymentsForLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Leases</link:label>
    <link:label id="lab_opk_PaymentsForLeases_documentation_en-US" xlink:label="lab_opk_PaymentsForLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PaymentsForLeases" xlink:href="opk-20220331.xsd#opk_PaymentsForLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PaymentsForLeases" xlink:to="lab_opk_PaymentsForLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_2ea4e2b4-4943-44de-908d-7decd8cdfb81_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SharesSurrenderedInLieuOfCashPayment_39afd4e7-67d5-48d4-b87f-8eef7b07f1a5_verboseLabel_en-US" xlink:label="lab_opk_SharesSurrenderedInLieuOfCashPayment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered in lieu of cash payment (in shares)</link:label>
    <link:label id="lab_opk_SharesSurrenderedInLieuOfCashPayment_label_en-US" xlink:label="lab_opk_SharesSurrenderedInLieuOfCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Surrendered in Lieu of Cash Payment</link:label>
    <link:label id="lab_opk_SharesSurrenderedInLieuOfCashPayment_documentation_en-US" xlink:label="lab_opk_SharesSurrenderedInLieuOfCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered in lieu of cash payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesSurrenderedInLieuOfCashPayment" xlink:href="opk-20220331.xsd#opk_SharesSurrenderedInLieuOfCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SharesSurrenderedInLieuOfCashPayment" xlink:to="lab_opk_SharesSurrenderedInLieuOfCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_b436cd0b-989a-4ead-a62b-537954aadbaf_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest&#160;rate&#160;on borrowings at March 31, 2022</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0975893e-5ade-4fc8-b78c-99c41298a323_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DravetSyndromeProductsMember_02fad804-1975-4384-ae1f-a9c0792e896d_terseLabel_en-US" xlink:label="lab_opk_DravetSyndromeProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dravet Syndrome Products</link:label>
    <link:label id="lab_opk_DravetSyndromeProductsMember_label_en-US" xlink:label="lab_opk_DravetSyndromeProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dravet Syndrome Products [Member]</link:label>
    <link:label id="lab_opk_DravetSyndromeProductsMember_documentation_en-US" xlink:label="lab_opk_DravetSyndromeProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dravet Syndrome Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DravetSyndromeProductsMember" xlink:href="opk-20220331.xsd#opk_DravetSyndromeProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DravetSyndromeProductsMember" xlink:to="lab_opk_DravetSyndromeProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_838b91b1-bf5f-4cd2-a508-5e8f2360663b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_737d1db5-00cc-491a-8015-aab0d0e051d7_verboseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities of equity method investees</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EquityMethodInvestmentExcludingVariableInterestEntity_bc6d04c7-98be-480c-b61c-1ac4c061f84a_terseLabel_en-US" xlink:label="lab_opk_EquityMethodInvestmentExcludingVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentExcludingVariableInterestEntity_label_en-US" xlink:label="lab_opk_EquityMethodInvestmentExcludingVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Excluding Variable Interest Entity</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentExcludingVariableInterestEntity_documentation_en-US" xlink:label="lab_opk_EquityMethodInvestmentExcludingVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Excluding Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentExcludingVariableInterestEntity" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentExcludingVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EquityMethodInvestmentExcludingVariableInterestEntity" xlink:to="lab_opk_EquityMethodInvestmentExcludingVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember_9ace3f69-c66c-48da-854a-7483cdea23e1_terseLabel_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities</link:label>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember_label_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR), First Twelve Months, Adjusted for Eurocurrency Liabilities [Member]</link:label>
    <link:label id="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember_documentation_en-US" xlink:label="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR), First Twelve Months, Adjusted for Eurocurrency Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" xlink:href="opk-20220331.xsd#opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" xlink:to="lab_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a1c42115-1efb-4f47-905b-cc5d0aeb2967_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8fcdc6ec-f554-4532-abba-622d829e0892_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_de70e781-b9bf-423f-89da-aa9971921197_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_320c7542-3136-47ea-abca-ce8f73a5ce92_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0dcd7805-6505-4fe3-97fb-d6b346a3a2a6_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b1589331-0198-4219-a6cc-ec529aa53dcd_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_11ff90ee-9e45-4653-99f4-d79f28b77227_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NewCreditAgreementMember_2767805f-1001-4e85-b143-bc21c76daf38_terseLabel_en-US" xlink:label="lab_opk_NewCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Agreement</link:label>
    <link:label id="lab_opk_NewCreditAgreementMember_label_en-US" xlink:label="lab_opk_NewCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Agreement [Member]</link:label>
    <link:label id="lab_opk_NewCreditAgreementMember_documentation_en-US" xlink:label="lab_opk_NewCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NewCreditAgreementMember" xlink:href="opk-20220331.xsd#opk_NewCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NewCreditAgreementMember" xlink:to="lab_opk_NewCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d03580e9-196a-4717-a5bd-2d6df64307bb_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Supplies_1751e12f-fb62-432f-b77b-cccdc60ed3ef_terseLabel_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_Supplies_label_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Supplies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Supplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Supplies" xlink:to="lab_us-gaap_Supplies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4fcb9a49-452c-4025-9563-a3eb7461dfac_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ConsoorcioBankMember_4ddc6d58-d778-44a0-9b10-c8bb7b3d4d49_terseLabel_en-US" xlink:label="lab_opk_ConsoorcioBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consoorcio Bank</link:label>
    <link:label id="lab_opk_ConsoorcioBankMember_label_en-US" xlink:label="lab_opk_ConsoorcioBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consoorcio Bank [Member]</link:label>
    <link:label id="lab_opk_ConsoorcioBankMember_documentation_en-US" xlink:label="lab_opk_ConsoorcioBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consoorcio Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ConsoorcioBankMember" xlink:href="opk-20220331.xsd#opk_ConsoorcioBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ConsoorcioBankMember" xlink:to="lab_opk_ConsoorcioBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_InterestExpenseNonoperating_b37c1131-26d7-4d4e-a9ea-25eaf3465043_negatedLabel_en-US" xlink:label="lab_opk_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_opk_InterestExpenseNonoperating_label_en-US" xlink:label="lab_opk_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:label id="lab_opk_InterestExpenseNonoperating_documentation_en-US" xlink:label="lab_opk_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestExpenseNonoperating" xlink:href="opk-20220331.xsd#opk_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_InterestExpenseNonoperating" xlink:to="lab_opk_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_5bbea464-68f3-482b-b058-6139fbf74f85_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_93d89572-e5ac-48e3-979d-3b63295886f5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_cd35ca3b-e7bc-40c2-9908-73c2f4c694b1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Converted debt amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_FineTechMember_d9de45f0-269b-4cf8-ad76-69be9cdba361_terseLabel_en-US" xlink:label="lab_opk_FineTechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FineTech</link:label>
    <link:label id="lab_opk_FineTechMember_label_en-US" xlink:label="lab_opk_FineTechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FineTech [Member]</link:label>
    <link:label id="lab_opk_FineTechMember_documentation_en-US" xlink:label="lab_opk_FineTechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FineTech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FineTechMember" xlink:href="opk-20220331.xsd#opk_FineTechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_FineTechMember" xlink:to="lab_opk_FineTechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_649d5a95-c961-42b1-bf9f-9f4d0b2e1cbc_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DrFrostandMrPfennigerMember_d063159b-c95b-4c04-ae1c-1401749101d7_terseLabel_en-US" xlink:label="lab_opk_DrFrostandMrPfennigerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Frost and Mr Pfenniger</link:label>
    <link:label id="lab_opk_DrFrostandMrPfennigerMember_label_en-US" xlink:label="lab_opk_DrFrostandMrPfennigerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Frost and Mr Pfenniger [Member]</link:label>
    <link:label id="lab_opk_DrFrostandMrPfennigerMember_documentation_en-US" xlink:label="lab_opk_DrFrostandMrPfennigerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Frost and Mr Pfenniger [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DrFrostandMrPfennigerMember" xlink:href="opk-20220331.xsd#opk_DrFrostandMrPfennigerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DrFrostandMrPfennigerMember" xlink:to="lab_opk_DrFrostandMrPfennigerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IL_057e35e4-aaf3-4d65-9e6f-3b8964708683_verboseLabel_en-US" xlink:label="lab_country_IL" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Israel</link:label>
    <link:label id="lab_country_IL_label_en-US" xlink:label="lab_country_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ISRAEL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IL" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL" xlink:to="lab_country_IL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_a564d63b-30e0-4bcc-8e54-5a3fa47bad2d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NicoyaMember_45562bcd-9d20-4fe3-9ca6-3a49640ec8ea_terseLabel_en-US" xlink:label="lab_opk_NicoyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nicoya</link:label>
    <link:label id="lab_opk_NicoyaMember_label_en-US" xlink:label="lab_opk_NicoyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nicoya [Member]</link:label>
    <link:label id="lab_opk_NicoyaMember_documentation_en-US" xlink:label="lab_opk_NicoyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nicoya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NicoyaMember" xlink:href="opk-20220331.xsd#opk_NicoyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NicoyaMember" xlink:to="lab_opk_NicoyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0b0a1bc9-3b29-4042-a339-1b0a42c4fe2d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_d72fc4fd-9601-4b35-bdc3-750c835fa05e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Accumulated Other Comprehensive Loss, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d88ac12f-14fb-4d43-82ed-e4493961d6e4_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_26cfb829-5807-4cb5-acc0-60f0b5d64bdd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt repurchase amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_ed653d5d-cf5c-4acf-a1d5-abb5b0357c62_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior period performance obligation revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_39b2c805-4dfb-425c-bda9-4add2ac46579_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_0dc1b997-ed1f-4d15-b5bc-e13aa71796de_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of credit risk and allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_a60aed98-90ff-4d49-b711-d278f85b6339_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_COVID19TestingRevenueConcentrationRiskMember_c33219e1-5cda-47f7-9850-a97d5cc2f1d8_terseLabel_en-US" xlink:label="lab_opk_COVID19TestingRevenueConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Testing Revenue Concentration Risk</link:label>
    <link:label id="lab_opk_COVID19TestingRevenueConcentrationRiskMember_label_en-US" xlink:label="lab_opk_COVID19TestingRevenueConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Testing Revenue Concentration Risk [Member]</link:label>
    <link:label id="lab_opk_COVID19TestingRevenueConcentrationRiskMember_documentation_en-US" xlink:label="lab_opk_COVID19TestingRevenueConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Testing Revenue Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestingRevenueConcentrationRiskMember" xlink:href="opk-20220331.xsd#opk_COVID19TestingRevenueConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_COVID19TestingRevenueConcentrationRiskMember" xlink:to="lab_opk_COVID19TestingRevenueConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6d46a33d-7ed8-4676-a328-4330e435321d_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b3a605c2-be64-413e-a618-904b7b5b8c54_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ba3c9559-354e-42ab-baa9-7bf3243b5dc6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_41289c5f-0d22-4f00-b186-84c68ac734bf_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_c0796bc3-5174-42ef-aebd-e1868f135ea3_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_d7ab8eef-e284-4fe4-973f-094d362d86ab_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3e97e0aa-0035-4547-826e-eca72ff25e39_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_ea4772e9-f0e0-4da9-b12d-3196f901ff5c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inter-segment allocation of interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d1cb0e4f-5042-4f98-b986-4b83489dde7f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_73238db6-e470-4bd1-b004-38aa11e40b7a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_80109580-d80b-48da-af5d-a12c1bfcd372_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a5fe3965-6f08-44ee-85f3-394a5861dc4d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ChromadexCorporationMember_8aeb8003-5fdc-406a-a843-3d4fddb5ac12_verboseLabel_en-US" xlink:label="lab_opk_ChromadexCorporationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChromaDex Corporation</link:label>
    <link:label id="lab_opk_ChromadexCorporationMember_label_en-US" xlink:label="lab_opk_ChromadexCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chromadex Corporation [Member]</link:label>
    <link:label id="lab_opk_ChromadexCorporationMember_documentation_en-US" xlink:label="lab_opk_ChromadexCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChromaDex corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChromadexCorporationMember" xlink:href="opk-20220331.xsd#opk_ChromadexCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ChromadexCorporationMember" xlink:to="lab_opk_ChromadexCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c8779582-2c2f-4f31-ba2c-9aa783635f86_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_4505b8a5-1653-4d88-a784-6e6f68382956_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_RelatedPartyTransactionShares_ef867edd-2703-4b02-a4fc-bb7fc9bcaec5_terseLabel_en-US" xlink:label="lab_opk_RelatedPartyTransactionShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received upon closing of transaction (in shares)</link:label>
    <link:label id="lab_opk_RelatedPartyTransactionShares_label_en-US" xlink:label="lab_opk_RelatedPartyTransactionShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Shares</link:label>
    <link:label id="lab_opk_RelatedPartyTransactionShares_documentation_en-US" xlink:label="lab_opk_RelatedPartyTransactionShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionShares" xlink:href="opk-20220331.xsd#opk_RelatedPartyTransactionShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_RelatedPartyTransactionShares" xlink:to="lab_opk_RelatedPartyTransactionShares" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_b80210e8-cc69-40ca-9e27-0aeadb05923b_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_5f1c3aec-8510-47ea-b859-798352db37f9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_label_en-US" xlink:label="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:to="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_87457bb5-9887-4e53-94ef-36e9f047fc02_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_05cb78f7-4427-45cb-8d40-57b59640bddf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e9bbc5fe-0810-477b-b9bd-3f48f0e47e28_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_a1eed7a4-c5bb-42b9-b8ab-0aa177ef0359_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_1c0e2734-4144-4cae-ad89-9895b321fd64_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_ed5fb6ad-dfbe-428c-9d34-a61d7e7e659f_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from investment in investees</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0267eb2b-167c-4f17-ae06-9775d3055b26_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivative Instrument Losses and Gains Recorded</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_d863a327-3a75-41e3-9549-978337ca4cc6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_7e09cd40-b500-4e8a-bc8d-aedd78139ecf_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a1ae5813-99c3-4af2-bece-ba1b743e3046_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OpkoChileMember_895da9cd-0923-4cc1-b481-2ff70c25ecba_terseLabel_en-US" xlink:label="lab_opk_OpkoChileMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Chile</link:label>
    <link:label id="lab_opk_OpkoChileMember_label_en-US" xlink:label="lab_opk_OpkoChileMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Chile [Member]</link:label>
    <link:label id="lab_opk_OpkoChileMember_documentation_en-US" xlink:label="lab_opk_OpkoChileMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opko Chile.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OpkoChileMember" xlink:href="opk-20220331.xsd#opk_OpkoChileMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OpkoChileMember" xlink:to="lab_opk_OpkoChileMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ed89d3c2-3814-4169-ab8b-3159bc64b7b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Beginning and Ending Balances of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_2e3bca5d-21de-4ab9-97f0-5dc44579b75a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_e839e786-6216-4e08-b46a-2ed45a074f5c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_0e78b859-87a7-4c60-aa01-e0ffa793c82c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_e9f996c5-8c5a-46f1-93c0-4ef0166d7cef_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_542c46ac-295d-4f80-b007-936a46d5e8b8_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net intangible assets other than goodwill</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ConvertibleSeniorNotesDue2025Member_befb5b8f-9693-48a5-a898-c8953fc09c9e_terseLabel_en-US" xlink:label="lab_opk_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025</link:label>
    <link:label id="lab_opk_ConvertibleSeniorNotesDue2025Member_label_en-US" xlink:label="lab_opk_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025 [Member]</link:label>
    <link:label id="lab_opk_ConvertibleSeniorNotesDue2025Member_documentation_en-US" xlink:label="lab_opk_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ConvertibleSeniorNotesDue2025Member" xlink:href="opk-20220331.xsd#opk_ConvertibleSeniorNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ConvertibleSeniorNotesDue2025Member" xlink:to="lab_opk_ConvertibleSeniorNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_66b2e846-8079-49b6-b4c0-feeb7a3bfec5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_3f0813ee-edd5-46bc-810c-c0a55c27aa0a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_67f5cd25-5df6-4d93-9ece-bcfe14f0f425_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_22818b20-1a7d-4fc6-9bfe-fd31078fd7d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (provision)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c5331f3d-b161-4b95-9f57-baf7f7317a57_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_053efd4b-5252-43af-be32-1c7cb45a0dbc_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d2618172-fdfe-4c19-af38-f1a01a25bf10_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e3c749b1-8c66-4a4b-9561-a5ec0369ce71_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_af112612-00a3-483a-a715-b40e1d1dd4b6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_391e66fd-48b9-4dee-b49a-164e34bd8613_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d92339e3-dbd7-44e0-a8b4-b5a5b984e98c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_2426dde7-0033-433f-8c1a-d76f901e8d96_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_12ca03e8-2973-4847-87d0-c0b6b420b39a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_46dcf0cd-976c-47a9-9915-0e494dbdda3d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a7ba25c6-409a-4c43-b3d6-58f3b1c0f327_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_beeff2fa-55f8-4424-8044-12f8b6c2243b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1be17a17-778a-4dbf-aba5-466c9515deb8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_451810f1-0cb2-45bf-9597-daafb1880aef_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_6ebe921c-33fd-4928-9ac9-079772f6435e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df388021-bd32-43e6-b6bf-c04b28908cf7_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_4d53b41e-f0ea-40f3-b2e8-a8602076d8d1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_613c8a9b-4b51-43dc-8260-b709fa43aacd_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, net</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_6d3b6a32-f666-45d7-b5f9-77a4a132b61b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_487c9638-38c7-4d81-b81b-76e73e6d0de1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_MX_2963fbe7-9eea-4e34-a4b5-64eef4f419ff_verboseLabel_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mexico</link:label>
    <link:label id="lab_country_MX_label_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEXICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_MX" xlink:to="lab_country_MX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_ba8aff3d-0b65-428a-85ae-e45fd72726b7_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_1f94efe8-6bb9-45ac-bab1-9a2552dd95e4_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_3f566079-e2ed-4384-b31f-90ed5e9b7ed1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operations and Assets for Operating Segments and Geographic Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_81e6565c-3bc9-4887-b2b2-79ecf865e9d7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e9f3c8f-caaf-4ed0-b758-fbda5c9ee8b8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_a210c65e-ca90-450d-8314-fcaa25961090_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_HealthInsurersMember_c7187e6a-9d2c-4c61-b4c2-8e166a96d690_terseLabel_en-US" xlink:label="lab_opk_HealthInsurersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare insurers</link:label>
    <link:label id="lab_opk_HealthInsurersMember_label_en-US" xlink:label="lab_opk_HealthInsurersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurers [Member]</link:label>
    <link:label id="lab_opk_HealthInsurersMember_documentation_en-US" xlink:label="lab_opk_HealthInsurersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_HealthInsurersMember" xlink:href="opk-20220331.xsd#opk_HealthInsurersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_HealthInsurersMember" xlink:to="lab_opk_HealthInsurersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementDevelopmentMilestonePayment_ac8fa4f5-b1bc-4900-a7e6-fd9707d0975b_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone payments</link:label>
    <link:label id="lab_opk_CollaborativeArrangementDevelopmentMilestonePayment_label_en-US" xlink:label="lab_opk_CollaborativeArrangementDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Development Milestone Payment</link:label>
    <link:label id="lab_opk_CollaborativeArrangementDevelopmentMilestonePayment_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Development Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementDevelopmentMilestonePayment" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementDevelopmentMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementDevelopmentMilestonePayment" xlink:to="lab_opk_CollaborativeArrangementDevelopmentMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0e0cd7d3-8b65-4b37-831c-30ee749cb6f3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_f87662ca-1f4e-44c9-b393-9ede5a6a3056_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeAgreementAdditionalMilestonePayment_991dd1dc-3f53-47bf-a85d-54f6fc719bfe_terseLabel_en-US" xlink:label="lab_opk_CollaborativeAgreementAdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment</link:label>
    <link:label id="lab_opk_CollaborativeAgreementAdditionalMilestonePayment_label_en-US" xlink:label="lab_opk_CollaborativeAgreementAdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Additional Milestone Payment</link:label>
    <link:label id="lab_opk_CollaborativeAgreementAdditionalMilestonePayment_documentation_en-US" xlink:label="lab_opk_CollaborativeAgreementAdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Additional Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeAgreementAdditionalMilestonePayment" xlink:href="opk-20220331.xsd#opk_CollaborativeAgreementAdditionalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeAgreementAdditionalMilestonePayment" xlink:to="lab_opk_CollaborativeAgreementAdditionalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_dc9de176-c12a-462f-8240-7dbf94fd9393_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_6cf232af-7c37-4833-a223-19c209860075_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_42b8aed8-cf6e-4ee9-8439-c71bdc58a4d2_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d2cbada-a266-4ca8-a81c-dffd02b82544_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_0f4720bb-c49c-4d93-9253-272cb2dd3051_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_7b3da055-176b-48f0-905a-564da6f729de_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c2981e27-5b17-4367-93a0-b52a1f232b24_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with no readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CURNAMember_cc90f2d7-5a28-48e6-b9c2-c6c3ee8b2252_terseLabel_en-US" xlink:label="lab_opk_CURNAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURNA</link:label>
    <link:label id="lab_opk_CURNAMember_label_en-US" xlink:label="lab_opk_CURNAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURNA [Member]</link:label>
    <link:label id="lab_opk_CURNAMember_documentation_en-US" xlink:label="lab_opk_CURNAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURNA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CURNAMember" xlink:href="opk-20220331.xsd#opk_CURNAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CURNAMember" xlink:to="lab_opk_CURNAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_09b31006-78ec-4d96-a62e-e093b5240beb_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f517de45-2d13-4a43-96a6-fbb6412fc02b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_905d834b-887b-40d4-bd10-203e39a4447e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption period three</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1f6fa59f-3aff-4c8b-bc70-41e77cb3ad73_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5ed5ae64-e446-4881-b4ea-cb3197c5ed33_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_GainLossOnConversionOfDebt_3922df94-8bb4-4525-b457-656b3a669a99_negatedTerseLabel_en-US" xlink:label="lab_opk_GainLossOnConversionOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on conversion of the 2025 Notes</link:label>
    <link:label id="lab_opk_GainLossOnConversionOfDebt_label_en-US" xlink:label="lab_opk_GainLossOnConversionOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Conversion of Debt</link:label>
    <link:label id="lab_opk_GainLossOnConversionOfDebt_documentation_en-US" xlink:label="lab_opk_GainLossOnConversionOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Conversion of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GainLossOnConversionOfDebt" xlink:href="opk-20220331.xsd#opk_GainLossOnConversionOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_GainLossOnConversionOfDebt" xlink:to="lab_opk_GainLossOnConversionOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4407ce2e-6230-42ea-acc3-da00a238dd04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OPKOBiologicsMember_1cc0bdc3-ac03-4b68-91c1-06fc445cfa0d_terseLabel_en-US" xlink:label="lab_opk_OPKOBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Biologics</link:label>
    <link:label id="lab_opk_OPKOBiologicsMember_label_en-US" xlink:label="lab_opk_OPKOBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Biologics [Member]</link:label>
    <link:label id="lab_opk_OPKOBiologicsMember_documentation_en-US" xlink:label="lab_opk_OPKOBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Biologics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOBiologicsMember" xlink:href="opk-20220331.xsd#opk_OPKOBiologicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OPKOBiologicsMember" xlink:to="lab_opk_OPKOBiologicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EquityMethodInvestmentVariableInterestEntity_16411387-a7ac-477d-8b5d-8514f487b21f_terseLabel_en-US" xlink:label="lab_opk_EquityMethodInvestmentVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest entity, equity method</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentVariableInterestEntity_label_en-US" xlink:label="lab_opk_EquityMethodInvestmentVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Variable Interest Entity</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentVariableInterestEntity_documentation_en-US" xlink:label="lab_opk_EquityMethodInvestmentVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentVariableInterestEntity" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EquityMethodInvestmentVariableInterestEntity" xlink:to="lab_opk_EquityMethodInvestmentVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_21242a38-de67-425e-96a7-b4da4ebdf75f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ContingentConsiderationMember_d2264b1d-40a6-4f73-8437-9df07cde82d7_terseLabel_en-US" xlink:label="lab_opk_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_opk_ContingentConsiderationMember_label_en-US" xlink:label="lab_opk_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_opk_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_opk_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ContingentConsiderationMember" xlink:href="opk-20220331.xsd#opk_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ContingentConsiderationMember" xlink:to="lab_opk_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AccruedClinicalTrialsCurrent_a8ddae06-3e36-4c42-b1c4-add3f0dbe32e_verboseLabel_en-US" xlink:label="lab_opk_AccruedClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_opk_AccruedClinicalTrialsCurrent_label_en-US" xlink:label="lab_opk_AccruedClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trials, Current</link:label>
    <link:label id="lab_opk_AccruedClinicalTrialsCurrent_documentation_en-US" xlink:label="lab_opk_AccruedClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trials.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedClinicalTrialsCurrent" xlink:href="opk-20220331.xsd#opk_AccruedClinicalTrialsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AccruedClinicalTrialsCurrent" xlink:to="lab_opk_AccruedClinicalTrialsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_16d0246c-4e7d-4cbe-a8fd-164a035781b6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_df98efcf-56e0-4eaa-8e3e-f846e8d7e5e1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_6b18cf36-e74d-4f50-b5c1-85fb79ec39e2_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ProductRegistrationsMember_18056cc8-9ad5-4570-a66e-54d99eca3f4a_terseLabel_en-US" xlink:label="lab_opk_ProductRegistrationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product registrations</link:label>
    <link:label id="lab_opk_ProductRegistrationsMember_label_en-US" xlink:label="lab_opk_ProductRegistrationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Registrations [Member]</link:label>
    <link:label id="lab_opk_ProductRegistrationsMember_documentation_en-US" xlink:label="lab_opk_ProductRegistrationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Registrations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProductRegistrationsMember" xlink:href="opk-20220331.xsd#opk_ProductRegistrationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ProductRegistrationsMember" xlink:to="lab_opk_ProductRegistrationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_a9595c15-5efd-444c-ad47-cede5844f9ab_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_604f783b-ab00-45d4-909e-c9caf740cccc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term line of credit, noncurrent</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fe7544c6-7cbf-494e-abbf-2eeab2e2e6a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SantanderBank2Member_3e01308a-5b76-4be1-9a64-783ad3e700c9_terseLabel_en-US" xlink:label="lab_opk_SantanderBank2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Santander Bank</link:label>
    <link:label id="lab_opk_SantanderBank2Member_label_en-US" xlink:label="lab_opk_SantanderBank2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Santander Bank2 [Member]</link:label>
    <link:label id="lab_opk_SantanderBank2Member_documentation_en-US" xlink:label="lab_opk_SantanderBank2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Santander Bank2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SantanderBank2Member" xlink:href="opk-20220331.xsd#opk_SantanderBank2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SantanderBank2Member" xlink:to="lab_opk_SantanderBank2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_5275e5a7-3eca-4c45-b1b1-e3c3f5047061_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement amount</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementUpfrontPayment_2a0982c2-f87c-4847-9cc1-192669a721b9_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial upfront payment</link:label>
    <link:label id="lab_opk_CollaborativeArrangementUpfrontPayment_label_en-US" xlink:label="lab_opk_CollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment</link:label>
    <link:label id="lab_opk_CollaborativeArrangementUpfrontPayment_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementUpfrontPayment" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementUpfrontPayment" xlink:to="lab_opk_CollaborativeArrangementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_b2aae5ae-2fd6-4ab1-9c9f-e7c989ab044f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OperatingLeasesMonthlyPaymentsYearOne_545d02dc-3fda-41a9-bd7c-a0274db54b12_terseLabel_en-US" xlink:label="lab_opk_OperatingLeasesMonthlyPaymentsYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease payments per month in first year</link:label>
    <link:label id="lab_opk_OperatingLeasesMonthlyPaymentsYearOne_label_en-US" xlink:label="lab_opk_OperatingLeasesMonthlyPaymentsYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Monthly Payments, Year One</link:label>
    <link:label id="lab_opk_OperatingLeasesMonthlyPaymentsYearOne_documentation_en-US" xlink:label="lab_opk_OperatingLeasesMonthlyPaymentsYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Monthly Payments, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OperatingLeasesMonthlyPaymentsYearOne" xlink:href="opk-20220331.xsd#opk_OperatingLeasesMonthlyPaymentsYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OperatingLeasesMonthlyPaymentsYearOne" xlink:to="lab_opk_OperatingLeasesMonthlyPaymentsYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0cada45f-2db5-4786-bce8-1a4667eb11d5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ecadbc49-912e-4517-98a3-434cb1e6c2bb_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f0b8205d-8313-47bb-8d17-31f84f7b4e38_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_69db006e-caff-4666-a21a-d566adb0f4e4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_57ccf432-8148-4d62-b93e-44882af9c9fe_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses:</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_d4b43ad1-c6bc-43c9-97be-e2134f2c7b3c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases short-term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_74152eb7-92ec-4572-be0b-2c522f8c38cc_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_d3e2ea3b-7a15-43e0-949c-6d8744ff7d8e_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_a7a94a96-bd69-405d-b567-76e852a80e4b_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant other observable inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5151c1fe-9ad8-47f4-b259-cb101b1b2711_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_94b2dfc0-0ade-40cc-aff9-3ea76a03f016_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d28d391-7569-4f42-a1f9-1c93d031f30b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_c5ebcc73-717e-480f-96eb-7338ebd55a03_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_a8ef7753-ad7a-4837-8435-ba514e206ec1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities associated with assets held-for-sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised_03a34841-39c5-4e58-aafa-d8b0f3c3568a_verboseLabel_en-US" xlink:label="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock warrant and common stock options exercised (in shares)</link:label>
    <link:label id="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised_label_en-US" xlink:label="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Options and Warrants Exercised</link:label>
    <link:label id="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised_documentation_en-US" xlink:label="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock warrant and common stock options exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" xlink:href="opk-20220331.xsd#opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" xlink:to="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_b30aa32c-7a59-44f8-b692-5189d3b7f701_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_9b5ad22a-c2b4-4b36-8002-e2875e9134af_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative gain (loss)</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_ef6eea82-5994-4e11-894e-31333e873f15_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments_ab833931-df6c-4cfd-a05d-49b48d5c47ec_negatedLabel_en-US" xlink:label="lab_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity securities and derivative instruments</link:label>
    <link:label id="lab_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments_label_en-US" xlink:label="lab_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Equity Securities, FV-NI And Derivative Instruments</link:label>
    <link:label id="lab_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments_documentation_en-US" xlink:label="lab_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Equity Securities, FV-NI And Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" xlink:href="opk-20220331.xsd#opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" xlink:to="lab_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cbaabded-e449-4461-b119-7546224e104b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, estimated useful lives</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_MuseumofScienceIncMember_81d0343e-8b42-4aa9-a5c7-c61ca73eb4c9_terseLabel_en-US" xlink:label="lab_opk_MuseumofScienceIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Museum of Science, Inc</link:label>
    <link:label id="lab_opk_MuseumofScienceIncMember_label_en-US" xlink:label="lab_opk_MuseumofScienceIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Museum of Science, Inc [Member]</link:label>
    <link:label id="lab_opk_MuseumofScienceIncMember_documentation_en-US" xlink:label="lab_opk_MuseumofScienceIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Museum of Science, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MuseumofScienceIncMember" xlink:href="opk-20220331.xsd#opk_MuseumofScienceIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_MuseumofScienceIncMember" xlink:to="lab_opk_MuseumofScienceIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_790b5e0a-168e-4833-8120-daf9289f818d_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_00f361d3-428e-4701-bbaa-eba8372aa4ec_terseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lines of credit and notes payable</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_label_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditCurrent" xlink:to="lab_us-gaap_LinesOfCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_3540476b-ff2e-4d05-8585-63fe3518aed5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SalesReturnsMember_27ed25b3-26a3-4383-a243-c16d946b92db_terseLabel_en-US" xlink:label="lab_opk_SalesReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_opk_SalesReturnsMember_label_en-US" xlink:label="lab_opk_SalesReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns [Member]</link:label>
    <link:label id="lab_opk_SalesReturnsMember_documentation_en-US" xlink:label="lab_opk_SalesReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesReturnsMember" xlink:href="opk-20220331.xsd#opk_SalesReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SalesReturnsMember" xlink:to="lab_opk_SalesReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_A5ConvertibleNotesMember_8361bd31-67e0-4193-b0f4-66e1439812c1_terseLabel_en-US" xlink:label="lab_opk_A5ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5% Convertible Notes</link:label>
    <link:label id="lab_opk_A5ConvertibleNotesMember_label_en-US" xlink:label="lab_opk_A5ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5% Convertible Notes [Member]</link:label>
    <link:label id="lab_opk_A5ConvertibleNotesMember_documentation_en-US" xlink:label="lab_opk_A5ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5% Convertible Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_A5ConvertibleNotesMember" xlink:href="opk-20220331.xsd#opk_A5ConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_A5ConvertibleNotesMember" xlink:to="lab_opk_A5ConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_4669876f-21b8-47b7-804b-0e07b072e0d3_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_1c592498-c21b-4448-8090-25bf4d05cd19_terseLabel_en-US" xlink:label="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_documentation_en-US" xlink:label="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" xlink:href="opk-20220331.xsd#opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BiceBankMember_f83f3b48-f42c-4bde-ba2f-d76b7e01742d_verboseLabel_en-US" xlink:label="lab_opk_BiceBankMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BICE Bank</link:label>
    <link:label id="lab_opk_BiceBankMember_label_en-US" xlink:label="lab_opk_BiceBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bice Bank [Member]</link:label>
    <link:label id="lab_opk_BiceBankMember_documentation_en-US" xlink:label="lab_opk_BiceBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BICE Bank.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BiceBankMember" xlink:href="opk-20220331.xsd#opk_BiceBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BiceBankMember" xlink:to="lab_opk_BiceBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_434f25df-f7fb-4ab2-aa1a-5dff7ce86e01_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_92a54205-7c4a-4151-b812-0bd265a5a72f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6d2a2122-494c-43bb-a7ad-cd49c0b0ef5e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax_c5c7d87c-5067-4260-a428-238cbab0c64b_totalLabel_en-US" xlink:label="lab_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) before investment losses</link:label>
    <link:label id="lab_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax_label_en-US" xlink:label="lab_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Before Investments in Investees, Extraordinary Items, Net of Tax</link:label>
    <link:label id="lab_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax_documentation_en-US" xlink:label="lab_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from continuing operations before investment losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax" xlink:href="opk-20220331.xsd#opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax" xlink:to="lab_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_c147b7ca-0dd2-49c5-b35f-cd3426666997_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_WeightedAverageRemainingLeaseTermAbstract_555839d0-da2d-4fc1-b7f0-86fe4f48ce4e_terseLabel_en-US" xlink:label="lab_opk_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_opk_WeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_opk_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_opk_WeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_opk_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_WeightedAverageRemainingLeaseTermAbstract" xlink:href="opk-20220331.xsd#opk_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_opk_WeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_dab77ed7-8a3e-4bdd-9382-3125398bc0a9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f58a236f-b7e3-47a9-bc1e-cd50a3b3eaee_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BioReferenceMember_031cb994-a556-4230-8b75-8816fc65bf72_terseLabel_en-US" xlink:label="lab_opk_BioReferenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioReference</link:label>
    <link:label id="lab_opk_BioReferenceMember_label_en-US" xlink:label="lab_opk_BioReferenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bio-Reference [Member]</link:label>
    <link:label id="lab_opk_BioReferenceMember_documentation_en-US" xlink:label="lab_opk_BioReferenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bio-Reference [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioReferenceMember" xlink:href="opk-20220331.xsd#opk_BioReferenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BioReferenceMember" xlink:to="lab_opk_BioReferenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_717bdac2-a829-450f-b40c-eb5ccd215153_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_d1ce899a-0211-4361-b8c9-ca3a5dd49336_verboseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets of equity method investees</link:label>
    <link:label id="lab_us-gaap_Assets_0f7e610d-e6f0-4083-aeb1-0c260f5d867f_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_5b040e3f-7734-477f-9a9c-b878233a2f3a_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ChargebacksDiscountsRebatesAndFeesMember_cba61e4f-4b13-4d47-9224-68640a99c7bd_terseLabel_en-US" xlink:label="lab_opk_ChargebacksDiscountsRebatesAndFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, discounts, rebates and fees</link:label>
    <link:label id="lab_opk_ChargebacksDiscountsRebatesAndFeesMember_label_en-US" xlink:label="lab_opk_ChargebacksDiscountsRebatesAndFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Discounts, Rebates And Fees [Member]</link:label>
    <link:label id="lab_opk_ChargebacksDiscountsRebatesAndFeesMember_documentation_en-US" xlink:label="lab_opk_ChargebacksDiscountsRebatesAndFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Discounts, Rebates And Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChargebacksDiscountsRebatesAndFeesMember" xlink:href="opk-20220331.xsd#opk_ChargebacksDiscountsRebatesAndFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ChargebacksDiscountsRebatesAndFeesMember" xlink:to="lab_opk_ChargebacksDiscountsRebatesAndFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_00549bbb-1e8d-4c6d-ab96-7239495d5d37_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0d501757-a909-4909-b4c1-2b78afca8dce_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable_9fd1c378-f3f5-4d84-b816-2f226b6f15ab_negatedTerseLabel_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in shares issuable under debt agreement (in shares)</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable_label_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Increase (Decrease) in Maximum Shares Issuable</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable_documentation_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Increase (Decrease) in Maximum Shares Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable" xlink:href="opk-20220331.xsd#opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable" xlink:to="lab_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_29dddb38-949f-4040-9540-86fe5da2ba1f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_96e70c4d-0930-44db-971c-d207066fd6e5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_18158c15-a972-48b3-9ebf-89c3f6eb524f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_99846830-c2e6-480b-a390-bbd43a07e555_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_486db6f4-322b-46db-9273-f0c931f0aac8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_WeightedAverageDiscountRateAbstract_868e3155-b092-48b7-973b-48f593b4514e_terseLabel_en-US" xlink:label="lab_opk_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_opk_WeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_opk_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_opk_WeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_opk_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_WeightedAverageDiscountRateAbstract" xlink:href="opk-20220331.xsd#opk_WeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_WeightedAverageDiscountRateAbstract" xlink:to="lab_opk_WeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_c33ca2d9-568b-4dcc-89b7-e44a381b5fce_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_16a6cb9b-7ca1-4d49-807c-7483ecdb9e6a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on notes payable</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_e0cf1138-c2a6-4336-890b-26610573fafa_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EstadoBankMember_d40e5bd9-d355-4f6a-807f-16e6966eff5f_verboseLabel_en-US" xlink:label="lab_opk_EstadoBankMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estado Bank</link:label>
    <link:label id="lab_opk_EstadoBankMember_label_en-US" xlink:label="lab_opk_EstadoBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estado Bank [Member]</link:label>
    <link:label id="lab_opk_EstadoBankMember_documentation_en-US" xlink:label="lab_opk_EstadoBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estado bank.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EstadoBankMember" xlink:href="opk-20220331.xsd#opk_EstadoBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EstadoBankMember" xlink:to="lab_opk_EstadoBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_e5489e46-c04a-473c-894f-9f52640bee71_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_f258d85b-e495-445d-8244-f2313557b25e_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_740310b5-c0fc-4e1a-bbea-f49f626b8fc3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LineOfCreditFacilityRevolvingCommitmentAxis_0cc7cecb-9a3e-41b3-a2d4-04005779939e_terseLabel_en-US" xlink:label="lab_opk_LineOfCreditFacilityRevolvingCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Revolving Commitment [Axis]</link:label>
    <link:label id="lab_opk_LineOfCreditFacilityRevolvingCommitmentAxis_label_en-US" xlink:label="lab_opk_LineOfCreditFacilityRevolvingCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Revolving Commitment [Axis]</link:label>
    <link:label id="lab_opk_LineOfCreditFacilityRevolvingCommitmentAxis_documentation_en-US" xlink:label="lab_opk_LineOfCreditFacilityRevolvingCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Revolving Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditFacilityRevolvingCommitmentAxis" xlink:href="opk-20220331.xsd#opk_LineOfCreditFacilityRevolvingCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LineOfCreditFacilityRevolvingCommitmentAxis" xlink:to="lab_opk_LineOfCreditFacilityRevolvingCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_46d36d35-f440-48b4-9922-7fa5a8823d36_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lines of Credit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_687eda88-8ae9-47e4-b719-b5658a46a72a_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_b0b368ec-3076-4dc6-9cc3-058e4deed654_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_48b9a8be-b363-4f19-81db-b790e1cc24e8_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_57f5d258-0c99-4fe2-92e0-153262e83b20_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_8224e130-5840-424d-8481-17e7bf7a9b42_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_53b9d36d-9e26-4d92-83f3-f275c8093411_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_e833c6ef-76c0-45ef-a8cd-9051e7861550_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_09445cbc-97e6-4df6-9bbd-1e817509cb0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_TestingTypeAxis_6f0da1c6-cf42-497a-976d-8e88d9b44373_terseLabel_en-US" xlink:label="lab_opk_TestingTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing Type [Axis]</link:label>
    <link:label id="lab_opk_TestingTypeAxis_label_en-US" xlink:label="lab_opk_TestingTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing Type [Axis]</link:label>
    <link:label id="lab_opk_TestingTypeAxis_documentation_en-US" xlink:label="lab_opk_TestingTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TestingTypeAxis" xlink:href="opk-20220331.xsd#opk_TestingTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_TestingTypeAxis" xlink:to="lab_opk_TestingTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_390717bd-29b1-4ee8-8e9d-fbb48301041f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_fd2d4499-c2b6-4130-99a2-0eb7422b9e0a_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_148c188a-e6be-4a0d-a740-895032eec7de_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LineOfCreditFacilityRevolvingCommitmentDomain_106a78fa-78d5-4018-9d3f-42b0ed535bca_terseLabel_en-US" xlink:label="lab_opk_LineOfCreditFacilityRevolvingCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Revolving Commitment [Domain]</link:label>
    <link:label id="lab_opk_LineOfCreditFacilityRevolvingCommitmentDomain_label_en-US" xlink:label="lab_opk_LineOfCreditFacilityRevolvingCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Revolving Commitment [Domain]</link:label>
    <link:label id="lab_opk_LineOfCreditFacilityRevolvingCommitmentDomain_documentation_en-US" xlink:label="lab_opk_LineOfCreditFacilityRevolvingCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Revolving Commitment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditFacilityRevolvingCommitmentDomain" xlink:href="opk-20220331.xsd#opk_LineOfCreditFacilityRevolvingCommitmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LineOfCreditFacilityRevolvingCommitmentDomain" xlink:to="lab_opk_LineOfCreditFacilityRevolvingCommitmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_07df1c5c-a749-474c-a21e-20532dfbcae3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_InterestIncomeNonoperating_fd096ffa-71e9-4050-9e50-8119709f7ec5_verboseLabel_en-US" xlink:label="lab_opk_InterestIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_opk_InterestIncomeNonoperating_label_en-US" xlink:label="lab_opk_InterestIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Nonoperating</link:label>
    <link:label id="lab_opk_InterestIncomeNonoperating_documentation_en-US" xlink:label="lab_opk_InterestIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestIncomeNonoperating" xlink:href="opk-20220331.xsd#opk_InterestIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_InterestIncomeNonoperating" xlink:to="lab_opk_InterestIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_526f08a0-5d99-462c-a945-2f4698da2949_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_12e7d6b6-3054-4192-bdd6-b77ff36233ba_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ad9734a1-5194-4e25-a267-a6dea57435a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_FrostRealEstateHoldingsLLCMember_c600e7f7-0281-4d67-a99b-0e40c87b8e8c_verboseLabel_en-US" xlink:label="lab_opk_FrostRealEstateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frost Real Estate Holdings LLC</link:label>
    <link:label id="lab_opk_FrostRealEstateHoldingsLLCMember_label_en-US" xlink:label="lab_opk_FrostRealEstateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frost Real Estate Holdings LLC [Member]</link:label>
    <link:label id="lab_opk_FrostRealEstateHoldingsLLCMember_documentation_en-US" xlink:label="lab_opk_FrostRealEstateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frost real estate holdings LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FrostRealEstateHoldingsLLCMember" xlink:href="opk-20220331.xsd#opk_FrostRealEstateHoldingsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_FrostRealEstateHoldingsLLCMember" xlink:to="lab_opk_FrostRealEstateHoldingsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c061b0b3-86d8-4ad1-9048-3cdb9534278a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_efcc5d52-1827-4e68-b6b7-357511a83546_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_44cb1772-1473-4aaf-9912-446761c9bb11_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_IncreaseDecreaseinForeignCurrencyMeasurement_e17ef6ea-059a-427e-bac5-85dd421ff633_terseLabel_en-US" xlink:label="lab_opk_IncreaseDecreaseinForeignCurrencyMeasurement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency measurement</link:label>
    <link:label id="lab_opk_IncreaseDecreaseinForeignCurrencyMeasurement_label_en-US" xlink:label="lab_opk_IncreaseDecreaseinForeignCurrencyMeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Foreign Currency Measurement</link:label>
    <link:label id="lab_opk_IncreaseDecreaseinForeignCurrencyMeasurement_documentation_en-US" xlink:label="lab_opk_IncreaseDecreaseinForeignCurrencyMeasurement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Foreign Currency Measurement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseinForeignCurrencyMeasurement" xlink:href="opk-20220331.xsd#opk_IncreaseDecreaseinForeignCurrencyMeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_IncreaseDecreaseinForeignCurrencyMeasurement" xlink:to="lab_opk_IncreaseDecreaseinForeignCurrencyMeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ae89e1bb-de21-4f4b-9024-4041a27920c5_totalLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_InCellDxIncMember_c804b1c0-643b-47ee-adfc-ed11dec1807f_terseLabel_en-US" xlink:label="lab_opk_InCellDxIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InCellDx, Inc</link:label>
    <link:label id="lab_opk_InCellDxIncMember_label_en-US" xlink:label="lab_opk_InCellDxIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InCellDx, Inc [Member]</link:label>
    <link:label id="lab_opk_InCellDxIncMember_documentation_en-US" xlink:label="lab_opk_InCellDxIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InCellDx, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InCellDxIncMember" xlink:href="opk-20220331.xsd#opk_InCellDxIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_InCellDxIncMember" xlink:to="lab_opk_InCellDxIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BancoDeSabadellMember_824ff679-02a2-458e-a62b-8feec54b7e26_terseLabel_en-US" xlink:label="lab_opk_BancoDeSabadellMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banco De Sabadell</link:label>
    <link:label id="lab_opk_BancoDeSabadellMember_label_en-US" xlink:label="lab_opk_BancoDeSabadellMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banco De Sabadell [Member]</link:label>
    <link:label id="lab_opk_BancoDeSabadellMember_documentation_en-US" xlink:label="lab_opk_BancoDeSabadellMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banco De Sabadell [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BancoDeSabadellMember" xlink:href="opk-20220331.xsd#opk_BancoDeSabadellMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BancoDeSabadellMember" xlink:to="lab_opk_BancoDeSabadellMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_0037502e-b8a3-49ce-80df-a61cef2d795d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_d1a13fcd-e0eb-4cb1-bf1f-3989cefd8a8a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products</link:label>
    <link:label id="lab_us-gaap_ProductMember_8a337514-b289-4ce5-986b-fe1906be73fb_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_6a7298a0-fcd4-4d28-b832-d320ffe4a2f8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid, net of refunds</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_6a9823b0-7088-45cc-8fac-45b1b658f8bc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_c98f75c8-6cde-462d-84d8-d9d8acaa515f_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NotesPayableAndOtherLongTermLiabilitiesMember_38d52732-dcb0-46fc-a8c5-f625f344a3bd_terseLabel_en-US" xlink:label="lab_opk_NotesPayableAndOtherLongTermLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable and Other Long-Term Liabilities</link:label>
    <link:label id="lab_opk_NotesPayableAndOtherLongTermLiabilitiesMember_label_en-US" xlink:label="lab_opk_NotesPayableAndOtherLongTermLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable And Other Long-Term Liabilities [Member]</link:label>
    <link:label id="lab_opk_NotesPayableAndOtherLongTermLiabilitiesMember_documentation_en-US" xlink:label="lab_opk_NotesPayableAndOtherLongTermLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable And Other Long-Term Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NotesPayableAndOtherLongTermLiabilitiesMember" xlink:href="opk-20220331.xsd#opk_NotesPayableAndOtherLongTermLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NotesPayableAndOtherLongTermLiabilitiesMember" xlink:to="lab_opk_NotesPayableAndOtherLongTermLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0ef3af33-a71a-4637-a3a5-b17ab17ecf9a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6983e68d-71b0-447d-b5ea-ce9678c5af38_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_58bdbbf2-87a6-4980-8be8-dedadae5f5ea_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_7f05e36b-8162-43d7-9c7e-f978d2b60bcb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_0292b271-7ebe-4158-977e-459fbdfb4b8e_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AssetsAndLiabilitiesLesseeTableTextBlock_4caabea0-dbd0-4c33-be1f-95527f51b661_terseLabel_en-US" xlink:label="lab_opk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Assets and Liabilities</link:label>
    <link:label id="lab_opk_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_opk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_opk_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_opk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="opk-20220331.xsd#opk_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_opk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_TestingTypeDomain_b68a21d4-5a0a-4626-953f-751cca5645f1_terseLabel_en-US" xlink:label="lab_opk_TestingTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing Type [Domain]</link:label>
    <link:label id="lab_opk_TestingTypeDomain_label_en-US" xlink:label="lab_opk_TestingTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing Type [Domain]</link:label>
    <link:label id="lab_opk_TestingTypeDomain_documentation_en-US" xlink:label="lab_opk_TestingTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TestingTypeDomain" xlink:href="opk-20220331.xsd#opk_TestingTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_TestingTypeDomain" xlink:to="lab_opk_TestingTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d68924f-1d15-43b9-9536-b91856c1e15f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_bd0c3fa3-81be-4401-ba50-969e05f049a9_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock - 8,655,082 and 8,655,082 shares at March 31, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_5772c497-2be3-49fe-8146-ead1bc032e1b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_695d91fa-05b5-46be-bb63-020bf2e06dfe_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_854c495c-df2e-4944-b823-def49b41f06d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LT notes payable included in long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AgreementAndPlanOfMergerMember_d51b1f91-a9e9-4903-b23d-ab15c29b4b01_terseLabel_en-US" xlink:label="lab_opk_AgreementAndPlanOfMergerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement and Plan of Merger</link:label>
    <link:label id="lab_opk_AgreementAndPlanOfMergerMember_label_en-US" xlink:label="lab_opk_AgreementAndPlanOfMergerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement and Plan of Merger [Member]</link:label>
    <link:label id="lab_opk_AgreementAndPlanOfMergerMember_documentation_en-US" xlink:label="lab_opk_AgreementAndPlanOfMergerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement and Plan of Merger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AgreementAndPlanOfMergerMember" xlink:href="opk-20220331.xsd#opk_AgreementAndPlanOfMergerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AgreementAndPlanOfMergerMember" xlink:to="lab_opk_AgreementAndPlanOfMergerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_dde67e32-f2f3-49d0-b597-8d0f10be15ec_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from investments in investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_9fd21a86-84a6-4f37-bb22-3b73b0ca646d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses from investments in investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_28bd782e-732e-4e69-94ea-afe1566b7838_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_8a811534-d819-4e2f-9e1d-c68737e368c7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e0741d9b-b70b-4941-b383-01bc9916bb4f_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable_4c581a61-fc75-4db0-a85a-d96a6d846a49_terseLabel_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable under debt agreement (in shares)</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable_label_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Maximum Shares Issuable</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable_documentation_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Maximum Shares Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable" xlink:href="opk-20220331.xsd#opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable" xlink:to="lab_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_5957004e-8f68-48df-a84d-65491ab2181d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_a222c858-f4d9-4642-aea2-1875f44f6d62_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bd6b873f-7520-41fb-a862-1123218ca6ea_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_729adc39-0d58-43a1-a56b-20bda44a0f56_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_37295d70-8b6b-449d-92a0-42ab7cc16484_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current litigation liability</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_686c7f46-7a15-4e48-9add-3b87829467b4_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage notes and other debt payables</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, by Current and Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember_ce848236-68c4-484c-8d57-fb1596b3f5b3_terseLabel_en-US" xlink:label="lab_opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than or equal to 50% of revolving commitment</link:label>
    <link:label id="lab_opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember_label_en-US" xlink:label="lab_opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Less Than or Equal To 50% Of Revolving Commitment [Member]</link:label>
    <link:label id="lab_opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember_documentation_en-US" xlink:label="lab_opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Less Than or Equal To 50% Of Revolving Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember" xlink:href="opk-20220331.xsd#opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember" xlink:to="lab_opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_0fa1443f-d69c-458b-b177-ed31b281ee1e_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7d1a452-27cc-41c4-a686-2fcfd9ab23bc_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_1e87336a-0395-4d87-9b24-6ac480550253_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NonDravetSyndromeProductsMember_ac00a76b-1520-4e79-a5d0-7b072deaa597_terseLabel_en-US" xlink:label="lab_opk_NonDravetSyndromeProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Dravet Syndrome Products</link:label>
    <link:label id="lab_opk_NonDravetSyndromeProductsMember_label_en-US" xlink:label="lab_opk_NonDravetSyndromeProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Dravet Syndrome Products [Member]</link:label>
    <link:label id="lab_opk_NonDravetSyndromeProductsMember_documentation_en-US" xlink:label="lab_opk_NonDravetSyndromeProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Dravet Syndrome Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NonDravetSyndromeProductsMember" xlink:href="opk-20220331.xsd#opk_NonDravetSyndromeProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NonDravetSyndromeProductsMember" xlink:to="lab_opk_NonDravetSyndromeProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_0cd14e0a-f0ad-4615-bea7-bb79a6964edc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Gains and Losses on Equity Securities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_22992c82-40cb-4d96-9adb-2ed2590e3959_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_ee41f3ac-b893-4730-87cf-831b6103a301_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying value of investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33dd7b5b-5311-40f6-a25a-2c9aa3626b08_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NIMSMember_d7ee9928-ff87-4aad-968a-1010a2077b3e_terseLabel_en-US" xlink:label="lab_opk_NIMSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIMS</link:label>
    <link:label id="lab_opk_NIMSMember_label_en-US" xlink:label="lab_opk_NIMSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIMS [Member]</link:label>
    <link:label id="lab_opk_NIMSMember_documentation_en-US" xlink:label="lab_opk_NIMSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIMS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NIMSMember" xlink:href="opk-20220331.xsd#opk_NIMSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NIMSMember" xlink:to="lab_opk_NIMSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_dadfa658-5f7e-4bd5-9854-c9c426b01a1a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of service revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_9d3c32d5-eb91-4a67-86ef-151264a147e1_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OPKOMexicoMember_3983c958-4ce1-4d0e-978b-85b963f266bd_terseLabel_en-US" xlink:label="lab_opk_OPKOMexicoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Mexico</link:label>
    <link:label id="lab_opk_OPKOMexicoMember_label_en-US" xlink:label="lab_opk_OPKOMexicoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Mexico [Member]</link:label>
    <link:label id="lab_opk_OPKOMexicoMember_documentation_en-US" xlink:label="lab_opk_OPKOMexicoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Mexico</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOMexicoMember" xlink:href="opk-20220331.xsd#opk_OPKOMexicoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OPKOMexicoMember" xlink:to="lab_opk_OPKOMexicoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_599fe784-954c-4a8c-8f10-72c53d8e7f90_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SecurityMember_d0d546a9-55a3-4429-9bb1-5e674547e3ce_terseLabel_en-US" xlink:label="lab_opk_SecurityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Bank</link:label>
    <link:label id="lab_opk_SecurityMember_label_en-US" xlink:label="lab_opk_SecurityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security [Member]</link:label>
    <link:label id="lab_opk_SecurityMember_documentation_en-US" xlink:label="lab_opk_SecurityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SecurityMember" xlink:href="opk-20220331.xsd#opk_SecurityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SecurityMember" xlink:to="lab_opk_SecurityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b839ed24-c80a-4a44-a48c-1c110c329e53_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_52defdd4-1ce9-470a-a6ad-c6309aea8da9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_d1d7deb2-6d63-4538-83c7-6a96f85f922a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5c9beb63-0300-4cf0-9aef-9445ed17dd00_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ChanceryCourtOfDelawareVsCompanyMember_8052b1bc-c137-402e-a9b0-cbebef0ad992_terseLabel_en-US" xlink:label="lab_opk_ChanceryCourtOfDelawareVsCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chancery Court of Delaware vs Company</link:label>
    <link:label id="lab_opk_ChanceryCourtOfDelawareVsCompanyMember_label_en-US" xlink:label="lab_opk_ChanceryCourtOfDelawareVsCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chancery Court of Delaware vs Company [Member]</link:label>
    <link:label id="lab_opk_ChanceryCourtOfDelawareVsCompanyMember_documentation_en-US" xlink:label="lab_opk_ChanceryCourtOfDelawareVsCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chancery Court of Delaware vs Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChanceryCourtOfDelawareVsCompanyMember" xlink:href="opk-20220331.xsd#opk_ChanceryCourtOfDelawareVsCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ChanceryCourtOfDelawareVsCompanyMember" xlink:to="lab_opk_ChanceryCourtOfDelawareVsCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_RoutineClinicalTestMember_a20f8aed-346c-41f7-a873-b7cfda31c963_terseLabel_en-US" xlink:label="lab_opk_RoutineClinicalTestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Routine Clinical Test</link:label>
    <link:label id="lab_opk_RoutineClinicalTestMember_label_en-US" xlink:label="lab_opk_RoutineClinicalTestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Routine Clinical Test [Member]</link:label>
    <link:label id="lab_opk_RoutineClinicalTestMember_documentation_en-US" xlink:label="lab_opk_RoutineClinicalTestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Routine Clinical Test</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RoutineClinicalTestMember" xlink:href="opk-20220331.xsd#opk_RoutineClinicalTestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_RoutineClinicalTestMember" xlink:to="lab_opk_RoutineClinicalTestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BusinessCombinationPeriodPriorToSigningOfAgreement_629250e2-b315-4147-94e7-c9e7e01492be_terseLabel_en-US" xlink:label="lab_opk_BusinessCombinationPeriodPriorToSigningOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period prior to signing of agreement</link:label>
    <link:label id="lab_opk_BusinessCombinationPeriodPriorToSigningOfAgreement_label_en-US" xlink:label="lab_opk_BusinessCombinationPeriodPriorToSigningOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Period Prior To Signing Of Agreement</link:label>
    <link:label id="lab_opk_BusinessCombinationPeriodPriorToSigningOfAgreement_documentation_en-US" xlink:label="lab_opk_BusinessCombinationPeriodPriorToSigningOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Period Prior To Signing Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationPeriodPriorToSigningOfAgreement" xlink:href="opk-20220331.xsd#opk_BusinessCombinationPeriodPriorToSigningOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BusinessCombinationPeriodPriorToSigningOfAgreement" xlink:to="lab_opk_BusinessCombinationPeriodPriorToSigningOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_91481366-72ea-4306-8017-c98f633aa87e_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTextBlock_dae19efc-5ff6-4ca7-ba5d-15b04be645cc_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock" xlink:to="lab_us-gaap_InvestmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8d5079c-96e2-404d-848e-33799d458fd4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_977e6113-c1d8-436d-b07f-49e8ab39b0cb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_RelatedPartyTransactionFutureContributionTerm_a09a1fd1-7aa6-4103-94b8-c2cf52097e51_terseLabel_en-US" xlink:label="lab_opk_RelatedPartyTransactionFutureContributionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party future contribution term</link:label>
    <link:label id="lab_opk_RelatedPartyTransactionFutureContributionTerm_label_en-US" xlink:label="lab_opk_RelatedPartyTransactionFutureContributionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Future Contribution, Term</link:label>
    <link:label id="lab_opk_RelatedPartyTransactionFutureContributionTerm_documentation_en-US" xlink:label="lab_opk_RelatedPartyTransactionFutureContributionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Future Contribution, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionFutureContributionTerm" xlink:href="opk-20220331.xsd#opk_RelatedPartyTransactionFutureContributionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_RelatedPartyTransactionFutureContributionTerm" xlink:to="lab_opk_RelatedPartyTransactionFutureContributionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BridgeLoanMember_92600c93-007f-495c-9a22-a93d2177a726_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swingline</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember" xlink:to="lab_us-gaap_BridgeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_7f20b494-27b1-4ff7-9a92-c86fdd7bbbb3_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock_5833960c-663d-4aba-98e2-374f1f89edcc_verboseLabel_en-US" xlink:label="lab_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Composition of Certain Financial Statement Captions</link:label>
    <link:label id="lab_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock_label_en-US" xlink:label="lab_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Composition of Certain Financial Statement Captions [Table Text Block]</link:label>
    <link:label id="lab_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock_documentation_en-US" xlink:label="lab_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Composition of certain financial statement captions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock" xlink:href="opk-20220331.xsd#opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock" xlink:to="lab_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetAbstract_c1664938-3c71-403b-bd01-8644a1e6be46_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net:</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract" xlink:to="lab_us-gaap_AccountsReceivableNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_7af73583-2950-47d8-afce-fd95d3cb5fcd_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_7a8b9975-c380-4cef-ad63-7ae9adef544d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2d73c9c6-dbf9-44e7-895b-8e313f1e7765_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities, principally contract liabilities, contingent consideration and lines of credit</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_40ebd8e4-5972-4788-823b-01a9aff245c6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3c840529-4396-433e-a3a5-81b67c9179ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PharmsynthezMember_e09a73d3-39da-441c-bf12-7c76a322c278_terseLabel_en-US" xlink:label="lab_opk_PharmsynthezMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmsynthez</link:label>
    <link:label id="lab_opk_PharmsynthezMember_label_en-US" xlink:label="lab_opk_PharmsynthezMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmsynthez [Member]</link:label>
    <link:label id="lab_opk_PharmsynthezMember_documentation_en-US" xlink:label="lab_opk_PharmsynthezMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmsynthez [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmsynthezMember" xlink:href="opk-20220331.xsd#opk_PharmsynthezMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PharmsynthezMember" xlink:to="lab_opk_PharmsynthezMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LeaderMedJointVentureMember_9c8f0385-f993-4410-bee8-53f88f8c0bab_terseLabel_en-US" xlink:label="lab_opk_LeaderMedJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LeaderMed Joint Venture</link:label>
    <link:label id="lab_opk_LeaderMedJointVentureMember_label_en-US" xlink:label="lab_opk_LeaderMedJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LeaderMed Joint Venture [Member]</link:label>
    <link:label id="lab_opk_LeaderMedJointVentureMember_documentation_en-US" xlink:label="lab_opk_LeaderMedJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LeaderMed Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LeaderMedJointVentureMember" xlink:href="opk-20220331.xsd#opk_LeaderMedJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LeaderMedJointVentureMember" xlink:to="lab_opk_LeaderMedJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_RegulatoryMilestonesMember_83963907-a417-41f8-a0bb-44dd0937e726_terseLabel_en-US" xlink:label="lab_opk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_opk_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_opk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_opk_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_opk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryMilestonesMember" xlink:href="opk-20220331.xsd#opk_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_RegulatoryMilestonesMember" xlink:to="lab_opk_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_e343ae6a-5da4-4ee2-948f-f269b2c9a00f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e0654251-737a-4e7a-b3dd-9a84532c15cf_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Principal Amounts, Unamortized Discount and Net Carrying Amounts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_f50374fe-01bd-4a15-a988-bae075921dfa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_601734c1-c3bd-4a8a-84ef-531861d16761_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1764e2b3-88d9-4413-b430-d77176f75522_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) per share, basic and diluted:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_19138d06-bd67-4209-813b-94e57a91a7e5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_e2169a4f-0d35-476b-b017-01a40deff6e9_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_f9200501-a9de-4d90-b11c-eba7669db9f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventorySupplies_270835b5-0245-4fe8-934d-49876bfeb8a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumable supplies</link:label>
    <link:label id="lab_us-gaap_OtherInventorySupplies_label_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Supplies, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventorySupplies" xlink:to="lab_us-gaap_OtherInventorySupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_464d743b-bb00-47fe-a837-a8aef73895e9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in foreign currency translation and other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_ba3bf32b-a194-4ec3-9c84-81d30d6f9c8c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_335d943d-64c1-4827-8c1e-ecccbc67d983_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gains and losses recognized during the period on equity securities still held at the reporting date</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SummaryOfSignificantAccountingPoliciesTable_5eb5d217-2f8a-4688-8f0c-202ed813dd79_terseLabel_en-US" xlink:label="lab_opk_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_opk_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_opk_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_opk_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_opk_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SummaryOfSignificantAccountingPoliciesTable" xlink:href="opk-20220331.xsd#opk_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_opk_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_604254df-5ce9-4899-a5f1-ec0c299ad8f4_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inter-segment sales</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0ba66de5-2457-48f1-9a94-3f078d04ce0e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_e2178721-50ed-4c17-b9ce-6464308cbef2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_04edce23-94d4-4f6e-812d-a73eb56ed6fb_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished products</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BankOfChileMember_9515ad12-8853-40b3-ba3a-2897bff16b82_verboseLabel_en-US" xlink:label="lab_opk_BankOfChileMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank of Chile</link:label>
    <link:label id="lab_opk_BankOfChileMember_label_en-US" xlink:label="lab_opk_BankOfChileMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank of Chile [Member]</link:label>
    <link:label id="lab_opk_BankOfChileMember_documentation_en-US" xlink:label="lab_opk_BankOfChileMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank of Chile.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BankOfChileMember" xlink:href="opk-20220331.xsd#opk_BankOfChileMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BankOfChileMember" xlink:to="lab_opk_BankOfChileMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_NeovascMember_855caa1b-407e-477c-b5c9-385b568fede5_terseLabel_en-US" xlink:label="lab_opk_NeovascMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neovasc</link:label>
    <link:label id="lab_opk_NeovascMember_label_en-US" xlink:label="lab_opk_NeovascMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neovasc [Member]</link:label>
    <link:label id="lab_opk_NeovascMember_documentation_en-US" xlink:label="lab_opk_NeovascMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neovasc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NeovascMember" xlink:href="opk-20220331.xsd#opk_NeovascMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_NeovascMember" xlink:to="lab_opk_NeovascMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_b36f66d9-6669-4ee2-ae51-fd4e579e8970_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, excluding current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_4ffe3d30-bebf-4cbb-8cff-d7022302e222_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_535781ab-e0da-430c-9abe-ad09f8d2cd47_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_6f737a4f-7885-45c3-a285-5fecece9fa46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3dcc7e3f-6769-4701-906d-34cc7ad51491_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a853d3ef-a7dc-4b55-87b8-f0e3b8bb781c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ConvertibleNotesMember_bdbb596d-86eb-43bc-9b95-8df4a1ce3fb8_terseLabel_en-US" xlink:label="lab_opk_ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_opk_ConvertibleNotesMember_label_en-US" xlink:label="lab_opk_ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes [Member]</link:label>
    <link:label id="lab_opk_ConvertibleNotesMember_documentation_en-US" xlink:label="lab_opk_ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ConvertibleNotesMember" xlink:href="opk-20220331.xsd#opk_ConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ConvertibleNotesMember" xlink:to="lab_opk_ConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_67c2d7b9-04ac-449f-9bd3-36eadcf7e42a_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:to="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4204e704-7a87-4e5b-a990-637a80710000_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_d7a91d95-b319-4f21-9872-9c9d39f0030b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by related parties (as a percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_7e8fa028-1c84-46cc-b782-b25a7722964b_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementPercentOfOutstandingShares_2c878555-8e09-4c6d-9887-911c31c23457_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementPercentOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding shares (as a percent)</link:label>
    <link:label id="lab_opk_CollaborativeArrangementPercentOfOutstandingShares_label_en-US" xlink:label="lab_opk_CollaborativeArrangementPercentOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Percent of Outstanding Shares</link:label>
    <link:label id="lab_opk_CollaborativeArrangementPercentOfOutstandingShares_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementPercentOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Percent of Outstanding Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementPercentOfOutstandingShares" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementPercentOfOutstandingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementPercentOfOutstandingShares" xlink:to="lab_opk_CollaborativeArrangementPercentOfOutstandingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments_03d071ee-4bf6-4860-8cad-50c9c9c304fd_terseLabel_en-US" xlink:label="lab_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional revenue-based milestones</link:label>
    <link:label id="lab_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments_label_en-US" xlink:label="lab_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Revenue-Based Milestone Payments</link:label>
    <link:label id="lab_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments_documentation_en-US" xlink:label="lab_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Revenue-Based Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments" xlink:href="opk-20220331.xsd#opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments" xlink:to="lab_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_cb0221b2-658d-4878-a599-f85c93e6df12_negatedLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net losses of equity method investees</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_131f9949-c1bd-4224-ab59-29dae2e66fd6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum_bcf3f0e4-0419-4c8b-b973-42d58b92d7e0_terseLabel_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum conversion notice</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum_label_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Notice Threshold, Maximum</link:label>
    <link:label id="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum_documentation_en-US" xlink:label="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Notice Threshold, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum" xlink:href="opk-20220331.xsd#opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum" xlink:to="lab_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_OPKOHealthEuropeMember_2c55dc5b-e276-4e7f-b475-e644a3567f7c_terseLabel_en-US" xlink:label="lab_opk_OPKOHealthEuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Health Europe</link:label>
    <link:label id="lab_opk_OPKOHealthEuropeMember_8e522eb5-2ea9-4ad2-8f4a-cea6546fd3f2_verboseLabel_en-US" xlink:label="lab_opk_OPKOHealthEuropeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Health Europe</link:label>
    <link:label id="lab_opk_OPKOHealthEuropeMember_label_en-US" xlink:label="lab_opk_OPKOHealthEuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Health Europe [Member]</link:label>
    <link:label id="lab_opk_OPKOHealthEuropeMember_documentation_en-US" xlink:label="lab_opk_OPKOHealthEuropeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPKO Health Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOHealthEuropeMember" xlink:href="opk-20220331.xsd#opk_OPKOHealthEuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_OPKOHealthEuropeMember" xlink:to="lab_opk_OPKOHealthEuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_e9f18649-f626-462c-afbe-f0c1e2948029_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_099ba602-f455-4172-b86f-5aab8c6ee40f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f2cd4154-233d-4ca5-ab0a-c465f44ae901_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_1b25cfa0-a4f7-454c-a15d-87165d3f48ee_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: inventory reserve</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SalesMilestonesMember_a3e7fbed-3d89-4ca3-bbe1-4e312bd27321_terseLabel_en-US" xlink:label="lab_opk_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones</link:label>
    <link:label id="lab_opk_SalesMilestonesMember_label_en-US" xlink:label="lab_opk_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:label id="lab_opk_SalesMilestonesMember_documentation_en-US" xlink:label="lab_opk_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesMilestonesMember" xlink:href="opk-20220331.xsd#opk_SalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SalesMilestonesMember" xlink:to="lab_opk_SalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c9f5b1d0-ccf2-430d-ab2c-bf0eb52b5823_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_221cf03f-0943-49f0-b0da-3c8e7d7988b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_770f39e5-d6ff-42a2-b395-e4c298f1c681_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SummaryOfSignificantAccountingPoliciesLineItems_684e10bb-3ccf-41f5-ae09-a5af879a613a_terseLabel_en-US" xlink:label="lab_opk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_opk_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_opk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_opk_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_opk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="opk-20220331.xsd#opk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_opk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_d34fde27-e0c3-4d23-9081-a6cac072c055_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_13012a27-755d-4e03-9142-46cedbc130ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_10cdc6c8-7677-4f48-8579-c3810f0b916a_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ee1ec4ae-9262-4daa-bc1d-d92a8ca5aab4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_78e0f509-e086-4e93-9e0d-4241de9d12db_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_54f5bc98-a3b8-4ef3-8224-4900a8c07097_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4289ca56-279d-4f32-bb44-226ace441e7e_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_8fea88bd-db9f-4377-b66b-66c4e3981d3e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption period one</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_966bba9a-d546-4b76-acd9-0975f5ecea07_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_672b9327-c89b-412a-921c-80a1814e982f_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_47454139-73a7-46e1-af79-2c3935d4db7f_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_6429120b-e0ca-4360-a24b-77463301d210_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_b40c4399-522f-4276-89ef-ed8d8c1bd0ce_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ed6ec8ec-ce57-4e41-a909-bcbf29423ec8_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6d3af374-43f5-4b5d-8c36-f50540b5bcc1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_1ff96a6a-9dad-4171-bc14-d93abea56f80_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c904d7d1-a023-4dda-8f1d-f029628518e7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_TaxesRecoverableCurrent_92b5ce1b-0705-4df0-bddf-1da5aec5e0cc_terseLabel_en-US" xlink:label="lab_opk_TaxesRecoverableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes recoverable</link:label>
    <link:label id="lab_opk_TaxesRecoverableCurrent_label_en-US" xlink:label="lab_opk_TaxesRecoverableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Recoverable, Current</link:label>
    <link:label id="lab_opk_TaxesRecoverableCurrent_documentation_en-US" xlink:label="lab_opk_TaxesRecoverableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Recoverable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TaxesRecoverableCurrent" xlink:href="opk-20220331.xsd#opk_TaxesRecoverableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_TaxesRecoverableCurrent" xlink:to="lab_opk_TaxesRecoverableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_895f5c7a-e69c-4518-94b1-ac5dfc6cab91_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition and shipping and handling costs</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a3bdff8c-da70-4abc-bb87-9e6e238d0d04_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of Common Stock options and warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_10c22748-ddeb-4aba-9ebc-48900180c33a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment_971fbe92-de20-498c-a0bd-eed1c237faab_terseLabel_en-US" xlink:label="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock issued for stock warrant and stock options exercised (in shares)</link:label>
    <link:label id="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment_label_en-US" xlink:label="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Options and Warrants Exercised, Net of Shares Surrendered in Lieu of Cash Payment</link:label>
    <link:label id="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment_documentation_en-US" xlink:label="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock issued for stock warrant and stock options exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" xlink:href="opk-20220331.xsd#opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" xlink:to="lab_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_InProcessResearchandDevelopment_5c714074-3557-4111-aa35-6a216ba02522_terseLabel_en-US" xlink:label="lab_opk_InProcessResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_opk_InProcessResearchandDevelopment_d3bbaeef-95fd-4b5a-9972-ea3b96311aba_negatedTerseLabel_en-US" xlink:label="lab_opk_InProcessResearchandDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:label id="lab_opk_InProcessResearchandDevelopment_label_en-US" xlink:label="lab_opk_InProcessResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:label id="lab_opk_InProcessResearchandDevelopment_documentation_en-US" xlink:label="lab_opk_InProcessResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InProcessResearchandDevelopment" xlink:href="opk-20220331.xsd#opk_InProcessResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_InProcessResearchandDevelopment" xlink:to="lab_opk_InProcessResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets_17701c39-9575-44d8-b071-84ffaa31d3b3_terseLabel_en-US" xlink:label="lab_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, in-process research and development and other intangible assets acquired</link:label>
    <link:label id="lab_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets_label_en-US" xlink:label="lab_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets</link:label>
    <link:label id="lab_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets_documentation_en-US" xlink:label="lab_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" xlink:href="opk-20220331.xsd#opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" xlink:to="lab_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_6fbab8c7-a247-4ac8-8afb-cc5b2a737eb0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_f5ec4582-3b44-41eb-a473-6b56ba71a52f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_fda49c7e-4bf5-40ae-ac4c-4989ce42a2de_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_StrategicAlliancesTextBlock_c83505c0-a92d-4625-a404-59a84915e531_terseLabel_en-US" xlink:label="lab_opk_StrategicAlliancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STRATEGIC ALLIANCES</link:label>
    <link:label id="lab_opk_StrategicAlliancesTextBlock_label_en-US" xlink:label="lab_opk_StrategicAlliancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliances [Text Block]</link:label>
    <link:label id="lab_opk_StrategicAlliancesTextBlock_documentation_en-US" xlink:label="lab_opk_StrategicAlliancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliances [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StrategicAlliancesTextBlock" xlink:href="opk-20220331.xsd#opk_StrategicAlliancesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_StrategicAlliancesTextBlock" xlink:to="lab_opk_StrategicAlliancesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e0945a8e-885b-4bf4-81be-0545514f9193_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_7b5c921b-1c09-4f70-b20b-ddd86f7c159e_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:to="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_d349be35-a19a-48e8-a676-19411ceb8d9b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_877ae70b-0843-458e-bcd1-99b7abd278c5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f3683395-8bc1-458a-b483-a78283d7ba79_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_a25c2b8b-f414-4423-bc39-987b3f5a7f23_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional investment in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_80279735-547b-40c9-a1ab-ab2cf4a930b1_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory received but not invoiced</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_373a3894-962b-410b-86aa-e7638ead0bf7_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_78ba6326-5dff-4df5-90d9-c2a9df3b4300_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3d7f8625-35ac-4f75-b1e5-bc820278ddd0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6d0c8489-7d9b-447f-b5ba-16d95dd103d6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementSalesMilestonePayment_1bf623a5-3958-471a-a642-dbc743ddbb7e_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments</link:label>
    <link:label id="lab_opk_CollaborativeArrangementSalesMilestonePayment_label_en-US" xlink:label="lab_opk_CollaborativeArrangementSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales Milestone Payment</link:label>
    <link:label id="lab_opk_CollaborativeArrangementSalesMilestonePayment_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementSalesMilestonePayment" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementSalesMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementSalesMilestonePayment" xlink:to="lab_opk_CollaborativeArrangementSalesMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_136d9673-7e6a-4332-9302-8e8e9a33af3b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_c67613e1-68ba-482c-8a7b-1848084c84a0_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_802317eb-ae3a-4d27-84b0-d760ae57f2ad_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6de63949-ec10-40ca-bfd4-81052e34dcc8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_StatesCitiesAndOtherMunicipalitiesMember_e82790fa-6684-4aef-adeb-456c0cc41ce8_terseLabel_en-US" xlink:label="lab_opk_StatesCitiesAndOtherMunicipalitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">States, Cities and Other Municipalities</link:label>
    <link:label id="lab_opk_StatesCitiesAndOtherMunicipalitiesMember_label_en-US" xlink:label="lab_opk_StatesCitiesAndOtherMunicipalitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">States, Cities and Other Municipalities [Member]</link:label>
    <link:label id="lab_opk_StatesCitiesAndOtherMunicipalitiesMember_documentation_en-US" xlink:label="lab_opk_StatesCitiesAndOtherMunicipalitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">States, Cities and Other Municipalities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StatesCitiesAndOtherMunicipalitiesMember" xlink:href="opk-20220331.xsd#opk_StatesCitiesAndOtherMunicipalitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_StatesCitiesAndOtherMunicipalitiesMember" xlink:to="lab_opk_StatesCitiesAndOtherMunicipalitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_22a2f290-86cb-472d-b00e-b9b3854c9fad_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, underlying equity in net assets</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Underlying Equity in Net Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:to="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45a3bda4-614b-4df6-94d3-e7b61ac00389_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_36a97cd6-421b-442a-9867-306325580acb_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f98d10f6-1e16-4611-83aa-9b100cbf23c9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_ScotiabankMember_51f07d46-4502-43b4-9122-10ec9afd6d93_terseLabel_en-US" xlink:label="lab_opk_ScotiabankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scotiabank</link:label>
    <link:label id="lab_opk_ScotiabankMember_label_en-US" xlink:label="lab_opk_ScotiabankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scotiabank [Member]</link:label>
    <link:label id="lab_opk_ScotiabankMember_documentation_en-US" xlink:label="lab_opk_ScotiabankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scotiabank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ScotiabankMember" xlink:href="opk-20220331.xsd#opk_ScotiabankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_ScotiabankMember" xlink:to="lab_opk_ScotiabankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_db2e0594-edb6-4d49-a5bf-e5a750f99ecf_terseLabel_en-US" xlink:label="lab_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:label id="lab_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="opk-20220331.xsd#opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_20c403e2-48e7-4d31-b190-4a2528608b6e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_43171ebc-ab56-4fbe-9bfd-9198cad7eb88_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_ef7316f5-d44c-415b-811e-4f19f5a87368_verboseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Elimination</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_c4da3f6d-b22b-4914-8ff0-490cce4fac8f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_ba8acc23-7332-410b-9112-96e00d079384_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact_6c93af6a-4f91-4f5e-8458-2618b41a6562_terseLabel_en-US" xlink:label="lab_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency impact</link:label>
    <link:label id="lab_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact_label_en-US" xlink:label="lab_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Currency Impact</link:label>
    <link:label id="lab_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact_documentation_en-US" xlink:label="lab_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Currency Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact" xlink:href="opk-20220331.xsd#opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact" xlink:to="lab_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_VBIVaccinesIncMember_167fdd9d-0582-47c8-8272-8eabd75c91ff_terseLabel_en-US" xlink:label="lab_opk_VBIVaccinesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VBI Vaccines Inc</link:label>
    <link:label id="lab_opk_VBIVaccinesIncMember_label_en-US" xlink:label="lab_opk_VBIVaccinesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VBI Vaccines Inc [Member]</link:label>
    <link:label id="lab_opk_VBIVaccinesIncMember_documentation_en-US" xlink:label="lab_opk_VBIVaccinesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VBI Vaccines Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_VBIVaccinesIncMember" xlink:href="opk-20220331.xsd#opk_VBIVaccinesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_VBIVaccinesIncMember" xlink:to="lab_opk_VBIVaccinesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_f81bf146-76f2-4d24-99b6-d5d2da095472_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash out flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b32f81ec-4c0f-4ccc-b42f-7e2090d78c38_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit&#160;line capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_7a3b0b0b-2a38-40e8-b3c0-a5611e6a51a6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Carrying Value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Financial Statement, Reported Amounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5336c3c7-4eb6-4719-aa3c-31551325c3e5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_3d952d7e-de1b-4413-81f2-fc53975e5e76_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_9b44566a-65f1-4b97-929d-ffb20176a1be_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b81133ea-a309-4151-8a58-f4e41f3c6b0e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember_32abfe62-275c-4b6b-b941-1274c566c35c_terseLabel_en-US" xlink:label="lab_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses. Unrealized (losses) on forward contracts are recorded in Accrued expenses.</link:label>
    <link:label id="lab_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember_label_en-US" xlink:label="lab_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets (Accrued Expenses) [Member]</link:label>
    <link:label id="lab_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember_documentation_en-US" xlink:label="lab_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets (Accrued Expenses) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" xlink:href="opk-20220331.xsd#opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" xlink:to="lab_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e757fa35-9181-4851-bdb7-0f61ba56bf5b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_834a2236-1b0f-4247-9d68-a6c9e4299041_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_91fc3aee-a1fa-4593-bfab-1892ca3c2e24_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 1, 2022 through December 31, 2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_9f61c01c-45b3-48b7-8f58-d8c46cfbca73_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_da99bb8c-6825-4b95-94d6-a584fd43c8a7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_9a010a2f-33b5-4184-be39-67ceac784179_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b25122b5-57af-421d-b0ba-fa2b678012ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_c16c8769-a569-4a3a-9ea1-a3430ae16b2d_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Method, Carrying Value and Underlying Equity in Net Assets of Unconsolidated Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTableTextBlock" xlink:to="lab_us-gaap_InvestmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5522e309-7283-48f8-a3a3-006d2b570b07_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently adopted accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_SharesReceivedAsGift_401ab3c8-c207-4c0f-914d-5419448cdf96_terseLabel_en-US" xlink:label="lab_opk_SharesReceivedAsGift" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received as a gift (in shares)</link:label>
    <link:label id="lab_opk_SharesReceivedAsGift_label_en-US" xlink:label="lab_opk_SharesReceivedAsGift" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received As Gift</link:label>
    <link:label id="lab_opk_SharesReceivedAsGift_documentation_en-US" xlink:label="lab_opk_SharesReceivedAsGift" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received As Gift</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedAsGift" xlink:href="opk-20220331.xsd#opk_SharesReceivedAsGift"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_SharesReceivedAsGift" xlink:to="lab_opk_SharesReceivedAsGift" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAbstract_fd2b1264-bebc-4e79-a5b6-f3fccdf28894_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Unclassified [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAbstract" xlink:to="lab_us-gaap_LongTermDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_585127d3-60f9-40d2-99ae-d41e84bfd28c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_0e8f3755-b568-4b3c-9a19-bbc4cec3c09c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_bf56689f-456d-4a47-9b9c-23810ae23efc_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_7f75af76-6d4a-4eba-8f88-30590e10024e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement_370be94a-4a48-4076-a9c5-c5529641dec2_terseLabel_en-US" xlink:label="lab_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading day period prior to closing date</link:label>
    <link:label id="lab_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement_label_en-US" xlink:label="lab_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Trading Day Period Prior To Signing Of Agreement</link:label>
    <link:label id="lab_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement_documentation_en-US" xlink:label="lab_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Trading Day Period Prior To Signing Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement" xlink:href="opk-20220331.xsd#opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement" xlink:to="lab_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_9c45e084-9027-47f6-a14c-b07e6bc56dd7_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases long-term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_8cbfba97-5518-4683-a433-1bfdd128658c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares_49075b3d-4eb4-4754-86aa-55944e77d13d_terseLabel_en-US" xlink:label="lab_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone payments (in shares)</link:label>
    <link:label id="lab_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares_label_en-US" xlink:label="lab_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Development Milestone Payment, Shares</link:label>
    <link:label id="lab_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares_documentation_en-US" xlink:label="lab_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Development Milestone Payment, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementDevelopmentMilestonePaymentShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares" xlink:to="lab_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4ea07eaa-3ed1-4fc4-97a8-e1d79b87183f_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_848f49ba-8209-425d-af43-01ef86ff99e9_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_52b3b2af-4e92-4725-8d0d-aa446b3c43af_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_fffb86d9-f8ba-4b94-9deb-26d6c67c2545_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_416c0980-ca22-43eb-b986-9400b0ab6620_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_c802f220-4c9a-475a-afe8-b178105226c0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_0c833a34-2279-42b6-bb42-ff80b8fb4d31_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_0d2e8249-aaad-4d14-a8d2-6c43d412e986_verboseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contracts</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_33dba5e6-9a45-486f-9278-5c06db1ec490_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contracts</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_96542f66-529b-41e5-a43d-627760c9a4fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_914ffbbb-678b-492c-8762-37db2295ad22_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_ab456646-6902-4f77-953d-5b73ce306cc8_terseLabel_en-US" xlink:label="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_label_en-US" xlink:label="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Warrants and Options, and Variable Interest Entities [Line Items]</link:label>
    <link:label id="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_documentation_en-US" xlink:label="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Warrants and Options, and Variable Interest Entities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" xlink:to="lab_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_bbe204f2-725c-4a92-abb7-4b92c5b879ec_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values and Presentation of Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_85ee7316-50c5-4121-8717-5c76900c00f2_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technologies</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_d08f77fe-b1c1-4976-8a4c-1f9669ba2b71_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_59e2ba2e-ece4-4570-8ede-f3d18027373a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities and Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_MilestoneDomain_3e53c6c8-afa0-49d1-8932-813fb958f4cd_terseLabel_en-US" xlink:label="lab_opk_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_opk_MilestoneDomain_label_en-US" xlink:label="lab_opk_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_opk_MilestoneDomain_documentation_en-US" xlink:label="lab_opk_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MilestoneDomain" xlink:href="opk-20220331.xsd#opk_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_MilestoneDomain" xlink:to="lab_opk_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_359c6844-a30a-4e7f-bf66-4fb42c2ee94f_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_8cb3f326-f85a-4d5e-909d-00b3141493c9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_982fde72-13ed-41c9-bd73-a163a2ad6b93_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_9f42c0ea-f46e-4854-9750-2322169789da_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_2f4d65ec-355b-4e6c-90e7-5676a69618a3_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_opk_AutomobilesandAircraftMember_ca30b134-a622-42b2-bdfb-a7c926bf2350_terseLabel_en-US" xlink:label="lab_opk_AutomobilesandAircraftMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automobiles and Aircraft</link:label>
    <link:label id="lab_opk_AutomobilesandAircraftMember_label_en-US" xlink:label="lab_opk_AutomobilesandAircraftMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automobiles and Aircraft [Member]</link:label>
    <link:label id="lab_opk_AutomobilesandAircraftMember_documentation_en-US" xlink:label="lab_opk_AutomobilesandAircraftMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automobiles and Aircraft [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AutomobilesandAircraftMember" xlink:href="opk-20220331.xsd#opk_AutomobilesandAircraftMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_opk_AutomobilesandAircraftMember" xlink:to="lab_opk_AutomobilesandAircraftMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0e15734-3f8c-46aa-ba73-af44e880654f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_ad8b9503-8e4a-4199-9e47-0a4fc51f7aa8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b3407ace-e015-4f1b-8439-204c65d479bb_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>opk-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b1bc5044-98fa-41ae-b2d0-b9b87eb185ce,g:64b4497f-89ba-4c5f-8ed3-b19012dfc871-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.opko.com/role/COVERPAGE" xlink:type="simple" xlink:href="opk-20220331.xsd#COVERPAGE"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/COVERPAGE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_22d0a993-cfcd-451f-9bb9-cc6bdb16cd75" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_DocumentType_22d0a993-cfcd-451f-9bb9-cc6bdb16cd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_baddcd67-9beb-4f17-bc7f-485417a74ff5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_DocumentQuarterlyReport_baddcd67-9beb-4f17-bc7f-485417a74ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6bedcce1-a32c-41db-b56e-ee9c7532a472" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_DocumentPeriodEndDate_6bedcce1-a32c-41db-b56e-ee9c7532a472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7a7539d7-f601-43e5-aee1-220dd931781e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_DocumentTransitionReport_7a7539d7-f601-43e5-aee1-220dd931781e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f488e0be-bff7-4a05-9b3b-22d71b6c066c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityFileNumber_f488e0be-bff7-4a05-9b3b-22d71b6c066c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1444f609-69f5-49ad-80c1-b3e20a51e3f1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityRegistrantName_1444f609-69f5-49ad-80c1-b3e20a51e3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_939a3e4c-c43b-48cf-9659-8ed83a9305b2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityIncorporationStateCountryCode_939a3e4c-c43b-48cf-9659-8ed83a9305b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ff3ba4ae-922c-4246-8912-de7f47939763" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityTaxIdentificationNumber_ff3ba4ae-922c-4246-8912-de7f47939763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c7b80bb6-3293-470e-a8a3-d6afe2f35dcd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityAddressAddressLine1_c7b80bb6-3293-470e-a8a3-d6afe2f35dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fe0b985b-fbdd-4da2-8671-e0a40a5d9bbc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityAddressCityOrTown_fe0b985b-fbdd-4da2-8671-e0a40a5d9bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d438d6fd-6de6-40e3-95e2-d2a7985762e2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityAddressStateOrProvince_d438d6fd-6de6-40e3-95e2-d2a7985762e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_33f39793-0ee4-401a-8ccf-caf2d0b73bd5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityAddressPostalZipCode_33f39793-0ee4-401a-8ccf-caf2d0b73bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ac5c2b00-0ca2-4cdc-91cf-05185ad95191" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_CityAreaCode_ac5c2b00-0ca2-4cdc-91cf-05185ad95191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e469bd61-9148-4483-95ba-3de43185d18f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_LocalPhoneNumber_e469bd61-9148-4483-95ba-3de43185d18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d4d05d74-8da5-4098-92ca-88f865c11edc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_Security12bTitle_d4d05d74-8da5-4098-92ca-88f865c11edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2ebefc06-4199-4edc-b89c-20e87e6edb81" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_TradingSymbol_2ebefc06-4199-4edc-b89c-20e87e6edb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b8d47933-7986-4b37-8a17-fb554d0c7fbf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_SecurityExchangeName_b8d47933-7986-4b37-8a17-fb554d0c7fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2999b2ea-ac35-4354-99ad-e9fe97e7db6d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityCurrentReportingStatus_2999b2ea-ac35-4354-99ad-e9fe97e7db6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4ea908a3-5751-42bb-a24b-fcc4514f67a5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityInteractiveDataCurrent_4ea908a3-5751-42bb-a24b-fcc4514f67a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6c465b5c-dbdf-408e-99c7-6b06ee98a1c2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityFilerCategory_6c465b5c-dbdf-408e-99c7-6b06ee98a1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_69860398-39f7-4b1a-9a1f-06ec4c82c46f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntitySmallBusiness_69860398-39f7-4b1a-9a1f-06ec4c82c46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_316bc268-c3be-448c-aa8f-b0b847b6707f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityEmergingGrowthCompany_316bc268-c3be-448c-aa8f-b0b847b6707f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3a1606f2-374d-44b9-9a54-16f8650fc667" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityShellCompany_3a1606f2-374d-44b9-9a54-16f8650fc667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f98784fa-2dc6-4b40-b2e9-c67967cc7328" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f98784fa-2dc6-4b40-b2e9-c67967cc7328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a82f7c8a-a4d9-488a-88a8-4fd27e1f7411" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_EntityCentralIndexKey_a82f7c8a-a4d9-488a-88a8-4fd27e1f7411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_86ac0d6f-3ee5-46a9-8dc2-55874744f3e0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_AmendmentFlag_86ac0d6f-3ee5-46a9-8dc2-55874744f3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f433ef81-80a8-43e1-98a0-09a3adaa030c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_DocumentFiscalYearFocus_f433ef81-80a8-43e1-98a0-09a3adaa030c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0dbeb0b1-18f8-4b71-8ca0-8ed616743e38" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0dbeb0b1-18f8-4b71-8ca0-8ed616743e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_edd6f60b-7573-4aaf-a858-c86685055bf2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2bdf3c3-5b87-4fe2-a7cd-050174f0f500" xlink:to="loc_dei_CurrentFiscalYearEndDate_edd6f60b-7573-4aaf-a858-c86685055bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="opk-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_158303a3-36d4-4aeb-8461-f296d1568941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_88372a8c-c496-4fa8-9087-dc4b0d8b4c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_158303a3-36d4-4aeb-8461-f296d1568941" xlink:to="loc_us-gaap_AssetsAbstract_88372a8c-c496-4fa8-9087-dc4b0d8b4c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_288e6a47-121b-42d3-a80b-a9c856e4c897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_88372a8c-c496-4fa8-9087-dc4b0d8b4c7c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_288e6a47-121b-42d3-a80b-a9c856e4c897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07ccc2b8-a5d3-44da-88bc-9a75a6704914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_288e6a47-121b-42d3-a80b-a9c856e4c897" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07ccc2b8-a5d3-44da-88bc-9a75a6704914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ec08ede8-0248-4a0f-aa6b-ecc2f89d30b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_288e6a47-121b-42d3-a80b-a9c856e4c897" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ec08ede8-0248-4a0f-aa6b-ecc2f89d30b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cffcc1b9-3a78-4bfe-bb42-3c2495416e31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_288e6a47-121b-42d3-a80b-a9c856e4c897" xlink:to="loc_us-gaap_InventoryNet_cffcc1b9-3a78-4bfe-bb42-3c2495416e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ef556937-3ee9-4a4c-893b-5cc965fe151f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_288e6a47-121b-42d3-a80b-a9c856e4c897" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ef556937-3ee9-4a4c-893b-5cc965fe151f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_69b6e81e-bba3-482a-9d24-76a1b383c8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_288e6a47-121b-42d3-a80b-a9c856e4c897" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_69b6e81e-bba3-482a-9d24-76a1b383c8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9c4e5821-8580-421e-8ff9-1056929268c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_288e6a47-121b-42d3-a80b-a9c856e4c897" xlink:to="loc_us-gaap_AssetsCurrent_9c4e5821-8580-421e-8ff9-1056929268c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4691c57f-861d-4ade-abbf-18bfc368b27e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_88372a8c-c496-4fa8-9087-dc4b0d8b4c7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4691c57f-861d-4ade-abbf-18bfc368b27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e1216616-bdb3-47b5-99d4-ebcf55c2f7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_88372a8c-c496-4fa8-9087-dc4b0d8b4c7c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e1216616-bdb3-47b5-99d4-ebcf55c2f7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InProcessResearchandDevelopment_10b1607f-707c-46da-a030-a0229e05dc4c" xlink:href="opk-20220331.xsd#opk_InProcessResearchandDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_88372a8c-c496-4fa8-9087-dc4b0d8b4c7c" xlink:to="loc_opk_InProcessResearchandDevelopment_10b1607f-707c-46da-a030-a0229e05dc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8343735d-3ee2-4b4d-9397-82fec4d07419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_88372a8c-c496-4fa8-9087-dc4b0d8b4c7c" xlink:to="loc_us-gaap_Goodwill_8343735d-3ee2-4b4d-9397-82fec4d07419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_0c116ec8-b18a-4477-a897-e539f309d6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_88372a8c-c496-4fa8-9087-dc4b0d8b4c7c" xlink:to="loc_us-gaap_LongTermInvestments_0c116ec8-b18a-4477-a897-e539f309d6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e486cd96-5bdf-42cd-af1a-03d1e6dbe956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_88372a8c-c496-4fa8-9087-dc4b0d8b4c7c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e486cd96-5bdf-42cd-af1a-03d1e6dbe956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d49e021a-636e-4828-aead-37e80966b243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_88372a8c-c496-4fa8-9087-dc4b0d8b4c7c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d49e021a-636e-4828-aead-37e80966b243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e3d9f330-2f1a-42f0-af09-88aca0e63d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_88372a8c-c496-4fa8-9087-dc4b0d8b4c7c" xlink:to="loc_us-gaap_Assets_e3d9f330-2f1a-42f0-af09-88aca0e63d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_69f4f235-197a-440f-ba48-c8166606f6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_158303a3-36d4-4aeb-8461-f296d1568941" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_69f4f235-197a-440f-ba48-c8166606f6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_e28a7541-08a2-4d56-853b-d211389c6aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_69f4f235-197a-440f-ba48-c8166606f6b6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_e28a7541-08a2-4d56-853b-d211389c6aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_948695d4-4542-41a1-999e-01c06e2a9f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e28a7541-08a2-4d56-853b-d211389c6aa5" xlink:to="loc_us-gaap_AccountsPayableCurrent_948695d4-4542-41a1-999e-01c06e2a9f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2aabdc28-1ddd-4ce6-a55f-37a1f690a7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e28a7541-08a2-4d56-853b-d211389c6aa5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2aabdc28-1ddd-4ce6-a55f-37a1f690a7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c5344c31-0456-4c01-b940-bf26df96f316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e28a7541-08a2-4d56-853b-d211389c6aa5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c5344c31-0456-4c01-b940-bf26df96f316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_ec280cf1-6fe1-48de-a53c-3eac381e2ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e28a7541-08a2-4d56-853b-d211389c6aa5" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_ec280cf1-6fe1-48de-a53c-3eac381e2ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_a9a3d05c-4fec-4f64-ac97-94b502666178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e28a7541-08a2-4d56-853b-d211389c6aa5" xlink:to="loc_us-gaap_LinesOfCreditCurrent_a9a3d05c-4fec-4f64-ac97-94b502666178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d35af0a4-c782-416a-9e68-56cb1851ef41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e28a7541-08a2-4d56-853b-d211389c6aa5" xlink:to="loc_us-gaap_LiabilitiesCurrent_d35af0a4-c782-416a-9e68-56cb1851ef41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4fcbee86-51c1-4f4e-999f-5638f2a9f56f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_69f4f235-197a-440f-ba48-c8166606f6b6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4fcbee86-51c1-4f4e-999f-5638f2a9f56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_3a19e4e3-f19a-4ddc-99f1-733f3aa3142a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_69f4f235-197a-440f-ba48-c8166606f6b6" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_3a19e4e3-f19a-4ddc-99f1-733f3aa3142a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_55223361-a1be-45b4-be61-d9ae3302931e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_69f4f235-197a-440f-ba48-c8166606f6b6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_55223361-a1be-45b4-be61-d9ae3302931e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b6479665-5b9a-4fdf-9f0a-3510a196377b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_69f4f235-197a-440f-ba48-c8166606f6b6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b6479665-5b9a-4fdf-9f0a-3510a196377b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_7a6cb38d-1645-442e-926d-ff7d3f539506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_69f4f235-197a-440f-ba48-c8166606f6b6" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_7a6cb38d-1645-442e-926d-ff7d3f539506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_76320139-bf98-4380-9990-03043d51c81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_69f4f235-197a-440f-ba48-c8166606f6b6" xlink:to="loc_us-gaap_Liabilities_76320139-bf98-4380-9990-03043d51c81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_dc9d3412-f77a-47c9-8d7f-0570569df324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_69f4f235-197a-440f-ba48-c8166606f6b6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_dc9d3412-f77a-47c9-8d7f-0570569df324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f6470f30-b5f4-4170-8537-a9cdd0443fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc9d3412-f77a-47c9-8d7f-0570569df324" xlink:to="loc_us-gaap_CommonStockValue_f6470f30-b5f4-4170-8537-a9cdd0443fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_da303e8f-9232-469b-9b24-798fc4fa86f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc9d3412-f77a-47c9-8d7f-0570569df324" xlink:to="loc_us-gaap_TreasuryStockValue_da303e8f-9232-469b-9b24-798fc4fa86f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cfe6ec11-acef-4a28-8a97-2b8aed4a58f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc9d3412-f77a-47c9-8d7f-0570569df324" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cfe6ec11-acef-4a28-8a97-2b8aed4a58f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_afb60728-ab92-4fd4-83dd-032244cf929f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc9d3412-f77a-47c9-8d7f-0570569df324" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_afb60728-ab92-4fd4-83dd-032244cf929f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_be96a063-5e2b-4ed4-b35d-45f2883d901c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc9d3412-f77a-47c9-8d7f-0570569df324" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_be96a063-5e2b-4ed4-b35d-45f2883d901c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0705ec49-5fec-47ea-a82b-ee6d79b39665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc9d3412-f77a-47c9-8d7f-0570569df324" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0705ec49-5fec-47ea-a82b-ee6d79b39665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9cd3c297-93ce-404e-9521-abb3d9739beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_69f4f235-197a-440f-ba48-c8166606f6b6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9cd3c297-93ce-404e-9521-abb3d9739beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="opk-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_137e134f-166a-44e5-8ffb-026868f61083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_228555f0-6f20-4192-85ba-c8bb8cebb5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_137e134f-166a-44e5-8ffb-026868f61083" xlink:to="loc_us-gaap_StockholdersEquityAbstract_228555f0-6f20-4192-85ba-c8bb8cebb5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8b564d5a-ff58-4379-94b4-bf4a9dbb8531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_228555f0-6f20-4192-85ba-c8bb8cebb5fd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8b564d5a-ff58-4379-94b4-bf4a9dbb8531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9a91b2b8-bb9e-4a39-bd3d-7f28f4412aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_228555f0-6f20-4192-85ba-c8bb8cebb5fd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9a91b2b8-bb9e-4a39-bd3d-7f28f4412aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6b25875d-4c26-4434-9fd0-366bf0ec141d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_228555f0-6f20-4192-85ba-c8bb8cebb5fd" xlink:to="loc_us-gaap_CommonStockSharesIssued_6b25875d-4c26-4434-9fd0-366bf0ec141d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_46c3cb29-3bc4-4354-a25d-8b728847259b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_228555f0-6f20-4192-85ba-c8bb8cebb5fd" xlink:to="loc_us-gaap_TreasuryStockShares_46c3cb29-3bc4-4354-a25d-8b728847259b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="opk-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fe94c139-0b7b-4c97-a793-29c31d6fc699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ae257dfc-3539-480a-8176-19e454434db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fe94c139-0b7b-4c97-a793-29c31d6fc699" xlink:to="loc_us-gaap_StatementTable_ae257dfc-3539-480a-8176-19e454434db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ab306190-b450-4150-9934-cadd7a929e1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ae257dfc-3539-480a-8176-19e454434db3" xlink:to="loc_srt_ProductOrServiceAxis_ab306190-b450-4150-9934-cadd7a929e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b81d842-82bf-43c7-9d00-840770a9189b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ab306190-b450-4150-9934-cadd7a929e1f" xlink:to="loc_srt_ProductsAndServicesDomain_8b81d842-82bf-43c7-9d00-840770a9189b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_99f804fb-0930-4305-a049-2cbe10b5c18c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8b81d842-82bf-43c7-9d00-840770a9189b" xlink:to="loc_us-gaap_ServiceMember_99f804fb-0930-4305-a049-2cbe10b5c18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4bb9c55f-ced6-4269-84b4-5eba299b00a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8b81d842-82bf-43c7-9d00-840770a9189b" xlink:to="loc_us-gaap_ProductMember_4bb9c55f-ced6-4269-84b4-5eba299b00a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_65beabff-7799-421d-b6ed-1cd65b268752" xlink:href="opk-20220331.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8b81d842-82bf-43c7-9d00-840770a9189b" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_65beabff-7799-421d-b6ed-1cd65b268752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ae257dfc-3539-480a-8176-19e454434db3" xlink:to="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_57e6530b-2533-47e5-9f1c-97f5a36d9177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_RevenuesAbstract_57e6530b-2533-47e5-9f1c-97f5a36d9177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a87aa26-0549-48e0-83a9-84b5cabefd67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_57e6530b-2533-47e5-9f1c-97f5a36d9177" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a87aa26-0549-48e0-83a9-84b5cabefd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1cd2cd8c-cece-4b8d-8711-d6ebf5a3d538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1cd2cd8c-cece-4b8d-8711-d6ebf5a3d538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c52ca1d7-dedf-4c3c-9ee4-bea6f6d1c8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c52ca1d7-dedf-4c3c-9ee4-bea6f6d1c8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61a2cdd0-c776-42cc-a533-241854adab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61a2cdd0-c776-42cc-a533-241854adab1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e47e49fa-d707-4f9b-bfd5-9d3ef7d58a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e47e49fa-d707-4f9b-bfd5-9d3ef7d58a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1591caa3-dea9-4469-a8ee-1564bb807c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1591caa3-dea9-4469-a8ee-1564bb807c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3d4c04b9-ded1-49c2-8e72-f6b87dfc2b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe7ff54-ccea-4f63-8366-bf5081d6628e" xlink:to="loc_us-gaap_OperatingExpenses_3d4c04b9-ded1-49c2-8e72-f6b87dfc2b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f5ab2b80-700c-48a8-9f2a-4a5129719e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_OperatingIncomeLoss_f5ab2b80-700c-48a8-9f2a-4a5129719e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e73cb9b2-dfd4-4b10-9cba-f284927c2fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e73cb9b2-dfd4-4b10-9cba-f284927c2fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestIncomeNonoperating_78b91f75-57d7-4241-baed-0543e7d68ac5" xlink:href="opk-20220331.xsd#opk_InterestIncomeNonoperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e73cb9b2-dfd4-4b10-9cba-f284927c2fc7" xlink:to="loc_opk_InterestIncomeNonoperating_78b91f75-57d7-4241-baed-0543e7d68ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InterestExpenseNonoperating_c5d74e3b-a4e1-4433-8172-b93614bac25f" xlink:href="opk-20220331.xsd#opk_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e73cb9b2-dfd4-4b10-9cba-f284927c2fc7" xlink:to="loc_opk_InterestExpenseNonoperating_c5d74e3b-a4e1-4433-8172-b93614bac25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_5ee5ef8a-05e4-400d-924c-9d3826eebaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e73cb9b2-dfd4-4b10-9cba-f284927c2fc7" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_5ee5ef8a-05e4-400d-924c-9d3826eebaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_37571fff-b817-42ec-8442-b259c98ede72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e73cb9b2-dfd4-4b10-9cba-f284927c2fc7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_37571fff-b817-42ec-8442-b259c98ede72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6309772f-9abe-427c-89a2-2d2a8e6fef99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e73cb9b2-dfd4-4b10-9cba-f284927c2fc7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6309772f-9abe-427c-89a2-2d2a8e6fef99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dab5d3e3-ff8b-4e5e-a785-a21eced34aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dab5d3e3-ff8b-4e5e-a785-a21eced34aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e74d6400-04fa-404d-97ad-2e93874c4ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e74d6400-04fa-404d-97ad-2e93874c4ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax_0cce8459-14c8-4770-b7e2-4d70ee758b07" xlink:href="opk-20220331.xsd#opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax_0cce8459-14c8-4770-b7e2-4d70ee758b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0dddf4f5-ec41-4084-b6cd-eaafad6bcc79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0dddf4f5-ec41-4084-b6cd-eaafad6bcc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ab9f4db2-b34d-4131-a672-3087d80ced64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_NetIncomeLoss_ab9f4db2-b34d-4131-a672-3087d80ced64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_37a0910a-dad2-4871-8b9c-c741a736f2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_EarningsPerShareAbstract_37a0910a-dad2-4871-8b9c-c741a736f2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b14d868f-ae42-4998-9bf9-25cbbff32e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37a0910a-dad2-4871-8b9c-c741a736f2f9" xlink:to="loc_us-gaap_EarningsPerShareBasic_b14d868f-ae42-4998-9bf9-25cbbff32e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_054fb6a5-1a90-4914-be5b-2b829b45d3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37a0910a-dad2-4871-8b9c-c741a736f2f9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_054fb6a5-1a90-4914-be5b-2b829b45d3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dd05403f-d0eb-47a8-9a15-ab494fc5e779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dd05403f-d0eb-47a8-9a15-ab494fc5e779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb448668-5046-40af-83c6-2e25d0c487f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74df5919-4443-4309-babc-e3bf943ed448" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb448668-5046-40af-83c6-2e25d0c487f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="opk-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_661fcafe-2387-4864-9bd6-1e31f05308bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f4d68f5-7582-475d-aeef-722d811bc7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_661fcafe-2387-4864-9bd6-1e31f05308bf" xlink:to="loc_us-gaap_NetIncomeLoss_0f4d68f5-7582-475d-aeef-722d811bc7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_735e25fb-d618-40a9-ba24-2e8bdcb84f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_661fcafe-2387-4864-9bd6-1e31f05308bf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_735e25fb-d618-40a9-ba24-2e8bdcb84f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_651206a6-b774-4046-9d7d-00957eb6cb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_735e25fb-d618-40a9-ba24-2e8bdcb84f5a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_651206a6-b774-4046-9d7d-00957eb6cb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_de78f766-cb48-4cb2-a219-be9ce996d70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_661fcafe-2387-4864-9bd6-1e31f05308bf" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_de78f766-cb48-4cb2-a219-be9ce996d70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="opk-20220331.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c8184903-d1cd-4e98-9c47-6c4bfd0761dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_645fa22c-371a-474e-b929-4d469812b415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c8184903-d1cd-4e98-9c47-6c4bfd0761dc" xlink:to="loc_us-gaap_StatementTable_645fa22c-371a-474e-b929-4d469812b415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_45ea1c58-8d5d-4c12-8add-0d460a3b4a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_645fa22c-371a-474e-b929-4d469812b415" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_45ea1c58-8d5d-4c12-8add-0d460a3b4a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_befd2af6-2874-420c-a70c-b04dd21169c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_45ea1c58-8d5d-4c12-8add-0d460a3b4a9a" xlink:to="loc_us-gaap_EquityComponentDomain_befd2af6-2874-420c-a70c-b04dd21169c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_069ab135-f46f-4463-b4b5-290cf349b857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_befd2af6-2874-420c-a70c-b04dd21169c4" xlink:to="loc_us-gaap_CommonStockMember_069ab135-f46f-4463-b4b5-290cf349b857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_4ccadd0c-d130-4dad-bb27-981af6e68838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_befd2af6-2874-420c-a70c-b04dd21169c4" xlink:to="loc_us-gaap_TreasuryStockMember_4ccadd0c-d130-4dad-bb27-981af6e68838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_399f80ec-aa03-4a93-9350-ce324a25bc64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_befd2af6-2874-420c-a70c-b04dd21169c4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_399f80ec-aa03-4a93-9350-ce324a25bc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_24dca3bb-5e9f-4961-ab49-51499c59a814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_befd2af6-2874-420c-a70c-b04dd21169c4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_24dca3bb-5e9f-4961-ab49-51499c59a814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f52f6d35-6b31-4cb8-ae7a-0ea21be53688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_befd2af6-2874-420c-a70c-b04dd21169c4" xlink:to="loc_us-gaap_RetainedEarningsMember_f52f6d35-6b31-4cb8-ae7a-0ea21be53688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_916ebb34-7bf8-4aee-b8b8-64a22c74b945" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_645fa22c-371a-474e-b929-4d469812b415" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_916ebb34-7bf8-4aee-b8b8-64a22c74b945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ed1deea9-6ef3-4fb3-828b-c187b604c71a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_916ebb34-7bf8-4aee-b8b8-64a22c74b945" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ed1deea9-6ef3-4fb3-828b-c187b604c71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fac982ab-5861-44df-8ba2-888d4cec017d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ed1deea9-6ef3-4fb3-828b-c187b604c71a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fac982ab-5861-44df-8ba2-888d4cec017d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ef13f2b9-3e06-4f53-800c-8dd19e470bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_645fa22c-371a-474e-b929-4d469812b415" xlink:to="loc_us-gaap_StatementLineItems_ef13f2b9-3e06-4f53-800c-8dd19e470bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ef13f2b9-3e06-4f53-800c-8dd19e470bc4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_04c6700f-8eef-4c56-ab23-1954b7768194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_SharesIssued_04c6700f-8eef-4c56-ab23-1954b7768194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_86a6f4ef-7d78-4c2d-ad53-b208f6abd1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_86a6f4ef-7d78-4c2d-ad53-b208f6abd1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_aee84bde-eb49-40f0-af17-4130d7eab0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_aee84bde-eb49-40f0-af17-4130d7eab0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d26d47c1-6463-4160-8029-fd1996f96477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d26d47c1-6463-4160-8029-fd1996f96477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_15a1d07b-75b8-4370-a9ce-fc57f7adad5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_15a1d07b-75b8-4370-a9ce-fc57f7adad5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_79c6c5c4-1d38-4a5e-8140-b42ed2a81559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_NetIncomeLoss_79c6c5c4-1d38-4a5e-8140-b42ed2a81559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e5e6fba9-e627-4849-9ab1-aeacd1e6cb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e5e6fba9-e627-4849-9ab1-aeacd1e6cb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_528e350c-583a-43e6-b833-65d9f877de4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_SharesIssued_528e350c-583a-43e6-b833-65d9f877de4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59548c0e-40fa-4449-9125-aeed82fed3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_edd20f25-4988-43cd-b3f1-d984c9ebceb7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59548c0e-40fa-4449-9125-aeed82fed3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_520a1a06-b9c4-404d-888f-91727296bde3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ef13f2b9-3e06-4f53-800c-8dd19e470bc4" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_520a1a06-b9c4-404d-888f-91727296bde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="opk-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b78ec1e3-9441-4bf3-a243-bf448337245b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36837751-bbe5-4b4c-9a44-4ada24e40351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b78ec1e3-9441-4bf3-a243-bf448337245b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36837751-bbe5-4b4c-9a44-4ada24e40351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a5a73a6b-ec3a-4d0f-be25-08ee1e284e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36837751-bbe5-4b4c-9a44-4ada24e40351" xlink:to="loc_us-gaap_NetIncomeLoss_a5a73a6b-ec3a-4d0f-be25-08ee1e284e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5b09fbcc-b53d-4734-86e1-384dd8aa7716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36837751-bbe5-4b4c-9a44-4ada24e40351" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5b09fbcc-b53d-4734-86e1-384dd8aa7716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e06de648-6dde-4cbd-9e28-aaf470447bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5b09fbcc-b53d-4734-86e1-384dd8aa7716" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e06de648-6dde-4cbd-9e28-aaf470447bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_016124aa-c48a-451a-9732-badbe6583e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5b09fbcc-b53d-4734-86e1-384dd8aa7716" xlink:to="loc_us-gaap_PaidInKindInterest_016124aa-c48a-451a-9732-badbe6583e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ffd3d8f9-ed60-4bc9-9fc1-b663ba7f33a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5b09fbcc-b53d-4734-86e1-384dd8aa7716" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ffd3d8f9-ed60-4bc9-9fc1-b663ba7f33a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6b7b9812-d72d-4d82-9504-765b4ad9cf19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5b09fbcc-b53d-4734-86e1-384dd8aa7716" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6b7b9812-d72d-4d82-9504-765b4ad9cf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f352bfa5-4809-4d6f-b1e2-aad6b2380d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5b09fbcc-b53d-4734-86e1-384dd8aa7716" xlink:to="loc_us-gaap_ShareBasedCompensation_f352bfa5-4809-4d6f-b1e2-aad6b2380d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_3ba6f196-86ff-45ba-8785-778aa733750b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5b09fbcc-b53d-4734-86e1-384dd8aa7716" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_3ba6f196-86ff-45ba-8785-778aa733750b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments_14703a02-5c26-40a5-a480-53b7363fecaf" xlink:href="opk-20220331.xsd#opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5b09fbcc-b53d-4734-86e1-384dd8aa7716" xlink:to="loc_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments_14703a02-5c26-40a5-a480-53b7363fecaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c7b91a76-d64e-4fe8-8251-50ba32130b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5b09fbcc-b53d-4734-86e1-384dd8aa7716" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c7b91a76-d64e-4fe8-8251-50ba32130b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_be1f7b2a-1176-4e6f-b540-6fff6ab36883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5b09fbcc-b53d-4734-86e1-384dd8aa7716" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_be1f7b2a-1176-4e6f-b540-6fff6ab36883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_675bdc4a-9b29-4c87-8799-ddfb7486b233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5b09fbcc-b53d-4734-86e1-384dd8aa7716" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_675bdc4a-9b29-4c87-8799-ddfb7486b233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3845ecba-d4c6-4688-8e1f-48982d1d664b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_675bdc4a-9b29-4c87-8799-ddfb7486b233" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3845ecba-d4c6-4688-8e1f-48982d1d664b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d47e033d-9261-4330-8ccb-066a66467d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_675bdc4a-9b29-4c87-8799-ddfb7486b233" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d47e033d-9261-4330-8ccb-066a66467d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ef64c35d-5a0a-4a9a-91f6-52d6ff0bfa2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_675bdc4a-9b29-4c87-8799-ddfb7486b233" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ef64c35d-5a0a-4a9a-91f6-52d6ff0bfa2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bffb138d-fe43-46b6-8965-7ec6d3e35ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_675bdc4a-9b29-4c87-8799-ddfb7486b233" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bffb138d-fe43-46b6-8965-7ec6d3e35ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6f6c14f5-b18f-4a61-bb30-247214ad6abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_675bdc4a-9b29-4c87-8799-ddfb7486b233" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6f6c14f5-b18f-4a61-bb30-247214ad6abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseinForeignCurrencyMeasurement_75ff747d-c262-4504-af9e-0087ce31336d" xlink:href="opk-20220331.xsd#opk_IncreaseDecreaseinForeignCurrencyMeasurement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_675bdc4a-9b29-4c87-8799-ddfb7486b233" xlink:to="loc_opk_IncreaseDecreaseinForeignCurrencyMeasurement_75ff747d-c262-4504-af9e-0087ce31336d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1ce510cb-85de-4836-a2d9-2836d8e886c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_675bdc4a-9b29-4c87-8799-ddfb7486b233" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1ce510cb-85de-4836-a2d9-2836d8e886c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ca5f634a-2afe-4ebd-877f-762034f1f5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_675bdc4a-9b29-4c87-8799-ddfb7486b233" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ca5f634a-2afe-4ebd-877f-762034f1f5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed40b799-c0ad-4e0a-ac80-196f8fa91d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36837751-bbe5-4b4c-9a44-4ada24e40351" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed40b799-c0ad-4e0a-ac80-196f8fa91d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d91905a9-3e29-402a-afe7-98ca66282f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b78ec1e3-9441-4bf3-a243-bf448337245b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d91905a9-3e29-402a-afe7-98ca66282f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1c48f61c-a546-41c6-858a-b6e364ea2427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d91905a9-3e29-402a-afe7-98ca66282f2f" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1c48f61c-a546-41c6-858a-b6e364ea2427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2097912e-be9e-4696-9b64-7b32d6a9d624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d91905a9-3e29-402a-afe7-98ca66282f2f" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2097912e-be9e-4696-9b64-7b32d6a9d624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_0c890b0c-3e6d-4da0-a884-3d13db05c5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d91905a9-3e29-402a-afe7-98ca66282f2f" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_0c890b0c-3e6d-4da0-a884-3d13db05c5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cd6251eb-f98d-4973-a02c-72dfd028dafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d91905a9-3e29-402a-afe7-98ca66282f2f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cd6251eb-f98d-4973-a02c-72dfd028dafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_947f412f-5eba-4f60-8af5-322cfa0589f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b78ec1e3-9441-4bf3-a243-bf448337245b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_947f412f-5eba-4f60-8af5-322cfa0589f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_e30191ad-29bd-4076-88c2-f3261d3a50cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_947f412f-5eba-4f60-8af5-322cfa0589f8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_e30191ad-29bd-4076-88c2-f3261d3a50cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_c6015645-d009-4dfc-a4f7-500ad524c97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_947f412f-5eba-4f60-8af5-322cfa0589f8" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_c6015645-d009-4dfc-a4f7-500ad524c97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_a0bc4524-101d-4049-aab5-36aa69a59428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_947f412f-5eba-4f60-8af5-322cfa0589f8" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_a0bc4524-101d-4049-aab5-36aa69a59428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95b2efcf-07e2-46aa-ae7b-942413b4b28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_947f412f-5eba-4f60-8af5-322cfa0589f8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95b2efcf-07e2-46aa-ae7b-942413b4b28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3fac536d-0952-4c0b-8f8c-118debec6a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_947f412f-5eba-4f60-8af5-322cfa0589f8" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3fac536d-0952-4c0b-8f8c-118debec6a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d45faa64-9640-4913-bae2-2f351b6ecb57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b78ec1e3-9441-4bf3-a243-bf448337245b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d45faa64-9640-4913-bae2-2f351b6ecb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cbbec24b-e749-4fdc-bb9c-43c0a58ae4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b78ec1e3-9441-4bf3-a243-bf448337245b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cbbec24b-e749-4fdc-bb9c-43c0a58ae4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4fdbbdc7-2686-4602-99b4-d402d7a6cb14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b78ec1e3-9441-4bf3-a243-bf448337245b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4fdbbdc7-2686-4602-99b4-d402d7a6cb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_183bdc82-6a87-4611-a1b9-b74f0ab0d243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b78ec1e3-9441-4bf3-a243-bf448337245b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_183bdc82-6a87-4611-a1b9-b74f0ab0d243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_fe735afe-2c26-4c4c-83ec-2dd984ab4483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_183bdc82-6a87-4611-a1b9-b74f0ab0d243" xlink:to="loc_us-gaap_InterestPaidNet_fe735afe-2c26-4c4c-83ec-2dd984ab4483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_39c26dca-8ebc-44b1-aff8-f428ee110293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_183bdc82-6a87-4611-a1b9-b74f0ab0d243" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_39c26dca-8ebc-44b1-aff8-f428ee110293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/BusinessandOrganization" xlink:type="simple" xlink:href="opk-20220331.xsd#BusinessandOrganization"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/BusinessandOrganization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9818527-1b66-491f-bbaf-73fac00e7cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_cf457cb8-46e8-4053-bfd7-c22855b641fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9818527-1b66-491f-bbaf-73fac00e7cec" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_cf457cb8-46e8-4053-bfd7-c22855b641fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/BusinessandOrganizationDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#BusinessandOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/BusinessandOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c314a7b5-8c60-4058-bb57-2aa8ae6b609a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c314a7b5-8c60-4058-bb57-2aa8ae6b609a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_15dfe042-6582-497d-9793-6824c66e2563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_15dfe042-6582-497d-9793-6824c66e2563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ecfc9888-cd94-4870-b6cc-f34e3950f997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_15dfe042-6582-497d-9793-6824c66e2563" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ecfc9888-cd94-4870-b6cc-f34e3950f997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8b47a530-0080-4160-ba56-6ced9c7e1cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ecfc9888-cd94-4870-b6cc-f34e3950f997" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8b47a530-0080-4160-ba56-6ced9c7e1cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7fa034f7-279f-4bbc-8b9d-ebc91f596267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7fa034f7-279f-4bbc-8b9d-ebc91f596267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_69988bc7-6716-4c38-a22b-82bcef0eb8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7fa034f7-279f-4bbc-8b9d-ebc91f596267" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_69988bc7-6716-4c38-a22b-82bcef0eb8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_WaterfordIrelandFacilityMember_bc68f846-6ebc-4962-adde-4193493e1c14" xlink:href="opk-20220331.xsd#opk_WaterfordIrelandFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_69988bc7-6716-4c38-a22b-82bcef0eb8d7" xlink:to="loc_opk_WaterfordIrelandFacilityMember_bc68f846-6ebc-4962-adde-4193493e1c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_af4b305d-d68b-47cf-a58d-834748aa42f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_af4b305d-d68b-47cf-a58d-834748aa42f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_823c4d2a-bada-4dd5-946d-9d1f7728ca6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_af4b305d-d68b-47cf-a58d-834748aa42f7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_823c4d2a-bada-4dd5-946d-9d1f7728ca6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DetectGenomixMember_77e5fd73-2839-4da0-949f-5ed0e8cced00" xlink:href="opk-20220331.xsd#opk_DetectGenomixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_823c4d2a-bada-4dd5-946d-9d1f7728ca6f" xlink:to="loc_opk_DetectGenomixMember_77e5fd73-2839-4da0-949f-5ed0e8cced00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_03ef1b33-40d1-4b34-a871-3d423217237b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:to="loc_dei_LegalEntityAxis_03ef1b33-40d1-4b34-a871-3d423217237b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2836ca25-a968-4c60-be77-35e895c525df" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_03ef1b33-40d1-4b34-a871-3d423217237b" xlink:to="loc_dei_EntityDomain_2836ca25-a968-4c60-be77-35e895c525df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_Sema4Member_224c32da-c74b-41dc-8d24-66815360fcde" xlink:href="opk-20220331.xsd#opk_Sema4Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2836ca25-a968-4c60-be77-35e895c525df" xlink:to="loc_opk_Sema4Member_224c32da-c74b-41dc-8d24-66815360fcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_559cdd3f-76fa-4d34-86fe-2b7826113aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_559cdd3f-76fa-4d34-86fe-2b7826113aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a52af880-0743-49fa-bb14-02d2ef098b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_559cdd3f-76fa-4d34-86fe-2b7826113aaa" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a52af880-0743-49fa-bb14-02d2ef098b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_29c61cab-1c10-4193-8078-c5d9468b7ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a52af880-0743-49fa-bb14-02d2ef098b4c" xlink:to="loc_us-gaap_SubsequentEventMember_29c61cab-1c10-4193-8078-c5d9468b7ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb517fa9-31d8-44d3-a526-26e2e6609913" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NumberofSalesEmployees_79c5f234-0b72-4063-b59f-28e09549ca75" xlink:href="opk-20220331.xsd#opk_NumberofSalesEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_opk_NumberofSalesEmployees_79c5f234-0b72-4063-b59f-28e09549ca75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8fc10641-60df-42b6-8e3a-f3ad26b83ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8fc10641-60df-42b6-8e3a-f3ad26b83ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_783e80c9-3cdb-4aa2-b911-aeb9cf6e80f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_783e80c9-3cdb-4aa2-b911-aeb9cf6e80f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments_1835f00c-6469-4a02-ab92-9d7d940a9ef9" xlink:href="opk-20220331.xsd#opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments_1835f00c-6469-4a02-ab92-9d7d940a9ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod_55719ee1-b3c5-472f-a215-5b2f4b591117" xlink:href="opk-20220331.xsd#opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod_55719ee1-b3c5-472f-a215-5b2f4b591117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationUpfrontConsiderationTransferred_02cb486b-6a89-4c5a-85fe-e472aa843f2d" xlink:href="opk-20220331.xsd#opk_BusinessCombinationUpfrontConsiderationTransferred"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_opk_BusinessCombinationUpfrontConsiderationTransferred_02cb486b-6a89-4c5a-85fe-e472aa843f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a30d02ff-a34a-4f75-bbef-6b7f5b2c1de1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a30d02ff-a34a-4f75-bbef-6b7f5b2c1de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DisposalGroupNumberOfFacilitiesSold_bfe4fd9c-7586-466d-ad4b-616ec2332135" xlink:href="opk-20220331.xsd#opk_DisposalGroupNumberOfFacilitiesSold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_opk_DisposalGroupNumberOfFacilitiesSold_bfe4fd9c-7586-466d-ad4b-616ec2332135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_405eb7cf-37d9-40d1-abf0-8e073131ead7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_405eb7cf-37d9-40d1-abf0-8e073131ead7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_619a1c13-2cb2-4b53-a623-ea8a4b55a718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cb648ace-121c-42ee-824a-f1fb56e4c31c" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_619a1c13-2cb2-4b53-a623-ea8a4b55a718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/ImpactofCOVID19" xlink:type="simple" xlink:href="opk-20220331.xsd#ImpactofCOVID19"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/ImpactofCOVID19" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_2ec094cb-1970-4f20-ab42-1dc8adc6558e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_8aa179d4-8f45-4411-9033-4773e6d981cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_2ec094cb-1970-4f20-ab42-1dc8adc6558e" xlink:to="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_8aa179d4-8f45-4411-9033-4773e6d981cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/ImpactofCOVID19Details" xlink:type="simple" xlink:href="opk-20220331.xsd#ImpactofCOVID19Details"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/ImpactofCOVID19Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_8cf5ad9b-44c9-4da9-96b4-f70210819d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_40537ef4-997c-4777-9b59-6441d8da2306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_8cf5ad9b-44c9-4da9-96b4-f70210819d67" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_40537ef4-997c-4777-9b59-6441d8da2306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_018cc4ca-10df-4f19-8e11-48c1f1fa5608" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_40537ef4-997c-4777-9b59-6441d8da2306" xlink:to="loc_srt_ProductOrServiceAxis_018cc4ca-10df-4f19-8e11-48c1f1fa5608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8a37fee7-0bc8-4347-9d39-41ecad66f30f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_018cc4ca-10df-4f19-8e11-48c1f1fa5608" xlink:to="loc_srt_ProductsAndServicesDomain_8a37fee7-0bc8-4347-9d39-41ecad66f30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_95ca98a5-0887-4d5c-877b-397522601b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a37fee7-0bc8-4347-9d39-41ecad66f30f" xlink:to="loc_us-gaap_ServiceMember_95ca98a5-0887-4d5c-877b-397522601b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestingMember_86eeaa49-8b2f-4da9-9f14-981cb3a39dca" xlink:href="opk-20220331.xsd#opk_COVID19TestingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a37fee7-0bc8-4347-9d39-41ecad66f30f" xlink:to="loc_opk_COVID19TestingMember_86eeaa49-8b2f-4da9-9f14-981cb3a39dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TestingTypeAxis_a26871f1-fcaa-4724-beae-0ba474c9d597" xlink:href="opk-20220331.xsd#opk_TestingTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_40537ef4-997c-4777-9b59-6441d8da2306" xlink:to="loc_opk_TestingTypeAxis_a26871f1-fcaa-4724-beae-0ba474c9d597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TestingTypeDomain_49251aa5-f115-4256-af77-01557fbca870" xlink:href="opk-20220331.xsd#opk_TestingTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_TestingTypeAxis_a26871f1-fcaa-4724-beae-0ba474c9d597" xlink:to="loc_opk_TestingTypeDomain_49251aa5-f115-4256-af77-01557fbca870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GenomicTestMember_3c8684dd-307a-4bbf-b7e1-ead6b0390482" xlink:href="opk-20220331.xsd#opk_GenomicTestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_TestingTypeDomain_49251aa5-f115-4256-af77-01557fbca870" xlink:to="loc_opk_GenomicTestMember_3c8684dd-307a-4bbf-b7e1-ead6b0390482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RoutineClinicalTestMember_fa36f1e9-b71c-4779-83b1-2b6bf6b06b4a" xlink:href="opk-20220331.xsd#opk_RoutineClinicalTestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_TestingTypeDomain_49251aa5-f115-4256-af77-01557fbca870" xlink:to="loc_opk_RoutineClinicalTestMember_fa36f1e9-b71c-4779-83b1-2b6bf6b06b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0a3cd95f-f45e-468f-91a7-b011cb25b79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_40537ef4-997c-4777-9b59-6441d8da2306" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0a3cd95f-f45e-468f-91a7-b011cb25b79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a0bfe1b4-adbd-4149-aad4-3af77827ea5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0a3cd95f-f45e-468f-91a7-b011cb25b79f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a0bfe1b4-adbd-4149-aad4-3af77827ea5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_COVID19TestingRevenueConcentrationRiskMember_5a01639a-95bd-420a-be98-4c06a948cc78" xlink:href="opk-20220331.xsd#opk_COVID19TestingRevenueConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a0bfe1b4-adbd-4149-aad4-3af77827ea5f" xlink:to="loc_opk_COVID19TestingRevenueConcentrationRiskMember_5a01639a-95bd-420a-be98-4c06a948cc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1e84f18f-b1c8-43f3-9cc0-20a3b0d084bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_40537ef4-997c-4777-9b59-6441d8da2306" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1e84f18f-b1c8-43f3-9cc0-20a3b0d084bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1648b049-d31c-449f-bd86-0ef7a112f192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1e84f18f-b1c8-43f3-9cc0-20a3b0d084bd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1648b049-d31c-449f-bd86-0ef7a112f192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4d4af620-470e-48c2-b2ef-358e544bb097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1648b049-d31c-449f-bd86-0ef7a112f192" xlink:to="loc_us-gaap_SalesRevenueNetMember_4d4af620-470e-48c2-b2ef-358e544bb097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_4ab55609-4f82-450a-8ace-f0328c868d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1648b049-d31c-449f-bd86-0ef7a112f192" xlink:to="loc_us-gaap_AccountsReceivableMember_4ab55609-4f82-450a-8ace-f0328c868d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_8a16dfd3-2107-4981-aada-c7ad42f4ca9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_40537ef4-997c-4777-9b59-6441d8da2306" xlink:to="loc_us-gaap_UnusualOrInfrequentItemLineItems_8a16dfd3-2107-4981-aada-c7ad42f4ca9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_a4a1763c-47b1-434d-9e0f-7c68967c48c7" xlink:href="opk-20220331.xsd#opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_8a16dfd3-2107-4981-aada-c7ad42f4ca9a" xlink:to="loc_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_a4a1763c-47b1-434d-9e0f-7c68967c48c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChangeInTestingVolumePercent_cf3686c4-ba3f-4726-8f27-059a08120cc5" xlink:href="opk-20220331.xsd#opk_ChangeInTestingVolumePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_8a16dfd3-2107-4981-aada-c7ad42f4ca9a" xlink:to="loc_opk_ChangeInTestingVolumePercent_cf3686c4-ba3f-4726-8f27-059a08120cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b7a2fca8-9bcf-48ab-927b-c6efa944e503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_8a16dfd3-2107-4981-aada-c7ad42f4ca9a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b7a2fca8-9bcf-48ab-927b-c6efa944e503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="opk-20220331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3c1148fb-c890-448a-8a74-d58f4cfde619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_58bbd939-9d77-4b25-8d1e-df7a1bd3fc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c1148fb-c890-448a-8a74-d58f4cfde619" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_58bbd939-9d77-4b25-8d1e-df7a1bd3fc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="opk-20220331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_72e50e1d-be9f-47cf-a571-d8f4205dce7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_72e50e1d-be9f-47cf-a571-d8f4205dce7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_20354df6-1544-41fd-abd0-3b0ab089dc33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_20354df6-1544-41fd-abd0-3b0ab089dc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e8afe8a1-6fe5-4bc4-8b52-c848cebdc3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_UseOfEstimates_e8afe8a1-6fe5-4bc4-8b52-c848cebdc3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_89035008-b8d1-4585-854d-daf8bab52eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_89035008-b8d1-4585-854d-daf8bab52eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_8dfc79c8-5d6c-4c52-bd90-0f3b1b8a4d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_8dfc79c8-5d6c-4c52-bd90-0f3b1b8a4d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b75b266e-3643-4f8d-bd86-29ea5c6dd129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b75b266e-3643-4f8d-bd86-29ea5c6dd129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_68d6ce07-a49f-467d-a4bb-70ae1291d504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_68d6ce07-a49f-467d-a4bb-70ae1291d504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_b8216377-43fa-4a5e-95ac-4701f18d9dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_b8216377-43fa-4a5e-95ac-4701f18d9dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_22d82b9b-a9fd-494b-93b9-edda5b3d53ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_22d82b9b-a9fd-494b-93b9-edda5b3d53ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_577701cd-6aeb-4fd1-9e11-45c0a7d1f397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_577701cd-6aeb-4fd1-9e11-45c0a7d1f397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_886512c1-87e7-4630-87c6-fac2c6a7a4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_886512c1-87e7-4630-87c6-fac2c6a7a4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_0a40ba32-1dc9-41bb-8689-3806cb6d2955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_0a40ba32-1dc9-41bb-8689-3806cb6d2955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_31ca343e-f487-42f7-95f1-450c3aed283c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_31ca343e-f487-42f7-95f1-450c3aed283c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_353cfd96-7770-48f7-acc0-c26cfbc8ff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_353cfd96-7770-48f7-acc0-c26cfbc8ff5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_4b3cd36c-50a9-46c2-a438-5e2913549aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_4b3cd36c-50a9-46c2-a438-5e2913549aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_599c252a-acd2-46a1-a8df-49ea6898f27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_599c252a-acd2-46a1-a8df-49ea6898f27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e503caf8-f1da-4cf9-9e48-18cb50384938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e503caf8-f1da-4cf9-9e48-18cb50384938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3f9559f7-93c9-44fa-a26d-b1b295cce336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3f9559f7-93c9-44fa-a26d-b1b295cce336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_45454b74-8bc7-4d94-bc3c-2ffe97009efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_45454b74-8bc7-4d94-bc3c-2ffe97009efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_1e7d1a2f-9be4-4d35-8b7e-005945528473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_1e7d1a2f-9be4-4d35-8b7e-005945528473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_3892f903-536b-4450-b631-abeaa96322c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_3892f903-536b-4450-b631-abeaa96322c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_15c1ca8e-37d3-484a-a811-a8f7cd405d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331eccd2-336e-4d32-ab5a-2da1c72518b2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_15c1ca8e-37d3-484a-a811-a8f7cd405d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ce2d2c28-6460-4f74-a48c-af363862bfff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:href="opk-20220331.xsd#opk_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce2d2c28-6460-4f74-a48c-af363862bfff" xlink:to="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_08eb03f4-4913-4874-8a02-b5838348ffb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_08eb03f4-4913-4874-8a02-b5838348ffb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bb310fbc-2e8b-4765-917e-2bafbb4d46fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_08eb03f4-4913-4874-8a02-b5838348ffb6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bb310fbc-2e8b-4765-917e-2bafbb4d46fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2673d1bb-0292-4a39-b101-31c898e68a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bb310fbc-2e8b-4765-917e-2bafbb4d46fe" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2673d1bb-0292-4a39-b101-31c898e68a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b164faa8-f7c6-464d-9796-e4d35c57a5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b164faa8-f7c6-464d-9796-e4d35c57a5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbf7448f-6e2e-4824-86af-4fe4929b97ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b164faa8-f7c6-464d-9796-e4d35c57a5fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbf7448f-6e2e-4824-86af-4fe4929b97ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b8e3e547-c365-4b26-8ac0-951b5579aec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbf7448f-6e2e-4824-86af-4fe4929b97ef" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b8e3e547-c365-4b26-8ac0-951b5579aec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_1f863197-ed2b-455d-b7d4-d874a85474fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbf7448f-6e2e-4824-86af-4fe4929b97ef" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_1f863197-ed2b-455d-b7d4-d874a85474fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_46d0f384-4cc9-49e4-8580-a6a3dba35c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbf7448f-6e2e-4824-86af-4fe4929b97ef" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_46d0f384-4cc9-49e4-8580-a6a3dba35c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_6d33c471-c773-4424-8631-dd89edbf3677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbf7448f-6e2e-4824-86af-4fe4929b97ef" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_6d33c471-c773-4424-8631-dd89edbf3677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AutomobilesandAircraftMember_02f21613-7db1-48a1-8ee4-0d1cbdf5242f" xlink:href="opk-20220331.xsd#opk_AutomobilesandAircraftMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbf7448f-6e2e-4824-86af-4fe4929b97ef" xlink:to="loc_opk_AutomobilesandAircraftMember_02f21613-7db1-48a1-8ee4-0d1cbdf5242f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1b3124d0-dba7-4790-9012-ed7f015ed603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1b3124d0-dba7-4790-9012-ed7f015ed603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8adb21a0-9486-406a-9b4f-40f3cf01cdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1b3124d0-dba7-4790-9012-ed7f015ed603" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8adb21a0-9486-406a-9b4f-40f3cf01cdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_d702d376-67ff-470b-8bea-f22599a4aca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8adb21a0-9486-406a-9b4f-40f3cf01cdd7" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_d702d376-67ff-470b-8bea-f22599a4aca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_d2cc6a0e-0184-4a81-9747-0783615d6f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8adb21a0-9486-406a-9b4f-40f3cf01cdd7" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_d2cc6a0e-0184-4a81-9747-0783615d6f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_7ec9199d-79c5-4d16-bf97-fc8a1be8f08c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8adb21a0-9486-406a-9b4f-40f3cf01cdd7" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_7ec9199d-79c5-4d16-bf97-fc8a1be8f08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f9da68bf-f190-4fd4-9cbb-4701dd6958d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f9da68bf-f190-4fd4-9cbb-4701dd6958d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_727d3cbd-3548-4d48-8bd7-f46a9a18d117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f9da68bf-f190-4fd4-9cbb-4701dd6958d0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_727d3cbd-3548-4d48-8bd7-f46a9a18d117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_1fbcd399-da8b-4c80-9a47-743789f581b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_727d3cbd-3548-4d48-8bd7-f46a9a18d117" xlink:to="loc_us-gaap_AccountsReceivableMember_1fbcd399-da8b-4c80-9a47-743789f581b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_44bc05c7-3d75-479c-829c-12702afd5377" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_srt_RangeAxis_44bc05c7-3d75-479c-829c-12702afd5377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e9b78af3-474b-44f9-b73e-dce0a0065ec2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_44bc05c7-3d75-479c-829c-12702afd5377" xlink:to="loc_srt_RangeMember_e9b78af3-474b-44f9-b73e-dce0a0065ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_315a8118-24cf-4e52-b41a-8d791e9e14b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e9b78af3-474b-44f9-b73e-dce0a0065ec2" xlink:to="loc_srt_MinimumMember_315a8118-24cf-4e52-b41a-8d791e9e14b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5471be72-0111-40c2-84e3-da03241b0955" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e9b78af3-474b-44f9-b73e-dce0a0065ec2" xlink:to="loc_srt_MaximumMember_5471be72-0111-40c2-84e3-da03241b0955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b3504832-87f8-4c04-9353-83489ef87961" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_srt_MajorCustomersAxis_b3504832-87f8-4c04-9353-83489ef87961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7f2484a1-ec28-4008-8a04-1abf35f3a2da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_b3504832-87f8-4c04-9353-83489ef87961" xlink:to="loc_srt_NameOfMajorCustomerDomain_7f2484a1-ec28-4008-8a04-1abf35f3a2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FederalAndStateGovernmentsMember_a04d9228-6011-45f6-9d1b-93fdfeb56755" xlink:href="opk-20220331.xsd#opk_FederalAndStateGovernmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f2484a1-ec28-4008-8a04-1abf35f3a2da" xlink:to="loc_opk_FederalAndStateGovernmentsMember_a04d9228-6011-45f6-9d1b-93fdfeb56755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StatesCitiesAndOtherMunicipalitiesMember_cfa11752-18c6-49ff-bf80-19bf8a317227" xlink:href="opk-20220331.xsd#opk_StatesCitiesAndOtherMunicipalitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f2484a1-ec28-4008-8a04-1abf35f3a2da" xlink:to="loc_opk_StatesCitiesAndOtherMunicipalitiesMember_cfa11752-18c6-49ff-bf80-19bf8a317227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_IndividualPatientsMember_32c532d0-edc6-4047-a7d6-c0f0c8bece5a" xlink:href="opk-20220331.xsd#opk_IndividualPatientsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f2484a1-ec28-4008-8a04-1abf35f3a2da" xlink:to="loc_opk_IndividualPatientsMember_32c532d0-edc6-4047-a7d6-c0f0c8bece5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_089b9406-e2ea-4b71-9982-fa19639d2b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_us-gaap_ReportingUnitAxis_089b9406-e2ea-4b71-9982-fa19639d2b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_fccadbe7-4c72-434a-9d5c-7efcfd386064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_089b9406-e2ea-4b71-9982-fa19639d2b0d" xlink:to="loc_us-gaap_ReportingUnitDomain_fccadbe7-4c72-434a-9d5c-7efcfd386064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DetectGenomixMember_83dc9305-4291-4275-9a87-a78b077bf4a4" xlink:href="opk-20220331.xsd#opk_DetectGenomixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_fccadbe7-4c72-434a-9d5c-7efcfd386064" xlink:to="loc_opk_DetectGenomixMember_83dc9305-4291-4275-9a87-a78b077bf4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOBiologicsMember_1254d9e8-c1c3-43b6-a0d4-eb8d7c70a5ae" xlink:href="opk-20220331.xsd#opk_OPKOBiologicsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_fccadbe7-4c72-434a-9d5c-7efcfd386064" xlink:to="loc_opk_OPKOBiologicsMember_1254d9e8-c1c3-43b6-a0d4-eb8d7c70a5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cbefbfae-78a1-445f-9e6b-2020b9b8ed61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cbefbfae-78a1-445f-9e6b-2020b9b8ed61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_82625515-1a25-4b1e-b727-58372c4efbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cbefbfae-78a1-445f-9e6b-2020b9b8ed61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_82625515-1a25-4b1e-b727-58372c4efbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_453a1244-d326-4986-b547-b689f8b884f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_82625515-1a25-4b1e-b727-58372c4efbdf" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_453a1244-d326-4986-b547-b689f8b884f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cbd9507b-b40e-4a72-bcab-5d40b444bcbd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cbd9507b-b40e-4a72-bcab-5d40b444bcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_df713f79-d19a-446f-ab6b-1388653335bd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cbd9507b-b40e-4a72-bcab-5d40b444bcbd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_df713f79-d19a-446f-ab6b-1388653335bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_27e23e62-f1ed-418b-b8ce-c3d125216bbf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_df713f79-d19a-446f-ab6b-1388653335bd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_27e23e62-f1ed-418b-b8ce-c3d125216bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e2ec97cc-be0b-4b05-ab61-0b16330d508b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e2ec97cc-be0b-4b05-ab61-0b16330d508b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d3b03ec-25e9-41c0-93b1-3d3891c776fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e2ec97cc-be0b-4b05-ab61-0b16330d508b" xlink:to="loc_us-gaap_EquityComponentDomain_3d3b03ec-25e9-41c0-93b1-3d3891c776fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7fdc3270-a4cf-4658-aaa6-889dde4e0f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3d3b03ec-25e9-41c0-93b1-3d3891c776fd" xlink:to="loc_us-gaap_RetainedEarningsMember_7fdc3270-a4cf-4658-aaa6-889dde4e0f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_645247b8-8d9a-46d0-ab4b-287cc007833a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3d3b03ec-25e9-41c0-93b1-3d3891c776fd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_645247b8-8d9a-46d0-ab4b-287cc007833a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:href="opk-20220331.xsd#opk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesTable_38767f6c-ffd5-4264-b999-9a5564d90a22" xlink:to="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_b0f91eae-e22e-42c2-b4c9-81d83ea9e952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_InventoryWriteDown_b0f91eae-e22e-42c2-b4c9-81d83ea9e952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets_ecee965b-c72c-4565-9991-aeebb43def07" xlink:href="opk-20220331.xsd#opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets_ecee965b-c72c-4565-9991-aeebb43def07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_318d6f31-1a9d-4268-917c-62629c842643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_Goodwill_318d6f31-1a9d-4268-917c-62629c842643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4a47b498-30a3-4086-9dba-b8283a124712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4a47b498-30a3-4086-9dba-b8283a124712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_07158741-36d7-4815-b935-43acbec09340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_07158741-36d7-4815-b935-43acbec09340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InProcessResearchandDevelopment_fdb799ac-d416-479e-ba61-496f6991466d" xlink:href="opk-20220331.xsd#opk_InProcessResearchandDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_opk_InProcessResearchandDevelopment_fdb799ac-d416-479e-ba61-496f6991466d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0d05a4a8-b827-4997-9ba6-5f889e2eb46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0d05a4a8-b827-4997-9ba6-5f889e2eb46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_eb3cd6cd-f54a-46e7-b4ef-e71023db2788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_eb3cd6cd-f54a-46e7-b4ef-e71023db2788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2e4b2b81-bbdc-41b9-9122-cf08481f73d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2e4b2b81-bbdc-41b9-9122-cf08481f73d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e700aaa0-7303-4387-9113-c11d8aeef9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_Depreciation_e700aaa0-7303-4387-9113-c11d8aeef9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1b468c8a-a96b-4378-b32e-179b40a0cc18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1b468c8a-a96b-4378-b32e-179b40a0cc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_84cffbaa-0dd2-4cf5-9599-02760a3fdb62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_84cffbaa-0dd2-4cf5-9599-02760a3fdb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_e7d4a4ed-431d-41d2-a97e-fcb5176fdc25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_e7d4a4ed-431d-41d2-a97e-fcb5176fdc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a0abc587-6aa3-414c-924c-379834126be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a0abc587-6aa3-414c-924c-379834126be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_c57aef52-0534-4654-a93f-bb0e61250290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_NumberOfReportableSegments_c57aef52-0534-4654-a93f-bb0e61250290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c3da9a52-afd2-4b98-a484-e26633a65c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c3da9a52-afd2-4b98-a484-e26633a65c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7da1eda-5fac-46c7-8172-bac4705a1b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_SummaryOfSignificantAccountingPoliciesLineItems_c1c41282-3895-4c8c-9c85-c4f1074917e6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7da1eda-5fac-46c7-8172-bac4705a1b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="opk-20220331.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2ca8c38d-6aea-4d86-a31e-e351fec60a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_a56f42eb-964d-4978-be1c-bc7ec2832231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2ca8c38d-6aea-4d86-a31e-e351fec60a43" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_a56f42eb-964d-4978-be1c-bc7ec2832231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#EarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9e4f513b-8e08-4ac6-a849-919c6c54d810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb24f2b9-dca5-49bf-a903-ec65a4a4a534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9e4f513b-8e08-4ac6-a849-919c6c54d810" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb24f2b9-dca5-49bf-a903-ec65a4a4a534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fcc0355a-61de-4f38-863c-13f87c812b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb24f2b9-dca5-49bf-a903-ec65a4a4a534" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fcc0355a-61de-4f38-863c-13f87c812b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a10f11b-378d-45e2-9b30-bbae021e9cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fcc0355a-61de-4f38-863c-13f87c812b4c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a10f11b-378d-45e2-9b30-bbae021e9cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_83181f14-92bc-4812-806f-ab3908e61dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a10f11b-378d-45e2-9b30-bbae021e9cda" xlink:to="loc_us-gaap_CommonStockMember_83181f14-92bc-4812-806f-ab3908e61dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd2ac46f-0b8a-4f50-9e92-f0b0c8ed528d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb24f2b9-dca5-49bf-a903-ec65a4a4a534" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd2ac46f-0b8a-4f50-9e92-f0b0c8ed528d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_aa3aab50-fdea-4e92-a4e7-afd9b402b013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd2ac46f-0b8a-4f50-9e92-f0b0c8ed528d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_aa3aab50-fdea-4e92-a4e7-afd9b402b013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_db508a9a-5440-4ce1-b96f-f371edc2b42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd2ac46f-0b8a-4f50-9e92-f0b0c8ed528d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_db508a9a-5440-4ce1-b96f-f371edc2b42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised_810a3f89-2ebd-4fd7-94cb-2c7187e2ccbe" xlink:href="opk-20220331.xsd#opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd2ac46f-0b8a-4f50-9e92-f0b0c8ed528d" xlink:to="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised_810a3f89-2ebd-4fd7-94cb-2c7187e2ccbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment_bc3cee17-01d2-4704-bd2d-13a0bf44c6ff" xlink:href="opk-20220331.xsd#opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd2ac46f-0b8a-4f50-9e92-f0b0c8ed528d" xlink:to="loc_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment_bc3cee17-01d2-4704-bd2d-13a0bf44c6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesSurrenderedInLieuOfCashPayment_62d47bb4-10a7-4c7c-b7fd-56718f699e6e" xlink:href="opk-20220331.xsd#opk_SharesSurrenderedInLieuOfCashPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd2ac46f-0b8a-4f50-9e92-f0b0c8ed528d" xlink:to="loc_opk_SharesSurrenderedInLieuOfCashPayment_62d47bb4-10a7-4c7c-b7fd-56718f699e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions" xlink:type="simple" xlink:href="opk-20220331.xsd#CompositionofCertainFinancialStatementCaptions"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_40825c38-8b3c-4a62-bba3-d7d70a843275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1ede3309-b467-4a97-be24-6d73164608ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_40825c38-8b3c-4a62-bba3-d7d70a843275" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1ede3309-b467-4a97-be24-6d73164608ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables" xlink:type="simple" xlink:href="opk-20220331.xsd#CompositionofCertainFinancialStatementCaptionsTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1beb5a99-f7bb-4b80-833a-c74234242343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock_d551b8d8-a60f-4d52-ae45-c59b0d8eb253" xlink:href="opk-20220331.xsd#opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1beb5a99-f7bb-4b80-833a-c74234242343" xlink:to="loc_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock_d551b8d8-a60f-4d52-ae45-c59b0d8eb253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_33df8f09-8591-41be-9576-ff814091af2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1beb5a99-f7bb-4b80-833a-c74234242343" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_33df8f09-8591-41be-9576-ff814091af2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#CompositionofCertainFinancialStatementCaptionsDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9c0bf284-21f4-4abb-8c94-bd21ca3a585d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_1bc8d246-2baa-4e65-b626-29c98756543a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9c0bf284-21f4-4abb-8c94-bd21ca3a585d" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_1bc8d246-2baa-4e65-b626-29c98756543a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fd6abcc8-b36d-4497-bde3-59293fbdd7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_1bc8d246-2baa-4e65-b626-29c98756543a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fd6abcc8-b36d-4497-bde3-59293fbdd7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fd6abcc8-b36d-4497-bde3-59293fbdd7e9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_eebf7956-c61a-4c29-a523-7ca72b6136b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:to="loc_us-gaap_CustomerRelationshipsMember_eebf7956-c61a-4c29-a523-7ca72b6136b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_97fa7622-c234-4dbc-94ff-91f987cf6408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_97fa7622-c234-4dbc-94ff-91f987cf6408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_e3698099-f82b-43f0-a1e9-7a7233d589c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:to="loc_us-gaap_TradeNamesMember_e3698099-f82b-43f0-a1e9-7a7233d589c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_cd217a04-9bd6-4eb0-9309-a598f590070f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_cd217a04-9bd6-4eb0-9309-a598f590070f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_6fd283ca-e789-4160-af6f-31d8ba5f3ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:to="loc_us-gaap_LicensingAgreementsMember_6fd283ca-e789-4160-af6f-31d8ba5f3ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProductRegistrationsMember_730d5ac2-1045-4de9-b5c5-c2534d718398" xlink:href="opk-20220331.xsd#opk_ProductRegistrationsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:to="loc_opk_ProductRegistrationsMember_730d5ac2-1045-4de9-b5c5-c2534d718398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_ab56c1f8-9598-45f4-a6ba-a221941ebc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a4ff97d-1e7b-4b9d-b358-721b8529b181" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_ab56c1f8-9598-45f4-a6ba-a221941ebc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_1bc8d246-2baa-4e65-b626-29c98756543a" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetAbstract_67243664-5d74-4182-85a4-050ba65572c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:to="loc_us-gaap_AccountsReceivableNetAbstract_67243664-5d74-4182-85a4-050ba65572c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_0a8d1fa2-1958-44c8-bd87-9efd645cd00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_67243664-5d74-4182-85a4-050ba65572c2" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_0a8d1fa2-1958-44c8-bd87-9efd645cd00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_66b634a9-5a2d-4bc0-92bf-3957a59623af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_67243664-5d74-4182-85a4-050ba65572c2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_66b634a9-5a2d-4bc0-92bf-3957a59623af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3ec86677-de29-4cb0-a015-41182f4bc19c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetAbstract_67243664-5d74-4182-85a4-050ba65572c2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3ec86677-de29-4cb0-a015-41182f4bc19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:to="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_95f49777-ebfb-4544-96ac-568ba749a16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:to="loc_us-gaap_OtherInventorySupplies_95f49777-ebfb-4544-96ac-568ba749a16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_eb2625f3-ca4b-44c5-9ca6-ae7d654c4934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:to="loc_us-gaap_InventoryFinishedGoods_eb2625f3-ca4b-44c5-9ca6-ae7d654c4934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_80d7e9ba-a068-42de-a172-c93f9b0d546b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:to="loc_us-gaap_InventoryWorkInProcess_80d7e9ba-a068-42de-a172-c93f9b0d546b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_8801ddca-2d02-417f-89ed-5c91f82adefd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:to="loc_us-gaap_InventoryRawMaterials_8801ddca-2d02-417f-89ed-5c91f82adefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_ac5fb174-1b55-444c-908b-fbb6023efc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:to="loc_us-gaap_InventoryValuationReserves_ac5fb174-1b55-444c-908b-fbb6023efc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2099637d-d5a9-409d-a9b2-379070cf8c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_b8e0d671-e4b2-43a3-847f-18547a00780d" xlink:to="loc_us-gaap_InventoryNet_2099637d-d5a9-409d-a9b2-379070cf8c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TaxesRecoverableCurrent_3dfc75a5-3179-4461-bf77-16f7af29636a" xlink:href="opk-20220331.xsd#opk_TaxesRecoverableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:to="loc_opk_TaxesRecoverableCurrent_3dfc75a5-3179-4461-bf77-16f7af29636a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_a71985df-bca3-4684-a1e6-28695734ae34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Supplies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:to="loc_us-gaap_Supplies_a71985df-bca3-4684-a1e6-28695734ae34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_2018849b-b3f3-4cb3-82f7-5dc73ef6ad1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:to="loc_us-gaap_PrepaidInsurance_2018849b-b3f3-4cb3-82f7-5dc73ef6ad1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_602db0b1-6821-42d0-b909-9026c16f9e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_602db0b1-6821-42d0-b909-9026c16f9e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5666dea6-4665-4c76-aad9-997dd365fdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:to="loc_us-gaap_OtherAssetsCurrent_5666dea6-4665-4c76-aad9-997dd365fdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4885afce-0847-4f76-ba13-656b138b7f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_36760b2a-d86f-415a-9a33-1a196846250e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4885afce-0847-4f76-ba13-656b138b7f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8a405dca-3b87-4ddb-b3da-5d31a922a1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8a405dca-3b87-4ddb-b3da-5d31a922a1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3df31aa2-6a85-4d08-b0c8-26ec5c4b039d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8a405dca-3b87-4ddb-b3da-5d31a922a1c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3df31aa2-6a85-4d08-b0c8-26ec5c4b039d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e8ba5382-af8f-4b55-9ba3-41b71dcdce8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8a405dca-3b87-4ddb-b3da-5d31a922a1c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e8ba5382-af8f-4b55-9ba3-41b71dcdce8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_28604bb2-3b34-4b35-b2f5-f5550178af93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8a405dca-3b87-4ddb-b3da-5d31a922a1c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_28604bb2-3b34-4b35-b2f5-f5550178af93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InventoryReceivedNotInvoicedCurrent_fc3f9fba-889e-4107-9a79-409e065d3607" xlink:href="opk-20220331.xsd#opk_InventoryReceivedNotInvoicedCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_opk_InventoryReceivedNotInvoicedCurrent_fc3f9fba-889e-4107-9a79-409e065d3607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedCommitmentsandContingenciesCurrent_72265df6-5a7b-4560-a7c3-241f25641931" xlink:href="opk-20220331.xsd#opk_AccruedCommitmentsandContingenciesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_opk_AccruedCommitmentsandContingenciesCurrent_72265df6-5a7b-4560-a7c3-241f25641931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_0c416bab-f15c-400a-8a2a-6abccbd2044b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_0c416bab-f15c-400a-8a2a-6abccbd2044b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f2d7f410-98e7-4502-9425-850b7111c175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f2d7f410-98e7-4502-9425-850b7111c175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedClinicalTrialsCurrent_e20a59e3-32c2-4829-b8e3-a240782aa6a4" xlink:href="opk-20220331.xsd#opk_AccruedClinicalTrialsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_opk_AccruedClinicalTrialsCurrent_e20a59e3-32c2-4829-b8e3-a240782aa6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5f6598fe-830b-4537-b0f0-a1dec4df25b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5f6598fe-830b-4537-b0f0-a1dec4df25b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_44752699-dbea-44c3-9f98-4aeccb7fb932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_44752699-dbea-44c3-9f98-4aeccb7fb932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_b7d4b03c-35c1-485d-9e33-d477ec327e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_b7d4b03c-35c1-485d-9e33-d477ec327e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b77f3b2a-cf3c-4aa1-9828-6edd0232a533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b77f3b2a-cf3c-4aa1-9828-6edd0232a533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0b7e5729-191a-4b54-b06b-5775104f3083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_53c4d188-b9fd-426f-b7bc-45519b14c498" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0b7e5729-191a-4b54-b06b-5775104f3083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_b8572770-e31b-4c18-9be6-05b5fd6f032e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_63c09f1c-020a-4b01-9ee8-50aee0b3c836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_63c09f1c-020a-4b01-9ee8-50aee0b3c836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_c61b3f5c-58ab-4d11-b318-3bd1fffb8958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent_c61b3f5c-58ab-4d11-b318-3bd1fffb8958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_148c3dee-e078-41bd-bfa2-db002447282f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_148c3dee-e078-41bd-bfa2-db002447282f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ec8960af-b1d3-4c03-bb95-f3575c28f224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ec8960af-b1d3-4c03-bb95-f3575c28f224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_3cbe05b2-22d2-4dc8-a837-d8242c2ababa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:to="loc_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent_3cbe05b2-22d2-4dc8-a837-d8242c2ababa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_74a11bd0-96ba-4573-bd9c-1c92163fcb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_ef17702c-aa25-44e6-8c01-60aca37009bb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_74a11bd0-96ba-4573-bd9c-1c92163fcb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#CompositionofCertainFinancialStatementCaptionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e0000266-7c31-4d70-a61c-457611bc29a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ca26d086-cff9-4f5b-ba46-70040cdfd6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e0000266-7c31-4d70-a61c-457611bc29a5" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ca26d086-cff9-4f5b-ba46-70040cdfd6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d89aa4f4-3446-4300-8a76-d0034e47e402" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ca26d086-cff9-4f5b-ba46-70040cdfd6af" xlink:to="loc_srt_RangeAxis_d89aa4f4-3446-4300-8a76-d0034e47e402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37829658-f74c-4e50-9754-133f02ca4854" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d89aa4f4-3446-4300-8a76-d0034e47e402" xlink:to="loc_srt_RangeMember_37829658-f74c-4e50-9754-133f02ca4854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1ab486e8-33bc-4fe2-9637-9060dcfe4a10" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_37829658-f74c-4e50-9754-133f02ca4854" xlink:to="loc_srt_MinimumMember_1ab486e8-33bc-4fe2-9637-9060dcfe4a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_06c6e4b0-b371-4084-9e71-b7babb98e4ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_37829658-f74c-4e50-9754-133f02ca4854" xlink:to="loc_srt_MaximumMember_06c6e4b0-b371-4084-9e71-b7babb98e4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f5676af-a742-4ea2-953a-d558f9882ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ca26d086-cff9-4f5b-ba46-70040cdfd6af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f5676af-a742-4ea2-953a-d558f9882ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f5676af-a742-4ea2-953a-d558f9882ea0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_c4c633b9-627e-42f8-aae0-0e4662a0d741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_c4c633b9-627e-42f8-aae0-0e4662a0d741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6b01f0d2-f188-4815-835d-3a4256cd3300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6b01f0d2-f188-4815-835d-3a4256cd3300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5ba2ad26-d08f-4bc8-819c-bcbb8229ac26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:to="loc_us-gaap_ProductMember_5ba2ad26-d08f-4bc8-819c-bcbb8229ac26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CovenantsNotToCompeteMember_2c1d905e-8654-467f-b1ee-305f5a1598b6" xlink:href="opk-20220331.xsd#opk_CovenantsNotToCompeteMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:to="loc_opk_CovenantsNotToCompeteMember_2c1d905e-8654-467f-b1ee-305f5a1598b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_38150ff9-10f2-4767-ba93-98cff0cd9030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:to="loc_us-gaap_TradeNamesMember_38150ff9-10f2-4767-ba93-98cff0cd9030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_7306a1df-29bf-443e-95bc-8d31f230bf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_7306a1df-29bf-443e-95bc-8d31f230bf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_46a15d63-eabe-4b6a-89b6-a6b8bd09cabe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0508886d-678c-467b-ba9e-2ff51173d0ab" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_46a15d63-eabe-4b6a-89b6-a6b8bd09cabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_fcd3a635-4372-4a7a-82f2-1a0e35f8f41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ca26d086-cff9-4f5b-ba46-70040cdfd6af" xlink:to="loc_us-gaap_ReportingUnitAxis_fcd3a635-4372-4a7a-82f2-1a0e35f8f41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_a105d41f-712e-4a27-8ace-5acd090a18b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_fcd3a635-4372-4a7a-82f2-1a0e35f8f41e" xlink:to="loc_us-gaap_ReportingUnitDomain_a105d41f-712e-4a27-8ace-5acd090a18b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DetectGenomixMember_55c7ebe3-8440-43c2-bb23-6c4623f3295b" xlink:href="opk-20220331.xsd#opk_DetectGenomixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_a105d41f-712e-4a27-8ace-5acd090a18b0" xlink:to="loc_opk_DetectGenomixMember_55c7ebe3-8440-43c2-bb23-6c4623f3295b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOBiologicsMember_4786984a-8104-4f70-875c-1a9091efb41a" xlink:href="opk-20220331.xsd#opk_OPKOBiologicsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_a105d41f-712e-4a27-8ace-5acd090a18b0" xlink:to="loc_opk_OPKOBiologicsMember_4786984a-8104-4f70-875c-1a9091efb41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_59baedc3-be1d-4423-94cb-75275e0d40cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ca26d086-cff9-4f5b-ba46-70040cdfd6af" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_59baedc3-be1d-4423-94cb-75275e0d40cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4839c2c0-fe6d-4ec1-82b1-2c0c4afb415b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_59baedc3-be1d-4423-94cb-75275e0d40cc" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4839c2c0-fe6d-4ec1-82b1-2c0c4afb415b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c0e4892f-b192-4807-9af0-77b477875f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_59baedc3-be1d-4423-94cb-75275e0d40cc" xlink:to="loc_us-gaap_Goodwill_c0e4892f-b192-4807-9af0-77b477875f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e8bb2b5f-a116-4736-96cd-915264e5482e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_59baedc3-be1d-4423-94cb-75275e0d40cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e8bb2b5f-a116-4736-96cd-915264e5482e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0eac4d99-0a2e-497c-8dff-98507f31c176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_59baedc3-be1d-4423-94cb-75275e0d40cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0eac4d99-0a2e-497c-8dff-98507f31c176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InProcessResearchandDevelopment_23155d91-5f76-4b4e-a30d-6329f8d3d3e8" xlink:href="opk-20220331.xsd#opk_InProcessResearchandDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_59baedc3-be1d-4423-94cb-75275e0d40cc" xlink:to="loc_opk_InProcessResearchandDevelopment_23155d91-5f76-4b4e-a30d-6329f8d3d3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e822ea79-ff90-43c5-b246-5d3cf6eb850a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_f56d9465-93fc-4584-833b-840ea595d0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e822ea79-ff90-43c5-b246-5d3cf6eb850a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_f56d9465-93fc-4584-833b-840ea595d0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0cf3026a-f822-4d53-89f5-1c8a394f8a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_f56d9465-93fc-4584-833b-840ea595d0b6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0cf3026a-f822-4d53-89f5-1c8a394f8a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a3fc09c0-bd48-43b2-90a3-545876153841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0cf3026a-f822-4d53-89f5-1c8a394f8a1e" xlink:to="loc_us-gaap_SegmentDomain_a3fc09c0-bd48-43b2-90a3-545876153841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmaceuticalMember_a75357c6-88cc-4b4d-a097-36ade7fd6d80" xlink:href="opk-20220331.xsd#opk_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a3fc09c0-bd48-43b2-90a3-545876153841" xlink:to="loc_opk_PharmaceuticalMember_a75357c6-88cc-4b4d-a097-36ade7fd6d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticsMember_7a00e22f-3424-4c35-ac7f-de7d1b7af526" xlink:href="opk-20220331.xsd#opk_DiagnosticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a3fc09c0-bd48-43b2-90a3-545876153841" xlink:to="loc_opk_DiagnosticsMember_7a00e22f-3424-4c35-ac7f-de7d1b7af526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_26f94f49-710e-4089-9964-ea7ba654c347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_f56d9465-93fc-4584-833b-840ea595d0b6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_26f94f49-710e-4089-9964-ea7ba654c347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26f94f49-710e-4089-9964-ea7ba654c347" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CURNAMember_5efbd718-b43f-4d26-ae96-b71047e4a926" xlink:href="opk-20220331.xsd#opk_CURNAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_CURNAMember_5efbd718-b43f-4d26-ae96-b71047e4a926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EirGenPharmaLimitedMember_fe454cef-16e9-4c0c-98fb-ef26465219b3" xlink:href="opk-20220331.xsd#opk_EirGenPharmaLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_EirGenPharmaLimitedMember_fe454cef-16e9-4c0c-98fb-ef26465219b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FineTechMember_7109644b-acb5-4e6d-9bd6-12f83ace0dbe" xlink:href="opk-20220331.xsd#opk_FineTechMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_FineTechMember_7109644b-acb5-4e6d-9bd6-12f83ace0dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOBiologicsMember_4d387f89-eb24-4890-a244-08eeea4243bf" xlink:href="opk-20220331.xsd#opk_OPKOBiologicsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_OPKOBiologicsMember_4d387f89-eb24-4890-a244-08eeea4243bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OpkoChileMember_1f137e02-4372-41d7-acd2-1362e6966f8b" xlink:href="opk-20220331.xsd#opk_OpkoChileMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_OpkoChileMember_1f137e02-4372-41d7-acd2-1362e6966f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOHealthEuropeMember_63b11a06-e505-40da-92cb-f6aba142bd31" xlink:href="opk-20220331.xsd#opk_OPKOHealthEuropeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_OPKOHealthEuropeMember_63b11a06-e505-40da-92cb-f6aba142bd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOMexicoMember_b9961c59-6c96-496d-b49d-cb5817ce5b00" xlink:href="opk-20220331.xsd#opk_OPKOMexicoMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_OPKOMexicoMember_b9961c59-6c96-496d-b49d-cb5817ce5b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransitionTherapeuticsInc.Member_7816e312-72fd-446f-9fdf-52a83f53f6b6" xlink:href="opk-20220331.xsd#opk_TransitionTherapeuticsInc.Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_TransitionTherapeuticsInc.Member_7816e312-72fd-446f-9fdf-52a83f53f6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioReferenceMember_fd4923bd-351d-407f-a445-97dc3c269e49" xlink:href="opk-20220331.xsd#opk_BioReferenceMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_BioReferenceMember_fd4923bd-351d-407f-a445-97dc3c269e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OpkoDiagnosticsMember_fab65fcc-faec-4828-bfca-302af60008c5" xlink:href="opk-20220331.xsd#opk_OpkoDiagnosticsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8843384-b8fe-47c6-9621-4f3d15357c5b" xlink:to="loc_opk_OpkoDiagnosticsMember_fab65fcc-faec-4828-bfca-302af60008c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_59523d1d-de19-4fe2-ab02-01536d998b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_f56d9465-93fc-4584-833b-840ea595d0b6" xlink:to="loc_us-gaap_GoodwillLineItems_59523d1d-de19-4fe2-ab02-01536d998b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_af194e44-6656-4e52-9393-21bdc3f53519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_59523d1d-de19-4fe2-ab02-01536d998b47" xlink:to="loc_us-gaap_GoodwillRollForward_af194e44-6656-4e52-9393-21bdc3f53519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9b8e4201-4d46-44cb-bfc9-9cd31686164b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_af194e44-6656-4e52-9393-21bdc3f53519" xlink:to="loc_us-gaap_Goodwill_9b8e4201-4d46-44cb-bfc9-9cd31686164b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f7725ff7-2bf6-42b9-9277-b8b202ec64af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_af194e44-6656-4e52-9393-21bdc3f53519" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f7725ff7-2bf6-42b9-9277-b8b202ec64af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_07c6d4a5-0608-4a2b-9594-bfa53ca774ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_af194e44-6656-4e52-9393-21bdc3f53519" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_07c6d4a5-0608-4a2b-9594-bfa53ca774ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dff44edd-6535-4351-aa2a-3c2851058485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_af194e44-6656-4e52-9393-21bdc3f53519" xlink:to="loc_us-gaap_Goodwill_dff44edd-6535-4351-aa2a-3c2851058485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/Investments" xlink:type="simple" xlink:href="opk-20220331.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_e359291a-1807-4b56-8671-882eddedf3e3" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock_d0e1b5ac-3552-4616-a965-55b6992b5cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_e359291a-1807-4b56-8671-882eddedf3e3" xlink:to="loc_us-gaap_InvestmentTextBlock_d0e1b5ac-3552-4616-a965-55b6992b5cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsTables" xlink:type="simple" xlink:href="opk-20220331.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_1a55efcc-b5f3-4390-bfa0-6ee18aceb565" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock_424b2541-751d-4ac5-ba06-c82e79700f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_1a55efcc-b5f3-4390-bfa0-6ee18aceb565" xlink:to="loc_us-gaap_InvestmentTableTextBlock_424b2541-751d-4ac5-ba06-c82e79700f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_4b01a885-d0d2-4d4b-8976-b5d14cf81982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_1a55efcc-b5f3-4390-bfa0-6ee18aceb565" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_4b01a885-d0d2-4d4b-8976-b5d14cf81982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_e699a6f3-13a4-403f-af8d-5027d9101f80" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_bbd236e4-a700-4259-87ca-91807e4d5d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_e699a6f3-13a4-403f-af8d-5027d9101f80" xlink:to="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_bbd236e4-a700-4259-87ca-91807e4d5d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentExcludingVariableInterestEntity_805e18d0-c4e6-43ab-95a3-db0d1fe0b97b" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentExcludingVariableInterestEntity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_bbd236e4-a700-4259-87ca-91807e4d5d8d" xlink:to="loc_opk_EquityMethodInvestmentExcludingVariableInterestEntity_805e18d0-c4e6-43ab-95a3-db0d1fe0b97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentVariableInterestEntity_73e089a5-2caf-4e71-8bac-81f218bc8d71" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentVariableInterestEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_bbd236e4-a700-4259-87ca-91807e4d5d8d" xlink:to="loc_opk_EquityMethodInvestmentVariableInterestEntity_73e089a5-2caf-4e71-8bac-81f218bc8d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_4cfeb0d0-57bd-4475-b24c-eeff383932d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_bbd236e4-a700-4259-87ca-91807e4d5d8d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_4cfeb0d0-57bd-4475-b24c-eeff383932d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_aeb4cbe3-e00f-4608-8568-55f45de461dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_bbd236e4-a700-4259-87ca-91807e4d5d8d" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_aeb4cbe3-e00f-4608-8568-55f45de461dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StockOptionandWarrantInvestments_b7360b60-f1bf-4ff4-855b-2afeec26846a" xlink:href="opk-20220331.xsd#opk_StockOptionandWarrantInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_bbd236e4-a700-4259-87ca-91807e4d5d8d" xlink:to="loc_opk_StockOptionandWarrantInvestments_b7360b60-f1bf-4ff4-855b-2afeec26846a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_2a892dfc-05aa-490c-ab42-766a934cc440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_bbd236e4-a700-4259-87ca-91807e4d5d8d" xlink:to="loc_us-gaap_LongTermInvestments_2a892dfc-05aa-490c-ab42-766a934cc440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract_649c160f-1d41-4af9-a323-0ad26bf4f6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_e699a6f3-13a4-403f-af8d-5027d9101f80" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract_649c160f-1d41-4af9-a323-0ad26bf4f6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_cf453413-7968-4f82-81cc-45df6f27d56e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract_649c160f-1d41-4af9-a323-0ad26bf4f6ae" xlink:to="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_cf453413-7968-4f82-81cc-45df6f27d56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets_ed123b98-7d92-47c6-945e-75c0db7652a9" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract_649c160f-1d41-4af9-a323-0ad26bf4f6ae" xlink:to="loc_opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets_ed123b98-7d92-47c6-945e-75c0db7652a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_f9018ead-cd27-4fde-ac34-278eba91b48a" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_f9018ead-cd27-4fde-ac34-278eba91b48a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_facf824a-e2a0-46f1-a257-6b2b26c10cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_facf824a-e2a0-46f1-a257-6b2b26c10cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fcef0fb9-932b-476b-9286-47f7803034fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_facf824a-e2a0-46f1-a257-6b2b26c10cdf" xlink:to="loc_us-gaap_ClassOfStockDomain_fcef0fb9-932b-476b-9286-47f7803034fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5156fd75-d1b1-4316-bc77-bc6f2b869322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fcef0fb9-932b-476b-9286-47f7803034fb" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5156fd75-d1b1-4316-bc77-bc6f2b869322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0272e416-95bd-4686-b63b-efcf92aaf7db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fcef0fb9-932b-476b-9286-47f7803034fb" xlink:to="loc_us-gaap_RestrictedStockMember_0272e416-95bd-4686-b63b-efcf92aaf7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_720c2381-5877-4af2-85a0-01abf32decdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_720c2381-5877-4af2-85a0-01abf32decdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_720c2381-5877-4af2-85a0-01abf32decdf" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmsynthezMember_d3e758a9-9622-4e88-a935-5d4c294c890a" xlink:href="opk-20220331.xsd#opk_PharmsynthezMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_PharmsynthezMember_d3e758a9-9622-4e88-a935-5d4c294c890a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CocrystalMember_b74b985d-f62d-416f-b3dc-51af7354f1e2" xlink:href="opk-20220331.xsd#opk_CocrystalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_CocrystalMember_b74b985d-f62d-416f-b3dc-51af7354f1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NonInvasiveMonitoringSystemsInc.Member_1842faae-1c8b-4f6e-9d55-855a1b646dcb" xlink:href="opk-20220331.xsd#opk_NonInvasiveMonitoringSystemsInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_NonInvasiveMonitoringSystemsInc.Member_1842faae-1c8b-4f6e-9d55-855a1b646dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NeovascMember_3b4532e1-8db4-4b6d-9d1c-3d9f3aeb04f0" xlink:href="opk-20220331.xsd#opk_NeovascMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_NeovascMember_3b4532e1-8db4-4b6d-9d1c-3d9f3aeb04f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InCellDxIncMember_218e1eb4-008c-4709-ac3b-772e5007f7d1" xlink:href="opk-20220331.xsd#opk_InCellDxIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_InCellDxIncMember_218e1eb4-008c-4709-ac3b-772e5007f7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioCardiaInc.Member_84cd7949-36c1-4b6e-b2dc-d1537130f373" xlink:href="opk-20220331.xsd#opk_BioCardiaInc.Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_BioCardiaInc.Member_84cd7949-36c1-4b6e-b2dc-d1537130f373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_XeneticBiosciencesInc.Member_7b146966-9236-46c2-857a-33f438ef6120" xlink:href="opk-20220331.xsd#opk_XeneticBiosciencesInc.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_XeneticBiosciencesInc.Member_7b146966-9236-46c2-857a-33f438ef6120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PhioPharmaceuticalsMember_de4ab131-99bc-4c7c-a68c-8b674aeb8452" xlink:href="opk-20220331.xsd#opk_PhioPharmaceuticalsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_PhioPharmaceuticalsMember_de4ab131-99bc-4c7c-a68c-8b674aeb8452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_VBIVaccinesIncMember_e447dc85-c526-4c1a-b9b6-28688302d019" xlink:href="opk-20220331.xsd#opk_VBIVaccinesIncMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_VBIVaccinesIncMember_e447dc85-c526-4c1a-b9b6-28688302d019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChromaDexMember_f26688bd-1d44-4cf4-9fd7-593cff32d81b" xlink:href="opk-20220331.xsd#opk_ChromaDexMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_ChromaDexMember_f26688bd-1d44-4cf4-9fd7-593cff32d81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EloxxPharmaceuticalsMember_6f0e07f3-820d-4dc4-b4b4-3af745ecb667" xlink:href="opk-20220331.xsd#opk_EloxxPharmaceuticalsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_EloxxPharmaceuticalsMember_6f0e07f3-820d-4dc4-b4b4-3af745ecb667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CAMP4Member_5f6d3bc1-f861-40b2-8bdf-bba45156c12c" xlink:href="opk-20220331.xsd#opk_CAMP4Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_CAMP4Member_5f6d3bc1-f861-40b2-8bdf-bba45156c12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_HealthSnapMember_a2e47cec-a2ef-4ced-a065-bf3f07e45787" xlink:href="opk-20220331.xsd#opk_HealthSnapMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_HealthSnapMember_a2e47cec-a2ef-4ced-a065-bf3f07e45787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LeaderMedMember_78b43e84-381c-4c8d-ba0a-b623e7250bc8" xlink:href="opk-20220331.xsd#opk_LeaderMedMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_LeaderMedMember_78b43e84-381c-4c8d-ba0a-b623e7250bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DetectGenomixMember_f4ef1f8e-6852-414e-8b50-3b8cfc6f7aa4" xlink:href="opk-20220331.xsd#opk_DetectGenomixMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_DetectGenomixMember_f4ef1f8e-6852-414e-8b50-3b8cfc6f7aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ZebraMember_d5fdad77-3caf-4b10-b8df-1d9af7c7a9a1" xlink:href="opk-20220331.xsd#opk_ZebraMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ce1a758-6892-4273-9e4c-f9fb5139b6ee" xlink:to="loc_opk_ZebraMember_d5fdad77-3caf-4b10-b8df-1d9af7c7a9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_ab3a15a8-0f72-42e5-82db-552b65929cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_ab3a15a8-0f72-42e5-82db-552b65929cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4debf188-8b21-4b27-9d2a-a6ae6116fbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_ab3a15a8-0f72-42e5-82db-552b65929cbe" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4debf188-8b21-4b27-9d2a-a6ae6116fbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_a3106de7-6f5b-4709-9b03-0d066475d91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4debf188-8b21-4b27-9d2a-a6ae6116fbe0" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_a3106de7-6f5b-4709-9b03-0d066475d91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_266f7c42-242c-4958-858d-a1aabd16aacf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_srt_ConsolidatedEntitiesAxis_266f7c42-242c-4958-858d-a1aabd16aacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_94e0eb50-ff24-44d0-9a90-d1c205d2afd6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_266f7c42-242c-4958-858d-a1aabd16aacf" xlink:to="loc_srt_ConsolidatedEntitiesDomain_94e0eb50-ff24-44d0-9a90-d1c205d2afd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_c5e9660b-07f6-48e2-8f10-4d907543a559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_94e0eb50-ff24-44d0-9a90-d1c205d2afd6" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_c5e9660b-07f6-48e2-8f10-4d907543a559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_675b30cf-7f09-4d6c-ad4e-a4227d023237" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_srt_CounterpartyNameAxis_675b30cf-7f09-4d6c-ad4e-a4227d023237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6164ca94-929b-4d19-bf3c-fe859836fed9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_675b30cf-7f09-4d6c-ad4e-a4227d023237" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6164ca94-929b-4d19-bf3c-fe859836fed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LeaderMedMember_df9b0900-a4ba-434b-971d-34963ca1a3bf" xlink:href="opk-20220331.xsd#opk_LeaderMedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6164ca94-929b-4d19-bf3c-fe859836fed9" xlink:to="loc_opk_LeaderMedMember_df9b0900-a4ba-434b-971d-34963ca1a3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5d68512d-406e-410c-a19d-2e4a79cedfe2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_srt_OwnershipAxis_5d68512d-406e-410c-a19d-2e4a79cedfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_007084f8-5630-48af-8301-0f9e63a6b525" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_5d68512d-406e-410c-a19d-2e4a79cedfe2" xlink:to="loc_srt_OwnershipDomain_007084f8-5630-48af-8301-0f9e63a6b525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LeaderMedJointVentureMember_20df0c93-fd32-4b99-a61c-b4cd1195362b" xlink:href="opk-20220331.xsd#opk_LeaderMedJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_007084f8-5630-48af-8301-0f9e63a6b525" xlink:to="loc_opk_LeaderMedJointVentureMember_20df0c93-fd32-4b99-a61c-b4cd1195362b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_441da562-a141-4411-8365-f6ae18c5798e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_441da562-a141-4411-8365-f6ae18c5798e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_643bda56-7edf-4d81-9929-f3192e6858f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_441da562-a141-4411-8365-f6ae18c5798e" xlink:to="loc_us-gaap_RelatedPartyDomain_643bda56-7edf-4d81-9929-f3192e6858f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_701bc2ea-ca0a-46f1-82af-03d6ae0f1384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_643bda56-7edf-4d81-9929-f3192e6858f8" xlink:to="loc_us-gaap_CorporateJointVentureMember_701bc2ea-ca0a-46f1-82af-03d6ae0f1384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_943bb446-5928-4b8b-a186-43e516de35e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_srt_ProductOrServiceAxis_943bb446-5928-4b8b-a186-43e516de35e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2a46b7b6-1c1a-4759-9f80-a55feb7b31e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_943bb446-5928-4b8b-a186-43e516de35e3" xlink:to="loc_srt_ProductsAndServicesDomain_2a46b7b6-1c1a-4759-9f80-a55feb7b31e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_b8142100-171f-4cb6-8078-c7d01db9fcc0" xlink:href="opk-20220331.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a46b7b6-1c1a-4759-9f80-a55feb7b31e8" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_b8142100-171f-4cb6-8078-c7d01db9fcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1ceb9214-98c1-439c-8f23-1dad9dcb5c9d" xlink:to="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a957a184-1d3e-4a9c-9aa3-d10d7730930b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a957a184-1d3e-4a9c-9aa3-d10d7730930b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b550b7b0-7954-4a37-9c95-3dd5f18995cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_Assets_b550b7b0-7954-4a37-9c95-3dd5f18995cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fcc1260b-d02c-40ac-9ebf-d50bcf009f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_Liabilities_fcc1260b-d02c-40ac-9ebf-d50bcf009f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_af029403-587b-4349-a2f3-11946b722164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_ProfitLoss_af029403-587b-4349-a2f3-11946b722164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_461aeb3f-89fb-44e1-9ab2-9db54be6ddd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_461aeb3f-89fb-44e1-9ab2-9db54be6ddd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquitySecurityFVNIOwnershipPercent_4e6edbc8-4f33-4692-890c-014f4f3c87dc" xlink:href="opk-20220331.xsd#opk_EquitySecurityFVNIOwnershipPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_opk_EquitySecurityFVNIOwnershipPercent_4e6edbc8-4f33-4692-890c-014f4f3c87dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_cb9ca8fe-38fc-4790-9b16-feab2d5085a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_cb9ca8fe-38fc-4790-9b16-feab2d5085a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NoncontrollingInterestSharesIssued_2bd44fdb-7428-4038-95b6-0bebf5b5b40e" xlink:href="opk-20220331.xsd#opk_NoncontrollingInterestSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_opk_NoncontrollingInterestSharesIssued_2bd44fdb-7428-4038-95b6-0bebf5b5b40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_e98233ef-2368-4a7b-b06b-a32c3e48cc03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_e98233ef-2368-4a7b-b06b-a32c3e48cc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85912a07-346c-4080-ab2e-488bba724c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85912a07-346c-4080-ab2e-488bba724c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_c309bc90-636b-4f88-8a43-362b6c136529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_c309bc90-636b-4f88-8a43-362b6c136529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_9e3a8920-ee5c-43ec-ae5f-05e020a0bda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_9e3a8920-ee5c-43ec-ae5f-05e020a0bda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedAsGift_31bcf960-fe74-41fb-815e-cec2433b346c" xlink:href="opk-20220331.xsd#opk_SharesReceivedAsGift"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems_21e79be6-ad12-4dcd-9ad3-75cfc8c32650" xlink:to="loc_opk_SharesReceivedAsGift_31bcf960-fe74-41fb-815e-cec2433b346c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_bcc90228-1bf3-4323-b585-c5b50891895e" xlink:href="opk-20220331.xsd#opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAbstract_fa266943-8174-416d-bf23-453c6fc99fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract_bcc90228-1bf3-4323-b585-c5b50891895e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAbstract_fa266943-8174-416d-bf23-453c6fc99fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_bf305263-c746-4c77-815f-0d275d270f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAbstract_fa266943-8174-416d-bf23-453c6fc99fa0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_bf305263-c746-4c77-815f-0d275d270f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_866d417a-8181-4c23-ab58-66462e31476a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAbstract_fa266943-8174-416d-bf23-453c6fc99fa0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_866d417a-8181-4c23-ab58-66462e31476a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_878654d4-21ee-4632-9756-2120eb042b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAbstract_fa266943-8174-416d-bf23-453c6fc99fa0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_878654d4-21ee-4632-9756-2120eb042b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/Debt" xlink:type="simple" xlink:href="opk-20220331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e45f385f-2279-41aa-abef-2948f0a48fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_082d18e2-ab5c-4807-a032-fe82128f88f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e45f385f-2279-41aa-abef-2948f0a48fe8" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_082d18e2-ab5c-4807-a032-fe82128f88f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtTables" xlink:type="simple" xlink:href="opk-20220331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_db6799d2-d6c1-443f-9646-089f0258e586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_9975ea5a-4854-4dd2-adf6-21dc22bbb600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_db6799d2-d6c1-443f-9646-089f0258e586" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_9975ea5a-4854-4dd2-adf6-21dc22bbb600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_20f9091d-61c5-4396-bb4b-01e4605b2bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_db6799d2-d6c1-443f-9646-089f0258e586" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_20f9091d-61c5-4396-bb4b-01e4605b2bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_164b8d53-f3fd-4c55-bca3-7e79616a4c30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_db6799d2-d6c1-443f-9646-089f0258e586" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_164b8d53-f3fd-4c55-bca3-7e79616a4c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtScheduleofDebtDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DebtScheduleofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DebtScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_650cb423-6974-49bf-82aa-b680570e91ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e30a42d4-efb6-462f-ba2e-116e910c98f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_650cb423-6974-49bf-82aa-b680570e91ca" xlink:to="loc_us-gaap_DebtInstrumentTable_e30a42d4-efb6-462f-ba2e-116e910c98f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9d4e734d-193e-41e7-9633-d5971891b98e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e30a42d4-efb6-462f-ba2e-116e910c98f0" xlink:to="loc_us-gaap_DebtInstrumentAxis_9d4e734d-193e-41e7-9633-d5971891b98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_157d7b56-b7bf-4e6e-b974-a36b23bb71cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d4e734d-193e-41e7-9633-d5971891b98e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_157d7b56-b7bf-4e6e-b974-a36b23bb71cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ConvertibleSeniorNotesDue2025Member_c55a896b-7ee1-45a0-98ec-eeee4bda873a" xlink:href="opk-20220331.xsd#opk_ConvertibleSeniorNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_157d7b56-b7bf-4e6e-b974-a36b23bb71cc" xlink:to="loc_opk_ConvertibleSeniorNotesDue2025Member_c55a896b-7ee1-45a0-98ec-eeee4bda873a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_A5ConvertibleNotesMember_60a04b73-6dd8-4a2c-b6d0-05a4e829dd6d" xlink:href="opk-20220331.xsd#opk_A5ConvertibleNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_157d7b56-b7bf-4e6e-b974-a36b23bb71cc" xlink:to="loc_opk_A5ConvertibleNotesMember_60a04b73-6dd8-4a2c-b6d0-05a4e829dd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NotesDueFebruary12033Member_4897104a-44e5-4daf-bb8e-b882ea3ada09" xlink:href="opk-20220331.xsd#opk_NotesDueFebruary12033Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_157d7b56-b7bf-4e6e-b974-a36b23bb71cc" xlink:to="loc_opk_NotesDueFebruary12033Member_4897104a-44e5-4daf-bb8e-b882ea3ada09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_86b4ab33-8962-4850-96b2-cf9749a0b30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e30a42d4-efb6-462f-ba2e-116e910c98f0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_86b4ab33-8962-4850-96b2-cf9749a0b30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3890c795-d210-473f-877c-f431b85879f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_86b4ab33-8962-4850-96b2-cf9749a0b30c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3890c795-d210-473f-877c-f431b85879f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_fb62dd66-84e8-4c6d-8279-5e9bf43077fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3890c795-d210-473f-877c-f431b85879f0" xlink:to="loc_us-gaap_ConvertibleDebtMember_fb62dd66-84e8-4c6d-8279-5e9bf43077fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_c9aae9b0-b7a8-49ea-9caf-1eb43c74aad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3890c795-d210-473f-877c-f431b85879f0" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_c9aae9b0-b7a8-49ea-9caf-1eb43c74aad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_0e56c7ea-1e4b-426a-8f70-533082f9d836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3890c795-d210-473f-877c-f431b85879f0" xlink:to="loc_us-gaap_LineOfCreditMember_0e56c7ea-1e4b-426a-8f70-533082f9d836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_34fe8a95-56ae-4114-9ab0-d6c5c66e1f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3890c795-d210-473f-877c-f431b85879f0" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_34fe8a95-56ae-4114-9ab0-d6c5c66e1f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1c28e818-4e98-40d2-bd5e-35233b68c546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e30a42d4-efb6-462f-ba2e-116e910c98f0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1c28e818-4e98-40d2-bd5e-35233b68c546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_861db5cb-2898-4ed3-b3c4-a4a70bf2d85c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1c28e818-4e98-40d2-bd5e-35233b68c546" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_861db5cb-2898-4ed3-b3c4-a4a70bf2d85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ConvertibleNotesMember_9676aef8-a618-4f52-8a31-9554f0425bc0" xlink:href="opk-20220331.xsd#opk_ConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_861db5cb-2898-4ed3-b3c4-a4a70bf2d85c" xlink:to="loc_opk_ConvertibleNotesMember_9676aef8-a618-4f52-8a31-9554f0425bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditAndNotesAndLoansPayableCurrentMember_73cf7881-8a88-4454-ba88-566494eacb90" xlink:href="opk-20220331.xsd#opk_LineOfCreditAndNotesAndLoansPayableCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_861db5cb-2898-4ed3-b3c4-a4a70bf2d85c" xlink:to="loc_opk_LineOfCreditAndNotesAndLoansPayableCurrentMember_73cf7881-8a88-4454-ba88-566494eacb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e26a7616-9fe2-42cf-9d53-5ec4d17ce6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_861db5cb-2898-4ed3-b3c4-a4a70bf2d85c" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e26a7616-9fe2-42cf-9d53-5ec4d17ce6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7070f6c8-f240-4437-9286-361b6a4add84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e30a42d4-efb6-462f-ba2e-116e910c98f0" xlink:to="loc_us-gaap_CreditFacilityAxis_7070f6c8-f240-4437-9286-361b6a4add84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3245c87a-5b98-488d-a28a-866597814532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_7070f6c8-f240-4437-9286-361b6a4add84" xlink:to="loc_us-gaap_CreditFacilityDomain_3245c87a-5b98-488d-a28a-866597814532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f2ca5e67-4824-4db4-9fad-fed454541119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_3245c87a-5b98-488d-a28a-866597814532" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f2ca5e67-4824-4db4-9fad-fed454541119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a9da8d56-4d6f-43b8-a175-c3d5c2062623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e30a42d4-efb6-462f-ba2e-116e910c98f0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a9da8d56-4d6f-43b8-a175-c3d5c2062623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_601677b5-3b1e-42b6-bfae-90625b0469c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9da8d56-4d6f-43b8-a175-c3d5c2062623" xlink:to="loc_us-gaap_LongTermDebt_601677b5-3b1e-42b6-bfae-90625b0469c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b286aa66-5b4b-406b-907a-50821f730a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9da8d56-4d6f-43b8-a175-c3d5c2062623" xlink:to="loc_us-gaap_LongTermDebtCurrent_b286aa66-5b4b-406b-907a-50821f730a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_44bfd9f8-54d0-412b-b8db-0dec2201d3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9da8d56-4d6f-43b8-a175-c3d5c2062623" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_44bfd9f8-54d0-412b-b8db-0dec2201d3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_59c45261-b434-4b4b-9cfa-09da921662eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_59c45261-b434-4b4b-9cfa-09da921662eb" xlink:to="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ca46bc02-aa4d-4d6b-bc33-e27d80adbf21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ca46bc02-aa4d-4d6b-bc33-e27d80adbf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_34b6f171-e060-4ff6-9728-747a680d877e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ca46bc02-aa4d-4d6b-bc33-e27d80adbf21" xlink:to="loc_us-gaap_ClassOfStockDomain_34b6f171-e060-4ff6-9728-747a680d877e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_95e7b631-179a-4995-9540-02d3de87c103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_34b6f171-e060-4ff6-9728-747a680d877e" xlink:to="loc_us-gaap_CommonStockMember_95e7b631-179a-4995-9540-02d3de87c103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_bccd96c8-3832-4bb9-b399-4865350cece4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_VariableRateAxis_bccd96c8-3832-4bb9-b399-4865350cece4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4569615d-05a8-4efc-9212-69c61ada4157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_bccd96c8-3832-4bb9-b399-4865350cece4" xlink:to="loc_us-gaap_VariableRateDomain_4569615d-05a8-4efc-9212-69c61ada4157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e13952dd-bb73-42ee-b01a-993afe620093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4569615d-05a8-4efc-9212-69c61ada4157" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e13952dd-bb73-42ee-b01a-993afe620093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember_6773cfab-5fe5-4cc4-b472-53a059d0d5e6" xlink:href="opk-20220331.xsd#opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4569615d-05a8-4efc-9212-69c61ada4157" xlink:to="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember_6773cfab-5fe5-4cc4-b472-53a059d0d5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember_8e3b492a-a206-4a2c-9ed8-dfba8c82d43a" xlink:href="opk-20220331.xsd#opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4569615d-05a8-4efc-9212-69c61ada4157" xlink:to="loc_opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember_8e3b492a-a206-4a2c-9ed8-dfba8c82d43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_081f3f12-0903-4813-96c4-54a6f423bfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_CreditFacilityAxis_081f3f12-0903-4813-96c4-54a6f423bfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_55287289-6b77-4e77-b29b-e54f22528c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_081f3f12-0903-4813-96c4-54a6f423bfc5" xlink:to="loc_us-gaap_CreditFacilityDomain_55287289-6b77-4e77-b29b-e54f22528c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2de05934-b88e-450f-962d-a148c53d62ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_55287289-6b77-4e77-b29b-e54f22528c6b" xlink:to="loc_us-gaap_LineOfCreditMember_2de05934-b88e-450f-962d-a148c53d62ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a8f6fd15-777e-4f5f-9a4f-571e8bdcd158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_55287289-6b77-4e77-b29b-e54f22528c6b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a8f6fd15-777e-4f5f-9a4f-571e8bdcd158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_a5ddde11-37d3-412f-92ac-36dd2514e76d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_55287289-6b77-4e77-b29b-e54f22528c6b" xlink:to="loc_us-gaap_BridgeLoanMember_a5ddde11-37d3-412f-92ac-36dd2514e76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_d63c8246-4847-40fe-b01a-a4467ca6f49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_55287289-6b77-4e77-b29b-e54f22528c6b" xlink:to="loc_us-gaap_LetterOfCreditMember_d63c8246-4847-40fe-b01a-a4467ca6f49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3c396b6f-256a-41a9-9aa9-5a1a455fd51a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3c396b6f-256a-41a9-9aa9-5a1a455fd51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cd4bfc8f-626c-416e-bf9f-4e512b27a0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3c396b6f-256a-41a9-9aa9-5a1a455fd51a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cd4bfc8f-626c-416e-bf9f-4e512b27a0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_9ead634e-3c0f-4d26-bb93-6729562f16e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cd4bfc8f-626c-416e-bf9f-4e512b27a0b6" xlink:to="loc_us-gaap_UnsecuredDebtMember_9ead634e-3c0f-4d26-bb93-6729562f16e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_b5f80023-47bd-41a6-ae94-fdef7805903d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cd4bfc8f-626c-416e-bf9f-4e512b27a0b6" xlink:to="loc_us-gaap_LineOfCreditMember_b5f80023-47bd-41a6-ae94-fdef7805903d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_e019cbe2-aca5-4475-8a32-9fbf81ec9376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cd4bfc8f-626c-416e-bf9f-4e512b27a0b6" xlink:to="loc_us-gaap_ConvertibleDebtMember_e019cbe2-aca5-4475-8a32-9fbf81ec9376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_aaf5a073-ffd9-451c-bb4d-d30c45b807a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cd4bfc8f-626c-416e-bf9f-4e512b27a0b6" xlink:to="loc_us-gaap_SeniorNotesMember_aaf5a073-ffd9-451c-bb4d-d30c45b807a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_309b7dbb-362c-4a27-98ad-25e3edf0c2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cd4bfc8f-626c-416e-bf9f-4e512b27a0b6" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_309b7dbb-362c-4a27-98ad-25e3edf0c2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_99e5e34e-c120-4903-9c5d-0001db7cc535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_DebtInstrumentAxis_99e5e34e-c120-4903-9c5d-0001db7cc535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6e0cac74-6047-4a50-bebf-bff71d0aac1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_99e5e34e-c120-4903-9c5d-0001db7cc535" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6e0cac74-6047-4a50-bebf-bff71d0aac1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NewCreditAgreementMember_12647a50-03af-4541-b4b0-a936e6972e73" xlink:href="opk-20220331.xsd#opk_NewCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6e0cac74-6047-4a50-bebf-bff71d0aac1c" xlink:to="loc_opk_NewCreditAgreementMember_12647a50-03af-4541-b4b0-a936e6972e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ConvertibleSeniorNotesDue2025Member_88ae14b2-eb47-4ab4-a3b5-3d442b1f97d6" xlink:href="opk-20220331.xsd#opk_ConvertibleSeniorNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6e0cac74-6047-4a50-bebf-bff71d0aac1c" xlink:to="loc_opk_ConvertibleSeniorNotesDue2025Member_88ae14b2-eb47-4ab4-a3b5-3d442b1f97d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_A5ConvertibleNotesMember_de5ba9bc-22a4-4c84-a2e3-88cb185c85d7" xlink:href="opk-20220331.xsd#opk_A5ConvertibleNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6e0cac74-6047-4a50-bebf-bff71d0aac1c" xlink:to="loc_opk_A5ConvertibleNotesMember_de5ba9bc-22a4-4c84-a2e3-88cb185c85d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NotesDueFebruary12033Member_da6ba75e-54d0-4dac-8b22-7595efe07c36" xlink:href="opk-20220331.xsd#opk_NotesDueFebruary12033Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6e0cac74-6047-4a50-bebf-bff71d0aac1c" xlink:to="loc_opk_NotesDueFebruary12033Member_da6ba75e-54d0-4dac-8b22-7595efe07c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e1bcd881-57e6-4381-b74b-ed2b521bd61d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e1bcd881-57e6-4381-b74b-ed2b521bd61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f225c56-795a-4a7b-a11a-4e3f754174bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e1bcd881-57e6-4381-b74b-ed2b521bd61d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f225c56-795a-4a7b-a11a-4e3f754174bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_24f1bef3-96f7-406a-bfb0-de86709d939f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f225c56-795a-4a7b-a11a-4e3f754174bd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_24f1bef3-96f7-406a-bfb0-de86709d939f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5dc3e09a-feaf-42e6-bc8f-2d798b22ba3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f225c56-795a-4a7b-a11a-4e3f754174bd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5dc3e09a-feaf-42e6-bc8f-2d798b22ba3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_1ec3d728-5825-42c6-8209-a7e2df7bef74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f225c56-795a-4a7b-a11a-4e3f754174bd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_1ec3d728-5825-42c6-8209-a7e2df7bef74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8abe1d03-c4e9-486b-96a8-17ba233acf7c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_srt_RangeAxis_8abe1d03-c4e9-486b-96a8-17ba233acf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_30630e5b-e88e-4015-91bd-80b2455c6276" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8abe1d03-c4e9-486b-96a8-17ba233acf7c" xlink:to="loc_srt_RangeMember_30630e5b-e88e-4015-91bd-80b2455c6276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c4d677d4-48b9-4be1-ba8b-8d4ab895ed8a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_30630e5b-e88e-4015-91bd-80b2455c6276" xlink:to="loc_srt_MinimumMember_c4d677d4-48b9-4be1-ba8b-8d4ab895ed8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2792804c-673d-409c-a1d8-237529dc2725" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_30630e5b-e88e-4015-91bd-80b2455c6276" xlink:to="loc_srt_MaximumMember_2792804c-673d-409c-a1d8-237529dc2725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ddd97c20-1a48-4e9e-a476-04344a5ee06f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ddd97c20-1a48-4e9e-a476-04344a5ee06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_967a90f7-3899-4fc5-b69b-a2e1bd05d1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ddd97c20-1a48-4e9e-a476-04344a5ee06f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_967a90f7-3899-4fc5-b69b-a2e1bd05d1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioReferenceMember_efaf238e-1314-40ae-a537-53ea7dff13f7" xlink:href="opk-20220331.xsd#opk_BioReferenceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_967a90f7-3899-4fc5-b69b-a2e1bd05d1e9" xlink:to="loc_opk_BioReferenceMember_efaf238e-1314-40ae-a537-53ea7dff13f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OPKOHealthEuropeMember_dfafa645-74ea-4efb-aaba-d541c9e31384" xlink:href="opk-20220331.xsd#opk_OPKOHealthEuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_967a90f7-3899-4fc5-b69b-a2e1bd05d1e9" xlink:to="loc_opk_OPKOHealthEuropeMember_dfafa645-74ea-4efb-aaba-d541c9e31384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditFacilityRevolvingCommitmentAxis_3ce24e9f-291c-4000-a9c1-0c4d49b54e43" xlink:href="opk-20220331.xsd#opk_LineOfCreditFacilityRevolvingCommitmentAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_opk_LineOfCreditFacilityRevolvingCommitmentAxis_3ce24e9f-291c-4000-a9c1-0c4d49b54e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditFacilityRevolvingCommitmentDomain_b1cc96c8-790d-4ae9-ba56-25aae9355464" xlink:href="opk-20220331.xsd#opk_LineOfCreditFacilityRevolvingCommitmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_LineOfCreditFacilityRevolvingCommitmentAxis_3ce24e9f-291c-4000-a9c1-0c4d49b54e43" xlink:to="loc_opk_LineOfCreditFacilityRevolvingCommitmentDomain_b1cc96c8-790d-4ae9-ba56-25aae9355464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember_51d23cc6-93fa-4059-a2b4-eccb54994ad3" xlink:href="opk-20220331.xsd#opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_LineOfCreditFacilityRevolvingCommitmentDomain_b1cc96c8-790d-4ae9-ba56-25aae9355464" xlink:to="loc_opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember_51d23cc6-93fa-4059-a2b4-eccb54994ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember_5e7d5a99-5e48-4aae-b133-8361827dac21" xlink:href="opk-20220331.xsd#opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_LineOfCreditFacilityRevolvingCommitmentDomain_b1cc96c8-790d-4ae9-ba56-25aae9355464" xlink:to="loc_opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember_5e7d5a99-5e48-4aae-b133-8361827dac21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1cb8f3df-ba77-4959-bb72-28a38b90ce30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1cb8f3df-ba77-4959-bb72-28a38b90ce30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_27ef0d40-22fe-4e21-ac88-6edefad3ef66" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1cb8f3df-ba77-4959-bb72-28a38b90ce30" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_27ef0d40-22fe-4e21-ac88-6edefad3ef66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fa348095-c1be-45fd-8933-3e5330606132" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_27ef0d40-22fe-4e21-ac88-6edefad3ef66" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fa348095-c1be-45fd-8933-3e5330606132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cf7a4304-e950-4ec4-bef4-ad3881f0e23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cf7a4304-e950-4ec4-bef4-ad3881f0e23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_206f4e82-51f1-4867-bb9a-073600adb413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cf7a4304-e950-4ec4-bef4-ad3881f0e23a" xlink:to="loc_us-gaap_TypeOfAdoptionMember_206f4e82-51f1-4867-bb9a-073600adb413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_0413886d-eb1a-453b-aac0-83289e9a4d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_206f4e82-51f1-4867-bb9a-073600adb413" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_0413886d-eb1a-453b-aac0-83289e9a4d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_38d0a7ce-52d7-496c-9c30-27abcdb1ac72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_38d0a7ce-52d7-496c-9c30-27abcdb1ac72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_21aa5d87-4029-4295-b380-fb05029340bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38d0a7ce-52d7-496c-9c30-27abcdb1ac72" xlink:to="loc_us-gaap_EquityComponentDomain_21aa5d87-4029-4295-b380-fb05029340bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_397f615a-adab-4e2a-9123-4b640a1fde57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21aa5d87-4029-4295-b380-fb05029340bc" xlink:to="loc_us-gaap_RetainedEarningsMember_397f615a-adab-4e2a-9123-4b640a1fde57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f67b09fc-9cea-4c76-8b61-74d182dd06db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21aa5d87-4029-4295-b380-fb05029340bc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f67b09fc-9cea-4c76-8b61-74d182dd06db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66b599cc-58cd-4649-abd2-ed11f5a873c1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7c2b1caa-1930-43d9-8a81-2b7cafe1a8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7c2b1caa-1930-43d9-8a81-2b7cafe1a8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_fbb7306f-d896-44a5-a87e-c26161b636db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_fbb7306f-d896-44a5-a87e-c26161b636db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_2d7dc40d-5c36-4603-977b-e61c09b7b6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LineOfCredit_2d7dc40d-5c36-4603-977b-e61c09b7b6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_dc0de6d1-9904-44f9-861d-956fbc0c7dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_dc0de6d1-9904-44f9-861d-956fbc0c7dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c6ea105-1bb3-4b21-ba9d-41785693511a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c6ea105-1bb3-4b21-ba9d-41785693511a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_7c762d0d-37ec-41a6-94d7-72513f419d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_7c762d0d-37ec-41a6-94d7-72513f419d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0a7d5fef-c19c-4959-9fca-3fd1d7ae4f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0a7d5fef-c19c-4959-9fca-3fd1d7ae4f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_db971637-d22b-4ab7-ae3c-d44d2c4c4769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_db971637-d22b-4ab7-ae3c-d44d2c4c4769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_11dd4ed8-22f5-4079-b074-a9e9a98b6d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_11dd4ed8-22f5-4079-b074-a9e9a98b6d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d5c223fe-1fe3-4ae0-9210-8baa74307fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d5c223fe-1fe3-4ae0-9210-8baa74307fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3a28dea8-eb77-4d55-88db-65b04ba5ea1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3a28dea8-eb77-4d55-88db-65b04ba5ea1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_7eedda53-f293-4aae-ba93-eea38788e47e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_7eedda53-f293-4aae-ba93-eea38788e47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_22932238-a35c-4c14-81e8-73de036ee075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_22932238-a35c-4c14-81e8-73de036ee075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GainLossOnConversionOfDebt_b466caa0-0047-43cf-b721-536100217d84" xlink:href="opk-20220331.xsd#opk_GainLossOnConversionOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_opk_GainLossOnConversionOfDebt_b466caa0-0047-43cf-b721-536100217d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable_9ec4fc2e-6b87-47fe-a2f6-9433c06d7c4b" xlink:href="opk-20220331.xsd#opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable_9ec4fc2e-6b87-47fe-a2f6-9433c06d7c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable_1e290230-3476-4d63-b157-7ee529c86f8b" xlink:href="opk-20220331.xsd#opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable_1e290230-3476-4d63-b157-7ee529c86f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromConvertibleDebtConversionFee_c02de2ba-b459-4bfd-b8d4-e03f46290165" xlink:href="opk-20220331.xsd#opk_ProceedsFromConvertibleDebtConversionFee"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_opk_ProceedsFromConvertibleDebtConversionFee_c02de2ba-b459-4bfd-b8d4-e03f46290165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_c7fbdb23-3a1a-47c7-9150-4950adfad1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_c7fbdb23-3a1a-47c7-9150-4950adfad1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_af4553d9-d37d-42b2-a6b7-a1bc7c45c909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_af4553d9-d37d-42b2-a6b7-a1bc7c45c909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2a9fde0-74ff-4bb8-8c3d-adf7b450b922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2a9fde0-74ff-4bb8-8c3d-adf7b450b922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_1877a839-c6c2-4292-acce-b228787b693c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentTerm_1877a839-c6c2-4292-acce-b228787b693c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum_639c8f9b-41f7-4c1a-af58-b019071b6207" xlink:href="opk-20220331.xsd#opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum_639c8f9b-41f7-4c1a-af58-b019071b6207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum_4ac03ef4-cac9-411c-822e-4d3fc96487ce" xlink:href="opk-20220331.xsd#opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum_4ac03ef4-cac9-411c-822e-4d3fc96487ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_93408de1-1169-404e-8454-f02b282510e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_93408de1-1169-404e-8454-f02b282510e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_60d720cb-aee2-4007-8ad4-1eb6ec1c3a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LongTermDebt_60d720cb-aee2-4007-8ad4-1eb6ec1c3a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_2d6d8a30-023b-4c10-bfe8-98da9bbb7071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_2d6d8a30-023b-4c10-bfe8-98da9bbb7071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9d693411-80ca-4452-beda-b4be56fd9d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9d693411-80ca-4452-beda-b4be56fd9d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_64481e5b-ef06-436e-810b-503363484962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_64481e5b-ef06-436e-810b-503363484962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_d56b2887-599d-4819-858d-cb2b92b398bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LongTermLineOfCredit_d56b2887-599d-4819-858d-cb2b92b398bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6000a5a7-8c80-4d26-a6d9-4eeff5f23ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_StockholdersEquity_6000a5a7-8c80-4d26-a6d9-4eeff5f23ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_901c88bc-4f53-4f89-979b-74aa313c91ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_Goodwill_901c88bc-4f53-4f89-979b-74aa313c91ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0a53f3a4-f47e-4acd-a6df-3786286cc256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0a53f3a4-f47e-4acd-a6df-3786286cc256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentsNumberofFinancialInstitutions_885b4e7f-4739-49ae-93b1-c2d4718b21f7" xlink:href="opk-20220331.xsd#opk_DebtInstrumentsNumberofFinancialInstitutions"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_opk_DebtInstrumentsNumberofFinancialInstitutions_885b4e7f-4739-49ae-93b1-c2d4718b21f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_b1260d65-70b5-40f9-948a-8ccd587fa6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_b1260d65-70b5-40f9-948a-8ccd587fa6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_40962dfb-366f-4f38-b606-e360a0f74d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4260ba5-49e1-4508-a721-815359ce176d" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_40962dfb-366f-4f38-b606-e360a0f74d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtScheduleofNotesDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DebtScheduleofNotesDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DebtScheduleofNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_98613e4c-6bdf-45ab-ba06-d82b8b824bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a7be0d02-972b-40bd-884f-e7e89fa98981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_98613e4c-6bdf-45ab-ba06-d82b8b824bb4" xlink:to="loc_us-gaap_DebtInstrumentTable_a7be0d02-972b-40bd-884f-e7e89fa98981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6c2e52b3-97f6-42a9-82fc-0f0b47f3b7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a7be0d02-972b-40bd-884f-e7e89fa98981" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6c2e52b3-97f6-42a9-82fc-0f0b47f3b7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_729e91e0-6d32-4fcd-bcf1-560621c7b989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6c2e52b3-97f6-42a9-82fc-0f0b47f3b7c1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_729e91e0-6d32-4fcd-bcf1-560621c7b989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f5dc8cb4-29f5-426f-b419-304f7e2ec068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_729e91e0-6d32-4fcd-bcf1-560621c7b989" xlink:to="loc_us-gaap_SeniorNotesMember_f5dc8cb4-29f5-426f-b419-304f7e2ec068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_32e02558-c77a-4049-9118-cc8f7fa243e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a7be0d02-972b-40bd-884f-e7e89fa98981" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_32e02558-c77a-4049-9118-cc8f7fa243e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_781e079e-cac1-4f3a-8ab9-1c6881b69671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_32e02558-c77a-4049-9118-cc8f7fa243e2" xlink:to="loc_us-gaap_TypeOfAdoptionMember_781e079e-cac1-4f3a-8ab9-1c6881b69671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_d65516bc-763f-4a79-9f7d-20f03075eb41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_781e079e-cac1-4f3a-8ab9-1c6881b69671" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_d65516bc-763f-4a79-9f7d-20f03075eb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_588de987-7895-4b38-ae19-9a21a553e361" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a7be0d02-972b-40bd-884f-e7e89fa98981" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_588de987-7895-4b38-ae19-9a21a553e361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_94a31f81-bfca-40dd-9d38-7cd2f1386136" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_588de987-7895-4b38-ae19-9a21a553e361" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_94a31f81-bfca-40dd-9d38-7cd2f1386136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ff02544e-0511-4391-aaa6-6425c1741ec2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_94a31f81-bfca-40dd-9d38-7cd2f1386136" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ff02544e-0511-4391-aaa6-6425c1741ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f5e608eb-4679-46e1-9240-adf8fd1851da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a7be0d02-972b-40bd-884f-e7e89fa98981" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f5e608eb-4679-46e1-9240-adf8fd1851da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DebtInstrumentRollForward_7bb7e602-8b1b-4902-adbb-b6d04a63bc3a" xlink:href="opk-20220331.xsd#opk_DebtInstrumentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f5e608eb-4679-46e1-9240-adf8fd1851da" xlink:to="loc_opk_DebtInstrumentRollForward_7bb7e602-8b1b-4902-adbb-b6d04a63bc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_c34f9779-20eb-4ed4-8fe2-3e8ea162d852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_DebtInstrumentRollForward_7bb7e602-8b1b-4902-adbb-b6d04a63bc3a" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_c34f9779-20eb-4ed4-8fe2-3e8ea162d852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9c246c99-16fc-4aa2-8768-b8fe2e8520d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_c34f9779-20eb-4ed4-8fe2-3e8ea162d852" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9c246c99-16fc-4aa2-8768-b8fe2e8520d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ff9cfd12-f798-43c8-bdd4-96ef40cd153d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_c34f9779-20eb-4ed4-8fe2-3e8ea162d852" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ff9cfd12-f798-43c8-bdd4-96ef40cd153d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_afa8bf33-f609-46d9-bc6d-7b723c5c4eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_DebtInstrumentRollForward_7bb7e602-8b1b-4902-adbb-b6d04a63bc3a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_afa8bf33-f609-46d9-bc6d-7b723c5c4eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4612580e-7fea-4b7e-94a2-423baccdc899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_afa8bf33-f609-46d9-bc6d-7b723c5c4eb9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4612580e-7fea-4b7e-94a2-423baccdc899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_e6362037-04c0-470c-8f8e-1c9c9dc954c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_afa8bf33-f609-46d9-bc6d-7b723c5c4eb9" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_e6362037-04c0-470c-8f8e-1c9c9dc954c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_023d9fe5-de43-4a5d-9e93-bee313512fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountAbstract_afa8bf33-f609-46d9-bc6d-7b723c5c4eb9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_023d9fe5-de43-4a5d-9e93-bee313512fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNetAbstract_4c3c0cd3-1cf6-494d-a979-5721339f3b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_DebtInstrumentRollForward_7bb7e602-8b1b-4902-adbb-b6d04a63bc3a" xlink:to="loc_us-gaap_DeferredFinanceCostsNetAbstract_4c3c0cd3-1cf6-494d-a979-5721339f3b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_d850f94a-7fc0-4a5d-a57f-db730e5518ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_4c3c0cd3-1cf6-494d-a979-5721339f3b80" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_d850f94a-7fc0-4a5d-a57f-db730e5518ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_73c24fa7-ee92-4b25-ba11-8c826ea556e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_4c3c0cd3-1cf6-494d-a979-5721339f3b80" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_73c24fa7-ee92-4b25-ba11-8c826ea556e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_65bb1cf8-8cff-420f-9592-8c2d3d237df4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_4c3c0cd3-1cf6-494d-a979-5721339f3b80" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_65bb1cf8-8cff-420f-9592-8c2d3d237df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAbstract_e3538309-4151-4f2b-bde8-31b4d9b4b4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_DebtInstrumentRollForward_7bb7e602-8b1b-4902-adbb-b6d04a63bc3a" xlink:to="loc_us-gaap_LongTermDebtAbstract_e3538309-4151-4f2b-bde8-31b4d9b4b4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_47325d0e-f45c-4605-ae27-cfc3358e2b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_e3538309-4151-4f2b-bde8-31b4d9b4b4b7" xlink:to="loc_us-gaap_LongTermDebt_47325d0e-f45c-4605-ae27-cfc3358e2b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9f33d748-3636-4ee4-ad4f-4f1c35cc6310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_e3538309-4151-4f2b-bde8-31b4d9b4b4b7" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9f33d748-3636-4ee4-ad4f-4f1c35cc6310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3702bbdd-7382-4215-89d8-4f0f42a80e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_e3538309-4151-4f2b-bde8-31b4d9b4b4b7" xlink:to="loc_us-gaap_LongTermDebt_3702bbdd-7382-4215-89d8-4f0f42a80e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtLinesofCreditDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DebtLinesofCreditDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DebtLinesofCreditDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_72bcde0b-b353-41aa-996e-062a289899a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_ebace9eb-83e9-417b-ae7d-91731565f617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_72bcde0b-b353-41aa-996e-062a289899a8" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_ebace9eb-83e9-417b-ae7d-91731565f617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_55ea8839-ea15-40f3-b674-74721bb60518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_ebace9eb-83e9-417b-ae7d-91731565f617" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_55ea8839-ea15-40f3-b674-74721bb60518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_55ea8839-ea15-40f3-b674-74721bb60518" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_JPMorganChaseMember_4cf46c85-5567-4844-8419-7a58ff2d5bd0" xlink:href="opk-20220331.xsd#opk_JPMorganChaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_JPMorganChaseMember_4cf46c85-5567-4844-8419-7a58ff2d5bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ItauBankMember_db13a4f7-a4a9-4fac-b8a3-6fa2b36e0995" xlink:href="opk-20220331.xsd#opk_ItauBankMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_ItauBankMember_db13a4f7-a4a9-4fac-b8a3-6fa2b36e0995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BankOfChileMember_78a670ef-9dee-4325-bd89-2ccf953770d6" xlink:href="opk-20220331.xsd#opk_BankOfChileMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_BankOfChileMember_78a670ef-9dee-4325-bd89-2ccf953770d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BiceBankMember_64dd2f52-996d-41a7-a2ce-5083cc4f5d30" xlink:href="opk-20220331.xsd#opk_BiceBankMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_BiceBankMember_64dd2f52-996d-41a7-a2ce-5083cc4f5d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ScotiabankMember_4ce6bd56-bcc1-4bff-8743-67974243c7da" xlink:href="opk-20220331.xsd#opk_ScotiabankMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_ScotiabankMember_4ce6bd56-bcc1-4bff-8743-67974243c7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SantanderBankMember_d17a1322-0347-437b-a1c1-a0072f209773" xlink:href="opk-20220331.xsd#opk_SantanderBankMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_SantanderBankMember_d17a1322-0347-437b-a1c1-a0072f209773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SecurityMember_ae420ab7-9f04-48c8-add8-da0a97f87ab0" xlink:href="opk-20220331.xsd#opk_SecurityMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_SecurityMember_ae420ab7-9f04-48c8-add8-da0a97f87ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EstadoBankMember_830ea88d-cf85-4b21-bf91-c3802e7b849f" xlink:href="opk-20220331.xsd#opk_EstadoBankMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_EstadoBankMember_830ea88d-cf85-4b21-bf91-c3802e7b849f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BCIBankMember_983f5bf4-847c-4a40-b03a-8170375a4196" xlink:href="opk-20220331.xsd#opk_BCIBankMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_BCIBankMember_983f5bf4-847c-4a40-b03a-8170375a4196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_Corpbanca1Member_9dd46260-7b46-4e3b-94c8-a0ae2e1a7223" xlink:href="opk-20220331.xsd#opk_Corpbanca1Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_Corpbanca1Member_9dd46260-7b46-4e3b-94c8-a0ae2e1a7223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InternationalBankMember_2c602943-7b39-499f-93d6-9bd90da2e258" xlink:href="opk-20220331.xsd#opk_InternationalBankMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_InternationalBankMember_2c602943-7b39-499f-93d6-9bd90da2e258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ConsoorcioBankMember_350816ad-aa13-4924-b83d-24bcf4ccb2dc" xlink:href="opk-20220331.xsd#opk_ConsoorcioBankMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_ConsoorcioBankMember_350816ad-aa13-4924-b83d-24bcf4ccb2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BancoDeSabadellMember_ee859cd8-0ec9-4b49-85db-61db808f6495" xlink:href="opk-20220331.xsd#opk_BancoDeSabadellMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_BancoDeSabadellMember_ee859cd8-0ec9-4b49-85db-61db808f6495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SantanderBank2Member_2b798b21-d3b0-487a-8cc9-0cb0e2680833" xlink:href="opk-20220331.xsd#opk_SantanderBank2Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3f3cdb3d-0ae8-4206-898c-78c8658d29a7" xlink:to="loc_opk_SantanderBank2Member_2b798b21-d3b0-487a-8cc9-0cb0e2680833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_f53b29a8-4c03-465b-9937-85d6243f0972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_ebace9eb-83e9-417b-ae7d-91731565f617" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_f53b29a8-4c03-465b-9937-85d6243f0972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_aae6cf07-1446-4e85-9782-67464a73085d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f53b29a8-4c03-465b-9937-85d6243f0972" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_aae6cf07-1446-4e85-9782-67464a73085d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_068ae5b2-d9a4-4942-8153-8303d2bb9434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f53b29a8-4c03-465b-9937-85d6243f0972" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_068ae5b2-d9a4-4942-8153-8303d2bb9434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_29779d4b-81ff-4a02-afa6-f3d3e7e62c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f53b29a8-4c03-465b-9937-85d6243f0972" xlink:to="loc_us-gaap_LineOfCredit_29779d4b-81ff-4a02-afa6-f3d3e7e62c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DebtNotesPayableandOtherDebtDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_74655e72-e755-4376-9dcc-0a96fbc005af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0f5bcaed-9770-4582-af98-bcdb8eeede86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_74655e72-e755-4376-9dcc-0a96fbc005af" xlink:to="loc_us-gaap_DebtInstrumentTable_0f5bcaed-9770-4582-af98-bcdb8eeede86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e4deba5e-163b-4b34-b2a9-b7e3e81b8ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0f5bcaed-9770-4582-af98-bcdb8eeede86" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e4deba5e-163b-4b34-b2a9-b7e3e81b8ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0f12156f-c2b0-4ae3-919c-4a99bb73439a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e4deba5e-163b-4b34-b2a9-b7e3e81b8ab9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0f12156f-c2b0-4ae3-919c-4a99bb73439a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NotesPayableAndOtherLongTermLiabilitiesMember_2626e178-ea98-4a5d-b2cb-784190a0122d" xlink:href="opk-20220331.xsd#opk_NotesPayableAndOtherLongTermLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0f12156f-c2b0-4ae3-919c-4a99bb73439a" xlink:to="loc_opk_NotesPayableAndOtherLongTermLiabilitiesMember_2626e178-ea98-4a5d-b2cb-784190a0122d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_27faff9f-f5ae-45d9-95cf-b5e9f5be8716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0f5bcaed-9770-4582-af98-bcdb8eeede86" xlink:to="loc_us-gaap_DebtInstrumentLineItems_27faff9f-f5ae-45d9-95cf-b5e9f5be8716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_cbd6dc08-1a33-4892-97f7-a47567880313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27faff9f-f5ae-45d9-95cf-b5e9f5be8716" xlink:to="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_cbd6dc08-1a33-4892-97f7-a47567880313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ba4331e1-56af-4d43-980b-85b8b0f5be36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_cbd6dc08-1a33-4892-97f7-a47567880313" xlink:to="loc_us-gaap_LongTermDebtCurrent_ba4331e1-56af-4d43-980b-85b8b0f5be36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_243180ee-b02f-478c-b9e9-f73871e6d4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_cbd6dc08-1a33-4892-97f7-a47567880313" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_243180ee-b02f-478c-b9e9-f73871e6d4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_49b1deb1-42d0-4368-b7ee-35ecd930163b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_cbd6dc08-1a33-4892-97f7-a47567880313" xlink:to="loc_us-gaap_LongTermDebt_49b1deb1-42d0-4368-b7ee-35ecd930163b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="simple" xlink:href="opk-20220331.xsd#AccumulatedOtherComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a7cb9a10-27ac-46cc-98cf-8761977da4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_6242292b-d9b8-474d-9790-f4919eded31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a7cb9a10-27ac-46cc-98cf-8761977da4ef" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_6242292b-d9b8-474d-9790-f4919eded31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="simple" xlink:href="opk-20220331.xsd#AccumulatedOtherComprehensiveLossTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ff61ec7a-ff81-42c7-9d09-7a35cfdcb1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_d2221410-945c-4d2c-a908-d8c2e4325cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ff61ec7a-ff81-42c7-9d09-7a35cfdcb1f3" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_d2221410-945c-4d2c-a908-d8c2e4325cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#AccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4e261284-6298-4f9b-92df-5634a036bf00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_100ce697-adbe-4c0a-b52c-6b197e9a9760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4e261284-6298-4f9b-92df-5634a036bf00" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_100ce697-adbe-4c0a-b52c-6b197e9a9760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8fc8746d-cd8d-4755-b7d2-c81e71c0429c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_100ce697-adbe-4c0a-b52c-6b197e9a9760" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8fc8746d-cd8d-4755-b7d2-c81e71c0429c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8154eaed-5e87-4eb2-b759-a27961ed0def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8fc8746d-cd8d-4755-b7d2-c81e71c0429c" xlink:to="loc_us-gaap_EquityComponentDomain_8154eaed-5e87-4eb2-b759-a27961ed0def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e2f6de39-5424-4d67-8b96-2781b644ed14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8154eaed-5e87-4eb2-b759-a27961ed0def" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e2f6de39-5424-4d67-8b96-2781b644ed14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8354df11-8428-486e-b16a-1c789e16f236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_100ce697-adbe-4c0a-b52c-6b197e9a9760" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8354df11-8428-486e-b16a-1c789e16f236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_cca531b1-72fe-4ec3-a0b3-7ed753abefcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8354df11-8428-486e-b16a-1c789e16f236" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_cca531b1-72fe-4ec3-a0b3-7ed753abefcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_76d4effb-ad96-4d22-a241-0106709b38e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_cca531b1-72fe-4ec3-a0b3-7ed753abefcf" xlink:to="loc_us-gaap_StockholdersEquity_76d4effb-ad96-4d22-a241-0106709b38e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9fd5532b-2c2c-46d2-bb3f-28ff6016a8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_cca531b1-72fe-4ec3-a0b3-7ed753abefcf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9fd5532b-2c2c-46d2-bb3f-28ff6016a8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4aaf46b4-aa49-469b-b814-23043f0c03bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_cca531b1-72fe-4ec3-a0b3-7ed753abefcf" xlink:to="loc_us-gaap_StockholdersEquity_4aaf46b4-aa49-469b-b814-23043f0c03bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="opk-20220331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_eb516079-4f99-4b4c-95c9-83d2440b3501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8deaa1de-72de-4e36-b6c5-cb85293ea728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_eb516079-4f99-4b4c-95c9-83d2440b3501" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_8deaa1de-72de-4e36-b6c5-cb85293ea728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="opk-20220331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8673eabd-a738-458e-a5c6-be5a0a503441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c5c6d1bd-f530-4eeb-9abc-2e8c24767711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8673eabd-a738-458e-a5c6-be5a0a503441" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c5c6d1bd-f530-4eeb-9abc-2e8c24767711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_b3b7d649-38e7-4ece-b5c6-d3982d821e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8673eabd-a738-458e-a5c6-be5a0a503441" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_b3b7d649-38e7-4ece-b5c6-d3982d821e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_06f7556b-fb7f-4a0e-beb3-74b440955dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8673eabd-a738-458e-a5c6-be5a0a503441" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_06f7556b-fb7f-4a0e-beb3-74b440955dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_65b7bdf8-b999-4cfa-be16-55e99fc414f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8673eabd-a738-458e-a5c6-be5a0a503441" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_65b7bdf8-b999-4cfa-be16-55e99fc414f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_986c8519-9f99-4d8c-8088-b15d81dafe5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d824dbf8-515e-4c3d-8dfc-e4a5f2c2bf09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_986c8519-9f99-4d8c-8088-b15d81dafe5d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d824dbf8-515e-4c3d-8dfc-e4a5f2c2bf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b3aaba23-3578-4b02-86d3-eb0ff4b3da48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d824dbf8-515e-4c3d-8dfc-e4a5f2c2bf09" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b3aaba23-3578-4b02-86d3-eb0ff4b3da48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31d2513e-65e9-424d-bd61-3d14012278a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b3aaba23-3578-4b02-86d3-eb0ff4b3da48" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31d2513e-65e9-424d-bd61-3d14012278a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_6059e4fc-7d4d-4a7b-b4eb-6e8344cbe52b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31d2513e-65e9-424d-bd61-3d14012278a1" xlink:to="loc_us-gaap_EquitySecuritiesMember_6059e4fc-7d4d-4a7b-b4eb-6e8344cbe52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_de48edf6-6766-4774-94e2-6993cba8273a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31d2513e-65e9-424d-bd61-3d14012278a1" xlink:to="loc_us-gaap_ForwardContractsMember_de48edf6-6766-4774-94e2-6993cba8273a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f99e0fd3-dad9-4091-9841-1f379cfbec15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d824dbf8-515e-4c3d-8dfc-e4a5f2c2bf09" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f99e0fd3-dad9-4091-9841-1f379cfbec15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61baa7cb-20d2-4b0c-b4b9-855b0f6a08f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f99e0fd3-dad9-4091-9841-1f379cfbec15" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61baa7cb-20d2-4b0c-b4b9-855b0f6a08f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9aee1ad0-46e8-494c-857e-c003192be9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61baa7cb-20d2-4b0c-b4b9-855b0f6a08f5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9aee1ad0-46e8-494c-857e-c003192be9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8c7afa72-6ebd-4e24-b3d5-93e3288d4b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61baa7cb-20d2-4b0c-b4b9-855b0f6a08f5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8c7afa72-6ebd-4e24-b3d5-93e3288d4b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3d3115b3-7f15-4327-9279-e16386d06eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61baa7cb-20d2-4b0c-b4b9-855b0f6a08f5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3d3115b3-7f15-4327-9279-e16386d06eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bd8dd27a-db95-4b91-bb37-416e4ef961ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d824dbf8-515e-4c3d-8dfc-e4a5f2c2bf09" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bd8dd27a-db95-4b91-bb37-416e4ef961ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_55e93c98-889f-4b2d-833d-ef919b68d2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bd8dd27a-db95-4b91-bb37-416e4ef961ad" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_55e93c98-889f-4b2d-833d-ef919b68d2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_2f0f136b-062d-4f77-8168-a06367f09251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_55e93c98-889f-4b2d-833d-ef919b68d2dc" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_2f0f136b-062d-4f77-8168-a06367f09251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_3931e19b-6323-4454-9e05-9ce8c3e51d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_55e93c98-889f-4b2d-833d-ef919b68d2dc" xlink:to="loc_us-gaap_DerivativeAssets_3931e19b-6323-4454-9e05-9ce8c3e51d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9bf480f4-1359-462a-9b78-13704d21db51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_55e93c98-889f-4b2d-833d-ef919b68d2dc" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9bf480f4-1359-462a-9b78-13704d21db51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_478049c7-2741-44f0-90ea-8243fbe0bcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bd8dd27a-db95-4b91-bb37-416e4ef961ad" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_478049c7-2741-44f0-90ea-8243fbe0bcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6ade72a8-8567-43e8-8b29-886f45369b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_478049c7-2741-44f0-90ea-8243fbe0bcf4" xlink:to="loc_us-gaap_DerivativeLiabilities_6ade72a8-8567-43e8-8b29-886f45369b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1037dbe0-be85-49f1-8e34-8bf6ae42fd53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_478049c7-2741-44f0-90ea-8243fbe0bcf4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1037dbe0-be85-49f1-8e34-8bf6ae42fd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_e4549f51-d99c-4e06-8990-2c63ab3b54bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_478049c7-2741-44f0-90ea-8243fbe0bcf4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_e4549f51-d99c-4e06-8990-2c63ab3b54bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d23ac6c8-dccb-421b-a6b0-b526ca0be390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bbcd1081-8f02-458b-9642-76cd5349051b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d23ac6c8-dccb-421b-a6b0-b526ca0be390" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bbcd1081-8f02-458b-9642-76cd5349051b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_2f47aade-8283-4ee9-8dcb-38eafa784ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bbcd1081-8f02-458b-9642-76cd5349051b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_2f47aade-8283-4ee9-8dcb-38eafa784ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b04557bb-47a0-4be9-b775-b35068b79648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2f47aade-8283-4ee9-8dcb-38eafa784ccc" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b04557bb-47a0-4be9-b775-b35068b79648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a1f9899b-696d-44cd-8c7c-78aff30f1d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b04557bb-47a0-4be9-b775-b35068b79648" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a1f9899b-696d-44cd-8c7c-78aff30f1d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6b80b527-11d9-43c0-878d-be29f2784f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b04557bb-47a0-4be9-b775-b35068b79648" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6b80b527-11d9-43c0-878d-be29f2784f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_76ca0841-2a48-4f0d-898d-b91f218e9e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bbcd1081-8f02-458b-9642-76cd5349051b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_76ca0841-2a48-4f0d-898d-b91f218e9e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_12a9f643-087f-40cb-be2e-4ae4e5b186cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_76ca0841-2a48-4f0d-898d-b91f218e9e9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_12a9f643-087f-40cb-be2e-4ae4e5b186cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_c478908c-f246-4540-8b7f-01ba775ba9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_12a9f643-087f-40cb-be2e-4ae4e5b186cd" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_c478908c-f246-4540-8b7f-01ba775ba9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_77d681b6-4d82-472b-96e7-77f66753b697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bbcd1081-8f02-458b-9642-76cd5349051b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_77d681b6-4d82-472b-96e7-77f66753b697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f38e1703-b6f2-404b-aa6f-9ffee3fffb54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_77d681b6-4d82-472b-96e7-77f66753b697" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f38e1703-b6f2-404b-aa6f-9ffee3fffb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3ad409ef-0474-4a4f-9f95-0e342d8b0945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f38e1703-b6f2-404b-aa6f-9ffee3fffb54" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3ad409ef-0474-4a4f-9f95-0e342d8b0945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d410c977-bdbe-4d25-98c3-b2488b708581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f38e1703-b6f2-404b-aa6f-9ffee3fffb54" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d410c977-bdbe-4d25-98c3-b2488b708581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_14be3295-6901-45e4-b1b1-a08b5b916701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f38e1703-b6f2-404b-aa6f-9ffee3fffb54" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_14be3295-6901-45e4-b1b1-a08b5b916701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fcbb7465-449d-4488-aa03-e011c84fd26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bbcd1081-8f02-458b-9642-76cd5349051b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fcbb7465-449d-4488-aa03-e011c84fd26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_3a93c388-d323-4e2b-b135-66c146e38ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fcbb7465-449d-4488-aa03-e011c84fd26b" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_3a93c388-d323-4e2b-b135-66c146e38ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#FairValueMeasurementsLevel3ReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_94f3d355-130f-4132-9f72-b628b11c5e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_ea00ac4d-81b7-45ec-b3cf-f178d6596b0c" xlink:href="opk-20220331.xsd#opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_94f3d355-130f-4132-9f72-b628b11c5e6c" xlink:to="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_ea00ac4d-81b7-45ec-b3cf-f178d6596b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_05b49dfe-115d-4bd6-9c3a-ed866400615f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_ea00ac4d-81b7-45ec-b3cf-f178d6596b0c" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_05b49dfe-115d-4bd6-9c3a-ed866400615f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eaa581a1-bcfb-4f59-87e3-a8e0b3cde043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_05b49dfe-115d-4bd6-9c3a-ed866400615f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eaa581a1-bcfb-4f59-87e3-a8e0b3cde043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ContingentConsiderationMember_d26121d6-7aa1-4433-8c4d-79ceced3bfe3" xlink:href="opk-20220331.xsd#opk_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eaa581a1-bcfb-4f59-87e3-a8e0b3cde043" xlink:to="loc_opk_ContingentConsiderationMember_d26121d6-7aa1-4433-8c4d-79ceced3bfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_ee77cd16-4557-42cb-bacc-88f7a45cc97f" xlink:href="opk-20220331.xsd#opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable_ea00ac4d-81b7-45ec-b3cf-f178d6596b0c" xlink:to="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_ee77cd16-4557-42cb-bacc-88f7a45cc97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bfbfa471-d941-43c2-a36c-91afafc2d17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems_ee77cd16-4557-42cb-bacc-88f7a45cc97f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bfbfa471-d941-43c2-a36c-91afafc2d17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_892aa168-1b75-4b50-aef9-b73465bf33f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bfbfa471-d941-43c2-a36c-91afafc2d17e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_892aa168-1b75-4b50-aef9-b73465bf33f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract_890d06e7-376d-4cff-9623-e09e02412fff" xlink:href="opk-20220331.xsd#opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bfbfa471-d941-43c2-a36c-91afafc2d17e" xlink:to="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract_890d06e7-376d-4cff-9623-e09e02412fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_24c1a503-89a1-41e7-9ffd-dcf4baaa0892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract_890d06e7-376d-4cff-9623-e09e02412fff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_24c1a503-89a1-41e7-9ffd-dcf4baaa0892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact_cd9cde07-b89a-490a-9cd3-cfb79c53b688" xlink:href="opk-20220331.xsd#opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract_890d06e7-376d-4cff-9623-e09e02412fff" xlink:to="loc_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact_cd9cde07-b89a-490a-9cd3-cfb79c53b688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fc770312-aeb5-46fa-87af-db8d2c65bf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bfbfa471-d941-43c2-a36c-91afafc2d17e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fc770312-aeb5-46fa-87af-db8d2c65bf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bb97c50c-a1c2-4686-9cc7-cb938c38f5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e5924a0c-f765-475f-b4b5-33e8c24bd524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bb97c50c-a1c2-4686-9cc7-cb938c38f5ba" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e5924a0c-f765-475f-b4b5-33e8c24bd524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5f50e9a1-4f6e-4c31-8150-b6767038c96a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e5924a0c-f765-475f-b4b5-33e8c24bd524" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5f50e9a1-4f6e-4c31-8150-b6767038c96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e50bf377-9e0b-4865-87ae-f00d273edb66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5f50e9a1-4f6e-4c31-8150-b6767038c96a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e50bf377-9e0b-4865-87ae-f00d273edb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_1eca32b1-c91d-4b59-929b-acbfc04c02d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e50bf377-9e0b-4865-87ae-f00d273edb66" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_1eca32b1-c91d-4b59-929b-acbfc04c02d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1600f11c-8995-4a31-a9e4-ad0576f44070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e50bf377-9e0b-4865-87ae-f00d273edb66" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1600f11c-8995-4a31-a9e4-ad0576f44070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78babcd0-99b7-47c7-9052-e38b73e28271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e5924a0c-f765-475f-b4b5-33e8c24bd524" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78babcd0-99b7-47c7-9052-e38b73e28271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ac76c7e2-d102-4701-9c49-ce661f9de051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78babcd0-99b7-47c7-9052-e38b73e28271" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ac76c7e2-d102-4701-9c49-ce661f9de051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContracts" xlink:type="simple" xlink:href="opk-20220331.xsd#DerivativeContracts"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DerivativeContracts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_445fcef9-4bb7-462d-b3fb-42e4c61ffb05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5ceb9cf5-cee6-4840-9095-544801acde8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_445fcef9-4bb7-462d-b3fb-42e4c61ffb05" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5ceb9cf5-cee6-4840-9095-544801acde8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContractsTables" xlink:type="simple" xlink:href="opk-20220331.xsd#DerivativeContractsTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DerivativeContractsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1f568e2c-53db-484e-b80e-c4b804b64bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_0372f0ac-4594-4ebb-9d51-c8ee2a566a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1f568e2c-53db-484e-b80e-c4b804b64bb9" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_0372f0ac-4594-4ebb-9d51-c8ee2a566a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_11f240f8-982c-4544-86ad-42b5caae1884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1f568e2c-53db-484e-b80e-c4b804b64bb9" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_11f240f8-982c-4544-86ad-42b5caae1884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DerivativeContractsBalanceSheetComponentDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d32e1695-7bb8-42ef-8271-519233ff4c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ded99093-48d2-4326-a307-94391bb6fb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d32e1695-7bb8-42ef-8271-519233ff4c5e" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ded99093-48d2-4326-a307-94391bb6fb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2b806178-0d62-407f-be0d-67431ec0210c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ded99093-48d2-4326-a307-94391bb6fb4b" xlink:to="loc_us-gaap_HedgingDesignationAxis_2b806178-0d62-407f-be0d-67431ec0210c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_36f0be2f-b639-493b-90e9-dde96bfac518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_2b806178-0d62-407f-be0d-67431ec0210c" xlink:to="loc_us-gaap_HedgingDesignationDomain_36f0be2f-b639-493b-90e9-dde96bfac518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a4e194ea-08f1-464b-85f7-79426ed92753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_36f0be2f-b639-493b-90e9-dde96bfac518" xlink:to="loc_us-gaap_NondesignatedMember_a4e194ea-08f1-464b-85f7-79426ed92753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bca0a4b6-5ba9-49f5-ac3b-423a7118aa11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ded99093-48d2-4326-a307-94391bb6fb4b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bca0a4b6-5ba9-49f5-ac3b-423a7118aa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2fce3e08-574e-4536-a5df-8ba3af38b9db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bca0a4b6-5ba9-49f5-ac3b-423a7118aa11" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2fce3e08-574e-4536-a5df-8ba3af38b9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_1c8cb6b4-3d6e-4add-a66c-93d8b34ab610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2fce3e08-574e-4536-a5df-8ba3af38b9db" xlink:to="loc_us-gaap_StockOptionMember_1c8cb6b4-3d6e-4add-a66c-93d8b34ab610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_c25af0d6-8cd0-4e8c-85db-5742e5012182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2fce3e08-574e-4536-a5df-8ba3af38b9db" xlink:to="loc_us-gaap_ForwardContractsMember_c25af0d6-8cd0-4e8c-85db-5742e5012182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_56f08a1f-164c-4bde-9ae7-cec9c0c1cc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ded99093-48d2-4326-a307-94391bb6fb4b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_56f08a1f-164c-4bde-9ae7-cec9c0c1cc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_94a169e6-fb7d-4d29-bd42-21a2b7ceb1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_56f08a1f-164c-4bde-9ae7-cec9c0c1cc4d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_94a169e6-fb7d-4d29-bd42-21a2b7ceb1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_c821616e-18be-4d11-9a09-0931aae77e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_94a169e6-fb7d-4d29-bd42-21a2b7ceb1d9" xlink:to="loc_us-gaap_InvestmentsMember_c821616e-18be-4d11-9a09-0931aae77e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember_a1e5f3ee-4c3c-4a54-a8bc-af29f7b007d0" xlink:href="opk-20220331.xsd#opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_94a169e6-fb7d-4d29-bd42-21a2b7ceb1d9" xlink:to="loc_opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember_a1e5f3ee-4c3c-4a54-a8bc-af29f7b007d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_44a2ca9e-fc8d-40ed-b21e-c84c9c1289ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ded99093-48d2-4326-a307-94391bb6fb4b" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_44a2ca9e-fc8d-40ed-b21e-c84c9c1289ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_73d3b92a-93f0-4118-9945-dcaef9faa8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_44a2ca9e-fc8d-40ed-b21e-c84c9c1289ed" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_73d3b92a-93f0-4118-9945-dcaef9faa8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#DerivativeContractsDerivativeGainsLossesDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1f0c11f4-fb09-48f3-b231-722d6d3b2986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4468a255-df2a-4616-b7ca-d85a0e4240d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1f0c11f4-fb09-48f3-b231-722d6d3b2986" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4468a255-df2a-4616-b7ca-d85a0e4240d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_787369b6-304e-4c21-8874-ae93c2ff4bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4468a255-df2a-4616-b7ca-d85a0e4240d7" xlink:to="loc_us-gaap_HedgingDesignationAxis_787369b6-304e-4c21-8874-ae93c2ff4bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_253e956d-d948-4198-963b-e9f17f054560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_787369b6-304e-4c21-8874-ae93c2ff4bac" xlink:to="loc_us-gaap_HedgingDesignationDomain_253e956d-d948-4198-963b-e9f17f054560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_481dff84-d210-41ce-a1e1-d3888e01e835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_253e956d-d948-4198-963b-e9f17f054560" xlink:to="loc_us-gaap_NondesignatedMember_481dff84-d210-41ce-a1e1-d3888e01e835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_19786fb3-10ff-4bbc-bea6-474f7e33e5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4468a255-df2a-4616-b7ca-d85a0e4240d7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_19786fb3-10ff-4bbc-bea6-474f7e33e5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_61dbb868-67dc-49e3-a6c5-2a8839ea2ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_19786fb3-10ff-4bbc-bea6-474f7e33e5dd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_61dbb868-67dc-49e3-a6c5-2a8839ea2ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_5cf25092-26d5-442a-8863-733bb8269b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_61dbb868-67dc-49e3-a6c5-2a8839ea2ecf" xlink:to="loc_us-gaap_StockOptionMember_5cf25092-26d5-442a-8863-733bb8269b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_e46cf045-2896-4601-a425-ac7ec8bcfe6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_61dbb868-67dc-49e3-a6c5-2a8839ea2ecf" xlink:to="loc_us-gaap_ForwardContractsMember_e46cf045-2896-4601-a425-ac7ec8bcfe6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f5c53cd9-225a-4106-8a00-32e6ae763d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4468a255-df2a-4616-b7ca-d85a0e4240d7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f5c53cd9-225a-4106-8a00-32e6ae763d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_dc4db281-47bb-4187-9326-575440f9942c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f5c53cd9-225a-4106-8a00-32e6ae763d81" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_dc4db281-47bb-4187-9326-575440f9942c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="opk-20220331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_443a9ab0-b96e-47c9-a6ac-71579b90f8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e240a35b-487f-4dbe-a51c-e7ccc3c17cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_443a9ab0-b96e-47c9-a6ac-71579b90f8f0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e240a35b-487f-4dbe-a51c-e7ccc3c17cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_e61b0440-d53a-4b39-b8e5-5f392c108f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_e61b0440-d53a-4b39-b8e5-5f392c108f7a" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_baf9c67e-ccc7-425b-a3b8-08bb39e515f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_us-gaap_CreditFacilityAxis_baf9c67e-ccc7-425b-a3b8-08bb39e515f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_59f23ba4-7caf-45f0-8bd6-ebb66ecb2817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_baf9c67e-ccc7-425b-a3b8-08bb39e515f7" xlink:to="loc_us-gaap_CreditFacilityDomain_59f23ba4-7caf-45f0-8bd6-ebb66ecb2817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2f4f03c3-9e30-48f5-b003-c06052a40425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_59f23ba4-7caf-45f0-8bd6-ebb66ecb2817" xlink:to="loc_us-gaap_LineOfCreditMember_2f4f03c3-9e30-48f5-b003-c06052a40425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_df9bdee0-39a1-42e9-af3f-819d4b292873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_59f23ba4-7caf-45f0-8bd6-ebb66ecb2817" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_df9bdee0-39a1-42e9-af3f-819d4b292873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f445462c-6d8a-4013-a58a-ae81c6e988f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_us-gaap_DebtInstrumentAxis_f445462c-6d8a-4013-a58a-ae81c6e988f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3ac2a32f-6542-4430-8096-9a68846dc694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f445462c-6d8a-4013-a58a-ae81c6e988f3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3ac2a32f-6542-4430-8096-9a68846dc694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NewCreditAgreementMember_a7b91100-7494-4469-ab5c-50061d9b7d86" xlink:href="opk-20220331.xsd#opk_NewCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3ac2a32f-6542-4430-8096-9a68846dc694" xlink:to="loc_opk_NewCreditAgreementMember_a7b91100-7494-4469-ab5c-50061d9b7d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7579c0d4-77bc-4c2e-a5db-dee5b1f7cbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7579c0d4-77bc-4c2e-a5db-dee5b1f7cbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ba2c72cf-3c0b-4455-b02b-c6a46a2d93ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7579c0d4-77bc-4c2e-a5db-dee5b1f7cbf3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ba2c72cf-3c0b-4455-b02b-c6a46a2d93ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_7fa4f16f-716c-4926-b5ea-f822a3cf6280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba2c72cf-3c0b-4455-b02b-c6a46a2d93ee" xlink:to="loc_us-gaap_UnsecuredDebtMember_7fa4f16f-716c-4926-b5ea-f822a3cf6280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1d844ce8-dc85-4c0b-98ab-f630829af1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba2c72cf-3c0b-4455-b02b-c6a46a2d93ee" xlink:to="loc_us-gaap_LineOfCreditMember_1d844ce8-dc85-4c0b-98ab-f630829af1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2d4e30d0-36cd-460d-90a0-bfac82e2c518" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_dei_LegalEntityAxis_2d4e30d0-36cd-460d-90a0-bfac82e2c518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2a2bb798-24f1-4247-81e6-812376d4821e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2d4e30d0-36cd-460d-90a0-bfac82e2c518" xlink:to="loc_dei_EntityDomain_2a2bb798-24f1-4247-81e6-812376d4821e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MednaxServicesIncMember_cf777941-ac62-4037-b83a-c2acb81df4da" xlink:href="opk-20220331.xsd#opk_MednaxServicesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2a2bb798-24f1-4247-81e6-812376d4821e" xlink:to="loc_opk_MednaxServicesIncMember_cf777941-ac62-4037-b83a-c2acb81df4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MuseumofScienceIncMember_659edd7e-ea92-4332-89dc-914ef1fb015a" xlink:href="opk-20220331.xsd#opk_MuseumofScienceIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2a2bb798-24f1-4247-81e6-812376d4821e" xlink:to="loc_opk_MuseumofScienceIncMember_659edd7e-ea92-4332-89dc-914ef1fb015a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3321320e-bb14-4841-aa98-9abeb1fcaaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3321320e-bb14-4841-aa98-9abeb1fcaaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_04e2e005-eb34-444d-ba8d-83c9e35bdd09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3321320e-bb14-4841-aa98-9abeb1fcaaf2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_04e2e005-eb34-444d-ba8d-83c9e35bdd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_a82abe20-fecd-406f-9292-b6ecbc0119b8" xlink:href="opk-20220331.xsd#opk_SharesReceivedUponClosingofXeneticTransactionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_04e2e005-eb34-444d-ba8d-83c9e35bdd09" xlink:to="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_a82abe20-fecd-406f-9292-b6ecbc0119b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6beddbd4-487a-42ca-97a7-927412b1cd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6beddbd4-487a-42ca-97a7-927412b1cd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cae75dbc-f8fe-4b95-a1a4-ef74c634e863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6beddbd4-487a-42ca-97a7-927412b1cd2e" xlink:to="loc_us-gaap_RelatedPartyDomain_cae75dbc-f8fe-4b95-a1a4-ef74c634e863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_8787ee2e-c1dc-4bfc-b3b2-55689d40d2c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cae75dbc-f8fe-4b95-a1a4-ef74c634e863" xlink:to="loc_srt_DirectorMember_8787ee2e-c1dc-4bfc-b3b2-55689d40d2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_64ca942f-9af8-407e-a4fe-ae7456b73bc8" xlink:href="opk-20220331.xsd#opk_SharesReceivedUponClosingofXeneticTransactionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cae75dbc-f8fe-4b95-a1a4-ef74c634e863" xlink:to="loc_opk_SharesReceivedUponClosingofXeneticTransactionMember_64ca942f-9af8-407e-a4fe-ae7456b73bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioCardiaInc.Member_f85fbf79-4a1d-4e3a-8835-655b10bc2089" xlink:href="opk-20220331.xsd#opk_BioCardiaInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cae75dbc-f8fe-4b95-a1a4-ef74c634e863" xlink:to="loc_opk_BioCardiaInc.Member_f85fbf79-4a1d-4e3a-8835-655b10bc2089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DrFrostandMrPfennigerMember_3e31d35c-22a0-470d-aa8c-a0d195a5ecdb" xlink:href="opk-20220331.xsd#opk_DrFrostandMrPfennigerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cae75dbc-f8fe-4b95-a1a4-ef74c634e863" xlink:to="loc_opk_DrFrostandMrPfennigerMember_3e31d35c-22a0-470d-aa8c-a0d195a5ecdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FrostRealEstateHoldingsLLCMember_b2a334af-9798-4c2c-9531-937b1063ff4a" xlink:href="opk-20220331.xsd#opk_FrostRealEstateHoldingsLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cae75dbc-f8fe-4b95-a1a4-ef74c634e863" xlink:to="loc_opk_FrostRealEstateHoldingsLLCMember_b2a334af-9798-4c2c-9531-937b1063ff4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_37bd18d1-e971-436b-aa84-e08958cfe9fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_37bd18d1-e971-436b-aa84-e08958cfe9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_37bd18d1-e971-436b-aa84-e08958cfe9fd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DetectGenomixMember_3c67eba6-9de9-475b-bd4e-ce27bda71188" xlink:href="opk-20220331.xsd#opk_DetectGenomixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_DetectGenomixMember_3c67eba6-9de9-475b-bd4e-ce27bda71188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmsynthezMember_c7d9694d-b5ca-4d07-a527-816533f26c47" xlink:href="opk-20220331.xsd#opk_PharmsynthezMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_PharmsynthezMember_c7d9694d-b5ca-4d07-a527-816533f26c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ZebraMember_0a36849c-f8ba-4ca3-bfbb-8763cd46d361" xlink:href="opk-20220331.xsd#opk_ZebraMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_ZebraMember_0a36849c-f8ba-4ca3-bfbb-8763cd46d361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NeovascMember_71c253ec-ee0d-4603-a4ed-e9e598d97ae3" xlink:href="opk-20220331.xsd#opk_NeovascMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_NeovascMember_71c253ec-ee0d-4603-a4ed-e9e598d97ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChromadexCorporationMember_b90617de-418f-481a-aff0-a7484a014a5d" xlink:href="opk-20220331.xsd#opk_ChromadexCorporationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_ChromadexCorporationMember_b90617de-418f-481a-aff0-a7484a014a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CocrystalMember_46d99aab-7638-4495-b7cd-057ea8b30344" xlink:href="opk-20220331.xsd#opk_CocrystalMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_CocrystalMember_46d99aab-7638-4495-b7cd-057ea8b30344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NIMSMember_7e19a393-a94c-4bf6-b2f9-ebc7645ade9e" xlink:href="opk-20220331.xsd#opk_NIMSMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_NIMSMember_7e19a393-a94c-4bf6-b2f9-ebc7645ade9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EloxxPharmaceuticalsMember_e86397e8-6b43-4330-955a-a51d7bb500be" xlink:href="opk-20220331.xsd#opk_EloxxPharmaceuticalsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_EloxxPharmaceuticalsMember_e86397e8-6b43-4330-955a-a51d7bb500be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BioCardiaInc.Member_94cba11c-5c16-496a-a85e-e2a5a7925519" xlink:href="opk-20220331.xsd#opk_BioCardiaInc.Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_BioCardiaInc.Member_94cba11c-5c16-496a-a85e-e2a5a7925519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LeaderMedMember_91758f16-0162-43ad-a18c-b3ccc35e21db" xlink:href="opk-20220331.xsd#opk_LeaderMedMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_LeaderMedMember_91758f16-0162-43ad-a18c-b3ccc35e21db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_InCellDxIncMember_354f63cd-56e0-4242-8a66-33733016bfa7" xlink:href="opk-20220331.xsd#opk_InCellDxIncMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bbc24db-e985-4ff9-b8af-59cb62b75f50" xlink:to="loc_opk_InCellDxIncMember_354f63cd-56e0-4242-8a66-33733016bfa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_424cae7a-6a02-4bfa-9f1a-59a44b890ead" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_srt_ConsolidatedEntitiesAxis_424cae7a-6a02-4bfa-9f1a-59a44b890ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_42ae2cbc-c1af-4d02-96c7-1f9707127207" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_424cae7a-6a02-4bfa-9f1a-59a44b890ead" xlink:to="loc_srt_ConsolidatedEntitiesDomain_42ae2cbc-c1af-4d02-96c7-1f9707127207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_6d11ecda-f474-4539-8871-eb3babf51f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_42ae2cbc-c1af-4d02-96c7-1f9707127207" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_6d11ecda-f474-4539-8871-eb3babf51f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0615879-a2dc-4cd3-9991-6567cc2b66eb" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7596c173-40eb-4fa4-bf11-c2ced66b9433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7596c173-40eb-4fa4-bf11-c2ced66b9433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_df43e569-b390-4240-ba15-6d294e38a984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_df43e569-b390-4240-ba15-6d294e38a984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3647726c-0d49-46a0-9e91-b1e4566fd4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3647726c-0d49-46a0-9e91-b1e4566fd4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_055da180-1321-4ed6-a18f-e3812290e7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_055da180-1321-4ed6-a18f-e3812290e7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_4a275f75-f92b-45ed-bdb8-5b0a224866b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_LineOfCredit_4a275f75-f92b-45ed-bdb8-5b0a224866b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionShares_faf9758e-bd03-4f51-b0f2-445e5bbac517" xlink:href="opk-20220331.xsd#opk_RelatedPartyTransactionShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_opk_RelatedPartyTransactionShares_faf9758e-bd03-4f51-b0f2-445e5bbac517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_291a4a2a-3c86-4d96-87c8-c1cad13669c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_291a4a2a-3c86-4d96-87c8-c1cad13669c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EquitySecurityFVNIOwnershipPercent_bcfec71b-2973-42ac-aed2-65ffa07626a3" xlink:href="opk-20220331.xsd#opk_EquitySecurityFVNIOwnershipPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_opk_EquitySecurityFVNIOwnershipPercent_bcfec71b-2973-42ac-aed2-65ffa07626a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionFutureContributions_3916448e-1317-4f3e-8a15-b88b5671aee5" xlink:href="opk-20220331.xsd#opk_RelatedPartyTransactionFutureContributions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_opk_RelatedPartyTransactionFutureContributions_3916448e-1317-4f3e-8a15-b88b5671aee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RelatedPartyTransactionFutureContributionTerm_fb8b7ac5-a5a3-4856-bfa7-5f3655260417" xlink:href="opk-20220331.xsd#opk_RelatedPartyTransactionFutureContributionTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_opk_RelatedPartyTransactionFutureContributionTerm_fb8b7ac5-a5a3-4856-bfa7-5f3655260417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_c732a21d-1171-4938-acc7-c7c38a0788d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_c732a21d-1171-4938-acc7-c7c38a0788d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OperatingLeasesMonthlyPaymentsYearOne_b0486396-db7f-4962-86d3-1460737fd958" xlink:href="opk-20220331.xsd#opk_OperatingLeasesMonthlyPaymentsYearOne"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_opk_OperatingLeasesMonthlyPaymentsYearOne_b0486396-db7f-4962-86d3-1460737fd958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OperatingLeasesMonthlyPaymentsYearFive_a51f0b8f-0fcf-4f73-b15b-56ac8d03bef7" xlink:href="opk-20220331.xsd#opk_OperatingLeasesMonthlyPaymentsYearFive"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_opk_OperatingLeasesMonthlyPaymentsYearFive_a51f0b8f-0fcf-4f73-b15b-56ac8d03bef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_12e56724-5baa-4934-979f-50e3d2202b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d7d9a381-82cd-4729-a25f-40c1e6fae9f5" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_12e56724-5baa-4934-979f-50e3d2202b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="opk-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_160c5e9d-a9f5-42fc-aa3b-96bc964f89bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ed29899e-21ae-42da-903c-7d14bd80ac2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_160c5e9d-a9f5-42fc-aa3b-96bc964f89bb" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ed29899e-21ae-42da-903c-7d14bd80ac2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f396fb8-b918-4be3-8ee5-fa414e4848ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_31140deb-80f6-4ce2-82c5-354db8680e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f396fb8-b918-4be3-8ee5-fa414e4848ba" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_31140deb-80f6-4ce2-82c5-354db8680e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_73b49fa4-b22b-4e37-ad99-d4b255970dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_31140deb-80f6-4ce2-82c5-354db8680e2c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_73b49fa4-b22b-4e37-ad99-d4b255970dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3f69044d-8cee-4852-8f49-10008ef84571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_73b49fa4-b22b-4e37-ad99-d4b255970dd0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3f69044d-8cee-4852-8f49-10008ef84571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_e134862a-9825-4428-b39d-9750f6bc5d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3f69044d-8cee-4852-8f49-10008ef84571" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_e134862a-9825-4428-b39d-9750f6bc5d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_ccd7b3fd-c6d2-421c-9f31-612add546baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3f69044d-8cee-4852-8f49-10008ef84571" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_ccd7b3fd-c6d2-421c-9f31-612add546baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_513c1d43-6b96-4f46-b6be-19a06c48b318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_31140deb-80f6-4ce2-82c5-354db8680e2c" xlink:to="loc_us-gaap_LitigationStatusAxis_513c1d43-6b96-4f46-b6be-19a06c48b318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_6ee51104-6d04-4a3a-89d4-f24ceff1b995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_513c1d43-6b96-4f46-b6be-19a06c48b318" xlink:to="loc_us-gaap_LitigationStatusDomain_6ee51104-6d04-4a3a-89d4-f24ceff1b995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_ec5394b5-8646-4762-b375-5536be63fb64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_6ee51104-6d04-4a3a-89d4-f24ceff1b995" xlink:to="loc_us-gaap_SettledLitigationMember_ec5394b5-8646-4762-b375-5536be63fb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_cfd7e448-18f2-4fa4-ba96-d375a0b9d4e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_31140deb-80f6-4ce2-82c5-354db8680e2c" xlink:to="loc_srt_LitigationCaseAxis_cfd7e448-18f2-4fa4-ba96-d375a0b9d4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f45f3f72-d7b7-41a7-aa0c-5dff34b6f77a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_cfd7e448-18f2-4fa4-ba96-d375a0b9d4e3" xlink:to="loc_srt_LitigationCaseTypeDomain_f45f3f72-d7b7-41a7-aa0c-5dff34b6f77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CivilInvestigativeDemandsMember_23d421a7-a8a4-4b7a-8d86-92a35bc60212" xlink:href="opk-20220331.xsd#opk_CivilInvestigativeDemandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f45f3f72-d7b7-41a7-aa0c-5dff34b6f77a" xlink:to="loc_opk_CivilInvestigativeDemandsMember_23d421a7-a8a4-4b7a-8d86-92a35bc60212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChanceryCourtOfDelawareVsCompanyMember_05cc7b7e-476a-4e1b-8f5b-d52daafe63c7" xlink:href="opk-20220331.xsd#opk_ChanceryCourtOfDelawareVsCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f45f3f72-d7b7-41a7-aa0c-5dff34b6f77a" xlink:to="loc_opk_ChanceryCourtOfDelawareVsCompanyMember_05cc7b7e-476a-4e1b-8f5b-d52daafe63c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SouthernDistrictOfNewYorkVsBioReferenceMember_56bcbfb5-6fd2-42a0-844f-4fa7dcd4e52a" xlink:href="opk-20220331.xsd#opk_SouthernDistrictOfNewYorkVsBioReferenceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f45f3f72-d7b7-41a7-aa0c-5dff34b6f77a" xlink:to="loc_opk_SouthernDistrictOfNewYorkVsBioReferenceMember_56bcbfb5-6fd2-42a0-844f-4fa7dcd4e52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_157cd345-873c-434d-98b9-c82d54cf6692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_31140deb-80f6-4ce2-82c5-354db8680e2c" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_157cd345-873c-434d-98b9-c82d54cf6692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1790ca6b-0bd2-42f8-b2ed-c9c89bb75ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_157cd345-873c-434d-98b9-c82d54cf6692" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1790ca6b-0bd2-42f8-b2ed-c9c89bb75ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_117cdbb1-0df3-4dbf-8d61-60f241479c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_157cd345-873c-434d-98b9-c82d54cf6692" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_117cdbb1-0df3-4dbf-8d61-60f241479c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_c1467bfb-59c6-40fb-9dd2-61556df654f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_157cd345-873c-434d-98b9-c82d54cf6692" xlink:to="loc_us-gaap_LitigationReserveCurrent_c1467bfb-59c6-40fb-9dd2-61556df654f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LossContingencyMilestonePayment_4e082f11-0e25-4366-b753-2bdc0c25a58e" xlink:href="opk-20220331.xsd#opk_LossContingencyMilestonePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_157cd345-873c-434d-98b9-c82d54cf6692" xlink:to="loc_opk_LossContingencyMilestonePayment_4e082f11-0e25-4366-b753-2bdc0c25a58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_0f7ac722-de74-458f-ab71-33d49b5fd0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_157cd345-873c-434d-98b9-c82d54cf6692" xlink:to="loc_us-gaap_PurchaseObligation_0f7ac722-de74-458f-ab71-33d49b5fd0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognition" xlink:type="simple" xlink:href="opk-20220331.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2765680a-a0bd-49c9-918c-e2d8442c1b36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_50a91195-d687-4d01-acd4-fb6b20504f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2765680a-a0bd-49c9-918c-e2d8442c1b36" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_50a91195-d687-4d01-acd4-fb6b20504f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="opk-20220331.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bbf0ecd9-520e-4791-96f7-87dce44aeb99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2abba1b0-7ece-40fc-a1bb-fae3d37d4ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bbf0ecd9-520e-4791-96f7-87dce44aeb99" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2abba1b0-7ece-40fc-a1bb-fae3d37d4ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock_c9b8b1bf-b871-40eb-84f8-b43d3d393e63" xlink:href="opk-20220331.xsd#opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bbf0ecd9-520e-4791-96f7-87dce44aeb99" xlink:to="loc_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock_c9b8b1bf-b871-40eb-84f8-b43d3d393e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_1e0178c9-d5e1-44b1-8a5f-89c53686d2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bbf0ecd9-520e-4791-96f7-87dce44aeb99" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_1e0178c9-d5e1-44b1-8a5f-89c53686d2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6422b7c7-8140-4c55-8b26-368687615875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_44ef4ec6-cd65-49c6-86ca-9f0b8b512a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6422b7c7-8140-4c55-8b26-368687615875" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_44ef4ec6-cd65-49c6-86ca-9f0b8b512a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7c5af198-e88b-46eb-9868-46bf15fb333c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_44ef4ec6-cd65-49c6-86ca-9f0b8b512a90" xlink:to="loc_srt_CounterpartyNameAxis_7c5af198-e88b-46eb-9868-46bf15fb333c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3166df68-4feb-439a-b659-849fe1249f8c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7c5af198-e88b-46eb-9868-46bf15fb333c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3166df68-4feb-439a-b659-849fe1249f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PfizerMember_65f559ed-5742-4856-bd2b-ef566be838bc" xlink:href="opk-20220331.xsd#opk_PfizerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3166df68-4feb-439a-b659-849fe1249f8c" xlink:to="loc_opk_PfizerMember_65f559ed-5742-4856-bd2b-ef566be838bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember_07f431bf-71da-4f16-8f70-af05b88a13f6" xlink:href="opk-20220331.xsd#opk_ViforFreseniusMedicalCarePharmaLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3166df68-4feb-439a-b659-849fe1249f8c" xlink:to="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember_07f431bf-71da-4f16-8f70-af05b88a13f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e2763036-106b-49a1-8d22-7ee8a78b1127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_44ef4ec6-cd65-49c6-86ca-9f0b8b512a90" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e2763036-106b-49a1-8d22-7ee8a78b1127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b05a96ef-9bfb-4b36-9860-46a758814305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e2763036-106b-49a1-8d22-7ee8a78b1127" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b05a96ef-9bfb-4b36-9860-46a758814305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f43ec1db-1a24-4aa1-9e26-5c9800acf2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b05a96ef-9bfb-4b36-9860-46a758814305" xlink:to="loc_us-gaap_ProductMember_f43ec1db-1a24-4aa1-9e26-5c9800acf2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6f2a01e2-1d85-415b-a075-bfa803a752c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_44ef4ec6-cd65-49c6-86ca-9f0b8b512a90" xlink:to="loc_srt_ProductOrServiceAxis_6f2a01e2-1d85-415b-a075-bfa803a752c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_435784cc-c18d-4cc0-9695-c7d580d1d930" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6f2a01e2-1d85-415b-a075-bfa803a752c6" xlink:to="loc_srt_ProductsAndServicesDomain_435784cc-c18d-4cc0-9695-c7d580d1d930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RayaldeeMember_f7f1d405-3d7c-4ce5-8dab-2fab0fa71bb3" xlink:href="opk-20220331.xsd#opk_RayaldeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_435784cc-c18d-4cc0-9695-c7d580d1d930" xlink:to="loc_opk_RayaldeeMember_f7f1d405-3d7c-4ce5-8dab-2fab0fa71bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_7f125cc9-9c94-45cd-8311-4ecab3b7e8c4" xlink:href="opk-20220331.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_435784cc-c18d-4cc0-9695-c7d580d1d930" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_7f125cc9-9c94-45cd-8311-4ecab3b7e8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7ca1bc1b-6d1c-4480-bbcd-1769ba35ac65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_44ef4ec6-cd65-49c6-86ca-9f0b8b512a90" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7ca1bc1b-6d1c-4480-bbcd-1769ba35ac65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_427f1813-fb3a-4909-a30a-e243dd496f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7ca1bc1b-6d1c-4480-bbcd-1769ba35ac65" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_427f1813-fb3a-4909-a30a-e243dd496f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AccruedExpensePayorOverpaymentReimbursementLiability_61982cc2-e457-461a-8b6a-03e9d0f31bf1" xlink:href="opk-20220331.xsd#opk_AccruedExpensePayorOverpaymentReimbursementLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7ca1bc1b-6d1c-4480-bbcd-1769ba35ac65" xlink:to="loc_opk_AccruedExpensePayorOverpaymentReimbursementLiability_61982cc2-e457-461a-8b6a-03e9d0f31bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9f9db6ee-01e5-4de8-a3c7-d23a1bc06abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7ca1bc1b-6d1c-4480-bbcd-1769ba35ac65" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9f9db6ee-01e5-4de8-a3c7-d23a1bc06abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_194d21ee-3096-4f3c-913b-69224152590d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7ca1bc1b-6d1c-4480-bbcd-1769ba35ac65" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_194d21ee-3096-4f3c-913b-69224152590d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#RevenueRecognitionScheduleofDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_00dbcd95-6acd-474e-8c13-e57799ec4ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a2abba6c-ced9-44e4-b0db-169b661f6520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_00dbcd95-6acd-474e-8c13-e57799ec4ad8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a2abba6c-ced9-44e4-b0db-169b661f6520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_46858f58-772c-4c0b-8893-a4ec68c7fff0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2abba6c-ced9-44e4-b0db-169b661f6520" xlink:to="loc_srt_ProductOrServiceAxis_46858f58-772c-4c0b-8893-a4ec68c7fff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a561e10c-fe56-4f0f-93b9-c095938642f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_46858f58-772c-4c0b-8893-a4ec68c7fff0" xlink:to="loc_srt_ProductsAndServicesDomain_a561e10c-fe56-4f0f-93b9-c095938642f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_101ada4d-be2d-4957-8d7f-610572fa5165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a561e10c-fe56-4f0f-93b9-c095938642f8" xlink:to="loc_us-gaap_ServiceMember_101ada4d-be2d-4957-8d7f-610572fa5165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_HealthInsurersMember_cc499b6f-e638-47d4-8555-458454a9b54f" xlink:href="opk-20220331.xsd#opk_HealthInsurersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServiceMember_101ada4d-be2d-4957-8d7f-610572fa5165" xlink:to="loc_opk_HealthInsurersMember_cc499b6f-e638-47d4-8555-458454a9b54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GovernmentPayersMember_6f4abd0c-e4bd-497e-a21c-e6aa31301d91" xlink:href="opk-20220331.xsd#opk_GovernmentPayersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServiceMember_101ada4d-be2d-4957-8d7f-610572fa5165" xlink:to="loc_opk_GovernmentPayersMember_6f4abd0c-e4bd-497e-a21c-e6aa31301d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ClientPayersMember_96bf7117-6f55-48a2-8d9f-d7ba0553b4f9" xlink:href="opk-20220331.xsd#opk_ClientPayersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServiceMember_101ada4d-be2d-4957-8d7f-610572fa5165" xlink:to="loc_opk_ClientPayersMember_96bf7117-6f55-48a2-8d9f-d7ba0553b4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PatientsMember_43cffa10-8033-42cc-b7f8-1e6e9a4754eb" xlink:href="opk-20220331.xsd#opk_PatientsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServiceMember_101ada4d-be2d-4957-8d7f-610572fa5165" xlink:to="loc_opk_PatientsMember_43cffa10-8033-42cc-b7f8-1e6e9a4754eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_758ff1c1-deb2-41a9-9e54-c2b3017baefa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2abba6c-ced9-44e4-b0db-169b661f6520" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_758ff1c1-deb2-41a9-9e54-c2b3017baefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4e36956a-430c-48f7-85a4-f5a586746c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_758ff1c1-deb2-41a9-9e54-c2b3017baefa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4e36956a-430c-48f7-85a4-f5a586746c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4f729103-d6ff-47be-9bd5-07584deed3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1c04490e-0e93-4e85-9fdb-b92ab798f43b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4f729103-d6ff-47be-9bd5-07584deed3d9" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1c04490e-0e93-4e85-9fdb-b92ab798f43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_157d3f1c-834d-42c5-a1af-e1f9cd819503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1c04490e-0e93-4e85-9fdb-b92ab798f43b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_157d3f1c-834d-42c5-a1af-e1f9cd819503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_cae93cb6-8ae1-40e5-a74d-fc2e659ea44b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_157d3f1c-834d-42c5-a1af-e1f9cd819503" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_cae93cb6-8ae1-40e5-a74d-fc2e659ea44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ChargebacksDiscountsRebatesAndFeesMember_795cad16-0709-45d3-9b8e-e7c6685dd191" xlink:href="opk-20220331.xsd#opk_ChargebacksDiscountsRebatesAndFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_cae93cb6-8ae1-40e5-a74d-fc2e659ea44b" xlink:to="loc_opk_ChargebacksDiscountsRebatesAndFeesMember_795cad16-0709-45d3-9b8e-e7c6685dd191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_GovernmentalMember_54aa9c1a-8ce5-4924-b48d-5bd55a33238b" xlink:href="opk-20220331.xsd#opk_GovernmentalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_cae93cb6-8ae1-40e5-a74d-fc2e659ea44b" xlink:to="loc_opk_GovernmentalMember_54aa9c1a-8ce5-4924-b48d-5bd55a33238b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesReturnsMember_37b53799-64bc-4d2d-a1b8-22438ea45965" xlink:href="opk-20220331.xsd#opk_SalesReturnsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_cae93cb6-8ae1-40e5-a74d-fc2e659ea44b" xlink:to="loc_opk_SalesReturnsMember_37b53799-64bc-4d2d-a1b8-22438ea45965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_12557015-ecd8-4f4e-b56e-7889b5118edc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1c04490e-0e93-4e85-9fdb-b92ab798f43b" xlink:to="loc_srt_ProductOrServiceAxis_12557015-ecd8-4f4e-b56e-7889b5118edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a1508ee9-56f9-4e3a-a79d-c33a62911240" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_12557015-ecd8-4f4e-b56e-7889b5118edc" xlink:to="loc_srt_ProductsAndServicesDomain_a1508ee9-56f9-4e3a-a79d-c33a62911240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RayaldeeMember_86df5f5a-dca4-4fad-b87b-d2a6867b8b1e" xlink:href="opk-20220331.xsd#opk_RayaldeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a1508ee9-56f9-4e3a-a79d-c33a62911240" xlink:to="loc_opk_RayaldeeMember_86df5f5a-dca4-4fad-b87b-d2a6867b8b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b1f88bcb-3c0d-478c-a6bf-10ccff980f2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1c04490e-0e93-4e85-9fdb-b92ab798f43b" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b1f88bcb-3c0d-478c-a6bf-10ccff980f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7eb0afd4-12d8-4f49-b3e5-b7456fdecb88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b1f88bcb-3c0d-478c-a6bf-10ccff980f2a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7eb0afd4-12d8-4f49-b3e5-b7456fdecb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_327bcada-0997-4866-a5ba-d4d8429bad81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7eb0afd4-12d8-4f49-b3e5-b7456fdecb88" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_327bcada-0997-4866-a5ba-d4d8429bad81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_853bf6f0-7e41-48ec-b2a5-1313508671d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7eb0afd4-12d8-4f49-b3e5-b7456fdecb88" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_853bf6f0-7e41-48ec-b2a5-1313508671d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments_5ae2d075-03b2-48af-8c9a-9ad586d4eb6b" xlink:href="opk-20220331.xsd#opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7eb0afd4-12d8-4f49-b3e5-b7456fdecb88" xlink:to="loc_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments_5ae2d075-03b2-48af-8c9a-9ad586d4eb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_7815e2d1-ff07-4b73-ba59-2dd895cfcd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7eb0afd4-12d8-4f49-b3e5-b7456fdecb88" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_7815e2d1-ff07-4b73-ba59-2dd895cfcd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a9c7a7eb-47c0-4b51-a753-a01f436b9cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b1f88bcb-3c0d-478c-a6bf-10ccff980f2a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a9c7a7eb-47c0-4b51-a753-a01f436b9cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales_4ddfd788-510c-43a2-8357-4204b2e8c632" xlink:href="opk-20220331.xsd#opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b1f88bcb-3c0d-478c-a6bf-10ccff980f2a" xlink:to="loc_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales_4ddfd788-510c-43a2-8357-4204b2e8c632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/RevenueRecognitionChangesinContractualLiabilitiesBalanceDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#RevenueRecognitionChangesinContractualLiabilitiesBalanceDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/RevenueRecognitionChangesinContractualLiabilitiesBalanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0175be92-3fb2-4ec0-9aea-be40c32d1a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_eef82ff5-fade-43e8-ad4e-af113980e5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0175be92-3fb2-4ec0-9aea-be40c32d1a6c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_eef82ff5-fade-43e8-ad4e-af113980e5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_658c0fe5-d2c9-48de-9dce-b49f3b7b61aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_eef82ff5-fade-43e8-ad4e-af113980e5ab" xlink:to="loc_us-gaap_ContractWithCustomerLiability_658c0fe5-d2c9-48de-9dce-b49f3b7b61aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9e6a22a9-9afa-4dc5-9c0a-67ec16b7cce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_eef82ff5-fade-43e8-ad4e-af113980e5ab" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9e6a22a9-9afa-4dc5-9c0a-67ec16b7cce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_6aa9928b-f493-4056-b981-523ac4f10fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_eef82ff5-fade-43e8-ad4e-af113980e5ab" xlink:to="loc_us-gaap_ContractWithCustomerLiability_6aa9928b-f493-4056-b981-523ac4f10fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/StrategicAlliances" xlink:type="simple" xlink:href="opk-20220331.xsd#StrategicAlliances"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/StrategicAlliances" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd16d840-f0c8-4abf-90fb-2875dcf38db2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_StrategicAlliancesTextBlock_98244eef-27b9-496d-8ec0-83f9556dd61f" xlink:href="opk-20220331.xsd#opk_StrategicAlliancesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd16d840-f0c8-4abf-90fb-2875dcf38db2" xlink:to="loc_opk_StrategicAlliancesTextBlock_98244eef-27b9-496d-8ec0-83f9556dd61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/StrategicAlliancesDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#StrategicAlliancesDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/StrategicAlliancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_00c92055-8ed3-4abc-8c10-e5ee11dadb87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_00c92055-8ed3-4abc-8c10-e5ee11dadb87" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9fc4b0ba-fd91-48e4-883a-6d70d1f83f53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_srt_ProductOrServiceAxis_9fc4b0ba-fd91-48e4-883a-6d70d1f83f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9fc4b0ba-fd91-48e4-883a-6d70d1f83f53" xlink:to="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_7cd6c4d5-ab39-4e56-88c3-962d2be683d8" xlink:href="opk-20220331.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_7cd6c4d5-ab39-4e56-88c3-962d2be683d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DravetSyndromeProductsMember_92107835-17e0-4baa-848b-69ff8d25bb50" xlink:href="opk-20220331.xsd#opk_DravetSyndromeProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:to="loc_opk_DravetSyndromeProductsMember_92107835-17e0-4baa-848b-69ff8d25bb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NonDravetSyndromeProductsMember_f0a7dc34-6238-49ef-9b9e-9122f2efa928" xlink:href="opk-20220331.xsd#opk_NonDravetSyndromeProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:to="loc_opk_NonDravetSyndromeProductsMember_f0a7dc34-6238-49ef-9b9e-9122f2efa928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3cef9b93-5863-4694-8140-a6fb8f3f4894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:to="loc_us-gaap_ProductMember_3cef9b93-5863-4694-8140-a6fb8f3f4894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryMilestonesMember_3ee779b9-6736-4929-9c37-f33db03f9f61" xlink:href="opk-20220331.xsd#opk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:to="loc_opk_RegulatoryMilestonesMember_3ee779b9-6736-4929-9c37-f33db03f9f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_SalesMilestonesMember_297b2290-d811-4b43-897c-b2a914fa5292" xlink:href="opk-20220331.xsd#opk_SalesMilestonesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:to="loc_opk_SalesMilestonesMember_297b2290-d811-4b43-897c-b2a914fa5292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ExclusiveOptionMember_ea57604b-9890-4406-921f-698b54d1a1d4" xlink:href="opk-20220331.xsd#opk_ExclusiveOptionMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4c2c96e5-8c39-48c7-82e8-de8051bb8edf" xlink:to="loc_opk_ExclusiveOptionMember_ea57604b-9890-4406-921f-698b54d1a1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MilestoneAxis_786da8db-7fa8-42a9-a121-4c9555ad242e" xlink:href="opk-20220331.xsd#opk_MilestoneAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_opk_MilestoneAxis_786da8db-7fa8-42a9-a121-4c9555ad242e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_MilestoneDomain_b409eb9b-c51b-4514-bce4-9a6c5ad6e4aa" xlink:href="opk-20220331.xsd#opk_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_MilestoneAxis_786da8db-7fa8-42a9-a121-4c9555ad242e" xlink:to="loc_opk_MilestoneDomain_b409eb9b-c51b-4514-bce4-9a6c5ad6e4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PhaseThreeInitiationMember_fe3d7ef4-9e2b-4cd3-a9f1-10a61c87a2ef" xlink:href="opk-20220331.xsd#opk_PhaseThreeInitiationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_MilestoneDomain_b409eb9b-c51b-4514-bce4-9a6c5ad6e4aa" xlink:to="loc_opk_PhaseThreeInitiationMember_fe3d7ef4-9e2b-4cd3-a9f1-10a61c87a2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryAndDevelopmentMember_f461931f-cf04-46c0-992b-c501c784803b" xlink:href="opk-20220331.xsd#opk_RegulatoryAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_MilestoneDomain_b409eb9b-c51b-4514-bce4-9a6c5ad6e4aa" xlink:to="loc_opk_RegulatoryAndDevelopmentMember_f461931f-cf04-46c0-992b-c501c784803b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_749b61fd-c771-4067-83a2-8b22c0cf1349" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_srt_RangeAxis_749b61fd-c771-4067-83a2-8b22c0cf1349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f26e8378-81a8-4594-aab7-f5d4dcdec63f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_749b61fd-c771-4067-83a2-8b22c0cf1349" xlink:to="loc_srt_RangeMember_f26e8378-81a8-4594-aab7-f5d4dcdec63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b7490dd9-c3c8-4a5d-95f1-005db6cde34a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f26e8378-81a8-4594-aab7-f5d4dcdec63f" xlink:to="loc_srt_MinimumMember_b7490dd9-c3c8-4a5d-95f1-005db6cde34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bd17459b-df6a-4919-958d-83469d311bac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f26e8378-81a8-4594-aab7-f5d4dcdec63f" xlink:to="loc_srt_MaximumMember_bd17459b-df6a-4919-958d-83469d311bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_dc29f4c2-63a8-46bc-aaff-22774243332d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_srt_CounterpartyNameAxis_dc29f4c2-63a8-46bc-aaff-22774243332d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_dc29f4c2-63a8-46bc-aaff-22774243332d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LeaderMedMember_ece22dae-5ec1-4eda-b7d7-2a66edb2b20b" xlink:href="opk-20220331.xsd#opk_LeaderMedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:to="loc_opk_LeaderMedMember_ece22dae-5ec1-4eda-b7d7-2a66edb2b20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CAMP4Member_e68668c4-7238-47d7-9122-266544452e03" xlink:href="opk-20220331.xsd#opk_CAMP4Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:to="loc_opk_CAMP4Member_e68668c4-7238-47d7-9122-266544452e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_NicoyaMember_10290f6e-d791-4d27-9b41-fa88ac2f2fb3" xlink:href="opk-20220331.xsd#opk_NicoyaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:to="loc_opk_NicoyaMember_10290f6e-d791-4d27-9b41-fa88ac2f2fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_EirGenPharmaLimitedMember_a021cfe1-439b-4f9f-b242-7764968f9c70" xlink:href="opk-20220331.xsd#opk_EirGenPharmaLimitedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:to="loc_opk_EirGenPharmaLimitedMember_a021cfe1-439b-4f9f-b242-7764968f9c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember_913b02db-f7e5-453f-84fc-0ea392cefdfd" xlink:href="opk-20220331.xsd#opk_ViforFreseniusMedicalCarePharmaLtdMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:to="loc_opk_ViforFreseniusMedicalCarePharmaLtdMember_913b02db-f7e5-453f-84fc-0ea392cefdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PfizerMember_1c7c8b82-7810-4e77-8a09-383726bcd0ce" xlink:href="opk-20220331.xsd#opk_PfizerMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3168b43d-a131-4d21-9059-bf1eafdc4dbf" xlink:to="loc_opk_PfizerMember_1c7c8b82-7810-4e77-8a09-383726bcd0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_851b7d71-e042-424a-9597-af04216a2615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_851b7d71-e042-424a-9597-af04216a2615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc37ef82-06be-4722-8f42-28e2026ba173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_851b7d71-e042-424a-9597-af04216a2615" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc37ef82-06be-4722-8f42-28e2026ba173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e79ef0a9-e949-4a84-8361-c1dcebe54c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc37ef82-06be-4722-8f42-28e2026ba173" xlink:to="loc_us-gaap_ProductMember_e79ef0a9-e949-4a84-8361-c1dcebe54c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_RegulatoryMilestonesMember_f7bf05b9-c3ea-4929-8244-3b07856a8725" xlink:href="opk-20220331.xsd#opk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc37ef82-06be-4722-8f42-28e2026ba173" xlink:to="loc_opk_RegulatoryMilestonesMember_f7bf05b9-c3ea-4929-8244-3b07856a8725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ExclusiveOptionMember_69cc4066-6513-4e05-b3e2-5deb391c5b42" xlink:href="opk-20220331.xsd#opk_ExclusiveOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc37ef82-06be-4722-8f42-28e2026ba173" xlink:to="loc_opk_ExclusiveOptionMember_69cc4066-6513-4e05-b3e2-5deb391c5b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_582626c3-c31c-45d2-be66-4e8c81035668" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_srt_OwnershipAxis_582626c3-c31c-45d2-be66-4e8c81035668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2712984a-8def-44c9-8c3b-68638dc63e2f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_582626c3-c31c-45d2-be66-4e8c81035668" xlink:to="loc_srt_OwnershipDomain_2712984a-8def-44c9-8c3b-68638dc63e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LeaderMedJointVentureMember_9eed39a0-4347-411d-b53f-70410fc9f640" xlink:href="opk-20220331.xsd#opk_LeaderMedJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2712984a-8def-44c9-8c3b-68638dc63e2f" xlink:to="loc_opk_LeaderMedJointVentureMember_9eed39a0-4347-411d-b53f-70410fc9f640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ba1ec0d9-67bc-4df9-8a4d-09d89484d23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ba1ec0d9-67bc-4df9-8a4d-09d89484d23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b418223e-a629-4065-9004-dbb230623693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ba1ec0d9-67bc-4df9-8a4d-09d89484d23d" xlink:to="loc_us-gaap_RelatedPartyDomain_b418223e-a629-4065-9004-dbb230623693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_810a47d6-4566-41ce-a64e-3ecb57a19bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b418223e-a629-4065-9004-dbb230623693" xlink:to="loc_us-gaap_CorporateJointVentureMember_810a47d6-4566-41ce-a64e-3ecb57a19bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_657f728e-36cb-4231-87cb-0888b708e6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_657f728e-36cb-4231-87cb-0888b708e6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7712f905-60c5-4d4a-8806-e07b15b404ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_657f728e-36cb-4231-87cb-0888b708e6ba" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7712f905-60c5-4d4a-8806-e07b15b404ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4c1c4c0a-f35b-45d0-a8c5-204fd6f93a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7712f905-60c5-4d4a-8806-e07b15b404ab" xlink:to="loc_us-gaap_SubsequentEventMember_4c1c4c0a-f35b-45d0-a8c5-204fd6f93a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392d2854-037e-4753-82a2-31e01f25238f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_e8ff129e-8cc6-431f-a512-832343b02112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_e8ff129e-8cc6-431f-a512-832343b02112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a1157ab-887a-43cd-ad10-92a32a6694f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a1157ab-887a-43cd-ad10-92a32a6694f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_76aee806-530f-49b3-88d6-0be3a04b43ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_76aee806-530f-49b3-88d6-0be3a04b43ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_21996b50-80f0-4506-9063-3331ffd7014d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_21996b50-80f0-4506-9063-3331ffd7014d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementUpfrontPaymentShares_49caeff9-20da-422c-8b9a-f0ee8eabcc31" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementUpfrontPaymentShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementUpfrontPaymentShares_49caeff9-20da-422c-8b9a-f0ee8eabcc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementPercentOfOutstandingShares_aff58428-aba6-46bd-adde-b2b5ff762d43" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementPercentOfOutstandingShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementPercentOfOutstandingShares_aff58428-aba6-46bd-adde-b2b5ff762d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementDevelopmentMilestonePayment_506ebfd9-714e-4511-b87e-46e8278c45e2" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementDevelopmentMilestonePayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementDevelopmentMilestonePayment_506ebfd9-714e-4511-b87e-46e8278c45e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementSalesMilestonePayment_95648feb-7737-45ea-aa96-a39146dd90b1" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementSalesMilestonePayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementSalesMilestonePayment_95648feb-7737-45ea-aa96-a39146dd90b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares_f3778200-bbe5-4b1f-89a4-90164ac131ce" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementDevelopmentMilestonePaymentShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares_f3778200-bbe5-4b1f-89a4-90164ac131ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale_2cddc9ea-9d4d-4715-9aa2-571b6e375624" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale_2cddc9ea-9d4d-4715-9aa2-571b6e375624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment_c897572e-599a-4919-a7a0-53becb8348ca" xlink:href="opk-20220331.xsd#opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment_c897572e-599a-4919-a7a0-53becb8348ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment_74be4cc1-b378-4f78-8f46-aea2656352e2" xlink:href="opk-20220331.xsd#opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment_74be4cc1-b378-4f78-8f46-aea2656352e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale_67ac5d66-3b6d-4b11-8fd8-67f6e622e2aa" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementPeriodAfterFirstCommercialSale"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale_67ac5d66-3b6d-4b11-8fd8-67f6e622e2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMaximumMilestonePayments_49a60054-69ea-4e67-924e-4254031fad55" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementMaximumMilestonePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementMaximumMilestonePayments_49a60054-69ea-4e67-924e-4254031fad55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime_d65e4381-3fd0-4cd2-a946-36247cbb8598" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime_d65e4381-3fd0-4cd2-a946-36247cbb8598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementUpfrontPayment_4dabcfee-4366-49cd-ae1c-0e276059fc30" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementUpfrontPayment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementUpfrontPayment_4dabcfee-4366-49cd-ae1c-0e276059fc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeAgreementAdditionalMilestonePayment_fe48d8b0-6b5b-4ca0-9f11-309461981111" xlink:href="opk-20220331.xsd#opk_CollaborativeAgreementAdditionalMilestonePayment"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeAgreementAdditionalMilestonePayment_fe48d8b0-6b5b-4ca0-9f11-309461981111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMilestonePayment_8fde9862-5d54-42b2-80cd-6ec672f5df3a" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementMilestonePayment"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_opk_CollaborativeArrangementMilestonePayment_8fde9862-5d54-42b2-80cd-6ec672f5df3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dfa9ba64-19c3-433d-b3af-d264d2363027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6cd99411-9a11-4c10-a36a-1556dbe8fe08" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dfa9ba64-19c3-433d-b3af-d264d2363027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/Segments" xlink:type="simple" xlink:href="opk-20220331.xsd#Segments"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/Segments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e4eb7f4f-cce1-4b93-8510-248f51398eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_6e37bc96-86b1-4d53-9fc4-9a8793cff728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e4eb7f4f-cce1-4b93-8510-248f51398eb1" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_6e37bc96-86b1-4d53-9fc4-9a8793cff728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SegmentsTables" xlink:type="simple" xlink:href="opk-20220331.xsd#SegmentsTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SegmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6c1561bd-ebdb-48bc-84d3-3441006e7b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f840d46c-34db-461a-9562-3527c1841ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6c1561bd-ebdb-48bc-84d3-3441006e7b2e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f840d46c-34db-461a-9562-3527c1841ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#SegmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SegmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cfe74fe6-37ea-4e9e-bfad-b1607fa4999e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b345bf7-1ed8-493d-8ef0-0fe92b66877a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cfe74fe6-37ea-4e9e-bfad-b1607fa4999e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b345bf7-1ed8-493d-8ef0-0fe92b66877a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_5401ffca-4c41-4a3e-9934-b40b0c43fce7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b345bf7-1ed8-493d-8ef0-0fe92b66877a" xlink:to="loc_srt_ConsolidationItemsAxis_5401ffca-4c41-4a3e-9934-b40b0c43fce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_157770ee-3077-4b76-81f6-f1dc94a4b41e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_5401ffca-4c41-4a3e-9934-b40b0c43fce7" xlink:to="loc_srt_ConsolidationItemsDomain_157770ee-3077-4b76-81f6-f1dc94a4b41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_24c33278-88a6-4c62-b8ee-e2f8ca2b995a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_157770ee-3077-4b76-81f6-f1dc94a4b41e" xlink:to="loc_us-gaap_IntersegmentEliminationMember_24c33278-88a6-4c62-b8ee-e2f8ca2b995a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ddf732b9-d8a5-4be1-a473-41c7b1845817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b345bf7-1ed8-493d-8ef0-0fe92b66877a" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_ddf732b9-d8a5-4be1-a473-41c7b1845817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_952930dc-2508-481c-a350-75210bcd6d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ddf732b9-d8a5-4be1-a473-41c7b1845817" xlink:to="loc_us-gaap_NumberOfReportableSegments_952930dc-2508-481c-a350-75210bcd6d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cf6ed452-ea80-4771-8548-739d5235632d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ddf732b9-d8a5-4be1-a473-41c7b1845817" xlink:to="loc_us-gaap_Revenues_cf6ed452-ea80-4771-8548-739d5235632d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c91beef9-58c4-4891-a827-27e04cc84c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ddf732b9-d8a5-4be1-a473-41c7b1845817" xlink:to="loc_us-gaap_InterestExpense_c91beef9-58c4-4891-a827-27e04cc84c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#SegmentsOperationsandAssetsInformationDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2ade7fb6-883b-4ad4-9c44-0df8bcd51b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fa89a2ee-c247-4e49-8a4d-d067db74f677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2ade7fb6-883b-4ad4-9c44-0df8bcd51b52" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fa89a2ee-c247-4e49-8a4d-d067db74f677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5c57bf9e-6d36-478d-bfe3-a0f7ee22a8c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fa89a2ee-c247-4e49-8a4d-d067db74f677" xlink:to="loc_srt_ProductOrServiceAxis_5c57bf9e-6d36-478d-bfe3-a0f7ee22a8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf1036de-1394-4627-b2ec-9165281d6797" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5c57bf9e-6d36-478d-bfe3-a0f7ee22a8c7" xlink:to="loc_srt_ProductsAndServicesDomain_cf1036de-1394-4627-b2ec-9165281d6797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_747f1478-e510-433b-9a74-ac44db8036c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf1036de-1394-4627-b2ec-9165281d6797" xlink:to="loc_us-gaap_ServiceMember_747f1478-e510-433b-9a74-ac44db8036c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_db88509d-bd37-4940-a2fe-92690cdb342c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf1036de-1394-4627-b2ec-9165281d6797" xlink:to="loc_us-gaap_ProductMember_db88509d-bd37-4940-a2fe-92690cdb342c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_TransferOfIntellectualPropertyAndOtherMember_1719db39-b319-4cca-b1b8-1daa4b107dd2" xlink:href="opk-20220331.xsd#opk_TransferOfIntellectualPropertyAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf1036de-1394-4627-b2ec-9165281d6797" xlink:to="loc_opk_TransferOfIntellectualPropertyAndOtherMember_1719db39-b319-4cca-b1b8-1daa4b107dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b8f33fc5-3c7f-442b-8445-041d088d884a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fa89a2ee-c247-4e49-8a4d-d067db74f677" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b8f33fc5-3c7f-442b-8445-041d088d884a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_452d70b7-6fce-4991-95de-293da314594e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b8f33fc5-3c7f-442b-8445-041d088d884a" xlink:to="loc_us-gaap_SegmentDomain_452d70b7-6fce-4991-95de-293da314594e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PharmaceuticalMember_8d17bffc-b0fe-4d9c-8630-3c674d94bc3e" xlink:href="opk-20220331.xsd#opk_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_452d70b7-6fce-4991-95de-293da314594e" xlink:to="loc_opk_PharmaceuticalMember_8d17bffc-b0fe-4d9c-8630-3c674d94bc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DiagnosticsMember_c6b8bebf-6bc8-46c3-9807-998e92549c37" xlink:href="opk-20220331.xsd#opk_DiagnosticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_452d70b7-6fce-4991-95de-293da314594e" xlink:to="loc_opk_DiagnosticsMember_c6b8bebf-6bc8-46c3-9807-998e92549c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f2a067ac-134d-46cb-80af-7b947fef629d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fa89a2ee-c247-4e49-8a4d-d067db74f677" xlink:to="loc_srt_ConsolidationItemsAxis_f2a067ac-134d-46cb-80af-7b947fef629d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_739bc9d3-b0ae-40d8-a027-7a7fe070d366" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_f2a067ac-134d-46cb-80af-7b947fef629d" xlink:to="loc_srt_ConsolidationItemsDomain_739bc9d3-b0ae-40d8-a027-7a7fe070d366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_20a64d25-b0c1-41b3-b19b-5ddb50bf41f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_739bc9d3-b0ae-40d8-a027-7a7fe070d366" xlink:to="loc_us-gaap_OperatingSegmentsMember_20a64d25-b0c1-41b3-b19b-5ddb50bf41f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_771e459d-dbf6-497a-8680-39f78887524e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_739bc9d3-b0ae-40d8-a027-7a7fe070d366" xlink:to="loc_us-gaap_CorporateNonSegmentMember_771e459d-dbf6-497a-8680-39f78887524e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f1a9b5c2-288c-40b5-b21f-1d579ff72ca7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fa89a2ee-c247-4e49-8a4d-d067db74f677" xlink:to="loc_srt_StatementGeographicalAxis_f1a9b5c2-288c-40b5-b21f-1d579ff72ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f1a9b5c2-288c-40b5-b21f-1d579ff72ca7" xlink:to="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_32bdfbf5-8cd5-4d50-a8fa-ec2429d5b839" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:to="loc_country_US_32bdfbf5-8cd5-4d50-a8fa-ec2429d5b839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_fd5849d5-08c6-47bb-baa4-3be99a418143" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:to="loc_country_IE_fd5849d5-08c6-47bb-baa4-3be99a418143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CL_a0f037f9-aa1d-4c2c-afe3-3258ce80429e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CL"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:to="loc_country_CL_a0f037f9-aa1d-4c2c-afe3-3258ce80429e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_eff8faef-0fd8-446e-85d9-900b48363bf4" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:to="loc_country_ES_eff8faef-0fd8-446e-85d9-900b48363bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IL_530438ae-fe42-4b3d-ac47-1904c6acb092" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IL"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:to="loc_country_IL_530438ae-fe42-4b3d-ac47-1904c6acb092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_88b75ab4-0c84-4616-856f-b8e3f979bacb" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:to="loc_country_MX_88b75ab4-0c84-4616-856f-b8e3f979bacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_OtherCountriesMember_da5c7331-271b-4d2b-a99c-772e3f7f3c1b" xlink:href="opk-20220331.xsd#opk_OtherCountriesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_175ec48c-e1b9-43ce-8e62-450c1d36099a" xlink:to="loc_opk_OtherCountriesMember_da5c7331-271b-4d2b-a99c-772e3f7f3c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fa89a2ee-c247-4e49-8a4d-d067db74f677" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_921359d7-a316-4ca5-8652-4647b17f7783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_921359d7-a316-4ca5-8652-4647b17f7783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_38663062-5016-4a06-8962-ae09ced532ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:to="loc_us-gaap_OperatingIncomeLoss_38663062-5016-4a06-8962-ae09ced532ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_975bb6d4-498a-40e3-a904-9f28a9c29d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_975bb6d4-498a-40e3-a904-9f28a9c29d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_8a8bd5b1-32b8-4e4f-8e16-8df5e88eab43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:to="loc_us-gaap_GainLossOnInvestments_8a8bd5b1-32b8-4e4f-8e16-8df5e88eab43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_74ced428-47e2-4a17-8b4b-1af88df0a407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:to="loc_us-gaap_Assets_74ced428-47e2-4a17-8b4b-1af88df0a407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_987973ca-d71f-4d7e-8b9f-f59fc55d2f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_865a81a9-4d79-4747-809f-2fe2be13a6e6" xlink:to="loc_us-gaap_Goodwill_987973ca-d71f-4d7e-8b9f-f59fc55d2f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/Leases" xlink:type="simple" xlink:href="opk-20220331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_878fb43d-7ab2-44f6-9b34-91eaa904c3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_b3293617-8854-4b4f-b7eb-b62e07839ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_878fb43d-7ab2-44f6-9b34-91eaa904c3dc" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_b3293617-8854-4b4f-b7eb-b62e07839ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_b36483fd-dc7f-45d7-a781-9f374b44ab8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_878fb43d-7ab2-44f6-9b34-91eaa904c3dc" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_b36483fd-dc7f-45d7-a781-9f374b44ab8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesTables" xlink:type="simple" xlink:href="opk-20220331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0413b36f-35a1-429c-add8-9739c2dbf4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AssetsAndLiabilitiesLesseeTableTextBlock_54cea75e-051b-45e0-a602-338973911585" xlink:href="opk-20220331.xsd#opk_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0413b36f-35a1-429c-add8-9739c2dbf4c6" xlink:to="loc_opk_AssetsAndLiabilitiesLesseeTableTextBlock_54cea75e-051b-45e0-a602-338973911585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a66dfbbe-bb79-4ec9-b5e1-f59e19220d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0413b36f-35a1-429c-add8-9739c2dbf4c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a66dfbbe-bb79-4ec9-b5e1-f59e19220d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_885c9971-5323-4473-99bd-2239a6d931c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0413b36f-35a1-429c-add8-9739c2dbf4c6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_885c9971-5323-4473-99bd-2239a6d931c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_15aa6214-2676-4be5-90c8-9882c4dc4f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0413b36f-35a1-429c-add8-9739c2dbf4c6" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_15aa6214-2676-4be5-90c8-9882c4dc4f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#LeasesLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a96ca412-96be-48cd-8247-0c547c5d07a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_20dee7c8-aa2f-4f76-809e-4cf56b69c0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a96ca412-96be-48cd-8247-0c547c5d07a8" xlink:to="loc_us-gaap_AssetsAbstract_20dee7c8-aa2f-4f76-809e-4cf56b69c0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7646032e-3195-498f-aec3-42ad540e893f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20dee7c8-aa2f-4f76-809e-4cf56b69c0f6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7646032e-3195-498f-aec3-42ad540e893f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_1d17c3ea-5edc-4969-989b-9954b86c9466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20dee7c8-aa2f-4f76-809e-4cf56b69c0f6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_1d17c3ea-5edc-4969-989b-9954b86c9466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_14c17180-4757-4c1a-8c1d-f458f42f4432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20dee7c8-aa2f-4f76-809e-4cf56b69c0f6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_14c17180-4757-4c1a-8c1d-f458f42f4432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_81336172-0fe3-47a7-8eb3-5eed73e5348b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a96ca412-96be-48cd-8247-0c547c5d07a8" xlink:to="loc_us-gaap_LiabilitiesAbstract_81336172-0fe3-47a7-8eb3-5eed73e5348b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1f5c3bad-84a2-4dbc-b7ca-36c502e678d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_81336172-0fe3-47a7-8eb3-5eed73e5348b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1f5c3bad-84a2-4dbc-b7ca-36c502e678d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_574cc7c1-96b3-4ec9-9cd3-da11fa775598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f5c3bad-84a2-4dbc-b7ca-36c502e678d8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_574cc7c1-96b3-4ec9-9cd3-da11fa775598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_c9ca4f7d-3821-411c-9efe-077240daeb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f5c3bad-84a2-4dbc-b7ca-36c502e678d8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_c9ca4f7d-3821-411c-9efe-077240daeb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_212fa27f-819f-4c58-aa98-ea577c1704fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_81336172-0fe3-47a7-8eb3-5eed73e5348b" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_212fa27f-819f-4c58-aa98-ea577c1704fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ef6ee234-9283-49bc-b1c6-70fd9e94504d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_212fa27f-819f-4c58-aa98-ea577c1704fc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ef6ee234-9283-49bc-b1c6-70fd9e94504d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8d35a5f6-b87d-4ed2-b341-c2c6d55d9682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_212fa27f-819f-4c58-aa98-ea577c1704fc" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8d35a5f6-b87d-4ed2-b341-c2c6d55d9682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_WeightedAverageRemainingLeaseTermAbstract_7dc513f0-086c-4891-bc28-1d9d6b77163c" xlink:href="opk-20220331.xsd#opk_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a96ca412-96be-48cd-8247-0c547c5d07a8" xlink:to="loc_opk_WeightedAverageRemainingLeaseTermAbstract_7dc513f0-086c-4891-bc28-1d9d6b77163c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_baab32dc-c164-4e81-b820-b54340eefde7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_WeightedAverageRemainingLeaseTermAbstract_7dc513f0-086c-4891-bc28-1d9d6b77163c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_baab32dc-c164-4e81-b820-b54340eefde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1136b0df-9ff9-4759-b65e-f003d68b3d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_WeightedAverageRemainingLeaseTermAbstract_7dc513f0-086c-4891-bc28-1d9d6b77163c" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1136b0df-9ff9-4759-b65e-f003d68b3d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_WeightedAverageDiscountRateAbstract_b4229dec-c696-4b62-9c44-f4dda137ed7e" xlink:href="opk-20220331.xsd#opk_WeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a96ca412-96be-48cd-8247-0c547c5d07a8" xlink:to="loc_opk_WeightedAverageDiscountRateAbstract_b4229dec-c696-4b62-9c44-f4dda137ed7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_56751a71-7934-44b9-87f2-926d96e5aa6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_WeightedAverageDiscountRateAbstract_b4229dec-c696-4b62-9c44-f4dda137ed7e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_56751a71-7934-44b9-87f2-926d96e5aa6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f3f0a92c-9268-43d7-91c2-c93c25f575b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_opk_WeightedAverageDiscountRateAbstract_b4229dec-c696-4b62-9c44-f4dda137ed7e" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f3f0a92c-9268-43d7-91c2-c93c25f575b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#LeasesLeaseLiabilityMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3fdf0219-f786-4b39-ab80-0598bac23a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_eb690d42-e94e-41b1-b6e1-f09a4e38ffca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3fdf0219-f786-4b39-ab80-0598bac23a0f" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_eb690d42-e94e-41b1-b6e1-f09a4e38ffca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cf1b048e-3b8b-494f-9d19-66c15220b186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_eb690d42-e94e-41b1-b6e1-f09a4e38ffca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cf1b048e-3b8b-494f-9d19-66c15220b186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_613ad924-7803-4b40-9b71-6cff0337966d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_eb690d42-e94e-41b1-b6e1-f09a4e38ffca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_613ad924-7803-4b40-9b71-6cff0337966d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e958483b-3ebd-4c8f-9d3b-8e97b8accb98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_eb690d42-e94e-41b1-b6e1-f09a4e38ffca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e958483b-3ebd-4c8f-9d3b-8e97b8accb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_668cfb45-5c9d-4b40-9c6b-a55ad56b77f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_eb690d42-e94e-41b1-b6e1-f09a4e38ffca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_668cfb45-5c9d-4b40-9c6b-a55ad56b77f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_17f9898d-c9e7-492c-ba9c-b9e2ce942da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_eb690d42-e94e-41b1-b6e1-f09a4e38ffca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_17f9898d-c9e7-492c-ba9c-b9e2ce942da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_2a87584e-321a-402d-87ed-c5dea9c8d578" xlink:href="opk-20220331.xsd#opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_eb690d42-e94e-41b1-b6e1-f09a4e38ffca" xlink:to="loc_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_2a87584e-321a-402d-87ed-c5dea9c8d578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_59f93a64-9350-4b0a-bdc1-13d93d0a2bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_eb690d42-e94e-41b1-b6e1-f09a4e38ffca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_59f93a64-9350-4b0a-bdc1-13d93d0a2bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8ea8b13d-e641-4724-a278-1d9c38d695fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_eb690d42-e94e-41b1-b6e1-f09a4e38ffca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8ea8b13d-e641-4724-a278-1d9c38d695fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_20cbcf03-e297-4b32-ada2-5d4dfb4674a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_eb690d42-e94e-41b1-b6e1-f09a4e38ffca" xlink:to="loc_us-gaap_OperatingLeaseLiability_20cbcf03-e297-4b32-ada2-5d4dfb4674a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a63e025c-7cb7-47fe-ad66-4d764d42bada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3fdf0219-f786-4b39-ab80-0598bac23a0f" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a63e025c-7cb7-47fe-ad66-4d764d42bada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_47f6cb57-638b-4779-a58b-74cdd87939af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a63e025c-7cb7-47fe-ad66-4d764d42bada" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_47f6cb57-638b-4779-a58b-74cdd87939af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_dc346111-939f-427c-9c11-a85373e32be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a63e025c-7cb7-47fe-ad66-4d764d42bada" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_dc346111-939f-427c-9c11-a85373e32be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_9917f2c3-7bca-475d-b898-3dade57dd739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a63e025c-7cb7-47fe-ad66-4d764d42bada" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_9917f2c3-7bca-475d-b898-3dade57dd739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_27b0eaa0-baec-4130-9463-22e07f9f2835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a63e025c-7cb7-47fe-ad66-4d764d42bada" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_27b0eaa0-baec-4130-9463-22e07f9f2835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_479b6a3c-8b51-478a-81e2-da8ac6f65977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a63e025c-7cb7-47fe-ad66-4d764d42bada" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_479b6a3c-8b51-478a-81e2-da8ac6f65977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour_c7a3eb7c-b850-4427-af47-89736894b999" xlink:href="opk-20220331.xsd#opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a63e025c-7cb7-47fe-ad66-4d764d42bada" xlink:to="loc_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour_c7a3eb7c-b850-4427-af47-89736894b999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b2981c12-de20-45f8-a829-3aeb0526bc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a63e025c-7cb7-47fe-ad66-4d764d42bada" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b2981c12-de20-45f8-a829-3aeb0526bc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_535c16d3-d90b-4cdb-b34a-7cc92a218701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a63e025c-7cb7-47fe-ad66-4d764d42bada" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_535c16d3-d90b-4cdb-b34a-7cc92a218701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_19778591-3caa-4f4d-b9b1-65644bec7537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a63e025c-7cb7-47fe-ad66-4d764d42bada" xlink:to="loc_us-gaap_FinanceLeaseLiability_19778591-3caa-4f4d-b9b1-65644bec7537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1" xlink:type="simple" xlink:href="opk-20220331.xsd#LeasesLeaseLiabilityMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7522733e-8362-4da9-bcee-0f4ab7848cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3f607b5f-eedb-4bb9-a5e4-7c0520232f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7522733e-8362-4da9-bcee-0f4ab7848cac" xlink:to="loc_us-gaap_OperatingLeaseCost_3f607b5f-eedb-4bb9-a5e4-7c0520232f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_1af1a8cb-8e2f-48fb-ae71-4f1c0197cf38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7522733e-8362-4da9-bcee-0f4ab7848cac" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_1af1a8cb-8e2f-48fb-ae71-4f1c0197cf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_6619404e-0cb7-43fc-9e65-ff76ac91f0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7522733e-8362-4da9-bcee-0f4ab7848cac" xlink:to="loc_us-gaap_VariableLeaseCost_6619404e-0cb7-43fc-9e65-ff76ac91f0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#LeasesLeaseCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_094fced2-7147-4906-b3cf-48837cd484e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_10f2c0c0-69fe-4cbe-a7d3-1ae41826cb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_094fced2-7147-4906-b3cf-48837cd484e7" xlink:to="loc_us-gaap_OperatingLeasePayments_10f2c0c0-69fe-4cbe-a7d3-1ae41826cb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_ea6da540-febd-4ecc-bb4a-0d5ecfe9ec17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_094fced2-7147-4906-b3cf-48837cd484e7" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_ea6da540-febd-4ecc-bb4a-0d5ecfe9ec17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_5e6b8fad-9b71-4e13-8dcf-1eefeeb74078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_094fced2-7147-4906-b3cf-48837cd484e7" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_5e6b8fad-9b71-4e13-8dcf-1eefeeb74078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PaymentsForLeases_6b0cf038-6514-4b40-9763-e4621a0d794b" xlink:href="opk-20220331.xsd#opk_PaymentsForLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_094fced2-7147-4906-b3cf-48837cd484e7" xlink:to="loc_opk_PaymentsForLeases_6b0cf038-6514-4b40-9763-e4621a0d794b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SubsequentEvents" xlink:type="simple" xlink:href="opk-20220331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b763dd16-d800-4ce9-89e2-f533d8d0bdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_09a3c669-5c67-4e70-9d0c-d07c9b4cf91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b763dd16-d800-4ce9-89e2-f533d8d0bdd1" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_09a3c669-5c67-4e70-9d0c-d07c9b4cf91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.opko.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="opk-20220331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.opko.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1540a9d0-f997-4a66-959f-728d12b1196b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1540a9d0-f997-4a66-959f-728d12b1196b" xlink:to="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7d802030-b538-46be-850e-6da4eb814a1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:to="loc_srt_CounterpartyNameAxis_7d802030-b538-46be-850e-6da4eb814a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_843f0197-17b2-4e79-b068-ce9adfd4a8f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7d802030-b538-46be-850e-6da4eb814a1a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_843f0197-17b2-4e79-b068-ce9adfd4a8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_PfizerMember_56320925-2bd3-491d-857a-ca838a970363" xlink:href="opk-20220331.xsd#opk_PfizerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_843f0197-17b2-4e79-b068-ce9adfd4a8f6" xlink:to="loc_opk_PfizerMember_56320925-2bd3-491d-857a-ca838a970363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_09a16824-04a8-4713-be15-99ea982ef933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:to="loc_us-gaap_TypeOfArrangementAxis_09a16824-04a8-4713-be15-99ea982ef933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_608cd7af-d19d-4344-804b-c1656d259185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_09a16824-04a8-4713-be15-99ea982ef933" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_608cd7af-d19d-4344-804b-c1656d259185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6f481ad7-6eb0-4014-9f4d-38832f2c9dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_608cd7af-d19d-4344-804b-c1656d259185" xlink:to="loc_us-gaap_ProductMember_6f481ad7-6eb0-4014-9f4d-38832f2c9dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ba3a8912-7ac6-4218-9003-12e676ca8dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ba3a8912-7ac6-4218-9003-12e676ca8dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a59bd878-3494-4bc1-9564-503e2b52ab6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ba3a8912-7ac6-4218-9003-12e676ca8dc3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a59bd878-3494-4bc1-9564-503e2b52ab6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_eb785a64-d953-401a-ba4b-b48b4202caef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a59bd878-3494-4bc1-9564-503e2b52ab6e" xlink:to="loc_us-gaap_SubsequentEventMember_eb785a64-d953-401a-ba4b-b48b4202caef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f9136c92-ee22-47ea-8ad2-a80c3e7d751b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f9136c92-ee22-47ea-8ad2-a80c3e7d751b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ee44e6-ca5a-4e45-94cb-5ba10756c4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f9136c92-ee22-47ea-8ad2-a80c3e7d751b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ee44e6-ca5a-4e45-94cb-5ba10756c4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_DetectGenomixMember_69d73c8e-0174-46e8-8a9b-378b07c83c47" xlink:href="opk-20220331.xsd#opk_DetectGenomixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ee44e6-ca5a-4e45-94cb-5ba10756c4b5" xlink:to="loc_opk_DetectGenomixMember_69d73c8e-0174-46e8-8a9b-378b07c83c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_AgreementAndPlanOfMergerMember_41e80b27-de66-4602-acf8-d5413c059ef0" xlink:href="opk-20220331.xsd#opk_AgreementAndPlanOfMergerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ee44e6-ca5a-4e45-94cb-5ba10756c4b5" xlink:to="loc_opk_AgreementAndPlanOfMergerMember_41e80b27-de66-4602-acf8-d5413c059ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2d880930-d5bd-43c9-9e00-8e9a10cbb2ab" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:to="loc_dei_LegalEntityAxis_2d880930-d5bd-43c9-9e00-8e9a10cbb2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bb266d7f-df0d-429e-b8ca-b7f505c2ed46" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2d880930-d5bd-43c9-9e00-8e9a10cbb2ab" xlink:to="loc_dei_EntityDomain_bb266d7f-df0d-429e-b8ca-b7f505c2ed46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_Sema4Member_fd7534ee-e442-4d4f-8613-a590e006703b" xlink:href="opk-20220331.xsd#opk_Sema4Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bb266d7f-df0d-429e-b8ca-b7f505c2ed46" xlink:to="loc_opk_Sema4Member_fd7534ee-e442-4d4f-8613-a590e006703b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e247ecef-310f-421f-bce6-1428832354fe" xlink:to="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_30323488-0fd9-4788-a16c-ebcebf2fadf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_30323488-0fd9-4788-a16c-ebcebf2fadf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c1273484-c757-4c59-bd6f-16b9fbe4a0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c1273484-c757-4c59-bd6f-16b9fbe4a0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments_92246405-f6b4-463f-93fd-c3e1a83db5e1" xlink:href="opk-20220331.xsd#opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments_92246405-f6b4-463f-93fd-c3e1a83db5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod_ff384d3d-8b59-4d0b-9771-41be5ff158df" xlink:href="opk-20220331.xsd#opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod_ff384d3d-8b59-4d0b-9771-41be5ff158df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationUpfrontConsiderationTransferred_3c24af8f-f455-49aa-a517-dd71b54a983e" xlink:href="opk-20220331.xsd#opk_BusinessCombinationUpfrontConsiderationTransferred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_opk_BusinessCombinationUpfrontConsiderationTransferred_3c24af8f-f455-49aa-a517-dd71b54a983e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f045f050-56a9-49bb-815d-2b2cd94866b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f045f050-56a9-49bb-815d-2b2cd94866b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_CollaborativeArrangementMilestonePayment_51cf2250-2c51-4747-a6c9-3c1b4010d0bd" xlink:href="opk-20220331.xsd#opk_CollaborativeArrangementMilestonePayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_opk_CollaborativeArrangementMilestonePayment_51cf2250-2c51-4747-a6c9-3c1b4010d0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement_5ce1796e-1f92-4421-96f6-7af50b52588a" xlink:href="opk-20220331.xsd#opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement_5ce1796e-1f92-4421-96f6-7af50b52588a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_opk_BusinessCombinationPeriodPriorToSigningOfAgreement_49e9339e-0b12-4e10-a8af-3804c4a606fc" xlink:href="opk-20220331.xsd#opk_BusinessCombinationPeriodPriorToSigningOfAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cbf7c14f-f9bd-4171-be8b-b50385346e38" xlink:to="loc_opk_BusinessCombinationPeriodPriorToSigningOfAgreement_49e9339e-0b12-4e10-a8af-3804c4a606fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116512462344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER PAGE - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OPKO Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">75-2402409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4400 Biscayne Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Miami<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">575-4100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OPK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681,525,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000944809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116514068936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 102,281<span></span>
</td>
<td class="nump">$ 134,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">212,755<span></span>
</td>
<td class="nump">259,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">99,406<span></span>
</td>
<td class="nump">86,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">23,274<span></span>
</td>
<td class="nump">27,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup', window );">Assets held for sale</a></td>
<td class="nump">316,353<span></span>
</td>
<td class="nump">314,994<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">754,069<span></span>
</td>
<td class="nump">823,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, net</a></td>
<td class="nump">81,899<span></span>
</td>
<td class="nump">79,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">890,498<span></span>
</td>
<td class="nump">321,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_InProcessResearchandDevelopment', window );">In-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">590,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">519,052<span></span>
</td>
<td class="nump">520,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments</a></td>
<td class="nump">9,472<span></span>
</td>
<td class="nump">10,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">42,768<span></span>
</td>
<td class="nump">44,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">9,100<span></span>
</td>
<td class="nump">9,534<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,306,858<span></span>
</td>
<td class="nump">2,399,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">94,240<span></span>
</td>
<td class="nump">82,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">157,316<span></span>
</td>
<td class="nump">193,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating leases</a></td>
<td class="nump">11,690<span></span>
</td>
<td class="nump">11,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Liabilities associated with assets held-for-sale</a></td>
<td class="nump">28,512<span></span>
</td>
<td class="nump">28,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Current portion of lines of credit and notes payable</a></td>
<td class="nump">17,412<span></span>
</td>
<td class="nump">14,695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">309,170<span></span>
</td>
<td class="nump">330,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">31,596<span></span>
</td>
<td class="nump">33,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes</a></td>
<td class="nump">210,520<span></span>
</td>
<td class="nump">187,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">125,030<span></span>
</td>
<td class="nump">148,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities, principally contract liabilities, contingent consideration and lines of credit</a></td>
<td class="nump">15,658<span></span>
</td>
<td class="nump">15,062<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">382,804<span></span>
</td>
<td class="nump">384,581<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">691,974<span></span>
</td>
<td class="nump">714,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock - $0.01 par value, 1,000,000,000 shares authorized; 690,138,033 and 690,082,283 shares issued at March 31, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">6,902<span></span>
</td>
<td class="nump">6,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock - 8,655,082 and 8,655,082 shares at March 31, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="num">(1,791)<span></span>
</td>
<td class="num">(1,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">3,191,139<span></span>
</td>
<td class="nump">3,222,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(31,415)<span></span>
</td>
<td class="num">(30,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,549,951)<span></span>
</td>
<td class="num">(1,511,976)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">1,614,884<span></span>
</td>
<td class="nump">1,685,126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 2,306,858<span></span>
</td>
<td class="nump">$ 2,399,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_InProcessResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-Process Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_InProcessResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123398962&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513954344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">690,138,033<span></span>
</td>
<td class="nump">690,082,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">8,655,082<span></span>
</td>
<td class="nump">8,655,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116514104728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 329,219<span></span>
</td>
<td class="nump">$ 545,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">117,537<span></span>
</td>
<td class="nump">112,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">18,312<span></span>
</td>
<td class="nump">19,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">22,025<span></span>
</td>
<td class="nump">12,577<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">401,643<span></span>
</td>
<td class="nump">506,728<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(72,424)<span></span>
</td>
<td class="nump">38,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income and (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_InterestIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(2,662)<span></span>
</td>
<td class="num">(5,395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Fair value changes of derivative instruments, net</a></td>
<td class="num">(132)<span></span>
</td>
<td class="num">(439)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(1,442)<span></span>
</td>
<td class="num">(927)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income and (expense), net</a></td>
<td class="num">(4,226)<span></span>
</td>
<td class="num">(6,756)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes and investment losses</a></td>
<td class="num">(76,650)<span></span>
</td>
<td class="nump">31,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="nump">21,266<span></span>
</td>
<td class="num">(560)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax', window );">Net income (loss) before investment losses</a></td>
<td class="num">(55,384)<span></span>
</td>
<td class="nump">31,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from investments in investees</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (55,433)<span></span>
</td>
<td class="nump">$ 31,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Income (loss) per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Income (loss) per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Income (loss) per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">660,302,426<span></span>
</td>
<td class="nump">640,853,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">660,302,426<span></span>
</td>
<td class="nump">640,853,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 286,599<span></span>
</td>
<td class="nump">$ 506,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service revenue</a></td>
<td class="nump">221,202<span></span>
</td>
<td class="nump">339,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">36,658<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service revenue</a></td>
<td class="nump">22,673<span></span>
</td>
<td class="nump">24,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Revenue from transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 5,962<span></span>
</td>
<td class="nump">$ 4,269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) from continuing operations before investment losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Nonoperating</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_InterestIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Income, Nonoperating</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_InterestIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116514068088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (55,433)<span></span>
</td>
<td class="nump">$ 31,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in foreign currency translation and other comprehensive loss</a></td>
<td class="num">(920)<span></span>
</td>
<td class="num">(9,070)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (56,353)<span></span>
</td>
<td class="nump">$ 22,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116516052888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,585,576<span></span>
</td>
<td class="nump">549,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,671,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,706<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">$ 3,152,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,225)<span></span>
</td>
<td class="num">$ (1,481,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation expense</a></td>
<td class="nump">2,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Common Stock options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options and warrants</a></td>
<td class="nump">308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">31,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(9,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,703,076<span></span>
</td>
<td class="nump">549,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">1,696,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,707<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">3,155,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,295)<span></span>
</td>
<td class="num">(1,450,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,585,576<span></span>
</td>
<td class="nump">549,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">1,671,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,706<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">3,152,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,225)<span></span>
</td>
<td class="num">(1,481,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,082,283<span></span>
</td>
<td class="nump">8,655,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 1,685,126<span></span>
</td>
<td class="num">$ (21,642)<span></span>
</td>
<td class="nump">$ 6,901<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">3,222,487<span></span>
</td>
<td class="num">$ (39,100)<span></span>
</td>
<td class="num">(30,495)<span></span>
</td>
<td class="num">(1,511,976)<span></span>
</td>
<td class="nump">$ 17,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 7,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Common Stock options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options and warrants</a></td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(55,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,138,033<span></span>
</td>
<td class="nump">8,655,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 1,614,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,902<span></span>
</td>
<td class="num">$ (1,791)<span></span>
</td>
<td class="nump">$ 3,191,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (31,415)<span></span>
</td>
<td class="num">$ (1,549,951)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116516154152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (55,433)<span></span>
</td>
<td class="nump">$ 31,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">27,814<span></span>
</td>
<td class="nump">19,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest</a></td>
<td class="nump">678<span></span>
</td>
<td class="nump">2,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Losses from investments in investees</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation &#8211; employees and non-employees</a></td>
<td class="nump">7,617<span></span>
</td>
<td class="nump">2,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Realized loss (gain) on disposal of fixed assets and sales of equity securities</a></td>
<td class="nump">61<span></span>
</td>
<td class="num">(3,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments', window );">Change in fair value of equity securities and derivative instruments</a></td>
<td class="nump">1,299<span></span>
</td>
<td class="num">(279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(957)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="num">(22,356)<span></span>
</td>
<td class="num">(1,033)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">44,421<span></span>
</td>
<td class="num">(35,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="num">(9,463)<span></span>
</td>
<td class="num">(27,912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">2,612<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">16,143<span></span>
</td>
<td class="nump">62,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_IncreaseDecreaseinForeignCurrencyMeasurement', window );">Foreign currency measurement</a></td>
<td class="nump">2,197<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(36,177)<span></span>
</td>
<td class="num">(27,126)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(19,856)<span></span>
</td>
<td class="nump">26,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sale of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property, plant and equipment</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(5,251)<span></span>
</td>
<td class="num">(9,245)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by used in investing activities</a></td>
<td class="num">(4,903)<span></span>
</td>
<td class="num">(1,106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from the exercise of common stock options and warrants</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on lines of credit</a></td>
<td class="nump">1,649,166<span></span>
</td>
<td class="nump">472,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="num">(1,657,193)<span></span>
</td>
<td class="num">(479,713)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(7,891)<span></span>
</td>
<td class="num">(7,192)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">221<span></span>
</td>
<td class="num">(447)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(32,429)<span></span>
</td>
<td class="nump">17,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">134,710<span></span>
</td>
<td class="nump">72,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">102,281<span></span>
</td>
<td class="nump">89,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">3,420<span></span>
</td>
<td class="nump">4,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid, net of refunds</a></td>
<td class="nump">$ 1,063<span></span>
</td>
<td class="nump">$ 1,470<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Equity Securities, FV-NI And Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_IncreaseDecreaseinForeignCurrencyMeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Foreign Currency Measurement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_IncreaseDecreaseinForeignCurrencyMeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116609534536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">BUSINESS AND ORGANIZATION</a></td>
<td class="text">BUSINESS AND ORGANIZATION<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">medical markets. Our diagnostics business includes BioReference Health, LLC, formerly known as BioReference Laboratories, Inc. (&#8220;BioReference&#8221;), one of the nation&#8217;s largest full service laboratories with an almost 250-person sales and marketing team to drive growth and leverage new products. Our pharmaceutical business features </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved treatment for secondary hyperparathyroidism (&#8220;SHPT&#8221;) in adults with stage 3 or 4 chronic kidney disease (&#8220;CKD&#8221;) and vitamin D insufficiency and a pipeline of products in various stages of development. Our leading product in development is Somatrogon (hGH-CTP), a once-weekly human growth hormone for which we have partnered with Pfizer, Inc. (&#8220;Pfizer&#8221;) and successfully completed a phase 3 study in August 2019. Regulatory applications for Somatrogon (hGH-CTP) have been submitted to the applicable regulatory bodies for review in several countries around the world.  In February 2022, the European Commission granted marketing authorization in the European Union for Somatrogon (hGH-CTP) under the brand name NGENLA&#174; to treat children and adolescents from as young as three years of age with growth disturbance due to insufficient secretion of growth hormone, and we recently received pricing approval in Germany. In January 2022, the Ministry of Health, Labour and Welfare in Japan approved NGENLA&#174; (Somatrogon) for the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone and we recently received pricing approval. In October 2021, Health Canada approved NGENLA&#174; for the long-term treatment of pediatric patients who have growth hormone deficiency, and Australia&#8217;s Therapeutic Goods Administration approved NGENLA&#174; for the long-term treatment of pediatric patients with growth disturbance due to insufficient secretion of growth hormone.  We also submitted the initial Biologics License Application (&#8220;BLA&#8221;) with the FDA for approval of Somatrogon (hGH-CTP) in the United States and Pfizer received a Complete Response Letter in January 2022.  Pfizer and OPKO are evaluating the FDA&#8217;s comments and will work with the agency to determine the best path forward for Somatrogon (hGH-CTP) in the United States.  We are incorporated in Delaware, and our principal executive offices are located in leased offices in Miami, Florida.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through BioReference, we provide laboratory testing services, primarily to customers in the larger metropolitan areas in New York, New Jersey, Florida, Texas, Maryland, California, Pennsylvania, Delaware, Washington, DC, Illinois and Massachusetts, as well as to customers in a number of other states.  We offer a comprehensive test menu of clinical diagnostics for blood, urine and tissue analysis.  This includes hematology, clinical chemistry, immunoassay, infectious&#160;diseases, serology, hormones, and toxicology assays, as well as Pap smear, anatomic pathology (biopsies) and other types of tissue analysis.  We market our laboratory testing services directly to physicians, geneticists, hospitals, clinics, correctional and other health facilities.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate established pharmaceutical platforms in Ireland, Chile, Spain, and Mexico, which are generating revenue and from which we expect to generate positive cash flow and facilitate future market entry for our products currently in development.  In addition, we have a development and commercial supply pharmaceutical company and a global supply chain operation and holding company in Ireland.  We own a specialty active pharmaceutical ingredients (&#8220;APIs&#8221;) manufacturer in Israel, which we expect will facilitate the development of our pipeline of molecules and compounds for our proprietary molecular diagnostic and therapeutic products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities are primarily performed at facilities in Woburn, MA, Waterford, Ireland, Kiryat Gat, Israel, and Barcelona, Spain.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, Sema4 Holdings Corp. (&#8220;Sema4&#8221;) and OPKO entered into an Agreement and Plan of Merger and Reorganization (the &#8220;GeneDx Merger Agreement&#8221;), pursuant to which Sema4 agreed to acquire OPKO&#8217;s wholly owned subsidiary, GeneDx LLC, formerly GeneDx, Inc. (&#8220;GeneDx&#8221;), subject to satisfaction of customary closing conditions (the &#8220;GeneDx Transaction&#8221;). The GeneDx Transaction closed on April 29, 2022. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the GeneDx Merger Agreement, Sema4 acquired GeneDx for an upfront payment of $150&#160;million in cash, subject to adjustments, plus 80.0&#160;million shares of Sema4&#8217;s Class A common stock, and Sema4 has agreed to pay up to an additional $150&#160;million in consideration subject to the satisfaction of certain revenue-based milestones over the next two years (which will be payable in cash or shares of Sema4&#8217;s Class A common stock at Sema4&#8217;s discretion). Based on the closing stock price of Sema4 as of April 29, 2022, the total upfront consideration represents approximately $322&#160;million, and the total aggregate consideration including potential milestones is approximately $472&#160;million.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December 31, 2021, GeneDx met the held-for-sale accounting criteria and, its related assets and liabilities are classified as held for sale in the consolidated balance sheet. GeneDx was included in our diagnostics segment as of March&#160;31, 2022 and December 31, 2021.</span></div>In June 2021, EirGen Pharma Limited (&#8220;EirGen&#8221;), our wholly owned subsidiary, entered into a definitive agreement to sell one of its facilities in Waterford, Ireland to Horizon Therapeutics plc for $65&#160;million in cash less certain assumed and accrued liabilities relating to transferred employees. The facility, which was formerly included in our pharmaceutical segment, housed EirGen&#8217;s sterile-fill-finish business and was no longer a core component of our ongoing operations and business strategy. The transaction closed in the third quarter of 2021. We recognized a gain on the sale of the facility in the third quarter of 2021 of $31.5&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513851944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impact of COVID-19<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock', window );">Impact of COVID-19</a></td>
<td class="text">IMPACT OF COVID-19<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to be a part of the coordinated public and private sector response to SARS-CoV-2, a novel strain of coronavirus, referred to as COVID-19.  There continues to be a high level of uncertainty relating to how the pandemic will evolve, how governments and consumers will react, progress on the distribution of vaccines and whether the pandemic will have a longer-term effect on the healthcare industry and patient habits. BioReference is providing COVID-19 solutions, including diagnostic molecular testing and serology antibody testing, to meet the testing needs of its customers, including physicians, health systems, long-term care facilities, governments, schools, employers, professional sports teams and entertainment venues, as well as the general public through relationships with retail pharmacy chains.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since the pandemic began in the U.S., we have invested in testing capabilities and infrastructure to meet demand for our molecular and antibody testing for COVID-19.  Throughout the last two years, we have managed our company-wide lab operations specimen acquisition, logistics, procurement, customer service, and initiatives to manage our cost structure to match the ever changing COVID-19 testing volumes and to manage efficiency gains in our core clinical lines of business.  We anticipate that COVID-19 will continue to impact our business in 2022 and demand for COVID-19 testing will fluctuate with the potential for increases and decreases in demand at different times and across different geographies; however, overall, we expect COVID-19 test demand to trend down in 2022 as compared to 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenue from services for the three months ended March 31, 2022 decreased by $220.4 million as compared to the three months ended March 31, 2021 due to lower COVID-19 testing volumes. We maintain our ability to quickly scale-up COVID-19 PCR testing capacity, even during periods of reduced demand.  In doing so, we are able to immediately and effectively respond to surges in positive cases and testing needs. We are unable to predict how long the demand will continue for our COVID-19 related testing, or whether pricing and reimbursement policies for testing will be sustained.  Excluding COVID-19 test volumes, for the three months ended March 31, 2022, genomic and routine clinical test volume increased 14.0% and 0.4% respectively, as compared to such volumes for the three months ended March 31, 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2022, the U.S. Health Resources and Services Administration ("HRSA") informed providers that, after March 22, 2022, it would stop accepting claims for testing and treatment for uninsured individuals under the HRSA COVID-19 Uninsured Program and that claims submitted prior to that date would be subject to eligibility and availability of funds. For the three months ended March 31, 2022, revenue for testing of uninsured individuals under the HRSA COVID-19 Uninsured Program represented approximately 7.9% of our COVID-19 testing revenue. As of March 31, 2022, less than 6% of our net accounts receivable was associated with claims for reimbursement for COVID-19 testing of uninsured individuals. Although we believe that our estimates for contractual allowances and patient price concessions are appropriate, actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=114868817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513858120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all information and notes required by GAAP for complete financial statements.  In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Company&#8217;s results of operations, financial position and cash flows have been made.  The results of operations and cash flows for the three months ended March 31, 2022 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2022 or any other future periods.  The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and our wholly-owned subsidiaries.  All intercompany accounts and transactions are eliminated in consolidation.   </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from these estimates.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase.  We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents.  These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Inventories are valued at the lower of cost and net realizable value.  Cost is determined by the first-in, first-out method.  We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value.  Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which are used in our testing laboratories.  Inventory obsolescence expense for the three months ended March 31, 2022 and 2021 was $0.6&#160;million and $3.1 million, respectively.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting.  Refer to Note 5.  Goodwill, in-process research and development (&#8220;IPR&amp;D&#8221;) and other intangible assets acquired in business combinations, licensing and other transactions was $1.4 billion at both March&#160;31, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values.  Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill.  At acquisition, we generally determine the fair value of intangible assets, including IPR&amp;D, using the &#8220;income method.&#8221;</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was $519.1&#160;million and $520.6&#160;million, respectively, at March&#160;31, 2022 and December&#160;31, 2021, Assets held for sale includes $151.8&#160;million of goodwill related to GeneDx. Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.  We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing.  Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net intangible assets other than goodwill was $890.5 million and $911.9 million, including IPR&amp;D of $590.2&#160;million at December&#160;31, 2021, respectively.  Intangible assets are highly vulnerable to impairment charges, particularly newly acquired assets for recently launched products and IPR&amp;D.  Considering the high risk nature of research and development and the industry&#8217;s success rate of bringing developmental compounds to market, IPR&amp;D impairment charges may occur in future periods.  Estimating the fair value of IPR&amp;D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon obtaining regulatory approval, IPR&amp;D assets are then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life.  If the project is abandoned, the IPR&amp;D asset is charged to expense.  Finite lived intangible assets are tested for impairment when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.  The testing includes a comparison of the carrying amount of the asset to its estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our estimates and assumptions in testing goodwill and other intangible assets, including IPR&amp;D, for</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impairment are reasonable and otherwise consistent with assumptions that marketplace participants would use in their estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of fair value. However, if future results are not consistent with our estimates and assumptions, including as a result of the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 global pandemic, then we may be exposed to additional impairment charges, which could be material.  We submitted the initial BLA with the FDA for approval of Somatrogon (hGH-CTP) in the United States and Pfizer received a Complete Response Letter in January 2022. Pfizer and OPKO are evaluating the FDA&#8217;s comments and will work with the agency to determine the best path forward for Somatrogon (hGH-CTP) in the United States.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we reclassified $590.0&#160;million of IPR&amp;D related to Somatrogon (hGH-CTP) from IPR&amp;D in our Condensed Consolidated Balance Sheet upon the approval of NGENLA (Somatrogon) in Europe and Japan. The assets will be amortized on a straight-line basis over their estimated useful life of approximately 12 years.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years.  We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up.  Amortization expense was $22.0 million and $12.6 million for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments.  Investments that are considered equity securities as of March&#160;31, 2022 and December&#160;31, 2021 are predominately carried at fair value.  Our debt under the credit agreement with JPMorgan Chase Bank, N.A. approximates fair value due to the variable rate of interest applicable to such debt.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates.  The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts.  Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange.  Refer to Note 9.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense.  Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability.  Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions.  The assumptions used in estimating fair value require significant judgment.  The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges.  For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At March&#160;31, 2022 and December&#160;31, 2021, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognized all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations.  Refer to Note 10.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Property, plant and equipment are recorded at cost or fair value if acquired in a business combination.  Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases.  The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, and automobiles - 3-5 years.  Expenditures for repairs and maintenance are charged to expense as incurred.  Depreciation expense was $5.8 million and $7.4 million for three months ended March 31, 2022 and 2021, respectively. Assets held under finance leases are included within Property, plant and equipment, net in our Consolidated Balance Sheets and are amortized over the shorter of their useful lives or the expected term of their related leases.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of long-lived assets.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment and assets held for sale, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment. Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in various countries and tax jurisdictions globally.&#160; For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results.&#160; For the three months ended March 31, 2022, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 606&#8221;).  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.  At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct.  We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied.  For a complete discussion of accounting for Revenues from services, Revenues from products and Revenue from transfer of intellectual property and other, refer to Note 13.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of credit risk and allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable.  Substantially all of our accounts receivable are with either companies in the healthcare industry or patients.  However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.   On March&#160;31, 2022 and December&#160;31, 2021, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were 10% and 6%, respectively, of our consolidated Accounts receivable, net. On March&#160;31, 2022 and December&#160;31, 2021, receivable balances (net of explicit and implicit price concessions) due directly from states, cities and other municipalities, specifically related to our real-time reverse-transcription polymerase chain reaction (real-time RT-PCR) assay to detect COVID-19, were 4.8% and 4.1% of our consolidated accounts receivable, net, respectively. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk.  At March&#160;31, 2022 and December&#160;31, 2021, receivables due from patients represented approximately 2.0% and 0.7%, respectively, of our consolidated Accounts receivable, net.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer&#8217;s ability to pay.  Actual results could differ from those estimates.  The allowance for credit losses was $2.0 million and $1.8 million at March&#160;31, 2022 and December&#160;31, 2021, respectively.  The credit loss expense for the three months ended March 31, 2022 and 2021 was $0.1 million and $0.3 million, respectively.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award.  That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award.  We record excess tax benefits realized from the exercise of stock options as cash flows from operations.  For the three months ended March 31, 2022 and 2021 we recorded $7.6 million and $2.6 million, respectively, of equity-based compensation expense.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include external and internal expenses.  External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs.  Research and development employee-related expenses include salaries, benefits and equity-based compensation expense.  Other internal research and </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.  We expense these costs in the period in which they are incurred.  We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received.  As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility, and which have no alternative future use.  For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed.  Once the development process has been completed the asset will be amortized over its remaining estimated useful life.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Our chief operating decision-maker (&#8220;CODM&#8221;) is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis.  We manage our operations in two reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of clinical and genomics laboratory operations through BioReference and point-of-care operations.  There are no significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is no inter-segment allocation of interest expense or income taxes.  Refer to Note 15.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shipping and handling costs.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not charge customers for shipping and handling costs.  Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The financial statements of certain of our foreign operations are measured using the local currency as the functional currency.  The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date and the local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods.  Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss). During the three months ended March 31, 2022 and 2021, we recorded $1.1&#160;million and $4.8&#160;million, respectively of transaction losses.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The consolidation of a variable interest entity (&#8220;VIE&#8221;) is required when an enterprise has a controlling financial interest.  A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE.  Refer to Note 6.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We have made strategic investments in development stage and emerging companies.  We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees.  For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations.  Refer to Note 6.  For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value.  Refer to Note 6.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently adopted accounting pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40).&#8221; ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2021, with early adoption permitted.   As required, we adopted ASU 2020-06 on January 1, 2022 and used the modified retrospective approach for all convertible debt instruments at the beginning of the period of adoptions.  Results for reporting periods beginning January 1, 2022 are presented under ASU 2020-06, while prior period amounts were not adjusted and continue to be reported in accordance with historic with accounting guidance. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the modified approach, entities will apply the guidance to all financial instruments that are outstanding as of the beginning of the year of adoption with the cumulative effect recognized as an adjustment to the opening balance of retained earnings. ASU 2020-06 eliminates the cash conversion and beneficial conversion feature models in ASC 470-20 that require an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of </span></div>equity. The adoption of ASU 2020-06 at January 1, 2022 resulted in an increase of the Convertible notes of $21.6&#160;million, a reduction of the Accumulated deficit of $17.5&#160;million and a reduction of Additional paid-in capital of $39.1&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513755368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is computed by dividing our net income (loss) by the weighted average number of shares of our common stock par value $0.01 per share (&#8220;Common Stock&#8221;) outstanding during the period.  Shares of Common Stock outstanding under the&#160;share lending&#160;arrangement entered into in conjunction with the 2025 Notes (as defined in Note 7) are excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.  Refer to Note 7.  For diluted earnings per share, the dilutive impact of stock options and warrants is determined by applying the &#8220;treasury stock&#8221; method.  The dilutive impact of the 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes (each, as defined and discussed in Note 7) has been considered using the &#8220;if converted&#8221; method. For periods in which their effect would be antidilutive, no effect is given to Common Stock issuable under outstanding options or warrants or the potentially dilutive shares issuable pursuant to the 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes in the dilutive computation.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A total of 57,985,925 and 74,623,270 potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the three months ended March 31, 2022, and 2021, respectively, because their inclusion would be antidilutive. A full presentation of diluted earnings per share has not been provided because the required adjustments to the numerator and denominator resulted in diluted earnings per share equivalent to basic earnings per share.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, 55,750 Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 55,750 shares of Common Stock.  Of the 55,750 Common Stock options and Common Stock warrants exercised, no shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;March 31, 2021, 117,500 Common Stock options or Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 117,500 shares of Common Stock.  Of the 117,500 Common Stock options and Common Stock warrants exercised, no shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513723720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS</a></td>
<td class="text">COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,979)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,637&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumable supplies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: inventory reserve</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes recoverable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,274&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technologies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product registrations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338,294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320,820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890,498&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,683&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory received but not invoiced</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases short-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgages and other debts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,062&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets and goodwill relate principally to our completed acquisitions of OPKO Renal, OPKO Biologics, EirGen and BioReference.  We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives.  The estimated useful lives by asset class are as follows:  technologies - 7-17 years, customer relationships - 7-20 years, product registrations - 7-10 years, covenants not to compete - 5 years, trade names - 5-10 years, other 9-13 years.  We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred.  Our goodwill is not tax deductible for income tax purposes in any jurisdiction in which we operate.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, GeneDx met the held-for-sale accounting criteria and its related assets and liabilities are recognized at the lower of carrying value or fair value less costs to sell in the consolidated balance sheet. In addition, at March 31, 2022 and December 31, 2021, Assets held for sale included $151.8&#160;million of goodwill related to GeneDx. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we reclassified $590.0&#160;million of IPR&amp;D related to Somatrogon from IPR&amp;D in our Condensed Consolidated Balance Sheet upon the approval of NGENLA (Somatrogon) in Europe and Japan. The assets will be amortized on a straight-line basis over their estimated useful life of approximately 12 years. Other changes in value of the intangible assets and goodwill during the three months ended March 31, 2022 and 2021 were primarily due to foreign currency fluctuations between the Chilean Peso, and the Euro against the U.S. dollar.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in Goodwill by reporting unit during the three months ended March 31, 2022.</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.619%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross goodwill  at January 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative impairment at January 1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CURNA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,827)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FineTech</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Biologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Chile</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Health Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transition Therapeutics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,421)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BioReference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">434,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(151,784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Diagnostics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">710,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38,023)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153,333)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">519,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other amounts for three months ended March 31, 2022 includes amounts related to GeneDx which is included as Assets held for sale at March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513908856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract', window );"><strong>Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">INVESTMENTS</a></td>
<td class="text">INVESTMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of March&#160;31, 2022 and December 31, 2021:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:46.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment type</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment Carrying Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Underlying Equity in Net Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment Carrying Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Underlying Equity in Net Assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable interest entity, equity method</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with no readily determinable fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants and options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Equity method investments</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity method investments consist of investments in Pharmsynthez (ownership 9%), Cocrystal Pharma, Inc. (&#8220;COCP&#8221;) (3%), Non-Invasive Monitoring Systems, Inc. (&#8220;NIMS&#8221;) (1%), Neovasc, Inc. (&#8220;Neovasc&#8221;) (1%), InCellDx, Inc. (&#8220;InCellDx&#8221;) (29%), BioCardia, Inc. (&#8220;BioCardia&#8221;) (1%), Xenetic Biosciences, Inc. (&#8220;Xenetic&#8221;) (1%), and LeaderMed Health Group Limited (&#8220;LeaderMed&#8221;) (47%).  The aggregate amount of assets, liabilities, and net losses of our equity method investees as of and for the three months ended March 31, 2022 were $222.1 million, $37.6 million, and $19.0 million, respectively.  The aggregate amount of assets, liabilities, and net losses of our equity method investees as of and for the year ended December 31, 2021 were $223.6&#160;million, $37.9&#160;million, and $69.4&#160;million, respectively. We have determined that we and/or our related parties can significantly influence control of our equity method investments through our board representation and/or voting power.  Accordingly, we account for our investment in these entities under the equity method and record our proportionate share of their losses in Loss from investments in investees in our Condensed Consolidated Statement of Operations.  The aggregate value of our equity method investments based on the quoted market prices of their respective shares of common stock and the number of shares held by us as of March&#160;31, 2022 and December 31, 2021 was $3.6 million and $4.5&#160;million, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity securities consist of investments in Phio Pharmaceuticals (&#8220;Phio&#8221;) (ownership 0.01%), VBI Vaccines Inc. (&#8220;VBI&#8221;) (1%), ChromaDex Corporation (&#8220;ChromaDex&#8221;) (0.1%), Eloxx Pharmaceuticals, Inc. (&#8220;Eloxx&#8221;) (1%), and CAMP4 Therapeutics Corporation (&#8220;CAMP4&#8221;) (5%) and HealthSnap, Inc. (7%).  We have determined that our ownership, along with that of our related parties, does not provide us with significant influence over the operations of these investments.  Accordingly, we account for our investment in these entities as equity securities, and we record changes in the fair value of these investments in Other income (expense) each reporting period when they have readily determinable fair value. Equity securities without a readily determinable fair value are adjusted to fair value when there is an observable price change. Net gains and losses on our equity securities for the three months ended March 31, 2022, and 2021 were as follows:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March&#160;31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity Securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gains and losses recognized during the period on equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net gains realized during the period on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,981)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized net gains and losses recognized during the period on equity securities still held at the reporting date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,162)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales of investments</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains (losses) included in earnings from sales of our investments are recorded in Other income (expense), net in our Condensed Consolidated Statement of Operations.  The cost of securities sold is based on the specific identification method.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants and options</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our equity method investments and equity securities, we hold options to purchase 47 thousand additional shares of BioCardia, all of which were vested as of March&#160;31, 2022 and December 31, 2021, and 33 thousand and 0.7 million to purchase additional shares of COCP and InCellDx, respectively.  We recorded the changes in the fair value of the options and warrants in Fair value changes of derivative instruments, net in our Condensed Consolidated Statement of Operations.  We also recorded the fair value of the options and warrants in Investments, net in our Condensed Consolidated Balance Sheet.  See further discussion of the Company&#8217;s options and warrants in Note 9 and Note 10.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in variable interest entities</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that we hold variable interests in LeaderMed, Detect Genomix, LLC (&#8220;Detect Genomix&#8221;) and Zebra Biologics, Inc. (&#8220;Zebra&#8221;). We made this determination as a result of our assessment that they do not have sufficient resources to carry out their principal activities without additional financial support.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2021, we and LeaderMed, a pharmaceutical development company with operations based in Asia, announced the formation of a joint venture to develop, manufacture and commercialize two of OPKO&#8217;s clinical stage, long-acting drug products in Greater China and eight other Asian territories. Under the terms of the agreements, we have granted the joint venture exclusive rights to develop, manufacture and commercialize (a) OPK88003, an oxyntomodulin analog being developed for the treatment of obesity and diabetes, and (b) Factor VIIa-CTP, a novel long acting coagulation factor being developed to treat hemophilia, in exchange for 4,703 shares 47% ownership interest in the joint venture. In addition, we received an upfront payment of $1.0&#160;million and will be reimbursed for clinical trial material and technical support we provide the joint venture.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the primary beneficiary of the joint venture, we evaluated our investment and our related parties&#8217; investment, as well as our investment combined with the related parties&#8217; investment to identify if we had the power to direct the activities that most significantly impact the economic performance of the joint venture. Based on the capital structure, governing documents and overall business operations of the joint venture, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact the joint venture&#8217;s economic performance and do not have an obligation to fund expected losses. We did determine that we can significantly influence control of the joint venture through our board representation and voting power. Therefore, we have the ability to exercise significant influence over the joint venture&#8217;s operations and account for our investment in the joint venture under the equity method.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, GeneDx LLC, a subsidiary of the Company, announced that it had entered into an agreement with Pediatrix Medical Group (&#8220;Pediatrix&#8221;), a provider of maternal-fetal, and pediatric medical and surgical subspecialty physician services, to offer genomic sequencing to support clinical diagnosis in neonatal intensive care units staffed by Pediatrix&#8217;s affiliated neonatologists. The offering is planned to include whole exome and whole genome sequencing and genomic support services under the brand Detect Genomix. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial capital investment in Detect Genomix was $245,000 for which we received a 49% ownership interest in Detect Genomix. We had been required to make additional capital contributions to Detect Genomix in accordance with our percentage interests if Detect Genomix were unable to generate positive cash flow from operations or is unable to obtain alternative financing.  We have not made any other investments in or loans to Detect Genomix through March 31, 2021. In January 2022, the Detect Genomix agreement was terminated.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the primary beneficiary of Detect Genomix, we evaluated our investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Detect Genomix.  Based on the capital structure, governing documents and overall business operations of Detect Genomix, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Detect Genomix&#8217;s economic performance.  We determined, however, that we can significantly influence control of Detect Genomix through our board representation and voting power.  Therefore, we have the ability to exercise significant influence over Detect Genomix&#8217;s operations and account for our investment in Detect Genomix under the equity method.  The joint venture was dissolved in January 2022.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own 1,260,000 shares of Zebra Series A-2 Preferred Stock and 900,000 shares of Zebra restricted common stock (ownership 29% at March&#160;31, 2022).  Zebra is a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drugs.  Dr. Richard Lerner, M.D., a former member of our Board of Directors, is a founder of Zebra and, along with Dr. Frost, serves as a member of Zebra&#8217;s Board of Directors.  </span></div>In order to determine the primary beneficiary of Zebra, we evaluated our investment and our related parties&#8217; investment, as well as our investment combined with the related parties&#8217; investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Zebra.  Based on the capital structure, governing documents and overall business operations of Zebra, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Zebra&#8217;s economic performance and have no obligation to fund expected losses.  We determined, however, that we can significantly influence control of Zebra through our board representation and voting power.  Therefore, we have the ability to exercise significant influence over Zebra&#8217;s operations and account for our investment in Zebra under the equity method.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI http://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI http://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513767752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT&#160;&#160;&#160;&#160;<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, our debt consisted of the following:</span></div><div style="margin-top:9pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Convertible Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2033 Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chilean and Spanish lines of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long term portion of notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance sheet captions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lines of credit and notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LT notes payable included in long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,272&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2020, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $100 million.  The line of credit called for a commitment fee equal to 0.25% per annum of the unused portion of the line. No funds were borrowed under this line of credit and we terminated this line of credit in June 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we issued $200.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in an underwritten public offering.  The 2025 Notes bear interest at a rate of 4.50% per year, payable semiannually in arrears on February&#160;15 and August&#160;15 of each year.  The notes mature on February&#160;15, 2025, unless earlier repurchased, redeemed or converted.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2025 Notes into shares of Common Stock at their option at any time prior to the close of business on the business day immediately preceding November&#160;15, 2024 only under the following circumstances:  (1)&#160;during any calendar quarter commencing after the calendar quarter ended March&#160;31, 2019 (and only during such calendar quarter), if the last reported sale price of our Common Stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2)&#160;during the five business day period after any five consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of 2025 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our Common Stock and the conversion rate on each such trading day; (3)&#160;if we call any or all of the 2025 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4)&#160;upon the occurrence of specified corporate events set forth in the indenture governing the 2025 Notes.  On or after November&#160;15, 2024, until the close of business on the business day immediately preceding the maturity date, holders of the 2025 Notes may convert their notes at any time, regardless of the foregoing conditions.  Upon conversion, we will pay or deliver, as the case may be, cash, shares of our Common Stock, or a combination of cash and shares of our Common Stock, at our election.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial and current conversion rate for the 2025 Notes is 236.7424 shares of Common Stock per $1,000 principal amount of 2025 Notes (equivalent to a conversion price of approximately $4.22 per share of Common Stock).  The conversion </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rate for the 2025 Notes is subject to adjustment in certain events but will not be adjusted for any accrued and unpaid interest.  In addition, following certain corporate events that occur prior to the maturity date of the 2025 Notes or if we deliver a notice of redemption, in certain circumstances the indenture governing the 2025 Notes requires an increase in the conversion rate of the 2025 Notes for a holder who elects to convert its notes in connection with such a corporate event or notice of redemption, as the case may be.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not redeem the 2025 Notes prior to February&#160;15, 2022.  We may redeem for cash any or all of the 2025 Notes, at our option, on or after February&#160;15, 2022, if the last reported sale price of our Common Stock has been at least 130% of the then current conversion price for the notes for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.  No sinking fund is provided for the 2025 Notes.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change, as defined in the indenture governing the 2025 Notes, prior to the maturity date of the 2025 Notes, holders may require us to repurchase for cash all or any portion of their notes at a repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.  The 2025 Notes are our senior unsecured obligations and rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2025 Notes; equal in right of payment to any of our existing and future liabilities that are not so subordinated; effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into exchange agreements with certain holders of the 2025 Notes, pursuant to which the holders exchanged $55.4&#160;million in aggregate principal amount of the outstanding 2025 Notes for 19,051,270 shares of our Common Stock (the &#8220;Exchange&#8221;). We recorded an $11.1&#160;million non-cash loss related to the Exchange during the second quarter of 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the issuance of the 2025 Notes, we agreed to loan up to 30,000,000 shares of our Common Stock to affiliates of the underwriter in order to assist investors in the 2025 Notes to hedge their position. Following consummation of the Exchange, the number of outstanding borrowed shares of Common Stock was reduced by approximately 8,105,175 shares. As of&#160;March&#160;31, 2022 and December 31, 2021, a total of&#160;21,144,825 and 21,144,825 shares remained outstanding under the&#160;share lending&#160;arrangement, respectively. We will not receive any of the proceeds from the sale of the borrowed shares, but we received a one-time nominal fee of $0.3 million for the newly issued shares. Shares of our Common Stock outstanding under the&#160;share lending&#160;arrangement are excluded from the calculation of basic and diluted earnings per share. See Note 4.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by ASC 470-20, &#8220;Debt with Conversion and Other Options,&#8221; we calculated the equity component of the 2025 Notes, taking into account both the fair value of the conversion option and the fair value of the&#160;share lending arrangement. The equity component was valued at&#160;$52.6 million&#160;at issue date and this amount was recorded as Additional paid-in capital, which resulted in a discount on the 2025 Notes. The discount is being amortized to Interest expense over the term of the 2025 Notes, which results in an effective interest rate on the 2025 Notes of 11.2%.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information related to the 2025 Notes which is included in our Condensed Consolidated Balance Sheet as of March&#160;31, 2022:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 Senior Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt Issuance Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,747)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,473)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adoption of ASU 2020-06</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,580&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,313)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40).&#8221; ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2021, with early adoption permitted.   As required, we adopted ASU 2020-06 on January 1, 2022 and used the modified retrospective approach for all convertible debt instruments at the beginning of the period of adoptions.  Results for reporting periods beginning January 1, 2022 are presented under ASU 2020-06, while prior period amounts were not adjusted and continue to be reported in accordance with historic accounting guidance. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the modified approach, entities will apply the guidance to all financial instruments that are outstanding as of the beginning of the year of adoption with the cumulative effect recognized as an adjustment to the opening balance of retained earnings. ASU 2020-06 eliminates the cash conversion and beneficial conversion feature models in ASC 470-20 that require an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity. The adoption of ASU 2020-06 at January 1, 2022 resulted in an increase of the Convertible notes of $21.6&#160;million, a reduction of the Accumulated deficit of $17.5&#160;million and a reduction of Additional paid-in capital of $39.1&#160;million.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, we issued a series of 5% Convertible Promissory Notes (the &#8220;2023 Convertible Notes&#8221;) in the aggregate principal amount of $55.0 million.  The 2023 Convertible Notes mature five years following the date of issuance.  Each holder of a 2023 Convertible Note has the option, from time to time, to convert all or any portion of the outstanding principal balance of such 2023 Convertible Note, together with accrued and unpaid interest thereon, into shares of our Common Stock at a conversion price of $5.00 per share.  We may redeem all or any part of the then issued and outstanding 2023 Convertible Notes, together with accrued and unpaid interest thereon, pro rata among the holders, upon no fewer than 30 days, and no more than 60 days, notice to the holders.  The 2023 Convertible Notes contain customary events of default and representations and warranties of OPKO.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchasers of the 2023 Convertible Notes included an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2013, we entered into note purchase agreements with respect to the issuance and sale of our 3.0% Senior Notes due 2033 (the &#8220;2033 Senior Notes&#8221;) in a private placement exempt from registration under the Securities Act.  We issued the 2033 Senior Notes on January&#160;30, 2013.  The 2033 Senior Notes, which totaled $175.0 million in original principal amount, bear interest at the rate of 3.0%&#160;per year, payable semiannually on February&#160;1 and August&#160;1 of each year.  The 2033 Senior Notes mature on February&#160;1, 2033, unless earlier repurchased, redeemed or converted.  Upon a fundamental change, as defined in the indenture governing the 2033 Senior Notes, subject to certain exceptions, the holders may require us to repurchase all or any portion of their 2033 Senior Notes for cash at a repurchase price equal to 100% of the principal amount of the 2033 Senior Notes being repurchased, plus any accrued and unpaid interest to, but not including, the related fundamental change repurchase date.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2013 to 2016, holders of the 2033 Senior Notes converted $143.2 million in aggregate principal amount into an aggregate of 21,539,873 shares of Common Stock. On February 1, 2019, approximately $28.8 million aggregate principal amount of 2033 Senior Notes were tendered by holders pursuant to such holders&#8217; option to require us to repurchase the 2033 Senior Notes as set forth in the indenture, governing the 2033 Senior Notes, following which repurchase only $3.0 million aggregate principal amount of the 2033 Senior Notes remained outstanding.  Holders of the remaining $3.0 million principal amount of the 2033 Senior Notes may require us to repurchase such notes for 100% of their principal amount, plus accrued and unpaid interest, on February 1, 2023, on February 1, 2028, or following the occurrence of a fundamental change as described above.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the 2033 Senior Notes, include, among others: (i) rights to convert the notes into shares of our Common Stock, including upon a fundamental change; and (ii) a coupon make-whole payment in the event of a conversion by the holders of the 2033 Senior Notes on or after February 1, 2017 but prior to February 1, 2019.  We determined that these specific terms were embedded derivatives.  Embedded derivatives are required to be separated from the host contract, the 2033 Senior Notes, and carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument.  We concluded that the embedded derivatives within the 2033 Senior Notes met these criteria and, as such, were valued separate and apart from the 2033 Senior Notes and recorded at fair value each reporting period.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting and financial reporting purposes, we combined these embedded derivatives and valued them together as one unit of accounting. In 2017, certain terms of the embedded derivatives expired pursuant to the original agreement and the embedded derivatives no longer met the criteria to be separated from the host contract and, as a result, the embedded derivatives were no longer required to be valued separate and apart from the 2033 Senior Notes and were reclassified to additional paid in capital. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, BioReference and certain of its subsidiaries entered into a credit agreement with JPMorgan Chase Bank, N.A. (&#8220;CB&#8221;), as lender and administrative agent, as amended (the &#8220;Credit Agreement&#8221;).  The Credit Agreement provides for a $75.0 million secured revolving credit facility and includes a $20.0 million sub-facility for swingline loans and a $20.0 million sub-facility for the issuance of letters of credit. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, the Credit Agreement was amended and restated (the &#8220;A&amp;R Credit Agreement&#8221;). The A&amp;R Credit Agreement is guaranteed by all of BioReference&#8217;s domestic subsidiaries.  The A&amp;R Credit Agreement is also secured by substantially all assets of BioReference and its domestic subsidiaries, as well as a non-recourse pledge by us of our equity interest in BioReference.  Availability under the A&amp;R Credit Agreement is based on a borrowing base composed of eligible accounts receivables of BioReference and certain of its subsidiaries, as specified therein.  As of March&#160;31, 2022, $64.8 million remained available for borrowing under the Credit Agreement. Principal under the Credit Agreement is due upon maturity on August 30, 2024. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At BioReference&#8217;s option, borrowings under the A&amp;R Credit Agreement (other than swingline loans) will bear interest at (i) the CB floating rate (defined as the higher of (a) the prime rate and (b) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) for an interest period of one month plus 2.50%) plus an applicable margin of 0.75% or (ii) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) plus an applicable margin of 1.75%.  Swingline loans will bear interest at the CB floating rate plus the applicable margin.  The A&amp;R Credit Agreement also calls for other customary fees and charges, including an unused commitment fee of 0.375% if the average quarterly availability is 50% or more of the revolving commitment, or 0.25% if the average quarterly availability is less than or equal to 50% of the revolving commitments.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2022 and December 31, 2021, no amount was outstanding under the A&amp;R Credit Agreement.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R Credit Agreement contains customary covenants and restrictions, including, without limitation, covenants that require BioReference and its subsidiaries to maintain a minimum fixed charge coverage ratio if availability under the new credit facility falls below a specified amount and to comply with laws and restrictions on the ability of BioReference and its subsidiaries to incur additional indebtedness or to pay dividends and make certain other distributions to the Company, subject to certain exceptions as specified therein.  Failure to comply with these covenants would constitute an event of default under the A&amp;R Credit Agreement, notwithstanding the ability of BioReference to meet its debt service obligations.  The A&amp;R Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the A&amp;R Credit Agreement and execution upon the collateral securing obligations under the A&amp;R Credit Agreement.  Substantially all the assets of BioReference and its subsidiaries are restricted from sale, transfer, lease, disposal or distributions to the Company, subject to certain exceptions. As of March&#160;31, 2022, BioReference and its subsidiaries had net assets of approximately $1,037.1 million, which included goodwill of $283.0 million and intangible assets of $199.5 million.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 29, 2022, the A&amp;R Credit Agreement was amended to, among other things, (i) waive specified defaults under the A&amp;R Credit Agreement resulting from certain internal reorganization transactions that resulted in both BioReference and GeneDx changing their respective forms of organization from New Jersey corporations to Delaware limited liability companies, (ii) provide for the disposition of GeneDx pursuant to the transactions contemplated by the merger agreement with Sema4, (iii) amend certain reporting requirements under the A&amp;R Credit Agreement and (iv) provide that the borrowers under the A&amp;R Credit Agreement may effect certain restricted payments to the extent necessary for their parent entities to pay income tax in respect of income earned by the borrowers. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the A&amp;R Credit Agreement with CB, we had line of credit agreements with thirteen other financial institutions as of March&#160;31, 2022 and eleven other financial institutions as of December&#160;31, 2021 in the U.S., Chile and Spain.  These lines of credit are used primarily as  sources of working capital for inventory purchases.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.575%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.001%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(Dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Balance Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lender</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest&#160;rate&#160;on<br/>borrowings at <br/>March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit&#160;line<br/>capacity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JPMorgan Chase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Itau Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bank of Chile</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BICE Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scotiabank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Santander Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Security Bank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estado Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BCI Bank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corpbanca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Bank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consoorcio Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Banco De Sabadell</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Santander Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.82%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,672&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022 and December&#160;31, 2021, the weighted average interest rate on our lines of credit was approximately 5.5% and 5.4%, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022 and December&#160;31, 2021, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the 2025 Notes, the A&amp;R Credit Agreement and amounts outstanding under lines of credit described above) as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:59.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The notes and other debt mature at various dates ranging from 2022 through 2026, bearing variable interest rates from 0.7% up to 3.8%.  The weighted average interest rate on the notes and other debt was 1.5% and 1.5% on March&#160;31, 2022 and December&#160;31, 2021. The notes are partially secured by our office space in Barcelona.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513889976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHENSIVE LOSS</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE LOSS<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, changes in Accumulated other comprehensive loss, net of tax, were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.370%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,495)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:20.25pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(920)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,415)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513876072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record fair values at an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.  We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.  These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had equity securities (refer to Note 6), forward foreign currency exchange contracts for inventory purchases (refer to Note 10) and contingent consideration related to the acquisitions of CURNA, OPKO Diagnostics and OPKO Renal that are required to be measured at fair value on a recurring basis.  In addition, in connection with our investment and our consulting agreement with BioCardia, we record the related BioCardia options at fair value as well as the warrants from COCP and InCellDx.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities measured at fair value on a recurring basis are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value measurements as of March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets for<br/>identical<br/>assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options/warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,191&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value measurements as of December&#160;31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets for<br/>identical<br/>assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options/warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,226&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and estimated fair value of our 2025 Notes, as well as the applicable fair value hierarchy tiers, are contained in the table below.  The fair value of the 2025 Notes is determined using inputs other than quoted prices in active markets that are directly observable.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="27" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no transfers between Level 1 and Level 2 and no transfers to or from Level 3 of the fair value hierarchy.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, the carrying value of our other financial instrument assets approximates their fair value due to their short-term nature or variable rate of interest.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of March&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent<br/>consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in results of operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,729&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of our financial instruments have been determined by using available market information and what we believe to be appropriate valuation methodologies.  We use the following methods and assumptions in estimating fair value:</span></div>Contingent consideration &#8211; We estimate the fair value of the contingent consideration utilizing a discounted cash flow model for the expected payments based on estimated timing and expected revenues.  We use several discount rates depending on each type of contingent consideration related to OPKO Diagnostics, CURNA and OPKO Renal transactions. As of March&#160;31, 2022, of the $2.7 million of contingent consideration, $0.5 million was recorded in Accrued expenses and $2.2 million was recorded in Other long-term liabilities.  As of December&#160;31, 2021, of the $2.8 million of contingent consideration, $0.5 million was recorded in Accrued expenses and $2.3 million was recorded in Other long-term liabilities. As a result of our execution of the CAMP4 Agreement (as defined in Note 14), we will have to pay a percentage of any payments received under the CAMP4 Agreement to the former CURNA stockholders.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513765272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Contracts<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE CONTRACTS</a></td>
<td class="text">DERIVATIVE CONTRACTS<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair values and the presentation of our derivative financial instruments in the Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:36.491%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Component</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock options/warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses.  Unrealized (losses) on forward contracts are recorded in Accrued expenses.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(462)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency forward exchange contracts with respect to the risk of exposure to exchange rate differences arising from inventory purchases on letters of credit.  Under these forward contracts, for any rate above or below the fixed rate, we receive or pay the difference between the spot rate and the fixed rate for the given amount at the settlement date.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To qualify the derivative instrument as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At March&#160;31, 2022 and December&#160;31, 2021, our derivative financial instruments did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognize the changes in Fair value of derivative instruments, net in our Condensed Consolidated Statement of Operations.  The following table summarizes the losses and gains recorded for the three and three months ended March 31, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative gain (loss):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock options/warrants </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116514178120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, GeneDx entered into an agreement with Mednax Services, Inc. (&#8220;Mednax Services&#8221;), a subsidiary of MEDNAX, Inc., (&#8220;MEDNAX&#8221;) pursuant to which the parties formed a joint venture under the brand Detect Genomix.  GeneDx&#8217;s initial capital investment in Detect Genomix was $245,000 for which GeneDx received a 49% ownership interest in Detect Genomix, and Mednax Services contributed $255,000 in exchange for a 51% ownership interest in Detect Genomix.  Adam Logal, the Company&#8217;s CFO, was the chair and sat on the Board of Managers of the joint venture.  Mednax Services provided administrative services to the joint venture pursuant to an administrative services agreement.  GeneDx provided laboratory services to the joint venture.  Dr. Roger Medel, a director of the Company, is the former Chief Executive Officer of MEDNAX and Mednax Services.  Dr. Medel continues to serve on the board of MEDNAX.  The joint venture was dissolved in January 2022.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 25, 2020, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $100 million.  The line of credit called for a commitment fee equal to 0.25% per annum of the unused portion of the line. We terminated this line of credit in June 2021 and as of March 31, 2022 and December 31, 2021, no amount was outstanding thereunder.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns approximately 9% of Pharmsynthez and Pharmsynthez is Xenetic&#8217;s largest and controlling stockholder. Dr. Richard Lerner, a director of the Company until his death on December 2, 2021, was a co-inventor of Xenetic&#8217;s technology and received 31,240 shares of Xenetic upon the closing of the Xenetic transactions described above.  Adam Logal, our Senior Vice President and Chief Financial Officer, is a director of Xenetic.   </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold investments in Zebra (ownership 29%), Neovasc (1%), ChromaDex Corporation (0.1%), COCP (3%), NIMS (1%), Eloxx (1%), BioCardia (1%) and LeaderMed Health Group Limited (47%).  These investments were considered related party transactions as a result of our executive management&#8217;s ownership interests and/or board representation in these entities.  See further discussion of our investments in Note 6.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, we entered into a Pledge Agreement with the Museum of Science, Inc. and the Museum of Science Endowment Fund, Inc. pursuant to which we agreed to contribute an aggregate of $1.0 million over a four-year period for constructing, equipping and the general operation of the Frost Science Museum.  Dr. Frost and Mr. Richard Pfenniger serve on the Board of Trustees of the Frost Science Museum and Mr. Pfenniger is the Vice Chairman of the Board of Trustees.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space from Frost Real Estate Holdings, LLC (&#8220;Frost Holdings&#8221;) in Miami, Florida, where our principal executive offices are located.  Effective August 1, 2019, we entered into an amendment to our lease agreement with Frost Holdings.  The lease, as amended, is for approximately 29,500 square feet of space.  The lease provides for payments of approximately $89 thousand per month in the first year increasing annually to $101 thousand per month in the fifth year, plus applicable sales tax.  The rent is inclusive of operating expenses, property taxes and parking.   </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioReference purchases and uses certain products acquired from InCellDx, a company in which we hold a 29% minority interest.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reimburse Dr.&#160;Frost for Company-related use by Dr.&#160;Frost and our other executives of an airplane owned by a company that is beneficially owned by Dr.&#160;Frost.  We reimburse Dr. Frost for out-of-pocket operating costs for the use of the airplane by Dr. Frost or Company executives for Company-related business.  We do not reimburse Dr.&#160;Frost for personal use of the airplane by Dr.&#160;Frost or any other executive.  For the three months ended March 31, 2022 and 2021, we reimbursed approximately $31&#160;thousand and $0&#160;thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513778312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:9pt;margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of CURNA, OPKO Diagnostics and OPKO Renal, we agreed to pay future consideration to the sellers upon the achievement of certain events.  As a result, as of March 31, 2022, we recorded $2.7 million as contingent consideration, with $0.5 million recorded within Accrued expenses and $2.2 million recorded within Other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets.  Refer to Note 5 and Note 17.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2019, the Company received a Civil Investigative Demand (&#8220;CID&#8221;) from the U.S. Department of Justice (&#8220;DOJ&#8221;), Washington, DC. The CID sets forth document requests and interrogatories in connection with allegations that the Company and certain of its affiliates violated the False Claims Act and/or the Anti-Kickback Statute. On January 13, 2022, the Federal Government notified the U.S.D.C., Middle District Florida, Jacksonville Division, that it is declining to intervene in the matter but retains the right, via the Attorney General, to consent to any proposed dismissal of the action by the Court. On February 9, 2022, the States of Florida, Georgia, and Commonwealth of Massachusetts notified the U.S.D.C., Middle District Florida, Jacksonville Division, that they are declining to intervene in the matter. Notwithstanding the above declinations, on February 17, 2022, the Company was served with the Relator&#8217;s Summons and Complaint (&#8220;Complaint&#8221;), which had been previously sealed. The complaint alleges violations of the False Claims Act, the California Fraud Preventions Act, the Florida False Claims Act, the Massachusetts False Claims Act, the Georgia False Medicaid Claims Act, and illegal kickbacks. The Company is reviewing and assessing the allegations made in the Complaint and, at this point, has not determined whether there is any merit to these claims nor can it determine the extent of any potential liability. While management cannot predict the outcome of these matters at this time, the ultimate outcome could be material to our business, financial condition, results of operations, and cash flows.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">         As previously reported, BioReference receives and is routinely required to respond to Civil Investigative Demands (&#8220;CID&#8221;) in the ordinary course of business. On November 26, 2019, BioReference received a CID from the DOJ. The CID states that DOJ is investigating whether BioReference paid unlawful remuneration to health care practitioners in violation of the Anti-Kickback Statute or Stark law and thus submitted or caused to be submitted false claims to government health care programs in violation of the False Claims Act. The time period covered by DOJ&#8217;s requests is January 1, 2011 through November 26, 2019. BioReference has fully cooperated with the DOJ by submitting the requested information and making current employees available for interviews, and the DOJ made a presentation to BioReference regarding its position. The parties have reached verbal agreement on the settlement amount, which is anticipated to be approximately $10&#160;million, excluding attorney fees. As of March&#160;31, 2022 and December 31, 2021, $10.5&#160;million and $10.0&#160;million was recorded in Accrued expenses, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2019, MabVax Therapeutics Holdings, Inc. filed a lawsuit in the Superior Court of California, County of San Diego against a number of individuals and entities, including the Company, Dr. Frost, Steven Rubin, the Company&#8217;s Executive Vice President-Administration, and an entity affiliated with Dr. Frost, based on the allegations raised in the SEC Complaint. The lawsuit seeks an award for actual and punitive damages, pre- and post-judgment interest; that the defendants be required to make full disclosure and accounting of their interests and transactions in plaintiff&#8217;s securities; costs of the suit, and reasonable attorney&#8217;s fees; and such other legal and equitable relief as the Court may deem proper under the circumstances. On January 31, 2022, plaintiffs entered into a confidential mutual release and settlement agreement with the Company, Dr. Frost, Frost Gamma Investment Trust, and Steve Rubin (the &#8220;Settlement Agreement&#8221;). The Settlement Agreement  has been approved by the United States Bankruptcy Court for the District of Delaware.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2019, former shareholders of Claros Diagnostics, Inc. filed a complaint in the Chancery Court of Delaware against the Company, alleging among other things, that the Company breached the Agreement and Plan of Merger dated October 13, 2011 by and among the Company, Claros Merger Subsidiary, LLC and Claros Diagnostics, Inc. (the &#8220;Claros Merger Agreement&#8221;): (i) by failing to make a milestone payment of $2.375&#160;million (payable in OPKO Common Stock) upon obtaining FDA approval of the Claros PSA test; and (ii) by repudiating its obligations to make additional future milestone payments as required under the Claros Merger Agreement. In January 2021, the Company and the shareholder representative entered into a settlement agreement providing, among other things, that the Company pay the shareholders $1.2&#160;million, which the Company has paid in full.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2017, the Civil Division of the United States Attorney&#8217;s Office for the Southern District of New York (the &#8220;SDNY&#8221;) informed BioReference that it believed that, from 2008 to 2012, BioReference had, in violation of the False Claims Act, improperly billed Medicare and TRICARE (both are federal government healthcare programs) for clinical laboratory services provided to hospital inpatient beneficiaries at certain hospitals.  In April 2019, the SDNY also informed BioReference that it believed that BioReference provided physicians subsidies for electronic health record systems prior to 2012 that violated regulations adopted by HHS in 2006 which allowed laboratories to provide these donations under certain conditions.  BioReference and the SDNY reached a settlement with respect to these matters and a final settlement and release, including BioReference&#8217;s payment of an approximately $11.5&#160;million settlement amount, was approved on September 22, 2020. The settlement amount has been paid. The amount of relator attorneys&#8217; fees is currently being negotiated.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may receive inquiries, document requests, CIDs or subpoenas from the Department of Justice, OCR, CMS, various payors and fiscal intermediaries, and other state and federal regulators regarding investigations, audits and reviews.  In addition to the matters discussed in this note, we are currently responding to CIDs, subpoenas, payor audits, and document requests for various matters relating to our laboratory operations.  Some pending or threatened proceedings against us may involve potentially substantial amounts as well as the possibility of civil, criminal, or administrative fines, penalties, or other sanctions, which could be material.  Settlements of suits involving the types of issues that we routinely confront may require monetary payments as well as corporate integrity agreements.  Additionally, qui tam or &#8220;whistleblower&#8221; actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act&#8217;s requirements for filing such suits.  Also, from time to time, we may detect issues of non-compliance with federal healthcare laws pertaining to claims submission and reimbursement practices and/or financial relationships with physicians, among other things.  We may avail ourselves of various mechanisms to address these issues, including participation in voluntary disclosure protocols.  Participating in voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action.  The Company generally has cooperated, and intends to continue to cooperate, with appropriate regulatory authorities as and when investigations, audits and inquiries arise.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to other litigation in the ordinary course of business.  While we cannot predict the ultimate outcome of legal matters, we accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss.  It&#8217;s reasonably possible the ultimate liability could exceed amounts currently estimated and we review established accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information.  To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.  Because of the high degree of judgment involved in establishing loss estimates, the ultimate outcome of such matters will differ from our estimates and such differences may be material to our business, financial condition, results of operations, and cash flows.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, we were committed to make future purchases for inventory and other items in 2022 that occur in the ordinary course of business under various purchase arrangements with fixed purchase provisions aggregating approximately $252.4 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513868408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text">REVENUE RECOGNITION<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from services, products and intellectual property as follows:</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from services</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for laboratory services is recognized at the time test results are reported, which approximates when services are provided and the performance obligations are satisfied.  Services are provided to patients covered by various third-party payor programs including various managed care organizations, as well as the Medicare and Medicaid programs.  Billings for services are included in revenue net of allowances for contractual discounts, allowances for differences between the amounts billed and estimated program payment amounts, and implicit price concessions provided to uninsured patients which are all elements of variable consideration.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are descriptions of our payors for laboratory services:</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Insurers.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules.  Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements.  Adjustments to the allowances, based on actual receipts from the third-party payors, are recorded upon settlement.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Payors.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursements from government payors are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid.  Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements.  Adjustments to the allowances, based on actual receipts from the government payors, are recorded upon settlement.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Client Payors.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Client payors include physicians, hospitals, employers, and other institutions for which services are performed on a wholesale basis, and are billed and recognized as revenue based on negotiated fee schedules.  Client payors also include cities, states and companies for which BioReference provides COVID-19 testing services.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patients.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients.  Insured patients (including amounts for coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers.  Collection of billings from patients is subject to credit risk and ability of the patients to pay.  Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with our policies and implicit price concessions.  Implicit price concessions represent differences between amounts billed and the estimated consideration that we expect to receive from patients, which considers historical collection experience and other factors including current market conditions.  Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement.  </span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, require us to estimate the potential for retroactive adjustments as an element of variable consideration in the recognition of revenue in the period the related services are rendered.  Actual amounts are adjusted in the period those adjustments become known. For the three months ended March 31, 2022 and 2021, positive revenue adjustments due to changes in estimates of implicit price concessions for performance obligations satisfied in prior periods of $2.0 million and $28.0 million, respectively, were recognized.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors, including government programs, may decide to deny payment or recoup payments for testing they contend were improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received.  Our revenues may be subject to retroactive adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payors in interpretations, requirements, and &#8220;conditions of participation&#8221; in various programs.  We have processed requests for recoupment from third-party payors in the ordinary course of our business, and it is likely that we will continue to do so in the future.  If a third-party payor denies payment for testing or recoups money from us in a later period, reimbursement for our testing could decline.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an integral part of our billing compliance program, we periodically assess our billing and coding practices, respond to payor audits on a routine basis, and investigate reported failures or suspected failures to comply with federal and state healthcare reimbursement requirements, as well as overpayment claims which may arise from time to time without fault on the part of the Company.  We may have an obligation to reimburse Medicare, Medicaid,&#160;and third-party payors for </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overpayments&#160;regardless of fault.  We have periodically identified and reported&#160;overpayments, reimbursed payors for&#160;overpayments&#160;and taken appropriate corrective action.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are also considered variable consideration and are included in the determination of the estimated transaction price for providing services.  These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and our historical settlement activity, including an assessment of the probability a significant reversal of cumulative revenue recognized will occur when the uncertainty is subsequently resolved.  Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. As of March&#160;31, 2022 and December&#160;31, 2021, we had liabilities of approximately $2.1 million and $5.0 million, respectively, within Accrued expenses and Other long-term liabilities related to reimbursements for payor overpayments.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of Revenue from services by payor for the three months ended March 31, 2022 and 2021 was as follows:</span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three months ended March&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,829&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,951&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from products</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from product sales when a customer obtains control of promised goods or services.  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and our evaluation of specific factors that may increase or decrease the risk of product returns.  Product revenues are recorded net of estimated rebates, chargebacks, discounts, co-pay assistance and other deductions (collectively, &#8220;Sales Deductions&#8221;) as well as estimated product returns which are all elements of variable consideration.  Allowances are recorded as a reduction of revenue at the time product revenues are recognized.  The actual amounts of consideration ultimately received may differ from our estimates.  If actual results in the future vary from our estimates, we will adjust these estimates, which would affect Revenue from products in the period such variances become known.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is distributed in the U.S. principally through the retail pharmacy channel, which initiates with the largest wholesalers in the U.S. (collectively, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Customers&#8221;).  In addition to distribution agreements with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers, we have entered into arrangements with many healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue for shipments of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time of delivery to customers after estimating Sales Deductions and product returns as elements of variable consideration utilizing historical information and market research projections. For the three months ended March 31, 2022 and 2021, we recognized $5.1 million and $5.8&#160;million, respectively, in net product revenue from sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents an analysis of product sales allowances and accruals for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-bottom:5pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chargebacks, discounts, rebates and fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Governmental </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Provision related to current period sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Credits or payments made</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,086)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales allowances and accruals as a percentage of gross </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62%</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chargebacks, discounts, rebates and fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Governmental </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Provision related to current period sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Credits or payments made</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales allowances and accruals as a percentage of gross </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63%</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:9pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes collected from customers related to revenues from services and revenues from products are excluded from revenues.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from intellectual property and other</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenues from the transfer of intellectual property generated through license, development, collaboration and/or commercialization agreements.  The terms of these agreements typically include payment to us for one or more of the following:  non-refundable, up-front license fees; development and commercialization milestone payments; funding of research and/or development activities; and royalties on sales of licensed products.  Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For research, development and/or commercialization agreements that result in revenues, we identify all material performance obligations, which may include a license to intellectual property and know-how, and research and development activities.  In order to determine the transaction price, in addition to any upfront payment, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract.  We constrain (reduce) our estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract.  When determining if variable consideration should be constrained, we consider whether there are factors outside of our control that could result in a significant reversal of revenue.  In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue.  These estimates are re-assessed each reporting period as required.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront License Fees:  If a license to our intellectual property is determined to be functional intellectual property distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement.  The revenue is recognized when the license is transferred to the customer and the customer is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.  If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development and Regulatory Milestone Payments:  Depending on facts and circumstances, we may conclude that it is appropriate to include the milestone in the estimated transaction price or that it is appropriate to fully constrain the milestone.  A milestone payment is included in the transaction price in the reporting period that we conclude that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods.  We may record revenues from certain milestones in a reporting period before the milestone is achieved if we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods.  We record a corresponding contract asset when this conclusion is reached.  Milestone payments that have been fully constrained are not included in the transaction price to date.  These milestones remain fully constrained until we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods.  We re-evaluate the probability of achievement of such development milestones and any related constraint each reporting period.  We adjust our estimate of the overall transaction price, including the amount of revenue recorded, if necessary.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Activities:  If we are entitled to reimbursement from our customers for specified research and development expenses, we account for them as separate performance obligations if distinct.  We also determine whether the research and development funding would result in revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation.  The corresponding revenues or offset to research and development expenses are recognized as the related performance obligations are satisfied.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales-based Milestone and Royalty Payments:  Our customers may be required to pay us sales-based milestone payments or royalties on future sales of commercial products.  We recognize revenues related to sales-based milestone and royalty payments upon the later to occur of (i) achievement of the customer&#8217;s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to our intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Potential Products and Services:  Arrangements may include an option for license rights, future supply of drug substance or drug product for either clinical development or commercial supply at the licensee&#8217;s election.  We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the inception of the contract and revenue is recognized only if the option is exercised and products or services are subsequently delivered or when the rights expire.  If the promise is based on market terms and not considered a material right, the option is accounted for if and when exercised.  If we are entitled to additional payments when the licensee exercises these options, any additional payments are generally recorded in license or other revenues when the licensee obtains control of the goods, which is upon delivery.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Three months ended March&#160;31, 2022 and 2021, revenue from transfer of intellectual property and other reflects $2.2&#160;million and $2.8&#160;million of revenue related to the Pfizer Transaction (as defined below).  For the three months ended March&#160;31, 2022 revenue from transfer of intellectual property and other includes $3.0&#160;million related to a sales milestone from VFMCRP (as defined below).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities relate to cash consideration that OPKO receives in advance of satisfying the related performance obligations. Changes in the contractual liabilities balance during the three months ended March 31, 2022 are as follows:</span></div><div style="margin-top:9pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized in the period from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in contracts liability at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513723720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Alliances<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_StrategicAlliancesTextBlock', window );">STRATEGIC ALLIANCES</a></td>
<td class="text">STRATEGIC ALLIANCES<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LeaderMed</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2021, we and LeaderMed Health Group Limited (&#8220;LeaderMed&#8221;), a pharmaceutical development company with operations based in Asia, announced the formation of a joint venture to develop, manufacture and commercialize two of OPKO&#8217;s clinical stage, long-acting drug products in Greater China and eight other Asian territories. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreements, we have granted the joint venture exclusive rights to develop, manufacture and commercialize (a) OPK88003, an oxyntomodulin analog being developed for the treatment of obesity and diabetes, and (b) Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia, in exchange for a 47% ownership </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest in the joint venture. In addition, we received an upfront payment of $1&#160;million and will be reimbursed for clinical trial material and technical support we provide the joint venture. We recognized the upfront payment of $1&#160;million as revenue from transfer of intellectual property and other during the year ended December 31, 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LeaderMed has agreed to be responsible for funding the joint venture&#8217;s operations, development and commercialization efforts and, together with its syndicate partners, initially invested $11&#160;million in exchange for a 53% ownership interest. We retain full rights to oxyntomodulin and Factor VIIa-CTP in all other geographies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CAMP4 Therapeutics</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2021, we entered into an exclusive license agreement (the &#8220;CAMP4 Agreement&#8221;) with CAMP4, pursuant to which we granted to CAMP4 an exclusive license to develop, manufacture, commercialize or improve therapeutics utilizing the AntagoNAT technology, an oligonucleotide platform developed under OPKO CURNA, which includes the molecule for the treatment of Dravet syndrome, together with any derivative or modification thereof (the &#8220;Licensed Compound&#8221;) and any pharmaceutical product that comprises or contains the Licensed Compound, alone or in combination with one or more other active ingredients (&#8220;Licensed Product&#8221;), worldwide. The CAMP4 Agreement grant covers human pharmaceutical, prophylactic, and therapeutic and certain diagnostic uses.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received an initial upfront payment of $1.5&#160;million and 3,373,008 shares of CAMP4&#8217;s Series A Prime Preferred Stock (&#8220;Preferred Stock&#8221;), which equates to approximately 9% of the outstanding shares of CAMP4, and we are eligible to receive up to $3.5&#160;million in development milestone payments for Dravet syndrome products, and $4&#160;million for non-Dravet syndrome products, as well as sales milestones of up to $90&#160;million for Dravet syndrome products and up to $90&#160;million for non-Dravet syndrome products. We may also receive double digit royalty payments on the net sales of royalty bearing products, subject to adjustment. In addition, upon achievement of certain development milestones, we will be eligible to receive equity consideration of up to 5,782,299 shares of Preferred Stock in connection with Dravet syndrome products and up to 1,082,248 shares of Preferred Stock in connection with non-Dravet syndrome products. In connection with our acquisition of CURNA, we agreed to pay future consideration to the sellers upon the achievement of certain events. As a result of our execution of the CAMP4 Agreement, we will have to pay a percentage of any payments received under the CAMP4 Agreement to the former CURNA stockholders. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the CAMP4 Agreement will remain in effect on a Licensed Product-by-Licensed Product and country by-country basis until such time as the royalty term expires for a Licensed Product in a country, and expires in its entirety upon the expiration of the royalty term for the last Licensed Product in the last country. CAMP4&#8217;s royalty obligations expire on the later of (i) the expiration, invalidation or abandonment date of the last patent right in connection with the royalty bearing product, or (ii) ten (10) years after a royalty bearing product&#8217;s first commercial sale in a country. In addition to termination rights for material breach and bankruptcy, CAMP4 is permitted to terminate the Agreement after a specified notice period.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NICOYA Macau Limited</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, EirGen, our wholly owned subsidiary, and NICOYA Macau Limited (&#8220;Nicoya&#8221;), a Macau corporation and an affiliate of NICOYA Therapeutics, entered into a Development and License Agreement (the &#8220;Nicoya Agreement&#8221;) granting Nicoya the exclusive rights for the development and commercialization of extended release calcifediol (the &#8220;Nicoya Product&#8221;) in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan (collectively, the &#8220;Nicoya Territory&#8221;). Extended release calcifediol is marketed in the U.S. by OPKO under the tradename </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The license grant to Nicoya covers the therapeutic and preventative use of the Nicoya Product for SHPT in non-dialysis and hemodialysis chronic kidney disease patients (the &#8220;Nicoya Field&#8221;).</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EirGen has received an initial upfront payment of $5&#160;million and is eligible to receive an additional $5&#160;million upon the first to occur of (A) a predetermined milestone and (B) the first anniversary of the effective date. EirGen is also eligible to receive up to an additional aggregate amount of $115&#160;million upon the achievement of certain development, regulatory and sales-based milestones by Nicoya for the Nicoya Product in the Nicoya Territory. EirGen will also receive tiered, double digit royalty payments at rates in the low double digits on net product sales within the Nicoya Territory and in the Nicoya Field.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nicoya will, at its sole cost and expense, be responsible for performing all development activities necessary to obtain all regulatory approvals for the Nicoya Product in the Nicoya Territory and for all commercial activities pertaining to the Nicoya Product in the Nicoya Territory.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Nicoya Agreement will remain in effect until such time as all royalty payment terms and extended payment terms have expired, and Nicoya shall have no further payment obligations to EirGen under the terms of the Nicoya Agreement. Nicoya&#8217;s royalty obligations expire on the later of (i) expiration of the last to expire valid patent claim </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">covering the Nicoya Product sold in the Nicoya Territory, (ii) expiration of all regulatory and data exclusivity applicable to the Nicoya Product in the Nicoya Territory, and (iii) on a product-by-product basis, ten (10) years after such Nicoya Product&#8217;s first commercial sale in the Nicoya Territory. In addition to termination rights for material breach and bankruptcy, Nicoya is permitted to terminate the Nicoya Agreement after a specified notice period.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vifor Fresenius Medical Care Renal Pharma Ltd</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, EirGen and Vifor Fresenius Medical Care Renal Pharma Ltd. (&#8220;VFMCRP&#8221;) entered into a Development and License Agreement (the &#8220;VFMCRP Agreement&#8221;) for the development and commercialization of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Product&#8221;) worldwide, except for (i) the U.S., (ii) any country in Central America or South America (including Mexico), (iii) Russia, (iv) China, (v) South Korea, (vi) Ukraine, (vii) Belorussia, (viii) Azerbaijan, (ix) Kazakhstan, (x) Taiwan (xi) the Middle East, and (xii) all countries of Africa (the &#8220;VFMCRP Territory&#8221;), as amended.  The license to VFMCRP potentially covers all therapeutic and prophylactic uses of the Product in human patients (the &#8220;VFMCRP Field&#8221;), provided that initially the license is for the use of the Product for the treatment or prevention of SHPT related to patients with CKD and vitamin D insufficiency/deficiency (the &#8220;VFMCRP Initial Indication&#8221;).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022 we recognized a milestone payment of $3.0&#160;million in revenue from transfer of intellectual property and other for the first sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May 23, 2021, we entered into an amendment to the VFMCRP Agreement pursuant to which the parties thereto agreed to include Japan as part of the VFMCRP Territory.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May 5, 2020, we entered into an amendment to the VFMCRP Agreement pursuant to which the parties agreed to exclude Mexico, South Korea, the Middle East and all of the countries of Africa from the VFMCRP Territory.  In addition, the parties agreed to certain amendments to the milestone structure and to reduce minimum royalties payable.  As revised, the Company has received a $3&#160;million payment triggered by the first marketing approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe and is eligible to receive up to an additional $17&#160;million in regulatory milestones and $207&#160;million in milestone payments tied to launch, pricing and sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and tiered, double-digit royalties.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to share responsibility with VFMCRP for the conduct of trials specified within an agreed-upon development plan, with each company leading certain activities within the plan.  EirGen will lead the manufacturing activities within and outside the VFMCRP Territory and the commercialization activities outside the VFMCRP Territory and outside the VFMCRP Field in the VFMCRP Territory and VFMCRP will lead the commercialization activities in the VFMCRP Territory and the VFMCRP Field.  For the initial development plan, the companies have agreed to certain cost sharing arrangements.  VFMCRP will be responsible for all other development costs that VFMCRP considers necessary to develop the Product for the use of the Product for the VFMCRP Initial Indication in the VFMCRP Territory in the VFMCRP Field except as otherwise provided in the VFMCRP Agreement.  The first of the clinical studies provided for in the development activities commenced in September 2018.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the VFMCRP Agreement, the parties entered into a letter agreement pursuant to which EirGen granted to VFMCRP an exclusive option (the &#8220;Option&#8221;) to acquire an exclusive license under certain EirGen patents and technology to use, import, offer for sale, sell, distribute and commercialize the Product in the U.S. solely for the treatment of SHPT in dialysis patients with CKD and vitamin D insufficiency (the &#8220;Dialysis Indication&#8221;).  Upon exercise of the Option, VFMCRP will reimburse EirGen for all of the development costs incurred by EirGen with respect to the Product for the Dialysis Indication in the U.S.  VFMCRP would also pay EirGen up to an additional aggregate amount of $555&#160;million of sales-based milestones upon the achievement of certain milestones and would be obligated to pay royalties at percentage rates that range from the mid-teens to the mid-twenties on sales of the Product in the U.S. for the Dialysis Indication.  To date, VFMCRP has not exercised its option.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received for regulatory milestones and sales milestones are non-refundable.  The regulatory milestones are payable if and when VFMCRP obtains approval from certain regulatory authorities and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met.  We account for the sales milestones as royalties and sales milestones payments will be recognized as revenue in the period in which the associated milestone is achieved or sales occur, assuming all other revenue recognition criteria are met.    </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2014, we entered into an exclusive worldwide agreement (the &#8220;Pfizer Agreement&#8221;) with Pfizer for the development and commercialization of our long-acting Somatrogon (hGH-CTP) for the treatment of growth hormone </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deficiency (&#8220;GHD&#8221;) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (the &#8220;Pfizer Transaction&#8221;).  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2022, the European Commission and Ministry of Health, Labour and Welfare in Japan approved the next-generation long-acting recombinant human growth hormone NGENLA (Somatrogon), a once-weekly injection to treat pediatric growth hormone deficiency, and we received pricing approvals in Germany and Japan. With the achievement of these milestones, we are entitled to receive an aggregate of $85.0&#160;million in milestone payments. Further, Canada and Australia approved NGENLA in October and November of 2021, respectively.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the FDA issued a Complete Response Letter for the BLA for Somatrogon (hGH-CTP). Pfizer and OPKO are evaluating the FDA&#8217;s comments and will work with the agency to determine the best path forward for Somatrogon (hGH-CTP) in the United States.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we entered into an Amended and Restated Development and Commercialization License Agreement (the &#8220;Restated Pfizer Agreement&#8221;) with Pfizer, effective January 1, 2020, pursuant to which the parties agreed, among other things, to share all costs for Manufacturing Activities, as defined in the Restated Pfizer Agreement, for developing a licensed product for the three indications included in the Restated Agreement.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2019, we and Pfizer announced that the global phase 3 trial evaluating Somatrogon dosed once-weekly in prepubertal children with GHD met its primary endpoint of non-inferiority to daily Genotropin&#174; (somatropin) for injection, as measured by annual height velocity at 12 months.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Pfizer Transaction, as restated, we received non-refundable and non-creditable upfront payments of $295.0 million and are eligible to receive up to an additional $275.0 million upon the achievement of certain regulatory milestones.  Pfizer received the exclusive license to commercialize Somatrogon worldwide.  In addition, we are eligible to receive initial tiered royalty payments associated with the commercialization of Somatrogon for adult GHD with percentage rates ranging from the high teens to mid-twenties.  Upon the launch of Somatrogon for pediatric GHD in certain major markets, the royalties will transition to regional, tiered gross profit sharing for both Somatrogon and Pfizer&#8217;s Genotropin&#174;.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement with Pfizer will remain in effect until the last sale of the licensed product, unless earlier terminated as permitted under the Pfizer Agreement.  In addition to termination rights for material breach and bankruptcy, Pfizer is permitted to terminate the Pfizer Agreement in its entirety, or with respect to one or more world regions, without cause after a specified notice period.  If the Pfizer Agreement is terminated by us for Pfizer&#8217;s uncured material breach, or by Pfizer without cause, provision has been made for transition of product and product responsibilities to us for the terminated regions, as well as continued supply of product by Pfizer or transfer of supply to us in order to support the terminated regions.       </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the non-refundable $295.0 million upfront payments as revenue as the research and development services were completed and as of both March 31, 2022 and December 31, 2021, we had no contract liabilities related to the Pfizer Transaction.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pfizer Transaction includes milestone payments of $275.0 million upon the achievement of certain milestones.  The milestones range from $20.0 million to $90.0 million each and are based on achievement of regulatory approval in the U.S. and regulatory approval and price approval in other major markets.  The milestone payments will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met.  To date, no revenue has been recognized related to the achievement of the milestones. See Note 17, Subsequent Events.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed strategic deals with numerous institutions and commercial partners.  In connection with these agreements, upon the achievement of certain milestones we are obligated to make certain payments and have royalty obligations upon sales of products developed under the license agreements.  At this time, we are unable to estimate the timing and amounts of payments as the obligations are based on future development of the licensed products.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_StrategicAlliancesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic Alliances [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_StrategicAlliancesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513701544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTS</a></td>
<td class="text">SEGMENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our operations in two reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of our clinical and genomics laboratory operations through BioReference and our point-of-care operations.  There are no significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is no inter-segment allocation of interest expense and income taxes.</span><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,599&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,951&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from products:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from transfer of intellectual property and other: </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,420)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,814&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from investment in investees:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,306,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,399,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>No customer represented more than 10% of our total consolidated revenue during the three months ended March 31, 2022 and 2021. As of March&#160;31, 2022 and December&#160;31, 2021, no customer represented more than 10% of our accounts receivable balance.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116518486216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating leases for office space, laboratory operations, research and development facilities, manufacturing locations, warehouses and certain equipment.  We determine if a contract contains a lease at inception or modification of a contract.  Our leases generally do not provide an implicit interest rate, and we therefore use our incremental borrowing rate as the discount rate when measuring operating lease liabilities.  The incremental borrowing rate represents an estimate of the interest rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment.  We used the incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date.  Many of our leases contain rental escalation, renewal options and/or termination options that are factored into our determination of lease payments as appropriate.  Variable lease payment amounts that cannot be determined at the commencement of the lease are not included in the right-to-use assets or liabilities.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the use of permitted practical expedients of not recording leases on our Consolidated Balance Sheet when the leases have terms of 12 months or less, and we elected not to separate nonlease components from lease components and instead account for each separate lease component and the nonlease components associated with that lease component as a single lease component.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of March 31, 2022 and December 31, 2021:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMy0wLTEtMS0zNTMzMA_c6bd7dfc-1515-470c-8640-321ba294369d">Finance lease assets</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of March 31, 2022:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 1, 2022 through December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total undiscounted future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Difference between lease payments and discounted lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense under operating leases and finance leases was $4.6 million and $0.7&#160;million, respectively, for the three months ended March 31, 2022, which includes $0.4 million of variable lease costs. Expense under operating leases and finance leases was $4.5 million and $0.6 million, respectively, for the three months ended March 31, 2021, which includes $0.7 million of variable lease costs. Operating lease costs and finance lease costs are included within Operating loss in the Condensed Consolidated Statement of Operations. Short-term lease costs were not material.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information is as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash out flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating leases for office space, laboratory operations, research and development facilities, manufacturing locations, warehouses and certain equipment.  We determine if a contract contains a lease at inception or modification of a contract.  Our leases generally do not provide an implicit interest rate, and we therefore use our incremental borrowing rate as the discount rate when measuring operating lease liabilities.  The incremental borrowing rate represents an estimate of the interest rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment.  We used the incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date.  Many of our leases contain rental escalation, renewal options and/or termination options that are factored into our determination of lease payments as appropriate.  Variable lease payment amounts that cannot be determined at the commencement of the lease are not included in the right-to-use assets or liabilities.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the use of permitted practical expedients of not recording leases on our Consolidated Balance Sheet when the leases have terms of 12 months or less, and we elected not to separate nonlease components from lease components and instead account for each separate lease component and the nonlease components associated with that lease component as a single lease component.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of March 31, 2022 and December 31, 2021:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMy0wLTEtMS0zNTMzMA_c6bd7dfc-1515-470c-8640-321ba294369d">Finance lease assets</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of March 31, 2022:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 1, 2022 through December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total undiscounted future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Difference between lease payments and discounted lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense under operating leases and finance leases was $4.6 million and $0.7&#160;million, respectively, for the three months ended March 31, 2022, which includes $0.4 million of variable lease costs. Expense under operating leases and finance leases was $4.5 million and $0.6 million, respectively, for the three months ended March 31, 2021, which includes $0.7 million of variable lease costs. Operating lease costs and finance lease costs are included within Operating loss in the Condensed Consolidated Statement of Operations. Short-term lease costs were not material.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information is as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash out flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513916456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 18, 2022, Sema4 and OPKO announced they had entered into a definitive agreement pursuant to which Sema4 has agreed to acquire OPKO&#8217;s wholly owned subsidiary, GeneDx, a leader in genomic testing and analysis. The GeneDx Transaction closed on April 29, 2022.  Under the terms of the GeneDx Merger Agreement, Sema4 acquired GeneDx for an upfront payment of $150&#160;million in cash, subject to adjustments, plus 80.0&#160;million shares in Sema4, with up to an additional $150&#160;million revenue-based milestones over the next two years (which will be payable in cash or Sema4 shares at Sema4&#8217;s discretion). Based on the closing stock price of Sema4 as of April 29, 2022, the total upfront consideration represents approximately $322&#160;million, and the total aggregate consideration including potential milestones is approximately $472&#160;million.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2022, Pfizer notified OPKO that NGENLA (Somatrogon), a once-weekly injection to treat pediatric growth hormone deficiency, has received pricing approval in Germany and Japan. NGENLA was granted marketing authorization by the Ministry of Health, Labour and Welfare in Japan and by the European Commission in January and February of this year, respectively. With the achievement of these milestones, we are entitled to receive an aggregate of $85.0&#160;million in milestone payments.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 9, 2022, the Company entered into an Agreement and Plan of Merger with Orca Acquisition Sub, Inc. (&#8220;Merger Sub &#8220;, a subsidiary of the Company formed for the purposes of this transaction), ModeX Therapeutics, Inc., (&#8220;ModeX&#8221; or &#8220;Seller&#8221;) and Sellers&#8217; representative (the &#8220;Merger Agreement&#8221;), pursuant to which Merger Sub was merged with and into ModeX, with ModeX becoming a wholly owned subsidiary of the Company (the &#8220;Merger&#8221;). The Company paid an aggregate of $300&#160;million for all of the outstanding equity of ModeX, as adjusted  by customary adjustments. The consideration paid at closing consisted of shares of our common stock, which was valued based on the average of the daily volume-weighted average price over the thirty (30) trading days prior to the date that is two (2) trading days prior to the signing of the Merger Agreement . In addition, the Company has made a number of management changes in connection with the Merger. Elias Zerhouni, M.D., Gary Nabel, M.D., PhD.,  and Alexis Borisy were appointed to the Board of the Company, with Dr. Zerhouni appointed as the Vice Chair. Elizabeth Nabel, one of the founders of ModeX, is the new Chief Medical Officer of the Company.  Dr. Gary Nabel has been named the CEO of ModeX and Chief Innovation Officer of the Company and Dr. Zerhouni has been named the President of the Company.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed all events and transactions that occurred after the March&#160;31, 2022 Condensed Consolidated Balance Sheet date, through the time of filing this Quarterly Report on Form 10-Q.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116516288904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text">Basis of presentation.  The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all information and notes required by GAAP for complete financial statements.  In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Company&#8217;s results of operations, financial position and cash flows have been made.  The results of operations and cash flows for the three months ended March 31, 2022 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2022 or any other future periods.  The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text">Principles of consolidation.  The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and our wholly-owned subsidiaries.  All intercompany accounts and transactions are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and </span>liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from these estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">Cash and cash equivalents.  Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase.  We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents.  These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Inventories are valued at the lower of cost and net realizable value.  Cost is determined by the first-in, first-out method.  We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value.  Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which are used in our testing laboratories.  Inventory obsolescence expense for the three months ended March 31, 2022 and 2021 was $0.6&#160;million and $3.1 million, respectively.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and intangible assets</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting.  Refer to Note 5.  Goodwill, in-process research and development (&#8220;IPR&amp;D&#8221;) and other intangible assets acquired in business combinations, licensing and other transactions was $1.4 billion at both March&#160;31, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values.  Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill.  At acquisition, we generally determine the fair value of intangible assets, including IPR&amp;D, using the &#8220;income method.&#8221;</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was $519.1&#160;million and $520.6&#160;million, respectively, at March&#160;31, 2022 and December&#160;31, 2021, Assets held for sale includes $151.8&#160;million of goodwill related to GeneDx. Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.  We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing.  Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net intangible assets other than goodwill was $890.5 million and $911.9 million, including IPR&amp;D of $590.2&#160;million at December&#160;31, 2021, respectively.  Intangible assets are highly vulnerable to impairment charges, particularly newly acquired assets for recently launched products and IPR&amp;D.  Considering the high risk nature of research and development and the industry&#8217;s success rate of bringing developmental compounds to market, IPR&amp;D impairment charges may occur in future periods.  Estimating the fair value of IPR&amp;D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon obtaining regulatory approval, IPR&amp;D assets are then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life.  If the project is abandoned, the IPR&amp;D asset is charged to expense.  Finite lived intangible assets are tested for impairment when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.  The testing includes a comparison of the carrying amount of the asset to its estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our estimates and assumptions in testing goodwill and other intangible assets, including IPR&amp;D, for</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impairment are reasonable and otherwise consistent with assumptions that marketplace participants would use in their estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of fair value. However, if future results are not consistent with our estimates and assumptions, including as a result of the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 global pandemic, then we may be exposed to additional impairment charges, which could be material.  We submitted the initial BLA with the FDA for approval of Somatrogon (hGH-CTP) in the United States and Pfizer received a Complete Response Letter in January 2022. Pfizer and OPKO are evaluating the FDA&#8217;s comments and will work with the agency to determine the best path forward for Somatrogon (hGH-CTP) in the United States.</span></div>In the first quarter of 2022, we reclassified $590.0&#160;million of IPR&amp;D related to Somatrogon (hGH-CTP) from IPR&amp;D in our Condensed Consolidated Balance Sheet upon the approval of NGENLA (Somatrogon) in Europe and Japan. The assets will be amortized on a straight-line basis over their estimated useful life of approximately 12 years.We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years.  We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments.  Investments that are considered equity securities as of March&#160;31, 2022 and December&#160;31, 2021 are predominately carried at fair value.  Our debt under the credit agreement with JPMorgan Chase Bank, N.A. approximates fair value due to the variable rate of interest applicable to such debt.</span>In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates.  The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts.  Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Contingent consideration</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense.  Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability.  Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions.  The assumptions used in estimating fair value require significant judgment.  The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative financial instruments</a></td>
<td class="text">Derivative financial instruments.  We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges.  For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At March&#160;31, 2022 and December&#160;31, 2021, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognized all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Property, plant and equipment are recorded at cost or fair value if acquired in a business combination.  Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases.  The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, and automobiles - 3-5 years.  Expenditures for repairs and maintenance are charged to expense as incurred.  Depreciation expense was $5.8 million and $7.4 million for three months ended March 31, 2022 and 2021, respectively. Assets held under finance leases are included within Property, plant and equipment, net in our Consolidated Balance Sheets and are amortized over the shorter of their useful lives or the expected term of their related leases.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of long-lived assets.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment and assets held for sale, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax </span><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment. Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in various countries and tax jurisdictions globally.&#160; For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results.&#160; For the three months ended March 31, 2022, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition and shipping and handling costs</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 606&#8221;).  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.  </span>We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.  At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct.  We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shipping and handling costs.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not charge customers for shipping and handling costs.  Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk and allowance for credit losses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of credit risk and allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable.  Substantially all of our accounts receivable are with either companies in the healthcare industry or patients.  However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</span>While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Allowance for doubtful accounts</a></td>
<td class="text">We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer&#8217;s ability to pay.  Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Equity-based compensation</a></td>
<td class="text">Equity-based compensation.  We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award.  That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award.  We record excess tax benefits realized from the exercise of stock options as cash flows from operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include external and internal expenses.  External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs.  Research and development employee-related expenses include salaries, benefits and equity-based compensation expense.  Other internal research and </span><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.  We expense these costs in the period in which they are incurred.  We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received.  As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility, and which have no alternative future use.  For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed.  Once the development process has been completed the asset will be amortized over its remaining estimated useful life.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Our chief operating decision-maker (&#8220;CODM&#8221;) is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis.  We manage our operations in two reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rayaldee</span> product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of clinical and genomics laboratory operations through BioReference and point-of-care operations.  There are no significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is no inter-segment allocation of interest expense or income taxes.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The financial statements of certain of our foreign operations are measured using the local currency as the functional currency.  The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date and the local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods.  Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss). During the three months ended March 31, 2022 and 2021, we recorded $1.1&#160;million and $4.8&#160;million, respectively of transaction losses.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable interest entities</a></td>
<td class="text">Variable interest entities.  The consolidation of a variable interest entity (&#8220;VIE&#8221;) is required when an enterprise has a controlling financial interest.  A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">Investments.  We have made strategic investments in development stage and emerging companies.  We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees.  For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations.  Refer to Note 6.  For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently adopted accounting pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40).&#8221; ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2021, with early adoption permitted.   As required, we adopted ASU 2020-06 on January 1, 2022 and used the modified retrospective approach for all convertible debt instruments at the beginning of the period of adoptions.  Results for reporting periods beginning January 1, 2022 are presented under ASU 2020-06, while prior period amounts were not adjusted and continue to be reported in accordance with historic with accounting guidance. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the modified approach, entities will apply the guidance to all financial instruments that are outstanding as of the beginning of the year of adoption with the cumulative effect recognized as an adjustment to the opening balance of retained earnings. ASU 2020-06 eliminates the cash conversion and beneficial conversion feature models in ASC 470-20 that require an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of </span></div>equity. The adoption of ASU 2020-06 at January 1, 2022 resulted in an increase of the Convertible notes of $21.6&#160;million, a reduction of the Accumulated deficit of $17.5&#160;million and a reduction of Additional paid-in capital of $39.1&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513874664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock', window );">Composition of Certain Financial Statement Captions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,979)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,637&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumable supplies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: inventory reserve</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes recoverable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,274&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technologies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product registrations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338,294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320,820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890,498&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,683&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory received but not invoiced</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases short-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgages and other debts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,062&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Changes in Goodwill</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in Goodwill by reporting unit during the three months ended March 31, 2022.</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.619%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross goodwill  at January 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative impairment at January 1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CURNA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,827)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FineTech</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Biologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Chile</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Health Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transition Therapeutics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,421)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BioReference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">434,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(151,784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPKO Diagnostics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">710,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38,023)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153,333)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">519,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Composition of certain financial statement captions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513978008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract', window );"><strong>Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Accounting Method, Carrying Value and Underlying Equity in Net Assets of Unconsolidated Investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of March&#160;31, 2022 and December 31, 2021:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:46.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment type</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment Carrying Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Underlying Equity in Net Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment Carrying Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Underlying Equity in Net Assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable interest entity, equity method</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with no readily determinable fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants and options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Net Gains and Losses on Equity Securities</a></td>
<td class="text">Net gains and losses on our equity securities for the three months ended March 31, 2022, and 2021 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March&#160;31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity Securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gains and losses recognized during the period on equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net gains realized during the period on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,981)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized net gains and losses recognized during the period on equity securities still held at the reporting date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,162)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI http://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI http://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116512326120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, our debt consisted of the following:</span></div><div style="margin-top:9pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Convertible Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2033 Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chilean and Spanish lines of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long term portion of notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance sheet captions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lines of credit and notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LT notes payable included in long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,272&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Principal Amounts, Unamortized Discount and Net Carrying Amounts</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information related to the 2025 Notes which is included in our Condensed Consolidated Balance Sheet as of March&#160;31, 2022:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 Senior Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt Issuance Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,747)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,473)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adoption of ASU 2020-06</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,580&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,313)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022 and December&#160;31, 2021, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the 2025 Notes, the A&amp;R Credit Agreement and amounts outstanding under lines of credit described above) as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:59.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Summary of Lines of Credit</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.575%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.001%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(Dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Balance Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lender</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest&#160;rate&#160;on<br/>borrowings at <br/>March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit&#160;line<br/>capacity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JPMorgan Chase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Itau Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bank of Chile</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BICE Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scotiabank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Santander Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Security Bank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estado Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BCI Bank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corpbanca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Bank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consoorcio Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Banco De Sabadell</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Santander Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.82%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,672&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116513686216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Changes in Accumulated Other Comprehensive Loss, Net of Tax</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, changes in Accumulated other comprehensive loss, net of tax, were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.370%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,495)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:20.25pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(920)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,415)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116516036472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities measured at fair value on a recurring basis are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value measurements as of March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets for<br/>identical<br/>assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options/warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,191&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value measurements as of December&#160;31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets for<br/>identical<br/>assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options/warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,226&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Carrying Amount and Estimated Fair Value of Long-Term Debt</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and estimated fair value of our 2025 Notes, as well as the applicable fair value hierarchy tiers, are contained in the table below.  The fair value of the 2025 Notes is determined using inputs other than quoted prices in active markets that are directly observable.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="27" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of the Beginning and Ending Balances of Level 3 Assets</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of March&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent<br/>consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in results of operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,729&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of the Beginning and Ending Balances of Level 3 Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of March&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent<br/>consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in results of operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,729&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116515947240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Contracts (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Fair Values and Presentation of Derivative Financial Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair values and the presentation of our derivative financial instruments in the Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:36.491%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Component</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock options/warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses.  Unrealized (losses) on forward contracts are recorded in Accrued expenses.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(462)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Derivative Instrument Losses and Gains Recorded</a></td>
<td class="text">The following table summarizes the losses and gains recorded for the three and three months ended March 31, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative gain (loss):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock options/warrants </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116519124424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of Revenue from services by payor for the three months ended March 31, 2022 and 2021 was as follows:</span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three months ended March&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,829&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,951&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock', window );">Schedule of Product Sales Allowances and Accruals</a></td>
<td class="text">The following table presents an analysis of product sales allowances and accruals for the three months ended March 31, 2022 and 2021:<div style="margin-bottom:5pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chargebacks, discounts, rebates and fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Governmental </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Provision related to current period sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Credits or payments made</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,086)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales allowances and accruals as a percentage of gross </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62%</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chargebacks, discounts, rebates and fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Governmental </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Provision related to current period sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Credits or payments made</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales allowances and accruals as a percentage of gross </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rayaldee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Changes in Contractual Liabilities Balance</a></td>
<td class="text">Changes in the contractual liabilities balance during the three months ended March 31, 2022 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized in the period from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in contracts liability at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Product Sales Allowances And Accruals [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116514178680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Operations and Assets for Operating Segments and Geographic Information</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,599&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,951&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from products:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from transfer of intellectual property and other: </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,420)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,814&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from investment in investees:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,306,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,399,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116517749048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Lease Assets and Liabilities</a></td>
<td class="text">The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of March 31, 2022 and December 31, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMy0wLTEtMS0zNTMzMA_c6bd7dfc-1515-470c-8640-321ba294369d">Finance lease assets</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lease Liability Maturity</a></td>
<td class="text"><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of March 31, 2022:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 1, 2022 through December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total undiscounted future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Difference between lease payments and discounted lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Lease Liability Maturity</a></td>
<td class="text"><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of March 31, 2022:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 1, 2022 through December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total undiscounted future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Difference between lease payments and discounted lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Cash Flow Information</a></td>
<td class="text">Supplemental cash flow information is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the three months ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash out flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116515738376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Organization (Details)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 29, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>facility</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>employee</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_NumberofSalesEmployees', window );">Number of sales employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=opk_DetectGenomixMember', window );">Detect Genomix | Sema4 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued in business combination (in shares) | shares</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments', window );">Additional revenue-based milestones</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod', window );">Revenue-based milestone period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_BusinessCombinationUpfrontConsiderationTransferred', window );">Total upfront consideration transferred</a></td>
<td class="nump">$ 322.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total aggregate consideration</a></td>
<td class="nump">$ 472.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Waterford, Ireland Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_DisposalGroupNumberOfFacilitiesSold', window );">Number of facilities sold | facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration from sale of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Revenue-Based Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Revenue-Based Milestone Payments, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_BusinessCombinationUpfrontConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Upfront Consideration Transferred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_BusinessCombinationUpfrontConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_DisposalGroupNumberOfFacilitiesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Number of Facilities Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_DisposalGroupNumberOfFacilitiesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_NumberofSalesEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Sales Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_NumberofSalesEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_DetectGenomixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_DetectGenomixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=opk_Sema4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=opk_Sema4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=opk_WaterfordIrelandFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=opk_WaterfordIrelandFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116509500264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impact of COVID-19 (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_TestingTypeAxis=opk_GenomicTestMember', window );">Genomic Test</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>Unusual or Infrequent Item, or Both [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ChangeInTestingVolumePercent', window );">Change in testing volume (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_TestingTypeAxis=opk_RoutineClinicalTestMember', window );">Routine Clinical Test</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>Unusual or Infrequent Item, or Both [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ChangeInTestingVolumePercent', window );">Change in testing volume (as a percent)</a></td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>Unusual or Infrequent Item, or Both [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax', window );">Increase (decrease) in revenue</a></td>
<td class="num">$ (220.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_COVID19TestingMember', window );">COVID-19 Testing | COVID-19 Testing Revenue Concentration Risk | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>Unusual or Infrequent Item, or Both [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">7.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_COVID19TestingMember', window );">COVID-19 Testing | COVID-19 Testing Revenue Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>Unusual or Infrequent Item, or Both [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_ChangeInTestingVolumePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Testing Volume, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_ChangeInTestingVolumePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Revenue from Contract with Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_TestingTypeAxis=opk_GenomicTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_TestingTypeAxis=opk_GenomicTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_TestingTypeAxis=opk_RoutineClinicalTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_TestingTypeAxis=opk_RoutineClinicalTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_COVID19TestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_COVID19TestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=opk_COVID19TestingRevenueConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=opk_COVID19TestingRevenueConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116506810408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for inventory obsolescence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets', window );">Goodwill, in-process research and development and other intangible assets acquired</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">519,052<span></span>
</td>
<td class="nump">520,601<span></span>
</td>
<td class="nump">519,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 710,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net intangible assets other than goodwill</a></td>
<td class="nump">890,500<span></span>
</td>
<td class="nump">911,900<span></span>
</td>
<td class="nump">890,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">890,498<span></span>
</td>
<td class="nump">321,683<span></span>
</td>
<td class="nump">890,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_InProcessResearchandDevelopment', window );">In-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">590,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,025<span></span>
</td>
<td class="nump">12,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for credit losses</a></td>
<td class="nump">1,979<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision related to current period sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity</a></td>
<td class="nump">1,614,884<span></span>
</td>
<td class="nump">1,685,126<span></span>
</td>
<td class="nump">1,614,884<span></span>
</td>
<td class="nump">1,696,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,671,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity</a></td>
<td class="num">(1,549,951)<span></span>
</td>
<td class="num">(1,511,976)<span></span>
</td>
<td class="num">(1,549,951)<span></span>
</td>
<td class="num">(1,450,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,481,833)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity</a></td>
<td class="nump">3,191,139<span></span>
</td>
<td class="nump">3,222,487<span></span>
</td>
<td class="nump">3,191,139<span></span>
</td>
<td class="nump">$ 3,155,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,152,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=opk_DetectGenomixMember', window );">Detect Genomix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">151,800<span></span>
</td>
<td class="nump">$ 151,800<span></span>
</td>
<td class="nump">$ 151,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=opk_OPKOBiologicsMember', window );">OPKO Biologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_InProcessResearchandDevelopment', window );">In-process research and development</a></td>
<td class="num">$ (590,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (590,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Concentration Risk | Accounts Receivable | Federal and State Governments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk | Accounts Receivable | States, Cities and Other Municipalities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable | Individual Patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery, Medical and Other Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery, Medical and Other Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and Improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and Improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=opk_AutomobilesandAircraftMember', window );">Automobiles and Aircraft | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=opk_AutomobilesandAircraftMember', window );">Automobiles and Aircraft | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 590,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_InProcessResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-Process Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_InProcessResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=opk_DetectGenomixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=opk_DetectGenomixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=opk_OPKOBiologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=opk_OPKOBiologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=opk_FederalAndStateGovernmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=opk_FederalAndStateGovernmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=opk_StatesCitiesAndOtherMunicipalitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=opk_StatesCitiesAndOtherMunicipalitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=opk_IndividualPatientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=opk_IndividualPatientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=opk_AutomobilesandAircraftMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=opk_AutomobilesandAircraftMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116516247048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised', window );">Number of common stock warrant and common stock options exercised (in shares)</a></td>
<td class="nump">55,750<span></span>
</td>
<td class="nump">117,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment', window );">Number of common stock issued for stock warrant and stock options exercised (in shares)</a></td>
<td class="nump">55,750<span></span>
</td>
<td class="nump">117,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SharesSurrenderedInLieuOfCashPayment', window );">Shares surrendered in lieu of cash payment (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive potential shares (in shares)</a></td>
<td class="nump">57,985,925<span></span>
</td>
<td class="nump">74,623,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_SharesSurrenderedInLieuOfCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares surrendered in lieu of cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_SharesSurrenderedInLieuOfCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock warrant and common stock options exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issued for stock warrant and stock options exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116515454024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts receivable, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 214,734<span></span>
</td>
<td class="nump">$ 261,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowance for credit losses</a></td>
<td class="num">(1,979)<span></span>
</td>
<td class="num">(1,839)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">212,755<span></span>
</td>
<td class="nump">259,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventories, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventorySupplies', window );">Consumable supplies</a></td>
<td class="nump">48,740<span></span>
</td>
<td class="nump">39,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">46,594<span></span>
</td>
<td class="nump">44,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in-process</a></td>
<td class="nump">2,795<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">6,435<span></span>
</td>
<td class="nump">6,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: inventory reserve</a></td>
<td class="num">(5,158)<span></span>
</td>
<td class="num">(4,779)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">99,406<span></span>
</td>
<td class="nump">86,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other current assets and prepaid expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_TaxesRecoverableCurrent', window );">Taxes recoverable</a></td>
<td class="nump">6,105<span></span>
</td>
<td class="nump">5,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Prepaid expenses</a></td>
<td class="nump">8,171<span></span>
</td>
<td class="nump">10,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">1,731<span></span>
</td>
<td class="nump">4,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">2,435<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">4,832<span></span>
</td>
<td class="nump">6,195<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">23,274<span></span>
</td>
<td class="nump">27,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(338,294)<span></span>
</td>
<td class="num">(320,820)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">890,498<span></span>
</td>
<td class="nump">321,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_InventoryReceivedNotInvoicedCurrent', window );">Inventory received but not invoiced</a></td>
<td class="nump">22,811<span></span>
</td>
<td class="nump">40,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AccruedCommitmentsandContingenciesCurrent', window );">Commitments and contingencies</a></td>
<td class="nump">26,940<span></span>
</td>
<td class="nump">27,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee benefits</a></td>
<td class="nump">50,332<span></span>
</td>
<td class="nump">45,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AccruedClinicalTrialsCurrent', window );">Clinical trials</a></td>
<td class="nump">4,167<span></span>
</td>
<td class="nump">4,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance leases short-term</a></td>
<td class="nump">2,451<span></span>
</td>
<td class="nump">2,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">2,717<span></span>
</td>
<td class="nump">2,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">47,153<span></span>
</td>
<td class="nump">69,299<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">157,316<span></span>
</td>
<td class="nump">193,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrentAbstract', window );"><strong>Other long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">2,242<span></span>
</td>
<td class="nump">2,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Mortgages and other debts payable</a></td>
<td class="nump">1,973<span></span>
</td>
<td class="nump">2,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance leases long-term</a></td>
<td class="nump">3,865<span></span>
</td>
<td class="nump">2,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent', window );">Other</a></td>
<td class="nump">7,374<span></span>
</td>
<td class="nump">7,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">15,658<span></span>
</td>
<td class="nump">15,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">314,324<span></span>
</td>
<td class="nump">314,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">832,727<span></span>
</td>
<td class="nump">246,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">49,774<span></span>
</td>
<td class="nump">49,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Covenants not to compete</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">12,917<span></span>
</td>
<td class="nump">12,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">5,766<span></span>
</td>
<td class="nump">5,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=opk_ProductRegistrationsMember', window );">Product registrations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">7,251<span></span>
</td>
<td class="nump">6,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">$ 6,033<span></span>
</td>
<td class="nump">$ 6,128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_AccruedClinicalTrialsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_AccruedClinicalTrialsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_AccruedCommitmentsandContingenciesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Commitments and Contingencies, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_AccruedCommitmentsandContingenciesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_InventoryReceivedNotInvoicedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory Received, Not Invoiced, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_InventoryReceivedNotInvoicedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_TaxesRecoverableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Taxes Recoverable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_TaxesRecoverableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventorySupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventorySupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations and noncurrent portion of deferred revenue not separately disclosed in the balance sheet.  Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=opk_ProductRegistrationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=opk_ProductRegistrationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116515615416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 519,052<span></span>
</td>
<td class="nump">$ 710,408<span></span>
</td>
<td class="nump">$ 520,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">890,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_InProcessResearchandDevelopment', window );">In-Process Research and Development</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(590,200)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=opk_DetectGenomixMember', window );">Detect Genomix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">151,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=opk_OPKOBiologicsMember', window );">OPKO Biologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_InProcessResearchandDevelopment', window );">In-Process Research and Development</a></td>
<td class="nump">$ 590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=opk_CovenantsNotToCompeteMember', window );">Covenants not to compete</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful lives</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_InProcessResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-Process Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_InProcessResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=opk_DetectGenomixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=opk_DetectGenomixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=opk_OPKOBiologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=opk_OPKOBiologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=opk_CovenantsNotToCompeteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=opk_CovenantsNotToCompeteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116508933368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions - Changes in Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 519,052<span></span>
</td>
<td class="nump">$ 710,408<span></span>
</td>
<td class="nump">$ 520,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative impairment at January 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,023)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="num">(153,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">519,052<span></span>
</td>
<td class="nump">710,408<span></span>
</td>
<td class="nump">520,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=opk_BioReferenceMember', window );">BioReference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">283,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">283,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember', window );">Pharmaceutical | CURNA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative impairment at January 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,827)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember', window );">Pharmaceutical | Rayaldee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">84,853<span></span>
</td>
<td class="nump">86,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative impairment at January 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="num">(1,701)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">84,853<span></span>
</td>
<td class="nump">86,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember', window );">Pharmaceutical | FineTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative impairment at January 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember', window );">Pharmaceutical | OPKO Biologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">139,784<span></span>
</td>
<td class="nump">139,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative impairment at January 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">139,784<span></span>
</td>
<td class="nump">139,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember', window );">Pharmaceutical | OPKO Chile</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">4,062<span></span>
</td>
<td class="nump">3,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative impairment at January 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">4,062<span></span>
</td>
<td class="nump">3,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember', window );">Pharmaceutical | OPKO Health Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">7,328<span></span>
</td>
<td class="nump">7,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative impairment at January 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">7,328<span></span>
</td>
<td class="nump">7,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember', window );">Pharmaceutical | OPKO Mexico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative impairment at January 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember', window );">Pharmaceutical | Transition Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative impairment at January 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember', window );">Diagnostics | BioReference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">283,025<span></span>
</td>
<td class="nump">434,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative impairment at January 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="num">(151,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">283,025<span></span>
</td>
<td class="nump">434,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember', window );">Diagnostics | OPKO Diagnostics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative impairment at January 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_BioReferenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_BioReferenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_CURNAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_CURNAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_EirGenPharmaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_EirGenPharmaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_FineTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_FineTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_OPKOBiologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_OPKOBiologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_OpkoChileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_OpkoChileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_OPKOHealthEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_OPKOHealthEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_OPKOMexicoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_OPKOMexicoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_TransitionTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_TransitionTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_OpkoDiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_OpkoDiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116512802008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract', window );"><strong>Investment Carrying Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentExcludingVariableInterestEntity', window );">Equity method investments</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">$ 263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentVariableInterestEntity', window );">Variable interest entity, equity method</a></td>
<td class="nump">773<span></span>
</td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">3,064<span></span>
</td>
<td class="nump">4,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities with no readily determinable fair value</a></td>
<td class="nump">5,403<span></span>
</td>
<td class="nump">5,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_StockOptionandWarrantInvestments', window );">Warrants and options</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Total carrying value of investments</a></td>
<td class="nump">9,472<span></span>
</td>
<td class="nump">10,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract', window );"><strong>Underlying Equity in Net Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets', window );">Equity method investment, underlying equity in net assets</a></td>
<td class="nump">4,497<span></span>
</td>
<td class="nump">3,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets', window );">Variable interest entity, equity method, underlying equity in net assets</a></td>
<td class="nump">$ 2,772<span></span>
</td>
<td class="nump">$ 3,043<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentExcludingVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Excluding Variable Interest Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentExcludingVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Variable Interest Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Variable Interest Entity, Underlying Equity in Net Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_StockOptionandWarrantInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Option and Warrant Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_StockOptionandWarrantInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116507818120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 14, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets of equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,306,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,399,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities of equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,219<span></span>
</td>
<td class="nump">$ 545,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,962<span></span>
</td>
<td class="nump">$ 4,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_LeaderMedMember', window );">LeaderMed | LeaderMed Joint Venture | Corporate Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_NoncontrollingInterestSharesIssued', window );">Joint venture (in shares)</a></td>
<td class="nump">4,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest in joint venture (as a percent)</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_LeaderMedMember', window );">LeaderMed | LeaderMed Joint Venture | Corporate Joint Venture | Transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Equity Method Investment, Nonconsolidated Investee or Group of Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets of equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities of equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net losses of equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember', window );">Pharmsynthez</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocrystalMember', window );">Cocrystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which warrants may be converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NonInvasiveMonitoringSystemsInc.Member', window );">Non-Invasive Monitoring Systems, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember', window );">Neovasc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_InCellDxIncMember', window );">InCellDx, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which warrants may be converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_BioCardiaInc.Member', window );">BioCardia, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Equity security investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which warrants may be converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_XeneticBiosciencesInc.Member', window );">Xenetic Biosciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PhioPharmaceuticalsMember', window );">Phio Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Equity security investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_VBIVaccinesIncMember', window );">VBI Vaccines Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Equity security investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ChromaDexMember', window );">ChromaDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Equity security investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_EloxxPharmaceuticalsMember', window );">Eloxx Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Equity security investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CAMP4Member', window );">CAMP4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Equity security investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_HealthSnapMember', window );">HealthSnap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Equity security investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_DetectGenomixMember', window );">Detect Genomix | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Additional investment in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember', window );">Zebra | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Zebra | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Zebra | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_SharesReceivedAsGift', window );">Shares received as a gift (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Warrants and Options, and Variable Interest Entities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquitySecurityFVNIOwnershipPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Security, FV-NI, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquitySecurityFVNIOwnershipPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_NoncontrollingInterestSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_NoncontrollingInterestSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_SharesReceivedAsGift">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Received As Gift</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_SharesReceivedAsGift</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_LeaderMedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_LeaderMedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=opk_LeaderMedJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=opk_LeaderMedJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NonInvasiveMonitoringSystemsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NonInvasiveMonitoringSystemsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_InCellDxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_InCellDxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_BioCardiaInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_BioCardiaInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_XeneticBiosciencesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_XeneticBiosciencesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PhioPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PhioPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_VBIVaccinesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_VBIVaccinesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ChromaDexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ChromaDexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_EloxxPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_EloxxPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CAMP4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CAMP4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_HealthSnapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_HealthSnapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_DetectGenomixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_DetectGenomixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116518116984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Schedule of Net Gains and Losses on Equity Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAbstract', window );"><strong>Equity Securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains and losses recognized during the period on equity securities</a></td>
<td class="num">$ (1,162)<span></span>
</td>
<td class="nump">$ 2,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains realized during the period on equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized net gains and losses recognized during the period on equity securities still held at the reporting date</a></td>
<td class="num">$ (1,162)<span></span>
</td>
<td class="num">$ (201)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116508898936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 230,264<span></span>
</td>
<td class="nump">$ 205,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=opk_ConvertibleNotesMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">210,520<span></span>
</td>
<td class="nump">187,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=opk_LineOfCreditAndNotesAndLoansPayableCurrentMember', window );">Current portion of lines of credit and notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">17,412<span></span>
</td>
<td class="nump">14,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">LT notes payable included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">2,331<span></span>
</td>
<td class="nump">2,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">16,531<span></span>
</td>
<td class="nump">13,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable, Other Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt, current maturities</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">1,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, excluding current maturities</a></td>
<td class="nump">2,331<span></span>
</td>
<td class="nump">2,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=opk_ConvertibleSeniorNotesDue2025Member', window );">Convertible Senior Notes Due 2025 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">141,267<span></span>
</td>
<td class="nump">119,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=opk_A5ConvertibleNotesMember', window );">5% Convertible Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">66,203<span></span>
</td>
<td class="nump">65,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=opk_NotesDueFebruary12033Member', window );">Notes Due February 1, 2033 | Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 3,050<span></span>
</td>
<td class="nump">$ 3,050<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=opk_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=opk_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=opk_LineOfCreditAndNotesAndLoansPayableCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=opk_LineOfCreditAndNotesAndLoansPayableCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_ConvertibleSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_ConvertibleSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_A5ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_A5ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_NotesDueFebruary12033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_NotesDueFebruary12033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116498891848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">48 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 25, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 31, 2013</div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>day </div>
<div>institution </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>institution </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts outstanding under line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,531,000<span></span>
</td>
<td class="nump">$ 13,672,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,614,884,000<span></span>
</td>
<td class="nump">1,685,126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,696,514,000<span></span>
</td>
<td class="nump">$ 1,671,551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Remaining principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,264,000<span></span>
</td>
<td class="nump">205,272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519,052,000<span></span>
</td>
<td class="nump">$ 520,601,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 710,408,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_DebtInstrumentsNumberofFinancialInstitutions', window );">Number of financial institutions | institution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,549,951,000)<span></span>
</td>
<td class="num">$ (1,511,976,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,450,755,000)<span></span>
</td>
<td class="num">(1,481,833,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,191,139,000<span></span>
</td>
<td class="nump">3,222,487,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,155,648,000<span></span>
</td>
<td class="nump">$ 3,152,694,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,642,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,458,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=opk_BioReferenceMember', window );">BioReference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=opk_OPKOHealthEuropeMember', window );">OPKO Health Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | OPKO Health Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Variable interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | OPKO Health Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Variable interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Remaining principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,531,000<span></span>
</td>
<td class="nump">$ 13,672,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2367424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued on converted debt (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,051,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,144,825<span></span>
</td>
<td class="nump">21,144,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_GainLossOnConversionOfDebt', window );">Loss on conversion of the 2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable', window );">Shares issuable under debt agreement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable', window );">Decrease in shares issuable under debt agreement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,105,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ProceedsFromConvertibleDebtConversionFee', window );">Proceeds one-time nominal fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Remaining principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,267,000<span></span>
</td>
<td class="nump">$ 119,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible debt, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Equivalent redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period one | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period one | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days applicable conversion price | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible debt, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period two | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days applicable conversion price | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible debt, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Equivalent redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period three | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025 | Redemption period three | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days applicable conversion price | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 5% Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum', window );">Minimum conversion notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum', window );">Maximum conversion notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Remaining principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,203,000<span></span>
</td>
<td class="nump">65,525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Notes Due February 1, 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Remaining principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,267,000<span></span>
</td>
<td class="nump">119,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Remaining principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,643,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Notes Due February 1, 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Equivalent redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Notes | Notes Due February 1, 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Equivalent redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Remaining principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,050,000<span></span>
</td>
<td class="nump">$ 3,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts outstanding under line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | New Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Long-term line of credit, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | New Credit Agreement | 50% or more of revolving commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | New Credit Agreement | Less than or equal to 50% of revolving commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember', window );">Swingline | Line of Credit | New Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit | New Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR | Revolving Credit Facility | Line of Credit | New Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember', window );">LIBOR, First 12 Months | Revolving Credit Facility | Line of Credit | New Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember', window );">LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Convertible Debt | Notes Due February 1, 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued on converted debt (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,539,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Conversion Notice Threshold, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Conversion Notice Threshold, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Increase (Decrease) in Maximum Shares Issuable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Maximum Shares Issuable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_DebtInstrumentsNumberofFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of financial institutions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_DebtInstrumentsNumberofFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_GainLossOnConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Conversion of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_GainLossOnConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_ProceedsFromConvertibleDebtConversionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Convertible Debt, Conversion Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_ProceedsFromConvertibleDebtConversionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_BioReferenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_BioReferenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_OPKOHealthEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_OPKOHealthEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_ConvertibleSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_ConvertibleSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_A5ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_A5ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_NotesDueFebruary12033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_NotesDueFebruary12033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_NewCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_NewCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_LineOfCreditFacilityRevolvingCommitmentAxis=opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_LineOfCreditFacilityRevolvingCommitmentAxis=opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_LineOfCreditFacilityRevolvingCommitmentAxis=opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_LineOfCreditFacilityRevolvingCommitmentAxis=opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116508909640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Schedule of Notes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNetAbstract', window );"><strong>Debt Issuance Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">$ 281<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Beginning balance</a></td>
<td class="nump">205,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Ending balance</a></td>
<td class="nump">230,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>2025 Senior Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Beginning balance</a></td>
<td class="nump">144,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Ending balance</a></td>
<td class="nump">144,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountAbstract', window );"><strong>Discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Beginning balance</a></td>
<td class="num">(22,747)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNetAbstract', window );"><strong>Debt Issuance Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Beginning balance</a></td>
<td class="num">(2,473)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Ending balance</a></td>
<td class="num">(3,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Beginning balance</a></td>
<td class="nump">119,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Ending balance</a></td>
<td class="nump">141,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Accounting Standards Update 2020-06 | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>2025 Senior Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountAbstract', window );"><strong>Discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Beginning balance</a></td>
<td class="nump">22,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNetAbstract', window );"><strong>Debt Issuance Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Beginning balance</a></td>
<td class="num">(1,104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Beginning balance</a></td>
<td class="nump">$ 21,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116515530520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Lines of Credit (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 103,204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 16,531,000<span></span>
</td>
<td class="nump">$ 13,672,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_JPMorganChaseMember', window );">JPMorgan Chase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at March 31, 2022</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_ItauBankMember', window );">Itau Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at March 31, 2022</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 1,890,000<span></span>
</td>
<td class="nump">1,603,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_BankOfChileMember', window );">Bank of Chile</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at March 31, 2022</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 1,914,000<span></span>
</td>
<td class="nump">1,048,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_BiceBankMember', window );">BICE Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at March 31, 2022</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 1,156,000<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_ScotiabankMember', window );">Scotiabank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at March 31, 2022</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 2,203,000<span></span>
</td>
<td class="nump">567,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_SantanderBankMember', window );">Santander Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at March 31, 2022</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 3,068,000<span></span>
</td>
<td class="nump">503,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_SecurityMember', window );">Security Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at March 31, 2022</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 378,000<span></span>
</td>
<td class="nump">1,111,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_EstadoBankMember', window );">Estado Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at March 31, 2022</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 2,052,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 2,052,000<span></span>
</td>
<td class="nump">2,540,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_BCIBankMember', window );">BCI Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at March 31, 2022</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 2,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 2,740,000<span></span>
</td>
<td class="nump">2,515,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_Corpbanca1Member', window );">Corpbanca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at March 31, 2022</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,935,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_InternationalBankMember', window );">International Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at March 31, 2022</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 881,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_ConsoorcioBankMember', window );">Consoorcio Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at March 31, 2022</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 249,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_BancoDeSabadellMember', window );">Banco De Sabadell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at March 31, 2022</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 556,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=opk_SantanderBank2Member', window );">Santander Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest&#160;rate&#160;on borrowings at March 31, 2022</a></td>
<td class="nump">1.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 556,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">&#160;Balance Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_JPMorganChaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_JPMorganChaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_ItauBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_ItauBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_BankOfChileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_BankOfChileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_BiceBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_BiceBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_ScotiabankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_ScotiabankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_SantanderBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_SantanderBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_SecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_SecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_EstadoBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_EstadoBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_BCIBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_BCIBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_Corpbanca1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_Corpbanca1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_InternationalBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_InternationalBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_ConsoorcioBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_ConsoorcioBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_BancoDeSabadellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_BancoDeSabadellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=opk_SantanderBank2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=opk_SantanderBank2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116518181512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Notes Payable and Other Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Mortgage notes and other debt payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 15,658<span></span>
</td>
<td class="nump">$ 15,062<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">230,264<span></span>
</td>
<td class="nump">205,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=opk_NotesPayableAndOtherLongTermLiabilitiesMember', window );">Notes Payable and Other Long-Term Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Mortgage notes and other debt payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">1,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">2,331<span></span>
</td>
<td class="nump">2,642<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 3,213<span></span>
</td>
<td class="nump">$ 3,664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=opk_NotesPayableAndOtherLongTermLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=opk_NotesPayableAndOtherLongTermLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116515251784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">$ (920)<span></span>
</td>
<td class="num">$ (9,070)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(30,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">$ (31,415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116507759272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 3,064<span></span>
</td>
<td class="nump">$ 4,226<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">3,079<span></span>
</td>
<td class="nump">4,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">2,729<span></span>
</td>
<td class="nump">2,837<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">3,191<span></span>
</td>
<td class="nump">2,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">3,064<span></span>
</td>
<td class="nump">4,226<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">3,064<span></span>
</td>
<td class="nump">4,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">2,729<span></span>
</td>
<td class="nump">2,837<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">2,729<span></span>
</td>
<td class="nump">2,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Common stock options/warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Common stock options/warrants | Quoted prices in active markets for identical assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Common stock options/warrants | Significant other observable inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Common stock options/warrants | Significant unobservable inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Forward contracts</a></td>
<td class="nump">462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forward contracts | Quoted prices in active markets for identical assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Forward contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forward contracts | Significant other observable inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Forward contracts</a></td>
<td class="nump">462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forward contracts | Significant unobservable inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Forward contracts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116506748728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Carrying Amount and Estimated Fair Value of Long-Term Debt (Details) - Notes<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value disclosure</a></td>
<td class="nump">$ 164,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value disclosure</a></td>
<td class="nump">164,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value disclosure</a></td>
<td class="nump">$ 141,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116517787336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Level 3 Reconciliation (Details) - Contingent consideration<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 2,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract', window );"><strong>Change in fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Included in results of operations</a></td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact', window );">Foreign currency impact</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 2,729<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Currency Impact</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=opk_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=opk_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116506742344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 2,729<span></span>
</td>
<td class="nump">$ 2,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">LT notes payable included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116639168200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Contracts - Balance Sheet Component (Details) - Not Designated as Hedging Instrument - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Common Stock options/warrants | Investments, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Forward contracts | Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses. Unrealized (losses) on forward contracts are recorded in Accrued expenses.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset</a></td>
<td class="num">$ (462)<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116515190264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Contracts - Derivative Gains (Losses) (Details) - Not Designated as Hedging Instrument - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative gain (loss)</a></td>
<td class="num">$ (132)<span></span>
</td>
<td class="num">$ (439)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Common Stock options/warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative gain (loss)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative gain (loss)</a></td>
<td class="num">$ (131)<span></span>
</td>
<td class="num">$ (460)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116507452264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 25, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts outstanding under line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,672,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Reimbursement paid to related party for travel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_DetectGenomixMember', window );">Detect Genomix | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Additional investment in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember', window );">Pharmsynthez</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember', window );">Zebra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Stock ownership (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember', window );">Zebra | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember', window );">Neovasc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ChromadexCorporationMember', window );">ChromaDex Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Equity security investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocrystalMember', window );">COCP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NIMSMember', window );">NIMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Equity security investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_EloxxPharmaceuticalsMember', window );">Eloxx Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Equity security investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_BioCardiaInc.Member', window );">BioCardia, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_EquitySecurityFVNIOwnershipPercent', window );">Equity security investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_LeaderMedMember', window );">LeaderMed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Stock ownership (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_InCellDxIncMember', window );">InCellDx, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_FrostRealEstateHoldingsLLCMember', window );">Frost Real Estate Holdings LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_OperatingLeasesMonthlyPaymentsYearOne', window );">Lease payments per month in first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_OperatingLeasesMonthlyPaymentsYearFive', window );">Lease payments per month in fifth year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=opk_SharesReceivedUponClosingofXeneticTransactionMember', window );">Shares Received Upon Closing of Xenetic Transaction | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_RelatedPartyTransactionShares', window );">Shares received upon closing of transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=opk_MednaxServicesIncMember', window );">Mednax Services, Inc. | Detect Genomix | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Additional investment in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=opk_MuseumofScienceIncMember', window );">Museum of Science, Inc | Dr Frost and Mr Pfenniger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_RelatedPartyTransactionFutureContributions', window );">Related party future contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_RelatedPartyTransactionFutureContributionTerm', window );">Related party future contribution term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts outstanding under line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | New Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit&#160;line capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_EquitySecurityFVNIOwnershipPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Security, FV-NI, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_EquitySecurityFVNIOwnershipPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_OperatingLeasesMonthlyPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Monthly Payments, Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_OperatingLeasesMonthlyPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_OperatingLeasesMonthlyPaymentsYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Monthly Payments, Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_OperatingLeasesMonthlyPaymentsYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_RelatedPartyTransactionFutureContributionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Future Contribution, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_RelatedPartyTransactionFutureContributionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_RelatedPartyTransactionFutureContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Future Contributions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_RelatedPartyTransactionFutureContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_RelatedPartyTransactionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_RelatedPartyTransactionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_DetectGenomixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_DetectGenomixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ChromadexCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ChromadexCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NIMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NIMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_EloxxPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_EloxxPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_BioCardiaInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_BioCardiaInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_LeaderMedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_LeaderMedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_InCellDxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_InCellDxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_FrostRealEstateHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_FrostRealEstateHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=opk_SharesReceivedUponClosingofXeneticTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=opk_SharesReceivedUponClosingofXeneticTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=opk_MednaxServicesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=opk_MednaxServicesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=opk_MuseumofScienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=opk_MuseumofScienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_DrFrostandMrPfennigerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_DrFrostandMrPfennigerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=opk_NewCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=opk_NewCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116515595064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 22, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 05, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,729<span></span>
</td>
<td class="nump">$ 2,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Inventory received but not invoiced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation | Civil Investigative Demands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Current litigation liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation | Chancery Court of Delaware vs Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_LossContingencyMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation | Southern District of New York vs BioReference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount</a></td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">LT notes payable included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_LossContingencyMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_LossContingencyMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=opk_CivilInvestigativeDemandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=opk_CivilInvestigativeDemandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=opk_ChanceryCourtOfDelawareVsCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=opk_ChanceryCourtOfDelawareVsCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=opk_SouthernDistrictOfNewYorkVsBioReferenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=opk_SouthernDistrictOfNewYorkVsBioReferenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116498879336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">87 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 05, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Prior period performance obligation revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AccruedExpensePayorOverpaymentReimbursementLiability', window );">Overpayment reimbursement liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,219,000<span></span>
</td>
<td class="nump">545,165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_RayaldeeMember', window );">Rayaldee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,479,000<span></span>
</td>
<td class="nump">15,645,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,962,000<span></span>
</td>
<td class="nump">4,269,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember', window );">Products | Transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_PfizerMember', window );">Pfizer | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_PfizerMember', window );">Pfizer | Products | Transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_ViforFreseniusMedicalCarePharmaLtdMember', window );">VFMCRP | Products | Transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_AccruedExpensePayorOverpaymentReimbursementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expense, Payor Overpayment Reimbursement, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_AccruedExpensePayorOverpaymentReimbursementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_RayaldeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_RayaldeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_ViforFreseniusMedicalCarePharmaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_ViforFreseniusMedicalCarePharmaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116512359656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 329,219<span></span>
</td>
<td class="nump">$ 545,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">286,599<span></span>
</td>
<td class="nump">506,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_HealthInsurersMember', window );">Healthcare insurers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">95,779<span></span>
</td>
<td class="nump">164,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_GovernmentPayersMember', window );">Government payers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27,588<span></span>
</td>
<td class="nump">73,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_ClientPayersMember', window );">Client payers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">159,040<span></span>
</td>
<td class="nump">262,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_PatientsMember', window );">Patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 4,192<span></span>
</td>
<td class="nump">$ 5,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_HealthInsurersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_HealthInsurersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_GovernmentPayersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_GovernmentPayersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_ClientPayersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_ClientPayersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_PatientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_PatientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116515454296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision related to current period sales</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">329,219<span></span>
</td>
<td class="nump">545,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_RayaldeeMember', window );">Rayaldee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">10,152<span></span>
</td>
<td class="nump">11,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision related to current period sales</a></td>
<td class="nump">8,353<span></span>
</td>
<td class="nump">9,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments', window );">Credits or payments made</a></td>
<td class="num">(9,302)<span></span>
</td>
<td class="num">(10,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">9,203<span></span>
</td>
<td class="nump">11,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 13,479<span></span>
</td>
<td class="nump">$ 15,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales', window );">Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales</a></td>
<td class="nump">62.00%<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_ChargebacksDiscountsRebatesAndFeesMember', window );">Chargebacks, discounts, rebates and fees | Rayaldee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 2,014<span></span>
</td>
<td class="nump">$ 2,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision related to current period sales</a></td>
<td class="nump">3,215<span></span>
</td>
<td class="nump">3,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments', window );">Credits or payments made</a></td>
<td class="num">(3,641)<span></span>
</td>
<td class="num">(4,454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">1,588<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_GovernmentalMember', window );">Governmental | Rayaldee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">5,499<span></span>
</td>
<td class="nump">5,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision related to current period sales</a></td>
<td class="nump">4,869<span></span>
</td>
<td class="nump">5,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments', window );">Credits or payments made</a></td>
<td class="num">(5,086)<span></span>
</td>
<td class="num">(5,297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">5,282<span></span>
</td>
<td class="nump">6,209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_SalesReturnsMember', window );">Returns | Rayaldee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">2,639<span></span>
</td>
<td class="nump">3,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision related to current period sales</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments', window );">Credits or payments made</a></td>
<td class="num">(575)<span></span>
</td>
<td class="num">(419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 2,333<span></span>
</td>
<td class="nump">$ 3,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance For Doubtful Accounts, Provision For Allowance As Percent Of Gross Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance For Doubtful Accounts Receivable, Decrease, Credits Or Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_RayaldeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_RayaldeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_ChargebacksDiscountsRebatesAndFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_ChargebacksDiscountsRebatesAndFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_GovernmentalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_GovernmentalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_SalesReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_SalesReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116515865688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Changes in Contractual Liabilities Balance (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract with Customer, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116505650968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Alliances (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">87 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 14, 2021</div></th>
<th class="th"><div>Jul. 06, 2021</div></th>
<th class="th"><div>Jun. 18, 2021</div></th>
<th class="th"><div>May 05, 2020</div></th>
<th class="th"><div>Oct. 21, 2019</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,219,000<span></span>
</td>
<td class="nump">$ 545,165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Milestone revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_LeaderMedMember', window );">LeaderMed | LeaderMed Joint Venture | Corporate Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest in joint venture (as a percent)</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Initial investment in joint venture</a></td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by related parties (as a percent)</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_CAMP4Member', window );">CAMP4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementUpfrontPaymentShares', window );">Upfront payment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,373,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementPercentOfOutstandingShares', window );">Outstanding shares (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale', window );">Period following first commercial sale in a country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_NicoyaMember', window );">Nicoya</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment', window );">Upfront payment from development and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale', window );">Period after first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_PfizerMember', window );">Pfizer | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementMaximumMilestonePayments', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime', window );">Annual height velocity at point in time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementUpfrontPayment', window );">Initial upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeAgreementAdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Milestone revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_PfizerMember', window );">Pfizer | Products | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Pfizer | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Pfizer | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_MilestoneAxis=opk_PhaseThreeInitiationMember', window );">Phase Three Initiation | Nicoya</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment', window );">Upfront payment from development and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_MilestoneAxis=opk_RegulatoryAndDevelopmentMember', window );">Regulatory and Development | Nicoya</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment', window );">Milestone payment from development and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,962,000<span></span>
</td>
<td class="nump">4,269,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other | LeaderMed | LeaderMed Joint Venture | Corporate Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other | CAMP4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other | VFMCRP | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other | Pfizer | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_DravetSyndromeProductsMember', window );">Dravet Syndrome Products | CAMP4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementDevelopmentMilestonePayment', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementSalesMilestonePayment', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares', window );">Development milestone payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,782,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_NonDravetSyndromeProductsMember', window );">Non-Dravet Syndrome Products | CAMP4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementDevelopmentMilestonePayment', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementSalesMilestonePayment', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares', window );">Development milestone payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,082,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,658,000<span></span>
</td>
<td class="nump">$ 33,945,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_RegulatoryMilestonesMember', window );">Regulatory Milestones | EirGen Pharma Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementMaximumMilestonePayments', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_SalesMilestonesMember', window );">Sales Milestones | EirGen Pharma Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementMaximumMilestonePayments', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_ExclusiveOptionMember', window );">Exclusive Option | VFMCRP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementMaximumMilestonePayments', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 555,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeAgreementAdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Additional Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeAgreementAdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Annual Height Velocity at Point in Time</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Development Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementDevelopmentMilestonePaymentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Development Milestone Payment, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementDevelopmentMilestonePaymentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementMaximumMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementMaximumMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementPercentOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Percent of Outstanding Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementPercentOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementPeriodAfterFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Period After First Commercial Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementPeriodAfterFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Period Following First Commercial Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Sales Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementUpfrontPaymentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Upfront Payment, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementUpfrontPaymentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Development And License Agreement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Development And License Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_LeaderMedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_LeaderMedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=opk_LeaderMedJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=opk_LeaderMedJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_CAMP4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_CAMP4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_NicoyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_NicoyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_MilestoneAxis=opk_PhaseThreeInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_MilestoneAxis=opk_PhaseThreeInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_MilestoneAxis=opk_RegulatoryAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_MilestoneAxis=opk_RegulatoryAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_ViforFreseniusMedicalCarePharmaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_ViforFreseniusMedicalCarePharmaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_DravetSyndromeProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_DravetSyndromeProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_NonDravetSyndromeProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_NonDravetSyndromeProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_EirGenPharmaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_EirGenPharmaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_ExclusiveOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_ExclusiveOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116512459176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Inter-segment sales</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Inter-segment allocation of interest expense</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116507139800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Operations and Assets Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 329,219<span></span>
</td>
<td class="nump">$ 545,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(72,424)<span></span>
</td>
<td class="nump">38,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">27,814<span></span>
</td>
<td class="nump">19,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss from investment in investees</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">2,306,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,399,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">519,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 710,408<span></span>
</td>
<td class="nump">520,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">291,808<span></span>
</td>
<td class="nump">512,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">8,462<span></span>
</td>
<td class="nump">7,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CL', window );">Chile</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">16,339<span></span>
</td>
<td class="nump">14,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">Spain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7,109<span></span>
</td>
<td class="nump">5,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,558<span></span>
</td>
<td class="nump">2,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">Mexico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">2,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=opk_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(10,768)<span></span>
</td>
<td class="num">(9,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss from investment in investees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">55,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember', window );">Pharmaceutical | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(18,108)<span></span>
</td>
<td class="num">(19,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">15,402<span></span>
</td>
<td class="nump">7,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss from investment in investees</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">1,099,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,114,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">236,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember', window );">Diagnostics | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(43,548)<span></span>
</td>
<td class="nump">67,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">12,412<span></span>
</td>
<td class="nump">12,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss from investment in investees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">1,152,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">283,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">286,599<span></span>
</td>
<td class="nump">506,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | Pharmaceutical | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | Diagnostics | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">286,599<span></span>
</td>
<td class="nump">506,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">36,658<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products | Pharmaceutical | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">36,658<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products | Diagnostics | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,962<span></span>
</td>
<td class="nump">4,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other | Pharmaceutical | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,962<span></span>
</td>
<td class="nump">4,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember', window );">Transfer of intellectual property and other | Diagnostics | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=opk_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=opk_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116515986840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 42,768<span></span>
</td>
<td class="nump">$ 44,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">$ 6,316<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 11,690<span></span>
</td>
<td class="nump">11,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,451<span></span>
</td>
<td class="nump">2,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">31,596<span></span>
</td>
<td class="nump">33,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 3,865<span></span>
</td>
<td class="nump">$ 2,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Discount Rate [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Lease Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116507437560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Liability Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">April 1, 2022 through December 31, 2022</a></td>
<td class="nump">$ 10,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">10,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">8,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">5,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">5,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">24,621<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted future minimum lease payments</a></td>
<td class="nump">64,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Difference between lease payments and discounted lease liabilities</a></td>
<td class="nump">10,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">54,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">April 1, 2022 through December 31, 2022</a></td>
<td class="nump">1,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">2,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total undiscounted future minimum lease payments</a></td>
<td class="nump">6,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Difference between lease payments and discounted lease liabilities</a></td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 6,316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, Payments, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116519080904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease expense</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116512547064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash out flows from operating leases</a></td>
<td class="nump">$ 4,288<span></span>
</td>
<td class="nump">$ 4,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash out flows from finance leases</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash out flows from finance leases</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_PaymentsForLeases', window );">Total</a></td>
<td class="nump">$ 4,819<span></span>
</td>
<td class="nump">$ 4,803<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_PaymentsForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_PaymentsForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140116509527992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 09, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Detect Genomix | Sema4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued in business combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments', window );">Additional revenue-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod', window );">Revenue-based milestone period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_BusinessCombinationUpfrontConsiderationTransferred', window );">Total upfront consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total aggregate consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 472.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Agreement and Plan of Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total aggregate consideration</a></td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement', window );">Trading day period prior to closing date</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_BusinessCombinationPeriodPriorToSigningOfAgreement', window );">Period prior to signing of agreement</a></td>
<td class="text">2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=opk_PfizerMember', window );">Pfizer | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_opk_CollaborativeArrangementMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Revenue-Based Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Revenue-Based Milestone Payments, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_BusinessCombinationPeriodPriorToSigningOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Period Prior To Signing Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_BusinessCombinationPeriodPriorToSigningOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Trading Day Period Prior To Signing Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_BusinessCombinationUpfrontConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Upfront Consideration Transferred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_BusinessCombinationUpfrontConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_opk_CollaborativeArrangementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">opk_CollaborativeArrangementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>opk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_DetectGenomixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_DetectGenomixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=opk_Sema4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=opk_Sema4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=opk_AgreementAndPlanOfMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=opk_AgreementAndPlanOfMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=opk_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=opk_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>opk-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:opk="http://www.opko.com/20220331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="opk-20220331.xsd" xlink:type="simple"/>
    <context id="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2d11b917135448a38fea47851772958f_I20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="i137b80025d3d4485b08482ba89272156_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0e59dec8141549aa8b911e469e798a72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f9c95a502354f4c9bd791e55a1b1acc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6fd3f89e217e4e329bca14b9905edffa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i85501a743668421b8f9b4903a091161f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5a1bb9d88fbc42c0b66fe51d04025dd1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4e961cfc73ca4fc995f9df88000a19c4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i66109927d116428aafb21943a884db23_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic3804ba279de40cdb6e0567ff03eedfd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied0a49adeefd4e1fac80ec50e4698621_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbf602f14f46471d9d178ec252d385a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6d0ba7a733345be9b1fdc07bf34b423_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22bb54bd14a34a3ab35f37edf368d2bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i646a74fab4f84bf98ac3afc12ad3422e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3ec1789e0468407da526985ac43b1656_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic4da1298681e4425aee6f3a5032a8365_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic6af8b25ddc04918b13d874863276327_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb2b0dab2c974aca988d625e077fe49b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfe95975785f4da2a0792b40c68274b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2b1a62808234ad7b78fb28d31a7ee36_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i08134a4538f24e06bd29a6faf920f1bf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idad4ab8f901e456a921f38433308a875_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i63a9708ca6b241cbbf8a971c348c1b9c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i95f76eb90058493b8b9714b06a32ca6a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i86a2019e2f9a4c668d4bcb4561aaf856_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if5ac38aea5024455837e4b0a72c6cc5c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2e33b9f98a1b4d2196ed092e6e422c9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf50959849a64f92b031a93fb028f210_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i776417f572dd43b785ccc5de1a3fdd29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3c39548fd884077aba54bc5130c8aa6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7dd9c60c32484868940a0edb35f5b606_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08082c8210bd41e08e8e6102a684ff8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1a9671afbc747319965e4950c1d5673_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2c2c25cd759044e8a8b1ac83a456a490_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia73d31bf5c2240cdb0ccd63c8a4348c1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i69f0a1d1a7fd49089a06dcef395b5c5b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifc66eff602d7434281e15843b60d6d9a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i91568ba4c6ad4c9bbb8a6d13b2cca42c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9d685f0119934d39a093d66dd07cd19f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie8f0316ac515435b82f539c2ec2dd817_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i632c4e422f024ca6bb911a55e1259fcb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i402dd9684c2f477db500daa02097978b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:DetectGenomixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:Sema4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-29</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="i906abe6eed0f4cd69f9561fd532d9d48_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">opk:WaterfordIrelandFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia99d14c06e6e4e28ad5a8c3f4c6cc028_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">opk:WaterfordIrelandFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59cf764445af4de7b91ff994ed949ca9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i086b3193d0a84e44b65e89593c24a20b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="opk:TestingTypeAxis">opk:GenomicTestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idce190630bea4cf9936f6557989275fb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="opk:TestingTypeAxis">opk:RoutineClinicalTestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id75b8d1d54904cb9bed9cb560d7ee790_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:COVID19TestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">opk:COVID19TestingRevenueConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i888fe358d78645888869e9e2f5f6b316_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:COVID19TestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">opk:COVID19TestingRevenueConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i77c9c6ea887e4115b1c0992f4beef719_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">opk:DetectGenomixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30dd8bae361a48dc85516ce870eae7cb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">opk:DetectGenomixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3cf8b83bf2c647cc819974ea2adb86c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80eb499192104b008d7af0e0148d19c8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie9f8b48ec3cc43d09aa306ad85bdfbd6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1ec064528f8b46c799fcf289c9791518_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i37bc1ddf248145949cf20c844e5cd267_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i52d41c803f754caab224bc8b150c6c59_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieada14ab28484d7f825d8053db57205d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie2a83411c64144f1b9355c9cfd56237d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i63f3da17eaeb419fa6e03d78593bf2bd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ide29c575be14417383ac7d390f9234c4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if2ff2edaeb5d4865a0321ebe71317039_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3d47b2edbf174a649ea86051fd83bd31_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i318d31f5642447988322e0b46296a5e2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idab50d068e1f4bfc9aa0aa0073ec3fdd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">opk:AutomobilesandAircraftMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie29d2a5269334fb397d32c99e041731a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">opk:AutomobilesandAircraftMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i530fe1c9f119438894b0dd5623106eed_D20220331-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">opk:FederalAndStateGovernmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i50900f2255f341c596bd800b3f7c7a4d_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">opk:FederalAndStateGovernmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c46f5c9a39a4c32b5cd190bec420d89_D20220331-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">opk:StatesCitiesAndOtherMunicipalitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6a7d513d6e904c0884c28baf601bb35d_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">opk:StatesCitiesAndOtherMunicipalitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie1dca7ce0a2b48abb1378746d081a87a_D20220331-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">opk:IndividualPatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2b22ccaca70a4b119871d37e30563967_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">opk:IndividualPatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib396f0384c4549d6ad4a1d99b89fcf7f_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="iceb6a701923f4d27a6905238cab5243d_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i04b7a30acb9a4f81a6cd5179f6dc9cd0_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i67b75a0644d1431cb32ac4d221554a5d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7e0d3411daf7457fa18aa8ab1b20c33e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i56733675f4354dacaf825a860ec99f82_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0e18e3e9d8bb41f0b30d8b956511195e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b12b303a8a149ee9de06097429266da_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7bc8466e91704c55a14be646d891acd3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i651cb43b8a074339b0ee2e20b061a461_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i09284eae734a4ba29ea813474543bb46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied8dda5c25884eaf9d82544f0dd21140_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic3692b70dac746208ee532bd6a7af7c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfa555861b884871b2953ab02fd8033e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie04e073effab4668baaebc0c91e50e9e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c1e9306ccee49fab2b6d9c8a64eaa45_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">opk:ProductRegistrationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i56e6470febfe488b82cf6de3a567026d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">opk:ProductRegistrationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i614f229d8ed7468cb77cc7cbb19df994_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4e7d2ec22c3f471facc97d6879e5b1be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7cd76bb4cb054c24a6c2232c8ce7f462_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i67eb7ca1a153436b9c63f40b1643cbb5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib4f4333f6b854395908e42b29b11c12c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if0e396b6f94a488d87020d832f3a71dd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie350ba9cd5734e9ca2f654f54c4f32e6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie02675a24f9347258a91c2e8689dac1f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0c94852de80d4e20b88966f2a5803300_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">opk:CovenantsNotToCompeteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i51146bd0393e4abea9ad351cc048bb8b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1f99fa3607f14b209d98541827fcf560_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1fcfed0a51964bf2bb060f3eac1da896_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i22564da49818430d93721eda04c22d10_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9eec319fe4fc4382817c6990539e0de1_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:CURNAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="if4fc148ac1604fe99eb055c71362744f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:CURNAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i199321e556e1463989019c01f39f4666_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:CURNAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6a7de7c9d3994710a52433ef3622e975_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:CURNAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4dc68b2fcd3343aca45a1f78bea968ab_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i29b82614912a4396b69e605161eac8c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa9e641d3a3f43bba301ff2922df3bc7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3d8091552aab4b19b8c4d08ef13537d5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idd18b46a79c64b6d83b27c4f2d210742_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:FineTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="idf902a5a04b14f7babb55f3b843e3a80_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:FineTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i114289ac9f494783bd9d11890dec12dc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:FineTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff62ea5a28684fc8a6b1dc70be867c32_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:FineTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i061dafbf8ba241378db298ff55bea551_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i30ac8d0d0c694b82a5397dcb0df95a8e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8b2c36299ad4032aad14bf2b2486edf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifd5e493ead0e4e5e9162c5c722db4e35_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOBiologicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie5febec8e3a34d12aeeeb1e3f39919ca_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoChileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ia9587f6a4f274caaba6009524613917d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoChileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id78bb5a3b0424167a9c9b348ea5cf5cc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoChileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i926fe15bf7e14648af39eaf884ccac95_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoChileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2eaedf3c190742929a4c020e7afc76b8_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i9565f1ff76984a2d87c2caae18caa32a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied7c009dbf6647c2a36b57156c5ce4de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic22ef152d20d46f5b505759af9ebb7f8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if107abf0de7a41faa040731b1223de77_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOMexicoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i1ec024cce2a2496984ae03706c8870ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOMexicoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefd76cc953044df3aa7d05cbb5e5cf00_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOMexicoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i076891eda5724f9e8facc0d32cf101a3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOMexicoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idf39b19d11f0451580b5298ca4e70ed2_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:TransitionTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i1a89597a3caa42bab28aa9233a6692fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:TransitionTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1a2689178204969b6be3b7c80a94903_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:TransitionTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id469bfa162ed497c8fd73817abe740dc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:TransitionTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i87bdb1d33c654930a1c1073348ae533c_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ifaf793477c8f470eaeaeaee2fe7d1534_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9c0e49d0f844798a8cde4028560528e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0be93569346549e6b40179e6f26f198c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8f702a5c58d541e398fbf371ddd14f4d_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i55f7b3a49175491f81bd49d3873d7ef6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56ce2a0713064856b4736ba58073e798_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2e77dbdc6364495093a3daccd4d4c89e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OpkoDiagnosticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0e74f63daa08493f8fddebb9af0d512f_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i2da87d4b1cea40abb7f65c8419989f04_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:PharmsynthezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ief9f3d5f2c21400fbcb87f69615b8cf1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:CocrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2a5eea0a1fa844b19b8baa7361a45542_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NonInvasiveMonitoringSystemsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4e737b98458d4a859ab982878352b552_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NeovascMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i61c6fa53ff434aeea2559a0e6fca1f8f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:InCellDxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iefc49f12f9a24f6a8438f9164321e4b9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:BioCardiaInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ide7dce2757b14a7e80beaf9e7f36bc70_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:XeneticBiosciencesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3e85d9626c1c441cb3ee913546454e58_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:LeaderMedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i345405f3f02b45a1bf5c9b950dde0383_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic8ff88bb39754838bea82d4aa6fe8b0d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib3269e9e5de645f7ab9c3fa24f73c940_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c994275c6324f47a249b3109e183353_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i735a6dd4044144048e04b19307ebbe2d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:PhioPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i93c10577f5fe4cf5aa85dbf6a728072b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:VBIVaccinesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idb8abbb296ab4fd6bec8792f90ed897c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ChromaDexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i745a5d9c8eda4157b142bcd4ae5184df_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:EloxxPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic9dabca72cbc43ae823846a3ceb570c6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:CAMP4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i74ad64c47d06402791389d97af41b417_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:HealthSnapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i045c2a8d58864ccc84d9e26f6de225bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:BioCardiaInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1b622c3fa27402b9211c7b4ccf25f7f_D20210914-20210914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:LeaderMedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">opk:LeaderMedJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-14</startDate>
            <endDate>2021-09-14</endDate>
        </period>
    </context>
    <context id="i36d25b2cfa03459783a6e94281295ca5_I20210914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:LeaderMedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">opk:LeaderMedJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-14</instant>
        </period>
    </context>
    <context id="ie8156096c5d249378540b9fe04c480dc_D20210914-20210914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:LeaderMedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">opk:LeaderMedJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-14</startDate>
            <endDate>2021-09-14</endDate>
        </period>
    </context>
    <context id="ibadd78e70def4793bd8033df5fdbe911_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:DetectGenomixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i4a78517025804d929c0e5e426c1b9a4b_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:DetectGenomixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i025ab7646b8144b688675d0f4247839f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0bba573814e746888e84c5b2aa904dc8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iced2ab36569e4ad68d856b5c48df2e03_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7e46f99237c8496ca82c13bda9e7f294_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idc38b647115245d9a1d1122f23f15088_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46d6876e7be847069467c27ec77a4a44_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:A5ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i487322626c254451bb84eeb5072abbac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:A5ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8fba9c7092e04a5ba143a73b73dada89_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie4a642fa3cc44c77b27622488a3dcf17_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a2bb52ee16c4f3cbd50cd8ebe53b377_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia66232faa6934fc58bd350c3c5087464_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ea90eb5c3a649d1a00ba71dfd8d4665_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i14a4df5ee1294c10a8f972615bb565fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1511200111f48499ddfcbcdc01ff960_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i70922a4b40e947b7a60140a1158f9de6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0fe0dcaa05548b79dc808f805d895bf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:LineOfCreditAndNotesAndLoansPayableCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i314f83bf93da4b8a953b12a86b015762_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:LineOfCreditAndNotesAndLoansPayableCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c5f0e2847a64769ab9be88846f125c4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iae497a6420cd4f4faf38ce9662826b4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77752216e0a74e5e94c99ae54b2ab33f_I20200225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-25</instant>
        </period>
    </context>
    <context id="i9ba35bd01ebf48fc928c6575df35dcf4_D20200225-20200225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-25</startDate>
            <endDate>2020-02-25</endDate>
        </period>
    </context>
    <context id="ia1b9e43d842649f78bdeeb877a771557_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie2696a40617340cf8c06f43678aedbcc_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i3d3e367b0c444609b24109041edeb01b_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i40061516e65d48a1b5e3f3064a40b794_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i9df45c289aa6458e8a7b184c9d9eb1f5_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i5f67d9074c764297ade8fcccc8dc5b7a_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i93cfe6ee9aef4ae3bb7d5b05ab545903_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i8f1f20509fa846cf8da8cbaef989bbe8_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="id0582da3183f40ca88c4cb1db58d7e0c_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i4609448adb58436ab818127efb5758c2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c2ad3f0dc804c1d9adea93dace26206_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia70bad4845e84935a8ef37f70822b5d7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i227355c0a3f841b09e53338c115c186d_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="id91a4eb6cea742e4b1b93c700e56993f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5e68b8b37fc848168cc743f1b5049318_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6b205efadb964c1cb4dff4ca72b078bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iacfe2e319d1e4f1cad4106efad251be5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i994823b7aa8d4a3aab131ffa60b3a73f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4045f45f8fc4c08bec50e050b1907c7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1a7f42702b824de08c6bd810d766790d_I20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:A5ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="i7ff2cf21d2ee42b7ba76f7ede2a71895_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:A5ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i3f373341aeaa45d6ab5311cefa00161e_I20130130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-01-30</instant>
        </period>
    </context>
    <context id="i36deaadef6af48b695564914f629b5db_D20130130-20130130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-30</startDate>
            <endDate>2013-01-30</endDate>
        </period>
    </context>
    <context id="i3247cd104cc0482786e56f99c0599cc1_D20130101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="icaf8381567b542449202a80cc3f77a99_D20130101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="if8c98930de814fef80fda4f22e14c6c6_I20190201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-01</instant>
        </period>
    </context>
    <context id="i1da72e5734474e44a7f6fca5196486fb_D20130101-20130131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NotesDueFebruary12033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-01-31</endDate>
        </period>
    </context>
    <context id="i7b4eb504ab9242d79f116b3ef21235d5_I20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-30</instant>
        </period>
    </context>
    <context id="i60f953c97dd24968839eeaafb2ffad17_I20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-30</instant>
        </period>
    </context>
    <context id="i0fdc1aa37b674237997e3b022f56dbf1_I20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-30</instant>
        </period>
    </context>
    <context id="i5ce132bbea2745af8c284fc6419ab2af_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4c287aafd1a44262b8db089d441d0bb1_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="ibbeb409c21e94c8a9efee99f6cb87652_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">opk:LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="i16716fcbd59e454387ebc09f7b61c881_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">opk:LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="i63c4e5c98e7243cfaba30273d9ca0a87_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="opk:LineOfCreditFacilityRevolvingCommitmentAxis">opk:LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="i525c6ba5bfb44a68bf4601181c4282fa_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:NewCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="opk:LineOfCreditFacilityRevolvingCommitmentAxis">opk:LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="i9be636d2eb7646a68e48135793798985_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:BioReferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib898228cd3484e429a53c453f0951cbe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:JPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie92eade637fa4c5b9fdf19e5892fcb78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:JPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6da40689dc7f4a57940604c58ea95ca9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ItauBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3b77ee2f3fcc47b49cb358c6cb4a05b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ItauBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc72bc81c8cf4007b02a8ed9c7371fab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BankOfChileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i42c606619dd84425ac6654cc299669d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BankOfChileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff25469e62df48448ca837a11e16442a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BiceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic54dc237b91f42858c86967daeeda551_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BiceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5db2a74d8f95441691817b18709c0fcb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ScotiabankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaabb83a0b7e84cc69c57763fdb275a6c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ScotiabankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2be89554ae224d2faa3b30914675e795_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id4836259242c4bb19d20c064b534eab1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e0c19da9e644a0394218df762658838_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic9cd8644076f4859be4a248297d5c636_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib013afdad6c7474cb6b2dcd9f1b5930b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:EstadoBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia0e78a0e78664a1dab1c8a3083fe0278_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:EstadoBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0241e35fea8242e191eb554ad8160555_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BCIBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idb458c405a9e4aa4840e82ae7757acf6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BCIBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd2141f359c14b2c98459ad1cfb7f950_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:Corpbanca1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id0f90114729e40eb8be4a760cfaff843_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:Corpbanca1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6754e9ff1da42ec9e1a4cc77eec4acd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:InternationalBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie9c38a5f8c564a40be8991b68c4b3ffc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:InternationalBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifcca8a13d6eb4da998ed98c0c425049d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ConsoorcioBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5ec848e00bda4f5681fac4c00ce92faa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:ConsoorcioBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d54584ff4454273875eb07cb16d7afd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BancoDeSabadellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5f26530ceb664987a7569db40b3af4e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:BancoDeSabadellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f72279f02e748babf4db23480b635fb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBank2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia5d45b4e640d41ceb4caa171b741efa1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">opk:SantanderBank2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if35733f1b3cb4b5e8d6885a8d8e2c00b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">opk:NotesPayableAndOtherLongTermLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibb18ba3550a7419cac96f92422977cff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">opk:NotesPayableAndOtherLongTermLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1aa77c7b6eb749fe884b2a879d8b362c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i073357239cf9481992cd2d0593039c41_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idace7175aff140538ca299c503a1f3fe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i590b5239584e49aabed9114cc2b084f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:OPKOHealthEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a645b4fb40d4c90b63cf8887a6813ce_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">opk:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="ib4a22c80a9934fab9c03ed0fda0558a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f44824dbb444200a5bdcdb490ef2b6c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id414151061b84ff297849734c822f37f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i422ca1837f244677badf0cc87f681909_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5e71299ca85d400ca49f6ca9cedc36ee_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if1f2bf6624724fa3aecc40088836c8be_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idff81e7e63834f27b0191f9f89a1a47c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibf4f3576ecda4c91b9dd4d47459c40de_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i91f678126fc847348f1523f27f8297d9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7bec48bd714c48508a9e6c19e44bf474_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i672ca210ee9a4a0bba0dfc16dae64dcd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idcb3f1c307104b52a50b42c818e7727d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i33c3fc92127145a39d48943be5758504_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2f7f39684e77498888d13da9df62d5b9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2b6b0142454d4f3c928a9719fc52a6aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ece04f6d15a44e8b8535afca85eea3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6167a5561ea048c0992072722768dc50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id20bcd0b3e1c441a9da0bd8ff7b7c148_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id821c49b028b4f61851f46ac73519641_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50def469aee442b7a18f3ee936adf68d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0175b050f64543bdbaed71566aab0b0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66b1ce0a8e104dd48bd6e56c4cca780b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f5b8f39523b4a5683ccaea181d847f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85019ba01b1f439c855e8144c410bd64_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedb36d1e48e34543b075c30a1123563a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6f84a8a9e11457c9fe326e89f4deef6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i940d0629800f44c09521f8583790b804_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if17f3344f32f4bd18794617bc4d70c76_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9eeb8b6fb39840dc8dd12bd08e9bde47_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i170972a9d6e34cec89fae7f37a41e059_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1a68d34ffea6486da4d468c553cccb2f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">opk:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie89c145a5bdf45b8b2c4856b5dd6d167_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">opk:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i19db139199c944d1a3ba5a1234a8c6cb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">opk:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic33ae5da06dc4f819b6dcd183aecaebe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0dd929a7397e49f0ab13af7ad0be9d63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b034a9ad25047b59a622208212d95e1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i339ef703a5544c01b8dbb210e3619b01_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c9e493caa0e47609d6a6dc891471ba6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie52baf79fca2489f9435b6f9e9014cda_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">opk:PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied8a1708f69d41239c1f9de8d8facd76_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5e8e55382c6349dba42db7b0d47c339c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i320a0c5cf0c54c369df4652d6c4aaee3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibf311fd02fe0429098a14a89aaff1a31_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if9043229605240dc9166035e1b850972_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5916426f99024163a0c1c7044beb1897_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i50674a6b6023457196ed8f17e7e4cf51_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:DetectGenomixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:MednaxServicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i4ecfd405f7e848e8a4e0bde064b5beaf_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:DetectGenomixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:MednaxServicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="iee2076cde68b4576afe09b95b5942af6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">opk:SharesReceivedUponClosingofXeneticTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4ae393d9880f48be85feb8757df68b73_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ZebraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ief99b9b8fe8e4816986a723ffacc2c18_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:ChromadexCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iba2fbb366c7942ee8c1f1d0688aeacd7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">opk:NIMSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ica59f07c68a7496dadf29dc004ea21da_I20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:DrFrostandMrPfennigerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:MuseumofScienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="ib24c230ab8774444a8491338133155c0_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:DrFrostandMrPfennigerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">opk:MuseumofScienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i86ce37219a974882a0746dff7fc5dd55_I20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">opk:FrostRealEstateHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="i02020232c72342119d53b27eaa44b338_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:CivilInvestigativeDemandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i522709e2d34e47b9b839338702492788_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:CivilInvestigativeDemandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idc90d86f2b4c4d5a8429f7ad7154f525_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:CivilInvestigativeDemandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70de44f4e3b347cfb81ce995f5cf73fe_I20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:ChanceryCourtOfDelawareVsCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-05</instant>
        </period>
    </context>
    <context id="i676c769373684cfba8382f5367b6370f_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:ChanceryCourtOfDelawareVsCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i3ef8f6dc8b5e486b8e9f8f96b1343e13_D20200922-20200922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">opk:SouthernDistrictOfNewYorkVsBioReferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-22</startDate>
            <endDate>2020-09-22</endDate>
        </period>
    </context>
    <context id="i4b576227129140fcb81ae5986936e0a5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:HealthInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0c5cff8bc69f43c19ce205c66e3547e9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:HealthInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i874e9141286747c28f30293d988fb218_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:GovernmentPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6e8101af777f47df9da8ece465836a9c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:GovernmentPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5d41bb470d9447f9a98b8d23e1a42b68_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:ClientPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7186cb07c47349b0b7397d1c5851b571_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:ClientPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4c5acb3b505f4483bf34a77f2c5e788e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i99d9faa02d9d40f389d88742df8865d3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id0e7950d75f0444d93f095f4040135b3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ief2e45330b2c4c668f762e3119a6fbae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idea7a07d482240c5a1a9daa77497e119_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7745e7dd9842490f8a4d3aa14b8bb285_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic32fd42c04ee410bade14b9fa49da67d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49b8dfcf4b0a47ceb082dba3ba22e4e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a4781da5440461fa4b0023e40c75529_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4e9ad9bd7fa74daeae00d3f5d5742096_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia2dedc717e1341d5886ca72f83560353_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4abfbe41a46e407a91e30f4caa372833_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i15c57ea2417945928b8420c5f3724908_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia48d7bc49b584c93b505e1441ca49b05_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib5e653d3db9e490db849e824a8a8a9a5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifeecfb112c664416a33c945ad8da2700_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56348d7a5e4f475181fad615300d4502_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2139d12433584f65aa24b38284d118c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie128a7c076a046209f0782cf5784b0a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d0eefa269f14f9f977234ed680b56f9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id28b381bb36e4f06a4682b864bdd7356_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6c111d78df63437e89c6efa75cc8851b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i111f3c1bfdd14e20811f5bc40a649d17_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:ChargebacksDiscountsRebatesAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0b398c50b3cd40b5b0170eef129c73b1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:GovernmentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i86896d2c37ea4f34aec16a43eaaedc8a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">opk:SalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i966cf82bdb2540cbba62a1e436cfbd92_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RayaldeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iba783e62870149cda0cee98d8bc74cf5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6880e4f214144d89a4f0b87a7b1c3f55_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5fd88e0b9dc2432ca9c87a42295d0f14_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:ViforFreseniusMedicalCarePharmaLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i31eed14eff354f918546bd944177b06f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:LeaderMedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">opk:LeaderMedJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib6c87132b4964cd485ec8ec605a41b8b_D20210706-20210706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:CAMP4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-06</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="ib5d22ca705ba48a9b83984b98bb175db_D20210706-20210706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:CAMP4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-06</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="if0c873c67ff541cd805db5011768482b_D20210706-20210706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:CAMP4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:DravetSyndromeProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-06</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="i2421576a6eb245f5963c8fd546b2202d_D20210706-20210706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:CAMP4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:NonDravetSyndromeProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-06</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="i10db571f9a22486186e3b342bd39d781_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:NicoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="ic69f79db9b644be990ff9dd9110a1bc1_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:NicoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="opk:MilestoneAxis">opk:PhaseThreeInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i5c7fb2b0fdc148b3a2a1cbb14048e04b_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:NicoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="opk:MilestoneAxis">opk:RegulatoryAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i9744194c20ba46758d55f0a601deef68_D20200505-20200505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-05</startDate>
            <endDate>2020-05-05</endDate>
        </period>
    </context>
    <context id="i9cd5fcc524ba4f4da070564f37ec0b94_D20200505-20200505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-05</startDate>
            <endDate>2020-05-05</endDate>
        </period>
    </context>
    <context id="i9b365c1cad364899b9b410fc05c6ee03_D20200505-20200505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:EirGenPharmaLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-05</startDate>
            <endDate>2020-05-05</endDate>
        </period>
    </context>
    <context id="i004085a346bb457f8e5d14f98a53a911_D20160501-20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:ViforFreseniusMedicalCarePharmaLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:ExclusiveOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="i439818f5135849e981ffb5c0b3e4a5fa_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="if1ab3dcfa70a42a4af7efe061a160e4c_D20191021-20191021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-21</startDate>
            <endDate>2019-10-21</endDate>
        </period>
    </context>
    <context id="ifdde5003bfd44ea6b9fbccdf4b85628d_D20150101-20150131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-01-31</endDate>
        </period>
    </context>
    <context id="i4213e7e67f624f758de6da611795d601_D20150101-20150131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-01-31</endDate>
        </period>
    </context>
    <context id="i89b406679fa14d95928f83c7db184e47_D20150101-20150131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-01-31</endDate>
        </period>
    </context>
    <context id="iec21a25c43404529ae8e1b869bd25df4_D20150101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">opk:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i248c2f7f347a4e28bf2c05816ec8ead1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4e591c4c9d6a40d7ba41cbe1d1512d6b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icdbda16c863b431ba3f7cf99e015a97d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib33dc7d9f44c424a9584b48898909842_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id3c4e79123684c96996efacf35e4cf15_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5ec2e176eb00448f977e91fc55c4ac65_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i44f799de78174d999399f2edd81a8ded_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i12f23d1e4f7149df81a204a4274bb85f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i39c1bc4e90f445ff86ac8569a2ddbc9d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i209dc12bb8ce4a749fed4f87ebc36e68_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2a55931e091d4a3c887296abefde8504_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i082e04104d194b92a685d699a64a0014_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idffcd8ebe9be487185a9b4b68675f7fe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id657dc78714d4c38b4795e9de8978786_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id8558bb5f637404994c8de52c35676cd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i393ae4fb48ac46c791cf4386477ae160_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic7b01ac51664446b81224ec66b765954_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i70da593d5a914041bc7e0c120158a9af_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4d5fcb23d84e40e0bd666630c86cc3ae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">opk:TransferOfIntellectualPropertyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i53640b46e2fd4c808aaed4db666adb92_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9e92aea3d2094ffebb2b18c6d66c89c7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i003285ed88bd4bfea42439162c0e7038_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifda4aeb385b4420c98ee831dcb7e2e3e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibfbd64ac384549c288a217c1e278ff5a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idb337610dc2a44669c089130ab28f864_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifd847808c4214f4fa04fde3ad6d1af41_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i343e534f8fb94404bbef65e665f2bd82_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia423aa5eee2b482c9db466bda75c3161_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i51de4ac755574afeb66162a7f5862660_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5d7aa53c3c054c22ac7e21fed6039914_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2814670edf7c4a62a9c261600d7c6daa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia46e96d43b2549a8a62460a4e0218f58_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieac6faccf2c2445a906e11ebfd78a899_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i644924ad6fec4277940108274a5fb5cf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaae85104e75449f082ec0bb4c1170ebc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id089ec5023d147288f24951b1c9d421c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i379322a119a345fc8841df842ee7ad3e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie15b0e5103c443a0a508317a579c958d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">opk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3beab81522d0420c95c34143d9e9a514_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">opk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib27f714c1aa84e6a935be26300cfaa00_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8886b20cd82e4c7e8073ac81cd611ee9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i437311d9507444baa08d2ca5476a8beb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i87097699235d4d2fb348f69eb54508e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">opk:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05c6a762af174fe8b29069a742a32bb3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib66ac7571d2d48f48825d3fd8073639a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f3663059edd4d60a02442357262179d_D20220509-20220509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000944809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">opk:AgreementAndPlanOfMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-09</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>opk:employee</measure>
    </unit>
    <unit id="facility">
        <measure>opk:facility</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>opk:segment</measure>
    </unit>
    <unit id="day">
        <measure>opk:day</measure>
    </unit>
    <unit id="institution">
        <measure>opk:institution</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180L2ZyYWc6NDUzYWFlY2ZkMDY4NGM5NWI3MWM3YjY5YzU0MzAzMDUvdGFibGU6MjJlMWIwYTZmYjJjNDdlYjg1ZGZjYzZiYWUxYzc1YjAvdGFibGVyYW5nZToyMmUxYjBhNmZiMmM0N2ViODVkZmNjNmJhZTFjNzViMF8yLTEtMS0xLTM1MzMw_ce42b0b4-3748-4fba-a623-29a68069cdbe">0000944809</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180L2ZyYWc6NDUzYWFlY2ZkMDY4NGM5NWI3MWM3YjY5YzU0MzAzMDUvdGFibGU6MjJlMWIwYTZmYjJjNDdlYjg1ZGZjYzZiYWUxYzc1YjAvdGFibGVyYW5nZToyMmUxYjBhNmZiMmM0N2ViODVkZmNjNmJhZTFjNzViMF8zLTEtMS0xLTM1MzMw_1695b842-d4b0-4abc-b58b-f2e281030a26">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180L2ZyYWc6NDUzYWFlY2ZkMDY4NGM5NWI3MWM3YjY5YzU0MzAzMDUvdGFibGU6MjJlMWIwYTZmYjJjNDdlYjg1ZGZjYzZiYWUxYzc1YjAvdGFibGVyYW5nZToyMmUxYjBhNmZiMmM0N2ViODVkZmNjNmJhZTFjNzViMF80LTEtMS0xLTM1MzMw_a682b275-5d60-4318-a5b2-f54d8bf6063b">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180L2ZyYWc6NDUzYWFlY2ZkMDY4NGM5NWI3MWM3YjY5YzU0MzAzMDUvdGFibGU6MjJlMWIwYTZmYjJjNDdlYjg1ZGZjYzZiYWUxYzc1YjAvdGFibGVyYW5nZToyMmUxYjBhNmZiMmM0N2ViODVkZmNjNmJhZTFjNzViMF81LTEtMS0xLTM1MzMw_19769624-1d96-4f1c-ab8f-58f7be816be4">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180L2ZyYWc6NDUzYWFlY2ZkMDY4NGM5NWI3MWM3YjY5YzU0MzAzMDUvdGFibGU6MjJlMWIwYTZmYjJjNDdlYjg1ZGZjYzZiYWUxYzc1YjAvdGFibGVyYW5nZToyMmUxYjBhNmZiMmM0N2ViODVkZmNjNmJhZTFjNzViMF82LTEtMS0xLTM1MzMw_1f0012ed-2f27-4478-bf45-1f6736a002dd">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ic4da1298681e4425aee6f3a5032a8365_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNS0wLTEtMS0zNTMzMA_919511f1-ba2b-471c-9afb-64ee3d8de324">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i3a645b4fb40d4c90b63cf8887a6813ce_D20190201-20190228"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182MS9mcmFnOmViY2RhNWI5ODE2MjQ5NDdiNjRhNWZhM2RhODZlNDI5L3RhYmxlOjA4Y2FhZjc4ZGQ2MTRmZmVhZjQ1ZGY1ZmNhNjczZGVlL3RhYmxlcmFuZ2U6MDhjYWFmNzhkZDYxNGZmZWFmNDVkZjVmY2E2NzNkZWVfMy0xLTEtMS0zNTMzMA_ed17d1c2-b8f4-4acb-bafd-853d7d79db80"
      unitRef="number">0.2367424</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMy0wLTEtMS0zNTMzMA_c6bd7dfc-1515-470c-8640-321ba294369d">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xODY2_75146f51-e45e-4d6c-982b-58c1bee82d61">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6MzIzYmVhM2QyOWVkNDQ1NThlYWU3MDc4NmY1ZTZkNGYvdGFibGVyYW5nZTozMjNiZWEzZDI5ZWQ0NDU1OGVhZTcwNzg2ZjVlNmQ0Zl8wLTAtMS0xLTM1MzMw_fcbc73c8-795b-466c-be27-42b486983a16">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xMzQ_34fc0e1e-908d-4876-ba04-5c913b111f09">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6MDQ4YWNlYzEyYWU2NGQzNmFlOTIwNzRmYzExYWYzMDMvdGFibGVyYW5nZTowNDhhY2VjMTJhZTY0ZDM2YWU5MjA3NGZjMTFhZjMwM18wLTAtMS0xLTM1MzMw_5cccf5fb-c6ac-47b0-a99f-a5f0ab7df0a9">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xODY3_e210bf1f-f84d-44d8-bc68-ab2fd26ab353">001-33528</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xODY4_3ffe151d-6676-4ddb-a448-d633b183c6e4">OPKO Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6NThiYzVjZjhjMjJmNDczYWI5YzlkNWVjZThlMGNjZDkvdGFibGVyYW5nZTo1OGJjNWNmOGMyMmY0NzNhYjljOWQ1ZWNlOGUwY2NkOV8wLTAtMS0xLTM1MzMw_230f1534-b2fb-47ee-bbdb-42d981f9b5d9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6NThiYzVjZjhjMjJmNDczYWI5YzlkNWVjZThlMGNjZDkvdGFibGVyYW5nZTo1OGJjNWNmOGMyMmY0NzNhYjljOWQ1ZWNlOGUwY2NkOV8wLTItMS0xLTM1MzMw_86ed2836-1ee1-4b34-ac4a-1032c0c13cce">75-2402409</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YzQ2NGE3MzIwMWNlNDA2NGExYmFlZTM3YTM0YzhkNjYvdGFibGVyYW5nZTpjNDY0YTczMjAxY2U0MDY0YTFiYWVlMzdhMzRjOGQ2Nl8wLTAtMS0xLTM1MzMw_3da85fd4-1a83-4bae-9b7d-1c3641c74bb6">4400 Biscayne Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YzQ2NGE3MzIwMWNlNDA2NGExYmFlZTM3YTM0YzhkNjYvdGFibGVyYW5nZTpjNDY0YTczMjAxY2U0MDY0YTFiYWVlMzdhMzRjOGQ2Nl8xLTAtMS0xLTM1MzMw_5b4514e9-ec4a-49d4-8a0a-13f7fccf7ab3">Miami</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YzQ2NGE3MzIwMWNlNDA2NGExYmFlZTM3YTM0YzhkNjYvdGFibGVyYW5nZTpjNDY0YTczMjAxY2U0MDY0YTFiYWVlMzdhMzRjOGQ2Nl8xLTEtMS0xLTM1MzMw_2a56636c-0036-465b-8514-09850aa7445c">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YzQ2NGE3MzIwMWNlNDA2NGExYmFlZTM3YTM0YzhkNjYvdGFibGVyYW5nZTpjNDY0YTczMjAxY2U0MDY0YTFiYWVlMzdhMzRjOGQ2Nl8xLTItMS0xLTM1MzMw_b5190482-a8db-434a-bf5e-f9d3db19ea10">33137</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YzQ2NGE3MzIwMWNlNDA2NGExYmFlZTM3YTM0YzhkNjYvdGFibGVyYW5nZTpjNDY0YTczMjAxY2U0MDY0YTFiYWVlMzdhMzRjOGQ2Nl80LTAtMS0xLTM1MzMw_8f58d8fc-04be-47aa-a308-243deb3c46c0">(305)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YzQ2NGE3MzIwMWNlNDA2NGExYmFlZTM3YTM0YzhkNjYvdGFibGVyYW5nZTpjNDY0YTczMjAxY2U0MDY0YTFiYWVlMzdhMzRjOGQ2Nl80LTEtMS0xLTM1MzMw_961bc631-1fad-4f68-ac3f-9371f38287e6">575-4100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YWQ2OWMzNDYyNTg0NDM3Yzk5MTlhNDEyNDIzZWNjN2UvdGFibGVyYW5nZTphZDY5YzM0NjI1ODQ0MzdjOTkxOWE0MTI0MjNlY2M3ZV8xLTAtMS0xLTM1MzMw_f4032598-7033-4d6c-b793-e39ef1ed3d4c">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YWQ2OWMzNDYyNTg0NDM3Yzk5MTlhNDEyNDIzZWNjN2UvdGFibGVyYW5nZTphZDY5YzM0NjI1ODQ0MzdjOTkxOWE0MTI0MjNlY2M3ZV8xLTEtMS0xLTM1MzMw_77e87e69-602f-4d2f-9010-dd0117e4c6c9">OPK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6YWQ2OWMzNDYyNTg0NDM3Yzk5MTlhNDEyNDIzZWNjN2UvdGFibGVyYW5nZTphZDY5YzM0NjI1ODQ0MzdjOTkxOWE0MTI0MjNlY2M3ZV8xLTItMS0xLTM1MzMw_ef223c6d-4ccf-40aa-8a9d-1e24aea1591d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xODY5_02fec727-55c2-4bbe-8d37-4db66497cc8d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xODcw_fd0eea8f-85ca-4b11-a49c-829303c45ba0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6ODhjMGJhYmZhZWYwNDIxYjgwMzRiN2Y0YTJhZTEzZjgvdGFibGVyYW5nZTo4OGMwYmFiZmFlZjA0MjFiODAzNGI3ZjRhMmFlMTNmOF8wLTAtMS0xLTM1MzMw_f01ec141-2870-4c4d-85a3-b62fa9b846a2">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6ODhjMGJhYmZhZWYwNDIxYjgwMzRiN2Y0YTJhZTEzZjgvdGFibGVyYW5nZTo4OGMwYmFiZmFlZjA0MjFiODAzNGI3ZjRhMmFlMTNmOF8xLTMtMS0xLTM1MzMw_cc5336ea-7541-43be-ab20-dc3de8b75c02">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGFibGU6ODhjMGJhYmZhZWYwNDIxYjgwMzRiN2Y0YTJhZTEzZjgvdGFibGVyYW5nZTo4OGMwYmFiZmFlZjA0MjFiODAzNGI3ZjRhMmFlMTNmOF8yLTMtMS0xLTM1MzMw_16337620-87c9-4174-9244-cee4940b66df">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xODcx_a58f9f4d-8bd2-4ec5-93fe-3b56e733f058">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i2d11b917135448a38fea47851772958f_I20220425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xL2ZyYWc6ZWFlYzg5OTAxYWUwNDA3MjlmNDIxYTI0ZTIyZDdiYTUvdGV4dHJlZ2lvbjplYWVjODk5MDFhZTA0MDcyOWY0MjFhMjRlMjJkN2JhNV8xODI5_1a9203e1-ab26-4d32-a242-0a2e80915c1f"
      unitRef="shares">681525181</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMy0xLTEtMS0zNTMzMA_f21be620-593a-467c-b3f0-2cf3aa7b9de8"
      unitRef="usd">102281000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMy0zLTEtMS0zNTMzMA_f2359377-174d-4fdb-9b76-9f187ffbc8b3"
      unitRef="usd">134710000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNS0xLTEtMS0zNTMzMA_8be66249-eed3-4de5-94d5-98145ec3f937"
      unitRef="usd">212755000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNS0zLTEtMS0zNTMzMA_54d56fde-eb1d-4261-9656-531493460ef7"
      unitRef="usd">259637000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNi0xLTEtMS0zNTMzMA_0a718205-148b-417e-b352-8c9fae0fa9a6"
      unitRef="usd">99406000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNi0zLTEtMS0zNTMzMA_b3bd4ad8-03d8-40b5-8712-ffe590fe3987"
      unitRef="usd">86502000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNy0xLTEtMS0zNTMzMA_8bc30df9-4afa-4520-8a14-ae587a479293"
      unitRef="usd">23274000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNy0zLTEtMS0zNTMzMA_29dfcede-0a9b-4eb8-881a-4f01c805f016"
      unitRef="usd">27170000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfOC0xLTEtMS0zNTMzMA_9aeb5dab-ca32-410f-bedb-7f3f580125ff"
      unitRef="usd">316353000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfOC0zLTEtMS0zNTMzMA_ba0c9d18-ccaf-4896-945c-525905363fe5"
      unitRef="usd">314994000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup>
    <us-gaap:AssetsCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfOS0xLTEtMS0zNTMzMA_9687977b-0f2c-4d81-b8b3-2d79c65950fc"
      unitRef="usd">754069000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfOS0zLTEtMS0zNTMzMA_9747d123-b27d-4905-aae1-9ebbbbb901c7"
      unitRef="usd">823013000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTAtMS0xLTEtMzUzMzA_ab2e6e0f-15d7-4e45-9a84-ce559f510e8d"
      unitRef="usd">81899000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTAtMy0xLTEtMzUzMzA_7e5d20cb-6454-412d-b311-f1f2d3be2d76"
      unitRef="usd">79727000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTEtMS0xLTEtMzUzMzA_2423f5bc-db3b-4b22-845f-8f82f5e6cb24"
      unitRef="usd">890498000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTEtMy0xLTEtMzUzMzA_52f6f430-6192-47b2-b8b4-99f1550657a2"
      unitRef="usd">321683000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <opk:InProcessResearchandDevelopment
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTItMS0xLTEtMzUzMzA_12f8e391-25c7-4b3b-9420-b14522dff48e"
      unitRef="usd">0</opk:InProcessResearchandDevelopment>
    <opk:InProcessResearchandDevelopment
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTItMy0xLTEtMzUzMzA_38ee1064-1c99-43d9-824b-1dce29ebd685"
      unitRef="usd">590200000</opk:InProcessResearchandDevelopment>
    <us-gaap:Goodwill
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTMtMS0xLTEtMzUzMzA_3c00cd13-239d-4c77-9af9-01acfe527a7f"
      unitRef="usd">519052000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTMtMy0xLTEtMzUzMzA_37eb9d92-ec99-47be-804b-4503e24b69ac"
      unitRef="usd">520601000</us-gaap:Goodwill>
    <us-gaap:LongTermInvestments
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTQtMS0xLTEtMzUzMzA_153bf782-c84a-4d4a-8ac0-53fe1dc7ceae"
      unitRef="usd">9472000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTQtMy0xLTEtMzUzMzA_0b5e89f6-3da8-43cf-98df-8421bddcbe70"
      unitRef="usd">10729000</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTUtMS0xLTEtMzUzMzA_81659776-9a19-40c4-9ccb-91ccbfc9a927"
      unitRef="usd">42768000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTUtMy0xLTEtMzUzMzA_d5713c88-02bb-498a-bbf8-d27fae2d9211"
      unitRef="usd">44228000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTYtMS0xLTEtMzUzMzA_7bff3223-450c-45ad-83f9-d341d843d707"
      unitRef="usd">9100000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTYtMy0xLTEtMzUzMzA_e3cd9b45-81d2-4c6a-99ed-55994b64ed87"
      unitRef="usd">9534000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTctMS0xLTEtMzUzMzA_6aea720f-37c3-4f6f-94ed-0c7e7d92f72a"
      unitRef="usd">2306858000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMTctMy0xLTEtMzUzMzA_e20f1e80-f79d-43d2-903c-49600e56a13d"
      unitRef="usd">2399715000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjAtMS0xLTEtMzUzMzA_ca537725-7c99-4d8f-ba08-adf36e00469d"
      unitRef="usd">94240000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjAtMy0xLTEtMzUzMzA_f4308b23-deda-4d7a-877c-3fac6288df65"
      unitRef="usd">82040000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjEtMS0xLTEtMzUzMzA_31521a56-9ac9-4625-bc30-b164d2987f21"
      unitRef="usd">157316000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjEtMy0xLTEtMzUzMzA_58422f3c-9dfe-4051-a7ae-0e74c4e94f27"
      unitRef="usd">193493000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjItMS0xLTEtMzUzMzA_50c04f68-4c60-4c37-ab31-fa1a51a13661"
      unitRef="usd">11690000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjItMy0xLTEtMzUzMzA_fb9d5126-4d8e-4fd6-b50b-d36a8cac96b0"
      unitRef="usd">11624000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjMtMS0xLTEtMzUzMzA_bd85dd97-b232-4233-91f3-411dc6952413"
      unitRef="usd">28512000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjMtMy0xLTEtMzUzMzA_83e5d292-ef5d-411f-b26f-90d00c4d1aff"
      unitRef="usd">28156000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjQtMS0xLTEtMzUzMzA_f162f9c9-bbc5-476d-9f0d-59cb6be7ad4b"
      unitRef="usd">17412000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjQtMy0xLTEtMzUzMzA_d8cb0ad9-a39b-485f-95c3-4986a8ebc7c3"
      unitRef="usd">14695000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjUtMS0xLTEtMzUzMzA_c1b1ebb7-8f55-4a2e-b1f4-6faae1ca104c"
      unitRef="usd">309170000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjUtMy0xLTEtMzUzMzA_25683b40-e79d-4623-bd27-ed098c9e53a9"
      unitRef="usd">330008000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjYtMS0xLTEtMzUzMzA_43954c33-2f8c-4808-a0bc-f63ed3c5fe65"
      unitRef="usd">31596000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjYtMy0xLTEtMzUzMzA_de0e7ce1-0ce9-4acc-a760-e1f1a264f6e2"
      unitRef="usd">33097000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjctMS0xLTEtMzUzMzA_c71ea73b-a1d3-4499-9228-6e6d6074916d"
      unitRef="usd">210520000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjctMy0xLTEtMzUzMzA_e7b329fa-a81a-407d-82c3-d00c461d822e"
      unitRef="usd">187935000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjgtMS0xLTEtMzUzMzA_081b196b-1dc5-4e97-bdd7-34ed4bcb6762"
      unitRef="usd">125030000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjgtMy0xLTEtMzUzMzA_e92b2f9a-3ff5-4fdb-8284-562c632be7fb"
      unitRef="usd">148487000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjktMS0xLTEtMzUzMzA_c60f58bd-47c4-4e19-86da-636dfe798fdd"
      unitRef="usd">15658000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMjktMy0xLTEtMzUzMzA_c5b79645-8211-4c2d-b366-20ac29cf1351"
      unitRef="usd">15062000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzAtMS0xLTEtMzUzMzA_6ab1bde8-c6c1-4cfc-84ad-6233665e0a78"
      unitRef="usd">382804000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzAtMy0xLTEtMzUzMzA_8be78217-a35a-4cde-8920-166707bd8e3d"
      unitRef="usd">384581000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzEtMS0xLTEtMzUzMzA_50348783-fca9-41ce-8e97-3f94784f8f56"
      unitRef="usd">691974000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzEtMy0xLTEtMzUzMzA_88d630b4-1b11-4e62-b4ba-b1969a1b579c"
      unitRef="usd">714589000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjoyMzk0Mzk5ZDJlZWU0OGNkOTBmYzRiYjU1ZTk5MDQ1Ml8xOQ_3bcd4241-7eb4-4028-beb8-640eb0c9e747"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjoyMzk0Mzk5ZDJlZWU0OGNkOTBmYzRiYjU1ZTk5MDQ1Ml8xOQ_3e31a9c7-2cd7-4f9c-a78f-0a64e8661112"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjoyMzk0Mzk5ZDJlZWU0OGNkOTBmYzRiYjU1ZTk5MDQ1Ml8zMw_4d9a7693-00a5-4f4e-880e-4460f8640cbc"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjoyMzk0Mzk5ZDJlZWU0OGNkOTBmYzRiYjU1ZTk5MDQ1Ml8zMw_84b904c9-8b09-4354-b7b8-cfadb7b53282"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjoyMzk0Mzk5ZDJlZWU0OGNkOTBmYzRiYjU1ZTk5MDQ1Ml81NQ_07e82c81-a720-4efc-9b61-54fc8bc844bc"
      unitRef="shares">690138033</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjoyMzk0Mzk5ZDJlZWU0OGNkOTBmYzRiYjU1ZTk5MDQ1Ml82Mg_2aaa09e1-ebed-43b4-a9c5-fe799bc6eadf"
      unitRef="shares">690082283</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMS0xLTEtMzUzMzA_58aa7e42-1468-4085-9ab5-1280d694af39"
      unitRef="usd">6902000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzctMy0xLTEtMzUzMzA_e488a678-b745-4d4e-b613-08b7ab498eae"
      unitRef="usd">6901000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockShares
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzgtMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjo4N2FiZDU2ZGY3MjA0ZmQ3OTM0OTkyZTMxOGVmOGZiNF8yMQ_93dcc49f-d83f-45a9-a45b-e8221c0b8771"
      unitRef="shares">8655082</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzgtMC0xLTEtMzUzMzAvdGV4dHJlZ2lvbjo4N2FiZDU2ZGY3MjA0ZmQ3OTM0OTkyZTMxOGVmOGZiNF8yOA_f6b4849d-6c74-4ca4-a382-ea8bb8e12741"
      unitRef="shares">8655082</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzgtMS0xLTEtMzUzMzA_dd95fe53-b24b-4c56-9bbc-8d95c3c82172"
      unitRef="usd">1791000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzgtMy0xLTEtMzUzMzA_ade995da-cb24-4b1e-87fa-c7d82a62df3e"
      unitRef="usd">1791000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzktMS0xLTEtMzUzMzA_3c579e14-f504-44d4-894e-d5d8532427ec"
      unitRef="usd">3191139000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfMzktMy0xLTEtMzUzMzA_2dfcc91c-08cd-43a5-90a7-7b60555b55f5"
      unitRef="usd">3222487000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDAtMS0xLTEtMzUzMzA_529c6e72-308a-45fc-a956-f6d2a4ef447c"
      unitRef="usd">-31415000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDAtMy0xLTEtMzUzMzA_83bef1f6-f9b9-49a9-8fdf-227f05fedf89"
      unitRef="usd">-30495000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDEtMS0xLTEtMzUzMzA_de2f0d27-3cd8-4cb9-8cf1-27cb72e218a1"
      unitRef="usd">-1549951000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDEtMy0xLTEtMzUzMzA_15d18622-ee98-4857-8292-c64a150d3974"
      unitRef="usd">-1511976000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDQtMS0xLTEtMzUzMzA_fb22003e-6f8a-4d98-8d0f-90a387e530db"
      unitRef="usd">1614884000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDQtMy0xLTEtMzUzMzA_2a8ae8ad-6503-4036-b2fd-2cd4c824d1b4"
      unitRef="usd">1685126000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDUtMS0xLTEtMzUzMzA_28c99eb9-ca10-4871-9cd5-815636747a5d"
      unitRef="usd">2306858000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18xOS9mcmFnOmZlN2EzMWFkNmFhNDQxYWQ4YWIxNjFjZGY2YWE5YmZlL3RhYmxlOjc3NjkxNGYyYjhmNjQ2NjE5Y2Y3M2Q2MDU1MTIwOWI0L3RhYmxlcmFuZ2U6Nzc2OTE0ZjJiOGY2NDY2MTljZjczZDYwNTUxMjA5YjRfNDUtMy0xLTEtMzUzMzA_89563672-ffda-46a4-b97f-338cb14dc380"
      unitRef="usd">2399715000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f9c95a502354f4c9bd791e55a1b1acc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMy0xLTEtMS0zNTMzMA_f8a04afe-b689-4dbf-b3c2-43fcb8f39a66"
      unitRef="usd">286599000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fd3f89e217e4e329bca14b9905edffa_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMy0zLTEtMS0zNTMzMA_372225d9-55ea-4ffa-aa1f-71937d6a7ea7"
      unitRef="usd">506951000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85501a743668421b8f9b4903a091161f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNC0xLTEtMS0zNTMzMA_a470b2df-cba8-4c73-ad9c-7a7ee3f7d3a7"
      unitRef="usd">36658000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a1bb9d88fbc42c0b66fe51d04025dd1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNC0zLTEtMS0zNTMzMA_ffad1752-cbfe-4031-8e00-0258af6c40e4"
      unitRef="usd">33945000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e961cfc73ca4fc995f9df88000a19c4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNS0xLTEtMS0zNTMzMA_00249b19-ca00-43d3-a43d-0946fa7bfda2"
      unitRef="usd">5962000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66109927d116428aafb21943a884db23_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNS0zLTEtMS0zNTMzMA_b26a5b3d-0430-47ea-aa2b-45b271c101a2"
      unitRef="usd">4269000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNi0xLTEtMS0zNTMzMA_b3661dca-a357-44ac-9ec0-193f705ee850"
      unitRef="usd">329219000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNi0zLTEtMS0zNTMzMA_debb286a-d31d-491a-b328-af687976acd6"
      unitRef="usd">545165000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2f9c95a502354f4c9bd791e55a1b1acc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfOC0xLTEtMS0zNTMzMA_e57b8ea8-a6dd-4bbb-886e-a03aab66b05b"
      unitRef="usd">221202000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6fd3f89e217e4e329bca14b9905edffa_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfOC0zLTEtMS0zNTMzMA_7a1d9636-10c4-4ea2-89c8-85a9ff2641c4"
      unitRef="usd">339429000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i85501a743668421b8f9b4903a091161f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfOS0xLTEtMS0zNTMzMA_511ba50c-b857-4a59-872c-c22b5c684b3a"
      unitRef="usd">22673000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5a1bb9d88fbc42c0b66fe51d04025dd1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfOS0zLTEtMS0zNTMzMA_f7e18221-8d71-44de-b888-44617672a042"
      unitRef="usd">24078000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTEtMS0xLTEtMzUzMzA_29de4488-ccfd-4121-bcc4-3cac71898855"
      unitRef="usd">117537000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTEtMy0xLTEtMzUzMzA_881614df-4012-4a25-a0a6-0decee5c0be3"
      unitRef="usd">112286000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTItMS0xLTEtMzUzMzA_9d1c1c82-fcf6-4123-a836-2846ad46abba"
      unitRef="usd">18312000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTItMy0xLTEtMzUzMzA_c868840d-190c-4103-a009-b1689ea6cca9"
      unitRef="usd">19315000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTQtMS0xLTEtMzUzMzA_fcddb405-e92e-4a00-aeaa-8758937f8083"
      unitRef="usd">-106000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTQtMy0xLTEtMzUzMzA_ff5b29f0-9c7b-4461-b45c-abb710fc662a"
      unitRef="usd">-957000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTUtMS0xLTEtMzUzMzA_a601e3e5-59b6-4eda-9471-c72b611e502a"
      unitRef="usd">22025000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTUtMy0xLTEtMzUzMzA_3909eddb-e8e6-411d-9b33-60cc2c9871ca"
      unitRef="usd">12577000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingExpenses
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTctMS0xLTEtMzUzMzA_72c42a07-fa3f-4982-ad4a-b8aa98e00e4d"
      unitRef="usd">401643000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTctMy0xLTEtMzUzMzA_b95cf624-919c-4cd6-94e5-b09ea4b23283"
      unitRef="usd">506728000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTgtMS0xLTEtMzUzMzA_47a89dfd-789c-4d1c-a103-cf7bbbb58785"
      unitRef="usd">-72424000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMTgtMy0xLTEtMzUzMzA_3552a372-4aed-4934-acb4-033f61d23ca8"
      unitRef="usd">38437000</us-gaap:OperatingIncomeLoss>
    <opk:InterestIncomeNonoperating
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjAtMS0xLTEtMzUzMzA_f4758e2b-910d-4f05-96c5-d45fddc6bbfa"
      unitRef="usd">10000</opk:InterestIncomeNonoperating>
    <opk:InterestIncomeNonoperating
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjAtMy0xLTEtMzUzMzA_d409292a-e232-44c6-be32-219122c47a57"
      unitRef="usd">5000</opk:InterestIncomeNonoperating>
    <opk:InterestExpenseNonoperating
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjEtMS0xLTEtMzUzMzA_7f06f4e4-c1a5-48ca-81d7-0f3e1a3b5d66"
      unitRef="usd">2662000</opk:InterestExpenseNonoperating>
    <opk:InterestExpenseNonoperating
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjEtMy0xLTEtMzUzMzA_0be3eeaa-373e-4b32-a88e-e976ea7aa2e8"
      unitRef="usd">5395000</opk:InterestExpenseNonoperating>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjItMS0xLTEtMzUzMzA_096dbfa8-567e-4567-8e3e-cb2908d6188e"
      unitRef="usd">-132000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjItMy0xLTEtMzUzMzA_d7fe104c-2128-474e-b666-91a384ae5c1c"
      unitRef="usd">-439000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjMtMS0xLTEtMzUzMzA_5af47c2c-da8e-4f72-a561-f8ee2280eb79"
      unitRef="usd">-1442000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjMtMy0xLTEtMzUzMzA_14c73d4b-3a26-46f3-97e2-6f9e7390081d"
      unitRef="usd">-927000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjQtMS0xLTEtMzUzMzA_1c18dc26-95da-4f28-89b6-ffe3fb46af96"
      unitRef="usd">-4226000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjQtMy0xLTEtMzUzMzA_2554828d-ff55-42cc-98c9-ee6e232c4b6b"
      unitRef="usd">-6756000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjUtMS0xLTEtMzUzMzA_24508596-bf1c-4e0d-89c5-6ffbe742a067"
      unitRef="usd">-76650000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjUtMy0xLTEtMzUzMzA_c43c4322-7bf7-4e07-90c6-2d097dde95b8"
      unitRef="usd">31681000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjYtMS0xLTEtMzUzMzA_d2a14a09-fbd3-4223-a941-6738bccea430"
      unitRef="usd">-21266000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjYtMy0xLTEtMzUzMzA_cf735dc8-b8a5-427c-87fc-fc7306a907ce"
      unitRef="usd">560000</us-gaap:IncomeTaxExpenseBenefit>
    <opk:IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjctMS0xLTEtMzUzMzA_abac7f00-cb27-4171-a8d0-63f8cc9d89be"
      unitRef="usd">-55384000</opk:IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax>
    <opk:IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjctMy0xLTEtMzUzMzA_2c685f56-3766-4d6a-928f-dfe4fd758b69"
      unitRef="usd">31121000</opk:IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjgtMS0xLTEtMzUzMzA_04b90bcb-b8b0-4500-aef5-1d0b895b3249"
      unitRef="usd">-49000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjgtMy0xLTEtMzUzMzA_e118202f-5ea9-472b-bd04-4516ecf31d63"
      unitRef="usd">-43000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjktMS0xLTEtMzUzMzA_07a060cb-e529-457f-9f3f-197c34701a9e"
      unitRef="usd">-55433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMjktMy0xLTEtMzUzMzA_5cf353fa-8fc5-412d-863b-25286cb646aa"
      unitRef="usd">31078000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMzktMS0xLTEtMzUzMzA_3de76f2e-15cd-4625-be79-a540c9b328a3"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMzktMS0xLTEtMzUzMzA_b8eaac05-9a5f-4f64-9175-4c976f8b4d7f"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMzktMy0xLTEtMzUzMzA_690a8eb1-9f14-4db1-87d0-b8b1bfde33fe"
      unitRef="usdPerShare">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfMzktMy0xLTEtMzUzMzA_9749e45c-be52-4819-b307-cfbb8ed5459e"
      unitRef="usdPerShare">0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNDEtMS0xLTEtMzUzMzA_5600001b-486f-40ba-94c1-1e7d72fb71b4"
      unitRef="shares">660302426</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNDEtMS0xLTEtMzUzMzA_b824e8d8-29df-4783-83e3-fe9c697f92bf"
      unitRef="shares">660302426</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNDEtMy0xLTEtMzUzMzA_1e0e06c7-f731-40d4-8d84-aae1abb6614a"
      unitRef="shares">640853200</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yNS9mcmFnOmQ4YmY3NzlhZmJjZDQ5NDhhMjU1MzZlMTE4MjJhZTRiL3RhYmxlOjI4YTI3NzBiMTAyYTQ1OGViOTNhNDliNmExN2RiMDc4L3RhYmxlcmFuZ2U6MjhhMjc3MGIxMDJhNDU4ZWI5M2E0OWI2YTE3ZGIwNzhfNDEtMy0xLTEtMzUzMzA_b1ba8089-c2cf-4f7e-a1d3-45ef73fd5a1b"
      unitRef="shares">640853200</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yOC9mcmFnOjQxZmRjMGM3NjRhOTQyNDVhMDYzY2NhMjQ0MGU5Yzg4L3RhYmxlOjlmMGEwNTZlZGI2NTQ5ZGY4ZWZmYjk1ZTE5MTg4ZjMyL3RhYmxlcmFuZ2U6OWYwYTA1NmVkYjY1NDlkZjhlZmZiOTVlMTkxODhmMzJfMi0xLTEtMS0zNTMzMA_569d9a4d-a6f0-414e-b2f4-072d28a25b9e"
      unitRef="usd">-55433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yOC9mcmFnOjQxZmRjMGM3NjRhOTQyNDVhMDYzY2NhMjQ0MGU5Yzg4L3RhYmxlOjlmMGEwNTZlZGI2NTQ5ZGY4ZWZmYjk1ZTE5MTg4ZjMyL3RhYmxlcmFuZ2U6OWYwYTA1NmVkYjY1NDlkZjhlZmZiOTVlMTkxODhmMzJfMi0zLTEtMS0zNTMzMA_7228f3a5-dd05-4a64-bf85-46b159ec61cb"
      unitRef="usd">31078000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yOC9mcmFnOjQxZmRjMGM3NjRhOTQyNDVhMDYzY2NhMjQ0MGU5Yzg4L3RhYmxlOjlmMGEwNTZlZGI2NTQ5ZGY4ZWZmYjk1ZTE5MTg4ZjMyL3RhYmxlcmFuZ2U6OWYwYTA1NmVkYjY1NDlkZjhlZmZiOTVlMTkxODhmMzJfNC0xLTEtMS0zNTMzMA_4dd504c9-7ecb-4137-94f4-5a11056d23a2"
      unitRef="usd">-920000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yOC9mcmFnOjQxZmRjMGM3NjRhOTQyNDVhMDYzY2NhMjQ0MGU5Yzg4L3RhYmxlOjlmMGEwNTZlZGI2NTQ5ZGY4ZWZmYjk1ZTE5MTg4ZjMyL3RhYmxlcmFuZ2U6OWYwYTA1NmVkYjY1NDlkZjhlZmZiOTVlMTkxODhmMzJfNC0zLTEtMS0zNTMzMA_01123ca9-8b4d-4761-9b6f-409d6864944c"
      unitRef="usd">-9070000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yOC9mcmFnOjQxZmRjMGM3NjRhOTQyNDVhMDYzY2NhMjQ0MGU5Yzg4L3RhYmxlOjlmMGEwNTZlZGI2NTQ5ZGY4ZWZmYjk1ZTE5MTg4ZjMyL3RhYmxlcmFuZ2U6OWYwYTA1NmVkYjY1NDlkZjhlZmZiOTVlMTkxODhmMzJfOS0xLTEtMS0zNTMzMA_a22fe0b4-65b4-4a29-bfe5-088137a9b2eb"
      unitRef="usd">-56353000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18yOC9mcmFnOjQxZmRjMGM3NjRhOTQyNDVhMDYzY2NhMjQ0MGU5Yzg4L3RhYmxlOjlmMGEwNTZlZGI2NTQ5ZGY4ZWZmYjk1ZTE5MTg4ZjMyL3RhYmxlcmFuZ2U6OWYwYTA1NmVkYjY1NDlkZjhlZmZiOTVlMTkxODhmMzJfOS0zLTEtMS0zNTMzMA_5940d681-7257-43d9-b2b7-530f2c226366"
      unitRef="usd">22008000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="ic3804ba279de40cdb6e0567ff03eedfd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi01LTEtMS0zNTMzMA_53f03fb8-d0d5-45d0-b421-c752ff8556a9"
      unitRef="shares">690082283</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic3804ba279de40cdb6e0567ff03eedfd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi03LTEtMS0zNTMzMA_fb3283a4-e21a-40ae-842e-c9d9038bd8f9"
      unitRef="usd">6901000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ied0a49adeefd4e1fac80ec50e4698621_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi05LTEtMS0zNTMzMA_f63aea21-d550-47b1-8ede-b8178b4ebfc3"
      unitRef="shares">8655082</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ied0a49adeefd4e1fac80ec50e4698621_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi0xMS0xLTEtMzUzMzA_cb46a799-f828-4134-ad9c-6be459f7c50f"
      unitRef="usd">-1791000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibbf602f14f46471d9d178ec252d385a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi0xMy0xLTEtMzUzMzA_3a40d007-234d-4394-8251-81b7c5c11bca"
      unitRef="usd">3222487000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia6d0ba7a733345be9b1fdc07bf34b423_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi0xNS0xLTEtMzUzMzA_97275988-08dd-4ab4-88f2-dac95dae6bca"
      unitRef="usd">-30495000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22bb54bd14a34a3ab35f37edf368d2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi0xNy0xLTEtMzUzMzA_7017e338-56e3-4f6d-b22f-2ce142f035a1"
      unitRef="usd">-1511976000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMi0yMS0xLTEtMzUzMzA_88cf3be2-6161-4c91-923a-91a292e90d44"
      unitRef="usd">1685126000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i646a74fab4f84bf98ac3afc12ad3422e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMy0xMy0xLTEtMzUzMzA_4af8e062-0859-4023-923d-387e7aaacef3"
      unitRef="usd">7617000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfMy0yMS0xLTEtMzUzMzA_27e17007-6d7e-4a53-bd5a-65a6d816b703"
      unitRef="usd">7617000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3ec1789e0468407da526985ac43b1656_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNC01LTEtMS0zNTMzMA_f3359923-fba4-4a1b-b432-09e6c00de6a9"
      unitRef="shares">55750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3ec1789e0468407da526985ac43b1656_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNC03LTEtMS0zNTMzMA_46257127-1165-45bb-ba9f-25c30566a9d8"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i646a74fab4f84bf98ac3afc12ad3422e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNC0xMy0xLTEtMzUzMzA_aba39d35-517b-4aa4-8f8c-7158d77a2db5"
      unitRef="usd">135000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNC0yMS0xLTEtMzUzMzA_d16de3a1-89fb-4687-9c92-7c7ba412f157"
      unitRef="usd">136000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic6af8b25ddc04918b13d874863276327_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNS0xMy0xLTEtMzUzMzA_fe353639-7a24-4669-8f82-e2e47717b18d"
      unitRef="usd">-39100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb2b0dab2c974aca988d625e077fe49b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNS0xNy0xLTEtMzUzMzA_ede1afa8-8cfe-403b-8d18-09eccd7d02db"
      unitRef="usd">17458000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibfe95975785f4da2a0792b40c68274b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNS0yMS0xLTEtMzUzMzA_0135d185-a5d5-4c46-97e5-e7406be19306"
      unitRef="usd">-21642000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="id2b1a62808234ad7b78fb28d31a7ee36_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNy0xNy0xLTEtMzUzMzA_0aeda4ca-8823-46ad-928e-d3f7ec810183"
      unitRef="usd">-55433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfNy0yMS0xLTEtMzUzMzA_a2f8c011-1aa0-4316-a2fc-27a95e05a3e2"
      unitRef="usd">-55433000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i08134a4538f24e06bd29a6faf920f1bf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOC0xNS0xLTEtMzUzMzA_11e13fe6-09d3-4775-96dc-b63d207264d9"
      unitRef="usd">-920000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOC0yMS0xLTEtMzUzMzA_e5457284-5174-4a58-9c07-b1d9506674c4"
      unitRef="usd">-920000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="idad4ab8f901e456a921f38433308a875_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS01LTEtMS0zNTMzMA_0bf79391-890b-43e1-9484-8d01309a48f2"
      unitRef="shares">690138033</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idad4ab8f901e456a921f38433308a875_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS03LTEtMS0zNTMzMA_18117c13-3154-4280-bc33-28df6106da43"
      unitRef="usd">6902000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i63a9708ca6b241cbbf8a971c348c1b9c_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS05LTEtMS0zNTMzMA_b786c731-8680-41d9-bbb3-7549afccc794"
      unitRef="shares">8655082</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63a9708ca6b241cbbf8a971c348c1b9c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS0xMS0xLTEtMzUzMzA_f4e42ee7-42c7-46ca-a391-64acf353ca1f"
      unitRef="usd">-1791000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95f76eb90058493b8b9714b06a32ca6a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS0xMy0xLTEtMzUzMzA_c3d54c9a-8c68-430c-89af-b3c4f46cdc73"
      unitRef="usd">3191139000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86a2019e2f9a4c668d4bcb4561aaf856_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS0xNS0xLTEtMzUzMzA_7f4aeb33-39e9-4fd1-a43f-dd98d286938e"
      unitRef="usd">-31415000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5ac38aea5024455837e4b0a72c6cc5c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS0xNy0xLTEtMzUzMzA_1f45ecce-95f5-4c7f-ac8c-c4efeb4d8f13"
      unitRef="usd">-1549951000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQwODk0MzNhMmIzNzQzZjQ4ZmViYTQ1ZDJhZjQwNDZmL3RhYmxlcmFuZ2U6NDA4OTQzM2EyYjM3NDNmNDhmZWJhNDVkMmFmNDA0NmZfOS0yMS0xLTEtMzUzMzA_c88e4d4f-c9a3-45d4-b3d4-5fcda99e25df"
      unitRef="usd">1614884000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i2e33b9f98a1b4d2196ed092e6e422c9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi01LTEtMS0zNTMzMA_e0dd765a-ea3d-48db-9199-ac08adaac069"
      unitRef="shares">670585576</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e33b9f98a1b4d2196ed092e6e422c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi03LTEtMS0zNTMzMA_3b952556-63cb-4c16-9734-1af22aaa6c93"
      unitRef="usd">6706000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="idf50959849a64f92b031a93fb028f210_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi05LTEtMS0zNTMzMA_5371623b-6a0b-4965-8701-84fe192e8232"
      unitRef="shares">549907</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf50959849a64f92b031a93fb028f210_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi0xMS0xLTEtMzUzMzA_077a987c-7879-44a7-b68a-e4dbd9a4a014"
      unitRef="usd">-1791000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i776417f572dd43b785ccc5de1a3fdd29_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi0xMy0xLTEtMzUzMzA_0550021f-29a3-4e6d-a0a2-68bd03bcb2ac"
      unitRef="usd">3152694000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if3c39548fd884077aba54bc5130c8aa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi0xNS0xLTEtMzUzMzA_24646164-a592-4888-8470-91d8ae8bc854"
      unitRef="usd">-4225000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7dd9c60c32484868940a0edb35f5b606_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi0xNy0xLTEtMzUzMzA_5be237b3-c563-46fe-9407-818bc5ee7316"
      unitRef="usd">-1481833000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08082c8210bd41e08e8e6102a684ff8b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMi0yMS0xLTEtMzUzMzA_4b6537a6-5783-49f7-b601-7597424fb735"
      unitRef="usd">1671551000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia1a9671afbc747319965e4950c1d5673_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMy0xMy0xLTEtMzUzMzA_bc173071-598f-498f-991a-787260541585"
      unitRef="usd">2647000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfMy0yMS0xLTEtMzUzMzA_d3bdb71c-82f3-4a47-b56d-5417eaabeeaf"
      unitRef="usd">2647000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2c2c25cd759044e8a8b1ac83a456a490_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfNC01LTEtMS0zNTMzMA_1b17e296-40c3-45a3-bc64-d92d07b5b518"
      unitRef="shares">117500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2c2c25cd759044e8a8b1ac83a456a490_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfNC03LTEtMS0zNTMzMA_2172d4e8-9a70-494d-a616-7f3a3b73a379"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia1a9671afbc747319965e4950c1d5673_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfNC0xMy0xLTEtMzUzMzA_6c359d29-cc42-4bad-8288-9a3311d09b30"
      unitRef="usd">307000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfNC0yMS0xLTEtMzUzMzA_0038e5d0-ac11-47d5-8702-b2fd48fa4a18"
      unitRef="usd">308000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="ia73d31bf5c2240cdb0ccd63c8a4348c1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfNy0xNy0xLTEtMzUzMzA_846104ca-41a2-4525-a2b9-05d4d67541da"
      unitRef="usd">31078000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfNy0yMS0xLTEtMzUzMzA_55c7b830-620c-49fb-b095-cafe5e227d46"
      unitRef="usd">31078000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i69f0a1d1a7fd49089a06dcef395b5c5b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOC0xNS0xLTEtMzUzMzA_47e8f5df-0e58-46ff-a29f-57d493a460af"
      unitRef="usd">-9070000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOC0yMS0xLTEtMzUzMzA_bdceb34c-4240-4723-919b-893c761c2f9e"
      unitRef="usd">-9070000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="ifc66eff602d7434281e15843b60d6d9a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS01LTEtMS0zNTMzMA_e8686a37-00f8-4307-9ad7-b3c9f9d43773"
      unitRef="shares">670703076</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc66eff602d7434281e15843b60d6d9a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS03LTEtMS0zNTMzMA_113e81e7-d384-4b03-9af9-b49511ebf4d4"
      unitRef="usd">6707000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i91568ba4c6ad4c9bbb8a6d13b2cca42c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS05LTEtMS0zNTMzMA_bdd7e993-eb63-482c-85f6-00280f704672"
      unitRef="shares">549907</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i91568ba4c6ad4c9bbb8a6d13b2cca42c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS0xMS0xLTEtMzUzMzA_b9e5ed18-85ac-4656-b409-e4ab2b6ffadc"
      unitRef="usd">-1791000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d685f0119934d39a093d66dd07cd19f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS0xMy0xLTEtMzUzMzA_9201a2e1-e6cf-4dfd-8e6a-6297a6598e68"
      unitRef="usd">3155648000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8f0316ac515435b82f539c2ec2dd817_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS0xNS0xLTEtMzUzMzA_b80761ad-94de-4c4d-bd93-d4dced17bf73"
      unitRef="usd">-13295000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i632c4e422f024ca6bb911a55e1259fcb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS0xNy0xLTEtMzUzMzA_a6b3ca4f-940a-4f86-8f9d-f8904a98a476"
      unitRef="usd">-1450755000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i402dd9684c2f477db500daa02097978b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zMS9mcmFnOjBlYTMzYmQ4MjRmMjQ0MTU4YjNjYmU1NjE0YWFlODNmL3RhYmxlOjQ4ZjNmODZlNjliYTQyOTA5YmVmMjg0MWI5ZjBkNzA2L3RhYmxlcmFuZ2U6NDhmM2Y4NmU2OWJhNDI5MDliZWYyODQxYjlmMGQ3MDZfOS0yMS0xLTEtMzUzMzA_4fc0450c-6546-40e7-a1cb-ac603a85256a"
      unitRef="usd">1696514000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMy0xLTEtMS0zNTMzMA_8badcd60-9a1d-4bf9-a93c-689f11fe25d5"
      unitRef="usd">-55433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMy0zLTEtMS0zNTMzMA_b993d9e5-04f7-40dd-adb6-6de8acd3d664"
      unitRef="usd">31078000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNi0xLTEtMS0zNTMzMA_bd5d0e63-ff74-40f3-b571-8b8c4e6345a8"
      unitRef="usd">27814000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNi0zLTEtMS0zNTMzMA_872b9ad8-9820-43a3-84b9-137570863ba1"
      unitRef="usd">19989000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PaidInKindInterest
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNy0xLTEtMS0zNTMzMA_a9e4eca8-ffac-41b7-a4a4-13e02923ef77"
      unitRef="usd">678000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNy0zLTEtMS0zNTMzMA_abd47f67-67cb-44d1-9a0d-3894392e4268"
      unitRef="usd">2585000</us-gaap:PaidInKindInterest>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfOC0xLTEtMS0zNTMzMA_80a1aac8-586e-4ebe-bc3f-8c29d15e800e"
      unitRef="usd">281000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfOC0zLTEtMS0zNTMzMA_3f7b0823-2676-40e0-bdac-99c2798042f8"
      unitRef="usd">222000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTAtMS0xLTEtMzUzMzA_50fdb5e4-fcdb-42e7-af15-1409412fb8a3"
      unitRef="usd">-49000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTAtMy0xLTEtMzUzMzA_50e0c144-924b-49e7-9e20-b4d2dfc12b3d"
      unitRef="usd">-43000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTEtMS0xLTEtMzUzMzA_e8094011-9318-49a6-be68-ebb9980e2283"
      unitRef="usd">7617000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTEtMy0xLTEtMzUzMzA_fbe74af1-853f-45dd-880c-22bdd93aeb77"
      unitRef="usd">2647000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTUtMS0xLTEtMzUzMzA_b0808da1-5bef-4f81-b273-eb35b7b42494"
      unitRef="usd">-61000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTUtMy0xLTEtMzUzMzA_c06a2c1c-15b7-4c66-8ccb-0e488402158b"
      unitRef="usd">3039000</us-gaap:GainLossOnDispositionOfAssets1>
    <opk:IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTgtMS0xLTEtMzUzMzA_10a28473-42e3-4680-b401-950210c02834"
      unitRef="usd">-1299000</opk:IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments>
    <opk:IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMTgtMy0xLTEtMzUzMzA_a20f319d-7595-4dd2-9a1e-f37b97d08118"
      unitRef="usd">279000</opk:IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjAtMS0xLTEtMzUzMzA_7b40202c-4583-4a70-a683-c8afb2bc58d9"
      unitRef="usd">-106000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjAtMy0xLTEtMzUzMzA_59782d3b-31d0-48f5-a39f-011712706212"
      unitRef="usd">-957000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjQtMS0xLTEtMzUzMzA_450a3386-736f-44a1-a3c1-9e17d9963ce1"
      unitRef="usd">-22356000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjQtMy0xLTEtMzUzMzA_0767bee0-30d8-4b27-bb50-eacc6e25e9cf"
      unitRef="usd">-1033000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjYtMS0xLTEtMzUzMzA_0b9f9491-f6ef-4dde-9afe-36e0e1760f96"
      unitRef="usd">-44421000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjYtMy0xLTEtMzUzMzA_45008fa7-90a1-4a11-ab1d-d807ad6a0e45"
      unitRef="usd">35238000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjctMS0xLTEtMzUzMzA_19e6e616-e6b8-4806-894e-b8512acde105"
      unitRef="usd">9463000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjctMy0xLTEtMzUzMzA_f71850c6-a43b-451e-a829-a95051b6888d"
      unitRef="usd">27912000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjgtMS0xLTEtMzUzMzA_92ef2329-4b9e-4d3a-bc4d-abcfb92f5f55"
      unitRef="usd">-2612000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjgtMy0xLTEtMzUzMzA_57fd001a-95bd-416b-9f72-bc91148b0b8f"
      unitRef="usd">-1415000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjktMS0xLTEtMzUzMzA_0859c111-c778-4bc4-875a-108f7608d7af"
      unitRef="usd">-511000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMjktMy0xLTEtMzUzMzA_688411d1-8312-48ce-b9ec-4dfbe0609a42"
      unitRef="usd">-1255000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzAtMS0xLTEtMzUzMzA_25a32327-af4b-4f82-b388-64c5e9f6a137"
      unitRef="usd">16143000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzAtMy0xLTEtMzUzMzA_ca249f99-c141-446e-884c-c0ff260a1aeb"
      unitRef="usd">62231000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <opk:IncreaseDecreaseinForeignCurrencyMeasurement
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzEtMS0xLTEtMzUzMzA_59361262-8b19-4d97-ab00-c55234e2e277"
      unitRef="usd">2197000</opk:IncreaseDecreaseinForeignCurrencyMeasurement>
    <opk:IncreaseDecreaseinForeignCurrencyMeasurement
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzEtMy0xLTEtMzUzMzA_05089e88-035f-4882-926d-b8a128a51108"
      unitRef="usd">946000</opk:IncreaseDecreaseinForeignCurrencyMeasurement>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzItMS0xLTEtMzUzMzA_c69e5015-e7a9-448e-b9f1-9f6b115b70b2"
      unitRef="usd">-4000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzItMy0xLTEtMzUzMzA_ffba4af4-8a6d-446a-b558-5a6d428ab773"
      unitRef="usd">-790000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzMtMS0xLTEtMzUzMzA_c437574b-2c63-4a17-9b64-07a087785130"
      unitRef="usd">-36177000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzMtMy0xLTEtMzUzMzA_ac5b4c07-b37d-4eb7-bd15-c4d4fa3241fa"
      unitRef="usd">-27126000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzYtMS0xLTEtMzUzMzA_090afc85-b373-4115-a709-c2192e0b9811"
      unitRef="usd">-19856000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzYtMy0xLTEtMzUzMzA_52e56f11-519a-48be-956f-68306de637d0"
      unitRef="usd">26037000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzktMS0xLTEtMzUzMzA_73f70656-3e98-497c-beb1-76d991590b3a"
      unitRef="usd">0</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfMzktMy0xLTEtMzUzMzA_5a5f1294-517b-4b39-94af-676f7e30bd79"
      unitRef="usd">8079000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNDMtMS0xLTEtMzUzMzA_5bcc9d15-b20b-44b9-9ab9-1819052ef1c4"
      unitRef="usd">348000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNDMtMy0xLTEtMzUzMzA_442cc5e7-589d-49f0-bdf0-f787773d88c0"
      unitRef="usd">60000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNDUtMS0xLTEtMzUzMzA_93549031-03b5-4664-b13f-12480a296b7f"
      unitRef="usd">5251000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNDUtMy0xLTEtMzUzMzA_456f078f-c518-4631-9a07-3278fccf09e1"
      unitRef="usd">9245000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNDYtMS0xLTEtMzUzMzA_dc99d5f1-ab5c-448c-92ef-bcd898befdcd"
      unitRef="usd">-4903000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNDYtMy0xLTEtMzUzMzA_b1d160c1-37e3-46dd-8699-dc1aad88ecf2"
      unitRef="usd">-1106000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTEtMS0xLTEtMzUzMzA_8110f3d8-9f17-4384-bffb-1b7b3557bed3"
      unitRef="usd">136000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTEtMy0xLTEtMzUzMzA_0102bd28-26c0-47b1-a23b-03ca78760cda"
      unitRef="usd">308000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTQtMS0xLTEtMzUzMzA_6c8ee646-1a1d-4ee8-a575-4d4ee95a9f36"
      unitRef="usd">1649166000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTQtMy0xLTEtMzUzMzA_004e1952-5f19-401b-828a-47edfc79079a"
      unitRef="usd">472213000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTUtMS0xLTEtMzUzMzA_ec5c79f3-1651-45a8-967f-e7743c256f62"
      unitRef="usd">1657193000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTUtMy0xLTEtMzUzMzA_1c19ae39-2060-4ffa-ad43-d469c22dd59d"
      unitRef="usd">479713000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTktMS0xLTEtMzUzMzA_a3df4a92-0725-4aa3-9e11-da14096e181c"
      unitRef="usd">-7891000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNTktMy0xLTEtMzUzMzA_629622e0-bfa3-4639-8208-ef20e7cf91cf"
      unitRef="usd">-7192000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjAtMS0xLTEtMzUzMzA_6760dfc3-b2d5-4b8e-a208-1847231d1371"
      unitRef="usd">221000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjAtMy0xLTEtMzUzMzA_5cf90384-702e-4d54-a30c-c1373beac330"
      unitRef="usd">-447000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjEtMS0xLTEtMzUzMzA_e7a8255b-fb0b-428e-91cf-50c86e0ba44b"
      unitRef="usd">-32429000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjEtMy0xLTEtMzUzMzA_ca06e956-f9f9-4174-ad85-07498ddd2938"
      unitRef="usd">17292000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjItMS0xLTEtMzUzMzA_8f8a1817-a187-4c56-9270-8f80da4875a2"
      unitRef="usd">134710000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i08082c8210bd41e08e8e6102a684ff8b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjItMy0xLTEtMzUzMzA_1e92d0cb-50e4-48fa-a653-066006a8c31f"
      unitRef="usd">72211000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjMtMS0xLTEtMzUzMzA_8d107a28-215e-4046-b6db-1f5551dea90d"
      unitRef="usd">102281000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i402dd9684c2f477db500daa02097978b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjMtMy0xLTEtMzUzMzA_8a3ff4ce-666c-42ae-9607-18a0e85a48a4"
      unitRef="usd">89503000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjUtMS0xLTEtMzUzMzA_debb568c-5c94-407d-8f30-de737a454092"
      unitRef="usd">3420000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjUtMy0xLTEtMzUzMzA_af3acd9d-0454-4d1d-a79b-b4b003a3ce28"
      unitRef="usd">4689000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjYtMS0xLTEtMzUzMzA_d6441740-c553-46ab-84b2-ce0646670ee7"
      unitRef="usd">1063000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y18zNC9mcmFnOjUwMDkxODUzZjU2MjQxN2E4YjVmYjMyOTMxZTdlNmRkL3RhYmxlOjEwZTdmNmM2ZGNlYjQ3MjM5YjY0ZDcwZmEzYjQ4M2M0L3RhYmxlcmFuZ2U6MTBlN2Y2YzZkY2ViNDcyMzliNjRkNzBmYTNiNDgzYzRfNjYtMy0xLTEtMzUzMzA_46848741-5798-4107-adf9-aa3a8fc9f079"
      unitRef="usd">1470000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzU3Nw_6fdd886f-d075-4608-a707-548badf9a653">BUSINESS AND ORGANIZATION&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;medical markets. Our diagnostics business includes BioReference Health, LLC, formerly known as BioReference Laboratories, Inc. (&#x201c;BioReference&#x201d;), one of the nation&#x2019;s largest full service laboratories with an almost 250-person sales and marketing team to drive growth and leverage new products. Our pharmaceutical business features &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approved treatment for secondary hyperparathyroidism (&#x201c;SHPT&#x201d;) in adults with stage 3 or 4 chronic kidney disease (&#x201c;CKD&#x201d;) and vitamin D insufficiency and a pipeline of products in various stages of development. Our leading product in development is Somatrogon (hGH-CTP), a once-weekly human growth hormone for which we have partnered with Pfizer, Inc. (&#x201c;Pfizer&#x201d;) and successfully completed a phase 3 study in August 2019. Regulatory applications for Somatrogon (hGH-CTP) have been submitted to the applicable regulatory bodies for review in several countries around the world.  In February 2022, the European Commission granted marketing authorization in the European Union for Somatrogon (hGH-CTP) under the brand name NGENLA&#xae; to treat children and adolescents from as young as three years of age with growth disturbance due to insufficient secretion of growth hormone, and we recently received pricing approval in Germany. In January 2022, the Ministry of Health, Labour and Welfare in Japan approved NGENLA&#xae; (Somatrogon) for the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone and we recently received pricing approval. In October 2021, Health Canada approved NGENLA&#xae; for the long-term treatment of pediatric patients who have growth hormone deficiency, and Australia&#x2019;s Therapeutic Goods Administration approved NGENLA&#xae; for the long-term treatment of pediatric patients with growth disturbance due to insufficient secretion of growth hormone.  We also submitted the initial Biologics License Application (&#x201c;BLA&#x201d;) with the FDA for approval of Somatrogon (hGH-CTP) in the United States and Pfizer received a Complete Response Letter in January 2022.  Pfizer and OPKO are evaluating the FDA&#x2019;s comments and will work with the agency to determine the best path forward for Somatrogon (hGH-CTP) in the United States.  We are incorporated in Delaware, and our principal executive offices are located in leased offices in Miami, Florida.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through BioReference, we provide laboratory testing services, primarily to customers in the larger metropolitan areas in New York, New Jersey, Florida, Texas, Maryland, California, Pennsylvania, Delaware, Washington, DC, Illinois and Massachusetts, as well as to customers in a number of other states.  We offer a comprehensive test menu of clinical diagnostics for blood, urine and tissue analysis.  This includes hematology, clinical chemistry, immunoassay, infectious&#160;diseases, serology, hormones, and toxicology assays, as well as Pap smear, anatomic pathology (biopsies) and other types of tissue analysis.  We market our laboratory testing services directly to physicians, geneticists, hospitals, clinics, correctional and other health facilities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate established pharmaceutical platforms in Ireland, Chile, Spain, and Mexico, which are generating revenue and from which we expect to generate positive cash flow and facilitate future market entry for our products currently in development.  In addition, we have a development and commercial supply pharmaceutical company and a global supply chain operation and holding company in Ireland.  We own a specialty active pharmaceutical ingredients (&#x201c;APIs&#x201d;) manufacturer in Israel, which we expect will facilitate the development of our pipeline of molecules and compounds for our proprietary molecular diagnostic and therapeutic products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our research and development activities are primarily performed at facilities in Woburn, MA, Waterford, Ireland, Kiryat Gat, Israel, and Barcelona, Spain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, Sema4 Holdings Corp. (&#x201c;Sema4&#x201d;) and OPKO entered into an Agreement and Plan of Merger and Reorganization (the &#x201c;GeneDx Merger Agreement&#x201d;), pursuant to which Sema4 agreed to acquire OPKO&#x2019;s wholly owned subsidiary, GeneDx LLC, formerly GeneDx, Inc. (&#x201c;GeneDx&#x201d;), subject to satisfaction of customary closing conditions (the &#x201c;GeneDx Transaction&#x201d;). The GeneDx Transaction closed on April 29, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the GeneDx Merger Agreement, Sema4 acquired GeneDx for an upfront payment of $150&#160;million in cash, subject to adjustments, plus 80.0&#160;million shares of Sema4&#x2019;s Class A common stock, and Sema4 has agreed to pay up to an additional $150&#160;million in consideration subject to the satisfaction of certain revenue-based milestones over the next two years (which will be payable in cash or shares of Sema4&#x2019;s Class A common stock at Sema4&#x2019;s discretion). Based on the closing stock price of Sema4 as of April 29, 2022, the total upfront consideration represents approximately $322&#160;million, and the total aggregate consideration including potential milestones is approximately $472&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December 31, 2021, GeneDx met the held-for-sale accounting criteria and, its related assets and liabilities are classified as held for sale in the consolidated balance sheet. GeneDx was included in our diagnostics segment as of March&#160;31, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;In June 2021, EirGen Pharma Limited (&#x201c;EirGen&#x201d;), our wholly owned subsidiary, entered into a definitive agreement to sell one of its facilities in Waterford, Ireland to Horizon Therapeutics plc for $65&#160;million in cash less certain assumed and accrued liabilities relating to transferred employees. The facility, which was formerly included in our pharmaceutical segment, housed EirGen&#x2019;s sterile-fill-finish business and was no longer a core component of our ongoing operations and business strategy. The transaction closed in the third quarter of 2021. We recognized a gain on the sale of the facility in the third quarter of 2021 of $31.5&#160;million.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <opk:NumberofSalesEmployees
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzY1_8a175340-0700-4fe2-b945-90b5225b3ef8"
      unitRef="employee">250</opk:NumberofSalesEmployees>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzg0ODI5MDcwODk3OA_54e3eba9-4777-4160-b66e-33be7385a9e7"
      unitRef="usd">150000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzg0ODI5MDcwODk5Mg_aa84fab9-4d52-49a1-b555-20778560379d"
      unitRef="shares">80000000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <opk:BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments
      contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzg0ODI5MDcwODk2NA_a45535cc-438e-4f68-9855-0e4138633e9a"
      unitRef="usd">150000000</opk:BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments>
    <opk:BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod
      contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzg0ODI5MDcwOTAzMw_f70b862f-a649-4d7e-8dab-2555bcc23882">P2Y</opk:BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod>
    <opk:BusinessCombinationUpfrontConsiderationTransferred
      contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzg0ODI5MDcwOTAwNg_ce6e4ff5-74df-45a8-b95e-79039bfe660a"
      unitRef="usd">322000000</opk:BusinessCombinationUpfrontConsiderationTransferred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzg0ODI5MDcwOTAyMA_2e2033f9-36c4-4d02-beac-9b955eeb2dd0"
      unitRef="usd">472000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <opk:DisposalGroupNumberOfFacilitiesSold
      contextRef="i906abe6eed0f4cd69f9561fd532d9d48_D20210601-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzA2Ng_d409bbfc-0f94-43c7-8366-e0e21750e369"
      unitRef="facility">1</opk:DisposalGroupNumberOfFacilitiesSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="ia99d14c06e6e4e28ad5a8c3f4c6cc028_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMzE0MQ_c099f855-9a47-4c02-8868-6aa6296aff3f"
      unitRef="usd">65000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i59cf764445af4de7b91ff994ed949ca9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180MC9mcmFnOjViNGMyODc2MjMwNjQ2MDY5ZmIzNTg4MTkyMGEzNjNiL3RleHRyZWdpb246NWI0YzI4NzYyMzA2NDYwNjlmYjM1ODgxOTIwYTM2M2JfMjc0ODc3OTA4MTI5MA_0280c7ad-da38-4c45-965f-8e9fedf346e4"
      unitRef="usd">31500000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180My9mcmFnOmI3N2E2YWRlY2U3NTRjMTViMGUzNGQwMTdmYTIyZjYxL3RleHRyZWdpb246Yjc3YTZhZGVjZTc1NGMxNWIwZTM0ZDAxN2ZhMjJmNjFfNjQ3Mw_d90c2036-ce3f-4c31-a6c5-c75fcd1109b8">IMPACT OF COVID-19&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We continue to be a part of the coordinated public and private sector response to SARS-CoV-2, a novel strain of coronavirus, referred to as COVID-19.  There continues to be a high level of uncertainty relating to how the pandemic will evolve, how governments and consumers will react, progress on the distribution of vaccines and whether the pandemic will have a longer-term effect on the healthcare industry and patient habits. BioReference is providing COVID-19 solutions, including diagnostic molecular testing and serology antibody testing, to meet the testing needs of its customers, including physicians, health systems, long-term care facilities, governments, schools, employers, professional sports teams and entertainment venues, as well as the general public through relationships with retail pharmacy chains.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Since the pandemic began in the U.S., we have invested in testing capabilities and infrastructure to meet demand for our molecular and antibody testing for COVID-19.  Throughout the last two years, we have managed our company-wide lab operations specimen acquisition, logistics, procurement, customer service, and initiatives to manage our cost structure to match the ever changing COVID-19 testing volumes and to manage efficiency gains in our core clinical lines of business.  We anticipate that COVID-19 will continue to impact our business in 2022 and demand for COVID-19 testing will fluctuate with the potential for increases and decreases in demand at different times and across different geographies; however, overall, we expect COVID-19 test demand to trend down in 2022 as compared to 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Revenue from services for the three months ended March 31, 2022 decreased by $220.4 million as compared to the three months ended March 31, 2021 due to lower COVID-19 testing volumes. We maintain our ability to quickly scale-up COVID-19 PCR testing capacity, even during periods of reduced demand.  In doing so, we are able to immediately and effectively respond to surges in positive cases and testing needs. We are unable to predict how long the demand will continue for our COVID-19 related testing, or whether pricing and reimbursement policies for testing will be sustained.  Excluding COVID-19 test volumes, for the three months ended March 31, 2022, genomic and routine clinical test volume increased 14.0% and 0.4% respectively, as compared to such volumes for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2022, the U.S. Health Resources and Services Administration ("HRSA") informed providers that, after March 22, 2022, it would stop accepting claims for testing and treatment for uninsured individuals under the HRSA COVID-19 Uninsured Program and that claims submitted prior to that date would be subject to eligibility and availability of funds. For the three months ended March 31, 2022, revenue for testing of uninsured individuals under the HRSA COVID-19 Uninsured Program represented approximately 7.9% of our COVID-19 testing revenue. As of March 31, 2022, less than 6% of our net accounts receivable was associated with claims for reimbursement for COVID-19 testing of uninsured individuals. Although we believe that our estimates for contractual allowances and patient price concessions are appropriate, actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock>
    <opk:IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f9c95a502354f4c9bd791e55a1b1acc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180My9mcmFnOmI3N2E2YWRlY2U3NTRjMTViMGUzNGQwMTdmYTIyZjYxL3RleHRyZWdpb246Yjc3YTZhZGVjZTc1NGMxNWIwZTM0ZDAxN2ZhMjJmNjFfMTA5OTUxMTY2MDg0NA_225a4d5f-3337-4b33-8058-7777e7e8d947"
      unitRef="usd">-220400000</opk:IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax>
    <opk:ChangeInTestingVolumePercent
      contextRef="i086b3193d0a84e44b65e89593c24a20b_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180My9mcmFnOmI3N2E2YWRlY2U3NTRjMTViMGUzNGQwMTdmYTIyZjYxL3RleHRyZWdpb246Yjc3YTZhZGVjZTc1NGMxNWIwZTM0ZDAxN2ZhMjJmNjFfNjU5NzA2OTgwMjE4OQ_96863489-5a8e-4b64-b8e6-1e206b2b4ede"
      unitRef="number">0.140</opk:ChangeInTestingVolumePercent>
    <opk:ChangeInTestingVolumePercent
      contextRef="idce190630bea4cf9936f6557989275fb_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180My9mcmFnOmI3N2E2YWRlY2U3NTRjMTViMGUzNGQwMTdmYTIyZjYxL3RleHRyZWdpb246Yjc3YTZhZGVjZTc1NGMxNWIwZTM0ZDAxN2ZhMjJmNjFfNjU5NzA2OTgwMjE5Mw_a60f2a25-c59d-455d-943b-97f99cbfe36c"
      unitRef="number">0.004</opk:ChangeInTestingVolumePercent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id75b8d1d54904cb9bed9cb560d7ee790_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180My9mcmFnOmI3N2E2YWRlY2U3NTRjMTViMGUzNGQwMTdmYTIyZjYxL3RleHRyZWdpb246Yjc3YTZhZGVjZTc1NGMxNWIwZTM0ZDAxN2ZhMjJmNjFfMjc0ODc3OTEyNTQ3Ng_950806e0-cf51-4648-91b8-8d4df3fe207f"
      unitRef="number">0.079</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i888fe358d78645888869e9e2f5f6b316_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180My9mcmFnOmI3N2E2YWRlY2U3NTRjMTViMGUzNGQwMTdmYTIyZjYxL3RleHRyZWdpb246Yjc3YTZhZGVjZTc1NGMxNWIwZTM0ZDAxN2ZhMjJmNjFfMjc0ODc3OTEyNTQ4Mg_c2b30ca5-2ca3-4a69-a77c-e472c8a402cc"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQxMDQ_b6344f30-3554-411a-a7a0-6516de668d16">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#x201c;GAAP&#x201d;) and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all information and notes required by GAAP for complete financial statements.  In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Company&#x2019;s results of operations, financial position and cash flows have been made.  The results of operations and cash flows for the three months ended March 31, 2022 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2022 or any other future periods.  The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and our wholly-owned subsidiaries.  All intercompany accounts and transactions are eliminated in consolidation.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase.  We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents.  These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Inventories are valued at the lower of cost and net realizable value.  Cost is determined by the first-in, first-out method.  We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value.  Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which are used in our testing laboratories.  Inventory obsolescence expense for the three months ended March 31, 2022 and 2021 was $0.6&#160;million and $3.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting.  Refer to Note 5.  Goodwill, in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) and other intangible assets acquired in business combinations, licensing and other transactions was $1.4 billion at both March&#160;31, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values.  Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill.  At acquisition, we generally determine the fair value of intangible assets, including IPR&amp;amp;D, using the &#x201c;income method.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill was $519.1&#160;million and $520.6&#160;million, respectively, at March&#160;31, 2022 and December&#160;31, 2021, Assets held for sale includes $151.8&#160;million of goodwill related to GeneDx. Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.  We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing.  Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net intangible assets other than goodwill was $890.5 million and $911.9 million, including IPR&amp;amp;D of $590.2&#160;million at December&#160;31, 2021, respectively.  Intangible assets are highly vulnerable to impairment charges, particularly newly acquired assets for recently launched products and IPR&amp;amp;D.  Considering the high risk nature of research and development and the industry&#x2019;s success rate of bringing developmental compounds to market, IPR&amp;amp;D impairment charges may occur in future periods.  Estimating the fair value of IPR&amp;amp;D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon obtaining regulatory approval, IPR&amp;amp;D assets are then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life.  If the project is abandoned, the IPR&amp;amp;D asset is charged to expense.  Finite lived intangible assets are tested for impairment when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.  The testing includes a comparison of the carrying amount of the asset to its estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe that our estimates and assumptions in testing goodwill and other intangible assets, including IPR&amp;amp;D, for&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;impairment are reasonable and otherwise consistent with assumptions that marketplace participants would use in their estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of fair value. However, if future results are not consistent with our estimates and assumptions, including as a result of the&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;COVID-19 global pandemic, then we may be exposed to additional impairment charges, which could be material.  We submitted the initial BLA with the FDA for approval of Somatrogon (hGH-CTP) in the United States and Pfizer received a Complete Response Letter in January 2022. Pfizer and OPKO are evaluating the FDA&#x2019;s comments and will work with the agency to determine the best path forward for Somatrogon (hGH-CTP) in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2022, we reclassified $590.0&#160;million of IPR&amp;amp;D related to Somatrogon (hGH-CTP) from IPR&amp;amp;D in our Condensed Consolidated Balance Sheet upon the approval of NGENLA (Somatrogon) in Europe and Japan. The assets will be amortized on a straight-line basis over their estimated useful life of approximately 12 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years.  We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up.  Amortization expense was $22.0 million and $12.6 million for the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments.  Investments that are considered equity securities as of March&#160;31, 2022 and December&#160;31, 2021 are predominately carried at fair value.  Our debt under the credit agreement with JPMorgan Chase Bank, N.A. approximates fair value due to the variable rate of interest applicable to such debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates.  The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts.  Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange.  Refer to Note 9.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense.  Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability.  Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions.  The assumptions used in estimating fair value require significant judgment.  The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges.  For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At March&#160;31, 2022 and December&#160;31, 2021, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognized all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations.  Refer to Note 10.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Property, plant and equipment are recorded at cost or fair value if acquired in a business combination.  Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases.  The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, and automobiles - 3-5 years.  Expenditures for repairs and maintenance are charged to expense as incurred.  Depreciation expense was $5.8 million and $7.4 million for three months ended March 31, 2022 and 2021, respectively. Assets held under finance leases are included within Property, plant and equipment, net in our Consolidated Balance Sheets and are amortized over the shorter of their useful lives or the expected term of their related leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of long-lived assets.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, such as property and equipment and assets held for sale, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment. Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in various countries and tax jurisdictions globally.&#160; For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results.&#160; For the three months ended March 31, 2022, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;Topic 606&#x201d;).  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.  At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct.  We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied.  For a complete discussion of accounting for Revenues from services, Revenues from products and Revenue from transfer of intellectual property and other, refer to Note 13.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of credit risk and allowance for credit losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable.  Substantially all of our accounts receivable are with either companies in the healthcare industry or patients.  However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.   On March&#160;31, 2022 and December&#160;31, 2021, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were 10% and 6%, respectively, of our consolidated Accounts receivable, net. On March&#160;31, 2022 and December&#160;31, 2021, receivable balances (net of explicit and implicit price concessions) due directly from states, cities and other municipalities, specifically related to our real-time reverse-transcription polymerase chain reaction (real-time RT-PCR) assay to detect COVID-19, were 4.8% and 4.1% of our consolidated accounts receivable, net, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk.  At March&#160;31, 2022 and December&#160;31, 2021, receivables due from patients represented approximately 2.0% and 0.7%, respectively, of our consolidated Accounts receivable, net.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer&#x2019;s ability to pay.  Actual results could differ from those estimates.  The allowance for credit losses was $2.0 million and $1.8 million at March&#160;31, 2022 and December&#160;31, 2021, respectively.  The credit loss expense for the three months ended March 31, 2022 and 2021 was $0.1 million and $0.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity-based compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award.  That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award.  We record excess tax benefits realized from the exercise of stock options as cash flows from operations.  For the three months ended March 31, 2022 and 2021 we recorded $7.6 million and $2.6 million, respectively, of equity-based compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include external and internal expenses.  External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs.  Research and development employee-related expenses include salaries, benefits and equity-based compensation expense.  Other internal research and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.  We expense these costs in the period in which they are incurred.  We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received.  As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility, and which have no alternative future use.  For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed.  Once the development process has been completed the asset will be amortized over its remaining estimated useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Our chief operating decision-maker (&#x201c;CODM&#x201d;) is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis.  We manage our operations in two reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of clinical and genomics laboratory operations through BioReference and point-of-care operations.  There are no significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is no inter-segment allocation of interest expense or income taxes.  Refer to Note 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shipping and handling costs.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not charge customers for shipping and handling costs.  Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The financial statements of certain of our foreign operations are measured using the local currency as the functional currency.  The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date and the local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods.  Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss). During the three months ended March 31, 2022 and 2021, we recorded $1.1&#160;million and $4.8&#160;million, respectively of transaction losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable interest entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The consolidation of a variable interest entity (&#x201c;VIE&#x201d;) is required when an enterprise has a controlling financial interest.  A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE&#x2019;s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE.  Refer to Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  We have made strategic investments in development stage and emerging companies.  We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees.  For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations.  Refer to Note 6.  For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value.  Refer to Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity's Own Equity (Subtopic 815-40).&#x201d; ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2021, with early adoption permitted.   As required, we adopted ASU 2020-06 on January 1, 2022 and used the modified retrospective approach for all convertible debt instruments at the beginning of the period of adoptions.  Results for reporting periods beginning January 1, 2022 are presented under ASU 2020-06, while prior period amounts were not adjusted and continue to be reported in accordance with historic with accounting guidance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the modified approach, entities will apply the guidance to all financial instruments that are outstanding as of the beginning of the year of adoption with the cumulative effect recognized as an adjustment to the opening balance of retained earnings. ASU 2020-06 eliminates the cash conversion and beneficial conversion feature models in ASC 470-20 that require an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of &lt;/span&gt;&lt;/div&gt;equity. The adoption of ASU 2020-06 at January 1, 2022 resulted in an increase of the Convertible notes of $21.6&#160;million, a reduction of the Accumulated deficit of $17.5&#160;million and a reduction of Additional paid-in capital of $39.1&#160;million.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQxMjU_08eedb84-890a-4f35-93e9-a8f5e82ce4ac">Basis of presentation.  The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#x201c;GAAP&#x201d;) and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all information and notes required by GAAP for complete financial statements.  In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Company&#x2019;s results of operations, financial position and cash flows have been made.  The results of operations and cash flows for the three months ended March 31, 2022 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2022 or any other future periods.  The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwMzM_ccc9b294-236d-43ec-b15e-e98a2e4a2a11">Principles of consolidation.  The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and our wholly-owned subsidiaries.  All intercompany accounts and transactions are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwMjg_a9354c6f-2e0a-4b9a-a051-b23d6bbac951">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and &lt;/span&gt;liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQxNDA_f76d314a-d5a1-44a7-aae9-d1077aae6cee">Cash and cash equivalents.  Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase.  We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents.  These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQxMjc_c2980754-c11e-4f89-9e8d-8153f4735c90">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Inventories are valued at the lower of cost and net realizable value.  Cost is determined by the first-in, first-out method.  We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value.  Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which are used in our testing laboratories.  Inventory obsolescence expense for the three months ended March 31, 2022 and 2021 was $0.6&#160;million and $3.1 million, respectively.&lt;/span&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjk5Ng_091bbd13-bd05-48a6-9f60-c1c9a002efed"
      unitRef="usd">600000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMzAwMw_ab0fb4cf-16b6-42c4-b0ab-bf23629ffd89"
      unitRef="usd">3100000</us-gaap:InventoryWriteDown>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwODU_e013fbfc-9cef-4427-aee9-01a057205205">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting.  Refer to Note 5.  Goodwill, in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) and other intangible assets acquired in business combinations, licensing and other transactions was $1.4 billion at both March&#160;31, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values.  Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill.  At acquisition, we generally determine the fair value of intangible assets, including IPR&amp;amp;D, using the &#x201c;income method.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill was $519.1&#160;million and $520.6&#160;million, respectively, at March&#160;31, 2022 and December&#160;31, 2021, Assets held for sale includes $151.8&#160;million of goodwill related to GeneDx. Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.  We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing.  Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net intangible assets other than goodwill was $890.5 million and $911.9 million, including IPR&amp;amp;D of $590.2&#160;million at December&#160;31, 2021, respectively.  Intangible assets are highly vulnerable to impairment charges, particularly newly acquired assets for recently launched products and IPR&amp;amp;D.  Considering the high risk nature of research and development and the industry&#x2019;s success rate of bringing developmental compounds to market, IPR&amp;amp;D impairment charges may occur in future periods.  Estimating the fair value of IPR&amp;amp;D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon obtaining regulatory approval, IPR&amp;amp;D assets are then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life.  If the project is abandoned, the IPR&amp;amp;D asset is charged to expense.  Finite lived intangible assets are tested for impairment when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.  The testing includes a comparison of the carrying amount of the asset to its estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe that our estimates and assumptions in testing goodwill and other intangible assets, including IPR&amp;amp;D, for&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;impairment are reasonable and otherwise consistent with assumptions that marketplace participants would use in their estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of fair value. However, if future results are not consistent with our estimates and assumptions, including as a result of the&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;COVID-19 global pandemic, then we may be exposed to additional impairment charges, which could be material.  We submitted the initial BLA with the FDA for approval of Somatrogon (hGH-CTP) in the United States and Pfizer received a Complete Response Letter in January 2022. Pfizer and OPKO are evaluating the FDA&#x2019;s comments and will work with the agency to determine the best path forward for Somatrogon (hGH-CTP) in the United States.&lt;/span&gt;&lt;/div&gt;In the first quarter of 2022, we reclassified $590.0&#160;million of IPR&amp;amp;D related to Somatrogon (hGH-CTP) from IPR&amp;amp;D in our Condensed Consolidated Balance Sheet upon the approval of NGENLA (Somatrogon) in Europe and Japan. The assets will be amortized on a straight-line basis over their estimated useful life of approximately 12 years.We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years.  We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <opk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMzk0Nw_0b31cbbb-8ffc-49f5-ab2c-6f541d2f0389"
      unitRef="usd">1400000000</opk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets>
    <opk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMzk0Nw_c9a49375-2757-473c-a05f-96c18ec0613a"
      unitRef="usd">1400000000</opk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMzg0ODI5MDczODM5MA_8c7974fd-fe9f-4a13-9b34-b61909939b28"
      unitRef="usd">519100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMzg0ODI5MDczODQyMQ_9209a2e3-8b36-48ff-9f2a-ac00eca514b0"
      unitRef="usd">520600000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i77c9c6ea887e4115b1c0992f4beef719_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTA5NDE3OA_77515025-1bb8-41da-874a-deb1e23015b4"
      unitRef="usd">151800000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i30dd8bae361a48dc85516ce870eae7cb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTA5NDE3OA_e60ee941-0f3e-458f-aef0-a08abac0a2e2"
      unitRef="usd">151800000</us-gaap:Goodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfNTMyOA_2e2f3a0e-1b63-4066-a15b-daf100f94093"
      unitRef="usd">890500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfNTMzNQ_36521611-e2c5-4599-a1d8-96ea43231eb8"
      unitRef="usd">911900000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3cf8b83bf2c647cc819974ea2adb86c0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDQxOQ_e6beb21d-f4c7-4550-ac3f-990f7e29e7a2"
      unitRef="usd">590200000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <opk:InProcessResearchandDevelopment
      contextRef="i80eb499192104b008d7af0e0148d19c8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDUzMg_6c576472-d3ea-4da8-9670-fb74a77b0fb8"
      unitRef="usd">-590000000</opk:InProcessResearchandDevelopment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie9f8b48ec3cc43d09aa306ad85bdfbd6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDUzMg_ed31b481-2f4f-458e-83fd-7958dbd3241b"
      unitRef="usd">590000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1ec064528f8b46c799fcf289c9791518_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDU1Mw_c4eb890c-1f3b-463b-ab4c-e1b9669f8cd9">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i37bc1ddf248145949cf20c844e5cd267_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfNzI1NA_ff871ea6-2345-4a36-9eee-fb5bdb785631">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i52d41c803f754caab224bc8b150c6c59_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfNzI2MA_6c205bc2-6413-4f9e-b3a3-4c7c53651237">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfNzQ4MQ_34700a43-14f3-4fb2-aaa5-ce0896ebcd6a"
      unitRef="usd">22000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfNzQ4OA_333fc9be-43b9-43b8-b7e9-533cd7a6b5a4"
      unitRef="usd">12600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwNTI_d9df3d4c-bc8b-4f46-ae00-80857d2dc416">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments.  Investments that are considered equity securities as of March&#160;31, 2022 and December&#160;31, 2021 are predominately carried at fair value.  Our debt under the credit agreement with JPMorgan Chase Bank, N.A. approximates fair value due to the variable rate of interest applicable to such debt.&lt;/span&gt;In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates.  The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts.  Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwMzY_d23a6df9-fd2b-4f73-a66f-b3c85197ee63">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense.  Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability.  Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions.  The assumptions used in estimating fair value require significant judgment.  The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.&lt;/span&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwOTk_e269f579-46fa-40a7-a51c-417e1be34edc">Derivative financial instruments.  We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges.  For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At March&#160;31, 2022 and December&#160;31, 2021, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognized all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwODc_fbaf2628-0c6d-4e5c-9cdc-ba0c1cc7a8db">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Property, plant and equipment are recorded at cost or fair value if acquired in a business combination.  Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases.  The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, and automobiles - 3-5 years.  Expenditures for repairs and maintenance are charged to expense as incurred.  Depreciation expense was $5.8 million and $7.4 million for three months ended March 31, 2022 and 2021, respectively. Assets held under finance leases are included within Property, plant and equipment, net in our Consolidated Balance Sheets and are amortized over the shorter of their useful lives or the expected term of their related leases.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ieada14ab28484d7f825d8053db57205d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTA4MTE_d6fe24b8-dcc4-4bec-b18c-d6541d0e80a8">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie2a83411c64144f1b9355c9cfd56237d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTA4NjI_b37371d6-9a1a-456b-b626-abf1e8c489fb">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i63f3da17eaeb419fa6e03d78593bf2bd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTA4NjU_d96dd03b-96b2-4815-ac0d-cc146431ddb0">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ide29c575be14417383ac7d390f9234c4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTA5MDA_5333c467-d03a-4598-83e0-f868ccf9b939">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if2ff2edaeb5d4865a0321ebe71317039_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTA5MDM_1613fe07-d45d-43b8-aa14-b800f32de1dd">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3d47b2edbf174a649ea86051fd83bd31_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTEwMTg_7091eea1-a818-446c-823f-2f9436ab96b2">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i318d31f5642447988322e0b46296a5e2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTEwMjE_29fa2aa4-060d-4111-9069-e8b294ee6d89">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="idab50d068e1f4bfc9aa0aa0073ec3fdd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTEwNDk_d0e6b039-6764-409f-b5b8-68c1ca71d64a">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie29d2a5269334fb397d32c99e041731a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTEwNTI_53191fcf-7920-4b1a-916d-c5efd2878d3c">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTExNjY_198a4c0d-1f3e-44c5-927a-bccb7397cd92"
      unitRef="usd">5800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTExNzM_2ec049ba-2d7c-42f9-842e-34cf4b596314"
      unitRef="usd">7400000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwMjE_56a35a68-915f-4aa3-a2e4-d8480004944b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of long-lived assets.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, such as property and equipment and assets held for sale, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.&lt;/span&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwMTc_68593fd9-d146-487e-a605-0f1dd4dc163a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax &lt;/span&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment. Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in various countries and tax jurisdictions globally.&#160; For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results.&#160; For the three months ended March 31, 2022, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwNTM_eb282167-4d63-4384-bd0d-f3877b19dcec">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;Topic 606&#x201d;).  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.  &lt;/span&gt;We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.  At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct.  We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied.&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shipping and handling costs.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not charge customers for shipping and handling costs.  Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.&lt;/span&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQxMDE_93cf5e5f-635d-4b13-a58e-47fe99f69bb4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of credit risk and allowance for credit losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable.  Substantially all of our accounts receivable are with either companies in the healthcare industry or patients.  However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.&lt;/span&gt;While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i530fe1c9f119438894b0dd5623106eed_D20220331-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTY0ODM_ee2e64bd-0f11-44f7-af9d-f2ea245e1a49"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i50900f2255f341c596bd800b3f7c7a4d_D20211231-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTY0OTA_554fcf9f-6cd7-431c-ae35-fafbe9a8abd9"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8c46f5c9a39a4c32b5cd190bec420d89_D20220331-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTY4NDg_ce520d1e-8b3c-43b7-a147-2c91146c22b1"
      unitRef="number">0.048</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6a7d513d6e904c0884c28baf601bb35d_D20211231-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTY4NTU_86085823-e451-4c22-909a-4f04988a0ce8"
      unitRef="number">0.041</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie1dca7ce0a2b48abb1378746d081a87a_D20220331-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTcxMDQ_96ab3be3-d56b-40bd-b404-d231954bcea9"
      unitRef="number">0.020</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2b22ccaca70a4b119871d37e30563967_D20211231-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTcxMTE_978d7da2-c383-4c85-8fe2-2b27dc0ffea8"
      unitRef="number">0.007</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwNTU_fe8f6653-9d75-4aa6-9361-4bb5969a904c">We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer&#x2019;s ability to pay.  Actual results could differ from those estimates.</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTc1Njc_206ab166-1d54-4381-bf1c-afef63dd4b6b"
      unitRef="usd">2000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTc1NzQ_62bbf2e1-34a7-4e9d-b6f0-0d903e74b877"
      unitRef="usd">1800000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTc2NTU_e1f4d966-edd1-4ce6-a522-97a444c0cda7"
      unitRef="usd">100000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMTc2NjI_cb0c1666-289c-4020-a74f-f5f7ba25b725"
      unitRef="usd">300000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwMDQ_da7ee4be-007a-46d9-a295-ecaabeadf645">Equity-based compensation.  We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award.  That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award.  We record excess tax benefits realized from the exercise of stock options as cash flows from operations.</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTA5OTA0OQ_00d405b6-3675-4866-ba91-37c5762d1c21"
      unitRef="usd">7600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTA5OTA0Mw_567e5860-efec-4968-ac47-05870cf71428"
      unitRef="usd">2600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQxMzg_bd49acee-fa69-46f5-a8cb-0b9afe7b966d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include external and internal expenses.  External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs.  Research and development employee-related expenses include salaries, benefits and equity-based compensation expense.  Other internal research and &lt;/span&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities.  We expense these costs in the period in which they are incurred.  We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received.  As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility, and which have no alternative future use.  For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed.  Once the development process has been completed the asset will be amortized over its remaining estimated useful life.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwNDE_54747c39-34cf-43a6-88f5-fd5f96382a39">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Our chief operating decision-maker (&#x201c;CODM&#x201d;) is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis.  We manage our operations in two reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee&lt;/span&gt; product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of clinical and genomics laboratory operations through BioReference and point-of-care operations.  There are no significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is no inter-segment allocation of interest expense or income taxes.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjA0Mjk_59b8144d-92d7-4ae8-bb8b-96be14d622c1"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjM5ODk_077784f1-0eb7-4cdf-9112-72b95eb391aa">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The financial statements of certain of our foreign operations are measured using the local currency as the functional currency.  The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date and the local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods.  Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss). During the three months ended March 31, 2022 and 2021, we recorded $1.1&#160;million and $4.8&#160;million, respectively of transaction losses.&lt;/span&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDQ0MA_a9a43f4d-afb9-4d48-85c0-178fad7af2db"
      unitRef="usd">1100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDQ2NQ_efee849b-e3fd-42c0-b66e-f5bbc1a59293"
      unitRef="usd">4800000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwNjk_bee5e7cd-0926-4d7c-b600-349121e747e4">Variable interest entities.  The consolidation of a variable interest entity (&#x201c;VIE&#x201d;) is required when an enterprise has a controlling financial interest.  A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE&#x2019;s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwNTg_798b4693-ebd5-4981-85bd-40773e3d5555">Investments.  We have made strategic investments in development stage and emerging companies.  We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees.  For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations.  Refer to Note 6.  For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjQwMjc_ed9cdf72-a134-416c-8df5-c25a0c438319">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity's Own Equity (Subtopic 815-40).&#x201d; ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2021, with early adoption permitted.   As required, we adopted ASU 2020-06 on January 1, 2022 and used the modified retrospective approach for all convertible debt instruments at the beginning of the period of adoptions.  Results for reporting periods beginning January 1, 2022 are presented under ASU 2020-06, while prior period amounts were not adjusted and continue to be reported in accordance with historic with accounting guidance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the modified approach, entities will apply the guidance to all financial instruments that are outstanding as of the beginning of the year of adoption with the cumulative effect recognized as an adjustment to the opening balance of retained earnings. ASU 2020-06 eliminates the cash conversion and beneficial conversion feature models in ASC 470-20 that require an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of &lt;/span&gt;&lt;/div&gt;equity. The adoption of ASU 2020-06 at January 1, 2022 resulted in an increase of the Convertible notes of $21.6&#160;million, a reduction of the Accumulated deficit of $17.5&#160;million and a reduction of Additional paid-in capital of $39.1&#160;million.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib396f0384c4549d6ad4a1d99b89fcf7f_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDUwMA_856536e2-bd38-435b-9408-e2525230ced2"
      unitRef="usd">21600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iceb6a701923f4d27a6905238cab5243d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDQ4NQ_2d5d7d61-860e-486f-8a4b-a31a072914e8"
      unitRef="usd">17500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i04b7a30acb9a4f81a6cd5179f6dc9cd0_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180Ni9mcmFnOmE1NDU5NThhMmQzOTQwZGJhYzVlYTRiNjE4ZDVkZmIxL3RleHRyZWdpb246YTU0NTk1OGEyZDM5NDBkYmFjNWVhNGI2MThkNWRmYjFfMjc0ODc3OTExMDUxNw_57d8ee44-f438-4151-9a2f-8f1f679207e5"
      unitRef="usd">-39100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjk5NA_368a1b79-e6b0-4f0e-a466-ce9ef907fb6d">EARNINGS (LOSS) PER SHARE&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic income (loss) per share is computed by dividing our net income (loss) by the weighted average number of shares of our common stock par value $0.01 per share (&#x201c;Common Stock&#x201d;) outstanding during the period.  Shares of Common Stock outstanding under the&#160;share lending&#160;arrangement entered into in conjunction with the 2025 Notes (as defined in Note 7) are excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.  Refer to Note 7.  For diluted earnings per share, the dilutive impact of stock options and warrants is determined by applying the &#x201c;treasury stock&#x201d; method.  The dilutive impact of the 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes (each, as defined and discussed in Note 7) has been considered using the &#x201c;if converted&#x201d; method. For periods in which their effect would be antidilutive, no effect is given to Common Stock issuable under outstanding options or warrants or the potentially dilutive shares issuable pursuant to the 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes in the dilutive computation.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A total of 57,985,925 and 74,623,270 potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the three months ended March 31, 2022, and 2021, respectively, because their inclusion would be antidilutive. A full presentation of diluted earnings per share has not been provided because the required adjustments to the numerator and denominator resulted in diluted earnings per share equivalent to basic earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, 55,750 Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 55,750 shares of Common Stock.  Of the 55,750 Common Stock options and Common Stock warrants exercised, no shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended&#160;March 31, 2021, 117,500 Common Stock options or Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 117,500 shares of Common Stock.  Of the 117,500 Common Stock options and Common Stock warrants exercised, no shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMTg2_7ec61557-caba-4176-9b5c-ab19352bb5ba"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i67b75a0644d1431cb32ac4d221554a5d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMTQ0Nw_2759604f-c62c-4d88-8caf-2830cdfe58a0"
      unitRef="shares">57985925</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7e0d3411daf7457fa18aa8ab1b20c33e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMTQ1NA_ce7cb999-1e0c-4755-8c34-a083a5d423ce"
      unitRef="shares">74623270</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjIzMA_9ab2e352-8dfc-4258-8b91-ee86ac36e126"
      unitRef="shares">55750</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjM2NA_3116b208-723b-4833-9bf3-a706cf0316cd"
      unitRef="shares">55750</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjM5OQ_9ab2e352-8dfc-4258-8b91-ee86ac36e126"
      unitRef="shares">55750</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised>
    <opk:SharesSurrenderedInLieuOfCashPayment
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjQ2MA_a83df8c8-d2c3-4df0-b6b2-32a457b7612f"
      unitRef="shares">0</opk:SharesSurrenderedInLieuOfCashPayment>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjYzNg_9e41f12f-7c28-414c-abe7-9f712a781410"
      unitRef="shares">117500</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjc2OQ_394ba2cd-b11f-491e-a2aa-9e9ed96c6a88"
      unitRef="shares">117500</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment>
    <opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjgwNA_9e41f12f-7c28-414c-abe7-9f712a781410"
      unitRef="shares">117500</opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised>
    <opk:SharesSurrenderedInLieuOfCashPayment
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjg2NQ_708c03e1-cc3e-4375-b9d5-9fc871db2cc7"
      unitRef="shares">0</opk:SharesSurrenderedInLieuOfCashPayment>
    <opk:SharesSurrenderedInLieuOfCashPayment
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y180OS9mcmFnOjMxMTY3ZjI5NDA4MTRkNTA4NDRjZGE0ZDMwZTZiNTNhL3RleHRyZWdpb246MzExNjdmMjk0MDgxNGQ1MDg0NGNkYTRkMzBlNmI1M2FfMjg2NQ_d067f0ca-23bb-4e4b-a3b2-0b84d3587144"
      unitRef="shares">0</opk:SharesSurrenderedInLieuOfCashPayment>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMTA5Ng_423fe275-63cb-433f-837b-fd3621cbb251">COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowance for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumable supplies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets and prepaid expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taxes recoverable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Covenants not to compete&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product registrations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory received but not invoiced&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commitments and contingencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases short-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgages and other debts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our intangible assets and goodwill relate principally to our completed acquisitions of OPKO Renal, OPKO Biologics, EirGen and BioReference.  We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives.  The estimated useful lives by asset class are as follows:  technologies - 7-17 years, customer relationships - 7-20 years, product registrations - 7-10 years, covenants not to compete - 5 years, trade names - 5-10 years, other 9-13 years.  We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred.  Our goodwill is not tax deductible for income tax purposes in any jurisdiction in which we operate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022 and December 31, 2021, GeneDx met the held-for-sale accounting criteria and its related assets and liabilities are recognized at the lower of carrying value or fair value less costs to sell in the consolidated balance sheet. In addition, at March 31, 2022 and December 31, 2021, Assets held for sale included $151.8&#160;million of goodwill related to GeneDx. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2022, we reclassified $590.0&#160;million of IPR&amp;amp;D related to Somatrogon from IPR&amp;amp;D in our Condensed Consolidated Balance Sheet upon the approval of NGENLA (Somatrogon) in Europe and Japan. The assets will be amortized on a straight-line basis over their estimated useful life of approximately 12 years. Other changes in value of the intangible assets and goodwill during the three months ended March 31, 2022 and 2021 were primarily due to foreign currency fluctuations between the Chilean Peso, and the Euro against the U.S. dollar.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in Goodwill by reporting unit during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross goodwill  at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative impairment at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;CURNA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Rayaldee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FineTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OPKO Biologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OPKO Chile&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OPKO Health Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OPKO Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transition Therapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BioReference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;434,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(151,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OPKO Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;710,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;519,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange and other amounts for three months ended March 31, 2022 includes amounts related to GeneDx which is included as Assets held for sale at March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <opk:CompositionOfCertainFinancialStatementCaptionsTableTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMTA5Nw_b6fa7b24-7dd9-4121-bd39-9ff76f4245d7">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowance for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumable supplies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets and prepaid expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taxes recoverable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Covenants not to compete&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product registrations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory received but not invoiced&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commitments and contingencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases short-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgages and other debts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</opk:CompositionOfCertainFinancialStatementCaptionsTableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMi0xLTEtMS0zNTMzMA_ea8c8557-78f8-4e05-986d-b4fefbd519c5"
      unitRef="usd">214734000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMi0zLTEtMS0zNTMzMA_eea29e60-1368-4640-8c87-356d2b0f63a3"
      unitRef="usd">261476000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMy0xLTEtMS0zNTMzMA_77bf0062-4036-4010-a312-8424385df6c2"
      unitRef="usd">1979000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMy0zLTEtMS0zNTMzMA_27d6addb-ebd9-4115-8702-e0c26a1e92ee"
      unitRef="usd">1839000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNC0xLTEtMS0zNTMzMA_aefcf394-74cf-4316-8fc0-32bf1dff8a51"
      unitRef="usd">212755000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNC0zLTEtMS0zNTMzMA_ccc2dbb2-0458-484d-8579-ee29c4533ec4"
      unitRef="usd">259637000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherInventorySupplies
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNi0xLTEtMS0zNTMzMA_10952f10-e1d1-4403-ac0a-f1c07b06ea74"
      unitRef="usd">48740000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNi0zLTEtMS0zNTMzMA_c17a2630-0f09-424d-8e66-8549e34af8f2"
      unitRef="usd">39447000</us-gaap:OtherInventorySupplies>
    <us-gaap:InventoryFinishedGoods
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNy0xLTEtMS0zNTMzMA_eab188df-2d6e-48c7-a187-3d7835fbdc25"
      unitRef="usd">46594000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNy0zLTEtMS0zNTMzMA_6b5ff161-1ed9-44a2-b4ec-0cf46f5bd863"
      unitRef="usd">44107000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfOC0xLTEtMS0zNTMzMA_1cec6b50-89ff-44f5-8497-65b11b75f1f5"
      unitRef="usd">2795000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfOC0zLTEtMS0zNTMzMA_a132ff68-b3ef-4d92-8933-6857824970ad"
      unitRef="usd">1615000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfOS0xLTEtMS0zNTMzMA_d3648183-c736-41a2-ac62-e10b67f0ba1b"
      unitRef="usd">6435000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfOS0zLTEtMS0zNTMzMA_bd949156-5069-4ae1-ae5a-1539ef3adaed"
      unitRef="usd">6112000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryValuationReserves
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTAtMS0xLTEtMzUzMzA_1f491cda-f184-49fa-8687-a58ae3f4b033"
      unitRef="usd">5158000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTAtMy0xLTEtMzUzMzA_058523d5-b344-461a-a9c8-f78003c7a4bd"
      unitRef="usd">4779000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTEtMS0xLTEtMzUzMzA_3609c972-d3ba-448a-9f2a-28f26765f61c"
      unitRef="usd">99406000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTEtMy0xLTEtMzUzMzA_2f16beef-0052-4935-b664-1a201919fe9b"
      unitRef="usd">86502000</us-gaap:InventoryNet>
    <opk:TaxesRecoverableCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTMtMS0xLTEtMzUzMzA_fbc44725-279a-4409-b44e-3b8ad008bbc5"
      unitRef="usd">6105000</opk:TaxesRecoverableCurrent>
    <opk:TaxesRecoverableCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTMtMy0xLTEtMzUzMzA_4332ca1c-8fb2-4b2a-a890-ab51633590f3"
      unitRef="usd">5598000</opk:TaxesRecoverableCurrent>
    <us-gaap:Supplies
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTQtMS0xLTEtMzUzMzA_c570a16b-042d-4a95-ae86-68edb0d1c010"
      unitRef="usd">8171000</us-gaap:Supplies>
    <us-gaap:Supplies
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTQtMy0xLTEtMzUzMzA_62a99355-5702-46e3-9d7e-baa3e7824497"
      unitRef="usd">10641000</us-gaap:Supplies>
    <us-gaap:PrepaidInsurance
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTgtMS0xLTEtMzUzMzA_c7ffd334-442f-48ab-9416-7c3851f1e143"
      unitRef="usd">1731000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTgtMy0xLTEtMzUzMzA_521ffe01-49d2-4aae-829a-6c773cda0fa4"
      unitRef="usd">4383000</us-gaap:PrepaidInsurance>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTktMS0xLTEtMzUzMzA_b4916923-4a4c-4099-ae83-73a720aa9b92"
      unitRef="usd">2435000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMTktMy0xLTEtMzUzMzA_97a3b7b8-46e2-43f3-b9e9-72dddfce1a78"
      unitRef="usd">353000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjAtMS0xLTEtMzUzMzA_8cdf629d-8bea-4b55-9a7a-f04072d16e05"
      unitRef="usd">4832000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjAtMy0xLTEtMzUzMzA_8938936c-aa9e-4fa1-bbde-0c6ea12d4f6f"
      unitRef="usd">6195000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjEtMS0xLTEtMzUzMzA_7fdfaf1d-ff35-4386-9260-2df99c96eb71"
      unitRef="usd">23274000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjEtMy0xLTEtMzUzMzA_18cc3be0-4be2-49fe-a54e-24a1640825c2"
      unitRef="usd">27170000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i56733675f4354dacaf825a860ec99f82_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjMtMS0xLTEtMzUzMzA_b0d907f2-aeb4-46c5-9129-898e2851da40"
      unitRef="usd">314324000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0e18e3e9d8bb41f0b30d8b956511195e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjMtMy0xLTEtMzUzMzA_936bdf51-7cb5-45b3-9755-76b752d22a95"
      unitRef="usd">314823000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7b12b303a8a149ee9de06097429266da_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjQtMS0xLTEtMzUzMzA_7e9be27e-207a-4309-bdeb-835e5016b830"
      unitRef="usd">832727000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7bc8466e91704c55a14be646d891acd3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjQtMy0xLTEtMzUzMzA_6cb11745-4768-4e32-a58d-9be4f520acc7"
      unitRef="usd">246101000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i651cb43b8a074339b0ee2e20b061a461_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjUtMS0xLTEtMzUzMzA_07d9e33c-b52b-443a-9ded-b850cd48d40c"
      unitRef="usd">49774000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i09284eae734a4ba29ea813474543bb46_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjUtMy0xLTEtMzUzMzA_83c09e91-15fe-424e-91ac-b517a5ad33fe"
      unitRef="usd">49770000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ied8dda5c25884eaf9d82544f0dd21140_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjctMS0xLTEtMzUzMzA_fb021fd3-336f-4549-83be-b40a39227a6a"
      unitRef="usd">12917000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic3692b70dac746208ee532bd6a7af7c5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjctMy0xLTEtMzUzMzA_1ab25362-f9a9-4163-beb1-09d3f689a466"
      unitRef="usd">12920000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icfa555861b884871b2953ab02fd8033e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjgtMS0xLTEtMzUzMzA_f8d480f1-d2a1-4ada-bfa7-434c18834087"
      unitRef="usd">5766000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie04e073effab4668baaebc0c91e50e9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjgtMy0xLTEtMzUzMzA_16ec490b-d49b-4761-8eda-4f140edf1775"
      unitRef="usd">5766000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2c1e9306ccee49fab2b6d9c8a64eaa45_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjktMS0xLTEtMzUzMzA_ceed0514-8951-410a-8d4f-3a097d35b8bb"
      unitRef="usd">7251000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i56e6470febfe488b82cf6de3a567026d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMjktMy0xLTEtMzUzMzA_69989b18-74e3-4eb1-b54d-0acd1b11b239"
      unitRef="usd">6995000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i614f229d8ed7468cb77cc7cbb19df994_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzAtMS0xLTEtMzUzMzA_54877ce0-2d7f-49a4-8728-df9a96bc64ad"
      unitRef="usd">6033000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4e7d2ec22c3f471facc97d6879e5b1be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzAtMy0xLTEtMzUzMzA_7a6486c6-7422-4dc6-ae64-fec86fb62eb7"
      unitRef="usd">6128000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzEtMS0xLTEtMzUzMzA_1d59b5ee-beee-426b-9c6e-1e9bb7a574a6"
      unitRef="usd">338294000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzEtMy0xLTEtMzUzMzA_9c3d7577-a5f8-4bd0-b0d4-fd3c24ecaf2e"
      unitRef="usd">320820000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzItMS0xLTEtMzUzMzA_a5527123-1c95-4c0e-965a-118dfedbd8f8"
      unitRef="usd">890498000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzItMy0xLTEtMzUzMzA_1811ec88-99de-48f8-ac03-3667d7609633"
      unitRef="usd">321683000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <opk:InventoryReceivedNotInvoicedCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzQtMS0xLTEtMzUzMzA_940aa3d3-2b19-4d1c-8d2b-9dcd8d054ae3"
      unitRef="usd">22811000</opk:InventoryReceivedNotInvoicedCurrent>
    <opk:InventoryReceivedNotInvoicedCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzQtMy0xLTEtMzUzMzA_cbee96c8-db96-4980-a502-5a6c302349b2"
      unitRef="usd">40446000</opk:InventoryReceivedNotInvoicedCurrent>
    <opk:AccruedCommitmentsandContingenciesCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzUtMS0xLTEtMzUzMzA_2d7f8412-7022-4647-a7a4-149029f3468e"
      unitRef="usd">26940000</opk:AccruedCommitmentsandContingenciesCurrent>
    <opk:AccruedCommitmentsandContingenciesCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzUtMy0xLTEtMzUzMzA_c8111959-b5b5-4c06-8712-20e78e5c22de"
      unitRef="usd">27819000</opk:AccruedCommitmentsandContingenciesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzYtMS0xLTEtMzUzMzA_1558e717-83c8-45fb-93ee-639743d660cc"
      unitRef="usd">50332000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzYtMy0xLTEtMzUzMzA_fb79ef7b-a162-4742-9c87-26cf2d1c4dae"
      unitRef="usd">45939000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzctMS0xLTEtMzUzMzA_06d8b18a-24b0-40c8-b910-be70f7430611"
      unitRef="usd">258000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzctMy0xLTEtMzUzMzA_47102ca6-ff09-45ca-ab74-9fa08dd0771e"
      unitRef="usd">258000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <opk:AccruedClinicalTrialsCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzgtMS0xLTEtMzUzMzA_736e94bc-771b-4d25-912d-fe334be6b639"
      unitRef="usd">4167000</opk:AccruedClinicalTrialsCurrent>
    <opk:AccruedClinicalTrialsCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfMzgtMy0xLTEtMzUzMzA_5865ca80-3e2a-49ca-8cd6-774cb9ffe6e1"
      unitRef="usd">4867000</opk:AccruedClinicalTrialsCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDAtMS0xLTEtMzUzMzA_83e79fff-a322-4d84-ab40-1228b0a6cad9"
      unitRef="usd">487000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDAtMy0xLTEtMzUzMzA_7003aa85-9333-418f-9566-3cf3c8b83ed5"
      unitRef="usd">487000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDEtMS0xLTEtMzUzMzA_bbcc95fb-1df9-47f9-ada6-c3304a6c03b9"
      unitRef="usd">2451000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDEtMy0xLTEtMzUzMzA_1cfcaad5-2a9b-4021-9337-6be3ebb7d5ae"
      unitRef="usd">2257000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDMtMS0xLTEtMzUzMzA_dba1758f-ca15-4767-a5ee-42cf5d3104db"
      unitRef="usd">2717000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDMtMy0xLTEtMzUzMzA_796e4edc-31be-4d95-bbe8-5ce050129fbb"
      unitRef="usd">2121000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDYtMS0xLTEtMzUzMzA_4d7ec5a9-2378-4834-ab8c-a89c1bd405de"
      unitRef="usd">47153000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDYtMy0xLTEtMzUzMzA_802ae0c4-0c04-4889-a14d-b1c9dddaddac"
      unitRef="usd">69299000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDctMS0xLTEtMzUzMzA_ec5cd979-fa21-4f12-a651-789357b4befd"
      unitRef="usd">157316000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNDctMy0xLTEtMzUzMzA_6e81cef4-cebc-407b-946a-89bde57e6893"
      unitRef="usd">193493000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTEtMS0xLTEtMzUzMzA_5ceeb7dc-194e-43fe-8e2b-58e5f6a4a787"
      unitRef="usd">2242000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTEtMy0xLTEtMzUzMzA_1b674dc8-2d67-4b9c-93f2-0b896aa9d6b0"
      unitRef="usd">2350000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTMtMS0xLTEtMzUzMzA_e26109da-d919-40ab-9a30-471e87455bb2"
      unitRef="usd">1973000</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTMtMy0xLTEtMzUzMzA_7dd09951-b52b-43f4-8b2b-e2941f951f4c"
      unitRef="usd">2224000</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTQtMS0xLTEtMzUzMzA_59ea4cc9-005e-416e-b556-9d99c7b1d6b4"
      unitRef="usd">3865000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTQtMy0xLTEtMzUzMzA_4a5a25f1-e775-42a4-98cd-14f94efa90de"
      unitRef="usd">2924000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTUtMS0xLTEtMzUzMzA_02b7ef5f-6a57-4ea9-8e20-354e87ca5ff0"
      unitRef="usd">204000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTUtMy0xLTEtMzUzMzA_4c6d8856-320c-4da7-ad88-3768825a80f1"
      unitRef="usd">208000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesAndDeferredRevenueNoncurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTYtMS0xLTEtMzUzMzA_0c608880-01fa-41e7-bed5-264c7fd1b070"
      unitRef="usd">7374000</us-gaap:OtherLiabilitiesAndDeferredRevenueNoncurrent>
    <us-gaap:OtherLiabilitiesAndDeferredRevenueNoncurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTYtMy0xLTEtMzUzMzA_eedeb179-e1b7-48e8-8c52-d5c0175b4dba"
      unitRef="usd">7356000</us-gaap:OtherLiabilitiesAndDeferredRevenueNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTctMS0xLTEtMzUzMzA_7360588c-39c7-4c4a-b501-55371bdde9da"
      unitRef="usd">15658000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOmQ1ZWI5NTVmMWMwMzQwMjA4ZmRhMmNlZDc5MTdlMmY1L3RhYmxlcmFuZ2U6ZDVlYjk1NWYxYzAzNDAyMDhmZGEyY2VkNzkxN2UyZjVfNTctMy0xLTEtMzUzMzA_f9351742-a8b0-42f4-86e2-d48b5dcdcd9b"
      unitRef="usd">15062000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i7cd76bb4cb054c24a6c2232c8ce7f462_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMzkz_37bc8bba-91df-4a49-bac5-288524a8008c">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i67eb7ca1a153436b9c63f40b1643cbb5_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMzk2_58abc8e3-3a58-40c7-8670-2affd6666292">P17Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib4f4333f6b854395908e42b29b11c12c_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNDMx_304cdc47-54da-451e-833c-45d2e653202d">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if0e396b6f94a488d87020d832f3a71dd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNDM0_8b9acaa1-a4be-4fcf-bc92-9ecba8e47115">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie350ba9cd5734e9ca2f654f54c4f32e6_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNDY4_d9f2f798-ae18-4487-99e4-4b685866902e">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie02675a24f9347258a91c2e8689dac1f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNDcx_c48517df-f089-4133-a3d5-5ee161bee06c">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i0c94852de80d4e20b88966f2a5803300_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNTA4_9a74c3e6-b408-4a5a-8d48-e0521828fd88">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i51146bd0393e4abea9ad351cc048bb8b_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNTMy_9ec2c753-3255-41e8-8946-a29eba2899ad">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1f99fa3607f14b209d98541827fcf560_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNTM1_a5f776d0-237f-49d1-b530-fee6af15e370">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1fcfed0a51964bf2bb060f3eac1da896_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNTUx_43dffc20-b53c-458b-982f-6ad6547eccde">P9Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i22564da49818430d93721eda04c22d10_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfNTU0_64a77a43-c4cc-47a9-8cc6-f7b48b89a6c1">P13Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:Goodwill
      contextRef="i77c9c6ea887e4115b1c0992f4beef719_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMjc0ODc3OTA3MDkzMQ_77515025-1bb8-41da-874a-deb1e23015b4"
      unitRef="usd">151800000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i30dd8bae361a48dc85516ce870eae7cb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMjc0ODc3OTA3MDkzMQ_e60ee941-0f3e-458f-aef0-a08abac0a2e2"
      unitRef="usd">151800000</us-gaap:Goodwill>
    <opk:InProcessResearchandDevelopment
      contextRef="i80eb499192104b008d7af0e0148d19c8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMjc0ODc3OTA3MjA2MQ_6c576472-d3ea-4da8-9670-fb74a77b0fb8"
      unitRef="usd">-590000000</opk:InProcessResearchandDevelopment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie9f8b48ec3cc43d09aa306ad85bdfbd6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMjc0ODc3OTA3MjA2MQ_ed31b481-2f4f-458e-83fd-7958dbd3241b"
      unitRef="usd">590000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1ec064528f8b46c799fcf289c9791518_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMjc0ODc3OTA3MjAxMg_c4eb890c-1f3b-463b-ab4c-e1b9669f8cd9">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RleHRyZWdpb246NWEzMGE4ZDkwMjM1NGNkNWE0ZDFjYTIxNTc0ZTNhMjFfMTA4OA_e143c443-3699-46f2-98d5-bd1f78919259">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in Goodwill by reporting unit during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross goodwill  at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative impairment at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;CURNA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Rayaldee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FineTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OPKO Biologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OPKO Chile&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OPKO Health Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OPKO Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transition Therapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BioReference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;434,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(151,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OPKO Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;710,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;519,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i9eec319fe4fc4382817c6990539e0de1_I20220101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMy0xLTEtMS0zNTMzMA_ffb78dfa-74f7-4309-a43e-287e11f457c7"
      unitRef="usd">4827000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="if4fc148ac1604fe99eb055c71362744f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMy0yLTEtMS0zNTMzMA_5ce1c8df-6c6a-4d99-aa4c-295b7a3f27eb"
      unitRef="usd">4827000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i199321e556e1463989019c01f39f4666_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMy00LTEtMS0zNTMzMA_1976217b-ee81-4627-82b7-11e1d198678c"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i6a7de7c9d3994710a52433ef3622e975_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMy01LTEtMS0zNTMzMA_f0e619c2-a02b-46b1-9163-f34f3f6bd80f"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4dc68b2fcd3343aca45a1f78bea968ab_I20220101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNC0xLTEtMS0zNTMzMA_cc692269-03e5-4022-a805-9f168512372d"
      unitRef="usd">86554000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i29b82614912a4396b69e605161eac8c8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNC0yLTEtMS0zNTMzMA_e584c55c-3310-432c-9304-2b7ef10eef4a"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ifa9e641d3a3f43bba301ff2922df3bc7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNC00LTEtMS0zNTMzMA_68a50649-4b19-4b30-9f5c-a7f962c66966"
      unitRef="usd">-1701000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i3d8091552aab4b19b8c4d08ef13537d5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNC01LTEtMS0zNTMzMA_2ffd8c9d-af66-4098-b03c-f269463f115a"
      unitRef="usd">84853000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idd18b46a79c64b6d83b27c4f2d210742_I20220101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNS0xLTEtMS0zNTMzMA_2b26470d-0727-449c-a8ac-0db11e521dcf"
      unitRef="usd">11698000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="idf902a5a04b14f7babb55f3b843e3a80_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNS0yLTEtMS0zNTMzMA_c7764c2c-0366-47c7-b191-e3fc6895fe7f"
      unitRef="usd">11698000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i114289ac9f494783bd9d11890dec12dc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNS00LTEtMS0zNTMzMA_d843dd2e-1797-4ba8-9dd2-903831181211"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="iff62ea5a28684fc8a6b1dc70be867c32_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNS01LTEtMS0zNTMzMA_6296043e-8c06-45c2-94a9-b3e2b1b6b108"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i061dafbf8ba241378db298ff55bea551_I20220101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNi0xLTEtMS0zNTMzMA_58b1841f-47ff-4b27-bed1-b05cc815c153"
      unitRef="usd">139784000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i30ac8d0d0c694b82a5397dcb0df95a8e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNi0yLTEtMS0zNTMzMA_89d3a9c9-286e-45df-af8e-ba2357dbaa46"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib8b2c36299ad4032aad14bf2b2486edf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNi00LTEtMS0zNTMzMA_fabacf02-4006-4b42-9c4a-eb4f743a9ff8"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ifd5e493ead0e4e5e9162c5c722db4e35_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNi01LTEtMS0zNTMzMA_c21837fe-0cdf-43bd-bbe9-97c570a1a7cc"
      unitRef="usd">139784000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie5febec8e3a34d12aeeeb1e3f39919ca_I20220101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNy0xLTEtMS0zNTMzMA_d4c4af48-dac1-4894-97bf-7033de8859e8"
      unitRef="usd">3760000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ia9587f6a4f274caaba6009524613917d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNy0yLTEtMS0zNTMzMA_087e1c9e-172d-47dd-aea9-80fd5020d24d"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="id78bb5a3b0424167a9c9b348ea5cf5cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNy00LTEtMS0zNTMzMA_4384a7d3-4adb-4ea1-9ae4-7e4beaa0eb0e"
      unitRef="usd">302000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i926fe15bf7e14648af39eaf884ccac95_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfNy01LTEtMS0zNTMzMA_73b290cd-c579-41b7-a5da-176a14766425"
      unitRef="usd">4062000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2eaedf3c190742929a4c020e7afc76b8_I20220101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOC0xLTEtMS0zNTMzMA_6b2c238a-f98b-4db1-ba2d-4a317005e32d"
      unitRef="usd">7478000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i9565f1ff76984a2d87c2caae18caa32a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOC0yLTEtMS0zNTMzMA_679d3b58-6444-4530-9873-c251bf8bf310"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ied7c009dbf6647c2a36b57156c5ce4de_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOC00LTEtMS0zNTMzMA_7f762a22-d6d1-4dc7-89b5-079207d88316"
      unitRef="usd">-150000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ic22ef152d20d46f5b505759af9ebb7f8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOC01LTEtMS0zNTMzMA_8350d5c9-aa60-40f4-a468-0e9e4623599d"
      unitRef="usd">7328000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if107abf0de7a41faa040731b1223de77_I20220101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOS0xLTEtMS0zNTMzMA_54a6212d-ba92-4113-aecd-cd7e0d21f698"
      unitRef="usd">100000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i1ec024cce2a2496984ae03706c8870ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOS0yLTEtMS0zNTMzMA_a6922b13-05ee-4494-96b5-fbfd4fdad874"
      unitRef="usd">100000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="iefd76cc953044df3aa7d05cbb5e5cf00_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOS00LTEtMS0zNTMzMA_ec4330df-cc60-45f4-9a78-3a3e9fbbbf6c"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i076891eda5724f9e8facc0d32cf101a3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfOS01LTEtMS0zNTMzMA_8996b834-4ff7-42ba-9478-ee733425ba3e"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idf39b19d11f0451580b5298ca4e70ed2_I20220101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTAtMS0xLTEtMzUzMzA_0232f136-722e-484a-b843-348dc6226ff1"
      unitRef="usd">3421000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i1a89597a3caa42bab28aa9233a6692fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTAtMi0xLTEtMzUzMzA_77100aab-0e81-42a9-9c6a-b8b3fe1d8f84"
      unitRef="usd">3421000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="if1a2689178204969b6be3b7c80a94903_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTAtNC0xLTEtMzUzMzA_ec0b8d17-61a8-4802-88a9-865ebade44b3"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="id469bfa162ed497c8fd73817abe740dc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTAtNS0xLTEtMzUzMzA_e1f5044f-031a-40c0-b5a2-165aed4d3417"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i87bdb1d33c654930a1c1073348ae533c_I20220101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTMtMS0xLTEtMzUzMzA_b1571b38-985d-44b4-80e3-f106e80e920f"
      unitRef="usd">434809000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ifaf793477c8f470eaeaeaee2fe7d1534_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTMtMi0xLTEtMzUzMzA_4552475d-3c18-43f7-b6cb-24ffdd4bc736"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="if9c0e49d0f844798a8cde4028560528e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTMtNC0xLTEtMzUzMzA_efb5eae6-6bfb-40c1-8a28-5a282782620f"
      unitRef="usd">-151784000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i0be93569346549e6b40179e6f26f198c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTMtNS0xLTEtMzUzMzA_f210b8b3-9992-48ce-8410-517d80076a11"
      unitRef="usd">283025000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8f702a5c58d541e398fbf371ddd14f4d_I20220101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTQtMS0xLTEtMzUzMzA_4072dfd4-1047-46ba-a671-f1ec173c8f00"
      unitRef="usd">17977000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i55f7b3a49175491f81bd49d3873d7ef6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTQtMi0xLTEtMzUzMzA_b15e238b-e8ae-43a7-93ac-c6f4bea762d1"
      unitRef="usd">17977000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i56ce2a0713064856b4736ba58073e798_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTQtNC0xLTEtMzUzMzA_4e9904d2-2452-4b0b-b38c-3b8a647050a8"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i2e77dbdc6364495093a3daccd4d4c89e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTQtNS0xLTEtMzUzMzA_18017c9e-a60e-4e13-88ad-e25d0edb77e3"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0e74f63daa08493f8fddebb9af0d512f_I20220101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTUtMS0xLTEtMzUzMzA_734ac1b9-afda-4005-a531-4362d0d57d21"
      unitRef="usd">710408000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTUtMi0xLTEtMzUzMzA_0625ed0e-c475-4b76-87fc-5bcb89522ca2"
      unitRef="usd">38023000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTUtNC0xLTEtMzUzMzA_d8ad223b-47e1-41e0-b454-7b91e8cf3a43"
      unitRef="usd">-153333000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181Mi9mcmFnOjVhMzBhOGQ5MDIzNTRjZDVhNGQxY2EyMTU3NGUzYTIxL3RhYmxlOjUyMTJlMjA0YTZiZTQ5ZjQ4YmRiNDk4N2QxODIyZTlhL3RhYmxlcmFuZ2U6NTIxMmUyMDRhNmJlNDlmNDhiZGI0OTg3ZDE4MjJlOWFfMTUtNS0xLTEtMzUzMzA_6cf14393-d033-4110-a9f4-bfea5c07c04b"
      unitRef="usd">519052000</us-gaap:Goodwill>
    <us-gaap:InvestmentTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNjg4NA_7b3a882b-52fe-4b4b-bd7d-adb724f7b29b">INVESTMENTS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of March&#160;31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investment Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Underlying Equity in Net Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investment Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Underlying Equity in Net Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable interest entity, equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with no readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%"&gt;Equity method investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity method investments consist of investments in Pharmsynthez (ownership 9%), Cocrystal Pharma, Inc. (&#x201c;COCP&#x201d;) (3%), Non-Invasive Monitoring Systems, Inc. (&#x201c;NIMS&#x201d;) (1%), Neovasc, Inc. (&#x201c;Neovasc&#x201d;) (1%), InCellDx, Inc. (&#x201c;InCellDx&#x201d;) (29%), BioCardia, Inc. (&#x201c;BioCardia&#x201d;) (1%), Xenetic Biosciences, Inc. (&#x201c;Xenetic&#x201d;) (1%), and LeaderMed Health Group Limited (&#x201c;LeaderMed&#x201d;) (47%).  The aggregate amount of assets, liabilities, and net losses of our equity method investees as of and for the three months ended March 31, 2022 were $222.1 million, $37.6 million, and $19.0 million, respectively.  The aggregate amount of assets, liabilities, and net losses of our equity method investees as of and for the year ended December 31, 2021 were $223.6&#160;million, $37.9&#160;million, and $69.4&#160;million, respectively. We have determined that we and/or our related parties can significantly influence control of our equity method investments through our board representation and/or voting power.  Accordingly, we account for our investment in these entities under the equity method and record our proportionate share of their losses in Loss from investments in investees in our Condensed Consolidated Statement of Operations.  The aggregate value of our equity method investments based on the quoted market prices of their respective shares of common stock and the number of shares held by us as of March&#160;31, 2022 and December 31, 2021 was $3.6 million and $4.5&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity securities consist of investments in Phio Pharmaceuticals (&#x201c;Phio&#x201d;) (ownership 0.01%), VBI Vaccines Inc. (&#x201c;VBI&#x201d;) (1%), ChromaDex Corporation (&#x201c;ChromaDex&#x201d;) (0.1%), Eloxx Pharmaceuticals, Inc. (&#x201c;Eloxx&#x201d;) (1%), and CAMP4 Therapeutics Corporation (&#x201c;CAMP4&#x201d;) (5%) and HealthSnap, Inc. (7%).  We have determined that our ownership, along with that of our related parties, does not provide us with significant influence over the operations of these investments.  Accordingly, we account for our investment in these entities as equity securities, and we record changes in the fair value of these investments in Other income (expense) each reporting period when they have readily determinable fair value. Equity securities without a readily determinable fair value are adjusted to fair value when there is an observable price change. Net gains and losses on our equity securities for the three months ended March 31, 2022, and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the three months ended March&#160;31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net gains and losses recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net gains realized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized net gains and losses recognized during the period on equity securities still held at the reporting date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales of investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains (losses) included in earnings from sales of our investments are recorded in Other income (expense), net in our Condensed Consolidated Statement of Operations.  The cost of securities sold is based on the specific identification method.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants and options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to our equity method investments and equity securities, we hold options to purchase 47 thousand additional shares of BioCardia, all of which were vested as of March&#160;31, 2022 and December 31, 2021, and 33 thousand and 0.7 million to purchase additional shares of COCP and InCellDx, respectively.  We recorded the changes in the fair value of the options and warrants in Fair value changes of derivative instruments, net in our Condensed Consolidated Statement of Operations.  We also recorded the fair value of the options and warrants in Investments, net in our Condensed Consolidated Balance Sheet.  See further discussion of the Company&#x2019;s options and warrants in Note 9 and Note 10.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in variable interest entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have determined that we hold variable interests in LeaderMed, Detect Genomix, LLC (&#x201c;Detect Genomix&#x201d;) and Zebra Biologics, Inc. (&#x201c;Zebra&#x201d;). We made this determination as a result of our assessment that they do not have sufficient resources to carry out their principal activities without additional financial support.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 14, 2021, we and LeaderMed, a pharmaceutical development company with operations based in Asia, announced the formation of a joint venture to develop, manufacture and commercialize two of OPKO&#x2019;s clinical stage, long-acting drug products in Greater China and eight other Asian territories. Under the terms of the agreements, we have granted the joint venture exclusive rights to develop, manufacture and commercialize (a) OPK88003, an oxyntomodulin analog being developed for the treatment of obesity and diabetes, and (b) Factor VIIa-CTP, a novel long acting coagulation factor being developed to treat hemophilia, in exchange for 4,703 shares 47% ownership interest in the joint venture. In addition, we received an upfront payment of $1.0&#160;million and will be reimbursed for clinical trial material and technical support we provide the joint venture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to determine the primary beneficiary of the joint venture, we evaluated our investment and our related parties&#x2019; investment, as well as our investment combined with the related parties&#x2019; investment to identify if we had the power to direct the activities that most significantly impact the economic performance of the joint venture. Based on the capital structure, governing documents and overall business operations of the joint venture, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact the joint venture&#x2019;s economic performance and do not have an obligation to fund expected losses. We did determine that we can significantly influence control of the joint venture through our board representation and voting power. Therefore, we have the ability to exercise significant influence over the joint venture&#x2019;s operations and account for our investment in the joint venture under the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, GeneDx LLC, a subsidiary of the Company, announced that it had entered into an agreement with Pediatrix Medical Group (&#x201c;Pediatrix&#x201d;), a provider of maternal-fetal, and pediatric medical and surgical subspecialty physician services, to offer genomic sequencing to support clinical diagnosis in neonatal intensive care units staffed by Pediatrix&#x2019;s affiliated neonatologists. The offering is planned to include whole exome and whole genome sequencing and genomic support services under the brand Detect Genomix. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our initial capital investment in Detect Genomix was $245,000 for which we received a 49% ownership interest in Detect Genomix. We had been required to make additional capital contributions to Detect Genomix in accordance with our percentage interests if Detect Genomix were unable to generate positive cash flow from operations or is unable to obtain alternative financing.  We have not made any other investments in or loans to Detect Genomix through March 31, 2021. In January 2022, the Detect Genomix agreement was terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to determine the primary beneficiary of Detect Genomix, we evaluated our investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Detect Genomix.  Based on the capital structure, governing documents and overall business operations of Detect Genomix, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Detect Genomix&#x2019;s economic performance.  We determined, however, that we can significantly influence control of Detect Genomix through our board representation and voting power.  Therefore, we have the ability to exercise significant influence over Detect Genomix&#x2019;s operations and account for our investment in Detect Genomix under the equity method.  The joint venture was dissolved in January 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We own 1,260,000 shares of Zebra Series A-2 Preferred Stock and 900,000 shares of Zebra restricted common stock (ownership 29% at March&#160;31, 2022).  Zebra is a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drugs.  Dr. Richard Lerner, M.D., a former member of our Board of Directors, is a founder of Zebra and, along with Dr. Frost, serves as a member of Zebra&#x2019;s Board of Directors.  &lt;/span&gt;&lt;/div&gt;In order to determine the primary beneficiary of Zebra, we evaluated our investment and our related parties&#x2019; investment, as well as our investment combined with the related parties&#x2019; investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Zebra.  Based on the capital structure, governing documents and overall business operations of Zebra, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Zebra&#x2019;s economic performance and have no obligation to fund expected losses.  We determined, however, that we can significantly influence control of Zebra through our board representation and voting power.  Therefore, we have the ability to exercise significant influence over Zebra&#x2019;s operations and account for our investment in Zebra under the equity method.</us-gaap:InvestmentTextBlock>
    <us-gaap:InvestmentTableTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNjg5NA_0ae9003a-da9d-4abb-baff-cc1d6f681bfa">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of March&#160;31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investment Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Underlying Equity in Net Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investment Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Underlying Equity in Net Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable interest entity, equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with no readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentTableTextBlock>
    <opk:EquityMethodInvestmentExcludingVariableInterestEntity
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMi0yLTEtMS0zNTMzMA_b39d7fa6-14c7-4aaf-9243-7cf7405243ef"
      unitRef="usd">217000</opk:EquityMethodInvestmentExcludingVariableInterestEntity>
    <us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMi00LTEtMS0zNTMzMA_ce337c95-895b-4d93-99ee-a83fa407621b"
      unitRef="usd">4497000</us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets>
    <opk:EquityMethodInvestmentExcludingVariableInterestEntity
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMi02LTEtMS0zNTMzMA_49d7ac36-ae83-4443-9e07-779dbee744f8"
      unitRef="usd">263000</opk:EquityMethodInvestmentExcludingVariableInterestEntity>
    <us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMi04LTEtMS0zNTMzMA_bc1153ab-bf7a-4f70-80f0-082b4686abe6"
      unitRef="usd">3577000</us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets>
    <opk:EquityMethodInvestmentVariableInterestEntity
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMy0yLTEtMS0zNTMzMA_da197235-8de9-464b-94e8-735c77749b4a"
      unitRef="usd">773000</opk:EquityMethodInvestmentVariableInterestEntity>
    <opk:EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMy00LTEtMS0zNTMzMA_2060c3e0-24a3-4123-9a94-0e23f9e45efb"
      unitRef="usd">2772000</opk:EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets>
    <opk:EquityMethodInvestmentVariableInterestEntity
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMy02LTEtMS0zNTMzMA_d2cb6359-b5a9-4db0-aee0-95a031b9bfbb"
      unitRef="usd">816000</opk:EquityMethodInvestmentVariableInterestEntity>
    <opk:EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfMy04LTEtMS0zNTMzMA_dbd63afa-97b9-4e3a-ab53-8d6ea9ec8ea5"
      unitRef="usd">3043000</opk:EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNC0yLTEtMS0zNTMzMA_3fd368e5-1167-4802-b904-47eb7832cb04"
      unitRef="usd">3064000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNC02LTEtMS0zNTMzMA_6cef44b3-ea3a-45ab-9646-67e7b7ecc735"
      unitRef="usd">4226000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNS0yLTEtMS0zNTMzMA_b32dd7a3-7231-43d7-9b44-b6d812c51152"
      unitRef="usd">5403000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNS02LTEtMS0zNTMzMA_702ab09a-f1fd-441f-98d2-72855e916db8"
      unitRef="usd">5408000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <opk:StockOptionandWarrantInvestments
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNi0yLTEtMS0zNTMzMA_b1cca7b1-9998-4ae8-87b0-5bd8be4b27e5"
      unitRef="usd">15000</opk:StockOptionandWarrantInvestments>
    <opk:StockOptionandWarrantInvestments
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNi02LTEtMS0zNTMzMA_af8ea7f1-e28b-4d21-ba49-a14c30e13665"
      unitRef="usd">16000</opk:StockOptionandWarrantInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNy0yLTEtMS0zNTMzMA_d2f7c1ad-c8e0-4904-828b-5d57b4419cf2"
      unitRef="usd">9472000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOmEwOTBhZTUwODY1YTRjYTlhNzkyZjlmYzhhNTQ5NzY4L3RhYmxlcmFuZ2U6YTA5MGFlNTA4NjVhNGNhOWE3OTJmOWZjOGE1NDk3NjhfNy02LTEtMS0zNTMzMA_df2728e9-1339-4ae6-9b8a-642a3df52950"
      unitRef="usd">10729000</us-gaap:LongTermInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i2da87d4b1cea40abb7f65c8419989f04_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMzEz_c987587f-d3ef-4b8c-ad28-8d55402bee88"
      unitRef="number">0.09</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ief9f3d5f2c21400fbcb87f69615b8cf1_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMzUx_ff4c87ff-a99a-4456-91bb-d0b852bc86b1"
      unitRef="number">0.03</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i2a5eea0a1fa844b19b8baa7361a45542_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNDA0_0a9844f5-8dfe-49c7-b5df-9f345a6e9a5d"
      unitRef="number">0.01</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i4e737b98458d4a859ab982878352b552_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNDM2_f938b0c8-1b39-41a4-bd13-468aa30cdc7b"
      unitRef="number">0.01</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i61c6fa53ff434aeea2559a0e6fca1f8f_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNDcw_8550f2f9-b086-4bb7-9b7f-f776ea7b1ebd"
      unitRef="number">0.29</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iefc49f12f9a24f6a8438f9164321e4b9_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNTA2_4b8d7905-59d4-4115-8999-9023f57eaa52"
      unitRef="number">0.01</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ide7dce2757b14a7e80beaf9e7f36bc70_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNTUw_3ebfd2c2-09e2-4813-8137-392e2e0a3a13"
      unitRef="number">0.01</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i3e85d9626c1c441cb3ee913546454e58_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMTA5OTUxMTY0MzgzMA_6b74935e-6ac9-4594-a789-719ac72d6fef"
      unitRef="number">0.47</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:Assets
      contextRef="i345405f3f02b45a1bf5c9b950dde0383_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNzI4_2b35e11e-08b1-4d9e-aa6b-783f2564ec08"
      unitRef="usd">222100000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i345405f3f02b45a1bf5c9b950dde0383_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNzMy_a71cfe62-42b3-4e24-b2ea-3f2ac545fe97"
      unitRef="usd">37600000</us-gaap:Liabilities>
    <us-gaap:ProfitLoss
      contextRef="ic8ff88bb39754838bea82d4aa6fe8b0d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNzQw_3d9a6a1c-f9ba-4740-a4de-e253122af1e2"
      unitRef="usd">-19000000</us-gaap:ProfitLoss>
    <us-gaap:Assets
      contextRef="ib3269e9e5de645f7ab9c3fa24f73c940_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfOTAy_c82173c4-d8a6-4401-b0a5-f90c7a9baef6"
      unitRef="usd">223600000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="ib3269e9e5de645f7ab9c3fa24f73c940_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfOTA2_3294dc7a-16a3-42f0-b621-ea89659f8b6e"
      unitRef="usd">37900000</us-gaap:Liabilities>
    <us-gaap:ProfitLoss
      contextRef="i0c994275c6324f47a249b3109e183353_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfOTE0_d0f9e205-6b8b-4234-bd04-5dd0136c7b7c"
      unitRef="usd">-69400000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMTUxOQ_b03889f8-637f-42a9-a703-7db7dc89fa8f"
      unitRef="usd">3600000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjc0ODc3OTA3NjQxNg_0b58d32a-b51a-440d-aa4b-3e9919a058b2"
      unitRef="usd">4500000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="i735a6dd4044144048e04b19307ebbe2d_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMTY0Nw_6d07e43c-eefd-4c21-b59c-f9af8862da4c"
      unitRef="number">0.0001</opk:EquitySecurityFVNIOwnershipPercent>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="i93c10577f5fe4cf5aa85dbf6a728072b_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMTY3OQ_ebca1b48-b37e-449a-a6c0-fc2ec5e6daa3"
      unitRef="number">0.01</opk:EquitySecurityFVNIOwnershipPercent>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="idb8abbb296ab4fd6bec8792f90ed897c_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMTcyMQ_55b70578-4f4a-4d01-8679-e0feec244537"
      unitRef="number">0.001</opk:EquitySecurityFVNIOwnershipPercent>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="i745a5d9c8eda4157b142bcd4ae5184df_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMTc2NQ_bf8a4df2-26a6-4516-a7af-2e2f4e273526"
      unitRef="number">0.01</opk:EquitySecurityFVNIOwnershipPercent>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="ic9dabca72cbc43ae823846a3ceb570c6_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMTgxNg_6616cbdc-27f4-4c9a-836f-7d66fe6c465c"
      unitRef="number">0.05</opk:EquitySecurityFVNIOwnershipPercent>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="i74ad64c47d06402791389d97af41b417_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMzg0ODI5MDcxMjc1Nw_3082c6fc-c956-43b4-8df9-fc98d1ac2ff8"
      unitRef="number">0.07</opk:EquitySecurityFVNIOwnershipPercent>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNjg4OA_9152b516-679f-4b74-a1c3-e5b6d108b69b">Net gains and losses on our equity securities for the three months ended March 31, 2022, and 2021 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the three months ended March&#160;31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net gains and losses recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net gains realized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized net gains and losses recognized during the period on equity securities still held at the reporting date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOjExOTkxNmQ0NjhiNzRhMGY5NTdmZGMyYjkyMWJiYjNiL3RhYmxlcmFuZ2U6MTE5OTE2ZDQ2OGI3NGEwZjk1N2ZkYzJiOTIxYmJiM2JfMy0xLTEtMS0zNTMzMA_8fbbb26f-9edc-4df9-a3c7-6976e7575a35"
      unitRef="usd">-1162000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOjExOTkxNmQ0NjhiNzRhMGY5NTdmZGMyYjkyMWJiYjNiL3RhYmxlcmFuZ2U6MTE5OTE2ZDQ2OGI3NGEwZjk1N2ZkYzJiOTIxYmJiM2JfMy0zLTEtMS0zNTMzMA_9e80955d-f23c-478c-9358-3ebd50e27f54"
      unitRef="usd">2780000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOjExOTkxNmQ0NjhiNzRhMGY5NTdmZGMyYjkyMWJiYjNiL3RhYmxlcmFuZ2U6MTE5OTE2ZDQ2OGI3NGEwZjk1N2ZkYzJiOTIxYmJiM2JfNC0xLTEtMS0zNTMzMA_1aad6664-9901-4523-a2b5-3776fc3a9b42"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOjExOTkxNmQ0NjhiNzRhMGY5NTdmZGMyYjkyMWJiYjNiL3RhYmxlcmFuZ2U6MTE5OTE2ZDQ2OGI3NGEwZjk1N2ZkYzJiOTIxYmJiM2JfNC0zLTEtMS0zNTMzMA_47a1857c-ca66-4336-843e-87733f7eee9f"
      unitRef="usd">2981000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOjExOTkxNmQ0NjhiNzRhMGY5NTdmZGMyYjkyMWJiYjNiL3RhYmxlcmFuZ2U6MTE5OTE2ZDQ2OGI3NGEwZjk1N2ZkYzJiOTIxYmJiM2JfNS0xLTEtMS0zNTMzMA_ff0db4d2-27a8-4db2-a6eb-b37120d031dc"
      unitRef="usd">-1162000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RhYmxlOjExOTkxNmQ0NjhiNzRhMGY5NTdmZGMyYjkyMWJiYjNiL3RhYmxlcmFuZ2U6MTE5OTE2ZDQ2OGI3NGEwZjk1N2ZkYzJiOTIxYmJiM2JfNS0zLTEtMS0zNTMzMA_97a7cbb3-71ee-4b29-b397-565387dc402b"
      unitRef="usd">-201000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i045c2a8d58864ccc84d9e26f6de225bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjgyOA_e4467966-b652-4375-ab5d-8ce167efda02"
      unitRef="shares">47000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="iefc49f12f9a24f6a8438f9164321e4b9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjgyOA_fc84d79c-64db-40b9-ba38-a995824da217"
      unitRef="shares">47000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ief9f3d5f2c21400fbcb87f69615b8cf1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjkyNA_ab791920-d7e7-4bf9-8198-381c210ddb0c"
      unitRef="shares">33000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i61c6fa53ff434aeea2559a0e6fca1f8f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjkyOA_965d2d2f-25e6-490d-980e-68dd03e38526"
      unitRef="shares">700000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <opk:NoncontrollingInterestSharesIssued
      contextRef="id1b622c3fa27402b9211c7b4ccf25f7f_D20210914-20210914"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjc0ODc3OTA3ODM4OA_c3efc113-a120-4427-8903-73504e16450a"
      unitRef="shares">4703</opk:NoncontrollingInterestSharesIssued>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i36d25b2cfa03459783a6e94281295ca5_I20210914"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjc0ODc3OTA3ODM5NQ_36eae7dd-3c9b-42bc-9cbc-129ced9ecb7a"
      unitRef="number">0.47</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8156096c5d249378540b9fe04c480dc_D20210914-20210914"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfMjc0ODc3OTA3ODM3NA_6a39db1e-d108-4fb1-8540-07c207feaaee"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ibadd78e70def4793bd8033df5fdbe911_D20200801-20200831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNDM1Mw_77bebb7f-a795-40ef-bbe3-00b2a847d966"
      unitRef="usd">245000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i4a78517025804d929c0e5e426c1b9a4b_I20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNDM4MA_b063342a-e16c-4a8f-ac39-6699f3e966df"
      unitRef="number">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i025ab7646b8144b688675d0f4247839f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNTU1OA_192b4ee2-b94d-47e5-866c-d631771902f1"
      unitRef="shares">1260000</us-gaap:InvestmentOwnedBalanceShares>
    <opk:SharesReceivedAsGift
      contextRef="i0bba573814e746888e84c5b2aa904dc8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNTYwOA_1db58503-29da-4af0-b29d-3ae6648beadc"
      unitRef="shares">900000</opk:SharesReceivedAsGift>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iced2ab36569e4ad68d856b5c48df2e03_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181NS9mcmFnOmVhNDg4YjVhYTZhOTQ1N2Y4ZGI5NzhkZjYyY2RhMDRmL3RleHRyZWdpb246ZWE0ODhiNWFhNmE5NDU3ZjhkYjk3OGRmNjJjZGEwNGZfNTY2Mg_23057728-8e3d-405a-8413-28883cf49479"
      unitRef="number">0.29</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTU3Mzg_a39f9a91-45a7-4740-a584-df305fd8d95f">DEBT&#160;&#160;&#160;&#160;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, our debt consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2033 Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Chilean and Spanish lines of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long term portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance sheet captions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current portion of lines of credit and notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;LT notes payable included in long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 25, 2020, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $100 million.  The line of credit called for a commitment fee equal to 0.25% per annum of the unused portion of the line. No funds were borrowed under this line of credit and we terminated this line of credit in June 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, we issued $200.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the &#x201c;2025 Notes&#x201d;) in an underwritten public offering.  The 2025 Notes bear interest at a rate of 4.50% per year, payable semiannually in arrears on February&#160;15 and August&#160;15 of each year.  The notes mature on February&#160;15, 2025, unless earlier repurchased, redeemed or converted.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their 2025 Notes into shares of Common Stock at their option at any time prior to the close of business on the business day immediately preceding November&#160;15, 2024 only under the following circumstances:  (1)&#160;during any calendar quarter commencing after the calendar quarter ended March&#160;31, 2019 (and only during such calendar quarter), if the last reported sale price of our Common Stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2)&#160;during the five business day period after any five consecutive trading day period (the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of 2025 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our Common Stock and the conversion rate on each such trading day; (3)&#160;if we call any or all of the 2025 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4)&#160;upon the occurrence of specified corporate events set forth in the indenture governing the 2025 Notes.  On or after November&#160;15, 2024, until the close of business on the business day immediately preceding the maturity date, holders of the 2025 Notes may convert their notes at any time, regardless of the foregoing conditions.  Upon conversion, we will pay or deliver, as the case may be, cash, shares of our Common Stock, or a combination of cash and shares of our Common Stock, at our election.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial and current conversion rate for the 2025 Notes is 236.7424 shares of Common Stock per $1,000 principal amount of 2025 Notes (equivalent to a conversion price of approximately $4.22 per share of Common Stock).  The conversion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rate for the 2025 Notes is subject to adjustment in certain events but will not be adjusted for any accrued and unpaid interest.  In addition, following certain corporate events that occur prior to the maturity date of the 2025 Notes or if we deliver a notice of redemption, in certain circumstances the indenture governing the 2025 Notes requires an increase in the conversion rate of the 2025 Notes for a holder who elects to convert its notes in connection with such a corporate event or notice of redemption, as the case may be.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may not redeem the 2025 Notes prior to February&#160;15, 2022.  We may redeem for cash any or all of the 2025 Notes, at our option, on or after February&#160;15, 2022, if the last reported sale price of our Common Stock has been at least 130% of the then current conversion price for the notes for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.  No sinking fund is provided for the 2025 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we undergo a fundamental change, as defined in the indenture governing the 2025 Notes, prior to the maturity date of the 2025 Notes, holders may require us to repurchase for cash all or any portion of their notes at a repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.  The 2025 Notes are our senior unsecured obligations and rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2025 Notes; equal in right of payment to any of our existing and future liabilities that are not so subordinated; effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we entered into exchange agreements with certain holders of the 2025 Notes, pursuant to which the holders exchanged $55.4&#160;million in aggregate principal amount of the outstanding 2025 Notes for 19,051,270 shares of our Common Stock (the &#x201c;Exchange&#x201d;). We recorded an $11.1&#160;million non-cash loss related to the Exchange during the second quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the issuance of the 2025 Notes, we agreed to loan up to 30,000,000 shares of our Common Stock to affiliates of the underwriter in order to assist investors in the 2025 Notes to hedge their position. Following consummation of the Exchange, the number of outstanding borrowed shares of Common Stock was reduced by approximately 8,105,175 shares. As of&#160;March&#160;31, 2022 and December 31, 2021, a total of&#160;21,144,825 and 21,144,825 shares remained outstanding under the&#160;share lending&#160;arrangement, respectively. We will not receive any of the proceeds from the sale of the borrowed shares, but we received a one-time nominal fee of $0.3 million for the newly issued shares. Shares of our Common Stock outstanding under the&#160;share lending&#160;arrangement are excluded from the calculation of basic and diluted earnings per share. See Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As required by ASC 470-20, &#x201c;Debt with Conversion and Other Options,&#x201d; we calculated the equity component of the 2025 Notes, taking into account both the fair value of the conversion option and the fair value of the&#160;share lending arrangement. The equity component was valued at&#160;$52.6 million&#160;at issue date and this amount was recorded as Additional paid-in capital, which resulted in a discount on the 2025 Notes. The discount is being amortized to Interest expense over the term of the 2025 Notes, which results in an effective interest rate on the 2025 Notes of 11.2%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth information related to the 2025 Notes which is included in our Condensed Consolidated Balance Sheet as of March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025 Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt Issuance Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adoption of ASU 2020-06&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity's Own Equity (Subtopic 815-40).&#x201d; ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. The ASU is effective for public entities for fiscal years beginning after December&#160;15, 2021, with early adoption permitted.   As required, we adopted ASU 2020-06 on January 1, 2022 and used the modified retrospective approach for all convertible debt instruments at the beginning of the period of adoptions.  Results for reporting periods beginning January 1, 2022 are presented under ASU 2020-06, while prior period amounts were not adjusted and continue to be reported in accordance with historic accounting guidance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the modified approach, entities will apply the guidance to all financial instruments that are outstanding as of the beginning of the year of adoption with the cumulative effect recognized as an adjustment to the opening balance of retained earnings. ASU 2020-06 eliminates the cash conversion and beneficial conversion feature models in ASC 470-20 that require an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity. The adoption of ASU 2020-06 at January 1, 2022 resulted in an increase of the Convertible notes of $21.6&#160;million, a reduction of the Accumulated deficit of $17.5&#160;million and a reduction of Additional paid-in capital of $39.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, we issued a series of 5% Convertible Promissory Notes (the &#x201c;2023 Convertible Notes&#x201d;) in the aggregate principal amount of $55.0 million.  The 2023 Convertible Notes mature five years following the date of issuance.  Each holder of a 2023 Convertible Note has the option, from time to time, to convert all or any portion of the outstanding principal balance of such 2023 Convertible Note, together with accrued and unpaid interest thereon, into shares of our Common Stock at a conversion price of $5.00 per share.  We may redeem all or any part of the then issued and outstanding 2023 Convertible Notes, together with accrued and unpaid interest thereon, pro rata among the holders, upon no fewer than 30 days, and no more than 60 days, notice to the holders.  The 2023 Convertible Notes contain customary events of default and representations and warranties of OPKO.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchasers of the 2023 Convertible Notes included an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2013, we entered into note purchase agreements with respect to the issuance and sale of our 3.0% Senior Notes due 2033 (the &#x201c;2033 Senior Notes&#x201d;) in a private placement exempt from registration under the Securities Act.  We issued the 2033 Senior Notes on January&#160;30, 2013.  The 2033 Senior Notes, which totaled $175.0 million in original principal amount, bear interest at the rate of 3.0%&#160;per year, payable semiannually on February&#160;1 and August&#160;1 of each year.  The 2033 Senior Notes mature on February&#160;1, 2033, unless earlier repurchased, redeemed or converted.  Upon a fundamental change, as defined in the indenture governing the 2033 Senior Notes, subject to certain exceptions, the holders may require us to repurchase all or any portion of their 2033 Senior Notes for cash at a repurchase price equal to 100% of the principal amount of the 2033 Senior Notes being repurchased, plus any accrued and unpaid interest to, but not including, the related fundamental change repurchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From 2013 to 2016, holders of the 2033 Senior Notes converted $143.2 million in aggregate principal amount into an aggregate of 21,539,873 shares of Common Stock. On February 1, 2019, approximately $28.8 million aggregate principal amount of 2033 Senior Notes were tendered by holders pursuant to such holders&#x2019; option to require us to repurchase the 2033 Senior Notes as set forth in the indenture, governing the 2033 Senior Notes, following which repurchase only $3.0 million aggregate principal amount of the 2033 Senior Notes remained outstanding.  Holders of the remaining $3.0 million principal amount of the 2033 Senior Notes may require us to repurchase such notes for 100% of their principal amount, plus accrued and unpaid interest, on February 1, 2023, on February 1, 2028, or following the occurrence of a fundamental change as described above.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the 2033 Senior Notes, include, among others: (i) rights to convert the notes into shares of our Common Stock, including upon a fundamental change; and (ii) a coupon make-whole payment in the event of a conversion by the holders of the 2033 Senior Notes on or after February 1, 2017 but prior to February 1, 2019.  We determined that these specific terms were embedded derivatives.  Embedded derivatives are required to be separated from the host contract, the 2033 Senior Notes, and carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument.  We concluded that the embedded derivatives within the 2033 Senior Notes met these criteria and, as such, were valued separate and apart from the 2033 Senior Notes and recorded at fair value each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For accounting and financial reporting purposes, we combined these embedded derivatives and valued them together as one unit of accounting. In 2017, certain terms of the embedded derivatives expired pursuant to the original agreement and the embedded derivatives no longer met the criteria to be separated from the host contract and, as a result, the embedded derivatives were no longer required to be valued separate and apart from the 2033 Senior Notes and were reclassified to additional paid in capital. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2015, BioReference and certain of its subsidiaries entered into a credit agreement with JPMorgan Chase Bank, N.A. (&#x201c;CB&#x201d;), as lender and administrative agent, as amended (the &#x201c;Credit Agreement&#x201d;).  The Credit Agreement provides for a $75.0 million secured revolving credit facility and includes a $20.0 million sub-facility for swingline loans and a $20.0 million sub-facility for the issuance of letters of credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2021, the Credit Agreement was amended and restated (the &#x201c;A&amp;amp;R Credit Agreement&#x201d;). The A&amp;amp;R Credit Agreement is guaranteed by all of BioReference&#x2019;s domestic subsidiaries.  The A&amp;amp;R Credit Agreement is also secured by substantially all assets of BioReference and its domestic subsidiaries, as well as a non-recourse pledge by us of our equity interest in BioReference.  Availability under the A&amp;amp;R Credit Agreement is based on a borrowing base composed of eligible accounts receivables of BioReference and certain of its subsidiaries, as specified therein.  As of March&#160;31, 2022, $64.8 million remained available for borrowing under the Credit Agreement. Principal under the Credit Agreement is due upon maturity on August 30, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At BioReference&#x2019;s option, borrowings under the A&amp;amp;R Credit Agreement (other than swingline loans) will bear interest at (i) the CB floating rate (defined as the higher of (a) the prime rate and (b) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) for an interest period of one month plus 2.50%) plus an applicable margin of 0.75% or (ii) the LIBOR rate (adjusted for statutory reserve requirements for Eurocurrency liabilities) plus an applicable margin of 1.75%.  Swingline loans will bear interest at the CB floating rate plus the applicable margin.  The A&amp;amp;R Credit Agreement also calls for other customary fees and charges, including an unused commitment fee of 0.375% if the average quarterly availability is 50% or more of the revolving commitment, or 0.25% if the average quarterly availability is less than or equal to 50% of the revolving commitments.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of March 31, 2022 and December 31, 2021, no amount was outstanding under the A&amp;amp;R Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The A&amp;amp;R Credit Agreement contains customary covenants and restrictions, including, without limitation, covenants that require BioReference and its subsidiaries to maintain a minimum fixed charge coverage ratio if availability under the new credit facility falls below a specified amount and to comply with laws and restrictions on the ability of BioReference and its subsidiaries to incur additional indebtedness or to pay dividends and make certain other distributions to the Company, subject to certain exceptions as specified therein.  Failure to comply with these covenants would constitute an event of default under the A&amp;amp;R Credit Agreement, notwithstanding the ability of BioReference to meet its debt service obligations.  The A&amp;amp;R Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the A&amp;amp;R Credit Agreement and execution upon the collateral securing obligations under the A&amp;amp;R Credit Agreement.  Substantially all the assets of BioReference and its subsidiaries are restricted from sale, transfer, lease, disposal or distributions to the Company, subject to certain exceptions. As of March&#160;31, 2022, BioReference and its subsidiaries had net assets of approximately $1,037.1 million, which included goodwill of $283.0 million and intangible assets of $199.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 29, 2022, the A&amp;amp;R Credit Agreement was amended to, among other things, (i) waive specified defaults under the A&amp;amp;R Credit Agreement resulting from certain internal reorganization transactions that resulted in both BioReference and GeneDx changing their respective forms of organization from New Jersey corporations to Delaware limited liability companies, (ii) provide for the disposition of GeneDx pursuant to the transactions contemplated by the merger agreement with Sema4, (iii) amend certain reporting requirements under the A&amp;amp;R Credit Agreement and (iv) provide that the borrowers under the A&amp;amp;R Credit Agreement may effect certain restricted payments to the extent necessary for their parent entities to pay income tax in respect of income earned by the borrowers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the A&amp;amp;R Credit Agreement with CB, we had line of credit agreements with thirteen other financial institutions as of March&#160;31, 2022 and eleven other financial institutions as of December&#160;31, 2021 in the U.S., Chile and Spain.  These lines of credit are used primarily as  sources of working capital for inventory purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(Dollars in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Balance Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lender&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest&#160;rate&#160;on&lt;br/&gt;borrowings at &lt;br/&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Credit&#160;line&lt;br/&gt;capacity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;JPMorgan Chase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Itau Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bank of Chile&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;BICE Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Scotiabank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Santander Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Security Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Estado Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BCI Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corpbanca&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consoorcio Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Banco De Sabadell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Santander Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022 and December&#160;31, 2021, the weighted average interest rate on our lines of credit was approximately 5.5% and 5.4%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022 and December&#160;31, 2021, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the 2025 Notes, the A&amp;amp;R Credit Agreement and amounts outstanding under lines of credit described above) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The notes and other debt mature at various dates ranging from 2022 through 2026, bearing variable interest rates from 0.7% up to 3.8%.  The weighted average interest rate on the notes and other debt was 1.5% and 1.5% on March&#160;31, 2022 and December&#160;31, 2021. The notes are partially secured by our office space in Barcelona.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTU3NDE_557dc244-5c74-4f36-bed5-749cef33ea11">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, our debt consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2033 Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Chilean and Spanish lines of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long term portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance sheet captions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current portion of lines of credit and notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;LT notes payable included in long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i7e46f99237c8496ca82c13bda9e7f294_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMS0xLTEtMS0zNTMzMA_c124cf43-a5cd-4f78-9274-d3fc87a4c4bf"
      unitRef="usd">141267000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="idc38b647115245d9a1d1122f23f15088_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMS0zLTEtMS0zNTMzMA_d3451135-89f0-44d7-97bb-067b1a7051e8"
      unitRef="usd">119360000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i46d6876e7be847069467c27ec77a4a44_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMi0xLTEtMS0zNTMzMA_970fe1c3-6c37-41f2-90c5-b6c084226273"
      unitRef="usd">66203000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i487322626c254451bb84eeb5072abbac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMi0zLTEtMS0zNTMzMA_17e50eb6-7f40-4d1d-94b0-780d9fa5945e"
      unitRef="usd">65525000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8fba9c7092e04a5ba143a73b73dada89_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMy0xLTEtMS0zNTMzMA_f902c829-e20f-4260-9ec1-ac0e8e8261f8"
      unitRef="usd">3050000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie4a642fa3cc44c77b27622488a3dcf17_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMy0zLTEtMS0zNTMzMA_48e5b8a2-64ab-43ef-bbb4-9251beb8585a"
      unitRef="usd">3050000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2a2bb52ee16c4f3cbd50cd8ebe53b377_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfNS0xLTEtMS0zNTMzMA_afe88224-0f53-4ef1-bbca-da98c87a4d50"
      unitRef="usd">16531000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia66232faa6934fc58bd350c3c5087464_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfNS0zLTEtMS0zNTMzMA_39b250f1-23c0-4bfa-8041-0e8e7622b68b"
      unitRef="usd">13672000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i9ea90eb5c3a649d1a00ba71dfd8d4665_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfNi0xLTEtMS0zNTMzMA_226b7cf9-883d-40c4-9b05-f6deaa2b0907"
      unitRef="usd">882000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i14a4df5ee1294c10a8f972615bb565fa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfNi0zLTEtMS0zNTMzMA_5b50337c-0d5e-4fc3-bfee-4344ae9782f6"
      unitRef="usd">1022000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9ea90eb5c3a649d1a00ba71dfd8d4665_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfNy0xLTEtMS0zNTMzMA_9f54f58e-47fd-4968-813a-8b0ee235207d"
      unitRef="usd">2331000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i14a4df5ee1294c10a8f972615bb565fa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfNy0zLTEtMS0zNTMzMA_2d280fd6-7396-492e-9375-f30cdedbc628"
      unitRef="usd">2642000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfOC0xLTEtMS0zNTMzMA_692c7a60-3555-4005-b839-ffed229d0b03"
      unitRef="usd">230264000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfOC0zLTEtMS0zNTMzMA_eb5292cf-d1f7-4a85-b2fe-0e4499c79195"
      unitRef="usd">205272000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib1511200111f48499ddfcbcdc01ff960_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTEtMS0xLTEtMzUzMzA_fd1364ff-3ee5-403c-a106-28bc60fb867e"
      unitRef="usd">210520000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i70922a4b40e947b7a60140a1158f9de6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTEtMy0xLTEtMzUzMzA_ada9d6b4-35cd-4768-88aa-83fdc5baacb6"
      unitRef="usd">187935000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if0fe0dcaa05548b79dc808f805d895bf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTItMS0xLTEtMzUzMzA_8ee7bae7-75ab-43ec-9abb-20ee17979990"
      unitRef="usd">17412000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i314f83bf93da4b8a953b12a86b015762_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTItMy0xLTEtMzUzMzA_13283ce3-d853-4c1e-ad79-cbc398af4abc"
      unitRef="usd">14695000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4c5f0e2847a64769ab9be88846f125c4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTMtMS0xLTEtMzUzMzA_39ab4a4d-4fc9-4e82-86d9-1ba73dac9fce"
      unitRef="usd">2331000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iae497a6420cd4f4faf38ce9662826b4e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTMtMy0xLTEtMzUzMzA_14161ee6-f27f-4bbc-b1f0-440f34188e2f"
      unitRef="usd">2642000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTQtMS0xLTEtMzUzMzA_a3331659-5b36-4f37-aba5-b0d1ef3051e5"
      unitRef="usd">230264000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmQ4YjA3ZGY0NjcwODQwNmQ4NDQ2ZTE5MzdmMjA2ZDJkL3RhYmxlcmFuZ2U6ZDhiMDdkZjQ2NzA4NDA2ZDg0NDZlMTkzN2YyMDZkMmRfMTQtMy0xLTEtMzUzMzA_1400be7e-21ce-49bd-b7eb-a7a5ba3a3c80"
      unitRef="usd">205272000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i77752216e0a74e5e94c99ae54b2ab33f_I20200225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjY3_496ef3a8-888d-4934-96bf-1d776b1176c7"
      unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i9ba35bd01ebf48fc928c6575df35dcf4_D20200225-20200225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMzI4_f7b9a0d3-3313-4b1b-b8ad-b589908a9ebc"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCredit
      contextRef="ia1b9e43d842649f78bdeeb877a771557_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNDUz_637f99d5-c303-4b95-9add-74e05b4b9e9f"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie2696a40617340cf8c06f43678aedbcc_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTE5_0ada0b1a-2302-4542-b83b-42fee1b2d32b"
      unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3d3e367b0c444609b24109041edeb01b_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNjg0_c0a934b1-d341-4347-8523-0bfaf87d27cf"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i40061516e65d48a1b5e3f3064a40b794_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTI4Nw_7251fabc-c971-487e-8265-e3e968a2a07d"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i9df45c289aa6458e8a7b184c9d9eb1f5_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTM1MQ_60883b02-bc64-4ed8-9de8-098859a9af5f"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i5f67d9074c764297ade8fcccc8dc5b7a_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTQ4NA_ffaf311f-eea7-4ef4-89ab-1734b21d968b"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i93cfe6ee9aef4ae3bb7d5b05ab545903_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTU1OA_520d04e2-724f-4415-a9fe-ac4b309e5696"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i8f1f20509fa846cf8da8cbaef989bbe8_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTU5MQ_6ad84543-d837-42f7-a5d0-fa9aa551b71a"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="id0582da3183f40ca88c4cb1db58d7e0c_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTc4Mg_94b1662a-423a-44f6-9156-a8d6a2b9700c"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ie2696a40617340cf8c06f43678aedbcc_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc1OA_7c174e29-f190-465d-bfcd-c0dd5801ff30"
      unitRef="usdPerShare">4.22</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i4609448adb58436ab818127efb5758c2_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMzg0ODI5MDcxNTIwMQ_6cc1bae3-6a4f-4ede-a1c3-b23feaf37c8a"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i7c2ad3f0dc804c1d9adea93dace26206_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMzg0ODI5MDcxNTIxNw_071d0f6e-3967-47a5-b007-615ba5789ff9"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ia70bad4845e84935a8ef37f70822b5d7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMzg0ODI5MDcxNTIwOQ_90aefee8-65ff-4039-bfa8-f7fcfd22fa42"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i4609448adb58436ab818127efb5758c2_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMzg0ODI5MDcxNTIyMw_26601551-b55a-427e-97aa-a42a707f88e5"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i5f67d9074c764297ade8fcccc8dc5b7a_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNDM0Nw_495f989d-d4b5-4341-9008-6ce921b2e559"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i227355c0a3f841b09e53338c115c186d_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTE4OQ_69273baa-fc42-4b0c-bb4a-2797f48eae3e"
      unitRef="usd">55400000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i227355c0a3f841b09e53338c115c186d_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTI1Ng_37dd201c-f941-42ea-9b8a-eb3362dd2d65"
      unitRef="shares">19051270</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <opk:GainLossOnConversionOfDebt
      contextRef="i227355c0a3f841b09e53338c115c186d_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTMxOQ_e905507b-53f8-42fe-944a-3bbd3d950225"
      unitRef="usd">-11100000</opk:GainLossOnConversionOfDebt>
    <opk:DebtInstrumentConvertibleDebtMaximumSharesIssuable
      contextRef="ie2696a40617340cf8c06f43678aedbcc_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTQzNw_19d62cd4-415f-47ec-bc5e-9e3e04b4b625"
      unitRef="shares">30000000</opk:DebtInstrumentConvertibleDebtMaximumSharesIssuable>
    <opk:DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable
      contextRef="i227355c0a3f841b09e53338c115c186d_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTY5OQ_5b447b2c-4dde-4e05-9437-0c80229e064e"
      unitRef="shares">-8105175</opk:DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="id91a4eb6cea742e4b1b93c700e56993f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTc1Mw_87f300c6-bddc-430e-a3a1-a787abb8f83f"
      unitRef="shares">21144825</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i5e68b8b37fc848168cc743f1b5049318_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTc2MQ_1b7da18b-6654-43ce-90bd-359ab4a7f014"
      unitRef="shares">21144825</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <opk:ProceedsFromConvertibleDebtConversionFee
      contextRef="id91a4eb6cea742e4b1b93c700e56993f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNTk2Mw_086cdda4-4b09-450b-9e3a-66a43309b15e"
      unitRef="usd">300000</opk:ProceedsFromConvertibleDebtConversionFee>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="ie2696a40617340cf8c06f43678aedbcc_I20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNjQzMw_0b7a0555-1ac2-41a2-bd36-94e842aea33f"
      unitRef="usd">52600000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i7e46f99237c8496ca82c13bda9e7f294_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNjcwOA_82ac124a-13f4-4770-af15-350bba48588e"
      unitRef="number">0.112</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTU3NjA_f8d9a94c-e1c9-4eea-a4f9-137c245c51c7">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth information related to the 2025 Notes which is included in our Condensed Consolidated Balance Sheet as of March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025 Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt Issuance Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adoption of ASU 2020-06&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022 and December&#160;31, 2021, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the 2025 Notes, the A&amp;amp;R Credit Agreement and amounts outstanding under lines of credit described above) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6b205efadb964c1cb4dff4ca72b078bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfMS0xLTEtMS0zNTMzMA_134c397a-b799-4b43-883e-72b7318a6083"
      unitRef="usd">144580000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i6b205efadb964c1cb4dff4ca72b078bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfMS0zLTEtMS0zNTMzMA_96d5b554-ba7b-4f11-bce8-1ca679570a12"
      unitRef="usd">22747000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i6b205efadb964c1cb4dff4ca72b078bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfMS01LTEtMS0zNTMzMA_af8d7d0e-3512-41bf-bb9f-8c0e39c1e828"
      unitRef="usd">2473000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i6b205efadb964c1cb4dff4ca72b078bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfMS03LTEtMS0zNTMzMA_9ec88805-e894-4268-993d-99da3d9f4235"
      unitRef="usd">119360000</us-gaap:LongTermDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="iacfe2e319d1e4f1cad4106efad251be5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfMy0zLTEtMS0zNTMzMA_f026ea0b-1476-4c89-8757-8bd7de23a1ba"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="iacfe2e319d1e4f1cad4106efad251be5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfMy01LTEtMS0zNTMzMA_3c438d58-39a7-49d5-9d1c-e7c7f439ef26"
      unitRef="usd">264000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="iacfe2e319d1e4f1cad4106efad251be5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfMy03LTEtMS0zNTMzMA_42e586f9-a61b-4479-a74a-706057d7ac2e"
      unitRef="usd">264000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i994823b7aa8d4a3aab131ffa60b3a73f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS0xLTEtMS0zOTUzMA_1c38fe42-4f4b-46bf-a5a0-e0d529e13eb0"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i994823b7aa8d4a3aab131ffa60b3a73f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS0zLTEtMS0zOTUzMA_3c84d621-ff42-447d-bd47-d99d5b6078cd"
      unitRef="usd">-22747000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i994823b7aa8d4a3aab131ffa60b3a73f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS01LTEtMS0zOTUzMA_2059ea8b-aea2-4747-840a-c72cd57d5e3b"
      unitRef="usd">1104000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i994823b7aa8d4a3aab131ffa60b3a73f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS03LTEtMS0zOTUzMA_2e799a0d-dfe4-4314-a44f-a39ca814f04a"
      unitRef="usd">21643000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie4045f45f8fc4c08bec50e050b1907c7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS0xLTEtMS0zNTMzMA_d17a1cb3-68c4-4618-95ea-b5bfc826069b"
      unitRef="usd">144580000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ie4045f45f8fc4c08bec50e050b1907c7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS0zLTEtMS0zNTMzMA_f172df26-46d8-4f13-9fa6-41dbeeae427d"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ie4045f45f8fc4c08bec50e050b1907c7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS01LTEtMS0zNTMzMA_9f6d7e1e-d190-45ca-a4af-b7d8be711db5"
      unitRef="usd">3313000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ie4045f45f8fc4c08bec50e050b1907c7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjUwZjBhNzIxNjlhMzRiYWVhOWM2OWNkYjY3YzAwMmE5L3RhYmxlcmFuZ2U6NTBmMGE3MjE2OWEzNGJhZWE5YzY5Y2RiNjdjMDAyYTlfNS03LTEtMS0zNTMzMA_41c5f797-386e-4bc4-aeb8-7e9fc9d509e7"
      unitRef="usd">141267000</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib396f0384c4549d6ad4a1d99b89fcf7f_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA5MTMyMQ_856536e2-bd38-435b-9408-e2525230ced2"
      unitRef="usd">21600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iceb6a701923f4d27a6905238cab5243d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA5MTM2OA_2d5d7d61-860e-486f-8a4b-a31a072914e8"
      unitRef="usd">17500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i04b7a30acb9a4f81a6cd5179f6dc9cd0_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA5MTQyMQ_57d8ee44-f438-4151-9a2f-8f1f679207e5"
      unitRef="usd">-39100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1a7f42702b824de08c6bd810d766790d_I20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNjg5Ng_acde52b7-0d35-4574-9526-b1fdc97f2449"
      unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1a7f42702b824de08c6bd810d766790d_I20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNjk5Ng_6d6ba3f2-5d71-4660-9e73-5202b51790f9"
      unitRef="usd">55000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="i7ff2cf21d2ee42b7ba76f7ede2a71895_D20180201-20180228"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNzAzNQ_787fcb03-e216-476b-b0d0-d6092a7b4b18">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i1a7f42702b824de08c6bd810d766790d_I20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNzM1MQ_0ee1433b-bed1-47cc-ba81-bd327baa184a"
      unitRef="usdPerShare">5.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <opk:DebtInstrumentConvertibleConversionNoticeThresholdMinimum
      contextRef="i7ff2cf21d2ee42b7ba76f7ede2a71895_D20180201-20180228"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNzU1Mw_37cb84e9-859e-4776-9ef4-707126638aea">P30D</opk:DebtInstrumentConvertibleConversionNoticeThresholdMinimum>
    <opk:DebtInstrumentConvertibleConversionNoticeThresholdMaximum
      contextRef="i7ff2cf21d2ee42b7ba76f7ede2a71895_D20180201-20180228"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfNzU3OQ_8e78282e-22dc-4863-b920-0dd4167062c0">P60D</opk:DebtInstrumentConvertibleConversionNoticeThresholdMaximum>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3f373341aeaa45d6ab5311cefa00161e_I20130130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfODA0MQ_ec2b2b05-4ddc-4055-bad3-106a13d2e29b"
      unitRef="number">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3f373341aeaa45d6ab5311cefa00161e_I20130130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfODI1OA_d5bbf2c6-73e0-49f8-aceb-a02e32733b71"
      unitRef="usd">175000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3f373341aeaa45d6ab5311cefa00161e_I20130130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfODMyMA_bb641089-7eaf-4b5d-bd17-19d637461ec7"
      unitRef="number">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i36deaadef6af48b695564914f629b5db_D20130130-20130130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfODc0NA_23339384-1941-45c6-91d5-e8991392ef05"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i3247cd104cc0482786e56f99c0599cc1_D20130101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfODk4NQ_0a5f0284-7a67-4113-b94c-542d1b182c00"
      unitRef="usd">143200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="icaf8381567b542449202a80cc3f77a99_D20130101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfOTAzOQ_e02fb7c1-5658-4003-93a5-67b7f03d18ab"
      unitRef="shares">21539873</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="if8c98930de814fef80fda4f22e14c6c6_I20190201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfOTEwMQ_fd782dac-a1da-49a8-9d55-51895e2efa3f"
      unitRef="usd">28800000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:LongTermDebt
      contextRef="if8c98930de814fef80fda4f22e14c6c6_I20190201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfOTM1Ng_6954c2af-acf1-4bb4-a0b0-cd3ef4fb96f3"
      unitRef="usd">3000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if8c98930de814fef80fda4f22e14c6c6_I20190201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfOTQ1OQ_8da0e983-8cf3-4b43-86b4-79e328208a62"
      unitRef="usd">3000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i1da72e5734474e44a7f6fca5196486fb_D20130101-20130131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfOTU0OA_0be9b38f-ce10-4c21-9447-e66368a1fe57"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7b4eb504ab9242d79f116b3ef21235d5_I20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTE0ODQ_17ae8856-88ba-4d23-891d-72a7cd8760dd"
      unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i60f953c97dd24968839eeaafb2ffad17_I20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTE1MzY_4f9a5dfd-32c7-4052-a250-d8793faeaa32"
      unitRef="usd">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0fdc1aa37b674237997e3b022f56dbf1_I20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTE1Nzg_77fc7888-9cfc-4595-90e7-7d0971ff8547"
      unitRef="usd">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i5ce132bbea2745af8c284fc6419ab2af_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTIyMTI_4fed9a6e-f4fc-4b86-ae5e-37f3240ddd84"
      unitRef="usd">64800000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4c287aafd1a44262b8db089d441d0bb1_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTI2ODQ_5b041950-afbd-41f3-9138-035cfe403282"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ibbeb409c21e94c8a9efee99f6cb87652_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTI3MTc_4699d50a-9460-4365-876c-d97ab0d0f425"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i16716fcbd59e454387ebc09f7b61c881_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTI4NDc_24626fdf-6382-4a35-b448-60b8ef3ad3c7"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i63c4e5c98e7243cfaba30273d9ca0a87_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTMwNTI_9f4f0a53-8ec4-4cbb-a7a8-f9f93f9122c2"
      unitRef="number">0.00375</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i525c6ba5bfb44a68bf4601181c4282fa_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTMxMzk_17c9d877-0450-4f6f-b6db-cde017a27938"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LongTermLineOfCredit
      contextRef="i5ce132bbea2745af8c284fc6419ab2af_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTMyODk_f058d18c-fe04-460c-b7c4-f44f136ad234"
      unitRef="usd">0</us-gaap:LongTermLineOfCredit>
    <us-gaap:StockholdersEquity
      contextRef="i9be636d2eb7646a68e48135793798985_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTQ2NTM_49c76381-d173-4cec-b45f-8a231b983fe5"
      unitRef="usd">1037100000</us-gaap:StockholdersEquity>
    <us-gaap:Goodwill
      contextRef="i9be636d2eb7646a68e48135793798985_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTQ2ODQ_6f52ca9c-611b-470b-9c32-ad6d9f5a1b64"
      unitRef="usd">283000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9be636d2eb7646a68e48135793798985_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTQ3MTI_ad76546b-002a-4b1f-ac2d-73bc853bfa7f"
      unitRef="usd">199500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <opk:DebtInstrumentsNumberofFinancialInstitutions
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTQ4MDM_85184fa9-a2fa-4f83-8f81-343683ec1104"
      unitRef="institution">13</opk:DebtInstrumentsNumberofFinancialInstitutions>
    <opk:DebtInstrumentsNumberofFinancialInstitutions
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTQ4MDM_85996cd7-ce46-42b3-968d-2f5b1aa677a5"
      unitRef="institution">13</opk:DebtInstrumentsNumberofFinancialInstitutions>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTU3NDQ_c9bcb09d-3f0d-4159-a579-32f13500bcb7">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(Dollars in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Balance Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lender&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest&#160;rate&#160;on&lt;br/&gt;borrowings at &lt;br/&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Credit&#160;line&lt;br/&gt;capacity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;JPMorgan Chase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Itau Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bank of Chile&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;BICE Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Scotiabank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Santander Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Security Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Estado Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BCI Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corpbanca&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consoorcio Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Banco De Sabadell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Santander Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="ib898228cd3484e429a53c453f0951cbe_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMi0yLTEtMS0zNTMzMA_aa74de24-a6cf-4b1c-a1db-cd04ad57838d"
      unitRef="number">0.0325</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib898228cd3484e429a53c453f0951cbe_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMi00LTEtMS0zNTMzMA_fe9ac166-9261-4774-b1b7-60649086a2e3"
      unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="ib898228cd3484e429a53c453f0951cbe_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMi02LTEtMS0zNTMzMA_035ba9f0-32c8-4138-8326-7abe57b68a32"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ie92eade637fa4c5b9fdf19e5892fcb78_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMi04LTEtMS0zNTMzMA_b3249219-a0f8-413d-a611-819ce5410f5c"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i6da40689dc7f4a57940604c58ea95ca9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMy0yLTEtMS0zNTMzMA_a1bf172e-6007-42af-81fa-48b72e3f2316"
      unitRef="number">0.0550</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i6da40689dc7f4a57940604c58ea95ca9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMy00LTEtMS0zNTMzMA_d7049de3-f1ef-47f4-b51e-bb4897bcf6fc"
      unitRef="usd">1900000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i6da40689dc7f4a57940604c58ea95ca9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMy02LTEtMS0zNTMzMA_ba7ab46c-f70c-4bdd-9761-3fd7feefad7b"
      unitRef="usd">1890000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i3b77ee2f3fcc47b49cb358c6cb4a05b0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMy04LTEtMS0zNTMzMA_3a7206c8-c539-47c1-808f-a57ba44f1210"
      unitRef="usd">1603000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="icc72bc81c8cf4007b02a8ed9c7371fab_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNC0yLTEtMS0zNTMzMA_4ee09470-4c9c-4f29-9c71-68484edbfc61"
      unitRef="number">0.0660</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="icc72bc81c8cf4007b02a8ed9c7371fab_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNC00LTEtMS0zNTMzMA_eee0b58a-69d5-4e97-a61e-0b80c25af854"
      unitRef="usd">2500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="icc72bc81c8cf4007b02a8ed9c7371fab_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNC02LTEtMS0zNTMzMA_da748c7b-5393-4d63-9f01-7a16f01fd48b"
      unitRef="usd">1914000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i42c606619dd84425ac6654cc299669d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNC04LTEtMS0zNTMzMA_630fbf9b-d49f-442c-aa16-b3e9379946ec"
      unitRef="usd">1048000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="iff25469e62df48448ca837a11e16442a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNS0yLTEtMS0zNTMzMA_0d5b5c17-526a-41b9-ac8e-dc8224fb980d"
      unitRef="number">0.0550</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iff25469e62df48448ca837a11e16442a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNS00LTEtMS0zNTMzMA_d99f2502-d6ef-4236-b4a6-1dd7d2e5cc81"
      unitRef="usd">2500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="iff25469e62df48448ca837a11e16442a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNS02LTEtMS0zNTMzMA_bb61f0c5-5d2d-4535-bab8-2ea344d68a28"
      unitRef="usd">1156000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ic54dc237b91f42858c86967daeeda551_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNS04LTEtMS0zNTMzMA_1f09f47a-c234-4441-9e52-518092f730e2"
      unitRef="usd">850000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i5db2a74d8f95441691817b18709c0fcb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNi0yLTEtMS0zNTMzMA_3a1fb7a3-0e90-4032-92de-a63524a3c3ea"
      unitRef="number">0.0550</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5db2a74d8f95441691817b18709c0fcb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNi00LTEtMS0zNTMzMA_4ebf4059-18a8-4793-a95e-88d4e59b1c29"
      unitRef="usd">5500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i5db2a74d8f95441691817b18709c0fcb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNi02LTEtMS0zNTMzMA_53175547-bd12-437d-a1ba-6b2496008e2c"
      unitRef="usd">2203000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="iaabb83a0b7e84cc69c57763fdb275a6c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNi04LTEtMS0zNTMzMA_15a7a3d5-0f89-44c6-a40f-fc4603975768"
      unitRef="usd">567000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i2be89554ae224d2faa3b30914675e795_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNy0yLTEtMS0zNTMzMA_620a87a8-736a-4790-a04e-cfdcad1966fd"
      unitRef="number">0.0550</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2be89554ae224d2faa3b30914675e795_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNy00LTEtMS0zNTMzMA_0c2bb816-88e1-490b-844d-4e69a7efa7f8"
      unitRef="usd">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i2be89554ae224d2faa3b30914675e795_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNy02LTEtMS0zNTMzMA_68824033-a506-4744-b08e-d4e1b9c52561"
      unitRef="usd">3068000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="id4836259242c4bb19d20c064b534eab1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfNy04LTEtMS0zNTMzMA_47b48e91-2823-4d25-ab52-26f6eac3d71c"
      unitRef="usd">503000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i0e0c19da9e644a0394218df762658838_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOC0yLTEtMS0zNTMzMA_9e1a6ca3-9544-4a2a-97ca-d3437ee7de72"
      unitRef="number">0.0550</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0e0c19da9e644a0394218df762658838_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOC00LTEtMS0zNTMzMA_273fdc2e-86a7-4ce6-8cfd-de8abf8f2e70"
      unitRef="usd">1400000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i0e0c19da9e644a0394218df762658838_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOC02LTEtMS0zNTMzMA_167a33af-0609-4279-bf37-07f171aad0c5"
      unitRef="usd">378000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ic9cd8644076f4859be4a248297d5c636_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOC04LTEtMS0zNTMzMA_7ac6e774-81b9-4540-b2d2-8a5f932ef3cd"
      unitRef="usd">1111000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="ib013afdad6c7474cb6b2dcd9f1b5930b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOS0yLTEtMS0zNTMzMA_5fd042ca-40a8-41ce-a2bf-81242203bc4b"
      unitRef="number">0.0550</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib013afdad6c7474cb6b2dcd9f1b5930b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOS00LTEtMS0zNTMzMA_eadcfbd7-9872-4e13-a5df-b3e1956910fd"
      unitRef="usd">2052000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="ib013afdad6c7474cb6b2dcd9f1b5930b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOS02LTEtMS0zNTMzMA_b4546788-a54f-4aea-8bdb-5808cc64d2d3"
      unitRef="usd">2052000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ia0e78a0e78664a1dab1c8a3083fe0278_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfOS04LTEtMS0zNTMzMA_008d48ac-4356-4caf-848d-06380b266b81"
      unitRef="usd">2540000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i0241e35fea8242e191eb554ad8160555_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTAtMi0xLTEtMzUzMzA_10bf9e7f-042c-4950-9011-16cf3bfbb7ff"
      unitRef="number">0.0500</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0241e35fea8242e191eb554ad8160555_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTAtNC0xLTEtMzUzMzA_e27ae081-2fdb-4c93-a830-163575cd1633"
      unitRef="usd">2740000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i0241e35fea8242e191eb554ad8160555_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTAtNi0xLTEtMzUzMzA_14f39ec2-5c1a-40d5-a874-63786740f484"
      unitRef="usd">2740000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="idb458c405a9e4aa4840e82ae7757acf6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTAtOC0xLTEtMzUzMzA_b1ac6134-6d89-4f91-931c-ba923eb5bc00"
      unitRef="usd">2515000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="icd2141f359c14b2c98459ad1cfb7f950_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTEtMi0xLTEtMzUzMzA_404af20a-2073-4524-8d0e-6535350051a6"
      unitRef="number">0.0500</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="icd2141f359c14b2c98459ad1cfb7f950_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTEtNC0xLTEtMzUzMzA_1411a32c-d3ab-42f1-a013-4cc2d4b134e9"
      unitRef="usd">0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="icd2141f359c14b2c98459ad1cfb7f950_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTEtNi0xLTEtMzUzMzA_2906bd3a-b8d3-4f5f-9d1d-88d5cf9efbf8"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="id0f90114729e40eb8be4a760cfaff843_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTEtOC0xLTEtMzUzMzA_ac9a095f-bcfa-4593-91ac-6aab278d3420"
      unitRef="usd">2935000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="ia6754e9ff1da42ec9e1a4cc77eec4acd_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItMi0xLTEtNDA0MTU_c41f0e8f-9183-4596-8b46-29f76d4ba1b1"
      unitRef="number">0.0550</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia6754e9ff1da42ec9e1a4cc77eec4acd_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItNC0xLTEtNDA0MTU_1d57d663-ac55-4bc8-a3c2-4df16358eea6"
      unitRef="usd">1500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="ia6754e9ff1da42ec9e1a4cc77eec4acd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItNi0xLTEtNDA0MTU_44eee8a8-ca6e-4538-b558-4d4c28f380a1"
      unitRef="usd">881000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ie9c38a5f8c564a40be8991b68c4b3ffc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItOC0xLTEtNDA0MTU_42b626e3-78f6-4937-bdbe-11356dab7e16"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="ifcca8a13d6eb4da998ed98c0c425049d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtMi0xLTEtNDA0MTU_9b29c08e-4b5a-4a19-841c-4692ca965bd3"
      unitRef="number">0.0500</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ifcca8a13d6eb4da998ed98c0c425049d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtNC0xLTEtNDA0MTU_343a3df0-9072-425a-8820-e6eb120eb51f"
      unitRef="usd">2000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="ifcca8a13d6eb4da998ed98c0c425049d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtNi0xLTEtNDA0MTU_991db1ce-cde4-4f6d-8cb0-e3dbd6c07e07"
      unitRef="usd">249000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i5ec848e00bda4f5681fac4c00ce92faa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtOC0xLTEtNDA0MTU_917ba11a-8dd5-4b6e-bcf8-2fa5e2da0669"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i8d54584ff4454273875eb07cb16d7afd_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItMi0xLTEtMzUzMzA_404f71cb-d1d7-42fe-a3c4-8b7d3178de3c"
      unitRef="number">0.0175</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i8d54584ff4454273875eb07cb16d7afd_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItNC0xLTEtMzUzMzA_399976d7-85f5-467d-aafc-a379d7e4eebd"
      unitRef="usd">556000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i8d54584ff4454273875eb07cb16d7afd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItNi0xLTEtMzUzMzA_e8870e2c-aca3-436a-9b12-4b430034f01b"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i5f26530ceb664987a7569db40b3af4e4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTItOC0xLTEtMzUzMzA_b83b3b96-d0e8-4be1-bac1-5cda307e6aeb"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i8f72279f02e748babf4db23480b635fb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtMi0xLTEtMzUzMzA_d611db66-2068-4934-b8db-a809f9f84cee"
      unitRef="number">0.0182</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i8f72279f02e748babf4db23480b635fb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtNC0xLTEtMzUzMzA_e3e11149-fc64-4395-a4bd-8b8b74a52002"
      unitRef="usd">556000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i8f72279f02e748babf4db23480b635fb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtNi0xLTEtMzUzMzA_e3be904f-3e91-4eb3-aa46-bb4cda5e9c09"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ia5d45b4e640d41ceb4caa171b741efa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTMtOC0xLTEtMzUzMzA_1dac47fc-bb60-42b3-a511-c19d8c60ca26"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTUtNC0xLTEtMzUzMzA_022d1146-8864-42fc-bdcb-ce245933d4ec"
      unitRef="usd">103204000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTUtNi0xLTEtMzUzMzA_1188507d-875d-4cff-815b-0788a476a3b4"
      unitRef="usd">16531000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOmJkYjlmNjc0NzBmOTQwNzJiZmIxZjJjZmQxMzIwOTJhL3RhYmxlcmFuZ2U6YmRiOWY2NzQ3MGY5NDA3MmJmYjFmMmNmZDEzMjA5MmFfMTUtOC0xLTEtMzUzMzA_eeb0a5f8-2cb8-46ee-b25f-90b29ba20f99"
      unitRef="usd">13672000</us-gaap:LineOfCredit>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i2a2bb52ee16c4f3cbd50cd8ebe53b377_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA4NTU3NQ_c5faec36-fc3a-4aa2-8ee0-560d07b2e900"
      unitRef="number">0.055</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="ia66232faa6934fc58bd350c3c5087464_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA4NTU3OQ_20546bee-828d-4279-a07e-05281f16a239"
      unitRef="number">0.054</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:LongTermDebtCurrent
      contextRef="if35733f1b3cb4b5e8d6885a8d8e2c00b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjRiNDJiYmYxMzU1ZDQ3MTFhYjA5N2M1NmMwNTUyNzgyL3RhYmxlcmFuZ2U6NGI0MmJiZjEzNTVkNDcxMWFiMDk3YzU2YzA1NTI3ODJfMS0xLTEtMS0zNTMzMA_617c4a7e-4d98-4660-acca-32ae34d20c90"
      unitRef="usd">882000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ibb18ba3550a7419cac96f92422977cff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjRiNDJiYmYxMzU1ZDQ3MTFhYjA5N2M1NmMwNTUyNzgyL3RhYmxlcmFuZ2U6NGI0MmJiZjEzNTVkNDcxMWFiMDk3YzU2YzA1NTI3ODJfMS0zLTEtMS0zNTMzMA_d226ca28-6b6d-497c-b124-a54fecec1bf8"
      unitRef="usd">1022000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if35733f1b3cb4b5e8d6885a8d8e2c00b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjRiNDJiYmYxMzU1ZDQ3MTFhYjA5N2M1NmMwNTUyNzgyL3RhYmxlcmFuZ2U6NGI0MmJiZjEzNTVkNDcxMWFiMDk3YzU2YzA1NTI3ODJfMi0xLTEtMS0zNTMzMA_396b3d62-b1f5-47a1-b6f9-528b93708417"
      unitRef="usd">2331000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibb18ba3550a7419cac96f92422977cff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjRiNDJiYmYxMzU1ZDQ3MTFhYjA5N2M1NmMwNTUyNzgyL3RhYmxlcmFuZ2U6NGI0MmJiZjEzNTVkNDcxMWFiMDk3YzU2YzA1NTI3ODJfMi0zLTEtMS0zNTMzMA_483d34c3-0ee0-4249-b025-78ae3dc3e7b5"
      unitRef="usd">2642000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="if35733f1b3cb4b5e8d6885a8d8e2c00b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjRiNDJiYmYxMzU1ZDQ3MTFhYjA5N2M1NmMwNTUyNzgyL3RhYmxlcmFuZ2U6NGI0MmJiZjEzNTVkNDcxMWFiMDk3YzU2YzA1NTI3ODJfMy0xLTEtMS0zNTMzMA_e382de36-921d-44fd-bd14-c530dcefebcf"
      unitRef="usd">3213000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibb18ba3550a7419cac96f92422977cff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RhYmxlOjRiNDJiYmYxMzU1ZDQ3MTFhYjA5N2M1NmMwNTUyNzgyL3RhYmxlcmFuZ2U6NGI0MmJiZjEzNTVkNDcxMWFiMDk3YzU2YzA1NTI3ODJfMy0zLTEtMS0zNTMzMA_13451677-afaa-4501-9806-f0a8eb7bc402"
      unitRef="usd">3664000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="i1aa77c7b6eb749fe884b2a879d8b362c_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA4NTU5NQ_11b93f28-ec8f-4e0e-ad56-c2a34c8242aa"
      unitRef="number">0.007</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="i073357239cf9481992cd2d0593039c41_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA4NTU5OQ_18ae31ba-c257-489e-affc-75898216a899"
      unitRef="number">0.038</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="idace7175aff140538ca299c503a1f3fe_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMjc0ODc3OTA4NTU4Mw_c41625d1-ac82-4345-a22b-5c6695b02bc6"
      unitRef="number">0.015</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i590b5239584e49aabed9114cc2b084f2_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y181OC9mcmFnOmEwYTQyNzVkYzA5ZjRhYjk5ZmVjZjNhYzVhOGYwMmQxL3RleHRyZWdpb246YTBhNDI3NWRjMDlmNGFiOTlmZWNmM2FjNWE4ZjAyZDFfMTU2NDk_c7693b43-beba-4b69-a88b-c8957773e93c"
      unitRef="number">0.015</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182NC9mcmFnOjdkMDE5N2IyZjA4MjRiNzdiODc1OTU0NTc2Y2JkYzA2L3RleHRyZWdpb246N2QwMTk3YjJmMDgyNGI3N2I4NzU5NTQ1NzZjYmRjMDZfMTU1_006fb6cf-e6ab-4931-8b30-c087f9c12be4">ACCUMULATED OTHER COMPREHENSIVE LOSS&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2022, changes in Accumulated other comprehensive loss, net of tax, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;currency&lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:20.25pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182NC9mcmFnOjdkMDE5N2IyZjA4MjRiNzdiODc1OTU0NTc2Y2JkYzA2L3RleHRyZWdpb246N2QwMTk3YjJmMDgyNGI3N2I4NzU5NTQ1NzZjYmRjMDZfMTQ2_8ff7105a-690e-47d0-ad4f-bfa6a53e9bb1">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2022, changes in Accumulated other comprehensive loss, net of tax, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;currency&lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:20.25pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="ib4a22c80a9934fab9c03ed0fda0558a8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182NC9mcmFnOjdkMDE5N2IyZjA4MjRiNzdiODc1OTU0NTc2Y2JkYzA2L3RhYmxlOjFlMjdhNThlMTYxNzQ0M2Y5MWY5YTc3MmNkNWMxODMwL3RhYmxlcmFuZ2U6MWUyN2E1OGUxNjE3NDQzZjkxZjlhNzcyY2Q1YzE4MzBfMS0xLTEtMS0zNTMzMA_30c0c5d1-7046-424c-944f-9d60ad32b45d"
      unitRef="usd">-30495000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2f44824dbb444200a5bdcdb490ef2b6c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182NC9mcmFnOjdkMDE5N2IyZjA4MjRiNzdiODc1OTU0NTc2Y2JkYzA2L3RhYmxlOjFlMjdhNThlMTYxNzQ0M2Y5MWY5YTc3MmNkNWMxODMwL3RhYmxlcmFuZ2U6MWUyN2E1OGUxNjE3NDQzZjkxZjlhNzcyY2Q1YzE4MzBfMi0xLTEtMS0zNTMzMA_1a0c62d4-aad9-4e12-840a-a761b64a31de"
      unitRef="usd">-920000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="id414151061b84ff297849734c822f37f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182NC9mcmFnOjdkMDE5N2IyZjA4MjRiNzdiODc1OTU0NTc2Y2JkYzA2L3RhYmxlOjFlMjdhNThlMTYxNzQ0M2Y5MWY5YTc3MmNkNWMxODMwL3RhYmxlcmFuZ2U6MWUyN2E1OGUxNjE3NDQzZjkxZjlhNzcyY2Q1YzE4MzBfNS0xLTEtMS0zNTMzMA_ba832a99-9e3d-4bc0-9f16-b7c12f53b2db"
      unitRef="usd">-31415000</us-gaap:StockholdersEquity>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMzI0OA_3c1a0f25-d51c-4f2a-907c-30c7ee86092b">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record fair values at an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.  We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.  These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, we had equity securities (refer to Note 6), forward foreign currency exchange contracts for inventory purchases (refer to Note 10) and contingent consideration related to the acquisitions of CURNA, OPKO Diagnostics and OPKO Renal that are required to be measured at fair value on a recurring basis.  In addition, in connection with our investment and our consulting agreement with BioCardia, we record the related BioCardia options at fair value as well as the warrants from COCP and InCellDx.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets and liabilities measured at fair value on a recurring basis are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value measurements as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quoted&lt;br/&gt;prices in&lt;br/&gt;active&lt;br/&gt;markets for&lt;br/&gt;identical&lt;br/&gt;assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options/warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value measurements as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quoted&lt;br/&gt;prices in&lt;br/&gt;active&lt;br/&gt;markets for&lt;br/&gt;identical&lt;br/&gt;assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options/warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and estimated fair value of our 2025 Notes, as well as the applicable fair value hierarchy tiers, are contained in the table below.  The fair value of the 2025 Notes is determined using inputs other than quoted prices in active markets that are directly observable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="27" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no transfers between Level 1 and Level 2 and no transfers to or from Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, the carrying value of our other financial instrument assets approximates their fair value due to their short-term nature or variable rate of interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent&lt;br/&gt;consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in results of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of our financial instruments have been determined by using available market information and what we believe to be appropriate valuation methodologies.  We use the following methods and assumptions in estimating fair value:&lt;/span&gt;&lt;/div&gt;Contingent consideration &#x2013; We estimate the fair value of the contingent consideration utilizing a discounted cash flow model for the expected payments based on estimated timing and expected revenues.  We use several discount rates depending on each type of contingent consideration related to OPKO Diagnostics, CURNA and OPKO Renal transactions. As of March&#160;31, 2022, of the $2.7 million of contingent consideration, $0.5 million was recorded in Accrued expenses and $2.2 million was recorded in Other long-term liabilities.  As of December&#160;31, 2021, of the $2.8 million of contingent consideration, $0.5 million was recorded in Accrued expenses and $2.3 million was recorded in Other long-term liabilities. As a result of our execution of the CAMP4 Agreement (as defined in Note 14), we will have to pay a percentage of any payments received under the CAMP4 Agreement to the former CURNA stockholders.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMzIzMQ_db8b3901-b29f-4b4c-8ce6-447c328632be">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets and liabilities measured at fair value on a recurring basis are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value measurements as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quoted&lt;br/&gt;prices in&lt;br/&gt;active&lt;br/&gt;markets for&lt;br/&gt;identical&lt;br/&gt;assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options/warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value measurements as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quoted&lt;br/&gt;prices in&lt;br/&gt;active&lt;br/&gt;markets for&lt;br/&gt;identical&lt;br/&gt;assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options/warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i422ca1837f244677badf0cc87f681909_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNS0xLTEtMS0zNTMzMA_19b846db-afb2-4508-8b8d-f48aa7e6b6ed"
      unitRef="usd">3064000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5e71299ca85d400ca49f6ca9cedc36ee_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNS0zLTEtMS0zNTMzMA_666d8cb2-8070-486a-8395-53f853634af3"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if1f2bf6624724fa3aecc40088836c8be_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNS01LTEtMS0zNTMzMA_8644ca3b-d619-4b8a-aef7-6ea52b6ab4a9"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNS03LTEtMS0zNTMzMA_42f9e64a-8ee1-4a17-816f-ba91679fb4e1"
      unitRef="usd">3064000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeAssets
      contextRef="idff81e7e63834f27b0191f9f89a1a47c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNi0xLTEtMS0zNTMzMA_621f632d-0cde-4543-93d6-63e965fdd251"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ibf4f3576ecda4c91b9dd4d47459c40de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNi0zLTEtMS0zNTMzMA_e80c3c8e-af0f-48c7-8195-cdcd216412d1"
      unitRef="usd">15000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i91f678126fc847348f1523f27f8297d9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNi01LTEtMS0zNTMzMA_f98988ea-cd5b-452d-bafc-af38d4f96760"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i7bec48bd714c48508a9e6c19e44bf474_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfNi03LTEtMS0zNTMzMA_9e5b0cf3-7d24-43ca-a690-f0374b23bc45"
      unitRef="usd">15000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i422ca1837f244677badf0cc87f681909_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfOC0xLTEtMS0zNTMzMA_c81e5b0f-243b-4722-9eb2-8bf2a6fb1d4e"
      unitRef="usd">3064000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5e71299ca85d400ca49f6ca9cedc36ee_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfOC0zLTEtMS0zNTMzMA_8e980d39-a58d-4e55-ae97-d43e712c1439"
      unitRef="usd">15000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if1f2bf6624724fa3aecc40088836c8be_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfOC01LTEtMS0zNTMzMA_cf9c39c5-5309-4f13-b78d-68f5ab65de32"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfOC03LTEtMS0zNTMzMA_1e07b206-f4a1-47a6-ac29-041065987e8f"
      unitRef="usd">3079000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i672ca210ee9a4a0bba0dfc16dae64dcd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTEtMS0xLTEtMzUzMzA_caddbbf1-df99-4e08-8b6a-9568dec3c06d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="idcb3f1c307104b52a50b42c818e7727d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTEtMy0xLTEtMzUzMzA_adb2f6b3-a468-4a34-837c-b04e1143cae9"
      unitRef="usd">462000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i33c3fc92127145a39d48943be5758504_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTEtNS0xLTEtMzUzMzA_fc1a65b8-a4b3-4158-975b-b80db5d9aace"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2f7f39684e77498888d13da9df62d5b9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTEtNy0xLTEtMzUzMzA_2a764ec3-6570-4993-958b-674930867f4b"
      unitRef="usd">462000</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i422ca1837f244677badf0cc87f681909_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTMtMS0xLTEtMzUzMzA_fd1d7211-c0b4-4006-aae3-e29dd5adc946"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5e71299ca85d400ca49f6ca9cedc36ee_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTMtMy0xLTEtMzUzMzA_eefdd3cb-e3f6-4876-9db8-17b34b06b11e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if1f2bf6624724fa3aecc40088836c8be_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTMtNS0xLTEtMzUzMzA_4f7d09be-43c4-4c39-b3af-8a720ab473db"
      unitRef="usd">2729000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTMtNy0xLTEtMzUzMzA_9f6a619a-dc5f-48b2-bcd4-e3238ce15833"
      unitRef="usd">2729000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i422ca1837f244677badf0cc87f681909_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTQtMS0xLTEtMzUzMzA_93cd13e8-6d51-4150-b02f-72c37cbacb10"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5e71299ca85d400ca49f6ca9cedc36ee_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTQtMy0xLTEtMzUzMzA_a2a6119f-d603-4238-9dbd-175eebb58e43"
      unitRef="usd">462000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if1f2bf6624724fa3aecc40088836c8be_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTQtNS0xLTEtMzUzMzA_ac1d6f39-858e-4479-841c-d8684d863ed6"
      unitRef="usd">2729000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmZmOWVlMjQ3MTcxZDQ3Mzk5MWFlMGZiMDAzMWRmZGU4L3RhYmxlcmFuZ2U6ZmY5ZWUyNDcxNzFkNDczOTkxYWUwZmIwMDMxZGZkZThfMTQtNy0xLTEtMzUzMzA_23c1ad69-1586-418f-b5b0-26654fda4c35"
      unitRef="usd">3191000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2b6b0142454d4f3c928a9719fc52a6aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNi0xLTEtMS0zNTMzMA_a7cfb6fc-f4a7-44c7-8c08-f930cff75d6e"
      unitRef="usd">4226000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1ece04f6d15a44e8b8535afca85eea3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNi0zLTEtMS0zNTMzMA_516008ce-1445-4a88-b93a-6a44d00dc4ca"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6167a5561ea048c0992072722768dc50_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNi01LTEtMS0zNTMzMA_b44a26d9-6e2e-4d94-ae4b-0a328da1dc4f"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNi03LTEtMS0zNTMzMA_38c84ec9-7783-4f4d-8c26-3713caf299c9"
      unitRef="usd">4226000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeAssets
      contextRef="id20bcd0b3e1c441a9da0bd8ff7b7c148_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNy0xLTEtMS0zNTMzMA_6e102044-01fc-488e-ace2-777b7a70834c"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id821c49b028b4f61851f46ac73519641_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNy0zLTEtMS0zNTMzMA_9094b5fc-f8d5-4007-a0c2-e8c8a8563f83"
      unitRef="usd">16000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i50def469aee442b7a18f3ee936adf68d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNy01LTEtMS0zNTMzMA_27d592e7-40c8-495b-a856-e9d819776c21"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0175b050f64543bdbaed71566aab0b0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfNy03LTEtMS0zNTMzMA_7e87a74f-be51-48cd-aafc-d0187eaa3e37"
      unitRef="usd">16000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i66b1ce0a8e104dd48bd6e56c4cca780b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOC0xLTEtMS0zNTMzMA_46d1569f-843c-453f-b682-8d371288e5b0"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i3f5b8f39523b4a5683ccaea181d847f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOC0zLTEtMS0zNTMzMA_f29768eb-3246-498f-a344-e8a992525130"
      unitRef="usd">122000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i85019ba01b1f439c855e8144c410bd64_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOC01LTEtMS0zNTMzMA_b11c1c5f-8a34-4ebd-b172-6be72870f745"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iedb36d1e48e34543b075c30a1123563a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOC03LTEtMS0zNTMzMA_01d46c2e-bebc-447e-852a-ead1cc9bff72"
      unitRef="usd">122000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2b6b0142454d4f3c928a9719fc52a6aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOS0xLTEtMS0zNTMzMA_f9f30453-4c6b-4956-9810-357b6b913ef0"
      unitRef="usd">4226000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1ece04f6d15a44e8b8535afca85eea3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOS0zLTEtMS0zNTMzMA_b049daeb-2d48-4cd4-805e-cda5f9aeb929"
      unitRef="usd">138000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6167a5561ea048c0992072722768dc50_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOS01LTEtMS0zNTMzMA_9ee39407-86be-4d6e-8072-76bd3a4c019e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfOS03LTEtMS0zNTMzMA_0b0a1dc7-f6cd-4971-8385-102b1aa68cc9"
      unitRef="usd">4364000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2b6b0142454d4f3c928a9719fc52a6aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTQtMS0xLTEtMzUzMzA_01cdf46b-07b2-4634-8c20-306ad7990cfd"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1ece04f6d15a44e8b8535afca85eea3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTQtMy0xLTEtMzUzMzA_a0e9d9fe-bbd1-415d-8b46-faa8dc6ca0f4"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6167a5561ea048c0992072722768dc50_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTQtNS0xLTEtMzUzMzA_7332cc8f-c5c6-4e9a-8392-2f664d621c1d"
      unitRef="usd">2837000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTQtNy0xLTEtMzUzMzA_206fd361-196e-4ccd-ad3b-57c499914a04"
      unitRef="usd">2837000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2b6b0142454d4f3c928a9719fc52a6aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTUtMS0xLTEtMzUzMzA_275766e6-e970-4cf6-8c2c-bfee46a3f082"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1ece04f6d15a44e8b8535afca85eea3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTUtMy0xLTEtMzUzMzA_347f1eac-2b15-4ac1-8ef1-44406fd16571"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6167a5561ea048c0992072722768dc50_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTUtNS0xLTEtMzUzMzA_7ee51255-d002-4238-94c1-8cc944f2c0b0"
      unitRef="usd">2837000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOmQzMTFjMzQxYmZjNzQxOTM4MjAwNTVmZTNlZWFiOTE2L3RhYmxlcmFuZ2U6ZDMxMWMzNDFiZmM3NDE5MzgyMDA1NWZlM2VlYWI5MTZfMTUtNy0xLTEtMzUzMzA_c7c49c6b-03b2-44fd-b514-b95285734784"
      unitRef="usd">2837000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMzI1MQ_5e8a9adb-034f-43ed-86de-483abf50ab34">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and estimated fair value of our 2025 Notes, as well as the applicable fair value hierarchy tiers, are contained in the table below.  The fair value of the 2025 Notes is determined using inputs other than quoted prices in active markets that are directly observable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="27" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ie6f84a8a9e11457c9fe326e89f4deef6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjIwZTBmMTU2YjA4YTQ1NzA4ZTIxOTFmY2FlOWZmMWI0L3RhYmxlcmFuZ2U6MjBlMGYxNTZiMDhhNDU3MDhlMjE5MWZjYWU5ZmYxYjRfMi0xLTEtMS0zNTMzMA_62ecbe8e-92d6-4dd1-9054-cf848aaa881c"
      unitRef="usd">141267000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i940d0629800f44c09521f8583790b804_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjIwZTBmMTU2YjA4YTQ1NzA4ZTIxOTFmY2FlOWZmMWI0L3RhYmxlcmFuZ2U6MjBlMGYxNTZiMDhhNDU3MDhlMjE5MWZjYWU5ZmYxYjRfMi0zLTEtMS0zNTMzMA_b92b6753-73ca-43d7-bbb1-1a5371b5b22d"
      unitRef="usd">164270000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="if17f3344f32f4bd18794617bc4d70c76_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjIwZTBmMTU2YjA4YTQ1NzA4ZTIxOTFmY2FlOWZmMWI0L3RhYmxlcmFuZ2U6MjBlMGYxNTZiMDhhNDU3MDhlMjE5MWZjYWU5ZmYxYjRfMi01LTEtMS0zNTMzMA_852fac91-fa67-4450-a15d-50f869136925"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i9eeb8b6fb39840dc8dd12bd08e9bde47_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjIwZTBmMTU2YjA4YTQ1NzA4ZTIxOTFmY2FlOWZmMWI0L3RhYmxlcmFuZ2U6MjBlMGYxNTZiMDhhNDU3MDhlMjE5MWZjYWU5ZmYxYjRfMi03LTEtMS0zNTMzMA_2ce05192-da96-42c0-aef9-16bb5947d1ec"
      unitRef="usd">164270000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i170972a9d6e34cec89fae7f37a41e059_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjIwZTBmMTU2YjA4YTQ1NzA4ZTIxOTFmY2FlOWZmMWI0L3RhYmxlcmFuZ2U6MjBlMGYxNTZiMDhhNDU3MDhlMjE5MWZjYWU5ZmYxYjRfMi05LTEtMS0zNTMzMA_04abf8c8-c652-4f5b-8142-7fa101acfa5f"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMzIzMg_44605afe-328b-4e5c-b272-a037be299e47">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent&lt;br/&gt;consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in results of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMzI2MA_0d3faf27-7913-42d3-bca2-c2f8b5b90204">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the beginning and ending balances of our Level 3 assets and liabilities as of March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent&lt;br/&gt;consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in results of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1a68d34ffea6486da4d468c553cccb2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjQzOTQ3YWRiNzJiNzRhZWZiMmJjZTQ3NjE4YmRhNzY1L3RhYmxlcmFuZ2U6NDM5NDdhZGI3MmI3NGFlZmIyYmNlNDc2MThiZGE3NjVfMi0xLTEtMS0zNTMzMA_ae542c00-87b7-44e4-84a1-19c334f1e7df"
      unitRef="usd">2837000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie89c145a5bdf45b8b2c4856b5dd6d167_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjQzOTQ3YWRiNzJiNzRhZWZiMmJjZTQ3NjE4YmRhNzY1L3RhYmxlcmFuZ2U6NDM5NDdhZGI3MmI3NGFlZmIyYmNlNDc2MThiZGE3NjVfNS0xLTEtMS0zNTMzMA_36b8cf5a-9e66-4029-bb82-2f013d889977"
      unitRef="usd">-106000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <opk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact
      contextRef="ie89c145a5bdf45b8b2c4856b5dd6d167_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjQzOTQ3YWRiNzJiNzRhZWZiMmJjZTQ3NjE4YmRhNzY1L3RhYmxlcmFuZ2U6NDM5NDdhZGI3MmI3NGFlZmIyYmNlNDc2MThiZGE3NjVfNi0xLTEtMS0zNTMzMA_9659d6f5-794a-446f-90f6-0be58d332dff"
      unitRef="usd">-2000</opk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i19db139199c944d1a3ba5a1234a8c6cb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RhYmxlOjQzOTQ3YWRiNzJiNzRhZWZiMmJjZTQ3NjE4YmRhNzY1L3RhYmxlcmFuZ2U6NDM5NDdhZGI3MmI3NGFlZmIyYmNlNDc2MThiZGE3NjVfOS0xLTEtMS0zNTMzMA_fc959ad6-e7ef-4246-9382-212b73b36fa0"
      unitRef="usd">2729000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMjc3OA_fbd37c62-8868-4087-9999-fda6b461ae79"
      unitRef="usd">2700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic33ae5da06dc4f819b6dcd183aecaebe_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMjgxMA_91155703-900f-41c5-9bb4-e918e6cf6df5"
      unitRef="usd">500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4c5f0e2847a64769ab9be88846f125c4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMjg1MA_9f7605fa-1486-4c02-bcfd-ba6e99d6d54d"
      unitRef="usd">2200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMjkxNg_b94c6bd4-d326-4f2d-803a-479c2ef372f5"
      unitRef="usd">2800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0dd929a7397e49f0ab13af7ad0be9d63_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMjk0OA_7cd6ba65-8920-4897-a6a6-afac9ade56d9"
      unitRef="usd">500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iae497a6420cd4f4faf38ce9662826b4e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y182Ny9mcmFnOmYwMTM3MTdjNDQ3ZDRjZWU4MGU2NmRhMTc0ZTM0M2FkL3RleHRyZWdpb246ZjAxMzcxN2M0NDdkNGNlZTgwZTY2ZGExNzRlMzQzYWRfMjk4OA_fe543472-4e7a-42bb-a12f-0225bd30f0f9"
      unitRef="usd">2300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RleHRyZWdpb246ZWMzZjE3NTEwODNjNGRjOGEzNmY4ODAyNzE0MTc5ZWNfMTIxMA_f568b21a-d5b9-47d3-b8a7-a16a3d8dcc25">DERIVATIVE CONTRACTS&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair values and the presentation of our derivative financial instruments in the Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance Sheet Component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock options/warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses.  Unrealized (losses) on forward contracts are recorded in Accrued expenses.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into foreign currency forward exchange contracts with respect to the risk of exposure to exchange rate differences arising from inventory purchases on letters of credit.  Under these forward contracts, for any rate above or below the fixed rate, we receive or pay the difference between the spot rate and the fixed rate for the given amount at the settlement date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To qualify the derivative instrument as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge.  At March&#160;31, 2022 and December&#160;31, 2021, our derivative financial instruments did not meet the documentation requirements to be designated as hedges.  Accordingly, we recognize the changes in Fair value of derivative instruments, net in our Condensed Consolidated Statement of Operations.  The following table summarizes the losses and gains recorded for the three and three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative gain (loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock options/warrants &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RleHRyZWdpb246ZWMzZjE3NTEwODNjNGRjOGEzNmY4ODAyNzE0MTc5ZWNfMTE4Nw_cef1441f-1dcb-46ce-aa6d-d12f77dea401">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair values and the presentation of our derivative financial instruments in the Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance Sheet Component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock options/warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses.  Unrealized (losses) on forward contracts are recorded in Accrued expenses.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i3b034a9ad25047b59a622208212d95e1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOjgwZTYwYjY1NzQ4YjQ3MGZiYjM2NjcyNGU0YmIwYWE0L3RhYmxlcmFuZ2U6ODBlNjBiNjU3NDhiNDcwZmJiMzY2NzI0ZTRiYjBhYTRfMy0zLTEtMS0zNTMzMA_191669e0-f0e7-47d7-98da-c932a60907d4"
      unitRef="usd">15000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i339ef703a5544c01b8dbb210e3619b01_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOjgwZTYwYjY1NzQ4YjQ3MGZiYjM2NjcyNGU0YmIwYWE0L3RhYmxlcmFuZ2U6ODBlNjBiNjU3NDhiNDcwZmJiMzY2NzI0ZTRiYjBhYTRfMy01LTEtMS0zNTMzMA_49e373fb-2071-404d-94fa-851aee1a051a"
      unitRef="usd">16000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i1c9e493caa0e47609d6a6dc891471ba6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOjgwZTYwYjY1NzQ4YjQ3MGZiYjM2NjcyNGU0YmIwYWE0L3RhYmxlcmFuZ2U6ODBlNjBiNjU3NDhiNDcwZmJiMzY2NzI0ZTRiYjBhYTRfNS0zLTEtMS0zNTMzMA_d276590d-638f-4bef-9c24-5f8c3a5f553b"
      unitRef="usd">-462000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ie52baf79fca2489f9435b6f9e9014cda_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOjgwZTYwYjY1NzQ4YjQ3MGZiYjM2NjcyNGU0YmIwYWE0L3RhYmxlcmFuZ2U6ODBlNjBiNjU3NDhiNDcwZmJiMzY2NzI0ZTRiYjBhYTRfNS01LTEtMS0zNTMzMA_c979c3f2-956e-41cb-ad34-bf2d4b7f2bf6"
      unitRef="usd">122000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RleHRyZWdpb246ZWMzZjE3NTEwODNjNGRjOGEzNmY4ODAyNzE0MTc5ZWNfMTIwNw_c33037bb-d8e4-40e6-b75c-eec859f534b6">The following table summarizes the losses and gains recorded for the three and three months ended March 31, 2022 and 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative gain (loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock options/warrants &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ied8a1708f69d41239c1f9de8d8facd76_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOmY2Zjg1MTRkOTRmMDQzOGVhMDZiMjE0NjhkOWM5NmI3L3RhYmxlcmFuZ2U6ZjZmODUxNGQ5NGYwNDM4ZWEwNmIyMTQ2OGQ5Yzk2YjdfNC02LTEtMS0zNTMzMA_17eabba7-9bc4-4258-9bde-d68f34e36acd"
      unitRef="usd">-1000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i5e8e55382c6349dba42db7b0d47c339c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOmY2Zjg1MTRkOTRmMDQzOGVhMDZiMjE0NjhkOWM5NmI3L3RhYmxlcmFuZ2U6ZjZmODUxNGQ5NGYwNDM4ZWEwNmIyMTQ2OGQ5Yzk2YjdfNC04LTEtMS0zNTMzMA_81ef41be-d6de-4f7a-91a6-edb4c2805a18"
      unitRef="usd">21000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i320a0c5cf0c54c369df4652d6c4aaee3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOmY2Zjg1MTRkOTRmMDQzOGVhMDZiMjE0NjhkOWM5NmI3L3RhYmxlcmFuZ2U6ZjZmODUxNGQ5NGYwNDM4ZWEwNmIyMTQ2OGQ5Yzk2YjdfNi02LTEtMS0zNTMzMA_d16242c4-f8cd-4a3a-8442-7994f30c486d"
      unitRef="usd">-131000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ibf311fd02fe0429098a14a89aaff1a31_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOmY2Zjg1MTRkOTRmMDQzOGVhMDZiMjE0NjhkOWM5NmI3L3RhYmxlcmFuZ2U6ZjZmODUxNGQ5NGYwNDM4ZWEwNmIyMTQ2OGQ5Yzk2YjdfNi04LTEtMS0zNTMzMA_3974f9af-4a3c-4547-8705-50934a2d3a65"
      unitRef="usd">-460000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="if9043229605240dc9166035e1b850972_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOmY2Zjg1MTRkOTRmMDQzOGVhMDZiMjE0NjhkOWM5NmI3L3RhYmxlcmFuZ2U6ZjZmODUxNGQ5NGYwNDM4ZWEwNmIyMTQ2OGQ5Yzk2YjdfNy02LTEtMS0zNTMzMA_1276d196-3f03-4972-9ee3-35efaa9103b5"
      unitRef="usd">-132000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i5916426f99024163a0c1c7044beb1897_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183MC9mcmFnOmVjM2YxNzUxMDgzYzRkYzhhMzZmODgwMjcxNDE3OWVjL3RhYmxlOmY2Zjg1MTRkOTRmMDQzOGVhMDZiMjE0NjhkOWM5NmI3L3RhYmxlcmFuZ2U6ZjZmODUxNGQ5NGYwNDM4ZWEwNmIyMTQ2OGQ5Yzk2YjdfNy04LTEtMS0zNTMzMA_773d645c-ccd8-4726-96cd-c6132ec6920d"
      unitRef="usd">-439000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfNDc3NQ_12dc6462-bedf-40c1-9361-d3356bc201bb">RELATED PARTY TRANSACTIONS&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020, GeneDx entered into an agreement with Mednax Services, Inc. (&#x201c;Mednax Services&#x201d;), a subsidiary of MEDNAX, Inc., (&#x201c;MEDNAX&#x201d;) pursuant to which the parties formed a joint venture under the brand Detect Genomix.  GeneDx&#x2019;s initial capital investment in Detect Genomix was $245,000 for which GeneDx received a 49% ownership interest in Detect Genomix, and Mednax Services contributed $255,000 in exchange for a 51% ownership interest in Detect Genomix.  Adam Logal, the Company&#x2019;s CFO, was the chair and sat on the Board of Managers of the joint venture.  Mednax Services provided administrative services to the joint venture pursuant to an administrative services agreement.  GeneDx provided laboratory services to the joint venture.  Dr. Roger Medel, a director of the Company, is the former Chief Executive Officer of MEDNAX and Mednax Services.  Dr. Medel continues to serve on the board of MEDNAX.  The joint venture was dissolved in January 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On February 25, 2020, we entered into a credit agreement with an affiliate of Dr. Frost, pursuant to which the lender committed to provide us with an unsecured line of credit in the amount of $100 million.  The line of credit called for a commitment fee equal to 0.25% per annum of the unused portion of the line. We terminated this line of credit in June 2021 and as of March 31, 2022 and December 31, 2021, no amount was outstanding thereunder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owns approximately 9% of Pharmsynthez and Pharmsynthez is Xenetic&#x2019;s largest and controlling stockholder. Dr. Richard Lerner, a director of the Company until his death on December 2, 2021, was a co-inventor of Xenetic&#x2019;s technology and received 31,240 shares of Xenetic upon the closing of the Xenetic transactions described above.  Adam Logal, our Senior Vice President and Chief Financial Officer, is a director of Xenetic.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hold investments in Zebra (ownership 29%), Neovasc (1%), ChromaDex Corporation (0.1%), COCP (3%), NIMS (1%), Eloxx (1%), BioCardia (1%) and LeaderMed Health Group Limited (47%).  These investments were considered related party transactions as a result of our executive management&#x2019;s ownership interests and/or board representation in these entities.  See further discussion of our investments in Note 6.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, we entered into a Pledge Agreement with the Museum of Science, Inc. and the Museum of Science Endowment Fund, Inc. pursuant to which we agreed to contribute an aggregate of $1.0 million over a four-year period for constructing, equipping and the general operation of the Frost Science Museum.  Dr. Frost and Mr. Richard Pfenniger serve on the Board of Trustees of the Frost Science Museum and Mr. Pfenniger is the Vice Chairman of the Board of Trustees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease office space from Frost Real Estate Holdings, LLC (&#x201c;Frost Holdings&#x201d;) in Miami, Florida, where our principal executive offices are located.  Effective August 1, 2019, we entered into an amendment to our lease agreement with Frost Holdings.  The lease, as amended, is for approximately 29,500 square feet of space.  The lease provides for payments of approximately $89 thousand per month in the first year increasing annually to $101 thousand per month in the fifth year, plus applicable sales tax.  The rent is inclusive of operating expenses, property taxes and parking.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BioReference purchases and uses certain products acquired from InCellDx, a company in which we hold a 29% minority interest.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reimburse Dr.&#160;Frost for Company-related use by Dr.&#160;Frost and our other executives of an airplane owned by a company that is beneficially owned by Dr.&#160;Frost.  We reimburse Dr. Frost for out-of-pocket operating costs for the use of the airplane by Dr. Frost or Company executives for Company-related business.  We do not reimburse Dr.&#160;Frost for personal use of the airplane by Dr.&#160;Frost or any other executive.  For the three months ended March 31, 2022 and 2021, we reimbursed approximately $31&#160;thousand and $0&#160;thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ibadd78e70def4793bd8033df5fdbe911_D20200801-20200831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMTA4NA_77bebb7f-a795-40ef-bbe3-00b2a847d966"
      unitRef="usd">245000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i4a78517025804d929c0e5e426c1b9a4b_I20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMTExNQ_b063342a-e16c-4a8f-ac39-6699f3e966df"
      unitRef="number">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i50674a6b6023457196ed8f17e7e4cf51_D20200801-20200831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMTE4OA_d30f4a3c-22ac-4790-b68b-e672feaccb90"
      unitRef="usd">255000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i4ecfd405f7e848e8a4e0bde064b5beaf_I20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMTIwOQ_d9b74682-c77b-4954-851a-1db4e938743f"
      unitRef="number">0.51</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i77752216e0a74e5e94c99ae54b2ab33f_I20200225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMTg3OQ_496ef3a8-888d-4934-96bf-1d776b1176c7"
      unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i9ba35bd01ebf48fc928c6575df35dcf4_D20200225-20200225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMTk0MA_f7b9a0d3-3313-4b1b-b8ad-b589908a9ebc"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCredit
      contextRef="ia1b9e43d842649f78bdeeb877a771557_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMzg0ODI5MDcxNjIzNQ_724ec36b-8bda-44c2-86a7-41568ce59e30"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i2da87d4b1cea40abb7f65c8419989f04_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjEzNQ_c2fbfc79-f7a2-475a-9265-d1ea479ce7bb"
      unitRef="number">0.09</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <opk:RelatedPartyTransactionShares
      contextRef="iee2076cde68b4576afe09b95b5942af6_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjMyMg_b42e0ced-ede0-4d07-955a-a53243c7da2e"
      unitRef="shares">31240</opk:RelatedPartyTransactionShares>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i4ae393d9880f48be85feb8757df68b73_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjU3MA_27d7064d-2de9-4521-910b-f5f02869ab15"
      unitRef="number">0.29</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i4e737b98458d4a859ab982878352b552_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjU4NA_a3003a6b-ffd5-4b7d-8f81-b2bd4dc64e8c"
      unitRef="number">0.01</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="ief99b9b8fe8e4816986a723ffacc2c18_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjYxMg_9d5584c1-4202-43c2-8ded-140a87378772"
      unitRef="number">0.001</opk:EquitySecurityFVNIOwnershipPercent>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ief9f3d5f2c21400fbcb87f69615b8cf1_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjYyMw_ff4c87ff-a99a-4456-91bb-d0b852bc86b1"
      unitRef="number">0.03</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="iba2fbb366c7942ee8c1f1d0688aeacd7_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjYzNA_08afefb2-dde9-4d35-9598-ee6d52685ffd"
      unitRef="number">0.01</opk:EquitySecurityFVNIOwnershipPercent>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="i745a5d9c8eda4157b142bcd4ae5184df_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjY0Ng_bf39d421-2e9e-4854-8469-0da48ce8ee8f"
      unitRef="number">0.01</opk:EquitySecurityFVNIOwnershipPercent>
    <opk:EquitySecurityFVNIOwnershipPercent
      contextRef="iefc49f12f9a24f6a8438f9164321e4b9_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMjY2Ng_416127fb-d292-4a4e-ad39-d4b22b66c6c0"
      unitRef="number">0.01</opk:EquitySecurityFVNIOwnershipPercent>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i3e85d9626c1c441cb3ee913546454e58_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMzg0ODI5MDcxNjI0NA_6b74935e-6ac9-4594-a789-719ac72d6fef"
      unitRef="number">0.47</us-gaap:VariableInterestEntityOwnershipPercentage>
    <opk:RelatedPartyTransactionFutureContributions
      contextRef="ica59f07c68a7496dadf29dc004ea21da_I20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMzA4OQ_33168278-7edf-4b81-968b-02c5a8c46457"
      unitRef="usd">1000000</opk:RelatedPartyTransactionFutureContributions>
    <opk:RelatedPartyTransactionFutureContributionTerm
      contextRef="ib24c230ab8774444a8491338133155c0_D20161101-20161130"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfNDc3Mw_6d1388d5-466e-4117-adee-1d11b1141fb7">P4Y</opk:RelatedPartyTransactionFutureContributionTerm>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i86ce37219a974882a0746dff7fc5dd55_I20190801"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMzY1MQ_2a5b1f55-3fc7-44a1-9e84-5d8ee49cf7c3"
      unitRef="sqft">29500</us-gaap:AreaOfRealEstateProperty>
    <opk:OperatingLeasesMonthlyPaymentsYearOne
      contextRef="i86ce37219a974882a0746dff7fc5dd55_I20190801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMzcyNg_9e16e6ec-323c-4dee-a009-8f3ffaa03861"
      unitRef="usd">89000</opk:OperatingLeasesMonthlyPaymentsYearOne>
    <opk:OperatingLeasesMonthlyPaymentsYearFive
      contextRef="i86ce37219a974882a0746dff7fc5dd55_I20190801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfMzc4MA_e2c795e5-2df2-4e18-b834-cefef4c1e4bf"
      unitRef="usd">101000</opk:OperatingLeasesMonthlyPaymentsYearFive>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i61c6fa53ff434aeea2559a0e6fca1f8f_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfNDAxOA_8550f2f9-b086-4bb7-9b7f-f776ea7b1ebd"
      unitRef="number">0.29</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfNDUwNQ_5076745b-7760-4a02-b3af-3524f0a88972"
      unitRef="usd">31000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183My9mcmFnOmQ3MzUxMDRiODY3YzRhYzdhNTM1MzRjNGQ5ZWIzN2IwL3RleHRyZWdpb246ZDczNTEwNGI4NjdjNGFjN2E1MzUzNGM0ZDllYjM3YjBfNDY4OA_dc3ae997-1e60-4d75-84ab-299ab5336fe4"
      unitRef="usd">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfNjM0Mw_85187583-4f2b-4fc9-ba66-3955a339966a">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisitions of CURNA, OPKO Diagnostics and OPKO Renal, we agreed to pay future consideration to the sellers upon the achievement of certain events.  As a result, as of March 31, 2022, we recorded $2.7 million as contingent consideration, with $0.5 million recorded within Accrued expenses and $2.2 million recorded within Other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets.  Refer to Note 5 and Note 17.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 1, 2019, the Company received a Civil Investigative Demand (&#x201c;CID&#x201d;) from the U.S. Department of Justice (&#x201c;DOJ&#x201d;), Washington, DC. The CID sets forth document requests and interrogatories in connection with allegations that the Company and certain of its affiliates violated the False Claims Act and/or the Anti-Kickback Statute. On January 13, 2022, the Federal Government notified the U.S.D.C., Middle District Florida, Jacksonville Division, that it is declining to intervene in the matter but retains the right, via the Attorney General, to consent to any proposed dismissal of the action by the Court. On February 9, 2022, the States of Florida, Georgia, and Commonwealth of Massachusetts notified the U.S.D.C., Middle District Florida, Jacksonville Division, that they are declining to intervene in the matter. Notwithstanding the above declinations, on February 17, 2022, the Company was served with the Relator&#x2019;s Summons and Complaint (&#x201c;Complaint&#x201d;), which had been previously sealed. The complaint alleges violations of the False Claims Act, the California Fraud Preventions Act, the Florida False Claims Act, the Massachusetts False Claims Act, the Georgia False Medicaid Claims Act, and illegal kickbacks. The Company is reviewing and assessing the allegations made in the Complaint and, at this point, has not determined whether there is any merit to these claims nor can it determine the extent of any potential liability. While management cannot predict the outcome of these matters at this time, the ultimate outcome could be material to our business, financial condition, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;         As previously reported, BioReference receives and is routinely required to respond to Civil Investigative Demands (&#x201c;CID&#x201d;) in the ordinary course of business. On November 26, 2019, BioReference received a CID from the DOJ. The CID states that DOJ is investigating whether BioReference paid unlawful remuneration to health care practitioners in violation of the Anti-Kickback Statute or Stark law and thus submitted or caused to be submitted false claims to government health care programs in violation of the False Claims Act. The time period covered by DOJ&#x2019;s requests is January 1, 2011 through November 26, 2019. BioReference has fully cooperated with the DOJ by submitting the requested information and making current employees available for interviews, and the DOJ made a presentation to BioReference regarding its position. The parties have reached verbal agreement on the settlement amount, which is anticipated to be approximately $10&#160;million, excluding attorney fees. As of March&#160;31, 2022 and December 31, 2021, $10.5&#160;million and $10.0&#160;million was recorded in Accrued expenses, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 8, 2019, MabVax Therapeutics Holdings, Inc. filed a lawsuit in the Superior Court of California, County of San Diego against a number of individuals and entities, including the Company, Dr. Frost, Steven Rubin, the Company&#x2019;s Executive Vice President-Administration, and an entity affiliated with Dr. Frost, based on the allegations raised in the SEC Complaint. The lawsuit seeks an award for actual and punitive damages, pre- and post-judgment interest; that the defendants be required to make full disclosure and accounting of their interests and transactions in plaintiff&#x2019;s securities; costs of the suit, and reasonable attorney&#x2019;s fees; and such other legal and equitable relief as the Court may deem proper under the circumstances. On January 31, 2022, plaintiffs entered into a confidential mutual release and settlement agreement with the Company, Dr. Frost, Frost Gamma Investment Trust, and Steve Rubin (the &#x201c;Settlement Agreement&#x201d;). The Settlement Agreement  has been approved by the United States Bankruptcy Court for the District of Delaware.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2019, former shareholders of Claros Diagnostics, Inc. filed a complaint in the Chancery Court of Delaware against the Company, alleging among other things, that the Company breached the Agreement and Plan of Merger dated October 13, 2011 by and among the Company, Claros Merger Subsidiary, LLC and Claros Diagnostics, Inc. (the &#x201c;Claros Merger Agreement&#x201d;): (i) by failing to make a milestone payment of $2.375&#160;million (payable in OPKO Common Stock) upon obtaining FDA approval of the Claros PSA test; and (ii) by repudiating its obligations to make additional future milestone payments as required under the Claros Merger Agreement. In January 2021, the Company and the shareholder representative entered into a settlement agreement providing, among other things, that the Company pay the shareholders $1.2&#160;million, which the Company has paid in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2017, the Civil Division of the United States Attorney&#x2019;s Office for the Southern District of New York (the &#x201c;SDNY&#x201d;) informed BioReference that it believed that, from 2008 to 2012, BioReference had, in violation of the False Claims Act, improperly billed Medicare and TRICARE (both are federal government healthcare programs) for clinical laboratory services provided to hospital inpatient beneficiaries at certain hospitals.  In April 2019, the SDNY also informed BioReference that it believed that BioReference provided physicians subsidies for electronic health record systems prior to 2012 that violated regulations adopted by HHS in 2006 which allowed laboratories to provide these donations under certain conditions.  BioReference and the SDNY reached a settlement with respect to these matters and a final settlement and release, including BioReference&#x2019;s payment of an approximately $11.5&#160;million settlement amount, was approved on September 22, 2020. The settlement amount has been paid. The amount of relator attorneys&#x2019; fees is currently being negotiated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may receive inquiries, document requests, CIDs or subpoenas from the Department of Justice, OCR, CMS, various payors and fiscal intermediaries, and other state and federal regulators regarding investigations, audits and reviews.  In addition to the matters discussed in this note, we are currently responding to CIDs, subpoenas, payor audits, and document requests for various matters relating to our laboratory operations.  Some pending or threatened proceedings against us may involve potentially substantial amounts as well as the possibility of civil, criminal, or administrative fines, penalties, or other sanctions, which could be material.  Settlements of suits involving the types of issues that we routinely confront may require monetary payments as well as corporate integrity agreements.  Additionally, qui tam or &#x201c;whistleblower&#x201d; actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act&#x2019;s requirements for filing such suits.  Also, from time to time, we may detect issues of non-compliance with federal healthcare laws pertaining to claims submission and reimbursement practices and/or financial relationships with physicians, among other things.  We may avail ourselves of various mechanisms to address these issues, including participation in voluntary disclosure protocols.  Participating in voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action.  The Company generally has cooperated, and intends to continue to cooperate, with appropriate regulatory authorities as and when investigations, audits and inquiries arise.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to other litigation in the ordinary course of business.  While we cannot predict the ultimate outcome of legal matters, we accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss.  It&#x2019;s reasonably possible the ultimate liability could exceed amounts currently estimated and we review established accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information.  To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.  Because of the high degree of judgment involved in establishing loss estimates, the ultimate outcome of such matters will differ from our estimates and such differences may be material to our business, financial condition, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, we were committed to make future purchases for inventory and other items in 2022 that occur in the ordinary course of business under various purchase arrangements with fixed purchase provisions aggregating approximately $252.4 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMjQ1_5beb9cd6-768b-4021-bd69-b69158306cf5"
      unitRef="usd">2700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic33ae5da06dc4f819b6dcd183aecaebe_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMjgy_ed3ddd0b-aceb-49fc-8189-ef0f13971d50"
      unitRef="usd">500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4c5f0e2847a64769ab9be88846f125c4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMzIy_5f6ac5a9-0746-43cd-83f9-c7b070035ae5"
      unitRef="usd">2200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i02020232c72342119d53b27eaa44b338_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMTQ0MA_a6ede8ae-c53b-49d0-a64f-8dd09e48ad3b"
      unitRef="usd">10000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationReserveCurrent
      contextRef="i522709e2d34e47b9b839338702492788_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMjc0ODc3OTA4NzgzOA_9bea715d-43df-4ab9-be20-fd46e2641533"
      unitRef="usd">10500000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="idc90d86f2b4c4d5a8429f7ad7154f525_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMjc0ODc3OTA4Nzg3MQ_dac662ec-63ef-42ea-b5f9-9932cc8ca5af"
      unitRef="usd">10000000</us-gaap:LitigationReserveCurrent>
    <opk:LossContingencyMilestonePayment
      contextRef="i70de44f4e3b347cfb81ce995f5cf73fe_I20190405"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMTg3Nw_75ea946e-c70f-493d-a8ae-32d252138a8d"
      unitRef="usd">2375000</opk:LossContingencyMilestonePayment>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i676c769373684cfba8382f5367b6370f_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMjI1Nw_456c2648-3c11-4d4f-8de8-4bc9b238002b"
      unitRef="usd">1200000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i3ef8f6dc8b5e486b8e9f8f96b1343e13_D20200922-20200922"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfMjc0ODc3OTA5MjIwNQ_481a53d5-7e5a-4b8c-9918-8307c91b3945"
      unitRef="usd">11500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:PurchaseObligation
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183Ni9mcmFnOmU0YjhjNjM2YTUxOTRmMzU5ZGM5ZTdiOWRkYjZlNzZhL3RleHRyZWdpb246ZTRiOGM2MzZhNTE5NGYzNTlkYzllN2I5ZGRiNmU3NmFfNjMzOA_0cbba1f7-08c0-47d8-9100-9827c934f5ed"
      unitRef="usd">252400000</us-gaap:PurchaseObligation>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMTY5NTU_d82ee311-9d06-4061-879c-425d395947a6">REVENUE RECOGNITION&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate revenues from services, products and intellectual property as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue for laboratory services is recognized at the time test results are reported, which approximates when services are provided and the performance obligations are satisfied.  Services are provided to patients covered by various third-party payor programs including various managed care organizations, as well as the Medicare and Medicaid programs.  Billings for services are included in revenue net of allowances for contractual discounts, allowances for differences between the amounts billed and estimated program payment amounts, and implicit price concessions provided to uninsured patients which are all elements of variable consideration.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are descriptions of our payors for laboratory services:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Healthcare Insurers.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules.  Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements.  Adjustments to the allowances, based on actual receipts from the third-party payors, are recorded upon settlement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Payors.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reimbursements from government payors are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid.  Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements.  Adjustments to the allowances, based on actual receipts from the government payors, are recorded upon settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Client Payors.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Client payors include physicians, hospitals, employers, and other institutions for which services are performed on a wholesale basis, and are billed and recognized as revenue based on negotiated fee schedules.  Client payors also include cities, states and companies for which BioReference provides COVID-19 testing services.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patients.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients.  Insured patients (including amounts for coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers.  Collection of billings from patients is subject to credit risk and ability of the patients to pay.  Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with our policies and implicit price concessions.  Implicit price concessions represent differences between amounts billed and the estimated consideration that we expect to receive from patients, which considers historical collection experience and other factors including current market conditions.  Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, require us to estimate the potential for retroactive adjustments as an element of variable consideration in the recognition of revenue in the period the related services are rendered.  Actual amounts are adjusted in the period those adjustments become known. For the three months ended March 31, 2022 and 2021, positive revenue adjustments due to changes in estimates of implicit price concessions for performance obligations satisfied in prior periods of $2.0 million and $28.0 million, respectively, were recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Third-party payors, including government programs, may decide to deny payment or recoup payments for testing they contend were improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received.  Our revenues may be subject to retroactive adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payors in interpretations, requirements, and &#x201c;conditions of participation&#x201d; in various programs.  We have processed requests for recoupment from third-party payors in the ordinary course of our business, and it is likely that we will continue to do so in the future.  If a third-party payor denies payment for testing or recoups money from us in a later period, reimbursement for our testing could decline.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As an integral part of our billing compliance program, we periodically assess our billing and coding practices, respond to payor audits on a routine basis, and investigate reported failures or suspected failures to comply with federal and state healthcare reimbursement requirements, as well as overpayment claims which may arise from time to time without fault on the part of the Company.  We may have an obligation to reimburse Medicare, Medicaid,&#160;and third-party payors for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;overpayments&#160;regardless of fault.  We have periodically identified and reported&#160;overpayments, reimbursed payors for&#160;overpayments&#160;and taken appropriate corrective action.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are also considered variable consideration and are included in the determination of the estimated transaction price for providing services.  These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and our historical settlement activity, including an assessment of the probability a significant reversal of cumulative revenue recognized will occur when the uncertainty is subsequently resolved.  Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. As of March&#160;31, 2022 and December&#160;31, 2021, we had liabilities of approximately $2.1 million and $5.0 million, respectively, within Accrued expenses and Other long-term liabilities related to reimbursements for payor overpayments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The composition of Revenue from services by payor for the three months ended March 31, 2022 and 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three months ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Client payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:4pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from product sales when a customer obtains control of promised goods or services.  The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.  Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and our evaluation of specific factors that may increase or decrease the risk of product returns.  Product revenues are recorded net of estimated rebates, chargebacks, discounts, co-pay assistance and other deductions (collectively, &#x201c;Sales Deductions&#x201d;) as well as estimated product returns which are all elements of variable consideration.  Allowances are recorded as a reduction of revenue at the time product revenues are recognized.  The actual amounts of consideration ultimately received may differ from our estimates.  If actual results in the future vary from our estimates, we will adjust these estimates, which would affect Revenue from products in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is distributed in the U.S. principally through the retail pharmacy channel, which initiates with the largest wholesalers in the U.S. (collectively, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Customers&#x201d;).  In addition to distribution agreements with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers, we have entered into arrangements with many healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue for shipments of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at the time of delivery to customers after estimating Sales Deductions and product returns as elements of variable consideration utilizing historical information and market research projections. For the three months ended March 31, 2022 and 2021, we recognized $5.1 million and $5.8&#160;million, respectively, in net product revenue from sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents an analysis of product sales allowances and accruals for the three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Chargebacks, discounts, rebates and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Governmental &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Provision related to current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Credits or payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; sales allowances and accruals as a percentage of gross &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Chargebacks, discounts, rebates and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Governmental &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Provision related to current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Credits or payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; sales allowances and accruals as a percentage of gross &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:4pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Taxes collected from customers related to revenues from services and revenues from products are excluded from revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from intellectual property and other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenues from the transfer of intellectual property generated through license, development, collaboration and/or commercialization agreements.  The terms of these agreements typically include payment to us for one or more of the following:  non-refundable, up-front license fees; development and commercialization milestone payments; funding of research and/or development activities; and royalties on sales of licensed products.  Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For research, development and/or commercialization agreements that result in revenues, we identify all material performance obligations, which may include a license to intellectual property and know-how, and research and development activities.  In order to determine the transaction price, in addition to any upfront payment, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract.  We constrain (reduce) our estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract.  When determining if variable consideration should be constrained, we consider whether there are factors outside of our control that could result in a significant reversal of revenue.  In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue.  These estimates are re-assessed each reporting period as required.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront License Fees:  If a license to our intellectual property is determined to be functional intellectual property distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement.  The revenue is recognized when the license is transferred to the customer and the customer is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.  If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Development and Regulatory Milestone Payments:  Depending on facts and circumstances, we may conclude that it is appropriate to include the milestone in the estimated transaction price or that it is appropriate to fully constrain the milestone.  A milestone payment is included in the transaction price in the reporting period that we conclude that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods.  We may record revenues from certain milestones in a reporting period before the milestone is achieved if we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods.  We record a corresponding contract asset when this conclusion is reached.  Milestone payments that have been fully constrained are not included in the transaction price to date.  These milestones remain fully constrained until we conclude that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods.  We re-evaluate the probability of achievement of such development milestones and any related constraint each reporting period.  We adjust our estimate of the overall transaction price, including the amount of revenue recorded, if necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and Development Activities:  If we are entitled to reimbursement from our customers for specified research and development expenses, we account for them as separate performance obligations if distinct.  We also determine whether the research and development funding would result in revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation.  The corresponding revenues or offset to research and development expenses are recognized as the related performance obligations are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales-based Milestone and Royalty Payments:  Our customers may be required to pay us sales-based milestone payments or royalties on future sales of commercial products.  We recognize revenues related to sales-based milestone and royalty payments upon the later to occur of (i) achievement of the customer&#x2019;s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to our intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Potential Products and Services:  Arrangements may include an option for license rights, future supply of drug substance or drug product for either clinical development or commercial supply at the licensee&#x2019;s election.  We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the inception of the contract and revenue is recognized only if the option is exercised and products or services are subsequently delivered or when the rights expire.  If the promise is based on market terms and not considered a material right, the option is accounted for if and when exercised.  If we are entitled to additional payments when the licensee exercises these options, any additional payments are generally recorded in license or other revenues when the licensee obtains control of the goods, which is upon delivery.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Three months ended March&#160;31, 2022 and 2021, revenue from transfer of intellectual property and other reflects $2.2&#160;million and $2.8&#160;million of revenue related to the Pfizer Transaction (as defined below).  For the three months ended March&#160;31, 2022 revenue from transfer of intellectual property and other includes $3.0&#160;million related to a sales milestone from VFMCRP (as defined below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities relate to cash consideration that OPKO receives in advance of satisfying the related performance obligations. Changes in the contractual liabilities balance during the three months ended March 31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized in the period from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts included in contracts liability at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMzc4Mg_0d9c5466-20e9-4448-833c-64d8056b39fd"
      unitRef="usd">2000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMzk1MA_f8e4256e-7af2-4655-8221-0f3b7cbcaa50"
      unitRef="usd">28000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <opk:AccruedExpensePayorOverpaymentReimbursementLiability
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfNjYwNw_4ca03b58-beec-43f5-a90c-5e5bc0debb26"
      unitRef="usd">2100000</opk:AccruedExpensePayorOverpaymentReimbursementLiability>
    <opk:AccruedExpensePayorOverpaymentReimbursementLiability
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfNjYxNA_abb20e23-3d0f-4dc1-811c-1da6c9da44b3"
      unitRef="usd">5000000</opk:AccruedExpensePayorOverpaymentReimbursementLiability>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMTY5NjA_197c1023-b65d-47e3-94b1-62064aa6e260">&lt;div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The composition of Revenue from services by payor for the three months ended March 31, 2022 and 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three months ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Client payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b576227129140fcb81ae5986936e0a5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfMi01LTEtMS0zNTMzMA_e498d3a2-c5bc-4cd4-ac40-e3f7a51a97d6"
      unitRef="usd">95779000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c5cff8bc69f43c19ce205c66e3547e9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfMi03LTEtMS0zNTMzMA_b7933619-e853-41e5-9040-1bc90f62b643"
      unitRef="usd">164829000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i874e9141286747c28f30293d988fb218_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfMy01LTEtMS0zNTMzMA_a396f2ac-524b-4815-92d1-84d0436e5500"
      unitRef="usd">27588000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e8101af777f47df9da8ece465836a9c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfMy03LTEtMS0zNTMzMA_a0e7aaca-d45a-43a3-9756-f9edb7e7398d"
      unitRef="usd">73658000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d41bb470d9447f9a98b8d23e1a42b68_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfNC01LTEtMS0zNTMzMA_7141beb7-1530-48a7-a072-1dbc921b1f11"
      unitRef="usd">159040000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7186cb07c47349b0b7397d1c5851b571_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfNC03LTEtMS0zNTMzMA_c783f49f-655e-4f3b-8fa4-a8188d97dc82"
      unitRef="usd">262907000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c5acb3b505f4483bf34a77f2c5e788e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfNS01LTEtMS0zNTMzMA_f1a8d340-8d4f-42ec-b9c5-fa2b8e9c2f10"
      unitRef="usd">4192000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99d9faa02d9d40f389d88742df8865d3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfNS03LTEtMS0zNTMzMA_5cb15d79-2e23-40ec-8030-b633457a7e4e"
      unitRef="usd">5557000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f9c95a502354f4c9bd791e55a1b1acc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfNi01LTEtMS0zNTMzMA_73ae7418-c68c-4940-8b8c-51db4a3146a4"
      unitRef="usd">286599000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fd3f89e217e4e329bca14b9905edffa_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmIzODU3ZjVkYWQzYTRiZGJhNDMzYTg3ODhiYWFmMjRlL3RhYmxlcmFuZ2U6YjM4NTdmNWRhZDNhNGJkYmE0MzNhODc4OGJhYWYyNGVfNi03LTEtMS0zNTMzMA_e4a3be07-ae01-4426-a29c-a8b8876e61f5"
      unitRef="usd">506951000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="id0e7950d75f0444d93f095f4040135b3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfODcxNw_1e665636-9f2e-44cb-bada-9d5d3a169b70"
      unitRef="usd">5100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ief2e45330b2c4c668f762e3119a6fbae_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfODg2Ng_c57b3e20-4696-4358-bd5f-6d74705d0feb"
      unitRef="usd">5800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <opk:ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMTY5NTc_cdbd2ce3-6cfb-4d30-984e-ba9c91041a5c">The following table presents an analysis of product sales allowances and accruals for the three months ended March 31, 2022 and 2021:&lt;div style="margin-bottom:5pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Chargebacks, discounts, rebates and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Governmental &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Provision related to current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Credits or payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; sales allowances and accruals as a percentage of gross &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Chargebacks, discounts, rebates and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Governmental &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Provision related to current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Credits or payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; sales allowances and accruals as a percentage of gross &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</opk:ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="idea7a07d482240c5a1a9daa77497e119_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMS0yLTEtMS0zNTMzMA_95c8f467-84f5-4686-a1dc-b26ecd79e9d5"
      unitRef="usd">2014000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i7745e7dd9842490f8a4d3aa14b8bb285_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMS00LTEtMS0zNTMzMA_160bef3c-f8b7-42e5-bb01-bedc2f1be267"
      unitRef="usd">5499000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ic32fd42c04ee410bade14b9fa49da67d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMS02LTEtMS0zNTMzMA_e4207f39-6a10-44a9-b60c-740e71599a6f"
      unitRef="usd">2639000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i49b8dfcf4b0a47ceb082dba3ba22e4e2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMS04LTEtMS0zNTMzMA_78880c5e-f240-448b-9f01-22b7cfc8005e"
      unitRef="usd">10152000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i7a4781da5440461fa4b0023e40c75529_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMi0yLTEtMS0zNTMzMA_69f753ac-4e6c-4ed8-b072-4d40aad2f793"
      unitRef="usd">3215000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i4e9ad9bd7fa74daeae00d3f5d5742096_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMi00LTEtMS0zNTMzMA_fb96cb2d-668b-4535-bbfc-380b4dd192ad"
      unitRef="usd">4869000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ia2dedc717e1341d5886ca72f83560353_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMi02LTEtMS0zNTMzMA_0a043b8d-e6ea-4b3b-927f-4c1bf775f4e1"
      unitRef="usd">269000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="id0e7950d75f0444d93f095f4040135b3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfMi04LTEtMS0zNTMzMA_a57b10b8-6400-45fe-9515-364ce19ae0cb"
      unitRef="usd">8353000</us-gaap:ProvisionForDoubtfulAccounts>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="i7a4781da5440461fa4b0023e40c75529_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNC0yLTEtMS0zNTMzMA_f67f6214-798b-4650-80b8-51f3d80cd826"
      unitRef="usd">3641000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="i4e9ad9bd7fa74daeae00d3f5d5742096_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNC00LTEtMS0zNTMzMA_74381b71-c8af-41ca-b125-2e6490696567"
      unitRef="usd">5086000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="ia2dedc717e1341d5886ca72f83560353_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNC02LTEtMS0zNTMzMA_1401386d-0c21-46f0-bf26-aa0ee55fc082"
      unitRef="usd">575000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="id0e7950d75f0444d93f095f4040135b3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNC04LTEtMS0zNTMzMA_f9393b3a-e2b1-4963-a03f-c13bb248f3ec"
      unitRef="usd">9302000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i4abfbe41a46e407a91e30f4caa372833_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNS0yLTEtMS0zNTMzMA_cea3fc1a-ef33-4934-8d19-e2528d581a8a"
      unitRef="usd">1588000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i15c57ea2417945928b8420c5f3724908_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNS00LTEtMS0zNTMzMA_5d8b5e86-79f1-4874-9464-56bd956161d7"
      unitRef="usd">5282000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ia48d7bc49b584c93b505e1441ca49b05_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNS02LTEtMS0zNTMzMA_99d09146-75dc-406b-91a4-1169781734c8"
      unitRef="usd">2333000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ib5e653d3db9e490db849e824a8a8a9a5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNS04LTEtMS0zNTMzMA_73cd6cff-3b1d-44f4-a4db-b29da351e789"
      unitRef="usd">9203000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0e7950d75f0444d93f095f4040135b3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfNy04LTEtMS0zNTMzMA_4032b70c-a70a-4e5e-b02f-2d480b3ccd8d"
      unitRef="usd">13479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <opk:AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales
      contextRef="id0e7950d75f0444d93f095f4040135b3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOmJlYmJiOGFmNTY5YjRmN2M5YjkxODEwNjJhYmE2ZmRiL3RhYmxlcmFuZ2U6YmViYmI4YWY1NjliNGY3YzliOTE4MTA2MmFiYTZmZGJfOC04LTEtMS0zNTMzMA_d09e747c-77c7-47e1-9ccb-835c28e16360"
      unitRef="number">0.62</opk:AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ifeecfb112c664416a33c945ad8da2700_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMS0yLTEtMS00MDgyOQ_ce2fc1e4-38dd-4ac6-82fd-ab588c5f448a"
      unitRef="usd">2332000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i56348d7a5e4f475181fad615300d4502_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMS00LTEtMS00MDgyOQ_0d9bddd5-8202-43af-8840-5cd3998aecbc"
      unitRef="usd">5812000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i2139d12433584f65aa24b38284d118c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMS02LTEtMS00MDgyOQ_c21056a5-06fd-4264-b094-d79d18e60317"
      unitRef="usd">3593000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ie128a7c076a046209f0782cf5784b0a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMS04LTEtMS00MDgyOQ_ec78926a-5823-4264-b872-8fdb3fd7fcfe"
      unitRef="usd">11737000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i4d0eefa269f14f9f977234ed680b56f9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMi0yLTEtMS00MDgyOQ_5691a5a5-1c4f-414a-aa2e-a496dcead81a"
      unitRef="usd">3815000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="id28b381bb36e4f06a4682b864bdd7356_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMi00LTEtMS00MDgyOQ_0bcd0457-b64f-4739-aaf5-1cc054239276"
      unitRef="usd">5694000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i6c111d78df63437e89c6efa75cc8851b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMi02LTEtMS00MDgyOQ_e3e8338b-2ddf-4076-ad21-49dbf072f757"
      unitRef="usd">313000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ief2e45330b2c4c668f762e3119a6fbae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfMi04LTEtMS00MDgyOQ_ad3511c5-a46c-4719-8ae4-73704b9d003a"
      unitRef="usd">9822000</us-gaap:ProvisionForDoubtfulAccounts>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="i4d0eefa269f14f9f977234ed680b56f9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNC0yLTEtMS00MDgyOQ_dae14588-c4d3-44bc-ad4d-a93d1386edf4"
      unitRef="usd">4454000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="id28b381bb36e4f06a4682b864bdd7356_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNC00LTEtMS00MDgyOQ_bf0e88a6-37c7-4455-8c36-a7fa1b0526bc"
      unitRef="usd">5297000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="i6c111d78df63437e89c6efa75cc8851b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNC02LTEtMS00MDgyOQ_adf9b731-0a05-4150-9cc3-2473637dccc6"
      unitRef="usd">419000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments
      contextRef="ief2e45330b2c4c668f762e3119a6fbae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNC04LTEtMS00MDgyOQ_e3853cbd-f9c6-4b48-b0da-9ebd3630f57e"
      unitRef="usd">10170000</opk:AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i111f3c1bfdd14e20811f5bc40a649d17_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNS0yLTEtMS00MDgyOQ_da933fa5-f45d-43c1-8f73-e46bc017e089"
      unitRef="usd">1693000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i0b398c50b3cd40b5b0170eef129c73b1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNS00LTEtMS00MDgyOQ_3fa7d634-5a75-433a-bafe-a8b9bbd0144d"
      unitRef="usd">6209000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i86896d2c37ea4f34aec16a43eaaedc8a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNS02LTEtMS00MDgyOQ_7bb47607-dade-4420-ad35-473cee138344"
      unitRef="usd">3487000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i966cf82bdb2540cbba62a1e436cfbd92_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNS04LTEtMS00MDgyOQ_f4745e1f-a0df-4a8f-9fd7-399f996914d3"
      unitRef="usd">11389000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief2e45330b2c4c668f762e3119a6fbae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfNy04LTEtMS00MDgyOQ_00816af9-790e-4e0d-a627-b4e4ced75d0d"
      unitRef="usd">15645000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <opk:AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales
      contextRef="ief2e45330b2c4c668f762e3119a6fbae_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjNhYmJjMTMyMGM2MzQzZjNhNzRlNzliMTQ0Mjc4ZjRmL3RhYmxlcmFuZ2U6M2FiYmMxMzIwYzYzNDNmM2E3NGU3OWIxNDQyNzhmNGZfOC04LTEtMS00MDgyOQ_a1c35501-b781-42e1-ad0f-2ef65880faf8"
      unitRef="number">0.63</opk:AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba783e62870149cda0cee98d8bc74cf5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMjc0ODc3OTA4NzI0MQ_ecf3cd7e-0de1-42f1-a341-6e338b18b424"
      unitRef="usd">2200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6880e4f214144d89a4f0b87a7b1c3f55_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMjc0ODc3OTA4ODA3NQ_baae4487-c92b-4787-8c26-317fbd997d03"
      unitRef="usd">2800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fd88e0b9dc2432ca9c87a42295d0f14_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMjc0ODc3OTA5MDk4OQ_413e644f-d764-4ecd-8d29-f3229caa5e1a"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RleHRyZWdpb246Njc2NjI2MTk3MjA3NDhjYTk4ODlhYTg3Njg2OGYxZDlfMTY5NjU_4f55e4df-479f-4593-b2e2-cbc0f3fd5792">Changes in the contractual liabilities balance during the three months ended March 31, 2022 are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized in the period from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts included in contracts liability at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjcyNTIwZjIyNGI3MjRiNmE5NjUzMGQxYWNmM2E0MTlkL3RhYmxlcmFuZ2U6NzI1MjBmMjI0YjcyNGI2YTk2NTMwZDFhY2YzYTQxOWRfMS0xLTEtMS0zNTMzMA_b9bc07aa-677d-46b6-bb0c-c87fa08850fa"
      unitRef="usd">466000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjcyNTIwZjIyNGI3MjRiNmE5NjUzMGQxYWNmM2E0MTlkL3RhYmxlcmFuZ2U6NzI1MjBmMjI0YjcyNGI2YTk2NTMwZDFhY2YzYTQxOWRfMi0xLTEtMS0zNTMzMA_cbd7997c-1518-42bb-9095-12dcbab06dce"
      unitRef="usd">462000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y183OS9mcmFnOjY3NjYyNjE5NzIwNzQ4Y2E5ODg5YWE4NzY4NjhmMWQ5L3RhYmxlOjcyNTIwZjIyNGI3MjRiNmE5NjUzMGQxYWNmM2E0MTlkL3RhYmxlcmFuZ2U6NzI1MjBmMjI0YjcyNGI2YTk2NTMwZDFhY2YzYTQxOWRfNC0xLTEtMS0zNTMzMA_b305add5-ec05-4c27-b8af-db3d92cdd07a"
      unitRef="usd">4000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <opk:StrategicAlliancesTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTYyNzU_269877b0-bcec-45c0-a313-c4751aec7596">STRATEGIC ALLIANCES&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;LeaderMed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 14, 2021, we and LeaderMed Health Group Limited (&#x201c;LeaderMed&#x201d;), a pharmaceutical development company with operations based in Asia, announced the formation of a joint venture to develop, manufacture and commercialize two of OPKO&#x2019;s clinical stage, long-acting drug products in Greater China and eight other Asian territories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreements, we have granted the joint venture exclusive rights to develop, manufacture and commercialize (a) OPK88003, an oxyntomodulin analog being developed for the treatment of obesity and diabetes, and (b) Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia, in exchange for a 47% ownership &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;interest in the joint venture. In addition, we received an upfront payment of $1&#160;million and will be reimbursed for clinical trial material and technical support we provide the joint venture. We recognized the upfront payment of $1&#160;million as revenue from transfer of intellectual property and other during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LeaderMed has agreed to be responsible for funding the joint venture&#x2019;s operations, development and commercialization efforts and, together with its syndicate partners, initially invested $11&#160;million in exchange for a 53% ownership interest. We retain full rights to oxyntomodulin and Factor VIIa-CTP in all other geographies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;CAMP4 Therapeutics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 6, 2021, we entered into an exclusive license agreement (the &#x201c;CAMP4 Agreement&#x201d;) with CAMP4, pursuant to which we granted to CAMP4 an exclusive license to develop, manufacture, commercialize or improve therapeutics utilizing the AntagoNAT technology, an oligonucleotide platform developed under OPKO CURNA, which includes the molecule for the treatment of Dravet syndrome, together with any derivative or modification thereof (the &#x201c;Licensed Compound&#x201d;) and any pharmaceutical product that comprises or contains the Licensed Compound, alone or in combination with one or more other active ingredients (&#x201c;Licensed Product&#x201d;), worldwide. The CAMP4 Agreement grant covers human pharmaceutical, prophylactic, and therapeutic and certain diagnostic uses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received an initial upfront payment of $1.5&#160;million and 3,373,008 shares of CAMP4&#x2019;s Series A Prime Preferred Stock (&#x201c;Preferred Stock&#x201d;), which equates to approximately 9% of the outstanding shares of CAMP4, and we are eligible to receive up to $3.5&#160;million in development milestone payments for Dravet syndrome products, and $4&#160;million for non-Dravet syndrome products, as well as sales milestones of up to $90&#160;million for Dravet syndrome products and up to $90&#160;million for non-Dravet syndrome products. We may also receive double digit royalty payments on the net sales of royalty bearing products, subject to adjustment. In addition, upon achievement of certain development milestones, we will be eligible to receive equity consideration of up to 5,782,299 shares of Preferred Stock in connection with Dravet syndrome products and up to 1,082,248 shares of Preferred Stock in connection with non-Dravet syndrome products. In connection with our acquisition of CURNA, we agreed to pay future consideration to the sellers upon the achievement of certain events. As a result of our execution of the CAMP4 Agreement, we will have to pay a percentage of any payments received under the CAMP4 Agreement to the former CURNA stockholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the CAMP4 Agreement will remain in effect on a Licensed Product-by-Licensed Product and country by-country basis until such time as the royalty term expires for a Licensed Product in a country, and expires in its entirety upon the expiration of the royalty term for the last Licensed Product in the last country. CAMP4&#x2019;s royalty obligations expire on the later of (i) the expiration, invalidation or abandonment date of the last patent right in connection with the royalty bearing product, or (ii) ten (10) years after a royalty bearing product&#x2019;s first commercial sale in a country. In addition to termination rights for material breach and bankruptcy, CAMP4 is permitted to terminate the Agreement after a specified notice period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NICOYA Macau Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2021, EirGen, our wholly owned subsidiary, and NICOYA Macau Limited (&#x201c;Nicoya&#x201d;), a Macau corporation and an affiliate of NICOYA Therapeutics, entered into a Development and License Agreement (the &#x201c;Nicoya Agreement&#x201d;) granting Nicoya the exclusive rights for the development and commercialization of extended release calcifediol (the &#x201c;Nicoya Product&#x201d;) in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan (collectively, the &#x201c;Nicoya Territory&#x201d;). Extended release calcifediol is marketed in the U.S. by OPKO under the tradename &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The license grant to Nicoya covers the therapeutic and preventative use of the Nicoya Product for SHPT in non-dialysis and hemodialysis chronic kidney disease patients (the &#x201c;Nicoya Field&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EirGen has received an initial upfront payment of $5&#160;million and is eligible to receive an additional $5&#160;million upon the first to occur of (A) a predetermined milestone and (B) the first anniversary of the effective date. EirGen is also eligible to receive up to an additional aggregate amount of $115&#160;million upon the achievement of certain development, regulatory and sales-based milestones by Nicoya for the Nicoya Product in the Nicoya Territory. EirGen will also receive tiered, double digit royalty payments at rates in the low double digits on net product sales within the Nicoya Territory and in the Nicoya Field.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nicoya will, at its sole cost and expense, be responsible for performing all development activities necessary to obtain all regulatory approvals for the Nicoya Product in the Nicoya Territory and for all commercial activities pertaining to the Nicoya Product in the Nicoya Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the Nicoya Agreement will remain in effect until such time as all royalty payment terms and extended payment terms have expired, and Nicoya shall have no further payment obligations to EirGen under the terms of the Nicoya Agreement. Nicoya&#x2019;s royalty obligations expire on the later of (i) expiration of the last to expire valid patent claim &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;covering the Nicoya Product sold in the Nicoya Territory, (ii) expiration of all regulatory and data exclusivity applicable to the Nicoya Product in the Nicoya Territory, and (iii) on a product-by-product basis, ten (10) years after such Nicoya Product&#x2019;s first commercial sale in the Nicoya Territory. In addition to termination rights for material breach and bankruptcy, Nicoya is permitted to terminate the Nicoya Agreement after a specified notice period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vifor Fresenius Medical Care Renal Pharma Ltd&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2016, EirGen and Vifor Fresenius Medical Care Renal Pharma Ltd. (&#x201c;VFMCRP&#x201d;) entered into a Development and License Agreement (the &#x201c;VFMCRP Agreement&#x201d;) for the development and commercialization of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;Product&#x201d;) worldwide, except for (i) the U.S., (ii) any country in Central America or South America (including Mexico), (iii) Russia, (iv) China, (v) South Korea, (vi) Ukraine, (vii) Belorussia, (viii) Azerbaijan, (ix) Kazakhstan, (x) Taiwan (xi) the Middle East, and (xii) all countries of Africa (the &#x201c;VFMCRP Territory&#x201d;), as amended.  The license to VFMCRP potentially covers all therapeutic and prophylactic uses of the Product in human patients (the &#x201c;VFMCRP Field&#x201d;), provided that initially the license is for the use of the Product for the treatment or prevention of SHPT related to patients with CKD and vitamin D insufficiency/deficiency (the &#x201c;VFMCRP Initial Indication&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2022 we recognized a milestone payment of $3.0&#160;million in revenue from transfer of intellectual property and other for the first sale of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective May 23, 2021, we entered into an amendment to the VFMCRP Agreement pursuant to which the parties thereto agreed to include Japan as part of the VFMCRP Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective May 5, 2020, we entered into an amendment to the VFMCRP Agreement pursuant to which the parties agreed to exclude Mexico, South Korea, the Middle East and all of the countries of Africa from the VFMCRP Territory.  In addition, the parties agreed to certain amendments to the milestone structure and to reduce minimum royalties payable.  As revised, the Company has received a $3&#160;million payment triggered by the first marketing approval of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Europe and is eligible to receive up to an additional $17&#160;million in regulatory milestones and $207&#160;million in milestone payments tied to launch, pricing and sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and tiered, double-digit royalties.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We plan to share responsibility with VFMCRP for the conduct of trials specified within an agreed-upon development plan, with each company leading certain activities within the plan.  EirGen will lead the manufacturing activities within and outside the VFMCRP Territory and the commercialization activities outside the VFMCRP Territory and outside the VFMCRP Field in the VFMCRP Territory and VFMCRP will lead the commercialization activities in the VFMCRP Territory and the VFMCRP Field.  For the initial development plan, the companies have agreed to certain cost sharing arrangements.  VFMCRP will be responsible for all other development costs that VFMCRP considers necessary to develop the Product for the use of the Product for the VFMCRP Initial Indication in the VFMCRP Territory in the VFMCRP Field except as otherwise provided in the VFMCRP Agreement.  The first of the clinical studies provided for in the development activities commenced in September 2018.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the VFMCRP Agreement, the parties entered into a letter agreement pursuant to which EirGen granted to VFMCRP an exclusive option (the &#x201c;Option&#x201d;) to acquire an exclusive license under certain EirGen patents and technology to use, import, offer for sale, sell, distribute and commercialize the Product in the U.S. solely for the treatment of SHPT in dialysis patients with CKD and vitamin D insufficiency (the &#x201c;Dialysis Indication&#x201d;).  Upon exercise of the Option, VFMCRP will reimburse EirGen for all of the development costs incurred by EirGen with respect to the Product for the Dialysis Indication in the U.S.  VFMCRP would also pay EirGen up to an additional aggregate amount of $555&#160;million of sales-based milestones upon the achievement of certain milestones and would be obligated to pay royalties at percentage rates that range from the mid-teens to the mid-twenties on sales of the Product in the U.S. for the Dialysis Indication.  To date, VFMCRP has not exercised its option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments received for regulatory milestones and sales milestones are non-refundable.  The regulatory milestones are payable if and when VFMCRP obtains approval from certain regulatory authorities and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met.  We account for the sales milestones as royalties and sales milestones payments will be recognized as revenue in the period in which the associated milestone is achieved or sales occur, assuming all other revenue recognition criteria are met.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2014, we entered into an exclusive worldwide agreement (the &#x201c;Pfizer Agreement&#x201d;) with Pfizer for the development and commercialization of our long-acting Somatrogon (hGH-CTP) for the treatment of growth hormone &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;deficiency (&#x201c;GHD&#x201d;) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (the &#x201c;Pfizer Transaction&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In early 2022, the European Commission and Ministry of Health, Labour and Welfare in Japan approved the next-generation long-acting recombinant human growth hormone NGENLA (Somatrogon), a once-weekly injection to treat pediatric growth hormone deficiency, and we received pricing approvals in Germany and Japan. With the achievement of these milestones, we are entitled to receive an aggregate of $85.0&#160;million in milestone payments. Further, Canada and Australia approved NGENLA in October and November of 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the FDA issued a Complete Response Letter for the BLA for Somatrogon (hGH-CTP). Pfizer and OPKO are evaluating the FDA&#x2019;s comments and will work with the agency to determine the best path forward for Somatrogon (hGH-CTP) in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we entered into an Amended and Restated Development and Commercialization License Agreement (the &#x201c;Restated Pfizer Agreement&#x201d;) with Pfizer, effective January 1, 2020, pursuant to which the parties agreed, among other things, to share all costs for Manufacturing Activities, as defined in the Restated Pfizer Agreement, for developing a licensed product for the three indications included in the Restated Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 21, 2019, we and Pfizer announced that the global phase 3 trial evaluating Somatrogon dosed once-weekly in prepubertal children with GHD met its primary endpoint of non-inferiority to daily Genotropin&#xae; (somatropin) for injection, as measured by annual height velocity at 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Pfizer Transaction, as restated, we received non-refundable and non-creditable upfront payments of $295.0 million and are eligible to receive up to an additional $275.0 million upon the achievement of certain regulatory milestones.  Pfizer received the exclusive license to commercialize Somatrogon worldwide.  In addition, we are eligible to receive initial tiered royalty payments associated with the commercialization of Somatrogon for adult GHD with percentage rates ranging from the high teens to mid-twenties.  Upon the launch of Somatrogon for pediatric GHD in certain major markets, the royalties will transition to regional, tiered gross profit sharing for both Somatrogon and Pfizer&#x2019;s Genotropin&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement with Pfizer will remain in effect until the last sale of the licensed product, unless earlier terminated as permitted under the Pfizer Agreement.  In addition to termination rights for material breach and bankruptcy, Pfizer is permitted to terminate the Pfizer Agreement in its entirety, or with respect to one or more world regions, without cause after a specified notice period.  If the Pfizer Agreement is terminated by us for Pfizer&#x2019;s uncured material breach, or by Pfizer without cause, provision has been made for transition of product and product responsibilities to us for the terminated regions, as well as continued supply of product by Pfizer or transfer of supply to us in order to support the terminated regions.       &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized the non-refundable $295.0 million upfront payments as revenue as the research and development services were completed and as of both March 31, 2022 and December 31, 2021, we had no contract liabilities related to the Pfizer Transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pfizer Transaction includes milestone payments of $275.0 million upon the achievement of certain milestones.  The milestones range from $20.0 million to $90.0 million each and are based on achievement of regulatory approval in the U.S. and regulatory approval and price approval in other major markets.  The milestone payments will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met.  To date, no revenue has been recognized related to the achievement of the milestones. See Note 17, Subsequent Events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have completed strategic deals with numerous institutions and commercial partners.  In connection with these agreements, upon the achievement of certain milestones we are obligated to make certain payments and have royalty obligations upon sales of products developed under the license agreements.  At this time, we are unable to estimate the timing and amounts of payments as the obligations are based on future development of the licensed products.&lt;/span&gt;&lt;/div&gt;</opk:StrategicAlliancesTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i36d25b2cfa03459783a6e94281295ca5_I20210914"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfNzI1_44df1b75-d4fd-4b81-8b4d-233278e09693"
      unitRef="number">0.47</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8156096c5d249378540b9fe04c480dc_D20210914-20210914"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfODE2_f457bdb7-2acd-4445-be26-9c9ef9a4c8ce"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31eed14eff354f918546bd944177b06f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMzg0ODI5MDcxOTUxMA_5afd41e0-50f7-4298-8d88-af47982123ce"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="id1b622c3fa27402b9211c7b4ccf25f7f_D20210914-20210914"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTI1OQ_c7454668-fdcd-46b6-855f-e811b216c84d"
      unitRef="usd">11000000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i36d25b2cfa03459783a6e94281295ca5_I20210914"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTI4MA_e172eb63-46d7-4f56-ac33-ceb1dab69a42"
      unitRef="number">0.53</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6c87132b4964cd485ec8ec605a41b8b_D20210706-20210706"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjIwMg_3184a4fa-b59a-482d-9a5b-293b149ec414"
      unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <opk:CollaborativeArrangementUpfrontPaymentShares
      contextRef="ib5d22ca705ba48a9b83984b98bb175db_D20210706-20210706"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjIwOQ_ba7ee28a-1e32-4941-b793-de1ba01b4db3"
      unitRef="shares">3373008</opk:CollaborativeArrangementUpfrontPaymentShares>
    <opk:CollaborativeArrangementPercentOfOutstandingShares
      contextRef="ib5d22ca705ba48a9b83984b98bb175db_D20210706-20210706"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjMxMw_35530510-ebe7-4201-9ac9-e8a572db3d59"
      unitRef="number">0.09</opk:CollaborativeArrangementPercentOfOutstandingShares>
    <opk:CollaborativeArrangementDevelopmentMilestonePayment
      contextRef="if0c873c67ff541cd805db5011768482b_D20210706-20210706"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjM4OQ_8932a9d9-469f-4051-ac8b-eb92030da73a"
      unitRef="usd">3500000</opk:CollaborativeArrangementDevelopmentMilestonePayment>
    <opk:CollaborativeArrangementDevelopmentMilestonePayment
      contextRef="i2421576a6eb245f5963c8fd546b2202d_D20210706-20210706"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjQ2MA_f13f2126-54b0-4508-81fa-81db36ae45be"
      unitRef="usd">4000000</opk:CollaborativeArrangementDevelopmentMilestonePayment>
    <opk:CollaborativeArrangementSalesMilestonePayment
      contextRef="if0c873c67ff541cd805db5011768482b_D20210706-20210706"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjUzNA_2f4e5039-51d5-4951-8415-64620e25e270"
      unitRef="usd">90000000</opk:CollaborativeArrangementSalesMilestonePayment>
    <opk:CollaborativeArrangementSalesMilestonePayment
      contextRef="i2421576a6eb245f5963c8fd546b2202d_D20210706-20210706"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjU3Ng_6ac62d69-6cd9-4878-8636-f67ea74c162d"
      unitRef="usd">90000000</opk:CollaborativeArrangementSalesMilestonePayment>
    <opk:CollaborativeArrangementDevelopmentMilestonePaymentShares
      contextRef="if0c873c67ff541cd805db5011768482b_D20210706-20210706"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjg1OA_784b374e-2608-4097-ba18-f85aa052f1ab"
      unitRef="shares">5782299</opk:CollaborativeArrangementDevelopmentMilestonePaymentShares>
    <opk:CollaborativeArrangementDevelopmentMilestonePaymentShares
      contextRef="i2421576a6eb245f5963c8fd546b2202d_D20210706-20210706"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjk0MQ_2ed94d01-a37b-4e7b-a524-8b0c62007cd7"
      unitRef="shares">1082248</opk:CollaborativeArrangementDevelopmentMilestonePaymentShares>
    <opk:CollaborativeArrangementPeriodFollowingFirstCommercialSale
      contextRef="ib5d22ca705ba48a9b83984b98bb175db_D20210706-20210706"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfNDA2OQ_a7b94a01-ec23-4c6d-88a1-7196b67c0095">P10Y</opk:CollaborativeArrangementPeriodFollowingFirstCommercialSale>
    <opk:ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment
      contextRef="i10db571f9a22486186e3b342bd39d781_D20210618-20210618"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfNTEyOQ_6ce9118f-0093-49bb-8f7c-4030ca0b9623"
      unitRef="usd">5000000</opk:ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment>
    <opk:ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment
      contextRef="ic69f79db9b644be990ff9dd9110a1bc1_D20210618-20210618"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfNTE3Mw_05f9cbde-8e17-4274-b265-01c2ee50e425"
      unitRef="usd">5000000</opk:ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment>
    <opk:ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment
      contextRef="i5c7fb2b0fdc148b3a2a1cbb14048e04b_D20210618-20210618"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfNTM2MQ_9f1978d1-54d1-457f-82c4-d204d77d6232"
      unitRef="usd">115000000</opk:ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment>
    <opk:CollaborativeArrangementPeriodAfterFirstCommercialSale
      contextRef="i10db571f9a22486186e3b342bd39d781_D20210618-20210618"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfNjU0NQ_5396c9cd-73a3-446a-a930-c7b290c2e373">P10Y</opk:CollaborativeArrangementPeriodAfterFirstCommercialSale>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fd88e0b9dc2432ca9c87a42295d0f14_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMjc0ODc3OTA5MTc1OQ_413e644f-d764-4ecd-8d29-f3229caa5e1a"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9744194c20ba46758d55f0a601deef68_D20200505-20200505"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfODIzNg_2d38acdb-b81c-4700-b6b5-c03b28d4e308"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <opk:CollaborativeArrangementMaximumMilestonePayments
      contextRef="i9cd5fcc524ba4f4da070564f37ec0b94_D20200505-20200505"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfODM1OA_ec90d9e3-f66d-41b4-8f7d-847722ae41c4"
      unitRef="usd">17000000</opk:CollaborativeArrangementMaximumMilestonePayments>
    <opk:CollaborativeArrangementMaximumMilestonePayments
      contextRef="i9b365c1cad364899b9b410fc05c6ee03_D20200505-20200505"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfODM5MA_4f6668c3-306a-4a81-a2e1-53ef358b3652"
      unitRef="usd">207000000</opk:CollaborativeArrangementMaximumMilestonePayments>
    <opk:CollaborativeArrangementMaximumMilestonePayments
      contextRef="i004085a346bb457f8e5d14f98a53a911_D20160501-20160531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTAxNjk_6b68d41c-3b17-49f8-b3a7-b1fb9cc79725"
      unitRef="usd">555000000</opk:CollaborativeArrangementMaximumMilestonePayments>
    <opk:CollaborativeArrangementMilestonePayment
      contextRef="i439818f5135849e981ffb5c0b3e4a5fa_D20220401-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMzg0ODI5MDcxOTk1OQ_fbdc6934-c8d8-41e8-a3cd-c31bfbf692b7"
      unitRef="usd">85000000</opk:CollaborativeArrangementMilestonePayment>
    <opk:CollaborativeArrangementAnnualHeightVelocityatPointinTime
      contextRef="if1ab3dcfa70a42a4af7efe061a160e4c_D20191021-20191021"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTI4Mzk_9ea04781-b646-42c6-adfe-0c9ee43fedf7">P12M</opk:CollaborativeArrangementAnnualHeightVelocityatPointinTime>
    <opk:CollaborativeArrangementUpfrontPayment
      contextRef="ifdde5003bfd44ea6b9fbccdf4b85628d_D20150101-20150131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTI5NjU_74d554a2-008f-4a1a-9178-c13a33fdb597"
      unitRef="usd">295000000</opk:CollaborativeArrangementUpfrontPayment>
    <opk:CollaborativeAgreementAdditionalMilestonePayment
      contextRef="ifdde5003bfd44ea6b9fbccdf4b85628d_D20150101-20150131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTMwMTY_1a0fd251-79e8-431b-a9c0-7db99e69b2e1"
      unitRef="usd">275000000</opk:CollaborativeAgreementAdditionalMilestonePayment>
    <opk:CollaborativeArrangementUpfrontPayment
      contextRef="ifdde5003bfd44ea6b9fbccdf4b85628d_D20150101-20150131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTQzMzA_fbae3ed5-5130-4bc8-9c7d-fada7af11fba"
      unitRef="usd">295000000</opk:CollaborativeArrangementUpfrontPayment>
    <opk:CollaborativeArrangementMaximumMilestonePayments
      contextRef="ifdde5003bfd44ea6b9fbccdf4b85628d_D20150101-20150131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTQ1OTQ_33bf2b15-991b-47ef-8e1e-814492d27de3"
      unitRef="usd">275000000</opk:CollaborativeArrangementMaximumMilestonePayments>
    <opk:CollaborativeArrangementMilestonePayment
      contextRef="i4213e7e67f624f758de6da611795d601_D20150101-20150131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTQ2Njg_ac2c4ecd-5e36-4452-a7a7-f8b178fb9a15"
      unitRef="usd">20000000</opk:CollaborativeArrangementMilestonePayment>
    <opk:CollaborativeArrangementMilestonePayment
      contextRef="i89b406679fa14d95928f83c7db184e47_D20150101-20150131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTQ2NzQ_2fef1d5f-8758-47e7-975d-a676b3960217"
      unitRef="usd">90000000</opk:CollaborativeArrangementMilestonePayment>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="iec21a25c43404529ae8e1b869bd25df4_D20150101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184Mi9mcmFnOmQ1MzUwMTA0YmFhMzQ5OGJiMmUwNzEyNWNlNDVlYzE4L3RleHRyZWdpb246ZDUzNTAxMDRiYWEzNDk4YmIyZTA3MTI1Y2U0NWVjMThfMTQ5OTU_0bcef0b4-d99e-4762-a961-8f2275843243"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RleHRyZWdpb246MjIxMmMxNDE1NWIxNDVmODg2N2IyYTIyZTFlMmJmOTVfMTAwNw_d14e300b-3692-4ccc-b431-bb7242de8945">SEGMENTS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage our operations in two reportable segments, pharmaceutical and diagnostics.  The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rayaldee&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product sales and our pharmaceutical research and development.  The diagnostics segment primarily consists of our clinical and genomics laboratory operations through BioReference and our point-of-care operations.  There are no significant inter-segment sales.  We evaluate the performance of each segment based on operating profit or loss.  There is no inter-segment allocation of interest expense and income taxes.&lt;/span&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from transfer of intellectual property and other: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from investment in investees:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chile&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,238,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,306,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,399,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;No customer represented more than 10% of our total consolidated revenue during the three months ended March 31, 2022 and 2021. As of March&#160;31, 2022 and December&#160;31, 2021, no customer represented more than 10% of our accounts receivable balance.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RleHRyZWdpb246MjIxMmMxNDE1NWIxNDVmODg2N2IyYTIyZTFlMmJmOTVfNTA_b8c0ec37-a056-46ad-a7df-0d9179b206f1"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:Revenues
      contextRef="i248c2f7f347a4e28bf2c05816ec8ead1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RleHRyZWdpb246MjIxMmMxNDE1NWIxNDVmODg2N2IyYTIyZTFlMmJmOTVfNDU0_1cffbf11-952d-42df-90d8-6d7fcb680f5b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:InterestExpense
      contextRef="i248c2f7f347a4e28bf2c05816ec8ead1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RleHRyZWdpb246MjIxMmMxNDE1NWIxNDVmODg2N2IyYTIyZTFlMmJmOTVfNTgw_b0c7bbf7-6487-41f7-b550-49d19d64165a"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RleHRyZWdpb246MjIxMmMxNDE1NWIxNDVmODg2N2IyYTIyZTFlMmJmOTVfMTAwMw_09fc6f1b-f572-4132-93a4-dacabe04da96">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from transfer of intellectual property and other: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from investment in investees:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chile&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,238,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,306,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,399,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e591c4c9d6a40d7ba41cbe1d1512d6b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMy01LTEtMS0zNTMzMA_ed692c6a-8a1a-45e9-9368-8341b234c744"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icdbda16c863b431ba3f7cf99e015a97d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMy03LTEtMS0zNTMzMA_60b8a07b-20d5-4461-a124-d9e5edfee015"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib33dc7d9f44c424a9584b48898909842_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNC01LTEtMS0zNTMzMA_3475d882-e0f9-4d9d-96f1-b8a106042a73"
      unitRef="usd">286599000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3c4e79123684c96996efacf35e4cf15_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNC03LTEtMS0zNTMzMA_fe6f1fc0-a2bb-4b72-adb3-8eb969e961a7"
      unitRef="usd">506951000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ec2e176eb00448f977e91fc55c4ac65_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNS01LTEtMS0zNTMzMA_ed866a9e-4600-4c24-af3f-ae8cfd0606a7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44f799de78174d999399f2edd81a8ded_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNS03LTEtMS0zNTMzMA_f3f8a40b-c825-44c3-8a57-5b3fc7316ac9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f9c95a502354f4c9bd791e55a1b1acc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNi01LTEtMS0zNTMzMA_520a2f3c-07da-495d-8763-e5e191fb1cb4"
      unitRef="usd">286599000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fd3f89e217e4e329bca14b9905edffa_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNi03LTEtMS0zNTMzMA_684d4548-3c6a-46b9-8b5f-45c190da4cde"
      unitRef="usd">506951000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12f23d1e4f7149df81a204a4274bb85f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfOC01LTEtMS0zNTMzMA_32af78a6-8250-4700-82d0-3fb4d547502d"
      unitRef="usd">36658000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39c1bc4e90f445ff86ac8569a2ddbc9d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfOC03LTEtMS0zNTMzMA_c0c63d6e-e3a9-49e2-bac9-38e622e8f6ec"
      unitRef="usd">33945000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i209dc12bb8ce4a749fed4f87ebc36e68_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfOS01LTEtMS0zNTMzMA_b8f84a84-ea78-490f-9276-4a54f0c5d87b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a55931e091d4a3c887296abefde8504_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfOS03LTEtMS0zNTMzMA_4389d89e-ae9c-40ac-9c28-655b74656569"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i082e04104d194b92a685d699a64a0014_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTAtNS0xLTEtMzUzMzA_cb74201e-81e4-4c8d-ae53-5943b7276d8b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idffcd8ebe9be487185a9b4b68675f7fe_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTAtNy0xLTEtMzUzMzA_2a617666-6898-4954-b70d-efa33e86b233"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85501a743668421b8f9b4903a091161f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTEtNS0xLTEtMzUzMzA_14d0fb3d-cc1c-48d4-a31c-16ebcc43814e"
      unitRef="usd">36658000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a1bb9d88fbc42c0b66fe51d04025dd1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTEtNy0xLTEtMzUzMzA_2a65e467-8303-464c-b5e3-a3ac6b707e93"
      unitRef="usd">33945000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id657dc78714d4c38b4795e9de8978786_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTMtNS0xLTEtMzUzMzA_f0f509ba-f944-4fe3-a89b-846300785f78"
      unitRef="usd">5962000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8558bb5f637404994c8de52c35676cd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTMtNy0xLTEtMzUzMzA_bee4abd4-e3f0-40a1-9602-d4069b7a8567"
      unitRef="usd">4269000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i393ae4fb48ac46c791cf4386477ae160_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTQtNS0xLTEtMzUzMzA_7d8426a2-b304-4070-9381-7a4a987a18fb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7b01ac51664446b81224ec66b765954_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTQtNy0xLTEtMzUzMzA_515fdf74-f062-47fe-ba42-7761cd7fa003"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70da593d5a914041bc7e0c120158a9af_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTUtNS0xLTEtMzUzMzA_da75a62d-a233-45d7-b90c-0a451fd8a9c0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d5fcb23d84e40e0bd666630c86cc3ae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTUtNy0xLTEtMzUzMzA_ec5a13b6-0a38-46ba-88a5-9e0efb88aabf"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e961cfc73ca4fc995f9df88000a19c4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTYtNS0xLTEtMzUzMzA_c8b680d9-057e-406a-a813-9e283e77180e"
      unitRef="usd">5962000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66109927d116428aafb21943a884db23_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTYtNy0xLTEtMzUzMzA_87bb4f58-bb86-4d3a-94fa-6369b2e09b39"
      unitRef="usd">4269000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i53640b46e2fd4c808aaed4db666adb92_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTgtNS0xLTEtMzUzMzA_b66a521c-01f2-4764-96e7-3ecb826aa637"
      unitRef="usd">-18108000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9e92aea3d2094ffebb2b18c6d66c89c7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTgtNy0xLTEtMzUzMzA_b42ae554-ecd8-4029-8e83-5cee8a0c7b00"
      unitRef="usd">-19157000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i003285ed88bd4bfea42439162c0e7038_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTktNS0xLTEtMzUzMzA_cf6d4aca-9379-4cf7-b4d5-49fc4850ba02"
      unitRef="usd">-43548000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifda4aeb385b4420c98ee831dcb7e2e3e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMTktNy0xLTEtMzUzMzA_34c0927f-71f8-4694-9659-80e7783cbb98"
      unitRef="usd">67014000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibfbd64ac384549c288a217c1e278ff5a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjAtNS0xLTEtMzUzMzA_d0a7b2a4-a670-4b5a-8495-6870bf008ca0"
      unitRef="usd">-10768000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idb337610dc2a44669c089130ab28f864_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjAtNy0xLTEtMzUzMzA_d56d7f74-ec05-4638-a056-2c37d0debff9"
      unitRef="usd">-9420000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjItNS0xLTEtMzUzMzA_f341982b-cd5c-4a24-957b-a005930301ac"
      unitRef="usd">-72424000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjItNy0xLTEtMzUzMzA_256dacc6-b205-4443-a7d9-b6fefb62f0e1"
      unitRef="usd">38437000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i53640b46e2fd4c808aaed4db666adb92_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjQtNS0xLTEtMzUzMzA_18c7cd3e-54c4-4a82-87ae-f118d912a438"
      unitRef="usd">15402000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9e92aea3d2094ffebb2b18c6d66c89c7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjQtNy0xLTEtMzUzMzA_f1daca15-7151-4b12-882e-19e8cb2d8527"
      unitRef="usd">7413000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i003285ed88bd4bfea42439162c0e7038_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjUtNS0xLTEtMzUzMzA_5f2191e3-71ea-4b00-9f73-2b0a1eb628dc"
      unitRef="usd">12412000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifda4aeb385b4420c98ee831dcb7e2e3e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjUtNy0xLTEtMzUzMzA_df9dac17-b8f8-40e2-ac88-d78cf626043d"
      unitRef="usd">12576000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibfbd64ac384549c288a217c1e278ff5a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjYtNS0xLTEtMzUzMzA_7bc43917-db32-419b-acfc-201e6e8eab76"
      unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idb337610dc2a44669c089130ab28f864_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjYtNy0xLTEtMzUzMzA_74c96fd4-3d49-4ed3-833a-3f5ae1e3ae70"
      unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjctNS0xLTEtMzUzMzA_69182511-f856-4298-8364-0c2167f94af6"
      unitRef="usd">27814000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjctNy0xLTEtMzUzMzA_bf71f211-f888-43db-9554-e1d821dca823"
      unitRef="usd">19989000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnInvestments
      contextRef="i53640b46e2fd4c808aaed4db666adb92_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjktNS0xLTEtMzUzMzA_365dfe16-b631-4ab3-a7b9-b6661ff6a29b"
      unitRef="usd">-49000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i9e92aea3d2094ffebb2b18c6d66c89c7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMjktNy0xLTEtMzUzMzA_0475e2c2-4181-43e7-b31d-25e3eef010a0"
      unitRef="usd">-43000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i003285ed88bd4bfea42439162c0e7038_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzAtNS0xLTEtMzUzMzA_77b467ac-8bd0-49f0-9470-5bf4b1acf90b"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ifda4aeb385b4420c98ee831dcb7e2e3e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzAtNy0xLTEtMzUzMzA_ae1964dd-5ce6-408a-b1cf-6a01599cfd5b"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ibfbd64ac384549c288a217c1e278ff5a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzEtNS0xLTEtMzUzMzA_b6e028db-8fc6-4cc3-b791-36f695ccf99f"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="idb337610dc2a44669c089130ab28f864_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzEtNy0xLTEtMzUzMzA_6e62b960-346b-4cfd-a430-bd0d70e6e7ad"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzItNS0xLTEtMzUzMzA_5370e331-4b01-495f-9748-fd26b0afaf19"
      unitRef="usd">-49000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzItNy0xLTEtMzUzMzA_a91c9152-db55-46b5-b7d1-da45e416d3c9"
      unitRef="usd">-43000</us-gaap:GainLossOnInvestments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd847808c4214f4fa04fde3ad6d1af41_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzQtNS0xLTEtMzUzMzA_82605179-06c7-4d2a-b1c6-e6c85888cf36"
      unitRef="usd">291808000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i343e534f8fb94404bbef65e665f2bd82_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzQtNy0xLTEtMzUzMzA_0bb08d54-6f85-4056-993b-7faf0c7fb388"
      unitRef="usd">512871000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia423aa5eee2b482c9db466bda75c3161_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzUtNS0xLTEtMzUzMzA_1641f832-318d-43b7-89d8-6f35a8e495d1"
      unitRef="usd">8462000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51de4ac755574afeb66162a7f5862660_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzUtNy0xLTEtMzUzMzA_2a797d38-dd07-4a29-8997-a48b0b15a85b"
      unitRef="usd">7129000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d7aa53c3c054c22ac7e21fed6039914_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzYtNS0xLTEtMzUzMzA_ebb46416-2fa8-490d-8af7-891086fd77c4"
      unitRef="usd">16339000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2814670edf7c4a62a9c261600d7c6daa_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzYtNy0xLTEtMzUzMzA_c870efbe-1bf6-4427-9f33-259585550a4d"
      unitRef="usd">14152000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia46e96d43b2549a8a62460a4e0218f58_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzctNS0xLTEtMzUzMzA_3927685d-7ea2-4608-9acb-942be7649b5e"
      unitRef="usd">7109000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieac6faccf2c2445a906e11ebfd78a899_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzctNy0xLTEtMzUzMzA_3faeb0e2-d7f1-49cb-a66c-70feafb01a48"
      unitRef="usd">5919000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i644924ad6fec4277940108274a5fb5cf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzgtNS0xLTEtMzUzMzA_c58982ca-11a3-4171-8eec-792d8487fe7f"
      unitRef="usd">1558000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaae85104e75449f082ec0bb4c1170ebc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzgtNy0xLTEtMzUzMzA_3938df38-8462-4490-98d9-447a34962c58"
      unitRef="usd">2512000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id089ec5023d147288f24951b1c9d421c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzktNS0xLTEtMzUzMzA_66b4a184-17fa-4d90-b1d8-449a9b097565"
      unitRef="usd">3750000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i379322a119a345fc8841df842ee7ad3e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfMzktNy0xLTEtMzUzMzA_61be33d3-5836-49b6-ae14-715603dd6e0b"
      unitRef="usd">2418000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie15b0e5103c443a0a508317a579c958d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNDAtNS0xLTEtMzUzMzA_420816c0-460b-4ee3-a1e9-94a00d4c6dd7"
      unitRef="usd">193000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3beab81522d0420c95c34143d9e9a514_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNDAtNy0xLTEtMzUzMzA_72c0d91e-f9e2-41db-b57e-74cc16d2307f"
      unitRef="usd">164000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNDEtNS0xLTEtMzUzMzA_641e8307-3f95-48b4-88fe-7594d1f4191e"
      unitRef="usd">329219000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOjY0NDYzOWI5ZDM5ODRmNWY5OGFhMGZmNjliMzViYzFjL3RhYmxlcmFuZ2U6NjQ0NjM5YjlkMzk4NGY1Zjk4YWEwZmY2OWIzNWJjMWNfNDEtNy0xLTEtMzUzMzA_d53cb4c5-038d-470b-b381-2193bf302f0f"
      unitRef="usd">545165000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Assets
      contextRef="ib27f714c1aa84e6a935be26300cfaa00_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfMi0xLTEtMS0zNTMzMA_5f4ebc48-d85c-4913-a827-f900384ddf4a"
      unitRef="usd">1099633000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8886b20cd82e4c7e8073ac81cd611ee9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfMi0zLTEtMS0zNTMzMA_649e4d6c-5ce8-4ea4-98a1-b30e9ff50fbe"
      unitRef="usd">1114460000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i437311d9507444baa08d2ca5476a8beb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfMy0xLTEtMS0zNTMzMA_44ffcbb5-7000-4bb4-834d-95a350fde4a6"
      unitRef="usd">1152173000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i87097699235d4d2fb348f69eb54508e6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfMy0zLTEtMS0zNTMzMA_7a6ad3c8-5a66-4e7b-962b-862e44624ece"
      unitRef="usd">1238583000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i05c6a762af174fe8b29069a742a32bb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfNC0xLTEtMS0zNTMzMA_b7b238d1-673c-423e-8b0a-6d4b342072b4"
      unitRef="usd">55052000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib66ac7571d2d48f48825d3fd8073639a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfNC0zLTEtMS0zNTMzMA_12e19004-2301-425e-abba-c906b1d25b85"
      unitRef="usd">46672000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfNS0xLTEtMS0zNTMzMA_36a76ba6-737a-44d7-a1d1-5c51a5c39e4c"
      unitRef="usd">2306858000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfNS0zLTEtMS0zNTMzMA_8e16f202-0624-4398-946c-e061a9c8d002"
      unitRef="usd">2399715000</us-gaap:Assets>
    <us-gaap:Goodwill
      contextRef="ib27f714c1aa84e6a935be26300cfaa00_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfNy0xLTEtMS0zNTMzMA_955dcd08-11ea-4abf-ae25-4274cd94a085"
      unitRef="usd">236028000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8886b20cd82e4c7e8073ac81cd611ee9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfNy0zLTEtMS0zNTMzMA_1712e324-2dd6-462c-b984-ba895802a6b8"
      unitRef="usd">237576000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i437311d9507444baa08d2ca5476a8beb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfOC0xLTEtMS0zNTMzMA_65878d9d-a0c6-478b-9edc-3ded7547928a"
      unitRef="usd">283024000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i87097699235d4d2fb348f69eb54508e6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfOC0zLTEtMS0zNTMzMA_86a2d57f-fb00-4d92-8c0a-ac566b5bfb87"
      unitRef="usd">283025000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfMTAtMS0xLTEtMzUzMzA_e01762de-2398-4f2b-8091-c53d1be2dc55"
      unitRef="usd">519052000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184NS9mcmFnOjIyMTJjMTQxNTViMTQ1Zjg4NjdiMmEyMmUxZTJiZjk1L3RhYmxlOmI0NWJhNzMwMTlmOTQ3YzlhMGMwMzFjMWViNTljNTZiL3RhYmxlcmFuZ2U6YjQ1YmE3MzAxOWY5NDdjOWEwYzAzMWMxZWI1OWM1NmJfMTAtMy0xLTEtMzUzMzA_ea5d0c35-f03a-446a-8436-8a2b20ffea99"
      unitRef="usd">520601000</us-gaap:Goodwill>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjUxMQ_fa5099e7-f49a-41f1-8945-ee31054051c6">LEASES&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have operating leases for office space, laboratory operations, research and development facilities, manufacturing locations, warehouses and certain equipment.  We determine if a contract contains a lease at inception or modification of a contract.  Our leases generally do not provide an implicit interest rate, and we therefore use our incremental borrowing rate as the discount rate when measuring operating lease liabilities.  The incremental borrowing rate represents an estimate of the interest rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment.  We used the incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date.  Many of our leases contain rental escalation, renewal options and/or termination options that are factored into our determination of lease payments as appropriate.  Variable lease payment amounts that cannot be determined at the commencement of the lease are not included in the right-to-use assets or liabilities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We elected the use of permitted practical expedients of not recording leases on our Consolidated Balance Sheet when the leases have terms of 12 months or less, and we elected not to separate nonlease components from lease components and instead account for each separate lease component and the nonlease components associated with that lease component as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of March 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMy0wLTEtMS0zNTMzMA_c6bd7dfc-1515-470c-8640-321ba294369d"&gt;Finance lease assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current maturities of operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current maturities of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 1, 2022 through December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total undiscounted future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Difference between lease payments and discounted lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense under operating leases and finance leases was $4.6 million and $0.7&#160;million, respectively, for the three months ended March 31, 2022, which includes $0.4 million of variable lease costs. Expense under operating leases and finance leases was $4.5 million and $0.6 million, respectively, for the three months ended March 31, 2021, which includes $0.7 million of variable lease costs. Operating lease costs and finance lease costs are included within Operating loss in the Condensed Consolidated Statement of Operations. Short-term lease costs were not material.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjUwNA_07bc7366-7ff9-4006-9286-601f4c6e1b18">LEASES&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have operating leases for office space, laboratory operations, research and development facilities, manufacturing locations, warehouses and certain equipment.  We determine if a contract contains a lease at inception or modification of a contract.  Our leases generally do not provide an implicit interest rate, and we therefore use our incremental borrowing rate as the discount rate when measuring operating lease liabilities.  The incremental borrowing rate represents an estimate of the interest rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment.  We used the incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date.  Many of our leases contain rental escalation, renewal options and/or termination options that are factored into our determination of lease payments as appropriate.  Variable lease payment amounts that cannot be determined at the commencement of the lease are not included in the right-to-use assets or liabilities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We elected the use of permitted practical expedients of not recording leases on our Consolidated Balance Sheet when the leases have terms of 12 months or less, and we elected not to separate nonlease components from lease components and instead account for each separate lease component and the nonlease components associated with that lease component as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of March 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMy0wLTEtMS0zNTMzMA_c6bd7dfc-1515-470c-8640-321ba294369d"&gt;Finance lease assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current maturities of operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current maturities of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 1, 2022 through December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total undiscounted future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Difference between lease payments and discounted lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense under operating leases and finance leases was $4.6 million and $0.7&#160;million, respectively, for the three months ended March 31, 2022, which includes $0.4 million of variable lease costs. Expense under operating leases and finance leases was $4.5 million and $0.6 million, respectively, for the three months ended March 31, 2021, which includes $0.7 million of variable lease costs. Operating lease costs and finance lease costs are included within Operating loss in the Condensed Consolidated Statement of Operations. Short-term lease costs were not material.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <opk:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjUyMA_e1c7c6bc-4a6e-40e0-bdd8-166eb702305d">The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of March 31, 2022 and December 31, 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMy0wLTEtMS0zNTMzMA_c6bd7dfc-1515-470c-8640-321ba294369d"&gt;Finance lease assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current maturities of operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current maturities of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</opk:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMi00LTEtMS0zNTMzMA_4d1eab8b-14e0-4a19-882e-fecd055fc60f"
      unitRef="usd">42768000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMi02LTEtMS0zNTMzMA_1a4a7eda-b48f-4a8a-84ed-17489a8b9b27"
      unitRef="usd">44228000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMy00LTEtMS0zNTMzMA_de441688-0b1b-4db2-9d86-ff106db9a5f7"
      unitRef="usd">6316000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMy02LTEtMS0zNTMzMA_f530ceed-f097-42a2-a7d5-e3bc6e74fcdc"
      unitRef="usd">5181000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfNy00LTEtMS0zNTMzMA_62b55b82-b113-42a0-a9e0-c10beeb73136"
      unitRef="usd">11690000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfNy02LTEtMS0zNTMzMA_663522c2-98a4-4e30-95c2-553f15ad6964"
      unitRef="usd">11624000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfOC00LTEtMS0zNTMzMA_6bcae11c-c1df-4c3a-b0a0-1bef8aa8e872"
      unitRef="usd">2451000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfOC02LTEtMS0zNTMzMA_95a01b8c-0cd7-4b60-bc13-0eec9d77fcef"
      unitRef="usd">2257000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTAtNC0xLTEtMzUzMzA_e8071d1c-bf4c-413b-ab7c-1b918359cb5b"
      unitRef="usd">31596000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTAtNi0xLTEtMzUzMzA_65bcacfb-512a-413a-bddd-b738fbbeaccd"
      unitRef="usd">33097000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTEtNC0xLTEtMzUzMzA_0d569f0a-58dd-44b6-aaca-de3e7bc2ecd6"
      unitRef="usd">3865000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTEtNi0xLTEtMzUzMzA_9183e604-5eaa-4d83-8159-d389bb6f87da"
      unitRef="usd">2924000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTQtNC0xLTEtMzUzMzA_78c133e1-38dc-4a83-b0ce-192598a536c4">P7Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTQtNi0xLTEtMzUzMzA_c5e3e230-c7c7-4400-99e1-6e498795988e">P7Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTUtNC0xLTEtMzUzMzA_09a615b2-925a-43a9-aeda-24f66856ef6e">P2Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTUtNi0xLTEtMzUzMzA_02dd5feb-dd6c-4680-8a0d-e7dec3c41350">P2Y4M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTctNC0xLTEtMzUzMzA_be5d8d41-462b-4721-8e0e-e29d86c35317"
      unitRef="number">0.045</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTctNi0xLTEtMzUzMzA_e8347d28-3915-4e1f-8b77-f362bd6b217f"
      unitRef="number">0.046</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTgtNC0xLTEtMzUzMzA_9528c38a-b3e8-4801-8610-e2f7710f621e"
      unitRef="number">0.058</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i0e59dec8141549aa8b911e469e798a72_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjAyN2YyZjkyNTQ1ZjRmOWU5YmVjMzE0ODRjNzkyM2U5L3RhYmxlcmFuZ2U6MDI3ZjJmOTI1NDVmNGY5ZTliZWMzMTQ4NGM3OTIzZTlfMTgtNi0xLTEtMzUzMzA_cb2c5120-3a32-45c5-9833-1cd633b56d7c"
      unitRef="number">0.048</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjUwOQ_9e7ccce5-da5c-447b-81ad-fc90a2e49f50">&lt;div style="margin-top:4pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 1, 2022 through December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total undiscounted future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Difference between lease payments and discounted lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjUxNA_7574dabe-5949-433e-a1e0-95e28a23b342">&lt;div style="margin-top:4pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 1, 2022 through December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total undiscounted future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Difference between lease payments and discounted lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfMS0xLTEtMS0zNTMzMA_8d079914-104e-4fd5-842f-236c33a6aba2"
      unitRef="usd">10435000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfMS0zLTEtMS0zNTMzMA_b8a5a57a-47fb-4f25-b577-a51d9fb51189"
      unitRef="usd">1930000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfMi0xLTEtMS0zNTMzMA_68c2e126-e93d-41ac-be42-5d81c11e0eb8"
      unitRef="usd">10115000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfMi0zLTEtMS0zNTMzMA_c5601c84-2c90-4409-9ba1-878f3585935c"
      unitRef="usd">2050000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfMy0xLTEtMS0zNTMzMA_2345b3b5-d58b-4d15-b485-ef306a2e2390"
      unitRef="usd">8220000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfMy0zLTEtMS0zNTMzMA_4ee96ab4-d3ef-4104-90cd-fc0761c42a87"
      unitRef="usd">1454000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNC0xLTEtMS0zNTMzMA_cb5e65e3-32d1-4561-b477-7e0cfd553176"
      unitRef="usd">5847000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNC0zLTEtMS0zNTMzMA_aead1ef5-78ee-42af-99c0-1caed39865da"
      unitRef="usd">919000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNS0xLTEtMS0zNTMzMA_ddb689d9-7db0-4936-aae6-87d6a497a869"
      unitRef="usd">5397000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNS0zLTEtMS0zNTMzMA_8dd95279-5716-44fc-8259-c0b03f2b23bb"
      unitRef="usd">329000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <opk:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNi0xLTEtMS0zNTMzMA_9ca1274c-3f86-4c4e-8be9-1cf2a1166580"
      unitRef="usd">24621000</opk:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <opk:FinanceLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNi0zLTEtMS0zNTMzMA_b305813e-dcd1-44c2-84f1-f7ddc4e98b75"
      unitRef="usd">0</opk:FinanceLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNy0xLTEtMS0zNTMzMA_26a3ddb1-455c-4d4b-8b6c-f1ba9d1dbbe7"
      unitRef="usd">64635000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfNy0zLTEtMS0zNTMzMA_31c0c367-6732-435d-9871-bf6807d1a019"
      unitRef="usd">6682000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfOC0xLTEtMS0zNTMzMA_bc062ee1-6404-47ee-a923-0c8e6ffbe037"
      unitRef="usd">10429000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfOC0zLTEtMS0zNTMzMA_e69ae199-6b79-4ba9-92e3-e059edbe1543"
      unitRef="usd">366000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfOS0xLTEtMS0zNTMzMA_de71b7b5-c7f8-47a7-be63-679c67d8c867"
      unitRef="usd">54206000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i137b80025d3d4485b08482ba89272156_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOmNkMTYzNzg2ZWU2YjRmYWQ4OGQ5NjA4ODliZGExM2VmL3RhYmxlcmFuZ2U6Y2QxNjM3ODZlZTZiNGZhZDg4ZDk2MDg4OWJkYTEzZWZfOS0zLTEtMS0zNTMzMA_160d68aa-a531-4659-8dc2-ee6338904f34"
      unitRef="usd">6316000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjAzOQ_4b29291d-e22a-46fa-b21b-e8c323cb365d"
      unitRef="usd">4600000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfNjA0NzMxMzk1NTQwOA_88ebc037-2062-4cde-9045-4b6803f2b492"
      unitRef="usd">700000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:VariableLeaseCost
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjEwMQ_a7a7564b-359e-47bc-9735-6fa7ce0c94fd"
      unitRef="usd">400000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjE4Mw_95758ae2-8c94-4f6f-b52b-dfa7ed6d02c1"
      unitRef="usd">4500000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjE5MA_71c8526d-364b-46fb-b3f9-9382c89d0100"
      unitRef="usd">600000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:VariableLeaseCost
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjI0NQ_52fdb3b4-a92b-4dc3-814e-a62f9c95b10b"
      unitRef="usd">700000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RleHRyZWdpb246ZGJjZDkwYTIwM2UxNGI5Y2FjZDU2ZGM3OTY4NDUyNmFfMjUwNQ_bc485e38-eca7-4fde-8906-147ce7923def">Supplemental cash flow information is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfMi0xLTEtMS0zNTMzMA_ac8b6e8c-8429-49fa-a0d6-40cbe90a0012"
      unitRef="usd">4288000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfMi0zLTEtMS0zNTMzMA_517bd5ca-a562-4db7-b8dc-a55fef458779"
      unitRef="usd">4245000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfMy0xLTEtMS0zNTMzMA_efaf101a-fcb4-43ee-9123-6112d9ef2ae8"
      unitRef="usd">33000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfMy0zLTEtMS0zNTMzMA_2ffb05c6-2626-42ea-a6ae-480b5b2ca27b"
      unitRef="usd">33000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfNC0xLTEtMS0zNTMzMA_cb287b9f-d652-4a0a-9991-97e0b3ab45fc"
      unitRef="usd">498000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfNC0zLTEtMS0zNTMzMA_7ec5ccef-a799-4063-8a0a-9e684fbb30dc"
      unitRef="usd">525000</us-gaap:FinanceLeasePrincipalPayments>
    <opk:PaymentsForLeases
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfNS0xLTEtMS0zNTMzMA_19395ff1-22f2-40eb-83cc-9d775c6c39e2"
      unitRef="usd">4819000</opk:PaymentsForLeases>
    <opk:PaymentsForLeases
      contextRef="i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y184OC9mcmFnOmRiY2Q5MGEyMDNlMTRiOWNhY2Q1NmRjNzk2ODQ1MjZhL3RhYmxlOjliNmZmM2NkY2MxYzRhMWJiYjllYWI2NGRiMTE1MGRhL3RhYmxlcmFuZ2U6OWI2ZmYzY2RjYzFjNGExYmJiOWVhYjY0ZGIxMTUwZGFfNS0zLTEtMS0zNTMzMA_dffc7385-4351-42e6-bd33-1ee340a701d2"
      unitRef="usd">4803000</opk:PaymentsForLeases>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMzI0_5c6ae607-dc1c-4ec8-84f1-3a3f5ee3c31c">SUBSEQUENT EVENTS&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On January 18, 2022, Sema4 and OPKO announced they had entered into a definitive agreement pursuant to which Sema4 has agreed to acquire OPKO&#x2019;s wholly owned subsidiary, GeneDx, a leader in genomic testing and analysis. The GeneDx Transaction closed on April 29, 2022.  Under the terms of the GeneDx Merger Agreement, Sema4 acquired GeneDx for an upfront payment of $150&#160;million in cash, subject to adjustments, plus 80.0&#160;million shares in Sema4, with up to an additional $150&#160;million revenue-based milestones over the next two years (which will be payable in cash or Sema4 shares at Sema4&#x2019;s discretion). Based on the closing stock price of Sema4 as of April 29, 2022, the total upfront consideration represents approximately $322&#160;million, and the total aggregate consideration including potential milestones is approximately $472&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2022, Pfizer notified OPKO that NGENLA (Somatrogon), a once-weekly injection to treat pediatric growth hormone deficiency, has received pricing approval in Germany and Japan. NGENLA was granted marketing authorization by the Ministry of Health, Labour and Welfare in Japan and by the European Commission in January and February of this year, respectively. With the achievement of these milestones, we are entitled to receive an aggregate of $85.0&#160;million in milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 9, 2022, the Company entered into an Agreement and Plan of Merger with Orca Acquisition Sub, Inc. (&#x201c;Merger Sub &#x201c;, a subsidiary of the Company formed for the purposes of this transaction), ModeX Therapeutics, Inc., (&#x201c;ModeX&#x201d; or &#x201c;Seller&#x201d;) and Sellers&#x2019; representative (the &#x201c;Merger Agreement&#x201d;), pursuant to which Merger Sub was merged with and into ModeX, with ModeX becoming a wholly owned subsidiary of the Company (the &#x201c;Merger&#x201d;). The Company paid an aggregate of $300&#160;million for all of the outstanding equity of ModeX, as adjusted  by customary adjustments. The consideration paid at closing consisted of shares of our common stock, which was valued based on the average of the daily volume-weighted average price over the thirty (30) trading days prior to the date that is two (2) trading days prior to the signing of the Merger Agreement . In addition, the Company has made a number of management changes in connection with the Merger. Elias Zerhouni, M.D., Gary Nabel, M.D., PhD.,  and Alexis Borisy were appointed to the Board of the Company, with Dr. Zerhouni appointed as the Vice Chair. Elizabeth Nabel, one of the founders of ModeX, is the new Chief Medical Officer of the Company.  Dr. Gary Nabel has been named the CEO of ModeX and Chief Innovation Officer of the Company and Dr. Zerhouni has been named the President of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reviewed all events and transactions that occurred after the March&#160;31, 2022 Condensed Consolidated Balance Sheet date, through the time of filing this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMjc0ODc3OTA3Mzc4NQ_54e3eba9-4777-4160-b66e-33be7385a9e7"
      unitRef="usd">150000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMjc0ODc3OTA3MzgwMg_aa84fab9-4d52-49a1-b555-20778560379d"
      unitRef="shares">80000000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <opk:BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments
      contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMjc0ODc3OTA3Mzg0OA_a45535cc-438e-4f68-9855-0e4138633e9a"
      unitRef="usd">150000000</opk:BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments>
    <opk:BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod
      contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMjc0ODc3OTA3Mzg5MQ_f70b862f-a649-4d7e-8dab-2555bcc23882">P2Y</opk:BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod>
    <opk:BusinessCombinationUpfrontConsiderationTransferred
      contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMjc0ODc3OTA3NDA4NA_ce6e4ff5-74df-45a8-b95e-79039bfe660a"
      unitRef="usd">322000000</opk:BusinessCombinationUpfrontConsiderationTransferred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMjc0ODc3OTA3NDE3NQ_2e2033f9-36c4-4d02-beac-9b955eeb2dd0"
      unitRef="usd">472000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <opk:CollaborativeArrangementMilestonePayment
      contextRef="i439818f5135849e981ffb5c0b3e4a5fa_D20220401-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMzg0ODI5MDcwMDM2OQ_a8e96ea1-0e87-407a-88f3-6f8308f226c5"
      unitRef="usd">85000000</opk:CollaborativeArrangementMilestonePayment>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i5f3663059edd4d60a02442357262179d_D20220509-20220509"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMzg0ODI5MDcwNzQxMA_66f6bfbd-b597-42cd-9715-b317beb973bf"
      unitRef="usd">300000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <opk:BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement
      contextRef="i5f3663059edd4d60a02442357262179d_D20220509-20220509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMzg0ODI5MDcwNzQyNA_c39d0483-7be4-4578-bc30-97b719a54a8c">P30D</opk:BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement>
    <opk:BusinessCombinationPeriodPriorToSigningOfAgreement
      contextRef="i5f3663059edd4d60a02442357262179d_D20220509-20220509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYWM4MTZmZjgwMDQ5NGVhMjk3OWM0MzRmMDBiMzdjL3NlYzoxY2FjODE2ZmY4MDA0OTRlYTI5NzljNDM0ZjAwYjM3Y185NC9mcmFnOmIwMDNkMmNjNDljMzQxYjk4NThhYzMzMzc4OGFjYWFjL3RleHRyZWdpb246YjAwM2QyY2M0OWMzNDFiOTg1OGFjMzMzNzg4YWNhYWNfMzg0ODI5MDcyMjkyMQ_ed9bb748-887b-43d1-8e7b-4ec703398e10">P2D</opk:BusinessCombinationPeriodPriorToSigningOfAgreement>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M+^H/&/6-XJOJ&\ +5XH7U>62); ]UP;P?LZYVMWH#IK/2!?_ U!+ P04
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M3V9F ,VVZ3BRZ3A2N&&UN#%B]U&:1ND]S/783P-VC/*EG[$<O8;V*B^/D"_
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M*ZK<UA53M9E8DF/'<T 5!*:6*MZ*,+>?A:T0W=A65E9XV5^_+=O8P9(,<U_
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M$<,PLH</8'\3T.N'+ZQ@^MWD^G]02P,$%     @ *HFI5.>8 .R7(   &&<
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M<8)("PL&E6(82K9K'3!"7%C6Z=K)'[3\B2]61RIDKJOB6K8V"HG92B "8"
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M_,.JG]BT3F@BQ9B@'#CY<R([].#'1V@!@VHW*#\4J>+*6*,8TR_]+M*'E4K
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MU^%7$X_40WUYH4-[489:6:\F/5%+<FW-S7B9 <CJ5Y4:[JHG!-!]7S'AO?_
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MG'X6=*:I!E )'_B Z<$:0*Y6!Y$ID5D/2BK)?9=W?C$0DOS6D^"U,@_-^B(
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MK.*&W7)9$_MQ/!Q/>B2.?OKA9#H=OW@9IR_]]# T>?$$.,XZK@*KK#;^G^<
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M1 3$Y584>9^N5 D)X5(F"Y_,I%"C2MJE$$W[B%':&"FEQ(%:IY3\AT))9 I
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MEC*P A6>OI-<VR! ,YL7ES]_((J@,;C8M-7^=CU;=U"/JW$A(TD,>$L7?#W
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M!V/HP+@='CWPDRQZ8C2(Q+ _'!XY;^31&M%YHR-HB7?:Q&ENJD*)_[U9F+(
M$?B_(X>/_>%C.GQ\Z/#WM[]WT>SH+M2NG\Q6QNK-&:B/4<6#.J.CQ(T1^5(
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MFS)LN7)AH;Z;0GA4J<@'2 W[TWF->MR2!H3>CHR>BU?KIVI<3ZGSG"RG1WT
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M)!OTYL/NA>[]4H/^".B-[Y>RK^PZ=R_MNMF;_#Z0;:'X[^@]>52XX:1C[[D
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MJFHY%2YK:&0/)E3L$%N0;1TTW7-5:*-,IE5%>HTU;:(O])*C.SF7)V\KG:N
MER-5P8?I2C3I]VCC3,QMZQ'3;S[_#,^ZL0:HA!W/RKCE)YQQ/6?7O;R?S)Y
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M];FI@'V[/C\]N?ZDGLT=3;9P=9$F28](]P[G_I'MP;.,BOI'/7>>A@I;GC;
M7B&Y70KHRH4URE #H<'_+&TZ-YV!89'H1"YAACPUR\^&71>FF2(9%= 5W'_'
MH@]:GRS8>K4-)$'';0FACN'AH.*W,=Y!M]QP"$M480N&WI)NQ-R2<^2(,MH#
ME^[SF$/7;AVE=/S\\PVYC%Y#I? % +L-;A;CT?$TO1;Y4FM=NS3N2>F<S51:
MX_"@^<A9RY;*J+V3FEQH$[,=9@>EAR>4YAZ\V<EGYB%<PL?D<GQT29D1C.KN
M$<L_'G'R??T",KG47$)8 Q-*MS5CYG$D5?O1TJ%D$Q#(0^D.!/$R]2H$*B1I
MF4!1>Y+Z*TH40YIUX-R162R3D%::1S(7#S<VAME3:M%A$0)=9MZ/!LL3ZM,#
M-;P(L[4S';6'I9??-]2>J*O3:RR[N)FH.V2(Z]FH+KEG 1;*R42S'5-+#@D+
M$FSEF8 \FM(Y127M,&KVACF!#%/@T\1;9:0E.9@+3WY]DB.%R' ?"FVW/+(2
MTQ!6# 9-DY14=<D8D\$4$]$L'2Y:/)[-4UIF2^3SV:5I4YH@C5!H&!%-@=C<
M],OYC.+(BFAHIH8HJXSA;JV0)#Y@2[9Q#1Q;AF0-M^S$B)G52F1QP=T8= :)
M5Z/+"%9F:?PFB2K.1%7>MI;?4Y&BH^8)!RQH'C0A 8$T[$<\D]P(1I=<(Y#Q
M:'@V'9%7YHW4-(0D?&[^XG8M8W ;0I]'1?3"JHR]B*\#[V(*:>8/"K7:1&(&
M8W*1=04<KLG8AJ-PZ;GORR6?VO1"5AH0.6RHHFY)LU0<H4^ W'."0)^JI!KZ
M)"N9M].04.U^],Z$!)X/[J6W#Z#%55E*$^G,W"LFQOR^ =QY.S0<#W?=&0;!
M%*(]A>!"N".W6FQJ:(IBE$KV7H2@"6P5L^WAA<YUSUD"RR_86(J<IJ-22PTO
MS:HRIR2Y14*>'(609QK>V'9.\\7$MLB*E0PW#UGD/$V5?(&!5W8=Y-RA!.XC
M9U/UN^C DR;%0\SF3K0HR6@J-!XVR*@.4(%D#ZFDB,[C<L'#)!X"D?1$85R#
M-*(H&[762$O0:D<4X.NP@ 'KOUC 8V^>5$DRY@$W^2[896=!.9# X^(QIMI4
M^VDF8HA;5*FX5,,L++/-I;R\:H1W#D.^27F'2)-A>;,%P7LCG]-CZ;TO%SDP
M"4JB L^P-?BEDX$ )1IMN%F9[L_ NA0?X*X-AMW&#(_MO65\E+F S1M\UXA:
MW@4@CO>\ W@TV,=*&3LD>)8ZP!,UFG[E-PSL"GFPVOE5 RN))8FYC5\\,CF%
ML>;<@?&-\8ZE[B/.J.;4B0,)RE%$E '*5I$-6>ZX0P_H&X*)"MXX_<LRP?7&
M[.H^R"#(;.ZIG)3:,%3 ?*J(QC\6H/I*U[&]#<S1R%9YD*?K?_;2L;?R+F)!
MG!1\:.G&Y$1"88AF&EGVC316NB8B/OB%1E7(WQ%-(#YWIWF$4$;."'0W?E?4
M0<KQ1-J&U.<F7:CP,E7(4[WBIQ08C!:"7!/!S$EZ198$W@UL5<)C7)P)8Y9(
M'/G+DS3YM8@,;,>_<=CD&CF>[+)@,O?'-RFF#.+Y_5A1CL;E8-2&WTWDR%C9
M)3U*]8TNC::(3!)XT^)*\@^%4G%Z>.)5&)=KR)#YS,;RA'%!/[3@>D(JEDV&
M&9\\0HP[Y/KW__0R+>[[G<O&\.]JVO2V9IB/\DQBW6.!#JF3(M]V FLEZBRW
M4-P+S5+SY"JDRG= 4BKJA1*GLP!VGN)"ZK045'M/_"X_P#U5D)YLN?0FO1I[
MT)K,7LVF+W-O,MWWBZK#T6_86IJFT"_U J=6E)^SE:OEQX G\ANXX7'Y)2$L
MNZ0?231F@:5'T]>O#N3'$OE+=&O^11S0+[J6/X(>0']Z /<7#N4M?:$#RD\D
M/_P+4$L#!!0    ( "J)J50[?_PX;!8  %U'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;.U<6W/;QI+^*U/:G"VI"J(D7G3QK<J6G<1UUK%*=I*'
MK7T8 D-R8A!@9@#)/+]^^S:# 05*=FJS#UO[(I$@,-/W_KI[R!?WM?OB5\8T
MZNNZK/S+@U73;)Z=G/A\9=;:C^J-J>"31>W6NH&W;GGB-\[H@AY:ER?CT]/S
MD[6VU<&K%W3MQKUZ4;=-:2MSXY1OUVOMMF],6=^_/#@["!=N[7+5X(635R\V
M>FD^F>;7S8V#=R=QE<*N3>5M72EG%B\/7I\]>S/%^^F&WZRY]\EKA9S,Z_H+
MOGE?O#PX18),:?(&5]#P[\Y<F[+$A8",/V7-@[@E/IB^#JO_2+P#+W/MS75=
M_FZ+9O7RX/) %6:AV[*YK>]_-L+/#-?+Z]+37W7/]TXO#E3>^J9>R\- P=I6
M_%]_%3DD#UR>[GE@+ ^,B6[>B*A\JQO]ZH6K[Y7#NV$U?$&LTM- G*U0*9\:
M!Y]:>*YY=6ON3-4:=6OR>EE9E-2+DP86QH]/<EGD#2\RWK/(1'VHJV;EU;NJ
M,$7_^1,@*%(U#E2]&3^ZX ?M1FIREJGQZ7C\R'J3R.6$UIL\P>7"U6MU#;0Z
ML :0=+-2UR1CX]1_OIY[NOY?CVPXC1M.:</IO@W?_?;NEU_?J=MWUQ]_^N7]
MY_<??QD2ZZ.+H#\^\QN=FY<'X'#>N#MS,+2R^MVHI:F,TXT!1R%6/?.*#]G<
M^$QM7%VT>>.5K@IEJP;\ !RCU25^LC&NV2H-#]4EN*E_IGH2"ZMT5VNG2CVO
M8<?:;;O/K8?]R9#^90JE&]6LC&K B55C? .?>7 6(,$AG9O:-:;(U/W*YBNE
M-T#'5PM^!NO<KTS5K8JWPX=WML!%@7Q<%4BFD%3E1M7STBXUVB[?[.&U7UA3
MC-2GP46:6FW@'E,!,7E]9QQ<FV_5G7:V;CVL;UUQO-$HE(W> K/PY-+I-7!8
MY65;V&H9;P82('H5*L<=(#IJ8)YIR5"B]R!H_(\T?S"%I=N0"7YCB[CV2+VQ
M)=C TI-\>^SSM@8U%S2L*@C9]4)IU!B*@1_+Q;I1LX7U>=T"D]GN785=+(!K
M>C\WS;T!>2.%>DWWJSE0(L(&Q9%6(J$H$@C+3;@Y8Y-:;TJ;VP;N JJ1#%C;
MDTI2L;>5K7R+\HX*$/VC6$!4$*_7=!E80Q'K>4FK>5C!D5Q'ZO/*B*6B(O#)
MPOC<V0V; #Q9MXXUY_?9ZC/UL]%ELR)]O">:'*C@UMCUO'5>B"#S7W4W6KF1
M-L5L4"A(+959UHTE&2V,.88=CV4;A5FT:$M#2XMG$C>>E=>3=Q9TFBKQ&S0W
MH#549J>YGOS ))7YN@'O1X6 OQK(B^+H+6B"Y1;\,CSJU0IHKD&Y:%BFLDA:
MA4N7(</BHLXB:9&$QKAU5$B/*^=TM60IC]3KX@\(PRQRH(DL,;*==8*6AXGF
M35 /[;/KL6B5%&7RVJ'IM9L:(TK3L'F-U$_H]A79\0T],*S[97>;V%-/\WO5
MC7MA2.F>1Z;;9@42!+L'\KI( D(I*//"+8,AXO]MY^^TG0<J?LITKDN;FHV\
M%?.02*TVJZV'>*@Q#:QJO[%@ /#20)BLM\9)U*R! (=1I;%-R]$+%<7BZR=
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M;#0%;0'6YB5RH2T2B1+ =XT]1 R(XF _#JT3XW! R_,6XBTL+*5Y@YB@M%_
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M9M<1&<XB1,O#)C3(BVM,*M("#Y0> ZH2$AZN(SD7 I7!FI881_B9#%#XT36
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M(Z2'%(\OQT3Q9#)!E)B-3R?"]-+54(%']3*%\.@DFP*0[)A"'>W<M4^=E-B
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M.^!X%MXT]89^0&5>-P JZ.7*:+ -O $^7]205N4-;A!_4>?5?P-02P,$%
M  @ *HFI5":#\&/;%0  R4,  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&ULO5QK<]LXLOTK*&]VRZZBW\XDV<FD2G%>GL2)*W9FZM:M^P$B(0D)17((
MTK;FU^_IQH,@12GQSN[]DD@4 30:W:=/-P _OROK;V:A5"/NEWEA?ME9-$WU
MS\-#DR[44IJ#LE(%?IF5]5(V^%K/#TU5*YEQHV5^>')T]-/A4NIBY\5S?G95
MOWA>MDVN"W55"],NE[)>O51Y>??+SO&.?_!9SQ<-/3A\\;R2<W6MFB_558UO
MAZ&73"]58719B%K-?MF9'/_SY1F]SR_\IM6=B3X+FLFT++_1EXOLEYTC$DCE
M*FVH!XG_;M6YRG/J"&+\X?K<"4-2P_BS[_T-SQUSF4JCSLO\=YTUBU]VGNZ(
M3,UDFS>?R[MWRLWG,?67EKGA?\6=>_=H1Z2M:<JE:PP)EKJP_\M[IX<?:7#B
M&IRPW'8@EO*5;.2+YW5Y)VIZ&[W1!YXJMX9PNJ!%N6YJ_*K1KGF!S[)1<YV*
M29YK6:3*/#]LT#']?)BZ3E[:3DXV='(J+LNB61CQNLA4UF]_"(&"5"=>JI<G
M6SN\E/6!.#U.Q,G1R<F6_D[#+$^YO],-_7VJY[+0?THRA$2<EX4I<YU):Q=%
M)JYJ9531V ?E3+S1!52A92ZN\5#!"!LC_G<R-=!6VOS?%HG.@D1G+-'9)KW?
M?)[<O'Y[<2XF'SY<3#Z>O[X>T_N#.Q$?X)FJOE29^%2(:U5!^JFJQ?$9*Q,J
MO5,\Y>Z]=TKFS4*\K<NV$A_T4C=XN/N/OST].3GZ.;S&WX]_WDN$%-5"PB%2
MU38ZA8XR=0OGKDA+(BV7E2Q6L&)T">BH6:>&/2<3NA 3HR7Z*(JRA;%EHEDH
M8;'%Z5Z*KZ5&3[?HKJV5:$H_0 +#+]H95H">TR0PVE+5M%#Z3[QY5U('GZ[>
M?R)ICY_\;$0*G;&0I@'&)"(OB_D^04$Q%UG=SD55EUF;8GDAVUO 6@-EG2^P
M_CP .[4H(63-DA<"O]>Z*6NMS('X GNO>0IXO#0T.GV1\UI9HV%U+^2M$O-:
M%HV;;W^"ZC[-6P-L$C6-9AXPXUVY1]-]^O3HZ)24*LK[50'(P)0P;SR0>3D7
M4\6SM5U"!*C;RDS3Y56#W.54&=VL>)!,RZEJE$GXV^YT3[R!"&CUV\6%W#^_
MN2(C*$KTU]-G6LIYF]N%G-D&PZ$Q-1Y5(+:4U4+G9 R0%#I8R&+.IH"^SY[\
M791WA:K-0E?X'=I5IJ$7U]1W("XPT2S3UK>A[EJE"MK,2!]M-:L!3:*2*S_1
M1\? 46"=<_T[?(:8:*67T[8V3C_!;IJ:8&!)=D$?J$FCTH4SJK:JRKJA46%'
MMSI38P+^SC*5<R"0,X#OB&7P/EJW4$==+B&"+,P,AH;72!<YA;06PV-,>)A;
M-&ND65N3QFF0E9*U4(3(XA54PC#@,/7X(/+_!<9CB^7E8568"CZKI[E=CUE;
M9+[3WM2"EW6.GO308&BQUC;4#+W"SO%K@B'GBB5GQ-!X;%88+H7"H9ZZ(2,@
M$\'ZRCQ?X=,M3 &R/CKN-+9N08]/QRS(K44#LH)98>$[CQMZ3C:T>1H$$C@]
MSU4)CX8%$PR<3RZOSL0-GLN*0=$0^/[:0MR?(MA5+ 6A(,:31>3XN4[!<R+@
M$+ND;(?!MON)_\TCL=48_YB("J;; F%H*G<+G2YHP( YI1-Q=- -<),,L :J
MT$NR<K;Q;J;X%[][^Y@@BL[+CY,;ZR4E\&=ED2G7\[)HTUR5#?E)!: @W(_
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M+K34V7ZC5!&Q&3RX(WZON H8XO$F\]JB4&!'R579L,9$:Y"\!U/(N!QH7>U
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M1I);8Q&VD@0=2(,G !C)T$5.,!A\S"HS$0G+^RE5-M%U&3C19BU+*@ DV.;
M$90KL6S,.*"?0'V"OY'>OZ5C8Q*PJH*7H;CSA'L*,/:-KO.4^0$U+!?D);H
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M#IZ8+F8T'O='BPOZR)T0G;WENK_SJ5GWW[RB<7\^F^(:]Q?0Z[,_QG)=0K_
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M^?_FD7^X]WE$(<W*?P3" P6R.WPIT:UVWYG<AL\K=MO#1RJPUXJ'WUQF($7
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MN,3(Z]3#XCU6SFX/$LR>/X385U%C!L:5RP2R<1B&J04&H' :Z.Y)<BE-8;@
MTC&0-PA .33I@_L<F66!1WJ:5$GFK&)N$T(?%NA.?%B8\T1($H#!/258PZQ
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M[*-G^NWMZ]PQQ23Y1KHT-([;.<QG-W+<5,VH&99/D"-/CTC*'8]P.0C6Y<"
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MNXTT_N&JJO3(J W>JGN.C(!ZZ<Z>6Z%7%$=ID"<ISU91D.8K^DE:>T:B17T
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M85C0MP):-J#]W!C_-.$ W=?'^G]02P,$%     @ *HFI5+,!B,W"!   7PP
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M=%6.5N7&R)4;9QZDP>'(+3,<1T'9"W@^E]+L-C9 ->#V_P)02P,$%     @
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MG*:_2]-'T_P%BH<Z?EM<S5(D9(&L@U^+/(3 :TC6S<84,JP"V>GM(,%@EV"
M)GA?3>Z4)+*)*:^#IOF]<5C)IF[F,NJ';B6;3F\'V82[;,*.;#H/9E-J82V8
M*D9U"SX&&JYBA#DZ2&B\2VB,)G2UTJE1_Q5%F2??H&#-&CEQ7)N8@4SP"BO6
MK2CC0= <(G5LR>&@04XE5,V1Z@RR='.PBF&-NANL J]MF].]NHCB*QE#E2Y
M4@JUB8!]E2&QACW?7/#0^EJ-@W%E6S19A6[%:MKEZS C*]R4]=3/5,;"R!DQ
M&DK,-,WE9RU3I6<D$W%C?M/2]T%,=2CJ1FXK$E;V*:[[-R!^YOTL;SAF)-*K
M?+]T[YVZH@=UV2^M#LZ!WQJQ%7Z**_\OF]4S$#Z42*E<PX$4.5V6165&?B?M
M]>64UO67M81CI9?BV@L]&W1D28EU]$Y,*F )M[W@ MI5J.VW.[NY?JY+)6W
MOJZ[7MBZE%9/*2ZH6_ ;3UQ=X*A/O3#TJH>NR3#DE/G5<]?3XTVCX=CGM&)X
M5QH>+)T?4,YIR[I8&::X#G_)>[$$#L2-2!.HNC.DP*96#FDX<'%/K7)17+H0
MI.LZ=$:Y-QYS6H6ZT1*JHZ"&=5^?-XV6'G<"SJMH-UJ&P/!N,]S,2B;#)?-J
M!O(#QU7$Y%&HV1GTWQ.Q5D;$6$MGQ8[1@7%G>_TD+DOMN+,&.:%0ZU8%<])D
MR!CSPJ"">E^/-Z7A84/(N>]5RM>[9D/FC[T6R*WL,5SV)IO5!F1:O4AR,Y_+
MR)R2QZU( TI7,[W.]\,IO/K/)C-U.3F<U4H7\X;>"5:G&*Y3K3MAPNKB<@9=
M@E=MZAKLP*Q-A9A5(8:KT-%8@,@?P]#,\CX+AL;'J@/#NR4$GWHC0P./AU5X
MFLQ:6U)FI8/ATO$]\'P7H[J6L%UGZ&LRR^8NWKJTX^36.XLS=UPKYFY+.[_=
M[C T2_8N3O;W"7DL&^XO^PWWM*WA/IQG[ZK0'7KY+86Z>/7?_XK$K1?[?-QP
M)^?6+^\J=H>A6L9U<<9M"%5F1JV*[G"3R?DF)C$<J\:6L,,W9>0= ,9HS[4$
M[.($/)4&CC6YDXE>J3?,I652=V@F=2V3NCB38K>A;@-)<EJ[]YB4=GZ'W;3;
M[C )R[HNSKJ?'__ZF5PK'>N%BC"8/<N:WM"LZ5G6]'#6_,Z[0*^!*AL/<0_#
MP\@MJ7HXJ3ZH1*TV*VP5+'%Z0Q.GM_=YR='$V9^-.GR[G63D6=;T<&9[$&]=
MZVV)S?.'7F_+@-[1=_E'K#?NFSG="V[ITL/I<K*]?9WH)()3F&XO_[ZH[&M>
MQVU7*J\G(JE>BJNVW\FMG,D42KO\ #\92(C<Z1>9)L4-'!:393]O/#!PW-(D
MQV\##A=B+=/\G5@T781>=[BBSKGC_*FI5NP8Z-?''69CB9?CQ'LG]2(5ZZ6*
MCD&X0!5V[ 2J>%CC'.C/Q<=L#YL$EGTMXN(/6(268/G0GWES2\B\XQK@&*QQ
M5]YYV )UUSB*0VT9GN,L/"D>: &0C@#Z/IFI%S7;%(T:0(H?8+[W@30?&E3+
M^KSC/N$84'%7K/7\XN.<\P 'U<H(QZG^2<_-JT@EYLQ2/1_Z!II;2N=X00N=
M*4!AWD_).A;E(QD2>NFB]CM&&SOFZ:Y%?"L%/D[##R):PJ]2"/H!1#(J-6]+
MA3??@H=CU%TD^I:Q_:&OBWW+Q7[GIY@? U+'/+P;),OA/DZ@_4'JK"Q]R[7^
MT#>YON56'Z^0/PXD?)ZP&Z2])W=P0KS=I(DRFU06T=ZJM_QUUN_D6*[TA[YT
M\"VU^G@5_7&@X//T.#F6DGV<*MM!Z3PI@>708.A;A\!2:8 7OQ\&2L<\/6[C
M LO! <Z-UQL5S_*/-(IP[U?K%)JK;P\W=!^7P!)G,/1M1&#Y,\!KU8]#!I^'
M=G?*@27> "=$')GN,V/9,ACZWB+8>P01+S@_#AE\'J\',I9] YP5KS;0^>AG
M%9?-ZI5*HU3,^Y5F@27,8.AKB=#R:(C7HA^&2\<\W?5S:/DW['C,#X&E\[B$
MEC'#H6\00DNB8>=S\Q\$"SY/M^Z'EGS#KJO@/_(Y86CY,ASZ$B"T%!K^_YX5
MGX3U)\LJ3QAOHQKM?34H_V[9@T@7^0-_L9S#0.<\UY-T^W6M[1NCU\6WA9ZU
M@9-1O%Q*,9-I;@!_GVMMOKW)OX"T^]+<Y?\ 4$L#!!0    ( "J)J521KH+^
M.@,  .D)   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;,U6WT_;,!#^
M5ZQH#R"QYD>;IJ"V$K1,FP03HMKV,.W!)-?&PK$SVZ'PW^_LA-"6-B">]M+&
MSGUWWW=WSGF\ENI>YP"&/!9<Z(F7&U.>^;Y.<RBH[LD2!+Y92E50@TNU\G6I
M@&8.5' _"H*A7U FO.G8[=VHZ5A6AC,!-XKHJBBH>KH +M<3+_2>-V[9*C=V
MPY^.2[J"!9@?Y8W"E=]ZR5@!0C,IB(+EQ#L/S^9A8 '.XB>#M=YX)E;*G93W
M=O$MFWB!900<4F-=4/Q[@!EP;CTAC[^-4Z^-:8&;S\_>OSCQ*.:.:IA)_HME
M)I]X(X]DL*05-[=R_14:0;'UETJNW2]9-[:!1])*&UDT8&10,%'_T\<F$1L
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MM\-M_&P[^%;#.'NW,,W6]'I,J5DE"]59N/?)K[J5;:5EG7RVTBJX;S99R.T
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M7V.^)]#4.U3%0 %?8\XWV!4M!<K)U_^<>=T"BA*A@UYG$SQN$Y'=B1[R^A9
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M*[DY.MQ<:+$H#].>A#;(+C_.N5GYLFA@OI\*H5\NB@[J ]S1/U!+ P04
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MDR>U.)>[^*'EI#Q'>B>UEEEY.2X/:I@&\'PDI7[Z88ZFKDY'G_T+4$L#!!0
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M;0W.R8-2CVYSE8Z"R E"@8EU#(S^%CA%(1P1R7AJ.(,VI0.NKU?L7[UW\O+
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M^2Y'4<'T+LM'OU$[)NH4_F''C?^1J_@?:>W-+O4_TG4V#*^=8'2$OB\.C]W
M.0&_\4 R[('^7ZBSB7HF[\8<R57,D33F2"XU1])UO2 @CGN,NR?,]\F)%SUI
MS)&<8XZZKN$<( LXXB)S%'!=8/ZG#2QI'))<Q2%)XY#D.0[9"SKL;/A=QS_>
MPYX5%?5&.<>E;[>.G_K/ CCG;7B6HX2M0>;<CN#7E.7YNVPHL3,GTJ50<+XU
MEUM&8R9U #Q?"_A!JH8^Y-;_@LS^!U!+ P04    "  JB:E4:P^ @?D-  "6
M6   &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6S%G&UOVS@2@/\*D=L]
M=($D)BE1+WMI@.:M=9LW-.CNA\-]4&PZT:TM>24YV0#[XX^49).RJ*&<1KTO
M;9R0H^$,^7 TY/CH.<W^R!\Y+]!?BWF2O]][+(KEKZ-1/GGDBR@_3)<\$7^9
MI=DB*L3'[&&4+S,>3<M.B_F(8NR-%E&<[!T?E;^[S8Z/TE4QCQ-^FZ%\M5A$
MV<L)GZ?/[_?(WOH77^.'QT+^8G1\M(P>^!TOOBUO,_%IM)$RC1<\R>,T01F?
MO=_[0'Z](6XH>Y1-?HOY<Z[]C.18[M/T#_EA/'V_AZ5*?,XGA901B?^>^"F?
MSZ4HH<B?M=2]S4-E1_WGM?2+<O1B-/=1SD_3^>_QM'A\OQ?LH2F?1:MY\35]
M_L3K$3$I;Y+.\_)?]%RWQ7MHLLJ+=%%W%AHLXJ3Z/_JKMH36@9*.#K3N0/MV
M<.H.SG8'KZ.#6W=PMSJX76-@=0>VU<'I4LFK.WA]Q^#7'?RM#L3MZ!#4'8+M
M,70](:P[A-MC"+H<A]>>P]NC\+NZ;)S=V]MD[6[2V]]D[7#2\GAGE[7+R;;/
MN[NLG5Y-^%$UX\OE<A85T?%1ECZC3+87\N0/Y9HK^XM5$B>2#W=%)OX:BW[%
M\1F_+] !NHZR+)(+%;T[XT44S_-?CD:%D"];C2:UK)-*%NV0=<'O#Q%E^XAB
MBK_=G:%W/YFDG,)2/D?)(7*PE$*<;BEGL)2KZ 4YI%2%U$+RQRCCN4'4>9]A
M!:5"82UK&KW\A$:H$MDI^**_X* 6K*0:Y'V$Y5VG3QO+L6[+?>IC?U+9W]!]
M;#-\MNY.J;)6G.1%7*SDEM YO,^PY#,^.=SV:1^Q7WJ+)9YMJESVL!UN#MX@
MY:J_"4FWE.O^Y@)6XTV/.5J-:#/YFU)&@C@;[- -=F@IUH&P,Q;.RU8BV"C0
MOR]% S0N^"+_#R#>V8AW2O%NA_C3C$_CXI__(![^E_P;FD3+:!(7+Z;Y7(GR
M2E$RG'HZ)MBAV,48'XV>#%JX&RU<4(L/BW25%#D285E>1,DT3A[0*IGR#)4Z
MI3,T*?4T*55)9KI2'G.(KE.U9MRV]H[GTT[EV49Y!BI__N>JPU[,H!IQ@\!M
M*V=J&C!"O5;3*]8>AQ=ZC+2E7IN:^H0QTCEH;S-H#QST5RY#:NFG918GDW@9
MS4T6\%K#H@ZFGL$ AI:84< ]_D93']3T8YI.G^.Y43V_91]&0O'8MGJ&EA1[
MN#W-+MLM?2*62- YD& SD  <R/5J<2]6A%@,LSB)A,VC.=*ICO[6/YJ&&[0G
MF;,U3K!)0^UPHW9HF2DB2DKX%)U'F9PP.4 M@E4PAH? (M&B/?+*55UWU#U\
M0)@;ALP '7-C0D+?L++KQJS1V&789ZR]MLV- Q(X3N=4(VK7(10F\E3@5DPC
M,<=NHWAZ$"?H-%K&Q?8R;XI7NPYQ!G&?VE (O*, [FMO& X)"7%"@_<,;2FE
M;N ;G-?>7QR!6L\-#+XSMJ5>V+V5$K4=$7@_.ETM5O/J%>5\-N.38A_=\BQ.
MIQ(='Z;I4OIU7_ST7_':)*T/&5SM!\0;Q*,*XP3F>*='/]<=&RN!$L]M8_S2
MT%2TQ+C;[(K.!,;SSF87O-Z)C0JX)!S"%53!E^)7NJ+NV-@_?)>UE\"EL24#
M/$$5NBF,[M=XXE6\HUH0/T@43Q50*1S' RYI1^T'3DB:EJY]TJ=I4T$%9 H#
M^21.O_(9SW@RX="(%>8H&\2DBF@4#G&O>8&B/.>%Z?5V3-L!JW@9\D%C*=;1
MU\>LU("PP,'0<Q7#*,RP<2+>OA[B^SF'1AZTWRI$\ ,IH-!%X6#QYO;+#?K$
MHWGQB,Y76;J$YHJC@.4,$BTZ"CD.C)S?R^2Z 'GTQ+/H@8M(O!!S/2]0%A7<
M^"X-"R2'#/]L6LZ[]VL.22'+@2/ *_%ZMU@M!!MW<XJ6>1@D!G04<AP8.;]%
M61S)N=QPAG%.6R3A0Q^VJJ*6 P=G5]%?K[*JHI8S2!SF*#8Y,)MVL2HLR3D,
M8*LJ;CDPMR[K+-&I(4O4%*E(Y P21+F*22X<1/7,H-12FCD<<W[+T!),<+D*
M;^Y;X\TBD'7AS=K/!:>,J_#FPG@[31,QEJ+<ZZ2O(:$*:>X@2'.U/"D,HK%N
M=Y0F*$G%VD/+Z$4N2=.)C46@:]DO7$4VU_+:N650@3C]5W<\B=,,79?ZGJVX
M3+8SZ,&*>.X@Q',5\5R84^4#9M%$!$5EGMIHYG;:CV(,166NHIL+TZU\?KP9
MX#Z:E':M+AZ(]YS4J% E,]04PH=4\,"E;H="BHTN'*6=JN<+=@F[+'E6G<6A
M=^+%:9K.YU&6J]_^(N8">%QW7C_0U[1U#RGM2,PKQC*8L?4$%.":2AMVNN^,
MM=G)F MXCREV,AA9=^6@49SG*Z&',-FDJ92T6&48::9.$YVQ=KY/YJH)];<V
M@K&A)27$=0.YX)JG#CU:-H>M^,I@OEZF>:Y&6\X5L4$7C]7"KSA@'"9M[V($
M>JMBBLX,?D?6/%$&,-4)4S4S'C+.2WKT=,=Y_:Q&:A!<[TQ!GL%,/N.3C$>Y
MW&5K!=Y&YS/63F<&1$PAO\O;VA$8#/_;+)UP/I4>YP=%O.!B8UK$,ILRX\;X
M@+6/IAS(>&HW8/!;>Y4($=-NL12Z"./(PT-M'YJV]OK:GY[AA ?*##*U?S!+
MYK),0LET5"-L0N^B'$62DA.AI^G$>6P13,@A!7=OIO88!N\Q/:-19GCW=PGU
MVOGPSZ:F)'0\P*)J V)]-J#=8HTRW3KEBS+[)ZU>)@03Z*W+4QN--TB"P5.[
MB&?):6Y-X7V!4C&3'M/Y=#V#9%PN)GM>I),_ZGVYR.*'!YZ9YKOE><3!AQB<
M6Y[:"CQX*Y!+\BF:2[MDF@>DAD;-8&EB+[!IIG8$SW+[X0WGD?A]G3*!5%.;
M@.<.,J,4LCT8V>HXN<BB\L;%-'J1A\CB/Z-;VE<4:-<E NT6 4SKMW9 E5V!
M[*.H[?F#.$ AU^M[GB_VIYQ/5N46T7!&M%S.XTFY\4^V8^YN1[7/\)TN1RGB
M>C^(N,5S"EC/5\3U!R&NKXCK_V#B6IX7!A:L^0JX_FZYC>]Q5B^L^8JX_B 9
M$E]QTX>#YUVQYK=CXHYHV%=H]=\^%0+9WTHU7P'7'R19XFNWK>"8="BJ^>UC
MKRX_*0+[EB/[-_.3( ,42/J*L_X@:>= <3/HE1)Y,ZR-+<^S!Y*!0G)@OY/5
M/Y <6Z39 \E $3?X4<25,ZD7<P/%W& 0Y@:*N<&;,G<<M)G;%4H&"KK!CX+N
MV@56[ 8*N\$@V T4=H/_"W;'01N[7<%DH%UDW9F[[.>&MPSIP>:S%%"#08 :
M*J"&,.!ZG Y<A*;T,I0L#!430YAB.Y\(75@$,@L40P7%L \4W_"8X")L)X<[
M@H!0T3&$<P"MTQ5ASX7QX; <AEZX& YD.074$ ;J^NZ%MDZ%6\W;W(5%EH/+
MY0_II1@;]KN]T$\O6)9GUTOA-7R3:H2PG>/U/(J==O(R;-_N\ABCK'O!*E*'
M,*D-\%.;T@6_SU91]H+*.B+'@:RC<!L&@R!0N^'?*SE@/6;[4LMIIH\="MV_
MQ7I) $QB?8L'BPRT(@!,AC =P=I%>PQ3LN?<78MIG/]UI-Z-;>'<.\':W7UL
M.4?30RD19;WFNNUD(N>('/6=+/B*LFF.OBVG<@^357@'V /-J]4!X$'RJ 1K
M]^TQ3+)^'OR\%K-U^=P%RC6P=OT>PPC<<LJKD$*P=AL?#Y(>)5B[4(][W'N
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MI.H3/_[.ZH"&!F_#4UG^HF/];N"A32$5SVIC[4&6Y-4__5HGHF6@<;H-H#:
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M@GZ^Y7IMUC>&H/GR,O\&4$L#!!0    ( "J)J51"\!T9Y 4  .DJ   9
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M!F$"]/J&Z^WO)N;(=S=\_AM02P,$%     @ *HFI5 ZP9S2Q @  E@<  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULQ55M3]LP$/XK5L0'D("D25]1
M&HF634,:&X*Q?9CVP237)L(OG>TT\.]W=M*00NFF:=*^M+9S]]SSG'UW<275
M@\X!#'GD3.BIEQNS.O-]G>; J3Z5*Q#X92$5IP:W:NGKE0*:.2?._# (ACZG
MA?"2V)U=JR26I6&%@&M%=,DY54\S8+*:>CUO<W!3+'-C#_PD7M$EW(*Y6UTK
MW/DM2E9P$+J0@BA83+WSWME\8NV=P=<"*MU9$ZOD7LH'N[G,IEY@"0&#U%@$
MBG]KF -C%@AI_&PPO3:D=>RN-^COG7;4<D\US"7[5F0FGWICCV2PH"4S-[+Z
M (V>@<5+)=/NEU2U[2CT2%IJ(WGCC QX(>I_^MCDH>. .+L=PL8A?.G0?\,A
M:APB)[1FYF1=4$.36,F**&N-:';A<N.\44TA["W>&H5?"_0SR7F:EKQDU$!&
M/IL<%)E+CN\AMQ>U!O)1:DT.+\#0@NDC<D+N;B_(X<$1.2"%(%]R66HJ,AW[
M!LE82#]M L_JP.$;@2-R)87)-7DG,LBV_7T4T2H)-TIFX5[ *ZI.2=0[)F$0
MACOXS/_<O;>'3M0F-G)XT5\F]E*DD@,YM D^.B:?L&"_WTAF"[.B*ONQAT*_
MI=!W%/IO4*C#IEMA&8;;=5DUTM AV<I?)R>3,(C]=3>#NXR"T;/5%LM!RW*P
MER56(]::P,>N%(CTB1A%A<;$897O2<*PA1_^KWL8M11&>Q7.8%D(48@E-AQ&
M10J[+J"&&'1S&P7]R6!W<L=MZ/$_>P+CUPRZ3V K_J2-/]D;'XO[-[HGK]]4
MU.OW7NKV.RV.@UJZSJ]162E,W2/:TW:XG+N>^N)\AD.GGA'/,/7$P@Z ]Z0)
M@P5"!J<C3(6JIT"],7+E&NF]--B6W3+'P0G*&N#WA91FL[$!VE&<_ )02P,$
M%     @ *HFI5#^=Y9M;!0  5A\  !D   !X;"]W;W)K<VAE971S+W-H965T
M-3$N>&ULM9E1;Z,X$,>_BA7M0RO=E6!CDE9II&YZU9VTE7K;W;UG)W$2JX"S
MQDEVI?OP9PC%$& @1_:EA61F^,_8\[,=)@>IWN(-YQK]"(,HOA]LM-[>.4Z\
MV/"0Q3=RRR/SS4JJD&ESJ]9.O%6<+5.G,'#P<.@[(1/18#I)/WM1TXG<Z4!$
M_$6A>!>&3/W\R -YN!^X@_<//HOU1B<?.-/)EJWY*]=?MR_*W#EYE*4(>10+
M&2'%5_>#!_=NY@\3A]3BF^"'N'"-DE3F4KXE-W\M[P?#1!$/^$(G(9CYM^<S
M'@1))*/C>Q9TD#\S<2Q>OT=_2I,WR<Q9S&<R^$<L]>9^,!Z@)5^Q7: _R\.?
M/$N()O$6,HC3O^B0V0X':+&+M0PS9Z,@%-'Q/_N1%:+@X'H-#CASP%T=2.9
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MA#B*X\?[/NSO'?RK$MK$R^SC,OO8R]8^S/X0SK5&F[A+<\#HD'%FF"4O7$G
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M<<OJJ+R-R2=&SGSK,)3&-B)^.+6M'RJWP=X?2TM<3%PW4C:3W;]02P,$%
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M.9J=E"F0%J1?I37)!#-FN.G HU1+@WK-E@+A1I:5?:=Q!^9,))6HM?R]4$(
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M0=D W%](+&PSL:W =_[T!5!+ P04    "  JB:E43(<$4\T"   =!P  &0
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M:3KZ94'_+]0.0/<KI>SCQHW(]H^8_ %02P,$%     @ *HFI5%GZ:R/% @
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M)P  &0   'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6RUFFUOVS@2Q[\*X7M
M%RAB/5&.NTF Q$[: $DN2*[=Q2WV!2V/8Z*2Z)*4DRSZX8^4%%-=6R-GL^J+
M1K(U?PZ'XQ^'I(X>A?RJE@":/&5IKHX'2ZU7'X9#E2PA8^I K" WWRR$S)@V
MM_)AJ%82V+PTRM)AX'GQ,&,\'YP<E9_=RI,C4>B4YW KB2JRC,GG,TC%X_'
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M9/7.5G6CQ:I\H6<FM!99>;DLE];V ?/]0@C]<F/?$=J\.7?R?U!+ P04
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M;1ET=LSZE*B]$8^N)'[M@+C? E\H_GT9[DQ\''6J7]LB'O?RN(MCG7L%"EN
M'4[?^FKWPY,KE;3V.OP+LWO!=QA?>MBES_UBTCG-VN=PO]%]^N*^NK"1A->-
M;@2#[V\L\@0T@#VD4'+WSC*=5C[=+PBI#8Y<R>!(;7"DW^!>(@BY-#="+A1I
MFS6\D"1H;/W=41#VMSLN#1)L"[#P9@**ZN)T50RLROQI8*,LG"W\Y1Y.I$R[
M"?!\JT"P<N .&-49=_$O4$L#!!0    ( "J)J53J&I_]QP,  /P0   9
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M<VAE971S+W-H965T-C(N>&ULA51-;]LP#/TK@M%#"W2QXR3>4#@&XG3#!JQ
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MW3*.3GB44DY%!N3Z'@QE7-^0*^O^K92UIB+7L6\P/4OB9UTJ:9M*>":5"7E
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MO10V7M;W@7JBQ<8>J>="PP'=#M=PAV+2&,#[I1!Z/S&G].96-OX74$L#!!0
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MSP;RMN7[[C2#$UD?'DPPC-TR%$V9R$F*_XPFUTF)3V5=*^%2-V,&>A6YJ>/
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MO?QE^;T3[Q?-!>?ZMJ(\_0502P,$%     @ *HFI5*3(PW?Z 0  M"@  !,
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M+GAM;%!+ 0(4 Q0    ( "J)J52PSNSZ[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( "J)J5297)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ *HFI5/38S?)!!0  9!4  !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( "J)J517FJ/G#@<
M -4;   8              " @80-  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    "  JB:E414N&UGX"  "K!@  &               @('(
M%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ *HFI5(7T
M5*=5!@  4AH  !@              ("!?!<  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( "J)J515+OE7U (  !X'   8
M  " @0<>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  J
MB:E4$;/PLP@&   <&P  &               @($1(0  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ *HFI5+:7&"^V!P  41X  !@
M         ("!3R<  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( "J)J50Y80<39@L  *X:   8              " @3LO  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  JB:E4IKGZ-GD'  !#$0
M&               @('7.@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ *HFI5.>8 .R7(   &&<  !D              ("!AD(  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  JB:E4L!X67# %
M   S#@  &0              @(%48P  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( "J)J51.!&-8>0D  ,P4   9              "
M@;MH  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ *HFI
M5 7>G8_H#0  W2@  !D              ("!:W(  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    "  JB:E4<=YD Z :   E4P  &0
M        @(&*@   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( "J)J52Y1RIJB0(  'H%   9              " @6&;  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ *HFI5!0?."D,!P  5!(
M !D              ("!(9X  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    "  JB:E4R3O@6<0$   _"P  &0              @(%DI0
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( "J)J53W3UWP
MI@@  &(4   9              " @5^J  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ *HFI5%0/'H]B$   +BD  !D
M ("!/+,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  J
MB:E4.W_\.&P6  !=1P  &0              @('5PP  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( "J)J50F@_!CVQ4  ,E#   9
M          " @7C:  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#
M%     @ *HFI5*U47 5>!0  @ P  !D              ("!BO   'AL+W=O
M<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  JB:E4\>3LM<\'  ")
M(P  &0              @($?]@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM
M;%!+ 0(4 Q0    ( "J)J53TL9'Y'0<  ,P/   9              " @27^
M  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ *HFI5$8Q
M\[;0'0  @6(  !D              ("!>04! 'AL+W=O<FMS:&5E=',O<VAE
M970R-2YX;6Q02P$"% ,4    "  JB:E4*%((A*P&   R#@  &0
M    @(& (P$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M "J)J53].WFV] ,  !P*   9              " @6,J 0!X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ *HFI5-DH<C?0!0  N X  !D
M             ("!CBX! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    "  JB:E4S/NZ('4"  !U!0  &0              @(&5- $ >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( "J)J53S,[']SP0
M -H.   9              " @4$W 0!X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ *HFI5!P1?DF" P  B0@  !D              ("!
M1SP! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  JB:E4
MLP&(S<($  !?#   &0              @($ 0 $ >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( "J)J52+0>DU<P0  %,*   9
M      " @?E$ 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ *HFI5&(S\M\.!0  $A   !D              ("!HTD! 'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  JB:E4$@Q3\AH$  #,#0
M&0              @('H3@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( "J)J537""V 'P,  .P*   9              " @3E3 0!X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ *HFI5./=WF$_
M"0  0#<  !D              ("!CU8! 'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    "  JB:E4D:Z"_CH#  #I"0  &0
M@($%8 $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( "J)
MJ52KE)>+G <  &,D   9              " @79C 0!X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ *HFI5%3G2$I"!0  S!T  !D
M         ("!26L! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M    "  JB:E4#3[AR(D&  "K*   &0              @('"< $ >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( "J)J51R\<6U'P,  -X)
M   9              " @8)W 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL
M4$L! A0#%     @ *HFI5-)'035V!P  *2T  !D              ("!V'H!
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  JB:E43J63
M:;$"   J!P  &0              @(&%@@$ >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;%!+ 0(4 Q0    ( "J)J52Q)DJ !00  !$1   9
M  " @6V% 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
M*HFI5&L/@('Y#0  EE@  !D              ("!J8D! 'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    "  JB:E4VJBI1 <$  "%$0  &0
M            @('9EP$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( "J)J51"\!T9Y 4  .DJ   9              " @1>< 0!X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ *HFI5!O.R8BG @
M[0<  !D              ("!,J(! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    "  JB:E4#K!G-+$"  "6!P  &0              @($0
MI0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( "J)J50_
MG>6;6P4  %8?   9              " @?BG 0!X;"]W;W)K<VAE971S+W-H
M965T-3$N>&UL4$L! A0#%     @ *HFI5/&1>.K1 @  6 H  !D
M     ("!BJT! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "J)J52CO%P".@<  $4G   9              "
M@7:\ 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ *HFI
M5*B?VL+K P  [PX  !D              ("!Y\,! 'AL+W=O<FMS:&5E=',O
M<VAE970U."YX;6Q02P$"% ,4    "  JB:E4ZAJ?_<<#  #\$   &0
M        @($)R $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0
M   ( "J)J51)UO2 . ,   4,   9              " @0?, 0!X;"]W;W)K
M<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ *HFI5'NP%QW]!   SQ4
M !D              ("!=L\! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q0
M2P$"% ,4    "  JB:E4S[D2@%L"  !\!0  &0              @(&JU $
M>&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( "J)J53O97*'
M"@@  )LQ   9              " @3S7 0!X;"]W;W)K<VAE971S+W-H965T
M-C,N>&UL4$L! A0#%     @ *HFI5$IY)(1J @  /P8  !D
M ("!?=\! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    "  J
MB:E49D9ZV+L'   :,   &0              @($>X@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( "J)J52$N01%T@,  *$-   9
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M970W,"YX;6Q02P$"% ,4    "  JB:E4*$V"M28#  !0$@  #0
M    @ '$^@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( "J)J527BKL<P
M !,"   +              "  17^ 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M "J)J51-74#MD@4  ! N   /              "  ?[^ 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    "  JB:E4VW:P<3$"  ")*0  &@
M@ &]! ( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  J
MB:E4I,C#=_H!  "T*   $P              @ $F!P( 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     3@!. %D5  !1"0(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>423</ContextCount>
  <ElementCount>388</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>183</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - COVER PAGE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/COVERPAGE</Role>
      <ShortName>COVER PAGE</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Business and Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/BusinessandOrganization</Role>
      <ShortName>Business and Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Impact of COVID-19</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/ImpactofCOVID19</Role>
      <ShortName>Impact of COVID-19</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108104 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110105 - Disclosure - Composition of Certain Financial Statement Captions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions</Role>
      <ShortName>Composition of Certain Financial Statement Captions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115106 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2120107 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Accumulated Other Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/AccumulatedOtherComprehensiveLoss</Role>
      <ShortName>Accumulated Other Comprehensive Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130109 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2136110 - Disclosure - Derivative Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DerivativeContracts</Role>
      <ShortName>Derivative Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2140111 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2142112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2144113 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2150114 - Disclosure - Strategic Alliances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/StrategicAlliances</Role>
      <ShortName>Strategic Alliances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2152115 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2156116 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2162117 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2206201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.opko.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Composition of Certain Financial Statement Captions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables</Role>
      <ShortName>Composition of Certain Financial Statement Captions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2316302 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/Investments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2321303 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/Debt</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2328304 - Disclosure - Accumulated Other Comprehensive Loss (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/AccumulatedOtherComprehensiveLoss</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - Derivative Contracts (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DerivativeContractsTables</Role>
      <ShortName>Derivative Contracts (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/DerivativeContracts</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2345307 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/RevenueRecognition</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2353308 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/Segments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2357309 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.opko.com/role/Leases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Business and Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/BusinessandOrganizationDetails</Role>
      <ShortName>Business and Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/BusinessandOrganization</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Impact of COVID-19 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/ImpactofCOVID19Details</Role>
      <ShortName>Impact of COVID-19 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/ImpactofCOVID19</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/EarningsLossPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Composition of Certain Financial Statement Captions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails</Role>
      <ShortName>Composition of Certain Financial Statement Captions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Composition of Certain Financial Statement Captions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails</Role>
      <ShortName>Composition of Certain Financial Statement Captions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Composition of Certain Financial Statement Captions - Changes in Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails</Role>
      <ShortName>Composition of Certain Financial Statement Captions - Changes in Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Investments - Summary of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails</Role>
      <ShortName>Investments - Summary of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Investments - Schedule of Net Gains and Losses on Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails</Role>
      <ShortName>Investments - Schedule of Net Gains and Losses on Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Debt - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DebtScheduleofDebtDetails</Role>
      <ShortName>Debt - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Debt - Schedule of Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.opko.com/role/DebtScheduleofNotesDetails</Role>
      <ShortName>Debt - Schedule of Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Debt - Lines of Credit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DebtLinesofCreditDetails</Role>
      <ShortName>Debt - Lines of Credit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Debt - Notes Payable and Other Debt (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails</Role>
      <ShortName>Debt - Notes Payable and Other Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Fair Value Measurements - Carrying Amount and Estimated Fair Value of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails</Role>
      <ShortName>Fair Value Measurements - Carrying Amount and Estimated Fair Value of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Fair Value Measurements - Level 3 Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails</Role>
      <ShortName>Fair Value Measurements - Level 3 Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Derivative Contracts - Balance Sheet Component (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails</Role>
      <ShortName>Derivative Contracts - Balance Sheet Component (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Derivative Contracts - Derivative Gains (Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails</Role>
      <ShortName>Derivative Contracts - Derivative Gains (Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/RelatedPartyTransactions</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/CommitmentsandContingencies</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue Recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Revenue Recognition - Schedule of Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Revenue Recognition - Changes in Contractual Liabilities Balance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/RevenueRecognitionChangesinContractualLiabilitiesBalanceDetails</Role>
      <ShortName>Revenue Recognition - Changes in Contractual Liabilities Balance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2451429 - Disclosure - Strategic Alliances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/StrategicAlliancesDetails</Role>
      <ShortName>Strategic Alliances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/StrategicAlliances</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Segments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SegmentsNarrativeDetails</Role>
      <ShortName>Segments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2455431 - Disclosure - Segments - Operations and Assets Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails</Role>
      <ShortName>Segments - Operations and Assets Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2458432 - Disclosure - Leases - Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2459433 - Disclosure - Leases - Lease Liability Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails</Role>
      <ShortName>Leases - Lease Liability Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2460434 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2461435 - Disclosure - Leases - Lease Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails</Role>
      <ShortName>Leases - Lease Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="opk-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.opko.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.opko.com/role/SubsequentEvents</ParentRole>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="opk-20220331.htm">opk-20220331.htm</File>
    <File>opk-20220331.xsd</File>
    <File>opk-20220331_cal.xml</File>
    <File>opk-20220331_def.xml</File>
    <File>opk-20220331_lab.xml</File>
    <File>opk-20220331_pre.xml</File>
    <File>opk-3312022xex311.htm</File>
    <File>opk-3312022xex312.htm</File>
    <File>opk-3312022xex321.htm</File>
    <File>opk-3312022xex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="976">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "opk-20220331.htm": {
   "axisCustom": 3,
   "axisStandard": 46,
   "contextCount": 423,
   "dts": {
    "calculationLink": {
     "local": [
      "opk-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "opk-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "opk-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "opk-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "opk-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "opk-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 769,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 3,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 8
   },
   "keyCustom": 68,
   "keyStandard": 320,
   "memberCustom": 99,
   "memberStandard": 71,
   "nsprefix": "opk",
   "nsuri": "http://www.opko.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - COVER PAGE",
     "role": "http://www.opko.com/role/COVERPAGE",
     "shortName": "COVER PAGE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.opko.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108104 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://www.opko.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110105 - Disclosure - Composition of Certain Financial Statement Captions",
     "role": "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions",
     "shortName": "Composition of Certain Financial Statement Captions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115106 - Disclosure - Investments",
     "role": "http://www.opko.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120107 - Disclosure - Debt",
     "role": "http://www.opko.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Accumulated Other Comprehensive Loss",
     "role": "http://www.opko.com/role/AccumulatedOtherComprehensiveLoss",
     "shortName": "Accumulated Other Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130109 - Disclosure - Fair Value Measurements",
     "role": "http://www.opko.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136110 - Disclosure - Derivative Contracts",
     "role": "http://www.opko.com/role/DerivativeContracts",
     "shortName": "Derivative Contracts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140111 - Disclosure - Related Party Transactions",
     "role": "http://www.opko.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142112 - Disclosure - Commitments and Contingencies",
     "role": "http://www.opko.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144113 - Disclosure - Revenue Recognition",
     "role": "http://www.opko.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "opk:StrategicAlliancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150114 - Disclosure - Strategic Alliances",
     "role": "http://www.opko.com/role/StrategicAlliances",
     "shortName": "Strategic Alliances",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "opk:StrategicAlliancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152115 - Disclosure - Segments",
     "role": "http://www.opko.com/role/Segments",
     "shortName": "Segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156116 - Disclosure - Leases",
     "role": "http://www.opko.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162117 - Disclosure - Subsequent Events",
     "role": "http://www.opko.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2206201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "opk:CompositionOfCertainFinancialStatementCaptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Composition of Certain Financial Statement Captions (Tables)",
     "role": "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables",
     "shortName": "Composition of Certain Financial Statement Captions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "opk:CompositionOfCertainFinancialStatementCaptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316302 - Disclosure - Investments (Tables)",
     "role": "http://www.opko.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321303 - Disclosure - Debt (Tables)",
     "role": "http://www.opko.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328304 - Disclosure - Accumulated Other Comprehensive Loss (Tables)",
     "role": "http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables",
     "shortName": "Accumulated Other Comprehensive Loss (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.opko.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - Derivative Contracts (Tables)",
     "role": "http://www.opko.com/role/DerivativeContractsTables",
     "shortName": "Derivative Contracts (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345307 - Disclosure - Revenue Recognition (Tables)",
     "role": "http://www.opko.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353308 - Disclosure - Segments (Tables)",
     "role": "http://www.opko.com/role/SegmentsTables",
     "shortName": "Segments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "opk:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2357309 - Disclosure - Leases (Tables)",
     "role": "http://www.opko.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "opk:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-1",
      "first": true,
      "lang": "en-US",
      "name": "opk:NumberofSalesEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Business and Organization (Details)",
     "role": "http://www.opko.com/role/BusinessandOrganizationDetails",
     "shortName": "Business and Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-1",
      "first": true,
      "lang": "en-US",
      "name": "opk:NumberofSalesEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i086b3193d0a84e44b65e89593c24a20b_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "opk:ChangeInTestingVolumePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Impact of COVID-19 (Details)",
     "role": "http://www.opko.com/role/ImpactofCOVID19Details",
     "shortName": "Impact of COVID-19 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i086b3193d0a84e44b65e89593c24a20b_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "opk:ChangeInTestingVolumePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:InventoryPolicyTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:InventoryPolicyTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Earnings (Loss) Per Share (Details)",
     "role": "http://www.opko.com/role/EarningsLossPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "opk:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "opk:CompositionOfCertainFinancialStatementCaptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Composition of Certain Financial Statement Captions (Details)",
     "role": "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
     "shortName": "Composition of Certain Financial Statement Captions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "opk:CompositionOfCertainFinancialStatementCaptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Composition of Certain Financial Statement Captions - Narrative (Details)",
     "role": "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
     "shortName": "Composition of Certain Financial Statement Captions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i0c94852de80d4e20b88966f2a5803300_D20220101-20220331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Composition of Certain Financial Statement Captions - Changes in Goodwill (Details)",
     "role": "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
     "shortName": "Composition of Certain Financial Statement Captions - Changes in Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i0e59dec8141549aa8b911e469e798a72_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "opk:EquityMethodInvestmentExcludingVariableInterestEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Investments - Summary of Investments (Details)",
     "role": "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails",
     "shortName": "Investments - Summary of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "opk:EquityMethodInvestmentExcludingVariableInterestEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Investments - Narrative (Details)",
     "role": "http://www.opko.com/role/InvestmentsNarrativeDetails",
     "shortName": "Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentQuotedMarketValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Investments - Schedule of Net Gains and Losses on Equity Securities (Details)",
     "role": "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails",
     "shortName": "Investments - Schedule of Net Gains and Losses on Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Debt - Schedule of Debt (Details)",
     "role": "http://www.opko.com/role/DebtScheduleofDebtDetails",
     "shortName": "Debt - Schedule of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "ib1511200111f48499ddfcbcdc01ff960_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.opko.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "opk:DebtInstrumentsNumberofFinancialInstitutions",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "opk:DebtInstrumentsNumberofFinancialInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "institution",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Debt - Schedule of Notes (Details)",
     "role": "http://www.opko.com/role/DebtScheduleofNotesDetails",
     "shortName": "Debt - Schedule of Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i6b205efadb964c1cb4dff4ca72b078bb_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Debt - Lines of Credit (Details)",
     "role": "http://www.opko.com/role/DebtLinesofCreditDetails",
     "shortName": "Debt - Lines of Credit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "ib898228cd3484e429a53c453f0951cbe_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Debt - Notes Payable and Other Debt (Details)",
     "role": "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails",
     "shortName": "Debt - Notes Payable and Other Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "if35733f1b3cb4b5e8d6885a8d8e2c00b_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails",
     "shortName": "Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "ib4a22c80a9934fab9c03ed0fda0558a8_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details)",
     "role": "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
     "shortName": "Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i940d0629800f44c09521f8583790b804_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Fair Value Measurements - Carrying Amount and Estimated Fair Value of Long-Term Debt (Details)",
     "role": "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails",
     "shortName": "Fair Value Measurements - Carrying Amount and Estimated Fair Value of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i940d0629800f44c09521f8583790b804_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i1a68d34ffea6486da4d468c553cccb2f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Fair Value Measurements - Level 3 Reconciliation (Details)",
     "role": "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails",
     "shortName": "Fair Value Measurements - Level 3 Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i1a68d34ffea6486da4d468c553cccb2f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i3b034a9ad25047b59a622208212d95e1_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Derivative Contracts - Balance Sheet Component (Details)",
     "role": "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
     "shortName": "Derivative Contracts - Balance Sheet Component (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i3b034a9ad25047b59a622208212d95e1_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "if9043229605240dc9166035e1b850972_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Derivative Contracts - Derivative Gains (Losses) (Details)",
     "role": "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails",
     "shortName": "Derivative Contracts - Derivative Gains (Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "if9043229605240dc9166035e1b850972_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.opko.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.opko.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Revenue Recognition - Narrative (Details)",
     "role": "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
     "shortName": "Revenue Recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i2e33b9f98a1b4d2196ed092e6e422c9c_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY",
     "role": "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i0c45accc2e48493ea26f23fbd5bddfe9_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Revenue Recognition - Schedule of Disaggregation of Revenue (Details)",
     "role": "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Schedule of Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4b576227129140fcb81ae5986936e0a5_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details)",
     "role": "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails",
     "shortName": "Revenue Recognition - Schedule of Product Sales Allowances and Accruals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i49b8dfcf4b0a47ceb082dba3ba22e4e2_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i0e59dec8141549aa8b911e469e798a72_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Revenue Recognition - Changes in Contractual Liabilities Balance (Details)",
     "role": "http://www.opko.com/role/RevenueRecognitionChangesinContractualLiabilitiesBalanceDetails",
     "shortName": "Revenue Recognition - Changes in Contractual Liabilities Balance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i0e59dec8141549aa8b911e469e798a72_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451429 - Disclosure - Strategic Alliances (Details)",
     "role": "http://www.opko.com/role/StrategicAlliancesDetails",
     "shortName": "Strategic Alliances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "id1b622c3fa27402b9211c7b4ccf25f7f_D20210914-20210914",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireInterestInJointVenture",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Segments - Narrative (Details)",
     "role": "http://www.opko.com/role/SegmentsNarrativeDetails",
     "shortName": "Segments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i248c2f7f347a4e28bf2c05816ec8ead1_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455431 - Disclosure - Segments - Operations and Assets Information (Details)",
     "role": "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
     "shortName": "Segments - Operations and Assets Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458432 - Disclosure - Leases - Lease Assets and Liabilities (Details)",
     "role": "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails",
     "shortName": "Leases - Lease Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459433 - Disclosure - Leases - Lease Liability Maturity (Details)",
     "role": "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails",
     "shortName": "Leases - Lease Liability Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i137b80025d3d4485b08482ba89272156_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460434 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.opko.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461435 - Disclosure - Leases - Lease Cash Flow Information (Details)",
     "role": "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails",
     "shortName": "Leases - Lease Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaidInKindInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "id89fa8902c75483fa147e3a3149d7af9_D20220429-20220429",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.opko.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i5f3663059edd4d60a02442357262179d_D20220509-20220509",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Business and Organization",
     "role": "http://www.opko.com/role/BusinessandOrganization",
     "shortName": "Business and Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Impact of COVID-19",
     "role": "http://www.opko.com/role/ImpactofCOVID19",
     "shortName": "Impact of COVID-19",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "opk-20220331.htm",
      "contextRef": "i4101cd89b7ba465c8f56a08013a53dcc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 183,
   "tag": {
    "country_CL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHILE",
        "verboseLabel": "Chile"
       }
      }
     },
     "localname": "CL",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_ES": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN",
        "verboseLabel": "Spain"
       }
      }
     },
     "localname": "ES",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRELAND",
        "terseLabel": "Ireland"
       }
      }
     },
     "localname": "IE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ISRAEL",
        "verboseLabel": "Israel"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEXICO",
        "verboseLabel": "Mexico"
       }
      }
     },
     "localname": "MX",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "verboseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.opko.com/role/COVERPAGE"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "opk_A5ConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5% Convertible Notes [Member]",
        "label": "5% Convertible Notes [Member]",
        "terseLabel": "5% Convertible Notes"
       }
      }
     },
     "localname": "A5ConvertibleNotesMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_AccruedClinicalTrialsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trials.",
        "label": "Accrued Clinical Trials, Current",
        "verboseLabel": "Clinical trials"
       }
      }
     },
     "localname": "AccruedClinicalTrialsCurrent",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_AccruedCommitmentsandContingenciesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Commitments and Contingencies, Current",
        "label": "Accrued Commitments and Contingencies, Current",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "AccruedCommitmentsandContingenciesCurrent",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_AccruedExpensePayorOverpaymentReimbursementLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Expense, Payor Overpayment Reimbursement, Liability",
        "label": "Accrued Expense, Payor Overpayment Reimbursement, Liability",
        "terseLabel": "Overpayment reimbursement liability"
       }
      }
     },
     "localname": "AccruedExpensePayorOverpaymentReimbursementLiability",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_AgreementAndPlanOfMergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement and Plan of Merger",
        "label": "Agreement and Plan of Merger [Member]",
        "terseLabel": "Agreement and Plan of Merger"
       }
      }
     },
     "localname": "AgreementAndPlanOfMergerMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Doubtful Accounts, Provision For Allowance As Percent Of Gross Sales",
        "label": "Allowance For Doubtful Accounts, Provision For Allowance As Percent Of Gross Sales",
        "terseLabel": "Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsProvisionForAllowanceAsPercentOfGrossSales",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "opk_AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Doubtful Accounts Receivable, Decrease, Credits Or Payments",
        "label": "Allowance For Doubtful Accounts Receivable, Decrease, Credits Or Payments",
        "negatedTerseLabel": "Credits or payments made"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableDecreaseCreditsOrPayments",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Lease Assets and Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "opk_AutomobilesandAircraftMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Automobiles and Aircraft [Member]",
        "label": "Automobiles and Aircraft [Member]",
        "terseLabel": "Automobiles and Aircraft"
       }
      }
     },
     "localname": "AutomobilesandAircraftMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BCIBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BCI Bank",
        "label": "BCI Bank [Member]",
        "terseLabel": "BCI Bank"
       }
      }
     },
     "localname": "BCIBankMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BancoDeSabadellMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Banco De Sabadell [Member]",
        "label": "Banco De Sabadell [Member]",
        "terseLabel": "Banco De Sabadell"
       }
      }
     },
     "localname": "BancoDeSabadellMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BankOfChileMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank of Chile.",
        "label": "Bank of Chile [Member]",
        "verboseLabel": "Bank of Chile"
       }
      }
     },
     "localname": "BankOfChileMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BiceBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BICE Bank.",
        "label": "Bice Bank [Member]",
        "verboseLabel": "BICE Bank"
       }
      }
     },
     "localname": "BiceBankMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BioCardiaInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioCardia, Inc. [Member]",
        "label": "BioCardia, Inc. [Member]",
        "terseLabel": "BioCardia, Inc."
       }
      }
     },
     "localname": "BioCardiaInc.Member",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BioReferenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bio-Reference [Member]",
        "label": "Bio-Reference [Member]",
        "terseLabel": "BioReference"
       }
      }
     },
     "localname": "BioReferenceMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Revenue-Based Milestone Payments",
        "label": "Business Combination, Consideration Transferred, Revenue-Based Milestone Payments",
        "terseLabel": "Additional revenue-based milestones"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredRevenueBasedMilestonePayments",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Revenue-Based Milestone Payments, Period",
        "label": "Business Combination, Consideration Transferred, Revenue-Based Milestone Payments, Period",
        "terseLabel": "Revenue-based milestone period"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredRevenueBasedMilestonePaymentsPeriod",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_BusinessCombinationPeriodPriorToSigningOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Period Prior To Signing Of Agreement",
        "label": "Business Combination, Period Prior To Signing Of Agreement",
        "terseLabel": "Period prior to signing of agreement"
       }
      }
     },
     "localname": "BusinessCombinationPeriodPriorToSigningOfAgreement",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets",
        "terseLabel": "Goodwill, in-process research and development and other intangible assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Trading Day Period Prior To Signing Of Agreement",
        "label": "Business Combination, Trading Day Period Prior To Signing Of Agreement",
        "terseLabel": "Trading day period prior to closing date"
       }
      }
     },
     "localname": "BusinessCombinationTradingDayPeriodPriorToSigningOfAgreement",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_BusinessCombinationUpfrontConsiderationTransferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Upfront Consideration Transferred",
        "label": "Business Combination, Upfront Consideration Transferred",
        "terseLabel": "Total upfront consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationUpfrontConsiderationTransferred",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CAMP4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CAMP4",
        "label": "CAMP4 [Member]",
        "terseLabel": "CAMP4"
       }
      }
     },
     "localname": "CAMP4Member",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_COVID19TestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Testing",
        "label": "COVID-19 Testing [Member]",
        "terseLabel": "COVID-19 Testing"
       }
      }
     },
     "localname": "COVID19TestingMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_COVID19TestingRevenueConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Testing Revenue Concentration Risk",
        "label": "COVID-19 Testing Revenue Concentration Risk [Member]",
        "terseLabel": "COVID-19 Testing Revenue Concentration Risk"
       }
      }
     },
     "localname": "COVID19TestingRevenueConcentrationRiskMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_CURNAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CURNA [Member]",
        "label": "CURNA [Member]",
        "terseLabel": "CURNA"
       }
      }
     },
     "localname": "CURNAMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ChanceryCourtOfDelawareVsCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chancery Court of Delaware vs Company",
        "label": "Chancery Court of Delaware vs Company [Member]",
        "terseLabel": "Chancery Court of Delaware vs Company"
       }
      }
     },
     "localname": "ChanceryCourtOfDelawareVsCompanyMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ChangeInTestingVolumePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Testing Volume, Percent",
        "label": "Change in Testing Volume, Percent",
        "terseLabel": "Change in testing volume (as a percent)"
       }
      }
     },
     "localname": "ChangeInTestingVolumePercent",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details"
     ],
     "xbrltype": "percentItemType"
    },
    "opk_ChargebacksDiscountsRebatesAndFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks, Discounts, Rebates And Fees [Member]",
        "label": "Chargebacks, Discounts, Rebates And Fees [Member]",
        "terseLabel": "Chargebacks, discounts, rebates and fees"
       }
      }
     },
     "localname": "ChargebacksDiscountsRebatesAndFeesMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ChromaDexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ChromaDex.",
        "label": "ChromaDex [Member]",
        "terseLabel": "ChromaDex"
       }
      }
     },
     "localname": "ChromaDexMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ChromadexCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ChromaDex corporation.",
        "label": "Chromadex Corporation [Member]",
        "verboseLabel": "ChromaDex Corporation"
       }
      }
     },
     "localname": "ChromadexCorporationMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_CivilInvestigativeDemandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Civil Investigative Demands",
        "label": "Civil Investigative Demands [Member]",
        "terseLabel": "Civil Investigative Demands"
       }
      }
     },
     "localname": "CivilInvestigativeDemandsMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ClientPayersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Client Payers [Member]",
        "label": "Client Payers [Member]",
        "terseLabel": "Client payers"
       }
      }
     },
     "localname": "ClientPayersMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_CocrystalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cocrystal.",
        "label": "Cocrystal [Member]",
        "terseLabel": "Cocrystal",
        "verboseLabel": "COCP"
       }
      }
     },
     "localname": "CocrystalMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_CollaborativeAgreementAdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Additional Milestone Payment",
        "label": "Collaborative Agreement, Additional Milestone Payment",
        "terseLabel": "Additional milestone payment"
       }
      }
     },
     "localname": "CollaborativeAgreementAdditionalMilestonePayment",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CollaborativeArrangementAnnualHeightVelocityatPointinTime": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Annual Height Velocity at Point in Time",
        "label": "Collaborative Arrangement, Annual Height Velocity at Point in Time",
        "terseLabel": "Annual height velocity at point in time"
       }
      }
     },
     "localname": "CollaborativeArrangementAnnualHeightVelocityatPointinTime",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_CollaborativeArrangementDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Development Milestone Payment",
        "label": "Collaborative Arrangement, Development Milestone Payment",
        "terseLabel": "Development milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementDevelopmentMilestonePayment",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CollaborativeArrangementDevelopmentMilestonePaymentShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Development Milestone Payment, Shares",
        "label": "Collaborative Arrangement, Development Milestone Payment, Shares",
        "terseLabel": "Development milestone payments (in shares)"
       }
      }
     },
     "localname": "CollaborativeArrangementDevelopmentMilestonePaymentShares",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_CollaborativeArrangementMaximumMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Milestone Payments",
        "label": "Collaborative Arrangement, Maximum Milestone Payments",
        "terseLabel": "Maximum milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumMilestonePayments",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CollaborativeArrangementMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payment",
        "label": "Collaborative Arrangement, Milestone Payment",
        "verboseLabel": "Milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePayment",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CollaborativeArrangementPercentOfOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Percent of Outstanding Shares",
        "label": "Collaborative Arrangement, Percent of Outstanding Shares",
        "terseLabel": "Outstanding shares (as a percent)"
       }
      }
     },
     "localname": "CollaborativeArrangementPercentOfOutstandingShares",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "opk_CollaborativeArrangementPeriodAfterFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Period After First Commercial Sale",
        "label": "Collaborative Arrangement, Period After First Commercial Sale",
        "terseLabel": "Period after first commercial sale"
       }
      }
     },
     "localname": "CollaborativeArrangementPeriodAfterFirstCommercialSale",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Period Following First Commercial Sale",
        "label": "Collaborative Arrangement, Period Following First Commercial Sale",
        "terseLabel": "Period following first commercial sale in a country"
       }
      }
     },
     "localname": "CollaborativeArrangementPeriodFollowingFirstCommercialSale",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_CollaborativeArrangementSalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Sales Milestone Payment",
        "label": "Collaborative Arrangement, Sales Milestone Payment",
        "terseLabel": "Sales milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementSalesMilestonePayment",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CollaborativeArrangementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Upfront Payment",
        "label": "Collaborative Arrangement, Upfront Payment",
        "terseLabel": "Initial upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontPayment",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_CollaborativeArrangementUpfrontPaymentShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Upfront Payment, Shares",
        "label": "Collaborative Arrangement, Upfront Payment, Shares",
        "terseLabel": "Upfront payment (in shares)"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontPaymentShares",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_CompositionOfCertainFinancialStatementCaptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Composition of certain financial statement captions.",
        "label": "Composition of Certain Financial Statement Captions [Table Text Block]",
        "verboseLabel": "Composition of Certain Financial Statement Captions"
       }
      }
     },
     "localname": "CompositionOfCertainFinancialStatementCaptionsTableTextBlock",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "opk_ConsoorcioBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consoorcio Bank",
        "label": "Consoorcio Bank [Member]",
        "terseLabel": "Consoorcio Bank"
       }
      }
     },
     "localname": "ConsoorcioBankMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Notes",
        "label": "Convertible Notes [Member]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleNotesMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ConvertibleSeniorNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2025 [Member]",
        "label": "Convertible Senior Notes Due 2025 [Member]",
        "terseLabel": "Convertible Senior Notes Due 2025"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2025Member",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_Corpbanca1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corpbanca1 [Member]",
        "label": "Corpbanca1 [Member]",
        "terseLabel": "Corpbanca"
       }
      }
     },
     "localname": "Corpbanca1Member",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_CovenantsNotToCompeteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Covenants not to compete.",
        "label": "Covenants Not to Compete [Member]",
        "terseLabel": "Covenants not to compete"
       }
      }
     },
     "localname": "CovenantsNotToCompeteMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_DebtInstrumentConvertibleConversionNoticeThresholdMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Conversion Notice Threshold, Maximum",
        "label": "Debt Instrument, Convertible, Conversion Notice Threshold, Maximum",
        "terseLabel": "Maximum conversion notice"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionNoticeThresholdMaximum",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_DebtInstrumentConvertibleConversionNoticeThresholdMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Conversion Notice Threshold, Minimum",
        "label": "Debt Instrument, Convertible, Conversion Notice Threshold, Minimum",
        "terseLabel": "Minimum conversion notice"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionNoticeThresholdMinimum",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Increase (Decrease) in Maximum Shares Issuable",
        "label": "Debt Instrument, Convertible Debt, Increase (Decrease) in Maximum Shares Issuable",
        "negatedTerseLabel": "Decrease in shares issuable under debt agreement (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtIncreaseDecreaseInMaximumSharesIssuable",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_DebtInstrumentConvertibleDebtMaximumSharesIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Maximum Shares Issuable",
        "label": "Debt Instrument, Convertible Debt, Maximum Shares Issuable",
        "terseLabel": "Shares issuable under debt agreement (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtMaximumSharesIssuable",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_DebtInstrumentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument [Roll Forward]",
        "label": "Debt Instrument [Roll Forward]",
        "terseLabel": "Debt Instrument [Roll Forward]"
       }
      }
     },
     "localname": "DebtInstrumentRollForward",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_DebtInstrumentsNumberofFinancialInstitutions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of financial institutions.",
        "label": "Debt Instruments, Number of Financial Institutions",
        "verboseLabel": "Number of financial institutions"
       }
      }
     },
     "localname": "DebtInstrumentsNumberofFinancialInstitutions",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "opk_DetectGenomixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detect Genomix",
        "label": "Detect Genomix [Member]",
        "terseLabel": "Detect Genomix"
       }
      }
     },
     "localname": "DetectGenomixMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails",
      "http://www.opko.com/role/SubsequentEventsDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_DiagnosticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diagnostics.",
        "label": "Diagnostics [Member]",
        "terseLabel": "Diagnostics",
        "verboseLabel": "Diagnostics"
       }
      }
     },
     "localname": "DiagnosticsMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_DisposalGroupNumberOfFacilitiesSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Number of Facilities Sold",
        "label": "Disposal Group, Number of Facilities Sold",
        "terseLabel": "Number of facilities sold"
       }
      }
     },
     "localname": "DisposalGroupNumberOfFacilitiesSold",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "opk_DrFrostandMrPfennigerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr Frost and Mr Pfenniger [Member]",
        "label": "Dr Frost and Mr Pfenniger [Member]",
        "terseLabel": "Dr Frost and Mr Pfenniger"
       }
      }
     },
     "localname": "DrFrostandMrPfennigerMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_DravetSyndromeProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dravet Syndrome Products",
        "label": "Dravet Syndrome Products [Member]",
        "terseLabel": "Dravet Syndrome Products"
       }
      }
     },
     "localname": "DravetSyndromeProductsMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_EirGenPharmaLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EirGen Pharma Limited [Member]",
        "label": "EirGen Pharma Limited [Member]",
        "terseLabel": "EirGen Pharma Limited",
        "verboseLabel": "Rayaldee"
       }
      }
     },
     "localname": "EirGenPharmaLimitedMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_EloxxPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eloxx Pharmaceuticals [Member]",
        "label": "Eloxx Pharmaceuticals [Member]",
        "terseLabel": "Eloxx Pharmaceuticals"
       }
      }
     },
     "localname": "EloxxPharmaceuticalsMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_EquityMethodInvestmentExcludingVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Excluding Variable Interest Entity",
        "label": "Equity Method Investment, Excluding Variable Interest Entity",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentExcludingVariableInterestEntity",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_EquityMethodInvestmentVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Variable Interest Entity",
        "label": "Equity Method Investment, Variable Interest Entity",
        "terseLabel": "Variable interest entity, equity method"
       }
      }
     },
     "localname": "EquityMethodInvestmentVariableInterestEntity",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Variable Interest Entity, Underlying Equity in Net Assets",
        "label": "Equity Method Investment, Variable Interest Entity, Underlying Equity in Net Assets",
        "terseLabel": "Variable interest entity, equity method, underlying equity in net assets"
       }
      }
     },
     "localname": "EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]",
        "label": "Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]",
        "terseLabel": "Equity Method Investments, Warrants and Options, and Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesAbstract",
     "nsuri": "http://www.opko.com/20220331",
     "xbrltype": "stringItemType"
    },
    "opk_EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Warrants and Options, and Variable Interest Entities [Line Items]",
        "label": "Equity Method Investments, Warrants and Options, and Variable Interest Entities [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsWarrantsandOptionsandVariableInterestEntitiesLineItems",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_EquitySecurityFVNIOwnershipPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Security, FV-NI, Ownership Percentage",
        "label": "Equity Security, FV-NI, Ownership Percent",
        "terseLabel": "Equity security investments (as a percent)"
       }
      }
     },
     "localname": "EquitySecurityFVNIOwnershipPercent",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "opk_EstadoBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estado bank.",
        "label": "Estado Bank [Member]",
        "verboseLabel": "Estado Bank"
       }
      }
     },
     "localname": "EstadoBankMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ExclusiveOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive Option [Member]",
        "label": "Exclusive Option [Member]",
        "terseLabel": "Exclusive Option"
       }
      }
     },
     "localname": "ExclusiveOptionMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Currency Impact",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Currency Impact",
        "terseLabel": "Foreign currency impact"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings [Abstract]",
        "terseLabel": "Change in fair value:"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsAbstract",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_FederalAndStateGovernmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal and State Governments",
        "label": "Federal and State Governments [Member]",
        "terseLabel": "Federal and State Governments"
       }
      }
     },
     "localname": "FederalAndStateGovernmentsMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liability, Payments, Due after Year Four",
        "label": "Finance Lease, Liability, Payments, Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_FineTechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FineTech.",
        "label": "FineTech [Member]",
        "terseLabel": "FineTech"
       }
      }
     },
     "localname": "FineTechMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_FrostRealEstateHoldingsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frost real estate holdings LLC.",
        "label": "Frost Real Estate Holdings LLC [Member]",
        "verboseLabel": "Frost Real Estate Holdings LLC"
       }
      }
     },
     "localname": "FrostRealEstateHoldingsLLCMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_GainLossOnConversionOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on Conversion of Debt",
        "label": "Gain (Loss) on Conversion of Debt",
        "negatedTerseLabel": "Loss on conversion of the 2025 Notes"
       }
      }
     },
     "localname": "GainLossOnConversionOfDebt",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_GenomicTestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genomic Test",
        "label": "Genomic Test [Member]",
        "terseLabel": "Genomic Test"
       }
      }
     },
     "localname": "GenomicTestMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_GovernmentPayersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Payers [Member]",
        "label": "Government Payers [Member]",
        "terseLabel": "Government payers"
       }
      }
     },
     "localname": "GovernmentPayersMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_GovernmentalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Governmental [Member]",
        "label": "Governmental [Member]",
        "terseLabel": "Governmental"
       }
      }
     },
     "localname": "GovernmentalMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_HealthInsurersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Insurers [Member]",
        "label": "Health Insurers [Member]",
        "terseLabel": "Healthcare insurers"
       }
      }
     },
     "localname": "HealthInsurersMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_HealthSnapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HealthSnap",
        "label": "HealthSnap [Member]",
        "terseLabel": "HealthSnap"
       }
      }
     },
     "localname": "HealthSnapMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_InCellDxIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "InCellDx, Inc [Member]",
        "label": "InCellDx, Inc [Member]",
        "terseLabel": "InCellDx, Inc"
       }
      }
     },
     "localname": "InCellDxIncMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_InProcessResearchandDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In-Process Research and Development",
        "label": "In-Process Research and Development",
        "negatedTerseLabel": "In-Process Research and Development",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchandDevelopment",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) from continuing operations before investment losses.",
        "label": "Income (Loss) from Continuing Operations, Before Investments in Investees, Extraordinary Items, Net of Tax",
        "totalLabel": "Net income (loss) before investment losses"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Equity Securities, FV-NI And Derivative Instruments",
        "label": "Increase (Decrease) In Equity Securities, FV-NI And Derivative Instruments",
        "negatedLabel": "Change in fair value of equity securities and derivative instruments"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Revenue from Contract with Customer, Excluding Assessed Tax",
        "label": "Increase (Decrease) in Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Increase (decrease) in revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_IncreaseDecreaseinForeignCurrencyMeasurement": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Foreign Currency Measurement",
        "label": "Increase (Decrease) in Foreign Currency Measurement",
        "terseLabel": "Foreign currency measurement"
       }
      }
     },
     "localname": "IncreaseDecreaseinForeignCurrencyMeasurement",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_IndividualPatientsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Individual Patients",
        "label": "Individual Patients [Member]",
        "terseLabel": "Individual Patients"
       }
      }
     },
     "localname": "IndividualPatientsMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_InterestExpenseNonoperating": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense, Nonoperating",
        "label": "Interest Expense, Nonoperating",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseNonoperating",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_InterestIncomeNonoperating": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Income, Nonoperating",
        "label": "Interest Income, Nonoperating",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeNonoperating",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_InternationalBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Bank",
        "label": "International Bank [Member]",
        "terseLabel": "International Bank"
       }
      }
     },
     "localname": "InternationalBankMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_InventoryReceivedNotInvoicedCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Received, Not Invoiced, Current",
        "label": "Inventory Received, Not Invoiced, Current",
        "terseLabel": "Inventory received but not invoiced"
       }
      }
     },
     "localname": "InventoryReceivedNotInvoicedCurrent",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_ItauBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Itau.",
        "label": "Itau Bank [Member]",
        "verboseLabel": "Itau Bank"
       }
      }
     },
     "localname": "ItauBankMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_JPMorganChaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JP Morgan Chase [Member]",
        "label": "JP Morgan Chase [Member]",
        "terseLabel": "JPMorgan Chase"
       }
      }
     },
     "localname": "JPMorganChaseMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_LeaderMedJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LeaderMed Joint Venture",
        "label": "LeaderMed Joint Venture [Member]",
        "terseLabel": "LeaderMed Joint Venture"
       }
      }
     },
     "localname": "LeaderMedJointVentureMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_LeaderMedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LeaderMed",
        "label": "LeaderMed [Member]",
        "terseLabel": "LeaderMed"
       }
      }
     },
     "localname": "LeaderMedMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_LineOfCreditAndNotesAndLoansPayableCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit and Notes and Loans Payable, Current",
        "label": "Line of Credit and Notes and Loans Payable, Current [Member]",
        "terseLabel": "Current portion of lines of credit and notes payable"
       }
      }
     },
     "localname": "LineOfCreditAndNotesAndLoansPayableCurrentMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, 50% Or More Of Revolving Commitment",
        "label": "Line Of Credit Facility, 50% Or More Of Revolving Commitment [Member]",
        "terseLabel": "50% or more of revolving commitment"
       }
      }
     },
     "localname": "LineOfCreditFacility50OrMoreOfRevolvingCommitmentMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Less Than or Equal To 50% Of Revolving Commitment",
        "label": "Line Of Credit Facility, Less Than or Equal To 50% Of Revolving Commitment [Member]",
        "terseLabel": "Less than or equal to 50% of revolving commitment"
       }
      }
     },
     "localname": "LineOfCreditFacilityLessThanOrEqualTo50OfRevolvingCommitmentMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_LineOfCreditFacilityRevolvingCommitmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Revolving Commitment",
        "label": "Line Of Credit Facility, Revolving Commitment [Axis]",
        "terseLabel": "Line Of Credit Facility, Revolving Commitment [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityRevolvingCommitmentAxis",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_LineOfCreditFacilityRevolvingCommitmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Revolving Commitment [Domain]",
        "label": "Line Of Credit Facility, Revolving Commitment [Domain]",
        "terseLabel": "Line Of Credit Facility, Revolving Commitment [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityRevolvingCommitmentDomain",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "London Interbank Offered Rate (LIBOR), First Twelve Months, Adjusted for Eurocurrency Liabilities [Member]",
        "label": "London Interbank Offered Rate (LIBOR), First Twelve Months, Adjusted for Eurocurrency Liabilities [Member]",
        "terseLabel": "LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORFirstTwelveMonthsAdjustedforEurocurrencyLiabilitiesMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "London Interbank Offered Rate (LIBOR), First Twelve Months [Member]",
        "label": "London Interbank Offered Rate (LIBOR), First Twelve Months [Member]",
        "terseLabel": "LIBOR, First 12 Months"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORFirstTwelveMonthsMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_LossContingencyMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Milestone Payment",
        "label": "Loss Contingency, Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "LossContingencyMilestonePayment",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_MednaxServicesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mednax Services, Inc.",
        "label": "Mednax Services, Inc. [Member]",
        "terseLabel": "Mednax Services, Inc."
       }
      }
     },
     "localname": "MednaxServicesIncMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Milestone [Axis]",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_MuseumofScienceIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Museum of Science, Inc [Member]",
        "label": "Museum of Science, Inc [Member]",
        "terseLabel": "Museum of Science, Inc"
       }
      }
     },
     "localname": "MuseumofScienceIncMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NIMSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NIMS [Member]",
        "label": "NIMS [Member]",
        "terseLabel": "NIMS"
       }
      }
     },
     "localname": "NIMSMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NeovascMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neovasc [Member]",
        "label": "Neovasc [Member]",
        "terseLabel": "Neovasc"
       }
      }
     },
     "localname": "NeovascMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NewCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Credit Agreement [Member]",
        "label": "New Credit Agreement [Member]",
        "terseLabel": "New Credit Agreement"
       }
      }
     },
     "localname": "NewCreditAgreementMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NicoyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nicoya",
        "label": "Nicoya [Member]",
        "terseLabel": "Nicoya"
       }
      }
     },
     "localname": "NicoyaMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NonDravetSyndromeProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Dravet Syndrome Products",
        "label": "Non-Dravet Syndrome Products [Member]",
        "terseLabel": "Non-Dravet Syndrome Products"
       }
      }
     },
     "localname": "NonDravetSyndromeProductsMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NonInvasiveMonitoringSystemsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Invasive Monitoring Systems, Inc. [Member]",
        "label": "Non-Invasive Monitoring Systems, Inc. [Member]",
        "terseLabel": "Non-Invasive Monitoring Systems, Inc."
       }
      }
     },
     "localname": "NonInvasiveMonitoringSystemsInc.Member",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NoncontrollingInterestSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Shares Issued",
        "label": "Noncontrolling Interest, Shares Issued",
        "terseLabel": "Joint venture (in shares)"
       }
      }
     },
     "localname": "NoncontrollingInterestSharesIssued",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_NotesDueFebruary12033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Due February 1, 2033 [Member]",
        "label": "Notes Due February 1, 2033 [Member]",
        "terseLabel": "Notes Due February 1, 2033"
       }
      }
     },
     "localname": "NotesDueFebruary12033Member",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NotesPayableAndOtherLongTermLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable And Other Long-Term Liabilities [Member]",
        "label": "Notes Payable And Other Long-Term Liabilities [Member]",
        "terseLabel": "Notes Payable and Other Long-Term Liabilities"
       }
      }
     },
     "localname": "NotesPayableAndOtherLongTermLiabilitiesMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_NumberofSalesEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Sales Employees",
        "label": "Number of Sales Employees",
        "terseLabel": "Number of sales employees"
       }
      }
     },
     "localname": "NumberofSalesEmployees",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "opk_OPKOBiologicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OPKO Biologics [Member]",
        "label": "OPKO Biologics [Member]",
        "terseLabel": "OPKO Biologics"
       }
      }
     },
     "localname": "OPKOBiologicsMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_OPKOHealthEuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OPKO Health Europe [Member]",
        "label": "OPKO Health Europe [Member]",
        "terseLabel": "OPKO Health Europe",
        "verboseLabel": "OPKO Health Europe"
       }
      }
     },
     "localname": "OPKOHealthEuropeMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_OPKOMexicoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OPKO Mexico",
        "label": "OPKO Mexico [Member]",
        "terseLabel": "OPKO Mexico"
       }
      }
     },
     "localname": "OPKOMexicoMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_OperatingLeasesMonthlyPaymentsYearFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Monthly Payments, Year Five",
        "label": "Operating Leases, Monthly Payments, Year Five",
        "terseLabel": "Lease payments per month in fifth year"
       }
      }
     },
     "localname": "OperatingLeasesMonthlyPaymentsYearFive",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_OperatingLeasesMonthlyPaymentsYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Monthly Payments, Year One",
        "label": "Operating Leases, Monthly Payments, Year One",
        "terseLabel": "Lease payments per month in first year"
       }
      }
     },
     "localname": "OperatingLeasesMonthlyPaymentsYearOne",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_OpkoChileMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opko Chile.",
        "label": "OPKO Chile [Member]",
        "terseLabel": "OPKO Chile"
       }
      }
     },
     "localname": "OpkoChileMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_OpkoDiagnosticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OPKO Diagnostics.",
        "label": "Opko Diagnostics [Member]",
        "terseLabel": "OPKO Diagnostics"
       }
      }
     },
     "localname": "OpkoDiagnosticsMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_PatientsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patients [Member]",
        "label": "Patients [Member]",
        "terseLabel": "Patients"
       }
      }
     },
     "localname": "PatientsMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_PaymentsForLeases": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Leases",
        "label": "Payments For Leases",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PaymentsForLeases",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer [Member]",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical [Member]",
        "label": "Pharmaceutical [Member]",
        "terseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_PharmsynthezMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmsynthez [Member]",
        "label": "Pharmsynthez [Member]",
        "terseLabel": "Pharmsynthez"
       }
      }
     },
     "localname": "PharmsynthezMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_PhaseThreeInitiationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase Three Initiation",
        "label": "Phase Three Initiation [Member]",
        "terseLabel": "Phase Three Initiation"
       }
      }
     },
     "localname": "PhaseThreeInitiationMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_PhioPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phio Pharmaceuticals [Member]",
        "label": "Phio Pharmaceuticals [Member]",
        "terseLabel": "Phio Pharmaceuticals"
       }
      }
     },
     "localname": "PhioPharmaceuticalsMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses and Other Current Assets (Accrued Expenses) [Member]",
        "label": "Prepaid Expenses and Other Current Assets (Accrued Expenses) [Member]",
        "terseLabel": "Unrealized gains on forward contracts are recorded in Other current assets and prepaid expenses. Unrealized (losses) on forward contracts are recorded in Accrued expenses."
       }
      }
     },
     "localname": "PrepaidExpensesandOtherCurrentAssetsAccruedExpensesMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ProceedsFromConvertibleDebtConversionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Convertible Debt, Conversion Fee",
        "label": "Proceeds From Convertible Debt, Conversion Fee",
        "terseLabel": "Proceeds one-time nominal fee"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebtConversionFee",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Development And License Agreement, Milestone Payment",
        "label": "Proceeds From Development And License Agreement, Milestone Payment",
        "terseLabel": "Milestone payment from development and license agreement"
       }
      }
     },
     "localname": "ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Development And License Agreement, Upfront Payment",
        "label": "Proceeds From Development And License Agreement, Upfront Payment",
        "terseLabel": "Upfront payment from development and license agreement"
       }
      }
     },
     "localname": "ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_ProductRegistrationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Registrations [Member]",
        "label": "Product Registrations [Member]",
        "terseLabel": "Product registrations"
       }
      }
     },
     "localname": "ProductRegistrationsMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_RayaldeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rayaldee [Member]",
        "label": "Rayaldee [Member]",
        "terseLabel": "Rayaldee"
       }
      }
     },
     "localname": "RayaldeeMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_RegulatoryAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory And Development [Member]",
        "label": "Regulatory And Development [Member]",
        "terseLabel": "Regulatory and Development"
       }
      }
     },
     "localname": "RegulatoryAndDevelopmentMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_RelatedPartyTransactionFutureContributionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Future Contribution, Term",
        "label": "Related Party Transaction, Future Contribution, Term",
        "terseLabel": "Related party future contribution term"
       }
      }
     },
     "localname": "RelatedPartyTransactionFutureContributionTerm",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "opk_RelatedPartyTransactionFutureContributions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Future Contributions",
        "label": "Related Party Transaction, Future Contributions",
        "terseLabel": "Related party future contribution"
       }
      }
     },
     "localname": "RelatedPartyTransactionFutureContributions",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_RelatedPartyTransactionShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Shares",
        "label": "Related Party Transaction, Shares",
        "terseLabel": "Shares received upon closing of transaction (in shares)"
       }
      }
     },
     "localname": "RelatedPartyTransactionShares",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_RoutineClinicalTestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Routine Clinical Test",
        "label": "Routine Clinical Test [Member]",
        "terseLabel": "Routine Clinical Test"
       }
      }
     },
     "localname": "RoutineClinicalTestMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestones [Member]",
        "label": "Sales Milestones [Member]",
        "terseLabel": "Sales Milestones"
       }
      }
     },
     "localname": "SalesMilestonesMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SalesReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Returns [Member]",
        "label": "Sales Returns [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SantanderBank2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Santander Bank2",
        "label": "Santander Bank2 [Member]",
        "terseLabel": "Santander Bank"
       }
      }
     },
     "localname": "SantanderBank2Member",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SantanderBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "santander Bank.",
        "label": "Santander Bank [Member]",
        "terseLabel": "Santander Bank"
       }
      }
     },
     "localname": "SantanderBankMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Product Sales Allowances And Accruals [Table Text Block]",
        "label": "Schedule Of Product Sales Allowances And Accruals [Table Text Block]",
        "terseLabel": "Schedule of Product Sales Allowances and Accruals"
       }
      }
     },
     "localname": "ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "opk_ScotiabankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scotiabank [Member]",
        "label": "Scotiabank [Member]",
        "terseLabel": "Scotiabank"
       }
      }
     },
     "localname": "ScotiabankMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SecurityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security.",
        "label": "Security [Member]",
        "terseLabel": "Security Bank"
       }
      }
     },
     "localname": "SecurityMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_Sema4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sema4",
        "label": "Sema4 [Member]",
        "terseLabel": "Sema4"
       }
      }
     },
     "localname": "Sema4Member",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SharesReceivedAsGift": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Received As Gift",
        "label": "Shares Received As Gift",
        "terseLabel": "Shares received as a gift (in shares)"
       }
      }
     },
     "localname": "SharesReceivedAsGift",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_SharesReceivedUponClosingofXeneticTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Received Upon Closing of Xenetic Transaction [Member]",
        "label": "Shares Received Upon Closing of Xenetic Transaction [Member]",
        "terseLabel": "Shares Received Upon Closing of Xenetic Transaction"
       }
      }
     },
     "localname": "SharesReceivedUponClosingofXeneticTransactionMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_SharesSurrenderedInLieuOfCashPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares surrendered in lieu of cash payment.",
        "label": "Shares Surrendered in Lieu of Cash Payment",
        "verboseLabel": "Shares surrendered in lieu of cash payment (in shares)"
       }
      }
     },
     "localname": "SharesSurrenderedInLieuOfCashPayment",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_SouthernDistrictOfNewYorkVsBioReferenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Southern District of New York vs BioReference",
        "label": "Southern District of New York vs BioReference [Member]",
        "terseLabel": "Southern District of New York vs BioReference"
       }
      }
     },
     "localname": "SouthernDistrictOfNewYorkVsBioReferenceMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_StatesCitiesAndOtherMunicipalitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "States, Cities and Other Municipalities",
        "label": "States, Cities and Other Municipalities [Member]",
        "terseLabel": "States, Cities and Other Municipalities"
       }
      }
     },
     "localname": "StatesCitiesAndOtherMunicipalitiesMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock warrant and common stock options exercised.",
        "label": "Stock Issued During Period, Shares, Stock Options and Warrants Exercised",
        "verboseLabel": "Number of common stock warrant and common stock options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock issued for stock warrant and stock options exercised.",
        "label": "Stock Issued During Period, Shares, Stock Options and Warrants Exercised, Net of Shares Surrendered in Lieu of Cash Payment",
        "terseLabel": "Number of common stock issued for stock warrant and stock options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "opk_StockOptionandWarrantInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option and Warrant Investments",
        "label": "Stock Option and Warrant Investments",
        "terseLabel": "Warrants and options"
       }
      }
     },
     "localname": "StockOptionandWarrantInvestments",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_StrategicAlliancesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic Alliances [Text Block]",
        "label": "Strategic Alliances [Text Block]",
        "terseLabel": "STRATEGIC ALLIANCES"
       }
      }
     },
     "localname": "StrategicAlliancesTextBlock",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliances"
     ],
     "xbrltype": "textBlockItemType"
    },
    "opk_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Significant Accounting Policies [Line Items]",
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Significant Accounting Policies [Table]",
        "label": "Summary of Significant Accounting Policies [Table]",
        "terseLabel": "Summary of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_TaxesRecoverableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taxes Recoverable, Current",
        "label": "Taxes Recoverable, Current",
        "terseLabel": "Taxes recoverable"
       }
      }
     },
     "localname": "TaxesRecoverableCurrent",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "opk_TestingTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Testing Type",
        "label": "Testing Type [Axis]",
        "terseLabel": "Testing Type [Axis]"
       }
      }
     },
     "localname": "TestingTypeAxis",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_TestingTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Testing Type",
        "label": "Testing Type [Domain]",
        "terseLabel": "Testing Type [Domain]"
       }
      }
     },
     "localname": "TestingTypeDomain",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_TransferOfIntellectualPropertyAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer Of Intellectual Property And Other [Member]",
        "label": "Transfer Of Intellectual Property And Other [Member]",
        "terseLabel": "Transfer of intellectual property and other",
        "verboseLabel": "Revenue from transfer of intellectual property and other"
       }
      }
     },
     "localname": "TransferOfIntellectualPropertyAndOtherMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_TransitionTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition Therapeutics, Inc. [Member]",
        "label": "Transition Therapeutics, Inc. [Member]",
        "terseLabel": "Transition Therapeutics"
       }
      }
     },
     "localname": "TransitionTherapeuticsInc.Member",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_VBIVaccinesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VBI Vaccines Inc [Member]",
        "label": "VBI Vaccines Inc [Member]",
        "terseLabel": "VBI Vaccines Inc"
       }
      }
     },
     "localname": "VBIVaccinesIncMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ViforFreseniusMedicalCarePharmaLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vifor Fresenius Medical Care Pharma Ltd [Member]",
        "label": "Vifor Fresenius Medical Care Pharma Ltd [Member]",
        "terseLabel": "VFMCRP"
       }
      }
     },
     "localname": "ViforFreseniusMedicalCarePharmaLtdMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_WaterfordIrelandFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Waterford, Ireland Facility",
        "label": "Waterford, Ireland Facility [Member]",
        "terseLabel": "Waterford, Ireland Facility"
       }
      }
     },
     "localname": "WaterfordIrelandFacilityMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Discount Rate [Abstract]",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Lease Term [Abstract]",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "opk_XeneticBiosciencesInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xenetic Biosciences, Inc. [Member]",
        "label": "Xenetic Biosciences, Inc. [Member]",
        "terseLabel": "Xenetic Biosciences, Inc."
       }
      }
     },
     "localname": "XeneticBiosciencesInc.Member",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "opk_ZebraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zebra [Member]",
        "label": "Zebra [Member]",
        "terseLabel": "Zebra"
       }
      }
     },
     "localname": "ZebraMember",
     "nsuri": "http://www.opko.com/20220331",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements, Captions [Line Items]",
        "terseLabel": "Condensed Financial Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r161",
      "r360",
      "r365",
      "r373",
      "r541",
      "r542",
      "r549",
      "r550",
      "r660",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r161",
      "r360",
      "r365",
      "r373",
      "r541",
      "r542",
      "r549",
      "r550",
      "r660",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r161",
      "r222",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r248",
      "r252",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r370",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r161",
      "r222",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r248",
      "r252",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r370",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r89",
      "r91",
      "r158",
      "r159",
      "r380",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r171",
      "r178",
      "r184",
      "r290",
      "r485",
      "r486",
      "r487",
      "r505",
      "r506",
      "r580",
      "r583",
      "r585",
      "r586",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r171",
      "r178",
      "r184",
      "r290",
      "r485",
      "r486",
      "r487",
      "r505",
      "r506",
      "r580",
      "r583",
      "r585",
      "r586",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r171",
      "r178",
      "r184",
      "r290",
      "r485",
      "r486",
      "r487",
      "r505",
      "r506",
      "r580",
      "r583",
      "r585",
      "r586",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r259",
      "r450",
      "r456",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r379",
      "r416",
      "r473",
      "r475",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r698",
      "r751",
      "r755",
      "r790",
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r379",
      "r416",
      "r473",
      "r475",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r698",
      "r751",
      "r755",
      "r790",
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r259",
      "r450",
      "r456",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r255",
      "r450",
      "r454",
      "r702",
      "r750",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/ImpactofCOVID19Details",
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r255",
      "r450",
      "r454",
      "r702",
      "r750",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/ImpactofCOVID19Details",
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r379",
      "r416",
      "r462",
      "r473",
      "r475",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r698",
      "r751",
      "r755",
      "r790",
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r379",
      "r416",
      "r462",
      "r473",
      "r475",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r698",
      "r751",
      "r755",
      "r790",
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r90",
      "r91",
      "r158",
      "r159",
      "r380",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "auth_ref": [
      "r161",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements [Table]",
        "terseLabel": "Condensed Financial Statements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r256",
      "r257",
      "r450",
      "r455",
      "r753",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r256",
      "r257",
      "r450",
      "r455",
      "r753",
      "r775",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r172",
      "r173",
      "r174",
      "r175",
      "r267",
      "r268",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r359",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r505",
      "r506",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r651",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r63",
      "r663"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r262",
      "r263"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss [Abstract]",
        "verboseLabel": "Accounts receivable, net:"
       }
      }
     },
     "localname": "AccountsReceivableNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r23",
      "r47",
      "r262",
      "r263"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Accounts receivable, net",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r29",
      "r30",
      "r68"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued expenses",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued expenses:"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Liabilities",
        "verboseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails",
      "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r29",
      "r30",
      "r68"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r50",
      "r96",
      "r97",
      "r98",
      "r739",
      "r763",
      "r767"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r106",
      "r107",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r95",
      "r98",
      "r106",
      "r107",
      "r108",
      "r168",
      "r169",
      "r170",
      "r547",
      "r758",
      "r759",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r94",
      "r98",
      "r106",
      "r107",
      "r108",
      "r547",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r48",
      "r488",
      "r663"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r485",
      "r486",
      "r487",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "verboseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r172",
      "r173",
      "r174",
      "r175",
      "r184",
      "r267",
      "r268",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r359",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r503",
      "r504",
      "r505",
      "r506",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r651",
      "r704",
      "r705",
      "r706",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r476",
      "r477",
      "r490",
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r477",
      "r480",
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r264",
      "r293",
      "r295",
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r54",
      "r264",
      "r293"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedTerseLabel": "Less: allowance for credit losses",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r122",
      "r140",
      "r399",
      "r629"
     ],
     "calculation": {
      "http://www.opko.com/role/DebtScheduleofNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AmortizationOfFinancingCostsAndDiscounts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r117",
      "r140",
      "r399",
      "r631"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.opko.com/role/DebtScheduleofNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AmortizationOfFinancingCostsAndDiscounts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt discount and debt issuance costs",
        "verboseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r140",
      "r399",
      "r411",
      "r412",
      "r631"
     ],
     "calculation": {
      "http://www.opko.com/role/DebtScheduleofNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "totalLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r140",
      "r324",
      "r333"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive potential shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of real estate property (in square feet)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r155",
      "r230",
      "r243",
      "r250",
      "r284",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r371",
      "r373",
      "r374",
      "r541",
      "r549",
      "r605",
      "r661",
      "r663",
      "r721",
      "r737"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Total assets of equity method investees"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r26",
      "r28",
      "r84",
      "r155",
      "r284",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r371",
      "r373",
      "r374",
      "r541",
      "r549",
      "r605",
      "r661",
      "r663"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r589"
     ],
     "calculation": {
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group.",
        "label": "Assets Held-for-sale, Not Part of Disposal Group",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroup",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r562",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BridgeLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place.",
        "label": "Bridge Loan [Member]",
        "terseLabel": "Swingline"
       }
      }
     },
     "localname": "BridgeLoanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and Improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r472",
      "r474",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Number of shares issued in business combination (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r522",
      "r523",
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total aggregate consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r139",
      "r531"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r521",
      "r524",
      "r529"
     ],
     "calculation": {
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails",
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r521",
      "r525"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r521",
      "r525"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r21",
      "r58",
      "r142"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r36",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r136",
      "r142",
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r136",
      "r618"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r153",
      "r155",
      "r187",
      "r188",
      "r189",
      "r191",
      "r193",
      "r202",
      "r203",
      "r204",
      "r284",
      "r360",
      "r365",
      "r366",
      "r367",
      "r373",
      "r374",
      "r414",
      "r415",
      "r418",
      "r419",
      "r605",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares into which warrants may be converted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r355",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r168",
      "r169",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.opko.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r46",
      "r663"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common Stock - $0.01 par value, 1,000,000,000 shares authorized; 690,138,033 and 690,082,283 shares issued at March 31, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "verboseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r101",
      "r103",
      "r104",
      "r114",
      "r728",
      "r745"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r113",
      "r126",
      "r727",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "verboseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r212",
      "r213",
      "r259",
      "r602",
      "r603",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r259",
      "r602",
      "r603",
      "r768",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r259",
      "r602",
      "r603",
      "r768",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r207",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risk and allowance for credit losses"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r212",
      "r213",
      "r259",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration percentage",
        "verboseLabel": "Concentration risk (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r212",
      "r213",
      "r259",
      "r602",
      "r603",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r149",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r548",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "verboseLabel": "Variable interest entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Changes in Contractual Liabilities Balance"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r430",
      "r431",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionChangesinContractualLiabilitiesBalanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability [Abstract]",
        "terseLabel": "Contract with Customer, Liability [Abstract]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionChangesinContractualLiabilitiesBalanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r430",
      "r431",
      "r451"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r430",
      "r431",
      "r451"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Milestone revenue recognized",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionChangesinContractualLiabilitiesBalanceDetails",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Prior period performance obligation revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r379",
      "r389",
      "r390",
      "r391",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "verboseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r39",
      "r722",
      "r735",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Notes"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "Corporate Joint Venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r252",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r118",
      "r702"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of service revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r210",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "verboseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Converted debt amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Shares issued on converted debt (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r152",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r393",
      "r400",
      "r401",
      "r403",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r39",
      "r41",
      "r42",
      "r154",
      "r161",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r409",
      "r410",
      "r411",
      "r412",
      "r632",
      "r722",
      "r723",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r42",
      "r405",
      "r723",
      "r735"
     ],
     "calculation": {
      "http://www.opko.com/role/DebtScheduleofNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Equity component of convertible debt"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r378",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price per share (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r71",
      "r378",
      "r422",
      "r423",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Number of consecutive trading days applicable conversion price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "verboseLabel": "Convertible debt, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Number of trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r376",
      "r409",
      "r410",
      "r630",
      "r632",
      "r633"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Debt face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r70",
      "r408",
      "r630",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r70",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate on notes payable"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r72",
      "r154",
      "r161",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r409",
      "r410",
      "r411",
      "r412",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Redemption period one"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Redemption period three"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Redemption period two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "verboseLabel": "Equivalent redemption price"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Debt repurchase amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r72",
      "r154",
      "r161",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r402",
      "r409",
      "r410",
      "r411",
      "r412",
      "r422",
      "r424",
      "r425",
      "r426",
      "r629",
      "r630",
      "r632",
      "r633",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r389",
      "r629",
      "r633"
     ],
     "calculation": {
      "http://www.opko.com/role/DebtScheduleofNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount [Abstract]",
        "terseLabel": "Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]",
        "terseLabel": "2025 Senior Notes"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r62",
      "r389",
      "r631"
     ],
     "calculation": {
      "http://www.opko.com/role/DebtScheduleofNotesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Net [Abstract]",
        "terseLabel": "Debt Issuance Cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r140",
      "r156",
      "r501",
      "r508",
      "r509",
      "r510"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r495",
      "r496"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r140",
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r140",
      "r225"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r87",
      "r88",
      "r91",
      "r599"
     ],
     "calculation": {
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract Type [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r86",
      "r91",
      "r92",
      "r565",
      "r680"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "verboseLabel": "Derivative asset"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "verboseLabel": "Derivative gain (loss)"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r91",
      "r563",
      "r566",
      "r569",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument Risk [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r576",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "DERIVATIVE CONTRACTS"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContracts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r560",
      "r563",
      "r569",
      "r571",
      "r572",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r87",
      "r88",
      "r91",
      "r599"
     ],
     "calculation": {
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Forward contracts"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r160",
      "r558",
      "r559",
      "r560",
      "r561",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "verboseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Technologies"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r450",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r338",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration from sale of facility"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Income (loss) per share, basic and diluted:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r115",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r185",
      "r187",
      "r191",
      "r192",
      "r193",
      "r197",
      "r198",
      "r586",
      "r587",
      "r729",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Income (loss) per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r115",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r187",
      "r191",
      "r192",
      "r193",
      "r197",
      "r198",
      "r586",
      "r587",
      "r729",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Income (loss) per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r618"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r106",
      "r107",
      "r108",
      "r168",
      "r169",
      "r170",
      "r173",
      "r181",
      "r183",
      "r201",
      "r290",
      "r421",
      "r427",
      "r485",
      "r486",
      "r487",
      "r505",
      "r506",
      "r585",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625",
      "r758",
      "r759",
      "r760",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity [Abstract]",
        "terseLabel": "Underlying Equity in Net Assets"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Financial Statement, Reported Amounts [Abstract]",
        "terseLabel": "Investment Carrying Value"
       }
      }
     },
     "localname": "EquityMethodInvestmentFinancialStatementReportedAmountsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r19",
      "r155",
      "r284",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r19",
      "r155",
      "r284",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": {
     "auth_ref": [
      "r19",
      "r155",
      "r284",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investments (as a percent)"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentQuotedMarketValue": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.",
        "label": "Equity Method Investment, Quoted Market Value",
        "terseLabel": "Market value"
       }
      }
     },
     "localname": "EquityMethodInvestmentQuotedMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.",
        "label": "Equity Method Investment, Underlying Equity in Net Assets",
        "terseLabel": "Equity method investment, underlying equity in net assets"
       }
      }
     },
     "localname": "EquityMethodInvestmentUnderlyingEquityInNetAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r597"
     ],
     "calculation": {
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "totalLabel": "Net gains and losses recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Gain (Loss) [Abstract]",
        "terseLabel": "Equity Securities:"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r276",
      "r748"
     ],
     "calculation": {
      "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedTerseLabel": "Less: Net gains realized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r276",
      "r748"
     ],
     "calculation": {
      "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized net gains and losses recognized during the period on equity securities still held at the reporting date"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsScheduleofNetGainsandLossesonEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r37",
      "r40",
      "r272",
      "r736",
      "r772",
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Common stock options/warrants"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity securities with no readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExtraordinaryAndUnusualItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unusual or Infrequent Items, or Both [Abstract]"
       }
      }
     },
     "localname": "ExtraordinaryAndUnusualItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails",
      "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r589",
      "r590",
      "r591",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails",
      "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r592",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation of the Beginning and Ending Balances of Level 3 Assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r589",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Carrying Amount and Estimated Fair Value of Long-Term Debt"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r391",
      "r409",
      "r410",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r590",
      "r670",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r391",
      "r409",
      "r410",
      "r589",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r391",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r391",
      "r463",
      "r464",
      "r469",
      "r471",
      "r590",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01",
        "verboseLabel": "Quoted prices in active markets for identical assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r391",
      "r409",
      "r410",
      "r463",
      "r464",
      "r469",
      "r471",
      "r590",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02",
        "verboseLabel": "Significant other observable inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r391",
      "r409",
      "r410",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r590",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "verboseLabel": "Significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r592",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of the Beginning and Ending Balances of Level 3 Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "verboseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r593"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Included in results of operations"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r592"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsLevel3ReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r391",
      "r409",
      "r410",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r670",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Measurements Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r562",
      "r568",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r637",
      "r641",
      "r649"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Finance lease expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r639",
      "r644"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails": {
       "order": 2.0,
       "parentTag": "opk_PaymentsForLeases",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash out flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r635",
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance leases short-term",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Lease Liability Maturity"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "verboseLabel": "Finance leases long-term"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total undiscounted future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "April 1, 2022 through December 31, 2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Difference between lease payments and discounted lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r638",
      "r644"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails": {
       "order": 3.0,
       "parentTag": "opk_PaymentsForLeases",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Financing cash out flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r634"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r646",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r645",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r294",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r402",
      "r420",
      "r576",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible assets, estimated useful lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less: accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r325",
      "r328",
      "r332",
      "r335",
      "r703",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r332",
      "r707"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r325",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r332",
      "r703"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Intangible assets, net:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r614",
      "r615",
      "r616",
      "r617"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency transaction gains (losses)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "terseLabel": "Forward contracts",
        "verboseLabel": "Forward contracts"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails",
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r563"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Fair value changes of derivative instruments, net"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Realized loss (gain) on disposal of fixed assets and sales of equity securities"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r120",
      "r140",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Loss from investment in investees"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "terseLabel": "Gain on sale of assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r211",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r314",
      "r315",
      "r663",
      "r720"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "netLabel": "Goodwill, ending balance",
        "terseLabel": "Goodwill, beginning balance",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r319",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill and intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r316",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "negatedTerseLabel": "Cumulative impairment at January 1"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r560",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r336",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r230",
      "r242",
      "r246",
      "r249",
      "r252"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes and investment losses"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r111",
      "r140",
      "r227",
      "r278",
      "r725",
      "r742"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Losses from investments in investees",
        "verboseLabel": "Loss from investments in investees"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r6",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r15",
      "r17",
      "r18",
      "r19",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r157",
      "r182",
      "r183",
      "r228",
      "r497",
      "r507",
      "r511",
      "r749"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "opk_IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit (provision)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r493",
      "r494",
      "r498",
      "r499",
      "r500",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "verboseLabel": "Income taxes paid, net of refunds"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r139",
      "r699"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other current assets and prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r327",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net intangible assets other than goodwill"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r327",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r323",
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r109",
      "r224",
      "r628",
      "r631",
      "r730"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Inter-segment allocation of interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r134",
      "r137",
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntersegmentEliminationMember": {
     "auth_ref": [
      "r222",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r248",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminating entries used in operating segment consolidation.",
        "label": "Intersegment Eliminations [Member]",
        "verboseLabel": "Intersegment Elimination"
       }
      }
     },
     "localname": "IntersegmentEliminationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "verboseLabel": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r22",
      "r81",
      "r663"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Inventory, net",
        "verboseLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Inventories, net:"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r82",
      "r150",
      "r200",
      "r306",
      "r308",
      "r310",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r81",
      "r309"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Less: inventory reserve"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "verboseLabel": "Work in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Provision for inventory obsolescence"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r769",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Investment owned (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r280",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTableTextBlock": {
     "auth_ref": [
      "r272",
      "r277",
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment.",
        "label": "Investment [Table Text Block]",
        "verboseLabel": "Accounting Method, Carrying Value and Underlying Equity in Net Assets of Unconsolidated Investments"
       }
      }
     },
     "localname": "InvestmentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTextBlock": {
     "auth_ref": [
      "r272",
      "r277",
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investment.",
        "label": "Investment [Text Block]",
        "verboseLabel": "INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "verboseLabel": "Investments, net"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease Cash Flow Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lease Liability Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "April 1, 2022 through December 31, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Difference between lease payments and discounted lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r67",
      "r155",
      "r244",
      "r284",
      "r360",
      "r361",
      "r362",
      "r365",
      "r366",
      "r367",
      "r369",
      "r371",
      "r373",
      "r374",
      "r542",
      "r549",
      "r550",
      "r605",
      "r661",
      "r662"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "verboseLabel": "Total liabilities of equity method investees"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r53",
      "r155",
      "r284",
      "r605",
      "r663",
      "r724",
      "r741"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r69",
      "r155",
      "r284",
      "r360",
      "r361",
      "r362",
      "r365",
      "r366",
      "r367",
      "r369",
      "r371",
      "r373",
      "r374",
      "r542",
      "r549",
      "r550",
      "r605",
      "r661",
      "r662",
      "r663"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r589"
     ],
     "calculation": {
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r42",
      "r43",
      "r155",
      "r284",
      "r360",
      "r361",
      "r362",
      "r365",
      "r366",
      "r367",
      "r369",
      "r371",
      "r373",
      "r374",
      "r542",
      "r549",
      "r550",
      "r605",
      "r661",
      "r662"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r14",
      "r16",
      "r19",
      "r339",
      "r343"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Liabilities associated with assets held-for-sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r42",
      "r723",
      "r735"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Balance Outstanding",
        "verboseLabel": "Amounts outstanding under line of credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r64",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "verboseLabel": "Interest\u00a0rate\u00a0on borrowings at March 31, 2022"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r64",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit\u00a0line capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r64",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtLinesofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Commitment fee (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r39",
      "r722"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line of Credit, Current",
        "terseLabel": "Current portion of lines of credit and notes payable"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r74",
      "r353",
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Current litigation liability"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement amount"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r42",
      "r390",
      "r406",
      "r409",
      "r410",
      "r723",
      "r738"
     ],
     "calculation": {
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.opko.com/role/DebtScheduleofNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Remaining principal",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Unclassified [Abstract]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, by Current and Noncurrent [Abstract]",
        "verboseLabel": "Mortgage notes and other debt payables"
       }
      }
     },
     "localname": "LongTermDebtByCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of notes payable",
        "verboseLabel": "Long-term debt, current maturities"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "verboseLabel": "Long-term debt, excluding current maturities"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.",
        "label": "Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "verboseLabel": "Variable interest rates"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "totalLabel": "Total carrying value of investments",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r72",
      "r356",
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "terseLabel": "Long-term line of credit, noncurrent"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails",
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r72",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails",
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery, Medical and Other Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership percentage by related parties (as a percent)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership interest in joint venture (as a percent)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r136",
      "r138",
      "r141"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r19",
      "r99",
      "r102",
      "r108",
      "r112",
      "r141",
      "r155",
      "r172",
      "r176",
      "r177",
      "r178",
      "r179",
      "r182",
      "r183",
      "r190",
      "r230",
      "r242",
      "r246",
      "r249",
      "r252",
      "r284",
      "r360",
      "r361",
      "r362",
      "r365",
      "r366",
      "r367",
      "r369",
      "r371",
      "r373",
      "r374",
      "r587",
      "r605",
      "r726",
      "r743"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Covenants not to compete"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Other income and (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Notes payable, fair value disclosure"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Notes Payable, Other Payables"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r230",
      "r242",
      "r246",
      "r249",
      "r252"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r642",
      "r649"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current maturities of operating leases",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r640",
      "r644"
     ],
     "calculation": {
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails": {
       "order": 1.0,
       "parentTag": "opk_PaymentsForLeases",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash out flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r646",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r645",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r20",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "BUSINESS AND ORGANIZATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r68"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r83",
      "r663"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r539",
      "r540",
      "r546"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Change in foreign currency translation and other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r100",
      "r103",
      "r539",
      "r540",
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive loss, net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventorySupplies": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory, Supplies, Gross",
        "terseLabel": "Consumable supplies"
       }
      }
     },
     "localname": "OtherInventorySupplies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations and noncurrent portion of deferred revenue not separately disclosed in the balance sheet.  Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months.",
        "label": "Other Liabilities and Deferred Revenue, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilitiesAndDeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other long-term liabilities",
        "verboseLabel": "Other long-term liabilities, principally contract liabilities, contingent consideration and lines of credit"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/DebtNotesPayableandOtherDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent [Abstract]",
        "verboseLabel": "Other long-term liabilities:"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLongTermDebtNoncurrent": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.",
        "label": "Other Long-term Debt, Noncurrent",
        "terseLabel": "Mortgages and other debts payable"
       }
      }
     },
     "localname": "OtherLongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "LT notes payable included in long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income and (expense), net:"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "verboseLabel": "Non-cash interest"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r129",
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Additional investment in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.",
        "label": "Payments to Acquire Interest in Joint Venture",
        "terseLabel": "Initial investment in joint venture"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r130",
      "r532",
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsCarryingAmountandEstimatedFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r26",
      "r56",
      "r57"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Other current assets and prepaid expenses",
        "verboseLabel": "Other current assets and prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "Other current assets and prepaid expenses:"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r24",
      "r27",
      "r311",
      "r313"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "verboseLabel": "Proceeds from the exercise of common stock options and warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r132",
      "r154"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "verboseLabel": "Borrowings on lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sale of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of property, plant and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product",
        "verboseLabel": "Products"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r19",
      "r99",
      "r102",
      "r108",
      "r135",
      "r155",
      "r172",
      "r182",
      "r183",
      "r230",
      "r242",
      "r246",
      "r249",
      "r252",
      "r284",
      "r360",
      "r361",
      "r362",
      "r365",
      "r366",
      "r367",
      "r369",
      "r371",
      "r373",
      "r374",
      "r539",
      "r544",
      "r545",
      "r555",
      "r556",
      "r587",
      "r605",
      "r731"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Net losses of equity method investees"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r85",
      "r342",
      "r641"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r61",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r342",
      "r778",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r38",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r116",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision related to current period sales"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Inventory received but not invoiced"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r55",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "verboseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net [Rollforward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r470",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r470",
      "r654",
      "r655",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r654"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Reimbursement paid to related party for travel"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r470",
      "r654",
      "r657",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r652",
      "r653",
      "r655",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r133",
      "r154"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedTerseLabel": "Repayments of lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r492",
      "r701",
      "r792"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r49",
      "r427",
      "r488",
      "r663",
      "r740",
      "r762",
      "r767"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r168",
      "r169",
      "r170",
      "r173",
      "r181",
      "r183",
      "r290",
      "r485",
      "r486",
      "r487",
      "r505",
      "r506",
      "r585",
      "r758",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings",
        "verboseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r221",
      "r222",
      "r241",
      "r247",
      "r248",
      "r255",
      "r256",
      "r259",
      "r449",
      "r450",
      "r702"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r151",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition and shipping and handling costs"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r440",
      "r453",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r110",
      "r155",
      "r221",
      "r222",
      "r241",
      "r247",
      "r248",
      "r255",
      "r256",
      "r259",
      "r284",
      "r360",
      "r361",
      "r362",
      "r365",
      "r366",
      "r367",
      "r369",
      "r371",
      "r373",
      "r374",
      "r605",
      "r731"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "verboseLabel": "Inter-segment sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofDebtDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r212",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r98",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Changes in Accumulated Other Comprehensive Loss, Net of Tax"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/StrategicAlliancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r72",
      "r161",
      "r409",
      "r411",
      "r422",
      "r424",
      "r425",
      "r426",
      "r629",
      "r630",
      "r633",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "verboseLabel": "Schedule of Principal Amounts, Unamortized Discount and Net Carrying Amounts"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r563",
      "r569",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Derivative Instrument Losses and Gains Recorded"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Fair Values and Presentation of Derivative Financial Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r19",
      "r155",
      "r282",
      "r284",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r319",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r319",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Changes in Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "verboseLabel": "Summary of Lines of Credit"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r230",
      "r233",
      "r245",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r230",
      "r233",
      "r245",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Operations and Assets for Operating Segments and Geographic Information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r217",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r259",
      "r348",
      "r349",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segment [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r217",
      "r219",
      "r220",
      "r230",
      "r234",
      "r246",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r258",
      "r259",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "SEGMENTS"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SegmentsNarrativeDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Segment reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/ImpactofCOVID19Details",
      "http://www.opko.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Equity-based compensation \u2013 employees and non-employees"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance, shares (in shares)",
        "periodStartLabel": "Beginning balance, shares (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r148",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r7",
      "r217",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r259",
      "r319",
      "r344",
      "r348",
      "r349",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsChangesinGoodwillDetails",
      "http://www.opko.com/role/SegmentsOperationsandAssetsInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r153",
      "r155",
      "r187",
      "r188",
      "r189",
      "r191",
      "r193",
      "r202",
      "r203",
      "r204",
      "r284",
      "r360",
      "r365",
      "r366",
      "r367",
      "r373",
      "r374",
      "r414",
      "r415",
      "r418",
      "r419",
      "r421",
      "r605",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r76",
      "r106",
      "r107",
      "r108",
      "r168",
      "r169",
      "r170",
      "r173",
      "r181",
      "r183",
      "r201",
      "r290",
      "r421",
      "r427",
      "r485",
      "r486",
      "r487",
      "r505",
      "r506",
      "r585",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625",
      "r758",
      "r759",
      "r760",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r201",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r45",
      "r46",
      "r421",
      "r427",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Exercise of Common Stock options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r76",
      "r421",
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Exercise of common stock options and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "verboseLabel": "Common Stock options/warrants"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DerivativeContractsBalanceSheetComponentDetails",
      "http://www.opko.com/role/DerivativeContractsDerivativeGainsLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r46",
      "r51",
      "r52",
      "r155",
      "r266",
      "r284",
      "r605",
      "r663"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Net assets"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r107",
      "r155",
      "r168",
      "r169",
      "r170",
      "r173",
      "r181",
      "r284",
      "r290",
      "r427",
      "r485",
      "r486",
      "r487",
      "r505",
      "r506",
      "r537",
      "r538",
      "r554",
      "r585",
      "r605",
      "r619",
      "r620",
      "r625",
      "r759",
      "r760",
      "r810"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Equity",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r626",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r626",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r626",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r626",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/BusinessandOrganizationDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r664",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "verboseLabel": "COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Supplies": {
     "auth_ref": [
      "r25",
      "r27",
      "r312",
      "r313"
     ],
     "calculation": {
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Supplies",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "Supplies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Technologies"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade names"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsDetails",
      "http://www.opko.com/role/CompositionofCertainFinancialStatementCaptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r402",
      "r420",
      "r576",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r75",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "verboseLabel": "Treasury"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r75",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "verboseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r75",
      "r428",
      "r429"
     ],
     "calculation": {
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury Stock - 8,655,082 and 8,655,082 shares at March 31, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r172",
      "r173",
      "r174",
      "r175",
      "r184",
      "r267",
      "r268",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r359",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r503",
      "r504",
      "r505",
      "r506",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r651",
      "r704",
      "r705",
      "r706",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/DebtScheduleofNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.opko.com/role/StrategicAlliancesDetails",
      "http://www.opko.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Net Gains and Losses on Equity Securities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual or Infrequent Item, or Both [Line Items]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Line Items]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemTable": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the nature and financial statement effect of an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Table]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Table]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Items, or Both, Disclosure [Text Block]",
        "terseLabel": "Impact of COVID-19"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/ImpactofCOVID19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r205",
      "r206",
      "r208",
      "r209",
      "r214",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RevenueRecognitionScheduleofProductSalesAllowancesandAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/InvestmentsNarrativeDetails",
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Stock ownership (as a percent)"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r643",
      "r649"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r186",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r185",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.opko.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/subtopic&trid=114868817"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(7)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "http://asc.fasb.org/topic&trid=75115024"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "http://asc.fasb.org/topic&trid=2197064"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123398962&loc=d3e400-110220"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=d3e5283-111683"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r793": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r794": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r795": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r796": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r797": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r798": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r799": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r800": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r801": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r802": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r803": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r804": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r805": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0000944809-22-000026-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000944809-22-000026-xbrl.zip
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M#8\';<YJ\=K1I)'YXI3(/]Y.Y1;\\Z?+ISC]^@_?>78)T_%\LGBVF-7[^<Q
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M&),2#456'&@J&I7*&'2I)1;PO@<].3\/R45ON5A^/GO<E\1:+0%.J4Z\F$E
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M:5T,! QYY;U.I40 XY"\=T!D4O(^%=UW [DI1);8F;,:!SZQ-Z7UL85(&&U
MK5E[00A[;R,=<8]&$')0R-B0DZY@H@P>T2<?"C(7=*[_!G(3<"S/.ES)!@.4
M6),#T#[IJ%N;B* 2*5&]?;>.)S2>=9C[8Q^(.4>+*@>.,F[X1"X$;ZO@%!QZ
MZKM]W! @R[,0DSDFYP#9&"BF(MIL5=+@@^.0>C G\P5 Y+[@J/"D1X-(@6B]
M<2UEFR!G45M&D?*0G07&W/M!Y.8P69Z=*%8D0* H+9!@T"8P.I8:O/$N1AM[
M;R>M,V-_TMTH48F"A I>9*]+F0$-1)-"<>2M[[V)W 0<R[..K+3%6K!X"A"
MLL^F4$FMB%RRJO<ZZY[<F3+NT1""BD-<_.$]H"XR:E!$JZ*MK$S_)WMO") E
MCA\&-%M7&:,,ZZR3YMQD5XG:*^=ZK[/N[C[HD7F4#!*:@W(RG@,B1% <#7((
M+B#5W@\?-X'&$N=YB]&@JW6)-&1#*8)+6#35'"1P5WVWC=WQY%A"0D+=%_-0
M-2FM(1@Q#\4Y-GD5O***M4:P?3>/&P)DB74\)1H'3K7*2"ZC!R76"$1MM8H
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M +#9<!JL"PQ!;G[4!1V(//9:K# K92S+Z!V<,ZD'6GD[=*^7@@=.6%(NH6*
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M^(>W+NN?MO0%P%[^JOF7WMY^7E"7,]_+W:C10_+G%1^/-$FI32E84*8!:.W
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M7.=MNG[3MUIC98I>@8KDVV5%[=\9]GI>OWGT)N_< /]IJF0?A!E;2YQ_5++
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M2\!=.[%R>A-PXQ)PGW\L#Y3>[H]F9K('5BDL<7:912J6I*Y+B;/S$ZO8V#J
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M:89)!ZJDO4\E+N=3/]J2N%M*>3FL_M1AKU):SV)<IZ,<K)M'E()HPE%O0+O
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M\+$"\#&Y=VIC*6#Y0"R)8\1=K)&B,D4@?IZZ1$@3JSSV16@9^WIN*KAZL:\
M!U$*>'"#^_7AY]&O_C<IX(OPE)]J/_3>/8<26A\ K=-E:#$W"AMKP($V&'&1
MM_),!2(.&ZF$890#M/*E/@Q5!KJ6,,VL--^%F.\$,_*$2!!,BH37"O&$@B$[
MS,&02>QMRHB+63C,N,SFNP:<9PW"7PLCR'>"YK)-QS\7]_IKLU8L\'R"'Y2%
MQQ>Q8'R?YGN)QC$&ON<%A05#)"E2*4L148EE/,%$JR(2Q]EC%HT5B\258/<2
MP.XY-X!+B%L<Q$UP8@&\5[!4(YE:@3BA#LF8&40%E;$U,8^USJ.%."D[6I6M
M65?CRG)BRXE=K2O+B2TG=K6N+"=V6>)IJ[>'>/L4YJGO1?VF[OE*9'0_L_D1
M3)>UA@/O?J_YTO3!7@94TG6'IN6GF.9OM56:=<_D*4>Y<JJ\? ->E2O+B5T6
M\%WAPHSWH/!CRE6M9T1O=8)V/]VA^.1[!T' \]VIH/=N5.SJ7@>FK3]^[DZQ
MI%^%[' 9LOMUR.YR>E>".9_$*?6(".L0CZE QB<*:<&Q5891J=G/X[?/K0E_
M!II7ZL$C]<!(K[4-#?6T2!%/8XX4203B5H%^2,-=DFYLX4T\';A=YB*%<]^/
M*A>HY7FUWT"E1^XNT1*,%@)&$_M(L<):>D.02@E'W,%/,G$X9$H2DSK/6.J7
M4OPE*YF/ JB$*\^%!2XB*.*2*&083I!-#2Q43G 1<B5@-9INGS2G?<5RZW")
M![PJ5[Z Z.O7_!?O(@V#TL<>WK/=!C#.O?]^U!T.^@/="6]S1T#V91WNN'>]
M*N9JOOX3GERJQH+:+N14&[:-[]73?-GJUZ_%-&(PLZ3)E*O;KU>WVLYTET\1
M!T4C!A:V&'PM;#12W!)$?.(2FIJ$&+ZDZC(B.%-:4RK,(A7&2,J]=!)1Y4!A
M$LF09)XA8*PV5DFJJ 'G/(YQA6%:X7<4M2Y+YJSS6O%(MZ9<*Y;(]"=;A7CL
M<6P3E":,P%KA. (@X$AK3[0Q<4RX7E)U*=>*YU 80XR66"IDJ0V!W,0C34))
M->%!A5(G- G5SCFN2,$J%$_79UKZM6+E'+WE&_"J7)E/[!\#;5H>_NNRLZU_
MP3_C;]Q0)NM#S=S18KWU+]/[8^M*82>_-EII.=U,!*S&I]U^%O3\3<^W\N:?
M;\\S-VB.5^(;7RR4\PV^_HHV_6Y N:FOS)DU$#RF#?D=WV0#>&W[<R)!PU@:
M31\!UG?;,)H+,$=8&O309<%CKW4'\.1!-WK7[;A0&L^%G_(,>AT^?Y]U=,=F
MNA4=#. /16T&P'+PX*,,9ONX!Q^=ZMX@M*4>-'W?P^N.+]R\=_;;NG><=<8I
M2F_OD^$"INZG$R5O#_CFOV'P^5I$K+:2Q&DJ,>:*P\*I$F4YXRG&AB7V&Y4;
MXR\U>^,W.(4U$9F>U]^13N$%W^C6N;[H;_QQ>UI@3B84<V:=2M.%,%&8ET(\
ML#9WBR(];P#G?2]<!4/2RS*4J-D+Q.8?OQ90 A81P"2H;*A!%%3U7W_HK;N$
M/P/0+$Y)DSN5M/[I/_7H+Z];@V8EVNO8S3R:=C T_<QENI?=J)>RK*_PK@ZL
MI7:PNQ/!3P?UCWL[VPWXY: !_ZGNUAH'4?T]?%3]M+_[%URW]_=NM%>#WW>C
M5Q_K!P>OE^@%[P:25U_&"+L"8]WK ')WAW /U[]_N#<@6]P#V?D2?;U.YEFH
M\!8M?=KW;\8_O!TO\5DG'TO^I;>CNX\6U_" "4Z8/Z_X^!H3-W&!BR/6-7KR
MZ./-_*,)IEI\EO#-)$GN_1AODGL_^]EM"=X42OS6;7_^F6#W/_11@Y6SWG9U
MB.+]#'PI=E3D3*&?N[VMJW=2L[Q389;+]%;ON[W $>'_>]Y';;B^V8\\K. N
MJNJ>;19OS4AEAAS]%[PI-Q<5>M@Y@E\>JUUNQ0N['0N?B3D=V5C]J28+-]^E
M@(3?JSH$(GZ>W82RY%!9A>-7"?UER:'[]P+J[T9[ 2>??QRU]T^J'ZJL=K+?
MK#<^7]1VX#D[AY>'M ;/^XRK'[Z(P\MC?KT7T&I7/^R>UQI'K:,/>[36^"R.
M/ASRHZ_PY)/OY*BQ*ZJ-8WYT4KV8W NH?ST\/VQLDUK[_[/WIDUM)=FZ\%]1
M<.^YT1VA=.<\5)T@@@*[FCX%N&Q<]=I?'#F";"%Q-!CC7_^NS+TU(&$;C# 2
M['.Z,&C8.W>N7$\^:^4:_OKX]L-;<KC7_?CNPVD7GK)S=/Q7]^#XX^>CO=.S
M@R__20>=^AS@-?YR>'SPY2#'&9A@+ _(RH01)SPB1Q-'6-% M:7"-16'&JQ[
MG%C75!QZC CW90'A%*4ZP8Z$0L "<2LY<DG#;](18:*7Q+NFX-":D.8?LZ,?
MC#0?C4[C((>SG@_B:>P-.Y]B:4O3;O5B=>1E/]^IHL"ZU QXS%4!5IYC?=8)
MH1L?9D7NGMK>26Z3E+<4>*/7\N/!(/;\96LT@,MVR[E8.1+J?V7QWJ6CTH]%
MT3WDA*V'P5. 9'=>%!4[>%$)<;>6X7$6837.G5XXG@ET)WP85U6[)SU/7O8'
MY8W1:-!QXW**<MQ_:>$RZ]/7;A,8Q>'NDLW$0Q"8>X-4] YL)J:0X6 S"4L(
M%C)09NG6MJ$KZ!_^8V1AJD^KM(D:&+C_LOP_&08:JV-E&+%H=6!"*//6H)P6
MC[B2!!E7,CE,D%IRP[D'C "C8ZU18N/(W/H->%,^V4QL,[&;]<EF8M?%8-XP
MM\T5AO6#IYY73^;KP+1KZBE^U1?XF,\)5CPY:WV*L!X.A&N,ALWJ?KH)//_H
M]9(OP%*:(G8<20$_N*4&N10%PEH3IJQQ-+K<XK[-Q K:?*U(H1XX+;?!U 93
MU_=DMD'2GX.DBQX383@.4A.DJ%"(LP!(2IU"@N%$/:622;FU36D;7U-?\,?2
M3]<23C?.'%B_ 6_*)YN)_:DIP4WB;Y/X^V,Y<&85B;] /+:;Q-^GD_C[':!9
MHV3;KZ78/O_SS?[QVS5Z@D>63=MNQ<\^9F*9Z]^T %GM^C_!][+T6HRT6]E[
M58*,KN3[W&HC?O@,8F.>":E^)(&8X6?XYIF^&T&I;I4__0P+>@]YSHRSE><Y
MBQ_.GO[Y8Y7/-.,;,M9-FE=U3WGYS5@??*P/BH/Z&5<W&VGM"5@P0HDN?O/K
M!_<8<\U7MYFM?0F$)3(^.9G.E;%?C_K^XPWFZ[NQFALZ#<=@$ _'@\M53 %\
M=-"_6 Q=W:CIV(&Q9JO6=@ME?FD[ >WWRN^[]CR[>[XU4=]X^D<]:=Z/S\;=
MXJTJ<;75?,V?[I17_OA6RD,S?;D$?YZFO9@ZOC-:D4;>A_&RZ3-^W%]4Y.M9
M >4-*UC+3VYBE9;KEV)5C_DFB8NKJGSS:*9N+WNA!C>9NR<Y/<W*6J^5=<?-
M^@D42OO-=FW/QY8=M?:BC[EN_<3%O9F5K.8_>8/&&'>K=?(30\MN)L[;M4'P
M3&/N+%4F1(Y]<#)B(55*F,484GB_GY<!H5>#RO8/7RQ&E56XMS\<CG/KOPUH
M;O#E8-+<X,-O\)F#+V_/_N0''^":.6SL^ U_^^'PP]NS-^3PPW/\]N\7W:.]
MP[-9&-F?%T=['V$,AZ<'9_M?#K_\^>7=AS_YN[._.KG1P;N]_YS"WQ>'>^_.
M%L/(#O=V^-'QGU\.Z//+/)9#N.[AWNG9N[]SHX._/AZ<O8"_=_#AV;M<[H,L
MAI$QD$UR&@4<!.(BMX3DE""O!$U)"R&MV=J6!K>QIFVJEZ-R[Q1+]O"EC583
M?+OVI8UNINT_&EZ[OJ6-[HARRP&T/P9QRW&SQ6=YVN_"] V?_^^X,[K<[_GN
M.$_8M4G(A_U>'L< 6 U\9#^SK3C<C*3D3<%&MH"-*?=J9Y:C2(E%'-N(-*<1
M>1,,9MH%G3(VM@TF3PP5GS A^GK^TK6,* 9LN;$!IB+P2)+U&D<O<.32:$E)
MPX@>6NO%HM9+9J,%"A2$P(BKW"D[AHB<)DH['EWR;&M;MZ40F1.M+$MI[96^
MH4)/@0K=)C_SQ\#M&VF9#2E:.WC\O-@YU3LNK3(&)4UU+N?$D0W&(^DB%R8I
MD'_:VB9M999948.-#39N,#;> AJ=2Q+31'CBDBL23 #V$#T5-# MK&K,Q U&
MQ(7^H& BXH"Q0I3EXE7,<*2I -I('*"A)\1YN[7-VI32-M?JB=F*#30^!6B\
M#6VT,F!GE56,,2Y<-(ZDX+%RB7''*6MHXR, R<,%VF@45<)HC; . )+6 4CJ
M1%&PWHA@HZQ $K>Y$0UO;,#QJ8(CI<X)[@+AEL'_K&,B,15#8E('ZGP#CH\!
M'!<8I,)$1<8T$C(RQ),,R%&:$/61<)HP$Y9DFUH0TC9*/AU\O,=\E 9S'S7F
MWJ8F4A0&D$P33@0WUFIG",D^S*B,MHHVMOK&(NWEHO=2:Y^8BQ1)(@GBWA!D
M*+/($$L-C08'SC/22BW:A"XC[9K:ZC^IW>)#*G2E4<C97%PE%V&)O6'5G2-^
MSK_'1QU=>*=. 0^;MJ IH;_^6&>H->IQUTBID5(CI49*C90>AY1N81_(?.#-
MDW4\:>X2V 2>V>0)M8%Q2N,-RE!?-11F?6>&Q_U9MG).5-[OU2G*)=ZKD)W=
M.:[S*@(+&G9&\74<?.KX^!*>O1]>1=\_Z96K_&6[X]B8$"LS(2Z7C_NX33IB
M21'6PB".*<LF1$!,JZBLM3XFMK6MVI+<^:BO 84&NALI/7HI-<;DZC?M%?2.
M:#;MC=VTE_Q^5$6B<HR.#"HB#FL N2 LDL+*H(ET"J_AIOT$\H6??XX#WQF6
M*K*^*N<TS'[T5O\\3_ZPE,6\L(.!+>5E'[&+[QK9;3@J7YL1PZ(G2IN(N=0<
MJV %E48+ZSES1 KY'6"^+C4FKY<J,V9O/,BG+05@JXR9\N91M98F:ZU)H%D9
MUA[N+J44)\:$ 8L()=AY 6J)0XXS,)=,E![C$$M*L1!M)9:;>?[8^<HZGE@_
M+55?)F!WU/.O'*\NJWDA3U_1\H8TW4:1%_-?N:1"$:H0 7DA+APHLC4)4>$9
M%A+4..BM[57EOC8ZO-;F<R.E1DJ-E-;I%*'9#^]Y/USR_%MGF0E,($&4 V8+
M]%8G[9$B0@>E+ U.P(;(E@/8&S5>:S5NP+:1TF8'-3]NR3^DW[_99N]YFUWR
MU0<B0V26(&T2;+-2*V2\H4CY+%-"$Q$J;[.KBLYM G!OIH3S]X1K>-3YC$X[
M(<3>+\T:_]8:?XTO%EPKAAA!2"+(60I+7!&/C(7%+GF,+&A8_I3G1@;5(4@^
M&]EY_2;74,4(R^GZ?L2'(1M[1/WH@A,:*352:J342*F1TD9+Z38YZ%[:I!T5
M(7C,#=&. "=17$M&5?ZOR4'??$:ZY-Q,D0DFF4'*4@Y6ES39N4E1I)$K190C
M.FQM,].&]72'!/1&[QMT;J1T!P=7<-3A8!WU1G'KK=$Z2"HB5BI%;ER3K;ZY
MF+Q8%R2&2&RR&FF?(N*8.:0#T3F4RON@ J;!;6T3U>9"KU'8:A,?OP$DSZ5H
MA%%":9%XL-1B9:CCV$M-%7<-R7L$@++D6L>$"0 0@:S([5X\E\BH*%!4'$L7
MB6%8;FU3TI;\+I7-?UX(_'I[.)M/-I]\"I]\ GDJAW'4ZGZG]_':RN?1!P@\
MNM"01DJ-E!HI-5)JI-1(J9%2(Z5&2K=R;@7JB)548TT9MT$YI9.C.C!B58SL
M)LF'7_%R@1VPW_/]L_@'& .-LVIESJK+9>\WMC%8[BW2($7$I0W(4!U18$GE
M<KV8:%82B3E;;DM\ZY+8ZZC'C?UW#]BP@@CQ!AM^,C8L.;(M3=IC0A"Q%B/.
MB$3PDD=462,B%I9%NE[8\ 0BQ(]&IW%0:C,/XFGL#3N?XN/WF6WL86$3&=)(
MJ9%2(Z5&2HV4&BDU4KH_BPMKPKCE@NE$><32!6JL3#89BA-QZ<<MKL(X=^<)
MY\P  VOL*!W;S]<&'[VT@]@;-6;8+<RPH]WEKHZ$1,)2E B;P!!72B C@T=.
MLD"QHI('L[4-8EZ/8*)&LY\B_C86X49YT1I,_ZF8ON1:BX(+137/58YR_4ZA
MD?%8(4>"$5A*Q3U?(TQ_ K%GO]FN[?G8LJ/6@1WXTQ8C[5P,@#YJQ]K5WGG5
M_/_"8)6$_ACT?=H_[V[].M<.A&]733G8P*W3R6 2.2"PH20QS1EC6%NM1(GB
MOU$1Y7+UJLY-4QYY9?CZ>JD\,G9)&69R=1OL$&>1(,,!;76 O1,;R\%(VMJ6
M!K<)TVU\S?'%G7I0KD"/'OAT]($!8]TVAQ]M\+N*^=E,(+TF7.2'4+3)J=P
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MA-'<6,F3H0XS8@U+#E.=*,$-(WIHK5\L82"8(I(RAZ3-E:>,%$@K3)#F*1(
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M*O9_+CM_YM2>D^#2P*O0YVY^Y'RG:?K0[$PL?PT6VZ#D.]37F_Q5 LK+Q6&
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M>3L));V.U=:*EBER/@@I?*3PX9H@#^<H;A5)]G'.X5:=I.3$G/.:P6?29:O
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M$S79,D?O[;C4RL\3MQI&Q?QEV)5-;EI)+,G#N8+'Y@%D-&QK*' %)&0/_$J
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MF<B$\=2Q:#FUR1G*#)4J1*X4SO&&I46UXQ-8URSLHJ@K&^]IA6..>Y6T\YS
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MKAR]8514--#5^MFK#"J:M^?]J1WT/_6')]EU"^L_F69G\B:C#7X9Q@]V -@
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M8 WEZB6-3 Z*):>R'N=P<OI&(!=-TJ#H1<^\!U4?&VL9!MU>"Q>2"]L2*==
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MP:>#_>.4G-(A6:1X4H@S;)#E+"*J520D<:&\>O2$[VFJ=HCXJ ./!P4>/]P
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M]/>V"1?<&]XNULL('.A,XAKE'J6(:\,!:EU""NQAB%H+$X'@L"TE%ZN^;T:
M]JFKFS5"JR0M3U1Q;X&P2HR-H%R"E20J-,&"#57%^6 !SB5JO,D[DS0@KD)
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MYG*@#O0,BQAS<0^.#'A\*+D4> HV:,67:UQ31^#!F+F8@I+>&\$PYR$Q:U7
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M=T8!!C:^K1]+2*$U[+7^B-WXZFOK[+@-=[0'XVM#RPY:.X-!A*N/8R>4;QJ
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M;81#/)A<\BM&9#5+EF,E*7'/7O M;AXK/C80V$#@#SH^UG# 'X1R= [E.%!
MZYE$-FJ&. ?Z9R)62"D37(R*\Z2! \K%HQ./ ^,:#M@ X"8 8,,!-P$=^;R'
M[ D1S#KDDK*()X61Q@DC#/2>2RVMBS+WQA2W5G3PSO'Q#C;\-@ZPQE2AU:ZY
M0BL6LK USARJ8J5WNDWRP*I:;YY7O)H2-DSPYEAWOA -#)8811GXNR$:Q"5W
MR/"HD6+"*Z6X<=P^>Z'4C9G@G1>U;I3VP2AM0VQ^C++/![<HEMBSB!'E-A]6
MI>#V6<,1CI0E$[F(R8';MZ74;1U5;=1] ]7][L(VC8V^#;6=C]8$ZIUDPN3.
MPV"C@\/(1M!B(RQFQ!F7'*BM)K)1VD9I&QO]L)1]/O@07)#,)HN,<J#LD5ED
MG6# SV6T!@0@6I&##YAO$B5_T+V-U\NX&D0_ZK>'[7BW+8X?6)WKS7-*9F.K
M[R:K]ON7O7:#8+>%8'LO%T(*+ 4F=12($*D0UY@B9S#/I;J<T@S(#.8%P>1B
M6[I-*WN]*0V_&QS9D#V:!D?N#$?FW1[I8^+<,10MD" NK$-&<HFDBLJIZ+UB
M(J?B4'ICQ^<1XLA3V/%98&2ML_;PN-7MM?K1!O@^4&CP:4[:W;(OE&R[7QTM
M;_: 'B)S^Z>=S[O"EY2U?36UM+_#RI8S.CNE4E0#R[<&R^^6Y(_3$)1E2-%2
M$#\H9!SGR,F@"?6"$$&?O1!;'&^2@WH/Y^%^R#.>/-C<%;UKP.8^P&:> ^9F
MK0X;BQ)) 7%.$C(Z4, >+40T1 :G*["YK2X<CPELGD)4[A_;[]M2YR=7F3S-
M*]\$YC::WN6=B'?#GO^\7U8+UJU>PZF"9 UNKH.;2P[Y$>^M<B3WJ]>(VZB1
M5@XCX8)VD3NJHLCU\1O'N0G ;3I#:_#B]O%BGF?9I*-5B:!(=3[V1@EREAMD
M"?<,1\*DS'C1!-J>9J#MH#>TG?GRC+UTX[(3M],^LRZ9N*2<_),]DG/[$_1H
MS-%M12?_W>L>'<3^R8P5:D(!MV2BEF2JTZ0\L2#B.F+$\XZRSL9*!*$<Y\3X
M1)^],%O\UI)7;T]['GH@H<'S!L\W%<]O*P#<X/G=XOE"5G,">ZNC080QDT,4
M$AFG+9*<6A:2H$9@<#GPEJ*F ?2[B QO7%NA\L0K-3!0_$HE\+Y3PMW,VH9/
MH\&PG<YG"^C3[?NKG[\_ZL^>6YTI:I^KW;<'PSD?+-=+_.O8]D\&Y]WA<?S6
M^JEWUHW]P7'[M+4240'67.S/@2H-5JO '?'1<FR=4REW>P"69;1)F"\GR?1J
MY]KWQX/Z*_9S%4I[%"=@BNC#1--K]X'8_?;ZVZ$W6@FM$@HL)L2=]L@&JI$.
M0G!,78Q: [==@,'_^7FK];+G^^>#[)^7I;=;K3==O]WZZ?_Y+PTK].O+_9=_
ME5_)KS^W5C?172H%,9G$@DC44P)2FG(;:1 $(XF (2;22,'M2<'[KX<I<0_S
MFY UQB+.!5A$XAP*V&E!G=?2D6<O%K,JLA3L];H(YM8.VE]B:[<'R]KKYU#-
M.Q"->#*8$XJ]-[OOKBL4U(H8+;8D6<T!(<!H.VL5D\1RD%;:",6MM8B!\1QB
M:V":4SZ@G9LG&:^0$R$AT$PNK(S&B@ T:;E0Q!Y(A)]?_.JOUUU_'A53#@8E
M=.!6"V/A'U0KS4!&A6C6_Q;7?Y<>)L.TPUXCXC)-!B5#+A"&N-36,NR#5V[5
M^K_IOHR=SJNO<P(P_O-U)4 2+Y,5#/"* 6^/E@J0 AQE\H *.C42<'L2X,\.
MM1 XT620PUH".7 YX0ZX0E)*QKS)&QT@P!(G*8O ;^W>2]L/[7E:,/G[];F!
MYR81&)>E/$FP!4PG0R1G%+QO9QHAN#4A.-BAA\ )@S)8(&$"SWVF<X5*8Y#!
ME"6AHK4YZW(Y#/Q_L1O!)<VR,/#MV/5QG@_45UQ7%D)4P4>J! @CMRIJ[*)-
M)JK$I/,*-[)P>[+P_NR019<"<'*$3:2(:[ &\%^%F*&11FR9)6R5+.0LJ7]'
M&V)_-X;6_T;;&1ZW_NCW1J>M?[=/VKEYVE@H)I==5RQ8U"(82:4GGG/B'8O1
M$":XY()'H9<V"_R.?"P_J-S(Q[0?<; C]@_>?]T]^ !C/RK':)SBAHF(I/5
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M,>SD2%C,B8D!!RXTXU02:Z*QT6/@  SX%G[6B@"=I[ 0P_XH/GNQ%X>M(UB
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M.;9&IZD/XM ZM>=C5%NG;'/41$ALI =GA1NFM,AAE10Q]USCX"\!DD67\F^
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M5]WB;7I;)*0]S.<W+#RYM$>9>;4B@_!1]M.&Y;A(?DJ)V0QR-<J<A%#&E,<
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M'!R\_PA<O5<4B++$.X:D]@#EDFAD1+3("9>\IA)+XV[MX. M:M ];Q(W\-G
MY\;"YZ4!PF8#X\:QP7%R&U$T)"H!.8/.9Q 9,N"X($Z"B]%&3E6X[>2V!CX;
M^'S$\+E.$//V\+,)8OZP(.;XF$^2044248"U0ESX7)+1)N14@'54!! T=UK9
M8N0FIQ<;S&PP\_%CYCU 9A-LO>M@ZSB;DWB1E%&(:1D1=^"FV^@T4M$D;X+
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MM;9T7N- E1+UB9)  9]I;A^H9%(Q1&H5T:84ZL@44 IU3$CAO+W/?IU3NP[
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MP6RHDDV::2*D<C PS@W%U&KL/4M*66,NH)TSP/M<XBE>AM&KHH%<DH1^-4_
M]L[&T3;HFI@FISQ!0@H-NB9FR# K$&R62I@%HJTK]:$$,VMZ07?**2_1M(=H
MO=J>BL0H A(Q:W4,[@]8^!+M>14$2MH;;1@.,5>MBDGC%"Q/E$;"O?2R2.8F
M6V@O!I[I@W]R!K2JW'FT\N)[Y_6G%)2FP7ID2;"@REF-3! "B6PACR *6):
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M( Z_G3$.+CY*%QZCA8!*9:Q9"KI(VRFJ#NQ;4RZ^/MI/<N\!HIHR\;OPN)-
MBMJ9";18:JR#ZK#7K4OBP@U7)UK)/(_"&QT5Y<PGZRS#5+%@O,56JZL3[2)9
M_OGQ*%_&-KBIT&WG^Q8(ZP:$=&P%0SKF-I;>.625U2B99%@RA%)/,SJRA?#8
MK?W']EL<PFKFX(0A4&O6DZ>U4Q"U!2Y86LI_',=/'CM3CC>GA#)=C7X$%5XZ
M*UP"?K-2NP0P3V!%/8?3/=F6?FZ*?GYTCKY^(LJ;H)5"F(.<Q9-,R,G@D \1
M$P5:N6$ZTP_]*?(I>9Q%Z1@,3[(6"U&=34RC\P+:KFL57QV][L2 <MRKNFE@
M4G?;F'P*/V_<H+*(BYH Y6ENNK"9YJ^6]I/+6V]O?OV4L-"!:(]2Q+F9,/;(
M*9\KQN;.F-(&ROBCI_W!O,&DB4C.YM?I2EX7J_)G!U3=9]8XC@D]4^AI:@R-
MI@0=/_@6^W;2%"<+6\.N;Q*SIQ)8<]0*K'&5Z_?7E8?6IFX]58!_H6'X5(@,
MP%>V<!6[J:WVZHIC56&)1MXJSRZX6/P<&2SM8IMO'Y9M-B A%;'.Q=[@>PXX
M/+; -O12(K8&Q>X+<%OB<7KV^_P"9(M8@>CFI6<9O6?G!LMV,)R.D,ITX4!A
MZF<DKZ-0]^UA!>33!8()]9MS9.R)-;F(HR%'^>12U&4T30@:G,9 5H<79-6?
M97I^"8N8<_9GYM\$.AYO:!UO">0R&G=!O2M=%8X#="?5J"[FLU((*[_@F#?/
M6\],%C&.:T=";M*0]<E2S-'UNI_MI,/0Q6+]<3#*-]B3P<$TN6>]-$P:-^7!
MU(%5HZD8\@53G9;^FYY5L1>;VC.EZ\4DF+FX,*9Z<30=BBYA7<PT$.MR5/F4
MVF^(#W CQ]T.@8R*8Z9T\SA9C\N '6A8<WZ<,HOS?3FGR+J.9*YY8Q*LF$LY
MK57C(:!5RI6S>KE;Q5JFVOW!R)92#3]!P>OGN4DN'O"N#8 -XZE)7C_AT[@H
MF0PT.B6Y!#D[<DV8 /%.&6VTN*RC9;[V?.M,62P9O*9;.YU/W'@EF28H$,5
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M_P7'<<R:T'"_":LJHLIF!*T@RSU%YX$!3%P7AT5TA@?%LCZP0$W4_+%068M
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M&@E"!2D9LEX(Q)W7R#)/$0\I>\=UC-GT1=IJYRUCMRGA-\R:,\<@YS'&W(/
M6QES[S"-G! :6)-[JA/3V,(QJ/4J)9>VC+E<QHS&LYQ.K+V0W'*<ZR0:XJ3V
MW+&4KEG/O#65+85AMV?.4DZ=I#(RI'22B!N6FQ&XB AA0@;K5"1R:::RUO%]
M!<=W?S08#'VWS0J_Z2[>WEMM"0LR.AZL,3H&HSWVG K,3:MOKP!N=>;T;>.H
M\;EZ*W?"(FZ)09H3C[@TU%LCA<M);ZW[^_;;_=XD.[7Z]FWPVJR^S3BS+*2<
M[)'SPBDPG-84HPA;3"B.3I!4$DS;>N<M8[?Z]HVRYNPQ:$APN2:*#Y$CGF1
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M=6,\'G;=0=&D=@;_V%7**+P?T#L?PTXL]I(&CJP-!O%(*-(<6V25)$YRRT@
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MV^FG_JP/]^Q@#?53CF /AT@<KI0PW\E@7S&REO&:GI+4+EC%*SJ\[W"6]=!
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M-C(9=X1:DL$%/GJ<;',+DNV(1>@(T?>/16"66\8(3W5&J#!*TM2H7,6&YIH
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M Z",_Q?T@6FA&QUG $",^E%=&V\R!I8-"-!J%;\3- $0#U'R_LM.X,X^HPP
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M6*)+G\)_((J#5$8X_)\PIF,4R_#"O5A6W_P=[OK83H8+UPW(J'\SL\GE>&*
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M:S27'8':6@*U;-+*E:)Y%N>1D<9&E*9QA)$2&*,(NFE".*$40XTI_^+TBXY
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M7@\\OY2_+O&;LCH%;QCW5%O+8)N<#6MJ>W/C&6R@-IP%UF+-&(9!9E5,@7;
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MEUUU4'51&(<ECSH!C6+L3<45X8W3G)V,I8I]X@1<9&(NT:F\Y?7+"9.)GN<
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MV0(MW276VI0ZQH)7P23./:?<&J&YXUH;;;#1G/Y\^'?1.:_&GEYM3W>?+V!
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MQ](BJPD#(TTUBTH1C>,=)2\;@M;&'*ZW.9228&.H"H1(3@' )$>)X<QJS0/
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M4RNRP,N_8$9H-B/[A[&5^MUN_S3'U(L!:0TBR)?O=.$NN0D]6,MZBXNAE4Y
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M'NP:49^UFH,:!3RUXL?MXT&GVZK-.X@X/,[!8>M%]#'[DQ/#?]-@<FW=RW8
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MC(-HTR@.FA#$/5F:_O'7:P.([;P2#8JX<WNT6$!AO"54<8]8TF"//(](NVC
METG4$B*ET)D_D;<E)2ODSC0QB-53[JL@Q"5*G3K?8D#?XZ#?Z//-]'FA>I-A
MH0F+*/@<4N2>(LT304G]_^R]>7/;1M(X_%507N=YG2J0P<7+WDV5(LF.]HDD
M1Y*3-\\_J0$P(!&# (-#,O/I?]T]@X.71%*4"$K8JHU%$D=/=T]/W^VZL+D'
M?;O7>0,;MV_HQH<:;>A74()T0Q6LZQ?:/L:=\;AD_-<LR3;U=33:R<ZDV9+<
MBRXS7=?&V AV47 M&[23KM/R=)L-7-VU;=Y[\V,7M)-75X[32(,ZN4<:*;!#
M*3"OTYBZHSEFM]?J]K!/D-EQ6X-^3V_97K>O]5R=:?H I(#:[1N'(@1>@4L%
M#]#WRHGO>3SFV&[#YND=Y^%\.Q'L'5)1B=8?Q-[8;,^@Z7RIJ*NGWQRX]&B,
MGQJ!MRN!=[F8%V([6M?@.,G*TJR6U>.\Q0:&V=*</N]ZGLTULR>JD!_O)VZ<
M,B]^@R]57E9O[&;O;K)WYY45WATPK@\&K:[=&[0LL%-: X.;+:YU!MRUN=ZQ
MS#<_FMU'M[-NG"^;.U\>5"[65 QE?RX3\.U&&7;[RA?0=$'8%7X:*7[?9()"
MCC>*V,Z$^9(<&][3[9[=:3D]KP^*&.NU;-XUP1 =.-V>VW?Z75#$.I9J:+L:
M3["['708_6(:4=J(TEHHQ(T@W:$@G=>*01*ZW3YC+=8Q<4I49]#JNX[1XB!-
MS?Y LSS30A>>J;\<.3K;KIL:R<[-H%SX? C-A$^_3;"GKNSNN]#/%]UYWLS\
M%N6.)<K;#;;Y5KVN*_N]<[_J=!PE:[JONH>YV1_1!_OHG\M?_[1L8V ,=+?%
M#8/!9O58RS9TN\7[CFF8CFUV.^[RB4P*\%N U$4NV"O)JR+^#'NP\B25G-O0
M?AGMX0#0+OXY_W;^SU?]XN;7N\NC/_M];CN:V0.4=XV6Y;B\!9*ZT[+L;I^2
M5:V!\>9'K;TJOUPR@ZH \B<<?KGEP51%[(N.WEB+I(RID8K"09JX<UVX5>5N
MY,-G/W2"S.5[%B*_L=A'6=[(D =DR.G=^:]_,K"5.EW+;IF= 0?+R79:@Y[9
M:8$PZ3E<<P:6YR+O+%98%S(D\I1;B7/IN'$ ZTE;>?H32'.L#G,<Q^!6WQJ8
MG!E=SS ]V^W8KNOQ 3&/GC./WIQ .^0>Z_SNST&GU^DS;K3ZP"@MR^MZ+;MC
MV"T7N(>[75<S''WY/-&M3Z"=D[PY@3:G?0=,A9[N]#M&UVV9*#Y ^[!;MND-
M6@.S;SC]@0LDT%!RK-8^MCUP]$<=.#MGH.; 69-MSK2+7__L&)YKF[:%D5)L
MT^.8K;YN\1;K&M[ &71L7;.7*RL/'SAS\\C%UXOG3/Y]S',.<FF\B1]6GQ E
M23XK9<5\DNL4_L'D"(1(W@F_MY7K412G+1R6,O/".Y M2ABE"O &V'0L:"O*
M.@-,!K6R*Y]\<I7<1:]]TM$=;!;;L?H=;O9;W&$];'/.6_V!UFWI%BAGO8%A
MNMP3XLT/,^X>H<CIN<S%.8\V$,#J.QW6Z^L=D^D:[_6U3L^=GXQTG4TF ;$Q
M"Q2')2/%"Z([8'TAQ'##^0E.WQ&3B9+WB]Z1*@LOF7>V\$V%S25K60:Q](=)
ME/@TZR3F <-S00[/D2[(RHW28:25MS ;MF:6KKYEV0P@ ;H=__#CRIVXZK;G
MWGB6,8?IRG]'<3GD9,A;=LS9UQ;5R;UGP1V;)F]^F)4N(%KF4#^/M96+]+PG
M<3(;]T^\^3>K"R@*J"<@[/[EZPYS^GK7\_J:9@TLT"0&O8%CF9:G:;;9<_[L
MO?GQ1DS3\O#D2$6U )O?,0_,KA(BM[J#A"R$EUM6QW/-G@[6OLGZNF,8%N!$
M9Z8VX-K*^SI]Q^4@1\R.93'#'?0-5^L:ELXL1^L,V*K['A0L!S51JZNM_OFU
M3-3JF^L!U$S4*E8]J-LTJ776_>;'CVN85CL=-;75$/8MLKKKC?9EHZIVCHD&
MU1+5^N,XN$ZI^P^KA+.#\H3B'F4I*>^@J\?1>,'CNFG*XJ$D=JR)K/4S.S9>
M_YX2-]9<^#-&8Q[(ALLKL5Y!#L=?@7\Q_K_QN7'Q]0_C_-L?_UR-SG__K__'
M7T'PQ^]GQL6G*__\YE0__W0UFL_AN(3? ;Y__C"N_OKCGX]_77PZ_?;'^+_P
MSM]&?_SUA_9_G\Z^G=]\N?N_3Q^7S=H N\#N\KZ#$]$&+6O@L1;3W&[+TAR;
M#S2F:;H!UJ1J]'<UL+TVJ6X/5"PT J\1>#N.!C0"[_D%WGS26D?O ;T<3%K#
M_ ?7[K7LONO QX['/:O3[_4&)/"L7<T6JE_=:9TJ/7:BO,YF!KR4EJ$'H+$M
MBX=+,7895K)P&YFUOLQ:[)C!/>8!35C+<VRK99F<MP:Z8;:ZNFZX ^X9C/??
M_&B:-6HO^,I;@AZ [M%LW:?8NO/JAN%YMM9QNBVC:X!597!0/+J,MZR^9G=L
MPV%&SZ[9UGT-OC#!_$^H3M2PE/W U(G/L0\4FK"@-(L:4;2V*%HZF,3H]^R!
MUW*[';!\F,9:@\% ;PUZ7+--9EL=SP'+9[ K1T^-?#G-EGT6-:+9LH_<LO/:
M0X\['3C9O1;K#08M2^N:K3[M6][M6YYMFYH+6[9CU&D,\FOP1E#CB5?;9F+G
M'N474QQ=8Q4+FSGG8OEC%).\;CS-NQ/>BWTF]($YZ'@>$,;P0-_2N-WJFX[3
M&KB]'EB$CCG@%%KK/WZF5&W*HYLV$XTHK:LHW9GJVXC2IQ:E\WJPZWE.S^QW
ML$^LCEZT;LMV3;.E<VY:&NMINBM$J;8K1]K^1>D#>G2>%PU+Y?=+W^>ZL@&X
M ?A% %RT=UFC.FG)-_=4:-S?]&55:1&=& _6CPRL-P^4AQC/4 ;86UJ-='%Y
M<ZKH/>6)RP&O,SOA?V> V=-;/)QK4A#8N2A.W3-X]L77\_$%7!/\=?[/K]_^
M^.NK=7$S&OWQ#YQT_SC6Y2>$Y>-?\P6!?\#SSHU?IW#R:@#3/Q<G'_W+FZ&.
MU^.=%_\,K3_P!/_]PCO_YTS[$TP,QKM:K^4ZNM.RN-,70V-,9GH=.#<=4W?F
MRP'M7J??,P9]R_&Z%N>:;>BLPTS7X@,7#F"V4 [XY:?KTU^_G%[<**>_P7^O
M[R_W6UHI]. [UZYT-=I[*735.YB?$BK_9;"N>*KH_;S3R34?,XM*BB\__^\E
M_!&"IN%P%ZLKILJ(N0IEQL,7?IA&"@-MT_-!@?5ON<*&,1?UPI,L3C(&?\ E
MHI1=/'?$$G&5B[\PY^_,CSF]B28!]3XD<'D4!%,EN@OAH@1VA^_Z **J?.(A
M/_FFPBL#SK#AAA\J0QY&8]B5*4\HT0;A9B$+IHF?M)6;$9=W*3<Q($KJVTX0
M8:DS_'4TB?U ,09B\6U%^4*=/*B0A,?C!.O:TO(AYSP>PL]'^3(+;(EUN/EU
M6.</Y,PF7APA,H3>C0_;I(X?Y(K'^@/-<'H=JV]Z3+=Z'':";H$USKR!%"Z8
M YO_,:/[=^=%3:[_WT1' N"?L@28(@%+X%,<)6N: WLNZW]^P?27HUV>..;E
MS9&)S\02?XN;'!LJ6[U>KV6!KMZRNUW>,DV;H\K/!C@-1N]H]_<C0@;&4*Z*
M;/X7=VBW,/>O+$F)3JHR";)$6<DRR8C%:,3ME&L6NC_D3$(\(RJ13^&O=)HG
M8"1G20+"^#+&?U$+ 4%J\_C2NR;XQ*\-;SW,6[">X9^,P8G';. M%R.> Z:W
M[$ZG \3J]?J=KF;V!NZ;'_M:^R'F$MR!/$9"2J4.$""3B,E"!:T]O(L%^Q%*
MZ)#(6>LX&MM^2.<K]I_P7=EI@H2VQV,0K5<<M*.,_\1 <I_[ ; =:,";)1^_
M<N;2+H_^9%:G8W8<4*W,/L=V1OW6H _,I7%+-_M=T^18'?VPX(H%-5HVD@/;
ME@AZP'EY*X_/$#CF7M5Y*T;:/>M\!LBB6>D$ZI3SWLWBNRAV$QZ^;J[IG/_Z
MI]?3['[7\%JL:Z%<ZO%6WV5VRP"Y9#N.8?;[QIL?T[M(F7(6)_/ZM/).:(!W
MP#R*30-WJ(I>GGX**$M"C9(2BZ7B<Z$1XGR(F"-5OV\K1$;4W9#+4)-#M0](
MZGQ50)ESJ!6!U,I(?9M5\52AVXD!B%(]<ZI\ ZP] 2#$0*#))(Z^^=C,!A32
M.DG)+P+T51S?R,.'./OBY,BZ./K3X5UN>5ZGU;-<KV5U6+]E#SJ\U1MHYL#V
M>+>K,1R"OFJ<5]'G"^V.DK/8$"R$(;#-'&^)9DS(L),(>V7X<&U%>/JU8+EY
MO6\-":LW#/<PPYV:8#D8')U WJ!E=AT+1*EFM&S.G-8 V*[#N6VXKO;F1ZOW
M ,.UM^JJM4]?PUEA;),4_NS!O3'V"O,]GTM?0SH"T7_QZ?3BER/EW36\,XVC
M(0A]-/FCT.'P!OX5MH4?HK&$^P%4V33F<->$NSY<#DK&,([N0,\= 3_"IB+O
MA./ST)FJY'R(N</]6W@C'A;D,< ==PL;$8ZC3V#SLW!*N_F_#+#4SL'!OIU#
M8'CLB@8H_LJ%MR%+X3W^/V)WVU,2 >=^Z"=I/,7#YV?.@A3LNU^8'64Q/?=W
M'GBB,9MX!7TI;SW-XFC"X3O8<V,_2:2-F#MI\,J/W([I WDF0&+@D3O;9["M
M_(Z:/CZ0.2,?M)_<^P!?);PB<< FX-0E#F51&@BGC,00V0B%'-O0=6&9@[[>
M]SJZV>E; PX?/,_N.)IM<HMU/)8+H]PO:IG:<B,4S[]C;*MC4T>36WX4 Q6&
MM*)Y7:X10LO]JJ#YGYQUSD\<>-^Y<?GKGZS/!UT.AJ7&^[V6I?58J]_WS%;7
MZYM:WS.,KM,!$[/SH(D)O%DP4S%'\?!DTV6HG+.I,J,BP@Z<H"B8=7:&I>^/
M=N/G@%&W1ND8) O[,G:84G&6*->9K2IGH=-6WJ%*:V@?Y.7P@R*_01%7^CIS
MMV,.!/(U#NF6/6XF63R)L)MP+@/2TKD)PO(\<OG_C[[/F$UXEOI.(EZOEN_'
M*^AO_0.JW_+K:QX$/);??T\+%%\E4A4OE6/:B\H[A&9V305^\L>H2WS!E?6C
M8!WC1]&ADEY*N"88I=-"K,CF3C0FL;O*1SR/MT7X<JB$;SB_;L)\]U'RKN.9
MW:Y)@]5<RP6E43,LRS [/:,+>!NX4MYU-*E\P1^-\O5\<N\"WG%^]&>WZW5M
MSW9;=F< <L]PW-:@IW=:MJGW;&X/>J;M@;:O/23VR+T/MJSDMBA+DQ3X%EF3
MDV>41(+@7XQWD$<7&!6/>0?^!(F%IWGIZ!7<.&LK")Y,"Q.7?J7'P,.EI0Q_
MH5H!VV*,#C\T@O/.P;BO0*O)X'J[:C&S6WC!D.>PNPS$J7(;!6"K2R$)U^87
M28,Z]^F K(EA<>_N<^MLM1/NM76!U1&U)VPJ?#6?X3_Q373M#T/X^M(K),Y2
M)X[+IJ^;\:=HYIH#5P.CL 5L#E9'IP=FKF-JP/UV3Q^PCL7Z#C+^O.?F>SQ9
MB*\!C0FR YY D>2<E N-'0^@N^BYV:)AA@V980IKF)[_^B=W![;=L_J@\_7L
MEF6Z>JO/\2_N], V'?2Y#B:HL0DO) +]N5"95P64-N@?1<!A5K]"FVS,7!!,
M2DAA(WP(:'1,Z/B*,T)UG\(8P%"AM/ON<@-'O*JMG 8^/.C_>#R*X)@&':A]
M OK.)Y2S%\SF0?[-YQ'^E[2,HX!_ ];]"0RX9"I:5X,M&/EDX\F%_12QV)W3
M*J1.<@)OS=]7N1&@P&M_0\%Y/&*^@.T?@ 'ND:"@MBR?Z474H3&IG!A^(AWH
M=_  GZ-RZ6+"G7+I@2DK$%0!IZT0*.52":4VSC?'_2/<4L>GE\4;:/'BR6=A
M"*8O873YP^G:F94N>?AG.(I\MS0Q"\C6,03J-5+J=PX+!,4VYK<^OT-RPC'/
M;XOQ\!5%.Q'"+W*<#+4PA7H1"Y[$?I-"8\@'R*QJL/X3"ZAH]WK$>4HB%7='
M'&5#P=XI+ ZQZOD![B]2]G\%\Q]>!<?V%9]$<8HG^T>0=8JNM7YM/]2K>@MS
M[('NT<_PF'4RSO;#,(+,B_]]LF4V;<4W;RMNKFXKOD&J8J](56QZD;^\7N1R
M6V"^Z8?9/;JG]-.SF]-SQ6@KYT<71Y].ST\O;J03YEHY.;L^_G)]?79YH1Q=
MG,#_CW[YX_KL6KG\J'P\NSBZ.#X[^D4YOKPX.;O)K[DZO?[RRPU=<OGY].H(
M?[A><D"OMQ=H\,V\Z-V37%Z.O<O?3J]^.SO]O9;31^B)[_T49*.SAOSZ(\K
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M+%5^^>58%1$/E!\S5_PBPH!@L?-D+J12O:X,/50L;>$U*G**:!E)JG@96'B
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MMK,XD0-1H@#%A*1V=6."@I2 $*-RU3:6/\JC>'9S2&*IZW.+6H0B"!H0SQC
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MIX:LAT#6312NIZ9H[56Q>D?Z:C:FX&D[Z]>_]W_](=R=1_H>%;OV'NE7/IW
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M+TO#^LQ27PQ$?U6*E:7J@YH4VC=ZU>IV<YVZ=%U\46+J'E%>^XXA5&V[I<]
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M63=48[#'-I.O ,,=M:_7;DIT8XS-"7Q3[1C/;I U!%J?0(;1F,LOVES&860
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M7RAJ==/<.VH;.VPE>;K]ACJUI<[&+3P;0_EPPH2B'M]9"!8^QBA>>WK$@6P
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MZ?,-&]]I[>[W]UG119]%V0^1A&>2!?!-EE!/48 9>=RA:6F>)VXG^-$,: N
ME(=Z!<W"+72U_!F@@G@>-5*F< C^]*5]W09+UR5K'I2T-$NC>"JNQHZ-^G?+
M&D._-8Q*,U=4;&(.-^1X%@LK1K; "S,'#PD)1K5ALLWSIL:R"RK_!CN3;I7[
MTD55)Y:W!SZS_<!/E_5*SAL> ES?2%EB<0@/$CDH8@?CU\6JL0-MEA3OP<?_
M!9LZ<7W:^U*AC0I_1$XN?\FULF.U&Y%M)ZZD3K)5_GL16EH932LMU43HYV1[
M\GWW7/U==@T?,Y?/PY@WW ;6 '86$TQ1Z69AV<:;Y+G#:>]%XE&HQQ!_@OR
MW<!3!ELDY<XHA&4-IZ(5><6>+]O\8E]ATO:E+H12!W@..)8IR8C%7#3Z5;"5
M-Q_;/!8+8(ZP%*202F874EI/PAZ 6]-1Y(J&K70C52>5NU!R/9Y>HI4Q7(GB
M!I>#/4NC$"$D>*2Q LJ;W#&BD3E>O>1WU-_0F4"_ER#"(K[0;62-Y7PAS<$2
M<8AS?"108 PH!WSAR0H6%J@$L#FI4RR@TT=E,T6)QZ=":,2<>K*CCB*@A!<^
MS)="=%N#HB&7D-R667ZQM<:SZU[EZWNTN]MYP=>[I^DMN[;DZ6BK>\LBN+[[
MGS</]SO5M<&;'YN.M,\.RG-VI-6-9P@X+<0&Q.%]]NN7LY.SFS^4HXL3Y?CH
M\]G-T2_*U>GUY9>KX]/K]0P1H[V= 5.][SEM NQH>I0NUXYIQ(@K/.\HS>D/
M/%7AN*8#9*$A]UM=,TKE'\<4X"U9(N)<E8 4#KC0!Q5+]Z'#12G.E241MV2M
MD%O%';,JPB:-D14#0M#LO27U>GYEXA@E/V5QS69+DD9$L2"'35#K%-"[/LY/
M$%CKK,:OYX<,4#,+!=[3JR!ZR;M05<!1*E.A%D2B3SSR"=WND/>YHCR. +E1
MC$%S> JJ] +[B%NP&5"'Y#C- <\VN)JXQ@NB._C1 QW0YW(4@^<E\&)\56E&
MD%%!GHV<;-+0((4,(0?-%#XX$C1\-L%D<QZ6AMLDLT%ASP.TMTCD2<"<8B"%
M4 V%_><G.!W"R96W9;[[Y:[^7,/I5#X*7"D><Z0AIK!;Y@>Y_99M&5G:IW0X
M"Y4C0&(@A8(<, 1D%P,*R!U)QL&2\0#STXW*04;H$T7='^P)UX?+@5IS0X]P
M? (RBP-T&C'<OF1W$$6=ZE ?9/U//(:%3JM#""0XJ-?2N%2XLS(0* .U-LZ'
M.=A3HORY$!L4.OR9LP"'A_S";)H9 L_]G0<>:N3P.GH%?2EO%3,0X+MC4->!
MHWPQP^B_+,R09?'*C]R.Z0/QF9_0Z()YY?AWC/]3A&5V@HJP<\H!*D+]!V#0
ME$H#(=4DAC!@SX9#G,TB_!1O^Y6)&0A6\1PEW_0'R98Y=HO3"M%\S<?,@K]"
M,/7(KX*6X#?N9-5HTR<06"??E',>#X&7B[C:[*P8X;40ST,&I%DQA&@Y^8.D
MTAT8J<#9T5U(XL].?.#G&'A6O /$YDWYPIN*]]0!ZTQ$%^7V&HC3 &>1D'!;
M952= )G1&L[/#SU_%YJZM+P1#]P6'#^MA 6\8O:">/)!0_89/:=P"V%(7$SK
M(&=0Z442!F@YC 20@(^FDXT>+6UGISI(Q):#1!(<)')X?/6E\!\ IL;)@QQS
M'W_(FQ!=L)!L N<3.D#$GA,Z4$?6TE1V)QYJ*K(2RDIZG/M7)FUVX- @2Y2^
MUIZ[C_P/9-(30*K(),HF=#_( ]<E2Q.DY>([96\^.9"L,J4IG\@"&L(W@.0N
M$N-6E'=R!)WT4>9CFB3LZ*\16)% @92GST7(6_I$T=7<5GYB21EDQTV!C$IS
MGDC2DP23FYJH,;M;I ^7BNIR!,\.Q +-!C4ZFI<]JZR:AC&#"+78%N)YI1"=
M?:(8Y(9@EKZL"M;\A1=9O=D7'=2ND+DDY?F%8P))W*+FA".*#$VKG"\EULK4
M&S'0J]2P"IT)O<"A\-G=@6P";.:Z6X3.>,"Q%*"5>VS@P3+1 )B+%1YYJ]W1
MOD,7I3Q<<\Y,^-B'(R$CC17?&<?$R%&Y+$$@O4,\( 8B%E^AQ@@',CU4PA,2
M*$!@'&RVY#'$G?#?+ 2^2,BGZ@-8P(R@O.+\11>/?A>EB(L;1B8T<'?;H.X^
MN>-G.9!MS*;Y0J0?=(;4((JD1"#WP!C4/.6:-CK+KY=I)4A4T.92 !*Y*(J+
M&#H>FGB[C7$AQ*P4',5G%V#PQV/2*G'S35 KHLUZ >(,S\T9$EDSDI82R&"3
M)YX\I-'&*.90AD*&HO7W!>=CB:4F)#E@.Y X!(Y#<KH<QWW%:AY^<3!/!]%C
M<S47\ 4JQ%2N$ATJ/H$27NQ*EDQAAM]W(Q,&%0^$FGUX@@;WE@@VIQ7\B@V>
M&]15IDH4P^RV>Y9AK>(ME 9O=17 7BJ0*@][5_HV1"2O D!Q%,V+]C;:[[P2
M *B^_'LI+=9;R=(C?R8R<TO'F)W)^"#:WA@CI(NY*Q6-*6I\<283';-PPGRW
MD)>'*%[.<#3C-$^?()N'R[E[49DD4XQRE./W<J15ID7.H7Q1V2?E65Z?/QAS
M"SMM:T%->_B<JV;V55Z+5((35.OHJM'3[MG.RCM\"FI-AO;A5()#'_4/W]=T
MZ.O]$RE7V355+0X#7OY,, _QLBH54M#Z^*?"2S3GMA*_2\\8^0H2,)@SX>T#
M*E(BE3 <)\@M=\!98# /VITR7P$>)MCCK=XMOY=9\NPNE(KIDG6A+;?"N8H+
M%LC"C0K2@5%NF-1JA$(32KM_84UL7L7LM#O?"5FSY'(43,DHBM,6FC3"1PI?
MD=NP,O*5PJ[D6Z,51_%7,AF%(U(*LA$ 3%K7$N;/#;_JX3V3W%HF!3WL$A59
M4MUVM^+L_%T@*"0;JQ@F#7\C%<K [S(,))373=K5#4Z&17$;1C3+-B:@R8.U
M_&8LLB"7I)>)A>0.R")'8];%1Q,N'8=/Y/1<-"/%D0Z !(&:6\UB*NXA"N2;
M>W*3%4HC<J6<8\K;7M7Y1-GY''WLMU%P*UP258^I<)7)2=D))=-4;0LX(5O%
ME>2%N(-GT S1(&+2?__@3?->WX"#X1'/^KKO7:)0^XG0<G2ZJ0EM4H"?*$.P
M!=#G*!*9@>KX\*7IWVXTQM"!4_J.*'VGH@L4I_\WY"FI@-X+'UJ@01(5V 80
M\.DI(ULU$ !)E\\<7&(!Z79PS60=,=A@80O3*N"81?\[=T'" 2A9<=C)#(U*
MROT,+"@]Q=82M'LX,1Y7;N?^!*;841Q'R"'TI<@@3T1B(^CG<F*O\([E_F7<
MLLN1DB\7TS739 XML%YTXPHW&<V>]L,5CCSQAS@$WG:M2KU9S,<B=E(*%&37
M<A7K5 8TZ0H[2%?05Z<K-(D'+RCQH XGJDP87EH%.F_3B.";JOSV\?SXZK.J
M7/A.-!7>_..C\\]6&1;*Q5LE+'0+LBH"X;L8_1%A;WA2D$YG?9WDZUCN$9>!
MP(HK_)YW+W5$&S.J03ER?#;TE<M=T#<SD%28@%N-@Y7.V+?]3C5Q?LDR[[A,
M(JZ"5E%+X;R, !-S0]G;.+(]A_O>5?JA+Q(;?;)/<XR6:$Z2R/$I2G*7!_JJ
M^7V%KZ<RSIVT*!<S9C_]?")NHQ3,D/(S1<9PC./G\X3B5*KI0"T.&A& -_;=
M5GJ'CFK,7/B2XSE@60@J]^+KRI LOK+B?QBSOS 7DZ*HLM)-K-'/M6$J#_#S
M""^0C$BMYA@9QIB("!HB)D*CX2MSF>&,@W55P$"&% Q6*$J?>!C!KQ,_A!.T
M9WU8S9EB=RSCS"7!TN4ADEXU7+J4\T1^I*'U[@^LXLKI?0+;:AF]1D\>D\K&
M%0,LNIQ7V1G46+.R/18>C8M:7G+QL'55[#7/CT'OHEA>!0Q<BHAHK\_[@L(J
MZ(T9_-)RX8IT80>LIIF49+,T*T+^5((N]M:R*%JY[W/;=AF$<S3N+$H>@0W,
M37&<C/;_NZ/O@1 3]-0CN*2=E93 M[W[Z?O*O2P,T>^;%'%^7JE6P/AHFS*8
M 4)2T-<5E:6Y77J8WNKZDB6L$)Z5-":URL\%%RX&_T!3ET3);2;Y\7,<N9F3
MYF:L_/:&Q[&/SZ05DC"@)2[G#V4Y?Z")+$2:?#BF#57O()L+\Y4F$@BQA5 L
MK@!'&I35WS[Z/'!7LR*=I%MRHMZ>Y<4'CT38XYVJ!*GFFRV1)DB*DYC= @:2
M:>C&$05("!4R4^IM65B&%Z,-=L\-I;DF$%D-_GHYB -MYI&K'B?<S4MON0^*
M>A9^/.207JJM8=A?G'XB#/'EZN)(%1E2)SX;AA$:U )/].45I\/QCE=R!S"
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MW8*)GQ^$6?SH \3$,=P3,R?-6#!#*S\$,1^&W!'D]=.1XL#SD-&5-/99D*A
M=-\9*;2."':!DMY%RI2S&'["A@KIB,&&XQ..S15"90)/!B(H/(R!LIC;U584
M9+040RZ2;Y!M^#>\Q4^S&!;N)_(1>"L\A5A,@!MF8QO>"G?(1R?RV=RE][-$
M23)GI-(]CEPG/"XB)DPFW/&]*?TX9M_\<3;.8;C#;Z9*=,?;#>L]'>M]CB,W
M<U(E\!T>)D#68<SY6-#1\Y#S;D'J9'$N$ *>)(+>>D?PF1+%2'OBJF\3/Z[(
M(GM:-!<4S"#%$LJ@7.H G\!E;#()IO@.IL31E 7I5($'<62V+'3@5[C,RY ;
ME80!#.V&)9Y4&L%72%#8L(GO<DE3DB7RX$E*RF83^(TY(Y_?$N=0!26<QPS$
M%P#,DS3"NLKR8!ES3H.!7;@AB"9T3^5"E!<H-X3$&$\"3F^'I\(O#O"?EP6+
M<O#BY BY*(YNX2.R%-[^$;\$QHOA36'&JV\AJ(4@6PIY?DL*_,219X, ?Q;B
M%AF8 98<'SD?I&RDV'!8,U!<4$K[XLDA\)F2X'/D3J$]$/.\LPW*=^Y3QYMD
MQ&)1>QIEL7(<C<< W74:.5]Q>SDL 0D*R,<?HPFBHR+=44RR(>S;(>Z8;(+0
MO-4MJZWC>@.X>/5ND:Q@&:3H?)A$B8]/?Q_S@.'6_W#GN^E(JH'5&Z4ZIY6W
M,!LTMRQ=?4M%:0-9 [M?;KH?_VW'/_RX$L15MSWW7NV8LR!6_XO@^NY_WOBZ
MPYR^WO6\OJ99 XLS8] ;.)9I>9IFFSWG3UTWWN1WC>)\#1,VY"T[YNQKBWFP
MQ/<LN&/3Y,T/LZ(-Y-H<P>9QO1(UGK<-:@;KB! BD,N=2(B)]V "\!BO I!8
M74!11C'W_O/F7P]3J >:-^U.V(PH"D7^._MQ&?67GSNZ\0P'2F\IDQY?G=V<
M'1_]HAP='U]^N;@YN_BD?+[\Y>SX[/1:.;HX44ZO;\[.CV[@T[HG:*T,(A">
M=YPL&!![L%% ]BO.B(78/PS$'LI')_;)% 3![J"Z@2?-!&Q*QY<]QN $\/%F
M5&H3N-H& 0Z2&.\]"D-4:J_X)(I)T_T(QI6B:ZW_!4LH%A:1G^##4: KJ!&[
MR@F8:*0$FSI->]%5(9='#%0G5L+ICR>@^^)3A8Q'E"9P/_Q%-B^=)&)P)5Y^
MG<(7I>Y$$ADN"'%HS%KJSQ[9\.KT^/3B9H8)KRXOX._CTW/XX7HKWGMB18V>
M^-X',\AWUF#&*^X(\YFY<"*CM5-AMS@*X6^'SQ3/[&/+@'571US?"_-9J!QE
MPRQ)<3-IPG+\>'3]$YBA20:(/KK^HEQ$;?JUI755A;1H[<,)MU.90HM_"GM9
MS%M*4('$771)VM;E1-C7[ZXS&Y;O.XK5TUJ&]CU=<P)@WY+V(W;>S]P%/ WE
MHW-;G:SS4Z!W.OW_$N7R#C[\G<&'RD/[>J=E:=^W"3[] P$N@582D :![Z%,
M$DIHP3PH:)S*E"@_3-(X$X( U-J8@[V66V.E]5UYP#AR.:C \\_!IHHS#\.U
M52^8Q'E'^ 05SS;Y!1!FOVH+XF,GF0V;!,0?K!Y7@-]5Y"+ R0%C(=ESJ,X4
M(E)X$/5.+B>)1'!'OHV03!,T"U/84<"[RE$""P:\ E0JN@3RS59%)=SS7P9R
M.YXJ0@ ;M+0,92LY%B(7$8TB-(TC=#G00LA8 .6?H$?M_GYDI?2L<F'2M0;0
M^I%+%) +2 #N*YYD02H0$]-A0F*!KJUB9P'NF,B0H)X+*T#MI;I4\O80I7"^
MF'QU;E3+<S$%0/Z"S2/]+PX9<VC'D(DB@!$''K),[-*8Y)$/)(^!I!4V&F8^
M_;B^^Z4V$N0+(6Z&]CFUU9)K[\ X$HX'NC1?+V(*V<$K3N(J']#)CF2*LC1)
M </$Y(6G=8$_2$^H<(=@>3)MLW$FC"RYNX X3C0,89WD-@.T"4J290I D2=W
MPNGI-@L(5G@R<#4C-PJ\"7\#_JON#A[XZ-M-I:!!4U)R>B$4;1YRSZ>E5G[Q
M."-_BQ0GP#!'U\=24 HTR)V)D))HCJOV\\)NPC?-B1A<5<(G#%T]* ($\]&N
M07'AHG:U"%%"V"'7 %CRTEU)LE>(K +5\'T5$P#Q_'Z+:9_*[1"BBR+&@>$Y
M\:K#^DCOPA_>&IUV-[>L5718H43.7XBW'3F2MO!@ES!+,+[5>^U.?J/P!<S>
M>^2Z9$H#'="5T$(LL@EJ)'2[.6@L^MU:]-9N+/I.8]$W%OU3F5)G8 0J9GD(
M/S\,]['#KQFZ05-QC*%(@R^"_/,)J(1!E)#(/K+AP%3.6?R5I\J5GWP]//?#
MF?3J8KP53\HL%B>%&]&)G"78/C 1:BJ<BOP;"%+A&\;;8E@SGEQ)! <MG@RD
M",!1!Z\(9336F<)=PIU!X0^IHTO_AH\'E.S-0+^N'02I#PX_RO4>Y^L]S==[
MA<YK9 PRYW0PEWXG=8?"0,,@ HT'5800[( BIB@QG63V7Z@_ :9S?)9HQ"=*
M[PXVM. QZ3GBP2(@GBBDH./?TO\N??_)/!TKE'B <"KJZ$ %7RJ7QZBW [H_
M\R02%NTY_^8[Q3?"F<^5TRR.#I"L1T$ZBK+A""E2">V2#J3(:,@":<8D#-0\
MTNO%T5A) 2K:,?@O@ 6GJ"  "1&I?/M)\="%S9AOP\)?ADP19!BL+F+J#VTZ
ML+))+<%M#3LN@N=Z"4^E)U$H1PA,3$M&,#+Q\H4EPA=W+';+P#?8AL=20?;\
M> S<(;JL$*0Q4( YXNF($;#71MP=SLN*>Y\.!O/<:L0'51G"2X5  9F<H"XK
M4%CP=_7U(DH%NX)VG5@_XF7A(14TX\-&PE<R ])/D;1XEK])<O["G00#72K>
M@!=ZS(^56Q9DZ X CI"V?#"EZ)A,:0'6B])\&Q+F%J"604S2^PNSZ?"VW66&
MLS)R;Q6F9/BW9-OF:2$4OTW2]7A3)8S[(3PA)RF<^6$T1F\Z< 'Q(CT'C$B\
M@&Q)+XCN*F9Q15HN;#.4Q3+=Y&%HE"%8I3&].+<S,_+Q%[<$$3J<Y-,+-]3L
M2_%KFR% Z%F*>0L.3U %_62$!O/<69O.)JG0.=3[@ [\+$;/GDN'[A9[+.%S
M;"W6AC@L@*-7BV?Z^<:<>4>!XHJ;0%ZY(I90B2   UQ6CCQ,!A)[&F_/ Q/>
M'!!S $2S<KP@ZS(V$'(+<'4F'XJ&/8])I(A0S<P*%Q*#O"SPT#T#5\&.K^9$
MP:TN#_Q;Z>#)[T1V+$A.9PJ\,D#?!M*5M !RB!:\*.56]6P <'%'K<&;Y>$N
M-L5R3%4/_7S)7]K7;5AD$+!88*=ZD73BH5<D!3"'<$.(\?\[,",Y:G\";,K%
M6'B<2JH+\AW>@IR(<,@#9"G16H)H=SFB2C&/CZX(EHJ(('G*E!"NDUXK8)M_
M^$%J+;\7R@K@FLF-%S.1HR(L%6*<!/:63XBH>@+)#QX#W1.\/C^^YJZ0H0DQ
MU@AV1_&"/":PU+<8^%_1'T;"#L6IE'P)4-#W4&M,J_"AL.?T@AGS0%VMYZBD
M=40N"C5@90>^0)>;B%_0%T)6'QY)B^9UB^8$;NU<E41LSB!+$%H(A3*2C((-
M9:4?WG+AAY7ZBOC=CN*8DF-1<OS.*R?6&'8?*7GD5,QO)CO# _&,&J4RCD(^
MS>GH@4TMGBV^('=% AIT3.>Y/#7++W*39NG#\Q3? ,R8&/C:5?/,(U5Q12A
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M ^@5H8BZ!/EK#[^+EH+""*V*$I4S"EQ9N;N7 7"K &DWQD4XZS*V-B;24MX
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MQ>\065#M?>"P'HOB:*_"N*[R6)EJ0NRT\6^)RU9(,[DR-!:@UZ?R,"8(1C@
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MS:I$ 8$5#TFX8GG)+/I\<:+J:!8TG)5,2UC$E6!/GTT"%OPA3I:+L]_42>7
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M_XJJ\A'G)F)T"CBKS:6E)KQ2(3#F"DM)9W_9&MLJ?'0W%%NQR?XD"O# 0CN
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M$@KMG[0R<L ^=W+MFOQSL(!A$V9LE0)T%QDT]&7FXT\T$9].\Z!'S*7$N6#
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MXU>Q0#;&"4/^7])]3J]NA#4$?[PO2_:3Q):FQ.GOZY=([_S'7_X?4$L#!!0
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M7$Q)9&)T:3614'-69R \&,LU8\+[2M70MP/Z>]7='<[WP6&%^SU;8*W>FS;
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MXR@L89W" ,A&7-.L(A%7.FJD8P;T'93=XV.[EWTM=VR:R9<_)\,9AHZ?QH-
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MJ\<=3"J[PY$(%1G.F2H1G$$%2=(8*(T30-4Y!;H=U[$II$<6*G2[7IYA[C(
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M.U0#D8RB5IE+A(/TQD5(>?.^4X?W^-I''ZD;<'_S]I@=? W(2KIMH/2^RF^
M./Q:WH&.;:1VL&7/2_4F)$H-M3);HK3 X,+Z3*Q ,FAVH(7707'U;=%ZR[);
MA]5]3%AK5?W_&K3('S@-S2?KKI*<IDRC$R0GP8D,SA&O621!QL284Z5NZ3XK
M[,V/..QJV\GLV];4CC:K4N1F5/8=WA3O8='[U<=%K<%G7Z[^9"%>*7%%49JC
M9"6N,Y(Q'+U6I5,S,!N5<;;.(5-[C$>X4E<FJD)Y_JMXUF=G+1!53=>XB>EA
MLC%JL7B+6#I04&';> LR+44HT(C!]0\C%5MN,W%'LF". RZ8-M>JDW\84=R1
M(_%PFMC'\C7J+#:3BV:"H+8LBX:R$#EX$DN"\:*LH.6XWE*1<*PT,V'KM,Z[
M!=3A\Q2Z<K99;[$G@_<<Y[^9-&D>9Z>3=S#Y.(S+K2F'XPQ2:J)<Z3$3;$#1
MEZ)R A33"82"5N7E6T4)VQ <H2_1B[%[O(%X!<_TZ3BM$'T]_+H;5._; #OA
M''Y#H#M3-VGOR<P][Q#L!L=]:=$9-&'E5JPTRA&72\,5I3+@#P2#5K[!8^3^
MEEV# U&_CW5[WD98.#JY=*,KY].C$<39W(\0*LZ4Z.R,T^GLK(3,R_I-EDG.
M*"7,L')=#!%;:BR))E&6@LLQMBG_L,]G'G:CH2>*F@/8=^?:_\\G&Z9ZA?]<
M_&#Q_6**MY!_*'___O;EI=D^??KT$P)N?HK-^9.%O9Y#F*T7P2:7?SV'F1^.
MIM<A3(?G%Z.[VOSM?M:3K]"N0UX]\!JW]P8)GV<P3H K\3#]_.,P,)%SY@R4
M$-):8WD('I(5B7O-31[L?FPW5[L\Z>5X.IO,BPOQZK);A'?)VX3>I$P:F1?!
MXIQB%(DBJ<BIYIK7:>*S U#G?NS-^,-[F)R7QP\T9=J8H(@(#(CD*.N0/1"'
MXU*!2NUBG::E5U$</FCH@^L;_=7O:]<*6Y97L9S,)XOV@(%;[;W&M3'(4';7
M Z(QGBAJ.<M&4"_K7,38 N;X&+^/E2OL%UR%5'+G5ZBD##FYLBM?\N,DXZ'<
MDPR$)HBX%+ DVI6X[<3]5SS'1_\];=UC.<7M(UT&PE!DQY,DD$,I:\4S"9X#
M84R#8S0ZNUE8L<H2=I!V4349[VK;Q]+IZ?HXEI%3DF"$3(0Y48Y=P1"GA2!)
M.<.L8Z'6R=5-+ ^UJ]29W5O5LK>5*ZP.UQ%=R81J@ZOJX=,N9 ]S!-65N5N%
MT-'LAY0%4R:A$XN^JPDX5T*I=>F,)%[HP$4(AL5X!'*XX_#I4&K8Q]H];S6=
M-../,)D-<<I[!^-A,WG=S&#Z? [(C[J\^J"\=>C/&@!&9"GTCZ.,!/#_9,!%
MU8@VA?!;?-1#NX?WY:2I9]">"^4_55< +J"M2[M13V4P@NB42@]Y'DG0Z,92
MY258[E+2J07)NYY_!,SV8KK>*^@OQ?4+A,G<3[ZPPL8*EK0X)5'IB92@T.GU
MI?B;Q<%:R\$+GSQM4V[TEH\X E+[,F"%>*Y$F;-5E/D>_YO%^F-UD#[@@H/S
M!R?2*IPZ<(0D9ARM\[3<6*@6SV^B.19_O;.E#\#^2N=M4%7UU[?C>AAOO3MO
M=PBA@]$K;?%M02>LH]$X11(O]U&-R,0:$TF6@@6KK'&5]G@.*84[//5#*6$?
M6U=)"KMT0 JP==G"H#GZ&)I8=#>(C#H1RXTC"EQ 8-28[*L(8"N<PSL%?7!U
M(QFLJZ$KG.ULNI]O_)>R]*V#"N<]XJ#H 7D$Y\ 35VHCEJ8C(AKI?:HS#=P*
MZ]C4T-'P-5:%X1A.\\D$TG"M4PI*1X,X&)2C**X]L=E0HH2@EF>7K&A5863_
M%>$&EJ/@OZ.)*WB'5V6X2%99?;T.287,8#V.5FE?MJE**J1'B28=5=0:6-Z,
MYGM2P!W CD(.?1J_0LG09W[DQQ'>G0',7I7?+O8M_A"+W()E.$>!PS]HXB0D
M!40H+D30-BI99UK8A>A8XL=>+'X@):SW2UH@JQI'[L;V,+%D/QRV$$8' BIX
M#[<@M)JEH&(@W!:$D 0)(DKBI3<T9)ZLJK/5=&AIW!%;'EH9^]B]WFG0U0UN
MIPVN9-F6R[>(*"M.K"]]M922F4JN0JL4X\=R,M"7[;>?^MS7<#T?]%SU69^.
MTP(5_OVJ\>.U[[+*7%O?<1(Q&VL9(K2(52J)"Z MU[FU=!)\#*X-R?M^[E'0
M7]78%6;]A=?Z-7/MU="'X6A16V_==0T#&J.9)N[_9^_=FMM(DC31OS(V[]X=
M]\O:SH.D*O5HCTK2D:I[=O>%%A</":<I0 V 4FE^_?$ "9(" 3*!S$B04%FW
MJ:E+9W[A_F6$NX=?"M9&TZG4R< 2-":5N4UH&J4-/H3LR=.EB0H:>)B79'X9
M4D5U66!KF67%) =%*/*9E+3@A3,@#8^&UIQSJ[+3.UA.Q7/H*>4!^Q=O1[2>
MV-(!4U-O81NJX_@)?35V+P%ZB+O%;<,V;%(HG5S-:X]USW.U3Z]P 9PQVEO'
MZX3R)TZ!!_R!,1BPCY2;-*+X.CO_.IE^_!'<]7#/%#0:2[AJX]TZB]Z7D*%@
M)D-&*\XWY]@.UI/B'ECC6P;]-7>G"\508A^G$/%-F,_)'OJ*_6H0[SQF@/+#
M^Z%M5!Z2X+ATF9QVE90)W(<2N9<^6<:,YO)LZQ/;%!UF)0R+0=>+I)H;R,AY
MM/0U.*ZE]@FY;12Y;U5T>,LUNB9T^&/R^>+S\]E\/OM6Z1Z^T-\LOY_9)")/
M(=3L6MI'9?;50>(@HDVA( \N=NI^U^OBZB&4Q\YZ.XPK]]UI#:J7%D6-6[#^
M?7JQP+Q&^&+V^?-DU0'D)>([LN?II_ 1STJ,5C)3(#M/MKDB605G$9(@SXK.
M9FER'(U0G2"?+KN&UUCCV_0SD6U.BF7025;/CDGPUD9 PQ/SM?- :G^/?GJ$
MV$NNS0LEB9[X['/M$WV6$\MH<FT:Q>I$B4+;G.$9O#8E)I9L+F.4PMT@.@W=
M#R+O!M>C/^):CP)Y'Y;X8;GJ+':S*]ED,'"F@<<HZWPS#C'X#(I;IXV7FO,V
M*7;=,9XB5P;328- V8](;UT _4X$6'R:G>??YR&3%?5+^+X@L-:(3%N>M)@(
M8C#@5;9@!?D717&?>9O8Z5XP3Y%#0VIFP-DNW<'6$4B8+JKK>0LW/V/!9EVP
M0.)^-3:K=C]* 63)/-N JHS2GF8/R#\+O8;0V(!C!+H#O]E=WY8/RUGZY[OY
M)-$:)A\_UFD7T5MNI(4L1 05HH6 ,D%6*HNDDK*F3=RO)_"?A7;#::]!X^N=
M\"]_K)'W]_5NE9]QGK/"[$"(0I)BUD-DM93/HP_>19/U&!&P>R">.*%Z:63
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MDF9,.255*=RI('0LM$,4(W),V[EZ,)3C7VW?7+.6%*-5AJBO/&V3RCD(@4E
MQGERJF1AVD0>'U5UR>UN9MNR&63P,DF235XE J.($+G48$SB9(9(%QKU#WD
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MR*D'=9$O9M/%['R2ZS7$JN1F@HM5%)!@U#NO "8P4<_G +Z0!:Q]4"HZSXB
M@X5/=Z'X.>YN!M'!@%OQ+DQ7Q.^":O [F=UXQK^/&49?#Q"@A[ 'OF>Y%UU
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MVRK,I#?81WI [Z-3>WPRS2AKX*-;O\M%&+BDP-OI?'XFK-8ES((H6B!YBON
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M:,/!7N:F"N_RU3>Z$D /8QG1[+@)=IA).VTXFY^156&'#S0 GX=3@D[K!]6
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M+O^Z+!_DXG48N!2<(Y9X4,91#%$8($B3,( 1$21!44 ]WREJKC>2N7VN:D,
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MGVG249C*&]"+A(2(^AYD1$E(622C(%$<$2?=.M+/W#3JD(/2:[?X&*]V:C0
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MP\Q-=NJ :]&*A8)1',40A3B&A/  QE$28!QJ]<+<5K>ZNYJ;AFW17H :+V@
MV[^_)]@]K6[#<3:RTG70U4/W3O!FKX'#\3>1'O9Y[)Q$T8Z1#H$\T<!D8FEG
M2%LX+>^8K-KY-EP)B3 FE!'H$<HAPH&"3'(%%2))1%7D4^ZYI>7LC65N,MR_
M]O;IX*C!Q]%NGCO1Z(PL^&,.S!0ET4>-:3L'S]P+HI^*AQNBR1'C2+8O*Z>)
M)[CDD##D091$$E)$%<0)I3$12$:ATTD=I][G)K/V@0X]9=5M;.R$=#3&QUX5
M&)#L<6)*1A5'-P3SBR@Y)8#]&NF?X_WO,KU_6$MQ^56NZ/WVP.1G[>TN>,@8
M0U$$E0H)1$)P2"/L0S^17/H!\Y7O5.SA1']SD[4&*J 5UET\\$JC=<\"WT6U
MK?,W&(&C.WAL?0&V#-9@=Z>P/W<QV"M;O 4O@Z>.[^IS\CSR%@0<2BIO<UN?
M<+4C10ZOMO5&/^;KE.^*'GY(,U-@=I$@$K!(8I@@4WU+_PB))"$,,0D)C@,_
MB*RFLV>AF)L4U;#:U5JS$KA+P%??$3F]T#@)SQ,HUO$RK3M#0&7)KG#K!:B-
MF6(L7$+T)AB3R0+Y1AL;Q^"_,SGM#!'LV_:$@81GFO\RW/#<QLX-V;F3]Z;K
MS_(I7QDONQ7U]>:Y_L<J(H-0[#.$* SB"$$41!@R11A$),:!8#26/.X7EV.-
M86Y?I':41HT3;*UX&4#'GK=7G!E>8S]B=O[TR.,P\A=KG"$X(Q3&F<21XEWL
M<7RGH!9GHHY'KK@WY>[,W\E'BNK=T] /(\:$J8N+%$328Y#&8:C_BFF !(X]
M9+VGWVIW=O)FH-D[=&V&3KO+/>T>6TX,JA[;[6W;[=W3GAQ,Y'!V#[^3SWC
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ML[PPB4?KR1/!@DKL*<@9IMIOQ+&)AB-0$$YC2;T(>=91* =[F)M"?[K]/Y]
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M$DZ+14,#G)OF[7""N@AOFI7UCJN2A'T*& \XFG;R^#W':&0MK<>DL@WLC+L
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M;NA>+O*.2X=POSY+(1_+^+$JGNS+M[PYON8ACA%3T$>)]L283R&+< *Q'ZI
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MZ$#_P0MH/^>@;_@&7E".D+L"[_\&/]U> 2=T?5QC"(L^!*A^;T_Y=#SN=:@
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M?'$*,9<<"AQ9PC'$8*8M[:0\O/;3Z<ZF1C8?WEU_??>U2ZFG,V#Z;37W!='
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M(,/4&)!$_Y<[Y/WH:JDL#5C5<KO$BY7@ 3&GCN/B$?L;'NW!MR$6VEV_+G4
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M 0V)TIBG4L<J\(#.J6ZF%]2NI<S=F6[+"?\>1@HGL?3C@TOQ&=PVJL2[ E;
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M)@A6<0HQBCBD6B<P90E)1*H2HR+O!% G.IB<<^)DA(B!2LJ W$.GX&N>V7V
M,K39<(!'EYH_IX )2+YT(4!C)5GR_7#"4B@U*-^4*NG4:^.E1&H0^E7JHZ;G
M.AHN]K4[LY=&J0@*2"Q3GF(%D;L#@F,M((^,.ZN<IAE2F,C,B\0:>YD<DYW+
M^E5X ?M_+PO7;![X KQ^J4MHYO0(>%HXE^(Z^%[)T)"&FT5-D/5K&)WL:5S3
MJ$G9(^.H\>%P\^B++FK_?.:KS<LWV^B:2[>BO'_>/*^T*^F^RL6S^Q=WGH&P
M*-$Q3#BS?$.%AL*D&&J5"A1GTF#C?=W,O]NI$5 E.7ARH@-3" SDGL3^)D0
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MNUYM<I=L9KG1Z\_\Q26>J3SN&(L8Q79]1HP(NS1G#/*(,LA(S")",A:CH R
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MST8O%OF]7M7K8I0FB%@32C+B[*BHJ!\@(<(1RC!#D4OW[%T_X&P_4S.JWJY
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M/<]\WD^ ^D[\W#S\)1:OXNMJN7DJ9ED<Q9C3% J4Z5Z[/(0T"!",,2%A*%!
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M3<&!A'DJ*,SB& O*DT2Y*C949"AW:G1T>;\Y4\#-R,<#C)X)J+>1G)^.EI9
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M1&D5*/9FE2$&?O!VY@>KS*,_%RYE?V!NA.5YOWEEMTM060,.YER!SW^'=[=
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M6;Q5X3<9X.V?LF>IZ^1FM7P5RJU7+ON=]M]W05FUR:$\#F&:B0"B,(^A'J<
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MLTAY."WL1\,M;;6+&Y>'>LT^(9;^*P:&J?6$TIM5<1Q5"1%F(<8$BI0*B$C
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M7];B2>^%7T7=:U=L[N4#^3E+<QR+%'.8A=H911F'-!$$,I&GF?)*%2=AF_*
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M"?ZL_^OE]*(7$\=[R#9I(V\<>XP^W2WV76!_>G%N;OH7H?Y1',W118RHBTD
M.>5JK\CB&%(12I@G293))*1I:M0,R$;HU&)4U;#B2OORR&+0$84QY/VG$SZ
M]$PM-7K7;]%3?DBIMLUHX^' FA]'^ !XI),(=T!;'4+8(M9Q_F!\J]&.'FR-
M:YXZ6%]K3^8/ZO6@-D.Z:WG=B8RFF$0A1S A@3Y9B%)%V+&$61(R1I(4)=*8
MM4_N/C5ZKA6L)P98#R(^1:^?@"_"Q#/3.H?#G#8O@F4D?FS"XX;Z6JWNX+C3
M:T8CLU9UFZS5_J%AN]$[L;DAQ=.W]>IUS@7_\.N/0O#;Y;Z_R#7;S%]+;IP%
M/,5YA"0,>9A %--<<U<*:1[B)&6AT*EU%J<3YJ*G=EBAP^M,J0ZV2F/=\DON
M= 9DK[3=+M9B'<RVM7[0]4R1&EBM-=BIK8?0_/9'A?+?P%YY<-T/L_6FUQXQ
MI[M@"_&C;HOM83G>)P^XPS R>UB7+=U^E56?Y9"9F=H<LUB2&.)0Q]20PIT2
M/7HYS460R #E))\MQ2/9",.(_*D0HP<HKQZ@IBB/[]):Q[I$&@)\E2;)58"C
M<IM\^%L].H!LP%>%]A.(PRN@WXE58S#!RI2;?_V7, W^O?Z5^E-=\2+TFHE%
M>Y3:=(',V&P@Z",Y=F_0OJJ&;+GCI7;;G?+/&3&C\DR[F<=\TO')H<TWI%BO
M-2?555:-+:&NV$NR+&(HSV!$A6ZN(86B$Y1"07A(61!'(K0J6>Z1-[5]W$Y=
M710)%K8A-E.0S8C (72>66&/VJ%8\FW@QVG%I"$NCMM1=,L<N=V$$0"G[23,
M+AM&+-_%0K_MOY'UYM?#FBP+O3U8+;_LQW2G><+S4.I.X%3MJ5+EHU":QC"(
M BHC$:1<"AMFZ1,X-6JI]06EPJ"A\04ST7M!-V,:EU!ZIIH+4;0F&U-HG+)-
MK]!1Z<84@F.^,;YN&.&4N?-WRH2RQ_7FM/(#)TAY,@F#7-&+<F40@A1',>1"
MHIRB4"K*L2&</H%3(YPO#V!9EH2\U"4A\Z7.[ZW". M=%++112&#O9S>!3 C
M'Y>P>B:?JI[FH*NG@AI;9)QR3Z_04;G'%()C[C&^;D#:PN-:E)WTKY?\F_IZ
MW,NO8OTHUKMZLR2DH<Q#2'*1*]8)8DBCF$-"PX1%BG=H8)ZLT"EJ:GRSU[:,
MJ&A]=6)VI;'%27HWO/WG8NY \\PF77@-*(OL^UZ:)QXX W"L=(,A7SR[S (C
M2+KR";IO,%X6@9$A;W('S*ZXI!67KN3XK-3\],_M?//KJ]@\K7@C1W+&N4@S
M$4=01E+'I'@ :9)G$/- A@$582(,)Y);R;7YIH^3.*H5!GI!E0>W5U-[<]5?
MA:T'9P9_+GD4$IQ"C'1%A8PSM7&/(AC3+*8!(RE2?K35N8([^$<]:M *BW=8
M #,_VOEWVO/K[TT=5P5JI32HM 8F:=(#VZT9HN2A UN?Y'=HRF8(QOD^;:87
M#WL_?-@6\Z4HBFNF;E_,M1M1_JA>275B4(0IS[#:WV>QWN2+-(<Y$@02J5X+
M:4HSK.M(S3?YO1*GYG7O% 8-C:_ 3N>!,T7[<3?C)*=H>N:C2X&TIB)C<)S2
M4+_442G(&(1C^C&_<!CU5"D;HLR[W]=#?26;[5K]]RBI&Q,<ADF,(,>AVO.+
M2,)<A!RR%&>Q\EQ3S#(;$K*0/34ZJNH4]DJ#G=9V_&,#OAD3>8+4,R?56H-2
M[4;!Y!7X/"\868#_$F2]Q]A+8OT% #KE+1OYHS+8 &".N6S(+0:R&IFORS02
M/41OL=)#01N]#T60H9#G%-(LH/K$)(0TQK%:#<KR/$PI198=)3OE36^#_?GZ
M]COX^_67/SZ!KY^N?_SQ_=-7^]Z2W1@;TI4KW'P3E-*S2@(##4T]-9HT L4M
MZ71*')=F3(P_(1:CB^S/0%HGD^A??"4_Y\_;YQ]EOF4YA%7]8H98@D.2AE"R
M+(&(TP 2G!#(\Y2D'*.4H-ST7,1>_-3<I$J[:NJO?F5OEPKX:A(PV4>S?YLO
MZZQ5P\9  Y>F_TS%+^">.:IKXE(Y*?@*U": >EEV1GA%W?Q QB_Z(QW2>%@%
MJR.<X2!V'.L,N.EH1SW##6X>_UQPEXNF->R:9%83[#>S)$^R($ "8IEBB+">
M]X<1AVF"\I#0*,2AY="_\X*FYY/N]-RE\0P:N7 ,IYD7>CE$OH_0=]C4&BI6
MJ71T/C6A!0,?0Q*.1;W'3(06<UM&(+1]>G!_-SW4KII_\7U>_./#+UT#>OUS
M7LQ(%$4,)QA*Q'.(4A1!(D@$0YPE$B&9\C2RB;1UR)J:R_A&5:!UK<NKM;*6
M\?TNB,VHP1%PGOEA(&9#VH[UH>&ZZ5BKO+%;CO49?J;A6.\E0VN;7M:"S<L;
MJY\7HCP46/+KYY7R6?Z[<K0I3RG.RCX440!1**ER)%+%(&$4*R^"D518#K(T
M$3L]MZ*I=9DW11KJVI8[&>!N1BNNL?2^M3RH>P7V"I=X7IO@.:#XR1P@QQ50
M!H)'+H,RA^*T%LKBVH&#F]B3X-N%N)?[*-RY/CQ?RP)/P>^7WX7.5IXO'S^0
M8EX<G7)E44XXBW,8<.7]H)B$D"0I5:M%.4&(!#))+8<]N=1O>OQ6E]R314O3
M-+ S3%>$-\+8^ND%>U-!::OE;"FG"V_&F^^VF)X)=F>73N@]+-)5[YIJ;^_M
M&GH]'/4"O]NQ64XU''?4E@]P3\9S>1$R[,WQ18EZK-QC48CUZSYJ$ZNW0,(S
MW=%<43]".8=Y1)07&Q&:,1:F"".;W6^;H,EM?>MRJ\5>WWW5FF5B22NT9C3K
M C#/C/FIV,R?RQ+9@[+-Q!'G ;(^3)S26*NP41FIS^1C<NG]_$">J ='Z5#\
MAU_U/15?'>K>KFE1-O>>I3AEF40IS(AN:"80ALJ?Y#!6>V$<Y2C-*+)S'\V%
M3\\W_*J<_$?R*.KZ6.U%K,K2SO( MHZS6WI]%HMAR#5> /;,/E_V9<75D1[]
MM2.<$N5&Z>R?.^T=NF'VD+DE)W/QX]*5-2PG!&9_!_NDDB_SI7*_;I1W-=]\
M)JQ\7^DNM0]/9'F__O3/+5D\K)+@7GX7KZO%JW*];E;/S_.RT* N<F0"(QS%
M*4PQ0U!Y0PQBGF10TC#)4QK+A,:F22:7JS,U-TIK#S9/NCQR#80V0 ])2H+_
MH7=7ZYT5@.W-,,]_<+!VW:PX_HKX9DK=K>1>@LH<L+.G:I(-'NI5*HT"#]4J
MJ4_O+0,'TP;4"CM8+O/TE7&7;:1T%G?+YR:]Q1W('>DN#H2,EO[B#I!F.HS#
MNUY6$:=N2^?+\DM>5",Y9H$D(4*QA#S-&40)IGJ*:P8%CT,:X5"(T'*F3KNP
MZ?GT>HZ1@EOSH?IV%',%Z8"CK YXS;QV-Y!Y?O?L2]V:6HXR;:<?'B_%;F?$
MO4N56[O9;>5M'5<,SJ_;/F_+SEQEDYPS<QIWSG3&0X*2"$894WP2*H^:I#B%
MD622YX1&,;5LNV L>WKTTE"]'JO>,974.D7/<$7,*,@+RIX9Z?K^YK9E?*N'
MQEK6"+E.\S.4/G;FGQTH9Y(!+6\PN&F,[HHL/HKJO[=+W7!@J99<CPP(!<[B
M."7_7W7ONB,WKJ6)_I^G$'" 0160[".)E$CV 09(7ZK:TRYGPG;51I_Z$> U
M4UV1BMRA")=S/_V0ND0HXZ(@%9*LZ8UVV9F2N-9'\=/BXKJ $%*;9T(PH#Q&
M(&4"D3!)PCB!WM5*SH_GM(8FK5+2"&?V(GE'V=T>T+K1S_5P359_I)0O^*F1
M]&=;R:4E[*!51RYC,G2UD8X1IZXR<EGY$]5%'&[R=S)^6N7OUNR;VGQYR:41
M5=VO5W(K-DW-2B;"D.&4@Z@,#U28 I;($& >XE@JQA+JE,KO,-;<W(-&7%#)
M&S0"!XW$[JZE2P!?=O,-"-O(%-*%6 ^OW"7HW%UN T(XD3^MU\OGY2%SQ*3#
M_77I"9/YMAQ5:3NN7&_I9Y+]GAN27F;_4O)7EN5V#W27MZI '82TA4)&2(4,
MZ)!)@-(H 5PQ6U4.4Y;2%"DI?,)8O$:?&^NV(]QL3RBK0AW85I6;6^5-7;0O
M-N2H1Z%FO]EQL_)&PWQDRM[+72+=E)];Y>UR<Z/&"O9";E#;T$^"26W%7N <
MVH[]'G)=#$Z[7F,<4QH+$@,4"FZVH#2UP38<Q$K&"0V5V9C2?L$VLZY.VKNM
M_2D,E4*1ADP 3B@$",,0$"PT(##B:11"!FT9;?<.C%<B.$6KQ:]VC$"P]?K%
MGA!^J\+1=;O4Z/6XNK'[E6B-?72^"S(:I41HA_*CA O]L/*?'8J>"P :KK1G
MV1%$&P/K-I=?U/I;9MLCWNE=VL:^Z$!ATP.+T[^JJU%"*"7F"0<)C")#NSH%
M+$X8B 5E#*9QRD.O*J!#"C<W@W.?&-,2M6>=T$$GT8V:?M34C,QI/6>E1X?%
MX>$;N#?C@ ).W-5Q>&B/^T&.,$8/+^J'W[XT3BFLE#%W"=":8("8V='3E# 0
MA5'(XA!C#IW:NKU^[-Q(TTKFX<C;P^/@[NRE]-B>32-4'P]FZ[UP=U;V F J
MOZ03$'Z.R"-]NWR.^XNG<R\>"?C*DWC\V[YU7HK-G?YUM9)[-E/%E]52+B23
MFJ4) 8G&"B N$T!)@H"@ EEC+F(1\ROS<FZHN1&-E=1N^HI*1AN6K?*.%LN^
MR+H96</@-3)'-5"58I8>TT;0P$HZ9'672V@,7-SE[' 3UW:YI/9Q:9>+=_1M
M+ENN@F*70D4E%# VM* X-1L^EF) 4J5!E$1QBEB$L(K\7&R'0\S/O]9(^.^^
M/6(/L'.C@&OP&'GA-Z*-DD-V3N^!&[P>##)Q0]?3*AXW<#USG?^&X>[^/^]^
M4]\SL:K-0T@)%-26,A'*+& 9*D QX8 DG*90QVG*G9JSGGKXW+[I5KZ@$M#=
ME#Y"[/).XAH<1EZR+0AZ;"N.L'#?7%R#R41;#)?7PVN#<4[GCFW&T2V3;3;.
M"=O><IR]QH^(I,H6[^HYO5?K;"7?Y_(=VZA%0JE6F"! $R2,.4$$(#H* 8Y%
M B516-/0A8W.CC W2FJ$#"HI R-F8.5T6Y/G@>PFJ4'@&9FIO)%Q7IH7M3]A
M8A1*_-O#ZMO_:^XMK8M_(OM74/VU7+WGGSK)$KZH5+..+U_H;U74 3$OS5<A
ME E*&05)PB! **: <AZ!1*48)69+ (6S*_+UH^>V?!OI@C<L_\O].WJ UV6+
MHC\*(Z_2'0#^QL3A2^-L2O0'8R)#HA'PWX8Q(T[KVV%$'-PPF0EQ6M"V 7'F
M"G_SX7V^,8]Y6]:O77[(I?K^G^IEP0FD2L8("!(R8SX@!!@R-D0DHB@4,*8J
M<2H[<7:$N?%/)6102QF48@9&3G?SX320E\V'J^$9F9B\D?$R'SJU[VT^G'[J
M9.9#IU)M\Z'[PJ&*S:M</#ZQ]5]U5$(22Z6E1&8Q*PH0-@N<I<SV=H0A98H1
MR9SZ%KD..+>E?J*$^D[BGE$C%S%W/:08#LG1CRJN 7& <O2GD1FY)OW!H#^X
M,/UI""Y7IS]S7]_2GJ?JA]CF7_6K+R.)I>(Q2&5J]C ))(! @8'9UJ2:))K&
ML=?)YZ4!YT8W5EY[J'>BKD[9(JT?XUR$W8UQA@1S9,:Y&L<>=4#=P!FX'NB%
M02>N"^H&P7%]4,?[>I;\,':3S);;3?9-[7.(WG\7RZU4\A>CADW5WU;;TSO]
MGJWS+'\H[M6Z[.QEI?NP44_%(A&4*VYX*81A")#0(3 FD 84H43)"$L9.KE)
MAQ9L;B36UJN5M14TF@7VU0E:NMF5VFAG'8]5"[S@SW(5ERIZ$MY@4^Y&C#]B
M(D<FT$GGT+^"R<" #UO@9"CAIJU_,C"D1^51AGZ^O[_\[:-M,[Y^>6M6R>9.
MOU-+]K=Y]!^VRM0SRQN7* F3F$=< !%!#% 8*\ H#X$PY*]LSBZE3DW6W(><
M&X$W4@>EV'9E-X('W\JJ:59T=Y>S(^Z7_?'#HSGVQM<%R!Y.?$=$W9W[PR,[
MD=/_NE?5ZT# #Z..@P+'!TUV@."G6/M@P?-.?\K^O#(?C%R]-;_.!%M^5453
M@)?%H29,20!1:LOS:0P8P1!P++1D,!(T=:YU?7:4N1%S+6C02!I84=UIXSR:
ME[EW$(Q&IMN3\/2@U_,XN3/J('A-1*)^KY47:5Z$H8,GS]\[&35>%+_-AI<O
M]B? $X50J_"1>_/'^NOJ2_:0ESEPMP]KI>R[LDAC&B>AB@&'MME)A#"@2&$@
MJ,(JC!"-N7,<B/_P<Z/,.H[IV<IKJVH6E<364F"-S.[,T&,Z+E/KN""/S+FG
MBBG?--%CI0*V 'RM@BT"?SL)ZNY$/2[Z$S'X"+/@1?/]0>S@_QX/G>S#T%_A
M]A?CBJ?X?4J*]<:>[16K929M$=8REB!33>T!&B$2P30%.%8,(!BF@(21_600
MG4+(C&7M],GH'F9NGX:VI$$CJN<1VP5@N\E_.+C&/\#O@Y0SA;@!T>6E-4]H
M>6C-OPZ]LQ>&F(0XW-1L",+QZKY5I)M*-OO2=Y*IB"HM0*)U"I"P-0E9(D&4
M\!!QE:)$>%:\/S&*SUL]4>&N3W^\__+UM_>?OCK6..C"T.W Z$I<1E[M>^F"
M/T>I =BA_L!5H(_'F;CV\UE%CRL^G[^T=Z'XU9/Z8DS/TG)XPY;66??E42G;
MN^Y6RLS:&VSY+BO$<F7[^A9O7LP_GE<%6_ZZ7FV?"_.(Y58:"\1>4W:8V2IY
M]USWEBEVAS(+26028BH 394M_(<D((@H "&F5**$:.G5FG="V>=FE=2M-':Z
MWP2U]D&I?IGIOP<@:"%@VTTV& 05"#?!#H:@C4.P!^**8_8IWS!78IWE>S,Z
M8<_QE>G3)F#JR1NZZ<!D\D_=PF#JB3G1$&%R$?I]=FV3V'VQ,5LU<D$Q5FD4
M02 B2<SV.I6 AU@#1!5A'%(>"N[S=3P>8FX?,2MAD.U$O ELO5*_C\L)'-V^
M =>A,S)5E\!\: 'SM0L8;PH]K_N@3'=BF$D)Z;R:A[S1<66/TVA5MG>Z9^O-
M2UF*D E+';]L-X9O; ?&LG^7^4GYMK*0LDC+"&#&S'8Z"B&@B!,@8J&3.*18
M)9'S";7/R',C@UKXX-E*'^A29MNE<B>T!SOX3X/#T?98X(Y]W%WC6@H>M"2_
M"2K9@[;P%ZCF2I0]#L;'0GNJP_(A4?<[2^^#7-?YNM?SICMS[Z/FJW/X7@_H
MV9!XG<D']7'%\CI"A,9I& H*05A9>(D E,4Q8!3*.,*8X3CUL?4.!Y@;N7_Y
MVUC4YMF>-1J/<'.S[:Y!8^R#\%*TP,HV0L_.<XH/VR_X<)!INP2?4?&H-_"Y
MZWJF0&^+C=E:KDO6L!O!Q^RY:3F&=1QR1!&(,8\ TAJ;Q4QC($BJ;<E]\W_0
M[T2D8[3YG8PTP@;KMK2>V<X=\+JM^8$@&_N(M,'JE9@C,($#',,F-G>,-VU.
M\V7%C]*9'6[ID4>R>GI>%5F5J/)6K3<LRW=UYG<NJK?LN1SRH+]80B"D:2A
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ML%_(\\--^ZF\J/;1-_/R'?YG8O>/;/U4O.3FV?^J3W=52!F&$@)()3,?S$@
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MCG 8L7[)QQ]35>F"PMV53(XO]^_F_77-;#FD+R]/?+5<I&&$(1(1$+"D <(
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M+^-'JH]67<JN/*S]+5L:TWB5J_KLO5B$4(8X4@H@KE. 2!H"(I@$22C,AE_
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MXA00JC10DDAB&[.$PLO5ZC3JW BC%,US-^*$KN,F96C,QMZ[E/(&.X&#6N+
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M2(9JNW,U?(.:M?Y23&K=]@;IT,CM_Z!!CWUWEO7^\&6W<40)@UPR!-((<9L
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MSKJC3\5$U#S>E'@1^55P=K!]O^=.]DFX2NWV=^.Z!_5L;;\/-'M;%8]>Q*%
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M#*H9>0/H5MO(_[']^/?7U4K^G2V7!R["KVN6%\O2$?(KR_*/-O0F@3 54&"
ME,V@PQ$%C$%AYC1)(A@G JK$AVK=AYX;JS:.?/5=E)6*RV*)*UNJSX]6/<!W
M8]!Q(!V9+!NA3QR0M 0/K.3!3U;VGX<C17_ !N4_C^$GI3I_6 Y9K<<3^A'8
MERKFLV)'6\4]UZOU4SF"-6,_&/(L%E#2))98 :G*TD01!"32,= B@10G*E'8
MRTIT&71NI%7+'.R$#EI2!W^6^[E2<,\0*Z<)<*.OH6$=F;@&0-2;L'P@&I2J
MG :>E*1\H#BD)Z][_8BI6&\6=W_G9D4_9L]UO"'E""5IRD":Z @@3C&@,95
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MGT<&#0[E;T\^/;!@!'^6<'BZ"R=\Q=R<CO-\<4;^K+N\,Y>FU]MW.3W2@WI
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MQG!E'V?/P,M3V+D96M<B,C*36?& 0?TIL +>V"VQ[3N:Z<RLUS&*KG7A,6R
MY:F!IHVK[%#U*)RRZ]HA8H4^*ZF>GBW?WZMUMI)U:$M"DBC&$H(TU!2@4,:
M4J: 1)$BB!M^($YYO3Z#SHT0CJ)B]F*;[40I^" 116>FP(U'A@9V9%X9!-,K
MXXZZ01HQ!NG,P#\P'JD;BN[8I OW]NPW7Z>NVQXN;[?%9O6DUKL(RMTG-E1$
M0YPD@"<I <CLPP!E$06<"R24@"*D7NSD-.K<Z*D1NFJYU(C="C-V^4Y?,0EN
M_#0XM*.?)PZ JG^7>Q^4AFU\[S3RI!3E!<8A1_G=[%^P[+,]TKO]GA4+KI,T
M)50#E*02(&:3V#@5((8D"IF*H=).)/3JJ7,C&1O^DA6;S"8EM-N\_6F%]2A8
MMH>MFS9Z@S&V9Z<?#EX%RX[TOKI4V?Z)DQ4I.U*B79[L^)<]XZBVO%#_W)H)
M>/_-_%$7-L$:)TSC%*02,5M[F0&B"0$P3&BHHC",D5-ELLY19K= =T(&I92>
M,4DG@73[LE\-S]A+]@"9 :NX.$$P;*S.R9&F#;?I4O8H8J;S8O\SF*:#_-O5
M$\_RTC_]=<UDEC^\8R_5_N/>_+'^NOJ2/>3FQW?Z]F&M2I)>0!QR12TG,&1;
M7QB*8%0D0"1)3%,4226<VSA?(\C<N*,6/)#L)7BN]M[/5G:;GBB6JZ+ZG6N)
MPZNGZ?+QSU3@C\Q,C1I!2X^;H)D-HTKC"2F5";ZN@EJ=X$X'.X4FFA7WTZ>I
M9F>B4ZJ19\GK4&L(:#L.OZYZ_&2'9$. T#Y,&^1Y U8RL/&C=8X9%2A1(4&
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MO"!")XF@@$"LU(QD[G1B2ELGGW/8LU^$-0*V+UTON%]@LEQ<_V2][@AEVQX
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M]\0E+HG1G@5A1;3/ELX>ZH5_E\!A.HI4W.HJZ&7 K..C@AJY*$%95+M5EJ*
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MB/,L7<->(:P#T!XUT80Q?B"ED4@R4AE<<5,8D2YR8L%PDG6P)8W)@ZE3?/F
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M_XK?\!D]B'65.<IQ''%%E%^<3-/=']SZY$AD'Y70B5"G4 21!F*SC80QFR!
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M?(/+,K_X6@IMW\Z6CZ_6W^ RP'QD@S1>"5I:I.#^Q'"3"EYIHB,D%PVPF(Z
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MF94Z NDQU*GC2_7*1Z.6;!?T/?"?AE-T Z'"@3R_^/KX S:#RF*D0BE/-$M
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M(T30 8A>+99?%DM:Q![%;!F/26" 5!.L-LVTG""-SV0FWK#"I5--T/0$4?W
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MXOP*?R'.OZH;,:3U?\[6GUY=K=:+S[C\^>]T>97KZ-S5"NE_^??P]X73GHO
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M=-OU9'YWB)GM;I*U8MMZ#5G424NV]@FP-D%1DD>GG?6-7.3]]$QKFIPNYQ\
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MZ^8.P<"0NKE#&-Z!'?N!!("5^NU8E0_K1?IS<]V0ZMCFQ 2$H'+5J:3[DI2
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M]@B1'<:MCX/& -"-(:<NQNKM6]QOX>_9YZO/+Q?+Y>*OFLX<OM WZV\7S+B
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MAUNQT>W%OOG6S'E!MZYQ0*JO=D?1# *6FBLNE=&Q2-FZX_68V_G3&&!C0'9
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MHS@FH+CO*R>'#Q\E;:1@X?4Z-V:[$<[^"_.GBKA$/]K <=^$#Z5+JAD]*E;
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MJ3\ KB-$,"&(UJOSV:OY"A/]>*N6G746Z1: Q.LIBR5!E%& UH8\&,6R2(/
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M]OHHH!G*3/@1D?$FM]V)A ]#Z?.,CC^E3$>#\/_^ZQU)$#?^N?G1YB?U7WW
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MO(]1-FVJ?R-8C2J.#N#UEFC_M&'.1Y+-Q67=J^8R\:PDF.C)$BC*0#01@?O
M3")353XXU_>45-6[U$P+HQZ,JY-EU"'.MD?1D _$.5-@,OVB0IU&X+."(HA%
MI?#H?:N\_'WT3#RA_F0Y/P*<(YC> 70^XOGY6;W)=YO97>1)2Z^B!F>(*<H:
M01>YU:"U) 896:)IDZIQ#T%]@><86=^..XS ^(G;7ES3_C*L+[N!IY(M*N6
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M$8PSMK:+'C*/J?]Z[X-$='^]]R'\FE@K#-6=UP\"D1?G8HH@$ZO)LBY!,+$
M9RF5XATKMV<)/T%8\+!'O293AY_F%FHKKPX"-%?FWL_+U:OE13PO%V>[[7W
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M"A@A?+! 1W&6X9.17+&$Q_B383I# G,ZR&T(Y!"#M=S,223C=X#CKNBT^)M
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M\""<)8^DDFY&&7O3L+24/,X\A,(J>""Z4EOZS'!?3:@H38$0MK["B&-MA#?
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M<&LM,C R,C S,S$N:'1M4$L! A0#%     @ *HFI5-/)9^O@&@  YB@! !
M             ( !SO@" &]P:RTR,#(R,#,S,2YX<V102P$"% ,4    "  J
MB:E4 )\M51@F   0> $ %               @ '<$P, ;W!K+3(P,C(P,S,Q
M7V-A;"YX;6Q02P$"% ,4    "  JB:E40/S*7ABX  "_RP< %
M    @ $F.@, ;W!K+3(P,C(P,S,Q7V1E9BYX;6Q02P$"% ,4    "  JB:E4
MRO:^9W5H 0#^N@X %               @ %P\@, ;W!K+3(P,C(P,S,Q7VQA
M8BYX;6Q02P$"% ,4    "  JB:E4OJQ8KZOM  !N?PH %
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M708 ;W!K+3,S,3(P,C)X97@S,C(N:'1M4$L%!@     *  H D (  +1A!@
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
